<SEC-DOCUMENT>0001682852-21-000017.txt : 20210506
<SEC-HEADER>0001682852-21-000017.hdr.sgml : 20210506
<ACCEPTANCE-DATETIME>20210506163056
ACCESSION NUMBER:		0001682852-21-000017
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		93
CONFORMED PERIOD OF REPORT:	20210331
FILED AS OF DATE:		20210506
DATE AS OF CHANGE:		20210506

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Moderna, Inc.
		CENTRAL INDEX KEY:			0001682852
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				813467528
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38753
		FILM NUMBER:		21898332

	BUSINESS ADDRESS:	
		STREET 1:		200 TECHNOLOGY SQUARE
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		6177146500

	MAIL ADDRESS:	
		STREET 1:		200 TECHNOLOGY SQUARE
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Moderna Therapeutics, Inc.
		DATE OF NAME CHANGE:	20160822
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>mrna-20210331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:0cbcbb00-411e-4aec-bde6-af04ca2907e0,g:4456e2fc-6666-4731-b603-d80176d3b13f,d:bba7ad915d1a4c4a8ebb50d13fae4c4e--><html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:mrna="http://www.modernatx.com/20210331" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt="http://fasb.org/srt/2020-01-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>mrna-20210331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80L2ZyYWc6NWRkZTViZjYxYzhmNDI3YmI2MWJjY2QyNzE0YzllZDgvdGFibGU6ODhkZjQ0YTRiYTZiNDdiMTk4MDJmODFjZDkxNTJhN2UvdGFibGVyYW5nZTo4OGRmNDRhNGJhNmI0N2IxOTgwMmY4MWNkOTE1MmE3ZV8wLTEtMS0xLTA_3c10cd0c-5743-49ec-9689-529aa74ee862">false</ix:nonNumeric><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80L2ZyYWc6NWRkZTViZjYxYzhmNDI3YmI2MWJjY2QyNzE0YzllZDgvdGFibGU6ODhkZjQ0YTRiYTZiNDdiMTk4MDJmODFjZDkxNTJhN2UvdGFibGVyYW5nZTo4OGRmNDRhNGJhNmI0N2IxOTgwMmY4MWNkOTE1MmE3ZV8xLTEtMS0xLTA_d8667f89-4e16-445b-9795-89d9fe48bc91">2021</ix:nonNumeric><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80L2ZyYWc6NWRkZTViZjYxYzhmNDI3YmI2MWJjY2QyNzE0YzllZDgvdGFibGU6ODhkZjQ0YTRiYTZiNDdiMTk4MDJmODFjZDkxNTJhN2UvdGFibGVyYW5nZTo4OGRmNDRhNGJhNmI0N2IxOTgwMmY4MWNkOTE1MmE3ZV8yLTEtMS0xLTA_7f175c7e-43e3-4668-8950-029239b5db32">Q1</ix:nonNumeric><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80L2ZyYWc6NWRkZTViZjYxYzhmNDI3YmI2MWJjY2QyNzE0YzllZDgvdGFibGU6ODhkZjQ0YTRiYTZiNDdiMTk4MDJmODFjZDkxNTJhN2UvdGFibGVyYW5nZTo4OGRmNDRhNGJhNmI0N2IxOTgwMmY4MWNkOTE1MmE3ZV8zLTEtMS0xLTA_83317291-94e3-41c1-9d30-681eb8a68438">0001682852</ix:nonNumeric><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80L2ZyYWc6NWRkZTViZjYxYzhmNDI3YmI2MWJjY2QyNzE0YzllZDgvdGFibGU6ODhkZjQ0YTRiYTZiNDdiMTk4MDJmODFjZDkxNTJhN2UvdGFibGVyYW5nZTo4OGRmNDRhNGJhNmI0N2IxOTgwMmY4MWNkOTE1MmE3ZV80LTEtMS0xLTA_ab5761c2-1d93-4209-b765-cb66a0e5befa">December 31</ix:nonNumeric><ix:nonNumeric contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfNC0wLTEtMS04Mzk4_763696f1-1b66-43b8-a5e9-0a8445cbb910">us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</ix:nonNumeric><ix:nonNumeric contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfNC0wLTEtMS04Mzk4_986006a3-947e-4a84-bf6d-3ecd8f99076a">us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</ix:nonNumeric><ix:nonNumeric contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfOS0wLTEtMS0w_7afc31d0-ede8-43d3-b946-27d55409b32b">us-gaap:OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfOS0wLTEtMS0w_d74ab000-ea21-4620-b930-521a5fdbab89">us-gaap:OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfMTAtMC0xLTEtMzUwNw_1c2fb28d-31b2-40b2-9ba8-7bc67b5a50d3">us-gaap:OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfMTAtMC0xLTEtMzUwNw_f985209d-7d9f-4e95-8466-842513c70552">us-gaap:OtherLiabilitiesCurrent</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="mrna-20210331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ie20e480bc066475e9f962590283234e4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i50495a74916c41eb8a2e6e9d510ddb50_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i40e5fc820d824be1931d54b51dd263a3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i90cf26aad24349bfa441914ac3d706fb_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e5ea10505f740f69843ae942d0421b8_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12127d667a294d78b6d78f889c39cd18_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i928ab86735d84580ac232ade8c6033ea_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93f5b8cccc84489b9789274a5e0b0890_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie93f0b234bf24c27b09e35245f5e26b6_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85c3685b8bc74888a7957153cba507be_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idaec3621e0754f54a55937521667819b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie42efe57bc7743f78f5470ae0d8b47c0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ee23f27c5a7409999bc27bf484c3683_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bd66b8c2d444db3ab9e16db494ca9ec_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6763fa662d34fe987498086ccaefa42_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51a24806337f4c398006c8c24a6291f9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00257f1c106c4f12b6139f8b838a1faf_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2898610162d44ebb1d6412f7f754f57_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if224da12bc8646a2934e52e6b2b0929d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3081299caa6b4213987da62a7e0e3b67_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ea0cb20ecbd485a9682c793a5f13edd_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7682e40394cc4e7db96f8cc4de55e962_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7811f82e8ed4667a6efb6a88cb1dc80_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ed66b7fc0fb48c9bb3d57e8be191929_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd4ae3b11c564cb6b97eb730e3ff7bb1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1138d8f10d6c45fdb458206ef7e763ce_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd57a755b6d2496f92d2b0ce1c6d8369_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16c2d8a9bebe4163981c7803f6359e72_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d0241871b0840c2a85a3c6334108769_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i353dc2cd5f49451798ef780c6af7ed46_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99ce1af211874ddda368b64fc0527881_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i199f99634c0c487e82b051148cdc8024_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ac58abcca77466fa78e3ac37f63f737_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11483b66bae440ceafe63983b7fbd5c9_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa5a33ce37614698a3418806ab20f9b2_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="program"><xbrli:measure>mrna:program</xbrli:measure></xbrli:unit><xbrli:context id="ib0bb072a6a064b47a2581435e9123a1f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1779a3029e943e597b2535a551359a3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08c08b2af4044913baf379746ada2802_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d7a2752ca8b473598e5f43e5290268c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i015500c719c5494988852885b84ddc22_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i615a67f1a6c2480c89cbe28e804d3b01_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CustomerDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0238e09dbf1a48c999216873131aac3a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CustomerDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb5c5d2d047b4d979b9497e8b26286bd_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:DefenseAdvancedResearchProjectsAgencyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib54c28109e8b4df6bd548f059a69eaa7_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrna:ContractOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:DefenseAdvancedResearchProjectsAgencyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a973ce00bdc4a798407694abf5f73a8_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic23af7a56e2749a0b4290de702518aa1_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f9df22e0ed44daba83573576518c077_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24305ac457e24ee79d1f0f5f58f89459_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d9fd4412ca74750b6b14d4722981e10_D20210418-20210418"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-18</xbrli:startDate><xbrli:endDate>2021-04-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide0d50c05a0f41209d23a6cda03d4b84_D20160901-20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="option"><xbrli:measure>mrna:option</xbrli:measure></xbrli:unit><xbrli:context id="if411e69e7ac54f6ea28f6658a5d6dac8_I20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89f03a0decbd475591590f9d2c6d5dec_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrna:ContractOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53791cfc661a48e88b2bc8d3c8c541f7_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrna:InitialProjectMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:TheBillAndMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9e09957e07f4e779b011ddea7dea3cb_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e13ec3698064dd7bac04dab36528b56_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fbd7587ea9a4f81bfca9dfda7f7c4d1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:OtherGrantRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0c6277e6e0841bbafa567ecc4fe413b_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:OtherGrantRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52aa31d81e134903a18093eb7e292280_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i086bb9318c0b4c0c8ef0461ff39d1327_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7427ffe751240d0a4ef3e3e238b47a2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:MerckMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c7a5f91086643518f876c3b89b411ae_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:MerckMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fb6b67fc6764af4b4bf084bb09b748b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:VertexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0c4ba70e8f6479882eff1b6b52f2792_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:VertexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a3a24c98e934216b6325e57f46e961a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:OtherCollaborativePartiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib62acba5ff5c46149175a78722d4f5d3_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:OtherCollaborativePartiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d71f6c708c04cfd9aa4a5147b897eae_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9d15e5fbe824ba297aa8586391ba7bc_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0424eee07b4f47f18f3baa3664b5c50f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ab46cc577f34aa3900c0f6c8856f7f9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i356bef623f834e84a7cdb447d141ccd3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60479f4cd58141ab88eb9674b785a4a1_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67533c70f1f24be1881a998a7ae2b79c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica0a9efa36764e4abe9a81143990ee12_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a4e0ae3d99d485a9d3576fc11b24069_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9bf1192916f64380bbdde4039cc78e4f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48e96e4a36ca4d209bbcd48d238ae70a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cb1f6a641814b1c8ad2ff7b4a2b8217_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b6a0be7eddd411e8225d14c0a674df3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3039ce5316a84c43a0d08915dea14050_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15456fe3d934468482ac959714d5a053_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb1895e1c5bc495fbeda6e5e2a787ef6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cb95c5356684e93a35e3bf790aca2fc_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6b7b9882f044ebba7637ec5e651772b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4dfcad9b1a5a494ea2d1f97c1cec871c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee5034c39f6946fd8be3fff0632e2766_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacbf0fb43aaa4d53bc16745f38512f25_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9af72ba73c864ba9a21e07312e1cad6f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e5f6ba69b244986a5d20a064920207d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6c00e9c4b7c4cab9106b940030ecc8d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i541125faaac24704993f4bb55ea03ffb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63ece81cf0b14c9d977ea0092b4cead4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i144b3354d900459db79935bb372dddac_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6806220f01c4d34bff60f27b6458a20_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc2d8b74fdcf4cf19b8d0602247a7ed5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie744a40ba7764cb6bc3cc3dc74a499fb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4039aa1d6baf4797ad803a7b6190baa8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1cde362d4524f9ba6d35c5ea6b396bd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05d95354ca2c445db703eebb828e4323_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6465ad5ef134815a47c8f454682eb9d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64e7c6ca7fa54146be90ea4732b08c96_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9f8683c12dc47549b560b34d4161e88_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39670918752c482d9b5985dd34a8435a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5913295f7ce94eaf82964fa6e5bebd39_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a2bf1e040654bc8a5d2177086572016_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79840680ee5c42f08b5791b046d4ab3f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcb2bea1b1bf4c1782b105cad231847c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a3a8d7ef2ea40a88c5b84eee83292fa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie01d3f7d975a464884d498263f3d023f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e628bbb40a646dfb1404d2cceaf4b58_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i123d9cb392064f7bbe194ed464f90c8f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb052beac6e745e59a97634f1deb8911_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d49a64ca5814a3b8323c954b990c2f1_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ed53e247dd44a8fbc05e34b092630a4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd19a0d5fe7648f19bcf7eb315e47574_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e7a5259755b49e49d483e9c3980d884_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia850cc3fdca949bdbacf65e2aa316867_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbba28371a0c4ac7b6d117d940658048_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a9ecc2c2f4c4165a295dd17a5a65f57_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f155650a70d4eeda45d6f57b5eb94af_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8803bb198614454eb655c9107db2f3b2_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bad47bc31eb4c3fa7e59c8591449292_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c36846f9be347ffadf3fb034bb04f1c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cbf1ef1e50043a6973a41f4362eca38_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id976144d8ac0470a8dfe87f5e0806e11_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9ead6d8a2d6496ab53b71dbf65c0e89_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ae8a6101db3483ea8c8e7878ef68c7b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6aa4efa157cf4cbcaf792243639a7365_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0598f69f1ada4de8ae9919743b2bdf0c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93f6a88f2c7c4d8085866d26873d36e9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if667a4d9f03441e794394bde2522c7d6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c4745cd6ed947bc9dc06de365526c6f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c0cd6f20ef146849ac96024e8997311_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34e70e75e95f41a89179d7b607304203_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie17de02d67874972813c65e1ee7828ab_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id52895ca9a52496199fbd7e4b81d30b8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa680536838a4ffd80a53a841c00e107_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i686e90a952424d579c987c59336787cd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59dd43638f654b5ca42787b1d4565122_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5f5b6e35e214612987f2dbe6605a881_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i900a81907e194a84ba164cb4e36677d2_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ab6f5001f864500b4c8e0d67181a3e1_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61150f006fb645cb98904910e2b941a8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie50812d5f7b44b30b8225d6636c4c4f4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bd7f75306414af4a89bd03391f700a7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if558e6ed91924e46b53fe8382ea023b2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie182a57ea61f416d8c4866418d5a465d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdaad432c7624d609795f42f421c205b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2ecdbe7a52f4cdaa512b1d59ef2091b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebde00942b24405f849061b1a6fad190_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1eca162cb334496bb26a5b7d49c7186_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88573437d7664c1a9e52c33298a5b456_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39475e82f8ca4c18b5f9b3233c43443b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e9e748f96b34220bf4fe5d60445b495_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3e11e356d35463abd4fb1e3057fcd5d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3574dd8d4ffe4445ac4435bdd763464d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1263c583aadd4aeeb0479db8950e9cad_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrna:FinancingRightOfUseAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6397562962643bba0441eaabef86729_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrna:FinancingRightOfUseAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7fb0180403444128af0ca00c287ab8b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25b18fc5d30a4a9ebd82c278f9fdee03_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2ee3c9e3ddc46fc8c50d787172d195f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3049e90ee7764f058dbbb38cd725aadc_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie53549975a3f42f6b2b2d3515ab79791_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc1f15c64a2e42b6b50c3be424cf6c44_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e89e827a1584b60805bbb05008f21f5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39195ff1bc64463eb3aa66b95e19bd36_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="campus"><xbrli:measure>mrna:campus</xbrli:measure></xbrli:unit><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i4c54e5c981c44426b958b7cd3aeb25d8_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:CambridgeMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31be9147cbb84c108e25cc00c3dd39a2_I20160831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCSouthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="extension_period"><xbrli:measure>mrna:extension_period</xbrli:measure></xbrli:unit><xbrli:context id="i72bd7d804e294a73a53c8fe39086669a_I20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCNorthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie56c1c32083543d8bb94f4fb0eba71d6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCNorthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5946e5f9891e4ba8aa1048e39fc8cd69_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCNorthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaad3817f49bd43e29ab66021c23b5529_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCNorthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i747a2e93fb1b437b9939b81676cc53b5_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">mrna:EmbeddedLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c1e58e30b1c4e8d8872e56716cb8e9f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">mrna:EmbeddedLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c10c5b4110f49df8c8e8f8f898bbe05_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCSouthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i97caad06f3f04504b59b69417b6a7236_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCSouthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id91f4c8df96343e8b99f1775d18c7d59_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCNorthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5b2cabe98664e3eac3b4393c8159043_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCNorthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc463e223e4f4f08b900edce1309004e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrna:PersonalizedMRNACancerVaccinesProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccb9f67ad61a42038f759003571a1508_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrna:PersonalizedMRNACancerVaccinesProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie54f228e1d5b4838858ccaebf45f0e9a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">mrna:SupplyAndManufacturingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8204f059459747e988e68765b4fa0190_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">mrna:ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic353f4f727e84c7988d44622743ab4c4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">mrna:ClinicalOperationsAndSupportCommitmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i570695e9c65448a685edf9c785db6a07_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">mrna:ClinicalOperationsAndSupportCommitmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1c2fd1d75924d69915c2130ff7af739_I20170626"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrna:TherapeuticAndProphylacticProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-06-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id39bf79de51448cbb53b0479ac1fc4fd_I20170626"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrna:DiagnosticProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-06-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9b8f829587545b1850dc3d645793a91_I20170626"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-06-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia56b7a15d277445c813a9b1e913dce91_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91b0e05ed30e415f9576819f14007d11_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrna:StockOptionAndIncentivePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1afaa9c0a57f43b09e758fb17bd26e7d_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie43ed5c918a0494eb0f43d56862c3e32_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26a6b2b2db7f4f52a54072c86dbb902c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53c9c75bd90d46278b4077d5e35f7d5b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c17046964e4496093fef93215168f9c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie18c5203639447448d73f34f409c6682_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia750d90906f64b3da90f3ea25a6e6c88_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e7259ec870c4de7815c0a34b19ed99c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf2c3f50e45f44bfa74451d6d87a3675_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22567b607e5a40439a3314231a4c0b31_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if820d61e1d2e4cb3a94f601c28956f74_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53f43d6f041a413d9ba3a5b6031c5bca_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:RestrictedStockAndRestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0ee58a110904b6ea810fa10add84823_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:RestrictedStockAndRestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f6bab6d04464aa58adc35f314641f71_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibca633e1d4664bcd8090d7383938bd13_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if11b06a738a64cf88f8e86ac44cbfe87_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7207e2b92904a3ea65000ec12644d42_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99e931e8a5cd44ea88397661762d28f1_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a4b450ab98d4f6b90381fecd841a0a5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b44e002e91945e5a00c7bcd2919634d_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i649444b931a542648a2d656ef5f35e1c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b71c01ae54c49e288fce1e85063a0c0_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="dose"><xbrli:measure>mrna:dose</xbrli:measure></xbrli:unit><xbrli:context id="i9c022d9b4fbe4b8b8966c5f007b5faf4_D20210401-20210507"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-05-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8a5bdf50ed34e1196383b6df3a4c6e7_I20210507"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-07</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ibba7ad915d1a4c4a8ebb50d13fae4c4e_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3.4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="margin-top:0.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-top:0.35pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Washington, DC 20549</span></div><div style="margin-bottom:6pt;margin-top:0.35pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:11.111%"><tr><td style="width:1.0%"></td><td style="width:56.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.208%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">FORM</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xL2ZyYWc6ZGViMWQwNTBiNDJjNGI5Y2FmMjMwYTk3YjhiNjgyN2MvdGFibGU6MWY0NTU5NjA1MWMwNGM0NmFiNjM3MDAzZjlkYjAwNGMvdGFibGVyYW5nZToxZjQ1NTk2MDUxYzA0YzQ2YWI2MzcwMDNmOWRiMDA0Y18wLTEtMS0xLTA_5d27b25b-eef7-4569-8162-3fb8f18e19de">10-Q</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:3.5pt;margin-top:1.55pt;padding-right:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Mark One)</span></div><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xL2ZyYWc6ZGViMWQwNTBiNDJjNGI5Y2FmMjMwYTk3YjhiNjgyN2MvdGV4dHJlZ2lvbjpkZWIxZDA1MGI0MmM0YjljYWYyMzBhOTdiOGI2ODI3Y18yMTI4_7a9e1316-1439-47f5-9a00-811087c23fe6">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:0.7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xL2ZyYWc6ZGViMWQwNTBiNDJjNGI5Y2FmMjMwYTk3YjhiNjgyN2MvdGV4dHJlZ2lvbjpkZWIxZDA1MGI0MmM0YjljYWYyMzBhOTdiOGI2ODI3Y18yMTI_76382121-7f6a-408f-af1a-0cb0587211fc">March 31, 2021</ix:nonNumeric> </span></div><div style="margin-top:3.4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OR</span></div><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xL2ZyYWc6ZGViMWQwNTBiNDJjNGI5Y2FmMjMwYTk3YjhiNjgyN2MvdGV4dHJlZ2lvbjpkZWIxZDA1MGI0MmM0YjljYWYyMzBhOTdiOGI2ODI3Y18yMTIz_9be6aef6-5588-400f-ba7f-2cf07392f6f4">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the transition period from _ to _ </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xL2ZyYWc6ZGViMWQwNTBiNDJjNGI5Y2FmMjMwYTk3YjhiNjgyN2MvdGV4dHJlZ2lvbjpkZWIxZDA1MGI0MmM0YjljYWYyMzBhOTdiOGI2ODI3Y18yMTI0_227d5e64-ac27-4105-aa1f-17d0a623ca05">001-38753</ix:nonNumeric> </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><img src="mrna-20210331_g1.jpg" alt="mrna-20210331_g1.jpg" style="height:48px;margin-bottom:5pt;vertical-align:text-bottom;width:212px"/></div><div style="margin-top:1.35pt;text-align:center"><span><br/></span></div><div style="margin-top:1.35pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xL2ZyYWc6ZGViMWQwNTBiNDJjNGI5Y2FmMjMwYTk3YjhiNjgyN2MvdGV4dHJlZ2lvbjpkZWIxZDA1MGI0MmM0YjljYWYyMzBhOTdiOGI2ODI3Y18yMTMx_92988674-c1db-4b53-9bd6-addc4cc670f6">Moderna, Inc.</ix:nonNumeric> </span></div><div style="margin-top:0.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in Its Charter)</span></div><div style="margin-bottom:6pt;margin-top:0.5pt;padding-right:15.75pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:49.572%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xL2ZyYWc6ZGViMWQwNTBiNDJjNGI5Y2FmMjMwYTk3YjhiNjgyN2MvdGFibGU6ZmE3OGI0NjE0MDNjNDkxZjlkYTkwMTM3OWJlZjliY2UvdGFibGVyYW5nZTpmYTc4YjQ2MTQwM2M0OTFmOWRhOTAxMzc5YmVmOWJjZV8wLTAtMS0xLTA_d60fca78-1f9e-4696-a7ef-1a1037b632b8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xL2ZyYWc6ZGViMWQwNTBiNDJjNGI5Y2FmMjMwYTk3YjhiNjgyN2MvdGFibGU6ZmE3OGI0NjE0MDNjNDkxZjlkYTkwMTM3OWJlZjliY2UvdGFibGVyYW5nZTpmYTc4YjQ2MTQwM2M0OTFmOWRhOTAxMzc5YmVmOWJjZV8wLTMtMS0xLTA_5fb19827-5965-4994-89e2-e5cf7bc1d6ab">81-3467528</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or Other Jurisdiction of Incorporation or Organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(IRS Employer Identification No.)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xL2ZyYWc6ZGViMWQwNTBiNDJjNGI5Y2FmMjMwYTk3YjhiNjgyN2MvdGFibGU6ZmE3OGI0NjE0MDNjNDkxZjlkYTkwMTM3OWJlZjliY2UvdGFibGVyYW5nZTpmYTc4YjQ2MTQwM2M0OTFmOWRhOTAxMzc5YmVmOWJjZV8zLTAtMS0xLTA_e93d0130-974d-4db4-aeee-d508fe537218">200 Technology Square</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xL2ZyYWc6ZGViMWQwNTBiNDJjNGI5Y2FmMjMwYTk3YjhiNjgyN2MvdGFibGU6ZmE3OGI0NjE0MDNjNDkxZjlkYTkwMTM3OWJlZjliY2UvdGFibGVyYW5nZTpmYTc4YjQ2MTQwM2M0OTFmOWRhOTAxMzc5YmVmOWJjZV80LTAtMS0xLTA_d6c78fe7-4939-4a87-92e1-1491ca971b51">Cambridge,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xL2ZyYWc6ZGViMWQwNTBiNDJjNGI5Y2FmMjMwYTk3YjhiNjgyN2MvdGFibGU6ZmE3OGI0NjE0MDNjNDkxZjlkYTkwMTM3OWJlZjliY2UvdGFibGVyYW5nZTpmYTc4YjQ2MTQwM2M0OTFmOWRhOTAxMzc5YmVmOWJjZV80LTEtMS0xLTA_42ef96d1-f7e1-48f1-ae75-a1189d0c9131">Massachusetts</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xL2ZyYWc6ZGViMWQwNTBiNDJjNGI5Y2FmMjMwYTk3YjhiNjgyN2MvdGFibGU6ZmE3OGI0NjE0MDNjNDkxZjlkYTkwMTM3OWJlZjliY2UvdGFibGVyYW5nZTpmYTc4YjQ2MTQwM2M0OTFmOWRhOTAxMzc5YmVmOWJjZV80LTMtMS0xLTA_e233e48b-0900-44de-b659-5548a40cac7f">02139</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:3.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xL2ZyYWc6ZGViMWQwNTBiNDJjNGI5Y2FmMjMwYTk3YjhiNjgyN2MvdGV4dHJlZ2lvbjpkZWIxZDA1MGI0MmM0YjljYWYyMzBhOTdiOGI2ODI3Y18yMTI1_e313c3af-49b1-485e-aaba-c07468ddbcf8">617</ix:nonNumeric>) <ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xL2ZyYWc6ZGViMWQwNTBiNDJjNGI5Y2FmMjMwYTk3YjhiNjgyN2MvdGV4dHJlZ2lvbjpkZWIxZDA1MGI0MmM0YjljYWYyMzBhOTdiOGI2ODI3Y18yMTI5_34ca2e50-a760-4c81-b34f-fd9e5fbe5b4a">714-6500</ix:nonNumeric> </span></div><div style="margin-top:0.8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="margin-bottom:6pt;margin-top:1.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:0.05pt;padding-left:9pt;padding-right:24.75pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:174%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trading symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xL2ZyYWc6ZGViMWQwNTBiNDJjNGI5Y2FmMjMwYTk3YjhiNjgyN2MvdGFibGU6MzE5MTE5NzgwMjZjNDFjNDk1ZDVhNTM4YmExYjRjOWQvdGFibGVyYW5nZTozMTkxMTk3ODAyNmM0MWM0OTVkNWE1MzhiYTFiNGM5ZF8xLTAtMS0xLTA_3b0a08d2-d5c1-4dcd-8329-26c195ddea17">Common stock, par value $0.0001 per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xL2ZyYWc6ZGViMWQwNTBiNDJjNGI5Y2FmMjMwYTk3YjhiNjgyN2MvdGFibGU6MzE5MTE5NzgwMjZjNDFjNDk1ZDVhNTM4YmExYjRjOWQvdGFibGVyYW5nZTozMTkxMTk3ODAyNmM0MWM0OTVkNWE1MzhiYTFiNGM5ZF8xLTEtMS0xLTA_9da0d589-1c52-4280-8508-cf3f1f514648">MRNA</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xL2ZyYWc6ZGViMWQwNTBiNDJjNGI5Y2FmMjMwYTk3YjhiNjgyN2MvdGFibGU6MzE5MTE5NzgwMjZjNDFjNDk1ZDVhNTM4YmExYjRjOWQvdGFibGVyYW5nZTozMTkxMTk3ODAyNmM0MWM0OTVkNWE1MzhiYTFiNGM5ZF8xLTItMS0xLTA_acdce358-fce1-4e5a-878b-b0ab1a8c9f5d">The NASDAQ Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:0.05pt;padding-left:9pt;padding-right:24.75pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xL2ZyYWc6ZGViMWQwNTBiNDJjNGI5Y2FmMjMwYTk3YjhiNjgyN2MvdGV4dHJlZ2lvbjpkZWIxZDA1MGI0MmM0YjljYWYyMzBhOTdiOGI2ODI3Y18yMTI2_629c1788-48ae-4ae7-8152-7d7937bb15d1">Yes</ix:nonNumeric>  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">No  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:0.05pt;padding-left:9pt;padding-right:24.75pt;text-indent:11.25pt"><span><br/></span></div><div style="margin-top:0.05pt;padding-left:9pt;padding-right:24.75pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xL2ZyYWc6ZGViMWQwNTBiNDJjNGI5Y2FmMjMwYTk3YjhiNjgyN2MvdGV4dHJlZ2lvbjpkZWIxZDA1MGI0MmM0YjljYWYyMzBhOTdiOGI2ODI3Y18yMTMw_86b430b4-d52b-41a5-9d59-f14a87e56570">Yes</ix:nonNumeric>  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">No  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:0.05pt;padding-left:9pt;padding-right:24.75pt;text-indent:11.25pt"><span><br/></span></div><div style="margin-top:0.05pt;padding-left:9pt;padding-right:24.75pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221;, and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:6pt;margin-top:0.05pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.737%"><tr><td style="width:1.0%"></td><td style="width:19.396%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.862%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.396%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.010%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xL2ZyYWc6ZGViMWQwNTBiNDJjNGI5Y2FmMjMwYTk3YjhiNjgyN2MvdGFibGU6ZjhhODc3ZTZkNGRjNDIyMzllZjRiNDljZmY3NTA0ODgvdGFibGVyYW5nZTpmOGE4NzdlNmQ0ZGM0MjIzOWVmNGI0OWNmZjc1MDQ4OF8wLTAtMS0xLTA_7916e6a7-c622-44db-af05-fd91179b51b4">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">o</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">o</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xL2ZyYWc6ZGViMWQwNTBiNDJjNGI5Y2FmMjMwYTk3YjhiNjgyN2MvdGFibGU6ZjhhODc3ZTZkNGRjNDIyMzllZjRiNDljZmY3NTA0ODgvdGFibGVyYW5nZTpmOGE4NzdlNmQ0ZGM0MjIzOWVmNGI0OWNmZjc1MDQ4OF8wLTgtMS0xLTA_84eed636-744e-4838-8aa6-c204d770ebf6">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xL2ZyYWc6ZGViMWQwNTBiNDJjNGI5Y2FmMjMwYTk3YjhiNjgyN2MvdGFibGU6ZjhhODc3ZTZkNGRjNDIyMzllZjRiNDljZmY3NTA0ODgvdGFibGVyYW5nZTpmOGE4NzdlNmQ0ZGM0MjIzOWVmNGI0OWNmZjc1MDQ4OF8xLTgtMS0xLTA_cbcf80ce-3586-412e-9d6c-52bfb29ea20d">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:0.05pt;padding-left:9pt;padding-right:24.75pt;text-indent:11.25pt"><span><br/></span></div><div style="margin-top:0.5pt;padding-left:9pt;padding-right:33.75pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="padding-left:20.25pt"><span><br/></span></div><div style="padding-left:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Yes </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xL2ZyYWc6ZGViMWQwNTBiNDJjNGI5Y2FmMjMwYTk3YjhiNjgyN2MvdGV4dHJlZ2lvbjpkZWIxZDA1MGI0MmM0YjljYWYyMzBhOTdiOGI2ODI3Y18yMTI3_08ac8790-f0ec-4d9a-aa73-21a0772d9229">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> No  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span></div><div style="padding-left:20.25pt"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:0.05pt;padding-left:9pt;padding-right:24.75pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of April 30, 2021, there were <ix:nonFraction unitRef="shares" contextRef="i50495a74916c41eb8a2e6e9d510ddb50_I20210430" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xL2ZyYWc6ZGViMWQwNTBiNDJjNGI5Y2FmMjMwYTk3YjhiNjgyN2MvdGV4dHJlZ2lvbjpkZWIxZDA1MGI0MmM0YjljYWYyMzBhOTdiOGI2ODI3Y18yMDM5_673d811d-44f8-4c55-88f2-6c524bf3fc7d">401,527,789</ix:nonFraction> shares of the registrant&#8217;s common stock, par value $0.0001 per share, outstanding.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ibba7ad915d1a4c4a8ebb50d13fae4c4e_7"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q (&#8220;Form 10-Q&#8221;), including the section entitled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; contains express or implied forward-looking statements that are based on our management&#8217;s belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by these forward-looking statements. Forward-looking statements in this Form 10-Q include, but are not limited to, statements about:</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our activities with respect to our COVID-19 vaccine, and our plans and expectations regarding future generations of our COVID-19 vaccine, including boosters, that we may develop in response to variants of the SARS-CoV-2 virus, ongoing clinical development, manufacturing and supply, pricing, commercialization, if approved, regulatory matters and third-party and governmental arrangements and potential arrangements;</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately, particularly with respect to the timely production and delivery of our COVID-19 vaccine;</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability and the ability of third parties with whom we contract to successfully manufacture our commercial products at scale, as well as drug substances, delivery vehicles, development candidates, and investigational medicines for preclinical and clinical use;</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our commercial products, investigational medicines and technology;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, timing, progress, results, and cost of our research and development programs and our current and future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available, and our research and development programs;</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ultimate impact of the current coronavirus pandemic, or the COVID-19 pandemic, or any other health epidemic, on our business, manufacturing, clinical trials, research programs, supply chain, regulatory review, healthcare systems or the global economy as a whole;</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to the direct or indirect impact of the COVID-19 pandemic or any future large-scale adverse health event, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays in diagnoses, initiation or continuation of treatment for diseases that may be addressed by our development candidates and investigational medicines, or in patient enrollment in clinical trials, potential clinical trials, regulatory review or supply chain disruptions, and other potential impacts to our business, the effectiveness or timeliness of steps taken by us to mitigate the impact of the pandemic, and our ability to execute business continuity plans to address disruptions caused by the COVID-19 pandemic or future large-scale adverse health event;</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our anticipated next steps for our development candidates and investigational medicines that may be slowed down due to the impact of the COVID-19 pandemic, including our resources being significantly diverted towards our COVID-19 vaccine efforts, particularly if the federal government seeks to require us to divert such resources;</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify research priorities and apply a risk-mitigated strategy to efficiently discover and develop development candidates and investigational medicines, including by applying learnings from one program to our other programs and from one modality to our other modalities;</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability and willingness of our third-party strategic collaborators to continue research and development activities relating to our development candidates and investigational medicines;</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain regulatory approval of our investigational medicines;</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully commercialize any future products, if approved;</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the pricing and reimbursement of our investigational medicines, if approved;</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the implementation of our business model, and strategic plans for our business, investigational medicines, and technology;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">estimates of our future expenses, revenues, capital requirements, and our needs for additional financing;</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential benefits of strategic collaboration agreements, our ability to enter into strategic collaborations or arrangements, and our ability to attract collaborators with development, regulatory, and commercialization expertise;</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future agreements with third parties in connection with the commercialization of our investigational medicines, if approved;</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size and growth potential of the markets for our investigational medicines, and our ability to serve those markets;</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our financial performance;</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance of our investigational medicines;</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments in the United States and foreign countries;</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to produce our products or investigational medicines with advantages in turnaround times or manufacturing cost;</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of competing therapies that are or may become available;</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to attract and retain key scientific or management personnel;</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of laws and regulations;</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments relating to our competitors and our industry; and</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other risks and uncertainties discussed in this Form 10-Q. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In some cases, forward-looking statements can be identified by terminology such as &#8220;will,&#8221; &#8220;may,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;aims,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the section entitled &#8220;Risk Factors&#8221; and elsewhere in this Form 10-Q. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those expressed or implied by the forward-looking statements. No forward-looking statement is a promise or a guarantee of future performance. </span></div><div style="margin-top:13.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements in this Form 10-Q represent our views as of the date of this Form 10-Q. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Form 10-Q.</span></div><div style="margin-top:13.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Form 10-Q includes statistical and other industry and market data that we obtained from industry publications and research, surveys, and studies conducted by third parties. Industry publications and third-party research, surveys, and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. We have not independently verified the information contained in such sources.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE REGARDING COMPANY REFERENCES</span></div><div style="margin-top:13.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context otherwise requires, the terms &#8220;Moderna,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; in this Form 10-Q refer to Moderna, Inc. and its consolidated subsidiaries. </span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">ADDITIONAL INFORMATION</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our website, www.modernatx.com including the Investor Relations section, www.investors.modernatx.com; and corporate blog www.modernatx.com/moderna-blog; as well as our social media channels: Facebook, www.facebook.com/modernatx; Twitter, www.twitter.com/modernatx; and LinkedIn, www.linkedin.com/company/modernatx; contain a significant amount of information about us, including financial and other information for investors. We encourage investors to visit these websites and social media channels as information is frequently updated and new information is shared.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ibba7ad915d1a4c4a8ebb50d13fae4c4e_10"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.974%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.15pt"><span><br/></span></div><div style="padding-left:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_13">Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_13">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_16">Condensed Consolidated Balance Sheets as of March 31, 2021 and December 31, 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_16">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_19">Condensed Consolidated Statements of Operations for the three months </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_19">ended March 31, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_19">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_22">Condensed Consolidated Statements of Comprehensive </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_22">Income (</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_22">Loss</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_22">)</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_22"> for the three months ended March 31, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_22">8</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_25">Condensed Consolidated Statements of Stockholders' Equity for the three months ended March 31, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_25">9</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_28">Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_28">10</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_31">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_31">11</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_91">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_91">27</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_97">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_97">42</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_100">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_100">42</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3.2pt;padding-left:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_106">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_106">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_109">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_109">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_118">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_118">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_121">SIGNATURES</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_121">45</a></span></div></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ibba7ad915d1a4c4a8ebb50d13fae4c4e_13"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Financial Statements</span></div><div style="margin-bottom:9pt"><span><br/></span></div><div id="ibba7ad915d1a4c4a8ebb50d13fae4c4e_16"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MODERNA, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited, in millions, except per share data)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfNC0xLTEtMS0w_0476eaa9-19e2-4447-a52f-2acf1e4043fd">5,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfNC0zLTEtMS0w_cdd9a885-7a5d-4739-99d3-95b2eb8b0525">2,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfNS0xLTEtMS0w_b96a64e7-5f63-4a2d-8558-45566583ec40">2,293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfNS0zLTEtMS0w_989bcf11-4920-4c63-8277-ca4345f2444e">1,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfNi0xLTEtMS0w_e9973ece-cc79-485e-8345-24d7eb6e1ac3">3,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfNi0zLTEtMS0w_47d9c2b1-62d9-4bcd-8902-7763d1a3520e">1,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfNy0xLTEtMS00MQ_83f10f02-0e9c-40c4-8976-a082f0228c38">494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfNy0zLTEtMS00MQ_d7c721bf-1d42-4b61-b8df-e775c6cdcf23">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfNy0xLTEtMS0w_777c49cc-7f59-4475-8421-f72acee2c125">264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfNy0zLTEtMS0w_f6c99844-1a7b-4067-949c-bfc7843c31fa">252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfOS0xLTEtMS0w_be775919-0fda-49e9-a67c-4e898b6de0db">11,703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfOS0zLTEtMS0w_c05d73fa-626d-42f5-a23d-e44b8687cd00">6,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments, non-current</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMTAtMS0xLTEtMA_f412703f-b5f6-42e2-bef4-356f1693d859">468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMTAtMy0xLTEtMA_cc879d02-51fa-4f99-88f3-57c7e383af54">639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMTEtMS0xLTEtMA_0fc40c26-7407-4acc-b09b-273d1eac2527">372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMTEtMy0xLTEtMA_2069c682-1d33-4182-992d-364eb3ddd708">297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMTItMS0xLTEtMA_6d14fd17-d518-4af9-b18b-6ecb93fd117c">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMTItMy0xLTEtMA_bd36b708-c668-45ae-95b6-d002467bb1c9">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, non-current</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMTMtMS0xLTEtMA_e1a40ac2-5670-43ad-abb1-2b3b1792880f">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMTMtMy0xLTEtMA_2d9c24a1-051e-42ad-8d62-0f5033b8d54b">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMTUtMS0xLTEtNzI0Ng_57ea2425-8ba9-4534-8d8f-d0efd87f63f1">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMTUtMy0xLTEtNzI0Ng_cb4200e7-c43c-483d-b254-c27a14b2eaf4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMTQtMS0xLTEtMA_c6febb28-3689-4d73-aece-4288fbad2006">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMTQtMy0xLTEtMA_7f48f985-d5b5-4c98-9d5a-3bb89572ebac">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMTUtMS0xLTEtMA_e5922a5c-bba0-462b-91b2-b9ccec0465fe">12,694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMTUtMy0xLTEtMA_ca8406bc-0a32-4c29-8509-ec7bd9d98924">7,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMTgtMS0xLTEtMA_439dd775-d048-4ab9-9db4-3cdccc225dae">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMTgtMy0xLTEtMA_6604b0ba-65ae-4a08-b295-d8eba72621e7">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMTktMS0xLTEtMA_b136063f-30d3-4bd5-9e37-f32fe4d0d0a8">753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMTktMy0xLTEtMA_4df15665-314e-4d19-a3ef-0287f8c4c00b">470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMjAtMS0xLTEtMA_94d1fffa-c9e7-4ee7-9948-9ab8522a471b">7,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMjAtMy0xLTEtMA_d92ee8a5-fd69-4616-bdbf-bee0c38425b8">3,867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMjEtMS0xLTEtMA_57ba53bb-d5ff-43a2-a978-54c4261f334a">149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMjEtMy0xLTEtMA_6893e425-b8df-44e4-872a-d977f8afa03b">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMjItMS0xLTEtMA_cf729c7e-29c7-4e64-8e72-9f2d620cc92a">8,441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMjItMy0xLTEtMA_5c2d8ada-6ee0-4b76-8380-c966fbd1fd4b">4,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, non-current</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMjMtMS0xLTEtMA_cebf301e-f5cf-4c04-8fe0-a2194f2e4bf5">179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMjMtMy0xLTEtMA_fe8aa081-f177-46d4-b99a-6533744e6656">177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMjQtMS0xLTEtMA_c131446c-ae3d-4997-bb27-f0542d0ef2a5">96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMjQtMy0xLTEtMA_5438e90d-6680-40ff-9f5b-c356712e2ebf">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMjUtMS0xLTEtMA_62f2bc23-a42e-4ebc-826e-c3bfa5a1d00c">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMjUtMy0xLTEtMA_74976d62-0c9b-43e6-bf53-b8ac33c6bee5">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMjYtMS0xLTEtMA_98aa9501-0b1f-45d4-b860-f2e50432bd5d">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMjYtMy0xLTEtMA_f3056482-43e1-4ea3-81f6-f1239e6cff3c">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMjctMS0xLTEtMA_678322a2-f36f-40e0-9581-63b49a424392">8,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMjctMy0xLTEtMA_329a7516-433e-4b1a-a927-2d8e4bc6504b">4,776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMjgtMS0xLTEtMA_41e48fe0-8fbc-4f09-b0e1-aa203c821501"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMjgtMy0xLTEtMA_63e7329a-8314-453e-b81e-937165eb172c"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjUzMDhjODk5NDNmYzQ2OGRiYTczYmIzMjE4OWEwODYzXzMx_75ab6fcb-d15d-4962-822a-ca78b60cb91a"><ix:nonFraction unitRef="usdPerShare" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjUzMDhjODk5NDNmYzQ2OGRiYTczYmIzMjE4OWEwODYzXzMx_c8f1bdce-7d85-4570-9e23-dff2853cbe7a">0.0001</ix:nonFraction></ix:nonFraction>; <ix:nonFraction unitRef="shares" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjUzMDhjODk5NDNmYzQ2OGRiYTczYmIzMjE4OWEwODYzXzM1_c2c4e14b-8239-4e03-8617-4f0669c6ac99"><ix:nonFraction unitRef="shares" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjUzMDhjODk5NDNmYzQ2OGRiYTczYmIzMjE4OWEwODYzXzM1_dd1a5844-0212-4338-96cd-7d8333f8f4ff">162</ix:nonFraction></ix:nonFraction>&#160;shares authorized as of March 31, 2021</span></div><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;and December 31, 2020; <ix:nonFraction unitRef="shares" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjUzMDhjODk5NDNmYzQ2OGRiYTczYmIzMjE4OWEwODYzXzk2_161e8ef7-166b-4b50-b296-6b3d8e8335ea"><ix:nonFraction unitRef="shares" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjUzMDhjODk5NDNmYzQ2OGRiYTczYmIzMjE4OWEwODYzXzk2_9dba75d8-567b-4814-8950-391d1cd4de70"><ix:nonFraction unitRef="shares" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjUzMDhjODk5NDNmYzQ2OGRiYTczYmIzMjE4OWEwODYzXzk2_b3b4fb03-2699-4eef-8a86-5cecb9b04001"><ix:nonFraction unitRef="shares" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjUzMDhjODk5NDNmYzQ2OGRiYTczYmIzMjE4OWEwODYzXzk2_c262cf78-4772-469f-8f00-832b6f789b6f">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding at March 31, 2021 and </span></div><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;December 31, 2020</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzAtMS0xLTEtMA_b9bfe478-a0c9-468a-bcf6-48af51ee25b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzAtMy0xLTEtMA_db1d7f86-d393-4c0e-ab0e-2e824f5ac487">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjFjMzA3ZWY1NDljODQyYjg4MjlkZTA2YWZiNTcwNDdmXzMyOTg1MzQ4ODM3Mzk_67a3c273-123e-4076-b7f7-192139235e1d"><ix:nonFraction unitRef="usdPerShare" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjFjMzA3ZWY1NDljODQyYjg4MjlkZTA2YWZiNTcwNDdmXzMyOTg1MzQ4ODM3Mzk_a39e22f5-83ab-40b2-8790-8543c24517a1">0.0001</ix:nonFraction></ix:nonFraction>; <ix:nonFraction unitRef="shares" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjFjMzA3ZWY1NDljODQyYjg4MjlkZTA2YWZiNTcwNDdmXzMyOTg1MzQ4ODM3NDc_26fab3f9-d77c-42b2-9196-769a7f2a7ece"><ix:nonFraction unitRef="shares" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjFjMzA3ZWY1NDljODQyYjg4MjlkZTA2YWZiNTcwNDdmXzMyOTg1MzQ4ODM3NDc_e75a45b6-9772-40e8-82eb-679b6f344102">1,600</ix:nonFraction></ix:nonFraction> shares authorized as of March 31, 2021 and December 31, 2020; <ix:nonFraction unitRef="shares" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjFjMzA3ZWY1NDljODQyYjg4MjlkZTA2YWZiNTcwNDdmXzMyOTg1MzQ4ODM3NTQ_982a6c86-919c-450e-ab7c-01442c573836"><ix:nonFraction unitRef="shares" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjFjMzA3ZWY1NDljODQyYjg4MjlkZTA2YWZiNTcwNDdmXzMyOTg1MzQ4ODM3NTQ_c3c1b4d2-d533-4b92-acf8-c0fa0962c46d">401</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjFjMzA3ZWY1NDljODQyYjg4MjlkZTA2YWZiNTcwNDdmXzMyOTg1MzQ4ODM3NjE_89293030-ac09-4346-afc1-3bfa19ec4c47"><ix:nonFraction unitRef="shares" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjFjMzA3ZWY1NDljODQyYjg4MjlkZTA2YWZiNTcwNDdmXzMyOTg1MzQ4ODM3NjE_d6c7e99c-ff05-44fc-8cdf-64bff4f71c2a">399</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March 31, 2021 and December 31, 2019, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzEtMS0xLTEtMA_7d74afe2-1bc5-499b-a45c-6905fc06dad5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzEtMy0xLTEtMA_c23e66b1-a91d-43c3-93b1-e5cf90dff21c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzItMS0xLTEtMA_f84d6e31-ea54-4725-abd2-b7c281896864">4,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzItMy0xLTEtMA_18520d6a-0e33-4d69-b2f7-961b4a1885bd">4,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzMtMS0xLTEtMA_e6b6eefa-d7b6-4afb-88ea-e23d8a6afdc5">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzMtMy0xLTEtMA_70b41982-df68-44a5-8a97-9200ecdbf8c2">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzQtMS0xLTEtMA_7ad898cf-83a5-45e1-9909-2aedfcefac01">1,023</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzQtMy0xLTEtMA_b483ff2b-1ecb-4aad-b0b9-cbc328e022e8">2,244</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzUtMS0xLTEtMA_cea39762-dbf7-49d0-a4d5-368215fdb248">3,838</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzUtMy0xLTEtMA_e0446953-e167-4940-b8ec-c3094ede3b4f">2,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzYtMS0xLTEtMA_1fe8cc78-892d-4a59-af27-81eea89bd829">12,694</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzYtMy0xLTEtMA_2983ee47-b166-414d-9c4e-9d1e72e9755a">7,337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="ibba7ad915d1a4c4a8ebb50d13fae4c4e_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MODERNA, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited, in millions, except per share data)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.407%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.654%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.295%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90cf26aad24349bfa441914ac3d706fb_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfMy02LTEtMS0w_4c30e0f4-9cfb-474b-a07f-a5a122962b22">1,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e5ea10505f740f69843ae942d0421b8_D20200101-20200331" decimals="-6" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfMy04LTEtMS0w_32114ee4-813f-4553-986b-deadddf4debf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12127d667a294d78b6d78f889c39cd18_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfNC02LTEtMS0xMTA_6f6182ee-ef34-4620-b1cb-f9b8799442ab">194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i928ab86735d84580ac232ade8c6033ea_D20200101-20200331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfNC04LTEtMS0xMjI4_2557df13-1d55-428f-a5a0-94b9a5fe4989">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f5b8cccc84489b9789274a5e0b0890_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfNC02LTEtMS0w_75cb93b3-7b4c-4dce-8b64-8cbad1485815">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie93f0b234bf24c27b09e35245f5e26b6_D20200101-20200331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfNC04LTEtMS0w_339a7a51-7680-4332-808b-be165c6453bb">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfNS02LTEtMS0w_a5a29843-6ecf-4cc8-945a-96f33bebea28">1,937</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfNS04LTEtMS0w_20a734ca-84a1-4ec6-b783-67d90eccc3a7">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfOC02LTEtMS0xMTM_b219f8a6-fad1-40c0-b331-e2f9112b6ba0">193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" format="ixt:zerodash" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfOC04LTEtMS0xMjMz_752e1a9a-3dee-43f6-b61e-58cea3fe6852">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfNy02LTEtMS0w_1b186da7-28b7-4fc0-bb92-6fb6bfdaa8b1">401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfNy04LTEtMS0w_911316f8-108a-4155-90fd-dcfb22c08584">115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfOC02LTEtMS0w_e5a4b7b0-06f9-4f71-b139-4e5ecbb4e2bb">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfOC04LTEtMS0w_25ed1a69-de5d-42b0-94af-b09e2028178f">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfOS02LTEtMS0w_6745ba07-dbaf-4840-997c-9a82a933d686">671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfOS04LTEtMS0w_a3bd937c-3e09-46c1-aefb-14fd35ddfdbd">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfMTAtNi0xLTEtMA_7335bd98-19e0-4285-a35e-c82a878e2b78">1,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfMTAtOC0xLTEtMA_54637d94-9cd3-498f-998b-9d96128cf307">131</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfMTEtNi0xLTEtMA_a3773d60-aeaf-474b-b33a-7ed71f70c54d">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfMTEtOC0xLTEtMA_b38e44bf-8572-4c85-a1b0-426b943b4972">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfMTItNi0xLTEtMA_b3164f39-9f82-4f8d-9dbd-5fbb8f60d35a">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfMTItOC0xLTEtMA_696c35f3-5c4b-4fc0-a16a-8e09191d980f">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfMTMtNi0xLTEtMA_e7641a86-6dfb-4546-92a4-5283b85b3837">1,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfMTMtOC0xLTEtMA_9868d65e-d007-43a8-a917-6e8117ffdef3">124</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfMTQtNi0xLTEtMA_17499976-14fe-4325-995a-0fc71ff43227">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfMTQtOC0xLTEtMA_9ed8c0b8-0983-4bc2-b09c-71ad5d4369c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfMTUtNi0xLTEtMA_f08c6030-f13e-48c8-84c8-e0aa7a71de84">1,221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfMTUtOC0xLTEtMA_5295e7f3-293a-44b5-80fd-e683d800b303">124</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfMjAtNi0xLTEtMzE0Mw_08e2fb9c-ef0d-4811-90ab-aa801bfdbc1e">3.05</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfMjAtOC0xLTEtMzE0Mw_9870cb74-c4f2-4731-aa70-0269f0579e26">0.35</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfMjEtNi0xLTEtMzU3OA_b04a7214-8e62-4a7e-8768-da6a2aa08391">2.84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfMjEtOC0xLTEtMzU4MA_b830a7b6-7d3f-41ab-9d08-5f566cbc4bd0">0.35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares used in calculation of earnings (loss) per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfMTctNi0xLTEtMA_6dd4853d-d23d-456e-9910-d8f163198c4c">400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfMTctOC0xLTEtMA_53cd964d-4a01-4b16-a7b7-6543d553e318">353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfMjYtNi0xLTEtMzc1OQ_3ad5032e-200a-4511-b4bb-de4a6baa1d4a">430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfMjYtOC0xLTEtMzc1OQ_3dac5de5-c804-4c7a-8330-e6bfd445631c">353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="ibba7ad915d1a4c4a8ebb50d13fae4c4e_22"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MODERNA, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited, in millions)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.705%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.288%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.432%"></td><td style="width:0.1%"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.050%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.984%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yMi9mcmFnOjFhZmE2YTZiZGY1NDRjYjFiZTFjYzk4MWQxNGUyZDIzL3RhYmxlOjA3MzI3M2I3MGZmODQ0ZjQ4MDQ4OTVlNTcxOGE3MDNlL3RhYmxlcmFuZ2U6MDczMjczYjcwZmY4NDRmNDgwNDg5NWU1NzE4YTcwM2VfMi01LTEtMS0w_663b4994-cd64-4579-93db-80b1f4e77168">1,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yMi9mcmFnOjFhZmE2YTZiZGY1NDRjYjFiZTFjYzk4MWQxNGUyZDIzL3RhYmxlOjA3MzI3M2I3MGZmODQ0ZjQ4MDQ4OTVlNTcxOGE3MDNlL3RhYmxlcmFuZ2U6MDczMjczYjcwZmY4NDRmNDgwNDg5NWU1NzE4YTcwM2VfMi03LTEtMS0w_a1dd70f0-acde-4874-b0e3-83bd024ab4ed">124</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on available-for-sale debt securities, net of tax of $<ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yMi9mcmFnOjFhZmE2YTZiZGY1NDRjYjFiZTFjYzk4MWQxNGUyZDIzL3RhYmxlOjA3MzI3M2I3MGZmODQ0ZjQ4MDQ4OTVlNTcxOGE3MDNlL3RhYmxlcmFuZ2U6MDczMjczYjcwZmY4NDRmNDgwNDg5NWU1NzE4YTcwM2VfNC0wLTEtMS0wL3RleHRyZWdpb246ZmJkOWRhZTY3NWFkNDNhZGI3NGYyMTJiOTlkOWMzOWJfODA_cb718e1a-d406-4d67-bd25-9925fcd7b9c2">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yMi9mcmFnOjFhZmE2YTZiZGY1NDRjYjFiZTFjYzk4MWQxNGUyZDIzL3RhYmxlOjA3MzI3M2I3MGZmODQ0ZjQ4MDQ4OTVlNTcxOGE3MDNlL3RhYmxlcmFuZ2U6MDczMjczYjcwZmY4NDRmNDgwNDg5NWU1NzE4YTcwM2VfNC0wLTEtMS0wL3RleHRyZWdpb246ZmJkOWRhZTY3NWFkNDNhZGI3NGYyMTJiOTlkOWMzOWJfODc_a2959c10-622d-4862-8b51-3a8bf86d2396">0</ix:nonFraction>, for the three months ended March 31, 2021 and 2020, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yMi9mcmFnOjFhZmE2YTZiZGY1NDRjYjFiZTFjYzk4MWQxNGUyZDIzL3RhYmxlOjA3MzI3M2I3MGZmODQ0ZjQ4MDQ4OTVlNTcxOGE3MDNlL3RhYmxlcmFuZ2U6MDczMjczYjcwZmY4NDRmNDgwNDg5NWU1NzE4YTcwM2VfNC01LTEtMS0w_32a272cf-67c5-4e14-bde9-e88504fdc092">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yMi9mcmFnOjFhZmE2YTZiZGY1NDRjYjFiZTFjYzk4MWQxNGUyZDIzL3RhYmxlOjA3MzI3M2I3MGZmODQ0ZjQ4MDQ4OTVlNTcxOGE3MDNlL3RhYmxlcmFuZ2U6MDczMjczYjcwZmY4NDRmNDgwNDg5NWU1NzE4YTcwM2VfNC03LTEtMS0w_e31d9da1-4580-4e6d-9193-a987e595a687">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yMi9mcmFnOjFhZmE2YTZiZGY1NDRjYjFiZTFjYzk4MWQxNGUyZDIzL3RhYmxlOjA3MzI3M2I3MGZmODQ0ZjQ4MDQ4OTVlNTcxOGE3MDNlL3RhYmxlcmFuZ2U6MDczMjczYjcwZmY4NDRmNDgwNDg5NWU1NzE4YTcwM2VfNy01LTEtMS0w_d2aa68f0-71c2-422f-87e2-d55d182679f2">1,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yMi9mcmFnOjFhZmE2YTZiZGY1NDRjYjFiZTFjYzk4MWQxNGUyZDIzL3RhYmxlOjA3MzI3M2I3MGZmODQ0ZjQ4MDQ4OTVlNTcxOGE3MDNlL3RhYmxlcmFuZ2U6MDczMjczYjcwZmY4NDRmNDgwNDg5NWU1NzE4YTcwM2VfNy03LTEtMS0w_900823b3-ac57-40e7-912a-5242eeaa6d03">132</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="ibba7ad915d1a4c4a8ebb50d13fae4c4e_25"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MODERNA, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE THREE MONTHS ENDED MARCH 31, 2021 AND 2020</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited, in millions)</span></div><div style="margin-bottom:3pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.670%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.345%"></td><td style="width:0.1%"></td></tr><tr style="height:30pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Stockholders&#8217; Equity</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i85c3685b8bc74888a7957153cba507be_I20201231" decimals="-6" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOjUzNDY0MGZmYzI1ODRlMWVhOGYxZmYzYjk5NDdjYTNiL3RhYmxlcmFuZ2U6NTM0NjQwZmZjMjU4NGUxZWE4ZjFmZjNiOTk0N2NhM2JfMi0xLTEtMS0w_ac5156aa-a827-4e39-9aae-e98f72d394c9">399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85c3685b8bc74888a7957153cba507be_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOjUzNDY0MGZmYzI1ODRlMWVhOGYxZmYzYjk5NDdjYTNiL3RhYmxlcmFuZ2U6NTM0NjQwZmZjMjU4NGUxZWE4ZjFmZjNiOTk0N2NhM2JfMi0zLTEtMS0w_7581390f-bce4-4c3f-91d9-293f921d4077">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaec3621e0754f54a55937521667819b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOjUzNDY0MGZmYzI1ODRlMWVhOGYxZmYzYjk5NDdjYTNiL3RhYmxlcmFuZ2U6NTM0NjQwZmZjMjU4NGUxZWE4ZjFmZjNiOTk0N2NhM2JfMi01LTEtMS0w_8e817825-d468-489f-ac0b-c02149f43d3e">4,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie42efe57bc7743f78f5470ae0d8b47c0_I20201231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOjUzNDY0MGZmYzI1ODRlMWVhOGYxZmYzYjk5NDdjYTNiL3RhYmxlcmFuZ2U6NTM0NjQwZmZjMjU4NGUxZWE4ZjFmZjNiOTk0N2NhM2JfMi03LTEtMS0w_eaf063b4-ab15-43ee-832d-9c4c4d648c8b">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ee23f27c5a7409999bc27bf484c3683_I20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOjUzNDY0MGZmYzI1ODRlMWVhOGYxZmYzYjk5NDdjYTNiL3RhYmxlcmFuZ2U6NTM0NjQwZmZjMjU4NGUxZWE4ZjFmZjNiOTk0N2NhM2JfMi05LTEtMS0w_6391b58e-48b2-4f75-9543-70a8955dad1b">2,244</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOjUzNDY0MGZmYzI1ODRlMWVhOGYxZmYzYjk5NDdjYTNiL3RhYmxlcmFuZ2U6NTM0NjQwZmZjMjU4NGUxZWE4ZjFmZjNiOTk0N2NhM2JfMi0xMS0xLTEtMA_df8e07bf-a4d3-432b-b04e-fe549eb74f76">2,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of options to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8bd66b8c2d444db3ab9e16db494ca9ec_D20210101-20210331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOjUzNDY0MGZmYzI1ODRlMWVhOGYxZmYzYjk5NDdjYTNiL3RhYmxlcmFuZ2U6NTM0NjQwZmZjMjU4NGUxZWE4ZjFmZjNiOTk0N2NhM2JfNS0xLTEtMS0w_c476e5ff-2e0a-4186-a425-00352cd4d253">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6763fa662d34fe987498086ccaefa42_D20210101-20210331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOjUzNDY0MGZmYzI1ODRlMWVhOGYxZmYzYjk5NDdjYTNiL3RhYmxlcmFuZ2U6NTM0NjQwZmZjMjU4NGUxZWE4ZjFmZjNiOTk0N2NhM2JfNS01LTEtMS0w_0703686a-ad95-48c7-a1ef-c1d587ddb8cd">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOjUzNDY0MGZmYzI1ODRlMWVhOGYxZmYzYjk5NDdjYTNiL3RhYmxlcmFuZ2U6NTM0NjQwZmZjMjU4NGUxZWE4ZjFmZjNiOTk0N2NhM2JfNS0xMS0xLTEtMA_598c6e54-2963-409e-8790-78baefcd36d0">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6763fa662d34fe987498086ccaefa42_D20210101-20210331" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOjUzNDY0MGZmYzI1ODRlMWVhOGYxZmYzYjk5NDdjYTNiL3RhYmxlcmFuZ2U6NTM0NjQwZmZjMjU4NGUxZWE4ZjFmZjNiOTk0N2NhM2JfNy01LTEtMS0w_edbfdebe-c59d-4ca7-b13e-fe93df08b212">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOjUzNDY0MGZmYzI1ODRlMWVhOGYxZmYzYjk5NDdjYTNiL3RhYmxlcmFuZ2U6NTM0NjQwZmZjMjU4NGUxZWE4ZjFmZjNiOTk0N2NhM2JfNy0xMS0xLTEtMA_1e54ceea-5faf-46cb-b94f-e4d7f36baf97">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51a24806337f4c398006c8c24a6291f9_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOjUzNDY0MGZmYzI1ODRlMWVhOGYxZmYzYjk5NDdjYTNiL3RhYmxlcmFuZ2U6NTM0NjQwZmZjMjU4NGUxZWE4ZjFmZjNiOTk0N2NhM2JfOC03LTEtMS0w_a00cc3e0-c834-4071-96d4-782e9f3e003a">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOjUzNDY0MGZmYzI1ODRlMWVhOGYxZmYzYjk5NDdjYTNiL3RhYmxlcmFuZ2U6NTM0NjQwZmZjMjU4NGUxZWE4ZjFmZjNiOTk0N2NhM2JfOC0xMS0xLTEtMA_27723ac4-b573-44b1-be5c-1c72b7ac774a">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00257f1c106c4f12b6139f8b838a1faf_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOjUzNDY0MGZmYzI1ODRlMWVhOGYxZmYzYjk5NDdjYTNiL3RhYmxlcmFuZ2U6NTM0NjQwZmZjMjU4NGUxZWE4ZjFmZjNiOTk0N2NhM2JfOS05LTEtMS0w_19c8f468-6b43-4592-bc13-02e9c2f6cd49">1,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOjUzNDY0MGZmYzI1ODRlMWVhOGYxZmYzYjk5NDdjYTNiL3RhYmxlcmFuZ2U6NTM0NjQwZmZjMjU4NGUxZWE4ZjFmZjNiOTk0N2NhM2JfOS0xMS0xLTEtMA_cf95e29f-4422-47fa-a983-5b88272fb93c">1,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie2898610162d44ebb1d6412f7f754f57_I20210331" decimals="-6" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOjUzNDY0MGZmYzI1ODRlMWVhOGYxZmYzYjk5NDdjYTNiL3RhYmxlcmFuZ2U6NTM0NjQwZmZjMjU4NGUxZWE4ZjFmZjNiOTk0N2NhM2JfMTAtMS0xLTEtMA_4d70c211-e446-4881-b1d1-395db739094b">401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2898610162d44ebb1d6412f7f754f57_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOjUzNDY0MGZmYzI1ODRlMWVhOGYxZmYzYjk5NDdjYTNiL3RhYmxlcmFuZ2U6NTM0NjQwZmZjMjU4NGUxZWE4ZjFmZjNiOTk0N2NhM2JfMTAtMy0xLTEtMA_21bd9a82-c881-4c53-a652-fe3b9df22b05">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if224da12bc8646a2934e52e6b2b0929d_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOjUzNDY0MGZmYzI1ODRlMWVhOGYxZmYzYjk5NDdjYTNiL3RhYmxlcmFuZ2U6NTM0NjQwZmZjMjU4NGUxZWE4ZjFmZjNiOTk0N2NhM2JfMTAtNS0xLTEtMA_d7b26725-ce9b-4d7a-a93f-f38eb822a6ed">4,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3081299caa6b4213987da62a7e0e3b67_I20210331" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOjUzNDY0MGZmYzI1ODRlMWVhOGYxZmYzYjk5NDdjYTNiL3RhYmxlcmFuZ2U6NTM0NjQwZmZjMjU4NGUxZWE4ZjFmZjNiOTk0N2NhM2JfMTAtNy0xLTEtMA_6ae46a88-e9a7-4a2e-9b93-5ddb9e72dd18">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ea0cb20ecbd485a9682c793a5f13edd_I20210331" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOjUzNDY0MGZmYzI1ODRlMWVhOGYxZmYzYjk5NDdjYTNiL3RhYmxlcmFuZ2U6NTM0NjQwZmZjMjU4NGUxZWE4ZjFmZjNiOTk0N2NhM2JfMTAtOS0xLTEtMA_3238a5c1-b5ff-4915-b97d-5727ef6dd1a8">1,023</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOjUzNDY0MGZmYzI1ODRlMWVhOGYxZmYzYjk5NDdjYTNiL3RhYmxlcmFuZ2U6NTM0NjQwZmZjMjU4NGUxZWE4ZjFmZjNiOTk0N2NhM2JfMTAtMTEtMS0xLTA_34e5497b-bec8-480e-88e8-656e587772ce">3,838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.670%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.345%"></td><td style="width:0.1%"></td></tr><tr style="height:30pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Stockholders&#8217; Equity</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7682e40394cc4e7db96f8cc4de55e962_I20191231" decimals="-6" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOmMwMzkyNWVkZWFhOTRhM2RiYzMzNmExMTA4OWQ3YzExL3RhYmxlcmFuZ2U6YzAzOTI1ZWRlYWE5NGEzZGJjMzM2YTExMDg5ZDdjMTFfMy0xLTEtMS0w_bdaa62aa-bd7e-4745-ad40-706aaaa6ac33">337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7682e40394cc4e7db96f8cc4de55e962_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOmMwMzkyNWVkZWFhOTRhM2RiYzMzNmExMTA4OWQ3YzExL3RhYmxlcmFuZ2U6YzAzOTI1ZWRlYWE5NGEzZGJjMzM2YTExMDg5ZDdjMTFfMy0zLTEtMS0w_a31c04a3-f052-4e5b-9670-0fffea99469a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7811f82e8ed4667a6efb6a88cb1dc80_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOmMwMzkyNWVkZWFhOTRhM2RiYzMzNmExMTA4OWQ3YzExL3RhYmxlcmFuZ2U6YzAzOTI1ZWRlYWE5NGEzZGJjMzM2YTExMDg5ZDdjMTFfMy01LTEtMS0w_b536adfa-53c2-44d7-8e48-454ebf466514">2,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ed66b7fc0fb48c9bb3d57e8be191929_I20191231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOmMwMzkyNWVkZWFhOTRhM2RiYzMzNmExMTA4OWQ3YzExL3RhYmxlcmFuZ2U6YzAzOTI1ZWRlYWE5NGEzZGJjMzM2YTExMDg5ZDdjMTFfMy03LTEtMS0w_42d12f50-d8cf-4b97-a152-a8bbcc88d808">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd4ae3b11c564cb6b97eb730e3ff7bb1_I20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOmMwMzkyNWVkZWFhOTRhM2RiYzMzNmExMTA4OWQ3YzExL3RhYmxlcmFuZ2U6YzAzOTI1ZWRlYWE5NGEzZGJjMzM2YTExMDg5ZDdjMTFfMy05LTEtMS0w_f7fe3b10-954d-4cd3-9975-32e634837b6c">1,497</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1138d8f10d6c45fdb458206ef7e763ce_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOmMwMzkyNWVkZWFhOTRhM2RiYzMzNmExMTA4OWQ3YzExL3RhYmxlcmFuZ2U6YzAzOTI1ZWRlYWE5NGEzZGJjMzM2YTExMDg5ZDdjMTFfMy0xMS0xLTEtMA_471b157a-7b5d-4337-bd07-1987803778ba">1,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from public offering of common stock, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOmMwMzkyNWVkZWFhOTRhM2RiYzMzNmExMTA4OWQ3YzExL3RhYmxlcmFuZ2U6YzAzOTI1ZWRlYWE5NGEzZGJjMzM2YTExMDg5ZDdjMTFfNC0wLTEtMS0zMjYwL3RleHRyZWdpb246ZmViYWEzMWEwNjQxNGNkNThhZWU0MTVlMTUwN2M4YmNfMzI5ODUzNDg4MzQwOA_792610fe-1875-4722-84a0-b67d3bd911bb">1</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibd57a755b6d2496f92d2b0ce1c6d8369_D20200101-20200331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOmMwMzkyNWVkZWFhOTRhM2RiYzMzNmExMTA4OWQ3YzExL3RhYmxlcmFuZ2U6YzAzOTI1ZWRlYWE5NGEzZGJjMzM2YTExMDg5ZDdjMTFfNC0xLTEtMS0xOTg_8dbace3d-6c63-4f73-924b-80fc223e720b">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16c2d8a9bebe4163981c7803f6359e72_D20200101-20200331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOmMwMzkyNWVkZWFhOTRhM2RiYzMzNmExMTA4OWQ3YzExL3RhYmxlcmFuZ2U6YzAzOTI1ZWRlYWE5NGEzZGJjMzM2YTExMDg5ZDdjMTFfNC01LTEtMS0xOTg_bf06107e-0638-4098-a542-4249a05b472d">550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOmMwMzkyNWVkZWFhOTRhM2RiYzMzNmExMTA4OWQ3YzExL3RhYmxlcmFuZ2U6YzAzOTI1ZWRlYWE5NGEzZGJjMzM2YTExMDg5ZDdjMTFfNC0xMS0xLTEtMTk4_c6a48488-d5a4-4ed6-8726-1c2b2b9541d2">550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibd57a755b6d2496f92d2b0ce1c6d8369_D20200101-20200331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOmMwMzkyNWVkZWFhOTRhM2RiYzMzNmExMTA4OWQ3YzExL3RhYmxlcmFuZ2U6YzAzOTI1ZWRlYWE5NGEzZGJjMzM2YTExMDg5ZDdjMTFfNS0xLTEtMS0w_edaa1990-f20a-4e80-8f30-a70d85e33535">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16c2d8a9bebe4163981c7803f6359e72_D20200101-20200331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOmMwMzkyNWVkZWFhOTRhM2RiYzMzNmExMTA4OWQ3YzExL3RhYmxlcmFuZ2U6YzAzOTI1ZWRlYWE5NGEzZGJjMzM2YTExMDg5ZDdjMTFfNS01LTEtMS0w_4c48cdf7-600b-45d4-b5f1-666e652b2994">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOmMwMzkyNWVkZWFhOTRhM2RiYzMzNmExMTA4OWQ3YzExL3RhYmxlcmFuZ2U6YzAzOTI1ZWRlYWE5NGEzZGJjMzM2YTExMDg5ZDdjMTFfNS0xMS0xLTEtMA_8171c706-ae09-4274-a5b5-fee892f16180">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16c2d8a9bebe4163981c7803f6359e72_D20200101-20200331" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOmMwMzkyNWVkZWFhOTRhM2RiYzMzNmExMTA4OWQ3YzExL3RhYmxlcmFuZ2U6YzAzOTI1ZWRlYWE5NGEzZGJjMzM2YTExMDg5ZDdjMTFfOC01LTEtMS0w_379f74fa-5a36-4ba6-945f-454d1a1702ef">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOmMwMzkyNWVkZWFhOTRhM2RiYzMzNmExMTA4OWQ3YzExL3RhYmxlcmFuZ2U6YzAzOTI1ZWRlYWE5NGEzZGJjMzM2YTExMDg5ZDdjMTFfOC0xMS0xLTEtMA_bcab9082-437f-4657-ab45-da450bc4c2b1">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d0241871b0840c2a85a3c6334108769_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOmMwMzkyNWVkZWFhOTRhM2RiYzMzNmExMTA4OWQ3YzExL3RhYmxlcmFuZ2U6YzAzOTI1ZWRlYWE5NGEzZGJjMzM2YTExMDg5ZDdjMTFfOS03LTEtMS0w_1ef21e62-37fe-4ef1-bb71-3902ebc8f5c1">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOmMwMzkyNWVkZWFhOTRhM2RiYzMzNmExMTA4OWQ3YzExL3RhYmxlcmFuZ2U6YzAzOTI1ZWRlYWE5NGEzZGJjMzM2YTExMDg5ZDdjMTFfOS0xMS0xLTEtMA_71b40fde-4b99-4131-a115-423aae29a853">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i353dc2cd5f49451798ef780c6af7ed46_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOmMwMzkyNWVkZWFhOTRhM2RiYzMzNmExMTA4OWQ3YzExL3RhYmxlcmFuZ2U6YzAzOTI1ZWRlYWE5NGEzZGJjMzM2YTExMDg5ZDdjMTFfMTAtOS0xLTEtMA_064fa6df-dd54-49f0-970d-26075030ef97">124</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOmMwMzkyNWVkZWFhOTRhM2RiYzMzNmExMTA4OWQ3YzExL3RhYmxlcmFuZ2U6YzAzOTI1ZWRlYWE5NGEzZGJjMzM2YTExMDg5ZDdjMTFfMTAtMTEtMS0xLTA_0a0fe1d0-e8b7-4037-a94b-630d82df380f">124</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i99ce1af211874ddda368b64fc0527881_I20200331" decimals="-6" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOmMwMzkyNWVkZWFhOTRhM2RiYzMzNmExMTA4OWQ3YzExL3RhYmxlcmFuZ2U6YzAzOTI1ZWRlYWE5NGEzZGJjMzM2YTExMDg5ZDdjMTFfMTEtMS0xLTEtMA_3ea75aa6-e271-4dd9-8e17-a6cf7ba0fd68">370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99ce1af211874ddda368b64fc0527881_I20200331" decimals="-6" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOmMwMzkyNWVkZWFhOTRhM2RiYzMzNmExMTA4OWQ3YzExL3RhYmxlcmFuZ2U6YzAzOTI1ZWRlYWE5NGEzZGJjMzM2YTExMDg5ZDdjMTFfMTEtMy0xLTEtMA_32e99912-9f7c-469c-881f-61fc37b44728">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i199f99634c0c487e82b051148cdc8024_I20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOmMwMzkyNWVkZWFhOTRhM2RiYzMzNmExMTA4OWQ3YzExL3RhYmxlcmFuZ2U6YzAzOTI1ZWRlYWE5NGEzZGJjMzM2YTExMDg5ZDdjMTFfMTEtNS0xLTEtMA_0ad795c7-4bac-44f9-8612-0c88a5665473">3,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ac58abcca77466fa78e3ac37f63f737_I20200331" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOmMwMzkyNWVkZWFhOTRhM2RiYzMzNmExMTA4OWQ3YzExL3RhYmxlcmFuZ2U6YzAzOTI1ZWRlYWE5NGEzZGJjMzM2YTExMDg5ZDdjMTFfMTEtNy0xLTEtMA_e0983218-b2e1-4484-9ed6-545eeb34ec45">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11483b66bae440ceafe63983b7fbd5c9_I20200331" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOmMwMzkyNWVkZWFhOTRhM2RiYzMzNmExMTA4OWQ3YzExL3RhYmxlcmFuZ2U6YzAzOTI1ZWRlYWE5NGEzZGJjMzM2YTExMDg5ZDdjMTFfMTEtOS0xLTEtMA_5c5c5ae5-a12d-4edb-a6ce-8d806177e221">1,621</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5a33ce37614698a3418806ab20f9b2_I20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOmMwMzkyNWVkZWFhOTRhM2RiYzMzNmExMTA4OWQ3YzExL3RhYmxlcmFuZ2U6YzAzOTI1ZWRlYWE5NGEzZGJjMzM2YTExMDg5ZDdjMTFfMTEtMTEtMS0xLTA_cae5c14d-6f82-4620-b021-b639da86aef6">1,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="ibba7ad915d1a4c4a8ebb50d13fae4c4e_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MODERNA, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited, in millions)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.294%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating activities</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMy0xLTEtMS0w_2d0988dd-93f6-47a5-ac7d-e870825d97a0">1,221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMy0zLTEtMS0w_357ca31c-3e5b-470b-be37-ba7e658f01d8">124</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfNS0xLTEtMS0w_a54fa068-309e-493c-a9c6-29aa74a6c980">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfNS0zLTEtMS0w_e8c24296-03b3-4722-b042-10b6ed449d44">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfNi0xLTEtMS0w_10039ab8-4cc8-44e3-b146-1a02707cf687">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfNi0zLTEtMS0w_e5f67a70-2984-4dcf-82c0-cf33f94b9e96">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization/accretion of investments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfNy0xLTEtMS0w_66e03bf6-e4e5-4813-8dd1-0f9a91334a7e">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfNy0zLTEtMS0w_62c646df-e69a-4539-8f0d-57ff6ef93c17">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfOS0xLTEtMS03MTMy_9d4a4184-313b-4d04-b081-c1785f16cca4">50</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" format="ixt:zerodash" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfOS0zLTEtMS03MTMw_baa51989-f911-4446-9d75-ae3622f8dfe5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in assets and liabilities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMTAtMS0xLTEtMA_2f130197-df0d-4bc8-9b53-b68f5f9b1662">1,819</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMTAtMy0xLTEtMA_36db44a9-f5fa-4325-8533-beedd13b83ea">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMTEtMS0xLTEtMA_76db64f0-1977-4181-932f-50978da2c0e6">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMTEtMy0xLTEtMA_7ac3e44f-dce2-4e5a-92b0-463c0815ab08">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 46pt;text-align:left;text-indent:-27pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMTItMS0xLTEtNDIzMg_01eef229-8819-4d6f-81c2-decade2328b8">448</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMTItMy0xLTEtNDIzMg_ab7d880a-8c65-4ce5-9a78-ee63f9400655">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets, operating leases</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" sign="-" name="mrna:IncreaseDecreaseInRightOfUseAssetOperatingLeases" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMTItMS0xLTEtMA_f25b0241-4587-435f-961a-15cca8cc7299">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" name="mrna:IncreaseDecreaseInRightOfUseAssetOperatingLeases" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMTItMy0xLTEtMA_71dddfa6-460c-4897-b698-0e98796d086a">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMTMtMS0xLTEtMA_b8157871-9567-4dbb-aac2-50980ca26a20">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMTMtMy0xLTEtMA_da77bd09-65d0-4cf2-934f-c45d68bc78c8">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMTQtMS0xLTEtMA_59b43011-7481-4684-b468-b1e15eeb1328">285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMTQtMy0xLTEtMA_04b598e8-1135-44c1-9a24-96505e7b351d">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMTUtMS0xLTEtMA_37e6ca08-af8d-4d9c-b406-06332b26c7b7">3,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMTUtMy0xLTEtMA_dd1a85d4-a26e-48a8-b430-802af24e4982">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" sign="-" name="mrna:OperatingLeaseLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMTYtMS0xLTEtMA_d581674b-a883-40dc-a7c6-30323459080a">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" name="mrna:OperatingLeaseLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMTYtMy0xLTEtMA_65a46054-d6c4-4210-b3a2-b635c620ca83">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMTctMS0xLTEtMA_284311db-8437-423f-aff4-8ab8c7bd0c08">93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMTctMy0xLTEtMA_2d467df9-cc67-4c33-b361-0f08eb39834a">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMTktMS0xLTEtMA_63bf216e-19ab-4a05-a9d8-b425cc2ec80f">2,971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMTktMy0xLTEtMA_6084a54b-9c89-4261-b26c-b42a8c4fe8bd">106</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investing activities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMjEtMS0xLTEtMA_1f8cd955-2031-4ec3-82ae-50f025d667c9">726</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMjEtMy0xLTEtMA_74b2cdd2-4e7e-4587-922b-ecb238ff200b">621</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from maturities of marketable securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMjItMS0xLTEtMA_9007e8e1-d625-4805-9804-813022f5b5af">339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMjItMy0xLTEtMA_063c435d-afac-492f-8f55-bf21c3590cf1">269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sales of marketable securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMjMtMS0xLTEtMA_619f44c1-b26e-44f9-8d9a-1fb0ac77c943">242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMjMtMy0xLTEtMA_69661cf7-589f-4196-bbfc-2d1d9d19271d">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMjQtMS0xLTEtMA_be39dbe5-db34-4f42-b682-23940c0aa7ba">35</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMjQtMy0xLTEtMA_957ffd7b-91f1-4db0-a6c7-ccaca11026aa">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMjUtMS0xLTEtMA_0b933777-264e-4d49-a29b-a335f7c1d3c5">180</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMjUtMy0xLTEtMA_44b9d09b-fd0f-4036-a0ae-43805bdb652e">316</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financing activities</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from public offerings of common stock, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMjctMS0xLTEtMA_8e1cdf90-2d14-49e3-8398-b64a6b087387">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMjctMy0xLTEtMA_abb53e81-1d33-46ca-a3d7-42a3b40dc0c3">550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock through equity plans, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" name="us-gaap:ProceedsFromStockPlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMjgtMS0xLTEtMA_7f2fa9bb-1025-4da7-8186-5344362efaf8">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" name="us-gaap:ProceedsFromStockPlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMjgtMy0xLTEtMA_3729bbbd-ab5a-4866-93b9-f0e762f385e7">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in financing lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" sign="-" name="mrna:ChargesToFinancingLeaseLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMzAtMS0xLTEtMA_606a9b5b-7589-413a-a9d6-eac46b6513fa">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" format="ixt:zerodash" name="mrna:ChargesToFinancingLeaseLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMzAtMy0xLTEtMA_2855f653-ed9b-45c3-8c07-2ba6f54b4fef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMzEtMS0xLTEtMA_e2a31cbe-7117-41a2-8722-17d70e78edd4">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMzEtMy0xLTEtMA_583cc585-7ea9-4c63-93f1-d412ae7465f7">578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMzItMS0xLTEtMA_9cf97664-6322-4f86-836d-d127ae0359fe">2,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMzItMy0xLTEtMA_913d0030-d48b-4736-ac97-52cf2c5b6a7f">156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, beginning of year</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMzMtMS0xLTEtMA_0ca1cfa8-4f74-402c-b149-33d017966b78">2,636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1138d8f10d6c45fdb458206ef7e763ce_I20191231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMzMtMy0xLTEtMA_d1c743f0-e2c8-412e-8e40-b12c87079713">248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, end of period</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMzQtMS0xLTEtMA_9c47e00f-770b-49fd-9ad9-0fb65fef5225">5,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5a33ce37614698a3418806ab20f9b2_I20200331" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMzQtMy0xLTEtMA_5fd41ce8-c2ba-48b8-ac06-1acde7f48ca9">404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-cash investing and financing activities</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment included in accounts payable and accrued liabilities</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMzctMS0xLTEtMA_c37e1cc2-fb7c-4bdf-96f8-1fa2855417da">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMzctMy0xLTEtMA_de6e0591-ff0b-4149-972f-c4abb9dc18fc">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets obtained through finance lease modifications and reassessments</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMzctMS0xLTEtMzI4Ng_1442ee62-6be6-48d8-93d0-2a4edf770fb3">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMzctMy0xLTEtMzI4OQ_b88f3fad-7d87-4244-8ba0-6e764213d046">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="ibba7ad915d1a4c4a8ebb50d13fae4c4e_31"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Contents</a></span></div></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div id="ibba7ad915d1a4c4a8ebb50d13fae4c4e_34"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MODERNA, INC.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8zNC9mcmFnOjk5MzU0ODBlODIyZTQ4ODFiZjY4ZmEyZDc5NDQ5NDk1L3RleHRyZWdpb246OTkzNTQ4MGU4MjJlNDg4MWJmNjhmYTJkNzk0NDk0OTVfNDI5Mg_05118176-b067-42a6-b744-3f18a62f7767" continuedAt="ic27e3c3f0e6b42b7b1eb6a223d5c3d31" escape="true">Description of the Business</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ic27e3c3f0e6b42b7b1eb6a223d5c3d31"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moderna, Inc. (collectively, with its consolidated subsidiaries, any of Moderna, we, us, or the Company) was incorporated in Delaware on July&#160;22, 2016. We are the successor in interest to Moderna LLC, a limited liability company formed under the laws of the State of Delaware in 2013. Our principal executive office is located at 200 Technology Square, Cambridge,&#160;MA.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biotechnology company creating a new generation of transformative medicines based on messenger RNA (mRNA), to improve the lives of patients. mRNA medicines are designed to direct the body&#8217;s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a broad spectrum of diseases. Our platform builds on continuous advances in basic and applied mRNA science, delivery technology, and manufacturing, providing us the capability to pursue in parallel a robust pipeline of new development candidates.&#160;We are developing vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with our strategic collaborators.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 18, 2020, we received an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the emergency use of the Moderna COVID-19 Vaccine (also referred to as mRNA-1273) in individuals 18 years of age or older. We have also received authorization for our COVID-19 vaccine from health agencies in Canada, Israel, the European Union, the United Kingdom, Switzerland, Singapore, Qatar, Taiwan, and the Philippines, and from the World Health Organization. Additional authorizations are currently under review in other countries.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March 31, 2021, we had <ix:nonFraction unitRef="program" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="INF" name="mrna:NumberOfDevelopmentProgram" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8zNC9mcmFnOjk5MzU0ODBlODIyZTQ4ODFiZjY4ZmEyZDc5NDQ5NDk1L3RleHRyZWdpb246OTkzNTQ4MGU4MjJlNDg4MWJmNjhmYTJkNzk0NDk0OTVfNzY5NjU4MTQwNDIxMw_61def3de-4dbe-4b30-bdc9-b26bdb39d68c">24</ix:nonFraction> mRNA development programs in our portfolio with 13 having entered the clinic. We have incurred significant expenses in connection with the discovery, development and commercialization of our products, and we expect to continue to incur significant expenses for the foreseeable future. We anticipate that our expenses will increase significantly in connection with the ongoing development and commercialization of our COVID-19 vaccine and ongoing activities to support our platform research, drug discovery and clinical development, including development of any new generations of boosters and vaccines against variants of SARS-CoV-2, infrastructure and Research Engine and Early Development Engine (which includes our Moderna Technology Center), digital infrastructure, creation of a portfolio of intellectual property, and administrative support. We may finance our future cash needs that exceed our operating costs through a combination of public or private equity offerings, structured financings and debt financings, government funding arrangements, strategic alliances and marketing, manufacturing, distribution and licensing arrangements. We may be unable to raise additional funds or enter into such other agreements on favorable terms, or at all.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our cash, cash equivalents, and investments as of&#160;March 31, 2021&#160;will be sufficient to enable us to fund our projected operations through at least the next 12&#160;months from the issuance of our financial statements. We are subject to numerous risks and uncertainties associated with pharmaceutical development and commercialization, and we are unable to predict the timing or amount of expenses or if we will be able to maintain profitability. If we are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce our operations.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div id="ibba7ad915d1a4c4a8ebb50d13fae4c4e_40"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80MC9mcmFnOmI1MTgxNTQ5ZjBlNTRkNjFiZjg3MWFjYTMwZjkzMjA0L3RleHRyZWdpb246YjUxODE1NDlmMGU1NGQ2MWJmODcxYWNhMzBmOTMyMDRfNzE1OQ_f854e289-51c0-4fa2-bc4f-497fab0fad54" continuedAt="i9ff9b769a44c43d0a05b73b8874c8a4c" escape="true">Summary of Basis of Presentation and Recent Accounting Standards</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i9ff9b769a44c43d0a05b73b8874c8a4c" continuedAt="ia8bc8bd3733648da9ac9487bbbffc4a3"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80MC9mcmFnOmI1MTgxNTQ5ZjBlNTRkNjFiZjg3MWFjYTMwZjkzMjA0L3RleHRyZWdpb246YjUxODE1NDlmMGU1NGQ2MWJmODcxYWNhMzBmOTMyMDRfNzY5NjU4MTQxMTA5Mg_eff05612-4337-4c62-b664-545a1ef3ee59" escape="true">The accompanying unaudited condensed consolidated financial statements that accompany these notes have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) for interim financial reporting, consistent in all material respects with those applied in our Annual Report on Form 10-K for the year ended December 31, 2020 (2020 Form 10-K). Any reference in these notes to applicable guidance is meant to refer to the authoritative accounting principles generally accepted in the United States as found in the Accounting Standard Codification (ASC) and Accounting Standards Update (ASU) of the Financial Accounting Standards Board (FASB). This report should be read in conjunction with the consolidated financial statements in our 2020 Form 10-K.</ix:nonNumeric></span></div></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Contents</a></span></div></div><ix:continuation id="ia8bc8bd3733648da9ac9487bbbffc4a3"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80MC9mcmFnOmI1MTgxNTQ5ZjBlNTRkNjFiZjg3MWFjYTMwZjkzMjA0L3RleHRyZWdpb246YjUxODE1NDlmMGU1NGQ2MWJmODcxYWNhMzBmOTMyMDRfNzY5NjU4MTQxMTA5MQ_1dc20d5a-f9fb-487a-95be-d8a21c1201a0" escape="true">The consolidated financial statements include the Company and its subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant accounting policies used in preparation of these condensed consolidated financial statements for the three months ended March 31, 2021 are consistent with those described in our 2020 Form 10-K.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80MC9mcmFnOmI1MTgxNTQ5ZjBlNTRkNjFiZjg3MWFjYTMwZjkzMjA0L3RleHRyZWdpb246YjUxODE1NDlmMGU1NGQ2MWJmODcxYWNhMzBmOTMyMDRfNzY5NjU4MTQwODU2Mw_a965e483-43ee-4e76-99f0-477d9f2d47fa" escape="true">We have made estimates and judgments affecting the amounts reported in our condensed consolidated financial statements and the accompanying notes. We base our estimates on historical experience and various relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods that are not readily apparent from other sources. Significant estimates relied upon in preparing these financial statements include, but are not limited to, critical accounting policies or estimates related to revenue recognition, research and development expenses, income tax provisions, stock-based compensation, leases, fair value of financial instruments, derivative financial instruments, inventory, and useful lives of property and equipment, income taxes and our valuation allowance on our deferred tax assets. The actual results that we experience may differ materially from our estimates.</ix:nonNumeric> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comprehensive Income (Loss)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80MC9mcmFnOmI1MTgxNTQ5ZjBlNTRkNjFiZjg3MWFjYTMwZjkzMjA0L3RleHRyZWdpb246YjUxODE1NDlmMGU1NGQ2MWJmODcxYWNhMzBmOTMyMDRfNzE3OA_6d5046ab-ab0d-4721-8830-6fcb976898ec" escape="true">Comprehensive income (loss) includes net income (loss) and other comprehensive loss for the period. Other comprehensive loss consists of unrealized gains/losses and gains/losses on our investments. Total comprehensive income (loss) for all periods presented has been disclosed in the condensed consolidated statements of comprehensive income (loss).</ix:nonNumeric></span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80MC9mcmFnOmI1MTgxNTQ5ZjBlNTRkNjFiZjg3MWFjYTMwZjkzMjA0L3RleHRyZWdpb246YjUxODE1NDlmMGU1NGQ2MWJmODcxYWNhMzBmOTMyMDRfNzE3OQ_062e175b-93f2-40c6-8617-6531bc85c251" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of accumulated other comprehensive income for the three months ended March 31, 2021 are as follows (in millions):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Loss on Available-for-Sale Debt Securities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income, balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0bb072a6a064b47a2581435e9123a1f_I20201231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80MC9mcmFnOmI1MTgxNTQ5ZjBlNTRkNjFiZjg3MWFjYTMwZjkzMjA0L3RhYmxlOjU4MGI4YzNiZTVjODQ0NmJiMjUwZTM4N2FhMjU0M2I4L3RhYmxlcmFuZ2U6NTgwYjhjM2JlNWM4NDQ2YmIyNTBlMzg3YWEyNTQzYjhfMS0xLTEtMS0w_bf705d2a-616b-4987-9e98-25edea419244">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1779a3029e943e597b2535a551359a3_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80MC9mcmFnOmI1MTgxNTQ5ZjBlNTRkNjFiZjg3MWFjYTMwZjkzMjA0L3RhYmxlOjU4MGI4YzNiZTVjODQ0NmJiMjUwZTM4N2FhMjU0M2I4L3RhYmxlcmFuZ2U6NTgwYjhjM2JlNWM4NDQ2YmIyNTBlMzg3YWEyNTQzYjhfMi0xLTEtMS0w_00664ee2-4956-479e-a5f5-6106fbb02678">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income, balance at March 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c08b2af4044913baf379746ada2802_I20210331" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80MC9mcmFnOmI1MTgxNTQ5ZjBlNTRkNjFiZjg3MWFjYTMwZjkzMjA0L3RhYmxlOjU4MGI4YzNiZTVjODQ0NmJiMjUwZTM4N2FhMjU0M2I4L3RhYmxlcmFuZ2U6NTgwYjhjM2JlNWM4NDQ2YmIyNTBlMzg3YWEyNTQzYjhfMy0xLTEtMS0w_03d02204-07e9-4a79-beb2-0b5757a16445">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Cash </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80MC9mcmFnOmI1MTgxNTQ5ZjBlNTRkNjFiZjg3MWFjYTMwZjkzMjA0L3RleHRyZWdpb246YjUxODE1NDlmMGU1NGQ2MWJmODcxYWNhMzBmOTMyMDRfNzE2Nw_b1676ed8-41d6-4384-8921-0efc54c812c2" escape="true">We include our restricted cash balance in the cash, cash equivalents and restricted cash reconciliation of operating, investing and financing activities in the condensed consolidated statements of cash flows.</ix:nonNumeric>&#160;</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80MC9mcmFnOmI1MTgxNTQ5ZjBlNTRkNjFiZjg3MWFjYTMwZjkzMjA0L3RleHRyZWdpb246YjUxODE1NDlmMGU1NGQ2MWJmODcxYWNhMzBmOTMyMDRfNzE2Mg_f469556b-437a-4fc7-80b0-1b68cae8b81b" escape="true"><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80MC9mcmFnOmI1MTgxNTQ5ZjBlNTRkNjFiZjg3MWFjYTMwZjkzMjA0L3RleHRyZWdpb246YjUxODE1NDlmMGU1NGQ2MWJmODcxYWNhMzBmOTMyMDRfNzE3Nw_67e21b4b-9c86-4e24-b3d1-8ca52e335717" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows (in millions):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80MC9mcmFnOmI1MTgxNTQ5ZjBlNTRkNjFiZjg3MWFjYTMwZjkzMjA0L3RhYmxlOjc3NzNlZDJlYTRmNjQxY2U4YTJkN2RlNGMzZWM3OTZkL3RhYmxlcmFuZ2U6Nzc3M2VkMmVhNGY2NDFjZThhMmQ3ZGU0YzNlYzc5NmRfMi0yLTEtMS0w_20b290a1-0993-4eb4-b7d3-4aa23b5effc5">5,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5a33ce37614698a3418806ab20f9b2_I20200331" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80MC9mcmFnOmI1MTgxNTQ5ZjBlNTRkNjFiZjg3MWFjYTMwZjkzMjA0L3RhYmxlOjc3NzNlZDJlYTRmNjQxY2U4YTJkN2RlNGMzZWM3OTZkL3RhYmxlcmFuZ2U6Nzc3M2VkMmVhNGY2NDFjZThhMmQ3ZGU0YzNlYzc5NmRfMi00LTEtMS0w_1e336229-0fb6-4282-8d4d-19f081fb1af1">392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80MC9mcmFnOmI1MTgxNTQ5ZjBlNTRkNjFiZjg3MWFjYTMwZjkzMjA0L3RhYmxlOjc3NzNlZDJlYTRmNjQxY2U4YTJkN2RlNGMzZWM3OTZkL3RhYmxlcmFuZ2U6Nzc3M2VkMmVhNGY2NDFjZThhMmQ3ZGU0YzNlYzc5NmRfMy0yLTEtMS04MDk4_20770850-c25b-4c6b-b05d-a22d64d4bf52">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5a33ce37614698a3418806ab20f9b2_I20200331" decimals="-6" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80MC9mcmFnOmI1MTgxNTQ5ZjBlNTRkNjFiZjg3MWFjYTMwZjkzMjA0L3RhYmxlOjc3NzNlZDJlYTRmNjQxY2U4YTJkN2RlNGMzZWM3OTZkL3RhYmxlcmFuZ2U6Nzc3M2VkMmVhNGY2NDFjZThhMmQ3ZGU0YzNlYzc5NmRfMy00LTEtMS04MDk4_e2129ba2-fa90-4aa6-9a47-73c6a973cc34">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, non-current </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80MC9mcmFnOmI1MTgxNTQ5ZjBlNTRkNjFiZjg3MWFjYTMwZjkzMjA0L3RhYmxlOjc3NzNlZDJlYTRmNjQxY2U4YTJkN2RlNGMzZWM3OTZkL3RhYmxlcmFuZ2U6Nzc3M2VkMmVhNGY2NDFjZThhMmQ3ZGU0YzNlYzc5NmRfNC0yLTEtMS0w_20978be1-eab4-47e1-a561-78bf69ec49e2">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5a33ce37614698a3418806ab20f9b2_I20200331" decimals="-6" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80MC9mcmFnOmI1MTgxNTQ5ZjBlNTRkNjFiZjg3MWFjYTMwZjkzMjA0L3RhYmxlOjc3NzNlZDJlYTRmNjQxY2U4YTJkN2RlNGMzZWM3OTZkL3RhYmxlcmFuZ2U6Nzc3M2VkMmVhNGY2NDFjZThhMmQ3ZGU0YzNlYzc5NmRfNC00LTEtMS0w_9830adb4-cb84-42a0-ba8f-0b69cf46ac4b">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash shown in the condensed consolidated<br/>&#160;&#160;&#160;&#160;statements of cash flows</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80MC9mcmFnOmI1MTgxNTQ5ZjBlNTRkNjFiZjg3MWFjYTMwZjkzMjA0L3RhYmxlOjc3NzNlZDJlYTRmNjQxY2U4YTJkN2RlNGMzZWM3OTZkL3RhYmxlcmFuZ2U6Nzc3M2VkMmVhNGY2NDFjZThhMmQ3ZGU0YzNlYzc5NmRfNS0yLTEtMS0w_68f99750-0889-4e7f-bd99-bbf99df85e8a">5,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5a33ce37614698a3418806ab20f9b2_I20200331" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80MC9mcmFnOmI1MTgxNTQ5ZjBlNTRkNjFiZjg3MWFjYTMwZjkzMjA0L3RhYmxlOjc3NzNlZDJlYTRmNjQxY2U4YTJkN2RlNGMzZWM3OTZkL3RhYmxlcmFuZ2U6Nzc3M2VkMmVhNGY2NDFjZThhMmQ3ZGU0YzNlYzc5NmRfNS00LTEtMS0w_fa0c32f4-e3b2-4a18-b213-4900e0de5932">404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80MC9mcmFnOmI1MTgxNTQ5ZjBlNTRkNjFiZjg3MWFjYTMwZjkzMjA0L3RleHRyZWdpb246YjUxODE1NDlmMGU1NGQ2MWJmODcxYWNhMzBmOTMyMDRfNzE1OA_8fd23fd0-57de-4692-98a5-0c62d1ce3c74" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Standards Not Yet Adopted</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial statements and disclosures.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="ibba7ad915d1a4c4a8ebb50d13fae4c4e_52"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81Mi9mcmFnOjI3MjY2M2FhYjhkZDQwMmU5Y2Q5OTIyN2EzNDFhOWE0L3RleHRyZWdpb246MjcyNjYzYWFiOGRkNDAyZTljZDk5MjI3YTM0MWE5YTRfNzY5NjU4MTQxMDU0Mw_4f3a27b8-0348-4918-b691-465264af0599" continuedAt="ib65e6fde8544418aab32c1d2b3ffbb6a" escape="true">Product Sales</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ib65e6fde8544418aab32c1d2b3ffbb6a" continuedAt="id81fcdbb8ce9433fae931b57b9ace3cc"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we began selling our COVID-19 vaccine to the U.S. Government and international governments. Under the supply agreements with these governments, we received or billed for upfront deposits for our future vaccine supply, which are initially recorded as deferred revenue. We recognize revenue based on the fixed price per dose when control of the product has transferred and customer acceptance has occurred as applicable, unless such acceptance provisions are deemed perfunctory. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81Mi9mcmFnOjI3MjY2M2FhYjhkZDQwMmU5Y2Q5OTIyN2EzNDFhOWE0L3RleHRyZWdpb246MjcyNjYzYWFiOGRkNDAyZTljZDk5MjI3YTM0MWE5YTRfNzY5NjU4MTQxMDU0NA_59203da8-b1e5-44e5-8d49-f3871dec8697" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales by customer geographic location was as follows (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.595%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d7a2752ca8b473598e5f43e5290268c_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81Mi9mcmFnOjI3MjY2M2FhYjhkZDQwMmU5Y2Q5OTIyN2EzNDFhOWE0L3RhYmxlOmQyNmY2YThiZDNlMjQxYTViYzIzMGRhZmMwZjgwOTdhL3RhYmxlcmFuZ2U6ZDI2ZjZhOGJkM2UyNDFhNWJjMjMwZGFmYzBmODA5N2FfMS0yLTEtMS0zMzIy_5d862327-dca7-4479-a88d-18f31d2499b1">1,358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015500c719c5494988852885b84ddc22_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81Mi9mcmFnOjI3MjY2M2FhYjhkZDQwMmU5Y2Q5OTIyN2EzNDFhOWE0L3RhYmxlOmQyNmY2YThiZDNlMjQxYTViYzIzMGRhZmMwZjgwOTdhL3RhYmxlcmFuZ2U6ZDI2ZjZhOGJkM2UyNDFhNWJjMjMwZGFmYzBmODA5N2FfMi0yLTEtMS0zMzIy_4ef4d35e-bfcc-4580-ba23-cb733b8b7460">375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90cf26aad24349bfa441914ac3d706fb_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81Mi9mcmFnOjI3MjY2M2FhYjhkZDQwMmU5Y2Q5OTIyN2EzNDFhOWE0L3RhYmxlOmQyNmY2YThiZDNlMjQxYTViYzIzMGRhZmMwZjgwOTdhL3RhYmxlcmFuZ2U6ZDI2ZjZhOGJkM2UyNDFhNWJjMjMwZGFmYzBmODA5N2FfMy0yLTEtMS0zMzIy_e91a551c-3a48-4847-bcd6-82927085b556">1,733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no product sales for the three months ended March 31, 2020. As of March 31, 2021, we had one commercial product authorized for use, our COVID-19 vaccine. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 and December 31, 2020, we had deferred revenue of $<ix:nonFraction unitRef="usd" contextRef="i615a67f1a6c2480c89cbe28e804d3b01_I20210331" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81Mi9mcmFnOjI3MjY2M2FhYjhkZDQwMmU5Y2Q5OTIyN2EzNDFhOWE0L3RleHRyZWdpb246MjcyNjYzYWFiOGRkNDAyZTljZDk5MjI3YTM0MWE5YTRfNzY5NjU4MTQxMDYxMg_6b5e7dd3-f7f0-458e-81b8-1481f1e2f67c">7.5</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i0238e09dbf1a48c999216873131aac3a_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81Mi9mcmFnOjI3MjY2M2FhYjhkZDQwMmU5Y2Q5OTIyN2EzNDFhOWE0L3RleHRyZWdpb246MjcyNjYzYWFiOGRkNDAyZTljZDk5MjI3YTM0MWE5YTRfNzY5NjU4MTQxMDU0Ng_28370291-0ea4-4453-9364-4e79ea4a2a32">3.8</ix:nonFraction>&#160;billion, respectively, related to customer deposits, classified as current deferred revenue in our consolidated balance sheet. Timing of product manufacturing, delivery and receipt of marketing approval will determine the period in which revenue is recognized.</span></div></ix:continuation><div><span><br/></span></div><div id="ibba7ad915d1a4c4a8ebb50d13fae4c4e_43"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:continuation id="id81fcdbb8ce9433fae931b57b9ace3cc" continuedAt="i637a91db01504b879c24eb16f3817a17">Grant Revenue</ix:continuation></span></div><div><span><br/></span></div><ix:continuation id="i637a91db01504b879c24eb16f3817a17" continuedAt="i3a1c4839212549c49198bda5a135abaf"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we entered into an agreement with the Defense Advanced Research Projects Agency (DARPA) for an award of up to $<ix:nonFraction unitRef="usd" contextRef="ibb5c5d2d047b4d979b9497e8b26286bd_D20200901-20200930" decimals="-6" format="ixt:numdotdecimal" name="mrna:RevenueFromGrantsMaximumAward" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80My9mcmFnOjY3ZDI2MDQ1NTM3YjRiMjA5YjI0OTc0MTJlYzg2OTU1L3RleHRyZWdpb246NjdkMjYwNDU1MzdiNGIyMDliMjQ5NzQxMmVjODY5NTVfMTUy_0ebeacc0-7f95-4aed-84bf-a240ce388f8b">56</ix:nonFraction>&#160;million to fund development of a mobile manufacturing prototype leveraging our existing manufacturing technology that is capable of rapidly producing vaccines and therapeutics. As of March 31, 2021, the committed funding, net of revenue earned was $<ix:nonFraction unitRef="usd" contextRef="ib54c28109e8b4df6bd548f059a69eaa7_I20200331" decimals="-6" format="ixt:numdotdecimal" name="mrna:RevenueFromGrantsCurrentFundingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80My9mcmFnOjY3ZDI2MDQ1NTM3YjRiMjA5YjI0OTc0MTJlYzg2OTU1L3RleHRyZWdpb246NjdkMjYwNDU1MzdiNGIyMDliMjQ5NzQxMmVjODY5NTVfMzY1_c5fab6c1-c07a-4148-8647-068f23331bf4">3</ix:nonFraction>&#160;million, with an additional $<ix:nonFraction unitRef="usd" contextRef="ib54c28109e8b4df6bd548f059a69eaa7_I20200331" decimals="-6" format="ixt:numdotdecimal" name="mrna:RevenueFromGrantsRemainingFundingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80My9mcmFnOjY3ZDI2MDQ1NTM3YjRiMjA5YjI0OTc0MTJlYzg2OTU1L3RleHRyZWdpb246NjdkMjYwNDU1MzdiNGIyMDliMjQ5NzQxMmVjODY5NTVfMzg4_c73d4fe1-a3fa-4852-9c60-af80f1b3153e">51</ix:nonFraction>&#160;million available if DARPA exercises additional contract options.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we entered into an agreement with the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), for an award of up to $<ix:nonFraction unitRef="usd" contextRef="i7a973ce00bdc4a798407694abf5f73a8_D20200401-20200430" decimals="-6" format="ixt:numdotdecimal" name="mrna:RevenueFromGrantsMaximumAward" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80My9mcmFnOjY3ZDI2MDQ1NTM3YjRiMjA5YjI0OTc0MTJlYzg2OTU1L3RleHRyZWdpb246NjdkMjYwNDU1MzdiNGIyMDliMjQ5NzQxMmVjODY5NTVfNzQx_85c61a5c-a153-403a-916c-fc103506bfc6">483</ix:nonFraction>&#160;million to accelerate development of mRNA-1273, our vaccine candidate against the novel coronavirus. In July 2020, we amended our agreement with BARDA to provide for an additional commitment of up to $<ix:nonFraction unitRef="usd" contextRef="ic23af7a56e2749a0b4290de702518aa1_I20200731" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherCommitment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80My9mcmFnOjY3ZDI2MDQ1NTM3YjRiMjA5YjI0OTc0MTJlYzg2OTU1L3RleHRyZWdpb246NjdkMjYwNDU1MzdiNGIyMDliMjQ5NzQxMmVjODY5NTVfOTM2_6b5fc3be-06c3-4783-a36c-33749806b5ed">472</ix:nonFraction>&#160;million to support late-stage clinical development of mRNA-1273, including the execution of a 30,000 participant Phase 3 study in the U.S. We further amended the agreement in March 2021 to provide for an additional commitment of $<ix:nonFraction unitRef="usd" contextRef="i4f9df22e0ed44daba83573576518c077_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherCommitment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80My9mcmFnOjY3ZDI2MDQ1NTM3YjRiMjA5YjI0OTc0MTJlYzg2OTU1L3RleHRyZWdpb246NjdkMjYwNDU1MzdiNGIyMDliMjQ5NzQxMmVjODY5NTVfNzY5NjU4MTQwMDIwNg_b950d7fc-b75b-456b-8314-75a5f9a66936">63</ix:nonFraction>&#160;million to further support late-stage clinical development, including Phase 2/3 mRNA-1273 pediatric studies. As of March 31, 2021, the maximum award from BARDA, inclusive of the March 2021 amendment, was approximately $<ix:nonFraction unitRef="usd" contextRef="i24305ac457e24ee79d1f0f5f58f89459_D20210101-20210331" decimals="-8" format="ixt:numdotdecimal" name="mrna:RevenueFromGrantsMaximumAward" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80My9mcmFnOjY3ZDI2MDQ1NTM3YjRiMjA5YjI0OTc0MTJlYzg2OTU1L3RleHRyZWdpb246NjdkMjYwNDU1MzdiNGIyMDliMjQ5NzQxMmVjODY5NTVfMTEzNA_2b7a71fe-8f9e-4b5e-bbde-7423cac1662f">1.0</ix:nonFraction>&#160;billion. Under the terms of the agreement, BARDA will fund the advancement of mRNA-1273 to FDA licensure. All contract options have been exercised. As of March 31, 2021, the remaining available funding net of revenue earned was $<ix:nonFraction unitRef="usd" contextRef="i4f9df22e0ed44daba83573576518c077_I20210331" decimals="-6" format="ixt:numdotdecimal" name="mrna:RevenueFromGrantsCurrentFundingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80My9mcmFnOjY3ZDI2MDQ1NTM3YjRiMjA5YjI0OTc0MTJlYzg2OTU1L3RleHRyZWdpb246NjdkMjYwNDU1MzdiNGIyMDliMjQ5NzQxMmVjODY5NTVfMTM1MA_b6ffc9e6-c071-47ac-9c9b-d5b58c16ef2b">317</ix:nonFraction>&#160;million. Subsequent to the end of the quarter, on April 18, 2021, we entered into a further amendment to the BARDA agreement, increasing the amount of potential reimbursements by $<ix:nonFraction unitRef="usd" contextRef="i1d9fd4412ca74750b6b14d4722981e10_D20210418-20210418" decimals="-6" format="ixt:numdotdecimal" name="mrna:RevenueFromGrantsPotentialReimbursement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80My9mcmFnOjY3ZDI2MDQ1NTM3YjRiMjA5YjI0OTc0MTJlYzg2OTU1L3RleHRyZWdpb246NjdkMjYwNDU1MzdiNGIyMDliMjQ5NzQxMmVjODY5NTVfNzY5NjU4MTQwMDgzMQ_f5c7f0d5-2950-4956-9f2d-acae9a61a2c9">236</ix:nonFraction>&#160;million in connection with costs associated with the Phase 3 clinical trials for mRNA-1273 and pharmacovigilance efforts. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2016, we received an award of up to $<ix:nonFraction unitRef="usd" contextRef="ide0d50c05a0f41209d23a6cda03d4b84_D20160901-20160930" decimals="-6" format="ixt:numdotdecimal" name="mrna:RevenueFromGrantsMaximumAward" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80My9mcmFnOjY3ZDI2MDQ1NTM3YjRiMjA5YjI0OTc0MTJlYzg2OTU1L3RleHRyZWdpb246NjdkMjYwNDU1MzdiNGIyMDliMjQ5NzQxMmVjODY5NTVfMTQwNA_6e5ba698-a779-455b-a3a2-ff72389a198e">126</ix:nonFraction>&#160;million from BARDA, to help fund our Zika vaccine program. <ix:nonFraction unitRef="option" contextRef="if411e69e7ac54f6ea28f6658a5d6dac8_I20160930" decimals="INF" format="ixt-sec:numwordsen" name="mrna:RevenueFromGrantsNumberOfContractOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80My9mcmFnOjY3ZDI2MDQ1NTM3YjRiMjA5YjI0OTc0MTJlYzg2OTU1L3RleHRyZWdpb246NjdkMjYwNDU1MzdiNGIyMDliMjQ5NzQxMmVjODY5NTVfMTQ1OA_30f897f5-0f0f-493f-b704-827ff963b5a5">Three</ix:nonFraction> of the <ix:nonFraction unitRef="option" contextRef="if411e69e7ac54f6ea28f6658a5d6dac8_I20160930" decimals="INF" format="ixt-sec:numwordsen" name="mrna:RevenueFromGrantsNumberOfContractOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80My9mcmFnOjY3ZDI2MDQ1NTM3YjRiMjA5YjI0OTc0MTJlYzg2OTU1L3RleHRyZWdpb246NjdkMjYwNDU1MzdiNGIyMDliMjQ5NzQxMmVjODY5NTVfMTQ2OA_3d5c88db-0b89-46f3-a9ed-32084cfef230">four</ix:nonFraction> contract options have been exercised. As of March 31, 2021, the remaining available funding net of revenue earned was $<ix:nonFraction unitRef="usd" contextRef="i89f03a0decbd475591590f9d2c6d5dec_I20210331" decimals="-6" format="ixt:numdotdecimal" name="mrna:RevenueFromGrantsCurrentFundingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80My9mcmFnOjY3ZDI2MDQ1NTM3YjRiMjA5YjI0OTc0MTJlYzg2OTU1L3RleHRyZWdpb246NjdkMjYwNDU1MzdiNGIyMDliMjQ5NzQxMmVjODY5NTVfMTU4Mg_e3e73a41-60f2-4dda-84c4-c7442cd5d208">69</ix:nonFraction>&#160;million, with an additional $<ix:nonFraction unitRef="usd" contextRef="i89f03a0decbd475591590f9d2c6d5dec_I20210331" decimals="-6" format="ixt:numdotdecimal" name="mrna:RevenueFromGrantsRemainingFundingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80My9mcmFnOjY3ZDI2MDQ1NTM3YjRiMjA5YjI0OTc0MTJlYzg2OTU1L3RleHRyZWdpb246NjdkMjYwNDU1MzdiNGIyMDliMjQ5NzQxMmVjODY5NTVfMTYwNQ_5f68101d-f15c-42ad-ad53-15059269d243">8</ix:nonFraction>&#160;million available if the final contract option is exercised.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2016, we entered a global health project framework agreement with the Bill and Melinda Gates Foundation (Gates Foundation) to advance mRNA-based development projects for various infectious diseases, including human immunodeficiency virus (HIV). As of March 31, 2021, the available funding net of revenue earned was $<ix:nonFraction unitRef="usd" contextRef="i53791cfc661a48e88b2bc8d3c8c541f7_I20210331" decimals="-6" format="ixt:numdotdecimal" name="mrna:RevenueFromGrantsRemainingFundingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80My9mcmFnOjY3ZDI2MDQ1NTM3YjRiMjA5YjI0OTc0MTJlYzg2OTU1L3RleHRyZWdpb246NjdkMjYwNDU1MzdiNGIyMDliMjQ5NzQxMmVjODY5NTVfMTk0NQ_bf0151b5-49f4-42bb-b9cd-d52d83db498f">11</ix:nonFraction>&#160;million, with up to an additional $<ix:nonFraction unitRef="usd" contextRef="i53791cfc661a48e88b2bc8d3c8c541f7_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80My9mcmFnOjY3ZDI2MDQ1NTM3YjRiMjA5YjI0OTc0MTJlYzg2OTU1L3RleHRyZWdpb246NjdkMjYwNDU1MzdiNGIyMDliMjQ5NzQxMmVjODY5NTVfMTk3NA_e90d5836-8da5-443d-adb2-875d9791001a">80</ix:nonFraction>&#160;million available if additional follow-on projects are approved. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80My9mcmFnOjY3ZDI2MDQ1NTM3YjRiMjA5YjI0OTc0MTJlYzg2OTU1L3RleHRyZWdpb246NjdkMjYwNDU1MzdiNGIyMDliMjQ5NzQxMmVjODY5NTVfMjE3MA_19be9836-725e-4711-b8b3-2866f88f8c56" continuedAt="i051d0014b6214f36af084b4ad19ece3f" escape="true">The following table summarizes grant revenue as of and for the period presented (in millions):</ix:nonNumeric></span></div></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Contents</a></span></div></div><div><ix:continuation id="i3a1c4839212549c49198bda5a135abaf"><ix:continuation id="i051d0014b6214f36af084b4ad19ece3f" continuedAt="ib0614247d89d4b66b94f6532f9f8ba5c"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.511%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BARDA</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9e09957e07f4e779b011ddea7dea3cb_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80My9mcmFnOjY3ZDI2MDQ1NTM3YjRiMjA5YjI0OTc0MTJlYzg2OTU1L3RhYmxlOjI1OGUzMTQ5NjNhMjRhMmQ5NzZjZWFlYjc1MDc3NDlmL3RhYmxlcmFuZ2U6MjU4ZTMxNDk2M2EyNGEyZDk3NmNlYWViNzUwNzc0OWZfMi01LTEtMS0w_a791cd69-c965-4c85-936e-ef965cb3b8c6">192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e13ec3698064dd7bac04dab36528b56_D20200101-20200331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80My9mcmFnOjY3ZDI2MDQ1NTM3YjRiMjA5YjI0OTc0MTJlYzg2OTU1L3RhYmxlOjI1OGUzMTQ5NjNhMjRhMmQ5NzZjZWFlYjc1MDc3NDlmL3RhYmxlcmFuZ2U6MjU4ZTMxNDk2M2EyNGEyZDk3NmNlYWViNzUwNzc0OWZfMi03LTEtMS0w_688c79c4-954a-4c77-9cd9-0a369a677d8d">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other grant revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fbd7587ea9a4f81bfca9dfda7f7c4d1_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80My9mcmFnOjY3ZDI2MDQ1NTM3YjRiMjA5YjI0OTc0MTJlYzg2OTU1L3RhYmxlOjI1OGUzMTQ5NjNhMjRhMmQ5NzZjZWFlYjc1MDc3NDlmL3RhYmxlcmFuZ2U6MjU4ZTMxNDk2M2EyNGEyZDk3NmNlYWViNzUwNzc0OWZfMy01LTEtMS0w_f4449efc-e70c-453d-9d97-58f6adc36284">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0c6277e6e0841bbafa567ecc4fe413b_D20200101-20200331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80My9mcmFnOjY3ZDI2MDQ1NTM3YjRiMjA5YjI0OTc0MTJlYzg2OTU1L3RhYmxlOjI1OGUzMTQ5NjNhMjRhMmQ5NzZjZWFlYjc1MDc3NDlmL3RhYmxlcmFuZ2U6MjU4ZTMxNDk2M2EyNGEyZDk3NmNlYWViNzUwNzc0OWZfMy03LTEtMS0w_3e3d842c-0b8e-40ff-b789-d3cebb6f7c0b">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total grant revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12127d667a294d78b6d78f889c39cd18_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80My9mcmFnOjY3ZDI2MDQ1NTM3YjRiMjA5YjI0OTc0MTJlYzg2OTU1L3RhYmxlOjI1OGUzMTQ5NjNhMjRhMmQ5NzZjZWFlYjc1MDc3NDlmL3RhYmxlcmFuZ2U6MjU4ZTMxNDk2M2EyNGEyZDk3NmNlYWViNzUwNzc0OWZfNC01LTEtMS0w_24ce2082-dcc3-4a7e-9f79-59544f7e61f1">194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i928ab86735d84580ac232ade8c6033ea_D20200101-20200331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80My9mcmFnOjY3ZDI2MDQ1NTM3YjRiMjA5YjI0OTc0MTJlYzg2OTU1L3RhYmxlOjI1OGUzMTQ5NjNhMjRhMmQ5NzZjZWFlYjc1MDc3NDlmL3RhYmxlcmFuZ2U6MjU4ZTMxNDk2M2EyNGEyZDk3NmNlYWViNzUwNzc0OWZfNC03LTEtMS0w_36376ed8-351d-4bf6-b131-21b976e31334">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></ix:continuation></ix:continuation></div><div><span><br/></span></div><div id="ibba7ad915d1a4c4a8ebb50d13fae4c4e_46"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80Ni9mcmFnOmFjMTg5NmExYjZiOTQ5MTJiZWUzNGYxNmZiNzQ5NjliL3RleHRyZWdpb246YWMxODk2YTFiNmI5NDkxMmJlZTM0ZjE2ZmI3NDk2OWJfNTIyMjQ_4931087b-b3f8-4a51-9c3b-b1cf7fb5b9bb" continuedAt="icfb064bc24414e33906407c1c71bd8c3" escape="true">Collaboration Agreements</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="icfb064bc24414e33906407c1c71bd8c3" continuedAt="i0e4cf90510ae488391a0926260303d74"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into collaboration agreements with strategic collaborators to accelerate the discovery and advancement of potential mRNA medicines across therapeutic areas. As of March 31, 2021 and December 31, 2020, we had collaboration agreements with AstraZeneca plc (AstraZeneca), Merck &amp; Co., Inc (Merck), Vertex Pharmaceuticals Incorporated and Vertex Pharmaceuticals (Europe) Limited (together, Vertex), and Chiesi Farmaceutici S.P.A. (Chiesi). Please refer to our 2020 Form 10-K under the heading &#8220;Third-Party Strategic Alliances&#8221; and Note 5 to our consolidated financial statements for further description of each of the collaboration agreements. </span></div><div><span><br/></span></div><ix:continuation id="ib0614247d89d4b66b94f6532f9f8ba5c"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our total consolidated revenue from our strategic collaborators for the periods presented (in millions):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.511%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Collaboration Revenue by Strategic Collaborator:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AstraZeneca</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52aa31d81e134903a18093eb7e292280_D20210101-20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80Ni9mcmFnOmFjMTg5NmExYjZiOTQ5MTJiZWUzNGYxNmZiNzQ5NjliL3RhYmxlOjdiMGE1MzU2NjU5ODQyODg5ZTQ0Y2U0ZjgxNDViMTVjL3RhYmxlcmFuZ2U6N2IwYTUzNTY2NTk4NDI4ODllNDRjZTRmODE0NWIxNWNfMi01LTEtMS0w_4bafe27c-14e9-4c59-9b13-4f43b6a90203">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i086bb9318c0b4c0c8ef0461ff39d1327_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80Ni9mcmFnOmFjMTg5NmExYjZiOTQ5MTJiZWUzNGYxNmZiNzQ5NjliL3RhYmxlOjdiMGE1MzU2NjU5ODQyODg5ZTQ0Y2U0ZjgxNDViMTVjL3RhYmxlcmFuZ2U6N2IwYTUzNTY2NTk4NDI4ODllNDRjZTRmODE0NWIxNWNfMi03LTEtMS0w_7f781811-7e82-4ef5-9c2b-c5b33a346a0f">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7427ffe751240d0a4ef3e3e238b47a2_D20210101-20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80Ni9mcmFnOmFjMTg5NmExYjZiOTQ5MTJiZWUzNGYxNmZiNzQ5NjliL3RhYmxlOjdiMGE1MzU2NjU5ODQyODg5ZTQ0Y2U0ZjgxNDViMTVjL3RhYmxlcmFuZ2U6N2IwYTUzNTY2NTk4NDI4ODllNDRjZTRmODE0NWIxNWNfMy01LTEtMS0w_f31cbce0-95b0-4de9-9e53-09803021e580">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c7a5f91086643518f876c3b89b411ae_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80Ni9mcmFnOmFjMTg5NmExYjZiOTQ5MTJiZWUzNGYxNmZiNzQ5NjliL3RhYmxlOjdiMGE1MzU2NjU5ODQyODg5ZTQ0Y2U0ZjgxNDViMTVjL3RhYmxlcmFuZ2U6N2IwYTUzNTY2NTk4NDI4ODllNDRjZTRmODE0NWIxNWNfMy03LTEtMS0w_d94596ab-0674-4ffc-8dfb-32ede7b592c9">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vertex</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fb6b67fc6764af4b4bf084bb09b748b_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80Ni9mcmFnOmFjMTg5NmExYjZiOTQ5MTJiZWUzNGYxNmZiNzQ5NjliL3RhYmxlOjdiMGE1MzU2NjU5ODQyODg5ZTQ0Y2U0ZjgxNDViMTVjL3RhYmxlcmFuZ2U6N2IwYTUzNTY2NTk4NDI4ODllNDRjZTRmODE0NWIxNWNfNC01LTEtMS0w_a6c2b325-f34d-49bc-88ae-57a9461bfb75">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0c4ba70e8f6479882eff1b6b52f2792_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80Ni9mcmFnOmFjMTg5NmExYjZiOTQ5MTJiZWUzNGYxNmZiNzQ5NjliL3RhYmxlOjdiMGE1MzU2NjU5ODQyODg5ZTQ0Y2U0ZjgxNDViMTVjL3RhYmxlcmFuZ2U6N2IwYTUzNTY2NTk4NDI4ODllNDRjZTRmODE0NWIxNWNfNC03LTEtMS0w_0eff8956-2a74-4e62-be43-9beaa386fe2f">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a3a24c98e934216b6325e57f46e961a_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80Ni9mcmFnOmFjMTg5NmExYjZiOTQ5MTJiZWUzNGYxNmZiNzQ5NjliL3RhYmxlOjdiMGE1MzU2NjU5ODQyODg5ZTQ0Y2U0ZjgxNDViMTVjL3RhYmxlcmFuZ2U6N2IwYTUzNTY2NTk4NDI4ODllNDRjZTRmODE0NWIxNWNfNS01LTEtMS0w_22a92c0d-3e9d-492e-9509-543d8049faa0">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib62acba5ff5c46149175a78722d4f5d3_D20200101-20200331" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80Ni9mcmFnOmFjMTg5NmExYjZiOTQ5MTJiZWUzNGYxNmZiNzQ5NjliL3RhYmxlOjdiMGE1MzU2NjU5ODQyODg5ZTQ0Y2U0ZjgxNDViMTVjL3RhYmxlcmFuZ2U6N2IwYTUzNTY2NTk4NDI4ODllNDRjZTRmODE0NWIxNWNfNS03LTEtMS0w_3123a3b1-2d8e-4e88-999a-79bca51601ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d71f6c708c04cfd9aa4a5147b897eae_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80Ni9mcmFnOmFjMTg5NmExYjZiOTQ5MTJiZWUzNGYxNmZiNzQ5NjliL3RhYmxlOjdiMGE1MzU2NjU5ODQyODg5ZTQ0Y2U0ZjgxNDViMTVjL3RhYmxlcmFuZ2U6N2IwYTUzNTY2NTk4NDI4ODllNDRjZTRmODE0NWIxNWNfNi01LTEtMS0w_5802dd9e-11ba-47cd-9f32-07d30d27855b">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9d15e5fbe824ba297aa8586391ba7bc_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80Ni9mcmFnOmFjMTg5NmExYjZiOTQ5MTJiZWUzNGYxNmZiNzQ5NjliL3RhYmxlOjdiMGE1MzU2NjU5ODQyODg5ZTQ0Y2U0ZjgxNDViMTVjL3RhYmxlcmFuZ2U6N2IwYTUzNTY2NTk4NDI4ODllNDRjZTRmODE0NWIxNWNfNi03LTEtMS0w_6220b52c-2b01-4e5c-b7b7-ff1585f2a0f6">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div><span><br/></span></div><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80Ni9mcmFnOmFjMTg5NmExYjZiOTQ5MTJiZWUzNGYxNmZiNzQ5NjliL3RleHRyZWdpb246YWMxODk2YTFiNmI5NDkxMmJlZTM0ZjE2ZmI3NDk2OWJfNTIyMDU_3af7e625-2969-43cc-b36c-aa7bba2eb3e2" continuedAt="i0787ee8a591346138f01fce6a0acbe19" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in the balances of our receivables and contract liabilities related to our strategic collaboration agreements during the three months ended March 31, 2021 (in millions):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.333%"><tr><td style="width:1.0%"></td><td style="width:38.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.883%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.883%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.885%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0424eee07b4f47f18f3baa3664b5c50f_I20201231" decimals="-6" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80Ni9mcmFnOmFjMTg5NmExYjZiOTQ5MTJiZWUzNGYxNmZiNzQ5NjliL3RhYmxlOmNiMjBkZWIwYWEyODQyMzliMzE3OWUxMjBmNzc4MjlkL3RhYmxlcmFuZ2U6Y2IyMGRlYjBhYTI4NDIzOWIzMTc5ZTEyMGY3NzgyOWRfMi0yLTEtMS0w_fb0eda69-b7d7-4753-b6b0-ca4a777047db">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d71f6c708c04cfd9aa4a5147b897eae_D20210101-20210331" decimals="-6" name="us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80Ni9mcmFnOmFjMTg5NmExYjZiOTQ5MTJiZWUzNGYxNmZiNzQ5NjliL3RhYmxlOmNiMjBkZWIwYWEyODQyMzliMzE3OWUxMjBmNzc4MjlkL3RhYmxlcmFuZ2U6Y2IyMGRlYjBhYTI4NDIzOWIzMTc5ZTEyMGY3NzgyOWRfMi00LTEtMS0w_8f3daeb7-673c-4504-8445-321412fa5ed6">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d71f6c708c04cfd9aa4a5147b897eae_D20210101-20210331" decimals="-6" name="mrna:ContractWithCustomerAssetDeductionsDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80Ni9mcmFnOmFjMTg5NmExYjZiOTQ5MTJiZWUzNGYxNmZiNzQ5NjliL3RhYmxlOmNiMjBkZWIwYWEyODQyMzliMzE3OWUxMjBmNzc4MjlkL3RhYmxlcmFuZ2U6Y2IyMGRlYjBhYTI4NDIzOWIzMTc5ZTEyMGY3NzgyOWRfMi02LTEtMS0w_19126233-7cd8-49bb-9164-6aaeec0f16e0">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ab46cc577f34aa3900c0f6c8856f7f9_I20210331" decimals="-6" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80Ni9mcmFnOmFjMTg5NmExYjZiOTQ5MTJiZWUzNGYxNmZiNzQ5NjliL3RhYmxlOmNiMjBkZWIwYWEyODQyMzliMzE3OWUxMjBmNzc4MjlkL3RhYmxlcmFuZ2U6Y2IyMGRlYjBhYTI4NDIzOWIzMTc5ZTEyMGY3NzgyOWRfMi04LTEtMS0w_19cdd169-7b71-409f-9432-58f13665cdaa">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0424eee07b4f47f18f3baa3664b5c50f_I20201231" decimals="-6" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80Ni9mcmFnOmFjMTg5NmExYjZiOTQ5MTJiZWUzNGYxNmZiNzQ5NjliL3RhYmxlOmNiMjBkZWIwYWEyODQyMzliMzE3OWUxMjBmNzc4MjlkL3RhYmxlcmFuZ2U6Y2IyMGRlYjBhYTI4NDIzOWIzMTc5ZTEyMGY3NzgyOWRfNC0yLTEtMS0w_aa167204-e3c4-4db2-a91c-acd3ae7715d2">240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d71f6c708c04cfd9aa4a5147b897eae_D20210101-20210331" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80Ni9mcmFnOmFjMTg5NmExYjZiOTQ5MTJiZWUzNGYxNmZiNzQ5NjliL3RhYmxlOmNiMjBkZWIwYWEyODQyMzliMzE3OWUxMjBmNzc4MjlkL3RhYmxlcmFuZ2U6Y2IyMGRlYjBhYTI4NDIzOWIzMTc5ZTEyMGY3NzgyOWRfNC00LTEtMS0w_e9d3a523-c406-4274-a6da-a50dcf9b5ab0">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d71f6c708c04cfd9aa4a5147b897eae_D20210101-20210331" decimals="-6" name="mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80Ni9mcmFnOmFjMTg5NmExYjZiOTQ5MTJiZWUzNGYxNmZiNzQ5NjliL3RhYmxlOmNiMjBkZWIwYWEyODQyMzliMzE3OWUxMjBmNzc4MjlkL3RhYmxlcmFuZ2U6Y2IyMGRlYjBhYTI4NDIzOWIzMTc5ZTEyMGY3NzgyOWRfNC02LTEtMS0w_6c9e1ef1-4003-452f-b3f3-56c814933e15">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ab46cc577f34aa3900c0f6c8856f7f9_I20210331" decimals="-6" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80Ni9mcmFnOmFjMTg5NmExYjZiOTQ5MTJiZWUzNGYxNmZiNzQ5NjliL3RhYmxlOmNiMjBkZWIwYWEyODQyMzliMzE3OWUxMjBmNzc4MjlkL3RhYmxlcmFuZ2U6Y2IyMGRlYjBhYTI4NDIzOWIzMTc5ZTEyMGY3NzgyOWRfNC04LTEtMS0w_8d56f548-5505-4fff-a392-99417589c4eb">235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0e4cf90510ae488391a0926260303d74">As of March 31, 2021, the aggregated amount of the transaction price allocated to performance obligations under our collaboration agreements that are unsatisfied or partially unsatisfied was $<ix:nonFraction unitRef="usd" contextRef="i6ab46cc577f34aa3900c0f6c8856f7f9_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80Ni9mcmFnOmFjMTg5NmExYjZiOTQ5MTJiZWUzNGYxNmZiNzQ5NjliL3RleHRyZWdpb246YWMxODk2YTFiNmI5NDkxMmJlZTM0ZjE2ZmI3NDk2OWJfMTE4Nw_5eb254bc-f56d-41bf-800f-f57e07e945c0">314</ix:nonFraction>&#160;million.</ix:continuation> </span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="ibba7ad915d1a4c4a8ebb50d13fae4c4e_55"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RleHRyZWdpb246MjI1MzcwNmEzNTA3NDAyYWJlMzg1NWEwMDdlZTRmZjFfMjEzMg_c11e8695-973a-4184-908b-4d330bbf2057" continuedAt="ie9b14ad668ea4fa3a9006a2481b80989" escape="true">Financial Instruments</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ie9b14ad668ea4fa3a9006a2481b80989" continuedAt="i0cc172bd310d4316b9a1a06d3862e649"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents and Investments</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RleHRyZWdpb246MjI1MzcwNmEzNTA3NDAyYWJlMzg1NWEwMDdlZTRmZjFfMjEzMw_3b52a339-5665-4783-a559-bcced929e6d7" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize our cash and available-for-sale securities by significant investment category at March 31, 2021 and December 31, 2020 (in millions):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.765%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and<br/>Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current<br/>Marketable<br/>Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-<br/>Current<br/>Marketable<br/>Securities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i356bef623f834e84a7cdb447d141ccd3_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMi0yLTEtMS0w_719bfe58-9ad0-4a56-9d7a-948fbf20ceaf">5,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i356bef623f834e84a7cdb447d141ccd3_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMi00LTEtMS0w_f8f7d673-bda2-440b-a438-297a66ea6900">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i356bef623f834e84a7cdb447d141ccd3_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMi02LTEtMS0w_922355d1-6788-4e8d-9a28-0c212a2a9f4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i356bef623f834e84a7cdb447d141ccd3_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMi04LTEtMS0w_05c792d8-544d-4963-8b78-9960e38794ee">5,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60479f4cd58141ab88eb9674b785a4a1_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMi0xMC0xLTEtMA_f47f7d2e-e620-4e6b-b2dc-6e0be9e1c8b3">5,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67533c70f1f24be1881a998a7ae2b79c_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMi0xMi0xLTEtMA_40258ed2-7546-473f-b1a6-5201e27eae8c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0a9efa36764e4abe9a81143990ee12_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMi0xNC0xLTEtMA_4b74cb9c-bf94-4922-b3ec-1ede22ffc20b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a4e0ae3d99d485a9d3576fc11b24069_I20210331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfNS0yLTEtMS0w_c561313c-fcd7-4b66-948b-e6514beac806">413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a4e0ae3d99d485a9d3576fc11b24069_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfNS00LTEtMS0w_a0ea150a-3ea0-4802-adbd-06c36a0d4715">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a4e0ae3d99d485a9d3576fc11b24069_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfNS02LTEtMS0w_99ab8275-ea8a-4e4a-83ab-917474e821b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a4e0ae3d99d485a9d3576fc11b24069_I20210331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfNS04LTEtMS0w_31861944-3d9f-44dd-9525-cf0b12a4799d">413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bf1192916f64380bbdde4039cc78e4f_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfNS0xMC0xLTEtMA_a57a6edf-5213-46eb-8d08-b9b86b189ff8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e96e4a36ca4d209bbcd48d238ae70a_I20210331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfNS0xMi0xLTEtMA_aab3ac08-cc76-43ed-9f74-73a57b971d65">413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cb1f6a641814b1c8ad2ff7b4a2b8217_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfNS0xNC0xLTEtMA_c3ba883e-8827-46fd-a6a7-5b1c5a13c473">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b6a0be7eddd411e8225d14c0a674df3_I20210331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfNi0yLTEtMS0w_2ee51331-0b7c-4be3-b45a-656966368a03">374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b6a0be7eddd411e8225d14c0a674df3_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfNi00LTEtMS0w_4fef361d-ae0d-4d74-86a6-022232de1e10">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b6a0be7eddd411e8225d14c0a674df3_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfNi02LTEtMS0w_3a0220c1-41dd-439f-877c-850227dacaa9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b6a0be7eddd411e8225d14c0a674df3_I20210331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfNi04LTEtMS0w_bae8ca9f-12d9-404c-a4bd-774454fb0f6b">374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3039ce5316a84c43a0d08915dea14050_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfNi0xMC0xLTEtMA_b171d894-f917-42f4-9e62-6653eb09ee76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15456fe3d934468482ac959714d5a053_I20210331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfNi0xMi0xLTEtMA_eaef5432-785d-41a4-a4f7-bad0b71e6720">374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb1895e1c5bc495fbeda6e5e2a787ef6_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfNi0xNC0xLTEtMA_a04f4eb9-ebd3-4663-bc53-404c2cc5c070">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities of U.S. government agencies and corporate entities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cb95c5356684e93a35e3bf790aca2fc_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfNy0yLTEtMS0w_b78ca678-84fb-4609-8ca5-e0cf0fb6da62">1,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cb95c5356684e93a35e3bf790aca2fc_I20210331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfNy00LTEtMS0w_5c62add8-73d8-4b58-83c4-7edc764729d2">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7cb95c5356684e93a35e3bf790aca2fc_I20210331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfNy02LTEtMS0w_3ba2cf00-327f-4ad2-8444-2a2dc9453e5a">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cb95c5356684e93a35e3bf790aca2fc_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfNy04LTEtMS0w_d70a20df-f480-4bc1-a260-a038c9f6f8cb">1,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ib6b7b9882f044ebba7637ec5e651772b_I20210331" xsi:nil="true" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfNy0xMC0xLTEtMA_047ce00a-4181-4414-8674-3cfe61b5503a"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dfcad9b1a5a494ea2d1f97c1cec871c_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfNy0xMi0xLTEtMA_26fe14a5-9074-4c90-a6c1-b39c8703938e">1,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee5034c39f6946fd8be3fff0632e2766_I20210331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfNy0xNC0xLTEtMA_529f3135-8f39-4036-97d4-882b98df48c4">468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacbf0fb43aaa4d53bc16745f38512f25_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfOC0yLTEtMS0w_96de523c-fa9a-4c5f-a3d1-93663b6f8e50">8,201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacbf0fb43aaa4d53bc16745f38512f25_I20210331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfOC00LTEtMS0w_b496dcc6-1b3b-4b67-b16a-3de6f204c803">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iacbf0fb43aaa4d53bc16745f38512f25_I20210331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfOC02LTEtMS0w_fa70c797-fa18-4f74-9833-d148da0dfd89">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacbf0fb43aaa4d53bc16745f38512f25_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfOC04LTEtMS0w_9422c52b-a4bf-4bb1-8d5a-6987c4db70e4">8,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9af72ba73c864ba9a21e07312e1cad6f_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfOC0xMC0xLTEtMA_28fc8140-423d-4afa-9dfd-2495421d5412">5,442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5f6ba69b244986a5d20a064920207d_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfOC0xMi0xLTEtMA_443de362-aec7-4a63-addd-8aa717f2c1e8">2,293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c00e9c4b7c4cab9106b940030ecc8d_I20210331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfOC0xNC0xLTEtMA_5af80cd9-8a80-4b94-b781-b37e52027821">468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and<br/>Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current<br/>Marketable<br/>Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-<br/>Current<br/>Marketable<br/>Securities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i541125faaac24704993f4bb55ea03ffb_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTItMi0xLTEtMA_21a43db1-3542-4aba-b857-c5205cbc46f7">2,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i541125faaac24704993f4bb55ea03ffb_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTItNC0xLTEtMA_0066eda1-99c4-4207-9e95-a282fe3b4b43">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i541125faaac24704993f4bb55ea03ffb_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTItNi0xLTEtMA_eda2032f-8962-40bd-8d68-a4ab791a75f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i541125faaac24704993f4bb55ea03ffb_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTItOC0xLTEtMA_af3145b1-9a24-4a4e-a592-3810614996da">2,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63ece81cf0b14c9d977ea0092b4cead4_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTItMTAtMS0xLTA_80e26083-5322-4cc8-abfc-199af96396e2">2,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i144b3354d900459db79935bb372dddac_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTItMTItMS0xLTA_e4f164a6-2747-43c2-9e09-03a304e76122">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6806220f01c4d34bff60f27b6458a20_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTItMTQtMS0xLTA_b2665547-8f85-4064-a186-827b797a8bb9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc2d8b74fdcf4cf19b8d0602247a7ed5_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTUtMi0xLTEtMA_de72e837-a181-4a4e-b6b0-0c32b27d375a">239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc2d8b74fdcf4cf19b8d0602247a7ed5_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTUtNC0xLTEtMA_6adc0b74-9ce9-4b71-b246-9995614f6ab9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc2d8b74fdcf4cf19b8d0602247a7ed5_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTUtNi0xLTEtMA_2b4f9e2e-e4f7-47ec-8c44-ea16a632d50f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc2d8b74fdcf4cf19b8d0602247a7ed5_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTUtOC0xLTEtMA_2feed037-cb9c-4034-9dd9-119a1eef461d">239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie744a40ba7764cb6bc3cc3dc74a499fb_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTUtMTAtMS0xLTA_c0e75103-b3dc-4905-9d63-dc07cac63204">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4039aa1d6baf4797ad803a7b6190baa8_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTUtMTItMS0xLTA_f8f7ff56-a0b4-441e-b692-175ed64a40cf">215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1cde362d4524f9ba6d35c5ea6b396bd_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTUtMTQtMS0xLTA_e98b2b50-fd9e-4352-a838-71e429f1da29">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05d95354ca2c445db703eebb828e4323_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTYtMi0xLTEtMA_95cc576c-f3eb-4127-b6d2-7a4584bfaed4">492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05d95354ca2c445db703eebb828e4323_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTYtNC0xLTEtMA_5802d5f1-fefb-4217-9447-2a7d23826c27">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05d95354ca2c445db703eebb828e4323_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTYtNi0xLTEtMA_b050eda4-ec5e-466b-8459-0e6f9dcbd459">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05d95354ca2c445db703eebb828e4323_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTYtOC0xLTEtMA_acde32a5-139d-48f1-a958-3ba9a622f225">492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6465ad5ef134815a47c8f454682eb9d_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTYtMTAtMS0xLTA_f8d28f94-df8f-43a5-beaa-701fa66fef10">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64e7c6ca7fa54146be90ea4732b08c96_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTYtMTItMS0xLTA_275805db-4aa0-46fd-994f-2140943cba19">492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9f8683c12dc47549b560b34d4161e88_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTYtMTQtMS0xLTA_142e13d2-63aa-4faf-92ca-d6fc4cecf5aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities of U.S. government agencies and corporate entities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39670918752c482d9b5985dd34a8435a_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTctMi0xLTEtMA_c72bc873-a458-4748-a1aa-81534aabbd4a">1,888</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39670918752c482d9b5985dd34a8435a_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTctNC0xLTEtMA_e2f98e3c-09c8-42ed-a37d-f6e990243faa">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39670918752c482d9b5985dd34a8435a_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTctNi0xLTEtMA_ba9afb40-9a62-4bd5-8812-9d5bb4db8802">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39670918752c482d9b5985dd34a8435a_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTctOC0xLTEtMA_52e78132-77b7-4813-aa96-b133c7b96e9d">1,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5913295f7ce94eaf82964fa6e5bebd39_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTctMTAtMS0xLTA_01e36514-095f-4036-beb7-479db70e19eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a2bf1e040654bc8a5d2177086572016_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTctMTItMS0xLTA_419162eb-d966-4e53-99a5-a75551398eeb">1,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79840680ee5c42f08b5791b046d4ab3f_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTctMTQtMS0xLTA_68125dd0-edac-4e6f-865f-eab1adb00e55">615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcb2bea1b1bf4c1782b105cad231847c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTgtMi0xLTEtMA_ec5420c3-8b02-4376-a96f-1b8977da2081">5,243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcb2bea1b1bf4c1782b105cad231847c_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTgtNC0xLTEtMA_d002e761-aba3-4729-8e6a-0f66d968ed3b">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcb2bea1b1bf4c1782b105cad231847c_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTgtNi0xLTEtMA_2599f9f7-df25-47ef-b0b4-a88d084acde1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcb2bea1b1bf4c1782b105cad231847c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTgtOC0xLTEtMA_8246daf2-6b6d-4221-bcc3-12d4ed7726f1">5,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a3a8d7ef2ea40a88c5b84eee83292fa_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTgtMTAtMS0xLTA_f10851e8-0a8d-41e0-b46b-75a436e7aa05">2,624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie01d3f7d975a464884d498263f3d023f_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTgtMTItMS0xLTA_4766016a-30b3-4666-be43-638eb2d428d7">1,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e628bbb40a646dfb1404d2cceaf4b58_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTgtMTQtMS0xLTA_f1006cb0-8801-473c-a739-8e0d7c1b1017">639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RleHRyZWdpb246MjI1MzcwNmEzNTA3NDAyYWJlMzg1NWEwMDdlZTRmZjFfMjEzNA_07c5e9a7-a668-4170-a949-085c7e40794e" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost and estimated fair value of marketable securities by contractual maturity at March 31, 2021 and December 31, 2020 are as follows (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one year or less</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjkyYTBlZGYzMTVhNDQ4MDI5Y2YwZjFlNDA1OWU5NTY4L3RhYmxlcmFuZ2U6OTJhMGVkZjMxNWE0NDgwMjljZjBmMWU0MDU5ZTk1NjhfMi0yLTEtMS0w_017ce37f-f893-4f09-aaea-30b97068fbfb">2,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjkyYTBlZGYzMTVhNDQ4MDI5Y2YwZjFlNDA1OWU5NTY4L3RhYmxlcmFuZ2U6OTJhMGVkZjMxNWE0NDgwMjljZjBmMWU0MDU5ZTk1NjhfMi00LTEtMS0w_f3187254-76cf-48dc-852a-8ff3ff770f91">2,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjkyYTBlZGYzMTVhNDQ4MDI5Y2YwZjFlNDA1OWU5NTY4L3RhYmxlcmFuZ2U6OTJhMGVkZjMxNWE0NDgwMjljZjBmMWU0MDU5ZTk1NjhfMy0yLTEtMS0w_a8c3123d-9744-4d15-a9dc-98f6f6f26f39">468</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjkyYTBlZGYzMTVhNDQ4MDI5Y2YwZjFlNDA1OWU5NTY4L3RhYmxlcmFuZ2U6OTJhMGVkZjMxNWE0NDgwMjljZjBmMWU0MDU5ZTk1NjhfMy00LTEtMS0w_ec911e70-9619-4ab8-80cd-832613947fd7">468</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjkyYTBlZGYzMTVhNDQ4MDI5Y2YwZjFlNDA1OWU5NTY4L3RhYmxlcmFuZ2U6OTJhMGVkZjMxNWE0NDgwMjljZjBmMWU0MDU5ZTk1NjhfNC0yLTEtMS0w_f590b52f-98d6-4a65-8ff1-e5edcf351aaf">2,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjkyYTBlZGYzMTVhNDQ4MDI5Y2YwZjFlNDA1OWU5NTY4L3RhYmxlcmFuZ2U6OTJhMGVkZjMxNWE0NDgwMjljZjBmMWU0MDU5ZTk1NjhfNC00LTEtMS0w_1179fec8-5160-4359-8c32-da48817308ae">2,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one year or less</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjcwOTZhYjY5N2VhMzQ4NDZiM2M5MTk5NzQ4MWZlNGYxL3RhYmxlcmFuZ2U6NzA5NmFiNjk3ZWEzNDg0NmIzYzkxOTk3NDgxZmU0ZjFfMi0yLTEtMS0zODI5_5b7bc61a-3e23-4159-84ae-83405d4eddcc">1,981</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjcwOTZhYjY5N2VhMzQ4NDZiM2M5MTk5NzQ4MWZlNGYxL3RhYmxlcmFuZ2U6NzA5NmFiNjk3ZWEzNDg0NmIzYzkxOTk3NDgxZmU0ZjFfMi00LTEtMS0zODI5_27dbb885-4365-4e86-9f3d-fdbcb5d98313">1,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjcwOTZhYjY5N2VhMzQ4NDZiM2M5MTk5NzQ4MWZlNGYxL3RhYmxlcmFuZ2U6NzA5NmFiNjk3ZWEzNDg0NmIzYzkxOTk3NDgxZmU0ZjFfMy0yLTEtMS0zODI5_72292bc9-1c2f-408a-bc56-315d70bca093">638</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjcwOTZhYjY5N2VhMzQ4NDZiM2M5MTk5NzQ4MWZlNGYxL3RhYmxlcmFuZ2U6NzA5NmFiNjk3ZWEzNDg0NmIzYzkxOTk3NDgxZmU0ZjFfMy00LTEtMS0zODI5_585ab18c-5f48-4296-90d4-4b6f2e229cfa">639</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjcwOTZhYjY5N2VhMzQ4NDZiM2M5MTk5NzQ4MWZlNGYxL3RhYmxlcmFuZ2U6NzA5NmFiNjk3ZWEzNDg0NmIzYzkxOTk3NDgxZmU0ZjFfNC0yLTEtMS02MDg5_68d98e47-960d-423c-836c-393c3c4131d5">2,619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjcwOTZhYjY5N2VhMzQ4NDZiM2M5MTk5NzQ4MWZlNGYxL3RhYmxlcmFuZ2U6NzA5NmFiNjk3ZWEzNDg0NmIzYzkxOTk3NDgxZmU0ZjFfNC00LTEtMS02MDkx_89b605a7-325d-41f7-8aec-ac8733c4ef36">2,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Contents</a></span></div></div><ix:continuation id="i0cc172bd310d4316b9a1a06d3862e649" continuedAt="ie89268a7197540c2a344ba785fe218fc"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with our investment policy, we place investments in investment grade securities with high credit quality issuers, and generally limit the amount of credit exposure to any one issuer. We evaluate securities for impairment at the end of each reporting period. Impairment is evaluated considering numerous factors, and their relative significance varies depending on the situation. Factors considered include whether a decline in fair value below the amortized cost basis is due to credit-related factors or noncredit-related factors, the financial condition and near-term prospects of the issuer, and our intent and ability to hold the investment to allow for an anticipated recovery in fair value. Any impairment that is not credit related is recognized in other comprehensive loss, net of applicable taxes. A credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings. We did <ix:nonFraction unitRef="usd" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RleHRyZWdpb246MjI1MzcwNmEzNTA3NDAyYWJlMzg1NWEwMDdlZTRmZjFfMzI5ODUzNDg4OTk4Nw_4e114cdb-e36b-4b11-8c84-624610858c8f"><ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RleHRyZWdpb246MjI1MzcwNmEzNTA3NDAyYWJlMzg1NWEwMDdlZTRmZjFfMzI5ODUzNDg4OTk4Nw_b23a0779-0d98-411b-9b4c-d04f5da2c8af">no</ix:nonFraction></ix:nonFraction>t recognize any impairment charges related to available-for-sale securities for the three months ended March 31, 2021 and 2020. We did not recognize any credit losses related allowance to available-for-sale securities as of March 31, 2021 and December 31, 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 and December 31, 2020, we did not have material gross unrealized losses. We neither intend to sell these investments, nor do we believe that we are more-likely-than-not to conclude we will have to sell them before recovery of their carrying values. We also believe that we will be able to collect both principal and interest amounts due to us at maturity.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used to value the assets and liabilities: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; or</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RleHRyZWdpb246MjI1MzcwNmEzNTA3NDAyYWJlMzg1NWEwMDdlZTRmZjFfNzY5NjU4MTM5ODA5Mg_9187fcc1-c26f-4d61-aaac-f5c7dfdbe891" continuedAt="if3be8010adb346628da24b8644ec5b4f" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize our financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2021 and December 31, 2020 (in millions):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at <br/>March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement Using</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i123d9cb392064f7bbe194ed464f90c8f_I20210331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjFhMjAxMzRkZDU5NzQ3MzA5MTY0NmM5OTYyY2EzNDBhL3RhYmxlcmFuZ2U6MWEyMDEzNGRkNTk3NDczMDkxNjQ2Yzk5NjJjYTM0MGFfMy0yLTEtMS00MDIw_e136ebc5-6962-40f6-bf6c-5bd15d89d3b0">537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb052beac6e745e59a97634f1deb8911_I20210331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjFhMjAxMzRkZDU5NzQ3MzA5MTY0NmM5OTYyY2EzNDBhL3RhYmxlcmFuZ2U6MWEyMDEzNGRkNTk3NDczMDkxNjQ2Yzk5NjJjYTM0MGFfMy00LTEtMS00MDIw_57e06bcf-c32a-4839-9978-0bd3f296f53f">537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d49a64ca5814a3b8323c954b990c2f1_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjFhMjAxMzRkZDU5NzQ3MzA5MTY0NmM5OTYyY2EzNDBhL3RhYmxlcmFuZ2U6MWEyMDEzNGRkNTk3NDczMDkxNjQ2Yzk5NjJjYTM0MGFfMy02LTEtMS00MDIw_e319f2b0-10a9-4ca5-8258-a6a2b51f877d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ed53e247dd44a8fbc05e34b092630a4_I20210331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjFhMjAxMzRkZDU5NzQ3MzA5MTY0NmM5OTYyY2EzNDBhL3RhYmxlcmFuZ2U6MWEyMDEzNGRkNTk3NDczMDkxNjQ2Yzk5NjJjYTM0MGFfNC0yLTEtMS00MDIw_4f1db935-7ffe-4b66-970a-bc4b07ee071b">413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd19a0d5fe7648f19bcf7eb315e47574_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjFhMjAxMzRkZDU5NzQ3MzA5MTY0NmM5OTYyY2EzNDBhL3RhYmxlcmFuZ2U6MWEyMDEzNGRkNTk3NDczMDkxNjQ2Yzk5NjJjYTM0MGFfNC00LTEtMS00MDIw_23acaf91-f8eb-4b21-94dc-41c80525ec61">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7a5259755b49e49d483e9c3980d884_I20210331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjFhMjAxMzRkZDU5NzQ3MzA5MTY0NmM5OTYyY2EzNDBhL3RhYmxlcmFuZ2U6MWEyMDEzNGRkNTk3NDczMDkxNjQ2Yzk5NjJjYTM0MGFfNC02LTEtMS00MDIw_e6187195-dcc4-45e3-ac89-ba2fc037a8e1">413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia850cc3fdca949bdbacf65e2aa316867_I20210331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjFhMjAxMzRkZDU5NzQ3MzA5MTY0NmM5OTYyY2EzNDBhL3RhYmxlcmFuZ2U6MWEyMDEzNGRkNTk3NDczMDkxNjQ2Yzk5NjJjYTM0MGFfNS0yLTEtMS00MDIw_480318e7-b798-487f-8f14-1b7f153def89">374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbba28371a0c4ac7b6d117d940658048_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjFhMjAxMzRkZDU5NzQ3MzA5MTY0NmM5OTYyY2EzNDBhL3RhYmxlcmFuZ2U6MWEyMDEzNGRkNTk3NDczMDkxNjQ2Yzk5NjJjYTM0MGFfNS00LTEtMS00MDIw_aa099777-9b43-408f-905e-12294f295224">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a9ecc2c2f4c4165a295dd17a5a65f57_I20210331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjFhMjAxMzRkZDU5NzQ3MzA5MTY0NmM5OTYyY2EzNDBhL3RhYmxlcmFuZ2U6MWEyMDEzNGRkNTk3NDczMDkxNjQ2Yzk5NjJjYTM0MGFfNS02LTEtMS00MDIw_e8e36547-9f0e-4a84-8c9a-d321cf516617">374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities of U.S. government agencies and corporate entities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f155650a70d4eeda45d6f57b5eb94af_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjFhMjAxMzRkZDU5NzQ3MzA5MTY0NmM5OTYyY2EzNDBhL3RhYmxlcmFuZ2U6MWEyMDEzNGRkNTk3NDczMDkxNjQ2Yzk5NjJjYTM0MGFfNi0yLTEtMS00MDIw_4f0cf24f-8ed3-436a-8ec7-2ad3b4db2f36">1,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8803bb198614454eb655c9107db2f3b2_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjFhMjAxMzRkZDU5NzQ3MzA5MTY0NmM5OTYyY2EzNDBhL3RhYmxlcmFuZ2U6MWEyMDEzNGRkNTk3NDczMDkxNjQ2Yzk5NjJjYTM0MGFfNi00LTEtMS00MDIw_2bd806d2-f7e1-4f84-be1e-9337814b5d6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bad47bc31eb4c3fa7e59c8591449292_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjFhMjAxMzRkZDU5NzQ3MzA5MTY0NmM5OTYyY2EzNDBhL3RhYmxlcmFuZ2U6MWEyMDEzNGRkNTk3NDczMDkxNjQ2Yzk5NjJjYTM0MGFfNi02LTEtMS00MDIw_1b5df990-18b6-4f89-bdca-e0aaffd96c6b">1,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments (Note 7)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c36846f9be347ffadf3fb034bb04f1c_I20210331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjFhMjAxMzRkZDU5NzQ3MzA5MTY0NmM5OTYyY2EzNDBhL3RhYmxlcmFuZ2U6MWEyMDEzNGRkNTk3NDczMDkxNjQ2Yzk5NjJjYTM0MGFfNy0yLTEtMS00MDIw_770a0520-a3d2-4492-a7ee-49fe6b6dc47a">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cbf1ef1e50043a6973a41f4362eca38_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjFhMjAxMzRkZDU5NzQ3MzA5MTY0NmM5OTYyY2EzNDBhL3RhYmxlcmFuZ2U6MWEyMDEzNGRkNTk3NDczMDkxNjQ2Yzk5NjJjYTM0MGFfNy00LTEtMS00MDIw_95bb58b2-70f3-46f5-90c3-2d01e86a3a69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id976144d8ac0470a8dfe87f5e0806e11_I20210331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjFhMjAxMzRkZDU5NzQ3MzA5MTY0NmM5OTYyY2EzNDBhL3RhYmxlcmFuZ2U6MWEyMDEzNGRkNTk3NDczMDkxNjQ2Yzk5NjJjYTM0MGFfNy02LTEtMS00MDIw_f8b81a1e-2af9-4ad9-8c9e-114aafe90553">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c36846f9be347ffadf3fb034bb04f1c_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjFhMjAxMzRkZDU5NzQ3MzA5MTY0NmM5OTYyY2EzNDBhL3RhYmxlcmFuZ2U6MWEyMDEzNGRkNTk3NDczMDkxNjQ2Yzk5NjJjYTM0MGFfOC0yLTEtMS02MDk1_bab71aeb-ee93-4455-9c55-a43fe8497616">3,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cbf1ef1e50043a6973a41f4362eca38_I20210331" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjFhMjAxMzRkZDU5NzQ3MzA5MTY0NmM5OTYyY2EzNDBhL3RhYmxlcmFuZ2U6MWEyMDEzNGRkNTk3NDczMDkxNjQ2Yzk5NjJjYTM0MGFfOC00LTEtMS02MDk3_dc2ada62-5df2-49a0-b5b1-53bf87edb1e4">537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id976144d8ac0470a8dfe87f5e0806e11_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjFhMjAxMzRkZDU5NzQ3MzA5MTY0NmM5OTYyY2EzNDBhL3RhYmxlcmFuZ2U6MWEyMDEzNGRkNTk3NDczMDkxNjQ2Yzk5NjJjYTM0MGFfOC02LTEtMS02MDk5_75cefc8c-56bd-4eb7-97fc-82b9b7a9be47">2,762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments (Note 7)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c36846f9be347ffadf3fb034bb04f1c_I20210331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjFhMjAxMzRkZDU5NzQ3MzA5MTY0NmM5OTYyY2EzNDBhL3RhYmxlcmFuZ2U6MWEyMDEzNGRkNTk3NDczMDkxNjQ2Yzk5NjJjYTM0MGFfMTAtMi0xLTEtNjcwMQ_f90d76eb-e68a-4228-92f4-088c408915a9">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cbf1ef1e50043a6973a41f4362eca38_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjFhMjAxMzRkZDU5NzQ3MzA5MTY0NmM5OTYyY2EzNDBhL3RhYmxlcmFuZ2U6MWEyMDEzNGRkNTk3NDczMDkxNjQ2Yzk5NjJjYTM0MGFfMTAtNC0xLTEtNjcwMQ_569bd19c-2393-4a87-9bd2-10605567e5d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id976144d8ac0470a8dfe87f5e0806e11_I20210331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjFhMjAxMzRkZDU5NzQ3MzA5MTY0NmM5OTYyY2EzNDBhL3RhYmxlcmFuZ2U6MWEyMDEzNGRkNTk3NDczMDkxNjQ2Yzk5NjJjYTM0MGFfMTAtNi0xLTEtNjcwMQ_207ba2a2-829e-4f93-869c-50b78a3fadae">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Contents</a></span></div></div><ix:continuation id="ie89268a7197540c2a344ba785fe218fc"><div style="margin-bottom:6pt"><ix:continuation id="if3be8010adb346628da24b8644ec5b4f"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.986%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement Using</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9ead6d8a2d6496ab53b71dbf65c0e89_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjc4MzQxZGU5MjFjYjRjYzc4MDIzNThiZTE3ZjEwNTkwL3RhYmxlcmFuZ2U6NzgzNDFkZTkyMWNiNGNjNzgwMjM1OGJlMTdmMTA1OTBfMy0yLTEtMS00MDAw_1baa8b19-b9a3-48ba-b96c-3a65ac00f896">621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae8a6101db3483ea8c8e7878ef68c7b_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjc4MzQxZGU5MjFjYjRjYzc4MDIzNThiZTE3ZjEwNTkwL3RhYmxlcmFuZ2U6NzgzNDFkZTkyMWNiNGNjNzgwMjM1OGJlMTdmMTA1OTBfMy00LTEtMS00MDEy_1a5a10b3-ab97-460a-af11-7903a2a02337">621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6aa4efa157cf4cbcaf792243639a7365_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjc4MzQxZGU5MjFjYjRjYzc4MDIzNThiZTE3ZjEwNTkwL3RhYmxlcmFuZ2U6NzgzNDFkZTkyMWNiNGNjNzgwMjM1OGJlMTdmMTA1OTBfMy02LTEtMS02MTA1_6aa31735-b42a-4230-899d-b4e4684a2798">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0598f69f1ada4de8ae9919743b2bdf0c_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjc4MzQxZGU5MjFjYjRjYzc4MDIzNThiZTE3ZjEwNTkwL3RhYmxlcmFuZ2U6NzgzNDFkZTkyMWNiNGNjNzgwMjM1OGJlMTdmMTA1OTBfNC0yLTEtMS00MDA0_ee2c62d5-2f3f-4278-ad64-31b56995e77a">239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f6a88f2c7c4d8085866d26873d36e9_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjc4MzQxZGU5MjFjYjRjYzc4MDIzNThiZTE3ZjEwNTkwL3RhYmxlcmFuZ2U6NzgzNDFkZTkyMWNiNGNjNzgwMjM1OGJlMTdmMTA1OTBfNC00LTEtMS00MDE2_7a85a382-6f76-4b3f-b376-d04e7863c6c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if667a4d9f03441e794394bde2522c7d6_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjc4MzQxZGU5MjFjYjRjYzc4MDIzNThiZTE3ZjEwNTkwL3RhYmxlcmFuZ2U6NzgzNDFkZTkyMWNiNGNjNzgwMjM1OGJlMTdmMTA1OTBfNC02LTEtMS00MDE2_509bfad6-aa8e-4780-8d3c-4344dff83f02">239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4745cd6ed947bc9dc06de365526c6f_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjc4MzQxZGU5MjFjYjRjYzc4MDIzNThiZTE3ZjEwNTkwL3RhYmxlcmFuZ2U6NzgzNDFkZTkyMWNiNGNjNzgwMjM1OGJlMTdmMTA1OTBfNS0yLTEtMS00MDA0_7b4caafa-8bae-4857-bb0e-ab33027eb37c">492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c0cd6f20ef146849ac96024e8997311_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjc4MzQxZGU5MjFjYjRjYzc4MDIzNThiZTE3ZjEwNTkwL3RhYmxlcmFuZ2U6NzgzNDFkZTkyMWNiNGNjNzgwMjM1OGJlMTdmMTA1OTBfNS00LTEtMS00MDE2_e3a31c44-e536-4fb2-b075-a59f010400e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34e70e75e95f41a89179d7b607304203_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjc4MzQxZGU5MjFjYjRjYzc4MDIzNThiZTE3ZjEwNTkwL3RhYmxlcmFuZ2U6NzgzNDFkZTkyMWNiNGNjNzgwMjM1OGJlMTdmMTA1OTBfNS02LTEtMS00MDE2_96aa9f2d-197f-4c22-93ca-d284404a2669">492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities of U.S. government agencies and corporate entities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie17de02d67874972813c65e1ee7828ab_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjc4MzQxZGU5MjFjYjRjYzc4MDIzNThiZTE3ZjEwNTkwL3RhYmxlcmFuZ2U6NzgzNDFkZTkyMWNiNGNjNzgwMjM1OGJlMTdmMTA1OTBfNi0yLTEtMS00MDA0_e6917657-1989-4df1-aec6-ad5642ea7f0c">1,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id52895ca9a52496199fbd7e4b81d30b8_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjc4MzQxZGU5MjFjYjRjYzc4MDIzNThiZTE3ZjEwNTkwL3RhYmxlcmFuZ2U6NzgzNDFkZTkyMWNiNGNjNzgwMjM1OGJlMTdmMTA1OTBfNi00LTEtMS00MDE2_712d9d86-8e85-4a12-b7c7-9d2bf3ad40c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa680536838a4ffd80a53a841c00e107_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjc4MzQxZGU5MjFjYjRjYzc4MDIzNThiZTE3ZjEwNTkwL3RhYmxlcmFuZ2U6NzgzNDFkZTkyMWNiNGNjNzgwMjM1OGJlMTdmMTA1OTBfNi02LTEtMS00MDE2_00e3911c-85f3-4670-af17-2962f83c4e32">1,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i686e90a952424d579c987c59336787cd_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjc4MzQxZGU5MjFjYjRjYzc4MDIzNThiZTE3ZjEwNTkwL3RhYmxlcmFuZ2U6NzgzNDFkZTkyMWNiNGNjNzgwMjM1OGJlMTdmMTA1OTBfNy0yLTEtMS02MTAx_f3a40054-248a-483e-bed9-183c3ffb9f9a">3,244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59dd43638f654b5ca42787b1d4565122_I20201231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjc4MzQxZGU5MjFjYjRjYzc4MDIzNThiZTE3ZjEwNTkwL3RhYmxlcmFuZ2U6NzgzNDFkZTkyMWNiNGNjNzgwMjM1OGJlMTdmMTA1OTBfNy00LTEtMS02MTAz_f914faa6-ae4f-41e6-a1f2-c4a97c768fb7">621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5f5b6e35e214612987f2dbe6605a881_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjc4MzQxZGU5MjFjYjRjYzc4MDIzNThiZTE3ZjEwNTkwL3RhYmxlcmFuZ2U6NzgzNDFkZTkyMWNiNGNjNzgwMjM1OGJlMTdmMTA1OTBfNy02LTEtMS02MTA1_29a24adc-db0a-48cd-89af-0eaf11b8244b">2,623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 and December 31, 2020, we did not have non-financial assets or liabilities measured at fair value on a recurring basis.</span></div></ix:continuation><div><span><br/></span></div><div id="ibba7ad915d1a4c4a8ebb50d13fae4c4e_1010"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDEwL2ZyYWc6NjcxOTY4N2JjOGIzNDcwMWIxMTQ0ODI1NWU5ZGJmMTYvdGV4dHJlZ2lvbjo2NzE5Njg3YmM4YjM0NzAxYjExNDQ4MjU1ZTlkYmYxNl83Njk2NTgxMzk2NjIx_37556f2a-70f1-468d-95ea-597d445e5272" continuedAt="i82e88a93d7cc4650bb21c92193a4f387" escape="true">Derivative Financial Instruments</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i82e88a93d7cc4650bb21c92193a4f387" continuedAt="i546ffeb12f154db999ff40406f1ff91d"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We transact business in various foreign currencies and have international sales and expenses denominated in foreign currencies. Therefore, we are exposed to certain risks arising from both our business operations and economic conditions. Our risk management strategy includes the use of derivative financial instruments to hedge foreign currency exchange rate fluctuations on monetary assets or liabilities denominated in foreign currencies. We do not enter into derivative financial contracts for speculative or trading purposes. We do not believe that we are exposed to more than a nominal amount of credit risk in our foreign currency hedges, as counterparties are large, global and well-capitalized financial institutions. We classify cash flows from our derivative transactions as cash flows from operating activities in our consolidated statements of cash flows.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Balance Sheet Hedges</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our foreign currency forward contracts, primarily accounts receivable, are not designated for hedge accounting treatment. Therefore, these forward contracts are accounted for as derivatives whereby the fair value of the contracts are reported as other current assets or other current liabilities on our condensed consolidated balance sheets, and gains and losses resulting from changes in the fair value are recorded as a component of other expense, net, in our condensed consolidated statements of operations. The gains and losses on these foreign currency forward contracts generally offset the gains and losses in the underlying foreign currency denominated assets and liabilities, which are also recorded to other expense, net, in our condensed consolidated statements of operations. </span></div></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Contents</a></span></div></div><ix:continuation id="i546ffeb12f154db999ff40406f1ff91d"><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDEwL2ZyYWc6NjcxOTY4N2JjOGIzNDcwMWIxMTQ0ODI1NWU5ZGJmMTYvdGV4dHJlZ2lvbjo2NzE5Njg3YmM4YjM0NzAxYjExNDQ4MjU1ZTlkYmYxNl83Njk2NTgxMzk2NjIw_8b828734-d369-44fc-94e4-875909ef5603" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total gross notional amount and fair value for foreign currency derivatives that are not designated as hedging instruments are accounted for as follows (in millions):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.792%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i900a81907e194a84ba164cb4e36677d2_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDEwL2ZyYWc6NjcxOTY4N2JjOGIzNDcwMWIxMTQ0ODI1NWU5ZGJmMTYvdGFibGU6OWQwNGFjOTQ5YzBkNDdkMTlmMWQ2ZjAwODY5ODljOWUvdGFibGVyYW5nZTo5ZDA0YWM5NDljMGQ0N2QxOWYxZDZmMDA4Njk4OWM5ZV80LTItMS0xLTE2OTk_73607bf0-31f1-4a45-93a2-e7cf92ccfd04">1,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i900a81907e194a84ba164cb4e36677d2_I20210331" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDEwL2ZyYWc6NjcxOTY4N2JjOGIzNDcwMWIxMTQ0ODI1NWU5ZGJmMTYvdGFibGU6OWQwNGFjOTQ5YzBkNDdkMTlmMWQ2ZjAwODY5ODljOWUvdGFibGVyYW5nZTo5ZDA0YWM5NDljMGQ0N2QxOWYxZDZmMDA4Njk4OWM5ZV80LTQtMS0xLTE2OTk_1232c105-5f16-4d25-903b-2a1d3a209eb0">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i900a81907e194a84ba164cb4e36677d2_I20210331" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDEwL2ZyYWc6NjcxOTY4N2JjOGIzNDcwMWIxMTQ0ODI1NWU5ZGJmMTYvdGFibGU6OWQwNGFjOTQ5YzBkNDdkMTlmMWQ2ZjAwODY5ODljOWUvdGFibGVyYW5nZTo5ZDA0YWM5NDljMGQ0N2QxOWYxZDZmMDA4Njk4OWM5ZV80LTYtMS0xLTE2OTk_5751f36a-b7f4-434c-9cbb-ffee0e1b579f">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ab6f5001f864500b4c8e0d67181a3e1_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDEwL2ZyYWc6NjcxOTY4N2JjOGIzNDcwMWIxMTQ0ODI1NWU5ZGJmMTYvdGFibGU6OWQwNGFjOTQ5YzBkNDdkMTlmMWQ2ZjAwODY5ODljOWUvdGFibGVyYW5nZTo5ZDA0YWM5NDljMGQ0N2QxOWYxZDZmMDA4Njk4OWM5ZV81LTItMS0xLTM0MDI_7dd85b89-9853-41ea-94c2-656cce3c74d7">1,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ab6f5001f864500b4c8e0d67181a3e1_I20210331" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDEwL2ZyYWc6NjcxOTY4N2JjOGIzNDcwMWIxMTQ0ODI1NWU5ZGJmMTYvdGFibGU6OWQwNGFjOTQ5YzBkNDdkMTlmMWQ2ZjAwODY5ODljOWUvdGFibGVyYW5nZTo5ZDA0YWM5NDljMGQ0N2QxOWYxZDZmMDA4Njk4OWM5ZV81LTQtMS0xLTM0MDQ_734993df-3860-4f18-8515-84ca2b50af47">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ab6f5001f864500b4c8e0d67181a3e1_I20210331" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDEwL2ZyYWc6NjcxOTY4N2JjOGIzNDcwMWIxMTQ0ODI1NWU5ZGJmMTYvdGFibGU6OWQwNGFjOTQ5YzBkNDdkMTlmMWQ2ZjAwODY5ODljOWUvdGFibGVyYW5nZTo5ZDA0YWM5NDljMGQ0N2QxOWYxZDZmMDA4Njk4OWM5ZV81LTYtMS0xLTM0MDY_9f79bc7c-0b53-4595-9069-c9ac346a4d85">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.792%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61150f006fb645cb98904910e2b941a8_I20201231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDEwL2ZyYWc6NjcxOTY4N2JjOGIzNDcwMWIxMTQ0ODI1NWU5ZGJmMTYvdGFibGU6ZjBlYTFiZWUzYTVmNDJlZGE1N2NkMWY4NDQ5NjhiY2MvdGFibGVyYW5nZTpmMGVhMWJlZTNhNWY0MmVkYTU3Y2QxZjg0NDk2OGJjY180LTItMS0xLTY3MjQ_b3bfbe0c-d7f4-499f-a8cc-b1d1140fe617">368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61150f006fb645cb98904910e2b941a8_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDEwL2ZyYWc6NjcxOTY4N2JjOGIzNDcwMWIxMTQ0ODI1NWU5ZGJmMTYvdGFibGU6ZjBlYTFiZWUzYTVmNDJlZGE1N2NkMWY4NDQ5NjhiY2MvdGFibGVyYW5nZTpmMGVhMWJlZTNhNWY0MmVkYTU3Y2QxZjg0NDk2OGJjY180LTQtMS0xLTY3MjQ_e482324e-f897-4083-8b58-15b208da0f7c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61150f006fb645cb98904910e2b941a8_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDEwL2ZyYWc6NjcxOTY4N2JjOGIzNDcwMWIxMTQ0ODI1NWU5ZGJmMTYvdGFibGU6ZjBlYTFiZWUzYTVmNDJlZGE1N2NkMWY4NDQ5NjhiY2MvdGFibGVyYW5nZTpmMGVhMWJlZTNhNWY0MmVkYTU3Y2QxZjg0NDk2OGJjY180LTYtMS0xLTY3MjQ_f3e8f6c6-4b70-4b15-91f1-81cac9e6300c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie50812d5f7b44b30b8225d6636c4c4f4_I20201231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDEwL2ZyYWc6NjcxOTY4N2JjOGIzNDcwMWIxMTQ0ODI1NWU5ZGJmMTYvdGFibGU6ZjBlYTFiZWUzYTVmNDJlZGE1N2NkMWY4NDQ5NjhiY2MvdGFibGVyYW5nZTpmMGVhMWJlZTNhNWY0MmVkYTU3Y2QxZjg0NDk2OGJjY181LTItMS0xLTcxMzY_bd8cb06f-4171-4491-9c12-82e7226a8a7b">368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie50812d5f7b44b30b8225d6636c4c4f4_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDEwL2ZyYWc6NjcxOTY4N2JjOGIzNDcwMWIxMTQ0ODI1NWU5ZGJmMTYvdGFibGU6ZjBlYTFiZWUzYTVmNDJlZGE1N2NkMWY4NDQ5NjhiY2MvdGFibGVyYW5nZTpmMGVhMWJlZTNhNWY0MmVkYTU3Y2QxZjg0NDk2OGJjY181LTQtMS0xLTcxMzg_c41575e1-5a3d-4f45-9698-9cb67d1b2d60">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie50812d5f7b44b30b8225d6636c4c4f4_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDEwL2ZyYWc6NjcxOTY4N2JjOGIzNDcwMWIxMTQ0ODI1NWU5ZGJmMTYvdGFibGU6ZjBlYTFiZWUzYTVmNDJlZGE1N2NkMWY4NDQ5NjhiY2MvdGFibGVyYW5nZTpmMGVhMWJlZTNhNWY0MmVkYTU3Y2QxZjg0NDk2OGJjY181LTYtMS0xLTcxNDA_7d85aa41-9959-462e-a438-113774d9f849">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">_________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As presented in the condensed consolidated balance sheet within other current assets.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As presented in the condensed consolidated balance sheet within other current liabilities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The effect of foreign currency forward contracts not designated as hedging instruments in our condensed consolidated statements of operations for the three months ended March 31, 2021 was as follows (in millions):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:56.062%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.773%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.773%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bd7f75306414af4a89bd03391f700a7_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDEwL2ZyYWc6NjcxOTY4N2JjOGIzNDcwMWIxMTQ0ODI1NWU5ZGJmMTYvdGFibGU6NmY4NmNjYmVmODljNGE1YTkyZWE2MjliNTk4ODAxZjIvdGFibGVyYW5nZTo2Zjg2Y2NiZWY4OWM0YTVhOTJlYTYyOWI1OTg4MDFmMl8yLTQtMS0xLTE3MDM_c02bdad6-9c47-4809-9632-6c3bb3cbcbf2">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if558e6ed91924e46b53fe8382ea023b2_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDEwL2ZyYWc6NjcxOTY4N2JjOGIzNDcwMWIxMTQ0ODI1NWU5ZGJmMTYvdGFibGU6NmY4NmNjYmVmODljNGE1YTkyZWE2MjliNTk4ODAxZjIvdGFibGVyYW5nZTo2Zjg2Y2NiZWY4OWM0YTVhOTJlYTYyOWI1OTg4MDFmMl8zLTQtMS0xLTM0MDA_f45e028a-8b08-49b9-8aa3-d107cf699f78">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There were no hedging activities for the three months ended March 31, 2020.</span></div></ix:continuation><div><span><br/></span></div><div id="ibba7ad915d1a4c4a8ebb50d13fae4c4e_1018"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">8. <ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDE4L2ZyYWc6YjY3MWE3OTc3OWMyNDYxNWJjODk5Y2M3ODAyM2I1ZmUvdGV4dHJlZ2lvbjpiNjcxYTc5Nzc5YzI0NjE1YmM4OTljYzc4MDIzYjVmZV83Njk2NTgxMzk0NTQ5_def1383f-fc2c-44b6-9639-8e87e9389f80" continuedAt="i9e4b9b414d03452facd840752de3dac5" escape="true">Inventory</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i9e4b9b414d03452facd840752de3dac5"><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDE4L2ZyYWc6YjY3MWE3OTc3OWMyNDYxNWJjODk5Y2M3ODAyM2I1ZmUvdGV4dHJlZ2lvbjpiNjcxYTc5Nzc5YzI0NjE1YmM4OTljYzc4MDIzYjVmZV83Njk2NTgxMzk0NTUw_70a119cf-cd44-46e7-ab67-2ac6a2766315" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory as of March 31, 2021 and December 31, 2020 consists of the following (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.288%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.986%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDE4L2ZyYWc6YjY3MWE3OTc3OWMyNDYxNWJjODk5Y2M3ODAyM2I1ZmUvdGFibGU6NzcyZGQ3NGQ5YzAzNDU2Y2ExNTlmODc2NmNjYmQxNmMvdGFibGVyYW5nZTo3NzJkZDc0ZDljMDM0NTZjYTE1OWY4NzY2Y2NiZDE2Y18yLTItMS0xLTE2ODQ_c691399e-6394-49cc-bcb4-cb6586112939">430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDE4L2ZyYWc6YjY3MWE3OTc3OWMyNDYxNWJjODk5Y2M3ODAyM2I1ZmUvdGFibGU6NzcyZGQ3NGQ5YzAzNDU2Y2ExNTlmODc2NmNjYmQxNmMvdGFibGVyYW5nZTo3NzJkZDc0ZDljMDM0NTZjYTE1OWY4NzY2Y2NiZDE2Y18yLTQtMS0xLTE2ODQ_1b472ff5-7d63-4a84-930f-642b814ad1ab">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in progress </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDE4L2ZyYWc6YjY3MWE3OTc3OWMyNDYxNWJjODk5Y2M3ODAyM2I1ZmUvdGFibGU6NzcyZGQ3NGQ5YzAzNDU2Y2ExNTlmODc2NmNjYmQxNmMvdGFibGVyYW5nZTo3NzJkZDc0ZDljMDM0NTZjYTE1OWY4NzY2Y2NiZDE2Y18zLTItMS0xLTE2ODQ_6443c51e-d2df-4cb3-9701-2379125cb19c">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDE4L2ZyYWc6YjY3MWE3OTc3OWMyNDYxNWJjODk5Y2M3ODAyM2I1ZmUvdGFibGU6NzcyZGQ3NGQ5YzAzNDU2Y2ExNTlmODc2NmNjYmQxNmMvdGFibGVyYW5nZTo3NzJkZDc0ZDljMDM0NTZjYTE1OWY4NzY2Y2NiZDE2Y18zLTQtMS0xLTE2ODQ_0a1be3f4-7839-4835-b6d7-39c21c4f8f79">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDE4L2ZyYWc6YjY3MWE3OTc3OWMyNDYxNWJjODk5Y2M3ODAyM2I1ZmUvdGFibGU6NzcyZGQ3NGQ5YzAzNDU2Y2ExNTlmODc2NmNjYmQxNmMvdGFibGVyYW5nZTo3NzJkZDc0ZDljMDM0NTZjYTE1OWY4NzY2Y2NiZDE2Y180LTItMS0xLTE2ODQ_56d440d2-e543-4645-9acf-38bb0921cf38">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDE4L2ZyYWc6YjY3MWE3OTc3OWMyNDYxNWJjODk5Y2M3ODAyM2I1ZmUvdGFibGU6NzcyZGQ3NGQ5YzAzNDU2Y2ExNTlmODc2NmNjYmQxNmMvdGFibGVyYW5nZTo3NzJkZDc0ZDljMDM0NTZjYTE1OWY4NzY2Y2NiZDE2Y180LTQtMS0xLTE2ODQ_7e6b7f57-e427-452a-89d7-f3ed4fafbbf5">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDE4L2ZyYWc6YjY3MWE3OTc3OWMyNDYxNWJjODk5Y2M3ODAyM2I1ZmUvdGFibGU6NzcyZGQ3NGQ5YzAzNDU2Y2ExNTlmODc2NmNjYmQxNmMvdGFibGVyYW5nZTo3NzJkZDc0ZDljMDM0NTZjYTE1OWY4NzY2Y2NiZDE2Y181LTItMS0xLTM0MjA_c79eb712-523e-49ce-9ca2-1a4794dea297">494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDE4L2ZyYWc6YjY3MWE3OTc3OWMyNDYxNWJjODk5Y2M3ODAyM2I1ZmUvdGFibGU6NzcyZGQ3NGQ5YzAzNDU2Y2ExNTlmODc2NmNjYmQxNmMvdGFibGVyYW5nZTo3NzJkZDc0ZDljMDM0NTZjYTE1OWY4NzY2Y2NiZDE2Y181LTQtMS0xLTM0MjI_78cfe4d2-0cf7-4b44-9e2f-46e4139757b6">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><div id="ibba7ad915d1a4c4a8ebb50d13fae4c4e_1032"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDMyL2ZyYWc6YmNlNzg3NmI0OTVlNDI1OWFjODMzOGM2Y2NlMzM1ZGUvdGV4dHJlZ2lvbjpiY2U3ODc2YjQ5NWU0MjU5YWM4MzM4YzZjY2UzMzVkZV83Njk2NTgxMzk0ODMz_8e32f3e2-581b-466c-b385-6c07362ec000" continuedAt="i16489c1a8c1849aca93dce7b816635ca" escape="true">Property and Equipment, Net</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i16489c1a8c1849aca93dce7b816635ca" continuedAt="i14818e3f4ece42e9a6fc90faaa3acbf2"><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDMyL2ZyYWc6YmNlNzg3NmI0OTVlNDI1OWFjODMzOGM2Y2NlMzM1ZGUvdGV4dHJlZ2lvbjpiY2U3ODc2YjQ5NWU0MjU5YWM4MzM4YzZjY2UzMzVkZV83Njk2NTgxMzk0ODM0_bea40f79-a076-4cd2-ba24-661911bbf4f7" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, as of March 31, 2021 and December 31, 2020 consists of the following (in&#160;millions):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie182a57ea61f416d8c4866418d5a465d_I20210331" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDMyL2ZyYWc6YmNlNzg3NmI0OTVlNDI1OWFjODMzOGM2Y2NlMzM1ZGUvdGFibGU6OGI3NjZkNjA0NTgzNDhkZDhlNDJmYmUwMTJmYmExZmIvdGFibGVyYW5nZTo4Yjc2NmQ2MDQ1ODM0OGRkOGU0MmZiZTAxMmZiYTFmYl8yLTItMS0xLTE2NTc_0b5b00cb-8f1c-42b4-aa37-f391c5ffa658">125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdaad432c7624d609795f42f421c205b_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDMyL2ZyYWc6YmNlNzg3NmI0OTVlNDI1OWFjODMzOGM2Y2NlMzM1ZGUvdGFibGU6OGI3NjZkNjA0NTgzNDhkZDhlNDJmYmUwMTJmYmExZmIvdGFibGVyYW5nZTo4Yjc2NmQ2MDQ1ODM0OGRkOGU0MmZiZTAxMmZiYTFmYl8yLTQtMS0xLTE2NTc_47a93624-cdaf-4d73-8570-583a7bfeece1">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2ecdbe7a52f4cdaa512b1d59ef2091b_I20210331" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDMyL2ZyYWc6YmNlNzg3NmI0OTVlNDI1OWFjODMzOGM2Y2NlMzM1ZGUvdGFibGU6OGI3NjZkNjA0NTgzNDhkZDhlNDJmYmUwMTJmYmExZmIvdGFibGVyYW5nZTo4Yjc2NmQ2MDQ1ODM0OGRkOGU0MmZiZTAxMmZiYTFmYl8zLTItMS0xLTE2NTc_ded67315-5cb1-44b3-b30e-63eefadb60d3">184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde00942b24405f849061b1a6fad190_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDMyL2ZyYWc6YmNlNzg3NmI0OTVlNDI1OWFjODMzOGM2Y2NlMzM1ZGUvdGFibGU6OGI3NjZkNjA0NTgzNDhkZDhlNDJmYmUwMTJmYmExZmIvdGFibGVyYW5nZTo4Yjc2NmQ2MDQ1ODM0OGRkOGU0MmZiZTAxMmZiYTFmYl8zLTQtMS0xLTE2NTc_d1a9e4dc-c8b3-4c64-aff4-aec4de8aa0fb">180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1eca162cb334496bb26a5b7d49c7186_I20210331" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDMyL2ZyYWc6YmNlNzg3NmI0OTVlNDI1OWFjODMzOGM2Y2NlMzM1ZGUvdGFibGU6OGI3NjZkNjA0NTgzNDhkZDhlNDJmYmUwMTJmYmExZmIvdGFibGVyYW5nZTo4Yjc2NmQ2MDQ1ODM0OGRkOGU0MmZiZTAxMmZiYTFmYl80LTItMS0xLTE2NTc_d7d50c22-af45-427f-aefc-ea0f0343e4d4">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88573437d7664c1a9e52c33298a5b456_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDMyL2ZyYWc6YmNlNzg3NmI0OTVlNDI1OWFjODMzOGM2Y2NlMzM1ZGUvdGFibGU6OGI3NjZkNjA0NTgzNDhkZDhlNDJmYmUwMTJmYmExZmIvdGFibGVyYW5nZTo4Yjc2NmQ2MDQ1ODM0OGRkOGU0MmZiZTAxMmZiYTFmYl80LTQtMS0xLTE2NTc_46f4044f-bcda-49b1-b3d8-46bfa3c434ec">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39475e82f8ca4c18b5f9b3233c43443b_I20210331" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDMyL2ZyYWc6YmNlNzg3NmI0OTVlNDI1OWFjODMzOGM2Y2NlMzM1ZGUvdGFibGU6OGI3NjZkNjA0NTgzNDhkZDhlNDJmYmUwMTJmYmExZmIvdGFibGVyYW5nZTo4Yjc2NmQ2MDQ1ODM0OGRkOGU0MmZiZTAxMmZiYTFmYl81LTItMS0xLTE2NTc_e3041e08-56e8-4ad8-9b63-66c281d0224e">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e9e748f96b34220bf4fe5d60445b495_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDMyL2ZyYWc6YmNlNzg3NmI0OTVlNDI1OWFjODMzOGM2Y2NlMzM1ZGUvdGFibGU6OGI3NjZkNjA0NTgzNDhkZDhlNDJmYmUwMTJmYmExZmIvdGFibGVyYW5nZTo4Yjc2NmQ2MDQ1ODM0OGRkOGU0MmZiZTAxMmZiYTFmYl81LTQtMS0xLTE2NTc_9e42e919-b5e8-4330-9990-8c89ff487dc0">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internally developed software</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3e11e356d35463abd4fb1e3057fcd5d_I20210331" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDMyL2ZyYWc6YmNlNzg3NmI0OTVlNDI1OWFjODMzOGM2Y2NlMzM1ZGUvdGFibGU6OGI3NjZkNjA0NTgzNDhkZDhlNDJmYmUwMTJmYmExZmIvdGFibGVyYW5nZTo4Yjc2NmQ2MDQ1ODM0OGRkOGU0MmZiZTAxMmZiYTFmYl82LTItMS0xLTE2NTc_fcb2cea0-f473-41d6-8fc9-89dac1a4b9dd">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3574dd8d4ffe4445ac4435bdd763464d_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDMyL2ZyYWc6YmNlNzg3NmI0OTVlNDI1OWFjODMzOGM2Y2NlMzM1ZGUvdGFibGU6OGI3NjZkNjA0NTgzNDhkZDhlNDJmYmUwMTJmYmExZmIvdGFibGVyYW5nZTo4Yjc2NmQ2MDQ1ODM0OGRkOGU0MmZiZTAxMmZiYTFmYl82LTQtMS0xLTE2NTc_2bfa9891-63b0-4c08-b9dd-085a60dfe9c3">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset, financing</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1263c583aadd4aeeb0479db8950e9cad_I20210331" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDMyL2ZyYWc6YmNlNzg3NmI0OTVlNDI1OWFjODMzOGM2Y2NlMzM1ZGUvdGFibGU6OGI3NjZkNjA0NTgzNDhkZDhlNDJmYmUwMTJmYmExZmIvdGFibGVyYW5nZTo4Yjc2NmQ2MDQ1ODM0OGRkOGU0MmZiZTAxMmZiYTFmYl83LTItMS0xLTE2NTc_a2220cef-f8a8-42da-b589-01357793b971">108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6397562962643bba0441eaabef86729_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDMyL2ZyYWc6YmNlNzg3NmI0OTVlNDI1OWFjODMzOGM2Y2NlMzM1ZGUvdGFibGU6OGI3NjZkNjA0NTgzNDhkZDhlNDJmYmUwMTJmYmExZmIvdGFibGVyYW5nZTo4Yjc2NmQ2MDQ1ODM0OGRkOGU0MmZiZTAxMmZiYTFmYl83LTQtMS0xLTE2NTc_05303dfc-a65c-4305-8351-47797e27c711">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fb0180403444128af0ca00c287ab8b_I20210331" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDMyL2ZyYWc6YmNlNzg3NmI0OTVlNDI1OWFjODMzOGM2Y2NlMzM1ZGUvdGFibGU6OGI3NjZkNjA0NTgzNDhkZDhlNDJmYmUwMTJmYmExZmIvdGFibGVyYW5nZTo4Yjc2NmQ2MDQ1ODM0OGRkOGU0MmZiZTAxMmZiYTFmYl84LTItMS0xLTE2NTc_f8daa549-acd0-45b1-b6b5-d73fd6ae7ae1">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25b18fc5d30a4a9ebd82c278f9fdee03_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDMyL2ZyYWc6YmNlNzg3NmI0OTVlNDI1OWFjODMzOGM2Y2NlMzM1ZGUvdGFibGU6OGI3NjZkNjA0NTgzNDhkZDhlNDJmYmUwMTJmYmExZmIvdGFibGVyYW5nZTo4Yjc2NmQ2MDQ1ODM0OGRkOGU0MmZiZTAxMmZiYTFmYl84LTQtMS0xLTE2NTc_2881a840-0a4d-441e-87dd-0b197a1ab13e">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDMyL2ZyYWc6YmNlNzg3NmI0OTVlNDI1OWFjODMzOGM2Y2NlMzM1ZGUvdGFibGU6OGI3NjZkNjA0NTgzNDhkZDhlNDJmYmUwMTJmYmExZmIvdGFibGVyYW5nZTo4Yjc2NmQ2MDQ1ODM0OGRkOGU0MmZiZTAxMmZiYTFmYl85LTItMS0xLTM0NDU_595f03a4-db2a-43ca-ae47-ac0a0911ab17">507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDMyL2ZyYWc6YmNlNzg3NmI0OTVlNDI1OWFjODMzOGM2Y2NlMzM1ZGUvdGFibGU6OGI3NjZkNjA0NTgzNDhkZDhlNDJmYmUwMTJmYmExZmIvdGFibGVyYW5nZTo4Yjc2NmQ2MDQ1ODM0OGRkOGU0MmZiZTAxMmZiYTFmYl85LTQtMS0xLTM0NDc_b036ab40-684e-4a83-ac16-b811f7f124a7">417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDMyL2ZyYWc6YmNlNzg3NmI0OTVlNDI1OWFjODMzOGM2Y2NlMzM1ZGUvdGFibGU6OGI3NjZkNjA0NTgzNDhkZDhlNDJmYmUwMTJmYmExZmIvdGFibGVyYW5nZTo4Yjc2NmQ2MDQ1ODM0OGRkOGU0MmZiZTAxMmZiYTFmYl8xMC0yLTEtMS0xNjU3_35602b67-3f9e-4827-a079-31f2db7c5868">135</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDMyL2ZyYWc6YmNlNzg3NmI0OTVlNDI1OWFjODMzOGM2Y2NlMzM1ZGUvdGFibGU6OGI3NjZkNjA0NTgzNDhkZDhlNDJmYmUwMTJmYmExZmIvdGFibGVyYW5nZTo4Yjc2NmQ2MDQ1ODM0OGRkOGU0MmZiZTAxMmZiYTFmYl8xMC00LTEtMS0xNjU3_fa84e276-0229-438c-8ad2-1fd109cc375d">120</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDMyL2ZyYWc6YmNlNzg3NmI0OTVlNDI1OWFjODMzOGM2Y2NlMzM1ZGUvdGFibGU6OGI3NjZkNjA0NTgzNDhkZDhlNDJmYmUwMTJmYmExZmIvdGFibGVyYW5nZTo4Yjc2NmQ2MDQ1ODM0OGRkOGU0MmZiZTAxMmZiYTFmYl8xMS0yLTEtMS0zNDQ5_3b5a6ca5-ff0c-494c-a807-442fea5de425">372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDMyL2ZyYWc6YmNlNzg3NmI0OTVlNDI1OWFjODMzOGM2Y2NlMzM1ZGUvdGFibGU6OGI3NjZkNjA0NTgzNDhkZDhlNDJmYmUwMTJmYmExZmIvdGFibGVyYW5nZTo4Yjc2NmQ2MDQ1ODM0OGRkOGU0MmZiZTAxMmZiYTFmYl8xMS00LTEtMS0zNDUx_f87a47dd-6374-40ad-b528-478bc0569e83">297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i14818e3f4ece42e9a6fc90faaa3acbf2">Depreciation and amortization expense for the three months ended March 31, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDMyL2ZyYWc6YmNlNzg3NmI0OTVlNDI1OWFjODMzOGM2Y2NlMzM1ZGUvdGV4dHJlZ2lvbjpiY2U3ODc2YjQ5NWU0MjU5YWM4MzM4YzZjY2UzMzVkZV8xMDk5NTExNjI3OTY2_bd9fc420-8749-494f-aa9a-7f03bd3e2637">15</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDMyL2ZyYWc6YmNlNzg3NmI0OTVlNDI1OWFjODMzOGM2Y2NlMzM1ZGUvdGV4dHJlZ2lvbjpiY2U3ODc2YjQ5NWU0MjU5YWM4MzM4YzZjY2UzMzVkZV8xMDk5NTExNjI3OTc0_4b88f02c-e509-4d9f-b50a-76804fc90655">7</ix:nonFraction> million, respectively.</ix:continuation> </span></div><div><span><br/></span></div><div id="ibba7ad915d1a4c4a8ebb50d13fae4c4e_58"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RleHRyZWdpb246YTMwOTRiODY4ODU2NGQ1Njg1ODFiZjAzNTRmYTNjNjlfMTE1Nw_ea1d72e6-d182-435f-b130-235f589c2228" continuedAt="i86e839d7202a46ee95f9f9df8643665a" escape="true">Other Balance Sheet Components</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i86e839d7202a46ee95f9f9df8643665a" continuedAt="i61e6ac45c2ca47859f5f63ad43bf25cc"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RleHRyZWdpb246YTMwOTRiODY4ODU2NGQ1Njg1ODFiZjAzNTRmYTNjNjlfMTE1NA_1554b878-a4b7-4284-80a5-884f48a989b9" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets, as of March 31, 2021 and December 31, 2020 consists of the following (in&#160;millions):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Down payments to manufacturing vendors</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="mrna:OtherPrepaidExpenseManufacturing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjllMTY0MDRhM2MxZDRkODY4MjU5ZWYzYzlmNmVhODI5L3RhYmxlcmFuZ2U6OWUxNjQwNGEzYzFkNGQ4NjgyNTllZjNjOWY2ZWE4MjlfMi0yLTEtMS0w_d2df87bc-f74a-45fe-aa41-bedf8180b14b">224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" name="mrna:OtherPrepaidExpenseManufacturing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjllMTY0MDRhM2MxZDRkODY4MjU5ZWYzYzlmNmVhODI5L3RhYmxlcmFuZ2U6OWUxNjQwNGEzYzFkNGQ4NjgyNTllZjNjOWY2ZWE4MjlfMi00LTEtMS0w_12125bb8-b92b-49cf-82ab-ed5add46881c">217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:OtherPrepaidExpenseCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjllMTY0MDRhM2MxZDRkODY4MjU5ZWYzYzlmNmVhODI5L3RhYmxlcmFuZ2U6OWUxNjQwNGEzYzFkNGQ4NjgyNTllZjNjOWY2ZWE4MjlfMy0yLTEtMS0w_b4b4a23a-c7e7-4477-9b70-e87bfb77412a">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" name="us-gaap:OtherPrepaidExpenseCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjllMTY0MDRhM2MxZDRkODY4MjU5ZWYzYzlmNmVhODI5L3RhYmxlcmFuZ2U6OWUxNjQwNGEzYzFkNGQ4NjgyNTllZjNjOWY2ZWE4MjlfMy00LTEtMS0w_7923817b-a344-446f-a1de-72c258c67a6f">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tenant incentives receivables</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="mrna:TenantIncentivesReceivablesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjllMTY0MDRhM2MxZDRkODY4MjU5ZWYzYzlmNmVhODI5L3RhYmxlcmFuZ2U6OWUxNjQwNGEzYzFkNGQ4NjgyNTllZjNjOWY2ZWE4MjlfNC0yLTEtMS0w_c7c2a070-6a8f-4e0e-af86-582925d5a163">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" name="mrna:TenantIncentivesReceivablesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjllMTY0MDRhM2MxZDRkODY4MjU5ZWYzYzlmNmVhODI5L3RhYmxlcmFuZ2U6OWUxNjQwNGEzYzFkNGQ4NjgyNTllZjNjOWY2ZWE4MjlfNC00LTEtMS0w_87029848-eb0b-4969-a05f-3ca4b56742ea">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest receivable on marketable securities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:InterestReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjllMTY0MDRhM2MxZDRkODY4MjU5ZWYzYzlmNmVhODI5L3RhYmxlcmFuZ2U6OWUxNjQwNGEzYzFkNGQ4NjgyNTllZjNjOWY2ZWE4MjlfNS0yLTEtMS0w_1c295ac0-c9ab-4f46-9e66-be9a98d3ac32">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" name="us-gaap:InterestReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjllMTY0MDRhM2MxZDRkODY4MjU5ZWYzYzlmNmVhODI5L3RhYmxlcmFuZ2U6OWUxNjQwNGEzYzFkNGQ4NjgyNTllZjNjOWY2ZWE4MjlfNS00LTEtMS0w_7301d110-42a1-45d6-8a81-cd3f2dfec8ca">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjllMTY0MDRhM2MxZDRkODY4MjU5ZWYzYzlmNmVhODI5L3RhYmxlcmFuZ2U6OWUxNjQwNGEzYzFkNGQ4NjgyNTllZjNjOWY2ZWE4MjlfNi0yLTEtMS0w_d944b4f2-edc2-4942-99ab-1c1d4bf6e752">264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjllMTY0MDRhM2MxZDRkODY4MjU5ZWYzYzlmNmVhODI5L3RhYmxlcmFuZ2U6OWUxNjQwNGEzYzFkNGQ4NjgyNTllZjNjOWY2ZWE4MjlfNi00LTEtMS0w_48f7cfd1-2895-4d3a-a978-bb604460551a">252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Contents</a></span></div></div><div><span><br/></span></div><ix:continuation id="i61e6ac45c2ca47859f5f63ad43bf25cc"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Liabilities</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RleHRyZWdpb246YTMwOTRiODY4ODU2NGQ1Njg1ODFiZjAzNTRmYTNjNjlfMTE1NQ_54e8e568-b36a-4228-8819-a4031decce62" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities, as of March 31, 2021 and December 31, 2020 consists of the following (in&#160;millions):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="mrna:AccruedClinicalTrials" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjE2ZTQzNDA1NThhMjQ3ZmZiN2IzNjRlOWRkZTMyZTlhL3RhYmxlcmFuZ2U6MTZlNDM0MDU1OGEyNDdmZmI3YjM2NGU5ZGRlMzJlOWFfMi0yLTEtMS0w_bb111e12-29e5-458a-b287-01362db94d4a">181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" name="mrna:AccruedClinicalTrials" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjE2ZTQzNDA1NThhMjQ3ZmZiN2IzNjRlOWRkZTMyZTlhL3RhYmxlcmFuZ2U6MTZlNDM0MDU1OGEyNDdmZmI3YjM2NGU5ZGRlMzJlOWFfMi00LTEtMS0w_12bb5f7e-13bc-4322-a9fd-00b34164ecf4">98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="mrna:RawMaterialsAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjE2ZTQzNDA1NThhMjQ3ZmZiN2IzNjRlOWRkZTMyZTlhL3RhYmxlcmFuZ2U6MTZlNDM0MDU1OGEyNDdmZmI3YjM2NGU5ZGRlMzJlOWFfMy0yLTEtMS00NDQ_eb72604a-4367-41ca-924b-6adb123a0e35">185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" name="mrna:RawMaterialsAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjE2ZTQzNDA1NThhMjQ3ZmZiN2IzNjRlOWRkZTMyZTlhL3RhYmxlcmFuZ2U6MTZlNDM0MDU1OGEyNDdmZmI3YjM2NGU5ZGRlMzJlOWFfMy00LTEtMS00NDQ_780d2541-5990-42a6-bbf0-bb6061e701a4">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjE2ZTQzNDA1NThhMjQ3ZmZiN2IzNjRlOWRkZTMyZTlhL3RhYmxlcmFuZ2U6MTZlNDM0MDU1OGEyNDdmZmI3YjM2NGU5ZGRlMzJlOWFfNC0yLTEtMS01NDUy_6c051066-a997-448e-9c78-9ce9d6306a2e">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjE2ZTQzNDA1NThhMjQ3ZmZiN2IzNjRlOWRkZTMyZTlhL3RhYmxlcmFuZ2U6MTZlNDM0MDU1OGEyNDdmZmI3YjM2NGU5ZGRlMzJlOWFfNC00LTEtMS01NDUy_2de46984-4cae-4c20-9abb-5e2246cdf99c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="mrna:AccruedDevelopmentOperation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjE2ZTQzNDA1NThhMjQ3ZmZiN2IzNjRlOWRkZTMyZTlhL3RhYmxlcmFuZ2U6MTZlNDM0MDU1OGEyNDdmZmI3YjM2NGU5ZGRlMzJlOWFfMy0yLTEtMS0w_4699a756-7ae5-43e7-96ed-fd8974c1dff1">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" name="mrna:AccruedDevelopmentOperation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjE2ZTQzNDA1NThhMjQ3ZmZiN2IzNjRlOWRkZTMyZTlhL3RhYmxlcmFuZ2U6MTZlNDM0MDU1OGEyNDdmZmI3YjM2NGU5ZGRlMzJlOWFfMy00LTEtMS0w_aa43c7fa-d727-4bbd-90d8-3bbb2b645bdc">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="mrna:AccruedManufacturing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjE2ZTQzNDA1NThhMjQ3ZmZiN2IzNjRlOWRkZTMyZTlhL3RhYmxlcmFuZ2U6MTZlNDM0MDU1OGEyNDdmZmI3YjM2NGU5ZGRlMzJlOWFfNC0yLTEtMS0w_93bbe7ac-7d71-4558-817b-b56e121e5e96">119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" name="mrna:AccruedManufacturing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjE2ZTQzNDA1NThhMjQ3ZmZiN2IzNjRlOWRkZTMyZTlhL3RhYmxlcmFuZ2U6MTZlNDM0MDU1OGEyNDdmZmI3YjM2NGU5ZGRlMzJlOWFfNC00LTEtMS0w_e6a7d4a3-c6ae-40ae-bdf0-f3c55ebd8d01">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other external goods and services </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="mrna:AccruedOtherExternalGoodsAndServicesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjE2ZTQzNDA1NThhMjQ3ZmZiN2IzNjRlOWRkZTMyZTlhL3RhYmxlcmFuZ2U6MTZlNDM0MDU1OGEyNDdmZmI3YjM2NGU5ZGRlMzJlOWFfNS0yLTEtMS0w_89b68eac-d073-4a42-a40f-f2760a8d977c">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" name="mrna:AccruedOtherExternalGoodsAndServicesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjE2ZTQzNDA1NThhMjQ3ZmZiN2IzNjRlOWRkZTMyZTlhL3RhYmxlcmFuZ2U6MTZlNDM0MDU1OGEyNDdmZmI3YjM2NGU5ZGRlMzJlOWFfNS00LTEtMS0w_25cf5a44-59f0-4d65-934e-45c113fb9995"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" name="mrna:AccruedOtherExternalGoodsAndServicesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjE2ZTQzNDA1NThhMjQ3ZmZiN2IzNjRlOWRkZTMyZTlhL3RhYmxlcmFuZ2U6MTZlNDM0MDU1OGEyNDdmZmI3YjM2NGU5ZGRlMzJlOWFfNS00LTEtMS0w_eb3062d2-ae54-460f-88c9-487f05830496">92</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation-related</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjE2ZTQzNDA1NThhMjQ3ZmZiN2IzNjRlOWRkZTMyZTlhL3RhYmxlcmFuZ2U6MTZlNDM0MDU1OGEyNDdmZmI3YjM2NGU5ZGRlMzJlOWFfNi0yLTEtMS0w_404626a9-0d2a-443c-8402-ea75970c487a">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjE2ZTQzNDA1NThhMjQ3ZmZiN2IzNjRlOWRkZTMyZTlhL3RhYmxlcmFuZ2U6MTZlNDM0MDU1OGEyNDdmZmI3YjM2NGU5ZGRlMzJlOWFfNi00LTEtMS0w_59e2ace2-d554-4dd0-9197-4c7a5923e329">95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="mrna:AccruedPropertyAndEquipmentCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjE2ZTQzNDA1NThhMjQ3ZmZiN2IzNjRlOWRkZTMyZTlhL3RhYmxlcmFuZ2U6MTZlNDM0MDU1OGEyNDdmZmI3YjM2NGU5ZGRlMzJlOWFfNy0yLTEtMS0w_173dd0a1-1244-4724-8573-e173e7e87993">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" name="mrna:AccruedPropertyAndEquipmentCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjE2ZTQzNDA1NThhMjQ3ZmZiN2IzNjRlOWRkZTMyZTlhL3RhYmxlcmFuZ2U6MTZlNDM0MDU1OGEyNDdmZmI3YjM2NGU5ZGRlMzJlOWFfNy00LTEtMS0w_808e0ba1-72ff-4632-90c2-9522edfda31b">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="mrna:Commercial" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjE2ZTQzNDA1NThhMjQ3ZmZiN2IzNjRlOWRkZTMyZTlhL3RhYmxlcmFuZ2U6MTZlNDM0MDU1OGEyNDdmZmI3YjM2NGU5ZGRlMzJlOWFfMTEtMi0xLTEtNTk2Ng_ea10dbfa-91b6-46a7-84d3-72d7c92a303c">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" name="mrna:Commercial" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjE2ZTQzNDA1NThhMjQ3ZmZiN2IzNjRlOWRkZTMyZTlhL3RhYmxlcmFuZ2U6MTZlNDM0MDU1OGEyNDdmZmI3YjM2NGU5ZGRlMzJlOWFfMTEtNC0xLTEtNTk2Ng_e0d6ce81-fa4c-4aee-b591-843e11792e82">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjE2ZTQzNDA1NThhMjQ3ZmZiN2IzNjRlOWRkZTMyZTlhL3RhYmxlcmFuZ2U6MTZlNDM0MDU1OGEyNDdmZmI3YjM2NGU5ZGRlMzJlOWFfOC0yLTEtMS0w_9b5ba396-c1e8-4509-9990-cd5e85cd85aa">753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjE2ZTQzNDA1NThhMjQ3ZmZiN2IzNjRlOWRkZTMyZTlhL3RhYmxlcmFuZ2U6MTZlNDM0MDU1OGEyNDdmZmI3YjM2NGU5ZGRlMzJlOWFfOC00LTEtMS0w_77a9d850-d715-486c-82b1-1f15b0424d0f">470</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Revenue </span></div><div><span><br/></span></div><ix:continuation id="i0787ee8a591346138f01fce6a0acbe19"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activities in deferred revenue for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the three months ended</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> March 31, 2021 (in millions):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.792%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ee3c9e3ddc46fc8c50d787172d195f_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjBjMWE2Yzg1ZGRhNzQzOTk4NmE1MGM2Nzc5OTY3OGVkL3RhYmxlcmFuZ2U6MGMxYTZjODVkZGE3NDM5OTg2YTUwYzY3Nzk5Njc4ZWRfMS0yLTEtMS00NjI3_4c9b02b1-5e23-46bd-b596-9e3111fbc366">3,799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90cf26aad24349bfa441914ac3d706fb_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjBjMWE2Yzg1ZGRhNzQzOTk4NmE1MGM2Nzc5OTY3OGVkL3RhYmxlcmFuZ2U6MGMxYTZjODVkZGE3NDM5OTg2YTUwYzY3Nzk5Njc4ZWRfMS00LTEtMS00NjUx_a47a5022-d3c3-43e1-81a3-40a471240877">4,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i90cf26aad24349bfa441914ac3d706fb_D20210101-20210331" decimals="-6" name="mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjBjMWE2Yzg1ZGRhNzQzOTk4NmE1MGM2Nzc5OTY3OGVkL3RhYmxlcmFuZ2U6MGMxYTZjODVkZGE3NDM5OTg2YTUwYzY3Nzk5Njc4ZWRfMS02LTEtMS00NjUx_5a784500-07f9-487f-a7fa-d0bd62762b15">796</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3049e90ee7764f058dbbb38cd725aadc_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjBjMWE2Yzg1ZGRhNzQzOTk4NmE1MGM2Nzc5OTY3OGVkL3RhYmxlcmFuZ2U6MGMxYTZjODVkZGE3NDM5OTg2YTUwYzY3Nzk5Njc4ZWRfMS04LTEtMS02MTI5_348edba7-a8de-4f3d-b8b2-a2dc6124ea40">7,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie53549975a3f42f6b2b2d3515ab79791_I20201231" decimals="-6" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjBjMWE2Yzg1ZGRhNzQzOTk4NmE1MGM2Nzc5OTY3OGVkL3RhYmxlcmFuZ2U6MGMxYTZjODVkZGE3NDM5OTg2YTUwYzY3Nzk5Njc4ZWRfMi0yLTEtMS00NjI3_7ad4a634-0405-4ad1-adc4-9f105a8d47cc">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12127d667a294d78b6d78f889c39cd18_D20210101-20210331" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjBjMWE2Yzg1ZGRhNzQzOTk4NmE1MGM2Nzc5OTY3OGVkL3RhYmxlcmFuZ2U6MGMxYTZjODVkZGE3NDM5OTg2YTUwYzY3Nzk5Njc4ZWRfMi00LTEtMS00NjUx_41f7a97c-147b-4fcc-8a41-628fece67681">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12127d667a294d78b6d78f889c39cd18_D20210101-20210331" decimals="-6" name="mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjBjMWE2Yzg1ZGRhNzQzOTk4NmE1MGM2Nzc5OTY3OGVkL3RhYmxlcmFuZ2U6MGMxYTZjODVkZGE3NDM5OTg2YTUwYzY3Nzk5Njc4ZWRfMi02LTEtMS00NjUx_fcf524ae-11be-4ae4-a439-81953ba83272">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc1f15c64a2e42b6b50c3be424cf6c44_I20210331" decimals="-6" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjBjMWE2Yzg1ZGRhNzQzOTk4NmE1MGM2Nzc5OTY3OGVkL3RhYmxlcmFuZ2U6MGMxYTZjODVkZGE3NDM5OTg2YTUwYzY3Nzk5Njc4ZWRfMi04LTEtMS02MTI5_b9f27372-6249-4cf6-bf9c-b12cebbc940e">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e89e827a1584b60805bbb05008f21f5_I20201231" decimals="-6" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjBjMWE2Yzg1ZGRhNzQzOTk4NmE1MGM2Nzc5OTY3OGVkL3RhYmxlcmFuZ2U6MGMxYTZjODVkZGE3NDM5OTg2YTUwYzY3Nzk5Njc4ZWRfMy0yLTEtMS00NjI3_04fbbeae-41af-45d1-b73e-bacb106bb246">240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f5b8cccc84489b9789274a5e0b0890_D20210101-20210331" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjBjMWE2Yzg1ZGRhNzQzOTk4NmE1MGM2Nzc5OTY3OGVkL3RhYmxlcmFuZ2U6MGMxYTZjODVkZGE3NDM5OTg2YTUwYzY3Nzk5Njc4ZWRfMy00LTEtMS00NjUx_17cc95a0-3fad-4e6d-ad47-ac3bda36a4c9">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93f5b8cccc84489b9789274a5e0b0890_D20210101-20210331" decimals="-6" name="mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjBjMWE2Yzg1ZGRhNzQzOTk4NmE1MGM2Nzc5OTY3OGVkL3RhYmxlcmFuZ2U6MGMxYTZjODVkZGE3NDM5OTg2YTUwYzY3Nzk5Njc4ZWRfMy02LTEtMS00NjUx_b6f0a777-22b0-4b9b-b700-8316c1fc7e34">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39195ff1bc64463eb3aa66b95e19bd36_I20210331" decimals="-6" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjBjMWE2Yzg1ZGRhNzQzOTk4NmE1MGM2Nzc5OTY3OGVkL3RhYmxlcmFuZ2U6MGMxYTZjODVkZGE3NDM5OTg2YTUwYzY3Nzk5Njc4ZWRfMy04LTEtMS02MTI5_3f86a555-40e3-4ff6-a349-8545ff268e68">235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjBjMWE2Yzg1ZGRhNzQzOTk4NmE1MGM2Nzc5OTY3OGVkL3RhYmxlcmFuZ2U6MGMxYTZjODVkZGE3NDM5OTg2YTUwYzY3Nzk5Njc4ZWRfNC0yLTEtMS02MTIz_d2e1875d-795d-4854-b033-d6fd631b366a">4,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjBjMWE2Yzg1ZGRhNzQzOTk4NmE1MGM2Nzc5OTY3OGVkL3RhYmxlcmFuZ2U6MGMxYTZjODVkZGE3NDM5OTg2YTUwYzY3Nzk5Njc4ZWRfNC00LTEtMS02MTI1_5354642f-1cb1-43cd-94d9-7304f68ec7d7">4,474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" name="mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjBjMWE2Yzg1ZGRhNzQzOTk4NmE1MGM2Nzc5OTY3OGVkL3RhYmxlcmFuZ2U6MGMxYTZjODVkZGE3NDM5OTg2YTUwYzY3Nzk5Njc4ZWRfNC02LTEtMS02MTI3_6575b2bc-68e2-4a1e-942a-a125681036a9">808</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjBjMWE2Yzg1ZGRhNzQzOTk4NmE1MGM2Nzc5OTY3OGVkL3RhYmxlcmFuZ2U6MGMxYTZjODVkZGE3NDM5OTg2YTUwYzY3Nzk5Njc4ZWRfNC04LTEtMS02MTI5_e909b971-bccf-462d-828e-7d8c337153c9">7,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div id="ibba7ad915d1a4c4a8ebb50d13fae4c4e_61"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="us-gaap:LesseeFinanceLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RleHRyZWdpb246NjY1Njg4N2NlOTA0NDdlN2JkN2Y4YmEyYTQ2M2FiYjZfNDg4NA_c5cc6084-b3b6-46c8-9751-f0989337d7be" continuedAt="i4adac04b60cc4c16b75ec881f08cd45d" escape="true"><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RleHRyZWdpb246NjY1Njg4N2NlOTA0NDdlN2JkN2Y4YmEyYTQ2M2FiYjZfNDg4OA_3cfd6129-9c62-4280-a1a4-f472e13d3105" continuedAt="i29a2bfe995f84e9f953a7712eea7a5da" escape="true">Leases</ix:nonNumeric></ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i4adac04b60cc4c16b75ec881f08cd45d" continuedAt="i75d2cc297e37481ab9a83c5b7d2a3a54"><ix:continuation id="i29a2bfe995f84e9f953a7712eea7a5da" continuedAt="i5d74ccc5731b44dcbec15c4deb1eb81e"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into various long-term non-cancelable lease arrangements for our facilities and equipment expiring at various times through 2032. Certain of these arrangements have free rent periods or escalating rent payment provisions. We recognize lease cost under such arrangements on a straight-line basis over the life of the leases. We have <ix:nonFraction unitRef="campus" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="mrna:OperatingLeaseNumberOfProperties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RleHRyZWdpb246NjY1Njg4N2NlOTA0NDdlN2JkN2Y4YmEyYTQ2M2FiYjZfMzY1_3b2f4191-c784-49b8-b94a-cc3db843dae5">two</ix:nonFraction> campuses in Massachusetts, our Cambridge facility and our Moderna Technology Center (MTC), located in Norwood.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cambridge facility</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We occupy a multi-building campus in Technology Square in Cambridge, Massachusetts with a mix of offices and research laboratory space totaling approximately <ix:nonFraction unitRef="sqft" contextRef="i4c54e5c981c44426b958b7cd3aeb25d8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RleHRyZWdpb246NjY1Njg4N2NlOTA0NDdlN2JkN2Y4YmEyYTQ2M2FiYjZfNjc2_09bf0cbc-d993-403f-9aea-b377f7dd122e">175,000</ix:nonFraction>&#160;square feet. Our Cambridge facility leases have expiry ranges from 2020 to 2029. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Finance Leases</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Moderna Technology Center manufacturing facility (MTC South)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August&#160;2016, we entered into a lease agreement for approximately&#160;<ix:nonFraction unitRef="sqft" contextRef="i31be9147cbb84c108e25cc00c3dd39a2_I20160831" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RleHRyZWdpb246NjY1Njg4N2NlOTA0NDdlN2JkN2Y4YmEyYTQ2M2FiYjZfMTc5NA_bac658d7-e684-4d06-8525-86ce6e88c9bc">200,000</ix:nonFraction>&#160;square feet of office, laboratory, and light manufacturing space, MTC South, in Norwood, Massachusetts. The lease will expire in September&#160;2032. We have the option to extend the term for&#160;<ix:nonFraction unitRef="extension_period" contextRef="i31be9147cbb84c108e25cc00c3dd39a2_I20160831" decimals="INF" format="ixt-sec:numwordsen" name="mrna:LesseeOperatingLeaseNumberOfExtensionPeriods" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RleHRyZWdpb246NjY1Njg4N2NlOTA0NDdlN2JkN2Y4YmEyYTQ2M2FiYjZfMTk4NA_80c44cca-72dc-424e-97ed-d342112753de">two</ix:nonFraction>&#160;extension periods of&#160;<ix:nonNumeric contextRef="i31be9147cbb84c108e25cc00c3dd39a2_I20160831" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RleHRyZWdpb246NjY1Njg4N2NlOTA0NDdlN2JkN2Y4YmEyYTQ2M2FiYjZfMjAwOA_6c1833a3-9714-46af-919e-fff13044fa84">ten years</ix:nonNumeric>&#160;each at market-based rents. The base rent is subject to increases over the term of the lease. </span></div></ix:continuation></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Contents</a></span></div></div><div><span><br/></span></div><ix:continuation id="i75d2cc297e37481ab9a83c5b7d2a3a54" continuedAt="i17ea4b0c7d8948879dfffa3da6b454d9"><ix:continuation id="i5d74ccc5731b44dcbec15c4deb1eb81e" continuedAt="ia663754aa8d944deb98935bf657045ab"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Moderna Technology Center North (MTC North)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, we entered into a lease agreement for office and laboratory space of approximately <ix:nonFraction unitRef="sqft" contextRef="i72bd7d804e294a73a53c8fe39086669a_I20190228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RleHRyZWdpb246NjY1Njg4N2NlOTA0NDdlN2JkN2Y4YmEyYTQ2M2FiYjZfMjI1Mw_c91fda9c-e07b-4244-818d-7d9b296dcecf">200,000</ix:nonFraction> square feet, MTC North, located in Norwood, Massachusetts. The lease commenced in the second quarter of 2019 and had an initial expiration date of 2031. We have the option to extend the lease for up to <ix:nonFraction unitRef="extension_period" contextRef="ie56c1c32083543d8bb94f4fb0eba71d6_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="mrna:LesseeOperatingLeaseNumberOfExtensionPeriods" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RleHRyZWdpb246NjY1Njg4N2NlOTA0NDdlN2JkN2Y4YmEyYTQ2M2FiYjZfMjQ1OA_718ef731-d20e-4cf0-ab33-e513f73fecfc">four</ix:nonFraction> additional <ix:nonNumeric contextRef="i5946e5f9891e4ba8aa1048e39fc8cd69_I20200331" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RleHRyZWdpb246NjY1Njg4N2NlOTA0NDdlN2JkN2Y4YmEyYTQ2M2FiYjZfNDg4Mg_3a430a3c-6e38-4539-9803-865489bbd852">five-year</ix:nonNumeric> terms. In May 2020, we entered into an amendment to the lease whereby we exercised an option available in the original lease to receive a tenant improvement allowance in the amount of $<ix:nonFraction unitRef="usd" contextRef="iaad3817f49bd43e29ab66021c23b5529_I20200531" decimals="-6" format="ixt:numdotdecimal" name="mrna:AllowanceForTenantImprovements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RleHRyZWdpb246NjY1Njg4N2NlOTA0NDdlN2JkN2Y4YmEyYTQ2M2FiYjZfMjk0NA_147d3a3d-1bc5-4a15-8538-c9cd830c2e1b">22</ix:nonFraction> million to be paid back over the term of the lease with interest and extend the term of the lease to 2035. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Embedded Leases</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into multiple contract manufacturing service agreements with third parties which contain embedded leases within the scope of ASC 842. As of March 31, 2021 and December 31, 2020, we had lease liabilities of $<ix:nonFraction unitRef="usd" contextRef="i747a2e93fb1b437b9939b81676cc53b5_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RleHRyZWdpb246NjY1Njg4N2NlOTA0NDdlN2JkN2Y4YmEyYTQ2M2FiYjZfNzY5NjU4MTQwMjcwNg_0549ae43-fbe8-47a9-99ef-f9989a02346b">73</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i8c1e58e30b1c4e8d8872e56716cb8e9f_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RleHRyZWdpb246NjY1Njg4N2NlOTA0NDdlN2JkN2Y4YmEyYTQ2M2FiYjZfNzY5NjU4MTQwMjcyMg_7453ffee-1c8e-4ea6-a782-5451dfd40722">24</ix:nonFraction>&#160;million, respectively, related to the embedded leases. As of March 31, 2021 and December 31, 2020, we had right-of-use assets of $<ix:nonFraction unitRef="usd" contextRef="i747a2e93fb1b437b9939b81676cc53b5_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RleHRyZWdpb246NjY1Njg4N2NlOTA0NDdlN2JkN2Y4YmEyYTQ2M2FiYjZfNzY5NjU4MTQwNjY1NA_160f2320-a5b4-4dd0-a8a8-57c6b2747a58">44</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="usd" contextRef="i8c1e58e30b1c4e8d8872e56716cb8e9f_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RleHRyZWdpb246NjY1Njg4N2NlOTA0NDdlN2JkN2Y4YmEyYTQ2M2FiYjZfNzY5NjU4MTQwNjY2Ng_b35d0945-8041-4b06-a599-6b5e644e2c20">zero</ix:nonFraction>, as certain embedded leases dedicated to our COVID-19 vaccine program were deemed to have no alternative use prior to the EUA from the FDA in December 2020. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="mrna:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RleHRyZWdpb246NjY1Njg4N2NlOTA0NDdlN2JkN2Y4YmEyYTQ2M2FiYjZfNDg4Mw_7b6e43db-199b-4686-b8ca-c6fc2a552d80" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating and financing lease right-of-use assets and lease liabilities as of March 31, 2021 and December 31, 2020 were as follows (in millions):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, operating, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfMy0yLTEtMS0w_5d7e7ee4-f521-4245-92d9-cbff3eb8216a">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfMy00LTEtMS0w_787c2cf8-ce0d-4aa3-8f2c-a9ed0634f10e">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfNC0wLTEtMS04Mzk4_763696f1-1b66-43b8-a5e9-0a8445cbb910"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfNC0wLTEtMS04Mzk4_986006a3-947e-4a84-bf6d-3ecd8f99076a"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, financing, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3) (4)</span></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfNC0yLTEtMS0w_0c37eaaf-8157-4777-9418-876b623be94c">99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfNC00LTEtMS0w_9f310f66-f068-46ca-9d8a-0b0909bab566">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="mrna:OperatingAndFinanceLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfNS0yLTEtMS0w_a585acde-93a7-4e4b-a4fe-376094ed673b">188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" name="mrna:OperatingAndFinanceLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfNS00LTEtMS0w_77a34044-f81a-49b4-9fd9-ad4644076571">145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfOS0wLTEtMS0w_7afc31d0-ede8-43d3-b946-27d55409b32b"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfOS0wLTEtMS0w_d74ab000-ea21-4620-b930-521a5fdbab89"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></span></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfOS0yLTEtMS0w_0312beff-9d57-4942-a05d-1a5206de38f1">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfOS00LTEtMS0w_090b1317-e514-4022-9ed6-1c3e410d3f26">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfMTAtMC0xLTEtMzUwNw_1c2fb28d-31b2-40b2-9ba8-7bc67b5a50d3"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfMTAtMC0xLTEtMzUwNw_f985209d-7d9f-4e95-8466-842513c70552"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfMTAtMi0xLTEtMTkyNg_4cbec68e-e8c2-438c-b5f8-c4bdae0f5662">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfMTAtNC0xLTEtMTkxMA_e0d0a4fe-0b88-49a0-b02d-191013a30673">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="mrna:OperatingAndFinanceLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfMTEtMi0xLTEtMzQ5OQ_f2fd0f44-30ec-4bff-a631-fc33c051b635">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" name="mrna:OperatingAndFinanceLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfMTEtNC0xLTEtMzQ5OQ_814ab94a-311e-4908-b0eb-4d0382bff469">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, non-current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfMTEtMi0xLTEtMA_5609911a-66a5-42c1-897c-1c3748cbd872">96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfMTEtNC0xLTEtMA_750ff97a-518f-4b6d-8745-e5e3c03d1388">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities, non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfMTItMi0xLTEtMA_3069ef13-8ac6-4753-aedd-88033dcf8563">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfMTItNC0xLTEtMA_323fd14f-5c03-4e85-9568-894e766899e5">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="mrna:OperatingAndFinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfMTMtMi0xLTEtMA_da5dd887-91a1-4148-aa48-7fe2931f04d5">234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" name="mrna:OperatingAndFinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfMTMtNC0xLTEtMA_4253e99a-64d6-4aa9-a18d-f8d925c74271">207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="mrna:OperatingAndFinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfMTQtMi0xLTEtMA_ee8c648f-c272-438e-a937-3ac7d85cb574">286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" name="mrna:OperatingAndFinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfMTQtNC0xLTEtMA_1646a81c-ad82-46e0-ac9c-fcda6594e64e">237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These assets are real estate related assets, which include land, office and laboratory spaces.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net of accumulated depreciation.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These assets are&#160;real estate assets related to the MTC North and MTC South leases as well as assets related to contract manufacturing service agreements.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in property and equipment in the condensed consolidated balance sheets, net of accumulated depreciation.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in other current liabilities in the condensed consolidated balance sheets.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RleHRyZWdpb246NjY1Njg4N2NlOTA0NDdlN2JkN2Y4YmEyYTQ2M2FiYjZfNDg4Ng_94be2dcc-ec7e-4108-b4cf-2e8354b9ad3a" continuedAt="id0338dc8a8b74cb5b1f242d0211297f2" escape="true"><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RleHRyZWdpb246NjY1Njg4N2NlOTA0NDdlN2JkN2Y4YmEyYTQ2M2FiYjZfNDg4OQ_1a199191-2936-4f40-9fb5-c0cd251e68f9" continuedAt="i617a78c67894478fba5b91b9ccd10807" escape="true">Future minimum lease payments under our non-cancelable lease agreements at March 31, 2021, are as follows (in&#160;millions):</ix:nonNumeric></ix:nonNumeric></span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Contents</a></span></div></div><ix:continuation id="i17ea4b0c7d8948879dfffa3da6b454d9" continuedAt="iaa2dd913f1e943289eab28542226c01b"><ix:continuation id="ia663754aa8d944deb98935bf657045ab" continuedAt="iefeaa4ffb8364edc94eefc095444aa05"><ix:continuation id="id0338dc8a8b74cb5b1f242d0211297f2" continuedAt="i8bb88b76c30b48e2ac98568d49415fb5"><ix:continuation id="i617a78c67894478fba5b91b9ccd10807" continuedAt="i75d8048714c242808ac93214b59fe70c"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:61.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.441%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Year</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financing Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(remainder of the year)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOjQ0NmZkN2Y4YWRmNjRjNzk4YjlhMDM5YWVhYWE4ZWFlL3RhYmxlcmFuZ2U6NDQ2ZmQ3ZjhhZGY2NGM3OThiOWEwMzlhZWFhYThlYWVfMS0yLTEtMS0w_6d0967db-80e6-479a-b7e8-94bddd1bc8fd">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOjQ0NmZkN2Y4YWRmNjRjNzk4YjlhMDM5YWVhYWE4ZWFlL3RhYmxlcmFuZ2U6NDQ2ZmQ3ZjhhZGY2NGM3OThiOWEwMzlhZWFhYThlYWVfMS00LTEtMS0w_2748c046-0d65-4c5b-8d4f-61670fc0298d">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOjQ0NmZkN2Y4YWRmNjRjNzk4YjlhMDM5YWVhYWE4ZWFlL3RhYmxlcmFuZ2U6NDQ2ZmQ3ZjhhZGY2NGM3OThiOWEwMzlhZWFhYThlYWVfMi0yLTEtMS0w_a4689178-8ecd-4a87-9b68-1526d7be979d">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOjQ0NmZkN2Y4YWRmNjRjNzk4YjlhMDM5YWVhYWE4ZWFlL3RhYmxlcmFuZ2U6NDQ2ZmQ3ZjhhZGY2NGM3OThiOWEwMzlhZWFhYThlYWVfMi00LTEtMS0w_e760c324-b5fb-4793-8a83-ebf4e2473aa8">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOjQ0NmZkN2Y4YWRmNjRjNzk4YjlhMDM5YWVhYWE4ZWFlL3RhYmxlcmFuZ2U6NDQ2ZmQ3ZjhhZGY2NGM3OThiOWEwMzlhZWFhYThlYWVfMy0yLTEtMS0w_8977d149-9f70-4bf5-9abb-49e09517b465">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOjQ0NmZkN2Y4YWRmNjRjNzk4YjlhMDM5YWVhYWE4ZWFlL3RhYmxlcmFuZ2U6NDQ2ZmQ3ZjhhZGY2NGM3OThiOWEwMzlhZWFhYThlYWVfMy00LTEtMS0w_62cb6f5a-742b-4a7c-9a47-20beeb9202b1">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOjQ0NmZkN2Y4YWRmNjRjNzk4YjlhMDM5YWVhYWE4ZWFlL3RhYmxlcmFuZ2U6NDQ2ZmQ3ZjhhZGY2NGM3OThiOWEwMzlhZWFhYThlYWVfNC0yLTEtMS0w_20d5c397-df52-48ec-9c92-6a28e3f61286">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOjQ0NmZkN2Y4YWRmNjRjNzk4YjlhMDM5YWVhYWE4ZWFlL3RhYmxlcmFuZ2U6NDQ2ZmQ3ZjhhZGY2NGM3OThiOWEwMzlhZWFhYThlYWVfNC00LTEtMS0w_9e8e00cb-8aaa-4015-8c9d-54ba521f76ed">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOjQ0NmZkN2Y4YWRmNjRjNzk4YjlhMDM5YWVhYWE4ZWFlL3RhYmxlcmFuZ2U6NDQ2ZmQ3ZjhhZGY2NGM3OThiOWEwMzlhZWFhYThlYWVfNS0yLTEtMS0w_15d4a455-9ece-405c-9502-650724907eb4">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOjQ0NmZkN2Y4YWRmNjRjNzk4YjlhMDM5YWVhYWE4ZWFlL3RhYmxlcmFuZ2U6NDQ2ZmQ3ZjhhZGY2NGM3OThiOWEwMzlhZWFhYThlYWVfNS00LTEtMS0w_caa4516a-e7e5-49d1-8712-5873e37b6189">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="mrna:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOjQ0NmZkN2Y4YWRmNjRjNzk4YjlhMDM5YWVhYWE4ZWFlL3RhYmxlcmFuZ2U6NDQ2ZmQ3ZjhhZGY2NGM3OThiOWEwMzlhZWFhYThlYWVfNi0yLTEtMS0w_7ce21088-499e-4b5b-a553-86d1e53cef9b">94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="mrna:FinanceLeaseLiabilityToBePaidAfterYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOjQ0NmZkN2Y4YWRmNjRjNzk4YjlhMDM5YWVhYWE4ZWFlL3RhYmxlcmFuZ2U6NDQ2ZmQ3ZjhhZGY2NGM3OThiOWEwMzlhZWFhYThlYWVfNi00LTEtMS0w_7833b085-7ead-416a-9e0d-91294955f8ba">428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOjQ0NmZkN2Y4YWRmNjRjNzk4YjlhMDM5YWVhYWE4ZWFlL3RhYmxlcmFuZ2U6NDQ2ZmQ3ZjhhZGY2NGM3OThiOWEwMzlhZWFhYThlYWVfNy0yLTEtMS0w_c62f8054-2d50-427f-a5eb-b5a9ce44d7df">171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOjQ0NmZkN2Y4YWRmNjRjNzk4YjlhMDM5YWVhYWE4ZWFlL3RhYmxlcmFuZ2U6NDQ2ZmQ3ZjhhZGY2NGM3OThiOWEwMzlhZWFhYThlYWVfNy00LTEtMS0w_6e959790-c278-4f2a-9e61-ad90242105b9">559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less amounts representing interest or imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOjQ0NmZkN2Y4YWRmNjRjNzk4YjlhMDM5YWVhYWE4ZWFlL3RhYmxlcmFuZ2U6NDQ2ZmQ3ZjhhZGY2NGM3OThiOWEwMzlhZWFhYThlYWVfOC0yLTEtMS0w_4a7ebc72-914b-4914-84b9-3b1623e5b531">68</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOjQ0NmZkN2Y4YWRmNjRjNzk4YjlhMDM5YWVhYWE4ZWFlL3RhYmxlcmFuZ2U6NDQ2ZmQ3ZjhhZGY2NGM3OThiOWEwMzlhZWFhYThlYWVfOC00LTEtMS0w_02a96aaa-f738-4e7b-9c02-e530a3729f30">376</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOjQ0NmZkN2Y4YWRmNjRjNzk4YjlhMDM5YWVhYWE4ZWFlL3RhYmxlcmFuZ2U6NDQ2ZmQ3ZjhhZGY2NGM3OThiOWEwMzlhZWFhYThlYWVfOS0yLTEtMS0w_7aebb77a-01f9-4cb7-9a86-f193dc00d71c">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" name="us-gaap:FinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOjQ0NmZkN2Y4YWRmNjRjNzk4YjlhMDM5YWVhYWE4ZWFlL3RhYmxlcmFuZ2U6NDQ2ZmQ3ZjhhZGY2NGM3OThiOWEwMzlhZWFhYThlYWVfOS00LTEtMS0w_633b0984-fca5-4966-840b-dc26da1d4679">183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes optional extensions in the MTC North and MTC South lease terms which represent a total of $<ix:nonFraction unitRef="usd" contextRef="i5c10c5b4110f49df8c8e8f8f898bbe05_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RleHRyZWdpb246NjY1Njg4N2NlOTA0NDdlN2JkN2Y4YmEyYTQ2M2FiYjZfNDUwMA_bd00fb58-e743-4a73-a3c0-a6d0fb3796e4">339</ix:nonFraction> million un-discounted future lease payments.</span></div></ix:continuation></ix:continuation></ix:continuation></ix:continuation><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"><ix:continuation id="iaa2dd913f1e943289eab28542226c01b" continuedAt="ia498b003bc6d4ecc821492026c2b6331"><ix:continuation id="iefeaa4ffb8364edc94eefc095444aa05" continuedAt="ic6d02bf141f3445abbda684fdec54ef7"><ix:continuation id="i8bb88b76c30b48e2ac98568d49415fb5" continuedAt="ia38dc0cdeaad44998e7cd6e78242b28b"><ix:continuation id="i75d8048714c242808ac93214b59fe70c" continuedAt="iaff7d3e65c0e4d42bef7b466b188d7cd">(2) </ix:continuation></ix:continuation></ix:continuation></ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia498b003bc6d4ecc821492026c2b6331"><ix:continuation id="ic6d02bf141f3445abbda684fdec54ef7"><ix:continuation id="ia38dc0cdeaad44998e7cd6e78242b28b"><ix:continuation id="iaff7d3e65c0e4d42bef7b466b188d7cd">MTC South interest is based on an imputed interest rate of <ix:nonFraction unitRef="number" contextRef="i97caad06f3f04504b59b69417b6a7236_D20210101-20210331" decimals="3" name="mrna:LeasesImputedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RleHRyZWdpb246NjY1Njg4N2NlOTA0NDdlN2JkN2Y4YmEyYTQ2M2FiYjZfNDgwOQ_516e96d2-56be-4a27-bb43-a58344b3bd71">17.2</ix:nonFraction>%. MTC North and the embedded lease interest is based upon incremental borrowing rates of <ix:nonFraction unitRef="number" contextRef="id91f4c8df96343e8b99f1775d18c7d59_D20210101-20210331" decimals="3" name="mrna:LeasesIncrementalBorrowingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RleHRyZWdpb246NjY1Njg4N2NlOTA0NDdlN2JkN2Y4YmEyYTQ2M2FiYjZfNDg3OQ_c09ebf26-4cad-46f3-a9f2-08b9d7cafabd">8.2</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ia5b2cabe98664e3eac3b4393c8159043_D20200101-20200331" decimals="3" name="mrna:LeasesIncrementalBorrowingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RleHRyZWdpb246NjY1Njg4N2NlOTA0NDdlN2JkN2Y4YmEyYTQ2M2FiYjZfNzY5NjU4MTQwOTUxMQ_9ef891fe-70e1-4606-8406-06b391943daf">0.6</ix:nonFraction>% respectively.</ix:continuation></ix:continuation></ix:continuation></ix:continuation> </span></div><div><span><br/></span></div><div id="ibba7ad915d1a4c4a8ebb50d13fae4c4e_67"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82Ny9mcmFnOjExOTRmMWVmMzFhNjQwOGE4M2M3OWEwOWVkMmY3YTk4L3RleHRyZWdpb246MTE5NGYxZWYzMWE2NDA4YTgzYzc5YTA5ZWQyZjdhOThfNTA2MA_257d36af-632b-4243-83f7-5b3f24e22436" continuedAt="i7b6e04625dca406f804985530829dfdd" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i7b6e04625dca406f804985530829dfdd" continuedAt="ie17ad874b2b147dcbfbaa7327e39ca27"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Strategic Collaborations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our strategic collaboration agreements, we are committed to perform certain research, development, and manufacturing activities. As part of our PCV Agreement and PCV/SAV Agreement with Merck, we are committed to perform certain research, development and manufacturing activities related to PCV products through an initial Phase 2 clinical trial up to a budgeted amount of $<ix:nonFraction unitRef="usd" contextRef="icc463e223e4f4f08b900edce1309004e_I20201231" decimals="-6" format="ixt:numdotdecimal" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82Ny9mcmFnOjExOTRmMWVmMzFhNjQwOGE4M2M3OWEwOWVkMmY3YTk4L3RleHRyZWdpb246MTE5NGYxZWYzMWE2NDA4YTgzYzc5YTA5ZWQyZjdhOThfNDQz_6a4d2039-e2d3-4016-a494-55db6f14ec28"><ix:nonFraction unitRef="usd" contextRef="iccb9f67ad61a42038f759003571a1508_I20210331" decimals="-6" format="ixt:numdotdecimal" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82Ny9mcmFnOjExOTRmMWVmMzFhNjQwOGE4M2M3OWEwOWVkMmY3YTk4L3RleHRyZWdpb246MTE5NGYxZWYzMWE2NDA4YTgzYzc5YTA5ZWQyZjdhOThfNDQz_8d4f5633-ef2f-4645-b7c3-57d900932eb4">243</ix:nonFraction></ix:nonFraction> million for both periods as of March 31, 2021 and December 31, 2020. Please refer to our 2020 Form 10-K Note 5 to our consolidated financial statements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently a party to any material legal proceedings.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification Obligations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As permitted under Delaware law, we indemnify our officers, directors, and employees for certain events, occurrences while the officer, or director is, or was, serving at our request in such capacity. The term of the indemnification is for the officer&#8217;s or director&#8217;s lifetime.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have standard indemnification arrangements in our leases for laboratory and office space that require us to indemnify the landlord against any liability for injury, loss, accident, or damage from any claims, actions, proceedings, or costs resulting from certain acts, breaches, violations, or non-performance under our leases.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into indemnification provisions under our agreements with counterparties in the ordinary course of business, typically with business partners, contractors, clinical sites and customers. Under these provisions, we generally indemnify and hold harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of our activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments we could be required to make under these indemnification provisions is unlimited.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through the three months ended March 31, 2021 and the year ended December 31, 2020, we had not experienced any losses related to these indemnification obligations, and no material claims were outstanding. We do not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Contents</a></span></div></div><div><span><br/></span></div><ix:continuation id="ie17ad874b2b147dcbfbaa7327e39ca27"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Commitments and Purchase Orders</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We enter into agreements in the normal course of business with vendors and contract manufacturing organizations (CMOs) for raw materials and manufacturing services and with vendors for preclinical research studies, clinical trials and other goods or services. As of March 31, 2021, we h</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ad </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$<ix:nonFraction unitRef="usd" contextRef="ie54f228e1d5b4838858ccaebf45f0e9a_I20210331" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82Ny9mcmFnOjExOTRmMWVmMzFhNjQwOGE4M2M3OWEwOWVkMmY3YTk4L3RleHRyZWdpb246MTE5NGYxZWYzMWE2NDA4YTgzYzc5YTA5ZWQyZjdhOThfMzYwMA_40eb0065-05b5-48f8-a497-cb807d6a3188">1.0</ix:nonFraction> billion of non-cancelable purchase commitments related to raw materials and manufacturing agreements, including the Lonza agreement, which are expected to be paid through 2022. As of March 31, 2021, we had $<ix:nonFraction unitRef="usd" contextRef="i8204f059459747e988e68765b4fa0190_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82Ny9mcmFnOjExOTRmMWVmMzFhNjQwOGE4M2M3OWEwOWVkMmY3YTk4L3RleHRyZWdpb246MTE5NGYxZWYzMWE2NDA4YTgzYzc5YTA5ZWQyZjdhOThfMzczNQ_4938a521-d19f-42da-bfb8-5652031c5500">30</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> of non-c</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ancelable purchase commitments related to clinical services and other goods and services which are expected to be paid through 2024. These amounts represent our minimum contractual obligations, including termination fees.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to purchase commitments, we have agreements with third parties for various services, including services related to clinical operations and support and contract manufacturing, for which we are not contractually able to terminate for convenience and avoid any and all future obligations to the vendors. Certain agreements provide for termination rights subject to termination fees or wind down costs. Under such agreements, we are contractually obligated to make certain payments to vendors, mainly, to reimburse them for their unrecoverable outlays incurred prior to cancellation. At March 31, 2021 and December 31, 2020, we had cancelable open purchase orders of $<ix:nonFraction unitRef="usd" contextRef="ic353f4f727e84c7988d44622743ab4c4_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82Ny9mcmFnOjExOTRmMWVmMzFhNjQwOGE4M2M3OWEwOWVkMmY3YTk4L3RleHRyZWdpb246MTE5NGYxZWYzMWE2NDA4YTgzYzc5YTA5ZWQyZjdhOThfNDYyMQ_43cc6b73-4a63-4af3-ab92-98f8d0f6502b">993</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i570695e9c65448a685edf9c785db6a07_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82Ny9mcmFnOjExOTRmMWVmMzFhNjQwOGE4M2M3OWEwOWVkMmY3YTk4L3RleHRyZWdpb246MTE5NGYxZWYzMWE2NDA4YTgzYzc5YTA5ZWQyZjdhOThfNDYyOA_2106a468-832b-4fac-843c-132b39013ee6">897</ix:nonFraction> million, respectively, in total under such agreements for our significant clinical operations and support and contract manufacturing. These amounts represent only our estimate of those items for which we had a contractual commitment to pay at March 31, 2021 and December 31, 2020, assuming we would not cancel these agreements. The actual amounts we pay in the future to the vendors under such agreements may differ from the purchase order amounts.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licenses to Patented Technology</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 26, 2017, we entered into sublicense agreements with Cellscript, LLC and its affiliate, mRNA RiboTherapeutics, Inc. to sublicense certain patent rights. Pursuant to each agreement, we are required to pay certain license fees, annual maintenance fees, minimum royalties on future net sales and milestone payments contingent on achievement of certain development, regulatory and commercial milestones for specified products, on a product-by-product basis. The development and regulatory milestone payments, up to $<ix:nonFraction unitRef="usd" contextRef="id1c2fd1d75924d69915c2130ff7af739_I20170626" decimals="-6" format="ixt:numdotdecimal" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentAndRegulatoryMilestonesMaximumAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82Ny9mcmFnOjExOTRmMWVmMzFhNjQwOGE4M2M3OWEwOWVkMmY3YTk4L3RleHRyZWdpb246MTE5NGYxZWYzMWE2NDA4YTgzYzc5YTA5ZWQyZjdhOThfNzY5NjU4MTQwMzg4NA_b1ca2da3-c845-4397-96b3-03fb60fcb054">2</ix:nonFraction>&#160;million for therapeutic and prophylactic products and up to $<ix:nonFraction unitRef="usd" contextRef="id39bf79de51448cbb53b0479ac1fc4fd_I20170626" decimals="-6" format="ixt:numdotdecimal" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentAndRegulatoryMilestonesMaximumAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82Ny9mcmFnOjExOTRmMWVmMzFhNjQwOGE4M2M3OWEwOWVkMmY3YTk4L3RleHRyZWdpb246MTE5NGYxZWYzMWE2NDA4YTgzYzc5YTA5ZWQyZjdhOThfNzY5NjU4MTQwMzg5OA_a0ad12c0-aec5-45ee-a546-11b1b71deef3">1</ix:nonFraction>&#160;million for diagnostic products will be recognized as a cost of the asset acquired upon resolution of the associated contingency and will be capitalized or expensed depending on the nature of the associated asset as of the date of recognition. Conversely, commercial milestone payments, up to $<ix:nonFraction unitRef="usd" contextRef="id9b8f829587545b1850dc3d645793a91_I20170626" decimals="-6" format="ixt:numdotdecimal" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82Ny9mcmFnOjExOTRmMWVmMzFhNjQwOGE4M2M3OWEwOWVkMmY3YTk4L3RleHRyZWdpb246MTE5NGYxZWYzMWE2NDA4YTgzYzc5YTA5ZWQyZjdhOThfNzY5NjU4MTQwMzkxMg_4c66e449-e56d-4b58-8df9-b24540b80992">24</ix:nonFraction>&#160;million, and royalties based on annual net sales of licensed products for therapeutic and prophylactic products will be accounted for as additional expense of the related product sales in the period in which the corresponding sales occur. We recognized $<ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82Ny9mcmFnOjExOTRmMWVmMzFhNjQwOGE4M2M3OWEwOWVkMmY3YTk4L3RleHRyZWdpb246MTE5NGYxZWYzMWE2NDA4YTgzYzc5YTA5ZWQyZjdhOThfNzY5NjU4MTQwMzk0Mg_a482589e-78f2-4730-a824-c1d2a237c18e">84</ix:nonFraction>&#160;million of royalty expenses associated with our product sales in the first quarter of 2021, which was recorded to cost of sales in our condensed consolidated statements of operations. We did not recognize any such royalties in the first quarter of 2020 as we did not have product sales in that quarter. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we have other in-license agreements with third parties which require us to make future development, regulatory and commercial milestone payments for specified products associated with the agreements. The achievement of these milestones was not deemed probable as of March 31, 2021.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="ibba7ad915d1a4c4a8ebb50d13fae4c4e_73"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RleHRyZWdpb246MGM1MzYyNTdmN2RkNDJmNjgwODIwODJmYzQyZTQxZGNfNjU5OA_ebe4d040-c67f-4327-8f7d-4a07f237aa9b" continuedAt="if75b6497f8c44110b04fb3dc7dbf473e" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="if75b6497f8c44110b04fb3dc7dbf473e" continuedAt="ic8a9055d67634ddd98f545a15caa8b44"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, we had a total of&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RleHRyZWdpb246MGM1MzYyNTdmN2RkNDJmNjgwODIwODJmYzQyZTQxZGNfMjk3Mg_8e81a287-6165-4697-b5da-5ab0e7506f1f">62</ix:nonFraction> million&#160;shares reserved for future issuance under our Equity Plans, of which <ix:nonFraction unitRef="shares" contextRef="ia56b7a15d277445c813a9b1e913dce91_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RleHRyZWdpb246MGM1MzYyNTdmN2RkNDJmNjgwODIwODJmYzQyZTQxZGNfMzA0NA_2928a6f8-1915-46c7-ba01-8406687b6e8b">35</ix:nonFraction> million shares were reserved for equity awards previously granted, and&#160;<ix:nonFraction unitRef="shares" contextRef="i91b0e05ed30e415f9576819f14007d11_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RleHRyZWdpb246MGM1MzYyNTdmN2RkNDJmNjgwODIwODJmYzQyZTQxZGNfMzExMA_7f0393d3-51d2-4cbd-bc31-658762d7781c">27</ix:nonFraction> million&#160;shares were available for future grants under the 2018 Equity Plan. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Options</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RleHRyZWdpb246MGM1MzYyNTdmN2RkNDJmNjgwODIwODJmYzQyZTQxZGNfNjYwMA_403b0ece-d114-4036-86b6-574231b01417" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our option activity during the three months ended March 31, 2021:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.987%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Options </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in millions)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Price per</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Share</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Grant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Date Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value per</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Share</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Term</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in&#160;millions)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at Outstanding at Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfMS0yLTEtMS0w_f1ffef46-a748-4bdb-98a2-cdfa188afb55">34.06</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfMS00LTEtMS0w_ee8a37c5-c427-47ae-b0bc-b075b0381812">17.14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="2" name="mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfMS02LTEtMS0w_8457aa7b-b443-4319-bb9d-52f2699428c9">9.12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1afaa9c0a57f43b09e758fb17bd26e7d_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfMS04LTEtMS0w_22c6add3-8567-4d52-bb2e-61a9236f72de">6.7</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfMS0xMC0xLTEtMA_9bd99c71-8b70-4af6-b6aa-dde0d070b2fa">2,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfMi0yLTEtMS0w_9c821d5f-3cb6-49e4-be09-c0479300362f">0.87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfMi00LTEtMS0w_793fec8b-8e0d-47c5-a7d4-dab7cd97eadc">171.07</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfMi02LTEtMS0w_ef24f3af-f265-454e-92f5-91465406d48b">75.13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-4" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfMy0yLTEtMS0w_ed1d958a-8fb0-40b4-96cb-7f47c75a7716">1.89</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfMy00LTEtMS0w_edf49100-74a7-4967-b5ed-129e9919be58">14.80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="2" name="mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfMy02LTEtMS0w_08b2f755-f3af-47ff-bdf7-43ac14bcdd0f">8.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfNC0yLTEtMS0w_2427eb17-a90d-47b4-86a0-d016b094dd54">0.09</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfNC00LTEtMS0w_e8eb17d3-e419-4eb8-be5e-04cc97641de0">23.92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="2" name="mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfNC02LTEtMS0w_f05b15d7-ac57-469d-b384-36be2ba56530">11.41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfNS0yLTEtMS0w_3d152261-ee20-4260-bbc7-45eab9790da2">32.95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfNS00LTEtMS0w_3522d71a-54ad-4a96-82cc-3eb109b38956">21.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="2" name="mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfNS02LTEtMS0w_069f4143-f82c-41cc-9747-5ed17d2d2757">10.91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfNS04LTEtMS0w_35597337-108f-4974-b187-2887847b66e6">6.6</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfNS0xMC0xLTEtMA_90a1dfd0-aecb-4b19-b20c-948a327865c5">3,649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfNi0yLTEtMS0w_00e77376-f1b7-48b1-a2f7-543522072d9c">17.65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfNi00LTEtMS0w_14c12933-562a-4835-899a-29e16b536cc8">11.61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="2" name="mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfNi02LTEtMS0w_11a25540-9c88-44c6-a3d6-9e527c9a0450">6.04</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfNi04LTEtMS0w_c92eb142-5fe4-494a-adb5-4271ab6d90a8">5.4</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfNi0xMC0xLTEtMA_5078e96d-cce3-47e5-915a-b7a1f03f32ac">2,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest at March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfNy0yLTEtMS0w_46f03ab9-538c-4aff-b6c7-cb27d7ddf553">15.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfNy00LTEtMS0w_acb88dbc-ec6b-4387-be0b-8c59d701db83">32.51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="2" name="mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfNy02LTEtMS0w_faa06510-c8c9-401b-961d-7595809b37f7">16.52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfNy04LTEtMS0w_895a6481-a30c-444c-9738-efb4d7951804">8.0</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfNy0xMC0xLTEtMA_7be576ed-8e02-4a3a-ac5a-912ad76caa2a">1,542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of common stock for those options in the money as of March 31, 2021.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of options exercised was $<ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RleHRyZWdpb246MGM1MzYyNTdmN2RkNDJmNjgwODIwODJmYzQyZTQxZGNfMzc0Ng_ac72a83e-0239-4fb5-a9f6-f4739373129e">250</ix:nonFraction> million for the three months ended March 31, 2021. The aggregate intrinsic value represents the difference between the exercise price and the selling price received by option holders upon the exercise of stock options during the period. The total consideration recorded as a result of stock option exercises&#160;was approximately $<ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RleHRyZWdpb246MGM1MzYyNTdmN2RkNDJmNjgwODIwODJmYzQyZTQxZGNfNDAzNQ_d97dac50-048f-4791-8988-72743ef8913b">28</ix:nonFraction> million for the three months ended March 31, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Common Stock Units (RSUs) and Performance Stock Units (PSUs)</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RleHRyZWdpb246MGM1MzYyNTdmN2RkNDJmNjgwODIwODJmYzQyZTQxZGNfNjYwOA_19c795f8-9b78-435a-b1b9-9fe6f734c40e" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our RSU and PSU activity during the three months ended March 31, 2021:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Units <br/>(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-Average<br/>Fair Value<br/>per Unit</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, non-vested at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie43ed5c918a0494eb0f43d56862c3e32_I20201231" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjU0MTgyYjU4M2I1OTQxNTQ5MjkzMzMwMjVmNGI3YjQ4L3RhYmxlcmFuZ2U6NTQxODJiNTgzYjU5NDE1NDkyOTMzMzAyNWY0YjdiNDhfMS0xLTEtMS0w_38eede53-f60c-4b9e-b941-ed024e325080">2.19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie43ed5c918a0494eb0f43d56862c3e32_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjU0MTgyYjU4M2I1OTQxNTQ5MjkzMzMwMjVmNGI3YjQ4L3RhYmxlcmFuZ2U6NTQxODJiNTgzYjU5NDE1NDkyOTMzMzAyNWY0YjdiNDhfMS0zLTEtMS0w_7ed7b6ca-eabe-4879-8968-a5c770c67ff5">30.85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i26a6b2b2db7f4f52a54072c86dbb902c_D20210101-20210331" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjU0MTgyYjU4M2I1OTQxNTQ5MjkzMzMwMjVmNGI3YjQ4L3RhYmxlcmFuZ2U6NTQxODJiNTgzYjU5NDE1NDkyOTMzMzAyNWY0YjdiNDhfMi0xLTEtMS0w_332a45ff-f541-4e0f-9d09-74ae026725bc">0.46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i26a6b2b2db7f4f52a54072c86dbb902c_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjU0MTgyYjU4M2I1OTQxNTQ5MjkzMzMwMjVmNGI3YjQ4L3RhYmxlcmFuZ2U6NTQxODJiNTgzYjU5NDE1NDkyOTMzMzAyNWY0YjdiNDhfMi0zLTEtMS0w_4728e5f3-4267-4c63-80ea-b0bb65fa4db2">165.19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i26a6b2b2db7f4f52a54072c86dbb902c_D20210101-20210331" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjU0MTgyYjU4M2I1OTQxNTQ5MjkzMzMwMjVmNGI3YjQ4L3RhYmxlcmFuZ2U6NTQxODJiNTgzYjU5NDE1NDkyOTMzMzAyNWY0YjdiNDhfMy0xLTEtMS0w_020e0fca-c923-4bd0-b5b0-fb6a712ec89c">0.24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i26a6b2b2db7f4f52a54072c86dbb902c_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjU0MTgyYjU4M2I1OTQxNTQ5MjkzMzMwMjVmNGI3YjQ4L3RhYmxlcmFuZ2U6NTQxODJiNTgzYjU5NDE1NDkyOTMzMzAyNWY0YjdiNDhfMy0zLTEtMS0w_0d009e68-515e-484b-b5ea-6909b3bcad6c">24.77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i26a6b2b2db7f4f52a54072c86dbb902c_D20210101-20210331" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjU0MTgyYjU4M2I1OTQxNTQ5MjkzMzMwMjVmNGI3YjQ4L3RhYmxlcmFuZ2U6NTQxODJiNTgzYjU5NDE1NDkyOTMzMzAyNWY0YjdiNDhfNC0xLTEtMS0w_4948c134-10d9-4195-bb7a-02506f8deca8">0.02</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i26a6b2b2db7f4f52a54072c86dbb902c_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjU0MTgyYjU4M2I1OTQxNTQ5MjkzMzMwMjVmNGI3YjQ4L3RhYmxlcmFuZ2U6NTQxODJiNTgzYjU5NDE1NDkyOTMzMzAyNWY0YjdiNDhfNC0zLTEtMS0w_8d686cdb-1fe8-4ab7-b0af-6e0e1e98f37c">32.39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, non-vested at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i53c9c75bd90d46278b4077d5e35f7d5b_I20210331" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjU0MTgyYjU4M2I1OTQxNTQ5MjkzMzMwMjVmNGI3YjQ4L3RhYmxlcmFuZ2U6NTQxODJiNTgzYjU5NDE1NDkyOTMzMzAyNWY0YjdiNDhfNS0xLTEtMS0w_8190f217-dc9a-480d-a107-3351911a3093">2.39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i53c9c75bd90d46278b4077d5e35f7d5b_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjU0MTgyYjU4M2I1OTQxNTQ5MjkzMzMwMjVmNGI3YjQ4L3RhYmxlcmFuZ2U6NTQxODJiNTgzYjU5NDE1NDkyOTMzMzAyNWY0YjdiNDhfNS0zLTEtMS0w_1055a59a-2e32-4745-b253-83ca00389ea0">57.28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of restricted stock units vested during the three months ended March 31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RestrictedStockExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RleHRyZWdpb246MGM1MzYyNTdmN2RkNDJmNjgwODIwODJmYzQyZTQxZGNfNzY5NjU4MTQxODM1OA_4036bcfb-f629-4be4-b39f-021b678d5e04">6</ix:nonFraction>&#160;million. The total intrinsic value of restricted stock units vested during the three months ended March 31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i26a6b2b2db7f4f52a54072c86dbb902c_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RleHRyZWdpb246MGM1MzYyNTdmN2RkNDJmNjgwODIwODJmYzQyZTQxZGNfNzY5NjU4MTQyNDA5NQ_d17f4227-fa75-4852-bd4e-e1fa1ebe2a5d">35</ix:nonFraction>&#160;million.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2021, we granted PSUs to certain senior executives with vesting that is contingent upon the achievement of specified preestablished goals over the performance period, generally <ix:nonNumeric contextRef="i9c17046964e4496093fef93215168f9c_D20210101-20210331" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RleHRyZWdpb246MGM1MzYyNTdmN2RkNDJmNjgwODIwODJmYzQyZTQxZGNfMzI5ODUzNDkxMjc0Nw_4fd37812-8f41-413b-9644-47b1a9c7c669">three years</ix:nonNumeric>. The actual number of common shares ultimately </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Contents</a></span></div></div><ix:continuation id="ic8a9055d67634ddd98f545a15caa8b44"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issued is calculated by multiplying the number of PSUs by a payout percentage ranging from <ix:nonFraction unitRef="number" contextRef="ie18c5203639447448d73f34f409c6682_I20210331" decimals="INF" name="mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RleHRyZWdpb246MGM1MzYyNTdmN2RkNDJmNjgwODIwODJmYzQyZTQxZGNfNzY5NjU4MTQxNzQyMw_a7da6f75-ffb6-42d7-8544-32e6674230df">0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ia750d90906f64b3da90f3ea25a6e6c88_I20210331" decimals="INF" name="mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RleHRyZWdpb246MGM1MzYyNTdmN2RkNDJmNjgwODIwODJmYzQyZTQxZGNfNzY5NjU4MTQxNzQyNw_24ca3e78-1388-4be2-bfca-700c1712ab5b">200</ix:nonFraction>%. The estimated fair value of PSUs is based on the grant date fair value.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Employee Stock Purchase Plan (ESPP)</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="shares" contextRef="i1e7259ec870c4de7815c0a34b19ed99c_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RleHRyZWdpb246MGM1MzYyNTdmN2RkNDJmNjgwODIwODJmYzQyZTQxZGNfMzI5ODUzNDkxMjczOQ_d8e7ebdd-0a09-4daf-a176-62483ea5d043">no</ix:nonFraction> shares sold under the ESPP during the three months ended March 31, 2021. As of March 31, 2021, <ix:nonFraction unitRef="shares" contextRef="ibf2c3f50e45f44bfa74451d6d87a3675_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RleHRyZWdpb246MGM1MzYyNTdmN2RkNDJmNjgwODIwODJmYzQyZTQxZGNfNTc5NQ_6228c592-1e2a-4235-9438-9d5da88e416e">4</ix:nonFraction>&#160;million shares were available for future issuance under the ESPP.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RleHRyZWdpb246MGM1MzYyNTdmN2RkNDJmNjgwODIwODJmYzQyZTQxZGNfNjYxMg_c33cc844-7c59-46e1-bd15-87d64761154d" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components and classification of stock-based compensation expense for the three months ended March 31, 2021 and 2020 as follows (in millions):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:71.742%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.931%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.208%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22567b607e5a40439a3314231a4c0b31_D20210101-20210331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOmRhYWJmNWUyZWQ2NTQ1OTQ4MDc5ODZlYTBkMjgxM2FhL3RhYmxlcmFuZ2U6ZGFhYmY1ZTJlZDY1NDU5NDgwNzk4NmVhMGQyODEzYWFfMi05LTEtMS0w_a8f986a3-24e3-4c29-92e6-4a7db1cc0032">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if820d61e1d2e4cb3a94f601c28956f74_D20200101-20200331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOmRhYWJmNWUyZWQ2NTQ1OTQ4MDc5ODZlYTBkMjgxM2FhL3RhYmxlcmFuZ2U6ZGFhYmY1ZTJlZDY1NDU5NDgwNzk4NmVhMGQyODEzYWFfMi0xMS0xLTEtMA_f468358b-f265-4614-9651-e93936af8212">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs and PSUs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53f43d6f041a413d9ba3a5b6031c5bca_D20210101-20210331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOmRhYWJmNWUyZWQ2NTQ1OTQ4MDc5ODZlYTBkMjgxM2FhL3RhYmxlcmFuZ2U6ZGFhYmY1ZTJlZDY1NDU5NDgwNzk4NmVhMGQyODEzYWFfMy05LTEtMS0w_181d7ba9-9050-45d5-baa4-bcde12871397">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ee58a110904b6ea810fa10add84823_D20200101-20200331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOmRhYWJmNWUyZWQ2NTQ1OTQ4MDc5ODZlYTBkMjgxM2FhL3RhYmxlcmFuZ2U6ZGFhYmY1ZTJlZDY1NDU5NDgwNzk4NmVhMGQyODEzYWFfMy0xMS0xLTEtMA_ce0793e6-e3df-48a2-a6d6-51f95002e812">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e7259ec870c4de7815c0a34b19ed99c_D20210101-20210331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOmRhYWJmNWUyZWQ2NTQ1OTQ4MDc5ODZlYTBkMjgxM2FhL3RhYmxlcmFuZ2U6ZGFhYmY1ZTJlZDY1NDU5NDgwNzk4NmVhMGQyODEzYWFfNC05LTEtMS0w_896679b2-d8fb-449e-84d9-205b8db30557">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f6bab6d04464aa58adc35f314641f71_D20200101-20200331" decimals="-6" format="ixt:zerodash" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOmRhYWJmNWUyZWQ2NTQ1OTQ4MDc5ODZlYTBkMjgxM2FhL3RhYmxlcmFuZ2U6ZGFhYmY1ZTJlZDY1NDU5NDgwNzk4NmVhMGQyODEzYWFfNC0xMS0xLTEtMA_5a474710-3ab2-4157-9e48-113173281252">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOmRhYWJmNWUyZWQ2NTQ1OTQ4MDc5ODZlYTBkMjgxM2FhL3RhYmxlcmFuZ2U6ZGFhYmY1ZTJlZDY1NDU5NDgwNzk4NmVhMGQyODEzYWFfNS05LTEtMS0w_644f190b-fb2d-4865-a109-b48aece2f61b">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOmRhYWJmNWUyZWQ2NTQ1OTQ4MDc5ODZlYTBkMjgxM2FhL3RhYmxlcmFuZ2U6ZGFhYmY1ZTJlZDY1NDU5NDgwNzk4NmVhMGQyODEzYWFfNS0xMS0xLTEtMA_b5c59ef8-5d8f-496a-add7-1d60d64d019a">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibca633e1d4664bcd8090d7383938bd13_D20210101-20210331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOmRhYWJmNWUyZWQ2NTQ1OTQ4MDc5ODZlYTBkMjgxM2FhL3RhYmxlcmFuZ2U6ZGFhYmY1ZTJlZDY1NDU5NDgwNzk4NmVhMGQyODEzYWFfNy05LTEtMS0zMTA0_4f4d0dca-a3fb-46cb-8a1f-ca5faaff60e8">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if11b06a738a64cf88f8e86ac44cbfe87_D20200101-20200331" decimals="-6" format="ixt:zerodash" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOmRhYWJmNWUyZWQ2NTQ1OTQ4MDc5ODZlYTBkMjgxM2FhL3RhYmxlcmFuZ2U6ZGFhYmY1ZTJlZDY1NDU5NDgwNzk4NmVhMGQyODEzYWFfNy0xMS0xLTEtMzU0Mg_edf45169-f2d0-49b7-8e23-5a6928bb0f48">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7207e2b92904a3ea65000ec12644d42_D20210101-20210331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOmRhYWJmNWUyZWQ2NTQ1OTQ4MDc5ODZlYTBkMjgxM2FhL3RhYmxlcmFuZ2U6ZGFhYmY1ZTJlZDY1NDU5NDgwNzk4NmVhMGQyODEzYWFfNi05LTEtMS0w_6ce8257f-f7c5-426d-91de-80c3f213f4ce">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99e931e8a5cd44ea88397661762d28f1_D20200101-20200331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOmRhYWJmNWUyZWQ2NTQ1OTQ4MDc5ODZlYTBkMjgxM2FhL3RhYmxlcmFuZ2U6ZGFhYmY1ZTJlZDY1NDU5NDgwNzk4NmVhMGQyODEzYWFfNi0xMS0xLTEtMA_740f24dc-b4dd-478f-a44c-c65fa74a9480">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4b450ab98d4f6b90381fecd841a0a5_D20210101-20210331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOmRhYWJmNWUyZWQ2NTQ1OTQ4MDc5ODZlYTBkMjgxM2FhL3RhYmxlcmFuZ2U6ZGFhYmY1ZTJlZDY1NDU5NDgwNzk4NmVhMGQyODEzYWFfNy05LTEtMS0w_67c74622-ad86-4a67-a14e-0b5bb4ee41cf">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b44e002e91945e5a00c7bcd2919634d_D20200101-20200331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOmRhYWJmNWUyZWQ2NTQ1OTQ4MDc5ODZlYTBkMjgxM2FhL3RhYmxlcmFuZ2U6ZGFhYmY1ZTJlZDY1NDU5NDgwNzk4NmVhMGQyODEzYWFfNy0xMS0xLTEtMA_328d63d5-4082-4858-ac69-79f41027c43a">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOmRhYWJmNWUyZWQ2NTQ1OTQ4MDc5ODZlYTBkMjgxM2FhL3RhYmxlcmFuZ2U6ZGFhYmY1ZTJlZDY1NDU5NDgwNzk4NmVhMGQyODEzYWFfOC05LTEtMS0w_5e6c1791-05c7-4a39-b0ae-555d3c2776ca">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOmRhYWJmNWUyZWQ2NTQ1OTQ4MDc5ODZlYTBkMjgxM2FhL3RhYmxlcmFuZ2U6ZGFhYmY1ZTJlZDY1NDU5NDgwNzk4NmVhMGQyODEzYWFfOC0xMS0xLTEtMA_f9911f9a-019d-4b05-9928-8befaa5b4dda">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, there was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RleHRyZWdpb246MGM1MzYyNTdmN2RkNDJmNjgwODIwODJmYzQyZTQxZGNfNjM3MA_ea8856be-bcaf-4c46-a9a1-64e91f7d96b4">337</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of total unrecognized compensation cost related to unvested stock-based compensation with respect to options, RSUs and PSUs granted. That cost is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RleHRyZWdpb246MGM1MzYyNTdmN2RkNDJmNjgwODIwODJmYzQyZTQxZGNfNjU4NQ_0f65cadc-1e26-4921-978e-0fb17d41f838">3.1</ix:nonNumeric> years at March 31, 2021.</span></div></ix:continuation><div><span><br/></span></div><div id="ibba7ad915d1a4c4a8ebb50d13fae4c4e_79"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83OS9mcmFnOmQ2Mjk3YjMzNzM0ODQ4NjA5OGU3ZGFhNDY0YTc0NjVjL3RleHRyZWdpb246ZDYyOTdiMzM3MzQ4NDg2MDk4ZTdkYWE0NjRhNzQ2NWNfMTA5Mw_c166249a-44c5-4bb8-8535-2048b2d83aa2" continuedAt="i87df42996e7f4360929e66ef3f6ac72c" escape="true">Income Taxes</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i87df42996e7f4360929e66ef3f6ac72c" continuedAt="i530e56c64e314771a5efccad10d80751"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to U.S. federal, state, and foreign income taxes. For the three months ended March 31, 2021 and 2020, we recorded provisions for income taxes of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83OS9mcmFnOmQ2Mjk3YjMzNzM0ODQ4NjA5OGU3ZGFhNDY0YTc0NjVjL3RleHRyZWdpb246ZDYyOTdiMzM3MzQ4NDg2MDk4ZTdkYWE0NjRhNzQ2NWNfNDk0NzgwMjMzNzA0Mw_17499976-14fe-4325-995a-0fc71ff43227">39</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and an immaterial amount, respectively. Our effective tax rate for the three months ended March 31, 2021 was lower than the U.S. statutory rate primarily due to the benefit of the foreign derived intangible income deduction, the benefit related to the release of the valuation allowance on the majority of our tax attributes and other deferred tax assets, as well as a discrete item for excess tax benefits related to stock-based compensation. Our effective tax rate for the three months ended March 31, 2020 was lower than the U.S. statutory rate primarily due to the valuation allowance.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities. These differences are measured using the enacted statutory tax rates that are expected to be in effect for the years in which differences are expected to reverse. On a periodic basis, we reassess any valuation allowances that we maintain on our deferred tax assets, weighing positive and negative evidence to assess the recoverability of the deferred tax assets. For the three months ended March 31, 2021, we reassessed the valuation allowance noting the increase in positive evidence, including significant revenue growth, expectations regarding future profitability, and successful supply chain and manufacturing capabilities to meet global product demand. After assessing both the positive evidence and negative evidence, we determined it was more likely than not that we will realize the majority of our deferred tax assets. Therefore, we determined we should reverse the majority of our valuation allowance through the annual effective tax rate (AETR) with respect to amounts we expect to realize through current year income. In addition, we have recorded a discrete benefit of $<ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83OS9mcmFnOmQ2Mjk3YjMzNzM0ODQ4NjA5OGU3ZGFhNDY0YTc0NjVjL3RleHRyZWdpb246ZDYyOTdiMzM3MzQ4NDg2MDk4ZTdkYWE0NjRhNzQ2NWNfMzI5ODUzNDkwMTM2OA_d7145a57-ec08-424b-9ba5-9e15a7b0ed98">49</ix:nonFraction>&#160;million related to the release of the valuation allowance on deferred tax assets that we expect to utilize in future years. We will maintain a valuation allowance on certain state tax attributes that we expect will expire prior to the utilization. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Coronavirus Aid, Relief and Economic Security Act (CARES Act) was signed into law. The CARES Act includes provisions relating to several aspects of corporate income taxes. We do not currently expect the CARES Act to have a significant impact on our provision for income taxes.</span></div></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Contents</a></span></div></div><ix:continuation id="i530e56c64e314771a5efccad10d80751"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have reviewed the tax positions taken, or to be taken, in our tax returns for all tax years currently open to examination by a taxing authority. Unrecognized tax benefits represent the aggregate tax effect of differences between tax return positions and the benefits recognized in the financial statements. As of March 31, 2021 and December 31, 2020, we had an immaterial amount of gross unrecognized tax benefits, which would affect our tax rate if recognized. We do not expect that our unrecognized tax benefits will materially increase within the next twelve months. We accrue interest and penalties related to unrecognized tax benefits as a component of our provision for income taxes. We did not recognize any material interest or penalties related to uncertain tax positions during the three months ended March 31, 2021 and 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file U.S. federal income tax returns and income tax returns in various state, local and foreign jurisdictions. We are not currently subject to any tax assessment from an income tax examination in the United States or any other major taxing jurisdiction since inception.</span></div></ix:continuation><div><span><br/></span></div><div id="ibba7ad915d1a4c4a8ebb50d13fae4c4e_85"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV84NS9mcmFnOjc5ZWMyYjZkNjg5MzQ5OWI4MDRhNmJiOGUyZGJlOTFlL3RleHRyZWdpb246NzllYzJiNmQ2ODkzNDk5YjgwNGE2YmI4ZTJkYmU5MWVfNzY5NjU4MTM5NjkzMQ_35e8b5a4-7802-4311-b41c-e6be4072ed48" continuedAt="i1d41e7b50c2c40b4b341b885c1554f4f" escape="true">Earnings per Share </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i1d41e7b50c2c40b4b341b885c1554f4f"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The computation of basic earnings per share (EPS) is based on the weighted-average number of our common shares outstanding. The computation of diluted EPS is based on the weighted-average number of our common shares outstanding and potential dilutive common shares outstanding during the period as determined by using the treasury stock method.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV84NS9mcmFnOjc5ZWMyYjZkNjg5MzQ5OWI4MDRhNmJiOGUyZGJlOTFlL3RleHRyZWdpb246NzllYzJiNmQ2ODkzNDk5YjgwNGE2YmI4ZTJkYmU5MWVfNDUy_7e68e738-ce36-4def-8f34-047fb6c9dccf" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted EPS for the three months ended March 31, 2021 and 2020 are calculated as follows (in millions, except per share data):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.788%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.986%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.5pt;text-align:left;text-indent:-13.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV84NS9mcmFnOjc5ZWMyYjZkNjg5MzQ5OWI4MDRhNmJiOGUyZGJlOTFlL3RhYmxlOjg2NDU2NGQwNjUzMzRhNWY5NGFiOGE1OTIyNzFjMWE1L3RhYmxlcmFuZ2U6ODY0NTY0ZDA2NTMzNGE1Zjk0YWI4YTU5MjI3MWMxYTVfMy05LTEtMS0w_f43105a8-00f7-466f-b48f-87f9f733c807">1,221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV84NS9mcmFnOjc5ZWMyYjZkNjg5MzQ5OWI4MDRhNmJiOGUyZGJlOTFlL3RhYmxlOjg2NDU2NGQwNjUzMzRhNWY5NGFiOGE1OTIyNzFjMWE1L3RhYmxlcmFuZ2U6ODY0NTY0ZDA2NTMzNGE1Zjk0YWI4YTU5MjI3MWMxYTVfMy0xMS0xLTEtMA_bb034464-8359-4c31-a334-f93eb09e1407">124</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;text-indent:-18pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted-average common shares outstanding</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV84NS9mcmFnOjc5ZWMyYjZkNjg5MzQ5OWI4MDRhNmJiOGUyZGJlOTFlL3RhYmxlOjg2NDU2NGQwNjUzMzRhNWY5NGFiOGE1OTIyNzFjMWE1L3RhYmxlcmFuZ2U6ODY0NTY0ZDA2NTMzNGE1Zjk0YWI4YTU5MjI3MWMxYTVfNS05LTEtMS0w_6dd4853d-d23d-456e-9910-d8f163198c4c">400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV84NS9mcmFnOjc5ZWMyYjZkNjg5MzQ5OWI4MDRhNmJiOGUyZGJlOTFlL3RhYmxlOjg2NDU2NGQwNjUzMzRhNWY5NGFiOGE1OTIyNzFjMWE1L3RhYmxlcmFuZ2U6ODY0NTY0ZDA2NTMzNGE1Zjk0YWI4YTU5MjI3MWMxYTVfNS0xMS0xLTEtMA_53cd964d-4a01-4b16-a7b7-6543d553e318">353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV84NS9mcmFnOjc5ZWMyYjZkNjg5MzQ5OWI4MDRhNmJiOGUyZGJlOTFlL3RhYmxlOjg2NDU2NGQwNjUzMzRhNWY5NGFiOGE1OTIyNzFjMWE1L3RhYmxlcmFuZ2U6ODY0NTY0ZDA2NTMzNGE1Zjk0YWI4YTU5MjI3MWMxYTVfNi05LTEtMS0zMTg2_a9d8739d-6e0e-458e-a61f-0ed5c3f5c9d5">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" format="ixt:zerodash" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV84NS9mcmFnOjc5ZWMyYjZkNjg5MzQ5OWI4MDRhNmJiOGUyZGJlOTFlL3RhYmxlOjg2NDU2NGQwNjUzMzRhNWY5NGFiOGE1OTIyNzFjMWE1L3RhYmxlcmFuZ2U6ODY0NTY0ZDA2NTMzNGE1Zjk0YWI4YTU5MjI3MWMxYTVfNi0xMS0xLTEtMzE4Ng_a86e028c-551b-47e1-8557-80edb830bc97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted-average common shares outstanding</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV84NS9mcmFnOjc5ZWMyYjZkNjg5MzQ5OWI4MDRhNmJiOGUyZGJlOTFlL3RhYmxlOjg2NDU2NGQwNjUzMzRhNWY5NGFiOGE1OTIyNzFjMWE1L3RhYmxlcmFuZ2U6ODY0NTY0ZDA2NTMzNGE1Zjk0YWI4YTU5MjI3MWMxYTVfNy05LTEtMS0zNTYw_e7b7a728-c34a-4780-9181-f6f5b8a273b1">430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV84NS9mcmFnOjc5ZWMyYjZkNjg5MzQ5OWI4MDRhNmJiOGUyZGJlOTFlL3RhYmxlOjg2NDU2NGQwNjUzMzRhNWY5NGFiOGE1OTIyNzFjMWE1L3RhYmxlcmFuZ2U6ODY0NTY0ZDA2NTMzNGE1Zjk0YWI4YTU5MjI3MWMxYTVfNy0xMS0xLTEtMzU2Mg_d6197514-dec2-4a4f-a900-84e1e79d59be">353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic EPS</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV84NS9mcmFnOjc5ZWMyYjZkNjg5MzQ5OWI4MDRhNmJiOGUyZGJlOTFlL3RhYmxlOjg2NDU2NGQwNjUzMzRhNWY5NGFiOGE1OTIyNzFjMWE1L3RhYmxlcmFuZ2U6ODY0NTY0ZDA2NTMzNGE1Zjk0YWI4YTU5MjI3MWMxYTVfNi05LTEtMS0w_08e2fb9c-ef0d-4811-90ab-aa801bfdbc1e">3.05</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV84NS9mcmFnOjc5ZWMyYjZkNjg5MzQ5OWI4MDRhNmJiOGUyZGJlOTFlL3RhYmxlOjg2NDU2NGQwNjUzMzRhNWY5NGFiOGE1OTIyNzFjMWE1L3RhYmxlcmFuZ2U6ODY0NTY0ZDA2NTMzNGE1Zjk0YWI4YTU5MjI3MWMxYTVfNi0xMS0xLTEtMA_9870cb74-c4f2-4731-aa70-0269f0579e26">0.35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted EPS</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV84NS9mcmFnOjc5ZWMyYjZkNjg5MzQ5OWI4MDRhNmJiOGUyZGJlOTFlL3RhYmxlOjg2NDU2NGQwNjUzMzRhNWY5NGFiOGE1OTIyNzFjMWE1L3RhYmxlcmFuZ2U6ODY0NTY0ZDA2NTMzNGE1Zjk0YWI4YTU5MjI3MWMxYTVfMTAtOS0xLTEtMzU2Mw_b04a7214-8e62-4a7e-8768-da6a2aa08391">2.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV84NS9mcmFnOjc5ZWMyYjZkNjg5MzQ5OWI4MDRhNmJiOGUyZGJlOTFlL3RhYmxlOjg2NDU2NGQwNjUzMzRhNWY5NGFiOGE1OTIyNzFjMWE1L3RhYmxlcmFuZ2U6ODY0NTY0ZDA2NTMzNGE1Zjk0YWI4YTU5MjI3MWMxYTVfMTAtMTEtMS0xLTM1NjY_b830a7b6-7d3f-41ab-9d08-5f566cbc4bd0">0.35</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV84NS9mcmFnOjc5ZWMyYjZkNjg5MzQ5OWI4MDRhNmJiOGUyZGJlOTFlL3RleHRyZWdpb246NzllYzJiNmQ2ODkzNDk5YjgwNGE2YmI4ZTJkYmU5MWVfNDU1_14b24698-d58b-4109-9bd5-74782da09dd6" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents, presented based on amounts outstanding as of March 31, 2020 were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because their inclusion would have been anti-dilutive (in millions):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.984%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i649444b931a542648a2d656ef5f35e1c_D20200101-20200331" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV84NS9mcmFnOjc5ZWMyYjZkNjg5MzQ5OWI4MDRhNmJiOGUyZGJlOTFlL3RhYmxlOmZhYTk1OTMwNGQ0ZTQwNjE4ZTVkYzVlOTY1ZThhOGI0L3RhYmxlcmFuZ2U6ZmFhOTU5MzA0ZDRlNDA2MThlNWRjNWU5NjVlOGE4YjRfMi0zLTEtMS0w_f5e13b90-fdb2-426f-bd82-f31aef280669">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted common stock units</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0b71c01ae54c49e288fce1e85063a0c0_D20200101-20200331" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV84NS9mcmFnOjc5ZWMyYjZkNjg5MzQ5OWI4MDRhNmJiOGUyZGJlOTFlL3RhYmxlOmZhYTk1OTMwNGQ0ZTQwNjE4ZTVkYzVlOTY1ZThhOGI0L3RhYmxlcmFuZ2U6ZmFhOTU5MzA0ZDRlNDA2MThlNWRjNWU5NjVlOGE4YjRfNC0zLTEtMS0w_e21acbec-eb3c-43fe-b6dd-a776830697f7">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV84NS9mcmFnOjc5ZWMyYjZkNjg5MzQ5OWI4MDRhNmJiOGUyZGJlOTFlL3RhYmxlOmZhYTk1OTMwNGQ0ZTQwNjE4ZTVkYzVlOTY1ZThhOGI0L3RhYmxlcmFuZ2U6ZmFhOTU5MzA0ZDRlNDA2MThlNWRjNWU5NjVlOGE4YjRfNS0zLTEtMS0w_908d7817-9efc-424c-a249-8a5ae0f052f0">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="ibba7ad915d1a4c4a8ebb50d13fae4c4e_88"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Contents</a></span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. <ix:nonNumeric contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV84OC9mcmFnOjgwNjAzZTY4MzUwNTRlMzhhZTgyNDhmNDRiNWU4OWJiL3RleHRyZWdpb246ODA2MDNlNjgzNTA1NGUzOGFlODI0OGY0NGI1ZTg5YmJfNTQz_78ca989c-39da-4ad5-815e-2027cd165b17" continuedAt="i08ee0cbf379f4dbf8ac46ccb985b8a85" escape="true">Subsequent Events</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i08ee0cbf379f4dbf8ac46ccb985b8a85"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to March 31, 2021, we have entered into additional supply agreements with customers to provide up to <ix:nonFraction unitRef="dose" contextRef="i9c022d9b4fbe4b8b8966c5f007b5faf4_D20210401-20210507" decimals="INF" format="ixt:numdotdecimal" name="mrna:NumberOfDosesOfVaccineCandidate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV84OC9mcmFnOjgwNjAzZTY4MzUwNTRlMzhhZTgyNDhmNDRiNWU4OWJiL3RleHRyZWdpb246ODA2MDNlNjgzNTA1NGUzOGFlODI0OGY0NGI1ZTg5YmJfNzY5NjU4MTQwNzI1OA_808ac99b-788c-4cc9-8047-26881b776c0d">47</ix:nonFraction>&#160;million doses of our COVID-19 vaccine based on the initial confirmed volume, subject to modifications.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to March 31, 2021, we have entered into additional binding purchase commitments with third-party contractual manufacturing organizations for our COVID-19 vaccine under existing or newly executed agreements. We are currently committed to minimum non-cancelable purchase obligations of $<ix:nonFraction unitRef="usd" contextRef="ic8a5bdf50ed34e1196383b6df3a4c6e7_I20210507" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV84OC9mcmFnOjgwNjAzZTY4MzUwNTRlMzhhZTgyNDhmNDRiNWU4OWJiL3RleHRyZWdpb246ODA2MDNlNjgzNTA1NGUzOGFlODI0OGY0NGI1ZTg5YmJfNzY5NjU4MTM5NzY2OQ_f3ffa23c-b83d-4dd4-87c4-57d83385c6b8">284</ix:nonFraction>&#160;million related to these agreements, which are expected to be paid through 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, on April 18, 2021, we entered into a further amendment to our existing agreement with BARDA, pursuant to which BARDA has agreed to fund the advancement of mRNA-1273 to potential licensure, including funding for clinical studies and manufacturing scale-up. The amendment increases the amount of potential reimbursements by $<ix:nonFraction unitRef="usd" contextRef="i1d9fd4412ca74750b6b14d4722981e10_D20210418-20210418" decimals="-6" format="ixt:numdotdecimal" name="mrna:RevenueFromGrantsPotentialReimbursement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV84OC9mcmFnOjgwNjAzZTY4MzUwNTRlMzhhZTgyNDhmNDRiNWU4OWJiL3RleHRyZWdpb246ODA2MDNlNjgzNTA1NGUzOGFlODI0OGY0NGI1ZTg5YmJfNzY5NjU4MTQwMDk2OQ_b35c6c82-d9f1-49bb-9189-5a93e6501fc2">236</ix:nonFraction>&#160;million in connection with costs associated with the Phase 3 clinical trials for mRNA-1273 and pharmacovigilance efforts, bringing the total BARDA support to approximately $<ix:nonFraction unitRef="usd" contextRef="i1d9fd4412ca74750b6b14d4722981e10_D20210418-20210418" decimals="-8" format="ixt:numdotdecimal" name="mrna:RevenueFromGrantsMaximumAward" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV84OC9mcmFnOjgwNjAzZTY4MzUwNTRlMzhhZTgyNDhmNDRiNWU4OWJiL3RleHRyZWdpb246ODA2MDNlNjgzNTA1NGUzOGFlODI0OGY0NGI1ZTg5YmJfNzY5NjU4MTQwMDk4Mw_c2f06a32-bee4-4afb-97ca-9499aa05669f">1.3</ix:nonFraction>&#160;billion.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div id="ibba7ad915d1a4c4a8ebb50d13fae4c4e_91"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited financial information and related notes included in this Form 10-Q and our consolidated financial statements and related notes and other financial information in our Annual Report on Form 10-K for the year ended December 31, 2020, which was filed with the SEC on February 26, 2021 (the &#8220;2020 Form 10-K&#8221;). Some of the information contained in this discussion and analysis or set forth elsewhere in this Form 10-Q, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in Part II, Item 1A - Risk Factors in this Form 10-Q, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines to improve the lives of patients. mRNA medicines are designed to direct the body&#8217;s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a broad spectrum of diseases. Our platform builds on continuous advances in basic and applied mRNA science, delivery technology, and manufacturing, providing us the capability to pursue in parallel a robust pipeline of new development candidates.&#160;We are developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, autoimmune diseases and cardiovascular diseases, independently and with our strategic collaborators. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within our platform, we develop technologies that enable the development of mRNA medicines for diverse applications. When we identify technologies that we believe could enable a new group of potential mRNA medicines with shared product features, we call that group a &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">modality.&#8221; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the programs within a modality may target diverse diseases, they share similar mRNA technologies, delivery technologies, and manufacturing processes to achieve shared product features. The programs within a modality will also generally share similar pharmacology profiles, including the desired dose response, the expected dosing regimen, the target tissue for protein expression, safety and tolerability goals, and pharmaceutical properties. Programs within a modality often have correlated technology risk, but because they pursue diverse diseases they often have uncorrelated biology risk. We have created six modalities to date:</span></div><div><span><br/></span></div><div style="padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">prophylactic vaccines;</span></div><div style="padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">systemic secreted and cell surface therapeutics;</span></div><div style="padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">cancer vaccines;</span></div><div style="padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">intratumoral immuno-oncology;</span></div><div style="padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">localized regenerative therapeutics; and</span></div><div style="padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">systemic intracellular therapeutics.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have designated our prophylactic vaccines and systemic secreted and cell surface therapeutics modalities as our &#8220;core modalities&#8221;. In these core modalities, our strategy is to invest in additional development candidates using our accumulated innovations in technology, our process insights and our preclinical and clinical experience. Our exploratory modalities continue to be a critical part of advancing our strategy to maximize the application of our potential mRNA medicines.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Contents</a></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Highlights</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Moderna COVID-19 Vaccine</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 18, 2020, the U.S. FDA authorized the emergency use of the Moderna COVID-19 Vaccine in individuals 18 years of age or older. We have also received authorization for our COVID-19 vaccine from health agencies in Canada, Israel, the European Union, the United Kingdom, Switzerland, Singapore, Qatar, Taiwan, and the Philippines, and from the World Health Organization. Additional authorizations are currently under review in other countries and by the World Health Organization. We plan to initiate the rolling submission of data to the U.S. FDA for a Biologics License Application for our COVID-19 vaccine in May 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into supply agreements with the U.S. Government and several other governments outside the United States for the supply of our COVID-19 vaccine. The agreements are generally subject to receipt of authorization or approval for the use and distribution of the vaccine from the relevant regulatory authority in each jurisdiction. Under these agreements, we are entitled to upfront deposits for our COVID-19 vaccine supply, initially recorded as deferred revenue. As of March 31, 2021, we had approximately $7.5 billion in deferred revenue in connection with the supply agreements with the U.S. Government and other governments, which will be recognized as revenue when revenue recognition criteria have been met. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the first quarter of 2021, we delivered approximately 88 million doses of our COVID-19 vaccine to the U.S. government and approximately 14 million doses to other governments, and recognized $1.7 billion in product sales. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2020, we delivered approximately 17 million doses of our COVID-19 vaccine to the U.S. government. Through April 12, 2021, we cumulatively delivered approximately 132 million doses globally, including approximately 117 million doses to the U.S. government and approximately 15 million doses delivered to other governments from our ex-U.S. supply chain. We remain on track to deliver the second 100 million doses to the U.S. government by end of May 2021 followed by another 100 million additional doses by end of July 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 29, 2021, we announced additional investments to facilitate the increased supply of our COVID-19 vaccine from our own and partnered manufacturing facilities. We anticipate these investments will increase our global 2022 capacity for the vaccine to up to 3 billion doses, depending upon the mix between the COVID-19 vaccine at the current 100 &#181;g dose level and potentially lower doses of our variant booster candidates and pediatric vaccines, which are subject to further regulatory approval and authorization. These investments are expected to facilitate a doubling of drug substance manufacturing from Lonza&#8217;s Switzerland-based facility, a more than doubling of formulation, fill and finish and drug substance manufacturing at Rovi&#8217;s Spain-based facility, as well as a 50% increase of drug substance at Moderna&#8217;s facilities in the U.S. When completed, the investments are expected to also result in an increase in safety stock of raw materials and finished product used to deliver committed volumes. These forecasted increases to our supply are subject in part to performance by our manufacturing partners, which will require ramping-up capabilities at their own facilities and the hiring of qualified manufacturing personnel. On April 29, 2021, we also announced an increase in our projected supply of the COVID-19 vaccine for 2021 to between 800 million and 1 billion doses.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Moderna COVID-19 Vaccine Clinical Studies </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An updated review of adjudicated cases has identified over 900 cases of COVID-19 in the Phase 3 clinical trial for mRNA-1273, which we refer to as the COVE study, as of April 9, 2021, including over 100 cases of severe COVID-19, as defined in the protocol, with a median follow-up of approximately 6 months after the second dose. Vaccine efficacy starting two weeks following the second dose and based on the updated adjudicated cases remains consistent with prior updates, including greater than 90% efficacy against all cases of COVID-19, and greater than 95% efficacy against severe cases of COVID-19. The COVE study is ongoing and reported results remain preliminary. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Phase 2/3 TeenCOVE study of mRNA-1273 in adolescents ages 12-17 years has completed enrollment in the U.S. An initial analysis of 3,235 participants randomized 2:1 in the TeenCOVE study showed a vaccine efficacy rate of 96% in seronegative participants who received at least one injection. The analysis included 12 cases starting 14 days after the first dose and based on the CDC definition of COVID-19. Because the incidence rate of COVID-19 is lower in adolescents, the case definition is less stringent than for the Phase 3 COVE study, resulting in vaccine efficacy against milder disease. The median duration for follow-up in this initial analysis was 35 days following the second dose. mRNA-1273 was generally well tolerated. The majority of adverse events were mild or moderate in severity. No serious safety concerns have been identified to date. The most common solicited local adverse event was injection site pain. The most common solicited systemic adverse events after the second dose of mRNA-1273 were headache, fatigue, myalgia and chills. We are continuing to collect data in the TeenCOVE study and are in discussions with regulators about a potential amendment to our regulatory filings.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Phase 2/3 KidCOVE study of mRNA-1273 in the pediatric population ages 6 months-11 years is currently enrolling. We expect to enroll 6,750 healthy pediatric participants in the U.S. and Canada into this two-part, dose escalation study. In Part 1, each participant ages 2 years to less than 12 years may receive one of two dose levels (50 &#181;g or 100 &#181;g). Also in Part 1, each participant ages six months to less than 2 years may receive one of three dose levels (25 &#181;g, 50 &#181;g and 100 &#181;g). An interim analysis will be conducted to determine which dose will be used in Part 2, the placebo-controlled expansion portion of the study.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Variant-Specific Booster Candidates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 24, we announced that we had completed manufacturing of clinical trial material for our variant-specific vaccine candidate, mRNA-1273.351, against the SARS-CoV-2 variant known as B.1.351 (first identified in the Republic of South Africa) and that this vaccine had been shipped to the National Institutes of Health (NIH) for a Phase 1 clinical trial to be led and funded by the NIH&#8217;s National Institute of Allergy and Infectious Diseases.  We are also developing a multivalent booster candidate, mRNA-1273.211, which combines mRNA-1273 (Moderna&#8217;s authorized vaccine against ancestral strains) and mRNA-1273.351 in a single vaccine.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Initial data from our Phase 2 study showed that a single 50 &#181;g dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2, B.1.351 and P.1 (another variant of concern, first identified in Brazil). A booster dose of mRNA-1273.351, the Company&#8217;s strain-matched booster, achieved higher neutralizing antibody titers against the B.1.351 variant of concern than a booster dose of mRNA-1273. Safety and tolerability profiles following third dose booster injections of 50 &#181;g of mRNA-1273 or mRNA-1273.351 were generally comparable to those observed after the second dose of mRNA-1273 in the previously reported Phase 2 and Phase 3 studies. Our Phase 2 study to evaluate three approaches to boosting is ongoing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preclinical studies, both mRNA-1273.351 and mRNA-1273.211 demonstrated increased neutralizing titers against SARS-CoV-2 variants of concern in mice. Specifically, this preclinical data confirms improved neutralizing titers with the mRNA-1273.351 vaccine primary series. The multi-valent vaccine provided the broadest level of immunity in mice. A boost at 6 months with mRNA-1273.351 closed the neutralizing titer gap for the variants of concern. Following the mRNA-1273.351 boost, neutralizing titers were comparable between the ancestral strain and the new B.1.351 variant.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Key Updates for our Other Development Candidates </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">CMV vaccine (mRNA-1647): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our vaccine against cytomegalovirus, or CMV (mRNA-1647) is a vaccine combining six mRNAs in a single vial, which encode for two antigens located on the surface of CMV: five mRNAs encoding the subunits that form the membrane-bound pentamer complex and one mRNA encoding the full-length membrane-bound glycoprotein B (gB). Both the pentamer and gB are essential for CMV to infect barrier epithelial surfaces and gain access to the body. mRNA-1647 is designed to produce an immune response against both the pentamer and gB for the prevention of CMV infection. </span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, we announced seven-month data from the Phase 2 study of mRNA-1647 at the 50 &#956;g, 100 &#956;g and 150 &#956;g dose levels. mRNA-1647 was generally well tolerated. The most common solicited local adverse reaction (AR) was injection site pain and the most common solicited systemic ARs were headache, fatigue, myalgia, arthralgia and chills. Rates of Grade 3 solicited ARs after the third vaccination were similar to, or lower than the rates of Grade 3 solicited ARs after the second vaccination. In CMV-seronegative participants in mRNA-1647 treatment groups after the third vaccination, neutralizing antibody geometric mean titers (GMTs) against epithelial cell infection were at least 20-fold higher than the baseline GMT of the CMV-seropositive group, and neutralizing antibody GMTs against fibroblast infection approximated the baseline GMT of the CMV-seropositive group. In CMV positive participants in mRNA-1647 treatment groups after the third vaccination, neutralizing antibody GMTs against epithelial cell infection increased to at least 6.8-fold over baseline, and neutralizing antibody GMTs against fibroblast infection increased to approximately 2-fold over baseline.</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the interim analysis of the Phase 2 study, the 100 &#956;g dose has been chosen for the Phase 3 pivotal study for mRNA-1647, which will evaluate the prevention of primary CMV infection in seronegative women ages 16-40 years. We plan to enroll approximately 8,000 participants from approximately 150 sites across the U.S., Europe and Asia-Pacific into the Phase 3 study, which is expected to begin in 2021. Moderna owns worldwide commercial rights for mRNA-1647.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Pediatric respiratory syncytial virus (RSV) vaccine (mRNA-1345):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> mRNA-1345 is a vaccine against RSV encoding for a prefusion F glycoprotein, which elicits a superior neutralizing antibody response compared to the postfusion state. The Phase 1 study of mRNA-1345 to evaluate the tolerability and reactogenicity of mRNA-1345 in younger adults, older adults and children is ongoing. All four cohorts of younger adults (ages 18-49 years) are fully enrolled. Dosing in the older adult cohort (ages 65-79 years) is ongoing. The age range of toddlers in this de-escalation Phase 1 study is 12-59 months.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Contents</a></span></div></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, we announced the first interim analysis of the Phase 1 study of mRNA-1345, through 1-month post-vaccination, of the younger adult cohorts. A single mRNA-1345 vaccination of 50 &#956;g (N=19) or 100 &#956;g (N=20) was generally well-tolerated in younger adults (ages 18-49 years). Ten participants received placebo. The most common local solicited adverse reaction was injection site pain, and the most common systemic solicited adverse reactions were headache, fatigue and myalgia. The majority of solicited adverse reactions occurred within 1-3 days after vaccination and resolved after 1-4 days. There were no deaths, no severe adverse events, no study discontinuations due to adverse events, and no adverse events that led to a study pause. mRNA-1345 was shown to increase RSV neutralizing antibodies in seropositive younger adults. Neutralizing antibodies were confirmed to be present at baseline in all participants, as expected. A single vaccination of mRNA-1345 at the 50 or 100 &#956;g dose level boosted neutralizing antibody titers against both serotypes of RSV-A and RSV-B with no apparent dose response. At month 1, the geometric mean fold rise in neutralizing antibody relative to baseline was at least 20.5 for RSV-A and at least 11.7 for RSV-B. At the 100 &#956;g dose level, the geometric mean fold rise (95% CI) in RSV-A neutralizing antibody titer at month 1 relative to baseline was 2.7 (2.1, 3.4) with mRNA-1777, our previous RSV vaccine candidate, compared to 21.0 (13.9, 31.8) with mRNA-1345. Both mRNA-1777 and mRNA-1345 encode for the prefusion RSV-F. We also intend to evaluate the potential of combinations of mRNA-1345 with our vaccines against other respiratory pathogens in children and separately in older adults. There is no approved vaccine for RSV. Moderna owns worldwide commercial rights to mRNA-1345.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Seasonal influenza (flu) (mRNA-1010, mRNA-10202 and mRNA-1030):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In January 2021, we announced our plans to test three development candidates for a seasonal influenza vaccine (mRNA-1010, mRNA-1020 and mRNA-1030), which will allow us to identify a candidate to take forward into pivotal efficacy studies. The vaccine will be administered as a single dose and will aim to elicit protection from all seasonal influenza viruses. Our first-generation flu program will evaluate multiple candidates comprising multiple antigen combinations against the four seasonal viruses recommended by the World Health Organization. In the future we also plan to evaluate the combination of a seasonal influenza vaccine with vaccines against other respiratory viruses with similar epidemiology. We also plan to explore potential combination vaccines against flu, SARS-CoV-2, RSV and human metapneumovirus (hMPV). We expect to begin a Phase 1 clinical trial for the seasonal influenza program in 2021.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Epstein-Barr virus (EBV) vaccine (mRNA-1189):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> mRNA-1189 is a vaccine against EBV containing five mRNAs that encode viral proteins (gp350, gB, gp42, gH and gL) in EBV. Similar to our CMV vaccine (mRNA-1647), the viral proteins in mRNA-1189 are expressed in their native membrane-bound form for recognition by the immune system. We are planning to begin a Phase 1 study of mRNA-1189 in 2021. There is no approved vaccine for EBV. Moderna owns worldwide commercial rights to mRNA-1189.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Propionic acidemia (PA) (mRNA-3927): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first participant has been dosed in the Phase 1 clinical trial for mRNA-3927, our therapy for the treatment of propionic acidemia, or PA. The Phase 1 study is designed to evaluate the safety and tolerability of mRN-3927 in patients with PA. PA, is a rare, life-threatening, inherited metabolic disorder due to a defect in the mitochondrial enzyme propionyl-CoA carboxylase, or PCC. It primarily affects the pediatric population. There is no approved therapy for PA, including no approved enzyme replacement therapy. We have received Rare Pediatric Disease Designation and Orphan Drug Designation from the FDA and Orphan Drug Designation from the European Commission for the PA program. The FDA has also granted Fast Track designation to mRNA-3927. We implemented a novel design for the Phase 1/2 study in 2020 to identify the optimal dose in the most efficient manner and to make the study less burdensome on patients, their families and clinical partners. This is the first development candidate to enter the clinic in our intracellular therapeutics modality. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">hMPV/PIV3 vaccine (mRNA-1653):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The first 10 subjects in the Phase 1b age de-escalation clinical trial of mRNA-1653 were enrolled and dosed prior to a COVID-19 related pause. The first two cohorts in the Phase 1b trial are fully enrolled and two further cohorts are enrolling.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Human immunodeficiency virus (HIV) (mRNA-1644 and mRNA-1574):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In January 2021, we announced two vaccine programs against HIV. mRNA-1644 is a novel approach to HIV vaccine strategy in humans designed to elicit broadly neutralizing HIV-1 antibodies (bNAbs) and is being developed in collaboration with the International AIDS Vaccine Initiative (IAVI) and the Bill and Melinda Gates Foundation (BMGF). A Phase 1 study for mRNA-1644 will use iterative human testing to validate the approach and antigens and multiple novel antigens will be used for germline-targeting and immuno-focusing. A second approach, mRNA-1574, is being evaluated in collaboration with the National Institutes of Health (NIH) and includes multiple native-like trimer antigens. We currently expect to begin phase 1 clinical trials for both mRNA-1644 and mRNA-1574 in 2021.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Nipah virus (mRNA-1215):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In January 2021, we announced a program to develop a vaccine against the Nipah virus, a zoonotic virus transmitted to humans from animals, contaminated food, or through direct human-to-human transmission and causes a range of illnesses including fatal encephalitis. The vaccine is being co-developed with the NIH&#8217;s Vaccine Research Center. We intend to initiate a Phase 1 clinical trial of mRNA-1215 in 2021, and anticipate the study will be sponsored by the NIH. </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Pipeline</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following chart shows our current pipeline of 24 development programs, grouped into modalities&#8212;first our two core modalities where we believe we have reduced the technology risk, followed by our four exploratory modalities in which we are continuing to investigate the clinical use of mRNA medicines.</span></div><div><span><br/></span></div><div style="text-align:center"><img src="mrna-20210331_g2.jpg" alt="mrna-20210331_g2.jpg" style="height:311px;margin-bottom:5pt;vertical-align:text-bottom;width:720px"/></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Abbreviations: GSD1a, Glycogen storage disease type 1a; H7N9, H7N9 influenza vaccine; IL-2, Interleukin 2: IL-12, interleukin 12; IL-23, interleukin 23; IL-36</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#947;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, interleu; OX40L, wildtype OX40 ligand; PD-L1, programmed death-ligand-1; VEGF-A, vascular endothelial growth factor&#160;A. </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The breadth of biology addressable using mRNA technology is reflected in our current development pipeline of 24 programs. The diversity of proteins made from mRNA within our development pipeline is shown in the figure below.</span></div><div style="text-align:center"><img src="mrna-20210331_g3.jpg" alt="mrna-20210331_g3.jpg" style="height:324px;margin-bottom:5pt;vertical-align:text-bottom;width:720px"/></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have developed six modalities, which are summarized as follows: </span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Prophylactic vaccines: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our prophylactic vaccines modality currently includes ten programs, six of which have entered into clinical trials and demonstrated desired pharmacology, in the form of immunogenicity, in positive Phase 1 clinical trials: H7N9 vaccine (mRNA-1851), RSV vaccine (mRNA-1777), human metapneumovirus (hMPV)/parainfluenza virus type 3 (PIV3) vaccine (mRNA-1653), Zika vaccine (mRNA-1893), CMV vaccine (mRNA-1647) and COVID-19 vaccine (mRNA-1273). We have ongoing Phase 1 trials for the Zika vaccine (mRNA-1893), pediatric RSV vaccine (mRNA-1345), hMPV/PIV3 vaccine (mRNA-1653) and Merck is conducting a Phase 1 trial for an additional RSV vaccine (mRNA-1172), which will be transitioned to Moderna after completion. Our COVID-19 vaccine (mRNA-1273) is described in detail above. Two other vaccines being developed as part of public health programs&#8213;H10N8 vaccine (mRNA-1440) and Chikungunya vaccine (mRNA-1388)&#8213;also produced positive Phase 1 clinical trial results, but are not being further developed without government or other funding. Our four pre-clinical programs within our prophylactic vaccines modality are for Epstein-Barr virus (mRNA-1189), seasonal influenza (mRNA-1010, mRNA-1020 and mRNA-1030), Nipah virus (mRNA-1215) and HIV (mRNA-1644 and mRNA-1574).</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Systemic secreted and cell surface therapeutics: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have four systemic secreted and cell surface therapeutics development candidates in our pipeline. Our secreted programs include our antibody against Chikungunya virus (mRNA-1944), Relaxin (mRNA-0184) for cardiac disorders, PD-L1 (mRNA-6981) for autoimmune hepatitis and IL-2 (mRNA-6231) for autoimmune disorders. Our antibody against Chikungunya virus (mRNA-1944) has had positive Phase 1 readouts to date. The remaining programs for Relaxin (mRNA-0184), PD-L1 (mRNA-6981) and IL-2 (mRNA-6231) are currently in preclinical development. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Cancer vaccines:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are currently developing two programs within our cancer vaccines modality. Our personalized cancer vaccine program mRNA-4157 is being developed in collaboration with Merck and is in a multiple-arm Phase 1 trial and a randomized Phase 2 trial. Our second program within this modality, mRNA-5671, is a KRAS vaccine. Our strategic collaborator Merck has a Phase 1 clinical trial ongoing for mRNA-5671.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Intratumoral immuno-oncology: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have three programs in this modality. The first program in this modality, OX40L (mRNA-2416), was designed to overcome technological challenges in advancing this modality, including engineering the mRNA sequence to minimize off-target effects, utilizing our proprietary lipid nanoparticles (LNPs) to enhance safety and tolerability, and to demonstrate expression of a membrane protein in patients. OX40L (mRNA-2416) is currently being evaluated in an ongoing Phase 1/2 trial in the United States and Israel, and protein expression has been demonstrated in a number of patients. Our second program, OX40L/IL-23/IL-36&#947; (Triplet) (mRNA-2752), is currently in a Phase 1 study that is designed as an open-label, multicenter study of intratumoral injections of Triplet (mRNA-2752) alone or in combination with durvalumab (anti-PD-L1) with sites in the United States and Israel. Our third program, IL-12 (MEDI1191), is being developed in collaboration with AstraZeneca. AstraZeneca is currently enrolling an open-label multicenter Phase 1 clinical trial of intratumoral injections of MEDI1191 alone and in combination with the checkpoint inhibitor, durvalumab.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Localized regenerative therapeutics:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our localized VEGF-A program, AZD8601, which is being developed by AstraZeneca, has completed a Phase 1a/b trial to describe its safety, tolerability, protein production, and activity in diabetic patients. The study has met its primary objectives of describing safety and tolerability and secondary objectives of demonstrating protein production and changes in blood flow post AZD8601 administration. We believe these data provide clinical proof of mechanism for our mRNA technology outside of the vaccine setting. AstraZeneca has initiated a Phase 2a study of AZD8601 for VEGF-A for ischemic heart disease in patients undergoing coronary artery bypass grafting (CABG) surgery with moderately impaired systolic function, and the trial is ongoing. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Systemic intracellular therapeutics: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have four systemic intracellular therapeutics development candidates in our pipeline. Our intracellular programs address propionic acidemia, or PA (mRNA-3927), methylmalonic acidemia, or MMA (mRNA-3705), phenylketonuria, or PKU (mRNA-3283), and glycogen storage disorder type 1a, or GSD1a (mRNA-3745). The first patient has been dosed in the Phase 1 clinical trial of mRNA-3927, our intracellular program to address PA. We plan to file new IND and CTA applications for our next-generation MMA candidate, mRNA-3705. mRNA-3705 received a Breakthrough Designation from the FDA. PKU (mRNA-3283) and GSD1a (mRNA-3745) are currently in preclinical development. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="ibba7ad915d1a4c4a8ebb50d13fae4c4e_94"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue for each period presented (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.262%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:47.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,937&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We began to record product sales for our COVID-19 vaccine subsequent to its authorization for emergency use by the FDA and Health Canada in December 2020. For the three months ended March 31, 2021, we recognized $1.7 billion of product sales from our COVID-19 vaccine, of which $1.4 billion was generated in the United States and $375 million was generated from the rest of the world.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than product sales, our revenue has been primarily derived from government-sponsored and private organizations including BARDA, DARPA and the Gates Foundation and from strategic alliances with AstraZeneca, Merck and Vertex to discover, develop, and commercialize potential mRNA medicines.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grant revenue was comprised as follows for the periods presented (in millions):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant revenue:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BARDA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total grant revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For the three months ended March 31, 2021, $190 million of BARDA grant revenue was related to our mRNA-1273 program and $2 million was related to our Zika vaccine program.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaborative revenue from our strategic alliances was comprised as follows for the periods presented (in millions): </span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue:</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AstraZeneca</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vertex</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:47.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenue</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our product sales to significantly increase in 2021 compared to 2020. As of March 31, 2021, we had signed supply agreements of approximately $17.3 billion for the future supply of our COVID-19 vaccine and had deferred revenue of $7.5 billion associated with customer deposits received or billable under these agreements. Additional supply agreements have been agreed upon since March 31, 2021, and others are under discussion for 2021 and 2022 deliveries. In addition, we expect to continue to receive funding from our contract with BARDA. As of March 31, 2021, the remaining available funding net of revenue earned was $317&#160;million. On April 18, 2021, we signed an amendment to our agreement with BARDA to increase total reimbursements by up to an additional $236 million. To the extent that existing or potential future products generate revenue, our revenue may vary due to many uncertainties in the independent development of our mRNA medicines and pursuant to our strategic alliances and other factors.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of sales</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of Sales includes raw materials, personnel and facility and other costs associated with manufacturing our commercial product. These costs include production materials, production costs at our manufacturing facilities, third-party manufacturing costs, and final formulation and packaging costs. Cost of Sales also includes shipping costs and royalties payable to third parties based on sales of our products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and development expenses</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The nature of our business and primary focus of our activities generate a significant amount of research and development costs. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses represent costs incurred by us for the following:</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cost to develop our platform;</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">discovery efforts leading to development candidates;</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preclinical, nonclinical, and clinical development costs for our programs;</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cost to develop our manufacturing technology and infrastructure; and</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">digital infrastructure costs.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The costs above comprise the following categories:</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">personnel-related expenses, including salaries, benefits, and stock-based compensation expense;</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred under agreements with third parties, such as consultants, investigative sites, contract research organizations (CROs) that conduct our preclinical studies and clinical trials, and in-licensing arrangements;</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses associated with developing manufacturing capabilities and acquiring materials for preclinical studies and clinical trials, including both internal manufacturing and third-party contract manufacturing organizations (CMOs);</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred for the procurement of materials, laboratory supplies, and non-capital equipment used in the research and development process; and</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facilities, depreciation, and amortization, and other direct and allocated expenses incurred as a result of research and development activities.</span></div><div style="padding-left:9pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use our employee and infrastructure resources for the advancement of our platform, and for discovering and developing programs. Due to the number of ongoing programs and our ability to use resources across several projects, indirect or shared operating costs incurred for our research and development programs are generally not recorded or maintained on a program- or modality-specific basis. The following table reflects our research and development expenses, including direct program-specific expenses summarized by modality and indirect or shared operating costs summarized under other research and development expenses during the three months ended March 31, 2021 and 2020 (in millions):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Program expenses by modality:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prophylactic vaccines</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer vaccines</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intratumoral immuno-oncology</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Systemic secreted and cell surface therapeutics</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Systemic intracellular therapeutics</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total program-specific expenses by modality</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other research and development expenses:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discovery programs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform research</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technical development and unallocated manufacturing expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shared discovery and development expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Contents</a></span></div></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Include a total of 30 and 24 development candidates at March 31, 2021 and 2020, respectively. Program-specific expenses include external costs and allocated manufacturing costs of pre-launch inventory, mRNA supply and consumables, and are reflected as of the beginning of the period in which the program was internally advanced to development or removed if development was ceased. </span></div><div style="padding-left:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8220;modality&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> refers to a group of programs with common product features and the associated combination of enabling mRNA technologies, delivery technologies, and manufacturing processes. The program-specific expenses by modality summarized in the table above include expenses we directly attribute to our programs, which consist primarily of external costs, such as fees paid to outside consultants, central laboratories, investigative sites, and CROs in connection with our preclinical studies and clinical trials, CMOs, and allocated manufacturing costs of inventory, mRNA supply and consumables. Costs to acquire and manufacture inventory, mRNA supply for preclinical studies and clinical trials are recognized and included in unallocated manufacturing expenses when incurred, and subsequently allocated to program-specific manufacturing costs after completion of the program-specific production. The timing of allocating manufacturing costs to the specific program varies depending on the program development and production schedule. We generally do not allocate personnel-related costs, including stock-based compensation, costs associated with our general platform research, technical development, and other shared costs on a program-specific basis. These costs were therefore excluded from the summary of program-specific expenses by modality.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discovery program expenses are costs associated with research activities for our programs in the preclinical discovery stage, and primarily consist of external costs for CROs and lab services, and allocated manufacturing cost of preclinical mRNA supply and consumables.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Platform research expenses are mainly costs to develop technical advances in mRNA science, delivery science, and manufacturing process design. These costs include personnel-related costs, computer equipment, facilities, preclinical mRNA supply and consumables, and other administrative costs to support our platform research. Technology development and unallocated manufacturing expenses are primarily related to non-program-specific manufacturing process development and manufacturing costs. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shared discovery and development expenses are research and development costs such as personnel-related costs and other costs, which are not otherwise included in development programs, discovery programs, platform research, technical development and unallocated manufacturing expenses, stock-based compensation, and other expenses.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The largest component of our total operating expenses has historically been our investment in research and development activities, including development of our platform, mRNA technologies, and manufacturing technologies. We expense research and development costs as incurred and cannot reasonably estimate the nature, timing, and estimated costs required to complete the development of the development candidates and investigational medicines we are currently developing or may develop in the future. There are numerous risks and uncertainties associated with the research and development of such development candidates and investigational medicines, including, but not limited to:</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">scope, progress, and expense of developing ongoing and future development candidates and investigational medicines;</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">entry in and completion of related preclinical studies;</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enrollment in and completion of subsequent clinical trials;</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">safety and efficacy of investigational medicines resulting from these clinical trials;</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in laws or regulations relevant to the investigational medicines in development;</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receipt of the required regulatory approvals; and</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commercialization, including establishing manufacturing and marketing capabilities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we continue to progress mRNA-1273 through the development process toward a Biologics License Application approval, indication expansion of mRNA-1273 and variant-specific vaccine candidates during the current pandemic, we expect to continue to incur significant additional expenses. At this time, the magnitude of these potential expenditures is not known. In connection with the BARDA agreement to accelerate development of mRNA-1273, significant grant revenue and expenses are expected in 2021. BARDA's funding is expected to offset those expenses that are covered under the BARDA agreement, subject to our obtaining reimbursement from BARDA. As of March 31, 2021, the remaining available funding net of revenue earned was $317&#160;million. On April 18, 2021, we signed an amendment to our agreement with BARDA, increasing the potential reimbursements thereunder by up to an additional $236 million in connection with the conduct of the Phase 3 clinical trial for mRNA-1273 and pharmacovigilance efforts.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in expectations or outcomes of any of the known or unknown risks and uncertainties may materially impact our expected research and development expenditures. Continued research and development is central to the ongoing activities of our business. Investigational medicines in later stages of clinical development, such as our CMV vaccine (mRNA-1647) and our COVID-19 vaccine, generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect our research and development costs to continue to increase in the foreseeable future as our investigational medicines progress through the development phases and identify and develop additional programs. There are numerous factors associated with the successful commercialization of any of our investigational medicines, including future trial </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">design and various regulatory requirements, many of which cannot be determined with accuracy at this time due to the early stage of development of our investigational medicines. Moreover, future commercial and regulatory factors beyond our control will impact our clinical development programs and plans.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, general and administrative expenses</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We started to incur sales and marketing expenses in the fourth quarter of 2020 to prepare for commercial operations in connection with the sale of our COVID-19 vaccine. Selling, general and administrative expenses consist primarily of personnel-related costs, including stock-based compensation, for executives, finance, legal, human resources, business development and other administrative and operational functions, professional fees, accounting and legal services, sales and marketing, information technology and facility-related costs, and expenses associated with obtaining and maintaining intellectual property, or IP. These costs relate to the operation of the business, unrelated to the research and development function, or any individual program.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate selling, general and administrative expenses will increase as we continue to expand the number of programs in development and to establish our commercial activities both within and outside the United States. We have already incurred additional expenses related to building out a regulatory, sales and marketing team to support the sale, marketing and distribution of our COVID-19 vaccine. If we obtain regulatory approval for any of our other investigational medicines, and do not enter into one or more third-party commercialization collaboration and manufacturing arrangements, we will incur significant additional expenses related to building out these functions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a broad IP portfolio covering our development and commercialization of mRNA vaccine and therapeutic programs, including those related to mRNA design, formulation, and manufacturing platform technologies. We regularly file patent applications to protect innovations arising from our research and development. We also hold trademarks and trademark applications in the United States and foreign jurisdictions. Costs to secure and defend our IP are expensed as incurred and are classified as selling, general and administrative expenses.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest income</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists of interest generated from our investments in cash and cash equivalents, money market funds, and high-quality fixed income securities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other expense, net</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net consists of interest expense, gains (losses) from the sale of investments in marketable securities, foreign currency transaction and remeasurement gains (losses), and other income and expense unrelated to our core operations. Interest expense is primarily derived from our finance leases related to our Moderna Technology Center manufacturing facility (MTC South), Moderna Technology Center North (MTC North), and certain contract manufacturing service agreements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur significant expenses as we continue our research and development and commercialization efforts. We expect our programs to mature and advance to later stage clinical development, and we expect expenses to increase as we seek regulatory approvals for our investigational medicines and commercialize any approved mRNA medicines. If we fail to sustain profitability on a continuing basis, we may incur losses in the future.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical accounting policies and significant judgments and estimates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these condensed consolidated financial statements requires us to make judgments and estimates that affect the reported amounts of assets, liabilities, revenues, and expenses and the disclosure of contingent assets and liabilities in our condensed consolidated financial statements. We base our estimates on historical experience, known trends and events, and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. On an ongoing basis, we evaluate our judgments and estimates in light of changes in circumstances, facts, and experience. The effects of material revisions in estimates, if any, are reflected in the condensed consolidated financial statements prospectively from the date of change in estimates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in our critical accounting policies and estimates in the preparation of our condensed consolidated financial statements during&#160;the three months ended March 31, 2021&#160;compared to those disclosed in our Annual Report on Form 10-K for the year ended&#160;December&#160;31, 2020, or 2020 Form 10-K.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently issued accounting pronouncements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have reviewed all recently issued standards and have determined that such standards will not have a material impact on our financial statements or do not otherwise apply to our operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of operations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our condensed consolidated statements of operations for each period presented (in millions):</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.986%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change 2021 vs. 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4750%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,937&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,929&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24113%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Expenses:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,266&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(131)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,397&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1066)%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,384&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1116)%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,221&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,345&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1085)%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue increased by $1.9 billion, for the three months ended March 31, 2021 compared to the same period in 2020, due to increases in product sales and grant revenue. Product revenue was $1.7 billion for the three months ended March 31, 2021 from sales of our COVID-19 vaccine. For the three months ended March 31, 2021, we delivered approximately 88 million doses to the U.S. government and approximately 14 million doses to other governments. We did not have product sales until December 2020. Grant revenue increased by $190 million for the three months ended March 31, 2021 compared to the same period in 2020, mainly driven by an increase in revenue from BARDA related to our mRNA-1273 vaccine development. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating expenses</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We began capitalizing our COVID-19 vaccine inventory costs in December 2020, in connection with an EUA from the FDA, and based upon our expectation that these costs would be recoverable through commercialization of our COVID-19 vaccine. Prior to the capitalization of our COVID-19 vaccine inventory costs, such costs were recorded as research and development expenses in the period incurred. We expensed $242 million of pre-launch inventory costs in 2020. Our cost of sales were $193&#160;million, or 11%, of our product sales, for the three months ended March 31, 2021, including third-party royalties of $84&#160;million. A portion of the inventory costs associated with our products sales for the three months ended March 31, 2021 was expensed previously. If inventory sold for the three months ended March 31, 2021 was valued at cost, our cost of sales for the period would have been $377 million, or 22% of our product sales. As of March 31, 2021, we had substantially utilized our zero-cost COVID-19 vaccine inventory. We expect that in future periods our cost of sales as a percentage of our product sales will increase, reflecting the full cost of manufacturing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased by $286 million, or 249%, for the three months ended March 31, 2021 compared to the same period in 2020. The increase was primarily attributable to an increase in clinical trial expenses of $219 million, an increase in manufacturing expenses related to our clinical trials of $25 million, an increase in personnel-related costs of $25 million, and an increase in consulting and outside services of $21 million. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These increases for the three-month period in 2021 were largely attributable to increased mRNA-1273 clinical development and headcount.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses increased by $53 million, or 221%, for the three months ended March 31, 2021 compared to the same period in 2020. The increase was mainly due to an increase in consulting and outside services of $17 million, an increase in personnel-related costs of $11 million, an increase in marketing and other expenses of $10&#160;million, an increase in legal and other licensing expenses of $7 million, and an increase in stock-based compensation of $4 million. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These increases for the three-month period in 2021 were primarily attributable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to increased headcount and our COVID-19 vaccine commercialization-related activities. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest income</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income decreased by $4 million, or 50%, for the three months ended March 31, 2021 compared to the same period in 2020. The decrease in interest income from our investments in marketable securities for the three-month period in 2021 was mainly driven by an overall lower interest rate environment. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other expense, net</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes other expense, net for each period presented (in millions):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.986%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change 2021 vs. 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other expense, net increased by $9 million, or 900%, for the three months ended March 31, 2021 compared to the same period in 2020. The increase in other expense, net for the period in 2021 was primarily due to losses in foreign currency transactions and remeasurements, partially offset by our balance sheet hedge activities. Our interest expense is primarily related to our finance leases.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income taxes</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our provision for income taxes for the three months ended March 31, 2021 was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$39 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as compared to an insignificant amount for the same period in 2020. Our effective tax rate for the three months ended March 31, 2021 was lower than the U.S. statutory rate primarily due to the benefit of the foreign derived intangible income deduction, the benefit related to the release of the valuation allowance on the majority of our tax attributes and other deferred tax assets, as well as a discrete item for excess tax benefits related to stock-based compensation. Our effective tax rate for the three months ended March 31, 2020 was lower than the U.S. statutory rate primarily due to the valuation allowance. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a periodic basis, we reassesses any valuation allowances that we maintain on our deferred tax assets, weighing positive and negative evidence to assess the recoverability of the deferred tax assets. In the first quarter of 2021, we reassessed the valuation allowance noting the increase in positive evidence, including significant revenue growth, expectations regarding future profitability, and successful supply chain and manufacturing capabilities to meet global product demand. After assessing both the positive evidence and negative evidence, we determined it was more likely than not that we will realize the majority of our deferred tax assets. Therefore, in the first quarter of 2021, we released our valuation allowance on the majority of our federal and state net operating losses and other deferred tax assets through the annual effective tax rate (AETR) as income is earned, resulting in a reduction in the AETR. In addition, we have recorded a discrete benefit of $49 million related to the deferred tax assets that we expect to utilize in future years. As of March 31, 2021, we continue to maintain a valuation allowance on certain state tax attributes. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Contents</a></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and capital resources</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, we had cash, cash equivalents and investments of $8.2 billion. Cash, cash equivalents and investments are invested in accordance with our investment policy, primarily with a view to liquidity and capital preservation. Investments, consisting primarily of government and corporate debt securities, are stated at fair value. As of March 31, 2021, we had current and non-current investments of approximately $2.3 billion and $468 million, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We historically funded our operations primarily from the sale of equity instruments and from proceeds from certain strategic alliance arrangements and grant agreements. Starting in August 2020, we have entered into supply agreements with the U.S. Government and several governments outside the United States for the supply of our COVID-19 vaccine and receive upfront deposits. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2021, we had </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$7.5&#160;billion</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in deferred revenue related to customer deposits received or billable.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In addition, as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2021, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BARDA has committed to fund up to $1.0&#160;billion to accelerate the clinical development and manufacturing process scale-up of our COVID-19 vaccine. Under the terms of the agreement, BARDA will fund the advancement of mRNA-1273 to FDA licensure and the scale-up of manufacturing processes. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2021, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the remaining available funding net of revenue earned was $317&#160;million. On April 18, 2021, we signed an amendment to our agreement with BARDA to increase total reimbursements by up to an additional $236 million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to work toward the large-scale technical development, manufacturing scale-up in several countries and larger scale deployment of our COVID-19 vaccine. To support the scale-up, we have expended and will need to continue to expend significant resources and capital. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash flow</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the primary sources and uses of cash for each period presented (in millions):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in):</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(180)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(316)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,817&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating activities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive cash flows from operations primarily from cash collected from customer deposits related to our COVID-19 vaccine supply agreements as well as certain government-sponsored and private organizations and strategic alliances. Our cash flows from operating activities are significantly affected by our use of cash for operating expenses and working capital to support the business. Prior to 2020, we historically experienced negative cash flows from operating activities as we have invested in mRNA technologies, development pipeline, digital infrastructure, manufacturing technology and infrastructure.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by operating activities for the three months ended March 31, 2021 was $3.0 billion and consisted of net income of $1.2 billion and non-cash adjustments, plus a net change in assets and liabilities of $1.8 billion. Non-cash items included deferred income taxes of $50 million, stock-based compensation of $30 million, depreciation and amortization of $15 million, and amortization of investment premium and discount of $5 million. The net change in assets and liabilities was mainly due to an increase in deferred revenue of $3.7 billion, an increase in accrued liabilities of $285 million, and an increase in other liabilities of $93 million, partially offset by an increase in accounts receivable of $1.8 billion, an increase in inventory of $448 million, an decrease in accounts payable of $15 million, and an increase in prepaid expenses and other assets of $12 million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the three months ended March 31, 2020 was $106 million and consisted of net loss of $124 million and non-cash adjustments of $28 million, minus a net change in assets and liabilities of $10 million. Non-cash items primarily included stock-based compensation of $20 million and depreciation and amortization of $7 million. The net change in assets and liabilities was primarily due to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an increase of right-of-use assets relating to operating leases of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$14 million and a decrease in accrued liabilities of $12 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, partially offset by an increase in operating lease liabilities of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$15 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing activities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary investing activities consist of purchases, sales, and maturities of our investments and capital expenditures for manufacturing, laboratory, computer equipment and software.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the three months ended March 31, 2021 was $180 million, which included purchases of marketable securities of $726&#160;million and purchases of property and equipment of $35 million, partially offset by proceeds from maturities of marketable securities of $339 million and proceeds from sales of marketable securities of $242 million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the three months ended March 31, 2020 was $316 million, which included purchases of marketable securities of $621 million and purchases of property and equipment of $6 million, partially offset by proceeds from maturities of marketable securities of $269 million and proceeds from sales of marketable securities of $42 million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing activities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generated cash from financing activities of $26 million for the three months ended March 31, 2021, primarily from net proceeds from the issuance of common stock in connection with the exercise of stock options under our equity plans of $28 million. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generated cash from financing activities of $578 million for the three months ended March 31, 2020, from net proceeds from an equity offering of $550&#160;million and net proceeds from the issuance of common stock in connection with the exercise of stock options under our equity plans of $28 million. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operation and funding requirements</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From our inception to the end of 2020, we incurred significant losses and negative cash flows from operations due to our significant research and development expenses. We generated net income in the first quarter of 2021 in connection with our product sales. We have an accumulated deficit of $1.0&#160;billion as of March 31, 2021. We expect our expenses to increase in connection with our ongoing activities, particularly as we continue research and development of our development candidates and clinical activities for our investigational medicines. We also expect our expenses to increase associated with manufacturing costs, including our arrangements with our international supply and manufacturing partners. Our ongoing work on mRNA-1273 will require significant cash outflows during 2021, most of which may not be reimbursed or otherwise paid for by our partners or collaborators.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our cash, cash equivalents, and investments as of March 31, 2021, will be sufficient to enable us to fund our projected operations through at least the next 12&#160;months from the issuance of our financial statements. We are subject to all the risks related to the development and commercialization of novel medicines, and we may encounter unforeseen expenses, difficulties, complications, delays, and other unknown factors including expenses related to the ongoing coronavirus pandemic, which may adversely affect our business. Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to sustain profitability on a continuing basis, we may be required to finance future cash needs through a combination of public or private equity offerings, structured financings and debt financings, government funding arrangements, potential future strategic alliances from which we receive upfront fees, milestone payments, and other forms of consideration, and marketing, manufacturing, distribution and licensing arrangements. If we are required to finance future cash needs, additional capital may not be available on reasonable terms, if at all. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back, or discontinue the development or commercialization of one or more of our investigational medicines, or slow down or cease work on one or more of our programs. If we raise additional funds through the issuance of additional equity or debt securities, it could result in dilution to our existing stockholders or increased fixed payment obligations, and any such securities may have rights senior to those of our common stock. If we incur indebtedness, we could become subject to covenants that would restrict our operations and potentially impair our competitiveness, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we raise funds through strategic alliances or marketing, distribution, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or investigational medicines or grant licenses on terms that may not be favorable to us. Any of these events could significantly harm our business, financial condition, and prospects.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Contents</a></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, other than disclosed at Note 11 and Note 12 to our condensed consolidated financial statements, there have been no material changes to our contractual obligations and commitments from those described under &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in our 2020 Form 10-K.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off balance sheet arrangements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, we did not have any off-balance sheet arrangements, as defined in Item&#160;303(a)(4)(ii) of Regulation S-K.</span></div><div id="ibba7ad915d1a4c4a8ebb50d13fae4c4e_97"></div><div style="margin-bottom:9pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 and December 31, 2020, we had cash, cash equivalents, and investments in marketable securities of $8.2 billion and $5.2 billion, respectively. Our investment portfolio is comprised of money market funds and marketable debt securities (including U.S. Treasury securities, debt securities of U.S. government agencies and corporate entities, and commercial paper), which are classified as available-for-sale securities. Our primary investment objectives are the preservation of capital and the maintenance of liquidity and our investment policy defines allowable investments based on quality of the institutions and financial instruments designed to minimize risk exposure. Our exposure to interest rate sensitivity is affected by changes in the general level of U.S. interest rates. Our available-for-sale securities are subject to interest rate risk and will fall in value if market interest rates increase. We generally hold investments in marketable debt securities to maturity to limit our exposure to interest rate risk. Due to the short-term maturities and low risk profiles of our investments, we do not anticipate a significant exposure to interest rate risk. If market interest rates were to increase immediately and uniformly by one percentage point from levels at March 31, 2021, the net fair value of our interest sensitive marketable securities would not experience a material change.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Risk</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue generating activities and operations have been primarily denominated in U.S. dollars. As we expand internationally, our results of operations and cash flows will become increasingly subject to fluctuations due to changes in foreign currency exchange rates. To help manage the exposure to foreign currency exchange rate fluctuations, we have implemented a balance sheet hedging program.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Balance Sheet Hedging Activities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use foreign currency forward contracts to mitigate foreign currency exchange risk associated with foreign currency-denominated monetary assets and liabilities. Notwithstanding our efforts to mitigate some foreign currency exchange risks, there can be no assurance that our hedging activities will adequately protect us against the risks associated with foreign currency fluctuations. We believe the counterparties to our foreign currency forward contracts are creditworthy multinational commercial banks. While we believe the risk of counterparty nonperformance is not material, a sustained decline in the financial stability of financial institutions as a result of disruption in the financial markets could affect our ability to secure creditworthy counterparties for our foreign currency hedging programs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, a hypothetical adverse movement of 10 percent in foreign currency exchange rates compared to the U.S. dollars across all maturities would have resulted in potential declines in the fair value on our foreign currency forward contracts used in balance sheet hedging of approximately $136 million. We expect that any increase or decrease in the fair value of the portfolio would be substantially offset by increases or decreases in the underlying exposures being hedged. </span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div id="ibba7ad915d1a4c4a8ebb50d13fae4c4e_100"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of&#160;March 31, 2021. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of&#160;March 31, 2021, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the three months ended March 31, 2021, which have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inherent Limitations on Effectiveness of Controls</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our Chief Executive Officer and Chief Financial Officer, believes that our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives and are effective at the reasonable assurance level. However, our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by the collusion of two or more people or by a management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div><span><br/></span></div><div id="ibba7ad915d1a4c4a8ebb50d13fae4c4e_103"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="ibba7ad915d1a4c4a8ebb50d13fae4c4e_106"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be subject to legal proceedings and claims in the ordinary course of business.&#160;We are not currently a party to any material legal proceedings.</span></div><div><span><br/></span></div><div id="ibba7ad915d1a4c4a8ebb50d13fae4c4e_109"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing in our common stock involves a high degree of risk. Information regarding risk and uncertainties related to our business appears in Part I, Item 1A. &#8220;Risk Factors&#8221; of our Annual Report on Form 10-K for the year ended December 31, 2020, which was filed with the Securities and Exchange Commission, or the SEC, on February 26, 2021. There have been no material changes from the risk factors previously disclosed in the Annual Report on Form 10-K. You should carefully consider the risks and uncertainties described below, together with all of the other information contained in this Quarterly Report on Form 10-Q, including &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and the condensed consolidated financial statements and the related notes. If any of the risks actually occur, it could harm our business, prospects, operating results and financial condition and future prospects. In such event, the market price of our common stock could decline and you could lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations. This Quarterly Report on Form 10-Q also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of factors that are described below and elsewhere in this Quarterly Report.</span></div><div><span><br/></span></div><div><span><br/></span></div><div id="ibba7ad915d1a4c4a8ebb50d13fae4c4e_118"></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Contents</a></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Exhibits listed below are filed or incorporated by reference as part of this Form 10-Q.</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit Index</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1*&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit101amendmentno6toba.htm">Amendment No. 6, dated February 16, 2021</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit101amendmentno6toba.htm">,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit101amendmentno6toba.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit101amendmentno6toba.htm">to Agreement No. HHSO100201600029C, by and between ModernaTX, Inc. and the Biomedical Advanced Research and Development Authority, dated as of April 16, 2020</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2*&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit102amendmentno7toba.htm">A</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit102amendmentno7toba.htm">mendment No. 7, dated March 12, 2021, to Agreement No. HHSO100201600029C, by and between ModernaTX, Inc. and the Biomedical Advanced Research and Development Authority, dated as of April 16, 2020</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3*&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit103formofpsuagreeme.htm">Form of Performance-Based Restricted Stock Unit Award Agreement under the 2018 Stock Option and Incentive Plan</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4*&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit104directorcompensa.htm">Amended and Restated Non-Employee Director Compensation Policy, effective April 28, 2021</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a4exhibit31103312021.htm">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a5exhibit31203312021.htm">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a6exhibit32103312021.htm">Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document - The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Link Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101.*)</span></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.150%"></td><td style="width:0.1%"></td></tr><tr style="height:35pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The certification furnished in Exhibit 32.1 hereto is deemed to accompany this Form 10-Q and will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Such certification will not be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portions of this exhibit (indicated by asterisks) have been omitted in accordance with the rules of the Securities and Exchange Commission. </span></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><div id="ibba7ad915d1a4c4a8ebb50d13fae4c4e_121"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba7ad915d1a4c4a8ebb50d13fae4c4e_10">Contents</a></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.850%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.173%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.199%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.378%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MODERNA, INC.</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ St&#233;phane Bancel</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 6, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">St&#233;phane Bancel</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Director</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Principal Executive Officer)</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ David W. Meline</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 6, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David W. Meline</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Principal Financial Officer)</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exhibit101amendmentno6toba.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i3a0eeab96d2a45a28dcd6a1413030fd3_1"></div><div style="min-height:81pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 10.1</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH &#8220;&#91;***&#93;&#8221;. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.705%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.288%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.238%"></td><td style="width:0.1%"></td></tr><tr><td colspan="18" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">AMENDMENT OF SOLICITATION&#47;MODIFICATION OF CONTRACT</font></td><td colspan="6" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1 CONTRACT ID CODE</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">PAGE OF PAGES</font></div><div style="padding-left:9.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1&#160;&#160;&#160;&#160;&#124;&#160;&#160;&#160;&#160;3</font></div></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2. AMENDMENT&#47;MODIFICATION NO.</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">P00006</font></div></td><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3. EFFECTIVE DATE</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">See Block 16C</font></div></td><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">4. REQUISITION&#47;PURCHASE REQ. NO.</font></td><td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">5. PROJECT NO. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(If applicable)</font></div></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">6. ISSUED BY&#160;&#160;&#160;&#160;CODE</font></td><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">ASPR-BARDA</font></td><td colspan="12" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">7 ADMINISTERED BY </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(If other than Item 6)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">CODE</font></div></td><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">ASPR-BARDA02</font></div></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">ASPR-BARDA</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">200 Independence Ave., S.W.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Room 640-G</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Washington DC 20201</font></div></td><td colspan="18" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">US DEPT OF HEALTH &#38; HUMAN SERVICES</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">ASST SEC OF PREPAREDNESS &#38; RESPONSE</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">ACQ MANAGEMENT, CONTRACTS, &#38; GRANTS</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">O&#8217;NEILL HOUSE OFFICE BUILDING</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Washington DC 20515</font></div></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">8. NAME AND ADDRESS OF CONTRACTOR </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(No., street, county, State and ZIP code) </font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(x)</font></td><td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">9A. AMENDMENT OF SOLICITATION NO.</font></td></tr><tr style="height:24pt"><td colspan="15" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">MODERNATX, INC 1492235</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Attn&#58; &#91;***&#93;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">MODERNATX, INC.&#160;&#160;&#160;&#160;200 TECHNOLOGY</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">200 TECHNOLOGY SQ</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">CAMBRIDGE MA 021393578</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">9B. DATED </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(SEE ITEM 11)</font></div></td></tr><tr style="height:19pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">x</font></td><td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">10A. MODIFICATION OF CONTRACT&#47;ORDER NO.</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">75A50120C00034</font></div></td></tr><tr style="height:19pt"><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">CODE 1492235</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FACILITYCODE</font></td><td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">10B. DATED </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(SEE ITEM 13)</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">04&#47;03&#47;2020</font></div></td></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS</font></td></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'MS Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9744;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'MS Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9744;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> is extended. </font><font style="color:#000000;font-family:'MS Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9744;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> is not extended.</font></div><div style="margin-bottom:3pt;padding-left:7.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended , by one of the following methods&#58; (a) By completing Items 8 and 15, and returning ________ copies of the amendment&#59; (b) By acknowledging receipt of this amendment on each copy of the offer submitted &#59; or (c) By separate letter or electronic communication which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGEMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted , such change may be made by letter or electronic communication, provided each letter or electronic communication makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.</font></div></td></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">12. ACCOUNTING AND APPROPRIATION DATA (if required)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">See Schedule</font></div></td></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">13. THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS&#47;ORDERS. IT MODIFIES THE CONTRACT&#47;ORDER NO. AS DESCRIBED IN ITEM 14.</font></td></tr><tr style="height:10pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">CHECK ONE</font></td><td colspan="30" rowspan="2" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:9.6pt;text-indent:-9.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">A&#160;&#160;&#160;&#160;THIS CHANGE ORDER IS ISSUED PURSUANT TO&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(Specify authority)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="30" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:9.6pt;text-indent:-9.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">B.&#160;&#160;&#160;&#160;THE ABOVE NUMBERED CONTRACT&#47;ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(such as changes in paying office, appropriation data, etc.)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> SET FORTH IN ITEM 14. PURSUANT TO THE AUTHORITY OF FAR 43.103(b).</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="30" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 10.6pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">C.&#160;&#160;&#160;&#160;THIS SUPPLEMENTALAGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF&#58;</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">X</font></td><td colspan="30" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">D. OTHER </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(Specify type of modification and authority)</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FAR 43.103(a)</font></div></td></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">E. IMPORTANT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#58; &#160;&#160;&#160;&#160;Contractor&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'MS Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9744;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> is not&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'MS Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9746;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> is required to sign this document and return </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> copies to the issuing office.</font></div></td></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">14. DESCRIPTION OF AMENDMENT&#47;MODIFICATION </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(Organized by UCF section headings, including solicitation&#47;contract subject matter where feasible.)</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Tax ID Number&#58; 27-0226313</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">DUNS Number&#58; 069723520</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The purpose of this modification is to</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1)Identify the batches&#47;lots and doses that have been transferred from Moderna &#91;***&#93; to CDC or designee &#91;***&#93; and</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2)Establish when PPQ activities become outside of the scope of this contract and will not be funded by BARDA.</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">This modification is not a funding action. All other contract terms and conditions remain unchanged.</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Period of Performance&#58; 04&#47;03&#47;2020 to 08&#47;31&#47;2023</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Continued ...</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Except as provided herein, all terms and conditions of the document referenced in Item 9 A or 10A, as heretofore changed, remains unchanged and in full force and effect.</font></div></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">15A NAME AND TITLE OF SIGNER </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(Type or print)</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Stephane Bancel, CEO</font></div></td><td colspan="18" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">16A. NAME AND TITLE OF CONTRACTING OFFICER&#47;Type or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">print)</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td></tr><tr><td colspan="12" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">15B. CONTRACTOR&#47;OFFEROR</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Stephane Bancel&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><br>(Signature of person authorized to sign)</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">15C. DATE SIGNED</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2&#47;16&#47;2021</font></div></td><td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">16B. UNITED STATES OF AMERICA</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><br>(Signature of Contracting Officer)</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">16C. DATE SIGNED</font></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Previous edition unusable</font></td><td colspan="18" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">STANDARD FORM 30 (REV 11&#47;2016)</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Prescribed by GSA FAR(48 CFR) 53.243</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.444%"><tr><td style="width:1.0%"></td><td style="width:8.117%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.654%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.877%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.235%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">CONTINUATION SHEET</font></td><td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">REFERENCE NO. OF DOCUMENT BEING CONTINUED</font></div><div style="margin-bottom:3pt;margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">75A50120C00034&#47;P00006</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">PAGE OF</font></div><div style="margin-bottom:3pt;margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2&#160;&#160;&#160;&#160;&#124;&#160;&#160;&#160;&#160;3</font></div></td></tr><tr><td colspan="24" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">NAME OF OFFEROR OR CONTRACTOR<br>MODERNATX, INC 1492235</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ITEM NO.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(A)</font></div></td><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">SUPPLIES&#47;SERVICES</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(B)</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">QUANTITY</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(C)</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">UNIT</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(D)</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">UNIT PRICE</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(E)</font></div></td><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AMOUNT</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(F)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="21" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Change Item 2 to read as follows (amount shown is tie obligated amount)&#58;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Base CLIN 0002 - Development of mRNA vaccine to BLA</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">0.00</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Accounting Info&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2020.199COV1.25103 Appr. Yr.&#58;  2020 CAN&#58; 199COV1 Object Class&#58; 25103</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Funded&#58; $0.00</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Accounting Info&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2020.199C014.25103 Appr. Yr.&#58;  2020 CAN&#58; 199C014 Object Class&#58; 25103</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Funded&#58; $0.00</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">NSN 7540-01-152-8067</font></td><td colspan="18" style="border-top:1pt solid #000000;padding:2px 1pt 2px 307.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OPTIONAL FORM 336 (4-86)<br>Sponsored by GSA<br>FAR (48 CFR) 53.110</font></td></tr></table></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i3a0eeab96d2a45a28dcd6a1413030fd3_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page 3 of 3</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">CONTINUATION PAGE</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1)&#160;&#160;&#160;&#160;The table below identifies the batches&#47;lots and doses transferred under this contract from Moderna &#91;***&#93; to CDC or designee &#91;***&#93;.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2)&#160;&#160;&#160;&#160;Identification of when PPQ activities become outside of the scope of this contract</font></div><div style="margin-bottom:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>exhibit102amendmentno7toba.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ib4fbad95e2474a9881d4dd2eb2ebfd90_1"></div><div style="min-height:81pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 10.2</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH &#8220;&#91;***&#93;&#8221;. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.934%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.693%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.658%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.210%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.210%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.903%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.244%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.146%"></td><td style="width:0.1%"></td></tr><tr><td colspan="18" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">AMENDMENT OF SOLICITATION&#47;MODIFICATION OF CONTRACT</font></td><td colspan="6" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1 CONTRACT ID CODE</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">PAGE OF PAGES</font></div><div style="padding-left:9.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1&#160;&#160;&#160;&#160;&#124;&#160;&#160;&#160;&#160;10</font></div></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2. AMENDMENT&#47;MODIFICATION NO.</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">P00007</font></div></td><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3. EFFECTIVE DATE</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">See Block 16C</font></div></td><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">4. REQUISITION&#47;PURCHASE REQ. NO. &#91;***&#93;</font></td><td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">5. PROJECT NO. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(If applicable)</font></div></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">6. ISSUED BY&#160;&#160;&#160;&#160;CODE</font></td><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">ASPR-BARDA</font></td><td colspan="12" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">7 ADMINISTERED BY </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(If other than Item 6)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">CODE</font></div></td><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">ASPR-BARDA02</font></div></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">ASPR-BARDA</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">200 Independence Ave., S.W.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Room 640-G</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Washington DC 20201</font></div></td><td colspan="18" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">US DEPT OF HEALTH &#38; HUMAN SERVICES</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">ASST SEC OF PREPAREDNESS &#38; RESPONSE</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">ACQ MANAGEMENT, CONTRACTS, &#38; GRANTS</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">O&#8217;NEILL HOUSE OFFICE BUILDING</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Washington DC 20515</font></div></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">8. NAME AND ADDRESS OF CONTRACTOR </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(No., street, county, State and ZIP code) </font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(x)</font></td><td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">9A. AMENDMENT OF SOLICITATION NO.</font></td></tr><tr style="height:24pt"><td colspan="15" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">MODERNATX, INC 1492235</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Attn&#58; &#91;***&#93;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">MODERNATX, INC.&#160;&#160;&#160;&#160;200 TECHNOLOGY</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">200 TECHNOLOGY SQ</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">CAMBRIDGE MA 021393578</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">9B. DATED </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(SEE ITEM 11)</font></div></td></tr><tr style="height:19pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">x</font></td><td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">10A. MODIFICATION OF CONTRACT&#47;ORDER NO.</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">75A50120C00034</font></div></td></tr><tr style="height:19pt"><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">CODE 1492235</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FACILITYCODE</font></td><td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">10B. DATED </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(SEE ITEM 13)</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">04&#47;03&#47;2020</font></div></td></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS</font></td></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'MS Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9744;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'MS Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9744;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> is extended. </font><font style="color:#000000;font-family:'MS Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9744;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> is not extended.</font></div><div style="margin-bottom:3pt;padding-left:7.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following methods&#58; (a) By completing Items 8 and 15, and returning _____________ copies of the amendment&#59; (b) By acknowledging receipt of this amendment on each copy of the offer submitted&#59; or (c) By separate letter or electronic communication which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGEMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by letter or electronic communication, provided each letter or electronic communication makes reference to the solicitation and this amendment and is received prior to the opening hour and dale </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">specified</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</font></div></td></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">12. ACCOUNTING AND APPROPRIATION DATA (if required)&#160;&#160;&#160;&#160;Net increase&#58;&#160;&#160;&#160;&#160;$62,705,357.06</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">See Schedule</font></div></td></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">13. THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS&#47;ORDERS. IT MODIFIES THE CONTRACT&#47;ORDER NO. AS DESCRIBED IN ITEM 14.</font></td></tr><tr style="height:10pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">CHECK ONE</font></td><td colspan="30" rowspan="2" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:9.6pt;text-indent:-9.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">A&#160;&#160;&#160;&#160;THIS CHANGE ORDER IS ISSUED PURSUANT TO&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(Specify authority)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="30" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:9.6pt;text-indent:-9.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">B.&#160;&#160;&#160;&#160;THE ABOVE NUMBERED CONTRACT&#47;ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(such as changes in paying office, appropriation data, etc.)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> SET FORTH IN ITEM 14. PURSUANT TO THE AUTHORITY OF FAR 43.103(b).</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="30" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 10.6pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">C.&#160;&#160;&#160;&#160;THIS SUPPLEMENTALAGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF&#58;</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">X</font></td><td colspan="30" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">D. OTHER </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(Specify type of modification and authority)</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FAR 43.103(a)</font></div></td></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">E. IMPORTANT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#58; &#160;&#160;&#160;&#160;Contractor&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'MS Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9744;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> is not&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'MS Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9746;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> is required to sign this document and return </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> copies to the issuing office.</font></div></td></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">14. DESCRIPTION OF AMENDMENT&#47;MODIFICATION </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(Organized by UCF section headings, including solicitation&#47;contract subject matter where feasible.)</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Tax ID Number&#58; 27-0226313</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">DUNS Number&#58; 069723520</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The purpose of this modification is to support the additional scope of the Clinical Development Plan (CLIN 0002) which includes direct increases to the clinical subcontractors on the P201(Work Breakdown Structure 1.4.2.1), the pediatric studies P203 (WBS 1.4.2.3), and program management WBS (1.1) to support expansion into this critical population.</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">This modification adds $62,705,357 to CLIN 0002 and increases CLIN 0002 to $961,387,795 from $898,682,438. CLIN 0002 remains cost plus fixed fee (CPFF). Fee was not applied to the additional scope</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Continued ...</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Except as provided herein, all terms and conditions of the document referenced in Item 9 A or 10A, as heretofore changed, remains unchanged and in full force and effect.</font></div></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">15A NAME AND TITLE OF SIGNER </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(Type or print)</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Stephane Bancel, CEO</font></div></td><td colspan="18" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">16A. NAME AND TITLE OF CONTRACTING OFFICER&#47;Type or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">print)</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div></td></tr><tr><td colspan="12" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">15B. CONTRACTOR&#47;OFFEROR</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Stephane Bancel&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><br>(Signature of person authorized to sign)</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">15C. DATE SIGNED</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3&#47;12&#47;2021</font></div></td><td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">16B. UNITED STATES OF AMERICA</font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><br>(Signature of Contracting Officer)</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">16C. DATE SIGNED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">03&#47;12&#47;2021</font></div></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Previous edition unusable</font></td><td colspan="18" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">STANDARD FORM 30 (REV 11&#47;2016)</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Prescribed by GSA FAR(48 CFR) 53.243</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:81pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.697%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.725%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.051%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">CONTINUATION SHEET</font></td><td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">REFERENCE NO. OF DOCUMENT BEING CONTINUED</font></div><div style="margin-bottom:3pt;margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">75A50120C00034&#47;P00007</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">PAGE OF</font></div><div style="margin-bottom:3pt;margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2&#160;&#160;&#160;&#160;&#124;&#160;&#160;&#160;&#160;10</font></div></td></tr><tr><td colspan="24" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">NAME OF OFFEROR OR CONTRACTOR<br>MODERNATX, INC 1492235</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ITEM NO.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(A)</font></div></td><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">SUPPLIES&#47;SERVICES</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(B)</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">QUANTITY</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(C)</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">UNIT</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(D)</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">UNIT PRICE</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(E)</font></div></td><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AMOUNT</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(F)</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">NSN 7540-01-152-8067</font></td><td colspan="18" style="border-top:1pt solid #000000;padding:2px 1pt 2px 307.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OPTIONAL FORM 336 (4-86)<br>Sponsored by GSA<br>FAR (48 CFR) 53.110</font></td></tr></table></div><div><img alt="image_01a.jpg" src="image_01a.jpg" style="height:707px;margin-bottom:5pt;vertical-align:text-bottom;width:719px"></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ib4fbad95e2474a9881d4dd2eb2ebfd90_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Contract #75A50120C00034</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Modification P00007</font></div></div><div style="margin-bottom:12pt"><font style="color:#2e74b5;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">C. Statement of Work<br>Updated with Modification P00007</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Independently, and not as an agent of the United States Government, the contractor shall furnish all necessary services, qualified professional, technical, and administrative personnel, material, equipment and facilities, not otherwise provided by the Government under the terms of this contract, as needed to perform the tasks set forth below.</font></div><div><font style="color:#1f4d78;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">mRNA-1273 Vaccine Development (WBS 1.0)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Contractor, Moderna, Inc. (&#8220;Moderna&#8221;) shall execute the preclinical, clinical, and chemistry, manufacturing and controls (CMC) activities required to license a vaccine against the SARS-CoV-2 virus (hereafter referred to as &#8220;mRNA-1273&#8221;).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Building upon early clinical development already underway, this proposal will support the late stage development, including the demonstration of clinical efficacy and generation of a dataset supportive of licensure. Moderna will additionally evaluate the platform manufacturing capabilities relative to the needs for supply in response to a pandemic.</font></div><div><font style="background-color:#ffff00;color:#1f4d78;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">** </font><font style="background-color:#ffff00;color:#1f4d78;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Program Management (WBS 1.1) &#8212; Updated with Mod P00007</font></div><div><font style="color:#1f4d78;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">mRNA-1273 Program Management (WBS 1.1.1)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Moderna&#8217;s mRNA-1273 program team is composed of a multidisciplinary, highly matrixed, group of functional leads with experience in, and responsibility for, integrating plans and operationalizing strategies across Research, Toxicology, CMC, Regulatory Affairs, Clinical Development, Medical Affairs, Market Access and Launch Readiness in support of vaccine deployment under Emergency Use Authorization and Quality. Collectively, the team has advanced ten programs to first-in-human studies within five years. The group will be led by a program lead (PL) who will oversee and coordinate the activities necessary to meet the program objective of licensure. The PL will be the point of accountability for the development and deployment of mRNA-1273. &#91;***&#93;. The Sub Principal Investigator will be responsible for ensure sufficient manufacturing capacity and production of mRNA-1273. A program management office (PMO) will be responsible for managing the cost and schedule constraints of the contract via an integrated master schedule and corresponding budget, identifying and managing program risk, and ensuring contract compliance. With the input from the mRNA-1273 project team, the PMO will be responsible for coordinating the drafting of and management to an integrated development plan. Upon execution of the contract, weekly meetings with BARDA will be held to monitor program performance and monthly and annual reports will be will delivered to BARDA for the record.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">In addition to</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">funding provided by BARDA, Moderna will contribute by</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">funding some of the subcontractor program management effort to support the contract. Note, this is not a cost sharing contract however this is to account for the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">funds contributed by Moderna.</font></div><div><font style="color:#1f4d78;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Nonclinical Toxicology (WBS 1.2)</font></div><div><font style="color:#2e74b5;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Development and Reproductive Toxicology of mRNA-1273 (WBS 1.2.2.1)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">To assess the risk of administering the vaccine to pregnant women, a complete GLP rat developmental and reproductive toxicology (DART) study is planned. Female Sprague Dawley rats will be dosed at the highest anticipated clinical dose level and include a control arm of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page 3 of 10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Contract #75A50120C00034</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Modification P00007</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">phosphate-buffered saline (PBS). As is typical for DART evaluations for vaccines, the animals will be immunized three times prior to mating and two times during gestation. Each group will have two cohorts (one group will undergo Cesarean section with examination of the uteri and embryos&#59; the other group will have natural delivery and will be terminated at weaning).</font></div><div><font style="color:#1f4d78;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Nonclinical (WBS 1.3)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For the purposes of this proposal it is assumed that the VRC continues to support nonclinical activities to develop murine and non-human primate efficacy studies, and animal models to assess the potential of vaccine- enhanced disease. The scope of work below will execute additional robustness experiments in these developed models.</font></div><div><font style="color:#2e74b5;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Assess Disease Enhancement (WBS 1.3.3.1)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The CoV spike protein expressed by the mRNA-1273 vaccine is stabilized in the prefusion conformation which should be optimal for inducing high quality antibody responses with low binding antibody to neutralizing antibody ratios. mRNA delivery and induction of CD8 T cells and Th1 CD4 T cells will avoid Th2-biased responses. The SARS-CoV-2 S protein expressed by the mRNA-1273 vaccine is stabilized in the pre-fusion conformation which should be optimal for inducing high functional antibody responses with low binding antibody to neutralizing antibody ratios, as it has been seen in RSV DS-Cav1 clinical trials and 2P-stabilized CoV S animal studies. In addition, mRNA vaccines induce Th1 skewed response as has been evident in several pre-clinical and clinical vaccine programs at Moderna, including pandemic flu and CMV (PMID 28457665, 29456015). By expressing pre-fusion SARS-CoV-2 S delivered with mRNA we should induce CD8 T cells and Th1-biased CD4 T cell responses as shown in both human, NHP, and murine studies, thus avoiding a Th2- biased response.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">We plan to perform studies in mouse and NHPs to assess the theoretical risk of vaccine induced disease enhancement triggered by CoV infection following vaccination with imRNA-1273. </font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#2e74b5;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Establish a Surrogate of Protection (WBS 1.3.3.2)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The primary endpoint for accelerated approval of a SARS-CoV-2 vaccine would be a neutralization assay. This endpoint must be supported with a body of pre-clinical work that demonstrates a correlation between </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page 4 of 10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Contract #75A50120C00034</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Modification P00007</font></div></div><div style="margin-bottom:0.12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">neutralizing titers and efficacy and that quantifies a protective serologic threshold titer using the same neutralization assay. Murine and NHP efficacy models are being developed in parallel to the Phase 1 clinical study. Building on data from these preliminary models and studies, Moderna will conduct NHP efficacy and murine passive transfer studies to confirm and refine the surrogate of protection.</font></div><div><font><br></font></div><div><font style="color:#2e74b5;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Clinical (WBS 1.4)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A Phase 1 study of mRNA-1273 in 120 healthy subjects 18-55 years of age will evaluate the safety and immunogenicity of two injections (28 days apart) at four dose levels (25, 50, 100 and 250 &#956;g). The proposed Phase 2 study will enroll n&#61;600 healthy subjects (&#62;18 years) to receive two injections, 28 days apart, of placebo or 50 or 100 pg mRNA-1273, at 1&#58;1&#58;1, age stratified (18-55 yrs&#59; &#62;55 yrs).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The total safety database from the mRNA-1273 Phase 1 and Phase 2 studies will be approximately 445 adult participants exposed and approximately 245 adult participants at the highest dose level. The proposed Phase 2 study (synopsis included below) is intended to support entry to subsequent Phase 3 study(ies). &#91;***&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="background-color:#ffff00;color:#1f4d78;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Phase 2 Safety and Immunogenicity Study (WBS 1.4.2.1) &#8212; Updated with Mod P00007</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Immediately following dose selection in the initial Phase 1 study the program will initiate a Phase 2 clinical study. The P201 study will confirm the safety and immunogenicity results from the open-label Phase 1, again testing a two-dose administration series 28d apart. Its assumed that 600 participants, randomized 1&#58;1&#58;1 active&#58; placebo, testing a two dose levels of mRNA-1273. Enrollment will be age-stratified participants 18 year of age and above into two age cohorts. Primary objectives will include standard clinical safety evaluation with conventional safety and SARS-CoV-2-specific IgG endpoints though a neutralizing antibody assay would be preferred if available. Secondary objectives will evaluate of the specific humoral response against SARS-CoV-2 by binding and neutralizing antibody (nAb) response. Safety will be followed through 6 months post-last vaccination and primary immunogenicity endpoint will be measured at D57. The study will enroll in the US under IND. The study will assess COVID-19 as exploratory endpoint which may extend the duration of followup accordingly. Clinical trial assessments will include measurement of SARS-CoV-2 S-specific binding antibody and neutralizing activity in sera. This will provide an indication of vaccine-induced antibody quality and relative potency. Historically, immune-complex mediated lung pathology has been associated with a high ratio of binding to functional antibody activity. In addition, vaccine-induced T cell responses will be evaluated by peptide pool stimulation to define the pattern of cytokine production. &#91;***&#93;. To support the EUA, an interim clinical study synopsis will be drafted based on D57 safety and immunogenicity data.</font></div><div><font style="background-color:#ffff00;color:#1f4d78;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">** Pediatrics (WBS 1.4.2.3) </font><font style="background-color:#ffff00;color:#2e74b5;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">- Updated with Mod P00007</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Moderna will conduct an initial pediatric study plan (PSP) under Pediatric Research Equity Act requirements during the IND phase. A deferral will be requested for children less than 6 months </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page 5 of 10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Contract #75A50120C00034</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Modification P00007</font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">of age at the time of initial BLA approval. Having demonstrated the mRNA-1273 is safe, tolerated, and effective in adults, Moderna will test the safety and immunogenicity of mRNA-1273 in a pediatric population with an aged-based step-down design.</font></div><div style="margin-bottom:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The P203 study is a Phase 2&#47;3, randomized, observer-blind, placebo controlled, study to evaluate the safety, reactogenicity, and effectiveness of mRNA-1273 SARS-CoV-2 vaccine in 3000 healthy adolescents 12 to &#60; 18 years of age. Participants will be randomly assigned to receive injections of either 100 &#956;g of mRNA-1273 vaccine or a placebo control in a 2&#58;1 randomization ratio. The goal of the study is to seek an indication for use of mRNA 1273 (100 pg IM, given as 2 injections, 28 days apart) in the 12 to &#60; 18 year age group. The basis for demonstrating vaccine effectiveness is proposed to be met by serum antibody (Ab) response measured in this adolescent age group. The approach to inferring vaccine effectiveness will depend on whether or not an accepted serum Ab threshold conferring protection against COVID-19 has been established. If an Ab threshold of protection has been established, effectiveness will be inferred based on the proportion of adolescent study participants with serum Ab levels (on study Day 57) meeting or exceeding the Ab threshold. If an Ab threshold of protection has not been established, effectiveness will be inferred based on demonstrating non-inferiority of the geometric mean value of serum nAb from adolescent participants compared to the geometric mean value of serum nAb from adults enrolled in the ongoing clinical endpoint efficacy trial (Study P301).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This adolescent study will monitor all participants for a total of 12 months following the second dose of vaccine or placebo. Safety assessments will include solicited ARs (7 days post each injection), unsolicited AEs (28 days post each injection), medically attended adverse events (MAAEs), serious adverse events (SAEs), and adverse event of special interest (AESI) (pediatric MIS C) throughout the study period.</font></div><div><font style="color:#2e74b5;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Phase 3 Pivotal Study (WBS 1.4.3.1)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Phase 3 Pivotal Study (WBS 1.4.3.1). The Phase 3 mRNA-1273-P301 study will confirm the trends observed during the Phase 1 and 2 trials, evaluating safety and efficacy in a larger number of subjects aged 18 and above. Approximately 30,000 subjects will be enrolled according to 1&#58;1 randomization (active&#58; placebo). Primary objectives will be 1) to demonstrate the efficacy of mRNA-1273 to prevent COVID-19 and 2) to evaluate the safety and reactogenicity of 2 injections of the mRNA-1273 vaccine given 28 days apart. Secondary objectives will evaluate&#58; the efficacy of mRNA-1273 to prevent severe COVID-19&#59; the efficacy of mRNA-1273 to prevent virologically confirmed SARS-CoV-2 infection or COVID-19 regardless of symptomatology or severity&#59; VE against a broad definition of COVID-19 disease&#59; VE to prevent death due to COVID-19 disease&#59; VE against allcause mortality&#59; the efficacy of mRNA-1273 to prevent COVID-19 after the first dose of investigational product (IP)&#59; the efficacy of mRNA-1273 to prevent COVID-19 in all study participants, regardless of evidence of prior SARS-CoV-2 infection&#59; the efficacy of mRNA-1273 to prevent asymptomatic SARS-CoV-2 infection.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The sample size of this Phase 3 is driven by the total number of cases to demonstrate VE (mRNA-1273 vs. placebo) to prevent COVID-19. &#91;***&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">On issuance of the EUA, in agreement with the FDA and OWS, the P301 study will offer vaccine to participants that were randomized to receive placebo and the study will transition to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page 6 of 10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Contract #75A50120C00034</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Modification P00007</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">an open label study. All 30K participants will return for a Participant Decision Visit. Participants will complete an updated ICF, a sera and NP swab sample will be collected to test for asymptomatic infection, and participants randomized to the placebo arm will be offered vaccine. After unblinding the sponsor will continue to leverage the clinical trial infrastructure. Doubling the exposed population will reduce the incidence of rare events potentially detectable with high confidence in the trial to approximately 1&#47;10,000 or 0.01%.</font></div><div><font style="color:#2e74b5;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Lot to Lot Consistency (WBS 1.4.3.2)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Based on FDA feedback received on 27 Aug this study is no longer required for licensure.</font></div><div><font style="color:#2e74b5;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Pediatrics (WBS 1.4.3.3)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Moderna plans to conduct an initial pediatric investigational plan under Pediatric Research Equity Act requirements during the IND phase. A deferral will be requested for children less than 17 years of age at the time of initial BLA approval. Having demonstrated the mRNA-1273 is safe, tolerated and effective in adults, Moderna will test the safety and immunogenicity of mRNA-1273 in a pediatric population with an aged-based step-down design&#58; children will be randomized into one of six treatment arms starting with the adolescents 1017 years of age, then 5-9 years of age, ending with children less than 5. In each age group, approximately 300 children will receive mRNA-1273 vaccine and 100 a placebo as control, for a total of 1200 children in P101. It is assumed subjects will receive a standard dose and regimen of vaccine matched to the adult dose and schedule.</font></div><div style="margin-bottom:12pt"><font style="color:#1f4d78;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Regulatory (WBS 1.5)</font></div><div><font style="color:#2e74b5;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">IND Preparation and Filing (WBS 1.5.1.1)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Moderna&#8217;s Regulatory Affairs group, in close collaboration with BARDA, will work to draft a comprehensive regulatory master plan to guide the preclinical, CMC and clinical development of mRNA-1273 within the first 90 days of the contract. An original investigational new drug application (IND) will be filed with the United States Food and Drug Administration (FDA) to support the clinical development of the Moderna product from Phase 2 onwards.</font></div><div><font style="color:#2e74b5;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">IND Maintenance (WBS 1.5.1.2)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Moderna-owned IND will be maintained to support the desired clinical development plan. As needed, meetings will be conducted to receive feedback and gain concurrence on the specifics of the development activities with the FDA. Moderna will file for Emergency Use Authorization, following the FDA guidance of EUA for COVID-19 vaccines. A product-specific VRBPAC will be held.</font></div><div><font style="color:#2e74b5;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">BLA Submission (WBS 1.5.2.1)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Moderna will submit a Biologics License Application (BLA) and seek approval for the mRNA-1273 vaccine.</font></div><div style="margin-bottom:12pt"><font style="color:#1f4d78;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CMC (WBS 1.6)</font></div><div><font style="color:#2e74b5;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">CTM Manufacture for Phase 2 (WBS 1.6.3.2)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page 7 of 10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Contract #75A50120C00034</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Modification P00007</font></div></div><div><font style="color:#2e74b5;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Process Development for Late Stage Clinical Supply (WBS 1.6.3.3)</font></div><div><font style="color:#2e74b5;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">mRNA Process Development</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Technical Development will confirm and optimize the process parameters for mRNA manufacture. &#91;***&#93;</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:0.12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page 8 of 10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Contract #75A50120C00034</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Modification P00007</font></div></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:0.12pt"><font style="color:#2e74b5;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">BLA Readiness (WBS 1.6.3.8)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In support of the Biologics License Application (BLA) due to the nature of the proposed timeline, it is likely that Moderna will need to complete some of process validation activities, primarily process characterization, after the completion of process performance qualification and before BLA filing. Moderna intends to rapidly develop a robust process for clinical manufacturing and PPQ, and then fully describe the acceptable design space for the process prior to BLA filing. Other activities to support this BLA filing, such as completing raw material qualification activities&#59; if not included in the BLA submission, will require a supplement to the initial BLA. In the initial BLA filing Moderna will describe its control strategy to cover the gap between initial BLA filing and the BLA supplement.</font></div><div><font style="color:#2e74b5;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Process Development for Full Commercial Scale (WBS 1.6.4.1)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The following section outlines the process development activities &#91;***&#93;. The goal of this work is to demonstrate the capability to produce mRNA-1273 at a scale that can support clinical demand.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page 9 of 10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Contract #75A50120C00034</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Modification P00007</font></div></div><div><font><br></font></div><div><font style="color:#2e74b5;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Controls (Analytical and Validation) (WBS 1.6.5)</font></div><div><font style="color:#2e74b5;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Potency Assay Development and Implementation (WBS 1.6.5.1)</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:0.12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div><font><br></font></div><div style="margin-bottom:0.12pt"><font style="color:#2e74b5;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Analytical Method Development and Validation (WBS 1.6.5.2)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Moderna has established a set of analytical methods that are applied to the release and stability testing of intermediates and DP. These methods are sufficient to assure the identity, strength, quality, purity and potency of the final product, and will have been qualified for use for mRNA-1273 as part of the Phase 2 CTM campaign. Robustness of product release and stability methods, structural characterization and identification of impurities to further support product specifications, product comparability assessment will continue to support Phase 3 development and licensure.</font></div><div><font style="color:#2e74b5;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Characterization Assay Development and Implementation (WBS 1.6.5.3)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A heightened characterization panel of analytical techniques will be used to assess any process modifications and to confirm process reproducibility for both drug substance and drug product during process development and scale up. As the applicability of the methods used in the heightened panel to elucidate quality attributes of drug substance and drug product is determined, these methods may be elevated to the respective release panel.</font></div><div><font style="color:#2e74b5;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Stability Studies (WBS 1.6.5.4)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Throughout the program, many studies will be undertaken &#91;***&#93;. This includes studies using development bench scale material, engineering lot material, and GMP material. This body of data will be used to apply interim and long-term shelf life to the drug product and process intermediates.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page 10 of 10</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>exhibit103formofpsuagreeme.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ib3dad21f0a734b999b4279f0f760ef8e_1"></div><div style="min-height:99pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 10.3</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH &#8220;&#91;***&#93;&#8221;. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">PERFORMANCE-BASED RESTRICTED STOCK UNIT AWARD AGREEMENT<br>FOR COMPANY EMPLOYEES<br>UNDER THE MODERNA, INC.<br>2018 STOCK OPTION AND INCENTIVE PLAN</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name of Grantee&#58;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Target Number of</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Restricted Stock Units&#58;  &#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Grant Date&#58;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;margin-top:24pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pursuant to the Moderna, Inc. 2018 Stock Option and Incentive Plan as amended through the date hereof (the &#8220;Plan&#8221;), Moderna, Inc. (the &#8220;Company&#8221;) hereby grants an award for the target number of Restricted Stock Units listed above (an &#8220;Award&#8221; and such target number, the &#8220;Target Award&#8221;) to the Grantee named above.  Each Restricted Stock Unit shall relate to one share of Common Stock, par value $0.0001 per share (the &#8220;Stock&#8221;) of the Company.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Restrictions on Transfer of Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of by the Grantee, and any shares of Stock issuable with respect to the Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of until (i) the Restricted Stock Units have vested as provided in Paragraph 2 of this Agreement and (ii) shares of Stock have been issued to the Grantee in accordance with the terms of the Plan and this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Vesting of Restricted Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The restrictions and conditions of Paragraph&#160;1 of this Agreement shall lapse on the Vesting Date specified in the vesting schedule attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> to this Agreement.  If a series of Vesting Dates is specified, then the restrictions and conditions in Paragraph&#160;1 shall lapse only with respect to the number of Restricted Stock Units specified as vested on such date.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Administrator may at any time accelerate the vesting schedule specified in this Paragraph 2.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Termination of Service Relationship</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If the Grantee&#8217;s Service Relationship with the Company or a Subsidiary terminates for any reason (including death or disability) prior to the first anniversary of the Grant Date listed above, then rights to any Restricted Stock Units under this Award shall be automatically and without notice terminate and be forfeited, and neither the Grantee nor any of his or her successors, heirs, assigns, or personal representatives will thereafter have any further rights or interests in such unvested Restricted Stock Units. If the Grantee&#8217;s Service Relationship with the Company or a Subsidiary terminates on or subsequent to the first </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">anniversary of the Grant Date listed above and prior to the Vesting Date, the Grantee shall be entitled to vesting of the Award solely as contemplated by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> hereto.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Issuance of Shares of Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, as soon as practicable following the Vesting Date (but in no event later than two and one-half months following the Vesting Date), the Company shall issue to the Grantee the number of shares of Stock equal to the aggregate number of Restricted Stock Units that have vested pursuant to Paragraph 2 of this Agreement on such date and the Grantee shall thereafter have all the rights of a stockholder of the Company with respect to such shares. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Incorporation of Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding anything herein to the contrary, this Agreement shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section 2(b) of the Plan.  Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   The Grantee shall, not later than the date as of which the receipt of this Award becomes a taxable event for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state, and local taxes required by law to be withheld on account of such taxable event.  The Company shall have the authority to cause the required minimum tax withholding obligation to be satisfied, in whole or in part, by withholding from shares of Stock to be issued to the Grantee a number of shares of Stock with an aggregate Fair Market Value that would satisfy the withholding amount due.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Section 409A of the Code.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  This Agreement shall be interpreted in such a manner that all provisions relating to the settlement of the Award are either exempt from the requirements of Section 409A of the Code as &#8220;short-term deferrals&#8221; as described in Section 409A of the Code or otherwise comply with the requirements of Section 409A of the Code.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">No Obligation to Continue Service Relationship</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or this Agreement to continue the Grantee&#8217;s Service Relationship with the Company or a Subsidiary and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate the Grantee&#8217;s Service Relationship with the Company or a Subsidiary at any time.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Integration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement constitutes the entire agreement between the parties with respect to this Award and supersedes all prior agreements and discussions between the parties concerning such subject matter.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Data Privacy Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In order to administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the &#8220;Relevant Companies&#8221;) may process any and all personal or professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;2</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">desirable for the administration of the Plan and&#47;or this Agreement (the &#8220;Relevant Information&#8221;).  By entering into this Agreement, the Grantee (i) authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information&#59; (ii) waives any privacy rights the Grantee may have with respect to the Relevant Information&#59; (iii) authorizes the Relevant Companies to store and transmit such information in electronic form&#59; and (iv) authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate.  The Grantee shall have access to, and the right to change, the Relevant Information.  Relevant Information will only be used in accordance with applicable law.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Grantee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Clawback Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Award shall be subject to the terms and conditions of the Company&#8217;s Policy for Recoupment of Executive Incentive Compensation, to the extent applicable and as in effect from time to time.</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font><br></font></div><div style="margin-bottom:36pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Moderna, Inc.</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">           By&#58; &#160; &#160;</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">           Name&#58; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                           Title&#58; &#160; </font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center;text-indent:36pt"><font><br></font></div><div style="margin-bottom:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The foregoing Agreement is hereby accepted, and the terms and conditions thereof hereby agreed to by the undersigned.  Electronic acceptance of this Agreement pursuant to the Company&#8217;s instructions to the Grantee (including through an online acceptance process) is acceptable.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Acceptance Date&#58;  </font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Appendix A </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Vesting Schedule</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Target Award shall initially be unvested.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Compensation and Talent Committee, at its first regularly scheduled meeting following the conclusion of the Performance Measurement Period shall determine the actual number of Restricted Stock Units that shall be credited as of the final day of such Performance Measurement Period (the last day of such Performance Measurement Period, the &#8220;Vesting Date&#8221;).  The number of Restricted Stock Units credited for such period shall equal the Target Award multiplied by the Performance Multiplier, as further multiplied by the Goal as Percent of Total shown below for the Award as a whole, subject to the terms and conditions hereof.  The Performance Multiplier shall be determined as set forth in the table below.  The number of Restricted Stock Units credited for a Performance Measurement Period (if any) shall be rounded up to the nearest whole share of Stock.  </font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.487%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.505%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.166%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.991%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.747%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Performance Metric</font></td><td colspan="6" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Performance Metric Goals</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Performance Multiplier</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Target Qty of RSU</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Goal as Percent of Total</font></td></tr><tr style="height:13pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #d9d9d9;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A</font></td><td colspan="3" rowspan="3" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maximum</font></td><td colspan="3" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">200%</font></td><td colspan="3" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-left:1pt solid #bfbfbf;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr style="height:13pt"><td colspan="3" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Target</font></td><td colspan="3" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100%</font></td><td colspan="3" style="border-left:1pt solid #d9d9d9;border-right:1pt solid #bfbfbf;border-top:1pt solid #d9d9d9;padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Threshold</font></td><td colspan="3" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50%</font></td><td colspan="3" style="border-left:1pt solid #d9d9d9;border-right:1pt solid #bfbfbf;border-top:1pt solid #d9d9d9;padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #d9d9d9;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B</font></td><td colspan="3" rowspan="3" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #bfbfbf;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maximum</font></td><td colspan="3" style="border-left:1pt solid #bfbfbf;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">200%</font></td><td colspan="3" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-left:1pt solid #d9d9d9;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr style="height:13pt"><td colspan="3" style="border-left:1pt solid #bfbfbf;border-top:1pt solid #bfbfbf;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Target</font></td><td colspan="3" style="border-left:1pt solid #bfbfbf;border-top:1pt solid #d9d9d9;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100%</font></td><td colspan="3" style="border-left:1pt solid #d9d9d9;border-right:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="border-left:1pt solid #bfbfbf;border-top:1pt solid #bfbfbf;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Threshold</font></td><td colspan="3" style="border-left:1pt solid #bfbfbf;border-top:1pt solid #d9d9d9;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50%</font></td><td colspan="3" style="border-left:1pt solid #d9d9d9;border-right:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #d9d9d9;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C</font></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #d9d9d9;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #bfbfbf;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maximum</font></td><td colspan="3" style="border-left:1pt solid #bfbfbf;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">200%</font></td><td colspan="3" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #d9d9d9;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr style="height:13pt"><td colspan="3" style="border-left:1pt solid #bfbfbf;border-top:1pt solid #bfbfbf;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Target</font></td><td colspan="3" style="border-left:1pt solid #bfbfbf;border-top:1pt solid #d9d9d9;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100%</font></td><td colspan="3" style="border-left:1pt solid #d9d9d9;border-right:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #bfbfbf;border-top:1pt solid #bfbfbf;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Threshold</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #bfbfbf;border-top:1pt solid #d9d9d9;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50%</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #d9d9d9;border-right:1pt solid #d9d9d9;border-top:1pt solid #d9d9d9;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Subject to the Grantee&#8217;s continued Service Relationship with the Company or a Subsidiary until the Vesting Date, as soon as practicable on or following the Vesting Date (but in no event later than two and one-half months following the Vesting Date), the Company shall issue to the Grantee a number of shares of Stock equal to the total number of Restricted Stock Units that have vested.  Notwithstanding the foregoing, if the Grantee terminates employment on or subsequent to the first anniversary of the Grant Date, but prior to the Vesting Date, then the Grantee shall be credited, subject to achievement of the applicable Performance Metric Goal during the Performance Measurement Period, in the number of Restricted Stock Units equal to the Target Award, multiplied by the applicable Performance Multiplier, multiplied by a fraction, where the numerator equals the number of days that the Grantee was in a Service Relationship with the Company during the Performance Measurement Period and the denominator equals the number of days in the Performance Measurement Period, and such credited Restricted Stock Units shall vest on the Vesting Date and be settled in a number of shares of Stock no later than two and one-half months after the Vesting Date&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, however, that no portion of the Award </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;4</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">shall vest pursuant to this sentence if&#58; (a) the Grantee is terminated for Cause (as defined in the Company&#8217;s Amended and Restated Executive Severance Plan, as last amended November 4, 2018 and as further amended from time to time), or (b) the Grantee is not in compliance with any contractual obligation to the Company, including non-compete or non-solicitation obligations, in each case, as determined in the sole discretion of the Compensation and Talent Committee.    </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Furthermore, notwithstanding the foregoing, in the event of a Sale Event during the Performance Measurement Period where the Award will not be assumed, continued or substituted by the Company&#8217;s successor or acquirer, the Performance Measurement Period shall be shortened such that the period shall be deemed to have concluded as of the closing of the Sale Event (the &#8220;Sale Event Closing Date&#8221;) and the Grantee shall vest, on the Sale Event Closing Date in a number of Restricted Stock Units equal to the greater of&#58; (a) the number of Restricted Stock Units equal to the Target Award multiplied by the applicable Performance Multiplier based upon performance through a date within one month of the Sale Event Closing Date, and (b) the number of Restricted Stock Units equal to the Target Award, subject to the Grantee&#8217;s continued Service Relationship with the Company or a Subsidiary on the Sale Event Closing Date (or as otherwise contemplated by the prior paragraph), and such vested Restricted Stock Units shall be settled immediately prior to the Sale Event Closing Date.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If the Performance Metric is between two of the Performance Metric Goals above, then the Performance Multiplier shall be determined by using linear interpolation between the two Performance Metric Goals.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Definitions</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For purposes of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,   </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;Performance Measurement Period&#8221; shall mean the period from January 1, 2021 to December 31, 2023.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;5</font></div><div><font><br></font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>5
<FILENAME>exhibit104directorcompensa.htm
<DESCRIPTION>EX-10.4
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ic2096876e51048b381953f884d5d46b9_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 10.4</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Moderna, Inc.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Amended and Restated Non-Employee Director Compensation Policy</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The purpose of this Amended and Restated Non-Employee Director Compensation Policy (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) of Moderna, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company or its subsidiaries (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Outside Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  In furtherance of the purpose stated above, all Outside Directors shall be paid compensation for services provided to the Company as set forth below&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:28.34pt;text-decoration:underline">Cash Retainers</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.7pt;text-decoration:underline">Annual Retainer for Board Membership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;  $60,000 for general availability and participation in meetings and on conference calls of our Board of Directors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Board of Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  No additional compensation for attending individual Board of Director meetings.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.02pt;text-decoration:underline">Additional Annual Retainer for Non-Executive Chairman of the Board of Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;  $65,000</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.7pt;text-decoration:underline">Additional Annual Retainers for Committee Membership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"></td><td style="width:81.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.405%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Audit Committee Chairperson&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$25,000</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Audit Committee non-Chairperson member&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$12,000</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Compensation &#38; Talent Committee Chairperson&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$20,000</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Compensation &#38; Talent Committee non-Chairperson member&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$10,000</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Nominating and Corporate Governance Committee Chairperson&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$15,000</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Nominating and Corporate Governance Committee non-Chairperson member&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$7,500</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Product Development Committee Chairperson&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$15,000</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Product Development non-Chairperson member&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$10,000</font></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No additional compensation for attending individual committee meetings.  All cash retainers will be paid quarterly, in arrears, or upon the earlier resignation or removal of the Outside Director.  Cash retainers owing to Outsider Directors shall be annualized, meaning that with respect to Outside Directors who join the Board of Directors during the calendar year, such amounts shall be pro-rated based on the number of calendar days served by such director.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">II.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:23.68pt;text-decoration:underline">Equity Retainers</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">All grants of equity retainer awards to Outside Directors pursuant to this Policy will be automatic and nondiscretionary and will be made in accordance with the following provisions&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:29.67pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  For purposes of this Policy, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means with respect to (i) any award of stock options the grant date fair value of the option (i.e., Black-Scholes Value) determined in accordance with the reasonable assumptions and methodologies employed by the Company for </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">calculating the fair value of options under ASC 718 and which shall generally reflect, when calculating the fair value, the average closing market price on the Nasdaq Global Market (or such other market on which the Company&#8217;s common stock is then principally listed) (the &#8220;NASDAQ&#8221;) of one share of the Company&#8217;s common stock over the preceding 20 trading days, up to and including the last trading day immediately preceding the grant date&#59; and (ii) any award of restricted stock and restricted stock units (&#8220;RSUs&#8217;) the product of (A)&#160;the average closing market price on the NASDAQ over the preceding 20 trading days, up to and including the last trading day immediately preceding the grant date of one share of the Company&#8217;s common stock on the grant date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and (B)&#160;the aggregate number of shares pursuant to such award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:26.34pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Revisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Compensation &#38; Talent Committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Compensation Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) in its discretion may change and otherwise revise the terms of awards to be granted under this Policy, including, without limitation, the number of shares subject thereto, for awards of the same or different type granted on or after the date the Compensation Committee determines to make any such change or revision.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:23.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sale Event Acceleration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event of a Sale Event (as defined in the Company&#8217;s 2018 Stock Option and Incentive Plan (as amended from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Stock Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)), the equity retainer awards granted to Outside Directors pursuant to this Policy shall become 100% vested and exercisable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:23.67pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">iv.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Initial Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Upon initial election to the Board of Directors, each new Outside Director will receive an initial, one-time equity grant (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Initial Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) with a Value of $400,000, of which 75% of the Value shall be delivered in the form of a non-statutory stock option and 25% of the Value shall be delivered in the form of RSUs.  The portion of the Initial Grant delivered as a stock option shall have an exercise price per share equal to the closing price of a share of the Company&#8217;s common stock on the date of grant and a term of ten years, and shall vest in full on the one-year anniversary of the grant date.  The portion of the Initial Grant delivered as RSUs shall vest in full on the one-year anniversary of the grant date.  All vesting of the Initial Grant shall cease if the director resigns from our Board of Directors or otherwise ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">v.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Annual Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. On the date of the Company&#8217;s Annual Meeting of Stockholders,  each Outside Director who will continue as a member of the Board of Directors following such Annual Meeting of Stockholders will receive an equity grant on the date of such Annual Meeting of Stockholders (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Annual Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) with a Value of $425,000, of which 75% of the Value shall be delivered in the form of a non-statutory stock option, and 25% of the Value shall be delivered in the form of RSUs.  The portion of the Annual Grant delivered as a stock option shall have an exercise price per share equal to the closing price of a share of the Company&#8217;s common stock on the date of grant and a term of ten years, and shall vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the next Annual Meeting of Stockholders.  The portion of the Annual Grant delivered as RSUs shall vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the next Annual Meeting of Stockholders. All vesting of the Annual Grant shall cease if the director resigns from our Board of Directors or otherwise ceases to serve as a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">director, unless the Board of Directors determines that the circumstances warrant continuation of vesting.  If a new Outside Director joins our Board of Directors on a date other than the date of the Company&#8217;s Annual Meeting of Stockholders, then such Outside Director will be granted a pro-rata portion of the Annual Grant based on the time between such Outside Director&#8217;s appointment and the next Annual Meeting of Stockholders, on the first eligible grant date following such Outside Director&#8217;s appointment to our Board of Directors.  </font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">III.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:19.02pt;text-decoration:underline">Expenses</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company will reimburse all reasonable out-of-pocket expenses incurred by Outside Directors in attending meetings of the Board of Directors or any committee thereof.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IV.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:19.68pt;text-decoration:underline">Maximum Annual Compensation</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The aggregate amount of compensation, including both equity compensation and cash compensation, paid to any Outside Director in a calendar year period shall not exceed $1,500,000 for the first year of service and $1,000,000 for each year of service thereafter (or such other limits as may be set forth in Section 3(b) of the Stock Plan or any similar provision of a successor plan).  For this purpose, the &#8220;amount&#8221; of equity compensation paid in a calendar year shall be determined based on the grant date fair value thereof, as determined in accordance with ASC 718 or its successor provision, but excluding the impact of estimated forfeitures related to service-based vesting conditions.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date Amended and Restated Policy Approved</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58; March 21, 2019, as amended March 27, 2020 and as further amended April 28, 2021.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>a4exhibit31103312021.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i0c9b6d408a9d42aa82323a815932cd47_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1 </font></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO RULES 13a-14(a)&#160;AND 15d-14(a)&#160;UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION&#160;302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-bottom:3pt;text-align:center"><font><br></font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, St&#233;phane Bancel, certify that&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form&#160;10-Q of Moderna,&#160;Inc.&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) for the registrant and have&#58;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:31.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.397%"><tr><td style="width:1.0%"></td><td style="width:23.741%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.741%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.630%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 6, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#47;s&#47; St&#233;phane Bancel</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">St&#233;phane Bancel</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>a5exhibit31203312021.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i1af579a156f4447db65100b052610a22_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO RULES 13a-14(a)&#160;AND 15d-14(a)&#160;UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION&#160;302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, David W. Meline, certify that&#58;</font></div><div style="margin-bottom:9pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form&#160;10-Q of Moderna,&#160;Inc.&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) for the registrant and have&#58;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.228%"><tr><td style="width:1.0%"></td><td style="width:24.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.933%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 6, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#47;s&#47; David W. Meline</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David W. Meline</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Financial Officer)</font></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>a6exhibit32103312021.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i731c3ef55b9c46d8a067af457c7bf91b_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">18 U.S.C. SECTION&#160;1350</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">AS ADOPTED PURSUANT TO SECTION&#160;906</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">In connection with the Quarterly Report on Form 10-Q of Moderna, Inc. (the &#8220;Company&#8221;) for the period ended March 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), we, St&#233;phane Bancel, Chief Executive Officer of the Company, and David W. Meline, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of our knowledge&#58; </font></div><div style="padding-left:40.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:10.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and </font></div><div style="padding-left:40.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div style="padding-left:4.5pt"><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.397%"><tr><td style="width:1.0%"></td><td style="width:23.741%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.741%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.630%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 6, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#47;s&#47; St&#233;phane Bancel</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">St&#233;phane Bancel</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 6, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#47;s&#47; David W. Meline</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David W. Meline</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>mrna-20210331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:0cbcbb00-411e-4aec-bde6-af04ca2907e0,g:4456e2fc-6666-4731-b603-d80176d3b13f-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mrna="http://www.modernatx.com/20210331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.modernatx.com/20210331">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrna-20210331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrna-20210331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrna-20210331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrna-20210331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.modernatx.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" roleURI="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS">
        <link:definition>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical" roleURI="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical">
        <link:definition>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" roleURI="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical">
        <link:definition>1007008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1008009 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionoftheBusiness" roleURI="http://www.modernatx.com/role/DescriptionoftheBusiness">
        <link:definition>2101101 - Disclosure - Description of the Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionoftheBusinessAdditionalInformationDetails" roleURI="http://www.modernatx.com/role/DescriptionoftheBusinessAdditionalInformationDetails">
        <link:definition>2402401 - Disclosure - Description of the Business - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofBasisofPresentationandRecentAccountingStandards" roleURI="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandards">
        <link:definition>2103102 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofBasisofPresentationandRecentAccountingStandardsPolicies" roleURI="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsPolicies">
        <link:definition>2204201 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofBasisofPresentationandRecentAccountingStandardsTables" roleURI="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsTables">
        <link:definition>2305301 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofBasisofPresentationandRecentAccountingStandardsComponentsofAccumulatedOtherComprehensivelossIncomeDetails" roleURI="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsComponentsofAccumulatedOtherComprehensivelossIncomeDetails">
        <link:definition>2406402 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards - Components of Accumulated Other Comprehensive (loss) Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofBasisofPresentationandRecentAccountingStandardsReconciliationofCashCashEquivalentsandRestrictedCashDetails" roleURI="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsReconciliationofCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>2407403 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductSales" roleURI="http://www.modernatx.com/role/ProductSales">
        <link:definition>2108103 - Disclosure - Product Sales</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductSalesTables" roleURI="http://www.modernatx.com/role/ProductSalesTables">
        <link:definition>2309302 - Disclosure - Product Sales (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductSalesDetails" roleURI="http://www.modernatx.com/role/ProductSalesDetails">
        <link:definition>2410404 - Disclosure - Product Sales (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GrantRevenue" roleURI="http://www.modernatx.com/role/GrantRevenue">
        <link:definition>2111104 - Disclosure - Grant Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GrantRevenueTables" roleURI="http://www.modernatx.com/role/GrantRevenueTables">
        <link:definition>2312303 - Disclosure - Grant Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GrantRevenueDetails" roleURI="http://www.modernatx.com/role/GrantRevenueDetails">
        <link:definition>2413405 - Disclosure - Grant Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationRevenue" roleURI="http://www.modernatx.com/role/CollaborationRevenue">
        <link:definition>2114105 - Disclosure - Collaboration Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationRevenueTables" roleURI="http://www.modernatx.com/role/CollaborationRevenueTables">
        <link:definition>2315304 - Disclosure - Collaboration Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationRevenueSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails" roleURI="http://www.modernatx.com/role/CollaborationRevenueSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails">
        <link:definition>2416406 - Disclosure - Collaboration Revenue - Summary of Total Consolidated Net Revenues from Strategic Collaborators (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationRevenueChangesinBalancesofReceivablesandContractLiabilitiesDetails" roleURI="http://www.modernatx.com/role/CollaborationRevenueChangesinBalancesofReceivablesandContractLiabilitiesDetails">
        <link:definition>2417407 - Disclosure - Collaboration Revenue - Changes in Balances of Receivables and Contract Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.modernatx.com/role/FinancialInstruments">
        <link:definition>2118106 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.modernatx.com/role/FinancialInstrumentsTables">
        <link:definition>2319305 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails" roleURI="http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails">
        <link:definition>2420408 - Disclosure - Financial Instruments - Summary of Cash and Available-for-Sale Securities by Significant Investment Category (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails" roleURI="http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails">
        <link:definition>2421409 - Disclosure - Financial Instruments - Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsNarrativeDetails" roleURI="http://www.modernatx.com/role/FinancialInstrumentsNarrativeDetails">
        <link:definition>2422410 - Disclosure - Financial Instruments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails" roleURI="http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails">
        <link:definition>2423411 - Disclosure - Financial Instruments - Financial Assets Measured At Fair Value On a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstruments" roleURI="http://www.modernatx.com/role/DerivativeFinancialInstruments">
        <link:definition>2124107 - Disclosure - Derivative Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsTables" roleURI="http://www.modernatx.com/role/DerivativeFinancialInstrumentsTables">
        <link:definition>2325306 - Disclosure - Derivative Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsBalanceSheetHedgesDetails" roleURI="http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails">
        <link:definition>2426412 - Disclosure - Derivative Financial Instruments - Balance Sheet Hedges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.modernatx.com/role/Inventory">
        <link:definition>2127108 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.modernatx.com/role/InventoryTables">
        <link:definition>2328307 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.modernatx.com/role/InventoryDetails">
        <link:definition>2429413 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNet" roleURI="http://www.modernatx.com/role/PropertyandEquipmentNet">
        <link:definition>2130109 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetTables" roleURI="http://www.modernatx.com/role/PropertyandEquipmentNetTables">
        <link:definition>2331308 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetDetails" roleURI="http://www.modernatx.com/role/PropertyandEquipmentNetDetails">
        <link:definition>2432414 - Disclosure - Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetComponents" roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponents">
        <link:definition>2133110 - Disclosure - Other Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetComponentsTables" roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsTables">
        <link:definition>2334309 - Disclosure - Other Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails" roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails">
        <link:definition>2435415 - Disclosure - Other Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetComponentsAccruedLiabilitiesDetails" roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails">
        <link:definition>2436416 - Disclosure - Other Balance Sheet Components - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetComponentsDeferredRevenueDetails" roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails">
        <link:definition>2437417 - Disclosure - Other Balance Sheet Components - Deferred Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.modernatx.com/role/Leases">
        <link:definition>2138111 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.modernatx.com/role/LeasesTables">
        <link:definition>2339310 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.modernatx.com/role/LeasesNarrativeDetails">
        <link:definition>2440418 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesBalanceSheetInformationDetails" roleURI="http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails">
        <link:definition>2441419 - Disclosure - Leases - Balance Sheet Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMinimumLeasePaymentsDetails" roleURI="http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails">
        <link:definition>2442420 - Disclosure - Leases - Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMinimumLeasePaymentsDetails_1" roleURI="http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1">
        <link:definition>2442420 - Disclosure - Leases - Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.modernatx.com/role/CommitmentsandContingencies">
        <link:definition>2143112 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesStrategicCollaborationsDetails" roleURI="http://www.modernatx.com/role/CommitmentsandContingenciesStrategicCollaborationsDetails">
        <link:definition>2444421 - Disclosure - Commitments and Contingencies - Strategic Collaborations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails" roleURI="http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails">
        <link:definition>2445422 - Disclosure - Commitments and Contingencies - Purchase Commitments and Purchase Orders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesLicensestoPatentedTechnologyDetails" roleURI="http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails">
        <link:definition>2446423 - Disclosure - Commitments and Contingencies - Licenses to Patented Technology (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.modernatx.com/role/StockBasedCompensation">
        <link:definition>2147113 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.modernatx.com/role/StockBasedCompensationTables">
        <link:definition>2348311 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>2449424 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationOptionsActivityDetails" roleURI="http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails">
        <link:definition>2450425 - Disclosure - Stock-Based Compensation - Options Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails" roleURI="http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails">
        <link:definition>2451426 - Disclosure - Stock-Based Compensation - Restricted Common Stock and Common Stock Units Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockBasedCompensationExpenseDetails" roleURI="http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails">
        <link:definition>2452427 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.modernatx.com/role/IncomeTaxes">
        <link:definition>2153114 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.modernatx.com/role/IncomeTaxesDetails">
        <link:definition>2454428 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShare" roleURI="http://www.modernatx.com/role/EarningsperShare">
        <link:definition>2155115 - Disclosure - Earnings per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShareTables" roleURI="http://www.modernatx.com/role/EarningsperShareTables">
        <link:definition>2356312 - Disclosure - Earnings per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails" roleURI="http://www.modernatx.com/role/EarningsperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails">
        <link:definition>2457429 - Disclosure - Earnings per Share - Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails" roleURI="http://www.modernatx.com/role/EarningsperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails">
        <link:definition>2458430 - Disclosure - Earnings per Share - Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.modernatx.com/role/SubsequentEvents">
        <link:definition>2159116 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.modernatx.com/role/SubsequentEventsDetails">
        <link:definition>2460431 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="mrna_ContractOptionsMember" abstract="true" name="ContractOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember" abstract="true" name="PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrna_ClinicalServicesMember" abstract="true" name="ClinicalServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrna_NumberOfDevelopmentProgram" abstract="false" name="NumberOfDevelopmentProgram" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="mrna_RevenueFromGrantsMaximumAward" abstract="false" name="RevenueFromGrantsMaximumAward" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_MTCSouthMember" abstract="true" name="MTCSouthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrna_LesseeOperatingLeaseNumberOfExtensionPeriods" abstract="false" name="LesseeOperatingLeaseNumberOfExtensionPeriods" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrna_RevenueFromGrantsRemainingFundingCapacity" abstract="false" name="RevenueFromGrantsRemainingFundingCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_EmbeddedLeasesMember" abstract="true" name="EmbeddedLeasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrna_TherapeuticAndProphylacticProductsMember" abstract="true" name="TherapeuticAndProphylacticProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_NoncurrentMarketableSecuritiesMember" abstract="true" name="NoncurrentMarketableSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrna_OperatingAndFinanceLeaseLiabilityNoncurrent" abstract="false" name="OperatingAndFinanceLeaseLiabilityNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_TenantIncentivesReceivablesCurrent" abstract="false" name="TenantIncentivesReceivablesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_AccruedOtherExternalGoodsAndServicesCurrent" abstract="false" name="AccruedOtherExternalGoodsAndServicesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_CustomerDepositsMember" abstract="true" name="CustomerDepositsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrna_RevenueFromGrantsNumberOfContractOptionsExercised" abstract="false" name="RevenueFromGrantsNumberOfContractOptionsExercised" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrna_ContractWithCustomerAssetDeductionsDuringPeriod" abstract="false" name="ContractWithCustomerAssetDeductionsDuringPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_DiagnosticProductsMember" abstract="true" name="DiagnosticProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrna_OperatingAndFinanceLeaseLiabilityCurrent" abstract="false" name="OperatingAndFinanceLeaseLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_MerckMember" abstract="true" name="MerckMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_LeasesImputedInterestRate" abstract="false" name="LeasesImputedInterestRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="mrna_PersonalizedMRNACancerVaccinesProductsMember" abstract="true" name="PersonalizedMRNACancerVaccinesProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrna_NorwoodMassachusettsMember" abstract="true" name="NorwoodMassachusettsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrna_AccruedManufacturing" abstract="false" name="AccruedManufacturing" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward" abstract="true" name="ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrna_TheBillAndMelindaGatesFoundationMember" abstract="true" name="TheBillAndMelindaGatesFoundationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrna_RestrictedStockAndRestrictedStockUnitsRSUMember" abstract="true" name="RestrictedStockAndRestrictedStockUnitsRSUMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrna_OtherGrantRevenueMember" abstract="true" name="OtherGrantRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrna_CollaborationArrangementMember" abstract="true" name="CollaborationArrangementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrna_AccruedDevelopmentOperation" abstract="false" name="AccruedDevelopmentOperation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_ProductSalesMember" abstract="true" name="ProductSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrna_ClinicalOperationsAndSupportCommitmentMember" abstract="true" name="ClinicalOperationsAndSupportCommitmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod" abstract="false" name="ContractWithCustomerLiabilityDeductionsDuringPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="mrna_ChangeInContractwithCustomerAssetRollForward" abstract="true" name="ChangeInContractwithCustomerAssetRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases" abstract="false" name="IncreaseDecreaseInRightOfUseAssetOperatingLeases" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_StockOptionAndIncentivePlan2018Member" abstract="true" name="StockOptionAndIncentivePlan2018Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="mrna_AllowanceForTenantImprovements" abstract="false" name="AllowanceForTenantImprovements" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_AstraZenecaMember" abstract="true" name="AstraZenecaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrna_RawMaterialsAccountsPayable" abstract="false" name="RawMaterialsAccountsPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_ChangeInContractWithCustomerLiabilityLineItems" abstract="true" name="ChangeInContractWithCustomerLiabilityLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrna_OperatingLeaseLiabilities" abstract="false" name="OperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="mrna_SupplyAndManufacturingAgreementsMember" abstract="true" name="SupplyAndManufacturingAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentAndRegulatoryMilestonesMaximumAmount" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentAndRegulatoryMilestonesMaximumAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_ChangeInContractwithCustomerLiabilityRollForward" abstract="true" name="ChangeInContractwithCustomerLiabilityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_ChargesToFinancingLeaseLiabilities" abstract="false" name="ChargesToFinancingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_OperatingAndFinanceLeaseRightOfUseAsset" abstract="false" name="OperatingAndFinanceLeaseRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_DefenseAdvancedResearchProjectsAgencyMember" abstract="true" name="DefenseAdvancedResearchProjectsAgencyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrna_OtherCollaborativePartiesMember" abstract="true" name="OtherCollaborativePartiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="mrna_FinanceLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="FinanceLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_ChangeInContractWithCustomerLiabilityTable" abstract="true" name="ChangeInContractWithCustomerLiabilityTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="mrna_RevenueFromGrantsCurrentFundingCapacity" abstract="false" name="RevenueFromGrantsCurrentFundingCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember" abstract="true" name="USGovernmentAgenciesAndCorporateDebtSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" abstract="true" name="BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrna_NumberOfDosesOfVaccineCandidate" abstract="false" name="NumberOfDosesOfVaccineCandidate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrna_VertexMember" abstract="true" name="VertexMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrna_OtherPrepaidExpenseManufacturing" abstract="false" name="OtherPrepaidExpenseManufacturing" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_MTCNorthMember" abstract="true" name="MTCNorthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrna_RevenueFromGrantsPotentialReimbursement" abstract="false" name="RevenueFromGrantsPotentialReimbursement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_Commercial" abstract="false" name="Commercial" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_OperatingAndFinanceLeaseLiability" abstract="false" name="OperatingAndFinanceLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_OperatingLeaseNumberOfProperties" abstract="false" name="OperatingLeaseNumberOfProperties" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrna_AccruedClinicalTrials" abstract="false" name="AccruedClinicalTrials" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_LeasesIncrementalBorrowingRate" abstract="false" name="LeasesIncrementalBorrowingRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="mrna_RevenueFromGrantsNumberOfContractOptions" abstract="false" name="RevenueFromGrantsNumberOfContractOptions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrna_FinancingRightOfUseAssetMember" abstract="true" name="FinancingRightOfUseAssetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrna_AccruedPropertyAndEquipmentCurrent" abstract="false" name="AccruedPropertyAndEquipmentCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_CambridgeMassachusettsMember" abstract="true" name="CambridgeMassachusettsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="mrna_InitialProjectMember" abstract="true" name="InitialProjectMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrna_CurrentMarketableSecuritiesMember" abstract="true" name="CurrentMarketableSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember" abstract="true" name="CollaborationArrangementIncludingArrangementsWithAffiliateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>mrna-20210331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:0cbcbb00-411e-4aec-bde6-af04ca2907e0,g:4456e2fc-6666-4731-b603-d80176d3b13f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.modernatx.com/role/CoverPage" xlink:type="simple" xlink:href="mrna-20210331.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="mrna-20210331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e70821df-c667-4466-8097-e3a987303cdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_12e963e8-6ad9-4306-b705-0377a519aaa4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e70821df-c667-4466-8097-e3a987303cdd" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_12e963e8-6ad9-4306-b705-0377a519aaa4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_61edce93-042d-4f3a-aa57-1886318f7d9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e70821df-c667-4466-8097-e3a987303cdd" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_61edce93-042d-4f3a-aa57-1886318f7d9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_781778e1-c830-4486-83ed-b46888e8c540" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e70821df-c667-4466-8097-e3a987303cdd" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_781778e1-c830-4486-83ed-b46888e8c540" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_ca70a181-661a-41a4-9e58-22d50965a812" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e70821df-c667-4466-8097-e3a987303cdd" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_ca70a181-661a-41a4-9e58-22d50965a812" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b4f8b492-7445-4ff4-b510-40370c17422a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e70821df-c667-4466-8097-e3a987303cdd" xlink:to="loc_us-gaap_LiabilitiesCurrent_b4f8b492-7445-4ff4-b510-40370c17422a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c07a2405-a671-45b3-b5c9-db3b80c9cb85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_431bf432-da96-4862-99e2-5fc4e87d895c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c07a2405-a671-45b3-b5c9-db3b80c9cb85" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_431bf432-da96-4862-99e2-5fc4e87d895c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_afc152a6-5553-43ff-881e-6ff7bd2a9eca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c07a2405-a671-45b3-b5c9-db3b80c9cb85" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_afc152a6-5553-43ff-881e-6ff7bd2a9eca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_dd5e17f8-ee1e-43a5-a226-fddcc8ac7856" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c07a2405-a671-45b3-b5c9-db3b80c9cb85" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_dd5e17f8-ee1e-43a5-a226-fddcc8ac7856" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_c8f3c13d-9907-4d60-8a9a-d2238254aa84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c07a2405-a671-45b3-b5c9-db3b80c9cb85" xlink:to="loc_us-gaap_InventoryNet_c8f3c13d-9907-4d60-8a9a-d2238254aa84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_97748225-c664-429f-9834-7062b15ba5bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c07a2405-a671-45b3-b5c9-db3b80c9cb85" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_97748225-c664-429f-9834-7062b15ba5bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e8fb4886-5072-43e7-a2b0-1509b984fba8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_c65eace8-ccc4-4ef9-8ce9-78f7f6131997" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e8fb4886-5072-43e7-a2b0-1509b984fba8" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_c65eace8-ccc4-4ef9-8ce9-78f7f6131997" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_5ec82152-eeee-46c9-a535-dcc047a3f8c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e8fb4886-5072-43e7-a2b0-1509b984fba8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_5ec82152-eeee-46c9-a535-dcc047a3f8c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_e734b4f7-0525-41ee-8634-0d93c7482345" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e8fb4886-5072-43e7-a2b0-1509b984fba8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_e734b4f7-0525-41ee-8634-0d93c7482345" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0d2ed4bd-5171-459d-be80-46cf6b069790" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e8fb4886-5072-43e7-a2b0-1509b984fba8" xlink:to="loc_us-gaap_AssetsCurrent_0d2ed4bd-5171-459d-be80-46cf6b069790" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_245e2149-5db6-486d-86d3-e3123ded0418" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e8fb4886-5072-43e7-a2b0-1509b984fba8" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_245e2149-5db6-486d-86d3-e3123ded0418" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_282ecf5d-a7ec-4018-b227-dbe0e7f3575b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e8fb4886-5072-43e7-a2b0-1509b984fba8" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_282ecf5d-a7ec-4018-b227-dbe0e7f3575b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_03f36ba7-e0e4-469e-8b48-96a0165640a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e8fb4886-5072-43e7-a2b0-1509b984fba8" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_03f36ba7-e0e4-469e-8b48-96a0165640a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1d1f6dd7-1c01-4ec2-853e-8fb0de104571" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_857437e5-a791-4f93-8788-ed11db1ac892" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1d1f6dd7-1c01-4ec2-853e-8fb0de104571" xlink:to="loc_us-gaap_PreferredStockValue_857437e5-a791-4f93-8788-ed11db1ac892" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_7db561f6-589f-4fdf-9b06-af98e5eba7ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1d1f6dd7-1c01-4ec2-853e-8fb0de104571" xlink:to="loc_us-gaap_CommonStockValue_7db561f6-589f-4fdf-9b06-af98e5eba7ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_7770e613-4847-4b66-9c44-e0edd4a5067b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1d1f6dd7-1c01-4ec2-853e-8fb0de104571" xlink:to="loc_us-gaap_AdditionalPaidInCapital_7770e613-4847-4b66-9c44-e0edd4a5067b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b3e64bdd-5f8e-4ba4-a56a-114a6e8cbadb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1d1f6dd7-1c01-4ec2-853e-8fb0de104571" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b3e64bdd-5f8e-4ba4-a56a-114a6e8cbadb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_88d40108-2bc2-4225-977c-978837b747cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1d1f6dd7-1c01-4ec2-853e-8fb0de104571" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_88d40108-2bc2-4225-977c-978837b747cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_babfd4d1-cac4-49da-9b74-491a7323b589" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_396223e0-4f9c-4f78-8106-5ae4ad99cce9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_babfd4d1-cac4-49da-9b74-491a7323b589" xlink:to="loc_us-gaap_AccountsPayableCurrent_396223e0-4f9c-4f78-8106-5ae4ad99cce9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1b319d0d-9817-495f-ab69-1ac4fd30a190" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_babfd4d1-cac4-49da-9b74-491a7323b589" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1b319d0d-9817-495f-ab69-1ac4fd30a190" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_564d3732-8608-425b-b142-393d45778e2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_babfd4d1-cac4-49da-9b74-491a7323b589" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_564d3732-8608-425b-b142-393d45778e2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_3bca0ae2-f9b0-4646-802d-42c35ee918c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_babfd4d1-cac4-49da-9b74-491a7323b589" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_3bca0ae2-f9b0-4646-802d-42c35ee918c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_a6abccfe-e4cc-4947-b81f-dcc592d5a3ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_1141116d-3e6b-48f5-bc63-b64625460652" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a6abccfe-e4cc-4947-b81f-dcc592d5a3ed" xlink:to="loc_us-gaap_Liabilities_1141116d-3e6b-48f5-bc63-b64625460652" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_21089890-429f-436e-81a1-6d7f8c6b823c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a6abccfe-e4cc-4947-b81f-dcc592d5a3ed" xlink:to="loc_us-gaap_CommitmentsAndContingencies_21089890-429f-436e-81a1-6d7f8c6b823c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4d8e3310-3965-4fc2-99f3-f2ca19d7b739" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a6abccfe-e4cc-4947-b81f-dcc592d5a3ed" xlink:to="loc_us-gaap_StockholdersEquity_4d8e3310-3965-4fc2-99f3-f2ca19d7b739" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="mrna-20210331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="mrna-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_15286db8-8006-4a1f-8d8c-17d28afef0e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_2ccf15a3-3b51-4d19-9112-acecf6040ae8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_15286db8-8006-4a1f-8d8c-17d28afef0e7" xlink:to="loc_us-gaap_Revenues_2ccf15a3-3b51-4d19-9112-acecf6040ae8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_8f4af330-3d55-49e9-9504-53df14b2bc01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_15286db8-8006-4a1f-8d8c-17d28afef0e7" xlink:to="loc_us-gaap_CostsAndExpenses_8f4af330-3d55-49e9-9504-53df14b2bc01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_cdcfb56c-25f8-4bca-9fa0-23e97ff73297" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c2b5b651-3d15-4ec6-953b-1917484690bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_cdcfb56c-25f8-4bca-9fa0-23e97ff73297" xlink:to="loc_us-gaap_OperatingIncomeLoss_c2b5b651-3d15-4ec6-953b-1917484690bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_cebab78e-a449-4aa0-a35b-5ee21378d831" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_cdcfb56c-25f8-4bca-9fa0-23e97ff73297" xlink:to="loc_us-gaap_InvestmentIncomeInterest_cebab78e-a449-4aa0-a35b-5ee21378d831" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_f7ac2b65-206c-4210-a3f9-1d65ac63f811" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_cdcfb56c-25f8-4bca-9fa0-23e97ff73297" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_f7ac2b65-206c-4210-a3f9-1d65ac63f811" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_eed16b1f-7860-4de7-813c-09b8302af9e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_c5a59140-3c87-4077-b45b-5ce15a5add4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_eed16b1f-7860-4de7-813c-09b8302af9e1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_c5a59140-3c87-4077-b45b-5ce15a5add4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_216e6339-6e1d-4659-aa0c-08bed47a84ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_eed16b1f-7860-4de7-813c-09b8302af9e1" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_216e6339-6e1d-4659-aa0c-08bed47a84ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_4946aea0-93d8-48f4-97a4-4e8e4d52384d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_eed16b1f-7860-4de7-813c-09b8302af9e1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_4946aea0-93d8-48f4-97a4-4e8e4d52384d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_11324c41-a28b-4ad7-81e7-7f27d0ddbd8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_177af469-2f57-4997-87c8-1b037b12fb9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_11324c41-a28b-4ad7-81e7-7f27d0ddbd8f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_177af469-2f57-4997-87c8-1b037b12fb9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ead4794c-3323-48a6-80be-449781618505" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_11324c41-a28b-4ad7-81e7-7f27d0ddbd8f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ead4794c-3323-48a6-80be-449781618505" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="mrna-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_0fb2e945-c459-475b-970c-12e2bd8f089f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4f4a8ed6-b2df-4b48-8ef7-4d8713b6f4a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_0fb2e945-c459-475b-970c-12e2bd8f089f" xlink:to="loc_us-gaap_NetIncomeLoss_4f4a8ed6-b2df-4b48-8ef7-4d8713b6f4a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5cf62d29-4f88-4fd8-9a4a-8dd4074b1839" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_0fb2e945-c459-475b-970c-12e2bd8f089f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5cf62d29-4f88-4fd8-9a4a-8dd4074b1839" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical" xlink:type="simple" xlink:href="mrna-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="mrna-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="simple" xlink:href="mrna-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="mrna-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b45e90f2-5c3f-42f1-9970-02efe8390fb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_ef7749d2-3c8e-4519-ba18-2f2189ddb1fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b45e90f2-5c3f-42f1-9970-02efe8390fb8" xlink:to="loc_us-gaap_ProceedsFromStockPlans_ef7749d2-3c8e-4519-ba18-2f2189ddb1fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChargesToFinancingLeaseLiabilities_d5ad0497-aa91-4934-b727-126129b2e6cc" xlink:href="mrna-20210331.xsd#mrna_ChargesToFinancingLeaseLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b45e90f2-5c3f-42f1-9970-02efe8390fb8" xlink:to="loc_mrna_ChargesToFinancingLeaseLiabilities_d5ad0497-aa91-4934-b727-126129b2e6cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_98480eb8-6e25-43bb-93e4-77d58b063be5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b45e90f2-5c3f-42f1-9970-02efe8390fb8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_98480eb8-6e25-43bb-93e4-77d58b063be5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_08bbc006-c774-4d13-8727-d41b9f4c521e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_869b44ac-1ec9-4dd7-a018-adbd55d1a57c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_08bbc006-c774-4d13-8727-d41b9f4c521e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_869b44ac-1ec9-4dd7-a018-adbd55d1a57c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_df18a65b-a4dc-4753-b66a-69edf3cf94c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_08bbc006-c774-4d13-8727-d41b9f4c521e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_df18a65b-a4dc-4753-b66a-69edf3cf94c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fb02cd51-39d2-451b-86d9-9987e54e25ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_08bbc006-c774-4d13-8727-d41b9f4c521e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fb02cd51-39d2-451b-86d9-9987e54e25ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_250eac17-0528-4561-a06e-7e975223e070" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases_29a9e551-81b4-44fd-baf3-c40a8963dde4" xlink:href="mrna-20210331.xsd#mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_250eac17-0528-4561-a06e-7e975223e070" xlink:to="loc_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases_29a9e551-81b4-44fd-baf3-c40a8963dde4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_79bac834-8eea-44c6-9c60-664e53db83c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_250eac17-0528-4561-a06e-7e975223e070" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_79bac834-8eea-44c6-9c60-664e53db83c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_f89e5b1a-7527-462c-9cb7-d3aa5d2986ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_250eac17-0528-4561-a06e-7e975223e070" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_f89e5b1a-7527-462c-9cb7-d3aa5d2986ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_80c34c3a-728b-43e5-aded-ce01999e5b3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_250eac17-0528-4561-a06e-7e975223e070" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_80c34c3a-728b-43e5-aded-ce01999e5b3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingLeaseLiabilities_ee417238-5903-4af9-aaab-c61f3ebd59d2" xlink:href="mrna-20210331.xsd#mrna_OperatingLeaseLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_250eac17-0528-4561-a06e-7e975223e070" xlink:to="loc_mrna_OperatingLeaseLiabilities_ee417238-5903-4af9-aaab-c61f3ebd59d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b8014fa9-271d-4bf3-8ca7-cd8e5c21d2cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_250eac17-0528-4561-a06e-7e975223e070" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b8014fa9-271d-4bf3-8ca7-cd8e5c21d2cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_0e0fcae2-b5f6-4814-871e-186f2ee8c7bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_250eac17-0528-4561-a06e-7e975223e070" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_0e0fcae2-b5f6-4814-871e-186f2ee8c7bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_95767032-d3d4-49e7-8d48-47044df754c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_250eac17-0528-4561-a06e-7e975223e070" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_95767032-d3d4-49e7-8d48-47044df754c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_07ab148d-d94e-4a7b-9a6d-8d2427221dd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_250eac17-0528-4561-a06e-7e975223e070" xlink:to="loc_us-gaap_ShareBasedCompensation_07ab148d-d94e-4a7b-9a6d-8d2427221dd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_691a5091-8499-40c5-a226-e9da1de681a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_250eac17-0528-4561-a06e-7e975223e070" xlink:to="loc_us-gaap_NetIncomeLoss_691a5091-8499-40c5-a226-e9da1de681a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_8792abf2-4a65-44d7-9638-9ec13aeb5c44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_250eac17-0528-4561-a06e-7e975223e070" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_8792abf2-4a65-44d7-9638-9ec13aeb5c44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_16d101f6-d907-48f1-a18b-f17227354746" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_250eac17-0528-4561-a06e-7e975223e070" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_16d101f6-d907-48f1-a18b-f17227354746" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_992a79d7-478c-4024-88c5-bd975767a5f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_250eac17-0528-4561-a06e-7e975223e070" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_992a79d7-478c-4024-88c5-bd975767a5f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ce74423e-9ce5-4d02-a99d-3ac6a909789e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_250eac17-0528-4561-a06e-7e975223e070" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ce74423e-9ce5-4d02-a99d-3ac6a909789e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a2903190-1999-44f0-b02c-02b880308307" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_596919f1-420c-44a2-948b-3615c008a68a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a2903190-1999-44f0-b02c-02b880308307" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_596919f1-420c-44a2-948b-3615c008a68a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_38b6c8e7-5949-4599-95fa-a5c68a6f6dfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a2903190-1999-44f0-b02c-02b880308307" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_38b6c8e7-5949-4599-95fa-a5c68a6f6dfb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_e1f9d5ce-7d10-4722-ae0e-6d387b13f4b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a2903190-1999-44f0-b02c-02b880308307" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_e1f9d5ce-7d10-4722-ae0e-6d387b13f4b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b5334455-7ac3-46e9-9f3c-1b9d554890ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a2903190-1999-44f0-b02c-02b880308307" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b5334455-7ac3-46e9-9f3c-1b9d554890ad" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/DescriptionoftheBusiness" xlink:type="simple" xlink:href="mrna-20210331.xsd#DescriptionoftheBusiness"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/DescriptionoftheBusiness" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/DescriptionoftheBusinessAdditionalInformationDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#DescriptionoftheBusinessAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/DescriptionoftheBusinessAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandards" xlink:type="simple" xlink:href="mrna-20210331.xsd#SummaryofBasisofPresentationandRecentAccountingStandards"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandards" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsPolicies" xlink:type="simple" xlink:href="mrna-20210331.xsd#SummaryofBasisofPresentationandRecentAccountingStandardsPolicies"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsTables" xlink:type="simple" xlink:href="mrna-20210331.xsd#SummaryofBasisofPresentationandRecentAccountingStandardsTables"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsComponentsofAccumulatedOtherComprehensivelossIncomeDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#SummaryofBasisofPresentationandRecentAccountingStandardsComponentsofAccumulatedOtherComprehensivelossIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsComponentsofAccumulatedOtherComprehensivelossIncomeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#SummaryofBasisofPresentationandRecentAccountingStandardsReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ecfc67d7-f03a-426f-abbe-bc9de1eb7e14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_eb971f69-c60f-43c1-a258-75ffa4b9f1c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ecfc67d7-f03a-426f-abbe-bc9de1eb7e14" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_eb971f69-c60f-43c1-a258-75ffa4b9f1c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_e8ccbd65-8ce0-4aa9-bf4d-7d32bb991613" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ecfc67d7-f03a-426f-abbe-bc9de1eb7e14" xlink:to="loc_us-gaap_RestrictedCashCurrent_e8ccbd65-8ce0-4aa9-bf4d-7d32bb991613" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_d9f3e401-1234-4930-a4e6-a1e14a98621c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ecfc67d7-f03a-426f-abbe-bc9de1eb7e14" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_d9f3e401-1234-4930-a4e6-a1e14a98621c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/ProductSales" xlink:type="simple" xlink:href="mrna-20210331.xsd#ProductSales"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/ProductSales" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/ProductSalesTables" xlink:type="simple" xlink:href="mrna-20210331.xsd#ProductSalesTables"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/ProductSalesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/ProductSalesDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#ProductSalesDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/ProductSalesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/GrantRevenue" xlink:type="simple" xlink:href="mrna-20210331.xsd#GrantRevenue"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/GrantRevenue" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/GrantRevenueTables" xlink:type="simple" xlink:href="mrna-20210331.xsd#GrantRevenueTables"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/GrantRevenueTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/GrantRevenueDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#GrantRevenueDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/GrantRevenueDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationRevenue" xlink:type="simple" xlink:href="mrna-20210331.xsd#CollaborationRevenue"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/CollaborationRevenue" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationRevenueTables" xlink:type="simple" xlink:href="mrna-20210331.xsd#CollaborationRevenueTables"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/CollaborationRevenueTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationRevenueSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#CollaborationRevenueSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/CollaborationRevenueSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationRevenueChangesinBalancesofReceivablesandContractLiabilitiesDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#CollaborationRevenueChangesinBalancesofReceivablesandContractLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/CollaborationRevenueChangesinBalancesofReceivablesandContractLiabilitiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstruments" xlink:type="simple" xlink:href="mrna-20210331.xsd#FinancialInstruments"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/FinancialInstruments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="mrna-20210331.xsd#FinancialInstrumentsTables"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6e15d5e3-cc2d-4c19-9d06-a2bd32529fd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_00292f79-61d2-4d1f-addd-e14a75ca2f90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6e15d5e3-cc2d-4c19-9d06-a2bd32529fd7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_00292f79-61d2-4d1f-addd-e14a75ca2f90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_13596268-c42a-4af7-a892-c1ff698bed47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6e15d5e3-cc2d-4c19-9d06-a2bd32529fd7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_13596268-c42a-4af7-a892-c1ff698bed47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e2ec911b-2a2b-4759-a72d-f7bf954b18ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6e15d5e3-cc2d-4c19-9d06-a2bd32529fd7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e2ec911b-2a2b-4759-a72d-f7bf954b18ba" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#FinancialInstrumentsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1e6fcdd1-4e50-41ec-bb0f-a0724c3d71c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_86aab2e9-4280-4b4e-b311-944df8e6a335" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1e6fcdd1-4e50-41ec-bb0f-a0724c3d71c9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_86aab2e9-4280-4b4e-b311-944df8e6a335" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_af0e8972-95e6-4682-857e-f56e6926819d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1e6fcdd1-4e50-41ec-bb0f-a0724c3d71c9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_af0e8972-95e6-4682-857e-f56e6926819d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_51515c62-b750-408e-88af-736e3295c758" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_94c6cb95-d79d-4831-9d5f-532acf2571f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_51515c62-b750-408e-88af-736e3295c758" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_94c6cb95-d79d-4831-9d5f-532acf2571f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_9a53c0f8-0150-4047-8310-c00c06c3c623" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_51515c62-b750-408e-88af-736e3295c758" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_9a53c0f8-0150-4047-8310-c00c06c3c623" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_5ca75ae8-5fec-4b35-a06e-32a564d34333" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ccef73de-103c-4e14-b89a-7f6784bf1a2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_5ca75ae8-5fec-4b35-a06e-32a564d34333" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ccef73de-103c-4e14-b89a-7f6784bf1a2c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/DerivativeFinancialInstruments" xlink:type="simple" xlink:href="mrna-20210331.xsd#DerivativeFinancialInstruments"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/DerivativeFinancialInstruments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/DerivativeFinancialInstrumentsTables" xlink:type="simple" xlink:href="mrna-20210331.xsd#DerivativeFinancialInstrumentsTables"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/DerivativeFinancialInstrumentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#DerivativeFinancialInstrumentsBalanceSheetHedgesDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/Inventory" xlink:type="simple" xlink:href="mrna-20210331.xsd#Inventory"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/Inventory" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/InventoryTables" xlink:type="simple" xlink:href="mrna-20210331.xsd#InventoryTables"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/InventoryTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/InventoryDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#InventoryDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_96ae7037-d5d1-40c1-a764-9c5745c711c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_d5aa953d-3ede-4a4f-800c-07fd15319fbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_96ae7037-d5d1-40c1-a764-9c5745c711c5" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_d5aa953d-3ede-4a4f-800c-07fd15319fbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_32fbf5c9-9519-40d7-9542-321174821244" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_96ae7037-d5d1-40c1-a764-9c5745c711c5" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_32fbf5c9-9519-40d7-9542-321174821244" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_dd6a3d69-b61c-46c5-8727-c67f3fc2fb0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_96ae7037-d5d1-40c1-a764-9c5745c711c5" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_dd6a3d69-b61c-46c5-8727-c67f3fc2fb0f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/PropertyandEquipmentNet" xlink:type="simple" xlink:href="mrna-20210331.xsd#PropertyandEquipmentNet"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/PropertyandEquipmentNet" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/PropertyandEquipmentNetTables" xlink:type="simple" xlink:href="mrna-20210331.xsd#PropertyandEquipmentNetTables"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/PropertyandEquipmentNetTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#PropertyandEquipmentNetDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/PropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_3352eb74-c917-429d-bab2-d11c578fac04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_4aa02249-3914-4086-a9d0-0572e628c5f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_3352eb74-c917-429d-bab2-d11c578fac04" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_4aa02249-3914-4086-a9d0-0572e628c5f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_72233082-cdab-435e-8951-bac1feb6197c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_3352eb74-c917-429d-bab2-d11c578fac04" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_72233082-cdab-435e-8951-bac1feb6197c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponents" xlink:type="simple" xlink:href="mrna-20210331.xsd#OtherBalanceSheetComponents"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/OtherBalanceSheetComponents" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsTables" xlink:type="simple" xlink:href="mrna-20210331.xsd#OtherBalanceSheetComponentsTables"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/OtherBalanceSheetComponentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_54424c0f-86c2-4b89-b668-4bd7cdc6a5f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_1aa04ac8-f784-4d0a-bd6c-bd44aaeb2e6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_54424c0f-86c2-4b89-b668-4bd7cdc6a5f3" xlink:to="loc_us-gaap_InterestReceivableCurrent_1aa04ac8-f784-4d0a-bd6c-bd44aaeb2e6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_TenantIncentivesReceivablesCurrent_1aa2f0ee-ee37-4b6c-85c6-dacc848f004b" xlink:href="mrna-20210331.xsd#mrna_TenantIncentivesReceivablesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_54424c0f-86c2-4b89-b668-4bd7cdc6a5f3" xlink:to="loc_mrna_TenantIncentivesReceivablesCurrent_1aa2f0ee-ee37-4b6c-85c6-dacc848f004b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OtherPrepaidExpenseManufacturing_614ccfb7-bb1a-427f-a690-30d1d03eb0f5" xlink:href="mrna-20210331.xsd#mrna_OtherPrepaidExpenseManufacturing"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_54424c0f-86c2-4b89-b668-4bd7cdc6a5f3" xlink:to="loc_mrna_OtherPrepaidExpenseManufacturing_614ccfb7-bb1a-427f-a690-30d1d03eb0f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_a672a020-0a02-4289-9d7a-5d094a43f406" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_54424c0f-86c2-4b89-b668-4bd7cdc6a5f3" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_a672a020-0a02-4289-9d7a-5d094a43f406" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#OtherBalanceSheetComponentsAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8d6bc3bd-5dd2-4ee4-9f04-6ecef8ea96cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedClinicalTrials_30acbb16-c76d-4302-8e4f-1363a457ecf5" xlink:href="mrna-20210331.xsd#mrna_AccruedClinicalTrials"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8d6bc3bd-5dd2-4ee4-9f04-6ecef8ea96cc" xlink:to="loc_mrna_AccruedClinicalTrials_30acbb16-c76d-4302-8e4f-1363a457ecf5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedOtherExternalGoodsAndServicesCurrent_3021f8c2-7f3f-4517-a959-b6c21b4f12af" xlink:href="mrna-20210331.xsd#mrna_AccruedOtherExternalGoodsAndServicesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8d6bc3bd-5dd2-4ee4-9f04-6ecef8ea96cc" xlink:to="loc_mrna_AccruedOtherExternalGoodsAndServicesCurrent_3021f8c2-7f3f-4517-a959-b6c21b4f12af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_57f3c03f-d109-454b-9b38-3f511bdee193" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8d6bc3bd-5dd2-4ee4-9f04-6ecef8ea96cc" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_57f3c03f-d109-454b-9b38-3f511bdee193" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_Commercial_43b09027-21cf-4fd9-9765-6a50df66ebf0" xlink:href="mrna-20210331.xsd#mrna_Commercial"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8d6bc3bd-5dd2-4ee4-9f04-6ecef8ea96cc" xlink:to="loc_mrna_Commercial_43b09027-21cf-4fd9-9765-6a50df66ebf0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RawMaterialsAccountsPayable_623e8900-cd6f-485f-b625-841e35a58ec9" xlink:href="mrna-20210331.xsd#mrna_RawMaterialsAccountsPayable"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8d6bc3bd-5dd2-4ee4-9f04-6ecef8ea96cc" xlink:to="loc_mrna_RawMaterialsAccountsPayable_623e8900-cd6f-485f-b625-841e35a58ec9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedManufacturing_75348484-5c61-4c7f-a5cb-23916a97ecc6" xlink:href="mrna-20210331.xsd#mrna_AccruedManufacturing"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8d6bc3bd-5dd2-4ee4-9f04-6ecef8ea96cc" xlink:to="loc_mrna_AccruedManufacturing_75348484-5c61-4c7f-a5cb-23916a97ecc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_921062f3-e0a4-480f-a7f9-b62ef5dc7074" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8d6bc3bd-5dd2-4ee4-9f04-6ecef8ea96cc" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_921062f3-e0a4-480f-a7f9-b62ef5dc7074" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedPropertyAndEquipmentCurrent_6c75615d-6334-48af-91dd-e444977d662c" xlink:href="mrna-20210331.xsd#mrna_AccruedPropertyAndEquipmentCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8d6bc3bd-5dd2-4ee4-9f04-6ecef8ea96cc" xlink:to="loc_mrna_AccruedPropertyAndEquipmentCurrent_6c75615d-6334-48af-91dd-e444977d662c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedDevelopmentOperation_dc2f8d6f-2453-4c8c-8f06-7ccf08eeb26e" xlink:href="mrna-20210331.xsd#mrna_AccruedDevelopmentOperation"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8d6bc3bd-5dd2-4ee4-9f04-6ecef8ea96cc" xlink:to="loc_mrna_AccruedDevelopmentOperation_dc2f8d6f-2453-4c8c-8f06-7ccf08eeb26e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#OtherBalanceSheetComponentsDeferredRevenueDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/Leases" xlink:type="simple" xlink:href="mrna-20210331.xsd#Leases"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/Leases" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesTables" xlink:type="simple" xlink:href="mrna-20210331.xsd#LeasesTables"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/LeasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#LeasesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/LeasesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#LeasesBalanceSheetInformationDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseLiabilityCurrent_fc336e52-34d0-4167-b525-9b6e080ce519" xlink:href="mrna-20210331.xsd#mrna_OperatingAndFinanceLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_58bcef95-1eda-40dd-bdb3-8761217e8922" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrna_OperatingAndFinanceLeaseLiabilityCurrent_fc336e52-34d0-4167-b525-9b6e080ce519" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_58bcef95-1eda-40dd-bdb3-8761217e8922" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_843c9d81-3f51-4e9b-bb15-f28b7ecad5a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrna_OperatingAndFinanceLeaseLiabilityCurrent_fc336e52-34d0-4167-b525-9b6e080ce519" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_843c9d81-3f51-4e9b-bb15-f28b7ecad5a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseRightOfUseAsset_8b9a58e0-6d18-4611-9cbc-cf17815300f1" xlink:href="mrna-20210331.xsd#mrna_OperatingAndFinanceLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ed0a707f-9d78-4d6e-b69d-10dc58cfd324" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrna_OperatingAndFinanceLeaseRightOfUseAsset_8b9a58e0-6d18-4611-9cbc-cf17815300f1" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ed0a707f-9d78-4d6e-b69d-10dc58cfd324" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_1a8b4d6f-e452-41a9-9217-85b558d6d167" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrna_OperatingAndFinanceLeaseRightOfUseAsset_8b9a58e0-6d18-4611-9cbc-cf17815300f1" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_1a8b4d6f-e452-41a9-9217-85b558d6d167" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseLiability_352b3ec4-4b7c-4846-a5c8-a3e261df925d" xlink:href="mrna-20210331.xsd#mrna_OperatingAndFinanceLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_902cd55a-e650-4080-b04f-af71c0312485" xlink:href="mrna-20210331.xsd#mrna_OperatingAndFinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrna_OperatingAndFinanceLeaseLiability_352b3ec4-4b7c-4846-a5c8-a3e261df925d" xlink:to="loc_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_902cd55a-e650-4080-b04f-af71c0312485" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseLiabilityCurrent_fb8f3204-15d9-4807-b521-d5a6da3a3144" xlink:href="mrna-20210331.xsd#mrna_OperatingAndFinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrna_OperatingAndFinanceLeaseLiability_352b3ec4-4b7c-4846-a5c8-a3e261df925d" xlink:to="loc_mrna_OperatingAndFinanceLeaseLiabilityCurrent_fb8f3204-15d9-4807-b521-d5a6da3a3144" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_08751322-bbe4-4f01-978e-e0e8f5fc8155" xlink:href="mrna-20210331.xsd#mrna_OperatingAndFinanceLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_43779001-27c5-4227-9cb9-1d52bbfcaa61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_08751322-bbe4-4f01-978e-e0e8f5fc8155" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_43779001-27c5-4227-9cb9-1d52bbfcaa61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_a35e11d8-a6fc-4913-bf15-1e8004b1e124" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_08751322-bbe4-4f01-978e-e0e8f5fc8155" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_a35e11d8-a6fc-4913-bf15-1e8004b1e124" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#LeasesMinimumLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_60d14907-0d2b-4000-b2cd-26055859f65b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_29a5e713-8fe1-4175-a889-5141a305209f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_60d14907-0d2b-4000-b2cd-26055859f65b" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_29a5e713-8fe1-4175-a889-5141a305209f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_158986aa-dae4-4b74-b1a8-f5a3052e1c24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_60d14907-0d2b-4000-b2cd-26055859f65b" xlink:to="loc_us-gaap_FinanceLeaseLiability_158986aa-dae4-4b74-b1a8-f5a3052e1c24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b750d06e-9fb9-41c2-b146-e0dd6928da3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_d4cccfde-336e-4d3b-8be4-d9ebf89bd466" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b750d06e-9fb9-41c2-b146-e0dd6928da3d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_d4cccfde-336e-4d3b-8be4-d9ebf89bd466" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0ba8648a-bb66-497d-8687-24a7d4ed191c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b750d06e-9fb9-41c2-b146-e0dd6928da3d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0ba8648a-bb66-497d-8687-24a7d4ed191c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_871a3684-310f-42af-a5d7-4ac4d7c294d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b750d06e-9fb9-41c2-b146-e0dd6928da3d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_871a3684-310f-42af-a5d7-4ac4d7c294d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_4456ac6f-7477-4e88-b3cd-c3a18c9d6c84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b750d06e-9fb9-41c2-b146-e0dd6928da3d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_4456ac6f-7477-4e88-b3cd-c3a18c9d6c84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_673e4d4a-4a4b-4771-9f62-c694a9ddcb0a" xlink:href="mrna-20210331.xsd#mrna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b750d06e-9fb9-41c2-b146-e0dd6928da3d" xlink:to="loc_mrna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_673e4d4a-4a4b-4771-9f62-c694a9ddcb0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_60de303e-f07b-481e-b5b7-4622afa1276b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b750d06e-9fb9-41c2-b146-e0dd6928da3d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_60de303e-f07b-481e-b5b7-4622afa1276b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="mrna-20210331.xsd#LeasesMinimumLeasePaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_6a323fe1-4aac-41d2-bd07-f81e9f783cfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_1069e7be-d161-43cb-a3d7-c5c3c5186e3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_6a323fe1-4aac-41d2-bd07-f81e9f783cfd" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_1069e7be-d161-43cb-a3d7-c5c3c5186e3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_f2b3c230-0ab5-446b-b080-86782564fb73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_6a323fe1-4aac-41d2-bd07-f81e9f783cfd" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_f2b3c230-0ab5-446b-b080-86782564fb73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_ba25ee65-7220-4cc9-8bd6-3ac02ffecdcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_6a323fe1-4aac-41d2-bd07-f81e9f783cfd" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_ba25ee65-7220-4cc9-8bd6-3ac02ffecdcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_aefb4073-5efa-4a57-b1b1-c0719e602385" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_6a323fe1-4aac-41d2-bd07-f81e9f783cfd" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_aefb4073-5efa-4a57-b1b1-c0719e602385" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_FinanceLeaseLiabilityToBePaidAfterYearFour_eea15e6a-94dd-4fec-88f3-a7bdaa5ac0e2" xlink:href="mrna-20210331.xsd#mrna_FinanceLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_6a323fe1-4aac-41d2-bd07-f81e9f783cfd" xlink:to="loc_mrna_FinanceLeaseLiabilityToBePaidAfterYearFour_eea15e6a-94dd-4fec-88f3-a7bdaa5ac0e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_8fce225f-0ffd-4ac1-abb1-d1dfbd71b094" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_6a323fe1-4aac-41d2-bd07-f81e9f783cfd" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_8fce225f-0ffd-4ac1-abb1-d1dfbd71b094" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_70ba3b40-aab0-4a05-be0b-5c8cb70ce30f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4e6ec2f5-94fa-48ef-a867-15581fbcc2d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_70ba3b40-aab0-4a05-be0b-5c8cb70ce30f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4e6ec2f5-94fa-48ef-a867-15581fbcc2d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_67089195-3249-496e-9206-3a5ecb61cde8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_70ba3b40-aab0-4a05-be0b-5c8cb70ce30f" xlink:to="loc_us-gaap_OperatingLeaseLiability_67089195-3249-496e-9206-3a5ecb61cde8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="mrna-20210331.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/CommitmentsandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/CommitmentsandContingenciesStrategicCollaborationsDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#CommitmentsandContingenciesStrategicCollaborationsDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/CommitmentsandContingenciesStrategicCollaborationsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#CommitmentsandContingenciesLicensestoPatentedTechnologyDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="mrna-20210331.xsd#StockBasedCompensation"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/StockBasedCompensation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="mrna-20210331.xsd#StockBasedCompensationTables"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#StockBasedCompensationOptionsActivityDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/IncomeTaxes" xlink:type="simple" xlink:href="mrna-20210331.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#IncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/IncomeTaxesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/EarningsperShare" xlink:type="simple" xlink:href="mrna-20210331.xsd#EarningsperShare"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/EarningsperShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/EarningsperShareTables" xlink:type="simple" xlink:href="mrna-20210331.xsd#EarningsperShareTables"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/EarningsperShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/EarningsperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#EarningsperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/EarningsperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_61fc64b5-ac83-49b0-9296-1ead3bbd6fb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7c89cf8d-db9b-490d-9b71-536628655b68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_61fc64b5-ac83-49b0-9296-1ead3bbd6fb5" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7c89cf8d-db9b-490d-9b71-536628655b68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_07d7aebc-347e-4e71-a867-99cc39e87e18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_61fc64b5-ac83-49b0-9296-1ead3bbd6fb5" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_07d7aebc-347e-4e71-a867-99cc39e87e18" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/EarningsperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#EarningsperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/EarningsperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/SubsequentEvents" xlink:type="simple" xlink:href="mrna-20210331.xsd#SubsequentEvents"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/SubsequentEvents" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#SubsequentEventsDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/SubsequentEventsDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>mrna-20210331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:0cbcbb00-411e-4aec-bde6-af04ca2907e0,g:4456e2fc-6666-4731-b603-d80176d3b13f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/CoverPage" xlink:type="simple" xlink:href="mrna-20210331.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CoverPage" xlink:type="extended" id="i2299a90303fd48a39db2139f978f81c3_CoverPage"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="mrna-20210331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended" id="if6f417a7ff9e4df1ab843e7dd354885d_CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="mrna-20210331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended" id="icfce8c9bf58e42448f5f786c39896809_CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="mrna-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended" id="i92707ed3a23c4900a2ad736914f4dd76_CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0a75ec5a-6776-4ebb-a164-6071029cb5f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_f9b0eb42-12b2-44c9-a9a8-592c1628a1e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0a75ec5a-6776-4ebb-a164-6071029cb5f1" xlink:to="loc_us-gaap_RevenuesAbstract_f9b0eb42-12b2-44c9-a9a8-592c1628a1e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_38420e22-53df-4b06-bcc3-644a9d46ed8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_f9b0eb42-12b2-44c9-a9a8-592c1628a1e0" xlink:to="loc_us-gaap_Revenues_38420e22-53df-4b06-bcc3-644a9d46ed8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_dc76d863-1de4-4c86-8e4e-b6d618861561" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0a75ec5a-6776-4ebb-a164-6071029cb5f1" xlink:to="loc_us-gaap_OperatingExpensesAbstract_dc76d863-1de4-4c86-8e4e-b6d618861561" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_aff30ca9-792d-402d-a340-0ae152a6fa04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_dc76d863-1de4-4c86-8e4e-b6d618861561" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_aff30ca9-792d-402d-a340-0ae152a6fa04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b6c3bc1c-568d-471d-9c10-3a40642e19a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_dc76d863-1de4-4c86-8e4e-b6d618861561" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b6c3bc1c-568d-471d-9c10-3a40642e19a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_90e6b576-8329-4797-980b-8ea6f519484e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_dc76d863-1de4-4c86-8e4e-b6d618861561" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_90e6b576-8329-4797-980b-8ea6f519484e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_074411f0-3384-451c-95b7-83c37825d731" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_dc76d863-1de4-4c86-8e4e-b6d618861561" xlink:to="loc_us-gaap_CostsAndExpenses_074411f0-3384-451c-95b7-83c37825d731" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c395af5d-3c2f-4660-b28f-43012ea3f969" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0a75ec5a-6776-4ebb-a164-6071029cb5f1" xlink:to="loc_us-gaap_OperatingIncomeLoss_c395af5d-3c2f-4660-b28f-43012ea3f969" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_787c411c-2cfc-4666-a45e-739ce49364d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0a75ec5a-6776-4ebb-a164-6071029cb5f1" xlink:to="loc_us-gaap_InvestmentIncomeInterest_787c411c-2cfc-4666-a45e-739ce49364d6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_4562ef4a-3f18-4d60-bccc-ef1f77b75c79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0a75ec5a-6776-4ebb-a164-6071029cb5f1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_4562ef4a-3f18-4d60-bccc-ef1f77b75c79" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_8fda757f-d4ca-4147-94a1-2a0813c493ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0a75ec5a-6776-4ebb-a164-6071029cb5f1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_8fda757f-d4ca-4147-94a1-2a0813c493ad" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_7945b75f-f031-41ea-91aa-82a3557e3498" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0a75ec5a-6776-4ebb-a164-6071029cb5f1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_7945b75f-f031-41ea-91aa-82a3557e3498" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a0466764-e9ed-4d86-b265-abf20eaca84f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0a75ec5a-6776-4ebb-a164-6071029cb5f1" xlink:to="loc_us-gaap_NetIncomeLoss_a0466764-e9ed-4d86-b265-abf20eaca84f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_00eb4446-8037-4afc-89df-4bf30c2578e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0a75ec5a-6776-4ebb-a164-6071029cb5f1" xlink:to="loc_us-gaap_EarningsPerShareAbstract_00eb4446-8037-4afc-89df-4bf30c2578e0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_bc8a5f8e-92ed-49db-9399-0a9b952ffef9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_00eb4446-8037-4afc-89df-4bf30c2578e0" xlink:to="loc_us-gaap_EarningsPerShareBasic_bc8a5f8e-92ed-49db-9399-0a9b952ffef9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_c91e2919-374a-4aa1-b411-d42bbf437218" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_00eb4446-8037-4afc-89df-4bf30c2578e0" xlink:to="loc_us-gaap_EarningsPerShareDiluted_c91e2919-374a-4aa1-b411-d42bbf437218" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_4757d66b-4ffd-4764-9d61-4ad6cdb26241" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0a75ec5a-6776-4ebb-a164-6071029cb5f1" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_4757d66b-4ffd-4764-9d61-4ad6cdb26241" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1a5046bd-d4dd-41a9-857f-664c1f20a175" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_4757d66b-4ffd-4764-9d61-4ad6cdb26241" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1a5046bd-d4dd-41a9-857f-664c1f20a175" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fc807b66-5da5-42f6-a6c7-ba6e9de095ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_4757d66b-4ffd-4764-9d61-4ad6cdb26241" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fc807b66-5da5-42f6-a6c7-ba6e9de095ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0b3c0729-4efe-45a6-94dd-4ce167b0b042" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0a75ec5a-6776-4ebb-a164-6071029cb5f1" xlink:to="loc_us-gaap_StatementTable_0b3c0729-4efe-45a6-94dd-4ce167b0b042" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ee7e7ef8-12ec-47d6-a40d-2c647877726d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0b3c0729-4efe-45a6-94dd-4ce167b0b042" xlink:to="loc_srt_ProductOrServiceAxis_ee7e7ef8-12ec-47d6-a40d-2c647877726d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ee7e7ef8-12ec-47d6-a40d-2c647877726d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ee7e7ef8-12ec-47d6-a40d-2c647877726d" xlink:to="loc_srt_ProductsAndServicesDomain_ee7e7ef8-12ec-47d6-a40d-2c647877726d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_70ce0cf4-bfb4-40ff-b33f-0b1649be8ebd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ee7e7ef8-12ec-47d6-a40d-2c647877726d" xlink:to="loc_srt_ProductsAndServicesDomain_70ce0cf4-bfb4-40ff-b33f-0b1649be8ebd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ProductSalesMember_3514c630-c9a0-4d57-a826-c4a7984b6bd5" xlink:href="mrna-20210331.xsd#mrna_ProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_70ce0cf4-bfb4-40ff-b33f-0b1649be8ebd" xlink:to="loc_mrna_ProductSalesMember_3514c630-c9a0-4d57-a826-c4a7984b6bd5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_21854a74-e3f2-4b0d-8ed1-5c13d9cb8a83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_70ce0cf4-bfb4-40ff-b33f-0b1649be8ebd" xlink:to="loc_us-gaap_GrantMember_21854a74-e3f2-4b0d-8ed1-5c13d9cb8a83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CollaborationArrangementMember_9fd9d4de-593a-4822-9a59-353b1ec2077a" xlink:href="mrna-20210331.xsd#mrna_CollaborationArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_70ce0cf4-bfb4-40ff-b33f-0b1649be8ebd" xlink:to="loc_mrna_CollaborationArrangementMember_9fd9d4de-593a-4822-9a59-353b1ec2077a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="mrna-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended" id="i789000b64637467d80d1b2a32576f031_CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical" xlink:type="simple" xlink:href="mrna-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical" xlink:type="extended" id="i8b31ab0748c14cbf8a41863df77202c4_CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="mrna-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="i80b9f69f716343169c3ea7c5e5a4039a_CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3d214021-8bb5-4b43-b3e4-38403ee3b7a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfa259bd-85b7-49c3-a6c9-9e608ee9dc99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3d214021-8bb5-4b43-b3e4-38403ee3b7a3" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfa259bd-85b7-49c3-a6c9-9e608ee9dc99" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_639a9441-b3c8-4779-9a9e-2cec967d3454" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfa259bd-85b7-49c3-a6c9-9e608ee9dc99" xlink:to="loc_us-gaap_SharesOutstanding_639a9441-b3c8-4779-9a9e-2cec967d3454" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f38e1923-0d14-46fa-b2dc-efc01071f88e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfa259bd-85b7-49c3-a6c9-9e608ee9dc99" xlink:to="loc_us-gaap_StockholdersEquity_f38e1923-0d14-46fa-b2dc-efc01071f88e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2948e0c6-d070-4936-a762-f34f062085ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfa259bd-85b7-49c3-a6c9-9e608ee9dc99" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2948e0c6-d070-4936-a762-f34f062085ba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_498c1f7c-52f0-4685-8fae-fae8c34c9c87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfa259bd-85b7-49c3-a6c9-9e608ee9dc99" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_498c1f7c-52f0-4685-8fae-fae8c34c9c87" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f0c00a89-823a-48a8-8fba-6c8fdf5d01a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfa259bd-85b7-49c3-a6c9-9e608ee9dc99" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f0c00a89-823a-48a8-8fba-6c8fdf5d01a1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_54a79ccf-8e95-4b08-9c89-bffad223642c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfa259bd-85b7-49c3-a6c9-9e608ee9dc99" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_54a79ccf-8e95-4b08-9c89-bffad223642c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_15af3f01-ee27-4d1b-a409-d36a8842399a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfa259bd-85b7-49c3-a6c9-9e608ee9dc99" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_15af3f01-ee27-4d1b-a409-d36a8842399a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_65c73c21-0d86-4eaa-b354-0c6249c3037e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfa259bd-85b7-49c3-a6c9-9e608ee9dc99" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_65c73c21-0d86-4eaa-b354-0c6249c3037e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fe6d3ca0-4b61-4f4a-93e1-fa53f8b7c14d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfa259bd-85b7-49c3-a6c9-9e608ee9dc99" xlink:to="loc_us-gaap_NetIncomeLoss_fe6d3ca0-4b61-4f4a-93e1-fa53f8b7c14d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_3e6ab666-9fb0-4ae8-88a1-ce89d2d29fbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_de1e0b71-7a6a-4290-a08a-d86426a11f6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ad353e1d-1e7b-456c-8136-8e34a75cb2c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3d214021-8bb5-4b43-b3e4-38403ee3b7a3" xlink:to="loc_us-gaap_StatementTable_ad353e1d-1e7b-456c-8136-8e34a75cb2c6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a35106ae-20f9-4fa8-96ea-16d027374305" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ad353e1d-1e7b-456c-8136-8e34a75cb2c6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a35106ae-20f9-4fa8-96ea-16d027374305" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a35106ae-20f9-4fa8-96ea-16d027374305_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a35106ae-20f9-4fa8-96ea-16d027374305" xlink:to="loc_us-gaap_EquityComponentDomain_a35106ae-20f9-4fa8-96ea-16d027374305_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_33b4f2f5-c002-4e06-8cf0-54da1fce247c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a35106ae-20f9-4fa8-96ea-16d027374305" xlink:to="loc_us-gaap_EquityComponentDomain_33b4f2f5-c002-4e06-8cf0-54da1fce247c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ebaa8b3c-698b-479c-b9e8-80d5e6168ed2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_33b4f2f5-c002-4e06-8cf0-54da1fce247c" xlink:to="loc_us-gaap_CommonStockMember_ebaa8b3c-698b-479c-b9e8-80d5e6168ed2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_89b86b28-45c7-4d25-915e-229cfd590380" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_33b4f2f5-c002-4e06-8cf0-54da1fce247c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_89b86b28-45c7-4d25-915e-229cfd590380" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ac4b279f-b1d1-4701-bc7a-5d8d551165a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_33b4f2f5-c002-4e06-8cf0-54da1fce247c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ac4b279f-b1d1-4701-bc7a-5d8d551165a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_95dd9b24-e95c-47b7-84ab-b118813007a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_33b4f2f5-c002-4e06-8cf0-54da1fce247c" xlink:to="loc_us-gaap_RetainedEarningsMember_95dd9b24-e95c-47b7-84ab-b118813007a6" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="simple" xlink:href="mrna-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="extended" id="iafb39602eb904636a74daa3e909d520c_CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="mrna-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended" id="i70a710a7fae0418faa2c99db4aed0fda_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/DescriptionoftheBusiness" xlink:type="simple" xlink:href="mrna-20210331.xsd#DescriptionoftheBusiness"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/DescriptionoftheBusiness" xlink:type="extended" id="i8ca10e467e07483cb43d426a81634241_DescriptionoftheBusiness"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/DescriptionoftheBusinessAdditionalInformationDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#DescriptionoftheBusinessAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/DescriptionoftheBusinessAdditionalInformationDetails" xlink:type="extended" id="id0ca09335ab34cbabbed8c5d6ce5ffa7_DescriptionoftheBusinessAdditionalInformationDetails"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandards" xlink:type="simple" xlink:href="mrna-20210331.xsd#SummaryofBasisofPresentationandRecentAccountingStandards"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandards" xlink:type="extended" id="ia87d8f8908294f55abfef2944406e7bd_SummaryofBasisofPresentationandRecentAccountingStandards"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsPolicies" xlink:type="simple" xlink:href="mrna-20210331.xsd#SummaryofBasisofPresentationandRecentAccountingStandardsPolicies"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsPolicies" xlink:type="extended" id="i4ebd6f8a4bf3453695f954756b2295dd_SummaryofBasisofPresentationandRecentAccountingStandardsPolicies"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsTables" xlink:type="simple" xlink:href="mrna-20210331.xsd#SummaryofBasisofPresentationandRecentAccountingStandardsTables"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsTables" xlink:type="extended" id="i0169dfdcb6174c29a9b433d3ed84ce5b_SummaryofBasisofPresentationandRecentAccountingStandardsTables"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsComponentsofAccumulatedOtherComprehensivelossIncomeDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#SummaryofBasisofPresentationandRecentAccountingStandardsComponentsofAccumulatedOtherComprehensivelossIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsComponentsofAccumulatedOtherComprehensivelossIncomeDetails" xlink:type="extended" id="i72bd8108fee14adf868b48390e94fafe_SummaryofBasisofPresentationandRecentAccountingStandardsComponentsofAccumulatedOtherComprehensivelossIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_481ef086-ac07-42c8-a242-8ff128768acc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_a6e8afcc-f1d4-4db2-be5b-f2b068549025" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_481ef086-ac07-42c8-a242-8ff128768acc" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_a6e8afcc-f1d4-4db2-be5b-f2b068549025" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0bd5d7f9-3926-4b3c-9985-720b1c658ca5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_a6e8afcc-f1d4-4db2-be5b-f2b068549025" xlink:to="loc_us-gaap_StockholdersEquity_0bd5d7f9-3926-4b3c-9985-720b1c658ca5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2e00748f-7faf-4588-8c7e-ef5394283509" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_a6e8afcc-f1d4-4db2-be5b-f2b068549025" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2e00748f-7faf-4588-8c7e-ef5394283509" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f6ef034a-4087-4b6b-9019-cb7d0b948d6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_74c87676-bd0b-4105-998d-7e93decc206d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_481ef086-ac07-42c8-a242-8ff128768acc" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_74c87676-bd0b-4105-998d-7e93decc206d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f2e7f186-21cc-4f0e-bf44-fb535b4cbd9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_74c87676-bd0b-4105-998d-7e93decc206d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f2e7f186-21cc-4f0e-bf44-fb535b4cbd9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f2e7f186-21cc-4f0e-bf44-fb535b4cbd9a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f2e7f186-21cc-4f0e-bf44-fb535b4cbd9a" xlink:to="loc_us-gaap_EquityComponentDomain_f2e7f186-21cc-4f0e-bf44-fb535b4cbd9a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8e53a396-573b-4cdb-8d14-959519f80cf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f2e7f186-21cc-4f0e-bf44-fb535b4cbd9a" xlink:to="loc_us-gaap_EquityComponentDomain_8e53a396-573b-4cdb-8d14-959519f80cf2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_c2e212f3-fcc8-429b-a773-932e2563d3d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8e53a396-573b-4cdb-8d14-959519f80cf2" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_c2e212f3-fcc8-429b-a773-932e2563d3d4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#SummaryofBasisofPresentationandRecentAccountingStandardsReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended" id="i19c003056a7f41fabe2b787a44fffb17_SummaryofBasisofPresentationandRecentAccountingStandardsReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/ProductSales" xlink:type="simple" xlink:href="mrna-20210331.xsd#ProductSales"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/ProductSales" xlink:type="extended" id="ia34af7924e71472a9697340808c745ac_ProductSales"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/ProductSalesTables" xlink:type="simple" xlink:href="mrna-20210331.xsd#ProductSalesTables"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/ProductSalesTables" xlink:type="extended" id="i1d3ee3390d3341b887252f0b4b4b6288_ProductSalesTables"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/ProductSalesDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#ProductSalesDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/ProductSalesDetails" xlink:type="extended" id="i51c06e8ba21d4e8e8f804721835b2a60_ProductSalesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_3c5254eb-145b-4ccd-85e2-9dd3b3a6bd58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_546ff38d-232b-4b9e-a0c0-2a56d75e6f01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3c5254eb-145b-4ccd-85e2-9dd3b3a6bd58" xlink:to="loc_us-gaap_Revenues_546ff38d-232b-4b9e-a0c0-2a56d75e6f01" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_24ad3889-b4b1-4bf1-9585-42c7fdb22e77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3c5254eb-145b-4ccd-85e2-9dd3b3a6bd58" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_24ad3889-b4b1-4bf1-9585-42c7fdb22e77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_4d511451-f709-40b5-9f4e-964eda216a94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3c5254eb-145b-4ccd-85e2-9dd3b3a6bd58" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_4d511451-f709-40b5-9f4e-964eda216a94" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_b7f80237-20a0-4909-8b63-994e970be61d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4d511451-f709-40b5-9f4e-964eda216a94" xlink:to="loc_srt_StatementGeographicalAxis_b7f80237-20a0-4909-8b63-994e970be61d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b7f80237-20a0-4909-8b63-994e970be61d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_b7f80237-20a0-4909-8b63-994e970be61d" xlink:to="loc_srt_SegmentGeographicalDomain_b7f80237-20a0-4909-8b63-994e970be61d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c059db5d-49fe-424b-9923-fd9b68e70c41" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_b7f80237-20a0-4909-8b63-994e970be61d" xlink:to="loc_srt_SegmentGeographicalDomain_c059db5d-49fe-424b-9923-fd9b68e70c41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b3969328-d278-4b70-b73a-33247e0503bc" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c059db5d-49fe-424b-9923-fd9b68e70c41" xlink:to="loc_country_US_b3969328-d278-4b70-b73a-33247e0503bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_b4844460-cb93-4370-8d66-9f0368f76230" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c059db5d-49fe-424b-9923-fd9b68e70c41" xlink:to="loc_us-gaap_NonUsMember_b4844460-cb93-4370-8d66-9f0368f76230" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8e78b7c8-9669-4076-a64a-daffaaf78643" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4d511451-f709-40b5-9f4e-964eda216a94" xlink:to="loc_srt_ProductOrServiceAxis_8e78b7c8-9669-4076-a64a-daffaaf78643" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8e78b7c8-9669-4076-a64a-daffaaf78643_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8e78b7c8-9669-4076-a64a-daffaaf78643" xlink:to="loc_srt_ProductsAndServicesDomain_8e78b7c8-9669-4076-a64a-daffaaf78643_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a8fbcfcb-4bf3-43d9-a052-d01783bd4bee" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8e78b7c8-9669-4076-a64a-daffaaf78643" xlink:to="loc_srt_ProductsAndServicesDomain_a8fbcfcb-4bf3-43d9-a052-d01783bd4bee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ProductSalesMember_83d5061e-6223-439c-918d-f9db3fe86aa7" xlink:href="mrna-20210331.xsd#mrna_ProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a8fbcfcb-4bf3-43d9-a052-d01783bd4bee" xlink:to="loc_mrna_ProductSalesMember_83d5061e-6223-439c-918d-f9db3fe86aa7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CustomerDepositsMember_0672295b-24e8-4839-91ac-c4293414ac14" xlink:href="mrna-20210331.xsd#mrna_CustomerDepositsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a8fbcfcb-4bf3-43d9-a052-d01783bd4bee" xlink:to="loc_mrna_CustomerDepositsMember_0672295b-24e8-4839-91ac-c4293414ac14" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/GrantRevenue" xlink:type="simple" xlink:href="mrna-20210331.xsd#GrantRevenue"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/GrantRevenue" xlink:type="extended" id="i707c7984f52d4b64b4bf49061feb425c_GrantRevenue"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/GrantRevenueTables" xlink:type="simple" xlink:href="mrna-20210331.xsd#GrantRevenueTables"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/GrantRevenueTables" xlink:type="extended" id="i235e12e1e24c46778f8d41ad71abd843_GrantRevenueTables"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/GrantRevenueDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#GrantRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/GrantRevenueDetails" xlink:type="extended" id="i017decaa03a24ebb91f11809812594e8_GrantRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_ebe3db45-55af-45ac-bf32-6f7e8f685222" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsMaximumAward_b8d713f7-acea-4e13-80bf-6bf6519d0345" xlink:href="mrna-20210331.xsd#mrna_RevenueFromGrantsMaximumAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ebe3db45-55af-45ac-bf32-6f7e8f685222" xlink:to="loc_mrna_RevenueFromGrantsMaximumAward_b8d713f7-acea-4e13-80bf-6bf6519d0345" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsCurrentFundingCapacity_aa57bd55-a19f-48d2-8c0b-b2df97cd94d7" xlink:href="mrna-20210331.xsd#mrna_RevenueFromGrantsCurrentFundingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ebe3db45-55af-45ac-bf32-6f7e8f685222" xlink:to="loc_mrna_RevenueFromGrantsCurrentFundingCapacity_aa57bd55-a19f-48d2-8c0b-b2df97cd94d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsRemainingFundingCapacity_16e0f02d-6adf-412f-b71e-882ddfa527d3" xlink:href="mrna-20210331.xsd#mrna_RevenueFromGrantsRemainingFundingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ebe3db45-55af-45ac-bf32-6f7e8f685222" xlink:to="loc_mrna_RevenueFromGrantsRemainingFundingCapacity_16e0f02d-6adf-412f-b71e-882ddfa527d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_9390e926-3b06-4081-b924-69c1c11ca464" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ebe3db45-55af-45ac-bf32-6f7e8f685222" xlink:to="loc_us-gaap_OtherCommitment_9390e926-3b06-4081-b924-69c1c11ca464" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsPotentialReimbursement_51dd4641-0643-4e5a-a3d9-107b520cbaeb" xlink:href="mrna-20210331.xsd#mrna_RevenueFromGrantsPotentialReimbursement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ebe3db45-55af-45ac-bf32-6f7e8f685222" xlink:to="loc_mrna_RevenueFromGrantsPotentialReimbursement_51dd4641-0643-4e5a-a3d9-107b520cbaeb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsNumberOfContractOptions_3758b4ff-8e99-4ff3-996d-4d6e3ac7634d" xlink:href="mrna-20210331.xsd#mrna_RevenueFromGrantsNumberOfContractOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ebe3db45-55af-45ac-bf32-6f7e8f685222" xlink:to="loc_mrna_RevenueFromGrantsNumberOfContractOptions_3758b4ff-8e99-4ff3-996d-4d6e3ac7634d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsNumberOfContractOptionsExercised_6e92e3f5-29e2-46b0-9cee-672fa4cffbc8" xlink:href="mrna-20210331.xsd#mrna_RevenueFromGrantsNumberOfContractOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ebe3db45-55af-45ac-bf32-6f7e8f685222" xlink:to="loc_mrna_RevenueFromGrantsNumberOfContractOptionsExercised_6e92e3f5-29e2-46b0-9cee-672fa4cffbc8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_d21f0aad-1fae-4ae3-9508-09122c6f8f6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ebe3db45-55af-45ac-bf32-6f7e8f685222" xlink:to="loc_us-gaap_Revenues_d21f0aad-1fae-4ae3-9508-09122c6f8f6c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_0fd61948-2247-4ec8-858d-ed3d8c0e4fd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ebe3db45-55af-45ac-bf32-6f7e8f685222" xlink:to="loc_us-gaap_ContractWithCustomerLiability_0fd61948-2247-4ec8-858d-ed3d8c0e4fd5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_73697845-45d4-49b1-890f-b0fc893c15e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ebe3db45-55af-45ac-bf32-6f7e8f685222" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_73697845-45d4-49b1-890f-b0fc893c15e6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_36452653-ce57-409a-aedf-4aadc7e48d3a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_73697845-45d4-49b1-890f-b0fc893c15e6" xlink:to="loc_srt_MajorCustomersAxis_36452653-ce57-409a-aedf-4aadc7e48d3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_36452653-ce57-409a-aedf-4aadc7e48d3a_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_36452653-ce57-409a-aedf-4aadc7e48d3a" xlink:to="loc_srt_NameOfMajorCustomerDomain_36452653-ce57-409a-aedf-4aadc7e48d3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ff5ac864-5d15-4acb-99f2-d93685d7d3d8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_36452653-ce57-409a-aedf-4aadc7e48d3a" xlink:to="loc_srt_NameOfMajorCustomerDomain_ff5ac864-5d15-4acb-99f2-d93685d7d3d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DefenseAdvancedResearchProjectsAgencyMember_d80d3667-8028-442e-9252-9bf7a9bd75d3" xlink:href="mrna-20210331.xsd#mrna_DefenseAdvancedResearchProjectsAgencyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ff5ac864-5d15-4acb-99f2-d93685d7d3d8" xlink:to="loc_mrna_DefenseAdvancedResearchProjectsAgencyMember_d80d3667-8028-442e-9252-9bf7a9bd75d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_5e073494-73c0-4fe6-92dc-c0242ea35d95" xlink:href="mrna-20210331.xsd#mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ff5ac864-5d15-4acb-99f2-d93685d7d3d8" xlink:to="loc_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_5e073494-73c0-4fe6-92dc-c0242ea35d95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_TheBillAndMelindaGatesFoundationMember_58cae11f-0865-443b-925c-311ede44248a" xlink:href="mrna-20210331.xsd#mrna_TheBillAndMelindaGatesFoundationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ff5ac864-5d15-4acb-99f2-d93685d7d3d8" xlink:to="loc_mrna_TheBillAndMelindaGatesFoundationMember_58cae11f-0865-443b-925c-311ede44248a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OtherGrantRevenueMember_e2447da3-0745-4f29-a8aa-3e80f7b17324" xlink:href="mrna-20210331.xsd#mrna_OtherGrantRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ff5ac864-5d15-4acb-99f2-d93685d7d3d8" xlink:to="loc_mrna_OtherGrantRevenueMember_e2447da3-0745-4f29-a8aa-3e80f7b17324" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_3972d9d5-de98-4610-894b-c8b9732bc032" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_73697845-45d4-49b1-890f-b0fc893c15e6" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_3972d9d5-de98-4610-894b-c8b9732bc032" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_3972d9d5-de98-4610-894b-c8b9732bc032_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_3972d9d5-de98-4610-894b-c8b9732bc032" xlink:to="loc_us-gaap_ProjectMember_3972d9d5-de98-4610-894b-c8b9732bc032_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_9992528a-8101-421d-9169-2077b8c9d6df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_3972d9d5-de98-4610-894b-c8b9732bc032" xlink:to="loc_us-gaap_ProjectMember_9992528a-8101-421d-9169-2077b8c9d6df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractOptionsMember_354b79ae-4c00-4739-bf67-2c27b4c96bb3" xlink:href="mrna-20210331.xsd#mrna_ContractOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_9992528a-8101-421d-9169-2077b8c9d6df" xlink:to="loc_mrna_ContractOptionsMember_354b79ae-4c00-4739-bf67-2c27b4c96bb3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_InitialProjectMember_b4d9b6f2-dd06-4e34-8477-a43391244e14" xlink:href="mrna-20210331.xsd#mrna_InitialProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_9992528a-8101-421d-9169-2077b8c9d6df" xlink:to="loc_mrna_InitialProjectMember_b4d9b6f2-dd06-4e34-8477-a43391244e14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_17f77a0e-79d2-4f34-8169-eb0c92b47239" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_73697845-45d4-49b1-890f-b0fc893c15e6" xlink:to="loc_srt_ProductOrServiceAxis_17f77a0e-79d2-4f34-8169-eb0c92b47239" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_17f77a0e-79d2-4f34-8169-eb0c92b47239_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_17f77a0e-79d2-4f34-8169-eb0c92b47239" xlink:to="loc_srt_ProductsAndServicesDomain_17f77a0e-79d2-4f34-8169-eb0c92b47239_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d3c508ec-42d2-4fbb-82ad-321ce5454d13" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_17f77a0e-79d2-4f34-8169-eb0c92b47239" xlink:to="loc_srt_ProductsAndServicesDomain_d3c508ec-42d2-4fbb-82ad-321ce5454d13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_aa612f50-0981-4cf4-a121-f6663f11cc47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d3c508ec-42d2-4fbb-82ad-321ce5454d13" xlink:to="loc_us-gaap_GrantMember_aa612f50-0981-4cf4-a121-f6663f11cc47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_324dc8cd-89d6-4dc5-8190-f55f4663b6d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_73697845-45d4-49b1-890f-b0fc893c15e6" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_324dc8cd-89d6-4dc5-8190-f55f4663b6d6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_324dc8cd-89d6-4dc5-8190-f55f4663b6d6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_324dc8cd-89d6-4dc5-8190-f55f4663b6d6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_324dc8cd-89d6-4dc5-8190-f55f4663b6d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_dc7e7d47-6782-4fc1-968a-1b89cf460461" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_324dc8cd-89d6-4dc5-8190-f55f4663b6d6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_dc7e7d47-6782-4fc1-968a-1b89cf460461" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_a7a88018-d373-4093-9259-f101fdc45cb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_dc7e7d47-6782-4fc1-968a-1b89cf460461" xlink:to="loc_us-gaap_SubsequentEventMember_a7a88018-d373-4093-9259-f101fdc45cb6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationRevenue" xlink:type="simple" xlink:href="mrna-20210331.xsd#CollaborationRevenue"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CollaborationRevenue" xlink:type="extended" id="i947b91df3c0a413d8145598d1496a12c_CollaborationRevenue"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationRevenueTables" xlink:type="simple" xlink:href="mrna-20210331.xsd#CollaborationRevenueTables"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CollaborationRevenueTables" xlink:type="extended" id="i1bc4ed83664a4f578f7a644c1cb00714_CollaborationRevenueTables"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationRevenueSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#CollaborationRevenueSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CollaborationRevenueSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails" xlink:type="extended" id="ie99d3e851cb34562963d39d45e24e101_CollaborationRevenueSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ea5b7bfc-a6c3-49e3-b755-c4cf6b8e09bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_47538b33-9b8a-4642-bfb8-e1d4c149cf02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ea5b7bfc-a6c3-49e3-b755-c4cf6b8e09bd" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_47538b33-9b8a-4642-bfb8-e1d4c149cf02" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_7925cd01-3f91-4480-b34e-0428e28f6664" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ea5b7bfc-a6c3-49e3-b755-c4cf6b8e09bd" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_7925cd01-3f91-4480-b34e-0428e28f6664" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_24c35f95-1bea-4982-875a-6cbad26613ec" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_7925cd01-3f91-4480-b34e-0428e28f6664" xlink:to="loc_srt_ProductOrServiceAxis_24c35f95-1bea-4982-875a-6cbad26613ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_24c35f95-1bea-4982-875a-6cbad26613ec_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_24c35f95-1bea-4982-875a-6cbad26613ec" xlink:to="loc_srt_ProductsAndServicesDomain_24c35f95-1bea-4982-875a-6cbad26613ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0c6c7a76-2d09-4426-bd21-1d1e8539cb80" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_24c35f95-1bea-4982-875a-6cbad26613ec" xlink:to="loc_srt_ProductsAndServicesDomain_0c6c7a76-2d09-4426-bd21-1d1e8539cb80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember_3bb9c8b0-a619-4246-826f-e9e954574976" xlink:href="mrna-20210331.xsd#mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0c6c7a76-2d09-4426-bd21-1d1e8539cb80" xlink:to="loc_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember_3bb9c8b0-a619-4246-826f-e9e954574976" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_741dde90-7ceb-4d17-8ffa-73f3f05b58c3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_7925cd01-3f91-4480-b34e-0428e28f6664" xlink:to="loc_srt_CounterpartyNameAxis_741dde90-7ceb-4d17-8ffa-73f3f05b58c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_741dde90-7ceb-4d17-8ffa-73f3f05b58c3_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_741dde90-7ceb-4d17-8ffa-73f3f05b58c3" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_741dde90-7ceb-4d17-8ffa-73f3f05b58c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e3aeb550-89df-4acc-b8b8-bb90ca9d7e5e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_741dde90-7ceb-4d17-8ffa-73f3f05b58c3" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e3aeb550-89df-4acc-b8b8-bb90ca9d7e5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AstraZenecaMember_4d9eead9-c28d-4050-b08e-123cad31b675" xlink:href="mrna-20210331.xsd#mrna_AstraZenecaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e3aeb550-89df-4acc-b8b8-bb90ca9d7e5e" xlink:to="loc_mrna_AstraZenecaMember_4d9eead9-c28d-4050-b08e-123cad31b675" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MerckMember_46856735-0177-409e-9beb-0db0945b1958" xlink:href="mrna-20210331.xsd#mrna_MerckMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e3aeb550-89df-4acc-b8b8-bb90ca9d7e5e" xlink:to="loc_mrna_MerckMember_46856735-0177-409e-9beb-0db0945b1958" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_VertexMember_95b3af77-3752-4bb3-8ea0-a4fd9a70347b" xlink:href="mrna-20210331.xsd#mrna_VertexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e3aeb550-89df-4acc-b8b8-bb90ca9d7e5e" xlink:to="loc_mrna_VertexMember_95b3af77-3752-4bb3-8ea0-a4fd9a70347b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OtherCollaborativePartiesMember_8dbd8e34-066f-4481-bd20-2178bb27c7df" xlink:href="mrna-20210331.xsd#mrna_OtherCollaborativePartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e3aeb550-89df-4acc-b8b8-bb90ca9d7e5e" xlink:to="loc_mrna_OtherCollaborativePartiesMember_8dbd8e34-066f-4481-bd20-2178bb27c7df" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationRevenueChangesinBalancesofReceivablesandContractLiabilitiesDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#CollaborationRevenueChangesinBalancesofReceivablesandContractLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CollaborationRevenueChangesinBalancesofReceivablesandContractLiabilitiesDetails" xlink:type="extended" id="ieca2c905283146da8f25e5988aa0c088_CollaborationRevenueChangesinBalancesofReceivablesandContractLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8e67b2d9-59b7-4b5f-ab0a-86d77295e2d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractwithCustomerAssetRollForward_c072be45-1a8e-43cb-9298-2d9560a98f2f" xlink:href="mrna-20210331.xsd#mrna_ChangeInContractwithCustomerAssetRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8e67b2d9-59b7-4b5f-ab0a-86d77295e2d5" xlink:to="loc_mrna_ChangeInContractwithCustomerAssetRollForward_c072be45-1a8e-43cb-9298-2d9560a98f2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_51a5479f-91c1-434c-a137-e22e093eef01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_ChangeInContractwithCustomerAssetRollForward_c072be45-1a8e-43cb-9298-2d9560a98f2f" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_51a5479f-91c1-434c-a137-e22e093eef01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_2cd273f1-d6e2-417e-82a5-88b9a1f6eb4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_ChangeInContractwithCustomerAssetRollForward_c072be45-1a8e-43cb-9298-2d9560a98f2f" xlink:to="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_2cd273f1-d6e2-417e-82a5-88b9a1f6eb4a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerAssetDeductionsDuringPeriod_a7a5692c-936e-4b3a-99d3-450d538eee17" xlink:href="mrna-20210331.xsd#mrna_ContractWithCustomerAssetDeductionsDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_ChangeInContractwithCustomerAssetRollForward_c072be45-1a8e-43cb-9298-2d9560a98f2f" xlink:to="loc_mrna_ContractWithCustomerAssetDeductionsDuringPeriod_a7a5692c-936e-4b3a-99d3-450d538eee17" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_de773d84-81fc-4b89-85c2-55990602a82e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward_3b58f885-cbd0-43be-9093-4351bd458db2" xlink:href="mrna-20210331.xsd#mrna_ChangeInContractwithCustomerLiabilityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8e67b2d9-59b7-4b5f-ab0a-86d77295e2d5" xlink:to="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward_3b58f885-cbd0-43be-9093-4351bd458db2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_0c28805f-8a89-406e-9e9c-64ac25080cc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward_3b58f885-cbd0-43be-9093-4351bd458db2" xlink:to="loc_us-gaap_ContractWithCustomerLiability_0c28805f-8a89-406e-9e9c-64ac25080cc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_52ac0a18-e226-46f9-8be4-21927b5324f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward_3b58f885-cbd0-43be-9093-4351bd458db2" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_52ac0a18-e226-46f9-8be4-21927b5324f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod_235f0500-ac43-4022-9787-4dae17315278" xlink:href="mrna-20210331.xsd#mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward_3b58f885-cbd0-43be-9093-4351bd458db2" xlink:to="loc_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod_235f0500-ac43-4022-9787-4dae17315278" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_a4f670bd-fdd4-452a-8b0e-f0daf83427c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_a126f49e-9d52-482d-b96a-6069f0362bd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8e67b2d9-59b7-4b5f-ab0a-86d77295e2d5" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_a126f49e-9d52-482d-b96a-6069f0362bd0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e6987214-e1a2-4214-a64c-b8d317a8bfaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8e67b2d9-59b7-4b5f-ab0a-86d77295e2d5" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e6987214-e1a2-4214-a64c-b8d317a8bfaf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f501bf87-c250-4684-bee9-cde49f4d9310" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e6987214-e1a2-4214-a64c-b8d317a8bfaf" xlink:to="loc_srt_ProductOrServiceAxis_f501bf87-c250-4684-bee9-cde49f4d9310" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f501bf87-c250-4684-bee9-cde49f4d9310_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_f501bf87-c250-4684-bee9-cde49f4d9310" xlink:to="loc_srt_ProductsAndServicesDomain_f501bf87-c250-4684-bee9-cde49f4d9310_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_215c245f-eeb9-4a19-a0b1-0ab629fd4ab8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_f501bf87-c250-4684-bee9-cde49f4d9310" xlink:to="loc_srt_ProductsAndServicesDomain_215c245f-eeb9-4a19-a0b1-0ab629fd4ab8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember_7740f005-a099-4490-8db7-db4284322a60" xlink:href="mrna-20210331.xsd#mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_215c245f-eeb9-4a19-a0b1-0ab629fd4ab8" xlink:to="loc_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember_7740f005-a099-4490-8db7-db4284322a60" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstruments" xlink:type="simple" xlink:href="mrna-20210331.xsd#FinancialInstruments"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/FinancialInstruments" xlink:type="extended" id="i072ddddf9bfb44968a4a76bcdbbc15d0_FinancialInstruments"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="mrna-20210331.xsd#FinancialInstrumentsTables"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsTables" xlink:type="extended" id="ib839310d2eaf4beb947993046cf33b09_FinancialInstrumentsTables"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails" xlink:type="extended" id="if155b25e4a714c958a4157657e52a649_FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c0a1d138-1163-42af-b057-5910742f3475" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_246132f4-18fd-4acf-b2e3-aa68d095681c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c0a1d138-1163-42af-b057-5910742f3475" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_246132f4-18fd-4acf-b2e3-aa68d095681c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_892d5d39-fb9b-4e27-9bea-8ef9a6787043" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c0a1d138-1163-42af-b057-5910742f3475" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_892d5d39-fb9b-4e27-9bea-8ef9a6787043" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_dfd9b1d1-6e7b-4b68-9160-3568f396ac1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c0a1d138-1163-42af-b057-5910742f3475" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_dfd9b1d1-6e7b-4b68-9160-3568f396ac1a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_27801edc-0191-4947-b2f1-7567b8f53a23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c0a1d138-1163-42af-b057-5910742f3475" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_27801edc-0191-4947-b2f1-7567b8f53a23" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_fcfd6f52-18c0-4b9c-8ac9-7b9e10b2c977" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c0a1d138-1163-42af-b057-5910742f3475" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_fcfd6f52-18c0-4b9c-8ac9-7b9e10b2c977" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_9c4aff7c-cd58-47ce-9a5c-8cdc33352cec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_fcfd6f52-18c0-4b9c-8ac9-7b9e10b2c977" xlink:to="loc_us-gaap_FinancialInstrumentAxis_9c4aff7c-cd58-47ce-9a5c-8cdc33352cec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9c4aff7c-cd58-47ce-9a5c-8cdc33352cec_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9c4aff7c-cd58-47ce-9a5c-8cdc33352cec" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9c4aff7c-cd58-47ce-9a5c-8cdc33352cec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02a82936-654d-49d5-8464-fba001c1bf55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9c4aff7c-cd58-47ce-9a5c-8cdc33352cec" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02a82936-654d-49d5-8464-fba001c1bf55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_6e121c03-7cad-41d6-8c86-2ff3697f301e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02a82936-654d-49d5-8464-fba001c1bf55" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_6e121c03-7cad-41d6-8c86-2ff3697f301e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_51998662-05f8-4aa1-abba-3138d7b3492e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02a82936-654d-49d5-8464-fba001c1bf55" xlink:to="loc_us-gaap_CertificatesOfDepositMember_51998662-05f8-4aa1-abba-3138d7b3492e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_a264899f-791c-47d3-bb95-cdfac918fd61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02a82936-654d-49d5-8464-fba001c1bf55" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_a264899f-791c-47d3-bb95-cdfac918fd61" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember_3ac8b13a-f035-43af-a148-09cadea79422" xlink:href="mrna-20210331.xsd#mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02a82936-654d-49d5-8464-fba001c1bf55" xlink:to="loc_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember_3ac8b13a-f035-43af-a148-09cadea79422" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_b2321993-6497-46aa-bb1e-f788dccc1416" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_fcfd6f52-18c0-4b9c-8ac9-7b9e10b2c977" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_b2321993-6497-46aa-bb1e-f788dccc1416" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_b2321993-6497-46aa-bb1e-f788dccc1416_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_b2321993-6497-46aa-bb1e-f788dccc1416" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_b2321993-6497-46aa-bb1e-f788dccc1416_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_21f30c50-be4c-402e-8cb7-96d61235a31b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_b2321993-6497-46aa-bb1e-f788dccc1416" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_21f30c50-be4c-402e-8cb7-96d61235a31b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_db019eca-8196-423a-baa6-b2af126bd2e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_21f30c50-be4c-402e-8cb7-96d61235a31b" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_db019eca-8196-423a-baa6-b2af126bd2e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CurrentMarketableSecuritiesMember_16f600cf-7eca-4e92-ab30-f3f9e02f7566" xlink:href="mrna-20210331.xsd#mrna_CurrentMarketableSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_21f30c50-be4c-402e-8cb7-96d61235a31b" xlink:to="loc_mrna_CurrentMarketableSecuritiesMember_16f600cf-7eca-4e92-ab30-f3f9e02f7566" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NoncurrentMarketableSecuritiesMember_f8af6226-9987-4580-ae45-ad6d875e897a" xlink:href="mrna-20210331.xsd#mrna_NoncurrentMarketableSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_21f30c50-be4c-402e-8cb7-96d61235a31b" xlink:to="loc_mrna_NoncurrentMarketableSecuritiesMember_f8af6226-9987-4580-ae45-ad6d875e897a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9612bf1d-5ec9-4e84-aa77-900faff7bb62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_fcfd6f52-18c0-4b9c-8ac9-7b9e10b2c977" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9612bf1d-5ec9-4e84-aa77-900faff7bb62" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9612bf1d-5ec9-4e84-aa77-900faff7bb62_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9612bf1d-5ec9-4e84-aa77-900faff7bb62" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9612bf1d-5ec9-4e84-aa77-900faff7bb62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_10e90ba9-1824-485d-bcba-a6f70ec0b960" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9612bf1d-5ec9-4e84-aa77-900faff7bb62" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_10e90ba9-1824-485d-bcba-a6f70ec0b960" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_52831fd5-01f6-4fb6-9fc8-08702979d658" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_10e90ba9-1824-485d-bcba-a6f70ec0b960" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_52831fd5-01f6-4fb6-9fc8-08702979d658" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_9771adbc-a41f-439f-922e-e598c9f63ef6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_10e90ba9-1824-485d-bcba-a6f70ec0b960" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_9771adbc-a41f-439f-922e-e598c9f63ef6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#FinancialInstrumentsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails" xlink:type="extended" id="i8bda2f989b954e52907cfa4520aee684_FinancialInstrumentsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended" id="ibbde3743696240b0accff433f99617d8_FinancialInstrumentsNarrativeDetails"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails" xlink:type="extended" id="i5305c17e718748bbaf5dc2045628c46f_FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1e92de6e-d6d2-498c-8bcf-1ca649f47aca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f7233376-2981-48ad-97eb-e6d173aeab91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1e92de6e-d6d2-498c-8bcf-1ca649f47aca" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f7233376-2981-48ad-97eb-e6d173aeab91" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_cd00384a-ce01-4d3b-9ebf-999147515a32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1e92de6e-d6d2-498c-8bcf-1ca649f47aca" xlink:to="loc_us-gaap_DerivativeAssets_cd00384a-ce01-4d3b-9ebf-999147515a32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_27aa5d0d-2643-4b2b-9f0b-b19d1a272ee3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1e92de6e-d6d2-498c-8bcf-1ca649f47aca" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_27aa5d0d-2643-4b2b-9f0b-b19d1a272ee3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_f2199f49-54d9-400a-99dc-39c01d902a7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1e92de6e-d6d2-498c-8bcf-1ca649f47aca" xlink:to="loc_us-gaap_DerivativeLiabilities_f2199f49-54d9-400a-99dc-39c01d902a7e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ecd2cb01-e539-4f16-b3f9-5789de7a7df3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1e92de6e-d6d2-498c-8bcf-1ca649f47aca" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ecd2cb01-e539-4f16-b3f9-5789de7a7df3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_35010087-f0f5-4c34-9ac0-10ff9fd6e5b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ecd2cb01-e539-4f16-b3f9-5789de7a7df3" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_35010087-f0f5-4c34-9ac0-10ff9fd6e5b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_35010087-f0f5-4c34-9ac0-10ff9fd6e5b5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_35010087-f0f5-4c34-9ac0-10ff9fd6e5b5" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_35010087-f0f5-4c34-9ac0-10ff9fd6e5b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_48ce3520-bd57-4ef3-8fe6-93dcaa4d526a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_35010087-f0f5-4c34-9ac0-10ff9fd6e5b5" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_48ce3520-bd57-4ef3-8fe6-93dcaa4d526a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_035acec8-d271-4792-8c3e-8fed3e9d4b5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_48ce3520-bd57-4ef3-8fe6-93dcaa4d526a" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_035acec8-d271-4792-8c3e-8fed3e9d4b5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_cc6db329-4090-4089-8677-06e69f67bafd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ecd2cb01-e539-4f16-b3f9-5789de7a7df3" xlink:to="loc_us-gaap_FinancialInstrumentAxis_cc6db329-4090-4089-8677-06e69f67bafd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cc6db329-4090-4089-8677-06e69f67bafd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_cc6db329-4090-4089-8677-06e69f67bafd" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cc6db329-4090-4089-8677-06e69f67bafd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b5aef028-382b-48d2-a30d-3eaba21e2a24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_cc6db329-4090-4089-8677-06e69f67bafd" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b5aef028-382b-48d2-a30d-3eaba21e2a24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_e1b3fc4b-a90a-4732-b687-b9521f41928f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b5aef028-382b-48d2-a30d-3eaba21e2a24" xlink:to="loc_us-gaap_MoneyMarketFundsMember_e1b3fc4b-a90a-4732-b687-b9521f41928f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_1814727c-d646-4dff-8c30-34bb48cfd5c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b5aef028-382b-48d2-a30d-3eaba21e2a24" xlink:to="loc_us-gaap_CertificatesOfDepositMember_1814727c-d646-4dff-8c30-34bb48cfd5c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_35a70762-db8a-4688-bf85-aa3e5cb187dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b5aef028-382b-48d2-a30d-3eaba21e2a24" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_35a70762-db8a-4688-bf85-aa3e5cb187dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember_76b67c8e-9aea-4358-86c2-aec120673b3e" xlink:href="mrna-20210331.xsd#mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b5aef028-382b-48d2-a30d-3eaba21e2a24" xlink:to="loc_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember_76b67c8e-9aea-4358-86c2-aec120673b3e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d3a3408-61a0-4f4a-a69a-863ff6402f66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ecd2cb01-e539-4f16-b3f9-5789de7a7df3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d3a3408-61a0-4f4a-a69a-863ff6402f66" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5d3a3408-61a0-4f4a-a69a-863ff6402f66_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d3a3408-61a0-4f4a-a69a-863ff6402f66" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5d3a3408-61a0-4f4a-a69a-863ff6402f66_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_235b1b22-c062-4f9b-9a44-1eee6571d5b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d3a3408-61a0-4f4a-a69a-863ff6402f66" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_235b1b22-c062-4f9b-9a44-1eee6571d5b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_8aba1ccb-ef59-4d26-8ea1-bb2574aba87a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_235b1b22-c062-4f9b-9a44-1eee6571d5b3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_8aba1ccb-ef59-4d26-8ea1-bb2574aba87a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_7505a5aa-3669-4b79-9911-f4592c80d82a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_235b1b22-c062-4f9b-9a44-1eee6571d5b3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_7505a5aa-3669-4b79-9911-f4592c80d82a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/DerivativeFinancialInstruments" xlink:type="simple" xlink:href="mrna-20210331.xsd#DerivativeFinancialInstruments"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/DerivativeFinancialInstruments" xlink:type="extended" id="if27e4a9a960747f483ef5f5af2ac9efe_DerivativeFinancialInstruments"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/DerivativeFinancialInstrumentsTables" xlink:type="simple" xlink:href="mrna-20210331.xsd#DerivativeFinancialInstrumentsTables"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/DerivativeFinancialInstrumentsTables" xlink:type="extended" id="idb82ceafe94f421bb37a1bfc1b0b41d7_DerivativeFinancialInstrumentsTables"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#DerivativeFinancialInstrumentsBalanceSheetHedgesDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails" xlink:type="extended" id="iabc8eaaf89be4edb88c48b472c7e2723_DerivativeFinancialInstrumentsBalanceSheetHedgesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_acf8eba0-8053-4869-87e2-ebb91ace2c25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_e1f4925b-6d99-43ed-bfc9-e8daff81e3a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_acf8eba0-8053-4869-87e2-ebb91ace2c25" xlink:to="loc_us-gaap_DerivativeNotionalAmount_e1f4925b-6d99-43ed-bfc9-e8daff81e3a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_9e3362f7-5d40-430a-9d43-e839fc13f619" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_acf8eba0-8053-4869-87e2-ebb91ace2c25" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_9e3362f7-5d40-430a-9d43-e839fc13f619" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_604a1a3f-002c-44d1-b229-eb24a575690e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_acf8eba0-8053-4869-87e2-ebb91ace2c25" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_604a1a3f-002c-44d1-b229-eb24a575690e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_8485a79f-024d-4a73-9f9b-c262bd699a32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_acf8eba0-8053-4869-87e2-ebb91ace2c25" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_8485a79f-024d-4a73-9f9b-c262bd699a32" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_9765cad2-e5b4-4e68-9b28-755dbfbb7107" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_acf8eba0-8053-4869-87e2-ebb91ace2c25" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_9765cad2-e5b4-4e68-9b28-755dbfbb7107" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_d2c8e9df-366a-4f61-80bf-b042d7520533" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_9765cad2-e5b4-4e68-9b28-755dbfbb7107" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_d2c8e9df-366a-4f61-80bf-b042d7520533" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_d2c8e9df-366a-4f61-80bf-b042d7520533_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_d2c8e9df-366a-4f61-80bf-b042d7520533" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_d2c8e9df-366a-4f61-80bf-b042d7520533_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_0fe809a6-1c32-4ac8-877c-2f35104a5363" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_d2c8e9df-366a-4f61-80bf-b042d7520533" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_0fe809a6-1c32-4ac8-877c-2f35104a5363" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_761642d8-63d1-44e8-be16-2b29cbc3d98b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0fe809a6-1c32-4ac8-877c-2f35104a5363" xlink:to="loc_us-gaap_ForeignExchangeContractMember_761642d8-63d1-44e8-be16-2b29cbc3d98b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3bf26de9-7d51-4339-ae73-0bd0df62f65f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_9765cad2-e5b4-4e68-9b28-755dbfbb7107" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3bf26de9-7d51-4339-ae73-0bd0df62f65f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3bf26de9-7d51-4339-ae73-0bd0df62f65f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3bf26de9-7d51-4339-ae73-0bd0df62f65f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3bf26de9-7d51-4339-ae73-0bd0df62f65f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_17a6a361-95c3-47b3-8b3a-216228345d7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3bf26de9-7d51-4339-ae73-0bd0df62f65f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_17a6a361-95c3-47b3-8b3a-216228345d7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember_4f90bf03-1d96-46b7-83f2-b960e7d6e311" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_17a6a361-95c3-47b3-8b3a-216228345d7e" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseMember_4f90bf03-1d96-46b7-83f2-b960e7d6e311" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_c787d57d-2217-4099-ad8c-d0769eaf4445" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_9765cad2-e5b4-4e68-9b28-755dbfbb7107" xlink:to="loc_us-gaap_HedgingDesignationAxis_c787d57d-2217-4099-ad8c-d0769eaf4445" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_c787d57d-2217-4099-ad8c-d0769eaf4445_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_c787d57d-2217-4099-ad8c-d0769eaf4445" xlink:to="loc_us-gaap_HedgingDesignationDomain_c787d57d-2217-4099-ad8c-d0769eaf4445_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_a961e83a-0228-446f-a20b-f616aa338f37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_c787d57d-2217-4099-ad8c-d0769eaf4445" xlink:to="loc_us-gaap_HedgingDesignationDomain_a961e83a-0228-446f-a20b-f616aa338f37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_2b2f5d5d-2dbe-487f-a0e1-8b2959299e7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_a961e83a-0228-446f-a20b-f616aa338f37" xlink:to="loc_us-gaap_NondesignatedMember_2b2f5d5d-2dbe-487f-a0e1-8b2959299e7a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/Inventory" xlink:type="simple" xlink:href="mrna-20210331.xsd#Inventory"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/Inventory" xlink:type="extended" id="i8d7a8d393e074b4b826fa772eeec7138_Inventory"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/InventoryTables" xlink:type="simple" xlink:href="mrna-20210331.xsd#InventoryTables"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/InventoryTables" xlink:type="extended" id="iab77aa0194a048b0a56db83cfdea5016_InventoryTables"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/InventoryDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#InventoryDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/InventoryDetails" xlink:type="extended" id="iba1befbfb9cf4d34bda02aaf688f8f12_InventoryDetails"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/PropertyandEquipmentNet" xlink:type="simple" xlink:href="mrna-20210331.xsd#PropertyandEquipmentNet"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/PropertyandEquipmentNet" xlink:type="extended" id="i0a717044d3fe4698aac8daa19418588c_PropertyandEquipmentNet"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/PropertyandEquipmentNetTables" xlink:type="simple" xlink:href="mrna-20210331.xsd#PropertyandEquipmentNetTables"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/PropertyandEquipmentNetTables" xlink:type="extended" id="i3473626fe4874735894892a6e4bf3512_PropertyandEquipmentNetTables"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#PropertyandEquipmentNetDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/PropertyandEquipmentNetDetails" xlink:type="extended" id="iaa2aa6b25c104582a9fa58a9876601b0_PropertyandEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f7660e9c-7531-4c8d-aaef-aace89465e07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_b33e8631-1af3-4747-b741-be856b9378f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f7660e9c-7531-4c8d-aaef-aace89465e07" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_b33e8631-1af3-4747-b741-be856b9378f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_e7236891-7f38-455a-b71a-d500a07645d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f7660e9c-7531-4c8d-aaef-aace89465e07" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_e7236891-7f38-455a-b71a-d500a07645d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_6fb87a98-290b-4d0e-8eed-0b8a1800ed93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f7660e9c-7531-4c8d-aaef-aace89465e07" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_6fb87a98-290b-4d0e-8eed-0b8a1800ed93" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_83b60f7c-b747-4dbc-9317-3eba8591ea2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f7660e9c-7531-4c8d-aaef-aace89465e07" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_83b60f7c-b747-4dbc-9317-3eba8591ea2a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_889ce3df-dca3-4c72-bf0c-3ae68a66faf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f7660e9c-7531-4c8d-aaef-aace89465e07" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_889ce3df-dca3-4c72-bf0c-3ae68a66faf6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0944dad4-783e-4807-8724-3738cecbc776" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_889ce3df-dca3-4c72-bf0c-3ae68a66faf6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0944dad4-783e-4807-8724-3738cecbc776" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0944dad4-783e-4807-8724-3738cecbc776_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0944dad4-783e-4807-8724-3738cecbc776" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0944dad4-783e-4807-8724-3738cecbc776_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3dd63b11-bcab-4a85-a62f-1f84657cf685" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0944dad4-783e-4807-8724-3738cecbc776" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3dd63b11-bcab-4a85-a62f-1f84657cf685" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_c15343d9-2364-4c54-8c6f-90d7172a72e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3dd63b11-bcab-4a85-a62f-1f84657cf685" xlink:to="loc_us-gaap_EquipmentMember_c15343d9-2364-4c54-8c6f-90d7172a72e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_7ae3c8a6-f5ea-47cc-9e36-72cec0595668" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3dd63b11-bcab-4a85-a62f-1f84657cf685" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_7ae3c8a6-f5ea-47cc-9e36-72cec0595668" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_51e471e9-c302-40ac-b4b5-e327827147db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3dd63b11-bcab-4a85-a62f-1f84657cf685" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_51e471e9-c302-40ac-b4b5-e327827147db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_8ba685e0-c693-4023-a731-de3e3928cd19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3dd63b11-bcab-4a85-a62f-1f84657cf685" xlink:to="loc_us-gaap_ComputerEquipmentMember_8ba685e0-c693-4023-a731-de3e3928cd19" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_2e66d2f5-620b-494f-9957-d9e2c862466c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3dd63b11-bcab-4a85-a62f-1f84657cf685" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_2e66d2f5-620b-494f-9957-d9e2c862466c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_FinancingRightOfUseAssetMember_b8d72ac9-2574-4721-af5f-bb809be22f2e" xlink:href="mrna-20210331.xsd#mrna_FinancingRightOfUseAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3dd63b11-bcab-4a85-a62f-1f84657cf685" xlink:to="loc_mrna_FinancingRightOfUseAssetMember_b8d72ac9-2574-4721-af5f-bb809be22f2e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_d9e9ab09-0daf-4305-9082-feae40af39f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3dd63b11-bcab-4a85-a62f-1f84657cf685" xlink:to="loc_us-gaap_ConstructionInProgressMember_d9e9ab09-0daf-4305-9082-feae40af39f0" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponents" xlink:type="simple" xlink:href="mrna-20210331.xsd#OtherBalanceSheetComponents"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/OtherBalanceSheetComponents" xlink:type="extended" id="id104a6e681bf4b4094342a42b3070c91_OtherBalanceSheetComponents"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsTables" xlink:type="simple" xlink:href="mrna-20210331.xsd#OtherBalanceSheetComponentsTables"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/OtherBalanceSheetComponentsTables" xlink:type="extended" id="i9e7d79269645450dbe83824b2e8f4ed3_OtherBalanceSheetComponentsTables"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended" id="iba67ff9d65a54a48975608f7296a631b_OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#OtherBalanceSheetComponentsAccruedLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="extended" id="i0374fec7df0e4d7e89bc2c52098ef0d4_OtherBalanceSheetComponentsAccruedLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#OtherBalanceSheetComponentsDeferredRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails" xlink:type="extended" id="i4d5d89315c1745539ab8c2619b57fbac_OtherBalanceSheetComponentsDeferredRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractWithCustomerLiabilityLineItems_d2914be8-6cb6-45bd-8f31-c7e4e257a218" xlink:href="mrna-20210331.xsd#mrna_ChangeInContractWithCustomerLiabilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward_1e69c33c-3bc9-4921-8dff-9c01a25bdef2" xlink:href="mrna-20210331.xsd#mrna_ChangeInContractwithCustomerLiabilityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityLineItems_d2914be8-6cb6-45bd-8f31-c7e4e257a218" xlink:to="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward_1e69c33c-3bc9-4921-8dff-9c01a25bdef2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_b75c45b8-1b2e-4b0a-ab61-63d7b0f61388" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward_1e69c33c-3bc9-4921-8dff-9c01a25bdef2" xlink:to="loc_us-gaap_ContractWithCustomerLiability_b75c45b8-1b2e-4b0a-ab61-63d7b0f61388" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_b1ad2ebe-8c6f-4725-b980-edb46987744f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward_1e69c33c-3bc9-4921-8dff-9c01a25bdef2" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_b1ad2ebe-8c6f-4725-b980-edb46987744f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod_2de9be5f-bc84-4313-806e-4918a3386f72" xlink:href="mrna-20210331.xsd#mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward_1e69c33c-3bc9-4921-8dff-9c01a25bdef2" xlink:to="loc_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod_2de9be5f-bc84-4313-806e-4918a3386f72" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_f26a3801-79bd-458f-a534-096989a45ade" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractWithCustomerLiabilityTable_2b2b68e2-30aa-4215-8247-37041022b081" xlink:href="mrna-20210331.xsd#mrna_ChangeInContractWithCustomerLiabilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityLineItems_d2914be8-6cb6-45bd-8f31-c7e4e257a218" xlink:to="loc_mrna_ChangeInContractWithCustomerLiabilityTable_2b2b68e2-30aa-4215-8247-37041022b081" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c38e5d1b-3c36-4a17-8d19-096da382e77d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityTable_2b2b68e2-30aa-4215-8247-37041022b081" xlink:to="loc_srt_ProductOrServiceAxis_c38e5d1b-3c36-4a17-8d19-096da382e77d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c38e5d1b-3c36-4a17-8d19-096da382e77d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c38e5d1b-3c36-4a17-8d19-096da382e77d" xlink:to="loc_srt_ProductsAndServicesDomain_c38e5d1b-3c36-4a17-8d19-096da382e77d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5be86880-798b-4f74-84f1-9235aa2e982c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c38e5d1b-3c36-4a17-8d19-096da382e77d" xlink:to="loc_srt_ProductsAndServicesDomain_5be86880-798b-4f74-84f1-9235aa2e982c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ProductSalesMember_7bcc20b2-56c3-4f01-a3e5-271bd0799599" xlink:href="mrna-20210331.xsd#mrna_ProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5be86880-798b-4f74-84f1-9235aa2e982c" xlink:to="loc_mrna_ProductSalesMember_7bcc20b2-56c3-4f01-a3e5-271bd0799599" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_83e88699-e560-4b9c-bdd2-6778f425af02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5be86880-798b-4f74-84f1-9235aa2e982c" xlink:to="loc_us-gaap_GrantMember_83e88699-e560-4b9c-bdd2-6778f425af02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CollaborationArrangementMember_acf2a515-f1ce-4fc1-961e-d662a4c33685" xlink:href="mrna-20210331.xsd#mrna_CollaborationArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5be86880-798b-4f74-84f1-9235aa2e982c" xlink:to="loc_mrna_CollaborationArrangementMember_acf2a515-f1ce-4fc1-961e-d662a4c33685" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/Leases" xlink:type="simple" xlink:href="mrna-20210331.xsd#Leases"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/Leases" xlink:type="extended" id="if5d0079fcc5749d1b34dd593d4ac3e66_Leases"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesTables" xlink:type="simple" xlink:href="mrna-20210331.xsd#LeasesTables"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/LeasesTables" xlink:type="extended" id="i043e2150f1b74650a821ab25a9ccf2ae_LeasesTables"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/LeasesNarrativeDetails" xlink:type="extended" id="ice3b41f79a424353a997921f5a8ad92e_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_ab07550a-6881-43fb-a15b-eb40f7636ccf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingLeaseNumberOfProperties_04c56bf9-98c3-4bfe-8ca5-a0ad1686dc35" xlink:href="mrna-20210331.xsd#mrna_OperatingLeaseNumberOfProperties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ab07550a-6881-43fb-a15b-eb40f7636ccf" xlink:to="loc_mrna_OperatingLeaseNumberOfProperties_04c56bf9-98c3-4bfe-8ca5-a0ad1686dc35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_c110d343-87ae-4093-a8c2-18827eea5f7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ab07550a-6881-43fb-a15b-eb40f7636ccf" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_c110d343-87ae-4093-a8c2-18827eea5f7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_33423aaa-802b-4d55-b77b-8438af7c0aaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ab07550a-6881-43fb-a15b-eb40f7636ccf" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_33423aaa-802b-4d55-b77b-8438af7c0aaa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods_1fcc9d7b-a7c5-4c00-9c61-0de6bf1a37ed" xlink:href="mrna-20210331.xsd#mrna_LesseeOperatingLeaseNumberOfExtensionPeriods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ab07550a-6881-43fb-a15b-eb40f7636ccf" xlink:to="loc_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods_1fcc9d7b-a7c5-4c00-9c61-0de6bf1a37ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AllowanceForTenantImprovements_f905f84e-54da-44a6-9a44-796a7cd91c0a" xlink:href="mrna-20210331.xsd#mrna_AllowanceForTenantImprovements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ab07550a-6881-43fb-a15b-eb40f7636ccf" xlink:to="loc_mrna_AllowanceForTenantImprovements_f905f84e-54da-44a6-9a44-796a7cd91c0a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_fc94983d-0fbe-466f-bf21-4369f16eb727" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ab07550a-6881-43fb-a15b-eb40f7636ccf" xlink:to="loc_us-gaap_OperatingLeaseLiability_fc94983d-0fbe-466f-bf21-4369f16eb727" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c35462d9-69ae-4d62-9660-1fd912e74360" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ab07550a-6881-43fb-a15b-eb40f7636ccf" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c35462d9-69ae-4d62-9660-1fd912e74360" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_eb42ff86-b730-46b8-999e-06be58ea7a77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ab07550a-6881-43fb-a15b-eb40f7636ccf" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_eb42ff86-b730-46b8-999e-06be58ea7a77" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_c6290185-44f9-411c-88b0-8cb42c2edefe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ab07550a-6881-43fb-a15b-eb40f7636ccf" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_c6290185-44f9-411c-88b0-8cb42c2edefe" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LeasesImputedInterestRate_726e862a-a22f-4cb2-b5f7-a740edbad88e" xlink:href="mrna-20210331.xsd#mrna_LeasesImputedInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ab07550a-6881-43fb-a15b-eb40f7636ccf" xlink:to="loc_mrna_LeasesImputedInterestRate_726e862a-a22f-4cb2-b5f7-a740edbad88e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LeasesIncrementalBorrowingRate_d7a9e307-06e7-4aaf-a2da-fa5c8d0552f7" xlink:href="mrna-20210331.xsd#mrna_LeasesIncrementalBorrowingRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ab07550a-6881-43fb-a15b-eb40f7636ccf" xlink:to="loc_mrna_LeasesIncrementalBorrowingRate_d7a9e307-06e7-4aaf-a2da-fa5c8d0552f7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_93e68231-ff6a-4efe-b116-c32078e4adb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ab07550a-6881-43fb-a15b-eb40f7636ccf" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_93e68231-ff6a-4efe-b116-c32078e4adb3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_b80bbd02-2615-4d11-8c78-3c13bed7ab53" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_93e68231-ff6a-4efe-b116-c32078e4adb3" xlink:to="loc_srt_StatementGeographicalAxis_b80bbd02-2615-4d11-8c78-3c13bed7ab53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b80bbd02-2615-4d11-8c78-3c13bed7ab53_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_b80bbd02-2615-4d11-8c78-3c13bed7ab53" xlink:to="loc_srt_SegmentGeographicalDomain_b80bbd02-2615-4d11-8c78-3c13bed7ab53_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4ea4f4ca-cf13-4bfe-869c-cabe929f43b5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_b80bbd02-2615-4d11-8c78-3c13bed7ab53" xlink:to="loc_srt_SegmentGeographicalDomain_4ea4f4ca-cf13-4bfe-869c-cabe929f43b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CambridgeMassachusettsMember_4714f322-3ca1-4e1b-81b8-92aaac590220" xlink:href="mrna-20210331.xsd#mrna_CambridgeMassachusettsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4ea4f4ca-cf13-4bfe-869c-cabe929f43b5" xlink:to="loc_mrna_CambridgeMassachusettsMember_4714f322-3ca1-4e1b-81b8-92aaac590220" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NorwoodMassachusettsMember_e4aad360-95af-4040-83bd-e5c4aff99609" xlink:href="mrna-20210331.xsd#mrna_NorwoodMassachusettsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4ea4f4ca-cf13-4bfe-869c-cabe929f43b5" xlink:to="loc_mrna_NorwoodMassachusettsMember_e4aad360-95af-4040-83bd-e5c4aff99609" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_0d93d5c9-77d8-4be7-9fbd-44b48fd9b3e8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_93e68231-ff6a-4efe-b116-c32078e4adb3" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_0d93d5c9-77d8-4be7-9fbd-44b48fd9b3e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_0d93d5c9-77d8-4be7-9fbd-44b48fd9b3e8_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_0d93d5c9-77d8-4be7-9fbd-44b48fd9b3e8" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_0d93d5c9-77d8-4be7-9fbd-44b48fd9b3e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_29336006-02b7-49a2-90d1-55576dd395dd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_0d93d5c9-77d8-4be7-9fbd-44b48fd9b3e8" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_29336006-02b7-49a2-90d1-55576dd395dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MTCSouthMember_07750643-8f86-463b-95a1-eebb75297679" xlink:href="mrna-20210331.xsd#mrna_MTCSouthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_29336006-02b7-49a2-90d1-55576dd395dd" xlink:to="loc_mrna_MTCSouthMember_07750643-8f86-463b-95a1-eebb75297679" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MTCNorthMember_a8b6581b-fb56-4478-a327-535c85c62008" xlink:href="mrna-20210331.xsd#mrna_MTCNorthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_29336006-02b7-49a2-90d1-55576dd395dd" xlink:to="loc_mrna_MTCNorthMember_a8b6581b-fb56-4478-a327-535c85c62008" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_0aff6184-aa25-4e4c-8e76-e9bf746ada55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_93e68231-ff6a-4efe-b116-c32078e4adb3" xlink:to="loc_us-gaap_LeaseContractualTermAxis_0aff6184-aa25-4e4c-8e76-e9bf746ada55" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_0aff6184-aa25-4e4c-8e76-e9bf746ada55_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_0aff6184-aa25-4e4c-8e76-e9bf746ada55" xlink:to="loc_us-gaap_LeaseContractualTermDomain_0aff6184-aa25-4e4c-8e76-e9bf746ada55_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_12a7fe9f-838c-4edd-9dd0-9bf7ebb398ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_0aff6184-aa25-4e4c-8e76-e9bf746ada55" xlink:to="loc_us-gaap_LeaseContractualTermDomain_12a7fe9f-838c-4edd-9dd0-9bf7ebb398ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_EmbeddedLeasesMember_cb198fa8-124f-4bb7-8743-1623c5375de1" xlink:href="mrna-20210331.xsd#mrna_EmbeddedLeasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_12a7fe9f-838c-4edd-9dd0-9bf7ebb398ef" xlink:to="loc_mrna_EmbeddedLeasesMember_cb198fa8-124f-4bb7-8743-1623c5375de1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#LeasesBalanceSheetInformationDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails" xlink:type="extended" id="i6ddbee09fb134767bd52ccb83405684c_LeasesBalanceSheetInformationDetails"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#LeasesMinimumLeasePaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails" xlink:type="extended" id="i6ce57c3f19854820bd65ed1117fe8ff7_LeasesMinimumLeasePaymentsDetails"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="mrna-20210331.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CommitmentsandContingencies" xlink:type="extended" id="ib3893cc242a347f5b89af5702900e979_CommitmentsandContingencies"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/CommitmentsandContingenciesStrategicCollaborationsDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#CommitmentsandContingenciesStrategicCollaborationsDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CommitmentsandContingenciesStrategicCollaborationsDetails" xlink:type="extended" id="ieb90265676234f63b3bab3625d4940b4_CommitmentsandContingenciesStrategicCollaborationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_66550c1d-5fbf-48f6-80f4-b8fd6f015d33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount_8137ddfd-3397-43a1-b1e6-4266566de206" xlink:href="mrna-20210331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_66550c1d-5fbf-48f6-80f4-b8fd6f015d33" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount_8137ddfd-3397-43a1-b1e6-4266566de206" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_685b9059-e65b-453b-947d-5881da690674" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_66550c1d-5fbf-48f6-80f4-b8fd6f015d33" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_685b9059-e65b-453b-947d-5881da690674" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_219747d3-1ff0-4e1a-8745-5395752cf929" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_685b9059-e65b-453b-947d-5881da690674" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_219747d3-1ff0-4e1a-8745-5395752cf929" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_219747d3-1ff0-4e1a-8745-5395752cf929_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_219747d3-1ff0-4e1a-8745-5395752cf929" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_219747d3-1ff0-4e1a-8745-5395752cf929_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0240b984-c33b-4cc5-8601-bce7edebda90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_219747d3-1ff0-4e1a-8745-5395752cf929" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0240b984-c33b-4cc5-8601-bce7edebda90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember_6a3a79e8-ef24-429c-a27d-5cd9f60c9680" xlink:href="mrna-20210331.xsd#mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0240b984-c33b-4cc5-8601-bce7edebda90" xlink:to="loc_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember_6a3a79e8-ef24-429c-a27d-5cd9f60c9680" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_350faf17-6741-489b-ae04-7ed3a5e273c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_685b9059-e65b-453b-947d-5881da690674" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_350faf17-6741-489b-ae04-7ed3a5e273c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_350faf17-6741-489b-ae04-7ed3a5e273c5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_350faf17-6741-489b-ae04-7ed3a5e273c5" xlink:to="loc_us-gaap_ProjectMember_350faf17-6741-489b-ae04-7ed3a5e273c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_76d34da9-bb52-4a5b-bcab-58445cb6a176" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_350faf17-6741-489b-ae04-7ed3a5e273c5" xlink:to="loc_us-gaap_ProjectMember_76d34da9-bb52-4a5b-bcab-58445cb6a176" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_PersonalizedMRNACancerVaccinesProductsMember_c151c358-11e0-4441-bd31-421a758ea174" xlink:href="mrna-20210331.xsd#mrna_PersonalizedMRNACancerVaccinesProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_76d34da9-bb52-4a5b-bcab-58445cb6a176" xlink:to="loc_mrna_PersonalizedMRNACancerVaccinesProductsMember_c151c358-11e0-4441-bd31-421a758ea174" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails" xlink:type="extended" id="i224ca73c0043499e9ea474bc36e4764b_CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_30269f93-6965-451e-98aa-34e21a1c186c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_40b683ba-dc1c-4850-8760-79504829385d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_30269f93-6965-451e-98aa-34e21a1c186c" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_40b683ba-dc1c-4850-8760-79504829385d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_32361a0e-bf3d-4361-9148-5402d754c46a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_30269f93-6965-451e-98aa-34e21a1c186c" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_32361a0e-bf3d-4361-9148-5402d754c46a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_a6e8037a-5a85-4de1-bbe7-c3f164d18213" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_32361a0e-bf3d-4361-9148-5402d754c46a" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_a6e8037a-5a85-4de1-bbe7-c3f164d18213" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_a6e8037a-5a85-4de1-bbe7-c3f164d18213_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_a6e8037a-5a85-4de1-bbe7-c3f164d18213" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_a6e8037a-5a85-4de1-bbe7-c3f164d18213_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_9e7a3f70-01e9-44e6-ae43-8a1af7f3f52c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_a6e8037a-5a85-4de1-bbe7-c3f164d18213" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_9e7a3f70-01e9-44e6-ae43-8a1af7f3f52c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_SupplyAndManufacturingAgreementsMember_d405c047-9466-4901-8def-bf79f54a1895" xlink:href="mrna-20210331.xsd#mrna_SupplyAndManufacturingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_9e7a3f70-01e9-44e6-ae43-8a1af7f3f52c" xlink:to="loc_mrna_SupplyAndManufacturingAgreementsMember_d405c047-9466-4901-8def-bf79f54a1895" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ClinicalOperationsAndSupportCommitmentMember_a3a20ec8-93bf-48cc-8559-3b1b58d1f81a" xlink:href="mrna-20210331.xsd#mrna_ClinicalOperationsAndSupportCommitmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_9e7a3f70-01e9-44e6-ae43-8a1af7f3f52c" xlink:to="loc_mrna_ClinicalOperationsAndSupportCommitmentMember_a3a20ec8-93bf-48cc-8559-3b1b58d1f81a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ClinicalServicesMember_6bbd6d1f-aae9-4792-8a4f-4148913b1e1c" xlink:href="mrna-20210331.xsd#mrna_ClinicalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_9e7a3f70-01e9-44e6-ae43-8a1af7f3f52c" xlink:to="loc_mrna_ClinicalServicesMember_6bbd6d1f-aae9-4792-8a4f-4148913b1e1c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#CommitmentsandContingenciesLicensestoPatentedTechnologyDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails" xlink:type="extended" id="id2a739036703443f8e3a0c7e37215522_CommitmentsandContingenciesLicensestoPatentedTechnologyDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_c0cd3928-c71c-49c5-98ca-459ec56ba0ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentAndRegulatoryMilestonesMaximumAmount_e1d9d854-a8a1-48a1-882b-be8c4a06573b" xlink:href="mrna-20210331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentAndRegulatoryMilestonesMaximumAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_c0cd3928-c71c-49c5-98ca-459ec56ba0ff" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentAndRegulatoryMilestonesMaximumAmount_e1d9d854-a8a1-48a1-882b-be8c4a06573b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount_18850aed-c5f0-4ad0-83dc-2697f8ee9abe" xlink:href="mrna-20210331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_c0cd3928-c71c-49c5-98ca-459ec56ba0ff" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount_18850aed-c5f0-4ad0-83dc-2697f8ee9abe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_6f8ec403-3296-4faa-a8c4-6737a639e735" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_c0cd3928-c71c-49c5-98ca-459ec56ba0ff" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_6f8ec403-3296-4faa-a8c4-6737a639e735" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_222fc1e1-db90-4778-a474-e9ab70a076a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_c0cd3928-c71c-49c5-98ca-459ec56ba0ff" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_222fc1e1-db90-4778-a474-e9ab70a076a2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_4795e2a1-e82f-46cb-9612-4e42224773a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_222fc1e1-db90-4778-a474-e9ab70a076a2" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_4795e2a1-e82f-46cb-9612-4e42224773a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_4795e2a1-e82f-46cb-9612-4e42224773a0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_4795e2a1-e82f-46cb-9612-4e42224773a0" xlink:to="loc_us-gaap_ProjectMember_4795e2a1-e82f-46cb-9612-4e42224773a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_a339b82f-bac7-45e3-b12a-e0cb9d813871" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_4795e2a1-e82f-46cb-9612-4e42224773a0" xlink:to="loc_us-gaap_ProjectMember_a339b82f-bac7-45e3-b12a-e0cb9d813871" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_TherapeuticAndProphylacticProductsMember_af20fcdd-d848-458f-93cc-c1949cd9cf7f" xlink:href="mrna-20210331.xsd#mrna_TherapeuticAndProphylacticProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_a339b82f-bac7-45e3-b12a-e0cb9d813871" xlink:to="loc_mrna_TherapeuticAndProphylacticProductsMember_af20fcdd-d848-458f-93cc-c1949cd9cf7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DiagnosticProductsMember_c86709d0-018e-4597-be32-2e9e42da4580" xlink:href="mrna-20210331.xsd#mrna_DiagnosticProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_a339b82f-bac7-45e3-b12a-e0cb9d813871" xlink:to="loc_mrna_DiagnosticProductsMember_c86709d0-018e-4597-be32-2e9e42da4580" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="mrna-20210331.xsd#StockBasedCompensation"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/StockBasedCompensation" xlink:type="extended" id="i95fc829857a24a839fbc8790e75421d8_StockBasedCompensation"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="mrna-20210331.xsd#StockBasedCompensationTables"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationTables" xlink:type="extended" id="i6f6f1640f3864586ae620dffac20389e_StockBasedCompensationTables"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" id="i3bd0a211a3e34b34b88d0375848e313e_StockBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0ac1c1f-20bd-4e6f-8eac-69cf1b53f148" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5d795ea1-dace-48b1-9033-21620adccbc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0ac1c1f-20bd-4e6f-8eac-69cf1b53f148" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5d795ea1-dace-48b1-9033-21620adccbc5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d83fc008-aa35-4457-b347-f6d30f3010e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0ac1c1f-20bd-4e6f-8eac-69cf1b53f148" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d83fc008-aa35-4457-b347-f6d30f3010e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_43698867-4d0a-4af9-bde7-d48ea9212d88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0ac1c1f-20bd-4e6f-8eac-69cf1b53f148" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_43698867-4d0a-4af9-bde7-d48ea9212d88" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_7d0df77c-bce8-4d2e-98eb-1624795e94e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0ac1c1f-20bd-4e6f-8eac-69cf1b53f148" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_7d0df77c-bce8-4d2e-98eb-1624795e94e1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f7b52be6-6373-48ef-a23b-49187b968ec6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0ac1c1f-20bd-4e6f-8eac-69cf1b53f148" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f7b52be6-6373-48ef-a23b-49187b968ec6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockExpense_1fbbf273-d920-4b34-b296-c564102c045b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0ac1c1f-20bd-4e6f-8eac-69cf1b53f148" xlink:to="loc_us-gaap_RestrictedStockExpense_1fbbf273-d920-4b34-b296-c564102c045b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_40bcfcea-e4d0-4133-b62b-72dad8ab056e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0ac1c1f-20bd-4e6f-8eac-69cf1b53f148" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_40bcfcea-e4d0-4133-b62b-72dad8ab056e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_42ba1ea0-167e-4bbb-b494-06ab641ab93a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0ac1c1f-20bd-4e6f-8eac-69cf1b53f148" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_42ba1ea0-167e-4bbb-b494-06ab641ab93a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage_e0e5bf40-2ebf-4119-83f3-d88178c67c27" xlink:href="mrna-20210331.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0ac1c1f-20bd-4e6f-8eac-69cf1b53f148" xlink:to="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage_e0e5bf40-2ebf-4119-83f3-d88178c67c27" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_3bc60a03-3637-44cb-94ee-210698859922" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0ac1c1f-20bd-4e6f-8eac-69cf1b53f148" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_3bc60a03-3637-44cb-94ee-210698859922" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ca3e1a66-41fa-4b93-971c-c21a1115d2c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0ac1c1f-20bd-4e6f-8eac-69cf1b53f148" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ca3e1a66-41fa-4b93-971c-c21a1115d2c8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_102aa7ba-bf5d-42f5-931a-dbd078db334e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0ac1c1f-20bd-4e6f-8eac-69cf1b53f148" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_102aa7ba-bf5d-42f5-931a-dbd078db334e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_93dbcec2-6ad4-4aa4-b63f-d745330b8572" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0ac1c1f-20bd-4e6f-8eac-69cf1b53f148" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_93dbcec2-6ad4-4aa4-b63f-d745330b8572" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8eaf16a7-4cb5-4bfe-accb-9553255bd00d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0ac1c1f-20bd-4e6f-8eac-69cf1b53f148" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8eaf16a7-4cb5-4bfe-accb-9553255bd00d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_6a6b1d42-bacf-4af4-afac-e6fdefdeac43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8eaf16a7-4cb5-4bfe-accb-9553255bd00d" xlink:to="loc_us-gaap_PlanNameAxis_6a6b1d42-bacf-4af4-afac-e6fdefdeac43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6a6b1d42-bacf-4af4-afac-e6fdefdeac43_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_6a6b1d42-bacf-4af4-afac-e6fdefdeac43" xlink:to="loc_us-gaap_PlanNameDomain_6a6b1d42-bacf-4af4-afac-e6fdefdeac43_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d4252bca-8de7-445f-84d0-124e8540c971" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_6a6b1d42-bacf-4af4-afac-e6fdefdeac43" xlink:to="loc_us-gaap_PlanNameDomain_d4252bca-8de7-445f-84d0-124e8540c971" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_StockOptionAndIncentivePlan2018Member_1ef6b4c3-e8c7-4951-9277-aa11a1450f42" xlink:href="mrna-20210331.xsd#mrna_StockOptionAndIncentivePlan2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d4252bca-8de7-445f-84d0-124e8540c971" xlink:to="loc_mrna_StockOptionAndIncentivePlan2018Member_1ef6b4c3-e8c7-4951-9277-aa11a1450f42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f2f49d57-e7d4-481a-bacd-52f44e3de413" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8eaf16a7-4cb5-4bfe-accb-9553255bd00d" xlink:to="loc_us-gaap_AwardTypeAxis_f2f49d57-e7d4-481a-bacd-52f44e3de413" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f2f49d57-e7d4-481a-bacd-52f44e3de413_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f2f49d57-e7d4-481a-bacd-52f44e3de413" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f2f49d57-e7d4-481a-bacd-52f44e3de413_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac29034d-b0ac-48bd-aee8-a6dc726ec97c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f2f49d57-e7d4-481a-bacd-52f44e3de413" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac29034d-b0ac-48bd-aee8-a6dc726ec97c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_264fb874-7c88-4c2e-ad58-fd522c75cd49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac29034d-b0ac-48bd-aee8-a6dc726ec97c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_264fb874-7c88-4c2e-ad58-fd522c75cd49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_d37c7bdd-93f2-4a6e-b72c-873295603dca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac29034d-b0ac-48bd-aee8-a6dc726ec97c" xlink:to="loc_us-gaap_EmployeeStockMember_d37c7bdd-93f2-4a6e-b72c-873295603dca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_856a4b8b-4a87-4a5e-86b5-49b672ef4ae0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac29034d-b0ac-48bd-aee8-a6dc726ec97c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_856a4b8b-4a87-4a5e-86b5-49b672ef4ae0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_afc2ee11-d896-43a2-9abf-be83fcf77494" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac29034d-b0ac-48bd-aee8-a6dc726ec97c" xlink:to="loc_us-gaap_PerformanceSharesMember_afc2ee11-d896-43a2-9abf-be83fcf77494" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f29893af-cdef-4731-8e98-21b58ce5410f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8eaf16a7-4cb5-4bfe-accb-9553255bd00d" xlink:to="loc_srt_RangeAxis_f29893af-cdef-4731-8e98-21b58ce5410f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f29893af-cdef-4731-8e98-21b58ce5410f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f29893af-cdef-4731-8e98-21b58ce5410f" xlink:to="loc_srt_RangeMember_f29893af-cdef-4731-8e98-21b58ce5410f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f7dcf83c-0264-4b99-877d-329242402e17" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f29893af-cdef-4731-8e98-21b58ce5410f" xlink:to="loc_srt_RangeMember_f7dcf83c-0264-4b99-877d-329242402e17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_88374bf5-ed23-4cf3-9457-57d760ff3e0a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f7dcf83c-0264-4b99-877d-329242402e17" xlink:to="loc_srt_MinimumMember_88374bf5-ed23-4cf3-9457-57d760ff3e0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1088fe4c-aaa0-41ce-9265-da19bb0fbee2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f7dcf83c-0264-4b99-877d-329242402e17" xlink:to="loc_srt_MaximumMember_1088fe4c-aaa0-41ce-9265-da19bb0fbee2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#StockBasedCompensationOptionsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails" xlink:type="extended" id="i6ddf40c197434bb8922c404856eb8ac7_StockBasedCompensationOptionsActivityDetails"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails" xlink:type="extended" id="i0c253c3ec9074508babe36b1c735df1c_StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d900abd-5b4a-4e8e-a48e-4025eb5badb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f11a4ee2-882a-41f4-8d0e-a91ab52e10c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d900abd-5b4a-4e8e-a48e-4025eb5badb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f11a4ee2-882a-41f4-8d0e-a91ab52e10c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7bcfb38e-9474-4378-84d3-00a86c776980" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f11a4ee2-882a-41f4-8d0e-a91ab52e10c1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7bcfb38e-9474-4378-84d3-00a86c776980" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9d55955a-8f70-4414-887a-74a6378b5f6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f11a4ee2-882a-41f4-8d0e-a91ab52e10c1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9d55955a-8f70-4414-887a-74a6378b5f6b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2ce19260-3ae7-415f-83c2-773e79a66108" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f11a4ee2-882a-41f4-8d0e-a91ab52e10c1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2ce19260-3ae7-415f-83c2-773e79a66108" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_73147641-7e62-4967-87ff-7c5505a5ddc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f11a4ee2-882a-41f4-8d0e-a91ab52e10c1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_73147641-7e62-4967-87ff-7c5505a5ddc0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9b86f0ee-a2b0-4978-9ec8-556ec3f34945" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6f1d1762-e909-4d63-a4f6-011422a2017b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d900abd-5b4a-4e8e-a48e-4025eb5badb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6f1d1762-e909-4d63-a4f6-011422a2017b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_928dc05b-4189-49d1-9264-d29ac3bd5c13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6f1d1762-e909-4d63-a4f6-011422a2017b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_928dc05b-4189-49d1-9264-d29ac3bd5c13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_180b8333-798d-4aa6-8619-fedca7a6a2c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6f1d1762-e909-4d63-a4f6-011422a2017b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_180b8333-798d-4aa6-8619-fedca7a6a2c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0698dc84-c183-42c1-adb2-58756822d365" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6f1d1762-e909-4d63-a4f6-011422a2017b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0698dc84-c183-42c1-adb2-58756822d365" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_46a8c75f-482a-46bf-91f0-01e3634db06f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6f1d1762-e909-4d63-a4f6-011422a2017b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_46a8c75f-482a-46bf-91f0-01e3634db06f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_91650c0b-2263-4c06-bc3d-5dae49d3bf99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c9e0b84f-29ae-4494-bec8-66136e962c93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d900abd-5b4a-4e8e-a48e-4025eb5badb4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c9e0b84f-29ae-4494-bec8-66136e962c93" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7bc95097-e1fe-4867-9856-8b744abcae94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c9e0b84f-29ae-4494-bec8-66136e962c93" xlink:to="loc_us-gaap_AwardTypeAxis_7bc95097-e1fe-4867-9856-8b744abcae94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7bc95097-e1fe-4867-9856-8b744abcae94_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7bc95097-e1fe-4867-9856-8b744abcae94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7bc95097-e1fe-4867-9856-8b744abcae94_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66fa8354-3da1-413d-9c60-77a87c4c5231" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7bc95097-e1fe-4867-9856-8b744abcae94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66fa8354-3da1-413d-9c60-77a87c4c5231" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_90d912ac-85b5-419f-b2ba-d9ff8100cc02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66fa8354-3da1-413d-9c60-77a87c4c5231" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_90d912ac-85b5-419f-b2ba-d9ff8100cc02" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended" id="i3e66195eb81d445380cdc19454cf2598_StockBasedCompensationStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f00eee61-7c7c-4bbc-9961-30678772d7b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_40fabb59-878c-4f3e-8758-aa2fa9c4cae5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f00eee61-7c7c-4bbc-9961-30678772d7b0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_40fabb59-878c-4f3e-8758-aa2fa9c4cae5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4d83f6d5-00d4-4f95-b3c6-0544554143d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f00eee61-7c7c-4bbc-9961-30678772d7b0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4d83f6d5-00d4-4f95-b3c6-0544554143d2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_88e6e944-fd14-457e-83f3-c10acc669a6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4d83f6d5-00d4-4f95-b3c6-0544554143d2" xlink:to="loc_us-gaap_AwardTypeAxis_88e6e944-fd14-457e-83f3-c10acc669a6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_88e6e944-fd14-457e-83f3-c10acc669a6e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_88e6e944-fd14-457e-83f3-c10acc669a6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_88e6e944-fd14-457e-83f3-c10acc669a6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0df19c3b-ed04-4eb6-b496-3d000f1a8adf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_88e6e944-fd14-457e-83f3-c10acc669a6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0df19c3b-ed04-4eb6-b496-3d000f1a8adf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7a840fdb-e181-49c6-8809-8e03f5565e12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0df19c3b-ed04-4eb6-b496-3d000f1a8adf" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7a840fdb-e181-49c6-8809-8e03f5565e12" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RestrictedStockAndRestrictedStockUnitsRSUMember_fbf2949e-f40d-483d-86db-43ab7f90d16f" xlink:href="mrna-20210331.xsd#mrna_RestrictedStockAndRestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0df19c3b-ed04-4eb6-b496-3d000f1a8adf" xlink:to="loc_mrna_RestrictedStockAndRestrictedStockUnitsRSUMember_fbf2949e-f40d-483d-86db-43ab7f90d16f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_7f7c7bf6-24ad-4e2d-b0ce-15491deb3b3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0df19c3b-ed04-4eb6-b496-3d000f1a8adf" xlink:to="loc_us-gaap_EmployeeStockMember_7f7c7bf6-24ad-4e2d-b0ce-15491deb3b3f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_b1ee03b3-bd51-481a-8872-7f34f62f54bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4d83f6d5-00d4-4f95-b3c6-0544554143d2" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_b1ee03b3-bd51-481a-8872-7f34f62f54bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b1ee03b3-bd51-481a-8872-7f34f62f54bd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b1ee03b3-bd51-481a-8872-7f34f62f54bd" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b1ee03b3-bd51-481a-8872-7f34f62f54bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_77ea7f0d-cb4b-413e-a237-416d73e33ff1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b1ee03b3-bd51-481a-8872-7f34f62f54bd" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_77ea7f0d-cb4b-413e-a237-416d73e33ff1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_31630095-5d24-4b4d-8284-2adf870ab830" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_77ea7f0d-cb4b-413e-a237-416d73e33ff1" xlink:to="loc_us-gaap_CostOfSalesMember_31630095-5d24-4b4d-8284-2adf870ab830" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_18e2134a-f973-4256-b0fe-d8c7dd589a20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_77ea7f0d-cb4b-413e-a237-416d73e33ff1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_18e2134a-f973-4256-b0fe-d8c7dd589a20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_5a291b0d-5a50-4e4b-9d78-a9c215cb5a0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_77ea7f0d-cb4b-413e-a237-416d73e33ff1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_5a291b0d-5a50-4e4b-9d78-a9c215cb5a0b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/IncomeTaxes" xlink:type="simple" xlink:href="mrna-20210331.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/IncomeTaxes" xlink:type="extended" id="i96d5777e7fa44b568fe0b3468639b9df_IncomeTaxes"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#IncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/IncomeTaxesDetails" xlink:type="extended" id="i7c28859d31ba45ab95ba9b5a3a815727_IncomeTaxesDetails"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/EarningsperShare" xlink:type="simple" xlink:href="mrna-20210331.xsd#EarningsperShare"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/EarningsperShare" xlink:type="extended" id="i4c1107d4fb1f4b5094b8ba8a1828ec8b_EarningsperShare"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/EarningsperShareTables" xlink:type="simple" xlink:href="mrna-20210331.xsd#EarningsperShareTables"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/EarningsperShareTables" xlink:type="extended" id="i4696e1ec3e3f4099a1c70f667525205e_EarningsperShareTables"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/EarningsperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#EarningsperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/EarningsperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails" xlink:type="extended" id="i65ccb930bc6e446ca185f0818bf14808_EarningsperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/EarningsperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#EarningsperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/EarningsperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails" xlink:type="extended" id="id1075015dcb24ef4bf68aba135c97533_EarningsperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d3c4a3d6-6a87-444c-9524-95dc76856a65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2691a2e0-26c0-4f70-9953-32cc8bf4eebc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d3c4a3d6-6a87-444c-9524-95dc76856a65" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2691a2e0-26c0-4f70-9953-32cc8bf4eebc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e9e48f09-d6d9-4762-b62f-0d53598c414b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d3c4a3d6-6a87-444c-9524-95dc76856a65" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e9e48f09-d6d9-4762-b62f-0d53598c414b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1788a6a7-1e2c-4464-adfb-624e3fcd313f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e9e48f09-d6d9-4762-b62f-0d53598c414b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1788a6a7-1e2c-4464-adfb-624e3fcd313f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1788a6a7-1e2c-4464-adfb-624e3fcd313f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1788a6a7-1e2c-4464-adfb-624e3fcd313f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1788a6a7-1e2c-4464-adfb-624e3fcd313f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b845727a-325f-4435-9d89-0f6ca80bba50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1788a6a7-1e2c-4464-adfb-624e3fcd313f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b845727a-325f-4435-9d89-0f6ca80bba50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_81df6646-4726-49fa-9441-737dceff2697" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b845727a-325f-4435-9d89-0f6ca80bba50" xlink:to="loc_us-gaap_EmployeeStockOptionMember_81df6646-4726-49fa-9441-737dceff2697" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f3d2968f-fa2f-42d7-81f3-8f103ef0e0ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b845727a-325f-4435-9d89-0f6ca80bba50" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f3d2968f-fa2f-42d7-81f3-8f103ef0e0ff" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/SubsequentEvents" xlink:type="simple" xlink:href="mrna-20210331.xsd#SubsequentEvents"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/SubsequentEvents" xlink:type="extended" id="i4f305515903d48668a62b88bd2762f05_SubsequentEvents"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/SubsequentEventsDetails" xlink:type="extended" id="ic7f90cbe1b0840a08fd90843f537be54_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_fe7ad874-b6af-4a78-9553-6548a1990d6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NumberOfDosesOfVaccineCandidate_0d76dcb9-d0e5-49a4-93a5-6c51adedf8ef" xlink:href="mrna-20210331.xsd#mrna_NumberOfDosesOfVaccineCandidate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_fe7ad874-b6af-4a78-9553-6548a1990d6a" xlink:to="loc_mrna_NumberOfDosesOfVaccineCandidate_0d76dcb9-d0e5-49a4-93a5-6c51adedf8ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_2dafdada-b501-4ad4-9765-df35d2fd1e79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_fe7ad874-b6af-4a78-9553-6548a1990d6a" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_2dafdada-b501-4ad4-9765-df35d2fd1e79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsPotentialReimbursement_cc6d1032-ff64-4f5b-90d2-780549f69e0d" xlink:href="mrna-20210331.xsd#mrna_RevenueFromGrantsPotentialReimbursement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_fe7ad874-b6af-4a78-9553-6548a1990d6a" xlink:to="loc_mrna_RevenueFromGrantsPotentialReimbursement_cc6d1032-ff64-4f5b-90d2-780549f69e0d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsMaximumAward_8051227a-7792-48bb-9d57-ec1510c3f0db" xlink:href="mrna-20210331.xsd#mrna_RevenueFromGrantsMaximumAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_fe7ad874-b6af-4a78-9553-6548a1990d6a" xlink:to="loc_mrna_RevenueFromGrantsMaximumAward_8051227a-7792-48bb-9d57-ec1510c3f0db" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_14ebdb0f-6b77-4519-98ca-056658411d25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_fe7ad874-b6af-4a78-9553-6548a1990d6a" xlink:to="loc_us-gaap_SubsequentEventTable_14ebdb0f-6b77-4519-98ca-056658411d25" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_7199261e-8f83-48f1-a87c-8f87ed2c459f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_14ebdb0f-6b77-4519-98ca-056658411d25" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_7199261e-8f83-48f1-a87c-8f87ed2c459f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7199261e-8f83-48f1-a87c-8f87ed2c459f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7199261e-8f83-48f1-a87c-8f87ed2c459f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7199261e-8f83-48f1-a87c-8f87ed2c459f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4f774dc5-754e-4534-945a-5ca980e90cd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7199261e-8f83-48f1-a87c-8f87ed2c459f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4f774dc5-754e-4534-945a-5ca980e90cd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_d9c6051e-7720-448f-933a-5d1f74221cd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_4f774dc5-754e-4534-945a-5ca980e90cd8" xlink:to="loc_us-gaap_SubsequentEventMember_d9c6051e-7720-448f-933a-5d1f74221cd2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_74491c7d-8658-4f6d-b746-3fb670b4a7ce" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_14ebdb0f-6b77-4519-98ca-056658411d25" xlink:to="loc_srt_MajorCustomersAxis_74491c7d-8658-4f6d-b746-3fb670b4a7ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_74491c7d-8658-4f6d-b746-3fb670b4a7ce_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_74491c7d-8658-4f6d-b746-3fb670b4a7ce" xlink:to="loc_srt_NameOfMajorCustomerDomain_74491c7d-8658-4f6d-b746-3fb670b4a7ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_59ee08da-64e7-45ea-b18d-fc9c342692e7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_74491c7d-8658-4f6d-b746-3fb670b4a7ce" xlink:to="loc_srt_NameOfMajorCustomerDomain_59ee08da-64e7-45ea-b18d-fc9c342692e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_d75540a6-95ad-461e-8a26-d5fff9e5c356" xlink:href="mrna-20210331.xsd#mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_59ee08da-64e7-45ea-b18d-fc9c342692e7" xlink:to="loc_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_d75540a6-95ad-461e-8a26-d5fff9e5c356" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>mrna-20210331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:0cbcbb00-411e-4aec-bde6-af04ca2907e0,g:4456e2fc-6666-4731-b603-d80176d3b13f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_59423978-3737-4ee6-9b92-3729d1d11bb2_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of office space (in sqft)</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty" xlink:to="lab_us-gaap_AreaOfRealEstateProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b3d66440-f794-44ae-a24c-a024802f3ab9_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ClinicalServicesMember_5b89779d-356b-4d99-8b60-fdd2b16ed521_terseLabel_en-US" xlink:label="lab_mrna_ClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Services</link:label>
    <link:label id="lab_mrna_ClinicalServicesMember_label_en-US" xlink:label="lab_mrna_ClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Services [Member]</link:label>
    <link:label id="lab_mrna_ClinicalServicesMember_documentation_en-US" xlink:label="lab_mrna_ClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ClinicalServicesMember" xlink:href="mrna-20210331.xsd#mrna_ClinicalServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ClinicalServicesMember" xlink:to="lab_mrna_ClinicalServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_ce543bcf-6c93-42b9-b69c-08ca2e98bc0f_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_792e41fa-6535-4ccd-b9ae-c98a7a1fd527_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_4d6c2c65-8783-4feb-81e6-223276d919ff_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_VertexMember_c2bb0f55-bf78-4b52-8a78-ec50a2353df3_terseLabel_en-US" xlink:label="lab_mrna_VertexMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vertex</link:label>
    <link:label id="lab_mrna_VertexMember_label_en-US" xlink:label="lab_mrna_VertexMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vertex [Member]</link:label>
    <link:label id="lab_mrna_VertexMember_documentation_en-US" xlink:label="lab_mrna_VertexMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vertex [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_VertexMember" xlink:href="mrna-20210331.xsd#mrna_VertexMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_VertexMember" xlink:to="lab_mrna_VertexMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_PersonalizedMRNACancerVaccinesProductsMember_cf331197-a9a0-439e-9317-77ea3e4c7b32_terseLabel_en-US" xlink:label="lab_mrna_PersonalizedMRNACancerVaccinesProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PCV products</link:label>
    <link:label id="lab_mrna_PersonalizedMRNACancerVaccinesProductsMember_label_en-US" xlink:label="lab_mrna_PersonalizedMRNACancerVaccinesProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personalized MRNA Cancer Vaccines Products [Member]</link:label>
    <link:label id="lab_mrna_PersonalizedMRNACancerVaccinesProductsMember_documentation_en-US" xlink:label="lab_mrna_PersonalizedMRNACancerVaccinesProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personalized MRNA Cancer Vaccines Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_PersonalizedMRNACancerVaccinesProductsMember" xlink:href="mrna-20210331.xsd#mrna_PersonalizedMRNACancerVaccinesProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_PersonalizedMRNACancerVaccinesProductsMember" xlink:to="lab_mrna_PersonalizedMRNACancerVaccinesProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ca6804dd-13d0-45b7-9bc0-8e02cbe8bdad_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_cb2c88e0-4a27-4027-a84c-14c28266eaf7_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_FinanceLeaseLiabilityToBePaidAfterYearFour_481ede02-c3f4-4baa-b81b-7dcfdd97d2f4_terseLabel_en-US" xlink:label="lab_mrna_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_mrna_FinanceLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_mrna_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:label id="lab_mrna_FinanceLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_mrna_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:href="mrna-20210331.xsd#mrna_FinanceLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_mrna_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_RevenueFromGrantsNumberOfContractOptionsExercised_ca435078-c64d-4efd-883a-1d7a226024da_terseLabel_en-US" xlink:label="lab_mrna_RevenueFromGrantsNumberOfContractOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of contract options exercised</link:label>
    <link:label id="lab_mrna_RevenueFromGrantsNumberOfContractOptionsExercised_label_en-US" xlink:label="lab_mrna_RevenueFromGrantsNumberOfContractOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Number Of Contract Options Exercised</link:label>
    <link:label id="lab_mrna_RevenueFromGrantsNumberOfContractOptionsExercised_documentation_en-US" xlink:label="lab_mrna_RevenueFromGrantsNumberOfContractOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Number Of Contract Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsNumberOfContractOptionsExercised" xlink:href="mrna-20210331.xsd#mrna_RevenueFromGrantsNumberOfContractOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_RevenueFromGrantsNumberOfContractOptionsExercised" xlink:to="lab_mrna_RevenueFromGrantsNumberOfContractOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_StockOptionAndIncentivePlan2018Member_c846fc71-5cec-44a6-b94a-12556df5bcfd_terseLabel_en-US" xlink:label="lab_mrna_StockOptionAndIncentivePlan2018Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Equity Plan</link:label>
    <link:label id="lab_mrna_StockOptionAndIncentivePlan2018Member_label_en-US" xlink:label="lab_mrna_StockOptionAndIncentivePlan2018Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option And Incentive Plan 2018 [Member]</link:label>
    <link:label id="lab_mrna_StockOptionAndIncentivePlan2018Member_documentation_en-US" xlink:label="lab_mrna_StockOptionAndIncentivePlan2018Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option And Incentive Plan 2018 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_StockOptionAndIncentivePlan2018Member" xlink:href="mrna-20210331.xsd#mrna_StockOptionAndIncentivePlan2018Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_StockOptionAndIncentivePlan2018Member" xlink:to="lab_mrna_StockOptionAndIncentivePlan2018Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_b07e04d0-d90f-44bb-a1af-55413af4f232_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_1eb334c9-5425-4e55-a5ff-b479b814f144_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Fair Value, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_CurrentMarketableSecuritiesMember_c27f6790-5062-45d5-928c-b3d8f68e04e9_verboseLabel_en-US" xlink:label="lab_mrna_CurrentMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current marketable securities</link:label>
    <link:label id="lab_mrna_CurrentMarketableSecuritiesMember_label_en-US" xlink:label="lab_mrna_CurrentMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Marketable Securities [Member]</link:label>
    <link:label id="lab_mrna_CurrentMarketableSecuritiesMember_documentation_en-US" xlink:label="lab_mrna_CurrentMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Marketable Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CurrentMarketableSecuritiesMember" xlink:href="mrna-20210331.xsd#mrna_CurrentMarketableSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_CurrentMarketableSecuritiesMember" xlink:to="lab_mrna_CurrentMarketableSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_858c4fc1-0a41-4b30-a8c3-02d9fbe37369_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_743469cc-3f3c-4fae-8225-012ae9a00ef0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_569214e4-d8b9-4db4-91cc-3d1a4c37b781_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_4406838a-b8d3-411f-8d64-a421db0d20fc_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_e68a407a-3a37-4371-99c0-be926d7f695c_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ad39a907-3407-43ff-86ac-176de153d693_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_024e3b9b-b2c8-4f81-ac54-c8d20c013e6e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_0418ff91-3432-42ee-9075-e2d324499af9_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xlink:to="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_d45e845e-02df-4954-b26a-64f5fbfa3cbf_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_65b4c5b2-3dde-4501-baf4-1c1687847451_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage_46b94dc5-f9ef-4695-8e66-d95434b8faff_terseLabel_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payout percentage</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage_label_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Payout Percentage</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage_documentation_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Payout Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage" xlink:href="mrna-20210331.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage" xlink:to="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_7fb34b6f-6d0d-4334-9246-03c652a6bce1_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_383d5a92-dce5-46fe-9a21-7938db8ec30b_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_AllowanceForTenantImprovements_60b775ed-1970-4a2b-9bc5-8fccd2fab2dc_terseLabel_en-US" xlink:label="lab_mrna_AllowanceForTenantImprovements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for tenant improvements</link:label>
    <link:label id="lab_mrna_AllowanceForTenantImprovements_label_en-US" xlink:label="lab_mrna_AllowanceForTenantImprovements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Tenant Improvements</link:label>
    <link:label id="lab_mrna_AllowanceForTenantImprovements_documentation_en-US" xlink:label="lab_mrna_AllowanceForTenantImprovements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Tenant Improvements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AllowanceForTenantImprovements" xlink:href="mrna-20210331.xsd#mrna_AllowanceForTenantImprovements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_AllowanceForTenantImprovements" xlink:to="lab_mrna_AllowanceForTenantImprovements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_e6fa7a50-9212-4989-a521-53403a1bf9a5_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Balances of Receivables and Contract Liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_959f358b-f7c5-423b-b36b-d8fc599fbb3e_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PSUs</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a8ffb2a1-c2ce-4c0c-8cfd-4e9c7398324b_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_124e40ee-7107-4ebb-a062-04a44d24be86_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_67ca325b-4960-460f-baa9-95468e0e20c5_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, non-vested at beginning of period (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b1c9866f-b717-4785-9e94-f717bcfad0f1_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, non-vested at end of period (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_NoncurrentMarketableSecuritiesMember_66db41fa-1b8d-4fac-be82-6434c477eaaf_verboseLabel_en-US" xlink:label="lab_mrna_NoncurrentMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent marketable securities</link:label>
    <link:label id="lab_mrna_NoncurrentMarketableSecuritiesMember_label_en-US" xlink:label="lab_mrna_NoncurrentMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent Marketable Securities [Member]</link:label>
    <link:label id="lab_mrna_NoncurrentMarketableSecuritiesMember_documentation_en-US" xlink:label="lab_mrna_NoncurrentMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent Marketable Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NoncurrentMarketableSecuritiesMember" xlink:href="mrna-20210331.xsd#mrna_NoncurrentMarketableSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_NoncurrentMarketableSecuritiesMember" xlink:to="lab_mrna_NoncurrentMarketableSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_87e1574b-5fab-4e2d-9418-3271983b804d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_3feb3256-de21-40d8-95b6-ac1d4f3d66c2_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total minimum lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_2a6d7577-caae-4202-9b85-f940907e11d2_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, non-current</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_2712ccb7-5a0c-42cc-8b22-d6c1d99598c7_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5218c0d8-b014-4d4d-8784-f29168adfaae_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_0f07403f-6ea3-490e-a036-89f8d89c4ed8_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_605d59ab-4ed7-4d5a-add1-8b15a3f1b755_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_b8554780-efae-46a3-9287-b634e7d132c6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d3f41c51-36f1-4594-9645-8086c58d6d94_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_3ef88083-960e-485c-a8ce-98bdfddb2e87_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock through equity plans, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_b0c6a226-c82b-423c-ae73-ff7fcd99fdad_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_ec710e3c-5a01-4d34-9ac4-baa81737736e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Activity</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_c7e850d4-fe7a-41e2-9f7f-5f4c0f1f09bd_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_4be7fc64-8e60-4167-a70b-bf681d5b0ccc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets, operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_14738c0f-52fb-4148-b482-ab2db07cedcb_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets, operating, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_7259bc4d-bd9f-425c-920b-8bb61be8401a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ddce6e48-bad8-4df0-afab-eaf6e8c89c6d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b60fda46-7c31-4786-b95c-3413323660aa_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_48cf79e7-33f4-4147-a9aa-0cb1472f0042_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_4e37120b-5aad-4e82-8be9-1ee506a7c1eb_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_a387bea0-83ac-48fb-adc1-166f0881cd74_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_da9ec322-229c-4b01-8918-6271119e60d4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Financial Assets Measured at Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_e5496619-3cba-47cc-8234-6ae17c668636_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unrecognized compensation cost related to non-vested stock-based compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ad8f5a66-a207-412c-bb50-beaa883f2c7b_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_fb79f049-b589-4617-93f6-03fc80eabc9e_terseLabel_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_label_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:to="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_61c6f1f9-a2c2-4b77-803f-aa39c004012c_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_deccd0f2-49f3-4af0-89df-9e387735a7bb_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_b1b48800-6924-4cb7-94f1-390de507d1ed_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_aa784424-6e60-4a0b-aeb9-41f6d78c33f2_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value $0.0001; 162&#160;shares authorized as of March 31, 2021 and December 31, 2020; no shares issued or outstanding at March 31, 2021 and December 31, 2020</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_AstraZenecaMember_bcf750ec-ff58-4614-9214-4d87a423ba3b_terseLabel_en-US" xlink:label="lab_mrna_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca</link:label>
    <link:label id="lab_mrna_AstraZenecaMember_label_en-US" xlink:label="lab_mrna_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca [Member]</link:label>
    <link:label id="lab_mrna_AstraZenecaMember_documentation_en-US" xlink:label="lab_mrna_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AstraZenecaMember" xlink:href="mrna-20210331.xsd#mrna_AstraZenecaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_AstraZenecaMember" xlink:to="lab_mrna_AstraZenecaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_5b1096d2-5b3d-4809-be95-c520076ae102_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_dc447738-225b-45bf-8bc2-20d43bdc46ab_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number&#160;of Options, Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_9e4f6520-6fb7-48ad-855a-0137334050e5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_InitialProjectMember_735d5470-e1a1-4552-9096-f0994524d99c_terseLabel_en-US" xlink:label="lab_mrna_InitialProjectMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial project</link:label>
    <link:label id="lab_mrna_InitialProjectMember_label_en-US" xlink:label="lab_mrna_InitialProjectMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Project [Member]</link:label>
    <link:label id="lab_mrna_InitialProjectMember_documentation_en-US" xlink:label="lab_mrna_InitialProjectMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Project [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_InitialProjectMember" xlink:href="mrna-20210331.xsd#mrna_InitialProjectMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_InitialProjectMember" xlink:to="lab_mrna_InitialProjectMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_05cdf13e-7b28-46d7-8963-b900e135d2a1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_7ae6909a-03a7-4ab8-bfb6-bdb4b7fd36a3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_a4417fc2-2ed5-453e-9780-6670eaf6dfba_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_MTCSouthMember_6e21c18a-b45a-49c9-a327-be414bb995af_terseLabel_en-US" xlink:label="lab_mrna_MTCSouthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MTC South</link:label>
    <link:label id="lab_mrna_MTCSouthMember_label_en-US" xlink:label="lab_mrna_MTCSouthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MTC South [Member]</link:label>
    <link:label id="lab_mrna_MTCSouthMember_documentation_en-US" xlink:label="lab_mrna_MTCSouthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MTC South</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MTCSouthMember" xlink:href="mrna-20210331.xsd#mrna_MTCSouthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_MTCSouthMember" xlink:to="lab_mrna_MTCSouthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_0f623617-b77c-43f4-b3fc-6338eb32d873_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in progress</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_123723b5-5887-45fc-a36e-342dc057fa99_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_10ba3cb8-c697-4658-9a34-963c4e3bf301_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_2ca70314-bedc-4d62-b984-ed9173ddbe3b_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e36d1bbd-21dd-4f46-b3f1-3951f1f081a2_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total collaboration revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_924b5b52-c00e-4dce-948e-82497c3405e9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_98ec6f34-7e1b-4724-ac57-3e2086b8a3e3_periodStartLabel_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (usd per share)</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_1897a323-0c5b-4198-8e98-3c2bdb5ef131_periodEndLabel_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (usd per share)</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:href="mrna-20210331.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:to="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_a5304d33-cc23-4ebc-87c6-25dfc4959100_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_ac262df6-f06e-409a-ac30-23dc16c02181_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_8c2ecac5-8423-4bad-addb-427b638884c3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_2941cfc3-b514-4aa5-a49d-3d3d6914be99_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_CambridgeMassachusettsMember_b2dd2594-ebaa-4bb8-8be4-bd835d1c2d93_terseLabel_en-US" xlink:label="lab_mrna_CambridgeMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cambridge leases</link:label>
    <link:label id="lab_mrna_CambridgeMassachusettsMember_label_en-US" xlink:label="lab_mrna_CambridgeMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cambridge, Massachusetts [Member]</link:label>
    <link:label id="lab_mrna_CambridgeMassachusettsMember_documentation_en-US" xlink:label="lab_mrna_CambridgeMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cambridge, Massachusetts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CambridgeMassachusettsMember" xlink:href="mrna-20210331.xsd#mrna_CambridgeMassachusettsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_CambridgeMassachusettsMember" xlink:to="lab_mrna_CambridgeMassachusettsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_da0f77bf-01d0-4a1b-a810-6e0ed24db39a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_03312cd4-bc7e-4c39-b397-03b8a96bb7ee_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_98469a1a-ebaf-42ae-a0a7-fbdd485b86dc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_CollaborationArrangementMember_0fd67ec3-009e-44ee-ab99-05e561697dc7_terseLabel_en-US" xlink:label="lab_mrna_CollaborationArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue</link:label>
    <link:label id="lab_mrna_CollaborationArrangementMember_label_en-US" xlink:label="lab_mrna_CollaborationArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement [Member]</link:label>
    <link:label id="lab_mrna_CollaborationArrangementMember_documentation_en-US" xlink:label="lab_mrna_CollaborationArrangementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CollaborationArrangementMember" xlink:href="mrna-20210331.xsd#mrna_CollaborationArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_CollaborationArrangementMember" xlink:to="lab_mrna_CollaborationArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_f74b1b14-5f3b-47cd-a6e7-50281d6fca1c_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_30c494f6-b394-4bc1-81c5-4286dc3c687b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember_33cdde95-7d91-4f03-9be3-f16033c7ce17_terseLabel_en-US" xlink:label="lab_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities of U.S. government agencies and corporate entities</link:label>
    <link:label id="lab_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies And Corporate Debt Securities [Member]</link:label>
    <link:label id="lab_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember_documentation_en-US" xlink:label="lab_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies And Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember" xlink:href="mrna-20210331.xsd#mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember" xlink:to="lab_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_aa30ea17-b08f-4783-9709-5ce1dd7bbf8d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_46be77ab-1340-4d89-ad9d-3d40b9aecf6f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_4e261f83-e9da-47cf-b831-e9446368d7ba_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_8ce39b61-9471-41d0-b58a-3e1c1b1d89ac_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_91e4b191-39b8-4d76-a573-a96d2d925c60_terseLabel_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Grant Date Fair Value per Share, Exercisable (usd per share)</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:href="mrna-20210331.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:to="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ff59a6b2-2154-4fc3-8d88-af4ab720527b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_d1549159-ea90-4cab-bb5d-c2cc263fc6df_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_958916c7-65be-4490-8f61-fc44819e0a36_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f92a785a-e648-4981-a5eb-260fa7659b72_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0ab5de83-ea13-4c25-8939-9b97d5226960_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Term, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_1e6b4cc7-5008-4b54-81a0-cecb8fec8a0b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from public offerings of common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_3af4ef64-8a9e-4db4-8b6e-4e0b065a6182_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_fc4f6a03-9b21-4a0a-a773-9847b845d846_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and Diluted Net Loss per Share Attributable to Common Stockholders</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_23da198a-0a18-49ba-94ae-d05a2bde2dcc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_AccruedPropertyAndEquipmentCurrent_b3887ecd-a10e-4188-bf9d-ac9848922bc6_terseLabel_en-US" xlink:label="lab_mrna_AccruedPropertyAndEquipmentCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_mrna_AccruedPropertyAndEquipmentCurrent_label_en-US" xlink:label="lab_mrna_AccruedPropertyAndEquipmentCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Property And Equipment, Current</link:label>
    <link:label id="lab_mrna_AccruedPropertyAndEquipmentCurrent_documentation_en-US" xlink:label="lab_mrna_AccruedPropertyAndEquipmentCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Property And Equipment, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedPropertyAndEquipmentCurrent" xlink:href="mrna-20210331.xsd#mrna_AccruedPropertyAndEquipmentCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_AccruedPropertyAndEquipmentCurrent" xlink:to="lab_mrna_AccruedPropertyAndEquipmentCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_dd2f0ca4-8865-4a12-8957-5a42b3b7ae63_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate number of shares authorized for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_f63cf5ce-874c-4040-abc9-82b2aa898726_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_TheBillAndMelindaGatesFoundationMember_d4bdc5cd-d207-4f57-b692-f81208c3c305_terseLabel_en-US" xlink:label="lab_mrna_TheBillAndMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Bill&#160;&amp; Melinda Gates Foundation</link:label>
    <link:label id="lab_mrna_TheBillAndMelindaGatesFoundationMember_label_en-US" xlink:label="lab_mrna_TheBillAndMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Bill&#160;And Melinda Gates Foundation [Member]</link:label>
    <link:label id="lab_mrna_TheBillAndMelindaGatesFoundationMember_documentation_en-US" xlink:label="lab_mrna_TheBillAndMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Bill&#160;And Melinda Gates Foundation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_TheBillAndMelindaGatesFoundationMember" xlink:href="mrna-20210331.xsd#mrna_TheBillAndMelindaGatesFoundationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_TheBillAndMelindaGatesFoundationMember" xlink:to="lab_mrna_TheBillAndMelindaGatesFoundationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_fcacb16b-c77f-4e7e-8317-f74fd36e3731_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for future grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_49b374b0-1dd2-4f81-b51e-ddc31f595541_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase commitments</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Remaining Minimum Amount Committed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:to="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_b452436c-b5dd-4244-939b-14cb7b4010bb_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Balance Sheet Components</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_77e00ff7-f035-408f-90a6-eafc3a722aa3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_6cbd346e-835a-4001-b7a4-4a2f3a534a8a_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_51558d98-a3b9-4bd1-92ad-5b38558e46c6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_dfd08e83-808d-40ef-90cb-1b7576f5db1b_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_1c9155c7-037f-4d29-84a4-8a028c1f8d31_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_21bd3277-da42-4583-9503-e37c979c3f33_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_e9ff3c8b-225a-4ca4-b5a3-db63b34d848c_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment included in accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_7a20a8b8-7617-43c7-8d52-f11db6b4f20a_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_c5f4c660-40a8-4502-aef8-1a3e6beceeb0_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4b106faf-efd3-46c1-baaa-e80f500e74e0_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_af455d4f-f488-4947-827a-11645f4a471b_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_f6836b62-c544-404b-bf25-64e21e412e9f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extension term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7f05c346-ea4e-4603-9bac-dfcb8932dfbd_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_fe001191-ec63-4576-9691-370c58e6d874_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_ad70df5c-b5ad-4e98-9613-bb158ce3c1de_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8d1c3af0-7f55-4492-9f66-2241ba1d6336_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_4bfa72cb-b7d2-4683-b662-e6728be0a46a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_979a9aa3-ff90-4d67-8960-a4689fc248c5_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_fc6eb9d8-38f7-48df-8526-3ed383acee36_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_71217725-8960-49b1-b2b6-557800cf8fc6_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_c58292b5-93c2-4929-a08a-d59d96ca5e70_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0c91d6f9-e868-48a6-8adc-d46807023cca_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ce631bb7-885e-421d-96e2-dea0bbf7ac53_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_d6d0c40a-936c-4cce-b9f2-289e791eab22_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_514eaa1e-87b4-459d-8c2b-fa2fbb0653e5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notional Amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_287de090-460d-4320-ab20-3629652c173d_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6c6d8722-c9db-4384-9c2f-a5409217a4dc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_e2ebdc94-ad59-44fc-8854-3d712da44055_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_6ea367e7-626e-43bf-8b43-02a5c3a33863_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_33344b66-5da6-405a-ab3c-d5afa49e3319_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_e5c0ce55-2a4e-4f40-8240-ffd124018e5a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from public offering of common stock, net of issuance costs of $1</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_215a36dd-413c-49bb-8fcd-072d5f666e4f_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue_4f4876d0-a1db-46ac-bb3c-79d305e93b78_terseLabel_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Grant Date Fair Value per Share (usd per share)</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested And Expected To Vest, Outstanding, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested And Expected To Vest, Outstanding, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue" xlink:href="mrna-20210331.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue" xlink:to="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c01a840b-abf6-4c94-86eb-0ebfc52c0614_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, non-vested at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_28206791-e7e6-473d-b025-79d8c732fb29_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, non-vested at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_17b45824-96eb-4be7-ad1d-921b351c4907_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ChangeInContractWithCustomerLiabilityLineItems_1c5d4b06-2e8e-40c6-bf16-770cb1826b4e_terseLabel_en-US" xlink:label="lab_mrna_ChangeInContractWithCustomerLiabilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Contract With Customer Liability [Line Items]</link:label>
    <link:label id="lab_mrna_ChangeInContractWithCustomerLiabilityLineItems_label_en-US" xlink:label="lab_mrna_ChangeInContractWithCustomerLiabilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Contract With Customer Liability [Line Items]</link:label>
    <link:label id="lab_mrna_ChangeInContractWithCustomerLiabilityLineItems_documentation_en-US" xlink:label="lab_mrna_ChangeInContractWithCustomerLiabilityLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Contract With Customer Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractWithCustomerLiabilityLineItems" xlink:href="mrna-20210331.xsd#mrna_ChangeInContractWithCustomerLiabilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityLineItems" xlink:to="lab_mrna_ChangeInContractWithCustomerLiabilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_1fca52da-458f-4160-ac88-0bfdc2c0f307_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_6b3ed143-ab7f-41d4-8210-747eca518bee_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0bfa92b3-defa-464f-9af7-ff6f78df88ff_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ContractWithCustomerAssetDeductionsDuringPeriod_8e0e8d4d-9f68-480b-92db-de64e2bb89ff_negatedTerseLabel_en-US" xlink:label="lab_mrna_ContractWithCustomerAssetDeductionsDuringPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_mrna_ContractWithCustomerAssetDeductionsDuringPeriod_label_en-US" xlink:label="lab_mrna_ContractWithCustomerAssetDeductionsDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Asset, Deductions During Period</link:label>
    <link:label id="lab_mrna_ContractWithCustomerAssetDeductionsDuringPeriod_documentation_en-US" xlink:label="lab_mrna_ContractWithCustomerAssetDeductionsDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Asset, Deductions During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerAssetDeductionsDuringPeriod" xlink:href="mrna-20210331.xsd#mrna_ContractWithCustomerAssetDeductionsDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ContractWithCustomerAssetDeductionsDuringPeriod" xlink:to="lab_mrna_ContractWithCustomerAssetDeductionsDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings_b81580be-0619-4f2d-b8de-c4f24e76b882_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment charges</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_LeasesImputedInterestRate_c71c3c06-06e1-4222-8fb2-2c247cc19d11_terseLabel_en-US" xlink:label="lab_mrna_LeasesImputedInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imputed interest rate</link:label>
    <link:label id="lab_mrna_LeasesImputedInterestRate_label_en-US" xlink:label="lab_mrna_LeasesImputedInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases, Imputed Interest Rate</link:label>
    <link:label id="lab_mrna_LeasesImputedInterestRate_documentation_en-US" xlink:label="lab_mrna_LeasesImputedInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases, Imputed Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LeasesImputedInterestRate" xlink:href="mrna-20210331.xsd#mrna_LeasesImputedInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_LeasesImputedInterestRate" xlink:to="lab_mrna_LeasesImputedInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_1b3b42f7-84da-466c-be18-6c138ee8faaf_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_201c4cf5-40a3-408e-9279-a421c5a7f3cf_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on available-for-sale debt securities, net of tax of $0 and $0, for the three months ended March 31, 2021 and 2020, respectively</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2e1b094a-92aa-44d6-8c71-0b8eafd5ec3f_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e21abfa8-f881-404f-b6cc-70f14ad58987_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_f992c892-6c34-4858-bab0-d14f9c8f2906_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_46de99a8-111f-4a85-8471-5c9893d9ae66_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Measure of Progress</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_43df5ce2-cff9-4b2f-9fd0-b04586279459_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on available-for-sale debt securities, tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_f1460457-6a31-48ac-b10a-933f49a0b4b0_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_00d91db9-965f-43d2-8860-51ebaf058c4c_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease Maturity</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_2304fc5e-7449-428d-aefa-8dd7cc549930_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_286953b1-f6cf-476b-9f18-b5d3778a3b52_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, Cumulative Catch-up Adjustment to Revenue, Change in Measure of Progress</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:to="lab_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ChangeInContractwithCustomerAssetRollForward_27636256-fa48-4ce5-a83e-d7001122e7b1_terseLabel_en-US" xlink:label="lab_mrna_ChangeInContractwithCustomerAssetRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Assets:</link:label>
    <link:label id="lab_mrna_ChangeInContractwithCustomerAssetRollForward_label_en-US" xlink:label="lab_mrna_ChangeInContractwithCustomerAssetRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract with Customer Asset [Roll Forward]</link:label>
    <link:label id="lab_mrna_ChangeInContractwithCustomerAssetRollForward_documentation_en-US" xlink:label="lab_mrna_ChangeInContractwithCustomerAssetRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract with Customer Asset [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractwithCustomerAssetRollForward" xlink:href="mrna-20210331.xsd#mrna_ChangeInContractwithCustomerAssetRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ChangeInContractwithCustomerAssetRollForward" xlink:to="lab_mrna_ChangeInContractwithCustomerAssetRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_f5fa51a7-a49f-4138-848c-f902bf9058f3_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_6645d0e3-7811-49ba-82cb-b8b790862957_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ClinicalOperationsAndSupportCommitmentMember_86f703d7-90de-44c5-a479-22c5b544fdea_terseLabel_en-US" xlink:label="lab_mrna_ClinicalOperationsAndSupportCommitmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical operations and support commitment</link:label>
    <link:label id="lab_mrna_ClinicalOperationsAndSupportCommitmentMember_label_en-US" xlink:label="lab_mrna_ClinicalOperationsAndSupportCommitmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Operations And Support Commitment [Member]</link:label>
    <link:label id="lab_mrna_ClinicalOperationsAndSupportCommitmentMember_documentation_en-US" xlink:label="lab_mrna_ClinicalOperationsAndSupportCommitmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Operations And Support Commitment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ClinicalOperationsAndSupportCommitmentMember" xlink:href="mrna-20210331.xsd#mrna_ClinicalOperationsAndSupportCommitmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ClinicalOperationsAndSupportCommitmentMember" xlink:to="lab_mrna_ClinicalOperationsAndSupportCommitmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_2078a21f-047d-4709-bb59-9db0ce2cd679_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization/accretion of investments</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net, Amortization of Discount and Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember_eb3653fa-46a5-4ba4-98d0-5b146f6ce694_terseLabel_en-US" xlink:label="lab_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Revenue by Strategic Collaborator:</link:label>
    <link:label id="lab_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember_label_en-US" xlink:label="lab_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Including Arrangements With Affiliate [Member]</link:label>
    <link:label id="lab_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember_documentation_en-US" xlink:label="lab_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Including Arrangements With Affiliate [Member] [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember" xlink:href="mrna-20210331.xsd#mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember" xlink:to="lab_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e9550228-a1e5-48cd-ade7-f3af1ed6e1e2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average period of cost expected to be recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b5e44a85-152c-4a63-90b7-80288f0cd948_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts representing interest or imputed interest, operating lease</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1ff010d3-61d0-4594-8332-4df5b73cbd9f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less amounts representing interest or imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_09e035c2-560c-46b9-be8f-f60e30e78eb1_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest of world</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_596c9753-a5fa-471a-8f64-1c0e782e2b58_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_FinancingRightOfUseAssetMember_742b83be-f81b-431b-a55d-3d7b20118db9_terseLabel_en-US" xlink:label="lab_mrna_FinancingRightOfUseAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset, financing</link:label>
    <link:label id="lab_mrna_FinancingRightOfUseAssetMember_label_en-US" xlink:label="lab_mrna_FinancingRightOfUseAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing, Right-Of-Use Asset [Member]</link:label>
    <link:label id="lab_mrna_FinancingRightOfUseAssetMember_documentation_en-US" xlink:label="lab_mrna_FinancingRightOfUseAssetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing, Right-Of-Use Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_FinancingRightOfUseAssetMember" xlink:href="mrna-20210331.xsd#mrna_FinancingRightOfUseAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_FinancingRightOfUseAssetMember" xlink:to="lab_mrna_FinancingRightOfUseAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a5c05ccf-975e-4904-a7c2-2aed6c3457af_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_a00b62a5-c7a1-4c0c-b674-918b4d9625ee_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_5db9a556-9f1f-455f-b927-0b1cdb88d83d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_7d34316c-8515-4f8c-bdcf-1d2c60453edc_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Revenue</link:label>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research, Development, and Computer Software Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_bc7fb704-d213-451f-8051-98d0bef4c44f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_014a0211-a6e7-4419-8f63-75cd5488c4f7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_ab4f072c-271d-4c14-8413-732434826cdc_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_64fc758e-6963-479a-a44a-17f34af1a079_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_13d01f9d-22dd-4c2e-bfdf-de4369f9c601_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Domain]</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:to="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_c810b26b-5725-462f-ba66-27ca72b80bb9_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_OtherCollaborativePartiesMember_bbc5436e-557b-4172-89e3-9bb1a0aeef25_terseLabel_en-US" xlink:label="lab_mrna_OtherCollaborativePartiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_mrna_OtherCollaborativePartiesMember_label_en-US" xlink:label="lab_mrna_OtherCollaborativePartiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Collaborative Parties [Member]</link:label>
    <link:label id="lab_mrna_OtherCollaborativePartiesMember_documentation_en-US" xlink:label="lab_mrna_OtherCollaborativePartiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Collaborative Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OtherCollaborativePartiesMember" xlink:href="mrna-20210331.xsd#mrna_OtherCollaborativePartiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_OtherCollaborativePartiesMember" xlink:to="lab_mrna_OtherCollaborativePartiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_fdc426a9-8b32-4f2e-939d-9cdb560c3807_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_7e1a021c-aded-46e3-ab88-1fceb8f725ca_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_f444172b-b31c-4c8b-a53e-2d801986fa12_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_ce2bb77a-485d-4824-bbcd-8977e6aa3b89_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_27a7d9c4-1f18-4bdc-ad60-4e3f733a2ae0_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_NorwoodMassachusettsMember_817bdb0b-029b-47d5-9304-89b47736e2db_terseLabel_en-US" xlink:label="lab_mrna_NorwoodMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Norwood leases</link:label>
    <link:label id="lab_mrna_NorwoodMassachusettsMember_label_en-US" xlink:label="lab_mrna_NorwoodMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Norwood, Massachusetts [Member]</link:label>
    <link:label id="lab_mrna_NorwoodMassachusettsMember_documentation_en-US" xlink:label="lab_mrna_NorwoodMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Norwood, Massachusetts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NorwoodMassachusettsMember" xlink:href="mrna-20210331.xsd#mrna_NorwoodMassachusettsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_NorwoodMassachusettsMember" xlink:to="lab_mrna_NorwoodMassachusettsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_c3163f42-d286-472d-9f98-0744c7c62cc2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_e7962099-f9cf-409a-acd0-6699f9b3edb8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_65142b9b-9d39-4bfc-ac9c-55c9336f06da_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_3d51a764-b89b-4634-88ff-cd6bf9b32592_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, liability</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_41cd6b14-6012-48bf-8404-f7bb5d92f3cf_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_4536e2ed-bd09-4348-b720-c466761f7489_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f980d86c-0f16-476a-8f52-64cb8bc71de3_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2185894b-be4f-48b8-b006-9f47e68186df_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_87199808-f5b2-4a67-b8b9-edcb3f0b6f50_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_8fa1d88a-b09e-491c-87cf-1fb706b879d3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_99f146d4-97ac-4db5-b27a-76b2b94e2b92_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_OtherPrepaidExpenseManufacturing_44806c3d-a09c-42c1-97b2-79197d0d728b_terseLabel_en-US" xlink:label="lab_mrna_OtherPrepaidExpenseManufacturing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Down payments to manufacturing vendors</link:label>
    <link:label id="lab_mrna_OtherPrepaidExpenseManufacturing_label_en-US" xlink:label="lab_mrna_OtherPrepaidExpenseManufacturing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense, Manufacturing</link:label>
    <link:label id="lab_mrna_OtherPrepaidExpenseManufacturing_documentation_en-US" xlink:label="lab_mrna_OtherPrepaidExpenseManufacturing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense, Manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OtherPrepaidExpenseManufacturing" xlink:href="mrna-20210331.xsd#mrna_OtherPrepaidExpenseManufacturing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_OtherPrepaidExpenseManufacturing" xlink:to="lab_mrna_OtherPrepaidExpenseManufacturing" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_facdfee2-ebce-49b8-8fca-84880d902fe9_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_d93b4bf8-4035-4360-8cb0-c034d18bc969_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d85b9bcd-ae7b-4542-b86a-d7da0fbf345b_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_361d8679-2051-4b9e-b936-d79b16c75d6d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_db714041-c152-4fd2-8260-89c50c3add6c_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_ec90d160-ec0a-44a9-ac47-72ace8122f5c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, non-current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_4cfc40e0-066c-4fc8-9af4-197c8afc5b83_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, non-current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_fdbc1689-c2d5-4aaa-ab34-b87a7009f840_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_28640996-8732-4e87-91f5-5b27735d77e7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Cash and Available-for-Sale Securities by Significant Investment Category</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_0c81e0db-96ad-4f16-a111-2314eb56d808_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_135921eb-00eb-4dd9-90b9-d66cd321bf2e_terseLabel_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (usd per share)</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xlink:href="mrna-20210331.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_b23978d1-c8b1-44de-9f3b-233168cb7f07_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_cbeae72f-5c4d-44eb-8003-32c99b9595db_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_6b34e1c0-fd74-4602-a4dc-714488715e98_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_585c78f3-46c2-4c84-be8d-3a58e5f9fe3f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_fd05f5fb-59c8-48fe-bb54-c1256967ab18_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_0bf06782-8fea-42ba-873e-38cc4dacc76b_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2e8857e5-4073-4cbf-8aac-b2d54b62f7c6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_e6284db3-0f97-4ad3-8b36-cd0e3a8af9e7_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_3684a7c4-bd20-458b-a276-e08d3795a453_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_645f0d31-d822-43bf-bf6c-b81c5c6ee6f5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_b3f74505-f6f6-4e90-8f7f-b62e8f365183_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_de86b8dd-1b80-4b86-9ddc-ea748c2d509f_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_da004443-d7c3-416d-affc-e0bfaa184251_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share available for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_8b9a970a-26b7-4855-9dcf-328e63035060_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_b0fda3d4-1cc0-4032-bb56-aecd46a15eaf_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_55dd7327-859e-44bc-ae9b-2de5edb860a4_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_b503c0bd-9032-4a71-8cd5-28c0fc81565d_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_AccruedOtherExternalGoodsAndServicesCurrent_433e3635-c1ce-45dc-a6f9-762d6f7343cf_terseLabel_en-US" xlink:label="lab_mrna_AccruedOtherExternalGoodsAndServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other external goods and services</link:label>
    <link:label id="lab_mrna_AccruedOtherExternalGoodsAndServicesCurrent_label_en-US" xlink:label="lab_mrna_AccruedOtherExternalGoodsAndServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Other External Goods And Services Current</link:label>
    <link:label id="lab_mrna_AccruedOtherExternalGoodsAndServicesCurrent_documentation_en-US" xlink:label="lab_mrna_AccruedOtherExternalGoodsAndServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Other External Goods And Services Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedOtherExternalGoodsAndServicesCurrent" xlink:href="mrna-20210331.xsd#mrna_AccruedOtherExternalGoodsAndServicesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_AccruedOtherExternalGoodsAndServicesCurrent" xlink:to="lab_mrna_AccruedOtherExternalGoodsAndServicesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_16003748-259b-4adf-b8fe-8952282222ba_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_e868c879-f47e-4a80-9ef8-9f9472145aa6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_92d43ed5-b8c0-49af-a1cd-1db2cdc61360_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_32118c39-213e-40d0-8641-5835eae5130a_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_RevenueFromGrantsCurrentFundingCapacity_76f67bf3-7474-4ce5-8858-fa2dae06fa48_terseLabel_en-US" xlink:label="lab_mrna_RevenueFromGrantsCurrentFundingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount committed for funding</link:label>
    <link:label id="lab_mrna_RevenueFromGrantsCurrentFundingCapacity_label_en-US" xlink:label="lab_mrna_RevenueFromGrantsCurrentFundingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Current Funding Capacity</link:label>
    <link:label id="lab_mrna_RevenueFromGrantsCurrentFundingCapacity_documentation_en-US" xlink:label="lab_mrna_RevenueFromGrantsCurrentFundingCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Current Funding Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsCurrentFundingCapacity" xlink:href="mrna-20210331.xsd#mrna_RevenueFromGrantsCurrentFundingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_RevenueFromGrantsCurrentFundingCapacity" xlink:to="lab_mrna_RevenueFromGrantsCurrentFundingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_040a783a-9b09-4a93-a235-ea69487482ef_terseLabel_en-US" xlink:label="lab_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BARDA</link:label>
    <link:label id="lab_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_label_en-US" xlink:label="lab_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biomedical Advanced Research And Development Authority [Member]</link:label>
    <link:label id="lab_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_documentation_en-US" xlink:label="lab_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biomedical Advanced Research And Development Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:href="mrna-20210331.xsd#mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:to="lab_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_RevenueFromGrantsPotentialReimbursement_97f92ad8-a49e-4c47-83d9-1aab9ee6534f_terseLabel_en-US" xlink:label="lab_mrna_RevenueFromGrantsPotentialReimbursement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential reimbursements</link:label>
    <link:label id="lab_mrna_RevenueFromGrantsPotentialReimbursement_label_en-US" xlink:label="lab_mrna_RevenueFromGrantsPotentialReimbursement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Potential Reimbursement</link:label>
    <link:label id="lab_mrna_RevenueFromGrantsPotentialReimbursement_documentation_en-US" xlink:label="lab_mrna_RevenueFromGrantsPotentialReimbursement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Potential Reimbursement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsPotentialReimbursement" xlink:href="mrna-20210331.xsd#mrna_RevenueFromGrantsPotentialReimbursement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_RevenueFromGrantsPotentialReimbursement" xlink:to="lab_mrna_RevenueFromGrantsPotentialReimbursement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_8e3d16b1-3e4f-47cb-be30-1d5f68fbea82_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Foreign Currency Derivatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives Not Designated as Hedging Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseRightOfUseAsset_d947a408-abdf-4781-8ce5-e6ff4e998123_totalLabel_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease, Right-Of-Use Asset</link:label>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease, Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseRightOfUseAsset" xlink:href="mrna-20210331.xsd#mrna_OperatingAndFinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_OperatingAndFinanceLeaseRightOfUseAsset" xlink:to="lab_mrna_OperatingAndFinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_bfed9479-1943-4d37-8303-ad89da9dd956_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_112d2a49-17e0-4720-a3b3-40032729e4d4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_da0bd97d-ba8f-488d-bc5b-c30d54d58705_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_b2d833af-d836-4706-8af2-50c6ce31910b_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2ff10669-4217-444f-8028-7cd65a59a5ba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_TherapeuticAndProphylacticProductsMember_00c8ffd8-b8e0-4ff4-96c6-d3e316226e80_terseLabel_en-US" xlink:label="lab_mrna_TherapeuticAndProphylacticProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Therapeutic and prophylactic products</link:label>
    <link:label id="lab_mrna_TherapeuticAndProphylacticProductsMember_label_en-US" xlink:label="lab_mrna_TherapeuticAndProphylacticProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Therapeutic And Prophylactic Products [Member]</link:label>
    <link:label id="lab_mrna_TherapeuticAndProphylacticProductsMember_documentation_en-US" xlink:label="lab_mrna_TherapeuticAndProphylacticProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Therapeutic And Prophylactic Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_TherapeuticAndProphylacticProductsMember" xlink:href="mrna-20210331.xsd#mrna_TherapeuticAndProphylacticProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_TherapeuticAndProphylacticProductsMember" xlink:to="lab_mrna_TherapeuticAndProphylacticProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0e0d70dc-07c7-43bf-ac45-6d5988d15605_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair&#160;Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_c421cb8d-e9c0-40af-a713-c751862b402b_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_2797305b-47b4-4d3b-873c-77d1c118e0ab_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_RestrictedStockAndRestrictedStockUnitsRSUMember_dcb47a79-af85-4039-b09b-b31032cd9620_terseLabel_en-US" xlink:label="lab_mrna_RestrictedStockAndRestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs and PSUs</link:label>
    <link:label id="lab_mrna_RestrictedStockAndRestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_mrna_RestrictedStockAndRestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock And Restricted Stock Units (RSU) [Member]</link:label>
    <link:label id="lab_mrna_RestrictedStockAndRestrictedStockUnitsRSUMember_documentation_en-US" xlink:label="lab_mrna_RestrictedStockAndRestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock And Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RestrictedStockAndRestrictedStockUnitsRSUMember" xlink:href="mrna-20210331.xsd#mrna_RestrictedStockAndRestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_RestrictedStockAndRestrictedStockUnitsRSUMember" xlink:to="lab_mrna_RestrictedStockAndRestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentAndRegulatoryMilestonesMaximumAmount_3cbd4765-1631-4937-9860-434cb457f49a_terseLabel_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentAndRegulatoryMilestonesMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and regulatory milestone payments</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentAndRegulatoryMilestonesMaximumAmount_label_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentAndRegulatoryMilestonesMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Development And Regulatory Milestones, Maximum Amount</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentAndRegulatoryMilestonesMaximumAmount_documentation_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentAndRegulatoryMilestonesMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Development And Regulatory Milestones, Maximum Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentAndRegulatoryMilestonesMaximumAmount" xlink:href="mrna-20210331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentAndRegulatoryMilestonesMaximumAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentAndRegulatoryMilestonesMaximumAmount" xlink:to="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentAndRegulatoryMilestonesMaximumAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_ae4e5115-445f-4bdb-9c71-404d31441d35_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5381b0c6-a40b-447a-a05c-55b3cd6d79e5_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_7b813305-2f8f-4180-a081-f3e8b302e93d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_bcb7303f-32c5-4055-9cd9-2d8428b80452_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_df902e59-f28c-4381-874f-6ec13a68c9b8_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_f883ef02-ae5f-4e87-9869-07d773656fda_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_0fca1df6-d5b2-4af1-89ac-5e6ecd863fbb_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_df096c2e-5418-4623-8d47-bd012de72f18_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ChangeInContractwithCustomerLiabilityRollForward_af6253b8-22fd-4322-acfd-1668892bf037_terseLabel_en-US" xlink:label="lab_mrna_ChangeInContractwithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Liabilities:</link:label>
    <link:label id="lab_mrna_ChangeInContractwithCustomerLiabilityRollForward_38e9f6af-5135-4a98-a29f-8ad45add7053_verboseLabel_en-US" xlink:label="lab_mrna_ChangeInContractwithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract with Customer Liability [Roll Forward]</link:label>
    <link:label id="lab_mrna_ChangeInContractwithCustomerLiabilityRollForward_label_en-US" xlink:label="lab_mrna_ChangeInContractwithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract with Customer Liability [Roll Forward]</link:label>
    <link:label id="lab_mrna_ChangeInContractwithCustomerLiabilityRollForward_documentation_en-US" xlink:label="lab_mrna_ChangeInContractwithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract with Customer Liability [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward" xlink:href="mrna-20210331.xsd#mrna_ChangeInContractwithCustomerLiabilityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward" xlink:to="lab_mrna_ChangeInContractwithCustomerLiabilityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_DefenseAdvancedResearchProjectsAgencyMember_1e46a5be-fd71-4ecf-a21a-4521bcb236a4_terseLabel_en-US" xlink:label="lab_mrna_DefenseAdvancedResearchProjectsAgencyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DARPA</link:label>
    <link:label id="lab_mrna_DefenseAdvancedResearchProjectsAgencyMember_label_en-US" xlink:label="lab_mrna_DefenseAdvancedResearchProjectsAgencyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defense Advanced Research Projects Agency [Member]</link:label>
    <link:label id="lab_mrna_DefenseAdvancedResearchProjectsAgencyMember_documentation_en-US" xlink:label="lab_mrna_DefenseAdvancedResearchProjectsAgencyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defense Advanced Research Projects Agency [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DefenseAdvancedResearchProjectsAgencyMember" xlink:href="mrna-20210331.xsd#mrna_DefenseAdvancedResearchProjectsAgencyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_DefenseAdvancedResearchProjectsAgencyMember" xlink:to="lab_mrna_DefenseAdvancedResearchProjectsAgencyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_84500067-06e2-48a1-8c4a-393d0cd21acb_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained through finance lease modifications and reassessments</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_RevenueFromGrantsRemainingFundingCapacity_ff64fd2b-9659-4c9a-8ad4-f789596de63d_terseLabel_en-US" xlink:label="lab_mrna_RevenueFromGrantsRemainingFundingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available funding</link:label>
    <link:label id="lab_mrna_RevenueFromGrantsRemainingFundingCapacity_label_en-US" xlink:label="lab_mrna_RevenueFromGrantsRemainingFundingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Remaining Funding Capacity</link:label>
    <link:label id="lab_mrna_RevenueFromGrantsRemainingFundingCapacity_documentation_en-US" xlink:label="lab_mrna_RevenueFromGrantsRemainingFundingCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Remaining Funding Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsRemainingFundingCapacity" xlink:href="mrna-20210331.xsd#mrna_RevenueFromGrantsRemainingFundingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_RevenueFromGrantsRemainingFundingCapacity" xlink:to="lab_mrna_RevenueFromGrantsRemainingFundingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4e6d1747-c985-4f0f-ab81-fe2858b60abb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled, forfeited (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockExpense_8438f8e8-1794-4832-9a54-3f5dc80abe4a_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockExpense_label_en-US" xlink:label="lab_us-gaap_RestrictedStockExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock or Unit Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockExpense" xlink:to="lab_us-gaap_RestrictedStockExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_2ab122b4-37c8-4109-ae77-027868f5648e_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_ff61bb65-0260-4944-9992-3f5af3ef6f92_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_38817be5-b956-48c0-80e1-b2c1d795439c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_818e206c-d9ad-40c0-af3f-023b9edc8897_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_0237b1d6-627f-446c-9f2d-aed848279017_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9b4df3f9-3aca-4663-a28c-42849083eca6_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseLiabilityCurrent_07ae6dca-f530-4da9-9d1d-80eab8df16c8_totalLabel_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current lease liabilities</link:label>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease, Liability, Current</link:label>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseLiabilityCurrent_documentation_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseLiabilityCurrent" xlink:href="mrna-20210331.xsd#mrna_OperatingAndFinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_OperatingAndFinanceLeaseLiabilityCurrent" xlink:to="lab_mrna_OperatingAndFinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_bafd17a4-c81c-4de5-bc46-a1e6fa0aee19_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_200413cd-ece8-4e1d-8175-57f673059543_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_5190ae98-ed23-421e-8ea3-fdebb5569d25_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_f2435b57-e72c-4a6c-b198-3af362f670de_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod_7c8293a7-257f-4af0-a332-9c172998208c_negatedTerseLabel_en-US" xlink:label="lab_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod_label_en-US" xlink:label="lab_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Deductions During Period</link:label>
    <link:label id="lab_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod_documentation_en-US" xlink:label="lab_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Deductions During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod" xlink:href="mrna-20210331.xsd#mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod" xlink:to="lab_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_2bad0275-5299-43a5-a1a0-46e5be6a7296_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_077fd723-f5ea-4a74-97b3-53f5ef67ed0c_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration paid</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_ab987306-59de-4d74-8595-5e32f822fdd4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantMember_c3ea500a-78c9-47ee-975e-fa4d717ab042_terseLabel_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant revenue</link:label>
    <link:label id="lab_us-gaap_GrantMember_label_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantMember" xlink:to="lab_us-gaap_GrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseLiability_d3403909-46c8-4a83-91d2-63b408cbf549_totalLabel_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseLiability_label_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease, Liability</link:label>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseLiability_documentation_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseLiability" xlink:href="mrna-20210331.xsd#mrna_OperatingAndFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_OperatingAndFinanceLeaseLiability" xlink:to="lab_mrna_OperatingAndFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0232b4ef-0b08-49b9-88a4-f20921b12f30_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_AccruedDevelopmentOperation_532161f2-500c-435c-8e70-bcd37ca62add_terseLabel_en-US" xlink:label="lab_mrna_AccruedDevelopmentOperation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development operations</link:label>
    <link:label id="lab_mrna_AccruedDevelopmentOperation_label_en-US" xlink:label="lab_mrna_AccruedDevelopmentOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Development Operation</link:label>
    <link:label id="lab_mrna_AccruedDevelopmentOperation_documentation_en-US" xlink:label="lab_mrna_AccruedDevelopmentOperation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Development Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedDevelopmentOperation" xlink:href="mrna-20210331.xsd#mrna_AccruedDevelopmentOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_AccruedDevelopmentOperation" xlink:to="lab_mrna_AccruedDevelopmentOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_07b774be-d60d-44d3-b876-2e00a235dbde_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_7c076b0f-2900-4ac1-a184-694b356facc8_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest or imputed interest</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_008ca55f-e06b-4caa-bcfb-5624b6e96412_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less amounts representing interest or imputed interest</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_5d900f23-ba33-499a-a826-4b4f2afb4f42_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture, fixtures and other</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Other Types [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_2b006325-7467-4bf1-a846-d36828d547dc_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_4f062abb-3cc5-4a73-81cc-df38885963ca_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_61a31328-4213-4005-a056-e126422eda09_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_041ad786-2786-4293-aedf-5e7d4a76b7f4_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_083eaf24-adf8-4f23-b20c-07cce1d2897f_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_OtherGrantRevenueMember_149c10e4-73b5-4b2f-9a58-d826693de20a_terseLabel_en-US" xlink:label="lab_mrna_OtherGrantRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other grant revenue</link:label>
    <link:label id="lab_mrna_OtherGrantRevenueMember_label_en-US" xlink:label="lab_mrna_OtherGrantRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other grant revenue [Member]</link:label>
    <link:label id="lab_mrna_OtherGrantRevenueMember_documentation_en-US" xlink:label="lab_mrna_OtherGrantRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other grant revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OtherGrantRevenueMember" xlink:href="mrna-20210331.xsd#mrna_OtherGrantRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_OtherGrantRevenueMember" xlink:to="lab_mrna_OtherGrantRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_24037b10-3eb1-46e8-af11-325284498a5c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:to="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_121fe8cf-6258-4701-9f1b-1b2ec25e49b8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_326decf1-8319-4647-8854-13a293728e78_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash, non-current</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_cdeb80e4-c00c-477a-b1d0-3510fa366dfc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_RevenueFromGrantsNumberOfContractOptions_d6b3cf54-38fa-4507-9355-e16c8e502dc5_verboseLabel_en-US" xlink:label="lab_mrna_RevenueFromGrantsNumberOfContractOptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of contract options</link:label>
    <link:label id="lab_mrna_RevenueFromGrantsNumberOfContractOptions_label_en-US" xlink:label="lab_mrna_RevenueFromGrantsNumberOfContractOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Number Of Contract Options</link:label>
    <link:label id="lab_mrna_RevenueFromGrantsNumberOfContractOptions_documentation_en-US" xlink:label="lab_mrna_RevenueFromGrantsNumberOfContractOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Number Of Contract Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsNumberOfContractOptions" xlink:href="mrna-20210331.xsd#mrna_RevenueFromGrantsNumberOfContractOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_RevenueFromGrantsNumberOfContractOptions" xlink:to="lab_mrna_RevenueFromGrantsNumberOfContractOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_5f6f96bc-30a1-4d5d-a35d-b07a9520575d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_a0a98534-3567-4bb8-9178-a29c569ed862_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other prepaid expenses</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1deabd02-6c40-489c-a6fd-b3e4de225275_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_c810a28f-ae34-4033-a5c2-08d69a0560af_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_bc36746b-165b-4eaa-a145-cc54185afbfc_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_a71b16d6-19f8-4d4c-b099-9a3ff64405e3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_c73411af-0d7f-4400-9e3d-74c85599bb12_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_MTCNorthMember_7f8087ec-a283-4378-a7ea-0c7f08da8c8d_terseLabel_en-US" xlink:label="lab_mrna_MTCNorthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MTC North</link:label>
    <link:label id="lab_mrna_MTCNorthMember_label_en-US" xlink:label="lab_mrna_MTCNorthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MTC North [Member]</link:label>
    <link:label id="lab_mrna_MTCNorthMember_documentation_en-US" xlink:label="lab_mrna_MTCNorthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MTC North</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MTCNorthMember" xlink:href="mrna-20210331.xsd#mrna_MTCNorthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_MTCNorthMember" xlink:to="lab_mrna_MTCNorthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_617722cc-b63a-4629-bc9e-9e4a7506ed20_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_98466abf-dc85-4344-90d7-80a76f9f47a2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_0b10905d-5e9d-4da5-8ef1-016d85066be6_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_a9a98346-2ed6-4c0d-926c-27c28b51f87b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled/forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_RawMaterialsAccountsPayable_92345c3c-ffa6-4962-a972-c68182b462a4_terseLabel_en-US" xlink:label="lab_mrna_RawMaterialsAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_mrna_RawMaterialsAccountsPayable_label_en-US" xlink:label="lab_mrna_RawMaterialsAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw Materials, Accounts Payable</link:label>
    <link:label id="lab_mrna_RawMaterialsAccountsPayable_documentation_en-US" xlink:label="lab_mrna_RawMaterialsAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw Materials, Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RawMaterialsAccountsPayable" xlink:href="mrna-20210331.xsd#mrna_RawMaterialsAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_RawMaterialsAccountsPayable" xlink:to="lab_mrna_RawMaterialsAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_79b86880-2c83-4475-b3e5-5422b7b59bd7_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_eac71662-f35c-49b3-a60c-4b200300351b_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, fair value disclosure</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3812773c-42eb-4e7c-9a9b-0ca08374a1dc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_c8903960-0acf-4c7a-acae-765dbf26d51f_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash investing and financing activities</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_19fca0dd-1481-4329-a40d-449814125e91_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_1d268e83-a719-4a5c-be21-0f7784753be8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_736b688f-3709-4b64-ae94-93cd98ca940b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2e02fbad-6df3-4724-b68a-f3b33e5d0a08_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number&#160;of Options (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_015a7cb6-7950-48be-9929-b1d903ee8bf5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e76c2070-c6ba-48d0-bdd4-d40a675f48be_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a094bed1-e032-4188-8891-1bba6404d658_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted weighted-average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_Commercial_538133fd-9586-4377-8618-05de6133d15e_terseLabel_en-US" xlink:label="lab_mrna_Commercial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial</link:label>
    <link:label id="lab_mrna_Commercial_label_en-US" xlink:label="lab_mrna_Commercial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial</link:label>
    <link:label id="lab_mrna_Commercial_documentation_en-US" xlink:label="lab_mrna_Commercial" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_Commercial" xlink:href="mrna-20210331.xsd#mrna_Commercial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_Commercial" xlink:to="lab_mrna_Commercial" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_b0dac111-063e-43d7-bad3-1871a8977066_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_1b3eea99-3b46-450f-8789-9a11f0f62986_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic EPS (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount_b4fa4deb-cd52-4099-bac6-6b7be94c378e_terseLabel_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial milestone payments</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount_label_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Commercial Milestones, Maximum Amount</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount_documentation_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Commercial Milestones, Maximum Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount" xlink:href="mrna-20210331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount" xlink:to="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_1daae1d8-5aac-4f1a-a799-ed54ac4cf98b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_b471ac94-a087-4773-b683-e77b6c13d972_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0466063f-2703-4e75-a237-dfcd72a12cea_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled, forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_449490a4-9d13-49a6-971e-e4ded0236499_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_56091526-6ab6-42e3-8dc8-1605038b4e69_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining performance obligations</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_a1cf9409-d4bb-44b2-8b74-4c6ee4a20371_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_e9f4efad-ed98-41f1-9079-0a320e2d8133_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Loss on Available-for-Sale Debt Securities</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_b3454e67-200c-43ea-914b-1d9ce23596fd_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_18e89426-4248-4553-84a3-a3739196ccbf_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_b4216529-5027-4286-8a6b-a52c7ac20308_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_f195bb7e-7eb3-4991-ac28-2965b246a0fa_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value $0.0001; 1,600 shares authorized as of March 31, 2021 and December 31, 2020; 401 and 399 shares issued and outstanding as of March 31, 2021 and December 31, 2019, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_c6d77d90-897c-407e-a2ad-f0d33f68dd57_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_0d66c801-5ed3-41a4-a6f0-149c551997fb_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_OperatingLeaseLiabilities_81016fcb-c325-4216-9bb2-bbfc9cc6f788_terseLabel_en-US" xlink:label="lab_mrna_OperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_mrna_OperatingLeaseLiabilities_label_en-US" xlink:label="lab_mrna_OperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liabilities</link:label>
    <link:label id="lab_mrna_OperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_mrna_OperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingLeaseLiabilities" xlink:href="mrna-20210331.xsd#mrna_OperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_OperatingLeaseLiabilities" xlink:to="lab_mrna_OperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_cda363f2-b8a0-4525-b1d4-d7b5d9c179f6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_d155b040-0d84-48bb-a60d-73c98b73b242_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_a774fece-770f-4b6e-8bc7-72146a15b489_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_322e4ac2-fd75-4b17-b932-108175fc39c0_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_fc976637-103e-484d-8f74-d0a52a312101_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_CustomerDepositsMember_b0f6e15b-0e4a-492d-aea6-9351f0d35ea2_terseLabel_en-US" xlink:label="lab_mrna_CustomerDepositsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer deposits</link:label>
    <link:label id="lab_mrna_CustomerDepositsMember_label_en-US" xlink:label="lab_mrna_CustomerDepositsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Deposits [Member]</link:label>
    <link:label id="lab_mrna_CustomerDepositsMember_documentation_en-US" xlink:label="lab_mrna_CustomerDepositsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Deposits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CustomerDepositsMember" xlink:href="mrna-20210331.xsd#mrna_CustomerDepositsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_CustomerDepositsMember" xlink:to="lab_mrna_CustomerDepositsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c2b32f2a-b05b-40f1-98ec-3ac7ef2c094b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_NumberOfDevelopmentProgram_a7ab411d-282b-405a-b198-fbb0331ac4c1_terseLabel_en-US" xlink:label="lab_mrna_NumberOfDevelopmentProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development program</link:label>
    <link:label id="lab_mrna_NumberOfDevelopmentProgram_label_en-US" xlink:label="lab_mrna_NumberOfDevelopmentProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Development Program</link:label>
    <link:label id="lab_mrna_NumberOfDevelopmentProgram_documentation_en-US" xlink:label="lab_mrna_NumberOfDevelopmentProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Development Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NumberOfDevelopmentProgram" xlink:href="mrna-20210331.xsd#mrna_NumberOfDevelopmentProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_NumberOfDevelopmentProgram" xlink:to="lab_mrna_NumberOfDevelopmentProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_23934bdc-c177-43a7-996a-9358d49fb2ec_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_b9a37692-97fc-4afb-a769-5d703f8bd021_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_79fd9a66-ac70-4e7b-9713-ccaf355f90bd_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_85d19019-b78d-4f48-b842-73b59c009223_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, asset</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_26b6507e-2dce-49e8-a3ef-f920bb83cf6c_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_74d3b743-d628-411a-8546-fbf381699115_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_e5fdebb4-b58f-4040-b26a-092594352a71_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Axis]</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProjectMember_06df2eb9-e8e6-42c0-871b-76535c7c1ff7_terseLabel_en-US" xlink:label="lab_us-gaap_ProjectMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Domain]</link:label>
    <link:label id="lab_us-gaap_ProjectMember_label_en-US" xlink:label="lab_us-gaap_ProjectMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProjectMember" xlink:to="lab_us-gaap_ProjectMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_e99180ec-7e62-4d8e-94eb-7fb349809be9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_DiagnosticProductsMember_62669a38-c5db-48ed-bcd3-850dd76ee7fd_terseLabel_en-US" xlink:label="lab_mrna_DiagnosticProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diagnostic products</link:label>
    <link:label id="lab_mrna_DiagnosticProductsMember_label_en-US" xlink:label="lab_mrna_DiagnosticProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diagnostic Products [Member]</link:label>
    <link:label id="lab_mrna_DiagnosticProductsMember_documentation_en-US" xlink:label="lab_mrna_DiagnosticProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diagnostic Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DiagnosticProductsMember" xlink:href="mrna-20210331.xsd#mrna_DiagnosticProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_DiagnosticProductsMember" xlink:to="lab_mrna_DiagnosticProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_214a8c60-b4c2-481e-b48d-862e470bd458_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_7c5229d2-5124-42dd-9ece-e6d7ab7fb23f_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_66037e10-cf9d-4de9-a09f-3a91d69875f3_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_fa8f0a87-3e10-4285-8fd6-d9364e93f54e_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_a5b9a763-796a-4bed-a033-38d838774ab9_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering expenses</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_LeasesIncrementalBorrowingRate_42d0cf13-bc78-44dc-9d67-e44adb8f6e8b_terseLabel_en-US" xlink:label="lab_mrna_LeasesIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental borrowing rate</link:label>
    <link:label id="lab_mrna_LeasesIncrementalBorrowingRate_label_en-US" xlink:label="lab_mrna_LeasesIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases, Incremental Borrowing Rate</link:label>
    <link:label id="lab_mrna_LeasesIncrementalBorrowingRate_documentation_en-US" xlink:label="lab_mrna_LeasesIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases, Incremental Borrowing Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LeasesIncrementalBorrowingRate" xlink:href="mrna-20210331.xsd#mrna_LeasesIncrementalBorrowingRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_LeasesIncrementalBorrowingRate" xlink:to="lab_mrna_LeasesIncrementalBorrowingRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_cc8b6601-d279-46d0-b6bc-cdc871a95b49_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f42ea814-f552-4b38-9705-95b26b396aa3_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_a5e24783-c948-438c-9087-d56b0cc5c2d7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_AccruedManufacturing_0990cd79-0efa-4f5e-82e5-58779c53bc60_terseLabel_en-US" xlink:label="lab_mrna_AccruedManufacturing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing</link:label>
    <link:label id="lab_mrna_AccruedManufacturing_label_en-US" xlink:label="lab_mrna_AccruedManufacturing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Manufacturing</link:label>
    <link:label id="lab_mrna_AccruedManufacturing_documentation_en-US" xlink:label="lab_mrna_AccruedManufacturing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedManufacturing" xlink:href="mrna-20210331.xsd#mrna_AccruedManufacturing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_AccruedManufacturing" xlink:to="lab_mrna_AccruedManufacturing" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_d46532fb-7ec7-43af-9efe-c4c644227c38_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_711512f7-3e20-499f-84a7-fba95881c86e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation-related</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_fe0e2fa2-bf25-4e2e-994a-9d4380143e82_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_5048dd5e-d8a0-4535-a4ee-f481b532e05f_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted common stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_e7fd2358-6a2d-4a62-96e5-21b110c9c7e3_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_42b37aaa-a00e-413a-927d-d284dcdf5379_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_41063e13-2896-464f-8929-1bd50b717a2a_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods_2e62eada-7ea9-43eb-9d22-4b3b61557c96_terseLabel_en-US" xlink:label="lab_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of extension periods</link:label>
    <link:label id="lab_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods_label_en-US" xlink:label="lab_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Extension Periods</link:label>
    <link:label id="lab_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods_documentation_en-US" xlink:label="lab_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Extension Periods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods" xlink:href="mrna-20210331.xsd#mrna_LesseeOperatingLeaseNumberOfExtensionPeriods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods" xlink:to="lab_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_bbd7d78e-8fbd-4c30-a7ab-418bbc3acf0c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_NumberOfDosesOfVaccineCandidate_26715324-a14b-4614-8d2a-e3e6769cdb9c_terseLabel_en-US" xlink:label="lab_mrna_NumberOfDosesOfVaccineCandidate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of doses of vaccine candidate</link:label>
    <link:label id="lab_mrna_NumberOfDosesOfVaccineCandidate_label_en-US" xlink:label="lab_mrna_NumberOfDosesOfVaccineCandidate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Doses Of Vaccine Candidate</link:label>
    <link:label id="lab_mrna_NumberOfDosesOfVaccineCandidate_documentation_en-US" xlink:label="lab_mrna_NumberOfDosesOfVaccineCandidate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Doses Of Vaccine Candidate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NumberOfDosesOfVaccineCandidate" xlink:href="mrna-20210331.xsd#mrna_NumberOfDosesOfVaccineCandidate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_NumberOfDosesOfVaccineCandidate" xlink:to="lab_mrna_NumberOfDosesOfVaccineCandidate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_c85214e9-f795-4ad7-a4ca-7f1dd92c8096_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_46a10f82-21bb-4cf2-b6e8-573bb59b44f4_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_9f086d76-90ed-4cdb-98a9-b7833f6767b4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_77ea38b6-802a-470d-81d9-5755705715ec_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_f70f3f6f-e9d3-4ba7-8837-2d65b6b04b1a_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_17a8f271-3bf9-412e-8446-4ae37aef0326_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_ca016524-ec42-4f59-a99c-1f3fd4556558_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing lease liabilities, non-current</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_01e24109-d7d8-4720-8044-78fc3de3c772_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing lease liabilities, non-current</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d989ea08-c9d1-48f2-99f1-c1dba562c453_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_4bff0a77-8436-4ce4-a520-04275ac10b7a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_28251aa5-2596-4db3-9ec2-db9c259e589c_totalLabel_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current lease liabilities</link:label>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease, Liability, Noncurrent</link:label>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_documentation_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:href="mrna-20210331.xsd#mrna_OperatingAndFinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:to="lab_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_2a261b86-317f-48b5-9843-3475d1bf7153_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_678790cb-be6f-415a-a8a0-1b9826dcb1df_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward_6aa443e1-6572-463d-b0ef-5ded4f3dfc57_terseLabel_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Grant Date Fair Value per Share</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Options, Outstanding, Weighted Average Grant Date Fair Value [Roll Forward]</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward_documentation_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Options, Outstanding, Weighted Average Grant Date Fair Value [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward" xlink:href="mrna-20210331.xsd#mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_05ae1442-aa46-4562-819d-3b711fbe6304_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_a1df7797-7809-48e6-b98f-fa863e075262_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_f6a03e7f-64d2-402e-aab6-dba35741c621_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_302a5bed-ace1-427f-b7fc-87ee984cf8aa_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_07606a27-4491-48fe-8b08-1e85e9131b9e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_4de3b77b-1292-43fd-8e28-e2dddf05a63f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_adc9984b-f561-48eb-950e-c8a229f141be_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_730f1814-abdd-4435-96b2-f36346be6cbb_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_9c2b827d-5cd9-47ed-b123-60cffe3e9ad5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_9e0cec7a-449b-427c-9aa9-700ebc39a7f0_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_fe698615-a7da-4976-aae1-04141fcfed2f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2601556d-ca38-451c-a72c-66586073a5fe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number&#160;of Options (in millions)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_ce9357df-cede-455c-a68d-57361f3ca2b0_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_8a2e1aac-65b0-4f01-a45d-33cd99c4812a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_a40141d7-ffdd-4b7e-b34e-f7263281f925_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internally developed software</link:label>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareDevelopmentMember" xlink:to="lab_us-gaap_SoftwareDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_6827fd2c-45d3-4754-8a9c-92757acb3892_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition and Deferred Revenue [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_515f7831-b825-40cc-81e6-8ccbad2c9001_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, non-current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_80e0f5f5-1b4c-433f-b6ed-c873baf75e05_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of restricted stock units</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ChangeInContractWithCustomerLiabilityTable_73b040eb-a47b-42a8-823a-6e98c5563e56_terseLabel_en-US" xlink:label="lab_mrna_ChangeInContractWithCustomerLiabilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer, Liability [Table]</link:label>
    <link:label id="lab_mrna_ChangeInContractWithCustomerLiabilityTable_label_en-US" xlink:label="lab_mrna_ChangeInContractWithCustomerLiabilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer, Liability [Table]</link:label>
    <link:label id="lab_mrna_ChangeInContractWithCustomerLiabilityTable_documentation_en-US" xlink:label="lab_mrna_ChangeInContractWithCustomerLiabilityTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractWithCustomerLiabilityTable" xlink:href="mrna-20210331.xsd#mrna_ChangeInContractWithCustomerLiabilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityTable" xlink:to="lab_mrna_ChangeInContractWithCustomerLiabilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_AssetsAndLiabilitiesLesseeTableTextBlock_003ac424-7bf6-42c4-afd1-a276a090c857_terseLabel_en-US" xlink:label="lab_mrna_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee</link:label>
    <link:label id="lab_mrna_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_mrna_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_mrna_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_mrna_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="mrna-20210331.xsd#mrna_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_mrna_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_4a1fb841-e8b2-44e2-a8de-749db9b7acbe_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold under the ESPP (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_6b924465-2562-4731-befa-f44683a74417_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_69190b7e-62ee-4354-9846-7e42d56877ed_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_8e80b46e-c640-4861-89b5-b77c3df315e8_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_e512d6a8-7f70-46e9-a837-f8c3bd1128b2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_06099f65-1c35-429f-8dc7-0d2254466997_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_aa748794-a73b-4711-bc7b-bee2f7abe5c4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount_bda8c25b-8f3a-4de7-8efd-7b1034b25d2c_verboseLabel_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Budgeted amount</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount_label_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Maximum Amount</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount_documentation_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Maximum Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount" xlink:href="mrna-20210331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount" xlink:to="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember_66b7cd99-d0ea-47aa-87ad-d606c6bdfa4d_terseLabel_en-US" xlink:label="lab_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PCV agreement</link:label>
    <link:label id="lab_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember_label_en-US" xlink:label="lab_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personalized MRNA Cancer Vaccines (PCV) Collaboration And License Agreement With Merck Sharp&#160;And Dohme Corp [Member]</link:label>
    <link:label id="lab_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember_documentation_en-US" xlink:label="lab_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personalized MRNA Cancer Vaccines (PCV) Collaboration And License Agreement With Merck Sharp&#160;And Dohme Corp [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember" xlink:href="mrna-20210331.xsd#mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember" xlink:to="lab_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_af2d57a6-9bcc-4343-932b-34cd99984141_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases_94afe9a8-a0b2-4ec5-8949-2cfd7558fd1d_negatedTerseLabel_en-US" xlink:label="lab_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets, operating leases</link:label>
    <link:label id="lab_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases_label_en-US" xlink:label="lab_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Right Of Use Asset, Operating Leases</link:label>
    <link:label id="lab_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases_documentation_en-US" xlink:label="lab_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Right Of Use Asset, Operating Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases" xlink:href="mrna-20210331.xsd#mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases" xlink:to="lab_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_79ecf37f-5bd6-40c4-89c5-5a1089dcd82d_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_36455fdc-5161-4b3d-be74-d4d262d2ffc7_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_dc7c019d-f9e1-49c9-903f-b45230f7c9fa_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from public offering of common stock, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_57c34582-9f25-4ac3-8f2e-cb6ca1139a58_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ProductSalesMember_64f12756-71ae-42cf-bcb9-feb80a7eeb49_terseLabel_en-US" xlink:label="lab_mrna_ProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales</link:label>
    <link:label id="lab_mrna_ProductSalesMember_label_en-US" xlink:label="lab_mrna_ProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Sales [Member]</link:label>
    <link:label id="lab_mrna_ProductSalesMember_documentation_en-US" xlink:label="lab_mrna_ProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ProductSalesMember" xlink:href="mrna-20210331.xsd#mrna_ProductSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ProductSalesMember" xlink:to="lab_mrna_ProductSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseMember_42aec6d1-be7d-40fa-a594-cf85ff4bcfb6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseMember" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_5da54ce8-91c2-4e7f-b6a5-7667d255c913_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_8955a322-46f7-4587-8ca0-df27fd318af6_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_6625febf-0839-461d-a2fe-7e2e8c9032d8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_MerckMember_4752e2e3-c738-4584-941e-3e164b0f2a12_terseLabel_en-US" xlink:label="lab_mrna_MerckMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck</link:label>
    <link:label id="lab_mrna_MerckMember_label_en-US" xlink:label="lab_mrna_MerckMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck [Member]</link:label>
    <link:label id="lab_mrna_MerckMember_documentation_en-US" xlink:label="lab_mrna_MerckMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MerckMember" xlink:href="mrna-20210331.xsd#mrna_MerckMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_MerckMember" xlink:to="lab_mrna_MerckMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4b2597a5-c24a-4b4d-a0a6-6f4529c2a294_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of options to purchase common stock, net (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9ad9fdc3-2d8c-4e1a-bd29-c95cc9c1f7df_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d2b7b5c0-806c-4eb3-ab75-ea58c62eb47e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_a53aab34-5201-490c-b4fc-1ee493d63e39_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest receivable on marketable securities</link:label>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivableCurrent" xlink:to="lab_us-gaap_InterestReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_22fb76cc-50b5-46c4-9efb-1f518a2d5caf_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_3180d8d1-09f1-4d81-a022-577086a09339_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets, financing, net</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_3bc4a7f0-13d8-4709-a301-4307adcb67bf_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_7552b744-221f-4259-9437-7c5f44e1ba46_netLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_15dd4497-5a73-4ec8-ab10-d3c0ddffb368_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_79eeedc6-11a4-4622-87ff-66ba0c08b5cc_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_854a4bed-0a34-4f7b-a947-0329846f9c13_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b657a01e-9b1b-4199-b065-9e6b5f6705d5_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic weighted-average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_4574a90e-c9c0-4bdb-9c34-0bc866c21ac9_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_a2e150d3-8fbf-42e3-9b5c-d14524e046ac_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled/forfeited (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_cb35d707-eff8-4f06-b444-e89f9878a9d3_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue_94cd96f1-577e-458b-b88f-2ed7829e2021_terseLabel_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled/forfeited (usd per share)</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue" xlink:href="mrna-20210331.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_OperatingLeaseNumberOfProperties_08eb537c-f6e7-4f75-a322-4452edd0b0eb_terseLabel_en-US" xlink:label="lab_mrna_OperatingLeaseNumberOfProperties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of campuses</link:label>
    <link:label id="lab_mrna_OperatingLeaseNumberOfProperties_label_en-US" xlink:label="lab_mrna_OperatingLeaseNumberOfProperties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Number Of Properties</link:label>
    <link:label id="lab_mrna_OperatingLeaseNumberOfProperties_documentation_en-US" xlink:label="lab_mrna_OperatingLeaseNumberOfProperties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Number Of Properties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingLeaseNumberOfProperties" xlink:href="mrna-20210331.xsd#mrna_OperatingLeaseNumberOfProperties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_OperatingLeaseNumberOfProperties" xlink:to="lab_mrna_OperatingLeaseNumberOfProperties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_71a34fd2-617b-4926-b8b8-618e2e86fe22_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_036d21e3-b401-4a82-9148-a68a815452e1_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_5b2df3a9-5aa0-461e-af89-0c2f04925001_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_fab8cce6-5046-4bee-b118-8bd9b9e14ac1_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of the Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_74d91f3b-52aa-4d98-8a4b-dcc820a3a81b_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_2f1c9ada-767f-49c0-8826-05398dddb762_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_a3f2b773-7906-4704-a8ee-fb923e425d3f_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_8432bf77-c52f-45bf-8601-371233017a5f_netLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total grant revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_a432865b-767c-4264-bdb4-d97478291eab_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_ddff9610-c9d4-4307-a2f6-bafb37ede995_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Common Stock Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_RevenueFromGrantsMaximumAward_008df13d-3fc8-47ad-bd7a-d93f552c47df_terseLabel_en-US" xlink:label="lab_mrna_RevenueFromGrantsMaximumAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award amount</link:label>
    <link:label id="lab_mrna_RevenueFromGrantsMaximumAward_label_en-US" xlink:label="lab_mrna_RevenueFromGrantsMaximumAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Maximum Award</link:label>
    <link:label id="lab_mrna_RevenueFromGrantsMaximumAward_documentation_en-US" xlink:label="lab_mrna_RevenueFromGrantsMaximumAward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Maximum Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsMaximumAward" xlink:href="mrna-20210331.xsd#mrna_RevenueFromGrantsMaximumAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_RevenueFromGrantsMaximumAward" xlink:to="lab_mrna_RevenueFromGrantsMaximumAward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_364e2e2b-d757-4fbf-b978-b30ec2e8b4c7_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_54d63799-5a8f-40fa-8c59-b8732feacb3d_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5991e1be-545e-49ea-8ccd-143f9afc9382_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_4eacdb63-488e-4883-90f2-803c88f37118_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_45675ff7-4833-4fd2-8ec5-3160b0f7a740_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_d6f0c929-3091-4124-b294-fd2631d57d97_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_fb78afbb-721d-41aa-bcd2-afb1aa9232f4_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_2e3654b0-3a1a-4b11-b918-bf68fac2fb3d_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_e3b41027-ac8f-4735-9f2e-befdc86d461c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted EPS (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_9f3f76e9-2013-4641-acf9-a1cd42ce5968_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing lease liabilities, current</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_c9f4e126-308a-4c79-a4c8-47a3cdf370fd_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_ad7324c5-af50-4ad8-9a5c-d6fb0ae458c6_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_448086e2-f3ca-42e7-a469-85b0d8cd4df4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ChargesToFinancingLeaseLiabilities_2bceb28c-ff95-458b-9073-511915c10393_terseLabel_en-US" xlink:label="lab_mrna_ChargesToFinancingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in financing lease liabilities</link:label>
    <link:label id="lab_mrna_ChargesToFinancingLeaseLiabilities_label_en-US" xlink:label="lab_mrna_ChargesToFinancingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charges To Financing Lease Liabilities</link:label>
    <link:label id="lab_mrna_ChargesToFinancingLeaseLiabilities_documentation_en-US" xlink:label="lab_mrna_ChargesToFinancingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charges To Financing Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChargesToFinancingLeaseLiabilities" xlink:href="mrna-20210331.xsd#mrna_ChargesToFinancingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ChargesToFinancingLeaseLiabilities" xlink:to="lab_mrna_ChargesToFinancingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_7104a367-2fc9-421c-b0d4-d254aaab43c2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_ed30cecb-a361-4183-b715-961c6a8a904b_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with customer, liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_3017575e-fed8-4a8b-8d8b-4bd6fc12ce7c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_e939ff76-2093-4572-b9d0-7f9e39c36e52_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_4cc575d7-6c61-405c-b2a0-79bf51c21c21_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Axis]</link:label>
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_label_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_a10dccb9-562f-4795-9589-6dddd036f746_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b6d143c3-a5dd-460d-a1ca-88da91d6ec5d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_861eda7c-75bb-4bfe-a2bb-11443023a0fb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_EmbeddedLeasesMember_2ed25a46-8f5f-453f-b7b8-106ddcbf9c49_terseLabel_en-US" xlink:label="lab_mrna_EmbeddedLeasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Embedded Leases</link:label>
    <link:label id="lab_mrna_EmbeddedLeasesMember_label_en-US" xlink:label="lab_mrna_EmbeddedLeasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Embedded Leases [Member]</link:label>
    <link:label id="lab_mrna_EmbeddedLeasesMember_documentation_en-US" xlink:label="lab_mrna_EmbeddedLeasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Embedded Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_EmbeddedLeasesMember" xlink:href="mrna-20210331.xsd#mrna_EmbeddedLeasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_EmbeddedLeasesMember" xlink:to="lab_mrna_EmbeddedLeasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_4ad6c98a-e9af-465c-ad75-28f1a17c7478_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_151fc899-886d-4681-bc81-a6c2582f2381_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Fair Value per Unit</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_0e46c298-6493-4359-ba33-9a5e58a933a7_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_59c77b87-3bdc-42f5-a237-4287bece5e62_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_AccruedClinicalTrials_410dcfa6-0b9b-4e6a-9cc7-53ce5b6b01a3_terseLabel_en-US" xlink:label="lab_mrna_AccruedClinicalTrials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical trials</link:label>
    <link:label id="lab_mrna_AccruedClinicalTrials_label_en-US" xlink:label="lab_mrna_AccruedClinicalTrials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trials</link:label>
    <link:label id="lab_mrna_AccruedClinicalTrials_documentation_en-US" xlink:label="lab_mrna_AccruedClinicalTrials" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trials</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedClinicalTrials" xlink:href="mrna-20210331.xsd#mrna_AccruedClinicalTrials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_AccruedClinicalTrials" xlink:to="lab_mrna_AccruedClinicalTrials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_10250731-6675-4fa0-b6cc-ffef8d7e89a7_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_SupplyAndManufacturingAgreementsMember_44d477d2-6b36-4cc1-909c-d7c5264a7d19_terseLabel_en-US" xlink:label="lab_mrna_SupplyAndManufacturingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply and manufacturing agreements</link:label>
    <link:label id="lab_mrna_SupplyAndManufacturingAgreementsMember_label_en-US" xlink:label="lab_mrna_SupplyAndManufacturingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply And Manufacturing Agreements [Member]</link:label>
    <link:label id="lab_mrna_SupplyAndManufacturingAgreementsMember_documentation_en-US" xlink:label="lab_mrna_SupplyAndManufacturingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply And Manufacturing Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_SupplyAndManufacturingAgreementsMember" xlink:href="mrna-20210331.xsd#mrna_SupplyAndManufacturingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_SupplyAndManufacturingAgreementsMember" xlink:to="lab_mrna_SupplyAndManufacturingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_b0406e16-f909-4640-8ea1-2abf620c0d39_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_3f592b18-40e0-4601-80e3-635995de1851_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_113d9df0-3fd9-472b-88ac-983a20d9aff9_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_TenantIncentivesReceivablesCurrent_e9fda994-2a7c-47f0-8fe7-58cf8a8daea1_terseLabel_en-US" xlink:label="lab_mrna_TenantIncentivesReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant incentives receivables</link:label>
    <link:label id="lab_mrna_TenantIncentivesReceivablesCurrent_label_en-US" xlink:label="lab_mrna_TenantIncentivesReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant Incentives Receivables, Current</link:label>
    <link:label id="lab_mrna_TenantIncentivesReceivablesCurrent_documentation_en-US" xlink:label="lab_mrna_TenantIncentivesReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant Incentives Receivables, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_TenantIncentivesReceivablesCurrent" xlink:href="mrna-20210331.xsd#mrna_TenantIncentivesReceivablesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_TenantIncentivesReceivablesCurrent" xlink:to="lab_mrna_TenantIncentivesReceivablesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_2b35d2b1-2d5e-4191-b62f-27db55d90bbd_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Basis of Presentation and Recent Accounting Standards</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_e4fefe80-57f5-4fb7-96d5-da3eabb22e4e_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3db52f27-8d0a-48d3-a2df-501554809a6b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding and Exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_e4123daf-4183-4827-b6b7-9d7b19f31875_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ContractOptionsMember_19288c84-8bc3-41fb-aadc-a905057c048a_terseLabel_en-US" xlink:label="lab_mrna_ContractOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract options</link:label>
    <link:label id="lab_mrna_ContractOptionsMember_label_en-US" xlink:label="lab_mrna_ContractOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Options [Member]</link:label>
    <link:label id="lab_mrna_ContractOptionsMember_documentation_en-US" xlink:label="lab_mrna_ContractOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractOptionsMember" xlink:href="mrna-20210331.xsd#mrna_ContractOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ContractOptionsMember" xlink:to="lab_mrna_ContractOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_75cc6a5f-5ce4-48eb-8779-a0af28fcd191_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Term, Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f018b443-665e-4652-b442-b8fe7b411f76_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b168dea8-3027-4f7e-a1c7-4cc7555fbafd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_e6837cfc-e08d-4896-ab06-6120948f575d_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_840c51fb-79ce-4058-98b5-4a30035c3c52_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price per Share, Exercisable (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_fe177fb6-62d5-4925-b105-1089401aab7d_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares used in calculation of earnings (loss) per share</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3c9aeae2-a1c3-4c2f-9d21-1f2b7567df71_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_916c3a19-2f0d-47d9-994e-12e6c9d46ee9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitment_0db605dc-dc8c-4554-add9-3edbb3d58094_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional commitment</link:label>
    <link:label id="lab_us-gaap_OtherCommitment_label_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitment" xlink:to="lab_us-gaap_OtherCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_5e1e2ce4-2a46-4664-b2d0-732aaf2b796a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_3332e8ad-cef6-4f95-82fa-cb6ad3525a1d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_64095262-b59f-4a02-b0de-01b8a09a32e0_terseLabel_en-US" xlink:label="lab_mrna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_mrna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_mrna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:label id="lab_mrna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_mrna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="mrna-20210331.xsd#mrna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_mrna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_93551d5b-7e0b-4790-b755-5234dcacbe08_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_c04978f1-86fd-4205-a0a0-de310ffd197b_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Table]</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" xlink:to="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_90c91fc1-334d-4c5e-8201-0574242dc258_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_cc2d4f15-37eb-466f-89ad-a7e989faa7e1_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_bd3a7abe-a9bd-4347-adc7-30249cda0bdb_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_4a05033d-c159-4bb4-9785-3930c0bb7328_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_81aaf523-f674-4cc8-af12-da66572c8f9c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_d2c71ecf-506a-4cfc-af7d-f0eba265b753_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price per Share (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_a1944b2e-06a8-4b1c-8fdd-d100df7bb2e7_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_49b650ab-cd6e-440d-ab06-12601dd5be67_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Standards and Recently Issued Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_68b8c710-1a3e-48f7-ba86-562ea08d54b8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>mrna-20210331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:0cbcbb00-411e-4aec-bde6-af04ca2907e0,g:4456e2fc-6666-4731-b603-d80176d3b13f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.modernatx.com/role/CoverPage" xlink:type="simple" xlink:href="mrna-20210331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_4240d653-d877-4332-8801-c55e7423f7e0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_7a3c44cb-8581-4414-8da1-f9af2e25be42" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4240d653-d877-4332-8801-c55e7423f7e0" xlink:to="loc_dei_DocumentType_7a3c44cb-8581-4414-8da1-f9af2e25be42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_92664799-9ff3-4c75-ab1e-f43fd187d663" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4240d653-d877-4332-8801-c55e7423f7e0" xlink:to="loc_dei_DocumentQuarterlyReport_92664799-9ff3-4c75-ab1e-f43fd187d663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_b0f68cfe-bbd3-481b-8d00-6d4c70120183" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4240d653-d877-4332-8801-c55e7423f7e0" xlink:to="loc_dei_DocumentPeriodEndDate_b0f68cfe-bbd3-481b-8d00-6d4c70120183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_05391004-57cc-4d49-9dc4-2004f75434b4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4240d653-d877-4332-8801-c55e7423f7e0" xlink:to="loc_dei_DocumentTransitionReport_05391004-57cc-4d49-9dc4-2004f75434b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_49735684-7549-4b18-bf0c-283d0be2d2a8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4240d653-d877-4332-8801-c55e7423f7e0" xlink:to="loc_dei_EntityFileNumber_49735684-7549-4b18-bf0c-283d0be2d2a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_a6b65c95-ef15-4267-9db4-8a4c2d97e64f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4240d653-d877-4332-8801-c55e7423f7e0" xlink:to="loc_dei_EntityRegistrantName_a6b65c95-ef15-4267-9db4-8a4c2d97e64f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_db3a85b1-b841-40e9-a284-e9fc665760c4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4240d653-d877-4332-8801-c55e7423f7e0" xlink:to="loc_dei_EntityIncorporationStateCountryCode_db3a85b1-b841-40e9-a284-e9fc665760c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_a1118d23-d940-4cc2-994a-6aa741935f74" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4240d653-d877-4332-8801-c55e7423f7e0" xlink:to="loc_dei_EntityTaxIdentificationNumber_a1118d23-d940-4cc2-994a-6aa741935f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_07095154-c58f-493b-8cc6-3b0bfe250c53" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4240d653-d877-4332-8801-c55e7423f7e0" xlink:to="loc_dei_EntityAddressAddressLine1_07095154-c58f-493b-8cc6-3b0bfe250c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_d34cf440-f0b8-4471-ae08-7b0899cc11b6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4240d653-d877-4332-8801-c55e7423f7e0" xlink:to="loc_dei_EntityAddressCityOrTown_d34cf440-f0b8-4471-ae08-7b0899cc11b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_fd9660f6-714e-4e54-bbfc-a1cc5e8508d7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4240d653-d877-4332-8801-c55e7423f7e0" xlink:to="loc_dei_EntityAddressStateOrProvince_fd9660f6-714e-4e54-bbfc-a1cc5e8508d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_4a50ea2a-3cd8-4881-861a-84a578dc509a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4240d653-d877-4332-8801-c55e7423f7e0" xlink:to="loc_dei_EntityAddressPostalZipCode_4a50ea2a-3cd8-4881-861a-84a578dc509a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_1b1d6a73-7ee2-476b-8d55-03ba6558fda5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4240d653-d877-4332-8801-c55e7423f7e0" xlink:to="loc_dei_CityAreaCode_1b1d6a73-7ee2-476b-8d55-03ba6558fda5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_f06e1417-a1db-469a-85ed-d754c6be92d3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4240d653-d877-4332-8801-c55e7423f7e0" xlink:to="loc_dei_LocalPhoneNumber_f06e1417-a1db-469a-85ed-d754c6be92d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_87ecbf2a-ca32-4b58-b027-db2228a12fc8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4240d653-d877-4332-8801-c55e7423f7e0" xlink:to="loc_dei_Security12bTitle_87ecbf2a-ca32-4b58-b027-db2228a12fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_b711ed71-7a4a-4f5b-a6a9-2f4b21042493" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4240d653-d877-4332-8801-c55e7423f7e0" xlink:to="loc_dei_TradingSymbol_b711ed71-7a4a-4f5b-a6a9-2f4b21042493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_faf2c2ee-1042-4ae4-ab74-0b95913c2f24" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4240d653-d877-4332-8801-c55e7423f7e0" xlink:to="loc_dei_SecurityExchangeName_faf2c2ee-1042-4ae4-ab74-0b95913c2f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_8186cbec-7ea0-4f1a-b23f-a8fc10b73575" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4240d653-d877-4332-8801-c55e7423f7e0" xlink:to="loc_dei_EntityCurrentReportingStatus_8186cbec-7ea0-4f1a-b23f-a8fc10b73575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_ed9fb8af-c865-45a7-b5f3-377ae109339b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4240d653-d877-4332-8801-c55e7423f7e0" xlink:to="loc_dei_EntityInteractiveDataCurrent_ed9fb8af-c865-45a7-b5f3-377ae109339b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_41ba2cf1-66f4-4758-88d3-6c5ce2db8f63" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4240d653-d877-4332-8801-c55e7423f7e0" xlink:to="loc_dei_EntityFilerCategory_41ba2cf1-66f4-4758-88d3-6c5ce2db8f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_9bb8b36b-9a11-4733-a8a4-ff62a51d4eeb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4240d653-d877-4332-8801-c55e7423f7e0" xlink:to="loc_dei_EntitySmallBusiness_9bb8b36b-9a11-4733-a8a4-ff62a51d4eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_7c81eb5c-7d33-44f2-802e-4bd8295cc576" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4240d653-d877-4332-8801-c55e7423f7e0" xlink:to="loc_dei_EntityEmergingGrowthCompany_7c81eb5c-7d33-44f2-802e-4bd8295cc576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_640bf343-a0b8-44b2-bb82-f776dfcdba98" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4240d653-d877-4332-8801-c55e7423f7e0" xlink:to="loc_dei_EntityShellCompany_640bf343-a0b8-44b2-bb82-f776dfcdba98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_e57826f9-3c6f-4356-a720-ed3639310b35" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4240d653-d877-4332-8801-c55e7423f7e0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_e57826f9-3c6f-4356-a720-ed3639310b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e9e491e9-3fba-45b1-a997-97db3aa0a0d8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4240d653-d877-4332-8801-c55e7423f7e0" xlink:to="loc_dei_AmendmentFlag_e9e491e9-3fba-45b1-a997-97db3aa0a0d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_4bbdd2e3-379e-4439-ae8a-1bdba7f16aa4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4240d653-d877-4332-8801-c55e7423f7e0" xlink:to="loc_dei_DocumentFiscalYearFocus_4bbdd2e3-379e-4439-ae8a-1bdba7f16aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_fa321ceb-35d7-4668-a678-250ed6fadb1b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4240d653-d877-4332-8801-c55e7423f7e0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_fa321ceb-35d7-4668-a678-250ed6fadb1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_aeeb9233-bd63-404a-9d56-50ad2d518bb9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4240d653-d877-4332-8801-c55e7423f7e0" xlink:to="loc_dei_EntityCentralIndexKey_aeeb9233-bd63-404a-9d56-50ad2d518bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_152a2c30-8aa2-48c5-a5d5-2aba07225112" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4240d653-d877-4332-8801-c55e7423f7e0" xlink:to="loc_dei_CurrentFiscalYearEndDate_152a2c30-8aa2-48c5-a5d5-2aba07225112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="mrna-20210331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_39ae2f04-822e-4f0e-994b-1d1877e7a3cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_5be63f70-fd2b-449b-8932-caf3287c9711" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_39ae2f04-822e-4f0e-994b-1d1877e7a3cb" xlink:to="loc_us-gaap_AssetsAbstract_5be63f70-fd2b-449b-8932-caf3287c9711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_f936d7a6-b95e-4701-821a-babf3933da8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5be63f70-fd2b-449b-8932-caf3287c9711" xlink:to="loc_us-gaap_AssetsCurrentAbstract_f936d7a6-b95e-4701-821a-babf3933da8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a7249778-b421-45f2-a920-c35da32732f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f936d7a6-b95e-4701-821a-babf3933da8d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a7249778-b421-45f2-a920-c35da32732f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_92c0915d-6562-495a-9d89-4076235b84b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f936d7a6-b95e-4701-821a-babf3933da8d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_92c0915d-6562-495a-9d89-4076235b84b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_a29d12ea-ef6d-42d0-9e9c-206bde0ea3c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f936d7a6-b95e-4701-821a-babf3933da8d" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_a29d12ea-ef6d-42d0-9e9c-206bde0ea3c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_9395f3d5-d4da-48a9-8428-68dcbeb8c41d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f936d7a6-b95e-4701-821a-babf3933da8d" xlink:to="loc_us-gaap_InventoryNet_9395f3d5-d4da-48a9-8428-68dcbeb8c41d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9648a4c3-d39e-4ea5-9c9f-52d6a3dff426" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f936d7a6-b95e-4701-821a-babf3933da8d" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9648a4c3-d39e-4ea5-9c9f-52d6a3dff426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7208dc14-463a-45df-8454-88cd065f70cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f936d7a6-b95e-4701-821a-babf3933da8d" xlink:to="loc_us-gaap_AssetsCurrent_7208dc14-463a-45df-8454-88cd065f70cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_0d2d12da-0054-4411-9369-b408b48cba08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5be63f70-fd2b-449b-8932-caf3287c9711" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_0d2d12da-0054-4411-9369-b408b48cba08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_94572f13-c8e1-4628-a5e1-62670bc1f363" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5be63f70-fd2b-449b-8932-caf3287c9711" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_94572f13-c8e1-4628-a5e1-62670bc1f363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_85f5e71b-53ab-40a0-965f-8f87b7cd834b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5be63f70-fd2b-449b-8932-caf3287c9711" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_85f5e71b-53ab-40a0-965f-8f87b7cd834b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_2904d541-778e-4ca8-ac3e-3f83a151d49e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5be63f70-fd2b-449b-8932-caf3287c9711" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_2904d541-778e-4ca8-ac3e-3f83a151d49e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_388c62c3-370d-497b-9bde-0056b5bffb12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5be63f70-fd2b-449b-8932-caf3287c9711" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_388c62c3-370d-497b-9bde-0056b5bffb12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_f482f811-9c43-4ce9-a4e4-0a708d5c43f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5be63f70-fd2b-449b-8932-caf3287c9711" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_f482f811-9c43-4ce9-a4e4-0a708d5c43f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_d8c09a70-11eb-4437-9d64-1a049e0cb718" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5be63f70-fd2b-449b-8932-caf3287c9711" xlink:to="loc_us-gaap_Assets_d8c09a70-11eb-4437-9d64-1a049e0cb718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9749cda8-1b8d-4a59-ae8a-62f121e55de5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_39ae2f04-822e-4f0e-994b-1d1877e7a3cb" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9749cda8-1b8d-4a59-ae8a-62f121e55de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_2da02c34-7a06-43e7-bd7a-ba6029dbf0de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9749cda8-1b8d-4a59-ae8a-62f121e55de5" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_2da02c34-7a06-43e7-bd7a-ba6029dbf0de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_a834b5ee-9352-4960-957e-a8bd75a08fde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2da02c34-7a06-43e7-bd7a-ba6029dbf0de" xlink:to="loc_us-gaap_AccountsPayableCurrent_a834b5ee-9352-4960-957e-a8bd75a08fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1dd3183d-2f98-4677-89c7-9cdcf51d76e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2da02c34-7a06-43e7-bd7a-ba6029dbf0de" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1dd3183d-2f98-4677-89c7-9cdcf51d76e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_dfba3e74-2a42-4374-972f-b6501abbce42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2da02c34-7a06-43e7-bd7a-ba6029dbf0de" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_dfba3e74-2a42-4374-972f-b6501abbce42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_ec20d92a-ae3c-4b4b-a4c0-0a5e92e9864d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2da02c34-7a06-43e7-bd7a-ba6029dbf0de" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_ec20d92a-ae3c-4b4b-a4c0-0a5e92e9864d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c204b71a-5403-428b-99c7-e610f161d981" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2da02c34-7a06-43e7-bd7a-ba6029dbf0de" xlink:to="loc_us-gaap_LiabilitiesCurrent_c204b71a-5403-428b-99c7-e610f161d981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_95d8b001-6110-4a95-aac3-31f243e15e88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9749cda8-1b8d-4a59-ae8a-62f121e55de5" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_95d8b001-6110-4a95-aac3-31f243e15e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5613f68f-d4e7-41b9-93b2-ff97944b9765" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9749cda8-1b8d-4a59-ae8a-62f121e55de5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5613f68f-d4e7-41b9-93b2-ff97944b9765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_f359ceda-fe46-4ec9-b121-5faae74b8197" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9749cda8-1b8d-4a59-ae8a-62f121e55de5" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_f359ceda-fe46-4ec9-b121-5faae74b8197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_ca8dfa50-5829-45da-a2c1-8ccc64f77d8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9749cda8-1b8d-4a59-ae8a-62f121e55de5" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_ca8dfa50-5829-45da-a2c1-8ccc64f77d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0fdd5361-2e0f-46f7-a9d2-8a939d7d523c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9749cda8-1b8d-4a59-ae8a-62f121e55de5" xlink:to="loc_us-gaap_Liabilities_0fdd5361-2e0f-46f7-a9d2-8a939d7d523c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_99c48b53-07f9-4481-85ff-e5254fc1bfc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9749cda8-1b8d-4a59-ae8a-62f121e55de5" xlink:to="loc_us-gaap_CommitmentsAndContingencies_99c48b53-07f9-4481-85ff-e5254fc1bfc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_a64caa2f-3004-4090-86b7-8aa31c396db4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9749cda8-1b8d-4a59-ae8a-62f121e55de5" xlink:to="loc_us-gaap_StockholdersEquityAbstract_a64caa2f-3004-4090-86b7-8aa31c396db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_45130c70-dcf5-4f1b-bded-da9723c622ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a64caa2f-3004-4090-86b7-8aa31c396db4" xlink:to="loc_us-gaap_PreferredStockValue_45130c70-dcf5-4f1b-bded-da9723c622ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_3e47fb80-0424-4bf1-aa49-6849b7522908" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a64caa2f-3004-4090-86b7-8aa31c396db4" xlink:to="loc_us-gaap_CommonStockValue_3e47fb80-0424-4bf1-aa49-6849b7522908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_96458691-bca3-4e97-a1c1-1e80f3128fcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a64caa2f-3004-4090-86b7-8aa31c396db4" xlink:to="loc_us-gaap_AdditionalPaidInCapital_96458691-bca3-4e97-a1c1-1e80f3128fcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8419c8e6-f5b1-4c64-b7c3-09c2d90fa3eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a64caa2f-3004-4090-86b7-8aa31c396db4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8419c8e6-f5b1-4c64-b7c3-09c2d90fa3eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1d32b286-9170-42b0-a821-8d5a94c3ea63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a64caa2f-3004-4090-86b7-8aa31c396db4" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1d32b286-9170-42b0-a821-8d5a94c3ea63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_11a07a5a-8754-4eda-9e86-ae23ccfdc961" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a64caa2f-3004-4090-86b7-8aa31c396db4" xlink:to="loc_us-gaap_StockholdersEquity_11a07a5a-8754-4eda-9e86-ae23ccfdc961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_2fd9c62b-0e57-441e-891a-634fad5520d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9749cda8-1b8d-4a59-ae8a-62f121e55de5" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_2fd9c62b-0e57-441e-891a-634fad5520d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="mrna-20210331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_3272b413-ebbd-4442-be23-611e1cfa6718" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_99272d66-c1d7-4785-b39c-24a99c7e32d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3272b413-ebbd-4442-be23-611e1cfa6718" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_99272d66-c1d7-4785-b39c-24a99c7e32d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_a3f4616c-eabc-4953-84ca-07d5a9aebf01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3272b413-ebbd-4442-be23-611e1cfa6718" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_a3f4616c-eabc-4953-84ca-07d5a9aebf01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_168681f9-d7ad-4fa6-95d9-8669b53cb9be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3272b413-ebbd-4442-be23-611e1cfa6718" xlink:to="loc_us-gaap_PreferredStockSharesIssued_168681f9-d7ad-4fa6-95d9-8669b53cb9be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_ae2b9134-3a9d-4d55-9b02-90c30d5a348e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3272b413-ebbd-4442-be23-611e1cfa6718" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_ae2b9134-3a9d-4d55-9b02-90c30d5a348e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_228a856a-2578-4337-9061-8a58fba81c2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3272b413-ebbd-4442-be23-611e1cfa6718" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_228a856a-2578-4337-9061-8a58fba81c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_c3d56b18-eca6-4cc0-9ab0-4c4f7d973662" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3272b413-ebbd-4442-be23-611e1cfa6718" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_c3d56b18-eca6-4cc0-9ab0-4c4f7d973662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_1d930034-e6f8-450f-b4c8-e99b81653cc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3272b413-ebbd-4442-be23-611e1cfa6718" xlink:to="loc_us-gaap_CommonStockSharesIssued_1d930034-e6f8-450f-b4c8-e99b81653cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_df6444ac-48b9-450c-89f2-b0adb4246cfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3272b413-ebbd-4442-be23-611e1cfa6718" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_df6444ac-48b9-450c-89f2-b0adb4246cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="mrna-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_35b64c0f-dfc7-4ac5-9eb8-dc343c10a77a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0b3c0729-4efe-45a6-94dd-4ce167b0b042" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_35b64c0f-dfc7-4ac5-9eb8-dc343c10a77a" xlink:to="loc_us-gaap_StatementTable_0b3c0729-4efe-45a6-94dd-4ce167b0b042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ee7e7ef8-12ec-47d6-a40d-2c647877726d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0b3c0729-4efe-45a6-94dd-4ce167b0b042" xlink:to="loc_srt_ProductOrServiceAxis_ee7e7ef8-12ec-47d6-a40d-2c647877726d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_70ce0cf4-bfb4-40ff-b33f-0b1649be8ebd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ee7e7ef8-12ec-47d6-a40d-2c647877726d" xlink:to="loc_srt_ProductsAndServicesDomain_70ce0cf4-bfb4-40ff-b33f-0b1649be8ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ProductSalesMember_3514c630-c9a0-4d57-a826-c4a7984b6bd5" xlink:href="mrna-20210331.xsd#mrna_ProductSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_70ce0cf4-bfb4-40ff-b33f-0b1649be8ebd" xlink:to="loc_mrna_ProductSalesMember_3514c630-c9a0-4d57-a826-c4a7984b6bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_21854a74-e3f2-4b0d-8ed1-5c13d9cb8a83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_70ce0cf4-bfb4-40ff-b33f-0b1649be8ebd" xlink:to="loc_us-gaap_GrantMember_21854a74-e3f2-4b0d-8ed1-5c13d9cb8a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CollaborationArrangementMember_9fd9d4de-593a-4822-9a59-353b1ec2077a" xlink:href="mrna-20210331.xsd#mrna_CollaborationArrangementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_70ce0cf4-bfb4-40ff-b33f-0b1649be8ebd" xlink:to="loc_mrna_CollaborationArrangementMember_9fd9d4de-593a-4822-9a59-353b1ec2077a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0a75ec5a-6776-4ebb-a164-6071029cb5f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0b3c0729-4efe-45a6-94dd-4ce167b0b042" xlink:to="loc_us-gaap_StatementLineItems_0a75ec5a-6776-4ebb-a164-6071029cb5f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_f9b0eb42-12b2-44c9-a9a8-592c1628a1e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0a75ec5a-6776-4ebb-a164-6071029cb5f1" xlink:to="loc_us-gaap_RevenuesAbstract_f9b0eb42-12b2-44c9-a9a8-592c1628a1e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_38420e22-53df-4b06-bcc3-644a9d46ed8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_f9b0eb42-12b2-44c9-a9a8-592c1628a1e0" xlink:to="loc_us-gaap_Revenues_38420e22-53df-4b06-bcc3-644a9d46ed8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_dc76d863-1de4-4c86-8e4e-b6d618861561" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0a75ec5a-6776-4ebb-a164-6071029cb5f1" xlink:to="loc_us-gaap_OperatingExpensesAbstract_dc76d863-1de4-4c86-8e4e-b6d618861561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_aff30ca9-792d-402d-a340-0ae152a6fa04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_dc76d863-1de4-4c86-8e4e-b6d618861561" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_aff30ca9-792d-402d-a340-0ae152a6fa04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b6c3bc1c-568d-471d-9c10-3a40642e19a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_dc76d863-1de4-4c86-8e4e-b6d618861561" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b6c3bc1c-568d-471d-9c10-3a40642e19a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_90e6b576-8329-4797-980b-8ea6f519484e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_dc76d863-1de4-4c86-8e4e-b6d618861561" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_90e6b576-8329-4797-980b-8ea6f519484e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_074411f0-3384-451c-95b7-83c37825d731" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_dc76d863-1de4-4c86-8e4e-b6d618861561" xlink:to="loc_us-gaap_CostsAndExpenses_074411f0-3384-451c-95b7-83c37825d731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c395af5d-3c2f-4660-b28f-43012ea3f969" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0a75ec5a-6776-4ebb-a164-6071029cb5f1" xlink:to="loc_us-gaap_OperatingIncomeLoss_c395af5d-3c2f-4660-b28f-43012ea3f969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_787c411c-2cfc-4666-a45e-739ce49364d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0a75ec5a-6776-4ebb-a164-6071029cb5f1" xlink:to="loc_us-gaap_InvestmentIncomeInterest_787c411c-2cfc-4666-a45e-739ce49364d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_4562ef4a-3f18-4d60-bccc-ef1f77b75c79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0a75ec5a-6776-4ebb-a164-6071029cb5f1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_4562ef4a-3f18-4d60-bccc-ef1f77b75c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_8fda757f-d4ca-4147-94a1-2a0813c493ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0a75ec5a-6776-4ebb-a164-6071029cb5f1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_8fda757f-d4ca-4147-94a1-2a0813c493ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_7945b75f-f031-41ea-91aa-82a3557e3498" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0a75ec5a-6776-4ebb-a164-6071029cb5f1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_7945b75f-f031-41ea-91aa-82a3557e3498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a0466764-e9ed-4d86-b265-abf20eaca84f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0a75ec5a-6776-4ebb-a164-6071029cb5f1" xlink:to="loc_us-gaap_NetIncomeLoss_a0466764-e9ed-4d86-b265-abf20eaca84f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_00eb4446-8037-4afc-89df-4bf30c2578e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0a75ec5a-6776-4ebb-a164-6071029cb5f1" xlink:to="loc_us-gaap_EarningsPerShareAbstract_00eb4446-8037-4afc-89df-4bf30c2578e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_bc8a5f8e-92ed-49db-9399-0a9b952ffef9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_00eb4446-8037-4afc-89df-4bf30c2578e0" xlink:to="loc_us-gaap_EarningsPerShareBasic_bc8a5f8e-92ed-49db-9399-0a9b952ffef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_c91e2919-374a-4aa1-b411-d42bbf437218" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_00eb4446-8037-4afc-89df-4bf30c2578e0" xlink:to="loc_us-gaap_EarningsPerShareDiluted_c91e2919-374a-4aa1-b411-d42bbf437218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_4757d66b-4ffd-4764-9d61-4ad6cdb26241" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0a75ec5a-6776-4ebb-a164-6071029cb5f1" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_4757d66b-4ffd-4764-9d61-4ad6cdb26241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1a5046bd-d4dd-41a9-857f-664c1f20a175" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_4757d66b-4ffd-4764-9d61-4ad6cdb26241" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1a5046bd-d4dd-41a9-857f-664c1f20a175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fc807b66-5da5-42f6-a6c7-ba6e9de095ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_4757d66b-4ffd-4764-9d61-4ad6cdb26241" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fc807b66-5da5-42f6-a6c7-ba6e9de095ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="mrna-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0b5df442-0612-42b9-b169-41578a05accb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b261f8ff-afdd-4b16-a495-714c2fd55b93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0b5df442-0612-42b9-b169-41578a05accb" xlink:to="loc_us-gaap_NetIncomeLoss_b261f8ff-afdd-4b16-a495-714c2fd55b93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_1e8bb86f-32b6-42de-b1e6-8d0fb1101076" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0b5df442-0612-42b9-b169-41578a05accb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_1e8bb86f-32b6-42de-b1e6-8d0fb1101076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_ec9f8b73-eca1-4d27-9599-543d60ae3510" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_1e8bb86f-32b6-42de-b1e6-8d0fb1101076" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_ec9f8b73-eca1-4d27-9599-543d60ae3510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_d72bdabc-3101-4e3b-9152-3f62d14b2a76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0b5df442-0612-42b9-b169-41578a05accb" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_d72bdabc-3101-4e3b-9152-3f62d14b2a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical" xlink:type="simple" xlink:href="mrna-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ebd7c3f6-c254-4a81-9b82-a7be830d10cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_fec7a68a-3677-41ff-a1c1-7418f861fbfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ebd7c3f6-c254-4a81-9b82-a7be830d10cb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_fec7a68a-3677-41ff-a1c1-7418f861fbfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="mrna-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_10f4bcc9-f27f-4eff-b8c7-c04060913715" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ad353e1d-1e7b-456c-8136-8e34a75cb2c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_10f4bcc9-f27f-4eff-b8c7-c04060913715" xlink:to="loc_us-gaap_StatementTable_ad353e1d-1e7b-456c-8136-8e34a75cb2c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a35106ae-20f9-4fa8-96ea-16d027374305" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ad353e1d-1e7b-456c-8136-8e34a75cb2c6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a35106ae-20f9-4fa8-96ea-16d027374305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_33b4f2f5-c002-4e06-8cf0-54da1fce247c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a35106ae-20f9-4fa8-96ea-16d027374305" xlink:to="loc_us-gaap_EquityComponentDomain_33b4f2f5-c002-4e06-8cf0-54da1fce247c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ebaa8b3c-698b-479c-b9e8-80d5e6168ed2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_33b4f2f5-c002-4e06-8cf0-54da1fce247c" xlink:to="loc_us-gaap_CommonStockMember_ebaa8b3c-698b-479c-b9e8-80d5e6168ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_89b86b28-45c7-4d25-915e-229cfd590380" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_33b4f2f5-c002-4e06-8cf0-54da1fce247c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_89b86b28-45c7-4d25-915e-229cfd590380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ac4b279f-b1d1-4701-bc7a-5d8d551165a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_33b4f2f5-c002-4e06-8cf0-54da1fce247c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ac4b279f-b1d1-4701-bc7a-5d8d551165a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_95dd9b24-e95c-47b7-84ab-b118813007a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_33b4f2f5-c002-4e06-8cf0-54da1fce247c" xlink:to="loc_us-gaap_RetainedEarningsMember_95dd9b24-e95c-47b7-84ab-b118813007a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3d214021-8bb5-4b43-b3e4-38403ee3b7a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ad353e1d-1e7b-456c-8136-8e34a75cb2c6" xlink:to="loc_us-gaap_StatementLineItems_3d214021-8bb5-4b43-b3e4-38403ee3b7a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfa259bd-85b7-49c3-a6c9-9e608ee9dc99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3d214021-8bb5-4b43-b3e4-38403ee3b7a3" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfa259bd-85b7-49c3-a6c9-9e608ee9dc99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_639a9441-b3c8-4779-9a9e-2cec967d3454" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfa259bd-85b7-49c3-a6c9-9e608ee9dc99" xlink:to="loc_us-gaap_SharesOutstanding_639a9441-b3c8-4779-9a9e-2cec967d3454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f38e1923-0d14-46fa-b2dc-efc01071f88e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfa259bd-85b7-49c3-a6c9-9e608ee9dc99" xlink:to="loc_us-gaap_StockholdersEquity_f38e1923-0d14-46fa-b2dc-efc01071f88e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2948e0c6-d070-4936-a762-f34f062085ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfa259bd-85b7-49c3-a6c9-9e608ee9dc99" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2948e0c6-d070-4936-a762-f34f062085ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_498c1f7c-52f0-4685-8fae-fae8c34c9c87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfa259bd-85b7-49c3-a6c9-9e608ee9dc99" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_498c1f7c-52f0-4685-8fae-fae8c34c9c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f0c00a89-823a-48a8-8fba-6c8fdf5d01a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfa259bd-85b7-49c3-a6c9-9e608ee9dc99" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f0c00a89-823a-48a8-8fba-6c8fdf5d01a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_54a79ccf-8e95-4b08-9c89-bffad223642c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfa259bd-85b7-49c3-a6c9-9e608ee9dc99" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_54a79ccf-8e95-4b08-9c89-bffad223642c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_15af3f01-ee27-4d1b-a409-d36a8842399a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfa259bd-85b7-49c3-a6c9-9e608ee9dc99" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_15af3f01-ee27-4d1b-a409-d36a8842399a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_65c73c21-0d86-4eaa-b354-0c6249c3037e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfa259bd-85b7-49c3-a6c9-9e608ee9dc99" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_65c73c21-0d86-4eaa-b354-0c6249c3037e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fe6d3ca0-4b61-4f4a-93e1-fa53f8b7c14d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfa259bd-85b7-49c3-a6c9-9e608ee9dc99" xlink:to="loc_us-gaap_NetIncomeLoss_fe6d3ca0-4b61-4f4a-93e1-fa53f8b7c14d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_3e6ab666-9fb0-4ae8-88a1-ce89d2d29fbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfa259bd-85b7-49c3-a6c9-9e608ee9dc99" xlink:to="loc_us-gaap_SharesOutstanding_3e6ab666-9fb0-4ae8-88a1-ce89d2d29fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_de1e0b71-7a6a-4290-a08a-d86426a11f6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfa259bd-85b7-49c3-a6c9-9e608ee9dc99" xlink:to="loc_us-gaap_StockholdersEquity_de1e0b71-7a6a-4290-a08a-d86426a11f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="simple" xlink:href="mrna-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_3bea85b6-9ca2-4d7e-8a96-e05ae11df727" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_4eaa9732-bc9a-4d90-930b-23f57bbfedf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_3bea85b6-9ca2-4d7e-8a96-e05ae11df727" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_4eaa9732-bc9a-4d90-930b-23f57bbfedf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="mrna-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_27101593-666e-4e4e-98c8-a989590cf12a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_67736ee1-601b-44b1-9130-9f043cb201d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_27101593-666e-4e4e-98c8-a989590cf12a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_67736ee1-601b-44b1-9130-9f043cb201d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f85bda20-7ec1-4e07-879f-8f5c27b1b402" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_67736ee1-601b-44b1-9130-9f043cb201d0" xlink:to="loc_us-gaap_NetIncomeLoss_f85bda20-7ec1-4e07-879f-8f5c27b1b402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e5e480d7-bcd8-49ca-bbc3-96c5dfccc600" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_67736ee1-601b-44b1-9130-9f043cb201d0" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e5e480d7-bcd8-49ca-bbc3-96c5dfccc600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_ee48cb48-422b-41d2-82db-c872c75854ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e5e480d7-bcd8-49ca-bbc3-96c5dfccc600" xlink:to="loc_us-gaap_ShareBasedCompensation_ee48cb48-422b-41d2-82db-c872c75854ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_d5556660-eafb-4681-b1ef-af89c22a52b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e5e480d7-bcd8-49ca-bbc3-96c5dfccc600" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_d5556660-eafb-4681-b1ef-af89c22a52b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_4b99b983-a09b-4dae-b7ab-e7243a337a60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e5e480d7-bcd8-49ca-bbc3-96c5dfccc600" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_4b99b983-a09b-4dae-b7ab-e7243a337a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_26866334-90cc-4ac6-a158-240d43c714ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e5e480d7-bcd8-49ca-bbc3-96c5dfccc600" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_26866334-90cc-4ac6-a158-240d43c714ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a074b1d3-b64c-4220-bfda-d09e55c39a4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e5e480d7-bcd8-49ca-bbc3-96c5dfccc600" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a074b1d3-b64c-4220-bfda-d09e55c39a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_985fd29b-13cc-461c-b32b-b2b8a039dd4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a074b1d3-b64c-4220-bfda-d09e55c39a4c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_985fd29b-13cc-461c-b32b-b2b8a039dd4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8c1d3b07-6d26-48f9-b737-5c00b9b19c54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a074b1d3-b64c-4220-bfda-d09e55c39a4c" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8c1d3b07-6d26-48f9-b737-5c00b9b19c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_a7ffc7c0-85cf-4ef4-bbc3-c2047dc487f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a074b1d3-b64c-4220-bfda-d09e55c39a4c" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_a7ffc7c0-85cf-4ef4-bbc3-c2047dc487f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases_6dd651ce-9844-479a-b52c-994c5bc67c6a" xlink:href="mrna-20210331.xsd#mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a074b1d3-b64c-4220-bfda-d09e55c39a4c" xlink:to="loc_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases_6dd651ce-9844-479a-b52c-994c5bc67c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_2469bfad-5f1a-45ff-919d-7294dea441ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a074b1d3-b64c-4220-bfda-d09e55c39a4c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_2469bfad-5f1a-45ff-919d-7294dea441ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2ac849df-106c-44bc-930c-11b12cbf4491" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a074b1d3-b64c-4220-bfda-d09e55c39a4c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2ac849df-106c-44bc-930c-11b12cbf4491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_1f6da1f1-38d0-4b73-94a0-e22c29bd72e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a074b1d3-b64c-4220-bfda-d09e55c39a4c" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_1f6da1f1-38d0-4b73-94a0-e22c29bd72e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingLeaseLiabilities_7d17ff61-e8be-4233-ba3d-436357a72ea1" xlink:href="mrna-20210331.xsd#mrna_OperatingLeaseLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a074b1d3-b64c-4220-bfda-d09e55c39a4c" xlink:to="loc_mrna_OperatingLeaseLiabilities_7d17ff61-e8be-4233-ba3d-436357a72ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_deec1133-6695-4a2e-bab3-1f776d9155e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a074b1d3-b64c-4220-bfda-d09e55c39a4c" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_deec1133-6695-4a2e-bab3-1f776d9155e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_281a5d9a-e1b3-432c-92c9-e83e89aeb9ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_67736ee1-601b-44b1-9130-9f043cb201d0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_281a5d9a-e1b3-432c-92c9-e83e89aeb9ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e31f99b0-5f0b-4a9d-ab44-3e668742bf9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_27101593-666e-4e4e-98c8-a989590cf12a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e31f99b0-5f0b-4a9d-ab44-3e668742bf9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_63f8d594-4b83-496b-9522-735424a5a03e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e31f99b0-5f0b-4a9d-ab44-3e668742bf9a" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_63f8d594-4b83-496b-9522-735424a5a03e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_5c75957e-e27e-4943-af6e-d405366d9cdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e31f99b0-5f0b-4a9d-ab44-3e668742bf9a" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_5c75957e-e27e-4943-af6e-d405366d9cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_1ef3e52f-193d-4620-88e9-5cc5357a1c33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e31f99b0-5f0b-4a9d-ab44-3e668742bf9a" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_1ef3e52f-193d-4620-88e9-5cc5357a1c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4069e42c-1e2d-4fd0-9302-515ef20539a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e31f99b0-5f0b-4a9d-ab44-3e668742bf9a" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4069e42c-1e2d-4fd0-9302-515ef20539a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f2b2c804-b3a2-4f88-a64d-7a542fddc1c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e31f99b0-5f0b-4a9d-ab44-3e668742bf9a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f2b2c804-b3a2-4f88-a64d-7a542fddc1c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a41bffa1-6e1e-4a34-b2c5-5e477792d43c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_27101593-666e-4e4e-98c8-a989590cf12a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a41bffa1-6e1e-4a34-b2c5-5e477792d43c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a7d6e78a-4415-4cb8-84bc-2829c1d6af2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a41bffa1-6e1e-4a34-b2c5-5e477792d43c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a7d6e78a-4415-4cb8-84bc-2829c1d6af2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_cfb998ef-5039-41da-9a27-7e51e898b655" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a41bffa1-6e1e-4a34-b2c5-5e477792d43c" xlink:to="loc_us-gaap_ProceedsFromStockPlans_cfb998ef-5039-41da-9a27-7e51e898b655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChargesToFinancingLeaseLiabilities_15fc8bf9-92ee-4e78-91be-71fcf75d7298" xlink:href="mrna-20210331.xsd#mrna_ChargesToFinancingLeaseLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a41bffa1-6e1e-4a34-b2c5-5e477792d43c" xlink:to="loc_mrna_ChargesToFinancingLeaseLiabilities_15fc8bf9-92ee-4e78-91be-71fcf75d7298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8efc4f6a-73fa-489b-9823-1afdf555dec7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a41bffa1-6e1e-4a34-b2c5-5e477792d43c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8efc4f6a-73fa-489b-9823-1afdf555dec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_99791142-8a4b-470d-beaa-dc4dbb3f7f7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_27101593-666e-4e4e-98c8-a989590cf12a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_99791142-8a4b-470d-beaa-dc4dbb3f7f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9bfeb05e-02e2-4e55-ae64-e6613ea9c893" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_27101593-666e-4e4e-98c8-a989590cf12a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9bfeb05e-02e2-4e55-ae64-e6613ea9c893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_db5a30a5-ff03-47f3-a808-797c76fffd4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_27101593-666e-4e4e-98c8-a989590cf12a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_db5a30a5-ff03-47f3-a808-797c76fffd4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7a35490b-48bb-43a5-9278-ec71d11689ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_27101593-666e-4e4e-98c8-a989590cf12a" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7a35490b-48bb-43a5-9278-ec71d11689ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_0de9524f-bdbb-4606-81ef-d837452e87f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7a35490b-48bb-43a5-9278-ec71d11689ea" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_0de9524f-bdbb-4606-81ef-d837452e87f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_19c76e0d-2da0-43d4-a34e-1c6695a11528" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7a35490b-48bb-43a5-9278-ec71d11689ea" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_19c76e0d-2da0-43d4-a34e-1c6695a11528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/DescriptionoftheBusiness" xlink:type="simple" xlink:href="mrna-20210331.xsd#DescriptionoftheBusiness"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/DescriptionoftheBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4e83c363-187a-43e3-9905-ee6ee06212b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_99edcd94-481c-475c-affe-283c410f2948" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4e83c363-187a-43e3-9905-ee6ee06212b8" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_99edcd94-481c-475c-affe-283c410f2948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/DescriptionoftheBusinessAdditionalInformationDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#DescriptionoftheBusinessAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/DescriptionoftheBusinessAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83d66ed3-dd7c-4023-842e-0c0a79ec927f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NumberOfDevelopmentProgram_2614c14d-baf7-45d5-9971-def32b81b298" xlink:href="mrna-20210331.xsd#mrna_NumberOfDevelopmentProgram"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83d66ed3-dd7c-4023-842e-0c0a79ec927f" xlink:to="loc_mrna_NumberOfDevelopmentProgram_2614c14d-baf7-45d5-9971-def32b81b298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandards" xlink:type="simple" xlink:href="mrna-20210331.xsd#SummaryofBasisofPresentationandRecentAccountingStandards"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandards" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ddce8334-1f27-4041-a8bc-4c75294d7341" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_d4a11108-9c1f-4b9d-a9aa-7ec0b6357913" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ddce8334-1f27-4041-a8bc-4c75294d7341" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_d4a11108-9c1f-4b9d-a9aa-7ec0b6357913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsPolicies" xlink:type="simple" xlink:href="mrna-20210331.xsd#SummaryofBasisofPresentationandRecentAccountingStandardsPolicies"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_678c6f15-657f-4eef-932e-18a29b8d0097" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ae4ef41b-78a6-4ccd-95ce-b39d2eac5526" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_678c6f15-657f-4eef-932e-18a29b8d0097" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ae4ef41b-78a6-4ccd-95ce-b39d2eac5526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_8ff39427-e326-4847-b42a-3c75459e4f6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_678c6f15-657f-4eef-932e-18a29b8d0097" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_8ff39427-e326-4847-b42a-3c75459e4f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_01e5c9ca-4819-43f2-b580-74a20e1146c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_678c6f15-657f-4eef-932e-18a29b8d0097" xlink:to="loc_us-gaap_UseOfEstimates_01e5c9ca-4819-43f2-b580-74a20e1146c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_b2378e4b-2dfe-45f9-91aa-6a2efc43164c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_678c6f15-657f-4eef-932e-18a29b8d0097" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_b2378e4b-2dfe-45f9-91aa-6a2efc43164c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_e013e7b4-72c7-46ee-86eb-963a60a733ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_678c6f15-657f-4eef-932e-18a29b8d0097" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_e013e7b4-72c7-46ee-86eb-963a60a733ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e87cd66a-721c-44a7-87bc-3d0804faa196" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_678c6f15-657f-4eef-932e-18a29b8d0097" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e87cd66a-721c-44a7-87bc-3d0804faa196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsTables" xlink:type="simple" xlink:href="mrna-20210331.xsd#SummaryofBasisofPresentationandRecentAccountingStandardsTables"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c72cba47-a447-4197-8dfe-d87a0ce99e1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_fd445770-a961-4ff0-ac7f-a9df395ccd67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c72cba47-a447-4197-8dfe-d87a0ce99e1d" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_fd445770-a961-4ff0-ac7f-a9df395ccd67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_bd560eaf-61be-4776-9b26-92790c979edb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c72cba47-a447-4197-8dfe-d87a0ce99e1d" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_bd560eaf-61be-4776-9b26-92790c979edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_2975ccb7-3c9e-41f0-81d1-cacbfc0972b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c72cba47-a447-4197-8dfe-d87a0ce99e1d" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_2975ccb7-3c9e-41f0-81d1-cacbfc0972b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsComponentsofAccumulatedOtherComprehensivelossIncomeDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#SummaryofBasisofPresentationandRecentAccountingStandardsComponentsofAccumulatedOtherComprehensivelossIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsComponentsofAccumulatedOtherComprehensivelossIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_073ef739-207d-4968-a28c-d193287ed993" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_74c87676-bd0b-4105-998d-7e93decc206d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_073ef739-207d-4968-a28c-d193287ed993" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_74c87676-bd0b-4105-998d-7e93decc206d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f2e7f186-21cc-4f0e-bf44-fb535b4cbd9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_74c87676-bd0b-4105-998d-7e93decc206d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f2e7f186-21cc-4f0e-bf44-fb535b4cbd9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8e53a396-573b-4cdb-8d14-959519f80cf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f2e7f186-21cc-4f0e-bf44-fb535b4cbd9a" xlink:to="loc_us-gaap_EquityComponentDomain_8e53a396-573b-4cdb-8d14-959519f80cf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_c2e212f3-fcc8-429b-a773-932e2563d3d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8e53a396-573b-4cdb-8d14-959519f80cf2" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_c2e212f3-fcc8-429b-a773-932e2563d3d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_481ef086-ac07-42c8-a242-8ff128768acc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_74c87676-bd0b-4105-998d-7e93decc206d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_481ef086-ac07-42c8-a242-8ff128768acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_a6e8afcc-f1d4-4db2-be5b-f2b068549025" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_481ef086-ac07-42c8-a242-8ff128768acc" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_a6e8afcc-f1d4-4db2-be5b-f2b068549025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0bd5d7f9-3926-4b3c-9985-720b1c658ca5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_a6e8afcc-f1d4-4db2-be5b-f2b068549025" xlink:to="loc_us-gaap_StockholdersEquity_0bd5d7f9-3926-4b3c-9985-720b1c658ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2e00748f-7faf-4588-8c7e-ef5394283509" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_a6e8afcc-f1d4-4db2-be5b-f2b068549025" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2e00748f-7faf-4588-8c7e-ef5394283509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f6ef034a-4087-4b6b-9019-cb7d0b948d6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_a6e8afcc-f1d4-4db2-be5b-f2b068549025" xlink:to="loc_us-gaap_StockholdersEquity_f6ef034a-4087-4b6b-9019-cb7d0b948d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#SummaryofBasisofPresentationandRecentAccountingStandardsReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f0e238a5-33bc-4bb0-a9e5-083b86a12c27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_47cceb2f-f2fd-44a2-9954-a6ad6d6cb75e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f0e238a5-33bc-4bb0-a9e5-083b86a12c27" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_47cceb2f-f2fd-44a2-9954-a6ad6d6cb75e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_c36c85ef-309a-42f8-95ae-d2bf011ca524" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f0e238a5-33bc-4bb0-a9e5-083b86a12c27" xlink:to="loc_us-gaap_RestrictedCashCurrent_c36c85ef-309a-42f8-95ae-d2bf011ca524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_e188dbe0-2576-4f63-98fe-9a8576ffe828" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f0e238a5-33bc-4bb0-a9e5-083b86a12c27" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_e188dbe0-2576-4f63-98fe-9a8576ffe828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b63d2aa6-558d-4083-9967-13a486239a7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f0e238a5-33bc-4bb0-a9e5-083b86a12c27" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b63d2aa6-558d-4083-9967-13a486239a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/ProductSales" xlink:type="simple" xlink:href="mrna-20210331.xsd#ProductSales"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/ProductSales" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8fd676a8-502f-4cf0-b92e-bbfa21ba558b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_ef49f02f-39b3-4f93-a8b3-bc6e86cb6674" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8fd676a8-502f-4cf0-b92e-bbfa21ba558b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_ef49f02f-39b3-4f93-a8b3-bc6e86cb6674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/ProductSalesTables" xlink:type="simple" xlink:href="mrna-20210331.xsd#ProductSalesTables"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/ProductSalesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f527a848-b51c-43f6-b286-95b88ee3d62f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_33daa015-e516-48ef-a0de-33f968547317" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f527a848-b51c-43f6-b286-95b88ee3d62f" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_33daa015-e516-48ef-a0de-33f968547317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/ProductSalesDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#ProductSalesDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/ProductSalesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_58951d7b-80a1-4b86-8039-4e7c7f564d7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_4d511451-f709-40b5-9f4e-964eda216a94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_58951d7b-80a1-4b86-8039-4e7c7f564d7a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_4d511451-f709-40b5-9f4e-964eda216a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_b7f80237-20a0-4909-8b63-994e970be61d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4d511451-f709-40b5-9f4e-964eda216a94" xlink:to="loc_srt_StatementGeographicalAxis_b7f80237-20a0-4909-8b63-994e970be61d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c059db5d-49fe-424b-9923-fd9b68e70c41" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_b7f80237-20a0-4909-8b63-994e970be61d" xlink:to="loc_srt_SegmentGeographicalDomain_c059db5d-49fe-424b-9923-fd9b68e70c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b3969328-d278-4b70-b73a-33247e0503bc" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c059db5d-49fe-424b-9923-fd9b68e70c41" xlink:to="loc_country_US_b3969328-d278-4b70-b73a-33247e0503bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_b4844460-cb93-4370-8d66-9f0368f76230" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c059db5d-49fe-424b-9923-fd9b68e70c41" xlink:to="loc_us-gaap_NonUsMember_b4844460-cb93-4370-8d66-9f0368f76230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8e78b7c8-9669-4076-a64a-daffaaf78643" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4d511451-f709-40b5-9f4e-964eda216a94" xlink:to="loc_srt_ProductOrServiceAxis_8e78b7c8-9669-4076-a64a-daffaaf78643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a8fbcfcb-4bf3-43d9-a052-d01783bd4bee" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8e78b7c8-9669-4076-a64a-daffaaf78643" xlink:to="loc_srt_ProductsAndServicesDomain_a8fbcfcb-4bf3-43d9-a052-d01783bd4bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ProductSalesMember_83d5061e-6223-439c-918d-f9db3fe86aa7" xlink:href="mrna-20210331.xsd#mrna_ProductSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a8fbcfcb-4bf3-43d9-a052-d01783bd4bee" xlink:to="loc_mrna_ProductSalesMember_83d5061e-6223-439c-918d-f9db3fe86aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CustomerDepositsMember_0672295b-24e8-4839-91ac-c4293414ac14" xlink:href="mrna-20210331.xsd#mrna_CustomerDepositsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a8fbcfcb-4bf3-43d9-a052-d01783bd4bee" xlink:to="loc_mrna_CustomerDepositsMember_0672295b-24e8-4839-91ac-c4293414ac14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_3c5254eb-145b-4ccd-85e2-9dd3b3a6bd58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4d511451-f709-40b5-9f4e-964eda216a94" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_3c5254eb-145b-4ccd-85e2-9dd3b3a6bd58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_546ff38d-232b-4b9e-a0c0-2a56d75e6f01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3c5254eb-145b-4ccd-85e2-9dd3b3a6bd58" xlink:to="loc_us-gaap_Revenues_546ff38d-232b-4b9e-a0c0-2a56d75e6f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_24ad3889-b4b1-4bf1-9585-42c7fdb22e77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3c5254eb-145b-4ccd-85e2-9dd3b3a6bd58" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_24ad3889-b4b1-4bf1-9585-42c7fdb22e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/GrantRevenue" xlink:type="simple" xlink:href="mrna-20210331.xsd#GrantRevenue"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/GrantRevenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_48d7ad79-0ef1-47cb-b202-488d8a406ab7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_9775696f-b59d-4f0f-a5d7-33d89a64b116" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_48d7ad79-0ef1-47cb-b202-488d8a406ab7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_9775696f-b59d-4f0f-a5d7-33d89a64b116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/GrantRevenueTables" xlink:type="simple" xlink:href="mrna-20210331.xsd#GrantRevenueTables"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/GrantRevenueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_35f6246b-df6f-4e01-bb9c-4ca6859ccbc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_c5c9aa4f-1578-4a8c-95c9-e827f7a66232" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_35f6246b-df6f-4e01-bb9c-4ca6859ccbc7" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_c5c9aa4f-1578-4a8c-95c9-e827f7a66232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/GrantRevenueDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#GrantRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/GrantRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_ee179090-6167-43c6-a203-d294bd85a4a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_73697845-45d4-49b1-890f-b0fc893c15e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_ee179090-6167-43c6-a203-d294bd85a4a1" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_73697845-45d4-49b1-890f-b0fc893c15e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_36452653-ce57-409a-aedf-4aadc7e48d3a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_73697845-45d4-49b1-890f-b0fc893c15e6" xlink:to="loc_srt_MajorCustomersAxis_36452653-ce57-409a-aedf-4aadc7e48d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ff5ac864-5d15-4acb-99f2-d93685d7d3d8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_36452653-ce57-409a-aedf-4aadc7e48d3a" xlink:to="loc_srt_NameOfMajorCustomerDomain_ff5ac864-5d15-4acb-99f2-d93685d7d3d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DefenseAdvancedResearchProjectsAgencyMember_d80d3667-8028-442e-9252-9bf7a9bd75d3" xlink:href="mrna-20210331.xsd#mrna_DefenseAdvancedResearchProjectsAgencyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ff5ac864-5d15-4acb-99f2-d93685d7d3d8" xlink:to="loc_mrna_DefenseAdvancedResearchProjectsAgencyMember_d80d3667-8028-442e-9252-9bf7a9bd75d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_5e073494-73c0-4fe6-92dc-c0242ea35d95" xlink:href="mrna-20210331.xsd#mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ff5ac864-5d15-4acb-99f2-d93685d7d3d8" xlink:to="loc_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_5e073494-73c0-4fe6-92dc-c0242ea35d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_TheBillAndMelindaGatesFoundationMember_58cae11f-0865-443b-925c-311ede44248a" xlink:href="mrna-20210331.xsd#mrna_TheBillAndMelindaGatesFoundationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ff5ac864-5d15-4acb-99f2-d93685d7d3d8" xlink:to="loc_mrna_TheBillAndMelindaGatesFoundationMember_58cae11f-0865-443b-925c-311ede44248a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OtherGrantRevenueMember_e2447da3-0745-4f29-a8aa-3e80f7b17324" xlink:href="mrna-20210331.xsd#mrna_OtherGrantRevenueMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ff5ac864-5d15-4acb-99f2-d93685d7d3d8" xlink:to="loc_mrna_OtherGrantRevenueMember_e2447da3-0745-4f29-a8aa-3e80f7b17324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_3972d9d5-de98-4610-894b-c8b9732bc032" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_73697845-45d4-49b1-890f-b0fc893c15e6" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_3972d9d5-de98-4610-894b-c8b9732bc032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_9992528a-8101-421d-9169-2077b8c9d6df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_3972d9d5-de98-4610-894b-c8b9732bc032" xlink:to="loc_us-gaap_ProjectMember_9992528a-8101-421d-9169-2077b8c9d6df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractOptionsMember_354b79ae-4c00-4739-bf67-2c27b4c96bb3" xlink:href="mrna-20210331.xsd#mrna_ContractOptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_9992528a-8101-421d-9169-2077b8c9d6df" xlink:to="loc_mrna_ContractOptionsMember_354b79ae-4c00-4739-bf67-2c27b4c96bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_InitialProjectMember_b4d9b6f2-dd06-4e34-8477-a43391244e14" xlink:href="mrna-20210331.xsd#mrna_InitialProjectMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_9992528a-8101-421d-9169-2077b8c9d6df" xlink:to="loc_mrna_InitialProjectMember_b4d9b6f2-dd06-4e34-8477-a43391244e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_17f77a0e-79d2-4f34-8169-eb0c92b47239" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_73697845-45d4-49b1-890f-b0fc893c15e6" xlink:to="loc_srt_ProductOrServiceAxis_17f77a0e-79d2-4f34-8169-eb0c92b47239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d3c508ec-42d2-4fbb-82ad-321ce5454d13" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_17f77a0e-79d2-4f34-8169-eb0c92b47239" xlink:to="loc_srt_ProductsAndServicesDomain_d3c508ec-42d2-4fbb-82ad-321ce5454d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_aa612f50-0981-4cf4-a121-f6663f11cc47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d3c508ec-42d2-4fbb-82ad-321ce5454d13" xlink:to="loc_us-gaap_GrantMember_aa612f50-0981-4cf4-a121-f6663f11cc47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_324dc8cd-89d6-4dc5-8190-f55f4663b6d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_73697845-45d4-49b1-890f-b0fc893c15e6" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_324dc8cd-89d6-4dc5-8190-f55f4663b6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_dc7e7d47-6782-4fc1-968a-1b89cf460461" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_324dc8cd-89d6-4dc5-8190-f55f4663b6d6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_dc7e7d47-6782-4fc1-968a-1b89cf460461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_a7a88018-d373-4093-9259-f101fdc45cb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_dc7e7d47-6782-4fc1-968a-1b89cf460461" xlink:to="loc_us-gaap_SubsequentEventMember_a7a88018-d373-4093-9259-f101fdc45cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_ebe3db45-55af-45ac-bf32-6f7e8f685222" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_73697845-45d4-49b1-890f-b0fc893c15e6" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_ebe3db45-55af-45ac-bf32-6f7e8f685222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsMaximumAward_b8d713f7-acea-4e13-80bf-6bf6519d0345" xlink:href="mrna-20210331.xsd#mrna_RevenueFromGrantsMaximumAward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ebe3db45-55af-45ac-bf32-6f7e8f685222" xlink:to="loc_mrna_RevenueFromGrantsMaximumAward_b8d713f7-acea-4e13-80bf-6bf6519d0345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsCurrentFundingCapacity_aa57bd55-a19f-48d2-8c0b-b2df97cd94d7" xlink:href="mrna-20210331.xsd#mrna_RevenueFromGrantsCurrentFundingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ebe3db45-55af-45ac-bf32-6f7e8f685222" xlink:to="loc_mrna_RevenueFromGrantsCurrentFundingCapacity_aa57bd55-a19f-48d2-8c0b-b2df97cd94d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsRemainingFundingCapacity_16e0f02d-6adf-412f-b71e-882ddfa527d3" xlink:href="mrna-20210331.xsd#mrna_RevenueFromGrantsRemainingFundingCapacity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ebe3db45-55af-45ac-bf32-6f7e8f685222" xlink:to="loc_mrna_RevenueFromGrantsRemainingFundingCapacity_16e0f02d-6adf-412f-b71e-882ddfa527d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_9390e926-3b06-4081-b924-69c1c11ca464" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ebe3db45-55af-45ac-bf32-6f7e8f685222" xlink:to="loc_us-gaap_OtherCommitment_9390e926-3b06-4081-b924-69c1c11ca464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsPotentialReimbursement_51dd4641-0643-4e5a-a3d9-107b520cbaeb" xlink:href="mrna-20210331.xsd#mrna_RevenueFromGrantsPotentialReimbursement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ebe3db45-55af-45ac-bf32-6f7e8f685222" xlink:to="loc_mrna_RevenueFromGrantsPotentialReimbursement_51dd4641-0643-4e5a-a3d9-107b520cbaeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsNumberOfContractOptions_3758b4ff-8e99-4ff3-996d-4d6e3ac7634d" xlink:href="mrna-20210331.xsd#mrna_RevenueFromGrantsNumberOfContractOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ebe3db45-55af-45ac-bf32-6f7e8f685222" xlink:to="loc_mrna_RevenueFromGrantsNumberOfContractOptions_3758b4ff-8e99-4ff3-996d-4d6e3ac7634d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsNumberOfContractOptionsExercised_6e92e3f5-29e2-46b0-9cee-672fa4cffbc8" xlink:href="mrna-20210331.xsd#mrna_RevenueFromGrantsNumberOfContractOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ebe3db45-55af-45ac-bf32-6f7e8f685222" xlink:to="loc_mrna_RevenueFromGrantsNumberOfContractOptionsExercised_6e92e3f5-29e2-46b0-9cee-672fa4cffbc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_d21f0aad-1fae-4ae3-9508-09122c6f8f6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ebe3db45-55af-45ac-bf32-6f7e8f685222" xlink:to="loc_us-gaap_Revenues_d21f0aad-1fae-4ae3-9508-09122c6f8f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_0fd61948-2247-4ec8-858d-ed3d8c0e4fd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ebe3db45-55af-45ac-bf32-6f7e8f685222" xlink:to="loc_us-gaap_ContractWithCustomerLiability_0fd61948-2247-4ec8-858d-ed3d8c0e4fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationRevenue" xlink:type="simple" xlink:href="mrna-20210331.xsd#CollaborationRevenue"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CollaborationRevenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_51b622fe-888d-4ea0-8213-d28c6853fbef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_081461b9-9437-4518-a889-8d412ab06c3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_51b622fe-888d-4ea0-8213-d28c6853fbef" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_081461b9-9437-4518-a889-8d412ab06c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationRevenueTables" xlink:type="simple" xlink:href="mrna-20210331.xsd#CollaborationRevenueTables"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CollaborationRevenueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_19b1b395-1b7a-4ca8-8583-ea8f2b21539e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_18af6478-4a9c-4ad2-9713-b568a254dd66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_19b1b395-1b7a-4ca8-8583-ea8f2b21539e" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_18af6478-4a9c-4ad2-9713-b568a254dd66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_7988497a-1b49-413f-b633-cd507de5d06e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_19b1b395-1b7a-4ca8-8583-ea8f2b21539e" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_7988497a-1b49-413f-b633-cd507de5d06e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationRevenueSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#CollaborationRevenueSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CollaborationRevenueSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_f7df3a73-ddb2-4e39-b5aa-1b67e9574ecf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_7925cd01-3f91-4480-b34e-0428e28f6664" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_f7df3a73-ddb2-4e39-b5aa-1b67e9574ecf" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_7925cd01-3f91-4480-b34e-0428e28f6664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_24c35f95-1bea-4982-875a-6cbad26613ec" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_7925cd01-3f91-4480-b34e-0428e28f6664" xlink:to="loc_srt_ProductOrServiceAxis_24c35f95-1bea-4982-875a-6cbad26613ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0c6c7a76-2d09-4426-bd21-1d1e8539cb80" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_24c35f95-1bea-4982-875a-6cbad26613ec" xlink:to="loc_srt_ProductsAndServicesDomain_0c6c7a76-2d09-4426-bd21-1d1e8539cb80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember_3bb9c8b0-a619-4246-826f-e9e954574976" xlink:href="mrna-20210331.xsd#mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0c6c7a76-2d09-4426-bd21-1d1e8539cb80" xlink:to="loc_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember_3bb9c8b0-a619-4246-826f-e9e954574976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_741dde90-7ceb-4d17-8ffa-73f3f05b58c3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_7925cd01-3f91-4480-b34e-0428e28f6664" xlink:to="loc_srt_CounterpartyNameAxis_741dde90-7ceb-4d17-8ffa-73f3f05b58c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e3aeb550-89df-4acc-b8b8-bb90ca9d7e5e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_741dde90-7ceb-4d17-8ffa-73f3f05b58c3" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e3aeb550-89df-4acc-b8b8-bb90ca9d7e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AstraZenecaMember_4d9eead9-c28d-4050-b08e-123cad31b675" xlink:href="mrna-20210331.xsd#mrna_AstraZenecaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e3aeb550-89df-4acc-b8b8-bb90ca9d7e5e" xlink:to="loc_mrna_AstraZenecaMember_4d9eead9-c28d-4050-b08e-123cad31b675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MerckMember_46856735-0177-409e-9beb-0db0945b1958" xlink:href="mrna-20210331.xsd#mrna_MerckMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e3aeb550-89df-4acc-b8b8-bb90ca9d7e5e" xlink:to="loc_mrna_MerckMember_46856735-0177-409e-9beb-0db0945b1958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_VertexMember_95b3af77-3752-4bb3-8ea0-a4fd9a70347b" xlink:href="mrna-20210331.xsd#mrna_VertexMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e3aeb550-89df-4acc-b8b8-bb90ca9d7e5e" xlink:to="loc_mrna_VertexMember_95b3af77-3752-4bb3-8ea0-a4fd9a70347b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OtherCollaborativePartiesMember_8dbd8e34-066f-4481-bd20-2178bb27c7df" xlink:href="mrna-20210331.xsd#mrna_OtherCollaborativePartiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e3aeb550-89df-4acc-b8b8-bb90ca9d7e5e" xlink:to="loc_mrna_OtherCollaborativePartiesMember_8dbd8e34-066f-4481-bd20-2178bb27c7df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ea5b7bfc-a6c3-49e3-b755-c4cf6b8e09bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_7925cd01-3f91-4480-b34e-0428e28f6664" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ea5b7bfc-a6c3-49e3-b755-c4cf6b8e09bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_47538b33-9b8a-4642-bfb8-e1d4c149cf02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ea5b7bfc-a6c3-49e3-b755-c4cf6b8e09bd" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_47538b33-9b8a-4642-bfb8-e1d4c149cf02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationRevenueChangesinBalancesofReceivablesandContractLiabilitiesDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#CollaborationRevenueChangesinBalancesofReceivablesandContractLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CollaborationRevenueChangesinBalancesofReceivablesandContractLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_63734fa3-32c3-45a2-871b-08fbce4e8040" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e6987214-e1a2-4214-a64c-b8d317a8bfaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_63734fa3-32c3-45a2-871b-08fbce4e8040" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e6987214-e1a2-4214-a64c-b8d317a8bfaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f501bf87-c250-4684-bee9-cde49f4d9310" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e6987214-e1a2-4214-a64c-b8d317a8bfaf" xlink:to="loc_srt_ProductOrServiceAxis_f501bf87-c250-4684-bee9-cde49f4d9310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_215c245f-eeb9-4a19-a0b1-0ab629fd4ab8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_f501bf87-c250-4684-bee9-cde49f4d9310" xlink:to="loc_srt_ProductsAndServicesDomain_215c245f-eeb9-4a19-a0b1-0ab629fd4ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember_7740f005-a099-4490-8db7-db4284322a60" xlink:href="mrna-20210331.xsd#mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_215c245f-eeb9-4a19-a0b1-0ab629fd4ab8" xlink:to="loc_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember_7740f005-a099-4490-8db7-db4284322a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8e67b2d9-59b7-4b5f-ab0a-86d77295e2d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e6987214-e1a2-4214-a64c-b8d317a8bfaf" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8e67b2d9-59b7-4b5f-ab0a-86d77295e2d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractwithCustomerAssetRollForward_c072be45-1a8e-43cb-9298-2d9560a98f2f" xlink:href="mrna-20210331.xsd#mrna_ChangeInContractwithCustomerAssetRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8e67b2d9-59b7-4b5f-ab0a-86d77295e2d5" xlink:to="loc_mrna_ChangeInContractwithCustomerAssetRollForward_c072be45-1a8e-43cb-9298-2d9560a98f2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_51a5479f-91c1-434c-a137-e22e093eef01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractwithCustomerAssetRollForward_c072be45-1a8e-43cb-9298-2d9560a98f2f" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_51a5479f-91c1-434c-a137-e22e093eef01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_2cd273f1-d6e2-417e-82a5-88b9a1f6eb4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractwithCustomerAssetRollForward_c072be45-1a8e-43cb-9298-2d9560a98f2f" xlink:to="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_2cd273f1-d6e2-417e-82a5-88b9a1f6eb4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerAssetDeductionsDuringPeriod_a7a5692c-936e-4b3a-99d3-450d538eee17" xlink:href="mrna-20210331.xsd#mrna_ContractWithCustomerAssetDeductionsDuringPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractwithCustomerAssetRollForward_c072be45-1a8e-43cb-9298-2d9560a98f2f" xlink:to="loc_mrna_ContractWithCustomerAssetDeductionsDuringPeriod_a7a5692c-936e-4b3a-99d3-450d538eee17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_de773d84-81fc-4b89-85c2-55990602a82e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractwithCustomerAssetRollForward_c072be45-1a8e-43cb-9298-2d9560a98f2f" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_de773d84-81fc-4b89-85c2-55990602a82e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward_3b58f885-cbd0-43be-9093-4351bd458db2" xlink:href="mrna-20210331.xsd#mrna_ChangeInContractwithCustomerLiabilityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8e67b2d9-59b7-4b5f-ab0a-86d77295e2d5" xlink:to="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward_3b58f885-cbd0-43be-9093-4351bd458db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_0c28805f-8a89-406e-9e9c-64ac25080cc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward_3b58f885-cbd0-43be-9093-4351bd458db2" xlink:to="loc_us-gaap_ContractWithCustomerLiability_0c28805f-8a89-406e-9e9c-64ac25080cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_52ac0a18-e226-46f9-8be4-21927b5324f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward_3b58f885-cbd0-43be-9093-4351bd458db2" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_52ac0a18-e226-46f9-8be4-21927b5324f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod_235f0500-ac43-4022-9787-4dae17315278" xlink:href="mrna-20210331.xsd#mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward_3b58f885-cbd0-43be-9093-4351bd458db2" xlink:to="loc_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod_235f0500-ac43-4022-9787-4dae17315278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_a4f670bd-fdd4-452a-8b0e-f0daf83427c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward_3b58f885-cbd0-43be-9093-4351bd458db2" xlink:to="loc_us-gaap_ContractWithCustomerLiability_a4f670bd-fdd4-452a-8b0e-f0daf83427c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_a126f49e-9d52-482d-b96a-6069f0362bd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8e67b2d9-59b7-4b5f-ab0a-86d77295e2d5" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_a126f49e-9d52-482d-b96a-6069f0362bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstruments" xlink:type="simple" xlink:href="mrna-20210331.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b93d12ac-d4e1-454f-86a6-2b0b4b57b7e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_eb13aed5-f817-4ca7-909b-9df1a4e0e94d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b93d12ac-d4e1-454f-86a6-2b0b4b57b7e5" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_eb13aed5-f817-4ca7-909b-9df1a4e0e94d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="mrna-20210331.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_da784b07-cbe6-49c0-9edf-599c988d5619" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_17f28d0c-1384-4cca-83d1-f720fe67d6d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_da784b07-cbe6-49c0-9edf-599c988d5619" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_17f28d0c-1384-4cca-83d1-f720fe67d6d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_f063a6fb-0112-4b44-b728-75c40f1fd25c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_da784b07-cbe6-49c0-9edf-599c988d5619" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_f063a6fb-0112-4b44-b728-75c40f1fd25c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_4bd94c59-159e-4ae5-b084-ad9043d1b6de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_da784b07-cbe6-49c0-9edf-599c988d5619" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_4bd94c59-159e-4ae5-b084-ad9043d1b6de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_54812987-cd79-43a3-9ae5-71dede4be416" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_fcfd6f52-18c0-4b9c-8ac9-7b9e10b2c977" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_54812987-cd79-43a3-9ae5-71dede4be416" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_fcfd6f52-18c0-4b9c-8ac9-7b9e10b2c977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_9c4aff7c-cd58-47ce-9a5c-8cdc33352cec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_fcfd6f52-18c0-4b9c-8ac9-7b9e10b2c977" xlink:to="loc_us-gaap_FinancialInstrumentAxis_9c4aff7c-cd58-47ce-9a5c-8cdc33352cec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02a82936-654d-49d5-8464-fba001c1bf55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9c4aff7c-cd58-47ce-9a5c-8cdc33352cec" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02a82936-654d-49d5-8464-fba001c1bf55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_6e121c03-7cad-41d6-8c86-2ff3697f301e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02a82936-654d-49d5-8464-fba001c1bf55" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_6e121c03-7cad-41d6-8c86-2ff3697f301e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_51998662-05f8-4aa1-abba-3138d7b3492e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02a82936-654d-49d5-8464-fba001c1bf55" xlink:to="loc_us-gaap_CertificatesOfDepositMember_51998662-05f8-4aa1-abba-3138d7b3492e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_a264899f-791c-47d3-bb95-cdfac918fd61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02a82936-654d-49d5-8464-fba001c1bf55" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_a264899f-791c-47d3-bb95-cdfac918fd61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember_3ac8b13a-f035-43af-a148-09cadea79422" xlink:href="mrna-20210331.xsd#mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02a82936-654d-49d5-8464-fba001c1bf55" xlink:to="loc_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember_3ac8b13a-f035-43af-a148-09cadea79422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_b2321993-6497-46aa-bb1e-f788dccc1416" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_fcfd6f52-18c0-4b9c-8ac9-7b9e10b2c977" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_b2321993-6497-46aa-bb1e-f788dccc1416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_21f30c50-be4c-402e-8cb7-96d61235a31b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_b2321993-6497-46aa-bb1e-f788dccc1416" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_21f30c50-be4c-402e-8cb7-96d61235a31b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_db019eca-8196-423a-baa6-b2af126bd2e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_21f30c50-be4c-402e-8cb7-96d61235a31b" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_db019eca-8196-423a-baa6-b2af126bd2e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CurrentMarketableSecuritiesMember_16f600cf-7eca-4e92-ab30-f3f9e02f7566" xlink:href="mrna-20210331.xsd#mrna_CurrentMarketableSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_21f30c50-be4c-402e-8cb7-96d61235a31b" xlink:to="loc_mrna_CurrentMarketableSecuritiesMember_16f600cf-7eca-4e92-ab30-f3f9e02f7566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NoncurrentMarketableSecuritiesMember_f8af6226-9987-4580-ae45-ad6d875e897a" xlink:href="mrna-20210331.xsd#mrna_NoncurrentMarketableSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_21f30c50-be4c-402e-8cb7-96d61235a31b" xlink:to="loc_mrna_NoncurrentMarketableSecuritiesMember_f8af6226-9987-4580-ae45-ad6d875e897a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9612bf1d-5ec9-4e84-aa77-900faff7bb62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_fcfd6f52-18c0-4b9c-8ac9-7b9e10b2c977" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9612bf1d-5ec9-4e84-aa77-900faff7bb62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_10e90ba9-1824-485d-bcba-a6f70ec0b960" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9612bf1d-5ec9-4e84-aa77-900faff7bb62" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_10e90ba9-1824-485d-bcba-a6f70ec0b960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_52831fd5-01f6-4fb6-9fc8-08702979d658" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_10e90ba9-1824-485d-bcba-a6f70ec0b960" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_52831fd5-01f6-4fb6-9fc8-08702979d658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_9771adbc-a41f-439f-922e-e598c9f63ef6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_10e90ba9-1824-485d-bcba-a6f70ec0b960" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_9771adbc-a41f-439f-922e-e598c9f63ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c0a1d138-1163-42af-b057-5910742f3475" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_fcfd6f52-18c0-4b9c-8ac9-7b9e10b2c977" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c0a1d138-1163-42af-b057-5910742f3475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_246132f4-18fd-4acf-b2e3-aa68d095681c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c0a1d138-1163-42af-b057-5910742f3475" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_246132f4-18fd-4acf-b2e3-aa68d095681c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_892d5d39-fb9b-4e27-9bea-8ef9a6787043" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c0a1d138-1163-42af-b057-5910742f3475" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_892d5d39-fb9b-4e27-9bea-8ef9a6787043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_dfd9b1d1-6e7b-4b68-9160-3568f396ac1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c0a1d138-1163-42af-b057-5910742f3475" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_dfd9b1d1-6e7b-4b68-9160-3568f396ac1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_27801edc-0191-4947-b2f1-7567b8f53a23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c0a1d138-1163-42af-b057-5910742f3475" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_27801edc-0191-4947-b2f1-7567b8f53a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#FinancialInstrumentsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_48ba97ca-874d-4c72-a84e-adca1ea94ac4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_759d90a0-f848-4020-9dfe-d1042ca14dfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_48ba97ca-874d-4c72-a84e-adca1ea94ac4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_759d90a0-f848-4020-9dfe-d1042ca14dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_4d84381b-16d4-41c2-9876-1caf366e2456" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_759d90a0-f848-4020-9dfe-d1042ca14dfe" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_4d84381b-16d4-41c2-9876-1caf366e2456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_32826bb1-8c8d-40f3-bc85-d1fd8fc7aa02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_759d90a0-f848-4020-9dfe-d1042ca14dfe" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_32826bb1-8c8d-40f3-bc85-d1fd8fc7aa02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9ba7348d-b8b6-465a-ae14-92bc403ecbae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_759d90a0-f848-4020-9dfe-d1042ca14dfe" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9ba7348d-b8b6-465a-ae14-92bc403ecbae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_3a7efb33-6134-46f0-bb18-a309a18488d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_48ba97ca-874d-4c72-a84e-adca1ea94ac4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_3a7efb33-6134-46f0-bb18-a309a18488d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_e906f4e8-968b-4bf3-8f91-df7756fc6d93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_3a7efb33-6134-46f0-bb18-a309a18488d8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_e906f4e8-968b-4bf3-8f91-df7756fc6d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_840001cc-51e3-46d2-9d1d-8f202e895c6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_3a7efb33-6134-46f0-bb18-a309a18488d8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_840001cc-51e3-46d2-9d1d-8f202e895c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_71599bdf-9b95-4cde-9fa0-0eb34106c451" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_3a7efb33-6134-46f0-bb18-a309a18488d8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_71599bdf-9b95-4cde-9fa0-0eb34106c451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_80ebfd93-3a7d-430f-aa99-c97f9d847a83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings_364197a9-3183-487d-ad07-d3fd9447766e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_80ebfd93-3a7d-430f-aa99-c97f9d847a83" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings_364197a9-3183-487d-ad07-d3fd9447766e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_80d56d6c-a1cc-4991-92eb-2945e113fbaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ecd2cb01-e539-4f16-b3f9-5789de7a7df3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_80d56d6c-a1cc-4991-92eb-2945e113fbaa" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ecd2cb01-e539-4f16-b3f9-5789de7a7df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_35010087-f0f5-4c34-9ac0-10ff9fd6e5b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ecd2cb01-e539-4f16-b3f9-5789de7a7df3" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_35010087-f0f5-4c34-9ac0-10ff9fd6e5b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_48ce3520-bd57-4ef3-8fe6-93dcaa4d526a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_35010087-f0f5-4c34-9ac0-10ff9fd6e5b5" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_48ce3520-bd57-4ef3-8fe6-93dcaa4d526a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_035acec8-d271-4792-8c3e-8fed3e9d4b5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_48ce3520-bd57-4ef3-8fe6-93dcaa4d526a" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_035acec8-d271-4792-8c3e-8fed3e9d4b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_cc6db329-4090-4089-8677-06e69f67bafd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ecd2cb01-e539-4f16-b3f9-5789de7a7df3" xlink:to="loc_us-gaap_FinancialInstrumentAxis_cc6db329-4090-4089-8677-06e69f67bafd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b5aef028-382b-48d2-a30d-3eaba21e2a24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_cc6db329-4090-4089-8677-06e69f67bafd" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b5aef028-382b-48d2-a30d-3eaba21e2a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_e1b3fc4b-a90a-4732-b687-b9521f41928f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b5aef028-382b-48d2-a30d-3eaba21e2a24" xlink:to="loc_us-gaap_MoneyMarketFundsMember_e1b3fc4b-a90a-4732-b687-b9521f41928f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_1814727c-d646-4dff-8c30-34bb48cfd5c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b5aef028-382b-48d2-a30d-3eaba21e2a24" xlink:to="loc_us-gaap_CertificatesOfDepositMember_1814727c-d646-4dff-8c30-34bb48cfd5c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_35a70762-db8a-4688-bf85-aa3e5cb187dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b5aef028-382b-48d2-a30d-3eaba21e2a24" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_35a70762-db8a-4688-bf85-aa3e5cb187dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember_76b67c8e-9aea-4358-86c2-aec120673b3e" xlink:href="mrna-20210331.xsd#mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b5aef028-382b-48d2-a30d-3eaba21e2a24" xlink:to="loc_mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember_76b67c8e-9aea-4358-86c2-aec120673b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d3a3408-61a0-4f4a-a69a-863ff6402f66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ecd2cb01-e539-4f16-b3f9-5789de7a7df3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d3a3408-61a0-4f4a-a69a-863ff6402f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_235b1b22-c062-4f9b-9a44-1eee6571d5b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d3a3408-61a0-4f4a-a69a-863ff6402f66" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_235b1b22-c062-4f9b-9a44-1eee6571d5b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_8aba1ccb-ef59-4d26-8ea1-bb2574aba87a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_235b1b22-c062-4f9b-9a44-1eee6571d5b3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_8aba1ccb-ef59-4d26-8ea1-bb2574aba87a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_7505a5aa-3669-4b79-9911-f4592c80d82a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_235b1b22-c062-4f9b-9a44-1eee6571d5b3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_7505a5aa-3669-4b79-9911-f4592c80d82a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1e92de6e-d6d2-498c-8bcf-1ca649f47aca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ecd2cb01-e539-4f16-b3f9-5789de7a7df3" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1e92de6e-d6d2-498c-8bcf-1ca649f47aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f7233376-2981-48ad-97eb-e6d173aeab91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1e92de6e-d6d2-498c-8bcf-1ca649f47aca" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f7233376-2981-48ad-97eb-e6d173aeab91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_cd00384a-ce01-4d3b-9ebf-999147515a32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1e92de6e-d6d2-498c-8bcf-1ca649f47aca" xlink:to="loc_us-gaap_DerivativeAssets_cd00384a-ce01-4d3b-9ebf-999147515a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_27aa5d0d-2643-4b2b-9f0b-b19d1a272ee3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1e92de6e-d6d2-498c-8bcf-1ca649f47aca" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_27aa5d0d-2643-4b2b-9f0b-b19d1a272ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_f2199f49-54d9-400a-99dc-39c01d902a7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1e92de6e-d6d2-498c-8bcf-1ca649f47aca" xlink:to="loc_us-gaap_DerivativeLiabilities_f2199f49-54d9-400a-99dc-39c01d902a7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/DerivativeFinancialInstruments" xlink:type="simple" xlink:href="mrna-20210331.xsd#DerivativeFinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/DerivativeFinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_3457e371-6c4d-4d99-b740-2ed981fa35dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_f720095a-cd0b-4aeb-9ef2-134e81f21e48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_3457e371-6c4d-4d99-b740-2ed981fa35dc" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_f720095a-cd0b-4aeb-9ef2-134e81f21e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/DerivativeFinancialInstrumentsTables" xlink:type="simple" xlink:href="mrna-20210331.xsd#DerivativeFinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/DerivativeFinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_237087fb-0dc3-4739-a941-5ed34d130e53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_f9fcc4f1-62eb-4b47-a93f-edffe6555e70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_237087fb-0dc3-4739-a941-5ed34d130e53" xlink:to="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_f9fcc4f1-62eb-4b47-a93f-edffe6555e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#DerivativeFinancialInstrumentsBalanceSheetHedgesDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_461a69db-3d8c-48ba-840e-6b1f56882d50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_9765cad2-e5b4-4e68-9b28-755dbfbb7107" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_461a69db-3d8c-48ba-840e-6b1f56882d50" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_9765cad2-e5b4-4e68-9b28-755dbfbb7107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_d2c8e9df-366a-4f61-80bf-b042d7520533" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_9765cad2-e5b4-4e68-9b28-755dbfbb7107" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_d2c8e9df-366a-4f61-80bf-b042d7520533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_0fe809a6-1c32-4ac8-877c-2f35104a5363" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_d2c8e9df-366a-4f61-80bf-b042d7520533" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_0fe809a6-1c32-4ac8-877c-2f35104a5363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_761642d8-63d1-44e8-be16-2b29cbc3d98b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0fe809a6-1c32-4ac8-877c-2f35104a5363" xlink:to="loc_us-gaap_ForeignExchangeContractMember_761642d8-63d1-44e8-be16-2b29cbc3d98b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3bf26de9-7d51-4339-ae73-0bd0df62f65f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_9765cad2-e5b4-4e68-9b28-755dbfbb7107" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3bf26de9-7d51-4339-ae73-0bd0df62f65f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_17a6a361-95c3-47b3-8b3a-216228345d7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3bf26de9-7d51-4339-ae73-0bd0df62f65f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_17a6a361-95c3-47b3-8b3a-216228345d7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember_4f90bf03-1d96-46b7-83f2-b960e7d6e311" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_17a6a361-95c3-47b3-8b3a-216228345d7e" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseMember_4f90bf03-1d96-46b7-83f2-b960e7d6e311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_c787d57d-2217-4099-ad8c-d0769eaf4445" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_9765cad2-e5b4-4e68-9b28-755dbfbb7107" xlink:to="loc_us-gaap_HedgingDesignationAxis_c787d57d-2217-4099-ad8c-d0769eaf4445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_a961e83a-0228-446f-a20b-f616aa338f37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_c787d57d-2217-4099-ad8c-d0769eaf4445" xlink:to="loc_us-gaap_HedgingDesignationDomain_a961e83a-0228-446f-a20b-f616aa338f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_2b2f5d5d-2dbe-487f-a0e1-8b2959299e7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_a961e83a-0228-446f-a20b-f616aa338f37" xlink:to="loc_us-gaap_NondesignatedMember_2b2f5d5d-2dbe-487f-a0e1-8b2959299e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_acf8eba0-8053-4869-87e2-ebb91ace2c25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_9765cad2-e5b4-4e68-9b28-755dbfbb7107" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_acf8eba0-8053-4869-87e2-ebb91ace2c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_e1f4925b-6d99-43ed-bfc9-e8daff81e3a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_acf8eba0-8053-4869-87e2-ebb91ace2c25" xlink:to="loc_us-gaap_DerivativeNotionalAmount_e1f4925b-6d99-43ed-bfc9-e8daff81e3a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_9e3362f7-5d40-430a-9d43-e839fc13f619" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_acf8eba0-8053-4869-87e2-ebb91ace2c25" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_9e3362f7-5d40-430a-9d43-e839fc13f619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_604a1a3f-002c-44d1-b229-eb24a575690e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_acf8eba0-8053-4869-87e2-ebb91ace2c25" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_604a1a3f-002c-44d1-b229-eb24a575690e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_8485a79f-024d-4a73-9f9b-c262bd699a32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_acf8eba0-8053-4869-87e2-ebb91ace2c25" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_8485a79f-024d-4a73-9f9b-c262bd699a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/Inventory" xlink:type="simple" xlink:href="mrna-20210331.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_a5e61002-79ce-4e39-9209-4920fd365997" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_e4d45813-808d-4721-9978-4db19b21ac97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_a5e61002-79ce-4e39-9209-4920fd365997" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_e4d45813-808d-4721-9978-4db19b21ac97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/InventoryTables" xlink:type="simple" xlink:href="mrna-20210331.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_34ac42c6-b626-4ab1-973f-7b4c1c6e023e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_b84eaefb-2457-4993-877b-4ba9be0b89d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_34ac42c6-b626-4ab1-973f-7b4c1c6e023e" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_b84eaefb-2457-4993-877b-4ba9be0b89d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/InventoryDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#InventoryDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_dac68a7a-a913-4954-8e3c-b009b857047b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_b9494b3b-25ec-4c58-8fff-51a0027c68c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_dac68a7a-a913-4954-8e3c-b009b857047b" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_b9494b3b-25ec-4c58-8fff-51a0027c68c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_baf7cf89-5350-431b-bd65-f8c3b6c09aef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_dac68a7a-a913-4954-8e3c-b009b857047b" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_baf7cf89-5350-431b-bd65-f8c3b6c09aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_da9501f1-72fc-4823-99e1-bd94030ef08d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_dac68a7a-a913-4954-8e3c-b009b857047b" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_da9501f1-72fc-4823-99e1-bd94030ef08d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_d1f2e6f1-338d-43a5-9b05-84d007e40474" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_dac68a7a-a913-4954-8e3c-b009b857047b" xlink:to="loc_us-gaap_InventoryNet_d1f2e6f1-338d-43a5-9b05-84d007e40474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/PropertyandEquipmentNet" xlink:type="simple" xlink:href="mrna-20210331.xsd#PropertyandEquipmentNet"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/PropertyandEquipmentNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_f688632b-6802-4d4c-9f21-06904df16329" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_7a7307a5-7a08-441a-ab24-ffbff160e84a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_f688632b-6802-4d4c-9f21-06904df16329" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_7a7307a5-7a08-441a-ab24-ffbff160e84a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/PropertyandEquipmentNetTables" xlink:type="simple" xlink:href="mrna-20210331.xsd#PropertyandEquipmentNetTables"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/PropertyandEquipmentNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_f021fcb1-9434-4972-ac36-174562d4d5da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1e5ad3dd-c5a9-40fd-b21d-a0000b0b2a02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_f021fcb1-9434-4972-ac36-174562d4d5da" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1e5ad3dd-c5a9-40fd-b21d-a0000b0b2a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#PropertyandEquipmentNetDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/PropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d3b52807-8592-4a44-8bda-ff06fe6fd1fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_889ce3df-dca3-4c72-bf0c-3ae68a66faf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d3b52807-8592-4a44-8bda-ff06fe6fd1fb" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_889ce3df-dca3-4c72-bf0c-3ae68a66faf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0944dad4-783e-4807-8724-3738cecbc776" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_889ce3df-dca3-4c72-bf0c-3ae68a66faf6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0944dad4-783e-4807-8724-3738cecbc776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3dd63b11-bcab-4a85-a62f-1f84657cf685" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0944dad4-783e-4807-8724-3738cecbc776" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3dd63b11-bcab-4a85-a62f-1f84657cf685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_c15343d9-2364-4c54-8c6f-90d7172a72e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3dd63b11-bcab-4a85-a62f-1f84657cf685" xlink:to="loc_us-gaap_EquipmentMember_c15343d9-2364-4c54-8c6f-90d7172a72e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_7ae3c8a6-f5ea-47cc-9e36-72cec0595668" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3dd63b11-bcab-4a85-a62f-1f84657cf685" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_7ae3c8a6-f5ea-47cc-9e36-72cec0595668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_51e471e9-c302-40ac-b4b5-e327827147db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3dd63b11-bcab-4a85-a62f-1f84657cf685" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_51e471e9-c302-40ac-b4b5-e327827147db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_8ba685e0-c693-4023-a731-de3e3928cd19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3dd63b11-bcab-4a85-a62f-1f84657cf685" xlink:to="loc_us-gaap_ComputerEquipmentMember_8ba685e0-c693-4023-a731-de3e3928cd19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_2e66d2f5-620b-494f-9957-d9e2c862466c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3dd63b11-bcab-4a85-a62f-1f84657cf685" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_2e66d2f5-620b-494f-9957-d9e2c862466c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_FinancingRightOfUseAssetMember_b8d72ac9-2574-4721-af5f-bb809be22f2e" xlink:href="mrna-20210331.xsd#mrna_FinancingRightOfUseAssetMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3dd63b11-bcab-4a85-a62f-1f84657cf685" xlink:to="loc_mrna_FinancingRightOfUseAssetMember_b8d72ac9-2574-4721-af5f-bb809be22f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_d9e9ab09-0daf-4305-9082-feae40af39f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3dd63b11-bcab-4a85-a62f-1f84657cf685" xlink:to="loc_us-gaap_ConstructionInProgressMember_d9e9ab09-0daf-4305-9082-feae40af39f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f7660e9c-7531-4c8d-aaef-aace89465e07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_889ce3df-dca3-4c72-bf0c-3ae68a66faf6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f7660e9c-7531-4c8d-aaef-aace89465e07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_b33e8631-1af3-4747-b741-be856b9378f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f7660e9c-7531-4c8d-aaef-aace89465e07" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_b33e8631-1af3-4747-b741-be856b9378f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_e7236891-7f38-455a-b71a-d500a07645d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f7660e9c-7531-4c8d-aaef-aace89465e07" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_e7236891-7f38-455a-b71a-d500a07645d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_6fb87a98-290b-4d0e-8eed-0b8a1800ed93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f7660e9c-7531-4c8d-aaef-aace89465e07" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_6fb87a98-290b-4d0e-8eed-0b8a1800ed93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_83b60f7c-b747-4dbc-9317-3eba8591ea2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f7660e9c-7531-4c8d-aaef-aace89465e07" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_83b60f7c-b747-4dbc-9317-3eba8591ea2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponents" xlink:type="simple" xlink:href="mrna-20210331.xsd#OtherBalanceSheetComponents"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/OtherBalanceSheetComponents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6ebd7301-c183-410c-a049-78c1b782b3b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_103f53cc-9540-4bd3-8a32-634d048804e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6ebd7301-c183-410c-a049-78c1b782b3b1" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_103f53cc-9540-4bd3-8a32-634d048804e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsTables" xlink:type="simple" xlink:href="mrna-20210331.xsd#OtherBalanceSheetComponentsTables"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/OtherBalanceSheetComponentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1e58b7e1-035c-4930-afa5-8287e7908647" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_fbb7d233-8806-4b39-8633-387a2b410952" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1e58b7e1-035c-4930-afa5-8287e7908647" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_fbb7d233-8806-4b39-8633-387a2b410952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_d2a3bd5d-f8d6-418f-abe9-f7ad4acf5283" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1e58b7e1-035c-4930-afa5-8287e7908647" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_d2a3bd5d-f8d6-418f-abe9-f7ad4acf5283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_649eee07-9ac9-4927-822a-eac7389a4413" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1e58b7e1-035c-4930-afa5-8287e7908647" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_649eee07-9ac9-4927-822a-eac7389a4413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_be05f05a-9073-4524-91bb-1e7bfe686195" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OtherPrepaidExpenseManufacturing_150edb4e-8052-4c14-b1dd-16cc8af497e2" xlink:href="mrna-20210331.xsd#mrna_OtherPrepaidExpenseManufacturing"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_be05f05a-9073-4524-91bb-1e7bfe686195" xlink:to="loc_mrna_OtherPrepaidExpenseManufacturing_150edb4e-8052-4c14-b1dd-16cc8af497e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_4cbe132c-3bc7-4c77-a9a9-9ec05e4c81ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_be05f05a-9073-4524-91bb-1e7bfe686195" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_4cbe132c-3bc7-4c77-a9a9-9ec05e4c81ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_TenantIncentivesReceivablesCurrent_5a522dc8-eb8e-49c4-8ddf-2f0f2acf1c50" xlink:href="mrna-20210331.xsd#mrna_TenantIncentivesReceivablesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_be05f05a-9073-4524-91bb-1e7bfe686195" xlink:to="loc_mrna_TenantIncentivesReceivablesCurrent_5a522dc8-eb8e-49c4-8ddf-2f0f2acf1c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_bf9bc197-d795-4b89-86d8-02c51ed1258b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_be05f05a-9073-4524-91bb-1e7bfe686195" xlink:to="loc_us-gaap_InterestReceivableCurrent_bf9bc197-d795-4b89-86d8-02c51ed1258b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_228ed46f-5936-4428-a2fe-6db2c3e98df3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_be05f05a-9073-4524-91bb-1e7bfe686195" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_228ed46f-5936-4428-a2fe-6db2c3e98df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#OtherBalanceSheetComponentsAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8e8d56a9-4545-4e65-b585-19cb2945f6c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedClinicalTrials_8f3a27a3-e05c-49a0-bd1d-ce3ed507b0e5" xlink:href="mrna-20210331.xsd#mrna_AccruedClinicalTrials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8e8d56a9-4545-4e65-b585-19cb2945f6c8" xlink:to="loc_mrna_AccruedClinicalTrials_8f3a27a3-e05c-49a0-bd1d-ce3ed507b0e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RawMaterialsAccountsPayable_b17d451d-587a-4cec-9d6f-e9ab296472f4" xlink:href="mrna-20210331.xsd#mrna_RawMaterialsAccountsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8e8d56a9-4545-4e65-b585-19cb2945f6c8" xlink:to="loc_mrna_RawMaterialsAccountsPayable_b17d451d-587a-4cec-9d6f-e9ab296472f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_3f226abc-2c54-425e-ab38-8c686b63fecb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8e8d56a9-4545-4e65-b585-19cb2945f6c8" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_3f226abc-2c54-425e-ab38-8c686b63fecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedDevelopmentOperation_93c0c1de-9533-4e0e-9091-08390d92d6d7" xlink:href="mrna-20210331.xsd#mrna_AccruedDevelopmentOperation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8e8d56a9-4545-4e65-b585-19cb2945f6c8" xlink:to="loc_mrna_AccruedDevelopmentOperation_93c0c1de-9533-4e0e-9091-08390d92d6d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedManufacturing_c556a703-e7fe-462f-a0b0-b73e9800431c" xlink:href="mrna-20210331.xsd#mrna_AccruedManufacturing"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8e8d56a9-4545-4e65-b585-19cb2945f6c8" xlink:to="loc_mrna_AccruedManufacturing_c556a703-e7fe-462f-a0b0-b73e9800431c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedOtherExternalGoodsAndServicesCurrent_3bbe4fcf-6726-4481-9ad9-2e01a4c62954" xlink:href="mrna-20210331.xsd#mrna_AccruedOtherExternalGoodsAndServicesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8e8d56a9-4545-4e65-b585-19cb2945f6c8" xlink:to="loc_mrna_AccruedOtherExternalGoodsAndServicesCurrent_3bbe4fcf-6726-4481-9ad9-2e01a4c62954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1eaaeed3-b755-4fd2-8b9b-b55629ad302d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8e8d56a9-4545-4e65-b585-19cb2945f6c8" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1eaaeed3-b755-4fd2-8b9b-b55629ad302d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedPropertyAndEquipmentCurrent_f4a9a63f-1925-47ea-9669-1774fdb23670" xlink:href="mrna-20210331.xsd#mrna_AccruedPropertyAndEquipmentCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8e8d56a9-4545-4e65-b585-19cb2945f6c8" xlink:to="loc_mrna_AccruedPropertyAndEquipmentCurrent_f4a9a63f-1925-47ea-9669-1774fdb23670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_Commercial_f52b9bb2-8d7c-4476-9bcf-04839242da06" xlink:href="mrna-20210331.xsd#mrna_Commercial"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8e8d56a9-4545-4e65-b585-19cb2945f6c8" xlink:to="loc_mrna_Commercial_f52b9bb2-8d7c-4476-9bcf-04839242da06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_4f49ac8b-f89b-440a-8534-f3635e9c8b33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8e8d56a9-4545-4e65-b585-19cb2945f6c8" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_4f49ac8b-f89b-440a-8534-f3635e9c8b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#OtherBalanceSheetComponentsDeferredRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fa7ba008-d84a-46e2-932e-92ac3936be2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractWithCustomerLiabilityTable_2b2b68e2-30aa-4215-8247-37041022b081" xlink:href="mrna-20210331.xsd#mrna_ChangeInContractWithCustomerLiabilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fa7ba008-d84a-46e2-932e-92ac3936be2b" xlink:to="loc_mrna_ChangeInContractWithCustomerLiabilityTable_2b2b68e2-30aa-4215-8247-37041022b081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c38e5d1b-3c36-4a17-8d19-096da382e77d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityTable_2b2b68e2-30aa-4215-8247-37041022b081" xlink:to="loc_srt_ProductOrServiceAxis_c38e5d1b-3c36-4a17-8d19-096da382e77d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5be86880-798b-4f74-84f1-9235aa2e982c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c38e5d1b-3c36-4a17-8d19-096da382e77d" xlink:to="loc_srt_ProductsAndServicesDomain_5be86880-798b-4f74-84f1-9235aa2e982c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ProductSalesMember_7bcc20b2-56c3-4f01-a3e5-271bd0799599" xlink:href="mrna-20210331.xsd#mrna_ProductSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5be86880-798b-4f74-84f1-9235aa2e982c" xlink:to="loc_mrna_ProductSalesMember_7bcc20b2-56c3-4f01-a3e5-271bd0799599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_83e88699-e560-4b9c-bdd2-6778f425af02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5be86880-798b-4f74-84f1-9235aa2e982c" xlink:to="loc_us-gaap_GrantMember_83e88699-e560-4b9c-bdd2-6778f425af02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CollaborationArrangementMember_acf2a515-f1ce-4fc1-961e-d662a4c33685" xlink:href="mrna-20210331.xsd#mrna_CollaborationArrangementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5be86880-798b-4f74-84f1-9235aa2e982c" xlink:to="loc_mrna_CollaborationArrangementMember_acf2a515-f1ce-4fc1-961e-d662a4c33685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractWithCustomerLiabilityLineItems_d2914be8-6cb6-45bd-8f31-c7e4e257a218" xlink:href="mrna-20210331.xsd#mrna_ChangeInContractWithCustomerLiabilityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityTable_2b2b68e2-30aa-4215-8247-37041022b081" xlink:to="loc_mrna_ChangeInContractWithCustomerLiabilityLineItems_d2914be8-6cb6-45bd-8f31-c7e4e257a218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward_1e69c33c-3bc9-4921-8dff-9c01a25bdef2" xlink:href="mrna-20210331.xsd#mrna_ChangeInContractwithCustomerLiabilityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityLineItems_d2914be8-6cb6-45bd-8f31-c7e4e257a218" xlink:to="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward_1e69c33c-3bc9-4921-8dff-9c01a25bdef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_b75c45b8-1b2e-4b0a-ab61-63d7b0f61388" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward_1e69c33c-3bc9-4921-8dff-9c01a25bdef2" xlink:to="loc_us-gaap_ContractWithCustomerLiability_b75c45b8-1b2e-4b0a-ab61-63d7b0f61388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_b1ad2ebe-8c6f-4725-b980-edb46987744f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward_1e69c33c-3bc9-4921-8dff-9c01a25bdef2" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_b1ad2ebe-8c6f-4725-b980-edb46987744f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod_2de9be5f-bc84-4313-806e-4918a3386f72" xlink:href="mrna-20210331.xsd#mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward_1e69c33c-3bc9-4921-8dff-9c01a25bdef2" xlink:to="loc_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod_2de9be5f-bc84-4313-806e-4918a3386f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_f26a3801-79bd-458f-a534-096989a45ade" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractwithCustomerLiabilityRollForward_1e69c33c-3bc9-4921-8dff-9c01a25bdef2" xlink:to="loc_us-gaap_ContractWithCustomerLiability_f26a3801-79bd-458f-a534-096989a45ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/Leases" xlink:type="simple" xlink:href="mrna-20210331.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3de06795-223c-4f95-a3e7-d5386230e061" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_1c1f3915-b7c0-4567-98af-73218a178205" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3de06795-223c-4f95-a3e7-d5386230e061" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_1c1f3915-b7c0-4567-98af-73218a178205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_4da2e60b-3b27-4f88-870f-a9a3eefdcc8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3de06795-223c-4f95-a3e7-d5386230e061" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_4da2e60b-3b27-4f88-870f-a9a3eefdcc8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesTables" xlink:type="simple" xlink:href="mrna-20210331.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_ccc0bc09-d762-4c89-b9be-f5442bedb9ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AssetsAndLiabilitiesLesseeTableTextBlock_514a92bf-5c2f-4260-877c-1d0ccd86dd39" xlink:href="mrna-20210331.xsd#mrna_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ccc0bc09-d762-4c89-b9be-f5442bedb9ae" xlink:to="loc_mrna_AssetsAndLiabilitiesLesseeTableTextBlock_514a92bf-5c2f-4260-877c-1d0ccd86dd39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_1cff50e9-7a1b-4cf1-a2fd-5b3b9bd86c49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ccc0bc09-d762-4c89-b9be-f5442bedb9ae" xlink:to="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_1cff50e9-7a1b-4cf1-a2fd-5b3b9bd86c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_5ad8ff2a-2755-492b-94ef-eac846c98d03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ccc0bc09-d762-4c89-b9be-f5442bedb9ae" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_5ad8ff2a-2755-492b-94ef-eac846c98d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_5f7ad3ef-b693-48ef-be2b-a8450734794c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_93e68231-ff6a-4efe-b116-c32078e4adb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5f7ad3ef-b693-48ef-be2b-a8450734794c" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_93e68231-ff6a-4efe-b116-c32078e4adb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_b80bbd02-2615-4d11-8c78-3c13bed7ab53" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_93e68231-ff6a-4efe-b116-c32078e4adb3" xlink:to="loc_srt_StatementGeographicalAxis_b80bbd02-2615-4d11-8c78-3c13bed7ab53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4ea4f4ca-cf13-4bfe-869c-cabe929f43b5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_b80bbd02-2615-4d11-8c78-3c13bed7ab53" xlink:to="loc_srt_SegmentGeographicalDomain_4ea4f4ca-cf13-4bfe-869c-cabe929f43b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CambridgeMassachusettsMember_4714f322-3ca1-4e1b-81b8-92aaac590220" xlink:href="mrna-20210331.xsd#mrna_CambridgeMassachusettsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4ea4f4ca-cf13-4bfe-869c-cabe929f43b5" xlink:to="loc_mrna_CambridgeMassachusettsMember_4714f322-3ca1-4e1b-81b8-92aaac590220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NorwoodMassachusettsMember_e4aad360-95af-4040-83bd-e5c4aff99609" xlink:href="mrna-20210331.xsd#mrna_NorwoodMassachusettsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4ea4f4ca-cf13-4bfe-869c-cabe929f43b5" xlink:to="loc_mrna_NorwoodMassachusettsMember_e4aad360-95af-4040-83bd-e5c4aff99609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_0d93d5c9-77d8-4be7-9fbd-44b48fd9b3e8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_93e68231-ff6a-4efe-b116-c32078e4adb3" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_0d93d5c9-77d8-4be7-9fbd-44b48fd9b3e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_29336006-02b7-49a2-90d1-55576dd395dd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_0d93d5c9-77d8-4be7-9fbd-44b48fd9b3e8" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_29336006-02b7-49a2-90d1-55576dd395dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MTCSouthMember_07750643-8f86-463b-95a1-eebb75297679" xlink:href="mrna-20210331.xsd#mrna_MTCSouthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_29336006-02b7-49a2-90d1-55576dd395dd" xlink:to="loc_mrna_MTCSouthMember_07750643-8f86-463b-95a1-eebb75297679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MTCNorthMember_a8b6581b-fb56-4478-a327-535c85c62008" xlink:href="mrna-20210331.xsd#mrna_MTCNorthMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_29336006-02b7-49a2-90d1-55576dd395dd" xlink:to="loc_mrna_MTCNorthMember_a8b6581b-fb56-4478-a327-535c85c62008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_0aff6184-aa25-4e4c-8e76-e9bf746ada55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_93e68231-ff6a-4efe-b116-c32078e4adb3" xlink:to="loc_us-gaap_LeaseContractualTermAxis_0aff6184-aa25-4e4c-8e76-e9bf746ada55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_12a7fe9f-838c-4edd-9dd0-9bf7ebb398ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_0aff6184-aa25-4e4c-8e76-e9bf746ada55" xlink:to="loc_us-gaap_LeaseContractualTermDomain_12a7fe9f-838c-4edd-9dd0-9bf7ebb398ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_EmbeddedLeasesMember_cb198fa8-124f-4bb7-8743-1623c5375de1" xlink:href="mrna-20210331.xsd#mrna_EmbeddedLeasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_12a7fe9f-838c-4edd-9dd0-9bf7ebb398ef" xlink:to="loc_mrna_EmbeddedLeasesMember_cb198fa8-124f-4bb7-8743-1623c5375de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_ab07550a-6881-43fb-a15b-eb40f7636ccf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_93e68231-ff6a-4efe-b116-c32078e4adb3" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_ab07550a-6881-43fb-a15b-eb40f7636ccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingLeaseNumberOfProperties_04c56bf9-98c3-4bfe-8ca5-a0ad1686dc35" xlink:href="mrna-20210331.xsd#mrna_OperatingLeaseNumberOfProperties"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ab07550a-6881-43fb-a15b-eb40f7636ccf" xlink:to="loc_mrna_OperatingLeaseNumberOfProperties_04c56bf9-98c3-4bfe-8ca5-a0ad1686dc35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_c110d343-87ae-4093-a8c2-18827eea5f7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ab07550a-6881-43fb-a15b-eb40f7636ccf" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_c110d343-87ae-4093-a8c2-18827eea5f7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_33423aaa-802b-4d55-b77b-8438af7c0aaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ab07550a-6881-43fb-a15b-eb40f7636ccf" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_33423aaa-802b-4d55-b77b-8438af7c0aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods_1fcc9d7b-a7c5-4c00-9c61-0de6bf1a37ed" xlink:href="mrna-20210331.xsd#mrna_LesseeOperatingLeaseNumberOfExtensionPeriods"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ab07550a-6881-43fb-a15b-eb40f7636ccf" xlink:to="loc_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods_1fcc9d7b-a7c5-4c00-9c61-0de6bf1a37ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AllowanceForTenantImprovements_f905f84e-54da-44a6-9a44-796a7cd91c0a" xlink:href="mrna-20210331.xsd#mrna_AllowanceForTenantImprovements"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ab07550a-6881-43fb-a15b-eb40f7636ccf" xlink:to="loc_mrna_AllowanceForTenantImprovements_f905f84e-54da-44a6-9a44-796a7cd91c0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_fc94983d-0fbe-466f-bf21-4369f16eb727" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ab07550a-6881-43fb-a15b-eb40f7636ccf" xlink:to="loc_us-gaap_OperatingLeaseLiability_fc94983d-0fbe-466f-bf21-4369f16eb727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c35462d9-69ae-4d62-9660-1fd912e74360" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ab07550a-6881-43fb-a15b-eb40f7636ccf" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c35462d9-69ae-4d62-9660-1fd912e74360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_eb42ff86-b730-46b8-999e-06be58ea7a77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ab07550a-6881-43fb-a15b-eb40f7636ccf" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_eb42ff86-b730-46b8-999e-06be58ea7a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_c6290185-44f9-411c-88b0-8cb42c2edefe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ab07550a-6881-43fb-a15b-eb40f7636ccf" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_c6290185-44f9-411c-88b0-8cb42c2edefe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LeasesImputedInterestRate_726e862a-a22f-4cb2-b5f7-a740edbad88e" xlink:href="mrna-20210331.xsd#mrna_LeasesImputedInterestRate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ab07550a-6881-43fb-a15b-eb40f7636ccf" xlink:to="loc_mrna_LeasesImputedInterestRate_726e862a-a22f-4cb2-b5f7-a740edbad88e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LeasesIncrementalBorrowingRate_d7a9e307-06e7-4aaf-a2da-fa5c8d0552f7" xlink:href="mrna-20210331.xsd#mrna_LeasesIncrementalBorrowingRate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ab07550a-6881-43fb-a15b-eb40f7636ccf" xlink:to="loc_mrna_LeasesIncrementalBorrowingRate_d7a9e307-06e7-4aaf-a2da-fa5c8d0552f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#LeasesBalanceSheetInformationDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_dfaffa4e-2709-4b1a-8fb1-f7563e518d25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_2f1ac869-5145-49a3-9a41-daa55baa57a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dfaffa4e-2709-4b1a-8fb1-f7563e518d25" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_2f1ac869-5145-49a3-9a41-daa55baa57a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_ec439e84-9d13-400a-ac26-5b1fbd22d941" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dfaffa4e-2709-4b1a-8fb1-f7563e518d25" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_ec439e84-9d13-400a-ac26-5b1fbd22d941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseRightOfUseAsset_05558de3-4435-4831-b1bc-fefac52cc948" xlink:href="mrna-20210331.xsd#mrna_OperatingAndFinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dfaffa4e-2709-4b1a-8fb1-f7563e518d25" xlink:to="loc_mrna_OperatingAndFinanceLeaseRightOfUseAsset_05558de3-4435-4831-b1bc-fefac52cc948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_6f783fa6-b78b-4c76-8c0b-2a7e3ac73686" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dfaffa4e-2709-4b1a-8fb1-f7563e518d25" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_6f783fa6-b78b-4c76-8c0b-2a7e3ac73686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_04fc5a4a-f2c7-4ca3-bc3e-a89b090fdd57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dfaffa4e-2709-4b1a-8fb1-f7563e518d25" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_04fc5a4a-f2c7-4ca3-bc3e-a89b090fdd57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseLiabilityCurrent_036a054a-5366-44b8-b760-42aff87bdb7e" xlink:href="mrna-20210331.xsd#mrna_OperatingAndFinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dfaffa4e-2709-4b1a-8fb1-f7563e518d25" xlink:to="loc_mrna_OperatingAndFinanceLeaseLiabilityCurrent_036a054a-5366-44b8-b760-42aff87bdb7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_228edccf-460b-4a85-855d-0bb1b97b74ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dfaffa4e-2709-4b1a-8fb1-f7563e518d25" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_228edccf-460b-4a85-855d-0bb1b97b74ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_3cd5199b-7fe0-4f3d-8ef3-85fefffaa507" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dfaffa4e-2709-4b1a-8fb1-f7563e518d25" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_3cd5199b-7fe0-4f3d-8ef3-85fefffaa507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_ae1a7f34-26e4-48c8-87a5-858fedb5e7a1" xlink:href="mrna-20210331.xsd#mrna_OperatingAndFinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dfaffa4e-2709-4b1a-8fb1-f7563e518d25" xlink:to="loc_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_ae1a7f34-26e4-48c8-87a5-858fedb5e7a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseLiability_af5ff664-9d61-43ce-b274-756ac684867c" xlink:href="mrna-20210331.xsd#mrna_OperatingAndFinanceLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dfaffa4e-2709-4b1a-8fb1-f7563e518d25" xlink:to="loc_mrna_OperatingAndFinanceLeaseLiability_af5ff664-9d61-43ce-b274-756ac684867c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_e3b0e55f-d539-4966-8c10-e8a3f3cefd1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dfaffa4e-2709-4b1a-8fb1-f7563e518d25" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_e3b0e55f-d539-4966-8c10-e8a3f3cefd1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_b14328a1-e0fe-4e59-bba6-9ed76550f2b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dfaffa4e-2709-4b1a-8fb1-f7563e518d25" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_b14328a1-e0fe-4e59-bba6-9ed76550f2b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_3cd5b2f5-9e73-4553-9162-b5ca8463871a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dfaffa4e-2709-4b1a-8fb1-f7563e518d25" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_3cd5b2f5-9e73-4553-9162-b5ca8463871a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#LeasesMinimumLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_434990e8-2f35-46ce-be21-12c7d4936948" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3e40b29e-2be8-48f2-bcfb-91cfb0251ff4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_434990e8-2f35-46ce-be21-12c7d4936948" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3e40b29e-2be8-48f2-bcfb-91cfb0251ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_c8276755-0a6b-4118-a1bf-695d9c110355" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3e40b29e-2be8-48f2-bcfb-91cfb0251ff4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_c8276755-0a6b-4118-a1bf-695d9c110355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9b958ae0-e240-456f-be66-bba822db3c6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3e40b29e-2be8-48f2-bcfb-91cfb0251ff4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9b958ae0-e240-456f-be66-bba822db3c6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3d88de28-29de-4f4c-b6a4-450bf9ca8703" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3e40b29e-2be8-48f2-bcfb-91cfb0251ff4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3d88de28-29de-4f4c-b6a4-450bf9ca8703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3447c774-a3b0-450c-b929-ade4b5bb4a68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3e40b29e-2be8-48f2-bcfb-91cfb0251ff4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3447c774-a3b0-450c-b929-ade4b5bb4a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5cbc7495-c5a9-4b74-9984-b7aeba995550" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3e40b29e-2be8-48f2-bcfb-91cfb0251ff4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5cbc7495-c5a9-4b74-9984-b7aeba995550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_fbcb41ee-23c4-48a2-ab78-5bba73430a53" xlink:href="mrna-20210331.xsd#mrna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3e40b29e-2be8-48f2-bcfb-91cfb0251ff4" xlink:to="loc_mrna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_fbcb41ee-23c4-48a2-ab78-5bba73430a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b5bbee4f-f83a-444d-b98c-c79dcfc81a67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3e40b29e-2be8-48f2-bcfb-91cfb0251ff4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b5bbee4f-f83a-444d-b98c-c79dcfc81a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_9b7aad95-4b45-4018-a16a-23c16828c262" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3e40b29e-2be8-48f2-bcfb-91cfb0251ff4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_9b7aad95-4b45-4018-a16a-23c16828c262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_6af3f319-9de3-4813-92a5-47a1a79d2d09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3e40b29e-2be8-48f2-bcfb-91cfb0251ff4" xlink:to="loc_us-gaap_OperatingLeaseLiability_6af3f319-9de3-4813-92a5-47a1a79d2d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_f05a1adb-2cbd-47ba-9d5b-26db02eb20b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_434990e8-2f35-46ce-be21-12c7d4936948" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_f05a1adb-2cbd-47ba-9d5b-26db02eb20b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_3b9d015d-4c66-40a6-9299-acde6c7b2504" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_f05a1adb-2cbd-47ba-9d5b-26db02eb20b1" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_3b9d015d-4c66-40a6-9299-acde6c7b2504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_99c44ad8-9635-442a-aa3d-cd0001086b64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_f05a1adb-2cbd-47ba-9d5b-26db02eb20b1" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_99c44ad8-9635-442a-aa3d-cd0001086b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_8e662224-426e-4f15-b0fc-0597ee86898c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_f05a1adb-2cbd-47ba-9d5b-26db02eb20b1" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_8e662224-426e-4f15-b0fc-0597ee86898c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_d75c10ea-ede3-4e16-9dd7-bbda9ac4f91e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_f05a1adb-2cbd-47ba-9d5b-26db02eb20b1" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_d75c10ea-ede3-4e16-9dd7-bbda9ac4f91e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_cc44ffb0-b3d7-48eb-8242-be39983f1824" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_f05a1adb-2cbd-47ba-9d5b-26db02eb20b1" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_cc44ffb0-b3d7-48eb-8242-be39983f1824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_FinanceLeaseLiabilityToBePaidAfterYearFour_6cb1919b-0026-43f0-b930-286aaf0d37be" xlink:href="mrna-20210331.xsd#mrna_FinanceLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_f05a1adb-2cbd-47ba-9d5b-26db02eb20b1" xlink:to="loc_mrna_FinanceLeaseLiabilityToBePaidAfterYearFour_6cb1919b-0026-43f0-b930-286aaf0d37be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_729e0c0a-59df-4d2b-b609-6748edb58e85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_f05a1adb-2cbd-47ba-9d5b-26db02eb20b1" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_729e0c0a-59df-4d2b-b609-6748edb58e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_8cf3b9ec-4018-4121-ac78-46165067ff83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_f05a1adb-2cbd-47ba-9d5b-26db02eb20b1" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_8cf3b9ec-4018-4121-ac78-46165067ff83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_248903ea-1ef4-4709-9235-f2eba4242637" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_f05a1adb-2cbd-47ba-9d5b-26db02eb20b1" xlink:to="loc_us-gaap_FinanceLeaseLiability_248903ea-1ef4-4709-9235-f2eba4242637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="mrna-20210331.xsd#LeasesMinimumLeasePaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="mrna-20210331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_75807a7e-c552-446d-a8b4-d01f71a5555e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3d346777-c558-4368-8ab2-52434047bde8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_75807a7e-c552-446d-a8b4-d01f71a5555e" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3d346777-c558-4368-8ab2-52434047bde8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CommitmentsandContingenciesStrategicCollaborationsDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#CommitmentsandContingenciesStrategicCollaborationsDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CommitmentsandContingenciesStrategicCollaborationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a11b01ca-7ef9-46de-8000-eed678687961" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_685b9059-e65b-453b-947d-5881da690674" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a11b01ca-7ef9-46de-8000-eed678687961" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_685b9059-e65b-453b-947d-5881da690674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_219747d3-1ff0-4e1a-8745-5395752cf929" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_685b9059-e65b-453b-947d-5881da690674" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_219747d3-1ff0-4e1a-8745-5395752cf929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0240b984-c33b-4cc5-8601-bce7edebda90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_219747d3-1ff0-4e1a-8745-5395752cf929" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0240b984-c33b-4cc5-8601-bce7edebda90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember_6a3a79e8-ef24-429c-a27d-5cd9f60c9680" xlink:href="mrna-20210331.xsd#mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0240b984-c33b-4cc5-8601-bce7edebda90" xlink:to="loc_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember_6a3a79e8-ef24-429c-a27d-5cd9f60c9680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_350faf17-6741-489b-ae04-7ed3a5e273c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_685b9059-e65b-453b-947d-5881da690674" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_350faf17-6741-489b-ae04-7ed3a5e273c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_76d34da9-bb52-4a5b-bcab-58445cb6a176" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_350faf17-6741-489b-ae04-7ed3a5e273c5" xlink:to="loc_us-gaap_ProjectMember_76d34da9-bb52-4a5b-bcab-58445cb6a176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_PersonalizedMRNACancerVaccinesProductsMember_c151c358-11e0-4441-bd31-421a758ea174" xlink:href="mrna-20210331.xsd#mrna_PersonalizedMRNACancerVaccinesProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_76d34da9-bb52-4a5b-bcab-58445cb6a176" xlink:to="loc_mrna_PersonalizedMRNACancerVaccinesProductsMember_c151c358-11e0-4441-bd31-421a758ea174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_66550c1d-5fbf-48f6-80f4-b8fd6f015d33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_685b9059-e65b-453b-947d-5881da690674" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_66550c1d-5fbf-48f6-80f4-b8fd6f015d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount_8137ddfd-3397-43a1-b1e6-4266566de206" xlink:href="mrna-20210331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_66550c1d-5fbf-48f6-80f4-b8fd6f015d33" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount_8137ddfd-3397-43a1-b1e6-4266566de206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b8a07e8d-1c21-45f6-8bdd-bda8e8aec0bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_32361a0e-bf3d-4361-9148-5402d754c46a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b8a07e8d-1c21-45f6-8bdd-bda8e8aec0bd" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_32361a0e-bf3d-4361-9148-5402d754c46a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_a6e8037a-5a85-4de1-bbe7-c3f164d18213" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_32361a0e-bf3d-4361-9148-5402d754c46a" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_a6e8037a-5a85-4de1-bbe7-c3f164d18213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_9e7a3f70-01e9-44e6-ae43-8a1af7f3f52c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_a6e8037a-5a85-4de1-bbe7-c3f164d18213" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_9e7a3f70-01e9-44e6-ae43-8a1af7f3f52c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_SupplyAndManufacturingAgreementsMember_d405c047-9466-4901-8def-bf79f54a1895" xlink:href="mrna-20210331.xsd#mrna_SupplyAndManufacturingAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_9e7a3f70-01e9-44e6-ae43-8a1af7f3f52c" xlink:to="loc_mrna_SupplyAndManufacturingAgreementsMember_d405c047-9466-4901-8def-bf79f54a1895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ClinicalOperationsAndSupportCommitmentMember_a3a20ec8-93bf-48cc-8559-3b1b58d1f81a" xlink:href="mrna-20210331.xsd#mrna_ClinicalOperationsAndSupportCommitmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_9e7a3f70-01e9-44e6-ae43-8a1af7f3f52c" xlink:to="loc_mrna_ClinicalOperationsAndSupportCommitmentMember_a3a20ec8-93bf-48cc-8559-3b1b58d1f81a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ClinicalServicesMember_6bbd6d1f-aae9-4792-8a4f-4148913b1e1c" xlink:href="mrna-20210331.xsd#mrna_ClinicalServicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_9e7a3f70-01e9-44e6-ae43-8a1af7f3f52c" xlink:to="loc_mrna_ClinicalServicesMember_6bbd6d1f-aae9-4792-8a4f-4148913b1e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_30269f93-6965-451e-98aa-34e21a1c186c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_32361a0e-bf3d-4361-9148-5402d754c46a" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_30269f93-6965-451e-98aa-34e21a1c186c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_40b683ba-dc1c-4850-8760-79504829385d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_30269f93-6965-451e-98aa-34e21a1c186c" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_40b683ba-dc1c-4850-8760-79504829385d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#CommitmentsandContingenciesLicensestoPatentedTechnologyDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ba31da57-1685-4fbf-a03d-f7c7e1c56975" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_222fc1e1-db90-4778-a474-e9ab70a076a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ba31da57-1685-4fbf-a03d-f7c7e1c56975" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_222fc1e1-db90-4778-a474-e9ab70a076a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_4795e2a1-e82f-46cb-9612-4e42224773a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_222fc1e1-db90-4778-a474-e9ab70a076a2" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_4795e2a1-e82f-46cb-9612-4e42224773a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_a339b82f-bac7-45e3-b12a-e0cb9d813871" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_4795e2a1-e82f-46cb-9612-4e42224773a0" xlink:to="loc_us-gaap_ProjectMember_a339b82f-bac7-45e3-b12a-e0cb9d813871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_TherapeuticAndProphylacticProductsMember_af20fcdd-d848-458f-93cc-c1949cd9cf7f" xlink:href="mrna-20210331.xsd#mrna_TherapeuticAndProphylacticProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_a339b82f-bac7-45e3-b12a-e0cb9d813871" xlink:to="loc_mrna_TherapeuticAndProphylacticProductsMember_af20fcdd-d848-458f-93cc-c1949cd9cf7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DiagnosticProductsMember_c86709d0-018e-4597-be32-2e9e42da4580" xlink:href="mrna-20210331.xsd#mrna_DiagnosticProductsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_a339b82f-bac7-45e3-b12a-e0cb9d813871" xlink:to="loc_mrna_DiagnosticProductsMember_c86709d0-018e-4597-be32-2e9e42da4580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_c0cd3928-c71c-49c5-98ca-459ec56ba0ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_222fc1e1-db90-4778-a474-e9ab70a076a2" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_c0cd3928-c71c-49c5-98ca-459ec56ba0ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentAndRegulatoryMilestonesMaximumAmount_e1d9d854-a8a1-48a1-882b-be8c4a06573b" xlink:href="mrna-20210331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentAndRegulatoryMilestonesMaximumAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_c0cd3928-c71c-49c5-98ca-459ec56ba0ff" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentAndRegulatoryMilestonesMaximumAmount_e1d9d854-a8a1-48a1-882b-be8c4a06573b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount_18850aed-c5f0-4ad0-83dc-2697f8ee9abe" xlink:href="mrna-20210331.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_c0cd3928-c71c-49c5-98ca-459ec56ba0ff" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount_18850aed-c5f0-4ad0-83dc-2697f8ee9abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_6f8ec403-3296-4faa-a8c4-6737a639e735" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_c0cd3928-c71c-49c5-98ca-459ec56ba0ff" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_6f8ec403-3296-4faa-a8c4-6737a639e735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="mrna-20210331.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0f8f32f3-9bfc-441d-b0d8-3089bf2fb74f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1ed4b6e3-d49a-41aa-aaf6-a834098f1dcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0f8f32f3-9bfc-441d-b0d8-3089bf2fb74f" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1ed4b6e3-d49a-41aa-aaf6-a834098f1dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="mrna-20210331.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1f80674d-7502-4245-a994-ff9e4caa8d3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_3cf0f484-34fa-4758-8ea5-64d62cd4cf44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1f80674d-7502-4245-a994-ff9e4caa8d3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_3cf0f484-34fa-4758-8ea5-64d62cd4cf44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_3019a291-a9e2-49d7-bf28-7f59d532fa71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1f80674d-7502-4245-a994-ff9e4caa8d3f" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_3019a291-a9e2-49d7-bf28-7f59d532fa71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_d56b596f-b536-4a46-896c-d86515c0eeb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1f80674d-7502-4245-a994-ff9e4caa8d3f" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_d56b596f-b536-4a46-896c-d86515c0eeb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_036da3be-2a39-4202-a0b7-1062bfa976be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8eaf16a7-4cb5-4bfe-accb-9553255bd00d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_036da3be-2a39-4202-a0b7-1062bfa976be" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8eaf16a7-4cb5-4bfe-accb-9553255bd00d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_6a6b1d42-bacf-4af4-afac-e6fdefdeac43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8eaf16a7-4cb5-4bfe-accb-9553255bd00d" xlink:to="loc_us-gaap_PlanNameAxis_6a6b1d42-bacf-4af4-afac-e6fdefdeac43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d4252bca-8de7-445f-84d0-124e8540c971" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_6a6b1d42-bacf-4af4-afac-e6fdefdeac43" xlink:to="loc_us-gaap_PlanNameDomain_d4252bca-8de7-445f-84d0-124e8540c971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_StockOptionAndIncentivePlan2018Member_1ef6b4c3-e8c7-4951-9277-aa11a1450f42" xlink:href="mrna-20210331.xsd#mrna_StockOptionAndIncentivePlan2018Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d4252bca-8de7-445f-84d0-124e8540c971" xlink:to="loc_mrna_StockOptionAndIncentivePlan2018Member_1ef6b4c3-e8c7-4951-9277-aa11a1450f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f2f49d57-e7d4-481a-bacd-52f44e3de413" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8eaf16a7-4cb5-4bfe-accb-9553255bd00d" xlink:to="loc_us-gaap_AwardTypeAxis_f2f49d57-e7d4-481a-bacd-52f44e3de413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac29034d-b0ac-48bd-aee8-a6dc726ec97c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f2f49d57-e7d4-481a-bacd-52f44e3de413" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac29034d-b0ac-48bd-aee8-a6dc726ec97c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_264fb874-7c88-4c2e-ad58-fd522c75cd49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac29034d-b0ac-48bd-aee8-a6dc726ec97c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_264fb874-7c88-4c2e-ad58-fd522c75cd49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_d37c7bdd-93f2-4a6e-b72c-873295603dca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac29034d-b0ac-48bd-aee8-a6dc726ec97c" xlink:to="loc_us-gaap_EmployeeStockMember_d37c7bdd-93f2-4a6e-b72c-873295603dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_856a4b8b-4a87-4a5e-86b5-49b672ef4ae0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac29034d-b0ac-48bd-aee8-a6dc726ec97c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_856a4b8b-4a87-4a5e-86b5-49b672ef4ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_afc2ee11-d896-43a2-9abf-be83fcf77494" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac29034d-b0ac-48bd-aee8-a6dc726ec97c" xlink:to="loc_us-gaap_PerformanceSharesMember_afc2ee11-d896-43a2-9abf-be83fcf77494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f29893af-cdef-4731-8e98-21b58ce5410f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8eaf16a7-4cb5-4bfe-accb-9553255bd00d" xlink:to="loc_srt_RangeAxis_f29893af-cdef-4731-8e98-21b58ce5410f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f7dcf83c-0264-4b99-877d-329242402e17" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f29893af-cdef-4731-8e98-21b58ce5410f" xlink:to="loc_srt_RangeMember_f7dcf83c-0264-4b99-877d-329242402e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_88374bf5-ed23-4cf3-9457-57d760ff3e0a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f7dcf83c-0264-4b99-877d-329242402e17" xlink:to="loc_srt_MinimumMember_88374bf5-ed23-4cf3-9457-57d760ff3e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1088fe4c-aaa0-41ce-9265-da19bb0fbee2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f7dcf83c-0264-4b99-877d-329242402e17" xlink:to="loc_srt_MaximumMember_1088fe4c-aaa0-41ce-9265-da19bb0fbee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0ac1c1f-20bd-4e6f-8eac-69cf1b53f148" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8eaf16a7-4cb5-4bfe-accb-9553255bd00d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0ac1c1f-20bd-4e6f-8eac-69cf1b53f148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5d795ea1-dace-48b1-9033-21620adccbc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0ac1c1f-20bd-4e6f-8eac-69cf1b53f148" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5d795ea1-dace-48b1-9033-21620adccbc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d83fc008-aa35-4457-b347-f6d30f3010e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0ac1c1f-20bd-4e6f-8eac-69cf1b53f148" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d83fc008-aa35-4457-b347-f6d30f3010e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_43698867-4d0a-4af9-bde7-d48ea9212d88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0ac1c1f-20bd-4e6f-8eac-69cf1b53f148" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_43698867-4d0a-4af9-bde7-d48ea9212d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_7d0df77c-bce8-4d2e-98eb-1624795e94e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0ac1c1f-20bd-4e6f-8eac-69cf1b53f148" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_7d0df77c-bce8-4d2e-98eb-1624795e94e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f7b52be6-6373-48ef-a23b-49187b968ec6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0ac1c1f-20bd-4e6f-8eac-69cf1b53f148" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f7b52be6-6373-48ef-a23b-49187b968ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockExpense_1fbbf273-d920-4b34-b296-c564102c045b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0ac1c1f-20bd-4e6f-8eac-69cf1b53f148" xlink:to="loc_us-gaap_RestrictedStockExpense_1fbbf273-d920-4b34-b296-c564102c045b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_40bcfcea-e4d0-4133-b62b-72dad8ab056e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0ac1c1f-20bd-4e6f-8eac-69cf1b53f148" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_40bcfcea-e4d0-4133-b62b-72dad8ab056e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_42ba1ea0-167e-4bbb-b494-06ab641ab93a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0ac1c1f-20bd-4e6f-8eac-69cf1b53f148" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_42ba1ea0-167e-4bbb-b494-06ab641ab93a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage_e0e5bf40-2ebf-4119-83f3-d88178c67c27" xlink:href="mrna-20210331.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0ac1c1f-20bd-4e6f-8eac-69cf1b53f148" xlink:to="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage_e0e5bf40-2ebf-4119-83f3-d88178c67c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_3bc60a03-3637-44cb-94ee-210698859922" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0ac1c1f-20bd-4e6f-8eac-69cf1b53f148" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_3bc60a03-3637-44cb-94ee-210698859922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ca3e1a66-41fa-4b93-971c-c21a1115d2c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0ac1c1f-20bd-4e6f-8eac-69cf1b53f148" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ca3e1a66-41fa-4b93-971c-c21a1115d2c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_102aa7ba-bf5d-42f5-931a-dbd078db334e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0ac1c1f-20bd-4e6f-8eac-69cf1b53f148" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_102aa7ba-bf5d-42f5-931a-dbd078db334e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_93dbcec2-6ad4-4aa4-b63f-d745330b8572" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0ac1c1f-20bd-4e6f-8eac-69cf1b53f148" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_93dbcec2-6ad4-4aa4-b63f-d745330b8572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#StockBasedCompensationOptionsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c3897804-7469-419f-9de3-d049e04f1e63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ca750467-003f-4448-8e30-f2b6c83c1794" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c3897804-7469-419f-9de3-d049e04f1e63" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ca750467-003f-4448-8e30-f2b6c83c1794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e8be2b26-a271-4423-9556-161ee2d25d33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ca750467-003f-4448-8e30-f2b6c83c1794" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e8be2b26-a271-4423-9556-161ee2d25d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a2220789-c31b-4255-9adf-c47a1f7d545b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ca750467-003f-4448-8e30-f2b6c83c1794" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a2220789-c31b-4255-9adf-c47a1f7d545b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f49d9c71-077f-4c9d-9064-d891dfa588c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ca750467-003f-4448-8e30-f2b6c83c1794" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f49d9c71-077f-4c9d-9064-d891dfa588c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_ae2c8f9e-4de9-468a-a273-acae745429b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ca750467-003f-4448-8e30-f2b6c83c1794" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_ae2c8f9e-4de9-468a-a273-acae745429b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_21a4a8ad-d008-4944-a390-401e855c0ad9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ca750467-003f-4448-8e30-f2b6c83c1794" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_21a4a8ad-d008-4944-a390-401e855c0ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f93df5a3-612a-4281-ae5f-54fa0fd1ff6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c3897804-7469-419f-9de3-d049e04f1e63" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f93df5a3-612a-4281-ae5f-54fa0fd1ff6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b81d4466-9d87-48aa-9a1d-d39a28f303d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f93df5a3-612a-4281-ae5f-54fa0fd1ff6c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b81d4466-9d87-48aa-9a1d-d39a28f303d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5b7dfba9-75d3-465e-9940-f8b5a1af5320" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f93df5a3-612a-4281-ae5f-54fa0fd1ff6c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5b7dfba9-75d3-465e-9940-f8b5a1af5320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_a21dcc08-877c-40ad-bbb7-050f0d829110" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f93df5a3-612a-4281-ae5f-54fa0fd1ff6c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_a21dcc08-877c-40ad-bbb7-050f0d829110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2a5a83e6-9e40-4433-a7e7-d4cbc0fa58d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f93df5a3-612a-4281-ae5f-54fa0fd1ff6c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2a5a83e6-9e40-4433-a7e7-d4cbc0fa58d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_dbc793e1-dada-48f0-a1bd-4f0f99357f2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f93df5a3-612a-4281-ae5f-54fa0fd1ff6c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_dbc793e1-dada-48f0-a1bd-4f0f99357f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward_22098074-570c-48e2-9b2a-3a281497a73e" xlink:href="mrna-20210331.xsd#mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c3897804-7469-419f-9de3-d049e04f1e63" xlink:to="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward_22098074-570c-48e2-9b2a-3a281497a73e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_e25a18d9-1af0-420e-b4a3-0466c128c677" xlink:href="mrna-20210331.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward_22098074-570c-48e2-9b2a-3a281497a73e" xlink:to="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_e25a18d9-1af0-420e-b4a3-0466c128c677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1c2f74f8-60e2-418e-9b00-ede7aa64ac85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward_22098074-570c-48e2-9b2a-3a281497a73e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1c2f74f8-60e2-418e-9b00-ede7aa64ac85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_c1f22536-57cf-4300-a54b-2763136f9905" xlink:href="mrna-20210331.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward_22098074-570c-48e2-9b2a-3a281497a73e" xlink:to="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_c1f22536-57cf-4300-a54b-2763136f9905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue_e3a15235-bb2b-4fc9-96a2-2ecc0224b7d7" xlink:href="mrna-20210331.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward_22098074-570c-48e2-9b2a-3a281497a73e" xlink:to="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue_e3a15235-bb2b-4fc9-96a2-2ecc0224b7d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_a55a577d-346e-4a48-bb07-e1e9b7000e2f" xlink:href="mrna-20210331.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward_22098074-570c-48e2-9b2a-3a281497a73e" xlink:to="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_a55a577d-346e-4a48-bb07-e1e9b7000e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_84394780-9207-4e2f-beac-4a34ce14b81e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c3897804-7469-419f-9de3-d049e04f1e63" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_84394780-9207-4e2f-beac-4a34ce14b81e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6bcb1812-9674-4a1a-8f3f-9d4d49169c24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_84394780-9207-4e2f-beac-4a34ce14b81e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6bcb1812-9674-4a1a-8f3f-9d4d49169c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_4de38015-51d3-4fc4-a3e2-f9589a7fcbd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_84394780-9207-4e2f-beac-4a34ce14b81e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_4de38015-51d3-4fc4-a3e2-f9589a7fcbd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_75f35184-fb25-4310-9b95-5339d130c0c3" xlink:href="mrna-20210331.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_84394780-9207-4e2f-beac-4a34ce14b81e" xlink:to="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_75f35184-fb25-4310-9b95-5339d130c0c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_cfc83863-a588-4fb9-80c9-d4c9d2ad3815" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_84394780-9207-4e2f-beac-4a34ce14b81e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_cfc83863-a588-4fb9-80c9-d4c9d2ad3815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0e222860-7659-483e-b844-7b1cf4deae9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_84394780-9207-4e2f-beac-4a34ce14b81e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0e222860-7659-483e-b844-7b1cf4deae9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c8ac3968-1667-4d1e-911a-baded2d312b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_84394780-9207-4e2f-beac-4a34ce14b81e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c8ac3968-1667-4d1e-911a-baded2d312b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_95e97673-d7ec-483a-94fb-e73e3493748e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_84394780-9207-4e2f-beac-4a34ce14b81e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_95e97673-d7ec-483a-94fb-e73e3493748e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_a09ce476-78af-46f8-b43b-6216d7a3f2ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c3897804-7469-419f-9de3-d049e04f1e63" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_a09ce476-78af-46f8-b43b-6216d7a3f2ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_fd3ea457-5e88-43e4-8769-107eb1e20d5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_a09ce476-78af-46f8-b43b-6216d7a3f2ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_fd3ea457-5e88-43e4-8769-107eb1e20d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_05b1fb8e-0874-4a28-998d-fa70957810e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_a09ce476-78af-46f8-b43b-6216d7a3f2ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_05b1fb8e-0874-4a28-998d-fa70957810e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue_fceec275-ff53-4a2d-888d-15f7f60b2edd" xlink:href="mrna-20210331.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_a09ce476-78af-46f8-b43b-6216d7a3f2ae" xlink:to="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue_fceec275-ff53-4a2d-888d-15f7f60b2edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_43e5533f-1cd9-4b56-ab41-6a18e43a3f0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_a09ce476-78af-46f8-b43b-6216d7a3f2ae" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_43e5533f-1cd9-4b56-ab41-6a18e43a3f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_d646659d-2273-4454-9f8c-c3dc3f39bf0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_a09ce476-78af-46f8-b43b-6216d7a3f2ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_d646659d-2273-4454-9f8c-c3dc3f39bf0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_05f9be58-2778-423a-8df2-a87c1bd631ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c9e0b84f-29ae-4494-bec8-66136e962c93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_05f9be58-2778-423a-8df2-a87c1bd631ec" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c9e0b84f-29ae-4494-bec8-66136e962c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7bc95097-e1fe-4867-9856-8b744abcae94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c9e0b84f-29ae-4494-bec8-66136e962c93" xlink:to="loc_us-gaap_AwardTypeAxis_7bc95097-e1fe-4867-9856-8b744abcae94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66fa8354-3da1-413d-9c60-77a87c4c5231" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7bc95097-e1fe-4867-9856-8b744abcae94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66fa8354-3da1-413d-9c60-77a87c4c5231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_90d912ac-85b5-419f-b2ba-d9ff8100cc02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66fa8354-3da1-413d-9c60-77a87c4c5231" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_90d912ac-85b5-419f-b2ba-d9ff8100cc02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d900abd-5b4a-4e8e-a48e-4025eb5badb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c9e0b84f-29ae-4494-bec8-66136e962c93" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d900abd-5b4a-4e8e-a48e-4025eb5badb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f11a4ee2-882a-41f4-8d0e-a91ab52e10c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d900abd-5b4a-4e8e-a48e-4025eb5badb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f11a4ee2-882a-41f4-8d0e-a91ab52e10c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7bcfb38e-9474-4378-84d3-00a86c776980" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f11a4ee2-882a-41f4-8d0e-a91ab52e10c1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7bcfb38e-9474-4378-84d3-00a86c776980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9d55955a-8f70-4414-887a-74a6378b5f6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f11a4ee2-882a-41f4-8d0e-a91ab52e10c1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9d55955a-8f70-4414-887a-74a6378b5f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2ce19260-3ae7-415f-83c2-773e79a66108" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f11a4ee2-882a-41f4-8d0e-a91ab52e10c1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2ce19260-3ae7-415f-83c2-773e79a66108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_73147641-7e62-4967-87ff-7c5505a5ddc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f11a4ee2-882a-41f4-8d0e-a91ab52e10c1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_73147641-7e62-4967-87ff-7c5505a5ddc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9b86f0ee-a2b0-4978-9ec8-556ec3f34945" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f11a4ee2-882a-41f4-8d0e-a91ab52e10c1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9b86f0ee-a2b0-4978-9ec8-556ec3f34945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6f1d1762-e909-4d63-a4f6-011422a2017b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d900abd-5b4a-4e8e-a48e-4025eb5badb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6f1d1762-e909-4d63-a4f6-011422a2017b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_928dc05b-4189-49d1-9264-d29ac3bd5c13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6f1d1762-e909-4d63-a4f6-011422a2017b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_928dc05b-4189-49d1-9264-d29ac3bd5c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_180b8333-798d-4aa6-8619-fedca7a6a2c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6f1d1762-e909-4d63-a4f6-011422a2017b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_180b8333-798d-4aa6-8619-fedca7a6a2c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0698dc84-c183-42c1-adb2-58756822d365" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6f1d1762-e909-4d63-a4f6-011422a2017b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0698dc84-c183-42c1-adb2-58756822d365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_46a8c75f-482a-46bf-91f0-01e3634db06f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6f1d1762-e909-4d63-a4f6-011422a2017b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_46a8c75f-482a-46bf-91f0-01e3634db06f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_91650c0b-2263-4c06-bc3d-5dae49d3bf99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6f1d1762-e909-4d63-a4f6-011422a2017b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_91650c0b-2263-4c06-bc3d-5dae49d3bf99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_711402be-7f3b-4b44-9efc-5ef59840cfa7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4d83f6d5-00d4-4f95-b3c6-0544554143d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_711402be-7f3b-4b44-9efc-5ef59840cfa7" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4d83f6d5-00d4-4f95-b3c6-0544554143d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_88e6e944-fd14-457e-83f3-c10acc669a6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4d83f6d5-00d4-4f95-b3c6-0544554143d2" xlink:to="loc_us-gaap_AwardTypeAxis_88e6e944-fd14-457e-83f3-c10acc669a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0df19c3b-ed04-4eb6-b496-3d000f1a8adf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_88e6e944-fd14-457e-83f3-c10acc669a6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0df19c3b-ed04-4eb6-b496-3d000f1a8adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7a840fdb-e181-49c6-8809-8e03f5565e12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0df19c3b-ed04-4eb6-b496-3d000f1a8adf" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7a840fdb-e181-49c6-8809-8e03f5565e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RestrictedStockAndRestrictedStockUnitsRSUMember_fbf2949e-f40d-483d-86db-43ab7f90d16f" xlink:href="mrna-20210331.xsd#mrna_RestrictedStockAndRestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0df19c3b-ed04-4eb6-b496-3d000f1a8adf" xlink:to="loc_mrna_RestrictedStockAndRestrictedStockUnitsRSUMember_fbf2949e-f40d-483d-86db-43ab7f90d16f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_7f7c7bf6-24ad-4e2d-b0ce-15491deb3b3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0df19c3b-ed04-4eb6-b496-3d000f1a8adf" xlink:to="loc_us-gaap_EmployeeStockMember_7f7c7bf6-24ad-4e2d-b0ce-15491deb3b3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_b1ee03b3-bd51-481a-8872-7f34f62f54bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4d83f6d5-00d4-4f95-b3c6-0544554143d2" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_b1ee03b3-bd51-481a-8872-7f34f62f54bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_77ea7f0d-cb4b-413e-a237-416d73e33ff1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b1ee03b3-bd51-481a-8872-7f34f62f54bd" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_77ea7f0d-cb4b-413e-a237-416d73e33ff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_31630095-5d24-4b4d-8284-2adf870ab830" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_77ea7f0d-cb4b-413e-a237-416d73e33ff1" xlink:to="loc_us-gaap_CostOfSalesMember_31630095-5d24-4b4d-8284-2adf870ab830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_18e2134a-f973-4256-b0fe-d8c7dd589a20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_77ea7f0d-cb4b-413e-a237-416d73e33ff1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_18e2134a-f973-4256-b0fe-d8c7dd589a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_5a291b0d-5a50-4e4b-9d78-a9c215cb5a0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_77ea7f0d-cb4b-413e-a237-416d73e33ff1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_5a291b0d-5a50-4e4b-9d78-a9c215cb5a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f00eee61-7c7c-4bbc-9961-30678772d7b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4d83f6d5-00d4-4f95-b3c6-0544554143d2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f00eee61-7c7c-4bbc-9961-30678772d7b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_40fabb59-878c-4f3e-8758-aa2fa9c4cae5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f00eee61-7c7c-4bbc-9961-30678772d7b0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_40fabb59-878c-4f3e-8758-aa2fa9c4cae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/IncomeTaxes" xlink:type="simple" xlink:href="mrna-20210331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4ea173bb-cb69-4423-9387-8c30bba42fa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_9aeafeb4-5def-4835-9048-b5efaee585bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4ea173bb-cb69-4423-9387-8c30bba42fa3" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_9aeafeb4-5def-4835-9048-b5efaee585bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c26c252d-bdcf-4550-9dff-a264dd26df87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_95446f11-934d-4b46-994e-097e7b76a1d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c26c252d-bdcf-4550-9dff-a264dd26df87" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_95446f11-934d-4b46-994e-097e7b76a1d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_48d04203-1857-4b8c-bff6-21e081eae261" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c26c252d-bdcf-4550-9dff-a264dd26df87" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_48d04203-1857-4b8c-bff6-21e081eae261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/EarningsperShare" xlink:type="simple" xlink:href="mrna-20210331.xsd#EarningsperShare"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/EarningsperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2aed30b6-b8cf-494b-98a4-b82a61c588e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_012b3768-dcb7-4efc-8efc-543ed3a87bc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2aed30b6-b8cf-494b-98a4-b82a61c588e9" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_012b3768-dcb7-4efc-8efc-543ed3a87bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/EarningsperShareTables" xlink:type="simple" xlink:href="mrna-20210331.xsd#EarningsperShareTables"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/EarningsperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a6cccebe-a2c4-4d50-8c7e-8a9001b39ae1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_f173783f-16d5-4636-ad03-4ca253355c52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a6cccebe-a2c4-4d50-8c7e-8a9001b39ae1" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_f173783f-16d5-4636-ad03-4ca253355c52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_a0a7224c-309e-41a6-acfa-61c97a5500b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a6cccebe-a2c4-4d50-8c7e-8a9001b39ae1" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_a0a7224c-309e-41a6-acfa-61c97a5500b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/EarningsperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#EarningsperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/EarningsperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b7f430da-5813-4b93-8d71-a78f3bd0d2f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_e44a2eba-3b4b-42f0-9455-8085caf07e17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b7f430da-5813-4b93-8d71-a78f3bd0d2f7" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_e44a2eba-3b4b-42f0-9455-8085caf07e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8d4514fe-0e77-4966-adbf-041c71193619" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_e44a2eba-3b4b-42f0-9455-8085caf07e17" xlink:to="loc_us-gaap_NetIncomeLoss_8d4514fe-0e77-4966-adbf-041c71193619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_716883fd-44d5-4c8d-841e-87abb7b4e19b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b7f430da-5813-4b93-8d71-a78f3bd0d2f7" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_716883fd-44d5-4c8d-841e-87abb7b4e19b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d4e674bc-b4ca-40ee-a401-50e804042c97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_716883fd-44d5-4c8d-841e-87abb7b4e19b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d4e674bc-b4ca-40ee-a401-50e804042c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_3695571b-9460-47ad-8265-d84c7a92c317" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_716883fd-44d5-4c8d-841e-87abb7b4e19b" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_3695571b-9460-47ad-8265-d84c7a92c317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9fc84664-eaef-4c8f-b9ad-ed8bf888444e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_716883fd-44d5-4c8d-841e-87abb7b4e19b" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9fc84664-eaef-4c8f-b9ad-ed8bf888444e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_f57586cc-f309-40ae-90ed-64cd37391f5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b7f430da-5813-4b93-8d71-a78f3bd0d2f7" xlink:to="loc_us-gaap_EarningsPerShareBasic_f57586cc-f309-40ae-90ed-64cd37391f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_075dbfd2-a550-4ff8-99b9-5022b1f23501" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b7f430da-5813-4b93-8d71-a78f3bd0d2f7" xlink:to="loc_us-gaap_EarningsPerShareDiluted_075dbfd2-a550-4ff8-99b9-5022b1f23501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/EarningsperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#EarningsperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/EarningsperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_fad22140-728f-476f-8fbe-8c69f045fd18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e9e48f09-d6d9-4762-b62f-0d53598c414b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fad22140-728f-476f-8fbe-8c69f045fd18" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e9e48f09-d6d9-4762-b62f-0d53598c414b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1788a6a7-1e2c-4464-adfb-624e3fcd313f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e9e48f09-d6d9-4762-b62f-0d53598c414b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1788a6a7-1e2c-4464-adfb-624e3fcd313f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b845727a-325f-4435-9d89-0f6ca80bba50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1788a6a7-1e2c-4464-adfb-624e3fcd313f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b845727a-325f-4435-9d89-0f6ca80bba50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_81df6646-4726-49fa-9441-737dceff2697" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b845727a-325f-4435-9d89-0f6ca80bba50" xlink:to="loc_us-gaap_EmployeeStockOptionMember_81df6646-4726-49fa-9441-737dceff2697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f3d2968f-fa2f-42d7-81f3-8f103ef0e0ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b845727a-325f-4435-9d89-0f6ca80bba50" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f3d2968f-fa2f-42d7-81f3-8f103ef0e0ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d3c4a3d6-6a87-444c-9524-95dc76856a65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e9e48f09-d6d9-4762-b62f-0d53598c414b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d3c4a3d6-6a87-444c-9524-95dc76856a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2691a2e0-26c0-4f70-9953-32cc8bf4eebc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d3c4a3d6-6a87-444c-9524-95dc76856a65" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2691a2e0-26c0-4f70-9953-32cc8bf4eebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/SubsequentEvents" xlink:type="simple" xlink:href="mrna-20210331.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_6de181bf-5a5e-4f9b-8aa5-a0939eadff2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_ddf7eaad-47ea-4973-8c87-453e2e4d9c72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_6de181bf-5a5e-4f9b-8aa5-a0939eadff2a" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_ddf7eaad-47ea-4973-8c87-453e2e4d9c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="mrna-20210331.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_b9341f80-abe5-4d87-9898-44c89b0857ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_14ebdb0f-6b77-4519-98ca-056658411d25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_b9341f80-abe5-4d87-9898-44c89b0857ce" xlink:to="loc_us-gaap_SubsequentEventTable_14ebdb0f-6b77-4519-98ca-056658411d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_7199261e-8f83-48f1-a87c-8f87ed2c459f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_14ebdb0f-6b77-4519-98ca-056658411d25" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_7199261e-8f83-48f1-a87c-8f87ed2c459f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4f774dc5-754e-4534-945a-5ca980e90cd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7199261e-8f83-48f1-a87c-8f87ed2c459f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4f774dc5-754e-4534-945a-5ca980e90cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_d9c6051e-7720-448f-933a-5d1f74221cd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_4f774dc5-754e-4534-945a-5ca980e90cd8" xlink:to="loc_us-gaap_SubsequentEventMember_d9c6051e-7720-448f-933a-5d1f74221cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_74491c7d-8658-4f6d-b746-3fb670b4a7ce" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_14ebdb0f-6b77-4519-98ca-056658411d25" xlink:to="loc_srt_MajorCustomersAxis_74491c7d-8658-4f6d-b746-3fb670b4a7ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_59ee08da-64e7-45ea-b18d-fc9c342692e7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_74491c7d-8658-4f6d-b746-3fb670b4a7ce" xlink:to="loc_srt_NameOfMajorCustomerDomain_59ee08da-64e7-45ea-b18d-fc9c342692e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_d75540a6-95ad-461e-8a26-d5fff9e5c356" xlink:href="mrna-20210331.xsd#mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_59ee08da-64e7-45ea-b18d-fc9c342692e7" xlink:to="loc_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_d75540a6-95ad-461e-8a26-d5fff9e5c356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_fe7ad874-b6af-4a78-9553-6548a1990d6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_14ebdb0f-6b77-4519-98ca-056658411d25" xlink:to="loc_us-gaap_SubsequentEventLineItems_fe7ad874-b6af-4a78-9553-6548a1990d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NumberOfDosesOfVaccineCandidate_0d76dcb9-d0e5-49a4-93a5-6c51adedf8ef" xlink:href="mrna-20210331.xsd#mrna_NumberOfDosesOfVaccineCandidate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_fe7ad874-b6af-4a78-9553-6548a1990d6a" xlink:to="loc_mrna_NumberOfDosesOfVaccineCandidate_0d76dcb9-d0e5-49a4-93a5-6c51adedf8ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_2dafdada-b501-4ad4-9765-df35d2fd1e79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_fe7ad874-b6af-4a78-9553-6548a1990d6a" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_2dafdada-b501-4ad4-9765-df35d2fd1e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsPotentialReimbursement_cc6d1032-ff64-4f5b-90d2-780549f69e0d" xlink:href="mrna-20210331.xsd#mrna_RevenueFromGrantsPotentialReimbursement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_fe7ad874-b6af-4a78-9553-6548a1990d6a" xlink:to="loc_mrna_RevenueFromGrantsPotentialReimbursement_cc6d1032-ff64-4f5b-90d2-780549f69e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsMaximumAward_8051227a-7792-48bb-9d57-ec1510c3f0db" xlink:href="mrna-20210331.xsd#mrna_RevenueFromGrantsMaximumAward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_fe7ad874-b6af-4a78-9553-6548a1990d6a" xlink:to="loc_mrna_RevenueFromGrantsMaximumAward_8051227a-7792-48bb-9d57-ec1510c3f0db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_01a.jpg
<TEXT>
begin 644 image_01a.jpg
MB5!.1PT*&@H    -24A$4@  #J(   YC" 8    :#XM1    "7!(67,  $SE
M  !,Y0%USO"5  0W2$E$051XG.S=![05U;WX\0"7WD$%#)&N("6*B"!14,1H
MC%$4$40""J*Q@B6(\/=9HO&I8 5L4024H@8!"_H($;!@(L%"$!"DBP+2>W'_
MUV^R[LVYY^RY=\J>,WO._7[6.NN]R)W?_&;VGOJ;V?,S!0
M             &C\+.X$                            8"=>1 4
M                     ( 6+Z("                          ! BQ=1
M 0                          H,6+J
M -#B150                           !H\2(J
M        M'@1%0                           %J\B H
M               M7D0%                          " %B^B @
M                    0(L740$                          *#%BZ@
M                          #0XD54
M:/$B*@                           +1X$14
M      !:O(@*                            +5Y$!0
M            @!8OH@(                          $"+%U$!
M                  "@Q8NH                            T.)%5
M                         &CQ(BH                           "T
M>!$5                            6KR("@
M     "U>1 4                          ( 6+Z("
M          ! BQ=1 0                          H,6+J
M                 -#B150                           !H\2(J
M                        M'@1%0                           %J\
MB H                            M7D0%
M  " %B^B @        GULY_]K-@?@.!LVL9LR@4(B_X,6] 7 0  @)*%:P
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MTT<;[YQSSC&8=<G".:,];+@>I3:6;*S7W&!;.U(;\\>V]@,   !R&6?;
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MF+,MFDW;&+D@E]C4AW@1M62SJ2\"   $%<4Y[?OOOZ^-V:E3)T-9 _&(\QJ
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MN=Y[\\TWM>?"8<3=?DF\!J VEIW<J(U1&_/*AG;4H3;FC:WM9UK<QUL   !
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MN._5Q7T-$ :UL63?6S&QS16UK_&SK-3&BOY1&RL:M;%@VTM4<=S$?;P%
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MG:W7 'Y0&\N=>RMNN9BDBT]M3(_:F'?4QJ*)82J.#<=;    P(U=5TL
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M:;\117S.W[SED0O'+U/<MB\3/Y,YQ1G'+5:V^W&N[UO=XB1Y/?_ZU[\VOGT
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MKP'\H#:66_=6HNY#)I;5+VIC=E^G4AO+9$N,L'%L.-X"    Q;'W:@D   !
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M=-2E2Q?7MBRN/6UH/]NO ?RB-I;L>RM1Y!)'?!ON$5$;"X[:6/0QJ(T!
MF>R_6@(   "0=6Y%:-MRLFU>,F*T;MJWWWX[<"XS9\[4QKSVVFL]Q["M+=-M
MV+!!E2U;-B/'QQ]_/+)Y?O'%%QGS.^FDDXJ<)M?;UY8B7USQ3SWU5&W\CS[Z
M*&NY1M''@K!]GZ$C#PSI1E^67^K7$_OTZ5/PW]-'A ["AGX310S=ERUW[MSI
M*X8\B!0F%[?MX<,//_2[.(A8^FCJ4Z=.-1)7XNCZ@/3/M6O7%CN]/!!J>I_Z
M[W__.U"_MBD7'5OV/5'$Y_Q-+U>/7Z;H<HG[?,B&8W.ZN/MQ2=BWVA GBO4L
M7T>Q;1L# "#7F#RGW;U[MZI=N[8VWH477N@YCLWW>EY__?6,O,J4*5/HI0\9
M3*-BQ8H%__[IIY^&GF\<YT3SYLU3S9LWU\[[JJNN<IW.AO:S_1K +VICR;ZW
M$D4N<<2WX1X1M;'@J(V9C6'#_3<;CK<   ! <>R_6@(   "0=;J;VW$76[*9
M3]!Y39@P03NMC!@>E-MHXQ,G3O0<P[:VU.G7KU]&CFW:M(EL?K???GO&_(HK
M[N=Z^]I2Y(LK?MVZ=;7QY0&C;.7JUL=&C1H5*(>@DK#/T)$'WW2YRU<5Q?;M
MVPL]++9PX<+0\[2AWT01HVK5JADQUJ]?[RO&7__ZUU"YR'Y0-_TSSSSC=W$0
ML=31U.7!U ,'#AB)*W'<'G2][[[[BIU^S)@QQO>IK[WV6J!^;5,N.K;L>Z*(
MS_F;7JX>OTS1Y1+W^9 -Q^9T<??CDK!OM2%.%.MYUJQ9UFUC  #D&M/GM/??
M?[\V7JE2I=277W[I*8;-]WH.'3JD?O[SGV?D-F+$B(*_2?WJ7+MV[8S,-ZYS
M(KE/>N*))V;,NVG3IJ[3V-!^ME\#!$%M++GW5J+()8[X-MPCHC86#K4Q<S%L
MN/]FP_$6    *$XRKI8     9)7NYG;<Q99LYA-T7O)U+MVTW;MW#YS+Q1=?
MK(VY9LT:SS%L:TL=*>)4JE0I(\]WWGG'^+QDY-*CCCJJT'S*E2NG-FW:5.1T
MN=Z^MA3YXHJO&WE<?O(0DE^[=NT*E*M;'[OTTDN#+)(C_6M#S9HU*W::).PS
M=-R*NS*"L>QCQHX=6_#?3#W,8T._26<BQK'''IL1X^.//_858]BP8:%RD2].
MZ*8?,&" W\4I9.G2I87BR1<@$,X55UQ1L#YOOOEFH[$EGJX?-&K4R/D2:U%T
M7WB0WR677!(X'WD -4B_MBD7'5OV/5'$Y_Q-+U>/7Z;H<HG[?,B&8W.ZN/MQ
M2=BWVA GBO7\\,,/6[>- 0"0:TR?TV[;MDU5JU9-&[-7KUZ>8MA^KT<&O4K/
MK4Z=.LY 64>.'%&-&S<N^.\OO?12J)SSQ7E.-&/&C(QYRXM*;FQH/]NO 8*@
M-I;<>RM1Y!)'?!ON$5$;"X?:V'^8B&'#_3<;CK<   ! <9)QM00    @JW0W
MM^,NMF0SGS#SZMJU:\:T5:I4"?1UL/W[]SO3IL>3>?AA6UNZ>?311S/R;-VZ
MM3IX\*#1^=QSSST9\QDR9(BG:7.Y?4W$R<O+RX@A#^F8$F5?/OKHH[7QBWL(
M0^?KK[\.G*NNC\D(O$&_,/CLL\\6BN7E);&HVS$JLJ]P:\<''WQ0G7KJJ07_
MN[A1WKVRI=^D,A&C;=NV&3'\/F!W_/''A\ZE6[=N&=/+PU)!'F;()WTA-=[0
MH4,#QT+F:.J??_ZYT?AN#QC*;\Z<.<5.WZI5*^T^->BYA3RH$[1?VY1+NEP_
M!^#\+5.N'K],<=OOQ,F68W.JN/NQR/5]JRUQ3*_G+EVZ6+>- 0"0:Z(XIW5[
ML4)>=%F^?+FG&#;?Z]FX<:/VQ9I77WU5O?WVVP7_NU:M6FK?OGV!\TT5M(U2
M_U[NS02Q8\>.C'G7K%FSR&EL:#^;KP&"HC:6S'LKJ6R^+U8<6^X141L+CMK8
M?YB(8<O]-QN.MP   $!1J.H!    R*"[.9[MPJN7G&R<U[OOOJN=?OSX\;[S
M>/GEE[6Q9!Y^V-:6;N3+9KI"X_#APXW-8]&B1:I"A0J%XLO#%5NW;O4T?2ZW
MKXDXU:M7SXCA]E"._/?4OY,1];.1HYN33SY9&W_6K%F^8XT>/3IPKFY][)57
M7O&=A^C0H4.A.'/GSBUVFJC;,4J#!P_6KK_4HKB,\KYY\V8C\[.EWZ0R$>/W
MO_]]1HS^_?M[GC[UX;PPN;SWWGO:&&^\\8;?17+( QGUZ]<O%,OTBY,ES9@Q
M8PK6I6P/43CEE%.T_:!/GS[%3NNV7079IW[UU5>A^K5-N:3+]7, SM\RY>KQ
MRQ23VY<IMAR;4\7=CT6N[UMMB6-R/<N7/>1E%=NV,0  <DT4Y[3R<HGNRXWR
MN_KJJSW%L/U>CWS=-3VW3ITZJ=_\YC<%__N..^X('#]=T#9*_?M//_TTT+QW
M[]Z=,>^6+5L6.8T-[6?S-4!0U,:2>6\EE<WWQ8ICRSTB:F/A4!NC-E84:F,
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M7D0%             $3N@P\^R'@1]:RSSHH[+0            #%X$54
M         $#D1HX<F?$BZCWWW!-W6@            "*P8NH
M  !7J2^.KERY,G"<CAT[9KR(^M%''QG,%            $ 4>!$5
M     . J]<71AQYZ*%",3S_]-.,EU)-..DG]]--/AK,%            8!HO
MH@(             7*6^/'K444>I[[[[SM?T.W?N5"U:M,AX$77FS)D190P
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M                          "@Q8NH
MT.)%5                            &CQ(BH
M      "T>!$5                            6KR("@
M             "U>1 4                          ( 6+Z("
M                  ! BQ=1 0                          H,6+J
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MR5>H'WWT4?733S]%EF^V]Z])6S]!A%VNN(YSNW?O5@T:-(AE_ASG 603^Q8
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M?9-\R3P_WXH5*T;>#VSHAP!*-O8M      #$C^MS!$5M28_:4M&H+9E%;0D
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M@AQ__O.?%QJ$(NY^$/?\ 207YY       ,2/ZW,D ;4E<Y)T3Y_:4CC4E@
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M,6.TVX)NY'A3DK1_C6/]>&7KNI-SOO+ERQ?D]M133VG_+NY^$/?\ 203YY
M     ,2/ZW,D ;4ELY)T3Y_:DG_4E@      -N**#P 2Z,8;;]3>Q)L^?7K<
MJ7EBXTW(J'+R$NO55U]UG7^E2I74O__][TCF&Z6SSSY;NSQ???55X)A??/&%
M-J;,BWS"Y>.'C=LOS$DM9*7^5J]>G?&W7MK_AQ]^H)_DJ*U;MZKFS9MG])7V
M[=NK P<.Q)U>:-V[=\]8ML:-&ZN??OHILGDF:?\:Q_KQ2K?N5JY<Z7PA_.*+
M+U9-FC11-6O65'EY>:I&C1I.WM)O!PT:I"9.G*@=2=J$SIT[%^1UVFFGJ2-'
MCA2;/P\+ $@*SB$!     (@?U^>P';4E\Y)T3Y_:DG_4E@      -N**#P 2
MJ%NW;MJ;>(L6+8H[-4]LO D954Y>8UU[[;6N.9QXXHEJSYX]D<PW*BU;MM0N
MR_KUZP/'E)OWNIBM6K4BGY#Y^&'C]@MSJE6KIFU?&:$V'>U?<GWXX8=.P36]
MGYQYYIEJ^_;M<:<7VN[=N[5?*W_AA1<BG6]2]J]QK1^O4G-:MFR9.O_\\U6I
M4J5<UV_Z3T9BO^222]2"!0N,Y23K)C^^/*0@@T=XR9^'!0 D!>>0      #$
MC^MSV(S:4C22<D^?VI)_U)8      +;BB@\ $NB$$T[0WL2+:I0]TVR\"1E5
M3EYC[=NW3YUTTDFN>?3KUR^2^4:E3ITZVN4(4T22$5)U,>O5JT<^(?/QP\;M
M%^:T:-%"V[[UZ]=W^E@JVK]DV+MWK]JX<:/ZZ*./U&.//:8Z=NR8T3\J5*B@
M_O2G/ZF#!P_&G:X18\>.S5A&V38.'3H4Z7R3LG^-:_UXE9J7VQ< O/[Z]^_O
M>S"0=/+5@%JU:A7$'#ITJ.?\>5@ 0%)P#@D     0/RX/H<MJ"U16TI';<D?
M:DL      )MQQ0< "52S9DWM3;Q=NW;%G9HG-MZ$C"HG/[&^^>8;UY%JY??2
M2R]%,M\H5*Y<6;L,!PX<"!QS__[]VI@R<B;YA,O'#QNW7YASPPTWN+9QNW;M
M"@UX0/OGMJ>>>JK80JJ,7'W//?<X#Q/D"BEX'W_\\8664T8\GC=O7N3S3L+^
M-<[UXY5N'98K5\X9B?KUUU]72Y8L43MW[G1&WUZU:I6:.7.FNO[ZZU75JE6U
MT\I7S.7O@NK=NW=!K,:-&SL/X/C-GX<% -B.<T@      .+']3GB1FV)VI(.
MM27_J"T!     &S&%1\ ))",#JF[B9>4T2)MO D954Y^8TV=.M4UETJ5*JG%
MBQ=',E_3\O+RM,MPY,B1P#&E0.%6 ""?</GX8>/V"W,6+ESH%/[<VKEZ]>K.
MZ,2;-V^F_7-<40\+E"Y=6O7HT4--GCQ9K5V[-NY4C7KZZ:<SEO>FFV[*RKR3
ML'^-<_UXE9Y?MV[=U)HU:XJ=3D:73BWLI_YD5.YMV[;YSF76K%F%XKSWWGN^
M\^=A 0!)P#DD      #QX_H<<:.V1&U)A]J2/]26      "VXXH/ !+(K8#T
MTT\_Q9V:)S;>A(PJIR"QBAJM5FY6RRB+4<S7I"C6I_1O74S9'L@G7#Y^V+C]
MPJP! P:XMG/^3UYPIOUSFY=1J_/W,1T[=E1CQXX-]55G&ZQ?OU[5J%&CT/*U
M;=O6^>)T-MB^?XU[_7B5FM_ @0-]#?(@Q]);;KE%VP[GGGNNKSSV[-FC&C5J
M5#!]GSY]?.?/PP( DH1S2       XL?U.>)$;8G:4KJXUX]7U);"B7O^
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M@["W#R >J$,"     ! ^VN<P%6-+_C&U3]^4_,DTQI;,.@\!     ,&@Q0<
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MI%TGK <%_#Q/PCX/ <0?=4@      ,)'^QPF8&S)N[#[]$W/GTQC;(FQ)0
M  #(!K3X ""B-FW:I!T >NJIIP+;YI(E2U*VU[1I4\?IF-@)&51,?N^?O&B<
MWRRTX\:-"V2[;C1NW#@E/OD[M\XYYQQ/Z1&//TR\?A&.@HY___[]M>=*3DY.
MAB-%)LAD";KC7;QX\;!#L^S;MT]=?/'%>6+KW+FS.GKT:-BAG1!F^1J%_,FT
MM6O7:H_'V6>?'>AVP[[/AKU] /%''1(     @/#1/H<)&%ORCK$ELS"VQ-@2
M     &0#6GP $&$]>O3(R(MGN>Z^^^Z4[;EY\343G9!.TPTJIB#V[_WWW]=^
M35.64J5*J:5+EQK1N3MDR)"4^(H4*6+-BNF4S(:JV^?!@P<3CT_QV,4@0KPE
M'M.]>_?:_JW._/GSC1X\SG:)Q^3''W_TG-[6K5NUQ[M&C1H^1.O-P8,'58<.
M'?+$U;Y]>^OO31)6^1J5_"E(8OPRX[174Z=.U1X/R:L@A7V?#7O[ **).B0
M     .&C?8Z@,;9DWM@)8TO>,+84C^T#     #*+%A\ 1-C&C1M5Z=*E4SKS
MI'/3;_)R7.7*E5,&FK9MV^8XK4QT0CI--ZB8@MH_><$P7<SUZM4SHG/WJZ^^
MTL8W>?)DQVF]]=9;VK1D&\3C3SQV,8@0;XG'=-6J5;9_JR/W#=VY4K5JU2!"
MAT.)Q^3SSS_WG-Z\>?.TQ_O<<\_U(5KWCAPYHJZZZJH\,;5LV;+ AW!T@B[S
MPBA?HY0_3K:_<.%"S^D-'SY<>SP>>>01'Z)-+^S[;-C;!Q!-U"$!      @?
M[7,$C;$E\\9.&%ORAK&E>&P?     )!9M/@ (.+&C!F3TIG7J%$C=?CP85^W
M\^"##Z9LY\X[[W255B8Z(9VF&U1,0>V?=.ZW;MTZ;=RF=.XV;]X\)9Z;;KK)
M<3HWW'!#2CK-FC4C'I_CL</$\PS^23RF;[[YINW?ZAPX<$![KC1MVC2(T.&0
MWX.?(T>.U![O7KUZ^1"M.\>.'4LI'Z6.Y'9&X[@]+!"U_'&R_<<>>\QS>DV:
M--$>C\6+%_L0;7IAWV?#WCZ :*(."0    ! ^&B?(VB,+3G'V%+^PAZ'8&PI
M'ML'     &06+3X B+CCQX^K=NW:I73HW7___;YMX\LOOU0E2Y;,DWZ%"A5\
MZ4P.JA/2:;I!Q11D)^N&#1M2OE)K6N>N[DN=I4J54CMV[+"=Q@\__*!*E"B1
MDDY! ZC$XSP>.TP\S^"?Q&/:HT</V[_5^?;;;[7GRAUWW!% Y' J>8!8ZA-N
M'3UZ5)UYYIG:XSUERA0?H[9/]J=/GSYY8CGCC#/4EBU;7*<9IX<%HI@_3K;O
M=;;TN7/G:H^%UVO%CK#OLV%O'T T48<$     "!\M,\1-,:6G&-L*7]ACT,P
MMA2/[0,     ,HL6'P#$P/;MVU7=NG7S=.@5*E1(O?;::Y[3EDYCW0# JZ^^
MZCK-3'1".DTWJ)B"[F2=-FV:=:S3Q1]VYZYTJ+=HT2(EIGONN<=V&O+EW>3U
MSS__?%>=]<3CG8GG&?R3>$R+%R^N-F[<:.NW.KHO=LLR>_;LH,*' \G'9<*$
M":[3>N:99[3'.B<G1^W?O]]S;&7+EG6<QNVWWYXGC1HU:J@U:]8X3B==7$'(
M9/EJ8OYX/>[)Z[_^^NNNXCATZ%#:&:O?>^\]5VDZ$?9]-NSM X@FZI
M (2/]CF"QMB2<XPMY8^Q)7^$/;83]O8!     )E%BP\ 8F+UZM7JU%-/S=.I
M5[AP8?7$$T^X3G/%BA76#(;)G872P>Q%)CHAG:8;5$R9Z&2][[[[TL9O0N?N
MXL6+5;%BQ?+$)/__^>>?%[CN9Y]]IHH6+9IG7?G_!0L6$$] \13$U/,,_D@^
MKFW:M%%'CAPI\+?)Y$N],E"<G%['CAV#W@78I!N8M5/N))LY<V9*&9:[N)D0
MX_#APRGI2%W$B:%#A^99OU*E2FKY\N6.8TD6EX<%3,P?/XY[\OKERI53RY8M
M<Y2&S,#>JU<O[7'(5/D5]GTV[.T#B";JD       A(_V.8+&V))SC"WEC[$E
M?X0]MA/V]@$     F46+#P!B9-VZ=>JLL\Y*Z=QKW[Z]^N*++VRG\_///ZN1
M(T>JDB5+IJ1UPPTWI!VPLBL3G9!.TPTJIDQTLDK']J677FITYZZ\$)T<5[5J
MU?(]+^4%S:I5JZ:L]]ACCQ%/P/'DQ^3S#-[ICFW;MFW5YLV;\_UM(KD7-6W:
M-"6=BA4KJI4K5V9J5U  W;$N4Z:,>O'%%]6Q8\<*7%\&=\>.'9OV08%KKKG&
M55P[=^Y,2>NRRRZSO?Z($2/2EE-^+D'(Q+9,S1^OQUWHXBA?OKSMV:O7KU^O
MKKSR2FTZ#1LV5+MW[W:\7VZ$?9\->_L HHDZ)       X:-]CJ QML38DDGY
MP]C2_X0]MA/V]@$     F46+#P!BYJ>??E+777>=MI.O5:M6:O3HT6K6K%G6
M@-.! P>LETJW;]]NS58X8<($:Z8^F;E2M_[@P8/5\>/''<63B0YIIQW6076
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M&JAV[=JIH4.'JG_^\Y]JUZY=OFP; +(==4@      ,)'^QQ!8VP)86!L"0
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M^QQ1QQA#=N*X P     0/GH4 0   #C&0PKP0]^^?5,&C-]YYYVPPT+ ..X
MD+VH0P(     $#[:YX@RQABR$\<=       ST*,(    P#$>4H ?IDR9HHH5
M*V:=1^7+EU<S9\X,.R1D ,<= +(7=4@      ,)'^QQ1QAA#=N*X P    !@
M!GH4 0   #C&0PKPR^3)DU6;-FW4NG7KP@X%&<1Q!X#L1!T2     (#PT3Y'
MU#'&D)TX[@      A(\>10    ".C1LW[L0"    V$$=$@    " \-$^!P
M     . &+Z("                          ! BQ=1 0
M            H,6+J                            -#B150
M                  !H\2(J                            M'@1%0
M                         %J\B H                            M
M7D0%                          " %B^B @
M    0(L740$                          *#%BZ@
M          #0XD54                            :/$B*@
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MH/6E=.GFY.2H8<.&J5FS9JEMV[99YYQ<P\N7+[?JXOD]H//TTT][CLN$\Q!
M]HI:'3(_8=4MXGPOS^^^[.=2N'!A5_&9TH\05+Z$Q=0ZDRGY;/IU 0  @&@R
MH2T0%::-YR0R8=PCD?1!7'_]]4:W00MB:AO5E'[]N+913=TOT\J?H/(%
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M&\_)%7;?1*+WWW_?:G_IVG:;-V\.K/\]*":V44WJUX]K&]7$_3*Q_(G"-0P
M    "!ZM0@"(@0T;-JB<G)R4#L2__.4OOJ0O#^MW[=K5MP$"$P<;@HHI7;I>
M.O>=;C=,\A)TRY8M4_9YT*!!MM.X_?;;4]9OT:*%JQ>LB4<O<=VR9<M:@X).
M39LV37M^UZU;5QT^?-AQ>C"?*>5,0;[[[KN4@719JE2IXF@B /FMK).<CJ0M
MV[#KO??>TUXK,E.T$[IKOV3)DFKUZM6.TC$M?_RV8\<.ZTM5B3&5*E7*U1?)
MK[ON.M?GO4GY3)FOK*^0)9X/F:@'RNSR.W?N=+2^S%0N#P_I8GO[[;<=QV/2
M>0@@>T6E#IF."76+.-_+@S@_'GSPP3SIGG7668[:RZ:TVQ-%_3I*9EJ=21=7
MF$R\+@   !!]IM1W36;:>$XN$_HF$B7O6].F3:U)F=+]N^GGG6EM5-/Z]>/:
M1C5MOTPM?Z)P#0,     @D>K$  B3AX0;-:LF:<'XNS8NW>OJE^_OB\#!"8.
M-@054V):I4N73KN=5U]]U8>]T&\W3),F34K95QD(V[Y]N^TTMF[=JDJ4*.'+
M0 WQZ"6N=]MMMSG>CURZLDB6Z=.GNTX39EB[=JUZ_OGG59<N7:P!Y/+ERZ<,
MQ%YPP06J>_?NUN^^^>:;L$,^00;D=.?ED"%#'*<EZ^C2>N211VRM+X.+YYY[
M;LKZ,GNMTZ]C;]NVS?H*4W):,BNR$R;E3Q!Z].B1$L^($2-<I94\Z.N$2?F<
M[67^NG7K5)DR94[$.WKTZ(S4 ^^XXPY7::2+3\I;ITPZ#P%DARC7(=,QH6X1
MYWNYG_=A(7UFR5]_??KIIQVE84J[/9'?^10VT^I,NKC"9.)U 0  @&B)8_L\
M:":.Y^0RH6\B4>)Y].<__]F:Y%SW[W[WOP?%M#:J:?WZ<6VCFK1?)I<_4;B&
M 0    #!HU4( !'WP ,/I'0:R@NCAPX=\GU;NB]FN&'B8$-0,26F]<HKKZ3=
MCKP0X>>@GBGY*E_X2-[7;MVZ.4Y'!D:3TVG>O#GQ^!1/XGI>'CI^XHDGM.?W
M[W__>]=I(EP+%BQ0__=__Z>=:;>@I4Z=.NK^^^]W-0.SGRZ]]%)M?#-FS'"<
MEEP?NK3:M&EC:_U%BQ9IU[_QQAL=QR(Z=NR8DI8,)LJ#[G:9E#]^6[Y\N2I<
MN'">6"I4J&!-KN&&Y*O;^ZM)^9SM9?X55UQQ(M;&C1NK(T>.9*0>^-%''[E*
M8]Z\>=K8SC[[;,=IF70> HBW.-0A=4RI6\3Y7N[G?5B\_OKK>=*4+\C^]--/
MCM(PI=V>R.]\"IMI=29=7&$R\;H   ! -,2U?9X))H[G"%/Z)A))/+?<<HOU
MI5:=H/K?@V):&]6T?OVXME%-VB]3RQ\1A6L8     ! \6H4 $&$K5Z[4SE[W
M[KOO!K;-\\X[SW/GHHF##4'%E)R6S"R8;EOGG'..VK=OG^=MZK8;AF7+EFGW
M\Q__^(?CM-Y\\TUM6DN6+"$>'^))7.>''WYPO/U<Z0;5Y$L[B!:9K7C8L&&J
M2)$B:<LLNXL\X" O?LV9,R>4?:E=N[8VKBU;MCA.:].F3=JTY($,.]+-6CQN
MW#C'L8@GGWQ2F]Z8,6-LIV%2_OA-7A!(CF7@P(&AQ&)2/F=SF?_&&V^<B%,>
MCID_?[[U]YFH!\JLTV[(>KK89'9YITPZ#P'$4YSJD#JFU"WB?"_W\SXL6K=N
MG2?-?OWZ.5K?I'9[(K_S*6RFU9ET<87)M.L"    YHM[^SP33!S/$:;T321:
MO'AQOO\>5/][4$QKHYK6KQ_7-JI)^V5J^2.B< T#     ()'JQ  (NSZZZ]/
MZ2ST,M._'<E?S'##Q,&&H&)*3DM>-)473M-MKU>O7IZWJ=MN&(8.'9JR?_+2
MAYL9+'?NW*F=K??>>^\E'I_B\4/RK+FYRZFGGIK1..!=[]Z]M<>R4Z=.ZOWW
MW[=F-4[\^^W;MZN//_[8&NR6&5U-*N=+E2JEC>7@P8..TSIPX( VK=*E2]M:
M_Y>__*5V?7D)P V9[5B7G@QNVF52_OA)SM$2)4JDQ#)W[MR,QR+BF,]1*_-W
M[=JE<G)R3L0Y8," $_]F4IF5[/#AP]K8BA<O[CBM.)Z' ,P2ISID,M/J%GXP
M\5Z^=NW:$XM77W[Y9<J^??/--X[2,+7=;MKU80(_ZTRY3,EGTZX+    F"_.
M[?-,,7$\)ZI]$]EX/L6Y7S^N;523]LO$\B=7MES#     (#\T2H$@(A:MVZ=
M]?!;<F?AV+%C ]WNBA4K/'<NFCC8$%1,NK2DD[E,F3)IM_G7O_XUD.UF6I,F
M35+VK5&C1J[3DY>LD].3;1"//_'XX="A0]IS6@9%$1UR']$=Q^194=.5,_)
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M\MFOZP(   !FBWO[/)-,&\^)<M^$B?WO0:%?WYZXME']VB_3RI]$<>HK 0
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M="_WHFG3IGGV<<B0(;ZE'<5VNU.[=NW2QE.Y<N50XO&#USI3$#*=ST%>%P
M (B/*+;/H\[+>$X4^R9RF="_'A;Z]>/;1HW:?GDI?X(0QSXI     ,@FV=&S
M P Q)#/!)7?*R4.&46#B8$-0,?F9UEUWW94VSOKUZZN]>_<&LETWIDZ=JHUS
MQ(@1KM-\Z*&'M&E.FS:->#S&4Y ??_Q1-6K4*$^Z P<.])PNHBU=.3-GSAQK
MD#I=>27G:J;4K%E3&\.6+5M<I[EY\V9MFK5JU?(O< <&#1J4$HL\#'+DR)$"
MUXUK_LB#_.G./SOYHG/TZ%%M>L6*%2MPW:CE<]3*_'3'.A-+)JU:M4H;@]W9
MH:-V'@*(KRC4(9.95K<H2-3NY6XE/SA9I$@1ZVL*?HE:N]T-.7^#.@_#XK7.
M%(1,YG/0UP4   #B(XKM\ZCS,IX3M;Z)1";TKX<EV_OUX]I&C>)^>2E_@A#'
M/BD     R";9T;,# #$T;-@P;<?<]]]_'W9H!3)QL"&HF/Q,Z_#APZIERY9I
M8[WIIIL"V:X;V[9M4X4*%<HW1J>Z=NVJW6_9%O%XBR<_>_;L4<V;-\^3ILRZ
M>_SX<4_I(OKR*V?FS9MG#13ISLD++[PP8S'* )HNAH,'#[I.4V:6UJ59IDP9
M'R.WKT.'#BFQ7''%%;;6C6O^3)\^/>V]4F;8=2/=S.!5JE0I<-THY7,4R_QT
MQSH32R:EFQVZ4J5*MM:/TGD((-ZB4(=,9EK=(C]1O)>[U:5+ESS[>?755_N:
M?I3:[6[MW+DSD/,P3%[K3$'(9#X'?5T    @/J+8/H\Z+^,Y4>J;2&9"_WI8
MLKU?/ZYMU"CNEY?R)PAQ[),"    @&R2'3T[ !!#FS9MT@X /?744X%M<\F2
M)2G;:]JTJ>-T3!QL""HFO_=/7C3.;Q;:<>/&!;)=-QHW;IP2G_R=6^><<XZG
M](C'N7W[]JF++[XX3YJ=.W>V9L@%"BIG^O?OKRVG<G)R,A9CJ5*EM#'((*M;
M^_?OUZ8IV\JT8\>.J9-//CDEEA=??-'6^G'-'QG8E]F'=7&XG;!CX\:-VO3.
M/OOL M>-2CYG<YEO8MTTF4Q(HHNQ>/'BMM:/RGD((/ZB4(=,9EK=(IULNI=+
MGUC1HD7S[.M''WWD^W:BT&[W8NW:M;Z?AV'S6F<*0J;R.5/7!0   .(ABNWS
M*/,ZGA.5O@F=*/2_!R6;^_7CVD:-XGYY+7^"$,<^*0    #()MG1LP, ,=6C
M1X^,/L!V]]UWIVS/S8NOF1AL<)IN4#$%L7_OO_^^]JL<N0,$2Y<N-6(09\B0
M(2GQR0"9?*'%*1E<T^WSX,&#B<>G>)+)3*K),V.V;]_>TPRK,%_B\=Z[=Z_M
MW^K,GS_?T^"J'VK6K*F-8<N6+:[3E %&79JU:M7R+W";YLR9DQ)'R9(EK5ED
M[8AS_K1JU4H;Q\R9,UVE-W?N7&UZ'3MV+'#=*.1SMI?Y0=0#$]/Y\<<?/<>X
M=>M6;8PU:M2PM7X4SD, T16W.J2.274+G6R[E__A#W_(LZ]!/:1F6KL]<3V[
M=?[\3)TZ57L>RKF4*:;5F9)CBE(^9^JZ    @+FRH7T>55['<X3I?1/I!-'_
M'A33VJA1[M>/:QLUBOOE1_D3U;X2     $ PS.S9 0#8(K-4EBY=.J5S3CKM
M_"8/V56N7#EEH&G;MFV.T\K$8(/3=(.**:C]DP<5T\5<KUX](P9QOOKJ*VU\
MDR=/=IS66V^]I4U+MD$\_L23Z,B1(^JJJZ[*DU;+EBT+'+36,>%<A'V)QVO5
MJE6V?ZLC]PW=>5FU:M4@0M=JWKRY-@89<'-K]NS9VC1E6YDV<.# E#A^^]O?
MVEX_SOGSV&./:>-P^^7X%UYX09O>Z-&C"US7]'RFS _^1=3//__<<XSSYLW3
MQGCNN>?:6M_T\Q! M,6M#JEC4MTB6;;=RP\=.J2J5:N6)];GGGLND&V9UFY/
M7&_APH6.8T@V?/AP;4R///*(Y[3M,JW.E!Q35/(YD]<%    S)4-[?.H\CJ>
M(TSNF\A/$/WO03&MC1K5?OVXME&CNE]^E#]1["L!      3'S)X= (!M8\:,
M2>F<:]2HD3I\^+"OVWGPP0=3MG/GG7>Z2BL3@PU.TPTJIJ#V3QXT;=VZ==JX
M31G$T0V.W'3338[3N>&&&U+2:=:L&?'X'(\X=NQ82GI2IKB=V=*4<Q'V)!ZO
M-]]\T_9O=0X<.* MDYHV;1I$Z%JZ@3599+#>+1F UZ5YQQUWV$XC<3VWLQ;O
MV[=/5:Q8,4]:\G6F;[_]UG8:IN:/'R1?BQ8MFA)'ITZ=7*5WW777:?=K\>+%
M!:YK<CY3YO]7$'6HQ'3\&#@?.7*D-L9>O7K96M_D\Q! ],6M#JEC4MTB43;>
MRR=.G)@GSI-//EG]_///@6W/I':[7_?P7$V:-/'E//3"M#I3<DQ1R>=,7Q<
M   P4S:TSS,M<=_#',\1IO9-%"2(_O>@F-9&C6J_?ES;J)G>+Y/*GRCVE0
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M.>*&-FIVXK@#     )!Y]"@"    <(R'%."W??OVJ3/.."//N=6E2Y>PPT+
M..X D%VH0\8/]_+LQ'$'    HHWV.>*$-FIVXK@#     ! .>A0!    .,9#
M"O!;KUZ]\IQ7E2M75C_\\$/882%@''< R"[4(>.'>WEVXK@#    T4;[''%"
M&S4[<=P!      @'/8H     '.,A!?AIZ-"A><ZIXL6+J]FS9X<=%@+&<0>
M[$,=,EZXEV<GCCL    0?;3/$1>T4;,3QQT     @/#0HP@   # ,1Y2@%_Z
M]NV;,EC\SCOOA!T6 L9Q!X#L1!TR/KB79R>..P   ! /M,\1![11LQ/''0
M  " <-&C"    , Q'E* 7Z9,F:**%2MFG4OERY=7,V?.##LD9 #''0"R$W7(
M^.!>GITX[@   $ \T#Y''-!&S4X<=P      PD6/(@    #'>$@!?IH\>;)J
MTZ:-6K=N7=BA((,X[@"0?:A#Q@OW\NS$<0<   "BC_8YXH(V:G;BN ,
M$!YZ% $    X-F[<N!,+    8 =U2       PD?['        ( ;O(@*
M                        +5Y$!0                          @!8O
MH@(                          $"+%U$!
M  "@Q8NH                            T.)%5
M         &CQ(BH                           "T>!$5
M                6KR("@                           "U>1 4
M                     ( 6+Z("                          ! BQ=1
M 0                          H,6+J
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M677SS3>K39LV^18/S&5*F1)57N]%?I?OV7+MAUW&$D\X3-LOX@&0S:A# @
M   0/MKGT<384CA,ZT,GGLPP;;^(!P    !@"GH4 2"FWGCC#56S9DW?!R'D
MA=86+5I87TS]]MMO"XPCK$&/,&)RDD:?/GU"W9^P//[XXXX'H60I4J2(&CUZ
M-/$$&,^"!0M4CQX]5,F2)3U?(_*U97D)'O%F0ID297[<D_THW[/IVJ?,CU8\
M?C%MOX@'0+:C#@D     0/AHGT<38TN99UH?.O%DAFG[13P      )/0HP@
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MG_?KM5]29Z_]76M?UUI[KP4  )#/J)_'DY;]1M]2T7*Y35];/'[1EB_B 0
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M>\W*=)$7'"ZZZ"(S8\:,J+.EBH;K='(<N73N:[O&$D\XM.6+> #D&YXA 0
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M)99?KUZ]7'78R?G>KU\_Z[XY__SS?8LQKN>^MFLL\81#6[Z(!T"^X1D2
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M6L]];==8X@F'MGP1#X!\Q#,D      #1HWZ.HM"W9*>M#9UXPJ$M7\0#
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M0P]%'7;.6;%BA;6L9=;LL&DY][5=8XDG'-KR13P 8,<S)!"LXLZG= L   "
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M.O>U76.))QS:\D4\ )"*9T@      *)'_3R_T;=DIZT-G7C"H2U?Q ,
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M'7D>\4+#-99X,L-^S]]X ,0?SY       $2/^GGNHF^I>/0QY&<\[/?\C0<
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M    P+7GGGONUP4   #(!,^0      !$C_HY         "_X$!4
M                  !6?(@*                            *SY$!0
M                        @!4?H@(                          ,"*
M#U$!                          !@Q8>H
M    L.)#5                            %CQ(2H
M          "L^! 5                            5GR("@
M                 "L^1 4                          ( 5'Z("
M                      # B@]1 0                          8,6'
MJ   Q,A__==_%;L                         ?N%K%0  8H0/40%HD0O7
MG6^__=;\[6]_,W_ZTY_,22>=9.K5JV?*E2MGRI<O;^K4J6/...,,,V#  /.?
M__S''#IT*.IP5>G2I4ML[T&???:9>>BAA\REEUYJFC9MZNQKV><%^UW^3OY-
M?B._#5J<CL,X[_<XE7,4*!\ 88G;_<,-N3Y^\LDG9LB0(:93ITZF4:-&IDJ5
M*J94J5*F<N7*YL@CCS2_^<UO3*]>O<SHT:/-XL6+?=OV]]]_;\:,&6-NOOEF
M<_KIISO;KE:MFBE=NK3S7_G_]NW;FUMNN<6\\LHKYJ>??O)MV_EL[MRYYJZ[
M[C)GG766<[^4>Z<L\F?YN\&#!YLOOO@BZC!C:?/FS6;BQ(EFT*!!IF/'CJ9)
MDR:F>O7JSC%=M6I5<\PQQSCGDQS3__N__VNV;]\>=<@   ! K&BIGV_<N-'T
M[-G3E"A10DU,V=!:3\RU<M8HRG:A9-J.0VWQ9$-;>X6V>))I.B\      /ZA
M50D 8B23CQ##7! ^]@L +>)\W9D^?;HY^^RS7=WSCC_^>*<CSR]QOC?_^]__
MCMT]Z.#!@^:YYYXS+5JT<%VF\E&>K"MI^$G#<>A&'/>[B+*<X_!<'K?C$$#\
MQ>7^X<:^??O,4T\]98X]]EC7U^_Z]>N;@0,'FOGSY[O>[@\__&#NN^\^YUG%
M[78K5*C@O. E Q%H$H=[I_CRRR^=%R4SW98,Z.#G"Y4:R\0/\O*DG$L=.G1P
M7IAT$[N\O'C]]=>;-6O6^!:/EG*.RWD!  " >(GZ.?# @0/FR2>?=#Z4RH5G
MTZCKB>F$7<[Y6'^)JEW(1MMQJ"T>K[2U5VB+QT;3>0$     \)^>EAD 0+'"
M;+B/4^-^/F._ (A*'*\[,LJKS/:7S;WOLLLN\V6TV+C>FW?NW&D:-&@0JV>#
MI4N7FM_^]K=9EZVD(6EE2]-QF*DX[G<-Y1S&\[C7?:"A? #D)^WW#[=FSY[M
M?* ?YK7\TT\_=:[!,G- MMN4V2=&CARI9K9KS??. H\\\HCKE_QDD?TU8L0(
MU>44%3F/NG7KYLS$GFT>#C_\<#-V[%A?XM)2SG$X+P   ! _43X'?OCAA\4.
M&ADG&NJ)-E&4<[[57Z)H%TI'VW&H+1XOM+57:(NGJ#BUG!<     @&!08P.
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M*,JH4:.R*:; RB4JMEBZ=^_N#!93%)G)5V9)D1>0;6G(RXQ^QQ5%.6L^+P
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M;<_]:]>NC46;LXVV>J*6<LZ'^DO4[4*)M!V'VN+)EK;V"FWQ)-)T7@
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M_G=SX, !Z[]K;'-.1W,],>IRSO7ZBX9VH0+:CD-M\?A!6WN%MG@*:#HO
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M-]QP@S-CGHWF-N=T--83M91S+M=?M+0+%=!V'&J+QP_:VBNTQ2.TG1<
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M]N.\    @&YQJY]K;G.VT5I/+$[<REEHJK]H:Q?2=AQJBT>3(-HKM,2C[;P
M     (1'=ZL2 , W47<N;-^^W8P?/][I,#CEE%-,]>K539DR99SEB"..</Y.
M_DU^([_U0UCYE8]:WG[[;6>DQW/..<<T:M3(:6"5O-6L6=,<=]QQSBQ40X8,
M<6:/.G#@@&_;CEN'$0#=-F[<Z%R_DJ\KG3MW3OEM4=<=&4U5KH=17Y_D_F*[
M3N[8L<-3>C(*;[K[Z?OOO^\J+>W7[1DS9A0:<?C--]\L].]1/U<4IT&#!M;X
MUJY=ZSJM-6O66--JV+!A1NMK/@Z3Q7F_QZF<W?KIIY]29OF=-&F2JS1RN7P
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M!0   '2+8_U<<YMS,LWUQ.+$I9PUUE^TM0MI.PZUQ1.V*-HK-,2C[;P
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M^+Z=N)8/@'C(M6?(HJZ7-]UTDZ<T+[_\<FMZV0SF590I4Z84NK_(GU]YY95
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M<U3/E    -!/8_T\3FW.<:XG:BWG.-1?M+4+:3L.M<6CD;;V"C_BT79>
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M:*F?QZG-.<[U1*WE'(?ZB[9V(6W'H;9XM-+67I%M/-K."P    ! N*)O50(
MA"+HSH4@9D3=L6.'-4WI@,A$$/D=/'APVL9/MR/[^1&?Q@XC /DA^;HCG4-]
M^_8U)4N63'O/J5BQHO.[.$ON%"]8YLZ=&TD\6[=NM<93HT:-M.NDVS]A+&'H
MU*F3==LRDJY7'W_\L35-F2DR"EZ.PUS?[T$(^WQOU:I5H>T,&C0HD.WX1=OU
M$$ \Q/$9LGOW[FEC\_IRI Q<94M/9@'Q@\P0GSPSP="A0WU)6Y,@[YT///"
M=1^-'S_><YHOO?22-<WAPX?[%K<;7NH2VLD+D[8\R8NQ40F[G./V3 D  (!H
M:*F?QZE-.<[U1*WE'(?ZB[9V(6W'H;9XM-+67I%M/-K."P    ! N*)O50(
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MG./X3 D  (!H:*F?QZE-.<[U1(WE')?ZB[9V(6W'H;9XM-+67I%M/-K."P
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MA'7O/.FDDU+VD?R=5\V;-_<UO6Q%59<(TKY]^ZQY*ENV;&0QA57.<7RF!
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M    .L6Q?AZ'-N=DFNJ)F=)4SG&MOVAK%])V'&J+)UO:VBNTQ5- VWD!
M  B'[M8[ (!OPNI<:->N7<HVCCON.+-___Z,TY#?-FG2)"6=MFW;NHJE4:-&
M*6FL6;/&^MOERY<7^EWSYLU3?G/[[;=;R[!KUZZNXI(92YHV;>K+_M#2800@
M-R1>2\J6+6M6KUZ=T6]M1HX<:;U&??SQQT&%GU;B]B^YY!+7ZW_WW7<IG5]U
MZM3Q---4<GF\_/++KM,0,MMXNIEUWGKK+4]INA'T<T5RNC)+>J:D;!HV;.A;
MV;SQQAO6M&0;;F9]UW0<>J5YO]O2T%[.7WSQ1:'ME"A1PBQ9LL3W[22*4_D
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MY^S9LUW'H;$ND>U^3UY7VO\R*==DTZ9-2]E'!<NX<>-<I:6QG(L2U7D!
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M_:MY__WWS9HU:YQKB.1+SB\92$,&FTL>*"-QZ=RY<Y$#XGF)25N=3<-Y 0
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M&?0LDT76D=ELLZ&Q+I'M?I</.B^__')/99IND9?D9086.6Z\T%C.-IK."P
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MAUS946<#  ! 7.53_;PH8=5;-=03\7_"V.\:VX6T'8=AQY,O[17:XDFD\;P
M     /B'#U$!    N!;4J,C(;Q,F3$@9!5<ZJ)';V.\ D#]XALQ-W,OS$_L=
M    B*]\JY]3?\E/[/?\Q'X'     "!8^=&B"    ,!7^?:2 H*W:]<NT[AQ
MXT+'5I<N7:(."P%COP- ?N$9,O=P+\]/['<    @WO*I?D[])3^QW_,3^QT
M    @.#E?HLB     -_ETTL*"$>/'CT*'5<U:M0P&S9LB#HL!(S]#@#YA6?(
MW,.]/#^QWP$  (!XRZ?Z.?67_,1^ST_L=P      @I?[+8H     ?)=/+RD@
M>(,'#RYT3)4M6]9\_/''48>%@+'? 2#_\ R96[B7YR?V.P   !!_^5(_I_Z2
MG]CO^8G]#@    ! .'*[11$   ! (/+E)04$KU>O7BD=PZ^__GK482%@['<
M_X^]>X&Z:[H3 #X>$8^(1&C"J*'$*VJ(5XQI!1/5&JO28C#U*F6F'J6E9&2,
MI3.6Q4(\8JC2BJA'1T4\1XWE46U-:Z':>K]"9S0B2((DR)FU[ZSO\^6[^W[?
MO>>><\^Y]_Y^:]U53>[YGWWV^>]]]LW=^VZZDS%DY_ L[T[N.P  =(9N^'SN
M\TMW<M^[D_L.    K=.Y_Z((  #DIALF*= :LV;-2H8,&5+)I1$C1B3WW7=?
MT46B!=QW@.YD#-DY/,N[D_L.  "=H1L^G_O\TIW<]^[DO@,  $#K=.Z_* (
M +GIADD*M,ZMM]Z:3)PX,7GEE5>*+@HMY+X#=!]CR,[B6=Z=W'<  &A_W?+Y
MW.>7[N2^=R?W'0   %JCL_]%$0  R,555UW5^P( @'H80P(  $#Q?#X'
M -*P$!4                 @"@+40$                 B+(0%0
M          " * M1 0                "(LA 5                 ( H
M"U$!                 (BR$!4                 @"@+40$
M        B+(0%0                " * M1 0                "(LA 5
M                 ( H"U$!                 (BR$!4
M    @"@+40$                 B+(0%0                " * M1 0
M              "(LA 5                 ( H"U$!
M (BR$!4                 @"@+40$                 B+(0%0
M          " * M1 0                "(LA 5                 ( H
M"U$!                 (BR$!4                 @"@+40$
M        B+(0%0                " * M1 0                "(LA 5
M                 ( H"U$!                 (BR$!4
M    @"@+40$                 B+(0%0                " * M1 0
M              "(LA 5                 ( H"U$!
M (BR$!4                 @"@+40$                 B+(0%0
M          " * M1 0                "(LA 5                 ( H
M"U$!                 (BR$!4                 @"@+40$
M        B+(0%0                " * M1 0                "(LA 5
M                 ( H"U$!                 (BR$!4
M    @"@+40$                 B+(0%0                " * M1 0
M              "(LA 5                 ( H"U$!
M (BR$!4                 @"@+40$                 B+(0%0
M          " * M1 0                "(LA 5                 ( H
M"U$!                 (BR$!4                 @"@+40$
M        B+(0%0                " * M1 0                "(LA 5
M                 ( H"U$!                 (BR$!4
M    @"@+40$                 B+(0%0                " * M1 0
M              "(LA 5                 ( H"U$!
M (BR$!4                 @"@+40$                 B+(0%0
M          " * M1 0                "(LA 5                 ( H
M"U$!                 (BR$!4                 @"@+40$
M        B+(0%0                " * M1 0                "(LA 5
M                 ( H"U$!                 (BR$!4
M    @"@+40$                 B+(0%0                " * M1 0
M              "(LA 5                 ( H"U$!
M (BR$!4                 @"@+40$                 B+(0%0
M          " * M1 0                "(LA 5                 ( H
M"U$!                 (BR$!4                 @"@+40$
M        B+(0%0                " * M1 0                "(LA 5
M                 ( H"U$!                 (BR$!4
M    @"@+40$                 B+(0%0                " * M1 0
M              "(LA 5                 ( H"U$!
M (BR$!4                 @"@+40$                 B+(0%0
M          " * M1 0                "(LA 5                 ( H
M"U$!                 (BR$!4                 @"@+40$
M        B+(0%0                " * M1 0                "(LA 5
M                 ( H"U$!                 (BR$!4
M    @"@+40$                 B+(0%0                " * M1 0
M              "(LA 5                 ( H"U$!
M (BR$!4                 @"@+40$                 B+(0%0
M          " * M1 0                "(LA 5                 ( H
M"U$!                 (BR$!4                 @"@+40$
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MECI#F>]CF<L&E(O^@E;((L]..>64JABGGGIJ(67)NXP /?0KM"/C2[J9_ <
M     *";^#8,H O<?OOM-1>A]KS....,W,YO(6I^+$2%]J M=88RW\<REPTH
M%_T%K9!%GBU9LJ2R^"KL!!AV" R+L\*?%5&6O,L(T$._0CLROJ2;R7\
M  "ZB6_# +K Y,F3>R=!C!PY,CHY8H,--D@^_OCC7,YO(6I^+$2%]J M=88R
MW\<REPTH%_T%K5"F/"M360"@$WG6TLWD/P       -W$MV$ '6[NW+G)D"%#
M>B=!A-U15UAAA>@$B;OOOCN7,EB(FA\+4:$]:$N=H<SWL<QE \I%?T$KE"G/
MRE06 .A$GK5T,_D/      ! -_%M&$"'N^"""WHG0$R8,*'R9[OMMEMT@L0!
M!QR02QDL1,V/A:C0'K2ESE#F^UCFL@'EHK^@%<J49V4J"P!T(L]:NIG\!P
M    H)OX-@R@PVV]]=:]$R"NNNJJRI]=>^VUT0D2JZRR2C)OWKS,RV A:GXL
M1(7VH"UUAC+?QS*7#2@7_06M4*8\*U-9 * 3>=;2S>0_        W<2W80 =
M[%>_^E7OY(<UUE@C6;!@0>7/WWOOO63X\.'121+3IDW+O!P6HN;'0E1H#]I2
M9RCS?2QSV8!RT5_0"F7*LS*5!0 ZD6<MW4S^ P      T$U\&P;0P8XYYIC>
MR0^''W[X<G_WC6]\(SI)8IMMMLF\'-VR$#4L])TY<V;R]:]_/1D_?GRR]MIK
M)T.&#*F\1HT:5?FS\'?A/3V+@IM5AH6HX5JF3Y^>?.$+7TC&C!E3N=ZUUEHK
MV62339*O?O6KR?>___UDT:)%F9:K1UA4?<,--R1''WUTLL,..R3KK+-.96??
M4(:1(T<FG_WL9Y,##SPPN>222Y(Y<^;D4H:8CS[Z*+GMMMLJ[6[<N'&5^EAI
MI962-==<L[)+\:&''II<<\TUR<LOO]RR,BU<N##Y\8]_7*FK[;??OI*3H:Y6
M77759+WUUJN4*]35>>>=ESS\\,/)QQ]_G-FYBV@;C92M%?E;AOXKZ[S\X(,/
MDMMOOSV9,F5*LOONNR>?^<QG*C]R$.IPW77733;;;+-DTJ1)R9EGGIG<>^^]
ME?/GI57Y78;[6$NKRZ;__?\Z"+O-?_&+7^SM/T(;V&*++9+##CNLTC[JR?OY
M\^=7?@ADK[WV2D:/'EV),V+$B$H;.OC@@Y/KKKLN6;)D2=/E#5Y__?7DHHLN
MJL3=:JNMDD]]ZE/)T*%#*Z_0;K?<<LMDO_WVJ[3K6;-F)6^]]58FYVU&F?J:
MF*+&08L7+Z[T>X<<<D@EYX8-&U;)]5 WH4XF3YZ<7'[YY=%[6.:^S'BE=MGD
M67IE*DLCY.0GVO'Y-9"\QBME'9^UXY@I*/L8)"M%_IM.-RBR?ELYKBKKOQ^6
MO1V7<8P7GJD''710I4\-_7>K%/T,ZY1Q+P       .3-MV$ '>K]]]^O3%SI
MF?SPX(,/+O?WO_SE+Z.3),+K-[_Y3:9EZ?2%J//FS4M..NFD9/755Z]9I_U?
MX;TGGWQRY=A&U!M_L->EEUZ:^GQ]W733395)P(.=+TRF"I.)LO+NN^\FIY]^
M>F6B;KW7O,(**R3[[KMO\OCCCS=TKGIB]_5?__5?E0E+]98K;V&R[G>^\YW*
MKLB-Y$BX9\<??WSRV&./I3YW*]M&T&A]YYF_>;?5(O/R%[_X16710ZV=M6N]
M-MIHH^3""R_,=')XWOF=]WUL1E%EZ]3^M]'WWWWWW<FG/_WI08\)/_#QW__]
MWS6O,2S*" LH!HL3)B+_[&<_:ZC^^@H+6<+$V3"1MI'\"/=NN^VV2[[WO>\E
M?_C#'U*?/XTB^II&\Z"(<="R9<N2*Z^\LJ[SAE=XKIYQQAF5B=4#76?1C%?D
M6=KZ21NCGE=6X[!&R<E/M,/SJ]'ZR^/S8IG'9^TV9@K:80R259RB_DTGCVO)
M.TZ:6$75;Q'CJK+513NTXW88XX7WA?ZWF>L<3"N?85G42;M\O@(      ("\
M^#8,H$/-F#&C=^+#V+%CH^\).XG$)DI\\YO?S+0L64W&*..DCMFS9U=^H;V1
M24U]7^'7]\,O\]<K[7GZO[)8B/JO__JO#9TS3!*Z[+++&J[C_L+$W?777S_U
MM8=)S%.G3JU[IX=&)EA=?/'%R8HKKMA0>?)TQQUWU#V1:J!7V)GAH8<>:NC<
MK6X;02/UG7?^YMU6B\C+!QYX(-ECCSV:OJ:P$\L++[Q0=UW6THK\SOL^-J.(
MLG5R_]O(^\..-8V<*^PX%.O/PB3O1LH;=H*YY99;ZKY?/6Z^^>:&%C/56V=Y
M*;*O::0.BA@'A5VM]MEGGU3U,6'"A-X%:D7=VUJ,5^19VOII)D8]KR(6HLK)
M3[3+\ZN1\^?Q>;',X[-V&S.URQ@DJSA%_9M.O8JHDRQC%56_18VKRE(7[=*.
MVVV,%W;P[MDM-LLVU>IG6)9U4N;/5P       ) GWX8!=*B)$R?V3GPXYYQS
MHN\Y__SSHQ,EPBX3'WSP069ER6HR1MDF=4R;-JTR$:A_F<:-&U?YN]___O?)
M@@4+*K_L'O[[HHLNJOQ=;#+1)9=<4M<YFYU(U?-J=B'J#W_XP]03A)YXXHG4
M=1[.&]L-)^PH$^H\['83ZGS1HD65"6,_^M&/DK_YF[^)EN7  P_LG435;)T'
M?1=_-_+*2YCD',O/S3??/#GOO/.2IYYZ*GG[[;<KNSR\\<8;R7WWW9=\][O?
M'7#B>[V*:!M!O?7=BOS-NZT6D9>UWONYSWVNTM:>>^ZY2MOKR:G[[[^_LDM$
M;!+LVFNOG3S__/-UW]O^6I7?>=_'9K2Z;)W>_];[_K"H(99[@[W";D1]=V0[
MZZRS4I4Y+,AYY957ZDV39-:L657W;>C0H<FQQQY;V:'LM==>2]Y___UDZ=*E
MR=RY<Y,''WRPLAM-6,A4;SO)6JUK;T5?4V\>%#$."M<<)CO'XFZ]]=;+/5_#
MA.I03V'WHK_^Z[_N?5\X/HSQB[JW,<8K\BQM_30;HYY7JQ>BRLE/M-/SJ][Z
MR^/S8IG'9^TV9AKHVLHT!LDJ3E'_IM.(5M=)EK&*JM\BQU5EJ8MV:,=E'^.%
MUS///)-<?OGER8X[[MC[OG_\QW]LZ#H'4\0S+&V=M-/G*P       ,B;;\,
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M65K=GK-4IN?*0+%:6;]E^9P<%%T76<NK';?[&.]WO_M=ZC94AF=8V<>]
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ML_*LDRS+5(9_,VOUY^2@Z+KHKZSMN-W'>.^]]U[F^9K'J]8SK.SC7@
M &@'O@T#Z "+%R].1HX<V3O1X?[[[T\5YZ&''JHY@>/QQQ]/7;XR3A9+HV\=
M]WV%23AIU?KE]K777KNNX_.NDZ+O7:TZS^.UX88;MK1.LI9'?A9Y[F;;1E!T
M_N91EJ+B!V$"_;>^]:UDI956RKS]#:;(_.ZKK.T_R+ILW=[_EJG_:#9.V"7N
MW_[MWY)APX8U=%\VW733Y-QSSTW>>>>=5&5.J\B^IK^B[]]::ZV52]]79%]F
MO%)-GN4?)^^<3QM?3@ZLW9Y?/?+,MTX>GY4ACC%(_G&:4<9K*;I,9?F<'!1=
M%SVTXT^4;8Q7AF=8V>H$        VI%OPP ZP TWW)#[!(X33C@A=?F*GGB3
ME9577CE:AH\__CAUS#!!*A8SG*L>>==)T?>N5IWG\5I]]=5;6B=9RR,_BSQW
MLVTC*#I_\RA+4?&7+%E2V4TD=IZPP\B!!QZ8W'333<ESSSV7O/ONN\FR9<LR
M+6N1^=U76=M_D'79NKW_+5/_D56<^?/G)^><<TZRQ19;-'1_PF3=RR^_?,!V
MG96B^YH\8C03I]8$^F;[OB+[,N.5:O(L_SAYYWS:^'*R/NWP_.HKSWSKY/%9
MT7&,05H3IQEEO):BRU26S\E!T741:,?+*]L8KPS/L++5"0       +0CWX8!
M=(!)DR;E/H$C[* 2=EY-H^B)-UG)8Z>!A0L71F..&C6JKN/SKI.B[UVM.@\3
MK(M2=![6TFD[C#7;-H*B\S>/LA05?\J4*=%SC!T[-GGRR2=S+VM9=GHI:_L/
MLBY;M_>_9>H_LHS3X['''DM..NFD9/3HT='8L=<!!QR0>BQ8KZ+[FCQB-!-G
MQ(@1N?1]1?9EQBO5Y%G^<?+.^;3QY63CROK\ZBO/?.OD\5G1<8Q!6A.G&66\
MEJ++5);/R4'1=1%HQ\LKVQBO#,^PLM4)        M"/?A@&TN5=??359<<45
MHQ,>LGZ%7XU/H^B)-UG99)--HF68.W=NZIAOO/%&S4E2]<B[3HJ^=[7J_.VW
MWTY5CBP4G8>UY)&?19Z[V;81%)V_>92EB/AAMY#8SA7#A@U+7GKII9:4M<C\
M[JNL[3_(NFS=WO^6J?_(,DY_8=+O77?=E7SM:U]+A@\?'CU/W]<WOO&-3,X;
M4X:^)H\8S<39:*.-,N_[PB3K(OLRXY5J\FQ@96K+6<>7D^F5Z?G57Y[7W<GC
MLR+C&(.T+DXSLBA#V#$SRVLING[+\CDY*+HNM.-J>8SQEBY=FGF^MO(95O9Q
M+P       +0#WX8!M+FSSCJK=X+#%[_XQ4QB[KWWWM$)%'OMM5>J>$5/O,G*
MSCOO'"W#L\\^FSKF,\\\$XTY8<*$NH[/NTZ*OG>UZORUUUY+58XL%)V'M=2J
MJS 9KZAS%]DV@J+S-X^R%!'_S#//C,;_[G>_V[*R%IG??96U_0=9EZW;^]\R
M]1]9QAE(V"WNQAMO3"9.G!@]7\_K5[_Z5>;G#LK0U^01HYDXX\>/S_SY6FN1
M6JL8KU239P,K4UO..KZ<S$;1SZ_^\KSN3AZ?%1G'&*1U<9H1*T-8%->(>?/F
M97HM1==O63XG!T77A79<+8\QWEMOO95YOK;R&5;V<2\       "T ]^& ;2Q
M9<N6+?=+WC???',F<4.<V 2*L//JG#ES&HY7],2;K(1=5&)EN//..U/'O/WV
MVZ,QCSWVV+J.S[M.BKYWM>K\YS__>:IR9*'H/*PEC_PL\MS-MHV@Z/S-HRQ%
MQ-]QQQVC\1]YY)&6E;7(_.ZKK.T_R+ILW=[_EJG_R#).O1YZZ*%DBRVVB)[W
MR"./S.6<9>AK\HC13)S##CLL\[[O][__?:%]F?%*-7DVL#*UY:SCR\GL%?'\
MZB_/Z^[D\5F1<8Q!6A>G&>'?)/N78<&"!0W%"(O-LKR6HNNW+)^3@Z+K0CNN
MEL<8+^PNFW6^MO(95O9Q+P       +0#WX8!M+'[[KNO=W+#J%&CDB5+EF02
M-\0)\6*3*,X^^^R&XQ4]\28KUUUW7;0,%UQP0>J8X=A8S)DS9]9U?-YU4O2]
M"_40._:**ZY(58XL%)V'M=3*SPLOO+"P<Q?9-H*B\S>/LA01?\R8,='X82>,
M5I6UR/SNJZSM/\BZ;-W>_Y:I_\@R3B/>>>>=9*NMMJHZ[Z:;;IK+^<K0U^01
MHYDXEU]^>>9]WT]^\I-"^S+CE6KR;&!E:LM9QY>3^6CU\ZN_/*^[D\=G1<8Q
M!FE=G&:LN>::565X_?77&XKQTY_^---K*;I^R_(Y.2BZ+K3C:GF,\>ZYYY[4
MY2G#,ZSLXUX       !H![X- VACAQQR2._DAA-//#'3V"%>;!+%QAMO7-F)
MM1%%3[S)2M@--E:&R9,GIXZYWW[[16.^^NJK=1V?=YT4?>]>>^VUZ+%''754
MJG+T>.:99Y:+%W;-J5?1>5A+K?S\ZE>_FCIF_YT.QHX=V]"YBVP;0='YFT=9
MBH@_9,B0:/P//_RPX5@+%RY,5=8B\[NOLK;_(.NR=7O_6Z;^(\LXC9H]>W;5
M>5=;;;5<SE6&OJ:_HN_?DT\^&3WV*U_Y2JIR!%.G3BVT+S->J2;/!E:FMIQU
M?#F9GU8^O_K+\[H[>7Q69!QCD-;%:<;ZZZ]?589?_.(7#<68,F5*IM=2=/V6
MY7-R,]>051SMN%H>8[SSSCLO=7G*\ PK^[@7        VH%OPP#:5-CE(TRD
M[)G<\,033V0:O];$C/"Z__[[&XI5],2;+.VYYYY591@V;%BJW6@7+UY<.;9_
MO'".>JV\\LI5QW_\\<<-EZ66,MR[29,F51V[SCKKI)I,UN.<<\Y9+MYIIYU6
M][%ER,-:8OD9=@U)NUORE5=>N5RL@1:\EZUM!&7(WQ[MTE9CUEUWW6C\N7/G
M-ASKZ:>?3EW6(O.[1][WL1EYE*V;^]\R]1]IX_1];Q@WIO'NN^]6G7?DR)&I
M8@VF+'U-7V7(@ZVWWCK:]RU=NC156;;99IO"QS+&*\N39P/+(DZ9QV%R<N#C
MVN'YU5_>?6RGCL^*C&,,TKHXS1@_?GQ5&7[XPQ\V%&.SS3;+]%K*4+]E^)S<
M[#5D$4<[CLMZC#=QXL2FRE.&9UB9Q[T       #0#GP;!M"F+K_\\MZ)#=MM
MMUTNY]A^^^VC$RG^_N__OJ$X99AXDY6[[[X[6HX9,V8T'.O::Z^-Q@KGJ-=:
M:ZU5=?P''WP0?6_X\[[O&SY\^*#QRW#O_O,__S-Z_"VWW)*J+&%BT08;;+!<
MK$86<I<A#VNIE9_77W]]JG@3)DQ8+LZ##S[8\+F+:AM!&?*W1[NTU9CPC(G%
MO^>>>QJ.-7WZ]-1E+3*_>^1]'YN11]FZN?\M4_^1-D[?]S[ZZ*.ISKMHT:*J
M\XX;-RY5K,&4I:_IJPQY4.M:TO1]3SWU5#16GFTIQGAE>?)L8%G$*?,X3$X.
M?%P[/+_ZR[N/[=3Q69%QC$%:%Z<9AQUV6%49CCCBB+J/O_/..S-]/@5EJ-\R
M?$YN]AJRB*,=QV4YQ@L[FJZXXHI-E:<,S[ RCWL!      "@'?@V#*!-[;##
M#KT3&RZ]]-)<SE%K8D;8B;61G4G*,/$F2SOOO'-5.<*N"HW\>GMX[]BQ8ZOB
M[+333@V5Y3.?^4Q5C#_^\8_1][[\\LO+O:^>B;AEN7>[[+)+U?&;;KIIJAT>
M^O]2_I>^]*6&CB]+'M:217X&]]Y[[W(QPNXCK3AW5FTC*$O^!NW25F-..>64
M:/Q&?Y0@[#RVY99;-E76(O,[R/L^-B.OLG5K_UNF_B-MG+[O#>TXC5_^\I=5
MY_WF-[^9*M9@RM37]"A#'BQ8L" 9/7ITU?%;;+%%\M%''S54CK_]V[^-EB7/
MME2+\<HGY-G LHA3]G&8G*Q]7#L\O_IK11_;B>.S(N,8@[0N3C.F39M658:P
MB^';;[\]Z+%AE^30KZZTTDJ97DM9ZK?HS\E97$.S<;3CN"S'>(<??GBT+(U>
M5]'/L+*.>V?.G)ELOOGFR2JKK%+)P9MNNJGA&        - *Y5HY 4!=^O[:
M]M"A0Y/Y\^?G<IXPF6O555>-3J;X]W__][KCE&'B399>>.&%RF2W_F4Y_OCC
MZXYQW'''51T_;-BPY/GGGV^H+/ONNV]5G$<>>23ZWC"!I>_[#CWTT$'CE^7>
MO?322Y7=B/K'").@EBU;5G><^^Z[KS*AI^?XE5=>.7GLL<=:>BUYJY6?C4R\
M_M.?_I1LO/'&RQT_>_;LU.<NHFT$9<G?H%W::LRO?_WK:/RP$\;]]]]?=YRI
M4Z<V/4&OR/P.\KZ/S<BK;-W:_Y:I_T@;I^][PWCNZ:>?;OB\!QYX8-5Y?_[S
MGZ>YA$&5J:_I498\"#L$Q6*<=-))=<>XZJJK*L=LM-%&+6U+M1BO?$*>#2R+
M.&4?A\G)VL>UP_.KOU;TL9TX/BLRCC%(Z^(TX]577TU66&&%JG+LO__^ RX>
M>_/--Y/==MNM\MZP@VJ6UU*6^BWZ<W(6U]!L'.VXMBS&>+?>>FNE_66QF+L,
MS["RC7MGS9H5C7'SS3<W% <       !:H5PK)P"H2Y@4T3,AX>_^[N]R/=<A
MAQP2G0BQXXX[UAVC+!-OLG3##3=$RQ-^@7_ITJ4UCPM_=^JIIT:/#;]\WJAS
MSSVW*LY99YU5];XPD:=GXETCYRO3O0N3;V*3#@\^^.!DWKQY@Q[_@Q_\H+*;
M;]]CPR_G%W$M>:N5GR>>>&+RP0<?#'CL,\\\DVR]]=;+'=?(#A)E:1M!F?*W
M7=IJ+6%R;^P<(T:,2.Z^^^X!CPT[BIQYYIF5]MMWDF#:LA:9WWG?QV;D6;9N
M['_+U'^DC=/__>NMMU[RT$,/U76^T">?=MII53'R'G>6J:\)RI0'!QUT4#1.
MN$\#/5]#F[_LLLMZ)XW?=MMM+6U+ S%>^7_R+/_K:H=QF)RL?5P[/+_Z:E4?
MVVGCLZ+C&(.T)DZS]MACCVA9_O(O_S*9,6-&\LHKKU3&$&$'U">??#+YWO>^
MEZRSSCJ5]X2%;W/FS,GT6LI4OT6.J[*ZAF;C:,>UI1WC!:%MA1_"#.^OM?-L
MH\KP#"O3N'>[[;:+QMAJJZT:B@,       "M4+Z5$P!$Q28CQ%ZC1HUJZCQK
MK+%&W>>J-<&BF6/37'.S$WK2NO322Z.39L(DD6G3IB5_^,,?D@4+%E1>81>7
MBR^^N/)W_=\?8H2_2R/L"-'_U^A77WWUY)IKKJGLE!LFSH0==/OO"!,F\RY>
MO+@J7MGO7=B)-^QFT/_8,+'PV]_^=O+  P\DK[_^>N6ZP\3#<.W3IT^/3N@Y
M^NBC*Q/-!I.V/;0Z'_L+DZ)B=;7IIIM6)N.'29DA1Y8L69+\[__^;W+GG7<F
M1QUU5._DLI[7+KOL4LGA1A35-LJ<OV5HJ\WD9=@=)>1.+%ZX3_OLLT]E(F&X
MSC#)==&B197)K)=??GGOO0WY&!9$9%'&HO([Z_N8I;S+UNG];]GZCRSBU'K?
M7GOME7S_^]^O[!;3DQLA!T([?_CAARL3]C?99).JX[;99INZ)@4WH^B^IDSW
MK[_WWGNOTF?%CATW;ESE>1F>J:%/6[AP8?+LL\\F5UQQ1;+SSCOWOJ]G=\4\
MVE!:QBORK!77589Q6#WDY,!QROK\2G/=C>3%0-IE?-8.<8Q!\HF3M2>>>*+F
MCHR#O7H6YS=S+66OWU:.J\I8%]IQ;8V,\4*]A!W5K[[ZZN3SG_]\[_LF3)A0
MJ;>T^=E?$<^PM'62]^>K6M_'A$71        4#86H@*TB7HGGEB(VEIWW'%'
MLNZZZZ:NLS"Y9O;LV4V5H=8..+5>8?)5K7.VP[V[YYY[DM&C1Z>N\Y577CGY
MYW_^Y[K/E_8\1>1C?V%283/YN??>>U<F>Z511-LH>_X6W5:;S<N77GJI:I>4
M>E]AL<=--]U4=]GK451^9WD?LY9WV3JY_\WJ'&6*TTS]]7_MN>>>R5MOO=5P
MO:919%]3IOL7$R:%[[OOOJGB'W'$$;V3L_-H0\TP7I%GK;BNHL=A]9*3[??\
M:J9\66B'\5D[Q F,0?*IUZR%Q9:Q1?NU7N&]YY]_?D/75DL[U&^KQE5EK0OM
MN+9FQGAA\>6;;[Y9LWQIM?H9EF6=9/GY*NSJ'#MFBRVV2'UM        D)?B
M5T@ 4)=Z)T%8B-IZ87>5DT\^N:&Z"Y.;OO6M;_5.XFG&AQ]^6/D%]GK.N^::
M:R8WWGACS5CM<N_>?OOMRF3R<#WUQ@^_LA\FU(4=-!J1MCT4E8_]A8G7W_G.
M=Y)APX;57>X--]PPN?+**YL^=ZO;1MGSM^BVFD5>AMTO3C_]]&3X\.%UGR^T
MN[#+2"-EKU<1^9WE?<Q:*\K6J?UOV?J/+.*$G?/"[G#CQX]O:+)^WU?8&>CZ
MZZ]ON#Z;551?4Z;[-Y"P(V"]$[8_]:E/)5===57#Y6LUXQ5YEO=U%3T.:T2W
MYV2[/;_2E"]-7@RD[..S=HC3PQ@DGWK-6NBCPZ[5@Y4I/,=NN>66AJ^MEG:I
MWU:,J\I<%]KQP!H9XX7QQ1EGG-&[0_RR9<NJWA.>U<UHY3.LEJ(_7X6=>F/'
MW'###9E<'P       &2I'"LD * #+%BP()DY<V9RY)%')MMNNVTR<N3(RB^S
MAU?X[_!GX=?2K[ONNLI[L_:[W_VN,M%LPH0)E4DQ0X<.K;S"Y+Q)DR8EYYUW
M7LMV,VN5\,OU85+.T4<?G6R__?:5A=A#A@Q)5EEEE<H.$%MNN65RT$$')1=>
M>&'RRBNO%%W<0BU<N+ R&?OK7_]Z95+WVFNO7<G-D"-CQHRIU%^8G#]KUJSD
MHX\^RO3<1;>-LNF$MAKNT]577YT<?OCAR;AQXRKM+;2]GNO8;;?=DJE3IR:_
M_>UO6U*>(O*[S/>Q%673_[:7,+DW[(YTYIEG)@<??'"RTTX[)1MLL$$R8L2(
MY>[;9IMMENRWWW[)V6>?G?SZU[\NNMBEZVO*)$P&#_U>N)_AOH4%:RNMM%)E
M G=/^YLQ8T;RWGOO%5W4AABOE$LGYEF9G]_]R<GV?7X5Q?@L.\8@Y1>>/3_X
MP0^2_???/]ETTTV3M=9:J](_AGL5^O.P<VJG]HWU*G)<50;:<6VUQGAA\?+8
ML6.3R9,G)].G3Z_\.$9?H4[[+Y8,8Y(L%/T,*WK<&Q:CAIU15UUUU<I.J#_^
M\8]S.0\        TRT)4         *)>?_WUJH6H8>$J        T#TL1 4
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M<N211R8S9\XL^I(       " @BA$!0       .AG'GWTT63<N'')2BNME*D
M->R*NM-..R7WW7=?T9<"        %$PA*@       $ _]OSSSR<77711<L@A
MAR1?^<I7DN'#AR=+++%$,FC0H$K!Z8(++IBLL,(*R:A1HY*Q8\<F%UQP0?+2
M2R\5W6T       "@)!2B @                 0I1 5
M ( HA:@                  $0I1 4                 ($HA*@
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M^+OP;^$SX;.=TIOYINSC>_#::Z\E8\>.3>:88X["?R8RW[1'&?/3%]X-
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MY_"]_+.?_6ROWXD0(\1JAS3S35\:W\//0<V*?SO-?--_YYN^]&X
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MO:Q*FUBL$TXX(76LF+3S35G']^J?(\\^^^RZ L\BYO):YIM_ZZ_S35G?#0
M       HBE5. /U$W@OP=MQQQVB\RRZ[+,=>\VE0],+0LIA__OGK\C!SYLRB
MNS6;,:1X97]& +J$':YJQZO==MLM=9PQ8\;4Q=E@@PUR[^^VVVX[._[(D2,K
M8VNGBU?"KEZU.^G=?//-3=N5*=?5;?_XQS^F[D-P[[WW1O,^?/CP3/%BTN8Z
MCR*>X)133HE>VX$''I@I7EGNO?RTAY^16E.F^SQZ].CH?;OMMMM2]R>\2[%8
MFV^^>>I8M;+,-V4=W\,O-]IOO_V2-]YXHVF_BWB7S#?=]<?YIJSO!@
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M?6M6Y!GSP0<?1&/-/__\J6/5*FH,[,3X7JO3<WDM\TUW_7&^R4,1[P8
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MCUD5/0:V<WQOI%-S>:VB<_UI'T^;R2L_>2GBW0        " =E&("M!/Y+T
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M=8R+>>JIIY(! P;,CM.H:*NWST&KKK_^^KIG__777V_:KB_D.JW''W\\^LL
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M1CCFF&/JVH58/_O9SS)?5U#4&-B)\;TGG9C+:YEO>M:?YIO>*/K=
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MLU:]^.*+R="A0^OBA-CA'&D4-0;&Y#V^MZ*=<WDM\TUK^M-\DY<BW@T
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MZZ*QPCEZ^E[1CC&P+.-[%GG.Y;7,-^:;OOQN         $"[E*L" H#,VKD
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M6>YSH_DW_"*G29,FM1SGQ1=?3(8.'9II+F_'&%B6\3V+/.?R6N8;\TU??C<
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M\C-EGLIRG\..M6&W]32Y[3I"F] VQ&A5N^>;(L?WGA0QUIAOS#?5ROIN
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MW#)9;;75NMW'\.?P=^'?PGAYS3779-J1O9-C8*?'][(QW_Q_97G/RN+3_FX
M        @$)4    @)1"X47MCE?5NQ&3'[D&/LV,@9TCUP          C2E$
M!0   $CIJ*..ZE:H,GSX\**[U&_)-?!I9@SL'+D&         &A,(2H   !
M2FNLL4:W8I6CCSZZZ"[U6W(-?)H9 SM'K@$         &E.("@
M      ! E$)4                  "B%*("                 !"E$!4
M                @"B%J                   1"E$!0
M   @2B$J                  !1"E$!                 (A2B H
M            0)1"5                   HA2B @                 0
MI1 5                 ( HA:@                  $0I1 4
M        ($HA*@                  40I1 0                "(4H@*
M                 $"40E0                  *(4H@(
M    $*40%0                " *(6H                  !$*40%
M             "!*(2H                  %$*40$
MB%*("@                ! E$)4                  "B%*("
M         !"E$!4                 @"B%J                   1"E$
M!0                 @2B$J                  !1"E$!
M     (A2B H                 0)1"5                   HA2B @
M               0I1 5                 ( HA:@
M $0I1 4                 ($HA*@                  40I1 0
M          "(4H@*                 $"40E0                  *(4
MH@(                 $*40%0                " *(6H
M      !$*40%                 "!*(2H                  %$*40$
M                B%*("@                ! E$)4
M  "B%*("                 !"E$!4                 @"B%J
M            1"E$!0                 @2B$J                  !1
M"E$!                 (A2B H                 0)1"5
M        HA2B @                 0I1 5                 ( HA:@
M                 $0I1 4                 ($HA*@
M    40I1 0                "(4H@*                 $"40E0
M             *(4H@(                 $*40%0                "
M*(6H                  !$*40%                 "!*(2H
M         %$*40$                 B%*("@                ! E$)4
M                  "B%*("                 !"E$!4
M    @"B%J                   1"E$!0                 @2B$J
M              !1"E$!                 (A2B H
M0)1"5                   HA2B @                 0I1 5
M         ( HA:@                  $0I1 4                 ($HA
M*@                  40I1 0                "(4H@*
M     $"40E0                  *(4H@(                 $*40%0
M              " *(6H                  !$*40%
M "!*(2H                  %$*40$                 B%*("@
M          ! E$)4    _A][]P$M25$OCO\17-(2%]V5GY*7L"19)(F@(F!
M1 011)*LXA,1C(@@H(AZ0()(4.&1E?#(B!A1$02>3P5!<ER0)$&6G+;_I^9_
M[GWWSM3<.]-ANF;V\SEGSL+N]+>KJZNJI[NJN@              HDQ$!0
M               @RD14                  "B3$0%
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M.VG0U[3'K>0)I$O]G#.E=MY32P^C.3^=DU=0GU[6OY_\Y"<M^YHZ=6KC.0L
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M>Y&>NJ3TC+ZNW]5SVG/P07D.Y3[,?5@J!O$^[)___&=T?__S/_]3V3X!
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M5U?=3C2KNWX/RG.HNLK+6/MNS@?W8>[#QOOTTWU86!FW.59XSE+&RN4
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M_4ZEK1POUIQR'W;AA1=&]WGBB2=6NE\     8,YF(BI 'UIYY96C'4L///!
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MK%C[G4);V4FL.>4^[.JKKX[N,[RDH1MA==QP+0TK/*^UUEK9>>>=5U&* 0
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M>P[57M'R$HN1YS>"^[!6=;>5G<::4^[#7GGEE>@^)TZ<V'&,=A/SP\L,
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M-ZO[=W79[40*]7N0GT/575Z"LMJ8*N.,)\7VN^ZVLM-8<\I]6!DKH@(
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M9_2I_:XNNYU(H7X/TG.HU,I+63'JCI-B^QW;UGU8^6GIU-577QW=9[^\I!0
M    Z$_]-0(%@&'__.<_&RL0-'<N'7/,,97M\\8;;VS9WUO>\I:N8M3=(=@\
M66OH<\TUU_0T'67'*!)GEUUVB6Y[^>67YTI'$-YRG3<]8=6%V+:A0[7?Q8XK
MA0[V(2GF?=WUHZHX90EON=]XXXU'I6>;;;9IK';2+WI5CHNT:9===EDTYIY[
M[EDHK=VHLNRE4/=3N#Y7<3W\QS_^46N[D4*^%G'555=EJZRR2G2_N^^^>Z7[
MCBGC^%-MH^J^3J::+T,^\I&/M,29,6/&\+^_[6UO&_[[DTXZJ6V<$TXXH27.
MRBNO//SOAQYZZ/#?;[OMMEVGLX@ZZMOQQQ\?W=_%%U^<.V:*[5[=]:N,."G6
MT;GGGKMEV_""EFZ$ =QE7MM2.M>]OF97J:SVJ>[SDV(]&JE?KW5UG]<RU9&&
M5'YO5WWL9=?;?GM&F6K[$]O^EEMN*3U-X65M>=.31]XXJ3VC3^UW==GM1 KU
M>Y">0Z567LJ*47><%-MO]V&]24NG+KSPPN@^3SSQQ$KW"P    #,V?IW! H
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M3^UW==GM1 KU>Y">0Z567H*ZZW09<5)LO]V']28MG=IWWWU;]A>>LX3G+0
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M<_!V^OTYE/NP<N/$I/+[T7U87-5M58B__/++CXH3GJ>$NI='6*DXEK;P]P
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MYMGAAQ]>>%4+>4_5>E&.0_MTUEEG9;OOOGOVEK>\I=$VA14+PB?\=_B[L(K
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M0OOM/JR]JMJJ;W_[VZ/:]? <)3Q/*2),.@TKH(:V)OQI$BH     ,!8340&
MTCWXX(,M@US"H!@  (!V]MMOOY956\)+E0  @.YX1@\P6.Z\\\YL@046&-6N
M?^4K7ZD[60    # ',9$5 "@=+___>];!KF\ZUWOJCM9  ! PF;/GIU]_.,?
M'W4?L?KJJS=6> ,  #KG&3W X'CRR2>S:=.FC6K3=]III\9S%     " 7C(1
M%0 HW9%''MDRR.600PZI.UD  $#B7GGEE6SKK;<>=2^QR2:;9,\]]US=20,
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M                 "#*1%0                  *),1 4
M    (,I$5                   HDQ$!0                 @RD14
M              "B3$0%                 "#*1%0
M *),1 4                 (,I$5                   HDQ$!0
M           @RD14                  "B3$0%                 "#*
M1%0                  *),1 4                 (,I$5
M        HDQ$!0                 @RD14                  "B3$0%
M                 "#*1%0                  *),1 4
M    (,I$5                   HDQ$!0                 @RD14
M              "B3$0%                 "#*1%0
M *),1 4                 (,I$5                   HDQ$!0
M           @RD14                  "B3$0%                 "#*
M1%0                  *),1 4                 (,I$5
M        HDQ$!0                 @RD14                  "B3$0%
M                 "#*1%0                  *),1 4
M    (,I$5                   HDQ$!0                 @RD14
M              "B3$0%                 "#*1%0
M *),1 4                 (,I$5                   HDQ$!0
M           @RD14                  "B3$0%                 "#*
M1%0                  *),1 4                 (,I$5
M        HDQ$!0                 @RD14                  "B3$0%
M                 "#*1%0                  *),1 4
M    (,I$5                   HDQ$!0                 @RD14
M              "B3$0%                 "#*1%0
M *),1 4                 (,I$5                   HDQ$!0
M           @RD14                  "B3$0%                 "#*
M1%0                  *),1 4                 (,I$5
M        HDQ$!0                 @RD14                  "B3$0%
M                 "#*1%0                  *),1 4
M    (,I$5                   HDQ$!0                 @RD14
M              "B3$0%                 "#*1%0
M *),1 4                 (,I$5                   HDQ$!0
M           @RD14                  "B3$0%                 "#*
M1%0                  *),1 4                 (,I$5
M        HDQ$!0                 @RD14                  "B3$0%
M                 "#*1%0   " _X^].P'[8MP?/WY*BY3VE$2[9(D62SHJ
M+93ET*$B2R'+Q2%[HA.RGK*42$ZVDJ7HA"P5HD113E('453:5+8H:^[_]9G?
M]3S_[_/]WO-\9[EGYOY.[]=US47US&<^,\_,/??,W L
M  "TZ(@*     ,!.Y"]_^4O>!0"B\.>??ZKITZ>K2RZY1+5NW5K5JU=/5:A0
M056I4D7ML\\^ZN"##U;'''.,&C1HD)HP88):M6I5TBD#
M -1.VA'U\\\_5X\]]IBZ]-)+58<.'523)DU4C1HU5+ERY9S_RI_;MV^O+KOL
M,O7,,\^H;[[Y)NF4 0"PWE=??:4F3IRH+KSP0M6Y<V?5L&%#5:U:->?^6JE2
M)56W;EW5O'ESYQX[8,  =<<==ZAITZ8YZP%1^."##]3UUU^O.G7JY'1RJ%BQ
MHK/(_\O?#1DR1"U:M(A\$LJ'.CF0'#JB DC"[-FSU?[[[^^I#*(\ @
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MKKONZCP?1I%G6IYC9(3MT@9=DF?I%2M61)H#$(1N=.9KKKDFZ;2@J&\
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MW;IUBR3/M#S'3)\^/>_^W7###9'F  3QZZ^_.AU/Y1V0S(XJ'5/E[Y \ZAL
M        HK!ERQ9GIK[,=X^5*E52GWSRB>]8O7OW#O0.,\WMBJ)XIWO333>5
MB+OOOOOZ:L=E2WNR3&E[]YVY/S*3I P"[,>.'3N<CH*Z<_K99Y\UDE>2;+PN
M3+#QVK*AC >0/JDO 3(+NXLNNBAPG+9MVVIOYM)9"P!L8+JQ::]>O;3QA@\?
M;C!K% )Y$:.[#_IY./)"9C[:;[_]C)S#IJ\'$Z+**3/6;KOMYKH=TQW&;#FN
M,J-6]K[*@_+FS9L]Q]BX<:.J6+&BD9<VY*-'G3P^490U;[[YIJI6K5I.3.F@
MFF]6.Q0&V^Z90*'A&G*G&WGXAQ]^2#JM5#-=%Y#GM%JU:FEC+EBPP$B>:7R.
MR7RG4J-&#>V^-6C0P/F(# !>4-\         $(7^_?OGO'N\]=9; \5Z\<47
M [W#3'.[(M/O=*4M9_8WV-&C1_N*84M[LDQI>_>=N3^77WYYH!AWWGFG]GP^
MZZRSC.25)!NO"Q-LO+9L*.,!I$_J2P!3%<E[[KE'>S._]-)+#68+ ,&9;FPZ
M9<H4;;R.'3L:S!J%8.C0H3GG@708C6)&#-W(9$&8OAY,B"JGS%B//?:8ZW8J
M5ZYL=/8I6XZKC/:4O:\R:Y-???KTR8ESZ*&'DH^A?*B3QR>JLF;APH7.J)/9
M<:7CR/_^]S\#F2-)MMTS@4+#->1.U\'P]]]_3SJM5(NB+G#====I8\JSHHD\
MT_8<LVG3)E6^?/GB[<CLJ&7*E-'NGSP# X 7U#<         F+9LV3)5MFS9
M$N\=98!-&:@T".E %>0=9IK;%9E^I_OTTT^7B"EM>?P.!&Q+>[),:7OWG;D_
M;[SQ1J 8\^?/UY[/^^^_OY&\DF3C=6&";=>6+64\@/1)?0F06=A]_?77@>.X
MW<QE]!0 L('IQJ:K5Z_6QFO8L*&YI&&]SS[[3)4K5R[G/'CAA1<BVV:;-FU"
MG\-1-+X.*ZJ<LF,-&## =5L'''" VK9M6^AMZK:;A*5+EVKW\S__^8_O6),G
M3];&6K)D"?D8R(<Z>7RB+/^F3IVJC7W000?1J:C V7;/! H-UY [CDW\HJ@+
MS)HU2QNS0X<.1O(4:7J.N?ONNXNW<<011SA_UZE3)^V^]>[=.[(\ *0+]U0
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M*.H"/__\L_'W VE]CEFP8$%Q?-F7K5NW.G\O'6VK5JVJW2\&] #@!?=4
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MUW4?%B]>'"K'L.*N(Q5)\CU2%.6H5TEN.ULAE&M>V%A_"</4\2QB8[T!
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M<"/;""JN.I(-[Y'<RM%[[KDG4 Y^)+GM;(50KGEA8_TE#-/W5!OK#0
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M44>RX3V2T)6C4N<-.OOM0P\]5")6:1V8D]QVID(HU[RRK?X21A3U#=OJ#0
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MXVPCZ8PJ,Z-*FV<Y%D\]]931^#9<6T4HXP&$18L;      "0&B9&-@4
M         #NGR9,GY[0[B&)B$]B%WSL  /G1&A,      *0&'5$!
M     $ 0V[9M4TV;-BW1YJ!/GSY)IX6(\7L' , ;6F,"     (#4H",J
M           (XIQSSBG1WJ!V[=KJZZ^_3CHM1(S?.P  WM :$P      I 8=
M40$             @%]#A@PIT=:@0H4*:N[<N4FGA8CQ>P< P#M:8P(
M@-2@(RH              /!CX,"!.9T1ITZ=FG1:B!B_=P  _*$U)@
M2 TZH@(              #^>?_YY5;Y\>:>-0?7JU=7KK[^>=$J( ;]W  #\
MH34F      !(#3JB @              OZ9-FZ8Z=^ZL5JU:E70JB!&_=P
MO*,U)@      2 TZH@(                  )A%:TP      %"P=!U/\RT
M                  #PCM:7      "@8-$1%0                  (%JT
MO@0       6+CJ@                   #1HO4E
M        M.B("@                           "TZH@(
M             $"+CJ@                           #0HB,J
M                    M.B("@                           "TZH@(
M                         $"+CJ@                           #0
MHB,J                            M.B("@
M     "TZH@(                          $"+CJ@
M          #0HB,J !2@O_SE+T:7"A4JJ-JU:ZNF39NJ'CUZJ.NOOU[-G#E3
M[=BQ([$<;?+((X_DY'?AA1<FG18                        0.;MZ^@
M/#'=$=5M:="@@;KKKKO4'W_\$7N.-NG0H4-.?E6K5E7;MV]/.C4
M               @4G;U] $ >!)71]2BI6W;MFKMVK6QYFB+Y<N7N^8X<>+$
MI-,#                        (F5/3Q\ 0"A!.G3^]--/:OWZ]>K--]]4
M(T:,4 <??+!KG)8M6ZK-FS?'GF/2!@\>[)IWY\Z=DTX/
M        B)3=O7\  )Z9ZN0Y:=(D5:5*%6VL_OW[6Y%C7/[XXP^UYYY[NN9=
MIDP9M6+%BJ33!                        ")C;^\? ( O)CMYSIPY4QNK
M;-FR:MFR95;D&(?ITZ>[YERTW'###4FG"0                       $3&
MWMX_  !?3'?R[-6KES;>\.'#K<DQ:IG'H$:-&MK<&S1HH';LV)%TJ@
M                 $ D[.W] P#PQ70GSRE3IFCC=>S8T9H<H[1ITR95OGSY
MXAQE=M0R9<IH\W_UU5>33A<                       "(A)V]?P  OIGN
MY+EZ]6IMO(8-&UJ38Y3NOOONXOR...((Y^\Z=>JDS;]W[]X)9PL
M              !$P\[>/P  WTQW\MR^?;LVWFZ[[69-CE$Z\, #B_,;/WZ\
M\W<3)DS0YE^A0@6U9<N6A#,&                        S+.S]P\ P#<Z
MHIJS8,&"XMPJ5ZZLMF[=ZOS]MFW;5-6J5;7[,&K4J(2S!@
M         ,RSK_</ " 0TYT\5Z]>K8W7J%$C:W*,R@477%"<6__^_4O\V_GG
MGZ_=AU:M6B63+                        ! A^WK_   ",=W)<\J4*=IX
M??OVM2;'*,A,L-6J52O.;<Z<.27^??[\^:[[L6C1HH2R!@
M         *)A5^\? $!@ICMYGGSRR=IXTD'5EARC,''BQ.*\FC=OKOV9_???
M7[L?%U]\<<S9 @                       -&RJ_</ " PDYT\9\R8H8W5
MJE4KM6/'#BMRC$KGSIV+\[K]]MNU/S-RY$CM?E2O7EW]_///,6<,
M                1,>NWC\ @,!,=?)\ZJFG5)4J57+BU*Q94RU?OMR*'*.R
M<N5*5:9,&2>G77;91:U;MT[[<U]__;4J5ZZ<=E^>?/+)F+,&
M            HF-/[Q\ 0"A!.GENW[Y=;=BP0<V9,T>-&#%"M6[=6AM#_O[S
MSS]/),<X#1TZM#BGXXX[KM2?/>FDD[3[TK5KUYBR!0
M     *)G3^\? $ H;IT\@RXRXV?W[MV=&5+__///2'.TP8X=.]3>>^]=G-/4
MJ5-+_?D77GA!NR\RH^JJ5:MBRAH                       "(EAV]?P
MH9GJ@"H=*3MUZJ0>??11M6[=NEARM,&,&3.*\ZE3IX[Z[;??2OWYWW__7=6K
M5T^[/S?>>&,\20,                        1LZ/W#P @--,SHLI2MFQ9
M=?311ZOGGGLNTAQMT+MW[^)\KKCB"D_K7'/--=K]:=BPH3/#*@
M             %#H[.C] P (+6@GSVW;MCDSG\Z?/U^-&C7*F0U5%^?((X]4
M*U>N3"3'J'WSS3>J8L6*Q?DL7;K4TWJ??/*)ZS[-FC4KXJP!
M          " Z"7?^P< 8(3)3I[OO?>>:M:L64ZLVK5K._]F0XXFC1X]NCB7
MPPX[S->Z[=NWU^[3::>=%E&V                        0'R2[_T# ##"
M="?/[[[[3C5OWCPG7MVZ==7Z]>NMR-&40PXYI#B7<>/&^5IW_/CQVGW:====
MU;???AM1Q@                       $ \DN_] P P(HI.GHL6+=+&[-6K
MES4YAO7!!Q\4YU&I4B7U_???^UI_Z]:MJG+ERMK]NO_^^R/*&@
M             (@''5$!("6BZN39K5NWG)AERI11RY8MLR;',"ZYY)+B/,X\
M\\Q ,?KW[Z_=K]:M6QO.%@                       (@7'5$!("6BZN0Y
M9LP8;=QAPX99DV-0O_SRBZI1HT9Q'K-GSPX49^[<N:[[MGCQ8L-9 P
M                 /&A(RH I$14G3P7+ERHC=NI4R=K<@SJZ:>?=LW)U'+I
MI9<FMG\                       ! 6'1$!8"4B*J3YX8-&[1Q]]Y[;VMR
M#*I[]^Z1=T2M6;.F,_,J                        4(CHB H *1%5)T_I
M1*F+6ZE2)6MR#&+UZM6J;-FRD7=$E67RY,F)[",
M   0%AU1 2 EHNKDN7W[=FW<W7;;S9H<@[CIIIN*M]^S9T\C,7OTZ*'=OV..
M.<9(?                        "!N=$0%@)2(JI/G^O7KM7$;-FQH38Y^
M_?GGGZI1HT;%VY\R98J1N!)'MW\R\^J:-6N,; ,
M  "($QU1 2 EHNKD^=Y[[VGCMFO7SIH<W;;AYO777R_^F5JU:JE??_W5R+8E
MCL33[>/PX<.-; ,                       "($QU1 2 EHNKD.7KT:&W<
MBRZZR)H<W;;AIE^_?L4_<]EEEQG=OL33[6/CQHV=F5@!
M      " 0D)'5 !(B:@Z>7;NW%D;=]JT:=;DZ+8-G>^__UY5JE2I^&<^_/!#
MH]M?LF2)ZW[.GCW;Z+8                       " J-$1%0!2(HI.GN^]
M]YXV9JU:M=2//_YH18ZE;4-G[-BQQ?_>NG5KH]LNTK9M6^U^GG'&&9%L#P
M                     (@*'5$!("5,=_+\]MMO5=.F3;4Q1X\>;46.^;:A
MTZY=N^)_'S-FC-%M%WG@@0>T^RDSL<J,K                        $"A
MH",J *2$R4Z>"Q8L<.V$>OCAAZO??OLM\1R];"/;TJ5+B_^M8L6*3F?;*'SW
MW7=JUUUWU>[K@P\^&,DV 0                      @"C0$14 4B)H)\_M
MV[>K#1LVJ/GSYSLSG7;LV-$U5NO6K9U.EG'G&'0;V2Z__/+B?^O;MZ_1[6;K
MUZ^?=E\//?302+<+                X/^Q=Q]0<A0''O"M+)"0$"*(<&01
M11))'&>R )^/9\MD$43FCAP/8V&;PW<<#PR((#"(<$C"9&,0R9B,;3@?'/'(
M48!)D@ A0+F^K^9[N]]JIV8U,SNA9_;W>V\>8G>ZJJ:ZNWJGN_]=    0"4)
MH@(TH$*!SFJ^#CSPP/#EEU]FNHVI@&NQ[QT\>'"GUDF_?OTZU4X
M      #((ND7@ 94JR#G$DLL$?;;;[_PU[_^-;-M%$0%              "
MZI%^ 6A E0QK]NC1(Q<X77'%%<.FFVX:1HT:%7[^\Y^'^^Z[+WS[[;>9:*,@
M*@               -2'] L                  $F"J
M    ) FB @                "0)(@*                 $"2("H
M             $F"J                   ) FB @                "0
M)(@*                 $"2("H                  $F"J
M        ) FB @                "0)(@*                 $"2("H
M                 $F"J                   ) FB @
M  "0)(@*                 $"2("H                  $F"J
M            ) FB @                "0)(@*                 $"2
M("H                  $F"J                   ) FB @
M      "0)(@*                 $"2("H                  $F"J
M                ) FB @                "0)(@*
M $"2("H                  $F"J                   ) FB @
M          "0)(@*                 $"2("H                  $F"
MJ                   ) FB @                "0)(@*
M     $"2("H                  $F"J                   ) FB @
M              "0)(@*                 $"2("H
M $F"J                   ) FB @                "0)(@*
M         $"2("H                  $F"J                   ) FB
M @                "0)(@*                 $"2("H
M     $F"J                   ) FB @                "0)(@*
M             $"2("H                  $F"J
M) FB @                "0)(@*                 $"2("H
M         $F"J                   ) FB @                "0)(@*
M                 $"2("H                  $F"J
M    ) FB @                "0)(@*                 $"2("H
M             $F"J                   ) FB @                "0
M)(@*                 $"2("H                  $F"J
M        ) FB @                "0)(@*                 $"2("H
M                 $F"J                   ) FB @
M  "0)(@*                 $"2("H                  $F"J
M            ) FB @                "0)(@*                 $"2
M("H                  $F"J                   ) FB @
M      "0)(@*                 $"2("H                  $F"J
M                ) FB @                "0)(@*
M $"2("H                  $F"J                   ) FB @
M          "0)(@*                 $"2("H                  $F"
MJ                   ) FB @                "0)(@*
M     $"2("H                  $F"J                   ) FB @
M              "0)(@*                 $"2("H
M $F"J                   ) FB @                "0)(@*
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MW1HVZM>O7Y@Y<V;NY]]\\TT8,&! ,I0T;MRX.K<::D<PCQ:"J
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MI3XK9.'"A>&JJZXJJM[XBN^;,&%"5?JK$BI1?];66V>W\\,//[SHNFHYS@$
M            4%N"J !-:N+$B:UAGZ%#AR;?L\$&&R3#0<<<<TS%VW///?<4
M'5CKZ!5G#7SBB2<:INZ[[[X[++OLLF77N=QRRX4I4Z8475^E@GV5# B64M:_
M__N_E]0_W;IU"Y=??GE%VU+,*TM!U&KW64J<6?B'/_QA67T79V>>/W]^1?NK
M$BI1?];66V>W\V*#J+4>YP              J"U!5( FM<,..[2&?,X]]]SD
M>RZXX()D*&CII9<.WWWW7<7:<LDEE^1"5.WK67?==</YYY\?7GKII?#%%U^$
M.7/FA$\^^20\]-!#X5__]5\[##8U0MWCQHU+UKWAAAOF?O=___=_8>;,F>&K
MK[[*_?OBBR_._2X50+OTTDN+JK-2P;Y*!@2++>OZZZ\O*\36HT>/\/SSSU>L
M+<6\LA)$K46?M3=KUJPP8L2(9+G#A@U;9-N.K]=>>RU<<<458<LMMVQ]W[_\
MR[]4M+\JH1+U9VV]=78[+R:(6H]Q#@            " VA)$!6A";[_]=FLP
M* :7/OKHH^3[/OWTT]"S9\]D .G&&V^L2%LF39J4+/^44T[)A3\[,F/&C#!J
MU*BRPV%9K/N,,\X(\^;-*[C<W+ESP^FGGYY<=O+DR475W5:E@GV5# BFRGKO
MO?="__[]<_^.L]?&V2)CX.[++[_,A:+?>>>=7'BOT"R^.^VT4]T_5S7+SU*?
M[;777LGRSCSSS ZW[84+%^9"B-V[=\^]_XX[[JAZ_Y>B4!BSTF76:[T5:D]G
M9&6< P            "@N@11 9K066>=U1KJ^<=__,<.W_NC'_TH&0;:>>>=
M.]V.-]YXHS5PU?9UP@DG%%U&##.-'#FRY/!4%NN. =AB'7_\\7G+QS+??//-
MHLN(&B6(>M!!!^7^N\LNNX3ITZ<77#8&V.(VW7[Y&+Q^__WWZ_JYJEE^5OKL
MEEMN2;;EM--.*[J,\>/'YY99==55NV00M5[;>J'VE"M+XQP
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MJMG_M>ZS.-ME^^4'#AR8"[.7(\ZDVA6#J/7:U@NUIQQ9&^=2LZK&5YP9%0
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MFU>7-C5R$+66?;;ZZJM7?-O^YIMONF00M5[;>J7*R>(X!P            !
M=0FB C2!V;-GAT&#!K6&=QYYY)&RRGGBB2<*AK&>>^ZYHLMIVY:VKQ@\J[9F
MJWO6K%G),I=99IFBEL]2@"V+;6KD(&HMRQDX<&!5]JNN&$1M]'*R.,X!
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M_'G;]PT8,* F;<Q*.>/'CZ_8?O7!!Q^$[MV["Z(V:#E9&^<
M *@N052 !K7%%ENT!G8NN^RRJM11*'@69V*-,[(NSM9;;YVW;)Q=<]Z\>26U
MX\$''URDC#C+9[/7'=\[=.C0O'*VVFJKDMH_;MRXO#+B+)9??/'%8I?]ZJNO
M<NWNT:-'TP91UUQSS;PR/OKHH^1[WWWWW47>M^&&&]:DC5DI9^;,F6&%%5;(
M6WZ]]=8+\^?/+ZD=8\:,J4KPLS,$44N3I7$NNNFFF\+ZZZ\?>O?NG?MO_'\
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M&EN]QKD8.HTSH,;M+_Y7"!4             H'($40$ J+D//_PP+X@:@ZL
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M88,--@@KK+!"Z-^_?RYP.F# @+#::JN%X<.'A\,//SQ<=]UU8>K4J?5N-@
M            4 )!5                   D@11 0                !(
M$D0%                 "!)$!4                 @"1!5
M        D@11 0                !($D0%                 "!)$!4
M                @"1!5                   D@11 0
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MBY.EOHTSR[5ORUEGG56W]E ;61WSL[1OT!BR_%VTTOM7-?:)K!S[G7,'
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MKJ51MX\66>Y;2I?5]=E(8WZ+K/8EV97%[Z*IMF5!5H[]6?NNWG:Y9COG#@
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MM:>1QA/G6CK6U<^U-/KV$66U;RE/%M=G(XWY;66Q+^D:G'-WSKTSLGC.'0
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M]-*I5"3A]])++RUR/\#I=^'TTT]7#SSP@.N7GV1BG=F$>^[<<T^':??< 0
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M,RG*BPC2G:4V$^M,%+7?I()[[GIAG/NSY5H]4:;ON0,       "PE_DGG "
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M]*7N)DV::+\+??KT*?(Y>5-Z_-O$ITV;YLOZG8KJ=S91V'U]$.3[K=L7,NN
MG\+8Y]E^+ERW;ITV%K_?I!^S:=,F:P8?NWWGYR*S6WBAJRN=<Z@,<M/5><()
M)V1-/" 1%?_#-5MJM(]W4;HVBHG">5_XV9?>=MMMMC'*C%1[]^X-9+U1$O8Y
MTR_<:\D,[K5PKR65;#@^=&V[?_]^SS%EXGJO08,&VG*2,!46NQBV;=L66@S"
MQ.]*E/K\>%[;4I)O=3/D5JQ84:U?OSZT.(HCB=IRK7+--=>HRI4K%_M;]\8;
M;XSD.DW"/7?GPCCW9].UND[8]]P!        %"_S3VT  +XK+"Q4K5JU*O)
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M&3CGG'-L^UQ9/OSPPTBO,Y.XY^Y.&.?^;+I6UPG[GCL       " XF7^J0T
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M%$?\9[W.K"BS=B:NMVG3ID:MTU0F78O&E^.>NYXIU^I^MFF8]]P!
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MHD6+',4NW^G!@P<GU5'<[^I,K#.>";])3;P6M3L.N>>>+-/7ZKKM-?V>.P
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MK63?NG7K6O?JXK\'\EV6I/=APX:E/?-R)M8I^$WJ#/?<G<OTM3KWW $
M (#L0B(J      #P7=!O]8]Z/     " [,3U)P           +(13[T
M (#O3!MX:UH\     (#L(S.!)EY[RNR)            0-0QZA(      /C.
MM,1/T^(!     &2?@H*"I&O/O+R\3(<%            I(U1EP      P'>F
M)7Z:%@\     (!KBKR,ET325SS__/.G:LV7+EB%%"@            2'49<
M     ,!WIB5^FA8/     " :XJ\C/_SPPY2?S<_/3[KVO.VVVT**%
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MM6OG^-KR][__O5J[=FVFPP8           !\Q2A+      "0-M,2/TV+!P
M   0;:M7KU;WW7>?ZM2IDZI;MZZJ4*&"*E>NG,K+RU.M6[=6 P<.5.^__WZF
MPP0            "P2A+                            :)&("@
M                     "T240$                          *!%(BH
M                          "T2$0%                          "
M%HFH                            T"(1%0
M     %HDH@(                          $"+1%0
M          !HD8@* $ $_;__]_^*77(-;0(                      . _
M,C(  (@@DBZ3T2;_9<+V+ENV3-UQQQWJ[+//5GEY>:I<N7+6(O\M_S9TZ%"U
M=.G2C,7GA6G;9%H\                     (#LE1L9&0"099PDW 6](+/8
M1\EHD__*Y/9^^NFG5A*DTWZD??OVQB=+FK9-IL4#
M ,A^N9&1 0!9)M-)J+F2T!<E[*-DN=HFF=K>D2-'JM*E2[ON2TJ5*J4>?OCA
M4&-URK1M,BT>                     $!NR(V,# #(,IE.0LV5A+XH81\E
MR]4VR<3V#APX,*FMRY8MJ_KW[V_-QKE__WYKD?_NUZ^?*E.F3-+GY;,F,6V;
M3(L'                     ) [<B,C P!R0!@)H[F6T!<EN9ITF4JNMDG8
MV_O$$T\DM7/-FC6MA$@[GWSRB:I1HT92N<<>>RR4F(MCVC:9%@\
M            (+?D1D8& .0 $E%S6ZXF7::2JVT2YO8N7[[<FI4S?IVE2Y=6
M'WSP0;%EERQ9HDJ5*E6DK,SBF2JY,@RF;9-I\0
M<D]N9&0 0 X@$36WY6K292JYVB9A;>^OO_ZJVK9MF]3& P8,<%S'W__^]Z3R
MK5NWMNK.!-.VR;1X                      "Y*3<R,@ @!Y"(FMMR->DR
ME5QHDPT;-JAQX\:IKEV[JN;-FZNJ5:L6V=[JU:NK-FW:J&NOO=;ZW!=??.';
MNE]^^>6D]BU?OKS:OGV[XSJV;MVJRI4KEU3/2R^]Y%N<;IBV3:;% P
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M7WVUY^WKWKU[4GVR#EE7&$S;)M/B 0                    #DMNAF9
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MY88;;M#&\NZ[[[K=K",D^5E79Z]>O3S7Z89IVV1:/
M  " W!;=C P 0!$F)*(ZB2F3]=C5M7'C1E6Q8D7KOVO6K&G-C"K)I3_^^*.5
MT+A^_7HK0;-)DR;:\ATZ=/ 4RQ577*&M;^C0H=H$PW@23]FR9:W/#QPXT)<V
MFCU[MBI9LF12/;???KLZ>/!@RK(OO_RR*E^^?%)9B<T-T]K$%.7*E;,]=A,Y
MV=X??OC!<[O(\:Z+9=6J5:ZW*V;ERI6^?K?<,FV;3(L'
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M]CLJ;35\^'"U??OVP!-1=8G&LKB=N3:>[&==G67+EO4Q<GNF;9-I\0
M                <AN)J "0)8),(O4SIDS68U?7O??>ZZJ.Q8L7)]7QF]_\
MQE'9Y<N7:V/HVK6KAZWYKQ$C1GAN(YE)4U>V9\^>GN,9.7*DMLYMV[9I/V]:
MF\0K4Z:,MAZ9L3)LO7KULOV>QR<5!IV(ZG=?(W[]]5=MG9)\&P;3MLFT>
M                    N8U$5 #($B2B>J_KM==><U7'YLV;D^JH7+FRH[)C
MQHS1QC!Z]&@OFV.9.W>NYS;*S\_7EITX<:+G>-Y[[SUMG7/FS-%^WK0VB6?*
MC*CBYY]_5AT[=BPV&35^:=BPH1HP8("5/)W.;)KQLG&V3M.VR;1X
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MRY8MGM9=JU8M;;T__OBCY^V1XTU79^W:M3W7Z89IVV1:/
M      " W$8B*@!D"1)1O=<ELTR&%5.]>O6T9;=MV^8ZAAB)WVL\#1HT<)W(
MZ'61A-,HM$F4R&R^M]]^N\K+RW.]/RI4J*">>>89U^MLTJ2)MKYOO_W6\W;(
M+*VZ.ILU:^:Y3C=,VR;3X@$                     Y+;LR\@ @!SE=R)J
M4#%ELAX38JI2I8JV[+Y]^SS%D6X\U:I5"RT1]?CCCX]$FT31X<.'U9(E2]2
M 0-<[Y>__O6OKM9U[KGG:NOY_////<?_V6>?:>OLT*&#YSK=,&V;3(L'
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M%ZOJU:O;]A7#A@US5/^;;[ZI+3]\^'#/,<NZ=77.G3O7<YUNF+9-IL4#
M                 ,AMN9&1 0 Y("J)J </'G15QXX=.[(J$;5%BQ;:LE]^
M^:6G.,36K5L]Q].F31MMV6^^^<9S/&Z9UB91EVI[/_C@ U6F3!EMVYQUUEF.
MZI<$X1(E2B25O^:::SS'W+U[=]^3D=TP;9M,BP<
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M:[1MT[]_?U<QZ6;9+%^^O-JQ8X?C.G[XX0=5KERYI'J*2[8-BFG;9%H\
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M/_KHHV++OO_^^];Q$5]6_O[QQQ^[CF/V[-G:_20SBD9UFTR-!P
M          "0>TA$!8 L86(BJNC0H8,VKM-..TU-FC1);=RX41TX<,": 77E
MRI7J@0<>4#5JU+ ^(XF1FS=OSLI$5-&M6S=M/8,'#U8'#QZT+2>)H4\]]=21
MV6)???557^*1I#U=XG#W[MW5CAT[BBW_W'//J?+ERQ<I*[.CNF%:F\C,FKIZ
MY-_#I(M!OEO???==RL_&D^]:\^;-D^JI7KVZ^NJKKSS'-FK4J*0Z97;;3S_]
MU+:,)%?6K%DSJ=R($2,\Q7#ZZ:=KVZA)DR:1W2:3XP$
M    Y);,9R@! %RS2SIUNX1AQ8H51Y(#W2[Y^?F.M]?/M@JRGGC[]NU39YYY
MIK9LTZ9-U1-//*'6K%FC"@L+U9X]>]277WZIGG[Z:=6F39LCG^O;MV_:;11O
MW+AQJF3)DDEE)3GXMMMN4^^]]Y[:LF6+E10JR<.K5JU28\:,T28"]N[=6QT^
M?-C1>DUMDZ...DI;3OX]3';Q2QS2SC*;[(8-&ZSVB___,KNPS%)[RRVW)"4)
MRU*Q8D7UP0<?I!W?K;?>FE2WS(PKQXPD2^[?O]]:)#E2/AL_:V[B?O/BZ*./
MUK:/K">JVV1Z/                     " W$$B*@!$D)>D2*^)B7Z0F2IU
M,VW:+?+9D2-'NMI>.WZU2U#MNW?O7G7))9=XJO_ZZZ\_DNCIY_Y^ZZVWK-D6
MO1Y7I4N75G???;?C]9G<)C)SKZZ<_'N8)%FT:]>N5MOZ]?UOU:I56C.A)GKX
MX8<])9U+F>'#AZ>U;KO]U*A1H\AN4Q3B 0                    #D!A)1
M 2""_$I$"].T:=-4[=JUBXU)$B!E=D>WVVO'KW8)NGV???99Q\F?-6O65./'
MC_>MC71V[]ZM!@T:I"I5JN1X>V4FU0LOO-":!=</)K3)C!DSM.7DWS-A\^;-
MZJ&''M+.0.MTD:3-R9,GJT.'#OD>W]*E2U7[]NT=Q]*N73OU\<<?I[U>N_TT
M=>K4R&Y35.(!                     &0_$E$! *'9MV^?>NZYY]055URA
M&C9LJ*I4J6+-\'CLL<>JCAT[6C.G%A869CK,C/GIIY_4BR^^J+IW[ZY..NDD
M=?311ULS&4HR:./&C56W;MW4I$F3K'8,B\Q.*LE\O7OW5F><<88ZYIAC5)DR
M9539LF6M_1:+:]2H46KCQHV^K]^$-I$D1TG>E'7+GYE*0DVT?OUZ-6'"!'7+
M+;=8R8;UZ]=7%2I4*)*$6+5J52MI5;YSHT>/5JM7KPXEMD\^^40-&3+$2IB4
M)&$Y7F21_Y9_&SQXL._)D;']=-111UDSH4Z9,L77^C.Q35&*!P
M          "0O4A$!0  R")>9\$%                      #0(4,!   @
MBY"("@                      _$2& @  0!8A$14
M     /B)# 4  ( L0B(J                      #P$QD*    681$5
M                    X"<R%    +((B:@                      ,!/
M9"@   !D$1)1 0                    " G\A0    R"+CQX\_L@
M                 *2+1%0                           !HD8@*
M                        +1)1 0                          H$4B
M*@                           +1(1 4
M ( 6B:@                           #0(A$5
M        6B2B @                          0(M$5
M             &B1B H                            M$E$!
M                  "@12(J                            M$A$!0
M                        @!:)J                            - B
M$14                           !:)*("
M  ! BT14                            :)&("@
M         "T240$                          *!%(BH           "
M_\_>G4#+4=6)XY?LD!!(6!(0V<,:MK"%00%918<1! ($(6%WV&0U(HRB.,B
M0%B"2A!,"/M.$E%D5X&9@4$$V9>P+Y) 0H#L]?O?.N>]_\OKVR_=_7JIZO?Y
MG%.'D'3=^^U;5;=KN=^Z         ! E$14                 @"B)J
M                1$E$!0                 @2B(J
M  !1$E$!                 (B2B H                 0)1$5
M            HB2B @                 0)1$5                 ( H
MB:@                  $1)1 4                 ($HB*@
M        41)1 0                "(DH@*                 $"41%0
M                 *(DH@(                 $"41%0
M  " *(FH                  !$240%                 "!*(BH
M             %$240$                 B)*("@                !
ME$14                  "B)*("                 ! E$14
M        @"B)J                   1$E$!0                 @2B(J
M                  !1$E$!                 (B2B H
M    0)1$5                   HB2B @                 0)1$5
M             ( HB:@                  $1)1 4
M($HB*@                  41)1 0                "(DH@*
M         $"41%0                  *(DH@(                 $"41
M%0                " *(FH                  !$240%
M     "!*(BH                  %$240$                 B)*("@
M              ! E$14                  "B)*("
M ! E$14                 @"B)J                   1$E$!0
M           @2B(J                  !1$E$!                 (B2
MB H                 0)1$5                   HB2B @
M       0)1$5                 ( HB:@                  $1)1 4
M                ($HB*@                  41)1 0
M  "(DH@*                 $"41%0                  *(DH@(
M            $"41%0                " *(FH                  !$
M240%                 "!*(BH                  %$240$
M        B)*("@                ! E$14                  "B)*("
M                 ! E$14                 @"B)J
M    1$E$!0                 @2B(J                  !1$E$! * +
M6K1H43)Y\N3DN...2[;88HMD\.#!2:]>O9)^_?HEJZ^^>K+99ILEN^^^>_+]
M[W\_F3!A0C)MVK1&APP             0 -(1 4 @"[F@0<>2#;::*/D2U_Z
M4ED+              !=C]'D %W(;W_[VX*DHF...:;184%3FC=O7O*C'_TH
M66655=+ES#//3.;/G]_HL/C_E)M\V6S)F./'CT]Z].C1);\[
M  #E,YH<H O9?OOM"Y**^O?OGWS^^>>-#@V:SAEGG%%PO)UUUEF-#HND:R>B
M_N4O?RE(0ATP8$!RX847)J^\\DHR9\Z<9-:L6<F##SZ8[+KKKDWUW0$
M        J(S1Y !=Q(LOOE@TJ6KBQ(F-#@^:SN#!@PN.M3 S*HW7E1-1-]UT
MT\6^2Z]>O9*GGGHJ^MF%"Q<FN^VV6]-\=P              *F,T.4 7,6;,
MF*))53OMM%.CPX.&J&62X:!!@PK*#LFI9%,S)IVV=__]]Q=\O]&C1W>XSL,/
M/]RT[0$             0&F,)@?H A8L6)#.Q%@LT6JII99*7GGEE4:'"757
MR\3#TTX[K:#LTT\_O6KE4UU=(1'UE%-.*?A^M]YZ:X?KS)X]NVG; P
M      " TAA-#M %3)X\N6B25<MRYIEG-CI,J+M:)A[.G3LW33P-LZ"&V5%#
M8FKX.[*I*R2B;K?==@7?[[GGGFMT6               9%QSC:X'(&J???9I
M33H:,&! --EJM=562Q8N7-CH4*&NFCWQD-)UA43455==M>#[S9PYL]%A 0
M          "0<<TUNAZ  A]^^&'2LV?/UJ2C,#OJ4DLM%4VXNN>>>QH=+M15
MLR<>4KJND(BZS#++%'R_^?/G-SHL               RKKE&UP-0X,(++VQ-
M.!H^?'CZ=SONN&,TX6K__?=O<+107\V>>$CIND(B:K-_/P
M:L/H<X F-W3HT-:$H_'CQZ=_-V'"A&A"4J]>O9*//OJHP1%#_4C,HX5$5
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MM=9M%A-F%O[6M[Y54=N%V9D7+%A0U?:JAFK4G[7MUMG]O-1$U'KW<P
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M31(_.Z->B:B-VM>+Q5.)K/5S09A)-?3Q2R^]=++99ILE-]]\<]EE
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M3,-LP94Z\\PSNV0B:J/V]6+QE"N+_5S/GCVCZ_?MV[?BF
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MLOWKV6:''')(U??M9Y]]MDLFHC9J7R\63[FRV,]-FC0INGY(=@8
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MU@T)@.7XZ*./)*)6*$O?M3/E#!LVK.K[]O3ITR6BYK"<+/9S
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M1\N*X8PSSI"(6J$L?=?.E//TTT]'U_W.=[Y341S!^>>?+Q$UA^5DL9\#
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M%<>H4:-JDOC9&1)1RY.E?BZXX88;D@TWW##IU:M7^M_P_P
M5(=$5( <>N:99UH3=GKW[IW,F#&C)O6$9,4^??I$DY=^]:M?+7']5UYY)4UZ
M;+_NL<<>6W(,'WSP0;+66FLMMO[==]^=R[J//_[XDNL^[KCC"M;OUZ]?\O++
M+Y=<1O#&&V\D2RVU5$%9^^VW7X?)@__\YS^3'7?<,?ULF$&U61-1]]IKKX(R
M_OK7OT8_>]---RWVN4,..:0N,6:IG-MNNRU:QDDGG51R&7?<<4>Z3U8[P;FS
M)**6)TO]7$@ZC7VW&V^\L=RO!0            ! A$14@!P*25\MB38'''!
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ML]%A P              99"("@                ! E$14
M      "B)*("                 ! E$14                 @"B)J
M                1$E$!0                 @2B(J
M  !1$E$!                 (B2B H                 0)1$5
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MTMECRY65=J0ZLKH]\]1OM\AJ6Y)=;?>5K%Q/QF++@JR<AV3M/*WM>LUTSQP
M    :*QLW!D&H&'"[ "Q!TBKK;9:V66=<<89!>6$ 3TS9\XLNZP9,V9$9_[X
MX0]_6'99G:%]JJ,>#WEWVVVW:!WA(7LE[KWWWFAYVV^_?2[C"0XXX(""]6O]
MUN+V;]LN55Z/EWH-:.C(QQ]_G P>/+BU[N.//SY3\=52-?OL%GEKIWIMX[P>
MHQV9-V]>M.W"X-M&&3IT:&L<+0/S)TR84#3.8F_]AVIJ.WB__1)F:ZBTK.[=
MNR=//?54C:(FZUQW=4S[Q.7I^J846?G=;__]0J)I2#@MUO<?=MAA-:FWJZC'
M^7O6[D]D+9X@3_U)7OOQ>EVK=B0O]TN..^ZXZ&]^F+FU5D+97_[REPOJ/?30
M0\LN*ROM2'5D=7OFJ=]ND=6VI/FY9^Z>>6=D\9XY     -!8^;@S#$#-S)T[
M-_H J7?OWF67M=EFFQ64L\DFFU0<6Q@XT+Z\4$<]:9_JJ,=#W@TVV"!:QWOO
MO5=1>:^__GJTO) D\<DGG^0NGC"#07C@W7[],.M.+;WXXHL5;?.\'B_U&M#0
MD:...JJUWC"(L.T@ARS$5TO5[+-;Y*V=ZK6-\WJ,=B3TI;&V6V655>H:1XLP
M,T]+#'W[]DUGH@Q",DC__OVCL8X=.[8AL=+U[++++D7[F_ONNZ^D,L+O4]O9
M54\ZZ:0:1TV6N>[JF/8IE+?KFR7)TN]^[/L]]]QS:5S%^OZ0,%N+>KN">IR_
M9^W^1-;BR5M_DM=^O%[7JAW)P_V2,!MJGSY]"N+XR4]^4O.Z_^,__J.@WC#C
MY-MOOUU6.5EH1ZHGB]LS;_UVBRRV)5V#>^;NF7=&UNZ9 P    "-EX\[PP#4
MS.>??QY]@+3\\LN754X8)!-[,^O!!Q]<<6P''71007FACE!7O6B?ZJC'0]X5
M5E@A6L>GGWY:47GA;</%XO[3G_Z4NWC.///,Z+IAP&;6Y/EXJ=> AF+^_.<_
M+]9V=]QQ1Z;BJ[5J]=EMY:V=ZK&-\WR,=N2EEUZ*MMT..^Q0MQC:.OKHHUMC
M&#5JU&+_UG8 ==METTTW;4BLX=B[]MIKT^T8!D@MM]QRZ<#_?OWZI8D&(T>.
M3*Z__OIDSIPY73*>!0L6)'?==5>Z'<.,<BWQ++OLLNGL=X<<<DAR]=579_(W
MN9CGGW\^Z=FS9W0_7'_]]=-!CDMRP@DGM*X3$@%:DJYJI1FW0S-QW=4Q[5,H
M3]<WI<C2[WZQ<\CPVUKL7#,DJ89DU5K4V^SJ<?Z>M?L368LG3_U)GOOQ>NSK
M'<G+_9)SSSTW&L>SSSY;\[K__O>_1^O^\8]_7%8YI;3C].G3DU_]ZE?)=[[S
MG?3Z(;QTH9'7;.4*+XJXX88;DB.//#+9:JNMDA577#&=&2Y<(PT8,"!-.AHQ
M8D1RZ:67)F^^^69-8@A]9FBC$,.66VZ9]JTAAI#(')*#PC5.B.'\\\]/]_^%
M"Q=65$\6CHOV\M1OMU7MMOSBBR^2R9,GIS,P?OWK7T_67GOM]%@*^^%**ZV4
MK+?>>NDLY.$8#K.'AVOB:@I)ZA=??''KO9>55UXY36P,2ZA_PPTW3/;>>^\T
MOCOOO#,][O-89S-PS]P]\\[(VCUS     *#Q\G%G&(":";,-Q!X@E?M&U7ON
MN2=:SL]__O.*8_O9SWX6+3/452_:ISKJ\9 WO*$_5D>E RSFSY]?-.[SSCLO
M=_&$@2?MUQLR9$A%L=1:GH^7>NSKQ82DGS#8IJ7.,.@F2_'50[7Z[+;RUD[U
MV,9Y/D8[4BRYXJ<__6G=8F@1!HB%)+F6&!Y^^.'%_OVQQQXKNJV?>.*)3M5=
MK-QB^]/X\>/3@7^EK#=HT*#DRBNO[%+QW'___45G_<I[?SQFS)BBWR,,H._(
MDT\^F0XT;_G\+;?<4E;=MD/S<=W5,>U3*$_7-TO2R-_]F([ZPR...*)H+"')
M/R3FU*+>9E:/WZ*LW9_(6CQYZD_RW(\W\KPK3_=+8C.I?>4K7ZE;_:&N]O6'
MMBM'1^T8$DM#$N$RRRQ3M,W;+O6X9BM'F$7WAS_\8?HRFU+J"4M(&-IKK[V2
MIYYZJN)ZVPK)]Z>>>FJ',Y7'EL&#!R?''W]\>BW6D7+*[&BY[+++JO)]8_+4
M;[=5K7WQT4<?30X__/ TZ;2<;;+FFFLF%UUT44DOCNI(2/C=9Y]]%KNF+_58
MV&*++9)SSCFG[!>8-*+.9N*>N7OFG9&E>^8     0#;DX\XP #43WH8=>X!T
MW'''E55.L;>UAP=4E9HP84*TS%_\XA<5EUDN[5,=]7C(&]XV'ZNCTADUBKTE
M.BQAH$>>XBGVQN(P\U<6Y?EXJ<>^7DQX\-]27Q@0]]9;;V4JOGJH5I_=5M[:
MJ1[;.,_':$?VWW__@OK#;"*UFKVD(Q,G3FR-H=A@RC#S0ZS-CCWVV$[576P?
M:K\_A42!0P\]M*3/MU_^[=_^+9D]>W93QQ-<<LDE2;=NW<J*)4]"F\4&JH<E
M#"Q_XXTWHNN%F7BVWGKKUL_NN>>>9==M.S0?UUT=TSZ+R]OUS9(T\G<_IJ/^
M,%R7AEG>BO6?HT>/KDF]S:P>OT59NC^1M7CRUI_DN1]OY'E77NZ73)LV+1K#
M 0<<4+<88M?%87GUU5=++J-8.W[TT4?)MMMN6[2M.UIJ=<U6CO!RFU577;6B
M^,,2$NC..NNLBF<F#:9,F5+RBY<Z6O;88X_DD4<>J;C]2EEJE8B:MWZ[K<[N
MBP\]]%"R\\X[=WK;A!ET7WGEE8J^P\TWWUQR(GFUCL-&U-ELW#-WS[PSLG3/
M'     #(AGS<&0:@9JZXXHKH0ZS[[KNOK'+"P*Y8.0\^^&#%L87!';$RPPP<
M]:)]JJ,>#WG766>=:!WOOOMN1>6]__[[1>/>::>=<A7/U5=?'5WOP@LOK"B6
M6LOS\=*H02XOO/!"TKMW[];ZB@WV:O9!.-7JL]O*6SO58QOG^1@MYMEGGXTF
MJIU\\LEUJ;^]T*^WQ%!L9LD++K@@VF;++[]\\L477U1<=[%]J/W^]+WO?:_U
M_[?::JMDW+AQ:5\T:]:L= DS380$P*%#AT;+V'[[[=.D@6:-IVU243E+WMQV
MVVU%OTN8K20F;)N6S_3ITZ>L0>TM;(?FX[JK8]IG<7F[OEF21O[NQRRI/PR_
MK_WZ]2O:A_[N=[^K2;W-JAZ_15FZ/Y&U>/+6G^2Y'V_4>5>>[I=,FC0I&L-_
M_==_U2V&D-@2BR&<5Y<JMG[XK1H^?'CK_X?KKS#3Z8LOOMBP:[9R7'/--=&9
M&#?88(-D[-BQ:>SA.X1DV9#@%WX+=]UUUVC=(T:,J&@&Z- V87;']N6MO_[Z
MR?GGGY\\\\PSR<<??YS.=AGZQ7">^(,?_"!9<<45RVJ'4MJOE*56B:AYZ[?;
MZNR^6*RMO_:UKZ7[7$C2#?M@RS[PP ,/I#,0QY*7!PX<F+S\\LMEU7_GG7<6
M' >A?SWFF&/2V1E#DG\X1N?-FY=\^.&'R<,//YS.(+S22BM5_-T;46<S<L_<
M/?-*9>V>.0    "0#?FX,PQ S80!XNT?(*V]]MK)HD6+RBJGV)N8PP"(2CW]
M]-/1,D-=]:)]JJ,>#WF_^M6O1NMX]-%'*RKOJ:>>*AKWAAMNF*MXCC_^^.AZ
M=]UU5T6QU%J>CY=Z[.LQ.^ZX8VM=87:)8K,K-"J^>JE6G]U6K)U"TE08G+GW
MWGNG@ZC#C#X]>O1($P%"?=MLLTUR]-%'IX-(8S.MU%(]MG&>C]&8&3-FI(-'
MV]<=MF,8O%=O8?]J&5P:!MN]\\X[T<]]\,$'Z7X7:[?KKKNN:O'$RK_UUEO3
M_X:!2!===%&',[K,GS\_&3-F3+2< P\\L"GC"0./^_;MF_XY;*/##CLLF3IU
M:O+VVV\G<^;,26<,"(,I-]UTTZ;HC\-L.L7ZGC PM*TP&#;TE2W_?LXYYU0E
M!MLA_UQW=4S[+"YOUS<=R=KO?E!*?WC]]=<7[?O#C%7_^,<_:E)O,ZK'^7N6
M[D]D+9Z\]2=Y[L?KL:_'Y.E^R8DGGAB-X?;;;Z];#"W75NV7$%NI8NN?<LHI
MZ7_##&HAD; C];AF*T>X9H@EX80DSY#\UI'0GDLOO73!NJ>==EI9,839](JU
MZY+N6X1['K%SR5+;H=''17MYZ[?;ZFQ;ME^W9\^>);T )"1JAON4[=</]\)F
MSIQ94MTAR7G0H$&+K3]X\."2SOG"NM_^]K?+_NZ-J+-9N6?NGGDELG;/'
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M9YA)^9!##DG^]*<_I5K/3BVSR-PSKZT=Y_DB_T[K3Z?NF0,     ^=1=HSH
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MM\3/O,4#  ! ^Y1?"_[QCW_L\[LS9LRHNGX\XH@CVA0I        ##Q&; (
M  !1>4O\S%L\    M$_YM>#QQQ_?YW=WWWWWJNO'VVZ[K4V1 @      P,!C
MQ"8    0E;?$S[S% P  0/N47PNNM-)*R=-//QW]WLTWWYP,&C2HU_>WVVZ[
M]@8+         XP1FP   $!4WA(_\Q8/    [5-Y/3AV[-CDP@LO3.;.G9LL
M7;HTF35K5O+M;W\[67[YY7M];]2H4<GCCS_>Z? !      "@T(S8!    $IB
MB9[]?;HI'@   #HGS35B2$*]\<8;.QTZ        %)X1F@   $!)WA(_\Q8/
M    G?.;W_PFV7;;;>N^/OR/__B/Y(DGGNATV        # @&*$)    E.0M
M\3-O\0   -!YCS[Z:'+222<E$R=.3-988XUDQ(@1R;+++IN,&3,FV7+++9.C
MCCHJ^<,?_M#I, $      &! ,4(3                 ( HB:@
M         $1)1 4                 ($HB*@                  41)1
M 0                "(DH@*                 $"41%0
M     *(DH@(                 $"41%0                " *(FH
M              !$240%@ +ZMW_[MWX_W4:;                9$]&!@ 4
MD*3+:MKD_^1A?>^]]][D*U_Y2K+]]MLG8\:,299==MG2)_QW^+<I4Z8D]]QS
M3\?B2R-OZY2W>               &+BZ(R,#8("I)^&NU1\ZRS:JIDW^3R?7
M][[[[BLE0=;;CVRWW7:Y3Y;,VSKE+1X               :^[LC( !A@.IV$
MVBT)?45B&U7KUC;IU/I.G3HU&3)D2,-]R>#!@Y-O?>M;;8VU7GE;I[S% P
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M4Z94U;',,LLD"Q<N;+BN%UYX(3JSZW'''==P7<W(VSKE+1X
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MO#3;98]6)Z(NO_SRT3A>??75U'6^\LHKT3I'CAR98>2UY6V=\A8/
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MQ1='ZSSMM--2U]F(O*U3WN(!             *"[=4=&!D 7&*B)J*^^^NJ
M2D1=:ZVUHF6?>^ZY5'$$(6$S;3SKK+-.M.R"!0M2Q].HO+5)T=5:W]MOOSU9
M9955:O85IYQR2EWU7W_]]='RIYYZ:NJ8P[)C==YPPPVIZVQ$WM8I;_$
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MH9ABLVP.'SX\F3]_?MUU_/.?_TR677;9JGKZ2[9ME;RM4][B 0
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MU&_9/_SA#Z7]H[QL^/M==]W5<!S77GMM=#N%&46+NDYYC0<
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M%   !A")J               0)9D*   #" 240$             @"S)4
M&$ DH@(              %F2H0  ,(!(1 4              +(D0P$ 8 "1
MB H              &1)A@( P  B$14              ,B2# 4 @ %D^O3I
M;WT               ":)1$5                 ( HB:@
M     $1)1 4                 ($HB*@                  41)1 0
M              "(DH@*                 $"41%0
M *(DH@(                 $"41%0                " *(FH
M          !$240%                 "!*(BH                  %$2
M40$                 B)*("@                ! E$14
M      "B)*("                 ! E$14                 @"B)J
M                1$E$!0                 @2B(J
M  !1$E$!                 (B2B H                 0)1$5
M            HB2B @                 0)1$5                 ( H
MB:@                  $1)1 4                 ($HB*@
M        41)1 0                "(DH@*                 $"41%0
M                 *(DH@(                 $"41%0
M  " *(FH                  !$240%                 "!*(BH
M             %$240$                 B)*("@                !
ME$14                  "B)*("                 ! E$14
M        @"B)J                   1$E$!0                 @2B(J
M                  !1$E$!                 (B2B H
M    0)1$5                   HB2B @                 0)1$5
M             ( HB:@                  $1)1 4
M($HB*@                  41)1 0                "(DH@*
M_#_V[@/LCJI.'/^20H $0D(@ 94>"1!::&%9Z0'1Y:<(A"8$"* _Z6V1A5U!
M798%@2!%)2BF(%U**,K2+;B[8&A+#1!Z34(*)77^_W-_S_OZYKWGON]M<^_,
MS>?S//,0DCOG?.?,S)GZG0,         41)1 0                "(DH@*
M                 $"41%0                  *(DH@(
M    $"41%0                " *(FH                  !$240%
M             "!*(BH                  %$240$
MB)*("@                ! E$14                  "B)*("
M         ! E$14                 @"B)J                   1$E$
M!0                 @2B(J                  !1$E$!
M     (B2B H                 0)1$5                   HB2B @
M               0)1$5                 ( HB:@
M $1)1 4                 ($HB*@                  41)1 0
M          "(DH@*                 $"41%0                  *(D
MH@(                 $"41%0                " *(FH
M      !$240%                 "!*(BH                  %$240$
M                B)*("@                ! E$14
M  "B)*("                 ! E$14                 @"B)J
M            1$E$!0                 @2B(J                  !1
M$E$!                 (B2B H                 0)1$5   6 8M6;(D
MF3)E2G+<<<<E6VVU53)DR)!D^>673_KUZY>LO?;:R19;;)'LN>>>R4DGG91,
MF# AF3Y]>K-#!@            "@"22B @# ,N;!!Q],-MEDD^3O_N[O*IH
M             %CV>)L<8!GRRU_^LBBIZ#O?^4ZSPX*6M&#!@N2?__F?DS77
M7+,PG7WVV<G"A0N;'1;_OTJ3+ULM&7/\^/%)KUZ]ELEE!P            "@
M<MXF!UB&[+CCCD5)1:NLLDKRZ:>?-CLT:#EGG756T?YVSCGG-#LLDF4[$?6/
M?_QC41+J@ $#DHLOOCB9-FU:\OGGGR=SYLQ)'GKHH62//?9HJ64'
M     * ZWB8'6$:\^.*+)9.J)DZ<V.SPH.4,&3*D:%\+(Z/2?,MR(NKFFV^^
MU+(LO_SRR=2I4Z._7;QX<3)JU*B6678              *KC;7* 9<299YY9
M,JEJEUUV:79XT!1I)AD.'CRXJ.R0G$HVM6+2:6<///! T?(=<<017<[SR"./
MM&Q[              !0'F^3 RP#%BU:5!B)L52BU7+++9=,FS:MV6%"PZ69
M>'CZZ:<7E7W&&6?4K7SJ:UE(1#WUU%.+EN^66V[I<IYY\^:U;'L
M     % >;Y,#+ .F3)E2,LFJ;3K[[+.;'28T7)J)A_/GSR\DGH914,/HJ"$Q
M-?P=V;0L)*+NL,,.1<OWW'//-3LL               RKK7>K@<@:M]]]VU/
M.AHP8$ TV>J+7_QBLGCQXF:'"@W5ZHF'E&]92$1=:ZVUBI9O]NS9S0X+
M         (",:ZVWZP$H\L$''R2]>_=N3SH*HZ,NM]QRT82K>^^]M]GA0D.U
M>N(AY5L6$E%76FFEHN5;N'!AL\,"             "#C6NOM>@"*7'SQQ>T)
M1R-'CBS\W<X[[QQ-N#K@@ .:'"TT5JLG'E*^92$1M=67#P            "
M='C['*#%#1\^O#WA:/SX\86_FS!A0C0A:?GEET\^^NBC)D<,C2,QCS8240$
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M4B)JVFT6$T86_OK7OUY5VX71F1<M6E37]JJ'>M2?M?56ZW9>;B)JH_LY
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MO?9*)?&S%HU*1&W6MEXJGFIDK9\+PDBJH8]?<<45DRVVV"*YZ::;*BX#
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M_H5D]FJ$D527Q4349FWKI>*I1M;ZN=BHJF$*(Z,"             % [B:@
M+63&C!E)GSY]VI-PGGGFF;+F>_[YYTLF8=UWWWT5QS%]^O1H6?OOOW_%9;5Y
M\\TWRTJ>:K6Z]]UWWVB9H:YRY"41M=+1=__PAS\4E?&%+WRA+K'44YKMW\@V
M*S6":1@MN%IGGWWV,IF(VJQMO50\E<IB/]>[=^_H_'W[]JTZ)@
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M/:79_HULL\,..ZSNV_:SSSZ[3":B-FM;+Q5/I;+8STV>/#DZ?TAV!@
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M#0F E?CHHX\DHE8I2\M:2SDC1HRH^[8]8\8,B:@Y+">+_1P
M .F2B J08TN6+%EJI,*;;KJI+N6&<F))06'DU3?>>*/;^8\YYICH_'???7==
MXEN6ZIXR94JTS.]\YSMES1\;+7?.G#D5Q1 2S"2B5B=+RUI+.8<??GC=M^U7
M7WU5(FH.R\EB/P<             0+HDH@+DV/WWW]^>L+/::JLE\^?/KTNY
MH9Q07BPQZ(<__&&W\T^:-"DZ[R677%*7^/)6]\477UQUF6'>6)F3)T\N:_Z5
M5UZY:-ZWWGJKHAA^^]O?2D2M4I:6M99RKKKJJKKO5[_[W>\DHN:PG"SV<P
M            I$LB*D".'7+((>T).R>>>&)=RP[EQ1*#UEMOO<)(K%T)HZ;&
MYMUOO_VJCJ?SZ(E#AP[-3=W[[KMOU75_\YO?C);Y^NNOES7_6FNM533OG__\
MYXIB..NLLR2B5BE+RUI+.4\]]51TWF]]ZUM5Q1%<>.&%$E%S6$X6^SD
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M'&/&C$DE\;,6$E$KDZ5^+KC^^NN3C3?>.%E^^>4+_PW_#P            !
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MPP8              "H@$14                 @"B)J
M    1$E$!0                 @2B(J                  !1$E$!
M             (B2B H                 0)1$5
MHB2B @                 0)1$5                 ( HB:@
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M>_8L? $_C#@3'LZ&[3/\]_[[[T^./?;8I;Z4'5Z,N>NNNZ)QK[ONNKF*9^#
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M,766U3Z[7(UJXT;TM_;1^AHU:E27+]W58QHX<&!A)+=JU'M[FCMW;K3,9HU
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M&VZX8;0[<SV/T)DU=&^N5ROV6:[5OUMF.=[>N.9BBO@Z6X1QJ<7O:0
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M_#W<][___1Z?N]MNNU6][[OKKKN:E"D       !0BSLV 0  @*BB%7X6+1\
M  #FK?P]W*!!@Y*77GHI^KS;;KLMZ=.G3[?G;[755LU-%@       (ARQR8
M   05;3"SZ+E P  P+Q5OH\;.G1H<NFEER:OO_YZ,GOV[&32I$G)3W_ZTV2Q
MQ1;K]KR! P<FSSSS3*O3!P       !*%J    ,#_$ROTG-=C?LH'  " ]+*\
MMPM%J!,F3&AUZ@       ,#_XPY-    H*1HA9]%RP<  (#T;K_]]F3++;>L
M^WW=UEMOG3S[[+.M3AL        HXPY-    H*1HA9]%RP<  (#LGGKJJ>3$
M$T],=MIIIV2%%59(%EUTT63AA1=.A@P9DFRZZ:;)F#%CDGOOO;?5:0(
M   1[M $                 "!*(2H                  %$*40$
M            B%*("@                ! E$)4                  "B
M%*("                 !"E$!4                 @"B%J
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MNBH:Z['''DL=JY/F>%!^/&^^^6:F&&&[V/B&+LEYY-5*19L7>2CBW"K*&@\
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MO+"/M#IECN?IO??>BU[/RR^_?.:8G3C.><R+/!1M;G7B&@\           !
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MOXG&_,E/?I(J3B?,\;SMM==>5>,:NEDWTKFZD\8YKWF1AZ+-K4Y=XP$
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M<P@=<=]]]]VLA]9K>BI$#85_>^ZY9W+EE5>6"O+SU@GCG/>\R$/1YE:GK?$
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M#>>;1:WU\,$''VQ)/HWXZ4]_&CV6HX\^NM6IM62<>VM>Y*%H<ZL3UG@
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M<DYKTJ1)T7S66FNMEN23AV]^\YO18[KZZJM;EE.SQ[DWYT4>BC:WVG6-!P
M         *!WS1\5&0#S@5I% T7+J95QBI#3H$&#HML6K2/J)Y]\TE ^:11M
M3-I=Y?&& J!O?>M;R0(++%!SG0A%PN%Y]3CPP -KQLE:W#5MVK1HO-#%, ^O
MO_YZ59>_DTXZ*9?81;+!!AMT.\9CCSTVM]BGGGIJ]!R-'S\^<\S?_O:WT9@_
M_O&/<\L[C7???3>:S^#!@UN23QY"P6GLF$+Q8ZLT>YQ[<U[DH6ASJQW7>
M          !ZW_Q1D0$P'^C40M2//OJHHPI1*SLR=CVR=AD+0L%FUGR&#1L6
MW384"C5+T<:DW=4ZWKOOOKM4]%-KK3CYY)/KBA\*F6K%^/CCCS/E' J?8_'Z
M]>N7*5ZYM]]^.UEWW76[Q1T]>G3#<8OFKKONZG:,H=-PZ#R9EYMOOCEZCDXY
MY93,,<,U%XMYRRVWY)9W&N'Z[:WKL%6>?_[YZ#&ULLMK,\>YM^=%'HHVM]IM
MC0<           "@.>:/B@R ^4"[%*+.GCT[58RI4Z=V5"'JAAMN&-WVN>>>
MRY1'$+H]9LUGL\TVBV[[ZJNO9LXGK:*-2;OKZ7CON^^^4N%/;&P^__G/UQ5_
MPH0)-=>;K 7,M;KE+;/,,IGB=9D^?7JRR2:;=(L9NOW-G3NWH;A%M/?>>W<[
MSMUVVRW7^*$PO$^?/E7GZ&M?^UKFF"-'CHR>]T:*T!OQSCOO],IUV$JUNH\N
MO?32+<NIF>/<V_,B#T6;6^VTQ@,           #0//-'10; ?*"(A:@+++!
M53ZA,"R-4(S8286H7__ZUZ/;WG3339GR")YZZJG,^1QZZ*'1;2=.G)@YG[2*
M-B;M;E['>_CAAT?'9LB0(77%#X5(H:M@+,;++[^<*>?)DR='XXT8,2)3O"!T
MQ=UJJZVZQ=M]]]U+G?DZS90I4Y*^??MV.];;;[\]]_VLM]YZ5><H_"RKM==>
M.]=XC7KII9=ROPY;+7SY0^R8%EIHH9;EU*QQ;M:\R$.1YE:[K/$
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MM?[ZZ^=R'38B[\+,4T\]-7I,!QUT4*:<VF6<FSTO\E"DN574-1X
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M%E>>HZ['99==EBI6$<>Y)\V>%Z&[;.RX0H?3M(HRM[H498T'
MH/44H@)TB%@11);BJ;QMN^VVT;Q"5[3?_O:WR:1)DY(//OB@U 'UL<<>2W[T
MHQ\E@P</+CTG%$:^\LHKN1Y77K'RB+///OM$XQQ[[+&E8J9:0F'HSW_^\T^[
MQ?Z?__-_<LDG%,W$"H='CAR93)TZ=9[;7W+))4G__OV[;1NZHZ91M#$)G>UB
M<<+/FRF60YA;__K7OWI\;KDPUS;88(.J.$LMM53F;H&AN"PVQT,AZ%__^M<>
MM[WOOOMJ=L%][[WWZL[AE%-.J;G^Y?E(ZYUWWJF*\<4O?C%UG%I"P7YEM\)F
M=A@\^^RSJXXOG,]0>%9+*+);=MEEJ[8[_?33,^40.T^#!@VJNV-G>'VIU4%Y
MG776274==FGTO,=R66RQQ9*++[XXF3-GSCRW#^OD66>=5;,(=8\]]DA]3$4<
MYUI:,2\^][G/18]MQ(@1F>(586YU*<(:#P           $ QM+Y""8#46E58
ME<6CCS[Z:7%@VL?X\>/K/MX\QZHWXY2;.7-FLL466T2W77OMM9-SSSTW>>:9
M9Y+ITZ<G[[__?O+<<\\E%UUT4;+99IM]^KQO?>M;#8]1N0LOO#!98($%JK8-
MQ<'?_>YW2X4GDR=/+A4[A>+AT!7O_///CQ;BC!HUJJ["J2*/R2*++!+=+OR\
MF6KE'_((XQRZR;[TTDNE\2O__T-15NB,>-AAAU45"8='Z+88BH4:\>Z[[R8;
M;[QQ5>Q0U+SOOOLFM]QR2ZE@]J.//DI>>^VU9,*$":5.Q['K+!0HO?#""[F,
M3=Z/M!Y__/&J&&$.Y244>9?'#ETWT\ZW1AUYY)%5QQBZ)8;C#$5SLV;-*CU"
MD5QX;GFWY,KYFD5/YRL4.)YQQAFE+I&A$W"X_L*:$;H_7WOMM<G!!Q]<<WZ'
M+TIX]=57,^74Z'GOZ9A66665Y(<__&'RYS__.9DR94IIOH?C"O/KSCOO3$X\
M\<1DI956JKG];KOMUF-!?Y:<6C7.M;1B7H1"X=CQA>L]JU;/K7*M7N,!
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MO<QY!P             ZG0H% ( .HA"U-4:-&E55C/C[W_^^U6G1RYQW
M         &!^H$(! *"#*$1MC>NOOS[IUZ]?:=P'#1J4W';;;:U.B29PW@$
M          " ^8$*!0" #J(0M76NN^ZZY M?^$(R:=*D5J="$SGO
M     $"G4Z$  -!!QHT;]^D#              "@40I1 0
M  "(4H@*                 $"40E0                  *(4H@(
M            $*40%0                " *(6H                  !$
M*40%                 "!*(2H                  %$*40$
M        B%*("@                ! E$)4                  "B%*("
M                 !"E$!4                 @"B%J
M    1"E$!0                 @2B$J                  !1"E$!
M             (A2B H                 0)1"5
MHA2B @                 0I1 5                 ( HA:@
M         $0I1 4                 ($HA*@                  40I1
M 0                "(4H@*                 $"40E0
M     *(4H@(                 $*40%0                " *(6H
M              !$*40%                 "!*(2H
M %$*40$                 B%*("@                ! E$)4
M          "B%*("                 !"E$!4                 @"B%
MJ                   1"E$!0                 @2B$J
M      !1"E$!                 (A2B H                 0)1"5
M                HA2B @                 0I1 5
M ( HA:@                  $0I1 4                 ($HA*@
M            40I1 0                "(4H@*            P/]EWPX$
M      3Y6R\P0GD$    L$14                  "6B H
M    P!)1 0                !8(BH                  $M$!0
M          !@B:@                  "P1%0                " ):("
M                 +!$5                   EH@*
M , 240$                 6"(J                  !+1 4
M        8(FH                   L$14                 @"6B @
M              "P1%0                  ):("@                #
M$E$!                 %@B*@                  2T0%
M     &")J                   +!$5                 ( EH@(
M            L$14                  "6B H                 P!)1
M 0                !8(BH                  $M$!0
M  !@B:@                  "P1%0                " ):("
M         +!$5                   EH@*                 , 240$
M                6"(J                  !+1 4
M8(FH                   L$14                 @"6B @
M      "P1%0                  ):("@                # $E$!
M             %@B*@                  2T0%                 &")
MJ                   +!$5                 ( EH@(
M    L$14                  "6B H                 P!)1 0
M          !8(BH                  $M$!0                !@B:@
M                 "P1%0                " ):("
M +!$5                   EH@*                 , 240$
M        6"(J                  !+1 4                 8(FH
M               L$14                 @"6B @                "P
M1%0                  ):("@                # $E$!
M     %@B*@                  2T0%                 &")J
M            +!$5                 ( EH@(                 L$14
M                  "6B H                 P!)1 0
M  !8(BH                  $M$!0                !@B:@
M         "P1%0                " ):("                 +!$5
M                EH@*                 , 240$
M6"(J                  !+1 4                 8(FH
M       L$14                 @"6B @                "P1%0
M             ):("@                # $E$!                 %@B
M*@                  2T0%                 &")J
M    +!$5                 ( EH@(                 L$14
M          "6B H                 P!)1 0                !8(BH
M                 $M$!0                !@B:@
M "P1%0                " ):("                 +!$5
M        EH@*                 , 240$                 6"(J
M              !+1 4                 8(FH                   L
M$14                 @"6B @                "P1%0
M     ):("@                # $E$!                 %@B*@
M            2T0%                 &")J                   +!$5
M                 ( EH@(                 L$14
M  "6B H                 P!)1 0                !8(BH
M         $M$!0                !@B:@                  "P1%0
M              " ):("                 +!$5
MEH@*                 , 240$                 6"(J
M      !+1 4                 8(FH                   L$14
M            @"6B @                "P1%0                  ):(
M"@                # $E$!                 %@B*@
M    2T0%                 &")J                   +!$5
M         ( EH@(                 L$14                  "6B H
M                P!)1 0                !8(BH
M $M$!0                !@B:@                  "P1%0
M      " ):("                 +!$5                   EH@*
M             , 240$                 6"(J                  !+
M1 4                 8(FH                   L$14
M    @"6B @                "P1%0                  ):("@
M          # $E$!                 %@B*@                  2T0%
M                 &")J                   +!$5
M ( EH@(                 L$14                  "6B H
M        P!)1 0                !8(BH                  $M$!0
M              !@B:@                  "P1%0                "
M):("                 +!$5                   EH@*
M     , 240$                 6"(J                  !+1 4
M            8(FH                   L$14                 @"6B
M @                "P1%0                  ):("@
M  # $E$!                 %@B*@                  2T0%
M         &")J                   +!$5                 ( EH@(
M                L$14                  "6B H
MP!)1 0                !8(BH                  $M$!0
M      !@B:@                  "P1%0                " ):("
M             +!$5                   EH@*                 , 2
M40$                 6"(J                  !+1 4
M    8(FH                   L$14                 @"6B @
M          "P1%0                  ):("@                # $E$!
M                 %@B*@                  2T0%
M &")J                   +!$5                 ( EH@(
M        L$14                  "6B H                 P!)1 0
M              !8(BH                  $M$!0                !@
MB:@                  "P1%0                " ):("
M     +!$5                   EH@*                 , 240$
M            6"(J                  !+1 4                 8(FH
M                   L$14                 @"6B @
M  "P1%0                  ):("@                # $E$!
M         %@B*@                  2T0%                 &")J
M                +!$5                 ( EH@(
ML$14                  "6B H                 P!)1 0
M      !8(BH                  $M$!0                !@B:@
M             "P1%0                " ):("                 +!$
M5                   EH@*                 , 240$
M    6"(J                  !+1 4                 8(FH
M           L$14                 @"6B @                "P1%0
M                 ):("@                # $E$!
M %@B*@                  2T0%                 &")J
M        +!$5                 ( EH@(                 L$14
M              "6B H                 P!)1 0                !8
M(BH                  $M$!0                !@B:@
M     "P1%0                " ):("                 +!$5
M            EH@*                 , 240$                 6"(J
M                  !+1 4                 8(FH       0^W8@
M "#(WWJ!$<HC          !@B:@                  "P1%0
M      " ):("                 +!$5                   EH@*
M             , 240$                 6"(J                  !+
M1 4                 8(FH                   L$14
M    @"6B @                "P1%0                  ):("@
M          # $E$!                 %@B*@                  2T0%
M                 &")J                   +!$5
M ( EH@(                 L$14                  "6B H
M        P!)1 0                !8(BH                  $M$!0
M              !@B:@                  "P1%0                "
M):("                 +!$5                   EH@*
M     , 240$                 6"(J                  !+1 4
M            8(FH                   L$14                 @"6B
M @                "P1%0                  ):("@
M  # $E$!                 %@B*@                  2T0%
M         &")J                   +!$5                 ( EH@(
M                L$14                  "6B H
MP!)1 0                !8(BH                  $M$!0
M      !@B:@                  "P1%0                " ):("
M             +!$5                   EH@*                 , 2
M40$                 6"(J                  !+1 4
M    8(FH                   L$14                 @"6B @
M          "P1%0                  ):("@                # $E$!
M                 %@B*@                  2T0%
M &")J                   +!$5                 ( EH@(
M        L$14                  "6B H                 P!)1 0
M              !8(BH                  $M$!0                !@
MB:@                  "P1%0                " ):("
M     +!$5                   EH@*                 , 240$
M            6"(J                  !+1 4                 8(FH
M                   L$14                 @"6B @
M  "P1%0                  ):("@                # $E$!
M         %@B*@                  2T0%                 &")J
M                +!$5                 ( EH@(
ML$14                  "6B H                 P!)1 0
M      !8(BH                  $M$!0                !@B:@
M             "P1%0                " ):("                 +!$
M5                   EH@*                 , 240$
M    6"(J                  !+1 4                 8(FH
M           L$14                 @"6B @                "P1%0
M                 ):("@                # $E$!
M %@B*@                  2T0%                 &")J
M        +!$5                 ( EH@(                 L$14
M              "6B H                 P!)1 0                !8
M(BH                  $M$!0                !@B:@
M     "P1%0                " ):("                 +!$5
M            EH@*                 , 240$                 6"(J
M                  !+1 4                 8(FH
M   L$14                 @"6B @                "P1%0
M         ):("@                # $E$!                 %@B*@
M                2T0%                 &")J
M+!$5                 ( EH@(                 L$14
M      "6B H                 P!)1 0                !8(BH
M             $M$!0                !@B:@                  "P1
M%0                " ):("                 +!$5
M    EH@*                 , 240$                 6"(J
M          !+1 4                 8(FH                   L$14
M                @"6B @                "P1%0
M ):("@                # $E$!                 %@B*@
M        2T0%                 &")J                   +!$5
M             ( EH@(                 L$14                  "6
MB H                 P!)1 0                !8(BH
M     $M$!0                !@B:@                  "P1%0
M          " ):("                 +!$5                   EH@*
M                 , 240$                 6"(J
M  !+1 4                 8(FH                   L$14
M        @"6B @                "P1%0                  ):("@
M              # $E$!                 %@B*@
M2T0%                 &")J                   +!$5
M     ( EH@(                 L$14                  "6B H
M            P!)1 0                !8(BH                  $M$
M!0                !@B:@                  "P1%0
M  " ):("                 +!$5                   EH@*
M         , 240$                 6"(J                  !+1 4
M                8(FH                   L$14
M@"6B @                "P1%0                  ):("@
M      # $E$!                 %@B*@                  2T0%
M             &")J                   +!$5                 ( E
MH@(                 L$14                  "6B H
M    P!)1 0                !8(BH                  $M$!0
M          !@B:@                  "P1%0                " ):("
M                 +!$5                   EH@*
M , 240$                 6"(J                  !+1 4
M        8(FH                   L$14                 @"6B @
M              "P1%0                  ):("@                #
M$E$!                 %@B*@                  2T0%
M     &")J                   +!$5                 ( EH@(
M            L$14                  "6B H                 P!)1
M 0                !8(BH                  $M$!0
M  !@B:@                  "P1%0                " ):("
M         +!$5                   EH@*                 , 240$
M                6"(J                  !+1 4
M8(FH                   L$14                 @"6B @
M      "P1%0                  ):("@                # $E$!
M             %@B*@                  2T0%                 &")
MJ                   +!$5                 ( EH@(
M    L$14                  "6B H                 P!)1 0
M          !8(BH                  $M$!0                !@B:@
M                 "P1%0                " ):("
M +!$5                   EH@*                 , 240$
M        6"(J                  !+1 4                 8(FH
M               L$14                 @"6B @                "P
M1%0                  ):("@                # $E&!V+<# 0    !!
M_M8+C% > 0               , 240$                 6"(J
M          !+1 4                 8(FH                   L$14
M                @"6B @                "P1%0
M ):("@                # $E$!                 %@B*@
M        2T0%                 &")J                   +!$5
M             ( EH@(                 L$14                  "6
MB H                 P!)1 0                !8(BH
M     $M$!0                !@B:@                  "P1%0
M          " ):("                 +!$5                   EH@*
M                 , 240$                 6"(J
M  !+1 4                 8(FH                   L$14
M        @"6B @                "P1%0                  ):("@
M              # $E$!                 %@B*@
M2T0%                 &")J                   +!$5
M     ( EH@(                 L$14                  "6B H
M            P!)1 0                !8(BH                  $M$
M!0                !@B:@                  "P1%0
M  " ):("                 +!$5                   EH@*
M         , 240$                 6"(J                  !+1 4
M                8(FH                   L$14
M@"6B @                "P1%0                  ):("@
M      # $E$!                 %@B*@                  2T0%
M             &")J                   +!$5                 ( E
MH@(                 L$14                  "6B H
M    P!)1 0                !8(BH                  $M$!0
M          !@B:@                  "P1%0                " ):("
M                 +!$5                   EH@*
M , 240$                 6"(J                  !+1 4
M        8(FH                   L$14                 @"6B @
M              "P1%0                  ):("@                #
M$E$!                 %@B*@                  2T0%
M     &")J                   +!$5                 ( EH@(
M            L$14                  "6B H                 P!)1
M 0                !8(BH                  $M$!0
M  !@B:@                  "P1%0                " ):("
M         +!$5                   EH@*                 , 240$
M                6"(J                  !+1 4
M8(FH                   L$14                 @"6B @
M      "P1%0                  ):("@                # $E$!
M             %@B*@                  2T0%                 &")
MJ                   +!$5                 ( EH@(
M    L$14                  "6B H                 P!)1 0
M          !8(BH                  $M$!0                !@B:@
M                 "P1%0                " ):("
M +!$5                   EH@*                 , 240$
M        6"(J                  !+1 4                 8(FH
M               L$14                 @"6B @                "P
M1%0                  ):("@                # $E$!
M     %@B*@                  2T0%                 &")J
M            +!$5                 ( EH@(                 L$14
M                  "6B H                 P!)1 0
M  !8(BH                  $M$!0                !@B:@
M         "P1%0                " ):("                 +!$5
M                EH@*                 , 240$
M6"(J                  !+1 4                 8(FH
M       L$14                 @"6B @                "P1%0
M             ):("@                # $E$!                 %@B
M*@                  2T0%                 &")J
M    +!$5                 ( EH@(                 L$14
M          "6B H                 P!)1 0                !8(BH
M                 $M$!0                !@B:@
M "P1%0                " ):("                 +!$5
M        EH@*                 , 240$                 6"(J
M              !+1 4                 8(FH                   L
M$14                 @"6B @                "P1%0
M     ):("@                # $E$!                 %@B*@
M            2T0%                 &")J                   +!$5
M                 ( EH@(                 L$14
M  "6B H                 P!)1 0                !8(BH
M         $M$!0                !@B:@                  "P1%0
M              " ):("                 +!$5
MEH@*                 , 240$                 6"(J
M      !+1 4                 8(FH                   L$14
M            @"6B @                "P1%0                  ):(
M"@                # $E$!                 %@B*@
M    2T0%                 &")J                   +!$5
M         ( EH@(                 L$14                  "6B H
M                P!)1 0                !8(BH
M $M$!0                !@B:@                  "P1%0
M      " ):("                 +!$5                   EH@*
M             , 240$                 6"(J                  !+
M1 4                 8(FH                   L$14
M    @"6B @                "P1%0                  ):("@
M          # $E$!                 %@B*@                  2T0%
M                 &")J                   +!$5
M ( EH@(                 L$14                  "6B H
M        P!)1 0                !8(BH                  $M$!0
M              !@B:@                  "P1%0                "
M):("                 +!$5                   EH@*
M     , 240$                 6"(J                  !+1 4
M            8(FH                   L$14                 @"6B
M @                "P1%0                  ):("@
M  # $E$!                 %@B*@                  2T0%
M         &")J                   +!$5                 ( EH@(
M                L$14                  "6B H
MP!)1 0                !8(BH                  $M$!0
M      !@B:@                  "P1%0                " ):("
M             +!$5                   EH@*                 , 2
M40$                 6"(J                  !+1 4
M    8(FH                   L$14                 @"6B @
M          "P1%0                  ):("@                # $E$!
M                 %@B*@                  2T0%
M &")J                   +!$5             (A].Q      $.1OO< (
MY1$    L$14                 @"6B @                "P1%0
M             ):("@                # $E$!                 %@B
M*@                  2T0%                 &")J
M    +!$5                 ( EH@(                 L$14
M          "6B H                 P!)1 0                !8(BH
M                 $M$!0                !@B:@
M "P1%0                " ):("                 +!$5
M        EH@*                 , 240$                 6"(J
M              !+1 4                 8(FH                   L
M$14                 @"6B @                "P1%0
M     ):("@                # $E$!                 %@B*@
M            2T0%                 &")J                   +!$5
M                 ( EH@(                 L$14
M  "6B H                 P!)1 0                !8(BH
M         $M$!0                !@B:@                  "P1%0
M              " ):("                 +!$5
MEH@*                 , 240$                 6"(J
M      !+1 4                 8(FH                   L$14
M            @"6B @                "P1%0                  ):(
M"@                # $E$!                 %@B*@
M    2T0%                 &")J                   +!$5
M         ( EH@(                 L$14                  "6B H
M                P!)1 0                !8(BH
M $M$!0                !@B:@                  "P1%0
M      " ):("                 +!$5                   EH@*
M             , 240$                 6"(J                  !+
M1 4                 8(FH                   L$14
M    @"6B @                "P1%0                  ):("@
M          # $E$!                 %@B*@                  2T0%
M                 &")J                   +!$5
M ( EH@(                 L$14                  "6B H
M        P!)1 0                !8(BH                  $M$!0
M              !@B:@                  "P1%0                "
M):("                 +!$5                   EH@*
M     , 240$                 6"(J                  !+1 4
M            8(FH                   L$14                 @"6B
M @                "P1%0                  ):("@
M  # $E$!                 %@B*@                  2T0%
M         &")J                   +!$5                 ( EH@(
M                L$14                  "6B H
MP!)1 0                !8(BH                  $M$!0
M      !@B:@                  "P1%0                " ):("
M             +!$5                   EH@*                 , 2
M40$                 6"(J                  !+1 4
M    8(FH                   L$14                 @"6B @
M          "P1%0                  ):("@                # $E$!
M                 %@B*@                  2T0%
M &")J                   +!$5                 ( EH@(
M        L$14                  "6B H                 P!)1 0
M              !8(BH                  $M$!0                !@
MB:@                  "P1%0                " ):("
M     +!$5                   EH@*                 , 240$
M            6"(J                  !+1 4                 8(FH
M                   L$14                 @"6B @
M  "P1%0                  ):("@                # $E$!
M         %@B*@                  2T0%                 &")J
M                +!$5                 ( EH@(
ML$14                  "6B H                 P!)1 0
M      !8(BH                  $M$!0                !@B:@
M             "P1%0                " ):("                 +!$
M5                   EH@*                 , 240$
M    6"(J                  !+1 4                 8(FH
M           L$14                 @"6B @                "P1%0
M                 ):("@                # $E$!
M %@B*@                  2T0%                 &")J
M        +!$5                 ( EH@(                 L$14
M              "6B H                 P!)1 0                !8
M(BH                  $M$!0                !@B:@
M     "P1%0                " ):("                 +!$5
M            EH@*                 , 240$                 6"(J
M                  !+1 4                 8(FH
M   L$14                 @"6B @                "P1%0
M         ):("@                # $E$!                 %@B*@
M                2T0%                 &")J
M+!$5                 ( EH@(                 L$14
M      "6B H                 P!)1 0                !8(BH
M             $M$!0                !@B:@                  "P1
M%0                " ):("                 +!$5
M    EH@*                 , 240$                 6"(J
M          !+1 4                 8(FH                   L$14
M                @"6B @                "P1%0
M ):("@                # $E$!                 %@B*@
M        2T0%                 &")J                   +!$5
M             ( EH@(                 L$14                  "6
MB H                 P!)1 0                !8(BH
M     $M$!0                !@B:@                  "P1%0
M          " ):("                 +!$5                   EH@*
M                 , 240$                 6"(J
M  !+1 4                 8(FH                   L$14
M        @"6B @                "P1%0                  ):("@
M              # $E$!                 %@B*@
M2T0%                 &")J                   +!$5
M     ( EH@(                 L$14                  "6B H
M            P!)1 0                !8(BH                  $M$
M!0                !@B:@                  "P1%0
M  " ):("                 +!$5                   EH@*
M         , 240$                 6"(J                  !+1 4
M                8(FH                   L$14
M@"6B @                "P1%0                  ):("@
M      # $E$!                 %@B*@                  2T0%
M             &")J                   +!$5                 ( E
MH@(                 L$14                  "6B H
M    P!)1 0                !8(BH      $#LVX$     @"!_ZP5&*(\
M         %@B*@                  2T0%                 &")J
M                +!$5                 ( EH@(
ML$14                  "6B H                 P!)1 0
M      !8(BH                  $M$!0                !@B:@
M             "P1%0                " ):("                 +!$
M5                   EH@*                 , 240$
M    6"(J                  !+1 4                 8(FH
M           L$14                 @"6B @                "P1%0
M                 ):("@                # $E$!
M %@B*@                  2T0%                 &")J
M        +!$5                 ( EH@(                 L$14
M              "6B H                 P!)1 0                !8
M(BH                  $M$!0                !@B:@
M     "P1%0                " ):("                 +!$5
M            EH@*                 , 240$                 6"(J
M                  !+1 4                 8(FH
M   L$14                 @"6B @                "P1%0
M         ):("@                # $E$!                 %@B*@
M                2T0%                 &")J
M+!$5                 ( EH@(                 L$14
M      "6B H                 P!)1 0                !8(BH
M             $M$!0                !@B:@                  "P1
M%0                " ):("                 +!$5
M    EH@*                 , 240$                 6"(J
M          !+1 4                 8(FH                   L$14
M                @"6B @                "P1%0
M ):("@                # $E$!                 %@B*@
M        2T0%                 &")J                   +!$5
M             ( EH@(                 L$14                  "6
MB H                 P!)1 0                !8(BH
M     $M$!0                !@B:@                  "P1%0
M          " ):("                 +!$5                   EH@*
M                 , 240$                 6"(J
M  !+1 4                 8(FH                   L$14
M        @"6B @                "P1%0                  ):("@
M              # $E$!                 %@B*@
M2T0%                 &")J                   +!$5
M     ( EH@(                 L$14                  "6B H
M            P!)1 0                !8(BH                  $M$
M!0                !@B:@                  "P1%0
M  " ):("                 +!$5                   EH@*
M         , 240$                 6"(J                  !+1 4
M                8(FH                   L$14
M@"6B @                "P1%0                  ):("@
M      # $E$!                 %@B*@                  2T0%
M             &")J                   +!$5                 ( E
MH@(                 L$14                  "6B H
M    P!)1 0                !8(BH                  $M$!0
M          !@B:@                  "P1%0                " ):("
M                 +!$5                   EH@*
M , 240$                 6"(J                  !+1 4
M        8(FH                   L$14                 @"6B @
M              "P1%0                  ):("@                #
M$E$!                 %@B*@                  2T0%
M     &")J                   +!$5                 ( EH@(
M            L$14                  "6B H                 P!)1
M 0                !8(BH                  $M$!0
M  !@B:@                  "P1%0                " ):("
M         +!$5                   EH@*                 , 240$
M                6"(J                  !+1 4
M8(FH                   L$14                 @"6B @
M      "P1%0                  ):("@                # $E$!
M             %@B*@                  2T0%                 &")
MJ                   +!$5                 ( EH@(
M    L$14                  "6B H                 P!)1 0
M          !8(BH                  $M$!0                !@B:@
M                 "P1%0                " ):("
M +!$5                   EH@*                 , 240$
M        6"(J                  !+1 4                 8(FH
M               L$14                 @"6B @                "P
M1%0                  ):("@                # $E$!
M     %@B*@                  2T0%                 &")J
M            +!$5                 ( EH@(                 L$14
M                  "6B H                 P!)1 0
M  !8(BH                  $M$!0                !@B:@
M         "P1%0                " ):("                 +!$5
M                EH@*                 , 240$
M6"(J                  !+1 4                 8(FH
M       L$14                 @"6B @                "P1%0
M             ):("@                # $E$!                 %@B
M*@                  2T0%                 &")J
M    +!$5                 ( EH@(                 L$14
M          "6B H                 P!)1 0                !8(BH
M                 $M$!0                !@B:@
M "P1%0                " ):("                 +!$5
M        EH@*                 , 240$                 6"(J
M              !+1 4                 8(FH                   L
M$14                 @"6B @                "P1%0
M     ):("@                # $E$!                 %@B*@
M            2T0%                 &")J                   +!$5
M                 ( EH@(                 L$14
M  "6B H                 P!)1 0                !8(BH
M         $M$!0                !@B:@                  "P1%0
M              " ):("                 +!$5
MEH@*                 , 240$                 6"(J
M      !+1 4                 8(FH                   L$14
M            @"6B @                "P1%0                  ):(
M"@                # $E$!                 %@B*@
M    2T0%                 &")J                   +!$5
M         ( EH@(                 L$14                  "6B H
M                P!)1 0                !8(BH
M $M$!0                !@B:@                  "P1%0
M      " ):("                 +!$5 !BWPX$      3Y6R\P0GD$
M            L$14                  "6B H                 P!)1
M 0                !8(BH                  $M$!0
M  !@B:@                  "P1%0                " ):("
M         +!$5                   EH@*                 , 240$
M                6"(J                  !+1 4
M8(FH                   L$14                 @"6B @
M      "P1%0                  ):("@                # $E$!
M             %@B*@                  2T0%                 &")
MJ                   +!$5                 ( EH@(
M    L$14                  "6B H                 P!)1 0
M          !8(BH                  $M$!0                !@B:@
M                 "P1%0                " ):("
M +!$5                   EH@*                 , 240$
M        6"(J                  !+1 4                 8(FH
M               L$14                 @"6B @                "P
M1%0                  ):("@                # $E$!
M     %@B*@                  2T0%                 &")J
M            +!$5                 ( EH@(                 L$14
M                  "6B H                 P!)1 0
M  !8(BH                  $M$!0                !@B:@
M         "P1%0                " ):("                 +!$5
M                EH@*                 , 240$
M6"(J                  !+1 4                 8(FH
M       L$14                 @"6B @                "P1%0
M             ):("@                # $E$!                 %@B
M*@                  2T0%                 &")J
M    +!$5                 ( EH@(                 L$14
M          "6B H                 P!)1 0                !8(BH
M                 $M$!0                !@B:@
M "P1%0                " ):("                 +!$5
M        EH@*                 , 240$                 6"(J
M              !+1 4                 8(FH                   L
M$14                 @"6B @                "P1%0
M     ):("@                # $E$!                 %@B*@
M            2T0%                 &")J                   +!$5
M                 ( EH@(                 L$14
M  "6B H                 P!)1 0                !8(BH
M         $M$!0                !@B:@                  "P1%0
M              " ):("                 +!$5
MEH@*                 , 240$                 6"(J
M      !+1 4                 8(FH                   L$14
M            @"6B @                "P1%0                  ):(
M"@                # $E$!                 %@B*@
M    2T0%                 &")J                   +!$5
M         ( EH@(                 L$14                  "6B H
M                P!)1 0                !8(BH
M $M$!0                !@B:@                  "P1%0
M      " ):("                 +!$5                   EH@*
M             , 240$                 6"(J                  !+
M1 4                 8(FH                   L$14
M    @"6B @                "P1%0                  ):("@
M          # $E$!                 %@B*@                  2T0%
M                 &")J                   +!$5
M ( EH@(                 L$14                  "6B H
M        P!)1 0                !8(BH                  $M$!0
M              !@B:@                  "P1%0                "
M):("                 +!$5                   EH@*
M     , 240$                 6"(J                  !+1 4
M            8(FH                   L$14                 @"6B
M @                "P1%0                  ):("@
M  # $E$!                 %@B*@                  2T0%
M         &")J                   +!$5                 ( EH@(
M                L$14                  "6B H
MP!)1 0                !8(BH                  $M$!0
M      !@B:@                  "P1%0                " ):("
M             +!$5                   EH@*                 , 2
M40$                 6"(J                  !+1 4
M    8(FH                   L$14                 @"6B @
M          "P1%0                  ):("@                # $E$!
M                 %@B*@                  2T0%
M &")J                   +!$5                 ( EH@(
M        L$14                  "6B H                 P!)1 0
M              !8(BH                  $M$!0                !@
MB:@                  "P1%0                " ):("
M     +!$5                   EH@*                 , 240$
M            6"(J                  !+1 4                 8(FH
M                   L$14                 @"6B @
M  "P1%0                  ):("@                # $E$!
M         %@B*@                  2T0%                 &")J
M                +!$5                 ( EH@(
ML$14                  "6B H                 P!)1 0
M      !8(BH                  $M$!0                !@B:@
M             "P1%0                " ):("                 +!$
M5                   EH@*                 , 240$
M    6"(J                  !+1 4                 8(FH
M           L$14                 @"6B @                "P1%0
M                 ):("@                # $E$!
M %@B*@                  2T0%                 &")J
M        +!$5                 ( EH@(                 L$14
M              "6B H                 P!)1 0                !8
M(BH                  $M$!0                !@B:@
M     "P1%0                " ):("                 +!$5
M            EH@*                 , 240$                 6"(J
M                  !+1 4                 8(FH
M   L$14                 @"6B @                "P1%0
M         ):("@                # $E$!                 %@B*@
M                2T0%                 &")J
M+!$5                 ( EH@(                 L$14
M      "6B H                 P!)1 0                !8(BH
M             $M$!0                !@B:@                  "P1
M%0                " ):("                 +!$5
M    EH@*                 , 240$                 6"(J
M          !+1 4             H/;M0     ! D+_U B.41P   $M$!0
M              !@B:@                  "P1%0                "
M):("                 +!$5                   EH@*
M     , 240$                 6"(J                  !+1 4
M            8(FH                   L$14                 @"6B
M @                "P1%0                  ):("@
M  # $E$!                 %@B*@                  2T0%
M         &")J                   +!$5                 ( EH@(
M                L$14                  "6B H
MP!)1 0                !8(BH                  $M$!0
M      !@B:@                  "P1%0                " ):("
M             +!$5                   EH@*                 , 2
M40$                 6"(J                  !+1 4
M    8(FH                   L$14                 @"6B @
M          "P1%0                  ):("@                # $E$!
M                 %@B*@                  2T0%
M &")J                   +!$5                 ( EH@(
M        L$14                  "6B H                 P!)1 0
M              !8(BH                  $M$!0                !@
MB:@                  "P1%0                " ):("
M     +!$5                   EH@*                 , 240$
M            6"(J                  !+1 4                 8(FH
M                   L$14                 @"6B @
M  "P1%0                  ):("@                # $E$!
M         %@B*@                  2T0%                 &")J
M                +!$5                 ( EH@(
ML$14                  "6B H                 P!)1 0
M      !8(BH                  $M$!0                !@B:@
M             "P1%0                " ):("                 +!$
M5                   EH@*                 , 240$
M    6"(J                  !+1 4                 8(FH
M           L$14                 @"6B @                "P1%0
M                 ):("@                # $E$!
M %@B*@                  2T0%                 &")J
M        +!$5                 ( EH@(                 L$14
M              "6B H                 P!)1 0                !8
M(BH                  $M$!0                !@B:@
M     "P1%0                " ):("                 +!$5
M            EH@*                 , 240$                 6"(J
M                  !+1 4                 8(FH
M   L$14                 @"6B @                "P1%0
M         ):("@                # $E$!                 %@B*@
M                2T0%                 &")J
M+!$5                 ( EH@(                 L$14
M      "6B H                 P!)1 0                !8(BH
M             $M$!0                !@B:@                  "P1
M%0                " ):("                 +!$5
M    EH@*                 , 240$                 6"(J
M          !+1 4                 8(FH                   L$14
M                @"6B @                "P1%0
M ):("@                # $E$!                 %@B*@
M        2T0%                 &")J                   +!$5
M             ( EH@(                 L$14                  "6
MB H                 P!)1 0                !8(BH
M     $M$!0                !@B:@                  "P1%0
M          " ):("                 +!$5                   EH@*
M                 , 240$                 6"(J
M  !+1 4                 8(FH                   L$14
M        @"6B @                "P1%0                  ):("@
M              # $E$!                 %@B*@
M2T0%                 &")J                   +!$5
M     ( EH@(                 L$14                  "6B H
M            P!)1 0                !8(BH                  $M$
M!0                !@B:@                  "P1%0
M  " ):("                 +!$5                   EH@*
=         , *J>6X9I\3C=4     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>mrna-20210331_g1.jpg
<TEXT>
begin 644 mrna-20210331_g1.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2764&AO=&]S:&]P(#,N,  X0DE-! 0
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M;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T
M;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP
M     $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M
M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D="
M0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M     $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M    0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'+
M       *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
M              !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R
M:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P
M4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P         +
M8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #P     $  0/
M 0 !.$))300F       .             #^    X0DE-! T       0   !X
M.$))3009       $    'CA"24T#\P      "0           0 X0DE-! H
M      $  #A"24TG$       "@ !          $X0DE- _4      $@ +V9F
M  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M      $ -0    $ +0    8       $X0DE- _@      '   /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H     /__________________
M__________\#Z   .$))300(       0     0   D    )      #A"24T$
M'@      !      X0DE-!!H      S4    &              #E   #XP
M       !                          $              ^,   #E
M                  $                         $     $       !N
M=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O
M<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   #E
M %)G:'1L;VYG   #XP    9S;&EC97-6;$QS     4]B:F,    !       %
M<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M       &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R
M871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U
M;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M3&5F=&QO;F<          $)T;VUL;VYG    Y0    !29VAT;&]N9P   ^,
M   #=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$58
M5     $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,
M8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T
M   /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU
M;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP
M965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S
M971L;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T
M<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@
M  P    "/_         X0DE-!!$       $! #A"24T$%       !     4X
M0DE-! P     &ND    !    H    "4   '@  !%8   &LT &  !_]C_X@Q8
M24-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A96B 'S@ "  D
M!@ Q  !A8W-P35-&5     !)14,@<U)'0@               0  ]M8  0
M  #3+4A0("
M             !%C<')T   !4    #-D97-C   !A    &QW='!T   !\
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M0S8Q.38V+3(N,0
M                    6%E:(        /-1  $    !%LQ865H@
M             %A96B        !OH@  ./4   .06%E:(        &*9  "W
MA0  &-I865H@        )*    ^$  "VSV1E<V,         %DE%0R!H='1P
M.B\O=W=W+FEE8RYC:               %DE%0R!H='1P.B\O=W=W+FEE8RYC
M:
M  !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U
M<B!S<&%C92 M('-21T(              "Y)14,@-C$Y-C8M,BXQ($1E9F%U
M;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M    9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN
M($E%0S8Q.38V+3(N,0              +%)E9F5R96YC92!6:65W:6YG($-O
M;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M     '9I97<      !.D_@ 47RX $,\4  /MS  $$PL  UR>     5A96B
M     $P)5@!0    5Q_G;65A<P         !
M H\    "<VEG(     !#4E0@8W5R=@        0     !0 *  \ %  9 !X
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M$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( "4
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M:M7+^J7U=RL8X[L&FH$0VRE@KL!_>%C!N_STN*<K,0*'?])1PX,?#'-.?N2
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M3X:@8G6.E9MGIXF91?9^Y78USM/Y#3N7'XN=T/K?4\CJ77\NH8]-AJZ=@6O
M:UC?^U%E7YSKOY?_ %'H^G=ZC5]0<VG;3DXF%D-UHR<<MJ<QX^@_]%LW[?Y:
M7NDZ@QKM(^HI/(Q@1#(,W'0XI8\?'BQF7Z/^LX?TWK;+*ZJW66N#*V N>]Q
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M)')$C#D$(@0UGA]@<&$QXOGX8?/^^OU'J6#TS&=DYMK::FCN=2?W:V_2>_\
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M_1;;)GTY+]FV=GTG?NJRC&)'%?4VMSY1D]NK]&..,W^]'B>:^J5;;:^N5/\
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M &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\
M= !O ', : !O '  ( !# %, -@    $ .$))300B      %^34T *@    @
M# $   ,    !#Z    $!  ,    ! X8   $"  ,    #    G@$&  ,    !
M  (   $2  ,    !  $   $5  ,    !  ,   $:  4    !    I $;  4
M   !    K $H  ,    !  (   $Q  (    >    M $R  (    4    TH=I
M  0    !    Z    2  "  (  @ +<;    G$  MQL   "<0061O8F4@4&AO
M=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.#HP.#HS," P-SHT,#HU,0     $
MD   !P    0P,C(QH $  P    '__P  H ( !     $   /CH , !     $
M  #E          8! P #     0 &   !&@ %     0   6X!&P %     0
M 78!*  #     0 "   " 0 $     0   7X" @ $     0
M2     $   !(     3A"24T#_0      "      !    _^$!@$U- "H    (
M  P!   #     0^@   ! 0 #     0.&   ! @ #     P   )X!!@ #
M 0 "   !$@ #     0     !%0 #     0 #   !&@ %     0   *0!&P %
M     0   *P!*  #     0 "   !,0 "    '@   +0!,@ "    %    -*'
M:0 $     0   .@   $@  @ "  (   #P     $   /      4%D;V)E(%!H
M;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3@Z,#@Z,S @,#<Z-# Z-3$
M!)    <    $,#(R,: !  ,    !__\  * "  0    !   #XZ #  0    !
M    Y0         & 0,  P    $ !@   1H !0    $   %N 1L !0    $
M  %V 2@  P    $  @   @$ !     $   %^ @( !     $
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M5R"-+M9\=/8&ZG0B%;+DQ@Q%0$PLSS&LJ,%TB8"]T46;EY8P3 !ZAZJ^"@%
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M'^LGB)HXQS\^(P/LU0B_XY?$?=O&Y%O#'XV+O[EQ]#;. ]A1>>?+ NT;MMT
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M?7)"O0,>F8X&.DDTBR*)%$"G76, J&GM;9."@0++#/;DX]Z6:S.A)X]2$K/
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M>53ZCT9H OQ'Q^(U:G$Q4=!149"0[)O'1$-'LXJ+CVB946K".CVR;1BR;(D
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M2N/9<32^BL7DY.9+5;'>:LD<41J5I8BSB4KI_']\,;0O\DVY'^3F,/\ :O\
MV]WOU/\ [_\ &?\ @.1_XM3_ *5]FL\_\S@ZS?[K^F/]D]U?]D-']\,;0O\
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M/+D)8Y["6-+I#SZF/+YP'2ZS;?1F[WM2J?*6]C[Y('), 6NTC ?$]K13(/\
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M ?X[B9EUU!_*910QA_?$=2#:@XV_COZ6P?Z]N<ZK3XJG9_$/U89CR1NB5/\
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M(J+9HT:H$30;-FZ)")(((D(DDD0J:92E* !-55454151% 554!550. JJ.
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M$B:(?PW8>*S]>L3<[,&TBLIT(-D%N^5,W?Z ,F?B9O!5\Y%7BL33PBO*TJ&
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M?<6'WE'CA]__ !0Y'_YWEKK+A]B'XYFP/_S,?_0M<%MP=41^+MVI_P CF/\
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M?%.LD*M7,=2#+8B0^?(9.^QYTR1>2L9B[IT=<)&W#<5H/=MVIX_B_4),^?\
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9-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>mrna-20210331_g2.jpg
<TEXT>
begin 644 mrna-20210331_g2.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#Z17AI9@  34T *@    @ ! $[  (
M   0   (2H=I  0    !   (6IR=  $    @   0TNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %!E=&5R($%S
M:V5W("AX*0  !9 #  (    4   0J) $  (    4   0O)*1  (    #,3(
M )*2  (    #,3(  .H<  <   @,   (G      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" )H!9$# 2(  A$! Q$!_\0
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MH **** "BBB@ HHHH Q/^$U\+?\ 0RZ/_P"!\7_Q5'_":^%O^AET?_P/B_\
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M!]?_ /":^%O^AET?_P #XO\ XJC_ (37PM_T,NC_ /@?%_\ %5\@44 ?7_\
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M7_)6-9_[8?\ HB.N)H ^O_\ A-?"W_0RZ/\ ^!\7_P 51_PFOA;_ *&71_\
MP/B_^*KY HH ^O\ _A-?"W_0RZ/_ .!\7_Q5'_":^%O^AET?_P #XO\ XJOD
M"B@#Z_\ ^$U\+?\ 0RZ/_P"!\7_Q5'_":^%O^AET?_P/B_\ BJ^0** /K_\
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MU SG(H ^KO\ A-?"W_0RZ/\ ^!\7_P 51_PFOA;_ *&71_\ P/B_^*KY HH
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M_P"$U\+?]#+H_P#X'Q?_ !5?.WQB_P"2L:S_ -L/_1$=<30!]?\ _":^%O\
MH9='_P# ^+_XJC_A-?"W_0RZ/_X'Q?\ Q5?(%% 'U_\ \)KX6_Z&71__  /B
M_P#BJ/\ A-?"W_0RZ/\ ^!\7_P 57R!10!]?_P#":^%O^AET?_P/B_\ BJ/^
M$U\+?]#+H_\ X'Q?_%5\@44 ?7__  FOA;_H9='_ / ^+_XJC_A-?"W_ $,N
MC_\ @?%_\57R!10!]?\ _":^%O\ H9='_P# ^+_XJC_A-?"W_0RZ/_X'Q?\
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M4S_A-?"W_0RZ/_X'Q?\ Q5?+?C7_ )'[Q!_V$[G_ -&M6)0!]?\ _":^%O\
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MZ&71_P#P/B_^*KY HH ^O_\ A-?"W_0RZ/\ ^!\7_P 51_PFOA;_ *&71_\
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M 'B% #'''.>"1W-.U+XD^+-7MY;?4=7:>&4QEHS!&%RC;E( 7@Y[C&< '(H
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MJ0VP.06"K@+M4MM4+C<^X],-SE !7J7[/_\ R/U[_P!@R3_T;%7EM>I?L_\
M_(_7O_8,D_\ 1L5 &'\8O^2L:S_VP_\ 1$=<37;?&+_DK&L_]L/_ $1'7$T
M%%%% !1110 4444 %%%% !1110 4444 %%%% 'JO@[^Q_P#A1NM?\)']N^P?
MVJF_[!L\W.V/&-_'7K6UX,\7:9K/CGPMH?AZWO$T[2K>X"2W[!II&:,]<$@
M8['';  %>0PZ_J<'AV?0XKG;IMQ,)I8/+4[G&,'=C</NC@&FZ+K>H>'=4CU'
M1[C[/=QA@DFQ7P",'A@1T/I0!ZA]BTSQAX O;BW\.Z?:75IK4-G:FU7RI)49
MT4"20Y+,=YRQXSSCBMKQ#H>AW'@GQ1"VEZ);7VD1H0FFVCA[9L9 :X95\TD
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ME.A1-[)Z%\;SGH>>1D'(--M/B)XKL-"&CVFM31V00QJ@52RJ>P<C</;!X[4
M5-%FU+3?&,)\*2.]^EPT5F_E LV<J#M88&0>XX_"NT\:W<7A7P7+X1DOQJ.M
MZA>_;]6D7E(7(!VCIR2%/X'ID >?Z-K-_P"']5BU+2)A!=PY\N0QJ^W((/#
MCH36SK7Q'\5>(=*DTW6-5^T6DA4O']GB3)!R.54'J/6@#F**** "BBB@ HHH
MH **** "MOP5_P C]X?_ .PG;?\ HU:Q*V_!7_(_>'_^PG;?^C5H V_C%_R5
MC6?^V'_HB.N)KMOC%_R5C6?^V'_HB.N)H **** "BBB@ HHHH **** /4O W
M]E?\*:\3_P#"0_;/[/\ MD'F_8=GF_>3&W?QUQG/;-:_A#Q=I6H>+O"'AKPU
M;7JZ;I\EQ*9M193,[M%+QA3@*-Q^N1P,<^3V^OZE:Z#=Z+!<[-/O'62>'RU.
M]E((.XC(Y Z&H]'UB^T'5H=2TF?[/=P9\N38K;<J5/# CH3VH ]4U.UT_P 5
M^!_$DMOX?T^VOM.UA+>TEM4\N64/,J8=R?F8[SDGC)S@8K;U7P_H+^$_%&G3
M:5H<%[H]BKK#86[M-;$1[D+W+!?,+;<X ''!SFO&HO%6M0:;?6$-\T=OJ$ZW
M%RJQJ"\@8,&#8RN" >".E:E[\3O&&HVDMM>ZT\L$T#V\D9@B 9&&#D!>O'WN
MHYP>30!Z;#HF@ZMX?71-(T+35O\ ^RPTEGJ-G)9WZO@_ODG9#O\ F&,!<>K8
M^6DT'0O"&D^%?#MKJEM9W$VM6C3RK)I,UW<W!9 6$4D?,>T$< $C&>#DGS"#
MXD>+K;0QI$.MSK9K&8@NQ"X4]A(1O'H.>!P.!46E_$#Q3HNBMI.F:S/!9L&
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M0KPM_P!"UH__ ( 1?_$UMT4 8G_"%>%O^A:T?_P B_\ B:/^$*\+?]"UH_\
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M_"%>%O\ H6M'_P# "+_XFC_A"O"W_0M:/_X 1?\ Q->.?\)'K?\ T&=0_P#
MI_\ &C_A(];_ .@SJ'_@4_\ C1_8E3^=!_K11_Y]O[T>Q_\ "%>%O^A:T?\
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MV]SJ?$6%5!5;.[=K?UT/3O\ A"O"W_0M:/\ ^ $7_P 31_PA7A;_ *%K1_\
MP B_^)KQS_A(];_Z#.H?^!3_ .-'_"1ZW_T&=0_\"G_QK?\ L2I_.CE_UHH_
M\^W]Z/8_^$*\+?\ 0M:/_P" $7_Q-'_"%>%O^A:T?_P B_\ B:\<_P"$CUO_
M *#.H?\ @4_^-'_"1ZW_ -!G4/\ P*?_ !H_L2I_.@_UHH_\^W]Z/8_^$*\+
M?]"UH_\ X 1?_$T?\(5X6_Z%K1__   B_P#B:\<_X2/6_P#H,ZA_X%/_ (T?
M\)'K?_09U#_P*?\ QH_L2I_.@_UHH_\ /M_>CV/_ (0KPM_T+6C_ /@!%_\
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M'_PA7A;_ *%K1_\ P B_^)H_X0KPM_T+6C_^ $7_ ,37CG_"1ZW_ -!G4/\
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MX_,\RRM5\J,2R;M2E&Q#T8_O. ?6A_AG\,X_,\RRM5\J,2R;M2E&Q#T8_O.
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M %[2?^@F@#G+WX4^#-1U"XO;S1O,N+F5II7^U3#<['). ^!R>U0_\*=\"?\
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M^%.^!/\ H!?^3D__ ,71_P *=\"?] +_ ,G)_P#XNO-_^$CUO_H,ZA_X%/\
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M3I/.#HESXIO?$D\-IITGGWGV2.[N6.^W$0"ED4(<_7<.1445WJ=IK%UJ%A?
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MJS;C[HY8?O#]WZGK51U+, H)8G  KXQO1(_35&S;.NHJ"R6=+1%NF#28Y_\
MK^]3U)1P&F:1=>)X?$$RW\<%GJ5\T3YMR\K11D*-K[P!P"/NG%9UOYG]II?:
M=>W$,E]KRVL,<;D(UO$-I)'\0VC'.?YUZA5+5]5MM%TR6^O-QCCP J#+.Q.
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M4 %%%% !1110 4444 %4M9_Y 5__ ->TG_H)J[5+6?\ D!7_ /U[2?\ H)H
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M;/"6I(FO]/AN;=X+F)98G&&1QD$5@:=?:WX"F)T??JFBDY?397)>$=S$Q_\
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M .AFL^NP\7>$M1BUJ>\L;:2ZM[ES)^Y4LRL>2"!SUKG_ .P-9_Z!-]_X#/\
MX5VX?$4I4HM26QYF+PF(AB)Q<'N^AGT5H?V!K/\ T";[_P !G_PH_L#6?^@3
M??\ @,_^%;>UI_S+[SE^KUOY']S,^BM#^P-9_P"@3??^ S_X4?V!K/\ T";[
M_P !G_PH]K3_ )E]X?5ZW\C^YF?16A_8&L_] F^_\!G_ ,*/[ UG_H$WW_@,
M_P#A1[6G_,OO#ZO6_D?W,SZ*T/[ UG_H$WW_ (#/_A1_8&L_] F^_P# 9_\
M"CVM/^9?>'U>M_(_N9GT5H?V!K/_ $";[_P&?_"C^P-9_P"@3??^ S_X4>UI
M_P R^\/J];^1_<S/KUCPG_R(NE_]?*?^E->>0>&=;N)EC32[I2QQF2(HH^I/
M%>J6.F_V/X>L+'=O,,\.YAW)F4G]2:\3.:U.5&,(N[O?\&?4\-X:M#$3J2BT
MN6VO>Z_R.GHHHKY@^Z"BBB@ HHHH **** "BBB@ HHHH *YOX@_\B+J'_;/_
M -&K725G:_I?]M:#=Z?N"&9,*QZ!@01G\0*WP\E"M"4MDU^9RXRG*KAJE..[
MBU]Z/ **U[GPIKUK<-$^DWCE3C=%"SJ?H0"*B_X1S6_^@-J'_@*_^%?=JM2:
MNI+[S\G>&KIV<']S,VBM+_A'-;_Z VH?^ K_ .%'_".:W_T!M0_\!7_PH]K3
M_F7WB^KUOY']S,VBM+_A'-;_ .@-J'_@*_\ A1_PCFM_] ;4/_ 5_P#"CVM/
M^9?>'U>M_(_N9FT5I?\ ".:W_P! ;4/_  %?_"C_ (1S6_\ H#:A_P" K_X4
M>UI_S+[P^KUOY']S,VBM+_A'-;_Z VH?^ K_ .%'_".:W_T!M0_\!7_PH]K3
M_F7WA]7K?R/[F9M%:7_".:W_ - ;4/\ P%?_  H_X1S6_P#H#:A_X"O_ (4>
MUI_S+[P^KUOY']S#PY_R-.E?]?L/_H8K-KM?!G@W4Y=>M[S4+66TM[5Q+^^0
MJSL#D  \]>]4->\$ZMIFIRI:6,]W;,Q,4D$9?Y>P('((KG6*H^W<.97LOU.Z
M6 Q/U6-3D=KOIY+\-#F:*TO^$<UO_H#:A_X"O_A1_P (YK?_ $!M0_\  5_\
M*Z/:T_YE]YP_5ZW\C^YF;16E_P (YK?_ $!M0_\  5_\*/\ A'-;_P"@-J'_
M ("O_A1[6G_,OO#ZO6_D?W,S:*TO^$<UO_H#:A_X"O\ X4?\(YK?_0&U#_P%
M?_"CVM/^9?>'U>M_(_N9FT5I?\(YK?\ T!M0_P# 5_\ "C_A'-;_ .@-J'_@
M*_\ A1[6G_,OO#ZO6_D?W,S:*TO^$<UO_H#:A_X"O_A1_P (YK?_ $!M0_\
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M_P YKFV@!.X3.JJS,,8X .,'T-=76;::N]W_ &=_Q*=3@^W>;_KK?;]GV?\
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MI_S+[P^KUOY']S,VBM+_ (1S6_\ H#:A_P" K_X4?\(YK?\ T!M0_P# 5_\
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M#CW%=]3*\)3@YM/37<\FEGV85:D:<6KMI;=ST'_A:FB?\^NH?]^T_P#BZ/\
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MT-=]7 _#C3;ZQN[XWVF:U9!D0*=3U%;D-R?N@ 8-=]0 4444 %%%% !1110
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M]'_Y^;[_ +^)_P#$T?VOA>[^X/\ 5W']E]YY=7K7A>-HO ^EK(,$SQM@^AN
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MOA>[^XR_U=Q_9?>>2UTWP\C9_'%DRC(C61F/H/+8?S(KM/\ A5>B?\_6H?\
M?Q/_ (BM[0?"^F^'4<:?&YDDX>65MS$>GH!]*YL5FM"=&4(7;:M]YV8'(,53
MQ,*E6R46GOVU+>E?\><G_7S/_P"CGJ[5+2O^/.3_ *^9_P#T<]7:^7/O HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M JEK/_("O_\ KVD_]!-7:I:S_P @*_\ ^O:3_P!!- %VBBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N*^)DFFS:58Z
M9>:.=8O;^YV6-LLOE,) ,E]_\( Z_6NUKA_B>='@TW3[W4M8DT>_M;G?I]U#
M"9G#X^8>7_$,=>@Z?0@$?PR.GV2ZIHL>B'1M5LY4:]A:X\\R[@2CB0_>&.W;
M/O7>5Y[\,KC2[N^U:[AU:[UC5[DQO=W=S9FW!49"*J] !STKT*@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *B,3EB1<2#)Z +Q
M^E2T4 1>2_\ S\R_DO\ \31Y+_\ /S+^2_\ Q-2T4 1>2_\ S\R_DO\ \31Y
M+_\ /S+^2_\ Q-2T4 1>2_\ S\R_DO\ \337A?RV_P!)EZ'LO^%3TV3_ %;?
M0T 9WE/_ ,]Y/R7_  H\I_\ GO)^2_X5E^(]5ETVTC6W^668D!L?= Z_S%<B
M=5U G)OKC\)6']:#NH8*=:'/>R/0O*?_ )[R?DO^%'E/_P ]Y/R7_"O//[4O
M_P#G^N?^_P W^-']J7__ #_7/_?YO\:#H_LR?\QZ'Y3_ //>3\E_PH\I_P#G
MO)^2_P"%>>?VI?\ _/\ 7/\ W^;_ !H_M2__ .?ZY_[_ #?XT!_9D_YCT/RG
M_P">\GY+_A1Y3_\ />3\E_PKSS^U+_\ Y_KG_O\ -_C1_:E__P _US_W^;_&
M@/[,G_,>A^4__/>3\E_PH\I_^>\GY+_A7GG]J7__ #_7/_?YO\:/[4O_ /G^
MN?\ O\W^- ?V9/\ F/0_*?\ Y[R?DO\ A1Y3_P#/>3\E_P *\\_M2_\ ^?ZY
M_P"_S?XT?VI?_P#/]<_]_F_QH#^S)_S'H?E/_P ]Y/R7_"CRG_Y[R?DO^%>>
MC5=0!R+ZX_&5O\:ZWPWJDNHVDBW!W2PD MC[P/3\>#0<]?!3HPY[W1J^4_\
MSWD_)?\ "CRG_P">\GY+_A7(ZYKMVVH2V]M*T,43%/D."2.IS65_:E__ ,_U
MS_W^;_&@TIY=4E%2;M<]#\I_^>\GY+_A1Y3_ //>3\E_PKSS^U+_ /Y_KG_O
M\W^-']J7_P#S_7/_ '^;_&@T_LR?\QZ'Y3_\]Y/R7_"CRG_Y[R?DO^%>>?VI
M?_\ /]<_]_F_QH_M2_\ ^?ZY_P"_S?XT!_9D_P"8]#\I_P#GO)^2_P"%'E/_
M ,]Y/R7_  KSS^U+_P#Y_KG_ +_-_C1_:E__ ,_US_W^;_&@/[,G_,>A^4__
M #WD_)?\*/*?_GO)^2_X5YY_:E__ ,_US_W^;_&C^U+_ /Y_KG_O\W^- ?V9
M/^8]#\I_^>\GY+_A1Y3_ //>3\E_PKSS^U+_ /Y_KG_O\W^-']J7_P#S_7/_
M '^;_&@/[,G_ #'H?E/_ ,]Y/R7_  JM>QL(8OWTA_TB'LO_ #U7VKB(M8U&
M&0.MY,Q'9W+ _@:[*.\^WZ1:7.-IDG@R!V(F4']10<N(PDZ"3;NC<\E_^?F7
M\E_^)H\E_P#GYE_)?_B:EHH.,B\E_P#GYE_)?_B:/)?_ )^9?R7_ .)J6B@"
M+R7_ .?F7\E_^)H\E_\ GYE_)?\ XFI:* (O)?\ Y^9?R7_XFCR7_P"?F7\E
M_P#B:EHH B\E_P#GYE_)?_B:/)?_ )^9?R7_ .)J6B@"+R7_ .?F7\E_^)H\
ME_\ GYE_)?\ XFI:* (O)?\ Y^9?R7_XFCR7_P"?F7\E_P#B:EJOJ$S6^FW4
MR<-'"[K]0":!I7=BE=ZO86,IBN=497'50H8CZX4XJO\ \)+I/_06E_[\G_XB
MO/68LQ9B22<DGO0JL[!4!9F.  ,DF@]Q9;2MJV>A?\)+I/\ T%I?^_)_^(H_
MX272?^@M+_WY/_Q%<(^GWD<J1R6DZ22?<5HB"WT&.:C2"66;R8XG>7)&Q5);
MCKQ0']GT'KS/[U_D=_\ \)+I/_06E_[\G_XBC_A)=)_Z"TO_ 'Y/_P 17G\D
M4D6WS8V3>H9=RD;@>A'M3*!_V;1[O\/\CT/_ (272?\ H+2_]^3_ /$4?\)+
MI/\ T%I?^_)_^(KSRB@?]FT>[_#_ "/0_P#A)=)_Z"TO_?D__$4?\)+I/_06
ME_[\G_XBO/** _LVCW?X?Y'H?_"2Z3_T%I?^_)_^(H_X272?^@M+_P!^3_\
M$5YY10']FT>[_#_(]-LM2L]1<I9ZDTCCG;M53^16KWDO_P _,OY+_P#$UY3;
MW$EK<QSPL5DC8,I%>MT'FXO#*@URO1D7DO\ \_,OY+_\31Y+_P#/S+^2_P#Q
M-2T4'$1>2_\ S\R_DO\ \31Y+_\ /S+^2_\ Q-2T4 1>2_\ S\R_DO\ \31Y
M+_\ /S+^2_\ Q-2T4 1>2_\ S\R_DO\ \31Y+_\ /S+^2_\ Q-2T4 1>2_\
MS\R_DO\ \31Y+_\ /S+^2_\ Q-2T4 1>2_\ S\R_DO\ \31Y+_\ /S+^2_\
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M_GYE_)?_ (FCR7_Y^9?R7_XFI:* (O)?_GYE_)?_ (FCR7_Y^9?R7_XFI:*
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M.H6LEVDBJ"(X4CWL[<YQ@@< G)H W:*YEO%\LFESW,6@ZG _V)KNV-Q''LF
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MS)1<7:0M-D_U;?0TZFR?ZMOH:"3BO&?_ "Y?]M/_ &6N6KJ?&?\ RY?]M/\
MV6N6H/I<#_N\?G^;"BBB@["U;Z;<W-LUQ$L8A5]A>25$&[&<?,14=S:S6=PT
M%RA21>HSG]16OIUU9P^'6CO4CF4WBEH2Y#;=O+#!!_I6N+R!+R]9+R%YGEC>
M)TN%B!B'1=Q!Z=QU-!QRKSC)JVG_  QR36DZV27;)B!W**^1R1VQUJ"NOM;J
MPDB@ N(;4+>2R*B2# ^4XP6' /8D#\#3FO;<:I;W,]S;^4MCMNHUE$GF'GY.
M22QSW]NM OK,KM.)R(B9H6E!3:I (+@-^ SD_A3*[ W<2RWAFOK>4O?0.C+(
MN"@8>_8=?I5#6KU+O39]UPDTB:E)Y0W D1XXQ_LT%0KRE*W*<]1110=85U/@
MS_E]_P"V?_LU<M74^#/^7W_MG_[-0<>._P!WE\OS1@:I_P A>\_Z[O\ ^A&J
MM6M4_P"0O>?]=W_]"-5:#II_ O0****"R>TLY[V1TME#%$+MN<* HZG)(%6!
MHM^9EC$*DM&90PE3:4'4[LX_6IM!FAAEOC<L%1K*1<%PI8G' )[G\:OZ9J<,
MS?9E5+6"&RECB\V899F(/+' Y-!RU*E2+?*M$85S93V@C,RC;("4='#JV#@X
M()%)):S0VT,\B8BGW>6V1\V#@_K6I.UM%HEK8W5QF02O*Q@VR^6.@&0P'/7K
M2W42W>AZ;':SPL8?.W"29(V +\9!;N*"E5>E^_\ F9GV&Y%C]L,3"WW[!(>
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MHH **** "BBB@ HHHH I:5_QYR?]?,__ *.>KM4M*_X\Y/\ KYG_ /1SU=H
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M]K:9XED@*)O>1V+N3@';QG\RE_X9U>?P;XNL8K3=<ZCJ<D]JGF(/,0F/!SG
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M@ HHHH **** "J6L_P#("O\ _KVD_P#035VJ6L_\@*__ .O:3_T$T 7:***
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M &8FJV37^2/L@N$,N0,D;,YZ<].E &1X!M;BR^']C;WMK+%,@EW02IM;F1R
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %*Q_X_-2_Z^1_Z)CJ[
M5*Q_X_-2_P"OD?\ HF.KM !1110 4444 %%%% !1110 4444 %%%% !1110
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M-?*(GFD25BR;=QS( ZY4$GGO6=X3GB@'P_N+B1((WCU&)3*VW+O(NU.?XCC
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M#CQW^[R^7YHZBBBB@^:"BBB@ HHHH **** "BBB@ HHHH *K7W^IB_Z^8/\
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MOF?_ -'/5V@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MLR?WI?\ OZW^-'V9/[TO_?UO\:EHH B^S)_>E_[^M_C1]F3^]+_W];_&I:*
M(OLR?WI?^_K?XT?9D_O2_P#?UO\ &I:* (OLR?WI?^_K?XT?9D_O2_\ ?UO\
M:EHH B^S)_>E_P"_K?XT?9D_O2_]_6_QJ6B@"+[,G]Z7_OZW^-'V9/[TO_?U
MO\:EHH B^S)_>E_[^M_C1]F3^]+_ -_6_P :EHH B^S)_>E_[^M_C1]F3^]+
M_P!_6_QJ6B@"+[,G]Z7_ +^M_C1]F3^]+_W];_&I:* (OLR?WI?^_K?XT?9D
M_O2_]_6_QJ6B@"+[,G]Z7_OZW^-'V9/[TO\ W];_ !J6B@#.LK=#>:CS)Q<
M?ZUO^>4?O5S[,G]Z7_OZW^-5['_C\U+_ *^1_P"B8ZNT 1?9D_O2_P#?UO\
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M-2T4 1?9D_O2_P#?UO\ &C[,G]Z7_OZW^-2T4 9VEVZ&S?)D_P"/B<<2L/\
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MG]Z7_OZW^-'V9/[TO_?UO\:EHH B^S)_>E_[^M_C1]F3^]+_ -_6_P :EHH
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MH[AD&60 JP'KM(!Q6G4--.S+335T%%%%(84444 %%%% !1110 4444 %%%%
M%*Q_X_-2_P"OD?\ HF.KM4K'_C\U+_KY'_HF.KM !1110 4444 %%%4=4UG3
MM%MQ-JEW';(QPN\\M] .3^%-)MV0FTE=EZBN7_X63X3_ .@K_P"2\O\ \31_
MPLGPG_T%?_):7_XFK]G/^5D>TAW1U%%<O_PLGPG_ -!7_P EI?\ XFC_ (63
MX3_Z"O\ Y+2__$T>SG_*P]I#NCJ**Y?_ (63X3_Z"O\ Y+2__$T?\+)\)_\
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M\/>&[S1_$]K*UO#':0:%'9EH')C$HE9BJAV+X /!- '84444 %%%% !1110
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M[$JIN8V4,'=E5$)P1G)(/'53TZ50T7PI]M\67NC7C/YMHDI6-&$;7#IPJJS
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M60\:'2;X/(2$4VSY?C/''/'-=5-XIL)/#D7EW$*W8TIK&6*6&9Y68GG:0PC
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MK(U"BBB@ HHHH I:5_QYR?\ 7S/_ .CGJ[5+2O\ CSD_Z^9__1SU=H ****
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M@>]<-;W MIW%M*8X9"P4*\FW:F20 6(!J?4?%6CZ5=O;7MRXEB023>5;R2K
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MZHKE5BE1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,?\ 4>_\D_\ [.O4:*/K%7N'U>EV/+O^%,?]1[_R3_\ LZ/^%,?]1[_R3_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F
MR?ZMOH:=39/]6WT- %*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ JM??ZF+_ *^8/_1JU9JM??ZF+_KY@_\
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M;_&I:* (OLR?WI?^_K?XT?9D_O2_]_6_QJ6B@"+[,G]Z7_OZW^-'V9/[TO\
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MI:* ,ZRMT-YJ/,G%P!_K6_YY1^]7/LR?WI?^_K?XU7L?^/S4O^OD?^B8ZNT
M1?9D_O2_]_6_QH^S)_>E_P"_K?XU+10!%]F3^]+_ -_6_P :/LR?WI?^_K?X
MU+10!%]F3^]+_P!_6_QH^S)_>E_[^M_C4M% $7V9/[TO_?UO\:/LR?WI?^_K
M?XU+10!%]F3^]+_W];_&C[,G]Z7_ +^M_C4M% $7V9/[TO\ W];_ !H^S)_>
ME_[^M_C4M% $7V9/[TO_ '];_&C[,G]Z7_OZW^-2T4 1?9D_O2_]_6_QH^S)
M_>E_[^M_C4M% $7V9/[TO_?UO\:/LR?WI?\ OZW^-2T4 1?9D_O2_P#?UO\
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MI:* (OLR?WI?^_K?XT?9D_O2_P#?UO\ &I:* (OLR?WI?^_K?XT?9D_O2_\
M?UO\:EHH B^S)_>E_P"_K?XT?9D_O2_]_6_QJ6B@"+[,G]Z7_OZW^-'V9/[T
MO_?UO\:EHH B^S)_>E_[^M_C5/5[=%T.^(,G%O(>96/\)]ZT:I:S_P @*_\
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M/_030!=HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHKE-=^(.G:'K%QI;VUU<W<,"2!(5'[QW8*D8R<EB3G@<#/I0
M!U=%8WA7Q);^*]!34K:"6WR[120RXW1NIP1QUK9H *YKQC=7%K+X=%M/+")M
M:@BD\MRN]"KY4XZ@X''M72UB^(]&N-8DT=K9XE%CJ45W)YA(RBJP(& >?F'I
M]: ,:?QW>0P:K?#1$.FZ3?-:7,QO,2, R@NB;,-@,"067T!-4[GQ9JNC:[XP
MN[VWCN;#2H;<Q0K=$%002,#9C+;B22<C '(P1:O?!VH7'@_Q/I236PGU>]FN
M(&+-M57*D!CMR#\IZ TSQ%X0U74W\3QV1L_)URVA1))9G5HI(QC!4(001WSQ
MZ4 :EUXBU>TMX?M&C6T,SH\\TD]\R6MM$H',DQBX<DXV!3P"<X'/.W7C74-:
M@\-W6AQ0QI<:LUK<Q_:SMD9%?Y0ZH=T9QNW<9P..3C=\0>'+N_\ $]EJT-GI
MNJ16]L\(L]2<HL3EU82H0CX;Y<'@' '-9-GX*UNRTRTW2:?<WUIKLFIY\QXH
MY4=6!'W6*G+],-TZ\T :L_C7R?"^L:Q_9^[^S+^2S\GSO]9LE$>[.WC.<XP?
M3-5M3\=7ME-KQM]$2>UT%E^TS/>;"ZE%?Y%V'+ $Y!(' Y.<"GJ?@_7YM&UO
M1;!]-^R:CJ#7J7,TL@D4/(LC1E A ^8$!MQXQQZ7;_PA?W5CXQACFM@VND&V
M+,V$Q$J?/\O'([9XH F_X3=K*Z==>T];"!M.?4H9$N/-8QIC<CKM&V3##@%A
MU 8]Y[/Q1>B[TQ-:TA;"#5B5M9$N?-*OMWJDHV*$8J#C!89!&?6IK?@N77+Z
MU\^:-+5=(GL)BI.\-($PRC&"!M)Y([5)!H.N7UYHO]O/8QV^CN90;25V:ZD"
M%$8JR@1@!F. 6R3C/'( S2O&.JZKX=M]6@\/92\=8K6*.Z9V+%BI:3$>(XQ@
MG=EN,<9.*QM<\</J?A7Q%;VLL-MJ&F&W)GTV^,\95Y%'RR!5(8892N!CWSQ>
M_P"$(OQX#T31Y#8W4VFW2SS6TS-]GNE!?*,=I.,/D94C*CCO52Z\"ZU>QZ[N
M&E6@U*UM88+>W=_+MA#)PF=@R-N.0!SQMP,T >BT444 %%%% !1110 C,J*6
M<A549))P *\ZUWXBW.IW4ND^ D2XE0[9]5D&8(/4)_?;]/K74^-](DUWP/JV
MG0%A+-;-Y84X+.OS*/H2 /QKS[P?/;W7AFPFM8TB1H@"B# ##AOU!KFQ%:5*
M*<5N95)N*T+FA>&K?39I+N:22^U&<[I[VX.Z1S_0>PKI%1(HFDE9411EF8X
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M(GC2PETVWN(;:\DNKBY>TCT\1J+@S)G>A!;:-H4DL6V@#KR,XF@>$]5TO7-
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MMS)/&\$+SOB:2-MG4D<@&LVBG.LIJS02G=;&]I$5Q&QS+NLRDBBY1B5BXR<
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M110 4444 %%%% !5+6?^0%?_ /7M)_Z":NU2UG_D!7__ %[2?^@F@"[1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $%
MZ,Z?<#]\,Q-_J/\ 6=/X?]KT]Z\-_LB2TUUM08_$F1+NSB826D>Z<'KL>7N!
M_=P,5[K<0BXMI869D$B%"R'##(QD'L:\8U[1[;2/$[Z)91>,-5G2W%P3:ZIG
MY#QG&W/7CWH ](\#?\BTO_(>_P!:_P#R,'_'S^/^SZ5T=<C\,[F"\\%QSVBW
MZPO-)M_M"X$TO!P?FP.,@\=JZZ@ HHHH **** "BBB@ HHHH **** "BBB@
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ML4444 %%%% !1110 4444 %%%% !1110 4CHLB%9%#*>H(R#2T4 5?[+T_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *;)_JV^AIU-D_U;?0T 4J*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "JU]_J8O\ KY@_]&K5FJU]_J8O
M^OF#_P!&K0!L4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %*
MQ_X_-2_Z^1_Z)CJ[5*Q_X_-2_P"OD?\ HF.KM !1110 4444 %%%% !1110
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M]XO^^!1]DM_^?>+_ +X%2T4 1?9+?_GWB_[X%'V2W_Y]XO\ O@5+10!G65M
M;S408(SBX 'R#C]U'5S[);_\^\7_ 'P*KV/_ !^:E_U\C_T3'5V@"+[);_\
M/O%_WP*/LEO_ ,^\7_? J6B@"+[);_\ /O%_WP*/LEO_ ,^\7_? J6B@"+[)
M;_\ /O%_WP*/LEO_ ,^\7_? J6B@"+[);_\ /O%_WP*/LEO_ ,^\7_? J6B@
M"+[);_\ /O%_WP*/LEO_ ,^\7_? J6B@"+[);_\ /O%_WP*/LEO_ ,^\7_?
MJ6B@"+[);_\ /O%_WP*/LEO_ ,^\7_? J6B@"+[);_\ /O%_WP*/LEO_ ,^\
M7_? J6B@"+[);_\ /O%_WP*/LEO_ ,^\7_? J6B@"+[);_\ /O%_WP*/LEO_
M ,^\7_? J6B@"+[);_\ /O%_WP*/LEO_ ,^\7_? J6B@"+[);_\ /O%_WP*/
MLEO_ ,^\7_? J6B@"+[);_\ /O%_WP*/LEO_ ,^\7_? J6B@#.TNV@:S<F",
M_P"D3CE!_P ]7JY]DM_^?>+_ +X%5]*_X\Y/^OF?_P!'/5V@"+[);_\ /O%_
MWP*/LEO_ ,^\7_? J6B@"+[);_\ /O%_WP*/LEO_ ,^\7_? J6B@"+[);_\
M/O%_WP*/LEO_ ,^\7_? J6B@"+[);_\ /O%_WP*/LEO_ ,^\7_? J6B@"+[)
M;_\ /O%_WP*/LEO_ ,^\7_? J6B@"+[);_\ /O%_WP*/LEO_ ,^\7_? J6B@
M"+[);_\ /O%_WP*/LEO_ ,^\7_? J6B@"+[);_\ /O%_WP*/LEO_ ,^\7_?
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MIV84444A!1110 4444 4M*_X\Y/^OF?_ -'/5VJ6E?\ 'G)_U\S_ /HYZNT
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MOW@(99'W,V[!4?*NP'GVPRX\'ZEJ.N1ZIJFM0R2I:3V@B@L3'&$D7&0#(QW
M\G)((P !U+=.\<S:S8:0=+TH/?ZI'-,+>>X*)!%&Q4L[A&(R=H "GEO;-)/X
MZFCMK-8=(,FH3:DVF2VIN0JPS!"V=^WE,;3G .ULXR-M $<G@*[2R2+3]<^R
M3)HD.C^>+7<0J-EI!\XP6&1C/&<@U<3PE<3^'WT#4KNQ_LHP"*.*PL7@DB((
M*L':5QD$9Y!R>3[L;QM);6NHQW^F%-4L[J*T2SMY_,6>24 Q[9"JX!SDDJ,
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!2L?^/S4O\
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MJX'#07-J^<^Q4$$>]<UXU\0R^+=)W^&]&O96L6^T1ZFR&+RL=?+SRQ..1^G
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M^OF#_P!&K0!L4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %*
MQ_X_-2_Z^1_Z)CJ[5*Q_X_-2_P"OD?\ HF.KM !1110 4444 %<?X^_Y</\
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MNV>E4V3_ %;?0TZFR?ZMOH:\X\@I4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %5K[_4Q?]?,'_HU:LU6OO\
M4Q?]?,'_ *-6@#8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M *5C_P ?FI?]?(_]$QU=JE8_\?FI?]?(_P#1,=7: "BBB@ HHHH *@O+*"_M
M6M[N,21MV]#ZCT-3T4TVG=#3:=T<V? ^F$_ZZZ'MO7_XFC_A!M-_Y[W?_?:_
M_$UTE%:^WJ_S'1]:K?S'-_\ "#:;_P ][O\ [[7_ .)H_P"$&TW_ )[W?_?:
M_P#Q-=)11[>K_,'UJM_,<W_P@VF_\][O_OM?_B:/^$&TW_GO=_\ ?:__ !-=
M)11[>K_,'UJM_,<W_P (-IO_ #WN_P#OM?\ XFC_ (0;3?\ GO=_]]K_ /$U
MTE%'MZO\P?6JW\QS?_"#:;_SWN_^^U_^)H_X0;3?^>]W_P!]K_\ $UTE%'MZ
MO\P?6JW\QS?_  @VF_\ />[_ .^U_P#B:!X'TP'_ %UT?;>O_P 37244>WJ_
MS!]:K?S$%E90:?:K;VJ;(U[>I]34]%%9-MN[.=MMW84444A!1110 4444 4M
M*_X\Y/\ KYG_ /1SU=JEI7_'G)_U\S_^CGJ[0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 52UG_D!7__ %[2?^@F
MKM4M9_Y 5_\ ]>TG_H)H NT444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!'<0BXMI869D$B%"R'##(QD'L:\>\0Z%9:7
MKHT;1G\6ZWJ"0?:)XX-4V"%"<#)*]3Z5[+7GFLZ+K4_Q"O\ 4_#'B'3+"Y2S
MCAN8)HM[A/O!F'3Z'\* -OX=S:?<>#H)M)N+^:%Y'WC4)=\T;@X9&/L1745Y
MU\,M-U>QMPL&O:=J6C1RRK(;>!@TDQ.2V\]>3U''I7HM !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4V3_5
MM]#3J;)_JV^AH I4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %5K[_4Q?]?,'_HU:LU6OO]3%_P!?,'_HU: -
MBBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH I6/\ Q^:E_P!?
M(_\ 1,=7:I6/_'YJ7_7R/_1,=7: "BBB@ HHHH **** "BBB@ HHHH ****
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M)]1V.:Z*N8\ >'=0\,^&WLM7DMI+J2ZEG8VK,4^<YP-P!KIZ "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J(VT#,2T$9).22@YJ
M6B@"+[);_P#/O%_WP*/LEO\ \^\7_? J6B@"+[);_P#/O%_WP*/LEO\ \^\7
M_? J6B@"+[);_P#/O%_WP*:]I;^6W[B+H?X!4]-D_P!6WT- &=]F@_YXQ_\
M? H^S0?\\8_^^!6?KMW);V\<<3%3(3EAUP/_ -=<X22<DY/O7E8K,8T*GLU&
M[/0H8)UH<[=CL_LT'_/&/_O@4?9H/^>,?_? KBZ*YO[8_N?C_P  W_LW^_\
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M^S0?\\8_^^!4E%>J>>1_9H/^>,?_ 'P*/LT'_/&/_O@5)10!']F@_P">,?\
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M%]DM_P#GWB_[X%'V2W_Y]XO^^!7GM%']L?W/Q_X ?V;_ '_P_P"">A?9+?\
MY]XO^^!1]DM_^?>+_O@5Y[11_;']S\?^ ']F_P!_\/\ @GH7V2W_ .?>+_O@
M4?9+?_GWB_[X%>>T4?VQ_<_'_@!_9O\ ?_#_ ()Z%]DM_P#GWB_[X%'V2W_Y
M]XO^^!7GRLR,&1BI'0@XKM-!O)+W3 TQW.C%"WKT/]:Z\)F$<1/D<;,YL1@W
M1CS7N7?LEO\ \^\7_? H^R6__/O%_P!\"I:*],X2+[);_P#/O%_WP*/LEO\
M\^\7_? J6B@"+[);_P#/O%_WP*/LEO\ \^\7_? J6B@"+[);_P#/O%_WP*/L
MEO\ \^\7_? J6B@"+[);_P#/O%_WP*/LEO\ \^\7_? J6B@"+[);_P#/O%_W
MP*/LEO\ \^\7_? J6B@"+[);_P#/O%_WP*/LEO\ \^\7_? J6B@"+[);_P#/
MO%_WP*/LEO\ \^\7_? J6B@"+[);_P#/O%_WP*/LEO\ \^\7_? J6B@"+[);
M_P#/O%_WP*/LEO\ \^\7_? J6B@"+[);_P#/O%_WP*/LEO\ \^\7_? J6B@"
M+[);_P#/O%_WP*/LEO\ \^\7_? J6B@"+[);_P#/O%_WP*/LEO\ \^\7_? J
M6B@#.LK: WFH@P1G%P /D''[J.KGV2W_ .?>+_O@57L?^/S4O^OD?^B8ZNT
M1?9+?_GWB_[X%'V2W_Y]XO\ O@5+10!%]DM_^?>+_O@4?9+?_GWB_P"^!4M%
M $7V2W_Y]XO^^!1]DM_^?>+_ +X%2T4 1?9+?_GWB_[X%'V2W_Y]XO\ O@5+
M10!%]DM_^?>+_O@4?9+?_GWB_P"^!4M% $7V2W_Y]XO^^!1]DM_^?>+_ +X%
M2T4 1?9+?_GWB_[X%'V2W_Y]XO\ O@5+10!%]DM_^?>+_O@4?9+?_GWB_P"^
M!4M% $7V2W_Y]XO^^!1]DM_^?>+_ +X%2T4 1?9+?_GWB_[X%'V2W_Y]XO\
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M_P#S[Q?]\"I:* (OLEO_ ,^\7_? H^R6_P#S[Q?]\"I:* (OLEO_ ,^\7_?
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MISPQE^7D'A3QZ '9T5P%AXIU/6]"O7M]9T6:7^SY)'CMXI(KBSE7@AHFD+$
MY&[Y"#@X(-5=*\67&E>'_"^DS:KI-E-<:3'=/>Z@I6-(MBA$"F4%Y"3R=P&%
M)QS@ 'I-%<#;>.M2U4Z/:Z1_9LES=WUQ8W,X+2P9BC+^;'M894C#;2>^W/\
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M* "BBB@ HHHH **** "BBB@ JM??ZF+_ *^8/_1JU9JM??ZF+_KY@_\ 1JT
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MB5"C;GDY Q63>>)+C4M3\->5YUC*NKRV=_:K,2-Z1.2I(P'7[K D<@@X!XH
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MY*S9Y5>$:=1QBSEO$G_+M_P+^E8==7JE@;ZW 0@2(<KGH?:L/^QK_P#YX?\
MCZ_XUX.88:M+$.<8MIVV]#UL'7IJBHMV:*%%7O[&O_\ GA_X^O\ C1_8U_\
M\\/_ !]?\:X/JU?^1_<SL]O2_F7WHHT5>_L:_P#^>'_CZ_XT?V-?_P#/#_Q]
M?\:/JU?^1_<P]O2_F7WHHT5>_L:__P">'_CZ_P"-']C7_P#SP_\ 'U_QH^K5
M_P"1_<P]O2_F7WHHT5>_L:__ .>'_CZ_XT?V-?\ _/#_ ,?7_&CZM7_D?W,/
M;TOYE]Z*-%7O[&O_ /GA_P"/K_C1_8U__P \/_'U_P :/JU?^1_<P]O2_F7W
MHHUN>&_^7G_@/]:I#1K_ /YX8_X&O^-;>EV!L;<AR#(YRV.@]J[\OPU:.(4Y
M1:2OOZ')C*]-T7%.[9>HHHKZ8\(**** "BBB@ HHHH **** "BBB@ JM??ZF
M+_KY@_\ 1JU9JM??ZF+_ *^8/_1JT 9?BK_D*1_]<1_Z$U8E=AKND/J 26W(
M\U!C:>-P^M8/_"/ZG_S[?^1%_P :^6QN&K.O*2BVGV/?PM>E[))R2L9M%:7_
M  C^I_\ /M_Y$7_&C_A']3_Y]O\ R(O^-<?U:O\ R/[F=/MZ7\R^]&;16E_P
MC^I_\^W_ )$7_&C_ (1_4_\ GV_\B+_C1]6K_P C^YA[>E_,OO1FT5I?\(_J
M?_/M_P"1%_QH_P"$?U/_ )]O_(B_XT?5J_\ (_N8>WI?S+[T9M%:7_"/ZG_S
M[?\ D1?\:/\ A']3_P"?;_R(O^-'U:O_ "/[F'MZ7\R^]&;16E_PC^I_\^W_
M )$7_&C_ (1_4_\ GV_\B+_C1]6K_P C^YA[>E_,OO1FUUOA7_D%R?\ 78_^
M@K6*OA[4BP!MPON9%_QKJ=,L1IUBL.=S9W,?4UZ>6X>K&MSRBTK=3AQU:G*E
MRQ=V6Z***^B/%"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** *5C_P ?FI?]?(_]$QU=JE8_\?FI?]?(_P#1,=7: "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@"EI7_'G)_U\S_^CGJ[5+2O^/.3_KYG_P#1SU=H **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *I:S_R K_\
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M^5HY;IRRGS)5< !QM(X+?>/.,"M/5?'Z7Y;3?!BG5-1D&WSD4^1;Y_C=\8_
M5Z4IRV/GHQ6XGAMQ-XZ\8W,/^H:XMX@1TWI&0_ZFMVX;K5'P_HT?AW1$LUE,
MTS,9;B=NLLC<LW^?2LWQEJ;Z?X9O)(,F>1?)A4=2[_*,>_.?PKR:\O:U.6/6
MR_0]&C'V<.:7J:?PJMOMO]M^)7&?[1NS#;M_TQB^52/J<_E7H,G^K;Z&LWPS
MHZ^'_"^G:4F/]%@5&([MC+'\6)-:4G^K;Z&OHXQ4(J*Z'BRDY-MF+JE_]AMP
M4 ,CG"YZ#WK#.M7Y/$V/8(O^%7?$G_+M_P "_I6'7S>88FM&NX1DTE;;T/:P
M="FZ*DU=LO?VS?\ _/?_ ,<7_"C^V;__ )[_ /CB_P"%4:*X/K-?^=_>SL]A
M2_E7W(O?VS?_ //?_P <7_"C^V;_ /Y[_P#CB_X51J6&WFN,^1#)+MZ[%)Q^
M5-8C$-V4W][$Z-%*[BON19_MF_\ ^>__ (XO^%']LW__ #W_ /'%_P *K-;S
M*7#0R QXWY4_+GIGTH^S3[0?(DP4W@[#]WU^GO3]OB?YI?>P]E0_E7W(L_VS
M?_\ /?\ \<7_  H_MF__ .>__CB_X53:-U179&"/G:Q'#8ZXIM3]9KK[;^]C
M]C1_E7W(O?VS?_\ /?\ \<7_  H_MF__ .>__CB_X51HH^LU_P"=_>P]A2_E
M7W(OC6K\'_7Y_P" +_A6YI=^;ZW)< 2(<-CH?>N4K<\-_P#+S_P'^M=^7XFM
M+$*$I-IWW]#CQE"FJ+DE9H-2UF:.Y:&UPH0X+$9)-4?[9O\ _GO_ ..+_A4%
M]_R$+C_KJW\S4%<M;%UW4?O-:]SHI8>DH+W47O[9O_\ GO\ ^.+_ (4?VS?_
M //?_P <7_"J-%9?6:_\[^]FGL*7\J^Y%[^V;_\ Y[_^.+_A1_;-_P#\]_\
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MU2TK_CSD_P"OF?\ ]'/5V@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ JEK/_ " K_P#Z]I/_ $$U=JEK/_("O_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %*Q_X_-2_P"OD?\
MHF.KM4K'_C\U+_KY'_HF.KM !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!2TK_CSD_Z^9_\ T<]7:I:5_P >
M<G_7S/\ ^CGJ[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 52UG_ ) 5_P#]>TG_ *":NU2UG_D!7_\ U[2?^@F@
M"[1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"BB@ ^R6_P#S[Q?]\"C[);_\^\7_ 'P*** #[);_ //O%_WP*/LEO_S[Q?\
M? HHH /LEO\ \^\7_? H^R6__/O%_P!\"BB@ ^R6_P#S[Q?]\"C[);_\^\7_
M 'P*** #[);_ //O%_WP*/LEO_S[Q?\ ? HHH /LEO\ \^\7_? H^R6__/O%
M_P!\"BB@ ^R6_P#S[Q?]\"C[);_\^\7_ 'P*** #[);_ //O%_WP*/LEO_S[
MQ?\ ? HHH /LEO\ \^\7_? H^R6__/O%_P!\"BB@ ^R6_P#S[Q?]\"C[);_\
M^\7_ 'P*** #[);_ //O%_WP*0V=L>MO$><\H*** %^R6_\ S[Q?]\"C[);_
M //O%_WP*** #[);_P#/O%_WP*/LEO\ \^\7_? HHH /LEO_ ,^\7_? H^R6
M_P#S[Q?]\"BB@ ^R6_\ S[Q?]\"C[);_ //O%_WP*** #[);_P#/O%_WP*/L
MEO\ \^\7_? HHH /LEO_ ,^\7_? H^R6_P#S[Q?]\"BB@ ^R6_\ S[Q?]\"C
M[);_ //O%_WP*** #[);_P#/O%_WP*/LEO\ \^\7_? HHH /LEO_ ,^\7_?
MH^R6_P#S[Q?]\"BB@ ^R6_\ S[Q?]\"C[);_ //O%_WP*** #[);_P#/O%_W
MP*/LEO\ \^\7_? HHH /LEO_ ,^\7_? H^R6_P#S[Q?]\"BB@ ^R6_\ S[Q?
M]\"C[);_ //O%_WP*** #[);_P#/O%_WP*/LEO\ \^\7_? HHH /LEO_ ,^\
M7_? H^R6_P#S[Q?]\"BB@ ^R6_\ S[Q?]\"C[);_ //O%_WP*** #[);_P#/
MO%_WP*/LEO\ \^\7_? HHH /LEO_ ,^\7_? H^R6_P#S[Q?]\"BB@ ^R6_\
MS[Q?]\"C[);_ //O%_WP*** #[);_P#/O%_WP*/LEO\ \^\7_? HHH 06=L,
MXMXADY/R#FE^R6__ #[Q?]\"BB@ ^R6__/O%_P!\"C[);_\ /O%_WP*** #[
M);_\^\7_ 'P*/LEO_P ^\7_? HHH /LEO_S[Q?\ ? H^R6__ #[Q?]\"BB@
M^R6__/O%_P!\"C[);_\ /O%_WP*** #[);_\^\7_ 'P*/LEO_P ^\7_? HHH
M /LEO_S[Q?\ ? H^R6__ #[Q?]\"BB@ ^R6__/O%_P!\"C[);_\ /O%_WP**
M* #[);_\^\7_ 'P*/LEO_P ^\7_? HHH /LEO_S[Q?\ ? H^R6__ #[Q?]\"
MBB@ ^R6__/O%_P!\"C[);_\ /O%_WP*** #[);_\^\7_ 'P*/LEO_P ^\7_?
M HHH /LEO_S[Q?\ ? H^R6__ #[Q?]\"BB@ ^R6__/O%_P!\"C[);_\ /O%_
MWP*** #[);_\^\7_ 'P*/LEO_P ^\7_? HHH /LEO_S[Q?\ ? H^R6__ #[Q
M?]\"BB@ ^R6__/O%_P!\"C[);_\ /O%_WP*** #[);_\^\7_ 'P*/LEO_P ^
M\7_? HHH /LEO_S[Q?\ ? H^R6__ #[Q?]\"BB@ ^R6__/O%_P!\"C[);_\
M/O%_WP*** #[);_\^\7_ 'P*/LEO_P ^\7_? HHH /LEO_S[Q?\ ? H^R6__
M #[Q?]\"BB@ ^R6__/O%_P!\"C[);_\ /O%_WP*** #[);_\^\7_ 'P*/LEO
M_P ^\7_? HHH /LEO_S[Q?\ ? H^R6__ #[Q?]\"BB@ ^R6__/O%_P!\"C[)
M;_\ /O%_WP*** #[);_\^\7_ 'P*/LEO_P ^\7_? HHH /LEO_S[Q?\ ? I#
M9VS*0UO$0>""@YHHH 7[);_\^\7_ 'P*/LEO_P ^\7_? HHH /LEO_S[Q?\
M? H^R6__ #[Q?]\"BB@ ^R6__/O%_P!\"C[);_\ /O%_WP*** #[);_\^\7_
M 'P*/LEO_P ^\7_? HHH /LEO_S[Q?\ ? H^R6__ #[Q?]\"BB@ ^R6__/O%
M_P!\"C[);_\ /O%_WP*** #[);_\^\7_ 'P*/LEO_P ^\7_? HHH /LEO_S[
MQ?\ ? H^R6__ #[Q?]\"BB@ ^R6__/O%_P!\"C[);_\ /O%_WP*** #[);_\
H^\7_ 'P*/LEO_P ^\7_? HHH >D:1+B-%09SA1BG444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>mrna-20210331_g3.jpg
<TEXT>
begin 644 mrna-20210331_g3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ) !0 # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** (_.C_OK^='G1_WU_.LNBKY2.8U/.C_ +Z_G1YT?]]?SK+HHY0YC4\Z
M/^^OYT>='_?7\ZRZ*.4.8U/.C_OK^='G1_WU_.LNBCE#F-3SH_[Z_G1YT?\
M?7\ZRZ*.4.8U/.C_ +Z_G1YT?]]?SK+HHY0YC4\Z/^^OYT>='_?7\ZRZ*.4.
M8U/.C_OK^='G1_WU_.LNBCE#F-3SH_[Z_G1YT?\ ?7\ZRZ*.4.8U/.C_ +Z_
MG1YT?]]?SK+HHY0YC4\Z/^^OYT>='_?7\ZRZ*.4.8U/.C_OK^='G1_WU_.LN
MBCE#F-3SH_[Z_G1YT?\ ?7\ZRZ*.4.8U/.C_ +Z_G1YT?]]?SK+HHY0YC4\Z
M/^^OYT>='_?7\ZRZ*.4.8U/.C_OK^='G1_WU_.LNBCE#F-3SH_[Z_G1YT?\
M?7\ZRZ*.4.8U/.C_ +Z_G1YT?]]?SK+HHY0YC4\Z/^^OYT>='_?7\ZRZ*.4.
M8U/.C_OK^='G1_WU_.LNBCE#F-3SH_[Z_G1YT?\ ?7\ZRZ*.4.8U/.C_ +Z_
MG1YT?]]?SK+HHY0YC4\Z/^^OYT>='_?7\ZRZ*.4.8U/.C_OK^='G1_WU_.LN
MBCE#F-3SH_[Z_G1YT?\ ?7\ZRZ*.4.8U/.C_ +Z_G1YT?]]?SK+HHY0YC4\Z
M/^^OYT>='_?7\ZRZ*.4.8U/.C_OK^='G1_WU_.LNBCE#F-3SH_[Z_G1YT?\
M?7\ZRZ*.4.8U/.C_ +Z_G1YT?]]?SK+HHY0YC4\Z/^^OYT>='_?7\ZRZ*.4.
M8U/.C_OK^='G1_WU_.LNBCE#F-3SH_[Z_G1YT?\ ?7\ZRZ*.4.8U/.C_ +Z_
MG1YT?]]?SK+HHY0YC4\Z/^^OYT>='_?7\ZRZ*.4.8U/.C_OK^='G1_WU_.LN
MBCE#F-3SH_[Z_G1YT?\ ?7\ZRZ*.4.8U/.C_ +Z_G1YT?]]?SK+HHY0YC4\Z
M/^^OYT>='_?7\ZRZ*.4.8U/.C_OK^='G1_WU_.LNBCE#F-3SH_[Z_G1YT?\
M?7\ZRZ*.4.8U/.C_ +Z_G1YT?]]?SK+HHY0YC4\Z/^^OYT>='_?7\ZRZ*.4.
M8U/.C_OK^='G1_WU_.LNBCE#F-3SH_[Z_G1YT?\ ?7\ZRZ*.4.8U/.C_ +Z_
MG1YT?]]?SK+HHY0YC4\Z/^^OYT>='_?7\ZRZ*.4.8U/.C_OK^='G1_WU_.LN
MBCE#F-3SH_[Z_G1YT?\ ?7\ZRZ*.4.8U/.C_ +Z_G1YT?]]?SK+HHY0YC4\Z
M/^^OYT>='_?7\ZRZ*.4.8U/.C_OK^='G1_WU_.LNBCE#F-3SH_[Z_G1YT?\
M?7\ZRZ*.4.8U/.C_ +Z_G1YT?]]?SK+HHY0YC4\Z/^^OYT>='_?7\ZRZ*.4.
M8U/.C_OK^='G1_WU_.LNBCE#F-3SH_[Z_G1YT?\ ?7\ZRZ*.4.8U/.C_ +Z_
MG1YT?]]?SK+HHY0YC4\Z/^^OYT>='_?7\ZRZ*.4.8U/.C_OK^='G1_WU_.LN
MBCE#F-3SH_[Z_G1YT?\ ?7\ZRZ*.4.8U/.C_ +Z_G1YT?]]?SK+HHY0YC4\Z
M/^^OYT>='_?7\ZRZ*.4.8U/.C_OK^='G1_WU_.LNBCE#F-3SH_[Z_G1YT?\
M?7\ZRZ*.4.8U/.C_ +Z_G1YT?]]?SK+HHY0YC4\Z/^^OYT>='_?7\ZRZ*.4.
M8U/.C_OK^='G1_WU_.LNBCE#F-3SH_[Z_G1YT?\ ?7\ZRZ*.4.8U/.C_ +Z_
MG1YT?]]?SK+HHY0YC4\Z/^^OYT>='_?7\ZRZ*.4.8U/.C_OK^='G1_WU_.LN
MBCE#F-3SH_[Z_G1YT?\ ?7\ZRZ*.4.8U/.C_ +Z_G1YT?]]?SK+HHY0YC4\Z
M/^^OYT>='_?7\ZRZ*.4.8U/.C_OK^='G1_WU_.LNBCE#F-3SH_[Z_G1YT?\
M?7\ZRZ*.4.8U/.C_ +Z_G1YT?]]?SK+HHY0YC4\Z/^^OYT>='_?7\ZRZ*.4.
M8U/.C_OK^='G1_WU_.LNA?O"CE#F"BBBJ)"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "A?O"BA?O"@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3R/0"H-<^*5UKUXM[-H6@QW[72WES=BQ\U[N11C]X)&90IZE4"J2<D5]N_\
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M(W!4+\A.2>TA^&?AA_ACI>I:[H-[J<ND^ ]0U2'3=6U2[VV]S'J)C52JR+L
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M1"+<)FB=2906(&T,F "<GG$MGZ+D&4Y;BLOEB\<G=3Y59VZ1M^;_ "W/=?\
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M3YKW_NV7ZL****9\*%%%% !1110 4444 %"_>%%"_>% !1110 4444 %%%%
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MQV]HS\@K'PK^T%I>M7&L66C_ !*M-7N(E@FOX+74$GEC4 *C2 ;BH"J "<#
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M7Y7U^J%7$_*_$#_F%_[?_P#; HHHJC\A"BBB@ HHHH **** "A?O"BA?O"@
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M /8EUS^S? =CJD5V7M+_ ,076DZC;"0M&KN%>VE"YPIW?NR1C<)5SG:*^O\
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MQ)H_O;48C< P( ). &..G)]&T'XP>']<UV#10]Q::G.2L,,T1(D(4L0'7<O
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M>&R/:@#Y8\/_ !@^+%G>:#=:KXHL+_3;/QU_PAMY FEQ12:DK.<W#L/]60,
M(@7IDD]^'DUA?#6H_&+5KWX-Z5X\TF+Q5?1S^(;Z2$MI^YL8*>3)+L7(<LN
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M'!!%>*>,/CIXVF^'>JZ;;QP>&/&-O;:'<6VK6\L=]')'?7"Q;VC>%51_E?*
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M:/J.M",,[V^FB(.J*I9G+321H  .[ GH 33$8/\ PH'X8?\ 1./"/_@BM?\
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MJ2)I;643OF%MBJ0>C$/EOGZXP!H?\--?#?[.;D:_,ULOV??.NEWACC\^)98
M["+"ET9=H8C).W[W%7;K]H'P':MIZ#69KN;4+"+4[6&QTZZNI)K>0.4=4BB9
MCQ&Y*XW (Q( &: /1**H:%KEAXFT6QU;2[E+S3KZ%+BWN(\[9(V *L,^H-7Z
M8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H7[PHH7[PH
M **** "BBB@ HHHH **** "BBB@ HHHH **** //_%5]XBU[S](T^QLIK&[:
M2WF:8Y:.,<,) >F\;L'!&"!QG->4Z3=7_P &O&,L6JNT]M'%'#J,J*?W]J.(
M+U1W:/F.0=<#/:OI:N5^(/@6+QMID8CE%GJMH3)97FW=L8C!5A_%&PX9>X]P
M*30TS6L[M)HXY(G66-U#(\9RK*1D$'N"*\"^+%_%\:OC%X;\!:7,+S2]'E:[
MUJ:%MR1MD;T8C@%4&S']Z8CL:D\(>,=1^%]]/HNJV4RZ5;G=-8)F2;303_K(
M>\UJ>3Q\R<CMBO;=$U33]2L8[_3);:YM;H;UN;7:5E]\CJ?KR*S-#,^(^CK.
M]CK*$6_V2.2WEF XA1BKQ2G_ &8Y8XR?168]JH:'JA\?>)EOO+$<<;))/%N5
MO)2#=LC8J2,O.SN.>4A4]Q7<)<<=:6'R;6(QP0QP1\G;$@49/L!0!YS^S'#]
ME^&<J=/^)G<G]5KU9YL#KGM@5YA\"5^R>!7CQC_3IS^>WBO0&N.#WH GDF^7
MU^G%4IYL9]:9-<=3G@<DY_6O'?'OQ=^W1RZ=X9NF$;/Y$^M0IYF'/'DVB_\
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M[VD9PIC.#MR>..<=ZY&'QSJ7BZ[TS31=1RSZC!;VKFXD";9P-BG.W(!RJXX
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M++LSC:0 PP/FKT'P?X7M?!/A/1O#UC)-+9:59Q64$EPP:1DC0(I8@ $X S@
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MLSVL/B*6*IJK1ES19Y[XC^+?_"/>(KO2_P"Q9[I;?:IFCF1<$JK[F5L80AB
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M=VQCO]*[OX8Z;!X@_9A@L_#Q^U7-RK?:XXE%M)))Y^;B(G<,G9NC#$C<H4Y
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MMDUJ:W<-#;C#2/$RD#*-\IW9&.>*XW5M8GU[_A&K>+7(["*\N(X+J($@2HS
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M4E2" ?QZ8QS7S;??LF^.;6 26?\ 9SQ1%XH].BNSA23GSE9E'WB6&"<@ >I
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MGAL=?3[1;*^!-$T,JN,=R%)P>@_$5C>%_'&B>++..]\/ZK9ZH-@F1(9U+#N
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MR'R=/*XQ^\8U:&F6JWQO! HN2,&0=3QC)]\<9ZXXJ+1VW6\GM(PJ_0 4444
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MUL?[>NDNK@_:[M8;,E1,RJ" 2P)  "Y(&<5RFOV_B+P/XXN=<\+VDNM6%_\
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M]F7*J:EJEMI,"2W4@B1Y4A7/5G=@J@?B:FCNH9?N31M]'%>:_$#3[KQ9\0-
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MR>!4,EW!%]^>-?JXKQVZUJ29=MUXI5_]FTM7<_F0O\ZK[K>\XW:_J?TQ&O\
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M2YR%B7NXXRYYR.Y&X]1\/_A?HGPYMI_[.CDN-1NCNO-4O'\VZNFZDNY]^<#
M_&NNK1U(P7+2^;ZO_)$*FYOFJ_=T_P""PHHHKF.D**Q/%OC70_ NEMJ.O:E!
MIMJ. TI^9SZ(HY8^P!->827WCCXW$QZ;]J\ ^"GX:^E4#4[Y/^F:_P#+%3_>
MZ]",C(K:%)R7,]%W_K<QG547RK5]OZV-CQY\9);?6G\)^"+%?$WC%AB2-3_H
MNGCION)!P,?W0<]N,C.A\+OA-'X(DN]:U>\.O>,M2^;4-8F&3V_=1#^",8
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MS;S2;E=QO- L[D#K+9.T#?7 ./\ QVG[.$MF>5[6K'?^ON/8HKB*?_5RH_\
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MM;L='CW7EU'!W"L<L?H!R:J-&AA_WCW[MW?WL.6,/>9>I&8*I). .237-_\
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MUE?^])\V?SXK8CA2)0$0* ,#BGT5NY-[G*HQCL@HHHI%!1110 4444 %%%%
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MHO\ -^;^21?K-U3Q!9Z6PC=FEN&^[;PC=(WX=OQJF5U?6NI_LFT/9?FF8?\
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MEB/6VT\;?P+GFE]:4_X,7+\%][T^ZX>TO\*N:>J>)--T7(N[N..3M$IW.?\
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MR>M:-GH=AIV#;6D4;#^(+EOS/-7EI<E>?Q34?17_ !?^06F]W8Y_[#K^H_\
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MB]M=#@/_ "SM4\Z7Z%CP/J*ZWIP.!13]K&/P02]=?^!^ ?684_X--+S?O/\
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MM]UW2RC_ .^F_P *A:ZEA7:&M[)/3.YOR%0-Y4_+_:;[Z_)'5V;U_P"#_P
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MFL/K$.C^Y&N_3]2"U\1>']/)CTNT:=QQML;4EC^.!G\ZL?V[K=YQ9Z$T2_\
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M)3.Q^H/R_I79T461,LQQ-N6F^1=HI1^^VK^;9';V\5I"L4$20Q*,+'&H51]
M*DI&X7-1TSS6VW=DM(2!UH4Y6D9=U "A@U+357;S6%X@\>>'_"X8:GJMO;R+
M_P L0V^7_OA<M^E(UITJE:7)2BY/LE<WZ*\^_P"%C:SKWR^&?"EY<QGI>ZF1
M:P_[P!Y8?3%-_P"$#\2^*,MXG\3206[==-T0&&/Z&0_,P]C2OV/1_L]T]<54
M4/*]Y?\ @*O;_MZQN^)/B1X=\*N8KW4HS=YP+2W_ 'LQ/8;%R1^.*PCXF\9^
M+?DT+0U\/V;?\Q#6O];CU6$<@_[V173>&_ N@^$E TK3(+63&#-MW2GZN<M^
MM;M&H>WPE#^!3YWWG^D5I][DCA-.^$>G/=I?^(KNX\4ZDO(DU _N4/\ L1#Y
M0/8YKN8XTAC6.-%1%&%51@ >@%.HIV..OBJV*:=65[;+HO1;+Y!112,P52S$
M  9)/:F<HM%<1K7Q;T>SNSI^D)-XEU;M9Z6OF!?=W^ZH]>3CTK-;PWXQ\;?-
MX@U0>&M,;_F%Z0^9V'I)-V^B\&E?L>K#+ZD8JIB6J<?[V[]([OULEYFWXI^*
M&A>%KC[&TSZCJS<)INGIYT[-Z$#[OXXK _L/QC\1OFUNZ;PEH;]-,L'!NY5]
M))?X<^@^A'>NQ\+^"M$\'VWE:1I\-KD8>8#=(_\ O.>3^=;E*W<T^MT,+I@X
M>]_/*S?RCM'_ ,F?9HR/#/A'2/!]@+/1["*RA_BV#+.?5F/+'ZFM>D;..#@T
MM4>54J3K3<ZC;;W;U845'YC;L8XJ2@S"@G S110!'YWM3E8.*:T7I3D7;]:
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M6M)<U1)"EI$K:A>+96=I9Q';!!"J*HZ<#']*Y^\U$\_,?SK)M]<N-O\ 9VI
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M_CV\,W3_ /7Q,D/\Z/MOBRX_U>FZ=:?]?%PS_P#H(I.M4>G,Q..*:M.HDO\
M$OR3_0Z2.)(5VQHJ+Z*,"G5S!T_Q9=?ZS5K"R_Z]K8R8_P"^S2?\(?J-Q_Q]
M^)M1?U^R[8/Y UE<P]A37QU5\N9_I;\3J*H76OZ98Y^T:C:P8[23*#_.L/\
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M>D _*E\\+TB _ 4UK+T=Q]&I/L\G:1OQYJ[TQ>QAW)/M1_YYX_!:/MC]D;\
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M?Y&@/9X=;U'\H_YM&_-=0V_^MFCC_P!]@*HS>)](@^_JEFI]//7/\ZIQ> M
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MM6_Z[*9?_0B:-0]G@X[U)/TBOS<OT(KSXH>%K7Y6U>&5NRVZM*2?0;0:J_\
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MFY/S=PHHHIF 4444 %%%% !47S\YS4M% %>IH\[1FCRU]*=3 ****0!1110
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MRM1_;4R_?TR['^ZH;^M!7O=O_)BHNH:.N=NGX^EI_P#6H_M;1.]LJGT-J?\
M"K7_  D2+]^QOH_]Z#_Z](?%%BOWS-'_ +T3?X4!RR_DE]__  "LNN:#&>5C
MB/O;$?\ LM.77]!;C?#^,!'_ ++5A?%6E-TNP/JC#^E2_P!O:9*,&\A(_P!I
MO\:!.+ZTY??_ /:E5?$&AH<B:%3[1G_"I8_$FC]5NX5[="#_ "JPNH::WW;F
MU/T=:DQ93'.('/\ P$T&3]GUC+[_ /@%7_A*-*_Y_HOS-*OB;2VSB^A'U;'\
MZN?8;;_GWB_[X%-;3;1\;K6%OK&#_2@B]#L_O7^17_X2+2_^?^W_ ._@I/\
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M_P#D3F_^$^T[M#>D>HMFI/\ A.K9ON:9JDGIMM#\WTYKI:*-1^TP_P#S[?\
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MZY;1OY;S:;=1W"(V =I9"0#@@X]ZT;F\@LK::XN9H[>WA0R232L%1% R6)/
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M>*"5.#M\):J1^!%M@TT?&#0!TL/%7_A(ZM_\C47OJQ69U45\/#6O1:BY_P!
MND6UO/1,$^5(?8%F4_[P]*SM0LKKPGJEM;VT:W*6,AOM-5AD30[65X,]G57(
M4^FSWK$F^+GAZXB>*33?%#QNI5E;PAJQ!!X(/^C5J>#;K2]:A:^L(]7 A_T9
M?[9L[NU>->&VHEPB-MY'*C'&,\5%M2[Z:FU>QP6VK6FJZ=SI>N+O=5&%6X"[
M@X]"ZAL^Z9ZDU<JAI;)%X+A9N+>/5&2WW>GF% !^)85?HCL$]PHHHJR HHJ/
M>: (I+9D8R0'8_=>S4ZWNEF)0C9*O5&ZU,IRH-0W-JMP 0=DB_=<=16$HN'O
M4_N-5)2TG]Y/7R[INGSZMJ%M8VR[[BXD6*-<XRS' KZ7M[QO,\B<;)NQ[./4
M5\VZ'.MKK%E,UY)IXCE5OM<,?F-%@_>"Y&<>F:_&_$&4*L\%?:\[]']B^^B^
M>A^G<&1G3CBK;VC;K_-VW^1I:UX+N](F,<-Q;:J\8E,RZ>7=[?RSA_,1E5D
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M^*HW\V5X-/M;7'DVT,7_ %SC"_RJQ113.=R<M6PHHHH$%%%% $>P],5)110
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M7 ( ZK7O@[X3\20O%?Z?.T4GVH2I!J%S )EN&#S+)Y<B[U9@#M;(!' %7?\
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MOV];'H1Q6(JTFO:/FCKN]5U^[?TN2?\ ")Z'_P! ;3__  %C_P */^$3T/\
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ML+.'+R?B^^CM:VWJPK$\7>*H/!^D_;9K:YOG:188;6S4-+,YR=JY('0,220
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M=RQLBAI)@NQ0&QG !Z$XYJ;Q)KFMZYJ4DVOW_P!HNA;I%Y6Q%940;5+%0,G
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ML0K;F!*_*P;D#J.*]+T#X/\ C#5-76WU#3I=(L5;,U\D\,NY<''E#<<DG'+
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M !130^6QBG4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*1CM&: %HJ/S3GIQ4E !1110 C+N&*%4+TI:* "BBB@ HHHH **** "BBB@
MI&4,,&EHH 8L84YZFGT44 %(RAN#2T4 (JA1@4M%% !1110 4J??7ZBDI4^^
MOU% "4444 %(S!>M+4<R%L$<T "S*?45)581LW:K(X % !1110 4444 %1.Y
MW$#BI:0J&ZB@!(V+#FG4=** "BBB@ HIID"MBG4 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1139&(7B@!=P]:6H-U/1QT- $E
M%%% !1110 4444 9^N:/'K5F87.R1?FCDQ]T_P"%>6Z_X=DM9#'>VQ5OX9EZ
M'Z'^E>Q4C*LBE64,IZ@C(JE*Q2E8\)ATVVA&U8!(<YW2#<:Z32O"-_K&,Q>1
M >KS#@_0=Z],CL;:%MT=O$C>JH :GIN0^8Q-)\(V&EX<I]IG_P">DO/Y"MNB
MBH("D)"@DG %9.H>(HK>X-I:1-?W_>&'HGN[=%%9EY8RW0#ZW=^8IY%C;$K&
M/KW;\>*I1;-(TW(O77BRU61H;&.34KA>"MO]Q?\ >?H*S;J?5;X?Z5>+81'_
M )8V?WOQ<_T%*UYY<8BMHEMH5X"H *S+Z1&FMH[BX:UM)7*SW /*C&0,]LGC
M-:J*1T*$8ZC%^P6=R8[6W:ZO#U$:F64_4GI^)%:4/AW4]5&VYV:=;-PRJV^9
ME[C/1?UJY#X@T/1X/L^G+YY'_+.S3>2?4MT_$FJ-YKNJZAD*4TR$]DQ)*?QZ
M#]:5Y/8GFG+96.DNM1L-!M8UGGCMHD4*BL>< 8  ZFN>OO'$\V5T^SVKVGN_
ME'U"#D_CBL"9[2RN,DM-=O\ Q,3+,_\ 6KMKX=UC5B&\E=.A/\=SR_X(.GXF
MCE2W%[.,=9,S-2O+K4 3?WLEPG4Q@^7$/^ C^M9]LLE\?)TVTDNL=K=/D'U;
MI79-X;\/^'PLNK7/VN;L+ELY_P!V,?X&I7\57$T8BTC3?*A'"S70\M1]$'/\
MJ?-_*BN;I!&'9_#O5+WYKRXAT^/NL?[U_P ^@_6K2Z/X1T"0"8MJUXO\+$S-
MG_='RC\:Y+2_'DWBIKJ?5;35K/1X&F4ZA=RVL-DWE2&-L*D[28RK8+J.!SBK
M4/CSPK#HC:G:ZUI*Z0LOD&]2\B\@2<#87#;=W(XSGFEONQ\LG\3.OD\57S1^
M786$-A". TYR1]$7@?G65=27=]G[;?W$X/6-&\M/R6N:TOXCZ'K%IH\IU*WL
M9M73S+.SO)XX[B89_A3=EC_NYJ/4/B'H%E;:M)'JEK?SZ7 ]Q<V=G<1R3HJ9
M#93=D<C'..>*I***48QV1T44$%M_JHDC]U'/YTYI/>L1/&.AS7E[:)K.GM=V
M,9EN[<72&2W0#):1<Y0<CDXJJ?'WAK^R5U7_ (2'2O[+9S&M[]MB\DL!DJ'W
M;<@ \9[55T6=$TE03W<=N 9'"YX [GZ#O6#'XXT>\F6*QU"TU%_-:%_LMU$_
ME.(VDPPW9R0IX )[XP"1W/PWU3PIJNBIJNF:UI>LSMA9[NWNHYA%)@$QY!.T
M@$<=:ER2(E+E1EVVFZIJ !MM,G*'H\^(E_7G]*T8?!.LS#,DUG;>WS2'^E=5
M<>+-&M?]9J=J#Z+(&/Z50F^(>B1_<N))_P#KE"Y_I6?-)[&//-[(SD^'=PP_
M>ZN0?2*W4?S)J9?AO!_'J=XW^[L7_P!EITGQ,T]?N6=])_VR"_S-5V^*$ Z:
M7=D>[(/ZT>^+]X7K?X=Z;%,DDTMS=A3N$<TGR9]P ,UL:SH-EKUNL-W%N"'*
M.IVLA]01TKEO^%I1_P#0)N/^_B?XTH^*=O\ Q:7=CZ,A_K2M(GEJ-W'R?#*(
ML?+U6Z1>P=4;]<5$WPQ?MK$GXVZG^M2K\5+#^*POE_X I_\ 9JD'Q3TGO;WR
M_6 ?XT_?*_>&?)\,;O\ @U9#_OV_^#52N/ASK4*DQ3V=S[99#_6M_P#X6EHW
M]R\_\!S3'^*NCK]V&]<^T&/YFB\PYJAP&I6-[H\RQ7]I):LQPK'#(WT8<54,
ME='XN\?+XDTXV,%@T$3.KM-.PW#!S\H'0^^:Y/S=U:J]M3HC=K4F,GO4,BQR
M?>16^H%,:2B-9+JXB@A3S)IG$<:9QEB< 9IE$EO<2V3;K6XGM3_TQE9?ZULV
M?Q U_3\ 7RW2#^&ZC#?J,&K[?"G7/+#">QW?\\]S_P \5C:CX*U_303+ILDJ
M#^.V82#\AS^E3>+,[PD=9IWQ@P0NHZ:R^LEJ^X?]\G!KJ]-\3Z#XJC\F*X@N
M&/6WG7#?]\M7A#3!9"C920=4<%6'X&HY,-@D<CH>X^AI."Z$NDNA[5JGPMT3
M4-S01R:=*>=ULV%S_NGBN-U?X5:Q8[GLY8M2B'\/^KD_(\'\ZI^%_B9J.@R)
M%>N^HZ?T(;F6,>H/\7T->S6%]!J=G#=6T@E@F4.CKW!J+RB9MSIGSE?03Z=,
M8;RWEM)?[DR%<_XT[3=7O=%F\W3[N2T?J1&?E;ZKT-?15]I]MJ4!AN[>.YB/
M5)5##]:XO5O@[H]XQ>SDGTUS_#&=Z?\ ?)_QJN==2U53W*O@WXK#4[J'3]7C
M6"YD.R.XCXC=NP(_A)_*O1J\UT7X-I8:I!=7>I&ZB@<2+"L6S<0<C)R>*K>/
MOB7K/AWQ-)86D$$<$:*P:9"QER.2.>G:H:3?NF4HJ3]P] \3:XOAO0KS4GB:
M86Z;O+4XR<X'ZFO*8_C=K/G%FL+(Q_W 7!_//]*U=+^,UEJ,+6FO:=Y44@V/
M)#^\C(/JIY _.F77PJT?7K4WGAK4U5&Y$;-YD7T_O+322^(J,5'XT;>@_&#2
M=398KY'TN8\9E^:,_P# AT_&NZBE2>-9(W62-AE64Y!^AKYSUKPQJ?AN3;J-
MHT4><"9?FB;_ (%_C5CP_P")-3\-R!M/N2L6<M;R?-$WX=OJ*;@GL4Z2>L3Z
M&HKC_"_Q*L-<9+>Z']GWS<".0_(Y_P!EOZ'FNPK)JVYSM..C"BBB@04444 %
M%%% !354[N:=10 4444 1O\ >H7[PI_'2C:.N* %HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HZ\444 ,\L9I]%% !D#J<45%(IW9ZTZ,
M$+S0 ^BBB@!&7=WQ2YIC28. ,U%UH L44BYVC/6EH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "E3[Z_44E*GWU^HH 2BBB@ HHHH **** "BBB@ HH
MI&&Y2* &&8>AIZL&&15=E*]14L*E5Y[TP)****0!1110 A4$Y(YI:** "BBF
M2,0O% #Z*CC8[L=:DH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ I&7<,4M% $7E'UI/+;/2IJ*=P <#%%%%( HHHH **** "BBB@ HHHH *YN
MXU*7Q!?RV%G<_8[.+(GO 1N<CJD?]6K>O8Y)+.=(6VS-&P1O1L<'\ZX>RL;]
M+>&TATN9944*3-A8P>YW=^?2KBEU-::CNS7EU"RT2S,&G(EM;KR\[=6/KD]3
M[FLN&6[U+,EI8W%TAY\YR(U;Z%NM:\'AVTTN%K_5IENI(AN+./W4?^ZO]3S5
M*^UB]UM2D>_3[$\'M-(/_9!^M6G_ "FW.Y:1*UK<+=6ZRJ"H.05;J"#@C\ZD
MZ@@\CO5>U/G8M=,MC<F/Y?DXB3ZMT_+)K7M_"(D7S-6N?.4<FWB)2(?4]6_&
MJ<DBI24=S'CO!-(8+&%[V4=4MQ\J_P"\W05HV_A.\O?GU&Z%K%U,%J>?Q<_T
MJ63Q7:6H%GHMH+ME^4>4-D*_CCG\*IW.GWNIKYFM7VR#K]FB.Q/H1U/XU-V_
M(B\Y;:%E=7T+PZ6M],MOM=UT*VHWL3_M.?\ &H;B\UK5%)FG32+;^Y#S)^+G
MI^%0_;K;3XQ%86ZHHXW$8_2LN:^EO;CRD$MY<?\ /&$;L?7L/QH4>I2A%:LM
M1Q:?I[%XHS<3GK-(=S$_4U%=:JP4F2184^N!^=7K'P;J-[AKN=;"(_\ +.'#
MR?B3P/PS6_8>#M)T]@XM1<3?\];@^8WZ]/PH<DA.I%;'S/8_#^ZAT;Q+IT?A
M_P .Q3ZI#>QG7+.21[F?SI'=!,!:CC# ']XWW1@&MR^\(ZHVNSZYI8TV^D74
M%NHK.\F>*-P;-;=]S"-BCC'!VME<CC.1]&WE];:3:--<2);P(.IX'T%?)GBC
MQEXE739]=&NI:1:IK=Q:M<WC06<%A!%).L?[PV\H5FV1H6D5@3@#:6S4IH<)
M\W0MZ;\+=;T_3[33R=),$UK8P7DR.ZM;&VG>4>0FSYPV[ RR;",_-TJI;^ ]
M>\0:3?VTEM8Z; K:NMM)(TBSS-<3.!YB>7A$Q\VX,V[Y3@5EV^M7\FL)>WNK
M17NH7=GHD@M/+C,,JF\93+&LD*OW!W8&#)D ?)B[8?$*XAT=-0E\8K>7.ZSD
MU6P>UB"Z3NN$69&=5'DJ%9U*S$OA"P8;6-/0T)X_A/X@NM;OIK@V$]O-:ZA;
M;3?7+),)Y4>/]PBHD& F&,9W$_.69JU_#?PI\16\EM-JD]KLAU.2]2*:[:\E
MC4VLD(!N&A1Y6!90#("P50-[8 KG;KXF71U+3-<AOHHK6*6]@-[L3RQ9_P!I
MVL98G&W9Y?\ &>WS9[TS5_B%K^M:?=7VG^()(;>"#5KR)XX(9%G6WN$6$993
M\A5CRN"P(.X'FEH!I7GP5NYK.PLWU"Q@BBTJ'3Y#%N;#+:W43%5VC<NZ=#@D
M9 ;IQGM?#=G<K+=76L:-HMG<2".-5TYFG9@H/S/*Z(3UP%V?+@_,=V!4\%75
M]*VN6E]?R:B]C?>3'<3)&CE3#%)@A%5>"Y XSC&<GFNB;Y1R<5HDMT,G^T)'
MQ'!&@]@*C>[=N^*J-<0KQYJY] <FGQQ37'^IM[B;_KG"Q_I5!<<TQ/4U&TE6
MUT#5YN4TJ\/^\@7^9J6/P?KTQ^73&3_KI,@_K2NB>:/<RS)3&DK>7X?^('_Y
M=H$_WK@?T%/'PUUYNOV-?K,Q_P#9:.9=Q<\>YS;24QI*Z<_#'7/[]G_W\;_"
MFM\+]=[/9G_MHW_Q-',NX<\>YR[24QI*Z63X9^(%Z1VK_2<_U%59OA[XBC_Y
M<%<?[$ZFCF7<?-'N8#24PM6I-X0UV'._2;K'^P _\C6;<:?=6O\ K[2ZA_ZZ
M0L/Z4]!W1$TE,\YD971VCD1@RNIP5(Z$5&70G&\9],T,G>F,](\._%X1HD&M
M0MD<?:[<9!]V7M^%>@Z7KFGZU#YEC=PW2_\ 3-@2/J.HKYS9::@:&82Q.T4H
MZ21L58?B*S<%T,94D]CZ-U30=.UJ/9?64-R/61 3^!ZBN+U;X-V%QN?3KN:Q
M?M&_[R/]>1^=<7I7Q*\0:3M4W2W\0_@NER?^^AS78:7\:+*;"ZC8S6C=Y(3Y
MB?XU'+*.QGRSCL<_+\'==64*ES8NG]_<X_3%>F^#_#Q\+Z!;Z>T_VAX]S,^,
M#).2 /2I-)\6:1K8'V/4(96/\&[:WY'FM:I<F]&1*4GHSYGU[6M3O]:O9;RY
MN%N%F93'YC*(\' 4 'C JSI?CSQ!H[#R-3FD0?\ +.X_>K^O/ZUZYXU^&=EX
MJ=KN!OL6I8P90,K)_OC^O6O(->\'ZGX;D*W]JR1YP)X_FC;\>WXUJFI'1&49
M*QW^@_&Z*0K'K-D8#T^T6WS+^*]1^M=A?:?H'Q$TM27BOHA]R:%L/&?8]1]#
M7SZ+?N*GL)KK2[D7%E<2VLX_Y:1-@_CZ_C0X+H)TUO'0ZOQ)\)]4T/?-8YU2
MS'/R#$RCW7O^%<OI=]=:3=>?8W$MG<*<$QG:?HP[_C7H_AGXP21[8-<AW#I]
MK@7_ -"7^HKJ=6\):#XZM1>1,GFL/DO;4C=^/K]#2YFM)"YW'2:.7T/XL+/#
M]E\06BR1,-K7$*;E(_VD_P *@\4>"],DTN;6_#US$UM&OF2VZOE-O<K_ '3[
M5B^(/ NI>&6+RI]JL\\74(X'^\O4?RK'CLT;Y@.&Z[3P?KZTTENBE%;Q8+$L
MBX8;E/K76>&?'6H>']D,Y;4+ <;&/[V,?[)[CV-<]';UH6.AW]_;37-K9R7,
M$+;'9",YQDX7J:IVMJ7))K4]CT?6[+7K07%E,LT?0CHRGT([&KU>'Z;-/8W0
MN["=K>Y4X9AT/^RZ]_QKTOPSXSAUDK;72BUU#'^KS\LGNA[_ $ZUC*-CEG3<
M=4=+1114&09%%1[3Z5(.@H **** "BBB@"/:?2I!T%%% !1110 4444 %%%%
M !1110 4444 %%%% !113?,6@!U%%% !1110 44R5CP*C!(Z4 3TBMN&<8I:
M* "BBB@ HHHH @8%6-"@L>*GQGJ,T8 Z"@ HHHH **** "BBB@ HJ.20K@#K
M1'(6R#0!)1110 4444 %%%% !1110 4J??7ZBDI(Y%:10#W% "T5'&SEOFZ5
M)0 U\[3CK4"LV[@G-6:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MZT44 (%"]!2T44 0;VZYIUU=PV-K+<W,T=O;PH9)9I6"HB@9+,3P !SDU)M&
M<XYKC_BO83W_ (1S%92ZE%:WMI>7-C#'YCSP13I)(BI_&=JDA1RV, $G%(#H
M=!\1:5XITY-0T74[/5[!R56ZL+A)XF(." RD@D'WJVMW ]U);+-&US&BR/"&
M&]58L%8CJ 2K 'OM/I7DWBGQ0UOIL_C3P]HVL6)L=1B-U!=VCV+:TDD:P$>3
M+M<LA:/:9$4DQ )D'GF=2\*:UX;UC5'FG\37]_<:9I/]HZAI\EY)YT0NY#?"
M$H=JN%8;4CQ*$8^6,DTKE6/H2D9@JEF("@9)/05\U>,(_%T/AO2I[&7Q8;>&
M:]:QM734OM$\)G4P"6:W+312B,'9]KAE0@@2 -FNJ8^([OX@,\L'B.#4GOE8
MP;IFTM-,-D-RDC_1VD$Y8<?OMV,?)1<.4]GM+R#4+6&ZM9H[FVF02130N'1U
M(R&4C@@CN*EKF?AC:3Z?\-_"MK=0R6US#I=K'+#,A1T81*"K \@@]C734R0H
MHHI@%%%% !1110 4444 %%%% !1110 4S:WF9[4^B@ HHHH **** "BBJ>IZ
MG%I=OO<%Y&.V.)?O.WH* W'W^H0:;;F:XDV(.!W+'T [FLI?M^K1FXNIWTBP
M_ACCQYS>Y/;Z"H[>U8S#4=4(DN/^64*_=B'H/?WJ"_OI[ZY2&)?-N&^Y%GY4
M']YO;^=:*)T1@HZL-$FN+?6DMEN9KF"2-G99WWE<$88'MGIBNIK*L-/M_#]K
M+<7$P:5AF:X?C..@'H/05E7>H76L,</)9V?\,:_+))[L>P]A2^)Z$-<[]TZ#
M5-/CU2QEM9"RJX'S+U!!R#^8K'A\)&9_]/O&NHATBC7RU;W;!Y^G2D\+AUNK
MQ(G=K- H^=BP$G<*3[8S[UL:M<2V>F74T";YHXRRKC/.*6JT)UB^5,HZEK5I
MH,:6L$(DN,?N[6$ 8'J?[HK)DTN\UE?/UFX$-J.1;K\J#ZCO^/Y5#H]W:6-J
M]QM-U>R-N,S'(;WS56[U*34+C:6:YF_ABA&['X#I^-6E8WC%1-!]3M[%?*T^
M$*.GF,/Z5CR7,U]=>7&LEY<_W$YQ]3T45L6'A.YO</?/]EA_YX1'+G_>;M^%
M=/8Z?;Z;"(;:%88QV4=?KZT<R6PI5$MCF+#P7+<8?4Y]B_\ /M;G _X$W4_A
MBNGLM/MM-A$5K D$8_A08_\ UU8K%U;Q5:Z8QA4&YN\?ZF,]/]X]JB[D8MRF
MS99@JEF(51R2:YG5?&\,.Z+3D%[*.#)G$2_CW_"N=U+4;O66/VR7]UGBWCXC
M'U_O?C57:%  X Z "K4>YK&GW&W<T^HW N+V9KF8?=!X1/\ =7M]>M1M3W98
MU)9@H]3Q5BRTJ_U3!M;5F0_\MI/D3]>3^%:72-KJ)1:F&MK4?#]OI-G*][JZ
M+=A24MX%'+=@0>3^E8ADVK\V V!D9Z9HO<%*^P+')--%#"GF32ML1<@9/U-;
M</@74G7?<W-K8IWY+D?R%<^[%N,8((Q\V"'ZXR.GUJ.Y#W39GEEN,\ RNS<#
MK]#Z4G?H)WZ,Z-]#\.6'%[KDEP_=(6 _103^M1-J7A.Q&8-'GO6'\4B$Y_[Z
M/]*P(K.23F*!F!^8A$//H/8U:30;MSRJH<YW,1RW=@/:I]63R]V:_P#PGB6W
M%EH5M;C.,LP'X_*.E5IOB-K,G*_9+=>IVH6P.QY/>JZ>'>[SJHQ_ O;N1]:E
M70($^\TC=R >/8=.E'NCY8]BI-XTUV7.=1*$<$1QH,,>@Z'\ZIR>(M8D)SJE
MT.<</MY[YP*V?[)M8^D>2,@%B3CU/7D4AL;=>D,:C&/N@_+Z'ZT778=EV.=D
MU;4).6U"\(Z\S,#CT//4U#]KO6QF[NG;ICSFY)[=>HKS?Q-'+I&K>*KM%=[.
M_P#$-A:3QCYECE46;1-CL""ZD^OE^]7F^)>J--=6-C=IJ&L6EOK+S6*Q!I%>
M&8"W$B* P)0_*!@N.>>#2YUV'H=S]HO3C;<W3#^]YK\@=3_]:C[9J*C(N;P#
M&X[99.G;%>7:]XJG6QL[[0_$_P#PG,]I<2S6\OD(0DOV&X/E%X$5'.0#L"[U
MSSG<M3^&_B)J%K;V%WJWB;3K[2&U7R)=2AN8YHL&U=PCSBW@CR) F-JYR0I)
M/%'.@/3EUC6H>%U"^4@8XD;&?7GM5B/Q=K\/(U.ZP/\ GIM;CUY'2O%&^)6M
M1W/A*YGU?9!>VUH\EC$+=+F9I&;S&$,D:F4'A?W$H9#R4;H?;F7OC QG YP.
MP''2FI)BT[$\/Q'\0V_W[B.3'420C@GH.,5H0?%K4X\":RMIAG:=NY#_ %K#
M96^A'UZ_X57DC!7'08Q\W9??GO19=A<L>QUG_"R='U!0-1T ,#U("/\ S --
MW_#_ %;[T;:<Y[X>/'Y9%<<\*\DJN>,J0.O93_C41@&< 9R<9Z9/<GCJ*++H
M+E70[9OAGI&J+NTG70V>B.5D_E@UC:A\*]=L\F)(;U!_SQ?:WY&N>^SA6WJI
M!ZY7(./\:T+7Q%K&GJJPZE=*%Z+OW ^V#Z4]>X>\MF95]I-WIK;;RTFM3_TT
M0@?GTJMY(KO;/XH:DL9CO;>UOX\?Q#:2!WXR/TKE;IEN[J:=(E@65RXBC^ZH
M/8>U--]2DWU,O[.,@XY]>];6E>+-:T7 MM0F\L?\LICYB_D:J>54MQI\]GL^
MT02P!QE3(A4$>U/0>CW.XTGXP2+M34[#/K+:G_V4_P"-=MI7B32/$D)2VN8I
M]PPT$@PWT*FO#/)H6+:X=25=>0R\$?0U#BC-TT]CU37OA3I>I;Y;$G3;@\XC
M&8R?=>WX5YYKG@O4_#Y8W5MO@'2XA^9/Q[C\:Z3PS\1KO362#4RUY:]/._Y:
M)]?[P_6O4+>YAO[9)H76:"1<AEY!%3=QW(YI0W/G18 0".1ZBKVCZG?:!<^?
M83M Y^\O5'_WE[UZMKWPYT[5"TUH/L%R><QCY&/NO^%>>:QX;OM!EV7D.U"<
M+,G,;?CV^AJ^9,U4U+0[_P ,_$:SUK;:WZK97C<88_NY/H?Z&F>(?AQ;7K/<
MZ85L[D\F+_EDY^G\)]Q7FC6X88(R/I74>&?&UYH>V"YW7MB. "<R1CV/<>QJ
M;6UB0XN.L3)FT^:PN6MKJ%K>=?X&[^X/<5K>&]:F\-WCRJK2VDN/.A7KQ_&O
MO[=Z] DATOQAIJME;F$\JZ\.A]CU!KBM7\.W.@R9D/G6A.%N .GLX[?7I3YE
M+1C4E+W9'2:EX=TWQ9;K?V,JQ7+#Y;B,<-[.._\ ,5QEYILUG<"UO83#.#N1
ME/#8_B1O\FKFGS7.EW'GV4GER'[R'[DG^\/ZUV%O=6'C"R:WN8MDZ<M$QPZ'
M^\I]/<4M8^@M:?H5O"/B*6\;[!>MNN57='-_SU4>O^T.]=17,V'@\:;J$5V]
M\TD,&7560 ]".6],5JV?B'3KZ80PW2M(?N@@C=],]?PJ':^AC*S=XFC1114D
M!1110 4444 %%%% !1110 4444 (6 ZFEJ YR<]:?#U-,"2BBD8[5)I +14:
MR\\BI* "BBB@!&Y4XJ"K%% #8QA:=110 4444 (0&ZT@C IU% !1110 4444
M %%%% !1110!6?.XYS4\>=HSUIU% !1110 44F1ZTM #6C#]:%0)TIU% !11
M10 444UVVKF@!U%1)-N;!%2T %%%% ",NY2/6HHX6\Q<\#(J:E3[Z_44 )17
M9?\ "/V'_/#_ ,?;_&C_ (1^P_YX?^/M_C6?.C7V;.-HKLO^$?L/^>'_ (^W
M^-'_  C]A_SP_P#'V_QHYT'LV<;179?\(_8?\\/_ !]O\:/^$?L/^>'_ (^W
M^-'.@]FSC:*[+_A'[#_GA_X^W^-(WAS3FZV^?^!M_C1SH/9LXZBNQ7P[IZC
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MSP_\?;_&C_A'[#_GA_X^W^-+G0O9LXVBNR_X1^P_YX?^/M_C1_PC]A_SP_\
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MR]+?_P ?;_&G?\(_8?\ /#_Q]O\ &CG0>S9QM%=E_P (_8?\\/\ Q]O\:/\
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M?;_&C_A'[#_GA_X^W^-'.@]FSC:5/OK]178_\(_8?\\/_'V_QH'A^P7D0?\
MC[?XT<Z#V;-&BBBL#H"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
6HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>mrna-20210331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:mrna="http://www.modernatx.com/20210331"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="mrna-20210331.xsd" xlink:type="simple"/>
    <context id="ie20e480bc066475e9f962590283234e4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i50495a74916c41eb8a2e6e9d510ddb50_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="i40e5fc820d824be1931d54b51dd263a3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i90cf26aad24349bfa441914ac3d706fb_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8e5ea10505f740f69843ae942d0421b8_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i12127d667a294d78b6d78f889c39cd18_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i928ab86735d84580ac232ade8c6033ea_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i93f5b8cccc84489b9789274a5e0b0890_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie93f0b234bf24c27b09e35245f5e26b6_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i85c3685b8bc74888a7957153cba507be_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idaec3621e0754f54a55937521667819b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie42efe57bc7743f78f5470ae0d8b47c0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0ee23f27c5a7409999bc27bf484c3683_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8bd66b8c2d444db3ab9e16db494ca9ec_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia6763fa662d34fe987498086ccaefa42_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i51a24806337f4c398006c8c24a6291f9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i00257f1c106c4f12b6139f8b838a1faf_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie2898610162d44ebb1d6412f7f754f57_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if224da12bc8646a2934e52e6b2b0929d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3081299caa6b4213987da62a7e0e3b67_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3ea0cb20ecbd485a9682c793a5f13edd_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7682e40394cc4e7db96f8cc4de55e962_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib7811f82e8ed4667a6efb6a88cb1dc80_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2ed66b7fc0fb48c9bb3d57e8be191929_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idd4ae3b11c564cb6b97eb730e3ff7bb1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1138d8f10d6c45fdb458206ef7e763ce_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibd57a755b6d2496f92d2b0ce1c6d8369_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i16c2d8a9bebe4163981c7803f6359e72_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4d0241871b0840c2a85a3c6334108769_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i353dc2cd5f49451798ef780c6af7ed46_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i99ce1af211874ddda368b64fc0527881_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i199f99634c0c487e82b051148cdc8024_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i9ac58abcca77466fa78e3ac37f63f737_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i11483b66bae440ceafe63983b7fbd5c9_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="iaa5a33ce37614698a3418806ab20f9b2_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ib0bb072a6a064b47a2581435e9123a1f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib1779a3029e943e597b2535a551359a3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i08c08b2af4044913baf379746ada2802_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6d7a2752ca8b473598e5f43e5290268c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i015500c719c5494988852885b84ddc22_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i615a67f1a6c2480c89cbe28e804d3b01_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CustomerDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i0238e09dbf1a48c999216873131aac3a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CustomerDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibb5c5d2d047b4d979b9497e8b26286bd_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:DefenseAdvancedResearchProjectsAgencyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib54c28109e8b4df6bd548f059a69eaa7_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:DefenseAdvancedResearchProjectsAgencyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrna:ContractOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i7a973ce00bdc4a798407694abf5f73a8_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="ic23af7a56e2749a0b4290de702518aa1_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i4f9df22e0ed44daba83573576518c077_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i24305ac457e24ee79d1f0f5f58f89459_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1d9fd4412ca74750b6b14d4722981e10_D20210418-20210418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-18</startDate>
            <endDate>2021-04-18</endDate>
        </period>
    </context>
    <context id="ide0d50c05a0f41209d23a6cda03d4b84_D20160901-20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="if411e69e7ac54f6ea28f6658a5d6dac8_I20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-30</instant>
        </period>
    </context>
    <context id="i89f03a0decbd475591590f9d2c6d5dec_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrna:ContractOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i53791cfc661a48e88b2bc8d3c8c541f7_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:TheBillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrna:InitialProjectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib9e09957e07f4e779b011ddea7dea3cb_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7e13ec3698064dd7bac04dab36528b56_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i5fbd7587ea9a4f81bfca9dfda7f7c4d1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:OtherGrantRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id0c6277e6e0841bbafa567ecc4fe413b_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:OtherGrantRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i52aa31d81e134903a18093eb7e292280_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i086bb9318c0b4c0c8ef0461ff39d1327_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="id7427ffe751240d0a4ef3e3e238b47a2_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:MerckMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7c7a5f91086643518f876c3b89b411ae_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:MerckMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4fb6b67fc6764af4b4bf084bb09b748b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:VertexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id0c4ba70e8f6479882eff1b6b52f2792_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:VertexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i1a3a24c98e934216b6325e57f46e961a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:OtherCollaborativePartiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib62acba5ff5c46149175a78722d4f5d3_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:OtherCollaborativePartiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i5d71f6c708c04cfd9aa4a5147b897eae_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if9d15e5fbe824ba297aa8586391ba7bc_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i0424eee07b4f47f18f3baa3664b5c50f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6ab46cc577f34aa3900c0f6c8856f7f9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i356bef623f834e84a7cdb447d141ccd3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i60479f4cd58141ab88eb9674b785a4a1_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i67533c70f1f24be1881a998a7ae2b79c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ica0a9efa36764e4abe9a81143990ee12_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8a4e0ae3d99d485a9d3576fc11b24069_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9bf1192916f64380bbdde4039cc78e4f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i48e96e4a36ca4d209bbcd48d238ae70a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5cb1f6a641814b1c8ad2ff7b4a2b8217_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5b6a0be7eddd411e8225d14c0a674df3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3039ce5316a84c43a0d08915dea14050_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i15456fe3d934468482ac959714d5a053_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ifb1895e1c5bc495fbeda6e5e2a787ef6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7cb95c5356684e93a35e3bf790aca2fc_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib6b7b9882f044ebba7637ec5e651772b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4dfcad9b1a5a494ea2d1f97c1cec871c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iee5034c39f6946fd8be3fff0632e2766_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iacbf0fb43aaa4d53bc16745f38512f25_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9af72ba73c864ba9a21e07312e1cad6f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i0e5f6ba69b244986a5d20a064920207d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie6c00e9c4b7c4cab9106b940030ecc8d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i541125faaac24704993f4bb55ea03ffb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i63ece81cf0b14c9d977ea0092b4cead4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i144b3354d900459db79935bb372dddac_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie6806220f01c4d34bff60f27b6458a20_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibc2d8b74fdcf4cf19b8d0602247a7ed5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie744a40ba7764cb6bc3cc3dc74a499fb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4039aa1d6baf4797ad803a7b6190baa8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia1cde362d4524f9ba6d35c5ea6b396bd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i05d95354ca2c445db703eebb828e4323_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if6465ad5ef134815a47c8f454682eb9d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i64e7c6ca7fa54146be90ea4732b08c96_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic9f8683c12dc47549b560b34d4161e88_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i39670918752c482d9b5985dd34a8435a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5913295f7ce94eaf82964fa6e5bebd39_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3a2bf1e040654bc8a5d2177086572016_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i79840680ee5c42f08b5791b046d4ab3f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idcb2bea1b1bf4c1782b105cad231847c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6a3a8d7ef2ea40a88c5b84eee83292fa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie01d3f7d975a464884d498263f3d023f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2e628bbb40a646dfb1404d2cceaf4b58_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i123d9cb392064f7bbe194ed464f90c8f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ieb052beac6e745e59a97634f1deb8911_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4d49a64ca5814a3b8323c954b990c2f1_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i0ed53e247dd44a8fbc05e34b092630a4_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ifd19a0d5fe7648f19bcf7eb315e47574_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4e7a5259755b49e49d483e9c3980d884_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia850cc3fdca949bdbacf65e2aa316867_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="icbba28371a0c4ac7b6d117d940658048_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5a9ecc2c2f4c4165a295dd17a5a65f57_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1f155650a70d4eeda45d6f57b5eb94af_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8803bb198614454eb655c9107db2f3b2_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3bad47bc31eb4c3fa7e59c8591449292_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2c36846f9be347ffadf3fb034bb04f1c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6cbf1ef1e50043a6973a41f4362eca38_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id976144d8ac0470a8dfe87f5e0806e11_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if9ead6d8a2d6496ab53b71dbf65c0e89_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6ae8a6101db3483ea8c8e7878ef68c7b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6aa4efa157cf4cbcaf792243639a7365_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0598f69f1ada4de8ae9919743b2bdf0c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i93f6a88f2c7c4d8085866d26873d36e9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if667a4d9f03441e794394bde2522c7d6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9c4745cd6ed947bc9dc06de365526c6f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4c0cd6f20ef146849ac96024e8997311_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i34e70e75e95f41a89179d7b607304203_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie17de02d67874972813c65e1ee7828ab_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id52895ca9a52496199fbd7e4b81d30b8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifa680536838a4ffd80a53a841c00e107_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i686e90a952424d579c987c59336787cd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i59dd43638f654b5ca42787b1d4565122_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib5f5b6e35e214612987f2dbe6605a881_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i900a81907e194a84ba164cb4e36677d2_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i0ab6f5001f864500b4c8e0d67181a3e1_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i61150f006fb645cb98904910e2b941a8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie50812d5f7b44b30b8225d6636c4c4f4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2bd7f75306414af4a89bd03391f700a7_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if558e6ed91924e46b53fe8382ea023b2_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie182a57ea61f416d8c4866418d5a465d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="icdaad432c7624d609795f42f421c205b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if2ecdbe7a52f4cdaa512b1d59ef2091b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iebde00942b24405f849061b1a6fad190_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id1eca162cb334496bb26a5b7d49c7186_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i88573437d7664c1a9e52c33298a5b456_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i39475e82f8ca4c18b5f9b3233c43443b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2e9e748f96b34220bf4fe5d60445b495_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if3e11e356d35463abd4fb1e3057fcd5d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3574dd8d4ffe4445ac4435bdd763464d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1263c583aadd4aeeb0479db8950e9cad_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrna:FinancingRightOfUseAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia6397562962643bba0441eaabef86729_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrna:FinancingRightOfUseAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib7fb0180403444128af0ca00c287ab8b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i25b18fc5d30a4a9ebd82c278f9fdee03_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib2ee3c9e3ddc46fc8c50d787172d195f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3049e90ee7764f058dbbb38cd725aadc_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie53549975a3f42f6b2b2d3515ab79791_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifc1f15c64a2e42b6b50c3be424cf6c44_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4e89e827a1584b60805bbb05008f21f5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i39195ff1bc64463eb3aa66b95e19bd36_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4c54e5c981c44426b958b7cd3aeb25d8_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:CambridgeMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i31be9147cbb84c108e25cc00c3dd39a2_I20160831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCSouthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-08-31</instant>
        </period>
    </context>
    <context id="i72bd7d804e294a73a53c8fe39086669a_I20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCNorthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="ie56c1c32083543d8bb94f4fb0eba71d6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCNorthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5946e5f9891e4ba8aa1048e39fc8cd69_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCNorthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="iaad3817f49bd43e29ab66021c23b5529_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCNorthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="i747a2e93fb1b437b9939b81676cc53b5_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">mrna:EmbeddedLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8c1e58e30b1c4e8d8872e56716cb8e9f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">mrna:EmbeddedLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5c10c5b4110f49df8c8e8f8f898bbe05_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCSouthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i97caad06f3f04504b59b69417b6a7236_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCSouthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id91f4c8df96343e8b99f1775d18c7d59_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCNorthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia5b2cabe98664e3eac3b4393c8159043_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCNorthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="icc463e223e4f4f08b900edce1309004e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrna:PersonalizedMRNACancerVaccinesProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iccb9f67ad61a42038f759003571a1508_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrna:PersonalizedMRNACancerVaccinesProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie54f228e1d5b4838858ccaebf45f0e9a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">mrna:SupplyAndManufacturingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8204f059459747e988e68765b4fa0190_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">mrna:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic353f4f727e84c7988d44622743ab4c4_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">mrna:ClinicalOperationsAndSupportCommitmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i570695e9c65448a685edf9c785db6a07_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">mrna:ClinicalOperationsAndSupportCommitmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id1c2fd1d75924d69915c2130ff7af739_I20170626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrna:TherapeuticAndProphylacticProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-26</instant>
        </period>
    </context>
    <context id="id39bf79de51448cbb53b0479ac1fc4fd_I20170626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrna:DiagnosticProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-26</instant>
        </period>
    </context>
    <context id="id9b8f829587545b1850dc3d645793a91_I20170626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <instant>2017-06-26</instant>
        </period>
    </context>
    <context id="ia56b7a15d277445c813a9b1e913dce91_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i91b0e05ed30e415f9576819f14007d11_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrna:StockOptionAndIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1afaa9c0a57f43b09e758fb17bd26e7d_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie43ed5c918a0494eb0f43d56862c3e32_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i26a6b2b2db7f4f52a54072c86dbb902c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i53c9c75bd90d46278b4077d5e35f7d5b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9c17046964e4496093fef93215168f9c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie18c5203639447448d73f34f409c6682_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia750d90906f64b3da90f3ea25a6e6c88_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1e7259ec870c4de7815c0a34b19ed99c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ibf2c3f50e45f44bfa74451d6d87a3675_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i22567b607e5a40439a3314231a4c0b31_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if820d61e1d2e4cb3a94f601c28956f74_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i53f43d6f041a413d9ba3a5b6031c5bca_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:RestrictedStockAndRestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie0ee58a110904b6ea810fa10add84823_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:RestrictedStockAndRestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i1f6bab6d04464aa58adc35f314641f71_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ibca633e1d4664bcd8090d7383938bd13_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if11b06a738a64cf88f8e86ac44cbfe87_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="if7207e2b92904a3ea65000ec12644d42_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i99e931e8a5cd44ea88397661762d28f1_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6a4b450ab98d4f6b90381fecd841a0a5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9b44e002e91945e5a00c7bcd2919634d_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i649444b931a542648a2d656ef5f35e1c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i0b71c01ae54c49e288fce1e85063a0c0_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i9c022d9b4fbe4b8b8966c5f007b5faf4_D20210401-20210507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-05-07</endDate>
        </period>
    </context>
    <context id="ic8a5bdf50ed34e1196383b6df3a4c6e7_I20210507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-07</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="program">
        <measure>mrna:program</measure>
    </unit>
    <unit id="option">
        <measure>mrna:option</measure>
    </unit>
    <unit id="campus">
        <measure>mrna:campus</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="extension_period">
        <measure>mrna:extension_period</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="dose">
        <measure>mrna:dose</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80L2ZyYWc6NWRkZTViZjYxYzhmNDI3YmI2MWJjY2QyNzE0YzllZDgvdGFibGU6ODhkZjQ0YTRiYTZiNDdiMTk4MDJmODFjZDkxNTJhN2UvdGFibGVyYW5nZTo4OGRmNDRhNGJhNmI0N2IxOTgwMmY4MWNkOTE1MmE3ZV8wLTEtMS0xLTA_3c10cd0c-5743-49ec-9689-529aa74ee862">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80L2ZyYWc6NWRkZTViZjYxYzhmNDI3YmI2MWJjY2QyNzE0YzllZDgvdGFibGU6ODhkZjQ0YTRiYTZiNDdiMTk4MDJmODFjZDkxNTJhN2UvdGFibGVyYW5nZTo4OGRmNDRhNGJhNmI0N2IxOTgwMmY4MWNkOTE1MmE3ZV8xLTEtMS0xLTA_d8667f89-4e16-445b-9795-89d9fe48bc91">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80L2ZyYWc6NWRkZTViZjYxYzhmNDI3YmI2MWJjY2QyNzE0YzllZDgvdGFibGU6ODhkZjQ0YTRiYTZiNDdiMTk4MDJmODFjZDkxNTJhN2UvdGFibGVyYW5nZTo4OGRmNDRhNGJhNmI0N2IxOTgwMmY4MWNkOTE1MmE3ZV8yLTEtMS0xLTA_7f175c7e-43e3-4668-8950-029239b5db32">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80L2ZyYWc6NWRkZTViZjYxYzhmNDI3YmI2MWJjY2QyNzE0YzllZDgvdGFibGU6ODhkZjQ0YTRiYTZiNDdiMTk4MDJmODFjZDkxNTJhN2UvdGFibGVyYW5nZTo4OGRmNDRhNGJhNmI0N2IxOTgwMmY4MWNkOTE1MmE3ZV8zLTEtMS0xLTA_83317291-94e3-41c1-9d30-681eb8a68438">0001682852</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80L2ZyYWc6NWRkZTViZjYxYzhmNDI3YmI2MWJjY2QyNzE0YzllZDgvdGFibGU6ODhkZjQ0YTRiYTZiNDdiMTk4MDJmODFjZDkxNTJhN2UvdGFibGVyYW5nZTo4OGRmNDRhNGJhNmI0N2IxOTgwMmY4MWNkOTE1MmE3ZV80LTEtMS0xLTA_ab5761c2-1d93-4209-b765-cb66a0e5befa">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfNC0wLTEtMS04Mzk4_763696f1-1b66-43b8-a5e9-0a8445cbb910">us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfNC0wLTEtMS04Mzk4_986006a3-947e-4a84-bf6d-3ecd8f99076a">us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfOS0wLTEtMS0w_7afc31d0-ede8-43d3-b946-27d55409b32b">us-gaap:OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfOS0wLTEtMS0w_d74ab000-ea21-4620-b930-521a5fdbab89">us-gaap:OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfMTAtMC0xLTEtMzUwNw_1c2fb28d-31b2-40b2-9ba8-7bc67b5a50d3">us-gaap:OtherLiabilitiesCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfMTAtMC0xLTEtMzUwNw_f985209d-7d9f-4e95-8466-842513c70552">us-gaap:OtherLiabilitiesCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xL2ZyYWc6ZGViMWQwNTBiNDJjNGI5Y2FmMjMwYTk3YjhiNjgyN2MvdGFibGU6MWY0NTU5NjA1MWMwNGM0NmFiNjM3MDAzZjlkYjAwNGMvdGFibGVyYW5nZToxZjQ1NTk2MDUxYzA0YzQ2YWI2MzcwMDNmOWRiMDA0Y18wLTEtMS0xLTA_5d27b25b-eef7-4569-8162-3fb8f18e19de">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xL2ZyYWc6ZGViMWQwNTBiNDJjNGI5Y2FmMjMwYTk3YjhiNjgyN2MvdGV4dHJlZ2lvbjpkZWIxZDA1MGI0MmM0YjljYWYyMzBhOTdiOGI2ODI3Y18yMTI4_7a9e1316-1439-47f5-9a00-811087c23fe6">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xL2ZyYWc6ZGViMWQwNTBiNDJjNGI5Y2FmMjMwYTk3YjhiNjgyN2MvdGV4dHJlZ2lvbjpkZWIxZDA1MGI0MmM0YjljYWYyMzBhOTdiOGI2ODI3Y18yMTI_76382121-7f6a-408f-af1a-0cb0587211fc">2021-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xL2ZyYWc6ZGViMWQwNTBiNDJjNGI5Y2FmMjMwYTk3YjhiNjgyN2MvdGV4dHJlZ2lvbjpkZWIxZDA1MGI0MmM0YjljYWYyMzBhOTdiOGI2ODI3Y18yMTIz_9be6aef6-5588-400f-ba7f-2cf07392f6f4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xL2ZyYWc6ZGViMWQwNTBiNDJjNGI5Y2FmMjMwYTk3YjhiNjgyN2MvdGV4dHJlZ2lvbjpkZWIxZDA1MGI0MmM0YjljYWYyMzBhOTdiOGI2ODI3Y18yMTI0_227d5e64-ac27-4105-aa1f-17d0a623ca05">001-38753</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xL2ZyYWc6ZGViMWQwNTBiNDJjNGI5Y2FmMjMwYTk3YjhiNjgyN2MvdGV4dHJlZ2lvbjpkZWIxZDA1MGI0MmM0YjljYWYyMzBhOTdiOGI2ODI3Y18yMTMx_92988674-c1db-4b53-9bd6-addc4cc670f6">Moderna, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xL2ZyYWc6ZGViMWQwNTBiNDJjNGI5Y2FmMjMwYTk3YjhiNjgyN2MvdGFibGU6ZmE3OGI0NjE0MDNjNDkxZjlkYTkwMTM3OWJlZjliY2UvdGFibGVyYW5nZTpmYTc4YjQ2MTQwM2M0OTFmOWRhOTAxMzc5YmVmOWJjZV8wLTAtMS0xLTA_d60fca78-1f9e-4696-a7ef-1a1037b632b8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xL2ZyYWc6ZGViMWQwNTBiNDJjNGI5Y2FmMjMwYTk3YjhiNjgyN2MvdGFibGU6ZmE3OGI0NjE0MDNjNDkxZjlkYTkwMTM3OWJlZjliY2UvdGFibGVyYW5nZTpmYTc4YjQ2MTQwM2M0OTFmOWRhOTAxMzc5YmVmOWJjZV8wLTMtMS0xLTA_5fb19827-5965-4994-89e2-e5cf7bc1d6ab">81-3467528</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xL2ZyYWc6ZGViMWQwNTBiNDJjNGI5Y2FmMjMwYTk3YjhiNjgyN2MvdGFibGU6ZmE3OGI0NjE0MDNjNDkxZjlkYTkwMTM3OWJlZjliY2UvdGFibGVyYW5nZTpmYTc4YjQ2MTQwM2M0OTFmOWRhOTAxMzc5YmVmOWJjZV8zLTAtMS0xLTA_e93d0130-974d-4db4-aeee-d508fe537218">200 Technology Square</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xL2ZyYWc6ZGViMWQwNTBiNDJjNGI5Y2FmMjMwYTk3YjhiNjgyN2MvdGFibGU6ZmE3OGI0NjE0MDNjNDkxZjlkYTkwMTM3OWJlZjliY2UvdGFibGVyYW5nZTpmYTc4YjQ2MTQwM2M0OTFmOWRhOTAxMzc5YmVmOWJjZV80LTAtMS0xLTA_d6c78fe7-4939-4a87-92e1-1491ca971b51">Cambridge,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xL2ZyYWc6ZGViMWQwNTBiNDJjNGI5Y2FmMjMwYTk3YjhiNjgyN2MvdGFibGU6ZmE3OGI0NjE0MDNjNDkxZjlkYTkwMTM3OWJlZjliY2UvdGFibGVyYW5nZTpmYTc4YjQ2MTQwM2M0OTFmOWRhOTAxMzc5YmVmOWJjZV80LTEtMS0xLTA_42ef96d1-f7e1-48f1-ae75-a1189d0c9131">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xL2ZyYWc6ZGViMWQwNTBiNDJjNGI5Y2FmMjMwYTk3YjhiNjgyN2MvdGFibGU6ZmE3OGI0NjE0MDNjNDkxZjlkYTkwMTM3OWJlZjliY2UvdGFibGVyYW5nZTpmYTc4YjQ2MTQwM2M0OTFmOWRhOTAxMzc5YmVmOWJjZV80LTMtMS0xLTA_e233e48b-0900-44de-b659-5548a40cac7f">02139</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xL2ZyYWc6ZGViMWQwNTBiNDJjNGI5Y2FmMjMwYTk3YjhiNjgyN2MvdGV4dHJlZ2lvbjpkZWIxZDA1MGI0MmM0YjljYWYyMzBhOTdiOGI2ODI3Y18yMTI1_e313c3af-49b1-485e-aaba-c07468ddbcf8">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xL2ZyYWc6ZGViMWQwNTBiNDJjNGI5Y2FmMjMwYTk3YjhiNjgyN2MvdGV4dHJlZ2lvbjpkZWIxZDA1MGI0MmM0YjljYWYyMzBhOTdiOGI2ODI3Y18yMTI5_34ca2e50-a760-4c81-b34f-fd9e5fbe5b4a">714-6500</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xL2ZyYWc6ZGViMWQwNTBiNDJjNGI5Y2FmMjMwYTk3YjhiNjgyN2MvdGFibGU6MzE5MTE5NzgwMjZjNDFjNDk1ZDVhNTM4YmExYjRjOWQvdGFibGVyYW5nZTozMTkxMTk3ODAyNmM0MWM0OTVkNWE1MzhiYTFiNGM5ZF8xLTAtMS0xLTA_3b0a08d2-d5c1-4dcd-8329-26c195ddea17">Common stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xL2ZyYWc6ZGViMWQwNTBiNDJjNGI5Y2FmMjMwYTk3YjhiNjgyN2MvdGFibGU6MzE5MTE5NzgwMjZjNDFjNDk1ZDVhNTM4YmExYjRjOWQvdGFibGVyYW5nZTozMTkxMTk3ODAyNmM0MWM0OTVkNWE1MzhiYTFiNGM5ZF8xLTEtMS0xLTA_9da0d589-1c52-4280-8508-cf3f1f514648">MRNA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xL2ZyYWc6ZGViMWQwNTBiNDJjNGI5Y2FmMjMwYTk3YjhiNjgyN2MvdGFibGU6MzE5MTE5NzgwMjZjNDFjNDk1ZDVhNTM4YmExYjRjOWQvdGFibGVyYW5nZTozMTkxMTk3ODAyNmM0MWM0OTVkNWE1MzhiYTFiNGM5ZF8xLTItMS0xLTA_acdce358-fce1-4e5a-878b-b0ab1a8c9f5d">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xL2ZyYWc6ZGViMWQwNTBiNDJjNGI5Y2FmMjMwYTk3YjhiNjgyN2MvdGV4dHJlZ2lvbjpkZWIxZDA1MGI0MmM0YjljYWYyMzBhOTdiOGI2ODI3Y18yMTI2_629c1788-48ae-4ae7-8152-7d7937bb15d1">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xL2ZyYWc6ZGViMWQwNTBiNDJjNGI5Y2FmMjMwYTk3YjhiNjgyN2MvdGV4dHJlZ2lvbjpkZWIxZDA1MGI0MmM0YjljYWYyMzBhOTdiOGI2ODI3Y18yMTMw_86b430b4-d52b-41a5-9d59-f14a87e56570">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xL2ZyYWc6ZGViMWQwNTBiNDJjNGI5Y2FmMjMwYTk3YjhiNjgyN2MvdGFibGU6ZjhhODc3ZTZkNGRjNDIyMzllZjRiNDljZmY3NTA0ODgvdGFibGVyYW5nZTpmOGE4NzdlNmQ0ZGM0MjIzOWVmNGI0OWNmZjc1MDQ4OF8wLTAtMS0xLTA_7916e6a7-c622-44db-af05-fd91179b51b4">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xL2ZyYWc6ZGViMWQwNTBiNDJjNGI5Y2FmMjMwYTk3YjhiNjgyN2MvdGFibGU6ZjhhODc3ZTZkNGRjNDIyMzllZjRiNDljZmY3NTA0ODgvdGFibGVyYW5nZTpmOGE4NzdlNmQ0ZGM0MjIzOWVmNGI0OWNmZjc1MDQ4OF8wLTgtMS0xLTA_84eed636-744e-4838-8aa6-c204d770ebf6">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xL2ZyYWc6ZGViMWQwNTBiNDJjNGI5Y2FmMjMwYTk3YjhiNjgyN2MvdGFibGU6ZjhhODc3ZTZkNGRjNDIyMzllZjRiNDljZmY3NTA0ODgvdGFibGVyYW5nZTpmOGE4NzdlNmQ0ZGM0MjIzOWVmNGI0OWNmZjc1MDQ4OF8xLTgtMS0xLTA_cbcf80ce-3586-412e-9d6c-52bfb29ea20d">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xL2ZyYWc6ZGViMWQwNTBiNDJjNGI5Y2FmMjMwYTk3YjhiNjgyN2MvdGV4dHJlZ2lvbjpkZWIxZDA1MGI0MmM0YjljYWYyMzBhOTdiOGI2ODI3Y18yMTI3_08ac8790-f0ec-4d9a-aa73-21a0772d9229">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i50495a74916c41eb8a2e6e9d510ddb50_I20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xL2ZyYWc6ZGViMWQwNTBiNDJjNGI5Y2FmMjMwYTk3YjhiNjgyN2MvdGV4dHJlZ2lvbjpkZWIxZDA1MGI0MmM0YjljYWYyMzBhOTdiOGI2ODI3Y18yMDM5_673d811d-44f8-4c55-88f2-6c524bf3fc7d"
      unitRef="shares">401527789</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfNC0xLTEtMS0w_0476eaa9-19e2-4447-a52f-2acf1e4043fd"
      unitRef="usd">5442000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfNC0zLTEtMS0w_cdd9a885-7a5d-4739-99d3-95b2eb8b0525"
      unitRef="usd">2624000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfNS0xLTEtMS0w_b96a64e7-5f63-4a2d-8558-45566583ec40"
      unitRef="usd">2293000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfNS0zLTEtMS0w_989bcf11-4920-4c63-8277-ca4345f2444e"
      unitRef="usd">1984000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfNi0xLTEtMS0w_e9973ece-cc79-485e-8345-24d7eb6e1ac3"
      unitRef="usd">3210000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfNi0zLTEtMS0w_47d9c2b1-62d9-4bcd-8902-7763d1a3520e"
      unitRef="usd">1391000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfNy0xLTEtMS00MQ_83f10f02-0e9c-40c4-8976-a082f0228c38"
      unitRef="usd">494000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfNy0zLTEtMS00MQ_d7c721bf-1d42-4b61-b8df-e775c6cdcf23"
      unitRef="usd">47000000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfNy0xLTEtMS0w_777c49cc-7f59-4475-8421-f72acee2c125"
      unitRef="usd">264000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfNy0zLTEtMS0w_f6c99844-1a7b-4067-949c-bfc7843c31fa"
      unitRef="usd">252000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfOS0xLTEtMS0w_be775919-0fda-49e9-a67c-4e898b6de0db"
      unitRef="usd">11703000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfOS0zLTEtMS0w_c05d73fa-626d-42f5-a23d-e44b8687cd00"
      unitRef="usd">6298000000</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMTAtMS0xLTEtMA_f412703f-b5f6-42e2-bef4-356f1693d859"
      unitRef="usd">468000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMTAtMy0xLTEtMA_cc879d02-51fa-4f99-88f3-57c7e383af54"
      unitRef="usd">639000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMTEtMS0xLTEtMA_0fc40c26-7407-4acc-b09b-273d1eac2527"
      unitRef="usd">372000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMTEtMy0xLTEtMA_2069c682-1d33-4182-992d-364eb3ddd708"
      unitRef="usd">297000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMTItMS0xLTEtMA_6d14fd17-d518-4af9-b18b-6ecb93fd117c"
      unitRef="usd">89000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMTItMy0xLTEtMA_bd36b708-c668-45ae-95b6-d002467bb1c9"
      unitRef="usd">90000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMTMtMS0xLTEtMA_e1a40ac2-5670-43ad-abb1-2b3b1792880f"
      unitRef="usd">11000000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMTMtMy0xLTEtMA_2d9c24a1-051e-42ad-8d62-0f5033b8d54b"
      unitRef="usd">11000000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMTUtMS0xLTEtNzI0Ng_57ea2425-8ba9-4534-8d8f-d0efd87f63f1"
      unitRef="usd">50000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMTUtMy0xLTEtNzI0Ng_cb4200e7-c43c-483d-b254-c27a14b2eaf4"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMTQtMS0xLTEtMA_c6febb28-3689-4d73-aece-4288fbad2006"
      unitRef="usd">1000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMTQtMy0xLTEtMA_7f48f985-d5b5-4c98-9d5a-3bb89572ebac"
      unitRef="usd">2000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMTUtMS0xLTEtMA_e5922a5c-bba0-462b-91b2-b9ccec0465fe"
      unitRef="usd">12694000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMTUtMy0xLTEtMA_ca8406bc-0a32-4c29-8509-ec7bd9d98924"
      unitRef="usd">7337000000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMTgtMS0xLTEtMA_439dd775-d048-4ab9-9db4-3cdccc225dae"
      unitRef="usd">8000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMTgtMy0xLTEtMA_6604b0ba-65ae-4a08-b295-d8eba72621e7"
      unitRef="usd">18000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMTktMS0xLTEtMA_b136063f-30d3-4bd5-9e37-f32fe4d0d0a8"
      unitRef="usd">753000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMTktMy0xLTEtMA_4df15665-314e-4d19-a3ef-0287f8c4c00b"
      unitRef="usd">470000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMjAtMS0xLTEtMA_94d1fffa-c9e7-4ee7-9948-9ab8522a471b"
      unitRef="usd">7531000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMjAtMy0xLTEtMA_d92ee8a5-fd69-4616-bdbf-bee0c38425b8"
      unitRef="usd">3867000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMjEtMS0xLTEtMA_57ba53bb-d5ff-43a2-a978-54c4261f334a"
      unitRef="usd">149000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMjEtMy0xLTEtMA_6893e425-b8df-44e4-872a-d977f8afa03b"
      unitRef="usd">34000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMjItMS0xLTEtMA_cf729c7e-29c7-4e64-8e72-9f2d620cc92a"
      unitRef="usd">8441000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMjItMy0xLTEtMA_5c2d8ada-6ee0-4b76-8380-c966fbd1fd4b"
      unitRef="usd">4389000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMjMtMS0xLTEtMA_cebf301e-f5cf-4c04-8fe0-a2194f2e4bf5"
      unitRef="usd">179000000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMjMtMy0xLTEtMA_fe8aa081-f177-46d4-b99a-6533744e6656"
      unitRef="usd">177000000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMjQtMS0xLTEtMA_c131446c-ae3d-4997-bb27-f0542d0ef2a5"
      unitRef="usd">96000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMjQtMy0xLTEtMA_5438e90d-6680-40ff-9f5b-c356712e2ebf"
      unitRef="usd">97000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMjUtMS0xLTEtMA_62f2bc23-a42e-4ebc-826e-c3bfa5a1d00c"
      unitRef="usd">138000000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMjUtMy0xLTEtMA_74976d62-0c9b-43e6-bf53-b8ac33c6bee5"
      unitRef="usd">110000000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMjYtMS0xLTEtMA_98aa9501-0b1f-45d4-b860-f2e50432bd5d"
      unitRef="usd">2000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMjYtMy0xLTEtMA_f3056482-43e1-4ea3-81f6-f1239e6cff3c"
      unitRef="usd">3000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMjctMS0xLTEtMA_678322a2-f36f-40e0-9581-63b49a424392"
      unitRef="usd">8856000000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMjctMy0xLTEtMA_329a7516-433e-4b1a-a927-2d8e4bc6504b"
      unitRef="usd">4776000000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMjgtMS0xLTEtMA_41e48fe0-8fbc-4f09-b0e1-aa203c821501"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMjgtMy0xLTEtMA_63e7329a-8314-453e-b81e-937165eb172c"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjUzMDhjODk5NDNmYzQ2OGRiYTczYmIzMjE4OWEwODYzXzMx_75ab6fcb-d15d-4962-822a-ca78b60cb91a"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjUzMDhjODk5NDNmYzQ2OGRiYTczYmIzMjE4OWEwODYzXzMx_c8f1bdce-7d85-4570-9e23-dff2853cbe7a"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjUzMDhjODk5NDNmYzQ2OGRiYTczYmIzMjE4OWEwODYzXzM1_c2c4e14b-8239-4e03-8617-4f0669c6ac99"
      unitRef="shares">162000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjUzMDhjODk5NDNmYzQ2OGRiYTczYmIzMjE4OWEwODYzXzM1_dd1a5844-0212-4338-96cd-7d8333f8f4ff"
      unitRef="shares">162000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjUzMDhjODk5NDNmYzQ2OGRiYTczYmIzMjE4OWEwODYzXzk2_161e8ef7-166b-4b50-b296-6b3d8e8335ea"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjUzMDhjODk5NDNmYzQ2OGRiYTczYmIzMjE4OWEwODYzXzk2_9dba75d8-567b-4814-8950-391d1cd4de70"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjUzMDhjODk5NDNmYzQ2OGRiYTczYmIzMjE4OWEwODYzXzk2_b3b4fb03-2699-4eef-8a86-5cecb9b04001"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjUzMDhjODk5NDNmYzQ2OGRiYTczYmIzMjE4OWEwODYzXzk2_c262cf78-4772-469f-8f00-832b6f789b6f"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzAtMS0xLTEtMA_b9bfe478-a0c9-468a-bcf6-48af51ee25b8"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzAtMy0xLTEtMA_db1d7f86-d393-4c0e-ab0e-2e824f5ac487"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjFjMzA3ZWY1NDljODQyYjg4MjlkZTA2YWZiNTcwNDdmXzMyOTg1MzQ4ODM3Mzk_67a3c273-123e-4076-b7f7-192139235e1d"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjFjMzA3ZWY1NDljODQyYjg4MjlkZTA2YWZiNTcwNDdmXzMyOTg1MzQ4ODM3Mzk_a39e22f5-83ab-40b2-8790-8543c24517a1"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjFjMzA3ZWY1NDljODQyYjg4MjlkZTA2YWZiNTcwNDdmXzMyOTg1MzQ4ODM3NDc_26fab3f9-d77c-42b2-9196-769a7f2a7ece"
      unitRef="shares">1600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjFjMzA3ZWY1NDljODQyYjg4MjlkZTA2YWZiNTcwNDdmXzMyOTg1MzQ4ODM3NDc_e75a45b6-9772-40e8-82eb-679b6f344102"
      unitRef="shares">1600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjFjMzA3ZWY1NDljODQyYjg4MjlkZTA2YWZiNTcwNDdmXzMyOTg1MzQ4ODM3NTQ_982a6c86-919c-450e-ab7c-01442c573836"
      unitRef="shares">401000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjFjMzA3ZWY1NDljODQyYjg4MjlkZTA2YWZiNTcwNDdmXzMyOTg1MzQ4ODM3NTQ_c3c1b4d2-d533-4b92-acf8-c0fa0962c46d"
      unitRef="shares">401000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjFjMzA3ZWY1NDljODQyYjg4MjlkZTA2YWZiNTcwNDdmXzMyOTg1MzQ4ODM3NjE_89293030-ac09-4346-afc1-3bfa19ec4c47"
      unitRef="shares">399000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjFjMzA3ZWY1NDljODQyYjg4MjlkZTA2YWZiNTcwNDdmXzMyOTg1MzQ4ODM3NjE_d6c7e99c-ff05-44fc-8cdf-64bff4f71c2a"
      unitRef="shares">399000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzEtMS0xLTEtMA_7d74afe2-1bc5-499b-a45c-6905fc06dad5"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzEtMy0xLTEtMA_c23e66b1-a91d-43c3-93b1-e5cf90dff21c"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzItMS0xLTEtMA_f84d6e31-ea54-4725-abd2-b7c281896864"
      unitRef="usd">4860000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzItMy0xLTEtMA_18520d6a-0e33-4d69-b2f7-961b4a1885bd"
      unitRef="usd">4802000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzMtMS0xLTEtMA_e6b6eefa-d7b6-4afb-88ea-e23d8a6afdc5"
      unitRef="usd">1000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzMtMy0xLTEtMA_70b41982-df68-44a5-8a97-9200ecdbf8c2"
      unitRef="usd">3000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzQtMS0xLTEtMA_7ad898cf-83a5-45e1-9909-2aedfcefac01"
      unitRef="usd">-1023000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzQtMy0xLTEtMA_b483ff2b-1ecb-4aad-b0b9-cbc328e022e8"
      unitRef="usd">-2244000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzUtMS0xLTEtMA_cea39762-dbf7-49d0-a4d5-368215fdb248"
      unitRef="usd">3838000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzUtMy0xLTEtMA_e0446953-e167-4940-b8ec-c3094ede3b4f"
      unitRef="usd">2561000000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzYtMS0xLTEtMA_1fe8cc78-892d-4a59-af27-81eea89bd829"
      unitRef="usd">12694000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xNi9mcmFnOjRjYjg3ZjUwZDI0MDRlN2M4ZTdjMDRhNTY4ODgwZTE3L3RhYmxlOjQ1Mjc1NDUzMzNjZjRmMTM5YTU5YjZlODViMGYxNTU3L3RhYmxlcmFuZ2U6NDUyNzU0NTMzM2NmNGYxMzlhNTliNmU4NWIwZjE1NTdfMzYtMy0xLTEtMA_2983ee47-b166-414d-9c4e-9d1e72e9755a"
      unitRef="usd">7337000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="i90cf26aad24349bfa441914ac3d706fb_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfMy02LTEtMS0w_4c30e0f4-9cfb-474b-a07f-a5a122962b22"
      unitRef="usd">1733000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8e5ea10505f740f69843ae942d0421b8_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfMy04LTEtMS0w_32114ee4-813f-4553-986b-deadddf4debf"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i12127d667a294d78b6d78f889c39cd18_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfNC02LTEtMS0xMTA_6f6182ee-ef34-4620-b1cb-f9b8799442ab"
      unitRef="usd">194000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i928ab86735d84580ac232ade8c6033ea_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfNC04LTEtMS0xMjI4_2557df13-1d55-428f-a5a0-94b9a5fe4989"
      unitRef="usd">4000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i93f5b8cccc84489b9789274a5e0b0890_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfNC02LTEtMS0w_75cb93b3-7b4c-4dce-8b64-8cbad1485815"
      unitRef="usd">10000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie93f0b234bf24c27b09e35245f5e26b6_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfNC04LTEtMS0w_339a7a51-7680-4332-808b-be165c6453bb"
      unitRef="usd">4000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfNS02LTEtMS0w_a5a29843-6ecf-4cc8-945a-96f33bebea28"
      unitRef="usd">1937000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfNS04LTEtMS0w_20a734ca-84a1-4ec6-b783-67d90eccc3a7"
      unitRef="usd">8000000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfOC02LTEtMS0xMTM_b219f8a6-fad1-40c0-b331-e2f9112b6ba0"
      unitRef="usd">193000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfOC04LTEtMS0xMjMz_752e1a9a-3dee-43f6-b61e-58cea3fe6852"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfNy02LTEtMS0w_1b186da7-28b7-4fc0-bb92-6fb6bfdaa8b1"
      unitRef="usd">401000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfNy04LTEtMS0w_911316f8-108a-4155-90fd-dcfb22c08584"
      unitRef="usd">115000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfOC02LTEtMS0w_e5a4b7b0-06f9-4f71-b139-4e5ecbb4e2bb"
      unitRef="usd">77000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfOC04LTEtMS0w_25ed1a69-de5d-42b0-94af-b09e2028178f"
      unitRef="usd">24000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfOS02LTEtMS0w_6745ba07-dbaf-4840-997c-9a82a933d686"
      unitRef="usd">671000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfOS04LTEtMS0w_a3bd937c-3e09-46c1-aefb-14fd35ddfdbd"
      unitRef="usd">139000000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfMTAtNi0xLTEtMA_7335bd98-19e0-4285-a35e-c82a878e2b78"
      unitRef="usd">1266000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfMTAtOC0xLTEtMA_54637d94-9cd3-498f-998b-9d96128cf307"
      unitRef="usd">-131000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfMTEtNi0xLTEtMA_a3773d60-aeaf-474b-b33a-7ed71f70c54d"
      unitRef="usd">4000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfMTEtOC0xLTEtMA_b38e44bf-8572-4c85-a1b0-426b943b4972"
      unitRef="usd">8000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfMTItNi0xLTEtMA_b3164f39-9f82-4f8d-9dbd-5fbb8f60d35a"
      unitRef="usd">-10000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfMTItOC0xLTEtMA_696c35f3-5c4b-4fc0-a16a-8e09191d980f"
      unitRef="usd">-1000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfMTMtNi0xLTEtMA_e7641a86-6dfb-4546-92a4-5283b85b3837"
      unitRef="usd">1260000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfMTMtOC0xLTEtMA_9868d65e-d007-43a8-a917-6e8117ffdef3"
      unitRef="usd">-124000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfMTQtNi0xLTEtMA_17499976-14fe-4325-995a-0fc71ff43227"
      unitRef="usd">39000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfMTQtOC0xLTEtMA_9ed8c0b8-0983-4bc2-b09c-71ad5d4369c2"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfMTUtNi0xLTEtMA_f08c6030-f13e-48c8-84c8-e0aa7a71de84"
      unitRef="usd">1221000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfMTUtOC0xLTEtMA_5295e7f3-293a-44b5-80fd-e683d800b303"
      unitRef="usd">-124000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfMjAtNi0xLTEtMzE0Mw_08e2fb9c-ef0d-4811-90ab-aa801bfdbc1e"
      unitRef="usdPerShare">3.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfMjAtOC0xLTEtMzE0Mw_9870cb74-c4f2-4731-aa70-0269f0579e26"
      unitRef="usdPerShare">-0.35</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfMjEtNi0xLTEtMzU3OA_b04a7214-8e62-4a7e-8768-da6a2aa08391"
      unitRef="usdPerShare">2.84</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfMjEtOC0xLTEtMzU4MA_b830a7b6-7d3f-41ab-9d08-5f566cbc4bd0"
      unitRef="usdPerShare">-0.35</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfMTctNi0xLTEtMA_6dd4853d-d23d-456e-9910-d8f163198c4c"
      unitRef="shares">400000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfMTctOC0xLTEtMA_53cd964d-4a01-4b16-a7b7-6543d553e318"
      unitRef="shares">353000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfMjYtNi0xLTEtMzc1OQ_3ad5032e-200a-4511-b4bb-de4a6baa1d4a"
      unitRef="shares">430000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xOS9mcmFnOmM5MzQyZTJiMzhiZTQ4NGQ5MWJkNzdjZDFmODhiMmZkL3RhYmxlOjNhZGE0OTdhMWU2ZDQzYjg5MTVmNDJjNmIyNjQ5NGNiL3RhYmxlcmFuZ2U6M2FkYTQ5N2ExZTZkNDNiODkxNWY0MmM2YjI2NDk0Y2JfMjYtOC0xLTEtMzc1OQ_3dac5de5-c804-4c7a-8330-e6bfd445631c"
      unitRef="shares">353000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yMi9mcmFnOjFhZmE2YTZiZGY1NDRjYjFiZTFjYzk4MWQxNGUyZDIzL3RhYmxlOjA3MzI3M2I3MGZmODQ0ZjQ4MDQ4OTVlNTcxOGE3MDNlL3RhYmxlcmFuZ2U6MDczMjczYjcwZmY4NDRmNDgwNDg5NWU1NzE4YTcwM2VfMi01LTEtMS0w_663b4994-cd64-4579-93db-80b1f4e77168"
      unitRef="usd">1221000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yMi9mcmFnOjFhZmE2YTZiZGY1NDRjYjFiZTFjYzk4MWQxNGUyZDIzL3RhYmxlOjA3MzI3M2I3MGZmODQ0ZjQ4MDQ4OTVlNTcxOGE3MDNlL3RhYmxlcmFuZ2U6MDczMjczYjcwZmY4NDRmNDgwNDg5NWU1NzE4YTcwM2VfMi03LTEtMS0w_a1dd70f0-acde-4874-b0e3-83bd024ab4ed"
      unitRef="usd">-124000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yMi9mcmFnOjFhZmE2YTZiZGY1NDRjYjFiZTFjYzk4MWQxNGUyZDIzL3RhYmxlOjA3MzI3M2I3MGZmODQ0ZjQ4MDQ4OTVlNTcxOGE3MDNlL3RhYmxlcmFuZ2U6MDczMjczYjcwZmY4NDRmNDgwNDg5NWU1NzE4YTcwM2VfNC0wLTEtMS0wL3RleHRyZWdpb246ZmJkOWRhZTY3NWFkNDNhZGI3NGYyMTJiOTlkOWMzOWJfODA_cb718e1a-d406-4d67-bd25-9925fcd7b9c2"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yMi9mcmFnOjFhZmE2YTZiZGY1NDRjYjFiZTFjYzk4MWQxNGUyZDIzL3RhYmxlOjA3MzI3M2I3MGZmODQ0ZjQ4MDQ4OTVlNTcxOGE3MDNlL3RhYmxlcmFuZ2U6MDczMjczYjcwZmY4NDRmNDgwNDg5NWU1NzE4YTcwM2VfNC0wLTEtMS0wL3RleHRyZWdpb246ZmJkOWRhZTY3NWFkNDNhZGI3NGYyMTJiOTlkOWMzOWJfODc_a2959c10-622d-4862-8b51-3a8bf86d2396"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yMi9mcmFnOjFhZmE2YTZiZGY1NDRjYjFiZTFjYzk4MWQxNGUyZDIzL3RhYmxlOjA3MzI3M2I3MGZmODQ0ZjQ4MDQ4OTVlNTcxOGE3MDNlL3RhYmxlcmFuZ2U6MDczMjczYjcwZmY4NDRmNDgwNDg5NWU1NzE4YTcwM2VfNC01LTEtMS0w_32a272cf-67c5-4e14-bde9-e88504fdc092"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yMi9mcmFnOjFhZmE2YTZiZGY1NDRjYjFiZTFjYzk4MWQxNGUyZDIzL3RhYmxlOjA3MzI3M2I3MGZmODQ0ZjQ4MDQ4OTVlNTcxOGE3MDNlL3RhYmxlcmFuZ2U6MDczMjczYjcwZmY4NDRmNDgwNDg5NWU1NzE4YTcwM2VfNC03LTEtMS0w_e31d9da1-4580-4e6d-9193-a987e595a687"
      unitRef="usd">-8000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yMi9mcmFnOjFhZmE2YTZiZGY1NDRjYjFiZTFjYzk4MWQxNGUyZDIzL3RhYmxlOjA3MzI3M2I3MGZmODQ0ZjQ4MDQ4OTVlNTcxOGE3MDNlL3RhYmxlcmFuZ2U6MDczMjczYjcwZmY4NDRmNDgwNDg5NWU1NzE4YTcwM2VfNy01LTEtMS0w_d2aa68f0-71c2-422f-87e2-d55d182679f2"
      unitRef="usd">1219000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yMi9mcmFnOjFhZmE2YTZiZGY1NDRjYjFiZTFjYzk4MWQxNGUyZDIzL3RhYmxlOjA3MzI3M2I3MGZmODQ0ZjQ4MDQ4OTVlNTcxOGE3MDNlL3RhYmxlcmFuZ2U6MDczMjczYjcwZmY4NDRmNDgwNDg5NWU1NzE4YTcwM2VfNy03LTEtMS0w_900823b3-ac57-40e7-912a-5242eeaa6d03"
      unitRef="usd">-132000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i85c3685b8bc74888a7957153cba507be_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOjUzNDY0MGZmYzI1ODRlMWVhOGYxZmYzYjk5NDdjYTNiL3RhYmxlcmFuZ2U6NTM0NjQwZmZjMjU4NGUxZWE4ZjFmZjNiOTk0N2NhM2JfMi0xLTEtMS0w_ac5156aa-a827-4e39-9aae-e98f72d394c9"
      unitRef="shares">399000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i85c3685b8bc74888a7957153cba507be_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOjUzNDY0MGZmYzI1ODRlMWVhOGYxZmYzYjk5NDdjYTNiL3RhYmxlcmFuZ2U6NTM0NjQwZmZjMjU4NGUxZWE4ZjFmZjNiOTk0N2NhM2JfMi0zLTEtMS0w_7581390f-bce4-4c3f-91d9-293f921d4077"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idaec3621e0754f54a55937521667819b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOjUzNDY0MGZmYzI1ODRlMWVhOGYxZmYzYjk5NDdjYTNiL3RhYmxlcmFuZ2U6NTM0NjQwZmZjMjU4NGUxZWE4ZjFmZjNiOTk0N2NhM2JfMi01LTEtMS0w_8e817825-d468-489f-ac0b-c02149f43d3e"
      unitRef="usd">4802000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie42efe57bc7743f78f5470ae0d8b47c0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOjUzNDY0MGZmYzI1ODRlMWVhOGYxZmYzYjk5NDdjYTNiL3RhYmxlcmFuZ2U6NTM0NjQwZmZjMjU4NGUxZWE4ZjFmZjNiOTk0N2NhM2JfMi03LTEtMS0w_eaf063b4-ab15-43ee-832d-9c4c4d648c8b"
      unitRef="usd">3000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0ee23f27c5a7409999bc27bf484c3683_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOjUzNDY0MGZmYzI1ODRlMWVhOGYxZmYzYjk5NDdjYTNiL3RhYmxlcmFuZ2U6NTM0NjQwZmZjMjU4NGUxZWE4ZjFmZjNiOTk0N2NhM2JfMi05LTEtMS0w_6391b58e-48b2-4f75-9543-70a8955dad1b"
      unitRef="usd">-2244000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOjUzNDY0MGZmYzI1ODRlMWVhOGYxZmYzYjk5NDdjYTNiL3RhYmxlcmFuZ2U6NTM0NjQwZmZjMjU4NGUxZWE4ZjFmZjNiOTk0N2NhM2JfMi0xMS0xLTEtMA_df8e07bf-a4d3-432b-b04e-fe549eb74f76"
      unitRef="usd">2561000000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i8bd66b8c2d444db3ab9e16db494ca9ec_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOjUzNDY0MGZmYzI1ODRlMWVhOGYxZmYzYjk5NDdjYTNiL3RhYmxlcmFuZ2U6NTM0NjQwZmZjMjU4NGUxZWE4ZjFmZjNiOTk0N2NhM2JfNS0xLTEtMS0w_c476e5ff-2e0a-4186-a425-00352cd4d253"
      unitRef="shares">2000000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ia6763fa662d34fe987498086ccaefa42_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOjUzNDY0MGZmYzI1ODRlMWVhOGYxZmYzYjk5NDdjYTNiL3RhYmxlcmFuZ2U6NTM0NjQwZmZjMjU4NGUxZWE4ZjFmZjNiOTk0N2NhM2JfNS01LTEtMS0w_0703686a-ad95-48c7-a1ef-c1d587ddb8cd"
      unitRef="usd">28000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOjUzNDY0MGZmYzI1ODRlMWVhOGYxZmYzYjk5NDdjYTNiL3RhYmxlcmFuZ2U6NTM0NjQwZmZjMjU4NGUxZWE4ZjFmZjNiOTk0N2NhM2JfNS0xMS0xLTEtMA_598c6e54-2963-409e-8790-78baefcd36d0"
      unitRef="usd">28000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia6763fa662d34fe987498086ccaefa42_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOjUzNDY0MGZmYzI1ODRlMWVhOGYxZmYzYjk5NDdjYTNiL3RhYmxlcmFuZ2U6NTM0NjQwZmZjMjU4NGUxZWE4ZjFmZjNiOTk0N2NhM2JfNy01LTEtMS0w_edbfdebe-c59d-4ca7-b13e-fe93df08b212"
      unitRef="usd">30000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOjUzNDY0MGZmYzI1ODRlMWVhOGYxZmYzYjk5NDdjYTNiL3RhYmxlcmFuZ2U6NTM0NjQwZmZjMjU4NGUxZWE4ZjFmZjNiOTk0N2NhM2JfNy0xMS0xLTEtMA_1e54ceea-5faf-46cb-b94f-e4d7f36baf97"
      unitRef="usd">30000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i51a24806337f4c398006c8c24a6291f9_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOjUzNDY0MGZmYzI1ODRlMWVhOGYxZmYzYjk5NDdjYTNiL3RhYmxlcmFuZ2U6NTM0NjQwZmZjMjU4NGUxZWE4ZjFmZjNiOTk0N2NhM2JfOC03LTEtMS0w_a00cc3e0-c834-4071-96d4-782e9f3e003a"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOjUzNDY0MGZmYzI1ODRlMWVhOGYxZmYzYjk5NDdjYTNiL3RhYmxlcmFuZ2U6NTM0NjQwZmZjMjU4NGUxZWE4ZjFmZjNiOTk0N2NhM2JfOC0xMS0xLTEtMA_27723ac4-b573-44b1-be5c-1c72b7ac774a"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i00257f1c106c4f12b6139f8b838a1faf_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOjUzNDY0MGZmYzI1ODRlMWVhOGYxZmYzYjk5NDdjYTNiL3RhYmxlcmFuZ2U6NTM0NjQwZmZjMjU4NGUxZWE4ZjFmZjNiOTk0N2NhM2JfOS05LTEtMS0w_19c8f468-6b43-4592-bc13-02e9c2f6cd49"
      unitRef="usd">1221000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOjUzNDY0MGZmYzI1ODRlMWVhOGYxZmYzYjk5NDdjYTNiL3RhYmxlcmFuZ2U6NTM0NjQwZmZjMjU4NGUxZWE4ZjFmZjNiOTk0N2NhM2JfOS0xMS0xLTEtMA_cf95e29f-4422-47fa-a983-5b88272fb93c"
      unitRef="usd">1221000000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="ie2898610162d44ebb1d6412f7f754f57_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOjUzNDY0MGZmYzI1ODRlMWVhOGYxZmYzYjk5NDdjYTNiL3RhYmxlcmFuZ2U6NTM0NjQwZmZjMjU4NGUxZWE4ZjFmZjNiOTk0N2NhM2JfMTAtMS0xLTEtMA_4d70c211-e446-4881-b1d1-395db739094b"
      unitRef="shares">401000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ie2898610162d44ebb1d6412f7f754f57_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOjUzNDY0MGZmYzI1ODRlMWVhOGYxZmYzYjk5NDdjYTNiL3RhYmxlcmFuZ2U6NTM0NjQwZmZjMjU4NGUxZWE4ZjFmZjNiOTk0N2NhM2JfMTAtMy0xLTEtMA_21bd9a82-c881-4c53-a652-fe3b9df22b05"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if224da12bc8646a2934e52e6b2b0929d_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOjUzNDY0MGZmYzI1ODRlMWVhOGYxZmYzYjk5NDdjYTNiL3RhYmxlcmFuZ2U6NTM0NjQwZmZjMjU4NGUxZWE4ZjFmZjNiOTk0N2NhM2JfMTAtNS0xLTEtMA_d7b26725-ce9b-4d7a-a93f-f38eb822a6ed"
      unitRef="usd">4860000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3081299caa6b4213987da62a7e0e3b67_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOjUzNDY0MGZmYzI1ODRlMWVhOGYxZmYzYjk5NDdjYTNiL3RhYmxlcmFuZ2U6NTM0NjQwZmZjMjU4NGUxZWE4ZjFmZjNiOTk0N2NhM2JfMTAtNy0xLTEtMA_6ae46a88-e9a7-4a2e-9b93-5ddb9e72dd18"
      unitRef="usd">1000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3ea0cb20ecbd485a9682c793a5f13edd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOjUzNDY0MGZmYzI1ODRlMWVhOGYxZmYzYjk5NDdjYTNiL3RhYmxlcmFuZ2U6NTM0NjQwZmZjMjU4NGUxZWE4ZjFmZjNiOTk0N2NhM2JfMTAtOS0xLTEtMA_3238a5c1-b5ff-4915-b97d-5727ef6dd1a8"
      unitRef="usd">-1023000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOjUzNDY0MGZmYzI1ODRlMWVhOGYxZmYzYjk5NDdjYTNiL3RhYmxlcmFuZ2U6NTM0NjQwZmZjMjU4NGUxZWE4ZjFmZjNiOTk0N2NhM2JfMTAtMTEtMS0xLTA_34e5497b-bec8-480e-88e8-656e587772ce"
      unitRef="usd">3838000000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i7682e40394cc4e7db96f8cc4de55e962_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOmMwMzkyNWVkZWFhOTRhM2RiYzMzNmExMTA4OWQ3YzExL3RhYmxlcmFuZ2U6YzAzOTI1ZWRlYWE5NGEzZGJjMzM2YTExMDg5ZDdjMTFfMy0xLTEtMS0w_bdaa62aa-bd7e-4745-ad40-706aaaa6ac33"
      unitRef="shares">337000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i7682e40394cc4e7db96f8cc4de55e962_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOmMwMzkyNWVkZWFhOTRhM2RiYzMzNmExMTA4OWQ3YzExL3RhYmxlcmFuZ2U6YzAzOTI1ZWRlYWE5NGEzZGJjMzM2YTExMDg5ZDdjMTFfMy0zLTEtMS0w_a31c04a3-f052-4e5b-9670-0fffea99469a"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib7811f82e8ed4667a6efb6a88cb1dc80_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOmMwMzkyNWVkZWFhOTRhM2RiYzMzNmExMTA4OWQ3YzExL3RhYmxlcmFuZ2U6YzAzOTI1ZWRlYWE5NGEzZGJjMzM2YTExMDg5ZDdjMTFfMy01LTEtMS0w_b536adfa-53c2-44d7-8e48-454ebf466514"
      unitRef="usd">2670000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2ed66b7fc0fb48c9bb3d57e8be191929_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOmMwMzkyNWVkZWFhOTRhM2RiYzMzNmExMTA4OWQ3YzExL3RhYmxlcmFuZ2U6YzAzOTI1ZWRlYWE5NGEzZGJjMzM2YTExMDg5ZDdjMTFfMy03LTEtMS0w_42d12f50-d8cf-4b97-a152-a8bbcc88d808"
      unitRef="usd">2000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idd4ae3b11c564cb6b97eb730e3ff7bb1_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOmMwMzkyNWVkZWFhOTRhM2RiYzMzNmExMTA4OWQ3YzExL3RhYmxlcmFuZ2U6YzAzOTI1ZWRlYWE5NGEzZGJjMzM2YTExMDg5ZDdjMTFfMy05LTEtMS0w_f7fe3b10-954d-4cd3-9975-32e634837b6c"
      unitRef="usd">-1497000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1138d8f10d6c45fdb458206ef7e763ce_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOmMwMzkyNWVkZWFhOTRhM2RiYzMzNmExMTA4OWQ3YzExL3RhYmxlcmFuZ2U6YzAzOTI1ZWRlYWE5NGEzZGJjMzM2YTExMDg5ZDdjMTFfMy0xMS0xLTEtMA_471b157a-7b5d-4337-bd07-1987803778ba"
      unitRef="usd">1175000000</us-gaap:StockholdersEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOmMwMzkyNWVkZWFhOTRhM2RiYzMzNmExMTA4OWQ3YzExL3RhYmxlcmFuZ2U6YzAzOTI1ZWRlYWE5NGEzZGJjMzM2YTExMDg5ZDdjMTFfNC0wLTEtMS0zMjYwL3RleHRyZWdpb246ZmViYWEzMWEwNjQxNGNkNThhZWU0MTVlMTUwN2M4YmNfMzI5ODUzNDg4MzQwOA_792610fe-1875-4722-84a0-b67d3bd911bb"
      unitRef="usd">1000000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ibd57a755b6d2496f92d2b0ce1c6d8369_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOmMwMzkyNWVkZWFhOTRhM2RiYzMzNmExMTA4OWQ3YzExL3RhYmxlcmFuZ2U6YzAzOTI1ZWRlYWE5NGEzZGJjMzM2YTExMDg5ZDdjMTFfNC0xLTEtMS0xOTg_8dbace3d-6c63-4f73-924b-80fc223e720b"
      unitRef="shares">30000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i16c2d8a9bebe4163981c7803f6359e72_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOmMwMzkyNWVkZWFhOTRhM2RiYzMzNmExMTA4OWQ3YzExL3RhYmxlcmFuZ2U6YzAzOTI1ZWRlYWE5NGEzZGJjMzM2YTExMDg5ZDdjMTFfNC01LTEtMS0xOTg_bf06107e-0638-4098-a542-4249a05b472d"
      unitRef="usd">550000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOmMwMzkyNWVkZWFhOTRhM2RiYzMzNmExMTA4OWQ3YzExL3RhYmxlcmFuZ2U6YzAzOTI1ZWRlYWE5NGEzZGJjMzM2YTExMDg5ZDdjMTFfNC0xMS0xLTEtMTk4_c6a48488-d5a4-4ed6-8726-1c2b2b9541d2"
      unitRef="usd">550000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ibd57a755b6d2496f92d2b0ce1c6d8369_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOmMwMzkyNWVkZWFhOTRhM2RiYzMzNmExMTA4OWQ3YzExL3RhYmxlcmFuZ2U6YzAzOTI1ZWRlYWE5NGEzZGJjMzM2YTExMDg5ZDdjMTFfNS0xLTEtMS0w_edaa1990-f20a-4e80-8f30-a70d85e33535"
      unitRef="shares">3000000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i16c2d8a9bebe4163981c7803f6359e72_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOmMwMzkyNWVkZWFhOTRhM2RiYzMzNmExMTA4OWQ3YzExL3RhYmxlcmFuZ2U6YzAzOTI1ZWRlYWE5NGEzZGJjMzM2YTExMDg5ZDdjMTFfNS01LTEtMS0w_4c48cdf7-600b-45d4-b5f1-666e652b2994"
      unitRef="usd">28000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOmMwMzkyNWVkZWFhOTRhM2RiYzMzNmExMTA4OWQ3YzExL3RhYmxlcmFuZ2U6YzAzOTI1ZWRlYWE5NGEzZGJjMzM2YTExMDg5ZDdjMTFfNS0xMS0xLTEtMA_8171c706-ae09-4274-a5b5-fee892f16180"
      unitRef="usd">28000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i16c2d8a9bebe4163981c7803f6359e72_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOmMwMzkyNWVkZWFhOTRhM2RiYzMzNmExMTA4OWQ3YzExL3RhYmxlcmFuZ2U6YzAzOTI1ZWRlYWE5NGEzZGJjMzM2YTExMDg5ZDdjMTFfOC01LTEtMS0w_379f74fa-5a36-4ba6-945f-454d1a1702ef"
      unitRef="usd">20000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOmMwMzkyNWVkZWFhOTRhM2RiYzMzNmExMTA4OWQ3YzExL3RhYmxlcmFuZ2U6YzAzOTI1ZWRlYWE5NGEzZGJjMzM2YTExMDg5ZDdjMTFfOC0xMS0xLTEtMA_bcab9082-437f-4657-ab45-da450bc4c2b1"
      unitRef="usd">20000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i4d0241871b0840c2a85a3c6334108769_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOmMwMzkyNWVkZWFhOTRhM2RiYzMzNmExMTA4OWQ3YzExL3RhYmxlcmFuZ2U6YzAzOTI1ZWRlYWE5NGEzZGJjMzM2YTExMDg5ZDdjMTFfOS03LTEtMS0w_1ef21e62-37fe-4ef1-bb71-3902ebc8f5c1"
      unitRef="usd">-8000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOmMwMzkyNWVkZWFhOTRhM2RiYzMzNmExMTA4OWQ3YzExL3RhYmxlcmFuZ2U6YzAzOTI1ZWRlYWE5NGEzZGJjMzM2YTExMDg5ZDdjMTFfOS0xMS0xLTEtMA_71b40fde-4b99-4131-a115-423aae29a853"
      unitRef="usd">-8000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i353dc2cd5f49451798ef780c6af7ed46_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOmMwMzkyNWVkZWFhOTRhM2RiYzMzNmExMTA4OWQ3YzExL3RhYmxlcmFuZ2U6YzAzOTI1ZWRlYWE5NGEzZGJjMzM2YTExMDg5ZDdjMTFfMTAtOS0xLTEtMA_064fa6df-dd54-49f0-970d-26075030ef97"
      unitRef="usd">-124000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOmMwMzkyNWVkZWFhOTRhM2RiYzMzNmExMTA4OWQ3YzExL3RhYmxlcmFuZ2U6YzAzOTI1ZWRlYWE5NGEzZGJjMzM2YTExMDg5ZDdjMTFfMTAtMTEtMS0xLTA_0a0fe1d0-e8b7-4037-a94b-630d82df380f"
      unitRef="usd">-124000000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i99ce1af211874ddda368b64fc0527881_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOmMwMzkyNWVkZWFhOTRhM2RiYzMzNmExMTA4OWQ3YzExL3RhYmxlcmFuZ2U6YzAzOTI1ZWRlYWE5NGEzZGJjMzM2YTExMDg5ZDdjMTFfMTEtMS0xLTEtMA_3ea75aa6-e271-4dd9-8e17-a6cf7ba0fd68"
      unitRef="shares">370000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i99ce1af211874ddda368b64fc0527881_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOmMwMzkyNWVkZWFhOTRhM2RiYzMzNmExMTA4OWQ3YzExL3RhYmxlcmFuZ2U6YzAzOTI1ZWRlYWE5NGEzZGJjMzM2YTExMDg5ZDdjMTFfMTEtMy0xLTEtMA_32e99912-9f7c-469c-881f-61fc37b44728"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i199f99634c0c487e82b051148cdc8024_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOmMwMzkyNWVkZWFhOTRhM2RiYzMzNmExMTA4OWQ3YzExL3RhYmxlcmFuZ2U6YzAzOTI1ZWRlYWE5NGEzZGJjMzM2YTExMDg5ZDdjMTFfMTEtNS0xLTEtMA_0ad795c7-4bac-44f9-8612-0c88a5665473"
      unitRef="usd">3268000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9ac58abcca77466fa78e3ac37f63f737_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOmMwMzkyNWVkZWFhOTRhM2RiYzMzNmExMTA4OWQ3YzExL3RhYmxlcmFuZ2U6YzAzOTI1ZWRlYWE5NGEzZGJjMzM2YTExMDg5ZDdjMTFfMTEtNy0xLTEtMA_e0983218-b2e1-4484-9ed6-545eeb34ec45"
      unitRef="usd">-6000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i11483b66bae440ceafe63983b7fbd5c9_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOmMwMzkyNWVkZWFhOTRhM2RiYzMzNmExMTA4OWQ3YzExL3RhYmxlcmFuZ2U6YzAzOTI1ZWRlYWE5NGEzZGJjMzM2YTExMDg5ZDdjMTFfMTEtOS0xLTEtMA_5c5c5ae5-a12d-4edb-a6ce-8d806177e221"
      unitRef="usd">-1621000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iaa5a33ce37614698a3418806ab20f9b2_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yNS9mcmFnOmFjZmJhMWY2OWM5ZjQyYjA4ODE4ODQ4MDE0NjU5MWMyL3RhYmxlOmMwMzkyNWVkZWFhOTRhM2RiYzMzNmExMTA4OWQ3YzExL3RhYmxlcmFuZ2U6YzAzOTI1ZWRlYWE5NGEzZGJjMzM2YTExMDg5ZDdjMTFfMTEtMTEtMS0xLTA_cae5c14d-6f82-4620-b021-b639da86aef6"
      unitRef="usd">1641000000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMy0xLTEtMS0w_2d0988dd-93f6-47a5-ac7d-e870825d97a0"
      unitRef="usd">1221000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMy0zLTEtMS0w_357ca31c-3e5b-470b-be37-ba7e658f01d8"
      unitRef="usd">-124000000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfNS0xLTEtMS0w_a54fa068-309e-493c-a9c6-29aa74a6c980"
      unitRef="usd">30000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfNS0zLTEtMS0w_e8c24296-03b3-4722-b042-10b6ed449d44"
      unitRef="usd">20000000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfNi0xLTEtMS0w_10039ab8-4cc8-44e3-b146-1a02707cf687"
      unitRef="usd">15000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfNi0zLTEtMS0w_e5f67a70-2984-4dcf-82c0-cf33f94b9e96"
      unitRef="usd">7000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfNy0xLTEtMS0w_66e03bf6-e4e5-4813-8dd1-0f9a91334a7e"
      unitRef="usd">-5000000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfNy0zLTEtMS0w_62c646df-e69a-4539-8f0d-57ff6ef93c17"
      unitRef="usd">-1000000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfOS0xLTEtMS03MTMy_9d4a4184-313b-4d04-b081-c1785f16cca4"
      unitRef="usd">-50000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfOS0zLTEtMS03MTMw_baa51989-f911-4446-9d75-ae3622f8dfe5"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMTAtMS0xLTEtMA_2f130197-df0d-4bc8-9b53-b68f5f9b1662"
      unitRef="usd">1819000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMTAtMy0xLTEtMA_36db44a9-f5fa-4325-8533-beedd13b83ea"
      unitRef="usd">2000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMTEtMS0xLTEtMA_76db64f0-1977-4181-932f-50978da2c0e6"
      unitRef="usd">12000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMTEtMy0xLTEtMA_7ac3e44f-dce2-4e5a-92b0-463c0815ab08"
      unitRef="usd">4000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMTItMS0xLTEtNDIzMg_01eef229-8819-4d6f-81c2-decade2328b8"
      unitRef="usd">448000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMTItMy0xLTEtNDIzMg_ab7d880a-8c65-4ce5-9a78-ee63f9400655"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInInventories>
    <mrna:IncreaseDecreaseInRightOfUseAssetOperatingLeases
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMTItMS0xLTEtMA_f25b0241-4587-435f-961a-15cca8cc7299"
      unitRef="usd">-2000000</mrna:IncreaseDecreaseInRightOfUseAssetOperatingLeases>
    <mrna:IncreaseDecreaseInRightOfUseAssetOperatingLeases
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMTItMy0xLTEtMA_71dddfa6-460c-4897-b698-0e98796d086a"
      unitRef="usd">14000000</mrna:IncreaseDecreaseInRightOfUseAssetOperatingLeases>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMTMtMS0xLTEtMA_b8157871-9567-4dbb-aac2-50980ca26a20"
      unitRef="usd">-15000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMTMtMy0xLTEtMA_da77bd09-65d0-4cf2-934f-c45d68bc78c8"
      unitRef="usd">2000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMTQtMS0xLTEtMA_59b43011-7481-4684-b468-b1e15eeb1328"
      unitRef="usd">285000000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMTQtMy0xLTEtMA_04b598e8-1135-44c1-9a24-96505e7b351d"
      unitRef="usd">-12000000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMTUtMS0xLTEtMA_37e6ca08-af8d-4d9c-b406-06332b26c7b7"
      unitRef="usd">3666000000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMTUtMy0xLTEtMA_dd1a85d4-a26e-48a8-b430-802af24e4982"
      unitRef="usd">-1000000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <mrna:OperatingLeaseLiabilities
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMTYtMS0xLTEtMA_d581674b-a883-40dc-a7c6-30323459080a"
      unitRef="usd">-2000000</mrna:OperatingLeaseLiabilities>
    <mrna:OperatingLeaseLiabilities
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMTYtMy0xLTEtMA_65a46054-d6c4-4210-b3a2-b635c620ca83"
      unitRef="usd">15000000</mrna:OperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMTctMS0xLTEtMA_284311db-8437-423f-aff4-8ab8c7bd0c08"
      unitRef="usd">93000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMTctMy0xLTEtMA_2d467df9-cc67-4c33-b361-0f08eb39834a"
      unitRef="usd">6000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMTktMS0xLTEtMA_63bf216e-19ab-4a05-a9d8-b425cc2ec80f"
      unitRef="usd">2971000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMTktMy0xLTEtMA_6084a54b-9c89-4261-b26c-b42a8c4fe8bd"
      unitRef="usd">-106000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMjEtMS0xLTEtMA_1f8cd955-2031-4ec3-82ae-50f025d667c9"
      unitRef="usd">726000000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMjEtMy0xLTEtMA_74b2cdd2-4e7e-4587-922b-ecb238ff200b"
      unitRef="usd">621000000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMjItMS0xLTEtMA_9007e8e1-d625-4805-9804-813022f5b5af"
      unitRef="usd">339000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMjItMy0xLTEtMA_063c435d-afac-492f-8f55-bf21c3590cf1"
      unitRef="usd">269000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMjMtMS0xLTEtMA_619f44c1-b26e-44f9-8d9a-1fb0ac77c943"
      unitRef="usd">242000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMjMtMy0xLTEtMA_69661cf7-589f-4196-bbfc-2d1d9d19271d"
      unitRef="usd">42000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMjQtMS0xLTEtMA_be39dbe5-db34-4f42-b682-23940c0aa7ba"
      unitRef="usd">35000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMjQtMy0xLTEtMA_957ffd7b-91f1-4db0-a6c7-ccaca11026aa"
      unitRef="usd">6000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMjUtMS0xLTEtMA_0b933777-264e-4d49-a29b-a335f7c1d3c5"
      unitRef="usd">-180000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMjUtMy0xLTEtMA_44b9d09b-fd0f-4036-a0ae-43805bdb652e"
      unitRef="usd">-316000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMjctMS0xLTEtMA_8e1cdf90-2d14-49e3-8398-b64a6b087387"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMjctMy0xLTEtMA_abb53e81-1d33-46ca-a3d7-42a3b40dc0c3"
      unitRef="usd">550000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockPlans
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMjgtMS0xLTEtMA_7f2fa9bb-1025-4da7-8186-5344362efaf8"
      unitRef="usd">28000000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMjgtMy0xLTEtMA_3729bbbd-ab5a-4866-93b9-f0e762f385e7"
      unitRef="usd">28000000</us-gaap:ProceedsFromStockPlans>
    <mrna:ChargesToFinancingLeaseLiabilities
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMzAtMS0xLTEtMA_606a9b5b-7589-413a-a9d6-eac46b6513fa"
      unitRef="usd">-2000000</mrna:ChargesToFinancingLeaseLiabilities>
    <mrna:ChargesToFinancingLeaseLiabilities
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMzAtMy0xLTEtMA_2855f653-ed9b-45c3-8c07-2ba6f54b4fef"
      unitRef="usd">0</mrna:ChargesToFinancingLeaseLiabilities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMzEtMS0xLTEtMA_e2a31cbe-7117-41a2-8722-17d70e78edd4"
      unitRef="usd">26000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMzEtMy0xLTEtMA_583cc585-7ea9-4c63-93f1-d412ae7465f7"
      unitRef="usd">578000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMzItMS0xLTEtMA_9cf97664-6322-4f86-836d-d127ae0359fe"
      unitRef="usd">2817000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMzItMy0xLTEtMA_913d0030-d48b-4736-ac97-52cf2c5b6a7f"
      unitRef="usd">156000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMzMtMS0xLTEtMA_0ca1cfa8-4f74-402c-b149-33d017966b78"
      unitRef="usd">2636000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1138d8f10d6c45fdb458206ef7e763ce_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMzMtMy0xLTEtMA_d1c743f0-e2c8-412e-8e40-b12c87079713"
      unitRef="usd">248000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMzQtMS0xLTEtMA_9c47e00f-770b-49fd-9ad9-0fb65fef5225"
      unitRef="usd">5453000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iaa5a33ce37614698a3418806ab20f9b2_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMzQtMy0xLTEtMA_5fd41ce8-c2ba-48b8-ac06-1acde7f48ca9"
      unitRef="usd">404000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMzctMS0xLTEtMA_c37e1cc2-fb7c-4bdf-96f8-1fa2855417da"
      unitRef="usd">21000000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMzctMy0xLTEtMA_de6e0591-ff0b-4149-972f-c4abb9dc18fc"
      unitRef="usd">7000000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMzctMS0xLTEtMzI4Ng_1442ee62-6be6-48d8-93d0-2a4edf770fb3"
      unitRef="usd">51000000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8yOC9mcmFnOjVkYzAzMTU2N2Y0NTRjOGViNTNhYjg4NDY2ZTNjMDJhL3RhYmxlOjE0MWJiNDJlN2JmMjQzNTQ4ZGUzZTA2ZDE2NDJiNDQzL3RhYmxlcmFuZ2U6MTQxYmI0MmU3YmYyNDM1NDhkZTNlMDZkMTY0MmI0NDNfMzctMy0xLTEtMzI4OQ_b88f3fad-7d87-4244-8ba0-6e764213d046"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8zNC9mcmFnOjk5MzU0ODBlODIyZTQ4ODFiZjY4ZmEyZDc5NDQ5NDk1L3RleHRyZWdpb246OTkzNTQ4MGU4MjJlNDg4MWJmNjhmYTJkNzk0NDk0OTVfNDI5Mg_05118176-b067-42a6-b744-3f18a62f7767">Description of the Business&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Moderna, Inc. (collectively, with its consolidated subsidiaries, any of Moderna, we, us, or the Company) was incorporated in Delaware on July&#160;22, 2016. We are the successor in interest to Moderna LLC, a limited liability company formed under the laws of the State of Delaware in 2013. Our principal executive office is located at 200 Technology Square, Cambridge,&#160;MA.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a biotechnology company creating a new generation of transformative medicines based on messenger RNA (mRNA), to improve the lives of patients. mRNA medicines are designed to direct the body&#x2019;s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a broad spectrum of diseases. Our platform builds on continuous advances in basic and applied mRNA science, delivery technology, and manufacturing, providing us the capability to pursue in parallel a robust pipeline of new development candidates.&#160;We are developing vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with our strategic collaborators.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 18, 2020, we received an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the emergency use of the Moderna COVID-19 Vaccine (also referred to as mRNA-1273) in individuals 18 years of age or older. We have also received authorization for our COVID-19 vaccine from health agencies in Canada, Israel, the European Union, the United Kingdom, Switzerland, Singapore, Qatar, Taiwan, and the Philippines, and from the World Health Organization. Additional authorizations are currently under review in other countries.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of March 31, 2021, we had 24 mRNA development programs in our portfolio with 13 having entered the clinic. We have incurred significant expenses in connection with the discovery, development and commercialization of our products, and we expect to continue to incur significant expenses for the foreseeable future. We anticipate that our expenses will increase significantly in connection with the ongoing development and commercialization of our COVID-19 vaccine and ongoing activities to support our platform research, drug discovery and clinical development, including development of any new generations of boosters and vaccines against variants of SARS-CoV-2, infrastructure and Research Engine and Early Development Engine (which includes our Moderna Technology Center), digital infrastructure, creation of a portfolio of intellectual property, and administrative support. We may finance our future cash needs that exceed our operating costs through a combination of public or private equity offerings, structured financings and debt financings, government funding arrangements, strategic alliances and marketing, manufacturing, distribution and licensing arrangements. We may be unable to raise additional funds or enter into such other agreements on favorable terms, or at all.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We believe that our cash, cash equivalents, and investments as of&#160;March 31, 2021&#160;will be sufficient to enable us to fund our projected operations through at least the next 12&#160;months from the issuance of our financial statements. We are subject to numerous risks and uncertainties associated with pharmaceutical development and commercialization, and we are unable to predict the timing or amount of expenses or if we will be able to maintain profitability. If we are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce our operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <mrna:NumberOfDevelopmentProgram
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8zNC9mcmFnOjk5MzU0ODBlODIyZTQ4ODFiZjY4ZmEyZDc5NDQ5NDk1L3RleHRyZWdpb246OTkzNTQ4MGU4MjJlNDg4MWJmNjhmYTJkNzk0NDk0OTVfNzY5NjU4MTQwNDIxMw_61def3de-4dbe-4b30-bdc9-b26bdb39d68c"
      unitRef="program">24</mrna:NumberOfDevelopmentProgram>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80MC9mcmFnOmI1MTgxNTQ5ZjBlNTRkNjFiZjg3MWFjYTMwZjkzMjA0L3RleHRyZWdpb246YjUxODE1NDlmMGU1NGQ2MWJmODcxYWNhMzBmOTMyMDRfNzE1OQ_f854e289-51c0-4fa2-bc4f-497fab0fad54">Summary of Basis of Presentation and Recent Accounting Standards&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements that accompany these notes have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) for interim financial reporting, consistent in all material respects with those applied in our Annual Report on Form 10-K for the year ended December 31, 2020 (2020 Form 10-K). Any reference in these notes to applicable guidance is meant to refer to the authoritative accounting principles generally accepted in the United States as found in the Accounting Standard Codification (ASC) and Accounting Standards Update (ASU) of the Financial Accounting Standards Board (FASB). This report should be read in conjunction with the consolidated financial statements in our 2020 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the Company and its subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The significant accounting policies used in preparation of these condensed consolidated financial statements for the three months ended March 31, 2021 are consistent with those described in our 2020 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have made estimates and judgments affecting the amounts reported in our condensed consolidated financial statements and the accompanying notes. We base our estimates on historical experience and various relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods that are not readily apparent from other sources. Significant estimates relied upon in preparing these financial statements include, but are not limited to, critical accounting policies or estimates related to revenue recognition, research and development expenses, income tax provisions, stock-based compensation, leases, fair value of financial instruments, derivative financial instruments, inventory, and useful lives of property and equipment, income taxes and our valuation allowance on our deferred tax assets. The actual results that we experience may differ materially from our estimates. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive income (loss) includes net income (loss) and other comprehensive loss for the period. Other comprehensive loss consists of unrealized gains/losses and gains/losses on our investments. Total comprehensive income (loss) for all periods presented has been disclosed in the condensed consolidated statements of comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of accumulated other comprehensive income for the three months ended March 31, 2021 are as follows (in millions):&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.567%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized Loss on Available-for-Sale Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive income, balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive income, balance at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Cash &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We include our restricted cash balance in the cash, cash equivalents and restricted cash reconciliation of operating, investing and financing activities in the condensed consolidated statements of cash flows.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash, non-current &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash shown in the condensed consolidated&lt;br/&gt;&#160;&#160;&#160;&#160;statements of cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Standards Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80MC9mcmFnOmI1MTgxNTQ5ZjBlNTRkNjFiZjg3MWFjYTMwZjkzMjA0L3RleHRyZWdpb246YjUxODE1NDlmMGU1NGQ2MWJmODcxYWNhMzBmOTMyMDRfNzY5NjU4MTQxMTA5Mg_eff05612-4337-4c62-b664-545a1ef3ee59">The accompanying unaudited condensed consolidated financial statements that accompany these notes have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) for interim financial reporting, consistent in all material respects with those applied in our Annual Report on Form 10-K for the year ended December 31, 2020 (2020 Form 10-K). Any reference in these notes to applicable guidance is meant to refer to the authoritative accounting principles generally accepted in the United States as found in the Accounting Standard Codification (ASC) and Accounting Standards Update (ASU) of the Financial Accounting Standards Board (FASB). This report should be read in conjunction with the consolidated financial statements in our 2020 Form 10-K.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80MC9mcmFnOmI1MTgxNTQ5ZjBlNTRkNjFiZjg3MWFjYTMwZjkzMjA0L3RleHRyZWdpb246YjUxODE1NDlmMGU1NGQ2MWJmODcxYWNhMzBmOTMyMDRfNzY5NjU4MTQxMTA5MQ_1dc20d5a-f9fb-487a-95be-d8a21c1201a0">The consolidated financial statements include the Company and its subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80MC9mcmFnOmI1MTgxNTQ5ZjBlNTRkNjFiZjg3MWFjYTMwZjkzMjA0L3RleHRyZWdpb246YjUxODE1NDlmMGU1NGQ2MWJmODcxYWNhMzBmOTMyMDRfNzY5NjU4MTQwODU2Mw_a965e483-43ee-4e76-99f0-477d9f2d47fa">We have made estimates and judgments affecting the amounts reported in our condensed consolidated financial statements and the accompanying notes. We base our estimates on historical experience and various relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods that are not readily apparent from other sources. Significant estimates relied upon in preparing these financial statements include, but are not limited to, critical accounting policies or estimates related to revenue recognition, research and development expenses, income tax provisions, stock-based compensation, leases, fair value of financial instruments, derivative financial instruments, inventory, and useful lives of property and equipment, income taxes and our valuation allowance on our deferred tax assets. The actual results that we experience may differ materially from our estimates.</us-gaap:UseOfEstimates>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80MC9mcmFnOmI1MTgxNTQ5ZjBlNTRkNjFiZjg3MWFjYTMwZjkzMjA0L3RleHRyZWdpb246YjUxODE1NDlmMGU1NGQ2MWJmODcxYWNhMzBmOTMyMDRfNzE3OA_6d5046ab-ab0d-4721-8830-6fcb976898ec">Comprehensive income (loss) includes net income (loss) and other comprehensive loss for the period. Other comprehensive loss consists of unrealized gains/losses and gains/losses on our investments. Total comprehensive income (loss) for all periods presented has been disclosed in the condensed consolidated statements of comprehensive income (loss).</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80MC9mcmFnOmI1MTgxNTQ5ZjBlNTRkNjFiZjg3MWFjYTMwZjkzMjA0L3RleHRyZWdpb246YjUxODE1NDlmMGU1NGQ2MWJmODcxYWNhMzBmOTMyMDRfNzE3OQ_062e175b-93f2-40c6-8617-6531bc85c251">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of accumulated other comprehensive income for the three months ended March 31, 2021 are as follows (in millions):&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.567%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized Loss on Available-for-Sale Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive income, balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive income, balance at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquity
      contextRef="ib0bb072a6a064b47a2581435e9123a1f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80MC9mcmFnOmI1MTgxNTQ5ZjBlNTRkNjFiZjg3MWFjYTMwZjkzMjA0L3RhYmxlOjU4MGI4YzNiZTVjODQ0NmJiMjUwZTM4N2FhMjU0M2I4L3RhYmxlcmFuZ2U6NTgwYjhjM2JlNWM4NDQ2YmIyNTBlMzg3YWEyNTQzYjhfMS0xLTEtMS0w_bf705d2a-616b-4987-9e98-25edea419244"
      unitRef="usd">3000000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ib1779a3029e943e597b2535a551359a3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80MC9mcmFnOmI1MTgxNTQ5ZjBlNTRkNjFiZjg3MWFjYTMwZjkzMjA0L3RhYmxlOjU4MGI4YzNiZTVjODQ0NmJiMjUwZTM4N2FhMjU0M2I4L3RhYmxlcmFuZ2U6NTgwYjhjM2JlNWM4NDQ2YmIyNTBlMzg3YWEyNTQzYjhfMi0xLTEtMS0w_00664ee2-4956-479e-a5f5-6106fbb02678"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity
      contextRef="i08c08b2af4044913baf379746ada2802_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80MC9mcmFnOmI1MTgxNTQ5ZjBlNTRkNjFiZjg3MWFjYTMwZjkzMjA0L3RhYmxlOjU4MGI4YzNiZTVjODQ0NmJiMjUwZTM4N2FhMjU0M2I4L3RhYmxlcmFuZ2U6NTgwYjhjM2JlNWM4NDQ2YmIyNTBlMzg3YWEyNTQzYjhfMy0xLTEtMS0w_03d02204-07e9-4a79-beb2-0b5757a16445"
      unitRef="usd">1000000</us-gaap:StockholdersEquity>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80MC9mcmFnOmI1MTgxNTQ5ZjBlNTRkNjFiZjg3MWFjYTMwZjkzMjA0L3RleHRyZWdpb246YjUxODE1NDlmMGU1NGQ2MWJmODcxYWNhMzBmOTMyMDRfNzE2Nw_b1676ed8-41d6-4384-8921-0efc54c812c2">We include our restricted cash balance in the cash, cash equivalents and restricted cash reconciliation of operating, investing and financing activities in the condensed consolidated statements of cash flows.</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80MC9mcmFnOmI1MTgxNTQ5ZjBlNTRkNjFiZjg3MWFjYTMwZjkzMjA0L3RleHRyZWdpb246YjUxODE1NDlmMGU1NGQ2MWJmODcxYWNhMzBmOTMyMDRfNzE2Mg_f469556b-437a-4fc7-80b0-1b68cae8b81b">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash, non-current &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash shown in the condensed consolidated&lt;br/&gt;&#160;&#160;&#160;&#160;statements of cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80MC9mcmFnOmI1MTgxNTQ5ZjBlNTRkNjFiZjg3MWFjYTMwZjkzMjA0L3RleHRyZWdpb246YjUxODE1NDlmMGU1NGQ2MWJmODcxYWNhMzBmOTMyMDRfNzE3Nw_67e21b4b-9c86-4e24-b3d1-8ca52e335717">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash, non-current &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash shown in the condensed consolidated&lt;br/&gt;&#160;&#160;&#160;&#160;statements of cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80MC9mcmFnOmI1MTgxNTQ5ZjBlNTRkNjFiZjg3MWFjYTMwZjkzMjA0L3RhYmxlOjc3NzNlZDJlYTRmNjQxY2U4YTJkN2RlNGMzZWM3OTZkL3RhYmxlcmFuZ2U6Nzc3M2VkMmVhNGY2NDFjZThhMmQ3ZGU0YzNlYzc5NmRfMi0yLTEtMS0w_20b290a1-0993-4eb4-b7d3-4aa23b5effc5"
      unitRef="usd">5442000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iaa5a33ce37614698a3418806ab20f9b2_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80MC9mcmFnOmI1MTgxNTQ5ZjBlNTRkNjFiZjg3MWFjYTMwZjkzMjA0L3RhYmxlOjc3NzNlZDJlYTRmNjQxY2U4YTJkN2RlNGMzZWM3OTZkL3RhYmxlcmFuZ2U6Nzc3M2VkMmVhNGY2NDFjZThhMmQ3ZGU0YzNlYzc5NmRfMi00LTEtMS0w_1e336229-0fb6-4282-8d4d-19f081fb1af1"
      unitRef="usd">392000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80MC9mcmFnOmI1MTgxNTQ5ZjBlNTRkNjFiZjg3MWFjYTMwZjkzMjA0L3RhYmxlOjc3NzNlZDJlYTRmNjQxY2U4YTJkN2RlNGMzZWM3OTZkL3RhYmxlcmFuZ2U6Nzc3M2VkMmVhNGY2NDFjZThhMmQ3ZGU0YzNlYzc5NmRfMy0yLTEtMS04MDk4_20770850-c25b-4c6b-b05d-a22d64d4bf52"
      unitRef="usd">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="iaa5a33ce37614698a3418806ab20f9b2_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80MC9mcmFnOmI1MTgxNTQ5ZjBlNTRkNjFiZjg3MWFjYTMwZjkzMjA0L3RhYmxlOjc3NzNlZDJlYTRmNjQxY2U4YTJkN2RlNGMzZWM3OTZkL3RhYmxlcmFuZ2U6Nzc3M2VkMmVhNGY2NDFjZThhMmQ3ZGU0YzNlYzc5NmRfMy00LTEtMS04MDk4_e2129ba2-fa90-4aa6-9a47-73c6a973cc34"
      unitRef="usd">1000000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80MC9mcmFnOmI1MTgxNTQ5ZjBlNTRkNjFiZjg3MWFjYTMwZjkzMjA0L3RhYmxlOjc3NzNlZDJlYTRmNjQxY2U4YTJkN2RlNGMzZWM3OTZkL3RhYmxlcmFuZ2U6Nzc3M2VkMmVhNGY2NDFjZThhMmQ3ZGU0YzNlYzc5NmRfNC0yLTEtMS0w_20978be1-eab4-47e1-a561-78bf69ec49e2"
      unitRef="usd">11000000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="iaa5a33ce37614698a3418806ab20f9b2_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80MC9mcmFnOmI1MTgxNTQ5ZjBlNTRkNjFiZjg3MWFjYTMwZjkzMjA0L3RhYmxlOjc3NzNlZDJlYTRmNjQxY2U4YTJkN2RlNGMzZWM3OTZkL3RhYmxlcmFuZ2U6Nzc3M2VkMmVhNGY2NDFjZThhMmQ3ZGU0YzNlYzc5NmRfNC00LTEtMS0w_9830adb4-cb84-42a0-ba8f-0b69cf46ac4b"
      unitRef="usd">11000000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80MC9mcmFnOmI1MTgxNTQ5ZjBlNTRkNjFiZjg3MWFjYTMwZjkzMjA0L3RhYmxlOjc3NzNlZDJlYTRmNjQxY2U4YTJkN2RlNGMzZWM3OTZkL3RhYmxlcmFuZ2U6Nzc3M2VkMmVhNGY2NDFjZThhMmQ3ZGU0YzNlYzc5NmRfNS0yLTEtMS0w_68f99750-0889-4e7f-bd99-bbf99df85e8a"
      unitRef="usd">5453000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iaa5a33ce37614698a3418806ab20f9b2_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80MC9mcmFnOmI1MTgxNTQ5ZjBlNTRkNjFiZjg3MWFjYTMwZjkzMjA0L3RhYmxlOjc3NzNlZDJlYTRmNjQxY2U4YTJkN2RlNGMzZWM3OTZkL3RhYmxlcmFuZ2U6Nzc3M2VkMmVhNGY2NDFjZThhMmQ3ZGU0YzNlYzc5NmRfNS00LTEtMS0w_fa0c32f4-e3b2-4a18-b213-4900e0de5932"
      unitRef="usd">404000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80MC9mcmFnOmI1MTgxNTQ5ZjBlNTRkNjFiZjg3MWFjYTMwZjkzMjA0L3RleHRyZWdpb246YjUxODE1NDlmMGU1NGQ2MWJmODcxYWNhMzBmOTMyMDRfNzE1OA_8fd23fd0-57de-4692-98a5-0c62d1ce3c74">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Standards Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81Mi9mcmFnOjI3MjY2M2FhYjhkZDQwMmU5Y2Q5OTIyN2EzNDFhOWE0L3RleHRyZWdpb246MjcyNjYzYWFiOGRkNDAyZTljZDk5MjI3YTM0MWE5YTRfNzY5NjU4MTQxMDU0Mw_4f3a27b8-0348-4918-b691-465264af0599">Product Sales&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, we began selling our COVID-19 vaccine to the U.S. Government and international governments. Under the supply agreements with these governments, we received or billed for upfront deposits for our future vaccine supply, which are initially recorded as deferred revenue. We recognize revenue based on the fixed price per dose when control of the product has transferred and customer acceptance has occurred as applicable, unless such acceptance provisions are deemed perfunctory. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product sales by customer geographic location was as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of world&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no product sales for the three months ended March 31, 2020. As of March 31, 2021, we had one commercial product authorized for use, our COVID-19 vaccine. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2021 and December 31, 2020, we had deferred revenue of $7.5&#160;billion and $3.8&#160;billion, respectively, related to customer deposits, classified as current deferred revenue in our consolidated balance sheet. Timing of product manufacturing, delivery and receipt of marketing approval will determine the period in which revenue is recognized.&lt;/span&gt;&lt;/div&gt;Grant Revenue&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, we entered into an agreement with the Defense Advanced Research Projects Agency (DARPA) for an award of up to $56&#160;million to fund development of a mobile manufacturing prototype leveraging our existing manufacturing technology that is capable of rapidly producing vaccines and therapeutics. As of March 31, 2021, the committed funding, net of revenue earned was $3&#160;million, with an additional $51&#160;million available if DARPA exercises additional contract options.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2020, we entered into an agreement with the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), for an award of up to $483&#160;million to accelerate development of mRNA-1273, our vaccine candidate against the novel coronavirus. In July 2020, we amended our agreement with BARDA to provide for an additional commitment of up to $472&#160;million to support late-stage clinical development of mRNA-1273, including the execution of a 30,000 participant Phase 3 study in the U.S. We further amended the agreement in March 2021 to provide for an additional commitment of $63&#160;million to further support late-stage clinical development, including Phase 2/3 mRNA-1273 pediatric studies. As of March 31, 2021, the maximum award from BARDA, inclusive of the March 2021 amendment, was approximately $1.0&#160;billion. Under the terms of the agreement, BARDA will fund the advancement of mRNA-1273 to FDA licensure. All contract options have been exercised. As of March 31, 2021, the remaining available funding net of revenue earned was $317&#160;million. Subsequent to the end of the quarter, on April 18, 2021, we entered into a further amendment to the BARDA agreement, increasing the amount of potential reimbursements by $236&#160;million in connection with costs associated with the Phase 3 clinical trials for mRNA-1273 and pharmacovigilance efforts. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2016, we received an award of up to $126&#160;million from BARDA, to help fund our Zika vaccine program. Three of the four contract options have been exercised. As of March 31, 2021, the remaining available funding net of revenue earned was $69&#160;million, with an additional $8&#160;million available if the final contract option is exercised.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2016, we entered a global health project framework agreement with the Bill and Melinda Gates Foundation (Gates Foundation) to advance mRNA-based development projects for various infectious diseases, including human immunodeficiency virus (HIV). As of March 31, 2021, the available funding net of revenue earned was $11&#160;million, with up to an additional $80&#160;million available if additional follow-on projects are approved. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes grant revenue as of and for the period presented (in millions):&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.511%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;BARDA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other grant revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total grant revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81Mi9mcmFnOjI3MjY2M2FhYjhkZDQwMmU5Y2Q5OTIyN2EzNDFhOWE0L3RleHRyZWdpb246MjcyNjYzYWFiOGRkNDAyZTljZDk5MjI3YTM0MWE5YTRfNzY5NjU4MTQxMDU0NA_59203da8-b1e5-44e5-8d49-f3871dec8697">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product sales by customer geographic location was as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of world&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:Revenues
      contextRef="i6d7a2752ca8b473598e5f43e5290268c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81Mi9mcmFnOjI3MjY2M2FhYjhkZDQwMmU5Y2Q5OTIyN2EzNDFhOWE0L3RhYmxlOmQyNmY2YThiZDNlMjQxYTViYzIzMGRhZmMwZjgwOTdhL3RhYmxlcmFuZ2U6ZDI2ZjZhOGJkM2UyNDFhNWJjMjMwZGFmYzBmODA5N2FfMS0yLTEtMS0zMzIy_5d862327-dca7-4479-a88d-18f31d2499b1"
      unitRef="usd">1358000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i015500c719c5494988852885b84ddc22_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81Mi9mcmFnOjI3MjY2M2FhYjhkZDQwMmU5Y2Q5OTIyN2EzNDFhOWE0L3RhYmxlOmQyNmY2YThiZDNlMjQxYTViYzIzMGRhZmMwZjgwOTdhL3RhYmxlcmFuZ2U6ZDI2ZjZhOGJkM2UyNDFhNWJjMjMwZGFmYzBmODA5N2FfMi0yLTEtMS0zMzIy_4ef4d35e-bfcc-4580-ba23-cb733b8b7460"
      unitRef="usd">375000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i90cf26aad24349bfa441914ac3d706fb_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81Mi9mcmFnOjI3MjY2M2FhYjhkZDQwMmU5Y2Q5OTIyN2EzNDFhOWE0L3RhYmxlOmQyNmY2YThiZDNlMjQxYTViYzIzMGRhZmMwZjgwOTdhL3RhYmxlcmFuZ2U6ZDI2ZjZhOGJkM2UyNDFhNWJjMjMwZGFmYzBmODA5N2FfMy0yLTEtMS0zMzIy_e91a551c-3a48-4847-bcd6-82927085b556"
      unitRef="usd">1733000000</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i615a67f1a6c2480c89cbe28e804d3b01_I20210331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81Mi9mcmFnOjI3MjY2M2FhYjhkZDQwMmU5Y2Q5OTIyN2EzNDFhOWE0L3RleHRyZWdpb246MjcyNjYzYWFiOGRkNDAyZTljZDk5MjI3YTM0MWE5YTRfNzY5NjU4MTQxMDYxMg_6b5e7dd3-f7f0-458e-81b8-1481f1e2f67c"
      unitRef="usd">7500000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i0238e09dbf1a48c999216873131aac3a_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81Mi9mcmFnOjI3MjY2M2FhYjhkZDQwMmU5Y2Q5OTIyN2EzNDFhOWE0L3RleHRyZWdpb246MjcyNjYzYWFiOGRkNDAyZTljZDk5MjI3YTM0MWE5YTRfNzY5NjU4MTQxMDU0Ng_28370291-0ea4-4453-9364-4e79ea4a2a32"
      unitRef="usd">3800000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <mrna:RevenueFromGrantsMaximumAward
      contextRef="ibb5c5d2d047b4d979b9497e8b26286bd_D20200901-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80My9mcmFnOjY3ZDI2MDQ1NTM3YjRiMjA5YjI0OTc0MTJlYzg2OTU1L3RleHRyZWdpb246NjdkMjYwNDU1MzdiNGIyMDliMjQ5NzQxMmVjODY5NTVfMTUy_0ebeacc0-7f95-4aed-84bf-a240ce388f8b"
      unitRef="usd">56000000</mrna:RevenueFromGrantsMaximumAward>
    <mrna:RevenueFromGrantsCurrentFundingCapacity
      contextRef="ib54c28109e8b4df6bd548f059a69eaa7_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80My9mcmFnOjY3ZDI2MDQ1NTM3YjRiMjA5YjI0OTc0MTJlYzg2OTU1L3RleHRyZWdpb246NjdkMjYwNDU1MzdiNGIyMDliMjQ5NzQxMmVjODY5NTVfMzY1_c5fab6c1-c07a-4148-8647-068f23331bf4"
      unitRef="usd">3000000</mrna:RevenueFromGrantsCurrentFundingCapacity>
    <mrna:RevenueFromGrantsRemainingFundingCapacity
      contextRef="ib54c28109e8b4df6bd548f059a69eaa7_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80My9mcmFnOjY3ZDI2MDQ1NTM3YjRiMjA5YjI0OTc0MTJlYzg2OTU1L3RleHRyZWdpb246NjdkMjYwNDU1MzdiNGIyMDliMjQ5NzQxMmVjODY5NTVfMzg4_c73d4fe1-a3fa-4852-9c60-af80f1b3153e"
      unitRef="usd">51000000</mrna:RevenueFromGrantsRemainingFundingCapacity>
    <mrna:RevenueFromGrantsMaximumAward
      contextRef="i7a973ce00bdc4a798407694abf5f73a8_D20200401-20200430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80My9mcmFnOjY3ZDI2MDQ1NTM3YjRiMjA5YjI0OTc0MTJlYzg2OTU1L3RleHRyZWdpb246NjdkMjYwNDU1MzdiNGIyMDliMjQ5NzQxMmVjODY5NTVfNzQx_85c61a5c-a153-403a-916c-fc103506bfc6"
      unitRef="usd">483000000</mrna:RevenueFromGrantsMaximumAward>
    <us-gaap:OtherCommitment
      contextRef="ic23af7a56e2749a0b4290de702518aa1_I20200731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80My9mcmFnOjY3ZDI2MDQ1NTM3YjRiMjA5YjI0OTc0MTJlYzg2OTU1L3RleHRyZWdpb246NjdkMjYwNDU1MzdiNGIyMDliMjQ5NzQxMmVjODY5NTVfOTM2_6b5fc3be-06c3-4783-a36c-33749806b5ed"
      unitRef="usd">472000000</us-gaap:OtherCommitment>
    <us-gaap:OtherCommitment
      contextRef="i4f9df22e0ed44daba83573576518c077_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80My9mcmFnOjY3ZDI2MDQ1NTM3YjRiMjA5YjI0OTc0MTJlYzg2OTU1L3RleHRyZWdpb246NjdkMjYwNDU1MzdiNGIyMDliMjQ5NzQxMmVjODY5NTVfNzY5NjU4MTQwMDIwNg_b950d7fc-b75b-456b-8314-75a5f9a66936"
      unitRef="usd">63000000</us-gaap:OtherCommitment>
    <mrna:RevenueFromGrantsMaximumAward
      contextRef="i24305ac457e24ee79d1f0f5f58f89459_D20210101-20210331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80My9mcmFnOjY3ZDI2MDQ1NTM3YjRiMjA5YjI0OTc0MTJlYzg2OTU1L3RleHRyZWdpb246NjdkMjYwNDU1MzdiNGIyMDliMjQ5NzQxMmVjODY5NTVfMTEzNA_2b7a71fe-8f9e-4b5e-bbde-7423cac1662f"
      unitRef="usd">1000000000.0</mrna:RevenueFromGrantsMaximumAward>
    <mrna:RevenueFromGrantsCurrentFundingCapacity
      contextRef="i4f9df22e0ed44daba83573576518c077_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80My9mcmFnOjY3ZDI2MDQ1NTM3YjRiMjA5YjI0OTc0MTJlYzg2OTU1L3RleHRyZWdpb246NjdkMjYwNDU1MzdiNGIyMDliMjQ5NzQxMmVjODY5NTVfMTM1MA_b6ffc9e6-c071-47ac-9c9b-d5b58c16ef2b"
      unitRef="usd">317000000</mrna:RevenueFromGrantsCurrentFundingCapacity>
    <mrna:RevenueFromGrantsPotentialReimbursement
      contextRef="i1d9fd4412ca74750b6b14d4722981e10_D20210418-20210418"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80My9mcmFnOjY3ZDI2MDQ1NTM3YjRiMjA5YjI0OTc0MTJlYzg2OTU1L3RleHRyZWdpb246NjdkMjYwNDU1MzdiNGIyMDliMjQ5NzQxMmVjODY5NTVfNzY5NjU4MTQwMDgzMQ_f5c7f0d5-2950-4956-9f2d-acae9a61a2c9"
      unitRef="usd">236000000</mrna:RevenueFromGrantsPotentialReimbursement>
    <mrna:RevenueFromGrantsMaximumAward
      contextRef="ide0d50c05a0f41209d23a6cda03d4b84_D20160901-20160930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80My9mcmFnOjY3ZDI2MDQ1NTM3YjRiMjA5YjI0OTc0MTJlYzg2OTU1L3RleHRyZWdpb246NjdkMjYwNDU1MzdiNGIyMDliMjQ5NzQxMmVjODY5NTVfMTQwNA_6e5ba698-a779-455b-a3a2-ff72389a198e"
      unitRef="usd">126000000</mrna:RevenueFromGrantsMaximumAward>
    <mrna:RevenueFromGrantsNumberOfContractOptions
      contextRef="if411e69e7ac54f6ea28f6658a5d6dac8_I20160930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80My9mcmFnOjY3ZDI2MDQ1NTM3YjRiMjA5YjI0OTc0MTJlYzg2OTU1L3RleHRyZWdpb246NjdkMjYwNDU1MzdiNGIyMDliMjQ5NzQxMmVjODY5NTVfMTQ1OA_30f897f5-0f0f-493f-b704-827ff963b5a5"
      unitRef="option">3</mrna:RevenueFromGrantsNumberOfContractOptions>
    <mrna:RevenueFromGrantsNumberOfContractOptionsExercised
      contextRef="if411e69e7ac54f6ea28f6658a5d6dac8_I20160930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80My9mcmFnOjY3ZDI2MDQ1NTM3YjRiMjA5YjI0OTc0MTJlYzg2OTU1L3RleHRyZWdpb246NjdkMjYwNDU1MzdiNGIyMDliMjQ5NzQxMmVjODY5NTVfMTQ2OA_3d5c88db-0b89-46f3-a9ed-32084cfef230"
      unitRef="option">4</mrna:RevenueFromGrantsNumberOfContractOptionsExercised>
    <mrna:RevenueFromGrantsCurrentFundingCapacity
      contextRef="i89f03a0decbd475591590f9d2c6d5dec_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80My9mcmFnOjY3ZDI2MDQ1NTM3YjRiMjA5YjI0OTc0MTJlYzg2OTU1L3RleHRyZWdpb246NjdkMjYwNDU1MzdiNGIyMDliMjQ5NzQxMmVjODY5NTVfMTU4Mg_e3e73a41-60f2-4dda-84c4-c7442cd5d208"
      unitRef="usd">69000000</mrna:RevenueFromGrantsCurrentFundingCapacity>
    <mrna:RevenueFromGrantsRemainingFundingCapacity
      contextRef="i89f03a0decbd475591590f9d2c6d5dec_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80My9mcmFnOjY3ZDI2MDQ1NTM3YjRiMjA5YjI0OTc0MTJlYzg2OTU1L3RleHRyZWdpb246NjdkMjYwNDU1MzdiNGIyMDliMjQ5NzQxMmVjODY5NTVfMTYwNQ_5f68101d-f15c-42ad-ad53-15059269d243"
      unitRef="usd">8000000</mrna:RevenueFromGrantsRemainingFundingCapacity>
    <mrna:RevenueFromGrantsRemainingFundingCapacity
      contextRef="i53791cfc661a48e88b2bc8d3c8c541f7_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80My9mcmFnOjY3ZDI2MDQ1NTM3YjRiMjA5YjI0OTc0MTJlYzg2OTU1L3RleHRyZWdpb246NjdkMjYwNDU1MzdiNGIyMDliMjQ5NzQxMmVjODY5NTVfMTk0NQ_bf0151b5-49f4-42bb-b9cd-d52d83db498f"
      unitRef="usd">11000000</mrna:RevenueFromGrantsRemainingFundingCapacity>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i53791cfc661a48e88b2bc8d3c8c541f7_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80My9mcmFnOjY3ZDI2MDQ1NTM3YjRiMjA5YjI0OTc0MTJlYzg2OTU1L3RleHRyZWdpb246NjdkMjYwNDU1MzdiNGIyMDliMjQ5NzQxMmVjODY5NTVfMTk3NA_e90d5836-8da5-443d-adb2-875d9791001a"
      unitRef="usd">80000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80My9mcmFnOjY3ZDI2MDQ1NTM3YjRiMjA5YjI0OTc0MTJlYzg2OTU1L3RleHRyZWdpb246NjdkMjYwNDU1MzdiNGIyMDliMjQ5NzQxMmVjODY5NTVfMjE3MA_19be9836-725e-4711-b8b3-2866f88f8c56">The following table summarizes grant revenue as of and for the period presented (in millions):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.511%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;BARDA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other grant revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total grant revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our total consolidated revenue from our strategic collaborators for the periods presented (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.511%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Collaboration Revenue by Strategic Collaborator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AstraZeneca&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Merck&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vertex&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="ib9e09957e07f4e779b011ddea7dea3cb_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80My9mcmFnOjY3ZDI2MDQ1NTM3YjRiMjA5YjI0OTc0MTJlYzg2OTU1L3RhYmxlOjI1OGUzMTQ5NjNhMjRhMmQ5NzZjZWFlYjc1MDc3NDlmL3RhYmxlcmFuZ2U6MjU4ZTMxNDk2M2EyNGEyZDk3NmNlYWViNzUwNzc0OWZfMi01LTEtMS0w_a791cd69-c965-4c85-936e-ef965cb3b8c6"
      unitRef="usd">192000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7e13ec3698064dd7bac04dab36528b56_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80My9mcmFnOjY3ZDI2MDQ1NTM3YjRiMjA5YjI0OTc0MTJlYzg2OTU1L3RhYmxlOjI1OGUzMTQ5NjNhMjRhMmQ5NzZjZWFlYjc1MDc3NDlmL3RhYmxlcmFuZ2U6MjU4ZTMxNDk2M2EyNGEyZDk3NmNlYWViNzUwNzc0OWZfMi03LTEtMS0w_688c79c4-954a-4c77-9cd9-0a369a677d8d"
      unitRef="usd">3000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5fbd7587ea9a4f81bfca9dfda7f7c4d1_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80My9mcmFnOjY3ZDI2MDQ1NTM3YjRiMjA5YjI0OTc0MTJlYzg2OTU1L3RhYmxlOjI1OGUzMTQ5NjNhMjRhMmQ5NzZjZWFlYjc1MDc3NDlmL3RhYmxlcmFuZ2U6MjU4ZTMxNDk2M2EyNGEyZDk3NmNlYWViNzUwNzc0OWZfMy01LTEtMS0w_f4449efc-e70c-453d-9d97-58f6adc36284"
      unitRef="usd">2000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id0c6277e6e0841bbafa567ecc4fe413b_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80My9mcmFnOjY3ZDI2MDQ1NTM3YjRiMjA5YjI0OTc0MTJlYzg2OTU1L3RhYmxlOjI1OGUzMTQ5NjNhMjRhMmQ5NzZjZWFlYjc1MDc3NDlmL3RhYmxlcmFuZ2U6MjU4ZTMxNDk2M2EyNGEyZDk3NmNlYWViNzUwNzc0OWZfMy03LTEtMS0w_3e3d842c-0b8e-40ff-b789-d3cebb6f7c0b"
      unitRef="usd">1000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i12127d667a294d78b6d78f889c39cd18_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80My9mcmFnOjY3ZDI2MDQ1NTM3YjRiMjA5YjI0OTc0MTJlYzg2OTU1L3RhYmxlOjI1OGUzMTQ5NjNhMjRhMmQ5NzZjZWFlYjc1MDc3NDlmL3RhYmxlcmFuZ2U6MjU4ZTMxNDk2M2EyNGEyZDk3NmNlYWViNzUwNzc0OWZfNC01LTEtMS0w_24ce2082-dcc3-4a7e-9f79-59544f7e61f1"
      unitRef="usd">194000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i928ab86735d84580ac232ade8c6033ea_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80My9mcmFnOjY3ZDI2MDQ1NTM3YjRiMjA5YjI0OTc0MTJlYzg2OTU1L3RhYmxlOjI1OGUzMTQ5NjNhMjRhMmQ5NzZjZWFlYjc1MDc3NDlmL3RhYmxlcmFuZ2U6MjU4ZTMxNDk2M2EyNGEyZDk3NmNlYWViNzUwNzc0OWZfNC03LTEtMS0w_36376ed8-351d-4bf6-b131-21b976e31334"
      unitRef="usd">4000000</us-gaap:Revenues>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80Ni9mcmFnOmFjMTg5NmExYjZiOTQ5MTJiZWUzNGYxNmZiNzQ5NjliL3RleHRyZWdpb246YWMxODk2YTFiNmI5NDkxMmJlZTM0ZjE2ZmI3NDk2OWJfNTIyMjQ_4931087b-b3f8-4a51-9c3b-b1cf7fb5b9bb">Collaboration Agreements&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into collaboration agreements with strategic collaborators to accelerate the discovery and advancement of potential mRNA medicines across therapeutic areas. As of March 31, 2021 and December 31, 2020, we had collaboration agreements with AstraZeneca plc (AstraZeneca), Merck &amp;amp; Co., Inc (Merck), Vertex Pharmaceuticals Incorporated and Vertex Pharmaceuticals (Europe) Limited (together, Vertex), and Chiesi Farmaceutici S.P.A. (Chiesi). Please refer to our 2020 Form 10-K under the heading &#x201c;Third-Party Strategic Alliances&#x201d; and Note 5 to our consolidated financial statements for further description of each of the collaboration agreements. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our total consolidated revenue from our strategic collaborators for the periods presented (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.511%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Collaboration Revenue by Strategic Collaborator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AstraZeneca&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Merck&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vertex&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents changes in the balances of our receivables and contract liabilities related to our strategic collaboration agreements during the three months ended March 31, 2021 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.333%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;As of March 31, 2021, the aggregated amount of the transaction price allocated to performance obligations under our collaboration agreements that are unsatisfied or partially unsatisfied was $314&#160;million.</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i52aa31d81e134903a18093eb7e292280_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80Ni9mcmFnOmFjMTg5NmExYjZiOTQ5MTJiZWUzNGYxNmZiNzQ5NjliL3RhYmxlOjdiMGE1MzU2NjU5ODQyODg5ZTQ0Y2U0ZjgxNDViMTVjL3RhYmxlcmFuZ2U6N2IwYTUzNTY2NTk4NDI4ODllNDRjZTRmODE0NWIxNWNfMi01LTEtMS0w_4bafe27c-14e9-4c59-9b13-4f43b6a90203"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i086bb9318c0b4c0c8ef0461ff39d1327_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80Ni9mcmFnOmFjMTg5NmExYjZiOTQ5MTJiZWUzNGYxNmZiNzQ5NjliL3RhYmxlOjdiMGE1MzU2NjU5ODQyODg5ZTQ0Y2U0ZjgxNDViMTVjL3RhYmxlcmFuZ2U6N2IwYTUzNTY2NTk4NDI4ODllNDRjZTRmODE0NWIxNWNfMi03LTEtMS0w_7f781811-7e82-4ef5-9c2b-c5b33a346a0f"
      unitRef="usd">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id7427ffe751240d0a4ef3e3e238b47a2_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80Ni9mcmFnOmFjMTg5NmExYjZiOTQ5MTJiZWUzNGYxNmZiNzQ5NjliL3RhYmxlOjdiMGE1MzU2NjU5ODQyODg5ZTQ0Y2U0ZjgxNDViMTVjL3RhYmxlcmFuZ2U6N2IwYTUzNTY2NTk4NDI4ODllNDRjZTRmODE0NWIxNWNfMy01LTEtMS0w_f31cbce0-95b0-4de9-9e53-09803021e580"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c7a5f91086643518f876c3b89b411ae_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80Ni9mcmFnOmFjMTg5NmExYjZiOTQ5MTJiZWUzNGYxNmZiNzQ5NjliL3RhYmxlOjdiMGE1MzU2NjU5ODQyODg5ZTQ0Y2U0ZjgxNDViMTVjL3RhYmxlcmFuZ2U6N2IwYTUzNTY2NTk4NDI4ODllNDRjZTRmODE0NWIxNWNfMy03LTEtMS0w_d94596ab-0674-4ffc-8dfb-32ede7b592c9"
      unitRef="usd">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4fb6b67fc6764af4b4bf084bb09b748b_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80Ni9mcmFnOmFjMTg5NmExYjZiOTQ5MTJiZWUzNGYxNmZiNzQ5NjliL3RhYmxlOjdiMGE1MzU2NjU5ODQyODg5ZTQ0Y2U0ZjgxNDViMTVjL3RhYmxlcmFuZ2U6N2IwYTUzNTY2NTk4NDI4ODllNDRjZTRmODE0NWIxNWNfNC01LTEtMS0w_a6c2b325-f34d-49bc-88ae-57a9461bfb75"
      unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id0c4ba70e8f6479882eff1b6b52f2792_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80Ni9mcmFnOmFjMTg5NmExYjZiOTQ5MTJiZWUzNGYxNmZiNzQ5NjliL3RhYmxlOjdiMGE1MzU2NjU5ODQyODg5ZTQ0Y2U0ZjgxNDViMTVjL3RhYmxlcmFuZ2U6N2IwYTUzNTY2NTk4NDI4ODllNDRjZTRmODE0NWIxNWNfNC03LTEtMS0w_0eff8956-2a74-4e62-be43-9beaa386fe2f"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1a3a24c98e934216b6325e57f46e961a_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80Ni9mcmFnOmFjMTg5NmExYjZiOTQ5MTJiZWUzNGYxNmZiNzQ5NjliL3RhYmxlOjdiMGE1MzU2NjU5ODQyODg5ZTQ0Y2U0ZjgxNDViMTVjL3RhYmxlcmFuZ2U6N2IwYTUzNTY2NTk4NDI4ODllNDRjZTRmODE0NWIxNWNfNS01LTEtMS0w_22a92c0d-3e9d-492e-9509-543d8049faa0"
      unitRef="usd">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib62acba5ff5c46149175a78722d4f5d3_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80Ni9mcmFnOmFjMTg5NmExYjZiOTQ5MTJiZWUzNGYxNmZiNzQ5NjliL3RhYmxlOjdiMGE1MzU2NjU5ODQyODg5ZTQ0Y2U0ZjgxNDViMTVjL3RhYmxlcmFuZ2U6N2IwYTUzNTY2NTk4NDI4ODllNDRjZTRmODE0NWIxNWNfNS03LTEtMS0w_3123a3b1-2d8e-4e88-999a-79bca51601ee"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5d71f6c708c04cfd9aa4a5147b897eae_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80Ni9mcmFnOmFjMTg5NmExYjZiOTQ5MTJiZWUzNGYxNmZiNzQ5NjliL3RhYmxlOjdiMGE1MzU2NjU5ODQyODg5ZTQ0Y2U0ZjgxNDViMTVjL3RhYmxlcmFuZ2U6N2IwYTUzNTY2NTk4NDI4ODllNDRjZTRmODE0NWIxNWNfNi01LTEtMS0w_5802dd9e-11ba-47cd-9f32-07d30d27855b"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if9d15e5fbe824ba297aa8586391ba7bc_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80Ni9mcmFnOmFjMTg5NmExYjZiOTQ5MTJiZWUzNGYxNmZiNzQ5NjliL3RhYmxlOjdiMGE1MzU2NjU5ODQyODg5ZTQ0Y2U0ZjgxNDViMTVjL3RhYmxlcmFuZ2U6N2IwYTUzNTY2NTk4NDI4ODllNDRjZTRmODE0NWIxNWNfNi03LTEtMS0w_6220b52c-2b01-4e5c-b7b7-ff1585f2a0f6"
      unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80Ni9mcmFnOmFjMTg5NmExYjZiOTQ5MTJiZWUzNGYxNmZiNzQ5NjliL3RleHRyZWdpb246YWMxODk2YTFiNmI5NDkxMmJlZTM0ZjE2ZmI3NDk2OWJfNTIyMDU_3af7e625-2969-43cc-b36c-aa7bba2eb3e2">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents changes in the balances of our receivables and contract liabilities related to our strategic collaboration agreements during the three months ended March 31, 2021 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.333%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activities in deferred revenue for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the three months ended&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; March 31, 2021 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.792%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(796)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Grant revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(808)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i0424eee07b4f47f18f3baa3664b5c50f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80Ni9mcmFnOmFjMTg5NmExYjZiOTQ5MTJiZWUzNGYxNmZiNzQ5NjliL3RhYmxlOmNiMjBkZWIwYWEyODQyMzliMzE3OWUxMjBmNzc4MjlkL3RhYmxlcmFuZ2U6Y2IyMGRlYjBhYTI4NDIzOWIzMTc5ZTEyMGY3NzgyOWRfMi0yLTEtMS0w_fb0eda69-b7d7-4753-b6b0-ca4a777047db"
      unitRef="usd">6000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
      contextRef="i5d71f6c708c04cfd9aa4a5147b897eae_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80Ni9mcmFnOmFjMTg5NmExYjZiOTQ5MTJiZWUzNGYxNmZiNzQ5NjliL3RhYmxlOmNiMjBkZWIwYWEyODQyMzliMzE3OWUxMjBmNzc4MjlkL3RhYmxlcmFuZ2U6Y2IyMGRlYjBhYTI4NDIzOWIzMTc5ZTEyMGY3NzgyOWRfMi00LTEtMS0w_8f3daeb7-673c-4504-8445-321412fa5ed6"
      unitRef="usd">5000000</us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress>
    <mrna:ContractWithCustomerAssetDeductionsDuringPeriod
      contextRef="i5d71f6c708c04cfd9aa4a5147b897eae_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80Ni9mcmFnOmFjMTg5NmExYjZiOTQ5MTJiZWUzNGYxNmZiNzQ5NjliL3RhYmxlOmNiMjBkZWIwYWEyODQyMzliMzE3OWUxMjBmNzc4MjlkL3RhYmxlcmFuZ2U6Y2IyMGRlYjBhYTI4NDIzOWIzMTc5ZTEyMGY3NzgyOWRfMi02LTEtMS0w_19126233-7cd8-49bb-9164-6aaeec0f16e0"
      unitRef="usd">2000000</mrna:ContractWithCustomerAssetDeductionsDuringPeriod>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i6ab46cc577f34aa3900c0f6c8856f7f9_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80Ni9mcmFnOmFjMTg5NmExYjZiOTQ5MTJiZWUzNGYxNmZiNzQ5NjliL3RhYmxlOmNiMjBkZWIwYWEyODQyMzliMzE3OWUxMjBmNzc4MjlkL3RhYmxlcmFuZ2U6Y2IyMGRlYjBhYTI4NDIzOWIzMTc5ZTEyMGY3NzgyOWRfMi04LTEtMS0w_19cdd169-7b71-409f-9432-58f13665cdaa"
      unitRef="usd">9000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i0424eee07b4f47f18f3baa3664b5c50f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80Ni9mcmFnOmFjMTg5NmExYjZiOTQ5MTJiZWUzNGYxNmZiNzQ5NjliL3RhYmxlOmNiMjBkZWIwYWEyODQyMzliMzE3OWUxMjBmNzc4MjlkL3RhYmxlcmFuZ2U6Y2IyMGRlYjBhYTI4NDIzOWIzMTc5ZTEyMGY3NzgyOWRfNC0yLTEtMS0w_aa167204-e3c4-4db2-a91c-acd3ae7715d2"
      unitRef="usd">240000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
      contextRef="i5d71f6c708c04cfd9aa4a5147b897eae_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80Ni9mcmFnOmFjMTg5NmExYjZiOTQ5MTJiZWUzNGYxNmZiNzQ5NjliL3RhYmxlOmNiMjBkZWIwYWEyODQyMzliMzE3OWUxMjBmNzc4MjlkL3RhYmxlcmFuZ2U6Y2IyMGRlYjBhYTI4NDIzOWIzMTc5ZTEyMGY3NzgyOWRfNC00LTEtMS0w_e9d3a523-c406-4274-a6da-a50dcf9b5ab0"
      unitRef="usd">5000000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress>
    <mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod
      contextRef="i5d71f6c708c04cfd9aa4a5147b897eae_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80Ni9mcmFnOmFjMTg5NmExYjZiOTQ5MTJiZWUzNGYxNmZiNzQ5NjliL3RhYmxlOmNiMjBkZWIwYWEyODQyMzliMzE3OWUxMjBmNzc4MjlkL3RhYmxlcmFuZ2U6Y2IyMGRlYjBhYTI4NDIzOWIzMTc5ZTEyMGY3NzgyOWRfNC02LTEtMS0w_6c9e1ef1-4003-452f-b3f3-56c814933e15"
      unitRef="usd">10000000</mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i6ab46cc577f34aa3900c0f6c8856f7f9_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80Ni9mcmFnOmFjMTg5NmExYjZiOTQ5MTJiZWUzNGYxNmZiNzQ5NjliL3RhYmxlOmNiMjBkZWIwYWEyODQyMzliMzE3OWUxMjBmNzc4MjlkL3RhYmxlcmFuZ2U6Y2IyMGRlYjBhYTI4NDIzOWIzMTc5ZTEyMGY3NzgyOWRfNC04LTEtMS0w_8d56f548-5505-4fff-a392-99417589c4eb"
      unitRef="usd">235000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i6ab46cc577f34aa3900c0f6c8856f7f9_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV80Ni9mcmFnOmFjMTg5NmExYjZiOTQ5MTJiZWUzNGYxNmZiNzQ5NjliL3RleHRyZWdpb246YWMxODk2YTFiNmI5NDkxMmJlZTM0ZjE2ZmI3NDk2OWJfMTE4Nw_5eb254bc-f56d-41bf-800f-f57e07e945c0"
      unitRef="usd">314000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RleHRyZWdpb246MjI1MzcwNmEzNTA3NDAyYWJlMzg1NWEwMDdlZTRmZjFfMjEzMg_c11e8695-973a-4184-908b-4d330bbf2057">Financial Instruments&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents and Investments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize our cash and available-for-sale securities by significant investment category at March 31, 2021 and December 31, 2020 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash and&lt;br/&gt;Cash&lt;br/&gt;Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Current&lt;br/&gt;Marketable&lt;br/&gt;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-&lt;br/&gt;Current&lt;br/&gt;Marketable&lt;br/&gt;Securities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities of U.S. government agencies and corporate entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash and&lt;br/&gt;Cash&lt;br/&gt;Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Current&lt;br/&gt;Marketable&lt;br/&gt;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-&lt;br/&gt;Current&lt;br/&gt;Marketable&lt;br/&gt;Securities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities of U.S. government agencies and corporate entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortized cost and estimated fair value of marketable securities by contractual maturity at March 31, 2021 and December 31, 2020 are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with our investment policy, we place investments in investment grade securities with high credit quality issuers, and generally limit the amount of credit exposure to any one issuer. We evaluate securities for impairment at the end of each reporting period. Impairment is evaluated considering numerous factors, and their relative significance varies depending on the situation. Factors considered include whether a decline in fair value below the amortized cost basis is due to credit-related factors or noncredit-related factors, the financial condition and near-term prospects of the issuer, and our intent and ability to hold the investment to allow for an anticipated recovery in fair value. Any impairment that is not credit related is recognized in other comprehensive loss, net of applicable taxes. A credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings. We did not recognize any impairment charges related to available-for-sale securities for the three months ended March 31, 2021 and 2020. We did not recognize any credit losses related allowance to available-for-sale securities as of March 31, 2021 and December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2021 and December 31, 2020, we did not have material gross unrealized losses. We neither intend to sell these investments, nor do we believe that we are more-likely-than-not to conclude we will have to sell them before recovery of their carrying values. We also believe that we will be able to collect both principal and interest amounts due to us at maturity.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used to value the assets and liabilities: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; or&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize our financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2021 and December 31, 2020 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value at &lt;br/&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities of U.S. government agencies and corporate entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative instruments (Note 7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative instruments (Note 7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities of U.S. government agencies and corporate entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2021 and December 31, 2020, we did not have non-financial assets or liabilities measured at fair value on a recurring basis.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RleHRyZWdpb246MjI1MzcwNmEzNTA3NDAyYWJlMzg1NWEwMDdlZTRmZjFfMjEzMw_3b52a339-5665-4783-a559-bcced929e6d7">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize our cash and available-for-sale securities by significant investment category at March 31, 2021 and December 31, 2020 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash and&lt;br/&gt;Cash&lt;br/&gt;Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Current&lt;br/&gt;Marketable&lt;br/&gt;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-&lt;br/&gt;Current&lt;br/&gt;Marketable&lt;br/&gt;Securities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities of U.S. government agencies and corporate entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash and&lt;br/&gt;Cash&lt;br/&gt;Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Current&lt;br/&gt;Marketable&lt;br/&gt;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-&lt;br/&gt;Current&lt;br/&gt;Marketable&lt;br/&gt;Securities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities of U.S. government agencies and corporate entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i356bef623f834e84a7cdb447d141ccd3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMi0yLTEtMS0w_719bfe58-9ad0-4a56-9d7a-948fbf20ceaf"
      unitRef="usd">5442000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i356bef623f834e84a7cdb447d141ccd3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMi00LTEtMS0w_f8f7d673-bda2-440b-a438-297a66ea6900"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i356bef623f834e84a7cdb447d141ccd3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMi02LTEtMS0w_922355d1-6788-4e8d-9a28-0c212a2a9f4c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i356bef623f834e84a7cdb447d141ccd3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMi04LTEtMS0w_05c792d8-544d-4963-8b78-9960e38794ee"
      unitRef="usd">5442000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i60479f4cd58141ab88eb9674b785a4a1_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMi0xMC0xLTEtMA_f47f7d2e-e620-4e6b-b2dc-6e0be9e1c8b3"
      unitRef="usd">5442000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i67533c70f1f24be1881a998a7ae2b79c_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMi0xMi0xLTEtMA_40258ed2-7546-473f-b1a6-5201e27eae8c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ica0a9efa36764e4abe9a81143990ee12_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMi0xNC0xLTEtMA_4b74cb9c-bf94-4922-b3ec-1ede22ffc20b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8a4e0ae3d99d485a9d3576fc11b24069_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfNS0yLTEtMS0w_c561313c-fcd7-4b66-948b-e6514beac806"
      unitRef="usd">413000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8a4e0ae3d99d485a9d3576fc11b24069_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfNS00LTEtMS0w_a0ea150a-3ea0-4802-adbd-06c36a0d4715"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8a4e0ae3d99d485a9d3576fc11b24069_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfNS02LTEtMS0w_99ab8275-ea8a-4e4a-83ab-917474e821b0"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8a4e0ae3d99d485a9d3576fc11b24069_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfNS04LTEtMS0w_31861944-3d9f-44dd-9525-cf0b12a4799d"
      unitRef="usd">413000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9bf1192916f64380bbdde4039cc78e4f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfNS0xMC0xLTEtMA_a57a6edf-5213-46eb-8d08-b9b86b189ff8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i48e96e4a36ca4d209bbcd48d238ae70a_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfNS0xMi0xLTEtMA_aab3ac08-cc76-43ed-9f74-73a57b971d65"
      unitRef="usd">413000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5cb1f6a641814b1c8ad2ff7b4a2b8217_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfNS0xNC0xLTEtMA_c3ba883e-8827-46fd-a6a7-5b1c5a13c473"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5b6a0be7eddd411e8225d14c0a674df3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfNi0yLTEtMS0w_2ee51331-0b7c-4be3-b45a-656966368a03"
      unitRef="usd">374000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5b6a0be7eddd411e8225d14c0a674df3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfNi00LTEtMS0w_4fef361d-ae0d-4d74-86a6-022232de1e10"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5b6a0be7eddd411e8225d14c0a674df3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfNi02LTEtMS0w_3a0220c1-41dd-439f-877c-850227dacaa9"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5b6a0be7eddd411e8225d14c0a674df3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfNi04LTEtMS0w_bae8ca9f-12d9-404c-a4bd-774454fb0f6b"
      unitRef="usd">374000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3039ce5316a84c43a0d08915dea14050_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfNi0xMC0xLTEtMA_b171d894-f917-42f4-9e62-6653eb09ee76"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i15456fe3d934468482ac959714d5a053_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfNi0xMi0xLTEtMA_eaef5432-785d-41a4-a4f7-bad0b71e6720"
      unitRef="usd">374000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifb1895e1c5bc495fbeda6e5e2a787ef6_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfNi0xNC0xLTEtMA_a04f4eb9-ebd3-4663-bc53-404c2cc5c070"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7cb95c5356684e93a35e3bf790aca2fc_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfNy0yLTEtMS0w_b78ca678-84fb-4609-8ca5-e0cf0fb6da62"
      unitRef="usd">1972000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7cb95c5356684e93a35e3bf790aca2fc_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfNy00LTEtMS0w_5c62add8-73d8-4b58-83c4-7edc764729d2"
      unitRef="usd">3000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7cb95c5356684e93a35e3bf790aca2fc_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfNy02LTEtMS0w_3ba2cf00-327f-4ad2-8444-2a2dc9453e5a"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7cb95c5356684e93a35e3bf790aca2fc_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfNy04LTEtMS0w_d70a20df-f480-4bc1-a260-a038c9f6f8cb"
      unitRef="usd">1974000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib6b7b9882f044ebba7637ec5e651772b_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfNy0xMC0xLTEtMA_047ce00a-4181-4414-8674-3cfe61b5503a"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4dfcad9b1a5a494ea2d1f97c1cec871c_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfNy0xMi0xLTEtMA_26fe14a5-9074-4c90-a6c1-b39c8703938e"
      unitRef="usd">1506000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iee5034c39f6946fd8be3fff0632e2766_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfNy0xNC0xLTEtMA_529f3135-8f39-4036-97d4-882b98df48c4"
      unitRef="usd">468000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iacbf0fb43aaa4d53bc16745f38512f25_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfOC0yLTEtMS0w_96de523c-fa9a-4c5f-a3d1-93663b6f8e50"
      unitRef="usd">8201000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iacbf0fb43aaa4d53bc16745f38512f25_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfOC00LTEtMS0w_b496dcc6-1b3b-4b67-b16a-3de6f204c803"
      unitRef="usd">3000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iacbf0fb43aaa4d53bc16745f38512f25_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfOC02LTEtMS0w_fa70c797-fa18-4f74-9833-d148da0dfd89"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iacbf0fb43aaa4d53bc16745f38512f25_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfOC04LTEtMS0w_9422c52b-a4bf-4bb1-8d5a-6987c4db70e4"
      unitRef="usd">8203000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9af72ba73c864ba9a21e07312e1cad6f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfOC0xMC0xLTEtMA_28fc8140-423d-4afa-9dfd-2495421d5412"
      unitRef="usd">5442000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0e5f6ba69b244986a5d20a064920207d_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfOC0xMi0xLTEtMA_443de362-aec7-4a63-addd-8aa717f2c1e8"
      unitRef="usd">2293000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie6c00e9c4b7c4cab9106b940030ecc8d_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfOC0xNC0xLTEtMA_5af80cd9-8a80-4b94-b781-b37e52027821"
      unitRef="usd">468000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i541125faaac24704993f4bb55ea03ffb_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTItMi0xLTEtMA_21a43db1-3542-4aba-b857-c5205cbc46f7"
      unitRef="usd">2624000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i541125faaac24704993f4bb55ea03ffb_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTItNC0xLTEtMA_0066eda1-99c4-4207-9e95-a282fe3b4b43"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i541125faaac24704993f4bb55ea03ffb_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTItNi0xLTEtMA_eda2032f-8962-40bd-8d68-a4ab791a75f1"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i541125faaac24704993f4bb55ea03ffb_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTItOC0xLTEtMA_af3145b1-9a24-4a4e-a592-3810614996da"
      unitRef="usd">2624000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i63ece81cf0b14c9d977ea0092b4cead4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTItMTAtMS0xLTA_80e26083-5322-4cc8-abfc-199af96396e2"
      unitRef="usd">2624000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i144b3354d900459db79935bb372dddac_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTItMTItMS0xLTA_e4f164a6-2747-43c2-9e09-03a304e76122"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie6806220f01c4d34bff60f27b6458a20_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTItMTQtMS0xLTA_b2665547-8f85-4064-a186-827b797a8bb9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ibc2d8b74fdcf4cf19b8d0602247a7ed5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTUtMi0xLTEtMA_de72e837-a181-4a4e-b6b0-0c32b27d375a"
      unitRef="usd">239000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibc2d8b74fdcf4cf19b8d0602247a7ed5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTUtNC0xLTEtMA_6adc0b74-9ce9-4b71-b246-9995614f6ab9"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibc2d8b74fdcf4cf19b8d0602247a7ed5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTUtNi0xLTEtMA_2b4f9e2e-e4f7-47ec-8c44-ea16a632d50f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibc2d8b74fdcf4cf19b8d0602247a7ed5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTUtOC0xLTEtMA_2feed037-cb9c-4034-9dd9-119a1eef461d"
      unitRef="usd">239000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie744a40ba7764cb6bc3cc3dc74a499fb_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTUtMTAtMS0xLTA_c0e75103-b3dc-4905-9d63-dc07cac63204"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4039aa1d6baf4797ad803a7b6190baa8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTUtMTItMS0xLTA_f8f7ff56-a0b4-441e-b692-175ed64a40cf"
      unitRef="usd">215000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia1cde362d4524f9ba6d35c5ea6b396bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTUtMTQtMS0xLTA_e98b2b50-fd9e-4352-a838-71e429f1da29"
      unitRef="usd">24000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i05d95354ca2c445db703eebb828e4323_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTYtMi0xLTEtMA_95cc576c-f3eb-4127-b6d2-7a4584bfaed4"
      unitRef="usd">492000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i05d95354ca2c445db703eebb828e4323_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTYtNC0xLTEtMA_5802d5f1-fefb-4217-9447-2a7d23826c27"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i05d95354ca2c445db703eebb828e4323_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTYtNi0xLTEtMA_b050eda4-ec5e-466b-8459-0e6f9dcbd459"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i05d95354ca2c445db703eebb828e4323_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTYtOC0xLTEtMA_acde32a5-139d-48f1-a958-3ba9a622f225"
      unitRef="usd">492000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if6465ad5ef134815a47c8f454682eb9d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTYtMTAtMS0xLTA_f8d28f94-df8f-43a5-beaa-701fa66fef10"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i64e7c6ca7fa54146be90ea4732b08c96_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTYtMTItMS0xLTA_275805db-4aa0-46fd-994f-2140943cba19"
      unitRef="usd">492000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic9f8683c12dc47549b560b34d4161e88_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTYtMTQtMS0xLTA_142e13d2-63aa-4faf-92ca-d6fc4cecf5aa"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i39670918752c482d9b5985dd34a8435a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTctMi0xLTEtMA_c72bc873-a458-4748-a1aa-81534aabbd4a"
      unitRef="usd">1888000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i39670918752c482d9b5985dd34a8435a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTctNC0xLTEtMA_e2f98e3c-09c8-42ed-a37d-f6e990243faa"
      unitRef="usd">4000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i39670918752c482d9b5985dd34a8435a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTctNi0xLTEtMA_ba9afb40-9a62-4bd5-8812-9d5bb4db8802"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i39670918752c482d9b5985dd34a8435a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTctOC0xLTEtMA_52e78132-77b7-4813-aa96-b133c7b96e9d"
      unitRef="usd">1892000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5913295f7ce94eaf82964fa6e5bebd39_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTctMTAtMS0xLTA_01e36514-095f-4036-beb7-479db70e19eb"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3a2bf1e040654bc8a5d2177086572016_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTctMTItMS0xLTA_419162eb-d966-4e53-99a5-a75551398eeb"
      unitRef="usd">1277000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i79840680ee5c42f08b5791b046d4ab3f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTctMTQtMS0xLTA_68125dd0-edac-4e6f-865f-eab1adb00e55"
      unitRef="usd">615000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="idcb2bea1b1bf4c1782b105cad231847c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTgtMi0xLTEtMA_ec5420c3-8b02-4376-a96f-1b8977da2081"
      unitRef="usd">5243000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="idcb2bea1b1bf4c1782b105cad231847c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTgtNC0xLTEtMA_d002e761-aba3-4729-8e6a-0f66d968ed3b"
      unitRef="usd">4000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="idcb2bea1b1bf4c1782b105cad231847c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTgtNi0xLTEtMA_2599f9f7-df25-47ef-b0b4-a88d084acde1"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idcb2bea1b1bf4c1782b105cad231847c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTgtOC0xLTEtMA_8246daf2-6b6d-4221-bcc3-12d4ed7726f1"
      unitRef="usd">5247000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6a3a8d7ef2ea40a88c5b84eee83292fa_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTgtMTAtMS0xLTA_f10851e8-0a8d-41e0-b46b-75a436e7aa05"
      unitRef="usd">2624000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie01d3f7d975a464884d498263f3d023f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTgtMTItMS0xLTA_4766016a-30b3-4666-be43-638eb2d428d7"
      unitRef="usd">1984000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2e628bbb40a646dfb1404d2cceaf4b58_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjJhNmVjNzMxOWViZjQ5YzJiNmZkYmExYzNhNmRkNGM1L3RhYmxlcmFuZ2U6MmE2ZWM3MzE5ZWJmNDljMmI2ZmRiYTFjM2E2ZGQ0YzVfMTgtMTQtMS0xLTA_f1006cb0-8801-473c-a739-8e0d7c1b1017"
      unitRef="usd">639000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RleHRyZWdpb246MjI1MzcwNmEzNTA3NDAyYWJlMzg1NWEwMDdlZTRmZjFfMjEzNA_07c5e9a7-a668-4170-a949-085c7e40794e">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortized cost and estimated fair value of marketable securities by contractual maturity at March 31, 2021 and December 31, 2020 are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjkyYTBlZGYzMTVhNDQ4MDI5Y2YwZjFlNDA1OWU5NTY4L3RhYmxlcmFuZ2U6OTJhMGVkZjMxNWE0NDgwMjljZjBmMWU0MDU5ZTk1NjhfMi0yLTEtMS0w_017ce37f-f893-4f09-aaea-30b97068fbfb"
      unitRef="usd">2291000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjkyYTBlZGYzMTVhNDQ4MDI5Y2YwZjFlNDA1OWU5NTY4L3RhYmxlcmFuZ2U6OTJhMGVkZjMxNWE0NDgwMjljZjBmMWU0MDU5ZTk1NjhfMi00LTEtMS0w_f3187254-76cf-48dc-852a-8ff3ff770f91"
      unitRef="usd">2293000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjkyYTBlZGYzMTVhNDQ4MDI5Y2YwZjFlNDA1OWU5NTY4L3RhYmxlcmFuZ2U6OTJhMGVkZjMxNWE0NDgwMjljZjBmMWU0MDU5ZTk1NjhfMy0yLTEtMS0w_a8c3123d-9744-4d15-a9dc-98f6f6f26f39"
      unitRef="usd">468000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjkyYTBlZGYzMTVhNDQ4MDI5Y2YwZjFlNDA1OWU5NTY4L3RhYmxlcmFuZ2U6OTJhMGVkZjMxNWE0NDgwMjljZjBmMWU0MDU5ZTk1NjhfMy00LTEtMS0w_ec911e70-9619-4ab8-80cd-832613947fd7"
      unitRef="usd">468000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjkyYTBlZGYzMTVhNDQ4MDI5Y2YwZjFlNDA1OWU5NTY4L3RhYmxlcmFuZ2U6OTJhMGVkZjMxNWE0NDgwMjljZjBmMWU0MDU5ZTk1NjhfNC0yLTEtMS0w_f590b52f-98d6-4a65-8ff1-e5edcf351aaf"
      unitRef="usd">2759000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjkyYTBlZGYzMTVhNDQ4MDI5Y2YwZjFlNDA1OWU5NTY4L3RhYmxlcmFuZ2U6OTJhMGVkZjMxNWE0NDgwMjljZjBmMWU0MDU5ZTk1NjhfNC00LTEtMS0w_1179fec8-5160-4359-8c32-da48817308ae"
      unitRef="usd">2761000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjcwOTZhYjY5N2VhMzQ4NDZiM2M5MTk5NzQ4MWZlNGYxL3RhYmxlcmFuZ2U6NzA5NmFiNjk3ZWEzNDg0NmIzYzkxOTk3NDgxZmU0ZjFfMi0yLTEtMS0zODI5_5b7bc61a-3e23-4159-84ae-83405d4eddcc"
      unitRef="usd">1981000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjcwOTZhYjY5N2VhMzQ4NDZiM2M5MTk5NzQ4MWZlNGYxL3RhYmxlcmFuZ2U6NzA5NmFiNjk3ZWEzNDg0NmIzYzkxOTk3NDgxZmU0ZjFfMi00LTEtMS0zODI5_27dbb885-4365-4e86-9f3d-fdbcb5d98313"
      unitRef="usd">1984000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjcwOTZhYjY5N2VhMzQ4NDZiM2M5MTk5NzQ4MWZlNGYxL3RhYmxlcmFuZ2U6NzA5NmFiNjk3ZWEzNDg0NmIzYzkxOTk3NDgxZmU0ZjFfMy0yLTEtMS0zODI5_72292bc9-1c2f-408a-bc56-315d70bca093"
      unitRef="usd">638000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjcwOTZhYjY5N2VhMzQ4NDZiM2M5MTk5NzQ4MWZlNGYxL3RhYmxlcmFuZ2U6NzA5NmFiNjk3ZWEzNDg0NmIzYzkxOTk3NDgxZmU0ZjFfMy00LTEtMS0zODI5_585ab18c-5f48-4296-90d4-4b6f2e229cfa"
      unitRef="usd">639000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjcwOTZhYjY5N2VhMzQ4NDZiM2M5MTk5NzQ4MWZlNGYxL3RhYmxlcmFuZ2U6NzA5NmFiNjk3ZWEzNDg0NmIzYzkxOTk3NDgxZmU0ZjFfNC0yLTEtMS02MDg5_68d98e47-960d-423c-836c-393c3c4131d5"
      unitRef="usd">2619000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjcwOTZhYjY5N2VhMzQ4NDZiM2M5MTk5NzQ4MWZlNGYxL3RhYmxlcmFuZ2U6NzA5NmFiNjk3ZWEzNDg0NmIzYzkxOTk3NDgxZmU0ZjFfNC00LTEtMS02MDkx_89b605a7-325d-41f7-8aec-ac8733c4ef36"
      unitRef="usd">2623000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RleHRyZWdpb246MjI1MzcwNmEzNTA3NDAyYWJlMzg1NWEwMDdlZTRmZjFfMzI5ODUzNDg4OTk4Nw_4e114cdb-e36b-4b11-8c84-624610858c8f"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RleHRyZWdpb246MjI1MzcwNmEzNTA3NDAyYWJlMzg1NWEwMDdlZTRmZjFfMzI5ODUzNDg4OTk4Nw_b23a0779-0d98-411b-9b4c-d04f5da2c8af"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RleHRyZWdpb246MjI1MzcwNmEzNTA3NDAyYWJlMzg1NWEwMDdlZTRmZjFfNzY5NjU4MTM5ODA5Mg_9187fcc1-c26f-4d61-aaac-f5c7dfdbe891">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize our financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2021 and December 31, 2020 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value at &lt;br/&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities of U.S. government agencies and corporate entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative instruments (Note 7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative instruments (Note 7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities of U.S. government agencies and corporate entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i123d9cb392064f7bbe194ed464f90c8f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjFhMjAxMzRkZDU5NzQ3MzA5MTY0NmM5OTYyY2EzNDBhL3RhYmxlcmFuZ2U6MWEyMDEzNGRkNTk3NDczMDkxNjQ2Yzk5NjJjYTM0MGFfMy0yLTEtMS00MDIw_e136ebc5-6962-40f6-bf6c-5bd15d89d3b0"
      unitRef="usd">537000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ieb052beac6e745e59a97634f1deb8911_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjFhMjAxMzRkZDU5NzQ3MzA5MTY0NmM5OTYyY2EzNDBhL3RhYmxlcmFuZ2U6MWEyMDEzNGRkNTk3NDczMDkxNjQ2Yzk5NjJjYTM0MGFfMy00LTEtMS00MDIw_57e06bcf-c32a-4839-9978-0bd3f296f53f"
      unitRef="usd">537000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4d49a64ca5814a3b8323c954b990c2f1_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjFhMjAxMzRkZDU5NzQ3MzA5MTY0NmM5OTYyY2EzNDBhL3RhYmxlcmFuZ2U6MWEyMDEzNGRkNTk3NDczMDkxNjQ2Yzk5NjJjYTM0MGFfMy02LTEtMS00MDIw_e319f2b0-10a9-4ca5-8258-a6a2b51f877d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0ed53e247dd44a8fbc05e34b092630a4_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjFhMjAxMzRkZDU5NzQ3MzA5MTY0NmM5OTYyY2EzNDBhL3RhYmxlcmFuZ2U6MWEyMDEzNGRkNTk3NDczMDkxNjQ2Yzk5NjJjYTM0MGFfNC0yLTEtMS00MDIw_4f1db935-7ffe-4b66-970a-bc4b07ee071b"
      unitRef="usd">413000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifd19a0d5fe7648f19bcf7eb315e47574_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjFhMjAxMzRkZDU5NzQ3MzA5MTY0NmM5OTYyY2EzNDBhL3RhYmxlcmFuZ2U6MWEyMDEzNGRkNTk3NDczMDkxNjQ2Yzk5NjJjYTM0MGFfNC00LTEtMS00MDIw_23acaf91-f8eb-4b21-94dc-41c80525ec61"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4e7a5259755b49e49d483e9c3980d884_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjFhMjAxMzRkZDU5NzQ3MzA5MTY0NmM5OTYyY2EzNDBhL3RhYmxlcmFuZ2U6MWEyMDEzNGRkNTk3NDczMDkxNjQ2Yzk5NjJjYTM0MGFfNC02LTEtMS00MDIw_e6187195-dcc4-45e3-ac89-ba2fc037a8e1"
      unitRef="usd">413000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia850cc3fdca949bdbacf65e2aa316867_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjFhMjAxMzRkZDU5NzQ3MzA5MTY0NmM5OTYyY2EzNDBhL3RhYmxlcmFuZ2U6MWEyMDEzNGRkNTk3NDczMDkxNjQ2Yzk5NjJjYTM0MGFfNS0yLTEtMS00MDIw_480318e7-b798-487f-8f14-1b7f153def89"
      unitRef="usd">374000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icbba28371a0c4ac7b6d117d940658048_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjFhMjAxMzRkZDU5NzQ3MzA5MTY0NmM5OTYyY2EzNDBhL3RhYmxlcmFuZ2U6MWEyMDEzNGRkNTk3NDczMDkxNjQ2Yzk5NjJjYTM0MGFfNS00LTEtMS00MDIw_aa099777-9b43-408f-905e-12294f295224"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5a9ecc2c2f4c4165a295dd17a5a65f57_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjFhMjAxMzRkZDU5NzQ3MzA5MTY0NmM5OTYyY2EzNDBhL3RhYmxlcmFuZ2U6MWEyMDEzNGRkNTk3NDczMDkxNjQ2Yzk5NjJjYTM0MGFfNS02LTEtMS00MDIw_e8e36547-9f0e-4a84-8c9a-d321cf516617"
      unitRef="usd">374000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1f155650a70d4eeda45d6f57b5eb94af_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjFhMjAxMzRkZDU5NzQ3MzA5MTY0NmM5OTYyY2EzNDBhL3RhYmxlcmFuZ2U6MWEyMDEzNGRkNTk3NDczMDkxNjQ2Yzk5NjJjYTM0MGFfNi0yLTEtMS00MDIw_4f0cf24f-8ed3-436a-8ec7-2ad3b4db2f36"
      unitRef="usd">1974000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8803bb198614454eb655c9107db2f3b2_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjFhMjAxMzRkZDU5NzQ3MzA5MTY0NmM5OTYyY2EzNDBhL3RhYmxlcmFuZ2U6MWEyMDEzNGRkNTk3NDczMDkxNjQ2Yzk5NjJjYTM0MGFfNi00LTEtMS00MDIw_2bd806d2-f7e1-4f84-be1e-9337814b5d6f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3bad47bc31eb4c3fa7e59c8591449292_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjFhMjAxMzRkZDU5NzQ3MzA5MTY0NmM5OTYyY2EzNDBhL3RhYmxlcmFuZ2U6MWEyMDEzNGRkNTk3NDczMDkxNjQ2Yzk5NjJjYTM0MGFfNi02LTEtMS00MDIw_1b5df990-18b6-4f89-bdca-e0aaffd96c6b"
      unitRef="usd">1974000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DerivativeAssets
      contextRef="i2c36846f9be347ffadf3fb034bb04f1c_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjFhMjAxMzRkZDU5NzQ3MzA5MTY0NmM5OTYyY2EzNDBhL3RhYmxlcmFuZ2U6MWEyMDEzNGRkNTk3NDczMDkxNjQ2Yzk5NjJjYTM0MGFfNy0yLTEtMS00MDIw_770a0520-a3d2-4492-a7ee-49fe6b6dc47a"
      unitRef="usd">1000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i6cbf1ef1e50043a6973a41f4362eca38_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjFhMjAxMzRkZDU5NzQ3MzA5MTY0NmM5OTYyY2EzNDBhL3RhYmxlcmFuZ2U6MWEyMDEzNGRkNTk3NDczMDkxNjQ2Yzk5NjJjYTM0MGFfNy00LTEtMS00MDIw_95bb58b2-70f3-46f5-90c3-2d01e86a3a69"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="id976144d8ac0470a8dfe87f5e0806e11_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjFhMjAxMzRkZDU5NzQ3MzA5MTY0NmM5OTYyY2EzNDBhL3RhYmxlcmFuZ2U6MWEyMDEzNGRkNTk3NDczMDkxNjQ2Yzk5NjJjYTM0MGFfNy02LTEtMS00MDIw_f8b81a1e-2af9-4ad9-8c9e-114aafe90553"
      unitRef="usd">1000000</us-gaap:DerivativeAssets>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2c36846f9be347ffadf3fb034bb04f1c_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjFhMjAxMzRkZDU5NzQ3MzA5MTY0NmM5OTYyY2EzNDBhL3RhYmxlcmFuZ2U6MWEyMDEzNGRkNTk3NDczMDkxNjQ2Yzk5NjJjYTM0MGFfOC0yLTEtMS02MDk1_bab71aeb-ee93-4455-9c55-a43fe8497616"
      unitRef="usd">3299000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6cbf1ef1e50043a6973a41f4362eca38_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjFhMjAxMzRkZDU5NzQ3MzA5MTY0NmM5OTYyY2EzNDBhL3RhYmxlcmFuZ2U6MWEyMDEzNGRkNTk3NDczMDkxNjQ2Yzk5NjJjYTM0MGFfOC00LTEtMS02MDk3_dc2ada62-5df2-49a0-b5b1-53bf87edb1e4"
      unitRef="usd">537000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id976144d8ac0470a8dfe87f5e0806e11_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjFhMjAxMzRkZDU5NzQ3MzA5MTY0NmM5OTYyY2EzNDBhL3RhYmxlcmFuZ2U6MWEyMDEzNGRkNTk3NDczMDkxNjQ2Yzk5NjJjYTM0MGFfOC02LTEtMS02MDk5_75cefc8c-56bd-4eb7-97fc-82b9b7a9be47"
      unitRef="usd">2762000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="i2c36846f9be347ffadf3fb034bb04f1c_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjFhMjAxMzRkZDU5NzQ3MzA5MTY0NmM5OTYyY2EzNDBhL3RhYmxlcmFuZ2U6MWEyMDEzNGRkNTk3NDczMDkxNjQ2Yzk5NjJjYTM0MGFfMTAtMi0xLTEtNjcwMQ_f90d76eb-e68a-4228-92f4-088c408915a9"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i6cbf1ef1e50043a6973a41f4362eca38_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjFhMjAxMzRkZDU5NzQ3MzA5MTY0NmM5OTYyY2EzNDBhL3RhYmxlcmFuZ2U6MWEyMDEzNGRkNTk3NDczMDkxNjQ2Yzk5NjJjYTM0MGFfMTAtNC0xLTEtNjcwMQ_569bd19c-2393-4a87-9bd2-10605567e5d4"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="id976144d8ac0470a8dfe87f5e0806e11_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjFhMjAxMzRkZDU5NzQ3MzA5MTY0NmM5OTYyY2EzNDBhL3RhYmxlcmFuZ2U6MWEyMDEzNGRkNTk3NDczMDkxNjQ2Yzk5NjJjYTM0MGFfMTAtNi0xLTEtNjcwMQ_207ba2a2-829e-4f93-869c-50b78a3fadae"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if9ead6d8a2d6496ab53b71dbf65c0e89_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjc4MzQxZGU5MjFjYjRjYzc4MDIzNThiZTE3ZjEwNTkwL3RhYmxlcmFuZ2U6NzgzNDFkZTkyMWNiNGNjNzgwMjM1OGJlMTdmMTA1OTBfMy0yLTEtMS00MDAw_1baa8b19-b9a3-48ba-b96c-3a65ac00f896"
      unitRef="usd">621000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6ae8a6101db3483ea8c8e7878ef68c7b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjc4MzQxZGU5MjFjYjRjYzc4MDIzNThiZTE3ZjEwNTkwL3RhYmxlcmFuZ2U6NzgzNDFkZTkyMWNiNGNjNzgwMjM1OGJlMTdmMTA1OTBfMy00LTEtMS00MDEy_1a5a10b3-ab97-460a-af11-7903a2a02337"
      unitRef="usd">621000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6aa4efa157cf4cbcaf792243639a7365_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjc4MzQxZGU5MjFjYjRjYzc4MDIzNThiZTE3ZjEwNTkwL3RhYmxlcmFuZ2U6NzgzNDFkZTkyMWNiNGNjNzgwMjM1OGJlMTdmMTA1OTBfMy02LTEtMS02MTA1_6aa31735-b42a-4230-899d-b4e4684a2798"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0598f69f1ada4de8ae9919743b2bdf0c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjc4MzQxZGU5MjFjYjRjYzc4MDIzNThiZTE3ZjEwNTkwL3RhYmxlcmFuZ2U6NzgzNDFkZTkyMWNiNGNjNzgwMjM1OGJlMTdmMTA1OTBfNC0yLTEtMS00MDA0_ee2c62d5-2f3f-4278-ad64-31b56995e77a"
      unitRef="usd">239000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i93f6a88f2c7c4d8085866d26873d36e9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjc4MzQxZGU5MjFjYjRjYzc4MDIzNThiZTE3ZjEwNTkwL3RhYmxlcmFuZ2U6NzgzNDFkZTkyMWNiNGNjNzgwMjM1OGJlMTdmMTA1OTBfNC00LTEtMS00MDE2_7a85a382-6f76-4b3f-b376-d04e7863c6c9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if667a4d9f03441e794394bde2522c7d6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjc4MzQxZGU5MjFjYjRjYzc4MDIzNThiZTE3ZjEwNTkwL3RhYmxlcmFuZ2U6NzgzNDFkZTkyMWNiNGNjNzgwMjM1OGJlMTdmMTA1OTBfNC02LTEtMS00MDE2_509bfad6-aa8e-4780-8d3c-4344dff83f02"
      unitRef="usd">239000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9c4745cd6ed947bc9dc06de365526c6f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjc4MzQxZGU5MjFjYjRjYzc4MDIzNThiZTE3ZjEwNTkwL3RhYmxlcmFuZ2U6NzgzNDFkZTkyMWNiNGNjNzgwMjM1OGJlMTdmMTA1OTBfNS0yLTEtMS00MDA0_7b4caafa-8bae-4857-bb0e-ab33027eb37c"
      unitRef="usd">492000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4c0cd6f20ef146849ac96024e8997311_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjc4MzQxZGU5MjFjYjRjYzc4MDIzNThiZTE3ZjEwNTkwL3RhYmxlcmFuZ2U6NzgzNDFkZTkyMWNiNGNjNzgwMjM1OGJlMTdmMTA1OTBfNS00LTEtMS00MDE2_e3a31c44-e536-4fb2-b075-a59f010400e9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i34e70e75e95f41a89179d7b607304203_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjc4MzQxZGU5MjFjYjRjYzc4MDIzNThiZTE3ZjEwNTkwL3RhYmxlcmFuZ2U6NzgzNDFkZTkyMWNiNGNjNzgwMjM1OGJlMTdmMTA1OTBfNS02LTEtMS00MDE2_96aa9f2d-197f-4c22-93ca-d284404a2669"
      unitRef="usd">492000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie17de02d67874972813c65e1ee7828ab_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjc4MzQxZGU5MjFjYjRjYzc4MDIzNThiZTE3ZjEwNTkwL3RhYmxlcmFuZ2U6NzgzNDFkZTkyMWNiNGNjNzgwMjM1OGJlMTdmMTA1OTBfNi0yLTEtMS00MDA0_e6917657-1989-4df1-aec6-ad5642ea7f0c"
      unitRef="usd">1892000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id52895ca9a52496199fbd7e4b81d30b8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjc4MzQxZGU5MjFjYjRjYzc4MDIzNThiZTE3ZjEwNTkwL3RhYmxlcmFuZ2U6NzgzNDFkZTkyMWNiNGNjNzgwMjM1OGJlMTdmMTA1OTBfNi00LTEtMS00MDE2_712d9d86-8e85-4a12-b7c7-9d2bf3ad40c5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifa680536838a4ffd80a53a841c00e107_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjc4MzQxZGU5MjFjYjRjYzc4MDIzNThiZTE3ZjEwNTkwL3RhYmxlcmFuZ2U6NzgzNDFkZTkyMWNiNGNjNzgwMjM1OGJlMTdmMTA1OTBfNi02LTEtMS00MDE2_00e3911c-85f3-4670-af17-2962f83c4e32"
      unitRef="usd">1892000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i686e90a952424d579c987c59336787cd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjc4MzQxZGU5MjFjYjRjYzc4MDIzNThiZTE3ZjEwNTkwL3RhYmxlcmFuZ2U6NzgzNDFkZTkyMWNiNGNjNzgwMjM1OGJlMTdmMTA1OTBfNy0yLTEtMS02MTAx_f3a40054-248a-483e-bed9-183c3ffb9f9a"
      unitRef="usd">3244000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i59dd43638f654b5ca42787b1d4565122_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjc4MzQxZGU5MjFjYjRjYzc4MDIzNThiZTE3ZjEwNTkwL3RhYmxlcmFuZ2U6NzgzNDFkZTkyMWNiNGNjNzgwMjM1OGJlMTdmMTA1OTBfNy00LTEtMS02MTAz_f914faa6-ae4f-41e6-a1f2-c4a97c768fb7"
      unitRef="usd">621000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib5f5b6e35e214612987f2dbe6605a881_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81NS9mcmFnOjIyNTM3MDZhMzUwNzQwMmFiZTM4NTVhMDA3ZWU0ZmYxL3RhYmxlOjc4MzQxZGU5MjFjYjRjYzc4MDIzNThiZTE3ZjEwNTkwL3RhYmxlcmFuZ2U6NzgzNDFkZTkyMWNiNGNjNzgwMjM1OGJlMTdmMTA1OTBfNy02LTEtMS02MTA1_29a24adc-db0a-48cd-89af-0eaf11b8244b"
      unitRef="usd">2623000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDEwL2ZyYWc6NjcxOTY4N2JjOGIzNDcwMWIxMTQ0ODI1NWU5ZGJmMTYvdGV4dHJlZ2lvbjo2NzE5Njg3YmM4YjM0NzAxYjExNDQ4MjU1ZTlkYmYxNl83Njk2NTgxMzk2NjIx_37556f2a-70f1-468d-95ea-597d445e5272">Derivative Financial Instruments&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We transact business in various foreign currencies and have international sales and expenses denominated in foreign currencies. Therefore, we are exposed to certain risks arising from both our business operations and economic conditions. Our risk management strategy includes the use of derivative financial instruments to hedge foreign currency exchange rate fluctuations on monetary assets or liabilities denominated in foreign currencies. We do not enter into derivative financial contracts for speculative or trading purposes. We do not believe that we are exposed to more than a nominal amount of credit risk in our foreign currency hedges, as counterparties are large, global and well-capitalized financial institutions. We classify cash flows from our derivative transactions as cash flows from operating activities in our consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Balance Sheet Hedges&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our foreign currency forward contracts, primarily accounts receivable, are not designated for hedge accounting treatment. Therefore, these forward contracts are accounted for as derivatives whereby the fair value of the contracts are reported as other current assets or other current liabilities on our condensed consolidated balance sheets, and gains and losses resulting from changes in the fair value are recorded as a component of other expense, net, in our condensed consolidated statements of operations. The gains and losses on these foreign currency forward contracts generally offset the gains and losses in the underlying foreign currency denominated assets and liabilities, which are also recorded to other expense, net, in our condensed consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total gross notional amount and fair value for foreign currency derivatives that are not designated as hedging instruments are accounted for as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.792%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Asset&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.792%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Asset&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;_________&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As presented in the condensed consolidated balance sheet within other current assets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As presented in the condensed consolidated balance sheet within other current liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The effect of foreign currency forward contracts not designated as hedging instruments in our condensed consolidated statements of operations for the three months ended March 31, 2021 was as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.861%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.773%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.773%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Statement of Operations Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other (expense) income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;There were no hedging activities for the three months ended March 31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDEwL2ZyYWc6NjcxOTY4N2JjOGIzNDcwMWIxMTQ0ODI1NWU5ZGJmMTYvdGV4dHJlZ2lvbjo2NzE5Njg3YmM4YjM0NzAxYjExNDQ4MjU1ZTlkYmYxNl83Njk2NTgxMzk2NjIw_8b828734-d369-44fc-94e4-875909ef5603">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total gross notional amount and fair value for foreign currency derivatives that are not designated as hedging instruments are accounted for as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.792%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Asset&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.792%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Asset&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;_________&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As presented in the condensed consolidated balance sheet within other current assets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As presented in the condensed consolidated balance sheet within other current liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The effect of foreign currency forward contracts not designated as hedging instruments in our condensed consolidated statements of operations for the three months ended March 31, 2021 was as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.861%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.773%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.773%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Statement of Operations Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other (expense) income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i900a81907e194a84ba164cb4e36677d2_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDEwL2ZyYWc6NjcxOTY4N2JjOGIzNDcwMWIxMTQ0ODI1NWU5ZGJmMTYvdGFibGU6OWQwNGFjOTQ5YzBkNDdkMTlmMWQ2ZjAwODY5ODljOWUvdGFibGVyYW5nZTo5ZDA0YWM5NDljMGQ0N2QxOWYxZDZmMDA4Njk4OWM5ZV80LTItMS0xLTE2OTk_73607bf0-31f1-4a45-93a2-e7cf92ccfd04"
      unitRef="usd">1367000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="i900a81907e194a84ba164cb4e36677d2_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDEwL2ZyYWc6NjcxOTY4N2JjOGIzNDcwMWIxMTQ0ODI1NWU5ZGJmMTYvdGFibGU6OWQwNGFjOTQ5YzBkNDdkMTlmMWQ2ZjAwODY5ODljOWUvdGFibGVyYW5nZTo5ZDA0YWM5NDljMGQ0N2QxOWYxZDZmMDA4Njk4OWM5ZV80LTQtMS0xLTE2OTk_1232c105-5f16-4d25-903b-2a1d3a209eb0"
      unitRef="usd">1000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="i900a81907e194a84ba164cb4e36677d2_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDEwL2ZyYWc6NjcxOTY4N2JjOGIzNDcwMWIxMTQ0ODI1NWU5ZGJmMTYvdGFibGU6OWQwNGFjOTQ5YzBkNDdkMTlmMWQ2ZjAwODY5ODljOWUvdGFibGVyYW5nZTo5ZDA0YWM5NDljMGQ0N2QxOWYxZDZmMDA4Njk4OWM5ZV80LTYtMS0xLTE2OTk_5751f36a-b7f4-434c-9cbb-ffee0e1b579f"
      unitRef="usd">1000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i0ab6f5001f864500b4c8e0d67181a3e1_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDEwL2ZyYWc6NjcxOTY4N2JjOGIzNDcwMWIxMTQ0ODI1NWU5ZGJmMTYvdGFibGU6OWQwNGFjOTQ5YzBkNDdkMTlmMWQ2ZjAwODY5ODljOWUvdGFibGVyYW5nZTo5ZDA0YWM5NDljMGQ0N2QxOWYxZDZmMDA4Njk4OWM5ZV81LTItMS0xLTM0MDI_7dd85b89-9853-41ea-94c2-656cce3c74d7"
      unitRef="usd">1367000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="i0ab6f5001f864500b4c8e0d67181a3e1_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDEwL2ZyYWc6NjcxOTY4N2JjOGIzNDcwMWIxMTQ0ODI1NWU5ZGJmMTYvdGFibGU6OWQwNGFjOTQ5YzBkNDdkMTlmMWQ2ZjAwODY5ODljOWUvdGFibGVyYW5nZTo5ZDA0YWM5NDljMGQ0N2QxOWYxZDZmMDA4Njk4OWM5ZV81LTQtMS0xLTM0MDQ_734993df-3860-4f18-8515-84ca2b50af47"
      unitRef="usd">1000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="i0ab6f5001f864500b4c8e0d67181a3e1_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDEwL2ZyYWc6NjcxOTY4N2JjOGIzNDcwMWIxMTQ0ODI1NWU5ZGJmMTYvdGFibGU6OWQwNGFjOTQ5YzBkNDdkMTlmMWQ2ZjAwODY5ODljOWUvdGFibGVyYW5nZTo5ZDA0YWM5NDljMGQ0N2QxOWYxZDZmMDA4Njk4OWM5ZV81LTYtMS0xLTM0MDY_9f79bc7c-0b53-4595-9069-c9ac346a4d85"
      unitRef="usd">1000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i61150f006fb645cb98904910e2b941a8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDEwL2ZyYWc6NjcxOTY4N2JjOGIzNDcwMWIxMTQ0ODI1NWU5ZGJmMTYvdGFibGU6ZjBlYTFiZWUzYTVmNDJlZGE1N2NkMWY4NDQ5NjhiY2MvdGFibGVyYW5nZTpmMGVhMWJlZTNhNWY0MmVkYTU3Y2QxZjg0NDk2OGJjY180LTItMS0xLTY3MjQ_b3bfbe0c-d7f4-499f-a8cc-b1d1140fe617"
      unitRef="usd">368000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="i61150f006fb645cb98904910e2b941a8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDEwL2ZyYWc6NjcxOTY4N2JjOGIzNDcwMWIxMTQ0ODI1NWU5ZGJmMTYvdGFibGU6ZjBlYTFiZWUzYTVmNDJlZGE1N2NkMWY4NDQ5NjhiY2MvdGFibGVyYW5nZTpmMGVhMWJlZTNhNWY0MmVkYTU3Y2QxZjg0NDk2OGJjY180LTQtMS0xLTY3MjQ_e482324e-f897-4083-8b58-15b208da0f7c"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="i61150f006fb645cb98904910e2b941a8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDEwL2ZyYWc6NjcxOTY4N2JjOGIzNDcwMWIxMTQ0ODI1NWU5ZGJmMTYvdGFibGU6ZjBlYTFiZWUzYTVmNDJlZGE1N2NkMWY4NDQ5NjhiY2MvdGFibGVyYW5nZTpmMGVhMWJlZTNhNWY0MmVkYTU3Y2QxZjg0NDk2OGJjY180LTYtMS0xLTY3MjQ_f3e8f6c6-4b70-4b15-91f1-81cac9e6300c"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ie50812d5f7b44b30b8225d6636c4c4f4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDEwL2ZyYWc6NjcxOTY4N2JjOGIzNDcwMWIxMTQ0ODI1NWU5ZGJmMTYvdGFibGU6ZjBlYTFiZWUzYTVmNDJlZGE1N2NkMWY4NDQ5NjhiY2MvdGFibGVyYW5nZTpmMGVhMWJlZTNhNWY0MmVkYTU3Y2QxZjg0NDk2OGJjY181LTItMS0xLTcxMzY_bd8cb06f-4171-4491-9c12-82e7226a8a7b"
      unitRef="usd">368000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="ie50812d5f7b44b30b8225d6636c4c4f4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDEwL2ZyYWc6NjcxOTY4N2JjOGIzNDcwMWIxMTQ0ODI1NWU5ZGJmMTYvdGFibGU6ZjBlYTFiZWUzYTVmNDJlZGE1N2NkMWY4NDQ5NjhiY2MvdGFibGVyYW5nZTpmMGVhMWJlZTNhNWY0MmVkYTU3Y2QxZjg0NDk2OGJjY181LTQtMS0xLTcxMzg_c41575e1-5a3d-4f45-9698-9cb67d1b2d60"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="ie50812d5f7b44b30b8225d6636c4c4f4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDEwL2ZyYWc6NjcxOTY4N2JjOGIzNDcwMWIxMTQ0ODI1NWU5ZGJmMTYvdGFibGU6ZjBlYTFiZWUzYTVmNDJlZGE1N2NkMWY4NDQ5NjhiY2MvdGFibGVyYW5nZTpmMGVhMWJlZTNhNWY0MmVkYTU3Y2QxZjg0NDk2OGJjY181LTYtMS0xLTcxNDA_7d85aa41-9959-462e-a438-113774d9f849"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i2bd7f75306414af4a89bd03391f700a7_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDEwL2ZyYWc6NjcxOTY4N2JjOGIzNDcwMWIxMTQ0ODI1NWU5ZGJmMTYvdGFibGU6NmY4NmNjYmVmODljNGE1YTkyZWE2MjliNTk4ODAxZjIvdGFibGVyYW5nZTo2Zjg2Y2NiZWY4OWM0YTVhOTJlYTYyOWI1OTg4MDFmMl8yLTQtMS0xLTE3MDM_c02bdad6-9c47-4809-9632-6c3bb3cbcbf2"
      unitRef="usd">35000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="if558e6ed91924e46b53fe8382ea023b2_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDEwL2ZyYWc6NjcxOTY4N2JjOGIzNDcwMWIxMTQ0ODI1NWU5ZGJmMTYvdGFibGU6NmY4NmNjYmVmODljNGE1YTkyZWE2MjliNTk4ODAxZjIvdGFibGVyYW5nZTo2Zjg2Y2NiZWY4OWM0YTVhOTJlYTYyOWI1OTg4MDFmMl8zLTQtMS0xLTM0MDA_f45e028a-8b08-49b9-8aa3-d107cf699f78"
      unitRef="usd">35000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDE4L2ZyYWc6YjY3MWE3OTc3OWMyNDYxNWJjODk5Y2M3ODAyM2I1ZmUvdGV4dHJlZ2lvbjpiNjcxYTc5Nzc5YzI0NjE1YmM4OTljYzc4MDIzYjVmZV83Njk2NTgxMzk0NTQ5_def1383f-fc2c-44b6-9639-8e87e9389f80">Inventory&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory as of March 31, 2021 and December 31, 2020 consists of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.288%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in progress &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDE4L2ZyYWc6YjY3MWE3OTc3OWMyNDYxNWJjODk5Y2M3ODAyM2I1ZmUvdGV4dHJlZ2lvbjpiNjcxYTc5Nzc5YzI0NjE1YmM4OTljYzc4MDIzYjVmZV83Njk2NTgxMzk0NTUw_70a119cf-cd44-46e7-ab67-2ac6a2766315">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory as of March 31, 2021 and December 31, 2020 consists of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.288%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in progress &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDE4L2ZyYWc6YjY3MWE3OTc3OWMyNDYxNWJjODk5Y2M3ODAyM2I1ZmUvdGFibGU6NzcyZGQ3NGQ5YzAzNDU2Y2ExNTlmODc2NmNjYmQxNmMvdGFibGVyYW5nZTo3NzJkZDc0ZDljMDM0NTZjYTE1OWY4NzY2Y2NiZDE2Y18yLTItMS0xLTE2ODQ_c691399e-6394-49cc-bcb4-cb6586112939"
      unitRef="usd">430000000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDE4L2ZyYWc6YjY3MWE3OTc3OWMyNDYxNWJjODk5Y2M3ODAyM2I1ZmUvdGFibGU6NzcyZGQ3NGQ5YzAzNDU2Y2ExNTlmODc2NmNjYmQxNmMvdGFibGVyYW5nZTo3NzJkZDc0ZDljMDM0NTZjYTE1OWY4NzY2Y2NiZDE2Y18yLTQtMS0xLTE2ODQ_1b472ff5-7d63-4a84-930f-642b814ad1ab"
      unitRef="usd">37000000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDE4L2ZyYWc6YjY3MWE3OTc3OWMyNDYxNWJjODk5Y2M3ODAyM2I1ZmUvdGFibGU6NzcyZGQ3NGQ5YzAzNDU2Y2ExNTlmODc2NmNjYmQxNmMvdGFibGVyYW5nZTo3NzJkZDc0ZDljMDM0NTZjYTE1OWY4NzY2Y2NiZDE2Y18zLTItMS0xLTE2ODQ_6443c51e-d2df-4cb3-9701-2379125cb19c"
      unitRef="usd">52000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDE4L2ZyYWc6YjY3MWE3OTc3OWMyNDYxNWJjODk5Y2M3ODAyM2I1ZmUvdGFibGU6NzcyZGQ3NGQ5YzAzNDU2Y2ExNTlmODc2NmNjYmQxNmMvdGFibGVyYW5nZTo3NzJkZDc0ZDljMDM0NTZjYTE1OWY4NzY2Y2NiZDE2Y18zLTQtMS0xLTE2ODQ_0a1be3f4-7839-4835-b6d7-39c21c4f8f79"
      unitRef="usd">9000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDE4L2ZyYWc6YjY3MWE3OTc3OWMyNDYxNWJjODk5Y2M3ODAyM2I1ZmUvdGFibGU6NzcyZGQ3NGQ5YzAzNDU2Y2ExNTlmODc2NmNjYmQxNmMvdGFibGVyYW5nZTo3NzJkZDc0ZDljMDM0NTZjYTE1OWY4NzY2Y2NiZDE2Y180LTItMS0xLTE2ODQ_56d440d2-e543-4645-9acf-38bb0921cf38"
      unitRef="usd">12000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDE4L2ZyYWc6YjY3MWE3OTc3OWMyNDYxNWJjODk5Y2M3ODAyM2I1ZmUvdGFibGU6NzcyZGQ3NGQ5YzAzNDU2Y2ExNTlmODc2NmNjYmQxNmMvdGFibGVyYW5nZTo3NzJkZDc0ZDljMDM0NTZjYTE1OWY4NzY2Y2NiZDE2Y180LTQtMS0xLTE2ODQ_7e6b7f57-e427-452a-89d7-f3ed4fafbbf5"
      unitRef="usd">1000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDE4L2ZyYWc6YjY3MWE3OTc3OWMyNDYxNWJjODk5Y2M3ODAyM2I1ZmUvdGFibGU6NzcyZGQ3NGQ5YzAzNDU2Y2ExNTlmODc2NmNjYmQxNmMvdGFibGVyYW5nZTo3NzJkZDc0ZDljMDM0NTZjYTE1OWY4NzY2Y2NiZDE2Y181LTItMS0xLTM0MjA_c79eb712-523e-49ce-9ca2-1a4794dea297"
      unitRef="usd">494000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDE4L2ZyYWc6YjY3MWE3OTc3OWMyNDYxNWJjODk5Y2M3ODAyM2I1ZmUvdGFibGU6NzcyZGQ3NGQ5YzAzNDU2Y2ExNTlmODc2NmNjYmQxNmMvdGFibGVyYW5nZTo3NzJkZDc0ZDljMDM0NTZjYTE1OWY4NzY2Y2NiZDE2Y181LTQtMS0xLTM0MjI_78cfe4d2-0cf7-4b44-9e2f-46e4139757b6"
      unitRef="usd">47000000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDMyL2ZyYWc6YmNlNzg3NmI0OTVlNDI1OWFjODMzOGM2Y2NlMzM1ZGUvdGV4dHJlZ2lvbjpiY2U3ODc2YjQ5NWU0MjU5YWM4MzM4YzZjY2UzMzVkZV83Njk2NTgxMzk0ODMz_8e32f3e2-581b-466c-b385-6c07362ec000">Property and Equipment, Net&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net, as of March 31, 2021 and December 31, 2020 consists of the following (in&#160;millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture, fixtures and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internally developed software&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use asset, financing&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Depreciation and amortization expense for the three months ended March 31, 2021 and 2020 was $15 million and $7 million, respectively.</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDMyL2ZyYWc6YmNlNzg3NmI0OTVlNDI1OWFjODMzOGM2Y2NlMzM1ZGUvdGV4dHJlZ2lvbjpiY2U3ODc2YjQ5NWU0MjU5YWM4MzM4YzZjY2UzMzVkZV83Njk2NTgxMzk0ODM0_bea40f79-a076-4cd2-ba24-661911bbf4f7">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net, as of March 31, 2021 and December 31, 2020 consists of the following (in&#160;millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture, fixtures and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internally developed software&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use asset, financing&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="ie182a57ea61f416d8c4866418d5a465d_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDMyL2ZyYWc6YmNlNzg3NmI0OTVlNDI1OWFjODMzOGM2Y2NlMzM1ZGUvdGFibGU6OGI3NjZkNjA0NTgzNDhkZDhlNDJmYmUwMTJmYmExZmIvdGFibGVyYW5nZTo4Yjc2NmQ2MDQ1ODM0OGRkOGU0MmZiZTAxMmZiYTFmYl8yLTItMS0xLTE2NTc_0b5b00cb-8f1c-42b4-aa37-f391c5ffa658"
      unitRef="usd">125000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="icdaad432c7624d609795f42f421c205b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDMyL2ZyYWc6YmNlNzg3NmI0OTVlNDI1OWFjODMzOGM2Y2NlMzM1ZGUvdGFibGU6OGI3NjZkNjA0NTgzNDhkZDhlNDJmYmUwMTJmYmExZmIvdGFibGVyYW5nZTo4Yjc2NmQ2MDQ1ODM0OGRkOGU0MmZiZTAxMmZiYTFmYl8yLTQtMS0xLTE2NTc_47a93624-cdaf-4d73-8570-583a7bfeece1"
      unitRef="usd">121000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="if2ecdbe7a52f4cdaa512b1d59ef2091b_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDMyL2ZyYWc6YmNlNzg3NmI0OTVlNDI1OWFjODMzOGM2Y2NlMzM1ZGUvdGFibGU6OGI3NjZkNjA0NTgzNDhkZDhlNDJmYmUwMTJmYmExZmIvdGFibGVyYW5nZTo4Yjc2NmQ2MDQ1ODM0OGRkOGU0MmZiZTAxMmZiYTFmYl8zLTItMS0xLTE2NTc_ded67315-5cb1-44b3-b30e-63eefadb60d3"
      unitRef="usd">184000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="iebde00942b24405f849061b1a6fad190_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDMyL2ZyYWc6YmNlNzg3NmI0OTVlNDI1OWFjODMzOGM2Y2NlMzM1ZGUvdGFibGU6OGI3NjZkNjA0NTgzNDhkZDhlNDJmYmUwMTJmYmExZmIvdGFibGVyYW5nZTo4Yjc2NmQ2MDQ1ODM0OGRkOGU0MmZiZTAxMmZiYTFmYl8zLTQtMS0xLTE2NTc_d1a9e4dc-c8b3-4c64-aff4-aec4de8aa0fb"
      unitRef="usd">180000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="id1eca162cb334496bb26a5b7d49c7186_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDMyL2ZyYWc6YmNlNzg3NmI0OTVlNDI1OWFjODMzOGM2Y2NlMzM1ZGUvdGFibGU6OGI3NjZkNjA0NTgzNDhkZDhlNDJmYmUwMTJmYmExZmIvdGFibGVyYW5nZTo4Yjc2NmQ2MDQ1ODM0OGRkOGU0MmZiZTAxMmZiYTFmYl80LTItMS0xLTE2NTc_d7d50c22-af45-427f-aefc-ea0f0343e4d4"
      unitRef="usd">5000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i88573437d7664c1a9e52c33298a5b456_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDMyL2ZyYWc6YmNlNzg3NmI0OTVlNDI1OWFjODMzOGM2Y2NlMzM1ZGUvdGFibGU6OGI3NjZkNjA0NTgzNDhkZDhlNDJmYmUwMTJmYmExZmIvdGFibGVyYW5nZTo4Yjc2NmQ2MDQ1ODM0OGRkOGU0MmZiZTAxMmZiYTFmYl80LTQtMS0xLTE2NTc_46f4044f-bcda-49b1-b3d8-46bfa3c434ec"
      unitRef="usd">5000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i39475e82f8ca4c18b5f9b3233c43443b_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDMyL2ZyYWc6YmNlNzg3NmI0OTVlNDI1OWFjODMzOGM2Y2NlMzM1ZGUvdGFibGU6OGI3NjZkNjA0NTgzNDhkZDhlNDJmYmUwMTJmYmExZmIvdGFibGVyYW5nZTo4Yjc2NmQ2MDQ1ODM0OGRkOGU0MmZiZTAxMmZiYTFmYl81LTItMS0xLTE2NTc_e3041e08-56e8-4ad8-9b63-66c281d0224e"
      unitRef="usd">15000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i2e9e748f96b34220bf4fe5d60445b495_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDMyL2ZyYWc6YmNlNzg3NmI0OTVlNDI1OWFjODMzOGM2Y2NlMzM1ZGUvdGFibGU6OGI3NjZkNjA0NTgzNDhkZDhlNDJmYmUwMTJmYmExZmIvdGFibGVyYW5nZTo4Yjc2NmQ2MDQ1ODM0OGRkOGU0MmZiZTAxMmZiYTFmYl81LTQtMS0xLTE2NTc_9e42e919-b5e8-4330-9990-8c89ff487dc0"
      unitRef="usd">13000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="if3e11e356d35463abd4fb1e3057fcd5d_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDMyL2ZyYWc6YmNlNzg3NmI0OTVlNDI1OWFjODMzOGM2Y2NlMzM1ZGUvdGFibGU6OGI3NjZkNjA0NTgzNDhkZDhlNDJmYmUwMTJmYmExZmIvdGFibGVyYW5nZTo4Yjc2NmQ2MDQ1ODM0OGRkOGU0MmZiZTAxMmZiYTFmYl82LTItMS0xLTE2NTc_fcb2cea0-f473-41d6-8fc9-89dac1a4b9dd"
      unitRef="usd">7000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i3574dd8d4ffe4445ac4435bdd763464d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDMyL2ZyYWc6YmNlNzg3NmI0OTVlNDI1OWFjODMzOGM2Y2NlMzM1ZGUvdGFibGU6OGI3NjZkNjA0NTgzNDhkZDhlNDJmYmUwMTJmYmExZmIvdGFibGVyYW5nZTo4Yjc2NmQ2MDQ1ODM0OGRkOGU0MmZiZTAxMmZiYTFmYl82LTQtMS0xLTE2NTc_2bfa9891-63b0-4c08-b9dd-085a60dfe9c3"
      unitRef="usd">7000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i1263c583aadd4aeeb0479db8950e9cad_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDMyL2ZyYWc6YmNlNzg3NmI0OTVlNDI1OWFjODMzOGM2Y2NlMzM1ZGUvdGFibGU6OGI3NjZkNjA0NTgzNDhkZDhlNDJmYmUwMTJmYmExZmIvdGFibGVyYW5nZTo4Yjc2NmQ2MDQ1ODM0OGRkOGU0MmZiZTAxMmZiYTFmYl83LTItMS0xLTE2NTc_a2220cef-f8a8-42da-b589-01357793b971"
      unitRef="usd">108000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="ia6397562962643bba0441eaabef86729_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDMyL2ZyYWc6YmNlNzg3NmI0OTVlNDI1OWFjODMzOGM2Y2NlMzM1ZGUvdGFibGU6OGI3NjZkNjA0NTgzNDhkZDhlNDJmYmUwMTJmYmExZmIvdGFibGVyYW5nZTo4Yjc2NmQ2MDQ1ODM0OGRkOGU0MmZiZTAxMmZiYTFmYl83LTQtMS0xLTE2NTc_05303dfc-a65c-4305-8351-47797e27c711"
      unitRef="usd">56000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="ib7fb0180403444128af0ca00c287ab8b_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDMyL2ZyYWc6YmNlNzg3NmI0OTVlNDI1OWFjODMzOGM2Y2NlMzM1ZGUvdGFibGU6OGI3NjZkNjA0NTgzNDhkZDhlNDJmYmUwMTJmYmExZmIvdGFibGVyYW5nZTo4Yjc2NmQ2MDQ1ODM0OGRkOGU0MmZiZTAxMmZiYTFmYl84LTItMS0xLTE2NTc_f8daa549-acd0-45b1-b6b5-d73fd6ae7ae1"
      unitRef="usd">63000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i25b18fc5d30a4a9ebd82c278f9fdee03_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDMyL2ZyYWc6YmNlNzg3NmI0OTVlNDI1OWFjODMzOGM2Y2NlMzM1ZGUvdGFibGU6OGI3NjZkNjA0NTgzNDhkZDhlNDJmYmUwMTJmYmExZmIvdGFibGVyYW5nZTo4Yjc2NmQ2MDQ1ODM0OGRkOGU0MmZiZTAxMmZiYTFmYl84LTQtMS0xLTE2NTc_2881a840-0a4d-441e-87dd-0b197a1ab13e"
      unitRef="usd">35000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDMyL2ZyYWc6YmNlNzg3NmI0OTVlNDI1OWFjODMzOGM2Y2NlMzM1ZGUvdGFibGU6OGI3NjZkNjA0NTgzNDhkZDhlNDJmYmUwMTJmYmExZmIvdGFibGVyYW5nZTo4Yjc2NmQ2MDQ1ODM0OGRkOGU0MmZiZTAxMmZiYTFmYl85LTItMS0xLTM0NDU_595f03a4-db2a-43ca-ae47-ac0a0911ab17"
      unitRef="usd">507000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDMyL2ZyYWc6YmNlNzg3NmI0OTVlNDI1OWFjODMzOGM2Y2NlMzM1ZGUvdGFibGU6OGI3NjZkNjA0NTgzNDhkZDhlNDJmYmUwMTJmYmExZmIvdGFibGVyYW5nZTo4Yjc2NmQ2MDQ1ODM0OGRkOGU0MmZiZTAxMmZiYTFmYl85LTQtMS0xLTM0NDc_b036ab40-684e-4a83-ac16-b811f7f124a7"
      unitRef="usd">417000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDMyL2ZyYWc6YmNlNzg3NmI0OTVlNDI1OWFjODMzOGM2Y2NlMzM1ZGUvdGFibGU6OGI3NjZkNjA0NTgzNDhkZDhlNDJmYmUwMTJmYmExZmIvdGFibGVyYW5nZTo4Yjc2NmQ2MDQ1ODM0OGRkOGU0MmZiZTAxMmZiYTFmYl8xMC0yLTEtMS0xNjU3_35602b67-3f9e-4827-a079-31f2db7c5868"
      unitRef="usd">135000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDMyL2ZyYWc6YmNlNzg3NmI0OTVlNDI1OWFjODMzOGM2Y2NlMzM1ZGUvdGFibGU6OGI3NjZkNjA0NTgzNDhkZDhlNDJmYmUwMTJmYmExZmIvdGFibGVyYW5nZTo4Yjc2NmQ2MDQ1ODM0OGRkOGU0MmZiZTAxMmZiYTFmYl8xMC00LTEtMS0xNjU3_fa84e276-0229-438c-8ad2-1fd109cc375d"
      unitRef="usd">120000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDMyL2ZyYWc6YmNlNzg3NmI0OTVlNDI1OWFjODMzOGM2Y2NlMzM1ZGUvdGFibGU6OGI3NjZkNjA0NTgzNDhkZDhlNDJmYmUwMTJmYmExZmIvdGFibGVyYW5nZTo4Yjc2NmQ2MDQ1ODM0OGRkOGU0MmZiZTAxMmZiYTFmYl8xMS0yLTEtMS0zNDQ5_3b5a6ca5-ff0c-494c-a807-442fea5de425"
      unitRef="usd">372000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDMyL2ZyYWc6YmNlNzg3NmI0OTVlNDI1OWFjODMzOGM2Y2NlMzM1ZGUvdGFibGU6OGI3NjZkNjA0NTgzNDhkZDhlNDJmYmUwMTJmYmExZmIvdGFibGVyYW5nZTo4Yjc2NmQ2MDQ1ODM0OGRkOGU0MmZiZTAxMmZiYTFmYl8xMS00LTEtMS0zNDUx_f87a47dd-6374-40ad-b528-478bc0569e83"
      unitRef="usd">297000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDMyL2ZyYWc6YmNlNzg3NmI0OTVlNDI1OWFjODMzOGM2Y2NlMzM1ZGUvdGV4dHJlZ2lvbjpiY2U3ODc2YjQ5NWU0MjU5YWM4MzM4YzZjY2UzMzVkZV8xMDk5NTExNjI3OTY2_bd9fc420-8749-494f-aa9a-7f03bd3e2637"
      unitRef="usd">15000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV8xMDMyL2ZyYWc6YmNlNzg3NmI0OTVlNDI1OWFjODMzOGM2Y2NlMzM1ZGUvdGV4dHJlZ2lvbjpiY2U3ODc2YjQ5NWU0MjU5YWM4MzM4YzZjY2UzMzVkZV8xMDk5NTExNjI3OTc0_4b88f02c-e509-4d9f-b50a-76804fc90655"
      unitRef="usd">7000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RleHRyZWdpb246YTMwOTRiODY4ODU2NGQ1Njg1ODFiZjAzNTRmYTNjNjlfMTE1Nw_ea1d72e6-d182-435f-b130-235f589c2228">Other Balance Sheet Components&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets, as of March 31, 2021 and December 31, 2020 consists of the following (in&#160;millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Down payments to manufacturing vendors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other prepaid expenses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tenant incentives receivables&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest receivable on marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities, as of March 31, 2021 and December 31, 2020 consists of the following (in&#160;millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Development operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other external goods and services &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation-related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Revenue &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activities in deferred revenue for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the three months ended&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; March 31, 2021 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.792%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(796)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Grant revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(808)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RleHRyZWdpb246YTMwOTRiODY4ODU2NGQ1Njg1ODFiZjAzNTRmYTNjNjlfMTE1NA_1554b878-a4b7-4284-80a5-884f48a989b9">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets, as of March 31, 2021 and December 31, 2020 consists of the following (in&#160;millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Down payments to manufacturing vendors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other prepaid expenses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tenant incentives receivables&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest receivable on marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <mrna:OtherPrepaidExpenseManufacturing
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjllMTY0MDRhM2MxZDRkODY4MjU5ZWYzYzlmNmVhODI5L3RhYmxlcmFuZ2U6OWUxNjQwNGEzYzFkNGQ4NjgyNTllZjNjOWY2ZWE4MjlfMi0yLTEtMS0w_d2df87bc-f74a-45fe-aa41-bedf8180b14b"
      unitRef="usd">224000000</mrna:OtherPrepaidExpenseManufacturing>
    <mrna:OtherPrepaidExpenseManufacturing
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjllMTY0MDRhM2MxZDRkODY4MjU5ZWYzYzlmNmVhODI5L3RhYmxlcmFuZ2U6OWUxNjQwNGEzYzFkNGQ4NjgyNTllZjNjOWY2ZWE4MjlfMi00LTEtMS0w_12125bb8-b92b-49cf-82ab-ed5add46881c"
      unitRef="usd">217000000</mrna:OtherPrepaidExpenseManufacturing>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjllMTY0MDRhM2MxZDRkODY4MjU5ZWYzYzlmNmVhODI5L3RhYmxlcmFuZ2U6OWUxNjQwNGEzYzFkNGQ4NjgyNTllZjNjOWY2ZWE4MjlfMy0yLTEtMS0w_b4b4a23a-c7e7-4477-9b70-e87bfb77412a"
      unitRef="usd">22000000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjllMTY0MDRhM2MxZDRkODY4MjU5ZWYzYzlmNmVhODI5L3RhYmxlcmFuZ2U6OWUxNjQwNGEzYzFkNGQ4NjgyNTllZjNjOWY2ZWE4MjlfMy00LTEtMS0w_7923817b-a344-446f-a1de-72c258c67a6f"
      unitRef="usd">16000000</us-gaap:OtherPrepaidExpenseCurrent>
    <mrna:TenantIncentivesReceivablesCurrent
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjllMTY0MDRhM2MxZDRkODY4MjU5ZWYzYzlmNmVhODI5L3RhYmxlcmFuZ2U6OWUxNjQwNGEzYzFkNGQ4NjgyNTllZjNjOWY2ZWE4MjlfNC0yLTEtMS0w_c7c2a070-6a8f-4e0e-af86-582925d5a163"
      unitRef="usd">10000000</mrna:TenantIncentivesReceivablesCurrent>
    <mrna:TenantIncentivesReceivablesCurrent
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjllMTY0MDRhM2MxZDRkODY4MjU5ZWYzYzlmNmVhODI5L3RhYmxlcmFuZ2U6OWUxNjQwNGEzYzFkNGQ4NjgyNTllZjNjOWY2ZWE4MjlfNC00LTEtMS0w_87029848-eb0b-4969-a05f-3ca4b56742ea"
      unitRef="usd">10000000</mrna:TenantIncentivesReceivablesCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjllMTY0MDRhM2MxZDRkODY4MjU5ZWYzYzlmNmVhODI5L3RhYmxlcmFuZ2U6OWUxNjQwNGEzYzFkNGQ4NjgyNTllZjNjOWY2ZWE4MjlfNS0yLTEtMS0w_1c295ac0-c9ab-4f46-9e66-be9a98d3ac32"
      unitRef="usd">8000000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjllMTY0MDRhM2MxZDRkODY4MjU5ZWYzYzlmNmVhODI5L3RhYmxlcmFuZ2U6OWUxNjQwNGEzYzFkNGQ4NjgyNTllZjNjOWY2ZWE4MjlfNS00LTEtMS0w_7301d110-42a1-45d6-8a81-cd3f2dfec8ca"
      unitRef="usd">9000000</us-gaap:InterestReceivableCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjllMTY0MDRhM2MxZDRkODY4MjU5ZWYzYzlmNmVhODI5L3RhYmxlcmFuZ2U6OWUxNjQwNGEzYzFkNGQ4NjgyNTllZjNjOWY2ZWE4MjlfNi0yLTEtMS0w_d944b4f2-edc2-4942-99ab-1c1d4bf6e752"
      unitRef="usd">264000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjllMTY0MDRhM2MxZDRkODY4MjU5ZWYzYzlmNmVhODI5L3RhYmxlcmFuZ2U6OWUxNjQwNGEzYzFkNGQ4NjgyNTllZjNjOWY2ZWE4MjlfNi00LTEtMS0w_48f7cfd1-2895-4d3a-a978-bb604460551a"
      unitRef="usd">252000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RleHRyZWdpb246YTMwOTRiODY4ODU2NGQ1Njg1ODFiZjAzNTRmYTNjNjlfMTE1NQ_54e8e568-b36a-4228-8819-a4031decce62">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities, as of March 31, 2021 and December 31, 2020 consists of the following (in&#160;millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Development operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other external goods and services &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation-related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <mrna:AccruedClinicalTrials
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjE2ZTQzNDA1NThhMjQ3ZmZiN2IzNjRlOWRkZTMyZTlhL3RhYmxlcmFuZ2U6MTZlNDM0MDU1OGEyNDdmZmI3YjM2NGU5ZGRlMzJlOWFfMi0yLTEtMS0w_bb111e12-29e5-458a-b287-01362db94d4a"
      unitRef="usd">181000000</mrna:AccruedClinicalTrials>
    <mrna:AccruedClinicalTrials
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjE2ZTQzNDA1NThhMjQ3ZmZiN2IzNjRlOWRkZTMyZTlhL3RhYmxlcmFuZ2U6MTZlNDM0MDU1OGEyNDdmZmI3YjM2NGU5ZGRlMzJlOWFfMi00LTEtMS0w_12bb5f7e-13bc-4322-a9fd-00b34164ecf4"
      unitRef="usd">98000000</mrna:AccruedClinicalTrials>
    <mrna:RawMaterialsAccountsPayable
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjE2ZTQzNDA1NThhMjQ3ZmZiN2IzNjRlOWRkZTMyZTlhL3RhYmxlcmFuZ2U6MTZlNDM0MDU1OGEyNDdmZmI3YjM2NGU5ZGRlMzJlOWFfMy0yLTEtMS00NDQ_eb72604a-4367-41ca-924b-6adb123a0e35"
      unitRef="usd">185000000</mrna:RawMaterialsAccountsPayable>
    <mrna:RawMaterialsAccountsPayable
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjE2ZTQzNDA1NThhMjQ3ZmZiN2IzNjRlOWRkZTMyZTlhL3RhYmxlcmFuZ2U6MTZlNDM0MDU1OGEyNDdmZmI3YjM2NGU5ZGRlMzJlOWFfMy00LTEtMS00NDQ_780d2541-5990-42a6-bbf0-bb6061e701a4"
      unitRef="usd">78000000</mrna:RawMaterialsAccountsPayable>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjE2ZTQzNDA1NThhMjQ3ZmZiN2IzNjRlOWRkZTMyZTlhL3RhYmxlcmFuZ2U6MTZlNDM0MDU1OGEyNDdmZmI3YjM2NGU5ZGRlMzJlOWFfNC0yLTEtMS01NDUy_6c051066-a997-448e-9c78-9ce9d6306a2e"
      unitRef="usd">84000000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjE2ZTQzNDA1NThhMjQ3ZmZiN2IzNjRlOWRkZTMyZTlhL3RhYmxlcmFuZ2U6MTZlNDM0MDU1OGEyNDdmZmI3YjM2NGU5ZGRlMzJlOWFfNC00LTEtMS01NDUy_2de46984-4cae-4c20-9abb-5e2246cdf99c"
      unitRef="usd">0</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <mrna:AccruedDevelopmentOperation
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjE2ZTQzNDA1NThhMjQ3ZmZiN2IzNjRlOWRkZTMyZTlhL3RhYmxlcmFuZ2U6MTZlNDM0MDU1OGEyNDdmZmI3YjM2NGU5ZGRlMzJlOWFfMy0yLTEtMS0w_4699a756-7ae5-43e7-96ed-fd8974c1dff1"
      unitRef="usd">71000000</mrna:AccruedDevelopmentOperation>
    <mrna:AccruedDevelopmentOperation
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjE2ZTQzNDA1NThhMjQ3ZmZiN2IzNjRlOWRkZTMyZTlhL3RhYmxlcmFuZ2U6MTZlNDM0MDU1OGEyNDdmZmI3YjM2NGU5ZGRlMzJlOWFfMy00LTEtMS0w_aa43c7fa-d727-4bbd-90d8-3bbb2b645bdc"
      unitRef="usd">29000000</mrna:AccruedDevelopmentOperation>
    <mrna:AccruedManufacturing
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjE2ZTQzNDA1NThhMjQ3ZmZiN2IzNjRlOWRkZTMyZTlhL3RhYmxlcmFuZ2U6MTZlNDM0MDU1OGEyNDdmZmI3YjM2NGU5ZGRlMzJlOWFfNC0yLTEtMS0w_93bbe7ac-7d71-4558-817b-b56e121e5e96"
      unitRef="usd">119000000</mrna:AccruedManufacturing>
    <mrna:AccruedManufacturing
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjE2ZTQzNDA1NThhMjQ3ZmZiN2IzNjRlOWRkZTMyZTlhL3RhYmxlcmFuZ2U6MTZlNDM0MDU1OGEyNDdmZmI3YjM2NGU5ZGRlMzJlOWFfNC00LTEtMS0w_e6a7d4a3-c6ae-40ae-bdf0-f3c55ebd8d01"
      unitRef="usd">53000000</mrna:AccruedManufacturing>
    <mrna:AccruedOtherExternalGoodsAndServicesCurrent
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjE2ZTQzNDA1NThhMjQ3ZmZiN2IzNjRlOWRkZTMyZTlhL3RhYmxlcmFuZ2U6MTZlNDM0MDU1OGEyNDdmZmI3YjM2NGU5ZGRlMzJlOWFfNS0yLTEtMS0w_89b68eac-d073-4a42-a40f-f2760a8d977c"
      unitRef="usd">58000000</mrna:AccruedOtherExternalGoodsAndServicesCurrent>
    <mrna:AccruedOtherExternalGoodsAndServicesCurrent
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjE2ZTQzNDA1NThhMjQ3ZmZiN2IzNjRlOWRkZTMyZTlhL3RhYmxlcmFuZ2U6MTZlNDM0MDU1OGEyNDdmZmI3YjM2NGU5ZGRlMzJlOWFfNS00LTEtMS0w_25cf5a44-59f0-4d65-934e-45c113fb9995"
      unitRef="usd">92000000</mrna:AccruedOtherExternalGoodsAndServicesCurrent>
    <mrna:AccruedOtherExternalGoodsAndServicesCurrent
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjE2ZTQzNDA1NThhMjQ3ZmZiN2IzNjRlOWRkZTMyZTlhL3RhYmxlcmFuZ2U6MTZlNDM0MDU1OGEyNDdmZmI3YjM2NGU5ZGRlMzJlOWFfNS00LTEtMS0w_eb3062d2-ae54-460f-88c9-487f05830496"
      unitRef="usd">92000000</mrna:AccruedOtherExternalGoodsAndServicesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjE2ZTQzNDA1NThhMjQ3ZmZiN2IzNjRlOWRkZTMyZTlhL3RhYmxlcmFuZ2U6MTZlNDM0MDU1OGEyNDdmZmI3YjM2NGU5ZGRlMzJlOWFfNi0yLTEtMS0w_404626a9-0d2a-443c-8402-ea75970c487a"
      unitRef="usd">33000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjE2ZTQzNDA1NThhMjQ3ZmZiN2IzNjRlOWRkZTMyZTlhL3RhYmxlcmFuZ2U6MTZlNDM0MDU1OGEyNDdmZmI3YjM2NGU5ZGRlMzJlOWFfNi00LTEtMS0w_59e2ace2-d554-4dd0-9197-4c7a5923e329"
      unitRef="usd">95000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <mrna:AccruedPropertyAndEquipmentCurrent
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjE2ZTQzNDA1NThhMjQ3ZmZiN2IzNjRlOWRkZTMyZTlhL3RhYmxlcmFuZ2U6MTZlNDM0MDU1OGEyNDdmZmI3YjM2NGU5ZGRlMzJlOWFfNy0yLTEtMS0w_173dd0a1-1244-4724-8573-e173e7e87993"
      unitRef="usd">17000000</mrna:AccruedPropertyAndEquipmentCurrent>
    <mrna:AccruedPropertyAndEquipmentCurrent
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjE2ZTQzNDA1NThhMjQ3ZmZiN2IzNjRlOWRkZTMyZTlhL3RhYmxlcmFuZ2U6MTZlNDM0MDU1OGEyNDdmZmI3YjM2NGU5ZGRlMzJlOWFfNy00LTEtMS0w_808e0ba1-72ff-4632-90c2-9522edfda31b"
      unitRef="usd">18000000</mrna:AccruedPropertyAndEquipmentCurrent>
    <mrna:Commercial
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjE2ZTQzNDA1NThhMjQ3ZmZiN2IzNjRlOWRkZTMyZTlhL3RhYmxlcmFuZ2U6MTZlNDM0MDU1OGEyNDdmZmI3YjM2NGU5ZGRlMzJlOWFfMTEtMi0xLTEtNTk2Ng_ea10dbfa-91b6-46a7-84d3-72d7c92a303c"
      unitRef="usd">5000000</mrna:Commercial>
    <mrna:Commercial
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjE2ZTQzNDA1NThhMjQ3ZmZiN2IzNjRlOWRkZTMyZTlhL3RhYmxlcmFuZ2U6MTZlNDM0MDU1OGEyNDdmZmI3YjM2NGU5ZGRlMzJlOWFfMTEtNC0xLTEtNTk2Ng_e0d6ce81-fa4c-4aee-b591-843e11792e82"
      unitRef="usd">7000000</mrna:Commercial>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjE2ZTQzNDA1NThhMjQ3ZmZiN2IzNjRlOWRkZTMyZTlhL3RhYmxlcmFuZ2U6MTZlNDM0MDU1OGEyNDdmZmI3YjM2NGU5ZGRlMzJlOWFfOC0yLTEtMS0w_9b5ba396-c1e8-4509-9990-cd5e85cd85aa"
      unitRef="usd">753000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjE2ZTQzNDA1NThhMjQ3ZmZiN2IzNjRlOWRkZTMyZTlhL3RhYmxlcmFuZ2U6MTZlNDM0MDU1OGEyNDdmZmI3YjM2NGU5ZGRlMzJlOWFfOC00LTEtMS0w_77a9d850-d715-486c-82b1-1f15b0424d0f"
      unitRef="usd">470000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ib2ee3c9e3ddc46fc8c50d787172d195f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjBjMWE2Yzg1ZGRhNzQzOTk4NmE1MGM2Nzc5OTY3OGVkL3RhYmxlcmFuZ2U6MGMxYTZjODVkZGE3NDM5OTg2YTUwYzY3Nzk5Njc4ZWRfMS0yLTEtMS00NjI3_4c9b02b1-5e23-46bd-b596-9e3111fbc366"
      unitRef="usd">3799000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
      contextRef="i90cf26aad24349bfa441914ac3d706fb_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjBjMWE2Yzg1ZGRhNzQzOTk4NmE1MGM2Nzc5OTY3OGVkL3RhYmxlcmFuZ2U6MGMxYTZjODVkZGE3NDM5OTg2YTUwYzY3Nzk5Njc4ZWRfMS00LTEtMS00NjUx_a47a5022-d3c3-43e1-81a3-40a471240877"
      unitRef="usd">4467000000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress>
    <mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod
      contextRef="i90cf26aad24349bfa441914ac3d706fb_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjBjMWE2Yzg1ZGRhNzQzOTk4NmE1MGM2Nzc5OTY3OGVkL3RhYmxlcmFuZ2U6MGMxYTZjODVkZGE3NDM5OTg2YTUwYzY3Nzk5Njc4ZWRfMS02LTEtMS00NjUx_5a784500-07f9-487f-a7fa-d0bd62762b15"
      unitRef="usd">796000000</mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i3049e90ee7764f058dbbb38cd725aadc_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjBjMWE2Yzg1ZGRhNzQzOTk4NmE1MGM2Nzc5OTY3OGVkL3RhYmxlcmFuZ2U6MGMxYTZjODVkZGE3NDM5OTg2YTUwYzY3Nzk5Njc4ZWRfMS04LTEtMS02MTI5_348edba7-a8de-4f3d-b8b2-a2dc6124ea40"
      unitRef="usd">7470000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ie53549975a3f42f6b2b2d3515ab79791_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjBjMWE2Yzg1ZGRhNzQzOTk4NmE1MGM2Nzc5OTY3OGVkL3RhYmxlcmFuZ2U6MGMxYTZjODVkZGE3NDM5OTg2YTUwYzY3Nzk5Njc4ZWRfMi0yLTEtMS00NjI3_7ad4a634-0405-4ad1-adc4-9f105a8d47cc"
      unitRef="usd">5000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
      contextRef="i12127d667a294d78b6d78f889c39cd18_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjBjMWE2Yzg1ZGRhNzQzOTk4NmE1MGM2Nzc5OTY3OGVkL3RhYmxlcmFuZ2U6MGMxYTZjODVkZGE3NDM5OTg2YTUwYzY3Nzk5Njc4ZWRfMi00LTEtMS00NjUx_41f7a97c-147b-4fcc-8a41-628fece67681"
      unitRef="usd">2000000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress>
    <mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod
      contextRef="i12127d667a294d78b6d78f889c39cd18_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjBjMWE2Yzg1ZGRhNzQzOTk4NmE1MGM2Nzc5OTY3OGVkL3RhYmxlcmFuZ2U6MGMxYTZjODVkZGE3NDM5OTg2YTUwYzY3Nzk5Njc4ZWRfMi02LTEtMS00NjUx_fcf524ae-11be-4ae4-a439-81953ba83272"
      unitRef="usd">2000000</mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ifc1f15c64a2e42b6b50c3be424cf6c44_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjBjMWE2Yzg1ZGRhNzQzOTk4NmE1MGM2Nzc5OTY3OGVkL3RhYmxlcmFuZ2U6MGMxYTZjODVkZGE3NDM5OTg2YTUwYzY3Nzk5Njc4ZWRfMi04LTEtMS02MTI5_b9f27372-6249-4cf6-bf9c-b12cebbc940e"
      unitRef="usd">5000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i4e89e827a1584b60805bbb05008f21f5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjBjMWE2Yzg1ZGRhNzQzOTk4NmE1MGM2Nzc5OTY3OGVkL3RhYmxlcmFuZ2U6MGMxYTZjODVkZGE3NDM5OTg2YTUwYzY3Nzk5Njc4ZWRfMy0yLTEtMS00NjI3_04fbbeae-41af-45d1-b73e-bacb106bb246"
      unitRef="usd">240000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
      contextRef="i93f5b8cccc84489b9789274a5e0b0890_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjBjMWE2Yzg1ZGRhNzQzOTk4NmE1MGM2Nzc5OTY3OGVkL3RhYmxlcmFuZ2U6MGMxYTZjODVkZGE3NDM5OTg2YTUwYzY3Nzk5Njc4ZWRfMy00LTEtMS00NjUx_17cc95a0-3fad-4e6d-ad47-ac3bda36a4c9"
      unitRef="usd">5000000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress>
    <mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod
      contextRef="i93f5b8cccc84489b9789274a5e0b0890_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjBjMWE2Yzg1ZGRhNzQzOTk4NmE1MGM2Nzc5OTY3OGVkL3RhYmxlcmFuZ2U6MGMxYTZjODVkZGE3NDM5OTg2YTUwYzY3Nzk5Njc4ZWRfMy02LTEtMS00NjUx_b6f0a777-22b0-4b9b-b700-8316c1fc7e34"
      unitRef="usd">10000000</mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i39195ff1bc64463eb3aa66b95e19bd36_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjBjMWE2Yzg1ZGRhNzQzOTk4NmE1MGM2Nzc5OTY3OGVkL3RhYmxlcmFuZ2U6MGMxYTZjODVkZGE3NDM5OTg2YTUwYzY3Nzk5Njc4ZWRfMy04LTEtMS02MTI5_3f86a555-40e3-4ff6-a349-8545ff268e68"
      unitRef="usd">235000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjBjMWE2Yzg1ZGRhNzQzOTk4NmE1MGM2Nzc5OTY3OGVkL3RhYmxlcmFuZ2U6MGMxYTZjODVkZGE3NDM5OTg2YTUwYzY3Nzk5Njc4ZWRfNC0yLTEtMS02MTIz_d2e1875d-795d-4854-b033-d6fd631b366a"
      unitRef="usd">4044000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjBjMWE2Yzg1ZGRhNzQzOTk4NmE1MGM2Nzc5OTY3OGVkL3RhYmxlcmFuZ2U6MGMxYTZjODVkZGE3NDM5OTg2YTUwYzY3Nzk5Njc4ZWRfNC00LTEtMS02MTI1_5354642f-1cb1-43cd-94d9-7304f68ec7d7"
      unitRef="usd">4474000000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress>
    <mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjBjMWE2Yzg1ZGRhNzQzOTk4NmE1MGM2Nzc5OTY3OGVkL3RhYmxlcmFuZ2U6MGMxYTZjODVkZGE3NDM5OTg2YTUwYzY3Nzk5Njc4ZWRfNC02LTEtMS02MTI3_6575b2bc-68e2-4a1e-942a-a125681036a9"
      unitRef="usd">808000000</mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV81OC9mcmFnOmEzMDk0Yjg2ODg1NjRkNTY4NTgxYmYwMzU0ZmEzYzY5L3RhYmxlOjBjMWE2Yzg1ZGRhNzQzOTk4NmE1MGM2Nzc5OTY3OGVkL3RhYmxlcmFuZ2U6MGMxYTZjODVkZGE3NDM5OTg2YTUwYzY3Nzk5Njc4ZWRfNC04LTEtMS02MTI5_e909b971-bccf-462d-828e-7d8c337153c9"
      unitRef="usd">7710000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RleHRyZWdpb246NjY1Njg4N2NlOTA0NDdlN2JkN2Y4YmEyYTQ2M2FiYjZfNDg4NA_c5cc6084-b3b6-46c8-9751-f0989337d7be">Leases&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into various long-term non-cancelable lease arrangements for our facilities and equipment expiring at various times through 2032. Certain of these arrangements have free rent periods or escalating rent payment provisions. We recognize lease cost under such arrangements on a straight-line basis over the life of the leases. We have two campuses in Massachusetts, our Cambridge facility and our Moderna Technology Center (MTC), located in Norwood.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cambridge facility&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We occupy a multi-building campus in Technology Square in Cambridge, Massachusetts with a mix of offices and research laboratory space totaling approximately 175,000&#160;square feet. Our Cambridge facility leases have expiry ranges from 2020 to 2029. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Finance Leases&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Moderna Technology Center manufacturing facility (MTC South)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August&#160;2016, we entered into a lease agreement for approximately&#160;200,000&#160;square feet of office, laboratory, and light manufacturing space, MTC South, in Norwood, Massachusetts. The lease will expire in September&#160;2032. We have the option to extend the term for&#160;two&#160;extension periods of&#160;ten years&#160;each at market-based rents. The base rent is subject to increases over the term of the lease. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Moderna Technology Center North (MTC North)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2019, we entered into a lease agreement for office and laboratory space of approximately 200,000 square feet, MTC North, located in Norwood, Massachusetts. The lease commenced in the second quarter of 2019 and had an initial expiration date of 2031. We have the option to extend the lease for up to four additional five-year terms. In May 2020, we entered into an amendment to the lease whereby we exercised an option available in the original lease to receive a tenant improvement allowance in the amount of $22 million to be paid back over the term of the lease with interest and extend the term of the lease to 2035. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Embedded Leases&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into multiple contract manufacturing service agreements with third parties which contain embedded leases within the scope of ASC 842. As of March 31, 2021 and December 31, 2020, we had lease liabilities of $73&#160;million and $24&#160;million, respectively, related to the embedded leases. As of March 31, 2021 and December 31, 2020, we had right-of-use assets of $44&#160;million and zero, as certain embedded leases dedicated to our COVID-19 vaccine program were deemed to have no alternative use prior to the EUA from the FDA in December 2020. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating and financing lease right-of-use assets and lease liabilities as of March 31, 2021 and December 31, 2020 were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets, operating, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfNC0wLTEtMS04Mzk4_763696f1-1b66-43b8-a5e9-0a8445cbb910"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfNC0wLTEtMS04Mzk4_986006a3-947e-4a84-bf6d-3ecd8f99076a"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets, financing, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3) (4)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfOS0wLTEtMS0w_7afc31d0-ede8-43d3-b946-27d55409b32b"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfOS0wLTEtMS0w_d74ab000-ea21-4620-b930-521a5fdbab89"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfMTAtMC0xLTEtMzUwNw_1c2fb28d-31b2-40b2-9ba8-7bc67b5a50d3"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfMTAtMC0xLTEtMzUwNw_f985209d-7d9f-4e95-8466-842513c70552"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing lease liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing lease liabilities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total non-current lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These assets are real estate related assets, which include land, office and laboratory spaces.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net of accumulated depreciation.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These assets are&#160;real estate assets related to the MTC North and MTC South leases as well as assets related to contract manufacturing service agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in property and equipment in the condensed consolidated balance sheets, net of accumulated depreciation.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in other current liabilities in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"&gt;Future minimum lease payments under our non-cancelable lease agreements at March 31, 2021, are as follows (in&#160;millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fiscal Year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financing Leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(remainder of the year)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less amounts representing interest or imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(376)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;______&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Includes optional extensions in the MTC North and MTC South lease terms which represent a total of $339 million un-discounted future lease payments.&lt;/span&gt;&lt;/div&gt;(2) MTC South interest is based on an imputed interest rate of 17.2%. MTC North and the embedded lease interest is based upon incremental borrowing rates of 8.2% and 0.6% respectively.</us-gaap:LesseeFinanceLeasesTextBlock>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RleHRyZWdpb246NjY1Njg4N2NlOTA0NDdlN2JkN2Y4YmEyYTQ2M2FiYjZfNDg4OA_3cfd6129-9c62-4280-a1a4-f472e13d3105">Leases&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into various long-term non-cancelable lease arrangements for our facilities and equipment expiring at various times through 2032. Certain of these arrangements have free rent periods or escalating rent payment provisions. We recognize lease cost under such arrangements on a straight-line basis over the life of the leases. We have two campuses in Massachusetts, our Cambridge facility and our Moderna Technology Center (MTC), located in Norwood.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cambridge facility&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We occupy a multi-building campus in Technology Square in Cambridge, Massachusetts with a mix of offices and research laboratory space totaling approximately 175,000&#160;square feet. Our Cambridge facility leases have expiry ranges from 2020 to 2029. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Finance Leases&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Moderna Technology Center manufacturing facility (MTC South)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August&#160;2016, we entered into a lease agreement for approximately&#160;200,000&#160;square feet of office, laboratory, and light manufacturing space, MTC South, in Norwood, Massachusetts. The lease will expire in September&#160;2032. We have the option to extend the term for&#160;two&#160;extension periods of&#160;ten years&#160;each at market-based rents. The base rent is subject to increases over the term of the lease. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Moderna Technology Center North (MTC North)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2019, we entered into a lease agreement for office and laboratory space of approximately 200,000 square feet, MTC North, located in Norwood, Massachusetts. The lease commenced in the second quarter of 2019 and had an initial expiration date of 2031. We have the option to extend the lease for up to four additional five-year terms. In May 2020, we entered into an amendment to the lease whereby we exercised an option available in the original lease to receive a tenant improvement allowance in the amount of $22 million to be paid back over the term of the lease with interest and extend the term of the lease to 2035. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Embedded Leases&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into multiple contract manufacturing service agreements with third parties which contain embedded leases within the scope of ASC 842. As of March 31, 2021 and December 31, 2020, we had lease liabilities of $73&#160;million and $24&#160;million, respectively, related to the embedded leases. As of March 31, 2021 and December 31, 2020, we had right-of-use assets of $44&#160;million and zero, as certain embedded leases dedicated to our COVID-19 vaccine program were deemed to have no alternative use prior to the EUA from the FDA in December 2020. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating and financing lease right-of-use assets and lease liabilities as of March 31, 2021 and December 31, 2020 were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets, operating, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfNC0wLTEtMS04Mzk4_763696f1-1b66-43b8-a5e9-0a8445cbb910"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfNC0wLTEtMS04Mzk4_986006a3-947e-4a84-bf6d-3ecd8f99076a"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets, financing, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3) (4)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfOS0wLTEtMS0w_7afc31d0-ede8-43d3-b946-27d55409b32b"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfOS0wLTEtMS0w_d74ab000-ea21-4620-b930-521a5fdbab89"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfMTAtMC0xLTEtMzUwNw_1c2fb28d-31b2-40b2-9ba8-7bc67b5a50d3"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfMTAtMC0xLTEtMzUwNw_f985209d-7d9f-4e95-8466-842513c70552"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing lease liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing lease liabilities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total non-current lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These assets are real estate related assets, which include land, office and laboratory spaces.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net of accumulated depreciation.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These assets are&#160;real estate assets related to the MTC North and MTC South leases as well as assets related to contract manufacturing service agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in property and equipment in the condensed consolidated balance sheets, net of accumulated depreciation.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in other current liabilities in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"&gt;Future minimum lease payments under our non-cancelable lease agreements at March 31, 2021, are as follows (in&#160;millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fiscal Year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financing Leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(remainder of the year)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less amounts representing interest or imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(376)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;______&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Includes optional extensions in the MTC North and MTC South lease terms which represent a total of $339 million un-discounted future lease payments.&lt;/span&gt;&lt;/div&gt;(2) MTC South interest is based on an imputed interest rate of 17.2%. MTC North and the embedded lease interest is based upon incremental borrowing rates of 8.2% and 0.6% respectively.</us-gaap:LesseeOperatingLeasesTextBlock>
    <mrna:OperatingLeaseNumberOfProperties
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RleHRyZWdpb246NjY1Njg4N2NlOTA0NDdlN2JkN2Y4YmEyYTQ2M2FiYjZfMzY1_3b2f4191-c784-49b8-b94a-cc3db843dae5"
      unitRef="campus">2</mrna:OperatingLeaseNumberOfProperties>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i4c54e5c981c44426b958b7cd3aeb25d8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RleHRyZWdpb246NjY1Njg4N2NlOTA0NDdlN2JkN2Y4YmEyYTQ2M2FiYjZfNjc2_09bf0cbc-d993-403f-9aea-b377f7dd122e"
      unitRef="sqft">175000</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i31be9147cbb84c108e25cc00c3dd39a2_I20160831"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RleHRyZWdpb246NjY1Njg4N2NlOTA0NDdlN2JkN2Y4YmEyYTQ2M2FiYjZfMTc5NA_bac658d7-e684-4d06-8525-86ce6e88c9bc"
      unitRef="sqft">200000</us-gaap:AreaOfRealEstateProperty>
    <mrna:LesseeOperatingLeaseNumberOfExtensionPeriods
      contextRef="i31be9147cbb84c108e25cc00c3dd39a2_I20160831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RleHRyZWdpb246NjY1Njg4N2NlOTA0NDdlN2JkN2Y4YmEyYTQ2M2FiYjZfMTk4NA_80c44cca-72dc-424e-97ed-d342112753de"
      unitRef="extension_period">2</mrna:LesseeOperatingLeaseNumberOfExtensionPeriods>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i31be9147cbb84c108e25cc00c3dd39a2_I20160831"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RleHRyZWdpb246NjY1Njg4N2NlOTA0NDdlN2JkN2Y4YmEyYTQ2M2FiYjZfMjAwOA_6c1833a3-9714-46af-919e-fff13044fa84">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i72bd7d804e294a73a53c8fe39086669a_I20190228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RleHRyZWdpb246NjY1Njg4N2NlOTA0NDdlN2JkN2Y4YmEyYTQ2M2FiYjZfMjI1Mw_c91fda9c-e07b-4244-818d-7d9b296dcecf"
      unitRef="sqft">200000</us-gaap:AreaOfRealEstateProperty>
    <mrna:LesseeOperatingLeaseNumberOfExtensionPeriods
      contextRef="ie56c1c32083543d8bb94f4fb0eba71d6_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RleHRyZWdpb246NjY1Njg4N2NlOTA0NDdlN2JkN2Y4YmEyYTQ2M2FiYjZfMjQ1OA_718ef731-d20e-4cf0-ab33-e513f73fecfc"
      unitRef="extension_period">4</mrna:LesseeOperatingLeaseNumberOfExtensionPeriods>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i5946e5f9891e4ba8aa1048e39fc8cd69_I20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RleHRyZWdpb246NjY1Njg4N2NlOTA0NDdlN2JkN2Y4YmEyYTQ2M2FiYjZfNDg4Mg_3a430a3c-6e38-4539-9803-865489bbd852">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <mrna:AllowanceForTenantImprovements
      contextRef="iaad3817f49bd43e29ab66021c23b5529_I20200531"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RleHRyZWdpb246NjY1Njg4N2NlOTA0NDdlN2JkN2Y4YmEyYTQ2M2FiYjZfMjk0NA_147d3a3d-1bc5-4a15-8538-c9cd830c2e1b"
      unitRef="usd">22000000</mrna:AllowanceForTenantImprovements>
    <us-gaap:OperatingLeaseLiability
      contextRef="i747a2e93fb1b437b9939b81676cc53b5_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RleHRyZWdpb246NjY1Njg4N2NlOTA0NDdlN2JkN2Y4YmEyYTQ2M2FiYjZfNzY5NjU4MTQwMjcwNg_0549ae43-fbe8-47a9-99ef-f9989a02346b"
      unitRef="usd">73000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i8c1e58e30b1c4e8d8872e56716cb8e9f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RleHRyZWdpb246NjY1Njg4N2NlOTA0NDdlN2JkN2Y4YmEyYTQ2M2FiYjZfNzY5NjU4MTQwMjcyMg_7453ffee-1c8e-4ea6-a782-5451dfd40722"
      unitRef="usd">24000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i747a2e93fb1b437b9939b81676cc53b5_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RleHRyZWdpb246NjY1Njg4N2NlOTA0NDdlN2JkN2Y4YmEyYTQ2M2FiYjZfNzY5NjU4MTQwNjY1NA_160f2320-a5b4-4dd0-a8a8-57c6b2747a58"
      unitRef="usd">44000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i8c1e58e30b1c4e8d8872e56716cb8e9f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RleHRyZWdpb246NjY1Njg4N2NlOTA0NDdlN2JkN2Y4YmEyYTQ2M2FiYjZfNzY5NjU4MTQwNjY2Ng_b35d0945-8041-4b06-a599-6b5e644e2c20"
      unitRef="usd">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <mrna:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RleHRyZWdpb246NjY1Njg4N2NlOTA0NDdlN2JkN2Y4YmEyYTQ2M2FiYjZfNDg4Mw_7b6e43db-199b-4686-b8ca-c6fc2a552d80">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating and financing lease right-of-use assets and lease liabilities as of March 31, 2021 and December 31, 2020 were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets, operating, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfNC0wLTEtMS04Mzk4_763696f1-1b66-43b8-a5e9-0a8445cbb910"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfNC0wLTEtMS04Mzk4_986006a3-947e-4a84-bf6d-3ecd8f99076a"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets, financing, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3) (4)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfOS0wLTEtMS0w_7afc31d0-ede8-43d3-b946-27d55409b32b"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfOS0wLTEtMS0w_d74ab000-ea21-4620-b930-521a5fdbab89"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfMTAtMC0xLTEtMzUwNw_1c2fb28d-31b2-40b2-9ba8-7bc67b5a50d3"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfMTAtMC0xLTEtMzUwNw_f985209d-7d9f-4e95-8466-842513c70552"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing lease liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing lease liabilities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total non-current lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These assets are real estate related assets, which include land, office and laboratory spaces.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net of accumulated depreciation.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These assets are&#160;real estate assets related to the MTC North and MTC South leases as well as assets related to contract manufacturing service agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in property and equipment in the condensed consolidated balance sheets, net of accumulated depreciation.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in other current liabilities in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</mrna:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfMy0yLTEtMS0w_5d7e7ee4-f521-4245-92d9-cbff3eb8216a"
      unitRef="usd">89000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfMy00LTEtMS0w_787c2cf8-ce0d-4aa3-8f2c-a9ed0634f10e"
      unitRef="usd">90000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfNC0yLTEtMS0w_0c37eaaf-8157-4777-9418-876b623be94c"
      unitRef="usd">99000000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfNC00LTEtMS0w_9f310f66-f068-46ca-9d8a-0b0909bab566"
      unitRef="usd">55000000</us-gaap:FinanceLeaseRightOfUseAsset>
    <mrna:OperatingAndFinanceLeaseRightOfUseAsset
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfNS0yLTEtMS0w_a585acde-93a7-4e4b-a4fe-376094ed673b"
      unitRef="usd">188000000</mrna:OperatingAndFinanceLeaseRightOfUseAsset>
    <mrna:OperatingAndFinanceLeaseRightOfUseAsset
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfNS00LTEtMS0w_77a34044-f81a-49b4-9fd9-ad4644076571"
      unitRef="usd">145000000</mrna:OperatingAndFinanceLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfOS0yLTEtMS0w_0312beff-9d57-4942-a05d-1a5206de38f1"
      unitRef="usd">7000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfOS00LTEtMS0w_090b1317-e514-4022-9ed6-1c3e410d3f26"
      unitRef="usd">6000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfMTAtMi0xLTEtMTkyNg_4cbec68e-e8c2-438c-b5f8-c4bdae0f5662"
      unitRef="usd">45000000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfMTAtNC0xLTEtMTkxMA_e0d0a4fe-0b88-49a0-b02d-191013a30673"
      unitRef="usd">24000000</us-gaap:FinanceLeaseLiabilityCurrent>
    <mrna:OperatingAndFinanceLeaseLiabilityCurrent
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfMTEtMi0xLTEtMzQ5OQ_f2fd0f44-30ec-4bff-a631-fc33c051b635"
      unitRef="usd">52000000</mrna:OperatingAndFinanceLeaseLiabilityCurrent>
    <mrna:OperatingAndFinanceLeaseLiabilityCurrent
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfMTEtNC0xLTEtMzQ5OQ_814ab94a-311e-4908-b0eb-4d0382bff469"
      unitRef="usd">30000000</mrna:OperatingAndFinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfMTEtMi0xLTEtMA_5609911a-66a5-42c1-897c-1c3748cbd872"
      unitRef="usd">96000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfMTEtNC0xLTEtMA_750ff97a-518f-4b6d-8745-e5e3c03d1388"
      unitRef="usd">97000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfMTItMi0xLTEtMA_3069ef13-8ac6-4753-aedd-88033dcf8563"
      unitRef="usd">138000000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfMTItNC0xLTEtMA_323fd14f-5c03-4e85-9568-894e766899e5"
      unitRef="usd">110000000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <mrna:OperatingAndFinanceLeaseLiabilityNoncurrent
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfMTMtMi0xLTEtMA_da5dd887-91a1-4148-aa48-7fe2931f04d5"
      unitRef="usd">234000000</mrna:OperatingAndFinanceLeaseLiabilityNoncurrent>
    <mrna:OperatingAndFinanceLeaseLiabilityNoncurrent
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfMTMtNC0xLTEtMA_4253e99a-64d6-4aa9-a18d-f8d925c74271"
      unitRef="usd">207000000</mrna:OperatingAndFinanceLeaseLiabilityNoncurrent>
    <mrna:OperatingAndFinanceLeaseLiability
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfMTQtMi0xLTEtMA_ee8c648f-c272-438e-a937-3ac7d85cb574"
      unitRef="usd">286000000</mrna:OperatingAndFinanceLeaseLiability>
    <mrna:OperatingAndFinanceLeaseLiability
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfMTQtNC0xLTEtMA_1646a81c-ad82-46e0-ac9c-fcda6594e64e"
      unitRef="usd">237000000</mrna:OperatingAndFinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RleHRyZWdpb246NjY1Njg4N2NlOTA0NDdlN2JkN2Y4YmEyYTQ2M2FiYjZfNDg4Ng_94be2dcc-ec7e-4108-b4cf-2e8354b9ad3a">Future minimum lease payments under our non-cancelable lease agreements at March 31, 2021, are as follows (in&#160;millions):&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fiscal Year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financing Leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(remainder of the year)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less amounts representing interest or imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(376)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;______&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Includes optional extensions in the MTC North and MTC South lease terms which represent a total of $339 million un-discounted future lease payments.&lt;/span&gt;&lt;/div&gt;(2) MTC South interest is based on an imputed interest rate of 17.2%. MTC North and the embedded lease interest is based upon incremental borrowing rates of 8.2% and 0.6% respectively.</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RleHRyZWdpb246NjY1Njg4N2NlOTA0NDdlN2JkN2Y4YmEyYTQ2M2FiYjZfNDg4OQ_1a199191-2936-4f40-9fb5-c0cd251e68f9">Future minimum lease payments under our non-cancelable lease agreements at March 31, 2021, are as follows (in&#160;millions):&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fiscal Year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financing Leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(remainder of the year)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less amounts representing interest or imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(376)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;______&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Includes optional extensions in the MTC North and MTC South lease terms which represent a total of $339 million un-discounted future lease payments.&lt;/span&gt;&lt;/div&gt;(2) MTC South interest is based on an imputed interest rate of 17.2%. MTC North and the embedded lease interest is based upon incremental borrowing rates of 8.2% and 0.6% respectively.</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOjQ0NmZkN2Y4YWRmNjRjNzk4YjlhMDM5YWVhYWE4ZWFlL3RhYmxlcmFuZ2U6NDQ2ZmQ3ZjhhZGY2NGM3OThiOWEwMzlhZWFhYThlYWVfMS0yLTEtMS0w_6d0967db-80e6-479a-b7e8-94bddd1bc8fd"
      unitRef="usd">12000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOjQ0NmZkN2Y4YWRmNjRjNzk4YjlhMDM5YWVhYWE4ZWFlL3RhYmxlcmFuZ2U6NDQ2ZmQ3ZjhhZGY2NGM3OThiOWEwMzlhZWFhYThlYWVfMS00LTEtMS0w_2748c046-0d65-4c5b-8d4f-61670fc0298d"
      unitRef="usd">46000000</us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOjQ0NmZkN2Y4YWRmNjRjNzk4YjlhMDM5YWVhYWE4ZWFlL3RhYmxlcmFuZ2U6NDQ2ZmQ3ZjhhZGY2NGM3OThiOWEwMzlhZWFhYThlYWVfMi0yLTEtMS0w_a4689178-8ecd-4a87-9b68-1526d7be979d"
      unitRef="usd">16000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOjQ0NmZkN2Y4YWRmNjRjNzk4YjlhMDM5YWVhYWE4ZWFlL3RhYmxlcmFuZ2U6NDQ2ZmQ3ZjhhZGY2NGM3OThiOWEwMzlhZWFhYThlYWVfMi00LTEtMS0w_e760c324-b5fb-4793-8a83-ebf4e2473aa8"
      unitRef="usd">48000000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOjQ0NmZkN2Y4YWRmNjRjNzk4YjlhMDM5YWVhYWE4ZWFlL3RhYmxlcmFuZ2U6NDQ2ZmQ3ZjhhZGY2NGM3OThiOWEwMzlhZWFhYThlYWVfMy0yLTEtMS0w_8977d149-9f70-4bf5-9abb-49e09517b465"
      unitRef="usd">16000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOjQ0NmZkN2Y4YWRmNjRjNzk4YjlhMDM5YWVhYWE4ZWFlL3RhYmxlcmFuZ2U6NDQ2ZmQ3ZjhhZGY2NGM3OThiOWEwMzlhZWFhYThlYWVfMy00LTEtMS0w_62cb6f5a-742b-4a7c-9a47-20beeb9202b1"
      unitRef="usd">12000000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOjQ0NmZkN2Y4YWRmNjRjNzk4YjlhMDM5YWVhYWE4ZWFlL3RhYmxlcmFuZ2U6NDQ2ZmQ3ZjhhZGY2NGM3OThiOWEwMzlhZWFhYThlYWVfNC0yLTEtMS0w_20d5c397-df52-48ec-9c92-6a28e3f61286"
      unitRef="usd">16000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOjQ0NmZkN2Y4YWRmNjRjNzk4YjlhMDM5YWVhYWE4ZWFlL3RhYmxlcmFuZ2U6NDQ2ZmQ3ZjhhZGY2NGM3OThiOWEwMzlhZWFhYThlYWVfNC00LTEtMS0w_9e8e00cb-8aaa-4015-8c9d-54ba521f76ed"
      unitRef="usd">12000000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOjQ0NmZkN2Y4YWRmNjRjNzk4YjlhMDM5YWVhYWE4ZWFlL3RhYmxlcmFuZ2U6NDQ2ZmQ3ZjhhZGY2NGM3OThiOWEwMzlhZWFhYThlYWVfNS0yLTEtMS0w_15d4a455-9ece-405c-9502-650724907eb4"
      unitRef="usd">17000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOjQ0NmZkN2Y4YWRmNjRjNzk4YjlhMDM5YWVhYWE4ZWFlL3RhYmxlcmFuZ2U6NDQ2ZmQ3ZjhhZGY2NGM3OThiOWEwMzlhZWFhYThlYWVfNS00LTEtMS0w_caa4516a-e7e5-49d1-8712-5873e37b6189"
      unitRef="usd">13000000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <mrna:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOjQ0NmZkN2Y4YWRmNjRjNzk4YjlhMDM5YWVhYWE4ZWFlL3RhYmxlcmFuZ2U6NDQ2ZmQ3ZjhhZGY2NGM3OThiOWEwMzlhZWFhYThlYWVfNi0yLTEtMS0w_7ce21088-499e-4b5b-a553-86d1e53cef9b"
      unitRef="usd">94000000</mrna:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <mrna:FinanceLeaseLiabilityToBePaidAfterYearFour
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOjQ0NmZkN2Y4YWRmNjRjNzk4YjlhMDM5YWVhYWE4ZWFlL3RhYmxlcmFuZ2U6NDQ2ZmQ3ZjhhZGY2NGM3OThiOWEwMzlhZWFhYThlYWVfNi00LTEtMS0w_7833b085-7ead-416a-9e0d-91294955f8ba"
      unitRef="usd">428000000</mrna:FinanceLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOjQ0NmZkN2Y4YWRmNjRjNzk4YjlhMDM5YWVhYWE4ZWFlL3RhYmxlcmFuZ2U6NDQ2ZmQ3ZjhhZGY2NGM3OThiOWEwMzlhZWFhYThlYWVfNy0yLTEtMS0w_c62f8054-2d50-427f-a5eb-b5a9ce44d7df"
      unitRef="usd">171000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOjQ0NmZkN2Y4YWRmNjRjNzk4YjlhMDM5YWVhYWE4ZWFlL3RhYmxlcmFuZ2U6NDQ2ZmQ3ZjhhZGY2NGM3OThiOWEwMzlhZWFhYThlYWVfNy00LTEtMS0w_6e959790-c278-4f2a-9e61-ad90242105b9"
      unitRef="usd">559000000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOjQ0NmZkN2Y4YWRmNjRjNzk4YjlhMDM5YWVhYWE4ZWFlL3RhYmxlcmFuZ2U6NDQ2ZmQ3ZjhhZGY2NGM3OThiOWEwMzlhZWFhYThlYWVfOC0yLTEtMS0w_4a7ebc72-914b-4914-84b9-3b1623e5b531"
      unitRef="usd">68000000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOjQ0NmZkN2Y4YWRmNjRjNzk4YjlhMDM5YWVhYWE4ZWFlL3RhYmxlcmFuZ2U6NDQ2ZmQ3ZjhhZGY2NGM3OThiOWEwMzlhZWFhYThlYWVfOC00LTEtMS0w_02a96aaa-f738-4e7b-9c02-e530a3729f30"
      unitRef="usd">376000000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOjQ0NmZkN2Y4YWRmNjRjNzk4YjlhMDM5YWVhYWE4ZWFlL3RhYmxlcmFuZ2U6NDQ2ZmQ3ZjhhZGY2NGM3OThiOWEwMzlhZWFhYThlYWVfOS0yLTEtMS0w_7aebb77a-01f9-4cb7-9a86-f193dc00d71c"
      unitRef="usd">103000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOjQ0NmZkN2Y4YWRmNjRjNzk4YjlhMDM5YWVhYWE4ZWFlL3RhYmxlcmFuZ2U6NDQ2ZmQ3ZjhhZGY2NGM3OThiOWEwMzlhZWFhYThlYWVfOS00LTEtMS0w_633b0984-fca5-4966-840b-dc26da1d4679"
      unitRef="usd">183000000</us-gaap:FinanceLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i5c10c5b4110f49df8c8e8f8f898bbe05_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RleHRyZWdpb246NjY1Njg4N2NlOTA0NDdlN2JkN2Y4YmEyYTQ2M2FiYjZfNDUwMA_bd00fb58-e743-4a73-a3c0-a6d0fb3796e4"
      unitRef="usd">339000000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <mrna:LeasesImputedInterestRate
      contextRef="i97caad06f3f04504b59b69417b6a7236_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RleHRyZWdpb246NjY1Njg4N2NlOTA0NDdlN2JkN2Y4YmEyYTQ2M2FiYjZfNDgwOQ_516e96d2-56be-4a27-bb43-a58344b3bd71"
      unitRef="number">0.172</mrna:LeasesImputedInterestRate>
    <mrna:LeasesIncrementalBorrowingRate
      contextRef="id91f4c8df96343e8b99f1775d18c7d59_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RleHRyZWdpb246NjY1Njg4N2NlOTA0NDdlN2JkN2Y4YmEyYTQ2M2FiYjZfNDg3OQ_c09ebf26-4cad-46f3-a9f2-08b9d7cafabd"
      unitRef="number">0.082</mrna:LeasesIncrementalBorrowingRate>
    <mrna:LeasesIncrementalBorrowingRate
      contextRef="ia5b2cabe98664e3eac3b4393c8159043_D20200101-20200331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RleHRyZWdpb246NjY1Njg4N2NlOTA0NDdlN2JkN2Y4YmEyYTQ2M2FiYjZfNzY5NjU4MTQwOTUxMQ_9ef891fe-70e1-4606-8406-06b391943daf"
      unitRef="number">0.006</mrna:LeasesIncrementalBorrowingRate>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82Ny9mcmFnOjExOTRmMWVmMzFhNjQwOGE4M2M3OWEwOWVkMmY3YTk4L3RleHRyZWdpb246MTE5NGYxZWYzMWE2NDA4YTgzYzc5YTA5ZWQyZjdhOThfNTA2MA_257d36af-632b-4243-83f7-5b3f24e22436">Commitments and Contingencies&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Strategic Collaborations&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under our strategic collaboration agreements, we are committed to perform certain research, development, and manufacturing activities. As part of our PCV Agreement and PCV/SAV Agreement with Merck, we are committed to perform certain research, development and manufacturing activities related to PCV products through an initial Phase 2 clinical trial up to a budgeted amount of $243 million for both periods as of March 31, 2021 and December 31, 2020. Please refer to our 2020 Form 10-K Note 5 to our consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are not currently a party to any material legal proceedings.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indemnification Obligations&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As permitted under Delaware law, we indemnify our officers, directors, and employees for certain events, occurrences while the officer, or director is, or was, serving at our request in such capacity. The term of the indemnification is for the officer&#x2019;s or director&#x2019;s lifetime.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have standard indemnification arrangements in our leases for laboratory and office space that require us to indemnify the landlord against any liability for injury, loss, accident, or damage from any claims, actions, proceedings, or costs resulting from certain acts, breaches, violations, or non-performance under our leases.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into indemnification provisions under our agreements with counterparties in the ordinary course of business, typically with business partners, contractors, clinical sites and customers. Under these provisions, we generally indemnify and hold harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of our activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments we could be required to make under these indemnification provisions is unlimited.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Through the three months ended March 31, 2021 and the year ended December 31, 2020, we had not experienced any losses related to these indemnification obligations, and no material claims were outstanding. We do not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Purchase Commitments and Purchase Orders&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We enter into agreements in the normal course of business with vendors and contract manufacturing organizations (CMOs) for raw materials and manufacturing services and with vendors for preclinical research studies, clinical trials and other goods or services. As of March 31, 2021, we h&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;ad &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$1.0 billion of non-cancelable purchase commitments related to raw materials and manufacturing agreements, including the Lonza agreement, which are expected to be paid through 2022. As of March 31, 2021, we had $30 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; of non-c&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;ancelable purchase commitments related to clinical services and other goods and services which are expected to be paid through 2024. These amounts represent our minimum contractual obligations, including termination fees.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to purchase commitments, we have agreements with third parties for various services, including services related to clinical operations and support and contract manufacturing, for which we are not contractually able to terminate for convenience and avoid any and all future obligations to the vendors. Certain agreements provide for termination rights subject to termination fees or wind down costs. Under such agreements, we are contractually obligated to make certain payments to vendors, mainly, to reimburse them for their unrecoverable outlays incurred prior to cancellation. At March 31, 2021 and December 31, 2020, we had cancelable open purchase orders of $993 million and $897 million, respectively, in total under such agreements for our significant clinical operations and support and contract manufacturing. These amounts represent only our estimate of those items for which we had a contractual commitment to pay at March 31, 2021 and December 31, 2020, assuming we would not cancel these agreements. The actual amounts we pay in the future to the vendors under such agreements may differ from the purchase order amounts.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Licenses to Patented Technology&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 26, 2017, we entered into sublicense agreements with Cellscript, LLC and its affiliate, mRNA RiboTherapeutics, Inc. to sublicense certain patent rights. Pursuant to each agreement, we are required to pay certain license fees, annual maintenance fees, minimum royalties on future net sales and milestone payments contingent on achievement of certain development, regulatory and commercial milestones for specified products, on a product-by-product basis. The development and regulatory milestone payments, up to $2&#160;million for therapeutic and prophylactic products and up to $1&#160;million for diagnostic products will be recognized as a cost of the asset acquired upon resolution of the associated contingency and will be capitalized or expensed depending on the nature of the associated asset as of the date of recognition. Conversely, commercial milestone payments, up to $24&#160;million, and royalties based on annual net sales of licensed products for therapeutic and prophylactic products will be accounted for as additional expense of the related product sales in the period in which the corresponding sales occur. We recognized $84&#160;million of royalty expenses associated with our product sales in the first quarter of 2021, which was recorded to cost of sales in our condensed consolidated statements of operations. We did not recognize any such royalties in the first quarter of 2020 as we did not have product sales in that quarter. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, we have other in-license agreements with third parties which require us to make future development, regulatory and commercial milestone payments for specified products associated with the agreements. The achievement of these milestones was not deemed probable as of March 31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount
      contextRef="icc463e223e4f4f08b900edce1309004e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82Ny9mcmFnOjExOTRmMWVmMzFhNjQwOGE4M2M3OWEwOWVkMmY3YTk4L3RleHRyZWdpb246MTE5NGYxZWYzMWE2NDA4YTgzYzc5YTA5ZWQyZjdhOThfNDQz_6a4d2039-e2d3-4016-a494-55db6f14ec28"
      unitRef="usd">243000000</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount
      contextRef="iccb9f67ad61a42038f759003571a1508_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82Ny9mcmFnOjExOTRmMWVmMzFhNjQwOGE4M2M3OWEwOWVkMmY3YTk4L3RleHRyZWdpb246MTE5NGYxZWYzMWE2NDA4YTgzYzc5YTA5ZWQyZjdhOThfNDQz_8d4f5633-ef2f-4645-b7c3-57d900932eb4"
      unitRef="usd">243000000</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="ie54f228e1d5b4838858ccaebf45f0e9a_I20210331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82Ny9mcmFnOjExOTRmMWVmMzFhNjQwOGE4M2M3OWEwOWVkMmY3YTk4L3RleHRyZWdpb246MTE5NGYxZWYzMWE2NDA4YTgzYzc5YTA5ZWQyZjdhOThfMzYwMA_40eb0065-05b5-48f8-a497-cb807d6a3188"
      unitRef="usd">1000000000.0</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="i8204f059459747e988e68765b4fa0190_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82Ny9mcmFnOjExOTRmMWVmMzFhNjQwOGE4M2M3OWEwOWVkMmY3YTk4L3RleHRyZWdpb246MTE5NGYxZWYzMWE2NDA4YTgzYzc5YTA5ZWQyZjdhOThfMzczNQ_4938a521-d19f-42da-bfb8-5652031c5500"
      unitRef="usd">30000000</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="ic353f4f727e84c7988d44622743ab4c4_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82Ny9mcmFnOjExOTRmMWVmMzFhNjQwOGE4M2M3OWEwOWVkMmY3YTk4L3RleHRyZWdpb246MTE5NGYxZWYzMWE2NDA4YTgzYzc5YTA5ZWQyZjdhOThfNDYyMQ_43cc6b73-4a63-4af3-ab92-98f8d0f6502b"
      unitRef="usd">993000000</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="i570695e9c65448a685edf9c785db6a07_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82Ny9mcmFnOjExOTRmMWVmMzFhNjQwOGE4M2M3OWEwOWVkMmY3YTk4L3RleHRyZWdpb246MTE5NGYxZWYzMWE2NDA4YTgzYzc5YTA5ZWQyZjdhOThfNDYyOA_2106a468-832b-4fac-843c-132b39013ee6"
      unitRef="usd">897000000</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentAndRegulatoryMilestonesMaximumAmount
      contextRef="id1c2fd1d75924d69915c2130ff7af739_I20170626"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82Ny9mcmFnOjExOTRmMWVmMzFhNjQwOGE4M2M3OWEwOWVkMmY3YTk4L3RleHRyZWdpb246MTE5NGYxZWYzMWE2NDA4YTgzYzc5YTA5ZWQyZjdhOThfNzY5NjU4MTQwMzg4NA_b1ca2da3-c845-4397-96b3-03fb60fcb054"
      unitRef="usd">2000000</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentAndRegulatoryMilestonesMaximumAmount>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentAndRegulatoryMilestonesMaximumAmount
      contextRef="id39bf79de51448cbb53b0479ac1fc4fd_I20170626"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82Ny9mcmFnOjExOTRmMWVmMzFhNjQwOGE4M2M3OWEwOWVkMmY3YTk4L3RleHRyZWdpb246MTE5NGYxZWYzMWE2NDA4YTgzYzc5YTA5ZWQyZjdhOThfNzY5NjU4MTQwMzg5OA_a0ad12c0-aec5-45ee-a546-11b1b71deef3"
      unitRef="usd">1000000</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentAndRegulatoryMilestonesMaximumAmount>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount
      contextRef="id9b8f829587545b1850dc3d645793a91_I20170626"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82Ny9mcmFnOjExOTRmMWVmMzFhNjQwOGE4M2M3OWEwOWVkMmY3YTk4L3RleHRyZWdpb246MTE5NGYxZWYzMWE2NDA4YTgzYzc5YTA5ZWQyZjdhOThfNzY5NjU4MTQwMzkxMg_4c66e449-e56d-4b58-8df9-b24540b80992"
      unitRef="usd">24000000</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82Ny9mcmFnOjExOTRmMWVmMzFhNjQwOGE4M2M3OWEwOWVkMmY3YTk4L3RleHRyZWdpb246MTE5NGYxZWYzMWE2NDA4YTgzYzc5YTA5ZWQyZjdhOThfNzY5NjU4MTQwMzk0Mg_a482589e-78f2-4730-a824-c1d2a237c18e"
      unitRef="usd">84000000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RleHRyZWdpb246MGM1MzYyNTdmN2RkNDJmNjgwODIwODJmYzQyZTQxZGNfNjU5OA_ebe4d040-c67f-4327-8f7d-4a07f237aa9b">Stock-Based Compensation&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2021, we had a total of&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;62 million&#160;shares reserved for future issuance under our Equity Plans, of which 35 million shares were reserved for equity awards previously granted, and&#160;27 million&#160;shares were available for future grants under the 2018 Equity Plan. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our option activity during the three months ended March 31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number&#160;of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Options &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Price per&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Grant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Date Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Value per&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at Outstanding at Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.89)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled/forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected to vest at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of common stock for those options in the money as of March 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total intrinsic value of options exercised was $250 million for the three months ended March 31, 2021. The aggregate intrinsic value represents the difference between the exercise price and the selling price received by option holders upon the exercise of stock options during the period. The total consideration recorded as a result of stock option exercises&#160;was approximately $28 million for the three months ended March 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Common Stock Units (RSUs) and Performance Stock Units (PSUs)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our RSU and PSU activity during the three months ended March 31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Units &lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-Average&lt;br/&gt;Fair Value&lt;br/&gt;per Unit&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, non-vested at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled/forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.02)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, non-vested at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total fair value of restricted stock units vested during the three months ended March 31, 2021 was $6&#160;million. The total intrinsic value of restricted stock units vested during the three months ended March 31, 2021 was $35&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the first quarter of 2021, we granted PSUs to certain senior executives with vesting that is contingent upon the achievement of specified preestablished goals over the performance period, generally three years. The actual number of common shares ultimately &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;issued is calculated by multiplying the number of PSUs by a payout percentage ranging from 0% to 200%. The estimated fair value of PSUs is based on the grant date fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2018 Employee Stock Purchase Plan (ESPP)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no shares sold under the ESPP during the three months ended March 31, 2021. As of March 31, 2021, 4&#160;million shares were available for future issuance under the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the components and classification of stock-based compensation expense for the three months ended March 31, 2021 and 2020 as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.194%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.931%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.507%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.507%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.208%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs and PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2021, there was &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$337 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of total unrecognized compensation cost related to unvested stock-based compensation with respect to options, RSUs and PSUs granted. That cost is expected to be recognized over a weighted-average period of 3.1 years at March 31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RleHRyZWdpb246MGM1MzYyNTdmN2RkNDJmNjgwODIwODJmYzQyZTQxZGNfMjk3Mg_8e81a287-6165-4697-b5da-5ab0e7506f1f"
      unitRef="shares">62000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ia56b7a15d277445c813a9b1e913dce91_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RleHRyZWdpb246MGM1MzYyNTdmN2RkNDJmNjgwODIwODJmYzQyZTQxZGNfMzA0NA_2928a6f8-1915-46c7-ba01-8406687b6e8b"
      unitRef="shares">35000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i91b0e05ed30e415f9576819f14007d11_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RleHRyZWdpb246MGM1MzYyNTdmN2RkNDJmNjgwODIwODJmYzQyZTQxZGNfMzExMA_7f0393d3-51d2-4cbd-bc31-658762d7781c"
      unitRef="shares">27000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RleHRyZWdpb246MGM1MzYyNTdmN2RkNDJmNjgwODIwODJmYzQyZTQxZGNfNjYwMA_403b0ece-d114-4036-86b6-574231b01417">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our option activity during the three months ended March 31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number&#160;of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Options &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Price per&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Grant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Date Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Value per&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at Outstanding at Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.89)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled/forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected to vest at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of common stock for those options in the money as of March 31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfMS0yLTEtMS0w_f1ffef46-a748-4bdb-98a2-cdfa188afb55"
      unitRef="shares">34060000.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfMS00LTEtMS0w_ee8a37c5-c427-47ae-b0bc-b075b0381812"
      unitRef="usdPerShare">17.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfMS02LTEtMS0w_8457aa7b-b443-4319-bb9d-52f2699428c9"
      unitRef="usdPerShare">9.12</mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i1afaa9c0a57f43b09e758fb17bd26e7d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfMS04LTEtMS0w_22c6add3-8567-4d52-bb2e-61a9236f72de">P6Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ibc252a4be2f74a21a0b81d251afe3cdf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfMS0xMC0xLTEtMA_9bd99c71-8b70-4af6-b6aa-dde0d070b2fa"
      unitRef="usd">2976000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfMi0yLTEtMS0w_9c821d5f-3cb6-49e4-be09-c0479300362f"
      unitRef="shares">870000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfMi00LTEtMS0w_793fec8b-8e0d-47c5-a7d4-dab7cd97eadc"
      unitRef="usdPerShare">171.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfMi02LTEtMS0w_ef24f3af-f265-454e-92f5-91465406d48b"
      unitRef="usdPerShare">75.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfMy0yLTEtMS0w_ed1d958a-8fb0-40b4-96cb-7f47c75a7716"
      unitRef="shares">1890000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfMy00LTEtMS0w_edf49100-74a7-4967-b5ed-129e9919be58"
      unitRef="usdPerShare">14.80</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfMy02LTEtMS0w_08b2f755-f3af-47ff-bdf7-43ac14bcdd0f"
      unitRef="usdPerShare">8.16</mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfNC0yLTEtMS0w_2427eb17-a90d-47b4-86a0-d016b094dd54"
      unitRef="shares">90000.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfNC00LTEtMS0w_e8eb17d3-e419-4eb8-be5e-04cc97641de0"
      unitRef="usdPerShare">23.92</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfNC02LTEtMS0w_f05b15d7-ac57-469d-b384-36be2ba56530"
      unitRef="usdPerShare">11.41</mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfNS0yLTEtMS0w_3d152261-ee20-4260-bbc7-45eab9790da2"
      unitRef="shares">32950000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfNS00LTEtMS0w_3522d71a-54ad-4a96-82cc-3eb109b38956"
      unitRef="usdPerShare">21.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfNS02LTEtMS0w_069f4143-f82c-41cc-9747-5ed17d2d2757"
      unitRef="usdPerShare">10.91</mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfNS04LTEtMS0w_35597337-108f-4974-b187-2887847b66e6">P6Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfNS0xMC0xLTEtMA_90a1dfd0-aecb-4b19-b20c-948a327865c5"
      unitRef="usd">3649000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfNi0yLTEtMS0w_00e77376-f1b7-48b1-a2f7-543522072d9c"
      unitRef="shares">17650000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfNi00LTEtMS0w_14c12933-562a-4835-899a-29e16b536cc8"
      unitRef="usdPerShare">11.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfNi02LTEtMS0w_11a25540-9c88-44c6-a3d6-9e527c9a0450"
      unitRef="usdPerShare">6.04</mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfNi04LTEtMS0w_c92eb142-5fe4-494a-adb5-4271ab6d90a8">P5Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfNi0xMC0xLTEtMA_5078e96d-cce3-47e5-915a-b7a1f03f32ac"
      unitRef="usd">2107000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfNy0yLTEtMS0w_46f03ab9-538c-4aff-b6c7-cb27d7ddf553"
      unitRef="shares">15300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfNy00LTEtMS0w_acb88dbc-ec6b-4387-be0b-8c59d701db83"
      unitRef="usdPerShare">32.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfNy02LTEtMS0w_faa06510-c8c9-401b-961d-7595809b37f7"
      unitRef="usdPerShare">16.52</mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfNy04LTEtMS0w_895a6481-a30c-444c-9738-efb4d7951804">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjRkODUxNWEwMDgzNDRhOGQ5Y2QyOGFjZjE0YTgwMmJlL3RhYmxlcmFuZ2U6NGQ4NTE1YTAwODM0NGE4ZDljZDI4YWNmMTRhODAyYmVfNy0xMC0xLTEtMA_7be576ed-8e02-4a3a-ac5a-912ad76caa2a"
      unitRef="usd">1542000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RleHRyZWdpb246MGM1MzYyNTdmN2RkNDJmNjgwODIwODJmYzQyZTQxZGNfMzc0Ng_ac72a83e-0239-4fb5-a9f6-f4739373129e"
      unitRef="usd">250000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RleHRyZWdpb246MGM1MzYyNTdmN2RkNDJmNjgwODIwODJmYzQyZTQxZGNfNDAzNQ_d97dac50-048f-4791-8988-72743ef8913b"
      unitRef="usd">28000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RleHRyZWdpb246MGM1MzYyNTdmN2RkNDJmNjgwODIwODJmYzQyZTQxZGNfNjYwOA_19c795f8-9b78-435a-b1b9-9fe6f734c40e">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our RSU and PSU activity during the three months ended March 31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Units &lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-Average&lt;br/&gt;Fair Value&lt;br/&gt;per Unit&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, non-vested at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled/forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.02)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, non-vested at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ie43ed5c918a0494eb0f43d56862c3e32_I20201231"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjU0MTgyYjU4M2I1OTQxNTQ5MjkzMzMwMjVmNGI3YjQ4L3RhYmxlcmFuZ2U6NTQxODJiNTgzYjU5NDE1NDkyOTMzMzAyNWY0YjdiNDhfMS0xLTEtMS0w_38eede53-f60c-4b9e-b941-ed024e325080"
      unitRef="shares">2190000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ie43ed5c918a0494eb0f43d56862c3e32_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjU0MTgyYjU4M2I1OTQxNTQ5MjkzMzMwMjVmNGI3YjQ4L3RhYmxlcmFuZ2U6NTQxODJiNTgzYjU5NDE1NDkyOTMzMzAyNWY0YjdiNDhfMS0zLTEtMS0w_7ed7b6ca-eabe-4879-8968-a5c770c67ff5"
      unitRef="usdPerShare">30.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i26a6b2b2db7f4f52a54072c86dbb902c_D20210101-20210331"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjU0MTgyYjU4M2I1OTQxNTQ5MjkzMzMwMjVmNGI3YjQ4L3RhYmxlcmFuZ2U6NTQxODJiNTgzYjU5NDE1NDkyOTMzMzAyNWY0YjdiNDhfMi0xLTEtMS0w_332a45ff-f541-4e0f-9d09-74ae026725bc"
      unitRef="shares">460000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i26a6b2b2db7f4f52a54072c86dbb902c_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjU0MTgyYjU4M2I1OTQxNTQ5MjkzMzMwMjVmNGI3YjQ4L3RhYmxlcmFuZ2U6NTQxODJiNTgzYjU5NDE1NDkyOTMzMzAyNWY0YjdiNDhfMi0zLTEtMS0w_4728e5f3-4267-4c63-80ea-b0bb65fa4db2"
      unitRef="usdPerShare">165.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i26a6b2b2db7f4f52a54072c86dbb902c_D20210101-20210331"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjU0MTgyYjU4M2I1OTQxNTQ5MjkzMzMwMjVmNGI3YjQ4L3RhYmxlcmFuZ2U6NTQxODJiNTgzYjU5NDE1NDkyOTMzMzAyNWY0YjdiNDhfMy0xLTEtMS0w_020e0fca-c923-4bd0-b5b0-fb6a712ec89c"
      unitRef="shares">240000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i26a6b2b2db7f4f52a54072c86dbb902c_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjU0MTgyYjU4M2I1OTQxNTQ5MjkzMzMwMjVmNGI3YjQ4L3RhYmxlcmFuZ2U6NTQxODJiNTgzYjU5NDE1NDkyOTMzMzAyNWY0YjdiNDhfMy0zLTEtMS0w_0d009e68-515e-484b-b5ea-6909b3bcad6c"
      unitRef="usdPerShare">24.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i26a6b2b2db7f4f52a54072c86dbb902c_D20210101-20210331"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjU0MTgyYjU4M2I1OTQxNTQ5MjkzMzMwMjVmNGI3YjQ4L3RhYmxlcmFuZ2U6NTQxODJiNTgzYjU5NDE1NDkyOTMzMzAyNWY0YjdiNDhfNC0xLTEtMS0w_4948c134-10d9-4195-bb7a-02506f8deca8"
      unitRef="shares">20000.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i26a6b2b2db7f4f52a54072c86dbb902c_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjU0MTgyYjU4M2I1OTQxNTQ5MjkzMzMwMjVmNGI3YjQ4L3RhYmxlcmFuZ2U6NTQxODJiNTgzYjU5NDE1NDkyOTMzMzAyNWY0YjdiNDhfNC0zLTEtMS0w_8d686cdb-1fe8-4ab7-b0af-6e0e1e98f37c"
      unitRef="usdPerShare">32.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i53c9c75bd90d46278b4077d5e35f7d5b_I20210331"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjU0MTgyYjU4M2I1OTQxNTQ5MjkzMzMwMjVmNGI3YjQ4L3RhYmxlcmFuZ2U6NTQxODJiNTgzYjU5NDE1NDkyOTMzMzAyNWY0YjdiNDhfNS0xLTEtMS0w_8190f217-dc9a-480d-a107-3351911a3093"
      unitRef="shares">2390000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i53c9c75bd90d46278b4077d5e35f7d5b_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOjU0MTgyYjU4M2I1OTQxNTQ5MjkzMzMwMjVmNGI3YjQ4L3RhYmxlcmFuZ2U6NTQxODJiNTgzYjU5NDE1NDkyOTMzMzAyNWY0YjdiNDhfNS0zLTEtMS0w_1055a59a-2e32-4745-b253-83ca00389ea0"
      unitRef="usdPerShare">57.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:RestrictedStockExpense
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RleHRyZWdpb246MGM1MzYyNTdmN2RkNDJmNjgwODIwODJmYzQyZTQxZGNfNzY5NjU4MTQxODM1OA_4036bcfb-f629-4be4-b39f-021b678d5e04"
      unitRef="usd">6000000</us-gaap:RestrictedStockExpense>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="i26a6b2b2db7f4f52a54072c86dbb902c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RleHRyZWdpb246MGM1MzYyNTdmN2RkNDJmNjgwODIwODJmYzQyZTQxZGNfNzY5NjU4MTQyNDA5NQ_d17f4227-fa75-4852-bd4e-e1fa1ebe2a5d"
      unitRef="usd">35000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="i9c17046964e4496093fef93215168f9c_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RleHRyZWdpb246MGM1MzYyNTdmN2RkNDJmNjgwODIwODJmYzQyZTQxZGNfMzI5ODUzNDkxMjc0Nw_4fd37812-8f41-413b-9644-47b1a9c7c669">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage
      contextRef="ie18c5203639447448d73f34f409c6682_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RleHRyZWdpb246MGM1MzYyNTdmN2RkNDJmNjgwODIwODJmYzQyZTQxZGNfNzY5NjU4MTQxNzQyMw_a7da6f75-ffb6-42d7-8544-32e6674230df"
      unitRef="number">0</mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage>
    <mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage
      contextRef="ia750d90906f64b3da90f3ea25a6e6c88_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RleHRyZWdpb246MGM1MzYyNTdmN2RkNDJmNjgwODIwODJmYzQyZTQxZGNfNzY5NjU4MTQxNzQyNw_24ca3e78-1388-4be2-bfca-700c1712ab5b"
      unitRef="number">2</mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i1e7259ec870c4de7815c0a34b19ed99c_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RleHRyZWdpb246MGM1MzYyNTdmN2RkNDJmNjgwODIwODJmYzQyZTQxZGNfMzI5ODUzNDkxMjczOQ_d8e7ebdd-0a09-4daf-a176-62483ea5d043"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ibf2c3f50e45f44bfa74451d6d87a3675_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RleHRyZWdpb246MGM1MzYyNTdmN2RkNDJmNjgwODIwODJmYzQyZTQxZGNfNTc5NQ_6228c592-1e2a-4235-9438-9d5da88e416e"
      unitRef="shares">4000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RleHRyZWdpb246MGM1MzYyNTdmN2RkNDJmNjgwODIwODJmYzQyZTQxZGNfNjYxMg_c33cc844-7c59-46e1-bd15-87d64761154d">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the components and classification of stock-based compensation expense for the three months ended March 31, 2021 and 2020 as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.194%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.931%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.507%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.507%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.208%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs and PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i22567b607e5a40439a3314231a4c0b31_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOmRhYWJmNWUyZWQ2NTQ1OTQ4MDc5ODZlYTBkMjgxM2FhL3RhYmxlcmFuZ2U6ZGFhYmY1ZTJlZDY1NDU5NDgwNzk4NmVhMGQyODEzYWFfMi05LTEtMS0w_a8f986a3-24e3-4c29-92e6-4a7db1cc0032"
      unitRef="usd">22000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if820d61e1d2e4cb3a94f601c28956f74_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOmRhYWJmNWUyZWQ2NTQ1OTQ4MDc5ODZlYTBkMjgxM2FhL3RhYmxlcmFuZ2U6ZGFhYmY1ZTJlZDY1NDU5NDgwNzk4NmVhMGQyODEzYWFfMi0xMS0xLTEtMA_f468358b-f265-4614-9651-e93936af8212"
      unitRef="usd">18000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i53f43d6f041a413d9ba3a5b6031c5bca_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOmRhYWJmNWUyZWQ2NTQ1OTQ4MDc5ODZlYTBkMjgxM2FhL3RhYmxlcmFuZ2U6ZGFhYmY1ZTJlZDY1NDU5NDgwNzk4NmVhMGQyODEzYWFfMy05LTEtMS0w_181d7ba9-9050-45d5-baa4-bcde12871397"
      unitRef="usd">7000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie0ee58a110904b6ea810fa10add84823_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOmRhYWJmNWUyZWQ2NTQ1OTQ4MDc5ODZlYTBkMjgxM2FhL3RhYmxlcmFuZ2U6ZGFhYmY1ZTJlZDY1NDU5NDgwNzk4NmVhMGQyODEzYWFfMy0xMS0xLTEtMA_ce0793e6-e3df-48a2-a6d6-51f95002e812"
      unitRef="usd">2000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1e7259ec870c4de7815c0a34b19ed99c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOmRhYWJmNWUyZWQ2NTQ1OTQ4MDc5ODZlYTBkMjgxM2FhL3RhYmxlcmFuZ2U6ZGFhYmY1ZTJlZDY1NDU5NDgwNzk4NmVhMGQyODEzYWFfNC05LTEtMS0w_896679b2-d8fb-449e-84d9-205b8db30557"
      unitRef="usd">1000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1f6bab6d04464aa58adc35f314641f71_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOmRhYWJmNWUyZWQ2NTQ1OTQ4MDc5ODZlYTBkMjgxM2FhL3RhYmxlcmFuZ2U6ZGFhYmY1ZTJlZDY1NDU5NDgwNzk4NmVhMGQyODEzYWFfNC0xMS0xLTEtMA_5a474710-3ab2-4157-9e48-113173281252"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOmRhYWJmNWUyZWQ2NTQ1OTQ4MDc5ODZlYTBkMjgxM2FhL3RhYmxlcmFuZ2U6ZGFhYmY1ZTJlZDY1NDU5NDgwNzk4NmVhMGQyODEzYWFfNS05LTEtMS0w_644f190b-fb2d-4865-a109-b48aece2f61b"
      unitRef="usd">30000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOmRhYWJmNWUyZWQ2NTQ1OTQ4MDc5ODZlYTBkMjgxM2FhL3RhYmxlcmFuZ2U6ZGFhYmY1ZTJlZDY1NDU5NDgwNzk4NmVhMGQyODEzYWFfNS0xMS0xLTEtMA_b5c59ef8-5d8f-496a-add7-1d60d64d019a"
      unitRef="usd">20000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibca633e1d4664bcd8090d7383938bd13_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOmRhYWJmNWUyZWQ2NTQ1OTQ4MDc5ODZlYTBkMjgxM2FhL3RhYmxlcmFuZ2U6ZGFhYmY1ZTJlZDY1NDU5NDgwNzk4NmVhMGQyODEzYWFfNy05LTEtMS0zMTA0_4f4d0dca-a3fb-46cb-8a1f-ca5faaff60e8"
      unitRef="usd">4000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if11b06a738a64cf88f8e86ac44cbfe87_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOmRhYWJmNWUyZWQ2NTQ1OTQ4MDc5ODZlYTBkMjgxM2FhL3RhYmxlcmFuZ2U6ZGFhYmY1ZTJlZDY1NDU5NDgwNzk4NmVhMGQyODEzYWFfNy0xMS0xLTEtMzU0Mg_edf45169-f2d0-49b7-8e23-5a6928bb0f48"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if7207e2b92904a3ea65000ec12644d42_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOmRhYWJmNWUyZWQ2NTQ1OTQ4MDc5ODZlYTBkMjgxM2FhL3RhYmxlcmFuZ2U6ZGFhYmY1ZTJlZDY1NDU5NDgwNzk4NmVhMGQyODEzYWFfNi05LTEtMS0w_6ce8257f-f7c5-426d-91de-80c3f213f4ce"
      unitRef="usd">14000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i99e931e8a5cd44ea88397661762d28f1_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOmRhYWJmNWUyZWQ2NTQ1OTQ4MDc5ODZlYTBkMjgxM2FhL3RhYmxlcmFuZ2U6ZGFhYmY1ZTJlZDY1NDU5NDgwNzk4NmVhMGQyODEzYWFfNi0xMS0xLTEtMA_740f24dc-b4dd-478f-a44c-c65fa74a9480"
      unitRef="usd">12000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6a4b450ab98d4f6b90381fecd841a0a5_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOmRhYWJmNWUyZWQ2NTQ1OTQ4MDc5ODZlYTBkMjgxM2FhL3RhYmxlcmFuZ2U6ZGFhYmY1ZTJlZDY1NDU5NDgwNzk4NmVhMGQyODEzYWFfNy05LTEtMS0w_67c74622-ad86-4a67-a14e-0b5bb4ee41cf"
      unitRef="usd">12000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9b44e002e91945e5a00c7bcd2919634d_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOmRhYWJmNWUyZWQ2NTQ1OTQ4MDc5ODZlYTBkMjgxM2FhL3RhYmxlcmFuZ2U6ZGFhYmY1ZTJlZDY1NDU5NDgwNzk4NmVhMGQyODEzYWFfNy0xMS0xLTEtMA_328d63d5-4082-4858-ac69-79f41027c43a"
      unitRef="usd">8000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOmRhYWJmNWUyZWQ2NTQ1OTQ4MDc5ODZlYTBkMjgxM2FhL3RhYmxlcmFuZ2U6ZGFhYmY1ZTJlZDY1NDU5NDgwNzk4NmVhMGQyODEzYWFfOC05LTEtMS0w_5e6c1791-05c7-4a39-b0ae-555d3c2776ca"
      unitRef="usd">30000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RhYmxlOmRhYWJmNWUyZWQ2NTQ1OTQ4MDc5ODZlYTBkMjgxM2FhL3RhYmxlcmFuZ2U6ZGFhYmY1ZTJlZDY1NDU5NDgwNzk4NmVhMGQyODEzYWFfOC0xMS0xLTEtMA_f9911f9a-019d-4b05-9928-8befaa5b4dda"
      unitRef="usd">20000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i40e5fc820d824be1931d54b51dd263a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RleHRyZWdpb246MGM1MzYyNTdmN2RkNDJmNjgwODIwODJmYzQyZTQxZGNfNjM3MA_ea8856be-bcaf-4c46-a9a1-64e91f7d96b4"
      unitRef="usd">337000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83My9mcmFnOjBjNTM2MjU3ZjdkZDQyZjY4MDgyMDgyZmM0MmU0MWRjL3RleHRyZWdpb246MGM1MzYyNTdmN2RkNDJmNjgwODIwODJmYzQyZTQxZGNfNjU4NQ_0f65cadc-1e26-4921-978e-0fb17d41f838">P3Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83OS9mcmFnOmQ2Mjk3YjMzNzM0ODQ4NjA5OGU3ZGFhNDY0YTc0NjVjL3RleHRyZWdpb246ZDYyOTdiMzM3MzQ4NDg2MDk4ZTdkYWE0NjRhNzQ2NWNfMTA5Mw_c166249a-44c5-4bb8-8535-2048b2d83aa2">Income Taxes&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are subject to U.S. federal, state, and foreign income taxes. For the three months ended March 31, 2021 and 2020, we recorded provisions for income taxes of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$39 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and an immaterial amount, respectively. Our effective tax rate for the three months ended March 31, 2021 was lower than the U.S. statutory rate primarily due to the benefit of the foreign derived intangible income deduction, the benefit related to the release of the valuation allowance on the majority of our tax attributes and other deferred tax assets, as well as a discrete item for excess tax benefits related to stock-based compensation. Our effective tax rate for the three months ended March 31, 2020 was lower than the U.S. statutory rate primarily due to the valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities. These differences are measured using the enacted statutory tax rates that are expected to be in effect for the years in which differences are expected to reverse. On a periodic basis, we reassess any valuation allowances that we maintain on our deferred tax assets, weighing positive and negative evidence to assess the recoverability of the deferred tax assets. For the three months ended March 31, 2021, we reassessed the valuation allowance noting the increase in positive evidence, including significant revenue growth, expectations regarding future profitability, and successful supply chain and manufacturing capabilities to meet global product demand. After assessing both the positive evidence and negative evidence, we determined it was more likely than not that we will realize the majority of our deferred tax assets. Therefore, we determined we should reverse the majority of our valuation allowance through the annual effective tax rate (AETR) with respect to amounts we expect to realize through current year income. In addition, we have recorded a discrete benefit of $49&#160;million related to the release of the valuation allowance on deferred tax assets that we expect to utilize in future years. We will maintain a valuation allowance on certain state tax attributes that we expect will expire prior to the utilization. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the Coronavirus Aid, Relief and Economic Security Act (CARES Act) was signed into law. The CARES Act includes provisions relating to several aspects of corporate income taxes. We do not currently expect the CARES Act to have a significant impact on our provision for income taxes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have reviewed the tax positions taken, or to be taken, in our tax returns for all tax years currently open to examination by a taxing authority. Unrecognized tax benefits represent the aggregate tax effect of differences between tax return positions and the benefits recognized in the financial statements. As of March 31, 2021 and December 31, 2020, we had an immaterial amount of gross unrecognized tax benefits, which would affect our tax rate if recognized. We do not expect that our unrecognized tax benefits will materially increase within the next twelve months. We accrue interest and penalties related to unrecognized tax benefits as a component of our provision for income taxes. We did not recognize any material interest or penalties related to uncertain tax positions during the three months ended March 31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We file U.S. federal income tax returns and income tax returns in various state, local and foreign jurisdictions. We are not currently subject to any tax assessment from an income tax examination in the United States or any other major taxing jurisdiction since inception.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83OS9mcmFnOmQ2Mjk3YjMzNzM0ODQ4NjA5OGU3ZGFhNDY0YTc0NjVjL3RleHRyZWdpb246ZDYyOTdiMzM3MzQ4NDg2MDk4ZTdkYWE0NjRhNzQ2NWNfNDk0NzgwMjMzNzA0Mw_17499976-14fe-4325-995a-0fc71ff43227"
      unitRef="usd">39000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV83OS9mcmFnOmQ2Mjk3YjMzNzM0ODQ4NjA5OGU3ZGFhNDY0YTc0NjVjL3RleHRyZWdpb246ZDYyOTdiMzM3MzQ4NDg2MDk4ZTdkYWE0NjRhNzQ2NWNfMzI5ODUzNDkwMTM2OA_d7145a57-ec08-424b-9ba5-9e15a7b0ed98"
      unitRef="usd">-49000000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV84NS9mcmFnOjc5ZWMyYjZkNjg5MzQ5OWI4MDRhNmJiOGUyZGJlOTFlL3RleHRyZWdpb246NzllYzJiNmQ2ODkzNDk5YjgwNGE2YmI4ZTJkYmU5MWVfNzY5NjU4MTM5NjkzMQ_35e8b5a4-7802-4311-b41c-e6be4072ed48">Earnings per Share &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The computation of basic earnings per share (EPS) is based on the weighted-average number of our common shares outstanding. The computation of diluted EPS is based on the weighted-average number of our common shares outstanding and potential dilutive common shares outstanding during the period as determined by using the treasury stock method.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted EPS for the three months ended March 31, 2021 and 2020 are calculated as follows (in millions, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.5pt;text-align:left;text-indent:-13.5pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;text-indent:-18pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic weighted-average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted weighted-average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following common stock equivalents, presented based on amounts outstanding as of March 31, 2020 were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because their inclusion would have been anti-dilutive (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.984%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted common stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV84NS9mcmFnOjc5ZWMyYjZkNjg5MzQ5OWI4MDRhNmJiOGUyZGJlOTFlL3RleHRyZWdpb246NzllYzJiNmQ2ODkzNDk5YjgwNGE2YmI4ZTJkYmU5MWVfNDUy_7e68e738-ce36-4def-8f34-047fb6c9dccf">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted EPS for the three months ended March 31, 2021 and 2020 are calculated as follows (in millions, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.5pt;text-align:left;text-indent:-13.5pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;text-indent:-18pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic weighted-average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted weighted-average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV84NS9mcmFnOjc5ZWMyYjZkNjg5MzQ5OWI4MDRhNmJiOGUyZGJlOTFlL3RhYmxlOjg2NDU2NGQwNjUzMzRhNWY5NGFiOGE1OTIyNzFjMWE1L3RhYmxlcmFuZ2U6ODY0NTY0ZDA2NTMzNGE1Zjk0YWI4YTU5MjI3MWMxYTVfMy05LTEtMS0w_f43105a8-00f7-466f-b48f-87f9f733c807"
      unitRef="usd">1221000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV84NS9mcmFnOjc5ZWMyYjZkNjg5MzQ5OWI4MDRhNmJiOGUyZGJlOTFlL3RhYmxlOjg2NDU2NGQwNjUzMzRhNWY5NGFiOGE1OTIyNzFjMWE1L3RhYmxlcmFuZ2U6ODY0NTY0ZDA2NTMzNGE1Zjk0YWI4YTU5MjI3MWMxYTVfMy0xMS0xLTEtMA_bb034464-8359-4c31-a334-f93eb09e1407"
      unitRef="usd">-124000000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV84NS9mcmFnOjc5ZWMyYjZkNjg5MzQ5OWI4MDRhNmJiOGUyZGJlOTFlL3RhYmxlOjg2NDU2NGQwNjUzMzRhNWY5NGFiOGE1OTIyNzFjMWE1L3RhYmxlcmFuZ2U6ODY0NTY0ZDA2NTMzNGE1Zjk0YWI4YTU5MjI3MWMxYTVfNS05LTEtMS0w_6dd4853d-d23d-456e-9910-d8f163198c4c"
      unitRef="shares">400000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV84NS9mcmFnOjc5ZWMyYjZkNjg5MzQ5OWI4MDRhNmJiOGUyZGJlOTFlL3RhYmxlOjg2NDU2NGQwNjUzMzRhNWY5NGFiOGE1OTIyNzFjMWE1L3RhYmxlcmFuZ2U6ODY0NTY0ZDA2NTMzNGE1Zjk0YWI4YTU5MjI3MWMxYTVfNS0xMS0xLTEtMA_53cd964d-4a01-4b16-a7b7-6543d553e318"
      unitRef="shares">353000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV84NS9mcmFnOjc5ZWMyYjZkNjg5MzQ5OWI4MDRhNmJiOGUyZGJlOTFlL3RhYmxlOjg2NDU2NGQwNjUzMzRhNWY5NGFiOGE1OTIyNzFjMWE1L3RhYmxlcmFuZ2U6ODY0NTY0ZDA2NTMzNGE1Zjk0YWI4YTU5MjI3MWMxYTVfNi05LTEtMS0zMTg2_a9d8739d-6e0e-458e-a61f-0ed5c3f5c9d5"
      unitRef="shares">30000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV84NS9mcmFnOjc5ZWMyYjZkNjg5MzQ5OWI4MDRhNmJiOGUyZGJlOTFlL3RhYmxlOjg2NDU2NGQwNjUzMzRhNWY5NGFiOGE1OTIyNzFjMWE1L3RhYmxlcmFuZ2U6ODY0NTY0ZDA2NTMzNGE1Zjk0YWI4YTU5MjI3MWMxYTVfNi0xMS0xLTEtMzE4Ng_a86e028c-551b-47e1-8557-80edb830bc97"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV84NS9mcmFnOjc5ZWMyYjZkNjg5MzQ5OWI4MDRhNmJiOGUyZGJlOTFlL3RhYmxlOjg2NDU2NGQwNjUzMzRhNWY5NGFiOGE1OTIyNzFjMWE1L3RhYmxlcmFuZ2U6ODY0NTY0ZDA2NTMzNGE1Zjk0YWI4YTU5MjI3MWMxYTVfNy05LTEtMS0zNTYw_e7b7a728-c34a-4780-9181-f6f5b8a273b1"
      unitRef="shares">430000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV84NS9mcmFnOjc5ZWMyYjZkNjg5MzQ5OWI4MDRhNmJiOGUyZGJlOTFlL3RhYmxlOjg2NDU2NGQwNjUzMzRhNWY5NGFiOGE1OTIyNzFjMWE1L3RhYmxlcmFuZ2U6ODY0NTY0ZDA2NTMzNGE1Zjk0YWI4YTU5MjI3MWMxYTVfNy0xMS0xLTEtMzU2Mg_d6197514-dec2-4a4f-a900-84e1e79d59be"
      unitRef="shares">353000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV84NS9mcmFnOjc5ZWMyYjZkNjg5MzQ5OWI4MDRhNmJiOGUyZGJlOTFlL3RhYmxlOjg2NDU2NGQwNjUzMzRhNWY5NGFiOGE1OTIyNzFjMWE1L3RhYmxlcmFuZ2U6ODY0NTY0ZDA2NTMzNGE1Zjk0YWI4YTU5MjI3MWMxYTVfNi05LTEtMS0w_08e2fb9c-ef0d-4811-90ab-aa801bfdbc1e"
      unitRef="usdPerShare">3.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV84NS9mcmFnOjc5ZWMyYjZkNjg5MzQ5OWI4MDRhNmJiOGUyZGJlOTFlL3RhYmxlOjg2NDU2NGQwNjUzMzRhNWY5NGFiOGE1OTIyNzFjMWE1L3RhYmxlcmFuZ2U6ODY0NTY0ZDA2NTMzNGE1Zjk0YWI4YTU5MjI3MWMxYTVfNi0xMS0xLTEtMA_9870cb74-c4f2-4731-aa70-0269f0579e26"
      unitRef="usdPerShare">-0.35</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV84NS9mcmFnOjc5ZWMyYjZkNjg5MzQ5OWI4MDRhNmJiOGUyZGJlOTFlL3RhYmxlOjg2NDU2NGQwNjUzMzRhNWY5NGFiOGE1OTIyNzFjMWE1L3RhYmxlcmFuZ2U6ODY0NTY0ZDA2NTMzNGE1Zjk0YWI4YTU5MjI3MWMxYTVfMTAtOS0xLTEtMzU2Mw_b04a7214-8e62-4a7e-8768-da6a2aa08391"
      unitRef="usdPerShare">2.84</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV84NS9mcmFnOjc5ZWMyYjZkNjg5MzQ5OWI4MDRhNmJiOGUyZGJlOTFlL3RhYmxlOjg2NDU2NGQwNjUzMzRhNWY5NGFiOGE1OTIyNzFjMWE1L3RhYmxlcmFuZ2U6ODY0NTY0ZDA2NTMzNGE1Zjk0YWI4YTU5MjI3MWMxYTVfMTAtMTEtMS0xLTM1NjY_b830a7b6-7d3f-41ab-9d08-5f566cbc4bd0"
      unitRef="usdPerShare">-0.35</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV84NS9mcmFnOjc5ZWMyYjZkNjg5MzQ5OWI4MDRhNmJiOGUyZGJlOTFlL3RleHRyZWdpb246NzllYzJiNmQ2ODkzNDk5YjgwNGE2YmI4ZTJkYmU5MWVfNDU1_14b24698-d58b-4109-9bd5-74782da09dd6">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following common stock equivalents, presented based on amounts outstanding as of March 31, 2020 were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because their inclusion would have been anti-dilutive (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.984%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted common stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i649444b931a542648a2d656ef5f35e1c_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV84NS9mcmFnOjc5ZWMyYjZkNjg5MzQ5OWI4MDRhNmJiOGUyZGJlOTFlL3RhYmxlOmZhYTk1OTMwNGQ0ZTQwNjE4ZTVkYzVlOTY1ZThhOGI0L3RhYmxlcmFuZ2U6ZmFhOTU5MzA0ZDRlNDA2MThlNWRjNWU5NjVlOGE4YjRfMi0zLTEtMS0w_f5e13b90-fdb2-426f-bd82-f31aef280669"
      unitRef="shares">45000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0b71c01ae54c49e288fce1e85063a0c0_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV84NS9mcmFnOjc5ZWMyYjZkNjg5MzQ5OWI4MDRhNmJiOGUyZGJlOTFlL3RhYmxlOmZhYTk1OTMwNGQ0ZTQwNjE4ZTVkYzVlOTY1ZThhOGI0L3RhYmxlcmFuZ2U6ZmFhOTU5MzA0ZDRlNDA2MThlNWRjNWU5NjVlOGE4YjRfNC0zLTEtMS0w_e21acbec-eb3c-43fe-b6dd-a776830697f7"
      unitRef="shares">2000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV84NS9mcmFnOjc5ZWMyYjZkNjg5MzQ5OWI4MDRhNmJiOGUyZGJlOTFlL3RhYmxlOmZhYTk1OTMwNGQ0ZTQwNjE4ZTVkYzVlOTY1ZThhOGI0L3RhYmxlcmFuZ2U6ZmFhOTU5MzA0ZDRlNDA2MThlNWRjNWU5NjVlOGE4YjRfNS0zLTEtMS0w_908d7817-9efc-424c-a249-8a5ae0f052f0"
      unitRef="shares">47000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="ie20e480bc066475e9f962590283234e4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV84OC9mcmFnOjgwNjAzZTY4MzUwNTRlMzhhZTgyNDhmNDRiNWU4OWJiL3RleHRyZWdpb246ODA2MDNlNjgzNTA1NGUzOGFlODI0OGY0NGI1ZTg5YmJfNTQz_78ca989c-39da-4ad5-815e-2027cd165b17">Subsequent Events&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to March 31, 2021, we have entered into additional supply agreements with customers to provide up to 47&#160;million doses of our COVID-19 vaccine based on the initial confirmed volume, subject to modifications.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to March 31, 2021, we have entered into additional binding purchase commitments with third-party contractual manufacturing organizations for our COVID-19 vaccine under existing or newly executed agreements. We are currently committed to minimum non-cancelable purchase obligations of $284&#160;million related to these agreements, which are expected to be paid through 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, on April 18, 2021, we entered into a further amendment to our existing agreement with BARDA, pursuant to which BARDA has agreed to fund the advancement of mRNA-1273 to potential licensure, including funding for clinical studies and manufacturing scale-up. The amendment increases the amount of potential reimbursements by $236&#160;million in connection with costs associated with the Phase 3 clinical trials for mRNA-1273 and pharmacovigilance efforts, bringing the total BARDA support to approximately $1.3&#160;billion.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <mrna:NumberOfDosesOfVaccineCandidate
      contextRef="i9c022d9b4fbe4b8b8966c5f007b5faf4_D20210401-20210507"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV84OC9mcmFnOjgwNjAzZTY4MzUwNTRlMzhhZTgyNDhmNDRiNWU4OWJiL3RleHRyZWdpb246ODA2MDNlNjgzNTA1NGUzOGFlODI0OGY0NGI1ZTg5YmJfNzY5NjU4MTQwNzI1OA_808ac99b-788c-4cc9-8047-26881b776c0d"
      unitRef="dose">47000000</mrna:NumberOfDosesOfVaccineCandidate>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="ic8a5bdf50ed34e1196383b6df3a4c6e7_I20210507"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV84OC9mcmFnOjgwNjAzZTY4MzUwNTRlMzhhZTgyNDhmNDRiNWU4OWJiL3RleHRyZWdpb246ODA2MDNlNjgzNTA1NGUzOGFlODI0OGY0NGI1ZTg5YmJfNzY5NjU4MTM5NzY2OQ_f3ffa23c-b83d-4dd4-87c4-57d83385c6b8"
      unitRef="usd">284000000</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <mrna:RevenueFromGrantsPotentialReimbursement
      contextRef="i1d9fd4412ca74750b6b14d4722981e10_D20210418-20210418"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV84OC9mcmFnOjgwNjAzZTY4MzUwNTRlMzhhZTgyNDhmNDRiNWU4OWJiL3RleHRyZWdpb246ODA2MDNlNjgzNTA1NGUzOGFlODI0OGY0NGI1ZTg5YmJfNzY5NjU4MTQwMDk2OQ_b35c6c82-d9f1-49bb-9189-5a93e6501fc2"
      unitRef="usd">236000000</mrna:RevenueFromGrantsPotentialReimbursement>
    <mrna:RevenueFromGrantsMaximumAward
      contextRef="i1d9fd4412ca74750b6b14d4722981e10_D20210418-20210418"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV84OC9mcmFnOjgwNjAzZTY4MzUwNTRlMzhhZTgyNDhmNDRiNWU4OWJiL3RleHRyZWdpb246ODA2MDNlNjgzNTA1NGUzOGFlODI0OGY0NGI1ZTg5YmJfNzY5NjU4MTQwMDk4Mw_c2f06a32-bee4-4afb-97ca-9499aa05669f"
      unitRef="usd">1300000000</mrna:RevenueFromGrantsMaximumAward>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865598885848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Moderna, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-3467528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">200 Technology Square<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">714-6500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MRNA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">401,527,789<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001682852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865598734536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 5,442<span></span>
</td>
<td class="nump">$ 2,624<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Investments</a></td>
<td class="nump">2,293<span></span>
</td>
<td class="nump">1,984<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">3,210<span></span>
</td>
<td class="nump">1,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">494<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">264<span></span>
</td>
<td class="nump">252<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">11,703<span></span>
</td>
<td class="nump">6,298<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Investments, non-current</a></td>
<td class="nump">468<span></span>
</td>
<td class="nump">639<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">372<span></span>
</td>
<td class="nump">297<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, operating leases</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash, non-current</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">12,694<span></span>
</td>
<td class="nump">7,337<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">753<span></span>
</td>
<td class="nump">470<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">7,531<span></span>
</td>
<td class="nump">3,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">149<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">8,441<span></span>
</td>
<td class="nump">4,389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, non-current</a></td>
<td class="nump">179<span></span>
</td>
<td class="nump">177<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Financing lease liabilities, non-current</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">8,856<span></span>
</td>
<td class="nump">4,776<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.0001; 162&#160;shares authorized as of March 31, 2021 and December 31, 2020; no shares issued or outstanding at March 31, 2021 and December 31, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.0001; 1,600 shares authorized as of March 31, 2021 and December 31, 2020; 401 and 399 shares issued and outstanding as of March 31, 2021 and December 31, 2019, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">4,860<span></span>
</td>
<td class="nump">4,802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,023)<span></span>
</td>
<td class="num">(2,244)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">3,838<span></span>
</td>
<td class="nump">2,561<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 12,694<span></span>
</td>
<td class="nump">$ 7,337<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865600465496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value (usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">162,000,000<span></span>
</td>
<td class="nump">162,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">1,600,000,000<span></span>
</td>
<td class="nump">1,600,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued (in shares)</a></td>
<td class="nump">401,000,000<span></span>
</td>
<td class="nump">399,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding (in shares)</a></td>
<td class="nump">401,000,000<span></span>
</td>
<td class="nump">399,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865600409096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 1,937<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">193<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">401<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">671<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">1,266<span></span>
</td>
<td class="num">(131)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income (loss) before income taxes</a></td>
<td class="nump">1,260<span></span>
</td>
<td class="num">(124)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 1,221<span></span>
</td>
<td class="num">$ (124)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings (loss) per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (usd per share)</a></td>
<td class="nump">$ 3.05<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (usd per share)</a></td>
<td class="nump">$ 2.84<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted average common shares used in calculation of earnings (loss) per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">430<span></span>
</td>
<td class="nump">353<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrna_ProductSalesMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 1,733<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">194<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrna_CollaborationArrangementMember', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrna_ProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrna_ProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrna_CollaborationArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrna_CollaborationArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865593034632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 1,221<span></span>
</td>
<td class="num">$ (124)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on available-for-sale debt securities, net of tax of $0 and $0, for the three months ended March 31, 2021 and 2020, respectively</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="nump">$ 1,219<span></span>
</td>
<td class="num">$ (132)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865594757896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Unrealized gain (loss) on available-for-sale debt securities, tax</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865600225544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at beginning of period (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">337,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Dec. 31, 2019</a></td>
<td class="nump">$ 1,175<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,670<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="num">$ (1,497)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from public offering of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from public offering of common stock, net of issuance costs of $1</a></td>
<td class="nump">550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options to purchase common stock, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options to purchase common stock</a></td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss, net of tax</a></td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(124)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(124)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">370,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Mar. 31, 2020</a></td>
<td class="nump">1,641<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">3,268<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(1,621)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at beginning of period (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">399,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Dec. 31, 2020</a></td>
<td class="nump">$ 2,561<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">4,802<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="num">(2,244)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options to purchase common stock, net (in shares)</a></td>
<td class="nump">1,890<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options to purchase common stock</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss, net of tax</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">1,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,221<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">401,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Mar. 31, 2021</a></td>
<td class="nump">$ 3,838<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,860<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">$ (1,023)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865594879960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering expenses</a></td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865598969560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 1,221<span></span>
</td>
<td class="num">$ (124)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Amortization/accretion of investments</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(50)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(1,819)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(448)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases', window );">Right-of-use assets, operating leases</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(15)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">285<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">3,666<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_OperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="nump">93<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">2,971<span></span>
</td>
<td class="num">(106)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(726)<span></span>
</td>
<td class="num">(621)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="nump">339<span></span>
</td>
<td class="nump">269<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from sales of marketable securities</a></td>
<td class="nump">242<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(35)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(180)<span></span>
</td>
<td class="num">(316)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from public offerings of common stock, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of common stock through equity plans, net</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ChargesToFinancingLeaseLiabilities', window );">Changes in financing lease liabilities</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">578<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents and restricted cash</a></td>
<td class="nump">2,817<span></span>
</td>
<td class="nump">156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of year</a></td>
<td class="nump">2,636<span></span>
</td>
<td class="nump">248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">5,453<span></span>
</td>
<td class="nump">404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment included in accounts payable and accrued liabilities</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Right-of-use assets obtained through finance lease modifications and reassessments</a></td>
<td class="nump">$ 51<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ChargesToFinancingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Charges To Financing Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ChargesToFinancingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Right Of Use Asset, Operating Leases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_OperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_OperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865594604120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of the Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Description of the Business</a></td>
<td class="text">Description of the Business<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moderna, Inc. (collectively, with its consolidated subsidiaries, any of Moderna, we, us, or the Company) was incorporated in Delaware on July&#160;22, 2016. We are the successor in interest to Moderna LLC, a limited liability company formed under the laws of the State of Delaware in 2013. Our principal executive office is located at 200 Technology Square, Cambridge,&#160;MA.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biotechnology company creating a new generation of transformative medicines based on messenger RNA (mRNA), to improve the lives of patients. mRNA medicines are designed to direct the body&#8217;s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a broad spectrum of diseases. Our platform builds on continuous advances in basic and applied mRNA science, delivery technology, and manufacturing, providing us the capability to pursue in parallel a robust pipeline of new development candidates.&#160;We are developing vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with our strategic collaborators.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 18, 2020, we received an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the emergency use of the Moderna COVID-19 Vaccine (also referred to as mRNA-1273) in individuals 18 years of age or older. We have also received authorization for our COVID-19 vaccine from health agencies in Canada, Israel, the European Union, the United Kingdom, Switzerland, Singapore, Qatar, Taiwan, and the Philippines, and from the World Health Organization. Additional authorizations are currently under review in other countries.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March 31, 2021, we had 24 mRNA development programs in our portfolio with 13 having entered the clinic. We have incurred significant expenses in connection with the discovery, development and commercialization of our products, and we expect to continue to incur significant expenses for the foreseeable future. We anticipate that our expenses will increase significantly in connection with the ongoing development and commercialization of our COVID-19 vaccine and ongoing activities to support our platform research, drug discovery and clinical development, including development of any new generations of boosters and vaccines against variants of SARS-CoV-2, infrastructure and Research Engine and Early Development Engine (which includes our Moderna Technology Center), digital infrastructure, creation of a portfolio of intellectual property, and administrative support. We may finance our future cash needs that exceed our operating costs through a combination of public or private equity offerings, structured financings and debt financings, government funding arrangements, strategic alliances and marketing, manufacturing, distribution and licensing arrangements. We may be unable to raise additional funds or enter into such other agreements on favorable terms, or at all.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our cash, cash equivalents, and investments as of&#160;March 31, 2021&#160;will be sufficient to enable us to fund our projected operations through at least the next 12&#160;months from the issuance of our financial statements. We are subject to numerous risks and uncertainties associated with pharmaceutical development and commercialization, and we are unable to predict the timing or amount of expenses or if we will be able to maintain profitability. If we are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce our operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865593348360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Basis of Presentation and Recent Accounting Standards<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Basis of Presentation and Recent Accounting Standards</a></td>
<td class="text">Summary of Basis of Presentation and Recent Accounting Standards<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements that accompany these notes have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) for interim financial reporting, consistent in all material respects with those applied in our Annual Report on Form 10-K for the year ended December 31, 2020 (2020 Form 10-K). Any reference in these notes to applicable guidance is meant to refer to the authoritative accounting principles generally accepted in the United States as found in the Accounting Standard Codification (ASC) and Accounting Standards Update (ASU) of the Financial Accounting Standards Board (FASB). This report should be read in conjunction with the consolidated financial statements in our 2020 Form 10-K.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the Company and its subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant accounting policies used in preparation of these condensed consolidated financial statements for the three months ended March 31, 2021 are consistent with those described in our 2020 Form 10-K.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made estimates and judgments affecting the amounts reported in our condensed consolidated financial statements and the accompanying notes. We base our estimates on historical experience and various relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods that are not readily apparent from other sources. Significant estimates relied upon in preparing these financial statements include, but are not limited to, critical accounting policies or estimates related to revenue recognition, research and development expenses, income tax provisions, stock-based compensation, leases, fair value of financial instruments, derivative financial instruments, inventory, and useful lives of property and equipment, income taxes and our valuation allowance on our deferred tax assets. The actual results that we experience may differ materially from our estimates. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comprehensive Income (Loss)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) includes net income (loss) and other comprehensive loss for the period. Other comprehensive loss consists of unrealized gains/losses and gains/losses on our investments. Total comprehensive income (loss) for all periods presented has been disclosed in the condensed consolidated statements of comprehensive income (loss).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of accumulated other comprehensive income for the three months ended March 31, 2021 are as follows (in millions):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Loss on Available-for-Sale Debt Securities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income, balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income, balance at March 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Cash </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We include our restricted cash balance in the cash, cash equivalents and restricted cash reconciliation of operating, investing and financing activities in the condensed consolidated statements of cash flows.&#160;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows (in millions):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,442&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, non-current </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash shown in the condensed consolidated<br/>&#160;&#160;&#160;&#160;statements of cash flows</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,453&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Standards Not Yet Adopted</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial statements and disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865594889000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Sales<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Product Sales</a></td>
<td class="text">Product Sales<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we began selling our COVID-19 vaccine to the U.S. Government and international governments. Under the supply agreements with these governments, we received or billed for upfront deposits for our future vaccine supply, which are initially recorded as deferred revenue. We recognize revenue based on the fixed price per dose when control of the product has transferred and customer acceptance has occurred as applicable, unless such acceptance provisions are deemed perfunctory. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales by customer geographic location was as follows (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.595%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,358&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no product sales for the three months ended March 31, 2020. As of March 31, 2021, we had one commercial product authorized for use, our COVID-19 vaccine. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 and December 31, 2020, we had deferred revenue of $7.5&#160;billion and $3.8&#160;billion, respectively, related to customer deposits, classified as current deferred revenue in our consolidated balance sheet. Timing of product manufacturing, delivery and receipt of marketing approval will determine the period in which revenue is recognized.</span></div>Grant Revenue<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we entered into an agreement with the Defense Advanced Research Projects Agency (DARPA) for an award of up to $56&#160;million to fund development of a mobile manufacturing prototype leveraging our existing manufacturing technology that is capable of rapidly producing vaccines and therapeutics. As of March 31, 2021, the committed funding, net of revenue earned was $3&#160;million, with an additional $51&#160;million available if DARPA exercises additional contract options.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we entered into an agreement with the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), for an award of up to $483&#160;million to accelerate development of mRNA-1273, our vaccine candidate against the novel coronavirus. In July 2020, we amended our agreement with BARDA to provide for an additional commitment of up to $472&#160;million to support late-stage clinical development of mRNA-1273, including the execution of a 30,000 participant Phase 3 study in the U.S. We further amended the agreement in March 2021 to provide for an additional commitment of $63&#160;million to further support late-stage clinical development, including Phase 2/3 mRNA-1273 pediatric studies. As of March 31, 2021, the maximum award from BARDA, inclusive of the March 2021 amendment, was approximately $1.0&#160;billion. Under the terms of the agreement, BARDA will fund the advancement of mRNA-1273 to FDA licensure. All contract options have been exercised. As of March 31, 2021, the remaining available funding net of revenue earned was $317&#160;million. Subsequent to the end of the quarter, on April 18, 2021, we entered into a further amendment to the BARDA agreement, increasing the amount of potential reimbursements by $236&#160;million in connection with costs associated with the Phase 3 clinical trials for mRNA-1273 and pharmacovigilance efforts. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2016, we received an award of up to $126&#160;million from BARDA, to help fund our Zika vaccine program. Three of the four contract options have been exercised. As of March 31, 2021, the remaining available funding net of revenue earned was $69&#160;million, with an additional $8&#160;million available if the final contract option is exercised.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2016, we entered a global health project framework agreement with the Bill and Melinda Gates Foundation (Gates Foundation) to advance mRNA-based development projects for various infectious diseases, including human immunodeficiency virus (HIV). As of March 31, 2021, the available funding net of revenue earned was $11&#160;million, with up to an additional $80&#160;million available if additional follow-on projects are approved. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes grant revenue as of and for the period presented (in millions):</span></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.511%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BARDA</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other grant revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total grant revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865593356792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Grant Revenue<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract', window );"><strong>Revenue Recognition and Deferred Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Grant Revenue</a></td>
<td class="text">Product Sales<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we began selling our COVID-19 vaccine to the U.S. Government and international governments. Under the supply agreements with these governments, we received or billed for upfront deposits for our future vaccine supply, which are initially recorded as deferred revenue. We recognize revenue based on the fixed price per dose when control of the product has transferred and customer acceptance has occurred as applicable, unless such acceptance provisions are deemed perfunctory. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales by customer geographic location was as follows (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.595%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,358&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no product sales for the three months ended March 31, 2020. As of March 31, 2021, we had one commercial product authorized for use, our COVID-19 vaccine. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 and December 31, 2020, we had deferred revenue of $7.5&#160;billion and $3.8&#160;billion, respectively, related to customer deposits, classified as current deferred revenue in our consolidated balance sheet. Timing of product manufacturing, delivery and receipt of marketing approval will determine the period in which revenue is recognized.</span></div>Grant Revenue<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we entered into an agreement with the Defense Advanced Research Projects Agency (DARPA) for an award of up to $56&#160;million to fund development of a mobile manufacturing prototype leveraging our existing manufacturing technology that is capable of rapidly producing vaccines and therapeutics. As of March 31, 2021, the committed funding, net of revenue earned was $3&#160;million, with an additional $51&#160;million available if DARPA exercises additional contract options.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we entered into an agreement with the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), for an award of up to $483&#160;million to accelerate development of mRNA-1273, our vaccine candidate against the novel coronavirus. In July 2020, we amended our agreement with BARDA to provide for an additional commitment of up to $472&#160;million to support late-stage clinical development of mRNA-1273, including the execution of a 30,000 participant Phase 3 study in the U.S. We further amended the agreement in March 2021 to provide for an additional commitment of $63&#160;million to further support late-stage clinical development, including Phase 2/3 mRNA-1273 pediatric studies. As of March 31, 2021, the maximum award from BARDA, inclusive of the March 2021 amendment, was approximately $1.0&#160;billion. Under the terms of the agreement, BARDA will fund the advancement of mRNA-1273 to FDA licensure. All contract options have been exercised. As of March 31, 2021, the remaining available funding net of revenue earned was $317&#160;million. Subsequent to the end of the quarter, on April 18, 2021, we entered into a further amendment to the BARDA agreement, increasing the amount of potential reimbursements by $236&#160;million in connection with costs associated with the Phase 3 clinical trials for mRNA-1273 and pharmacovigilance efforts. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2016, we received an award of up to $126&#160;million from BARDA, to help fund our Zika vaccine program. Three of the four contract options have been exercised. As of March 31, 2021, the remaining available funding net of revenue earned was $69&#160;million, with an additional $8&#160;million available if the final contract option is exercised.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2016, we entered a global health project framework agreement with the Bill and Melinda Gates Foundation (Gates Foundation) to advance mRNA-based development projects for various infectious diseases, including human immunodeficiency virus (HIV). As of March 31, 2021, the available funding net of revenue earned was $11&#160;million, with up to an additional $80&#160;million available if additional follow-on projects are approved. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes grant revenue as of and for the period presented (in millions):</span></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.511%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BARDA</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other grant revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total grant revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865593030744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Revenue<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">Collaboration Revenue</a></td>
<td class="text">Collaboration Agreements<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into collaboration agreements with strategic collaborators to accelerate the discovery and advancement of potential mRNA medicines across therapeutic areas. As of March 31, 2021 and December 31, 2020, we had collaboration agreements with AstraZeneca plc (AstraZeneca), Merck &amp; Co., Inc (Merck), Vertex Pharmaceuticals Incorporated and Vertex Pharmaceuticals (Europe) Limited (together, Vertex), and Chiesi Farmaceutici S.P.A. (Chiesi). Please refer to our 2020 Form 10-K under the heading &#8220;Third-Party Strategic Alliances&#8221; and Note 5 to our consolidated financial statements for further description of each of the collaboration agreements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our total consolidated revenue from our strategic collaborators for the periods presented (in millions):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.511%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.263%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Collaboration Revenue by Strategic Collaborator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AstraZeneca</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vertex</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in the balances of our receivables and contract liabilities related to our strategic collaboration agreements during the three months ended March 31, 2021 (in millions):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.333%"><tr><td style="width:1.0%"/><td style="width:38.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.883%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.883%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.885%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>As of March 31, 2021, the aggregated amount of the transaction price allocated to performance obligations under our collaboration agreements that are unsatisfied or partially unsatisfied was $314&#160;million.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 730<br> -URI http://asc.fasb.org/subtopic&amp;trid=2197926<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865593348360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Financial Instruments</a></td>
<td class="text">Financial Instruments<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents and Investments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize our cash and available-for-sale securities by significant investment category at March 31, 2021 and December 31, 2020 (in millions):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.765%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and<br/>Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current<br/>Marketable<br/>Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-<br/>Current<br/>Marketable<br/>Securities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,442&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,442&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,442&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities of U.S. government agencies and corporate entities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,972&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,201&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,203&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,442&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,293&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and<br/>Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current<br/>Marketable<br/>Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-<br/>Current<br/>Marketable<br/>Securities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities of U.S. government agencies and corporate entities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,888&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,243&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,247&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,624&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,984&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">639&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost and estimated fair value of marketable securities by contractual maturity at March 31, 2021 and December 31, 2020 are as follows (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one year or less</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,291&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,293&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,759&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,761&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one year or less</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,981&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,984&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">639&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,619&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,623&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with our investment policy, we place investments in investment grade securities with high credit quality issuers, and generally limit the amount of credit exposure to any one issuer. We evaluate securities for impairment at the end of each reporting period. Impairment is evaluated considering numerous factors, and their relative significance varies depending on the situation. Factors considered include whether a decline in fair value below the amortized cost basis is due to credit-related factors or noncredit-related factors, the financial condition and near-term prospects of the issuer, and our intent and ability to hold the investment to allow for an anticipated recovery in fair value. Any impairment that is not credit related is recognized in other comprehensive loss, net of applicable taxes. A credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings. We did not recognize any impairment charges related to available-for-sale securities for the three months ended March 31, 2021 and 2020. We did not recognize any credit losses related allowance to available-for-sale securities as of March 31, 2021 and December 31, 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 and December 31, 2020, we did not have material gross unrealized losses. We neither intend to sell these investments, nor do we believe that we are more-likely-than-not to conclude we will have to sell them before recovery of their carrying values. We also believe that we will be able to collect both principal and interest amounts due to us at maturity.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used to value the assets and liabilities: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; or</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize our financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2021 and December 31, 2020 (in millions):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.650%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at <br/>March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement Using</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities of U.S. government agencies and corporate entities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments (Note 7)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,299&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,762&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments (Note 7)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.986%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement Using</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities of U.S. government agencies and corporate entities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,244&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,623&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 and December 31, 2020, we did not have non-financial assets or liabilities measured at fair value on a recurring basis.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865600315208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Financial Instruments</a></td>
<td class="text">Derivative Financial Instruments<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We transact business in various foreign currencies and have international sales and expenses denominated in foreign currencies. Therefore, we are exposed to certain risks arising from both our business operations and economic conditions. Our risk management strategy includes the use of derivative financial instruments to hedge foreign currency exchange rate fluctuations on monetary assets or liabilities denominated in foreign currencies. We do not enter into derivative financial contracts for speculative or trading purposes. We do not believe that we are exposed to more than a nominal amount of credit risk in our foreign currency hedges, as counterparties are large, global and well-capitalized financial institutions. We classify cash flows from our derivative transactions as cash flows from operating activities in our consolidated statements of cash flows.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Balance Sheet Hedges</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our foreign currency forward contracts, primarily accounts receivable, are not designated for hedge accounting treatment. Therefore, these forward contracts are accounted for as derivatives whereby the fair value of the contracts are reported as other current assets or other current liabilities on our condensed consolidated balance sheets, and gains and losses resulting from changes in the fair value are recorded as a component of other expense, net, in our condensed consolidated statements of operations. The gains and losses on these foreign currency forward contracts generally offset the gains and losses in the underlying foreign currency denominated assets and liabilities, which are also recorded to other expense, net, in our condensed consolidated statements of operations. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total gross notional amount and fair value for foreign currency derivatives that are not designated as hedging instruments are accounted for as follows (in millions):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.594%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.792%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,367&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.594%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.792%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">_________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As presented in the condensed consolidated balance sheet within other current assets.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As presented in the condensed consolidated balance sheet within other current liabilities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The effect of foreign currency forward contracts not designated as hedging instruments in our condensed consolidated statements of operations for the three months ended March 31, 2021 was as follows (in millions):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.861%"><tr><td style="width:1.0%"/><td style="width:56.062%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.773%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.773%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There were no hedging activities for the three months ended March 31, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865593340248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text">Inventory<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory as of March 31, 2021 and December 31, 2020 consists of the following (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.288%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:47.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.986%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March&#160;31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in progress </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865599851848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">Property and Equipment, Net<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, as of March 31, 2021 and December 31, 2020 consists of the following (in&#160;millions):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internally developed software</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset, financing</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">507&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>Depreciation and amortization expense for the three months ended March 31, 2021 and 2020 was $15 million and $7 million, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865593320664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Other Balance Sheet Components</a></td>
<td class="text">Other Balance Sheet Components<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets, as of March 31, 2021 and December 31, 2020 consists of the following (in&#160;millions):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Down payments to manufacturing vendors</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tenant incentives receivables</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest receivable on marketable securities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Liabilities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities, as of March 31, 2021 and December 31, 2020 consists of the following (in&#160;millions):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other external goods and services </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation-related</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">753&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Revenue </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activities in deferred revenue for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the three months ended</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> March 31, 2021 (in millions):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.792%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,799&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,467&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(796)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,470&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,044&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,474&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(808)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,710&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865594855064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into various long-term non-cancelable lease arrangements for our facilities and equipment expiring at various times through 2032. Certain of these arrangements have free rent periods or escalating rent payment provisions. We recognize lease cost under such arrangements on a straight-line basis over the life of the leases. We have two campuses in Massachusetts, our Cambridge facility and our Moderna Technology Center (MTC), located in Norwood.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cambridge facility</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We occupy a multi-building campus in Technology Square in Cambridge, Massachusetts with a mix of offices and research laboratory space totaling approximately 175,000&#160;square feet. Our Cambridge facility leases have expiry ranges from 2020 to 2029. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Finance Leases</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Moderna Technology Center manufacturing facility (MTC South)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August&#160;2016, we entered into a lease agreement for approximately&#160;200,000&#160;square feet of office, laboratory, and light manufacturing space, MTC South, in Norwood, Massachusetts. The lease will expire in September&#160;2032. We have the option to extend the term for&#160;two&#160;extension periods of&#160;ten years&#160;each at market-based rents. The base rent is subject to increases over the term of the lease. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Moderna Technology Center North (MTC North)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, we entered into a lease agreement for office and laboratory space of approximately 200,000 square feet, MTC North, located in Norwood, Massachusetts. The lease commenced in the second quarter of 2019 and had an initial expiration date of 2031. We have the option to extend the lease for up to four additional five-year terms. In May 2020, we entered into an amendment to the lease whereby we exercised an option available in the original lease to receive a tenant improvement allowance in the amount of $22 million to be paid back over the term of the lease with interest and extend the term of the lease to 2035. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Embedded Leases</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into multiple contract manufacturing service agreements with third parties which contain embedded leases within the scope of ASC 842. As of March 31, 2021 and December 31, 2020, we had lease liabilities of $73&#160;million and $24&#160;million, respectively, related to the embedded leases. As of March 31, 2021 and December 31, 2020, we had right-of-use assets of $44&#160;million and zero, as certain embedded leases dedicated to our COVID-19 vaccine program were deemed to have no alternative use prior to the EUA from the FDA in December 2020. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating and financing lease right-of-use assets and lease liabilities as of March 31, 2021 and December 31, 2020 were as follows (in millions):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, operating, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfNC0wLTEtMS04Mzk4_763696f1-1b66-43b8-a5e9-0a8445cbb910"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfNC0wLTEtMS04Mzk4_986006a3-947e-4a84-bf6d-3ecd8f99076a"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, financing, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3) (4)</span></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfOS0wLTEtMS0w_7afc31d0-ede8-43d3-b946-27d55409b32b"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfOS0wLTEtMS0w_d74ab000-ea21-4620-b930-521a5fdbab89"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></span></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfMTAtMC0xLTEtMzUwNw_1c2fb28d-31b2-40b2-9ba8-7bc67b5a50d3"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfMTAtMC0xLTEtMzUwNw_f985209d-7d9f-4e95-8466-842513c70552"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, non-current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities, non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These assets are real estate related assets, which include land, office and laboratory spaces.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net of accumulated depreciation.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These assets are&#160;real estate assets related to the MTC North and MTC South leases as well as assets related to contract manufacturing service agreements.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in property and equipment in the condensed consolidated balance sheets, net of accumulated depreciation.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in other current liabilities in the condensed consolidated balance sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Future minimum lease payments under our non-cancelable lease agreements at March 31, 2021, are as follows (in&#160;millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:61.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.441%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Year</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financing Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(remainder of the year)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less amounts representing interest or imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(376)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes optional extensions in the MTC North and MTC South lease terms which represent a total of $339 million un-discounted future lease payments.</span></div>(2) MTC South interest is based on an imputed interest rate of 17.2%. MTC North and the embedded lease interest is based upon incremental borrowing rates of 8.2% and 0.6% respectively.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into various long-term non-cancelable lease arrangements for our facilities and equipment expiring at various times through 2032. Certain of these arrangements have free rent periods or escalating rent payment provisions. We recognize lease cost under such arrangements on a straight-line basis over the life of the leases. We have two campuses in Massachusetts, our Cambridge facility and our Moderna Technology Center (MTC), located in Norwood.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cambridge facility</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We occupy a multi-building campus in Technology Square in Cambridge, Massachusetts with a mix of offices and research laboratory space totaling approximately 175,000&#160;square feet. Our Cambridge facility leases have expiry ranges from 2020 to 2029. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Finance Leases</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Moderna Technology Center manufacturing facility (MTC South)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August&#160;2016, we entered into a lease agreement for approximately&#160;200,000&#160;square feet of office, laboratory, and light manufacturing space, MTC South, in Norwood, Massachusetts. The lease will expire in September&#160;2032. We have the option to extend the term for&#160;two&#160;extension periods of&#160;ten years&#160;each at market-based rents. The base rent is subject to increases over the term of the lease. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Moderna Technology Center North (MTC North)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, we entered into a lease agreement for office and laboratory space of approximately 200,000 square feet, MTC North, located in Norwood, Massachusetts. The lease commenced in the second quarter of 2019 and had an initial expiration date of 2031. We have the option to extend the lease for up to four additional five-year terms. In May 2020, we entered into an amendment to the lease whereby we exercised an option available in the original lease to receive a tenant improvement allowance in the amount of $22 million to be paid back over the term of the lease with interest and extend the term of the lease to 2035. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Embedded Leases</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into multiple contract manufacturing service agreements with third parties which contain embedded leases within the scope of ASC 842. As of March 31, 2021 and December 31, 2020, we had lease liabilities of $73&#160;million and $24&#160;million, respectively, related to the embedded leases. As of March 31, 2021 and December 31, 2020, we had right-of-use assets of $44&#160;million and zero, as certain embedded leases dedicated to our COVID-19 vaccine program were deemed to have no alternative use prior to the EUA from the FDA in December 2020. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating and financing lease right-of-use assets and lease liabilities as of March 31, 2021 and December 31, 2020 were as follows (in millions):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, operating, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfNC0wLTEtMS04Mzk4_763696f1-1b66-43b8-a5e9-0a8445cbb910"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfNC0wLTEtMS04Mzk4_986006a3-947e-4a84-bf6d-3ecd8f99076a"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, financing, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3) (4)</span></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfOS0wLTEtMS0w_7afc31d0-ede8-43d3-b946-27d55409b32b"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfOS0wLTEtMS0w_d74ab000-ea21-4620-b930-521a5fdbab89"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></span></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfMTAtMC0xLTEtMzUwNw_1c2fb28d-31b2-40b2-9ba8-7bc67b5a50d3"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfMTAtMC0xLTEtMzUwNw_f985209d-7d9f-4e95-8466-842513c70552"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, non-current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities, non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These assets are real estate related assets, which include land, office and laboratory spaces.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net of accumulated depreciation.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These assets are&#160;real estate assets related to the MTC North and MTC South leases as well as assets related to contract manufacturing service agreements.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in property and equipment in the condensed consolidated balance sheets, net of accumulated depreciation.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in other current liabilities in the condensed consolidated balance sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Future minimum lease payments under our non-cancelable lease agreements at March 31, 2021, are as follows (in&#160;millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:61.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.441%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Year</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financing Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(remainder of the year)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less amounts representing interest or imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(376)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes optional extensions in the MTC North and MTC South lease terms which represent a total of $339 million un-discounted future lease payments.</span></div>(2) MTC South interest is based on an imputed interest rate of 17.2%. MTC North and the embedded lease interest is based upon incremental borrowing rates of 8.2% and 0.6% respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865593404264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Strategic Collaborations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our strategic collaboration agreements, we are committed to perform certain research, development, and manufacturing activities. As part of our PCV Agreement and PCV/SAV Agreement with Merck, we are committed to perform certain research, development and manufacturing activities related to PCV products through an initial Phase 2 clinical trial up to a budgeted amount of $243 million for both periods as of March 31, 2021 and December 31, 2020. Please refer to our 2020 Form 10-K Note 5 to our consolidated financial statements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently a party to any material legal proceedings.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification Obligations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As permitted under Delaware law, we indemnify our officers, directors, and employees for certain events, occurrences while the officer, or director is, or was, serving at our request in such capacity. The term of the indemnification is for the officer&#8217;s or director&#8217;s lifetime.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have standard indemnification arrangements in our leases for laboratory and office space that require us to indemnify the landlord against any liability for injury, loss, accident, or damage from any claims, actions, proceedings, or costs resulting from certain acts, breaches, violations, or non-performance under our leases.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into indemnification provisions under our agreements with counterparties in the ordinary course of business, typically with business partners, contractors, clinical sites and customers. Under these provisions, we generally indemnify and hold harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of our activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments we could be required to make under these indemnification provisions is unlimited.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through the three months ended March 31, 2021 and the year ended December 31, 2020, we had not experienced any losses related to these indemnification obligations, and no material claims were outstanding. We do not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Commitments and Purchase Orders</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We enter into agreements in the normal course of business with vendors and contract manufacturing organizations (CMOs) for raw materials and manufacturing services and with vendors for preclinical research studies, clinical trials and other goods or services. As of March 31, 2021, we h</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ad </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$1.0 billion of non-cancelable purchase commitments related to raw materials and manufacturing agreements, including the Lonza agreement, which are expected to be paid through 2022. As of March 31, 2021, we had $30 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> of non-c</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ancelable purchase commitments related to clinical services and other goods and services which are expected to be paid through 2024. These amounts represent our minimum contractual obligations, including termination fees.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to purchase commitments, we have agreements with third parties for various services, including services related to clinical operations and support and contract manufacturing, for which we are not contractually able to terminate for convenience and avoid any and all future obligations to the vendors. Certain agreements provide for termination rights subject to termination fees or wind down costs. Under such agreements, we are contractually obligated to make certain payments to vendors, mainly, to reimburse them for their unrecoverable outlays incurred prior to cancellation. At March 31, 2021 and December 31, 2020, we had cancelable open purchase orders of $993 million and $897 million, respectively, in total under such agreements for our significant clinical operations and support and contract manufacturing. These amounts represent only our estimate of those items for which we had a contractual commitment to pay at March 31, 2021 and December 31, 2020, assuming we would not cancel these agreements. The actual amounts we pay in the future to the vendors under such agreements may differ from the purchase order amounts.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licenses to Patented Technology</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 26, 2017, we entered into sublicense agreements with Cellscript, LLC and its affiliate, mRNA RiboTherapeutics, Inc. to sublicense certain patent rights. Pursuant to each agreement, we are required to pay certain license fees, annual maintenance fees, minimum royalties on future net sales and milestone payments contingent on achievement of certain development, regulatory and commercial milestones for specified products, on a product-by-product basis. The development and regulatory milestone payments, up to $2&#160;million for therapeutic and prophylactic products and up to $1&#160;million for diagnostic products will be recognized as a cost of the asset acquired upon resolution of the associated contingency and will be capitalized or expensed depending on the nature of the associated asset as of the date of recognition. Conversely, commercial milestone payments, up to $24&#160;million, and royalties based on annual net sales of licensed products for therapeutic and prophylactic products will be accounted for as additional expense of the related product sales in the period in which the corresponding sales occur. We recognized $84&#160;million of royalty expenses associated with our product sales in the first quarter of 2021, which was recorded to cost of sales in our condensed consolidated statements of operations. We did not recognize any such royalties in the first quarter of 2020 as we did not have product sales in that quarter. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we have other in-license agreements with third parties which require us to make future development, regulatory and commercial milestone payments for specified products associated with the agreements. The achievement of these milestones was not deemed probable as of March 31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865593089224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, we had a total of&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62 million&#160;shares reserved for future issuance under our Equity Plans, of which 35 million shares were reserved for equity awards previously granted, and&#160;27 million&#160;shares were available for future grants under the 2018 Equity Plan. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Options</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our option activity during the three months ended March 31, 2021:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.987%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Options </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Price per</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Share</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Grant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Date Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value per</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Share</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Term</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in&#160;millions)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at Outstanding at Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.06&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,976&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.89)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.95&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.65&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest at March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of common stock for those options in the money as of March 31, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of options exercised was $250 million for the three months ended March 31, 2021. The aggregate intrinsic value represents the difference between the exercise price and the selling price received by option holders upon the exercise of stock options during the period. The total consideration recorded as a result of stock option exercises&#160;was approximately $28 million for the three months ended March 31, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Common Stock Units (RSUs) and Performance Stock Units (PSUs)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our RSU and PSU activity during the three months ended March 31, 2021:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.038%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Units <br/>(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-Average<br/>Fair Value<br/>per Unit</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, non-vested at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.02)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, non-vested at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.39&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of restricted stock units vested during the three months ended March 31, 2021 was $6&#160;million. The total intrinsic value of restricted stock units vested during the three months ended March 31, 2021 was $35&#160;million.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2021, we granted PSUs to certain senior executives with vesting that is contingent upon the achievement of specified preestablished goals over the performance period, generally three years. The actual number of common shares ultimately </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issued is calculated by multiplying the number of PSUs by a payout percentage ranging from 0% to 200%. The estimated fair value of PSUs is based on the grant date fair value.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Employee Stock Purchase Plan (ESPP)</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no shares sold under the ESPP during the three months ended March 31, 2021. As of March 31, 2021, 4&#160;million shares were available for future issuance under the ESPP.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components and classification of stock-based compensation expense for the three months ended March 31, 2021 and 2020 as follows (in millions):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.194%"><tr><td style="width:1.0%"/><td style="width:71.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.931%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.507%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.507%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.208%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs and PSUs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, there was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$337 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of total unrecognized compensation cost related to unvested stock-based compensation with respect to options, RSUs and PSUs granted. That cost is expected to be recognized over a weighted-average period of 3.1 years at March 31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865594706824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to U.S. federal, state, and foreign income taxes. For the three months ended March 31, 2021 and 2020, we recorded provisions for income taxes of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$39 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and an immaterial amount, respectively. Our effective tax rate for the three months ended March 31, 2021 was lower than the U.S. statutory rate primarily due to the benefit of the foreign derived intangible income deduction, the benefit related to the release of the valuation allowance on the majority of our tax attributes and other deferred tax assets, as well as a discrete item for excess tax benefits related to stock-based compensation. Our effective tax rate for the three months ended March 31, 2020 was lower than the U.S. statutory rate primarily due to the valuation allowance.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities. These differences are measured using the enacted statutory tax rates that are expected to be in effect for the years in which differences are expected to reverse. On a periodic basis, we reassess any valuation allowances that we maintain on our deferred tax assets, weighing positive and negative evidence to assess the recoverability of the deferred tax assets. For the three months ended March 31, 2021, we reassessed the valuation allowance noting the increase in positive evidence, including significant revenue growth, expectations regarding future profitability, and successful supply chain and manufacturing capabilities to meet global product demand. After assessing both the positive evidence and negative evidence, we determined it was more likely than not that we will realize the majority of our deferred tax assets. Therefore, we determined we should reverse the majority of our valuation allowance through the annual effective tax rate (AETR) with respect to amounts we expect to realize through current year income. In addition, we have recorded a discrete benefit of $49&#160;million related to the release of the valuation allowance on deferred tax assets that we expect to utilize in future years. We will maintain a valuation allowance on certain state tax attributes that we expect will expire prior to the utilization. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Coronavirus Aid, Relief and Economic Security Act (CARES Act) was signed into law. The CARES Act includes provisions relating to several aspects of corporate income taxes. We do not currently expect the CARES Act to have a significant impact on our provision for income taxes.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have reviewed the tax positions taken, or to be taken, in our tax returns for all tax years currently open to examination by a taxing authority. Unrecognized tax benefits represent the aggregate tax effect of differences between tax return positions and the benefits recognized in the financial statements. As of March 31, 2021 and December 31, 2020, we had an immaterial amount of gross unrecognized tax benefits, which would affect our tax rate if recognized. We do not expect that our unrecognized tax benefits will materially increase within the next twelve months. We accrue interest and penalties related to unrecognized tax benefits as a component of our provision for income taxes. We did not recognize any material interest or penalties related to uncertain tax positions during the three months ended March 31, 2021 and 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file U.S. federal income tax returns and income tax returns in various state, local and foreign jurisdictions. We are not currently subject to any tax assessment from an income tax examination in the United States or any other major taxing jurisdiction since inception.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865598522888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings per Share</a></td>
<td class="text">Earnings per Share <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The computation of basic earnings per share (EPS) is based on the weighted-average number of our common shares outstanding. The computation of diluted EPS is based on the weighted-average number of our common shares outstanding and potential dilutive common shares outstanding during the period as determined by using the treasury stock method.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted EPS for the three months ended March 31, 2021 and 2020 are calculated as follows (in millions, except per share data):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.788%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.986%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.5pt;text-align:left;text-indent:-13.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;text-indent:-18pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted-average common shares outstanding</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted-average common shares outstanding</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic EPS</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted EPS</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents, presented based on amounts outstanding as of March 31, 2020 were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because their inclusion would have been anti-dilutive (in millions):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.984%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted common stock units</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865593102840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to March 31, 2021, we have entered into additional supply agreements with customers to provide up to 47&#160;million doses of our COVID-19 vaccine based on the initial confirmed volume, subject to modifications.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to March 31, 2021, we have entered into additional binding purchase commitments with third-party contractual manufacturing organizations for our COVID-19 vaccine under existing or newly executed agreements. We are currently committed to minimum non-cancelable purchase obligations of $284&#160;million related to these agreements, which are expected to be paid through 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, on April 18, 2021, we entered into a further amendment to our existing agreement with BARDA, pursuant to which BARDA has agreed to fund the advancement of mRNA-1273 to potential licensure, including funding for clinical studies and manufacturing scale-up. The amendment increases the amount of potential reimbursements by $236&#160;million in connection with costs associated with the Phase 3 clinical trials for mRNA-1273 and pharmacovigilance efforts, bringing the total BARDA support to approximately $1.3&#160;billion.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865591183064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Basis of Presentation and Recent Accounting Standards (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">The accompanying unaudited condensed consolidated financial statements that accompany these notes have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) for interim financial reporting, consistent in all material respects with those applied in our Annual Report on Form 10-K for the year ended December 31, 2020 (2020 Form 10-K). Any reference in these notes to applicable guidance is meant to refer to the authoritative accounting principles generally accepted in the United States as found in the Accounting Standard Codification (ASC) and Accounting Standards Update (ASU) of the Financial Accounting Standards Board (FASB). This report should be read in conjunction with the consolidated financial statements in our 2020 Form 10-K.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">The consolidated financial statements include the Company and its subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">We have made estimates and judgments affecting the amounts reported in our condensed consolidated financial statements and the accompanying notes. We base our estimates on historical experience and various relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods that are not readily apparent from other sources. Significant estimates relied upon in preparing these financial statements include, but are not limited to, critical accounting policies or estimates related to revenue recognition, research and development expenses, income tax provisions, stock-based compensation, leases, fair value of financial instruments, derivative financial instruments, inventory, and useful lives of property and equipment, income taxes and our valuation allowance on our deferred tax assets. The actual results that we experience may differ materially from our estimates.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text">Comprehensive income (loss) includes net income (loss) and other comprehensive loss for the period. Other comprehensive loss consists of unrealized gains/losses and gains/losses on our investments. Total comprehensive income (loss) for all periods presented has been disclosed in the condensed consolidated statements of comprehensive income (loss).<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted cash</a></td>
<td class="text">We include our restricted cash balance in the cash, cash equivalents and restricted cash reconciliation of operating, investing and financing activities in the condensed consolidated statements of cash flows.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Standards and Recently Issued Accounting Standards</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Standards Not Yet Adopted</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial statements and disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865594746056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Basis of Presentation and Recent Accounting Standards (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Components of Accumulated Other Comprehensive Income</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of accumulated other comprehensive income for the three months ended March 31, 2021 are as follows (in millions):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Loss on Available-for-Sale Debt Securities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income, balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income, balance at March 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Reconciliation of Cash and Cash Equivalents</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows (in millions):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,442&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, non-current </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash shown in the condensed consolidated<br/>&#160;&#160;&#160;&#160;statements of cash flows</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,453&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Reconciliation of Restricted Cash</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows (in millions):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,442&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, non-current </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash shown in the condensed consolidated<br/>&#160;&#160;&#160;&#160;statements of cash flows</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,453&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865595255944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Sales (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Revenue from External Customers by Geographic Areas</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales by customer geographic location was as follows (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.595%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,358&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865593422616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Grant Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract', window );"><strong>Revenue Recognition and Deferred Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue</a></td>
<td class="text">The following table summarizes grant revenue as of and for the period presented (in millions):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.511%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BARDA</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other grant revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total grant revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our total consolidated revenue from our strategic collaborators for the periods presented (in millions):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.511%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.263%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Collaboration Revenue by Strategic Collaborator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AstraZeneca</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vertex</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865594634136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue</a></td>
<td class="text">The following table summarizes grant revenue as of and for the period presented (in millions):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.511%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BARDA</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other grant revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total grant revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our total consolidated revenue from our strategic collaborators for the periods presented (in millions):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.511%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.263%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Collaboration Revenue by Strategic Collaborator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AstraZeneca</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vertex</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Changes in Balances of Receivables and Contract Liabilities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in the balances of our receivables and contract liabilities related to our strategic collaboration agreements during the three months ended March 31, 2021 (in millions):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.333%"><tr><td style="width:1.0%"/><td style="width:38.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.883%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.883%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.885%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activities in deferred revenue for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the three months ended</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> March 31, 2021 (in millions):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.792%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,799&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,467&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(796)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,470&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,044&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,474&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(808)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,710&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865594799144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Summary of Cash and Available-for-Sale Securities by Significant Investment Category</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize our cash and available-for-sale securities by significant investment category at March 31, 2021 and December 31, 2020 (in millions):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.765%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and<br/>Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current<br/>Marketable<br/>Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-<br/>Current<br/>Marketable<br/>Securities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,442&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,442&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,442&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities of U.S. government agencies and corporate entities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,972&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,201&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,203&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,442&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,293&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and<br/>Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current<br/>Marketable<br/>Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-<br/>Current<br/>Marketable<br/>Securities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities of U.S. government agencies and corporate entities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,888&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,243&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,247&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,624&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,984&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">639&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost and estimated fair value of marketable securities by contractual maturity at March 31, 2021 and December 31, 2020 are as follows (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one year or less</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,291&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,293&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,759&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,761&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one year or less</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,981&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,984&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">639&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,619&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,623&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Financial Assets Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize our financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2021 and December 31, 2020 (in millions):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.650%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at <br/>March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement Using</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities of U.S. government agencies and corporate entities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments (Note 7)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,299&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,762&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments (Note 7)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.986%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement Using</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities of U.S. government agencies and corporate entities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,244&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,623&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865593055080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Schedule Of Foreign Currency Derivatives</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total gross notional amount and fair value for foreign currency derivatives that are not designated as hedging instruments are accounted for as follows (in millions):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.594%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.792%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,367&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.594%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.792%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">_________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As presented in the condensed consolidated balance sheet within other current assets.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As presented in the condensed consolidated balance sheet within other current liabilities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The effect of foreign currency forward contracts not designated as hedging instruments in our condensed consolidated statements of operations for the three months ended March 31, 2021 was as follows (in millions):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.861%"><tr><td style="width:1.0%"/><td style="width:56.062%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.773%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.773%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109998890-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865593418408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Current</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory as of March 31, 2021 and December 31, 2020 consists of the following (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.288%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:47.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.986%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March&#160;31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in progress </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865594536008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, as of March 31, 2021 and December 31, 2020 consists of the following (in&#160;millions):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internally developed software</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset, financing</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">507&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865594788232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets, as of March 31, 2021 and December 31, 2020 consists of the following (in&#160;millions):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Down payments to manufacturing vendors</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tenant incentives receivables</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest receivable on marketable securities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities, as of March 31, 2021 and December 31, 2020 consists of the following (in&#160;millions):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other external goods and services </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation-related</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">753&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Changes in Balances of Receivables and Contract Liabilities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in the balances of our receivables and contract liabilities related to our strategic collaboration agreements during the three months ended March 31, 2021 (in millions):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.333%"><tr><td style="width:1.0%"/><td style="width:38.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.883%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.883%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.885%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activities in deferred revenue for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the three months ended</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> March 31, 2021 (in millions):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.792%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,799&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,467&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(796)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,470&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,044&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,474&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(808)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,710&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865594779816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Assets And Liabilities, Lessee</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating and financing lease right-of-use assets and lease liabilities as of March 31, 2021 and December 31, 2020 were as follows (in millions):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, operating, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfNC0wLTEtMS04Mzk4_763696f1-1b66-43b8-a5e9-0a8445cbb910"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfNC0wLTEtMS04Mzk4_986006a3-947e-4a84-bf6d-3ecd8f99076a"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, financing, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3) (4)</span></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfOS0wLTEtMS0w_7afc31d0-ede8-43d3-b946-27d55409b32b"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfOS0wLTEtMS0w_d74ab000-ea21-4620-b930-521a5fdbab89"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></span></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfMTAtMC0xLTEtMzUwNw_1c2fb28d-31b2-40b2-9ba8-7bc67b5a50d3"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJiYTdhZDkxNWQxYTRjNGE4ZWJiNTBkMTNmYWU0YzRlL3NlYzpiYmE3YWQ5MTVkMWE0YzRhOGViYjUwZDEzZmFlNGM0ZV82MS9mcmFnOjY2NTY4ODdjZTkwNDQ3ZTdiZDdmOGJhMmE0NjNhYmI2L3RhYmxlOmVmY2RhODE5NmZjOTQxZjc5NTk3N2M1NTFlY2M5MjM4L3RhYmxlcmFuZ2U6ZWZjZGE4MTk2ZmM5NDFmNzk1OTc3YzU1MWVjYzkyMzhfMTAtMC0xLTEtMzUwNw_f985209d-7d9f-4e95-8466-842513c70552"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, non-current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities, non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These assets are real estate related assets, which include land, office and laboratory spaces.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net of accumulated depreciation.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These assets are&#160;real estate assets related to the MTC North and MTC South leases as well as assets related to contract manufacturing service agreements.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in property and equipment in the condensed consolidated balance sheets, net of accumulated depreciation.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in other current liabilities in the condensed consolidated balance sheets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Finance Lease Maturity</a></td>
<td class="text">Future minimum lease payments under our non-cancelable lease agreements at March 31, 2021, are as follows (in&#160;millions):<div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:61.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.441%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Year</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financing Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(remainder of the year)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less amounts representing interest or imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(376)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes optional extensions in the MTC North and MTC South lease terms which represent a total of $339 million un-discounted future lease payments.</span></div>(2) MTC South interest is based on an imputed interest rate of 17.2%. MTC North and the embedded lease interest is based upon incremental borrowing rates of 8.2% and 0.6% respectively.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Operating Lease Maturity</a></td>
<td class="text">Future minimum lease payments under our non-cancelable lease agreements at March 31, 2021, are as follows (in&#160;millions):<div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:61.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.441%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Year</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financing Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(remainder of the year)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less amounts representing interest or imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(376)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes optional extensions in the MTC North and MTC South lease terms which represent a total of $339 million un-discounted future lease payments.</span></div>(2) MTC South interest is based on an imputed interest rate of 17.2%. MTC North and the embedded lease interest is based upon incremental borrowing rates of 8.2% and 0.6% respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865594824232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock', window );">Options Activity</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our option activity during the three months ended March 31, 2021:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.987%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Options </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Price per</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Share</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Grant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Date Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value per</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Share</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Term</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in&#160;millions)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at Outstanding at Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.06&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,976&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.89)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.95&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.65&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest at March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of common stock for those options in the money as of March 31, 2021.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Restricted Common Stock Units Activity</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our RSU and PSU activity during the three months ended March 31, 2021:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.038%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Units <br/>(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-Average<br/>Fair Value<br/>per Unit</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, non-vested at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.02)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, non-vested at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.39&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components and classification of stock-based compensation expense for the three months ended March 31, 2021 and 2020 as follows (in millions):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.194%"><tr><td style="width:1.0%"/><td style="width:71.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.931%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.507%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.507%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.208%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs and PSUs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865594711192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and Diluted Net Loss per Share Attributable to Common Stockholders</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted EPS for the three months ended March 31, 2021 and 2020 are calculated as follows (in millions, except per share data):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.788%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.986%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.5pt;text-align:left;text-indent:-13.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;text-indent:-18pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted-average common shares outstanding</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted-average common shares outstanding</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic EPS</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted EPS</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents, presented based on amounts outstanding as of March 31, 2020 were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because their inclusion would have been anti-dilutive (in millions):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.984%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted common stock units</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865594879400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of the Business - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>program</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_NumberOfDevelopmentProgram', window );">Development program</a></td>
<td class="nump">24<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_NumberOfDevelopmentProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Development Program</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_NumberOfDevelopmentProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865676231416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Basis of Presentation and Recent Accounting Standards - Components of Accumulated Other Comprehensive (loss) Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period</a></td>
<td class="nump">$ 2,561<span></span>
</td>
<td class="nump">$ 1,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period</a></td>
<td class="nump">3,838<span></span>
</td>
<td class="nump">$ 1,641<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized Loss on Available-for-Sale Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AOCIAttributableToParentNetOfTaxRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865598642200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Basis of Presentation and Recent Accounting Standards - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 5,442<span></span>
</td>
<td class="nump">$ 2,624<span></span>
</td>
<td class="nump">$ 392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash, non-current</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows</a></td>
<td class="nump">$ 5,453<span></span>
</td>
<td class="nump">$ 2,636<span></span>
</td>
<td class="nump">$ 404<span></span>
</td>
<td class="nump">$ 248<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865600002600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Sales (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 1,937<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">7,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,867<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrna_ProductSalesMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">1,733<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrna_CustomerDepositsMember', window );">Customer deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">1,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of world | Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrna_ProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrna_ProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrna_CustomerDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrna_CustomerDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865682516072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Grant Revenue (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 18, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($) </div>
<div>option</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,937<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with customer, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with customer, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=mrna_DefenseAdvancedResearchProjectsAgencyMember', window );">DARPA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RevenueFromGrantsMaximumAward', window );">Award amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=mrna_DefenseAdvancedResearchProjectsAgencyMember', window );">DARPA | Contract options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RevenueFromGrantsCurrentFundingCapacity', window );">Amount committed for funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RevenueFromGrantsRemainingFundingCapacity', window );">Available funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember', window );">BARDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RevenueFromGrantsMaximumAward', window );">Award amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 483<span></span>
</td>
<td class="nump">$ 126<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RevenueFromGrantsCurrentFundingCapacity', window );">Amount committed for funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Additional commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RevenueFromGrantsNumberOfContractOptions', window );">Number of contract options | option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RevenueFromGrantsNumberOfContractOptionsExercised', window );">Number of contract options exercised | option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember', window );">BARDA | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RevenueFromGrantsMaximumAward', window );">Award amount</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RevenueFromGrantsPotentialReimbursement', window );">Potential reimbursements</a></td>
<td class="nump">$ 236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember', window );">BARDA | Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember', window );">BARDA | Contract options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RevenueFromGrantsCurrentFundingCapacity', window );">Amount committed for funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RevenueFromGrantsRemainingFundingCapacity', window );">Available funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=mrna_TheBillAndMelindaGatesFoundationMember', window );">The Bill&#160;&amp; Melinda Gates Foundation | Initial project</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RevenueFromGrantsRemainingFundingCapacity', window );">Available funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with customer, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=mrna_OtherGrantRevenueMember', window );">Other grant revenue | Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_RevenueFromGrantsCurrentFundingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Grants, Current Funding Capacity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_RevenueFromGrantsCurrentFundingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_RevenueFromGrantsMaximumAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Grants, Maximum Award</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_RevenueFromGrantsMaximumAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_RevenueFromGrantsNumberOfContractOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Grants, Number Of Contract Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_RevenueFromGrantsNumberOfContractOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_RevenueFromGrantsNumberOfContractOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Grants, Number Of Contract Options Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_RevenueFromGrantsNumberOfContractOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_RevenueFromGrantsPotentialReimbursement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Grants, Potential Reimbursement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_RevenueFromGrantsPotentialReimbursement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_RevenueFromGrantsRemainingFundingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Grants, Remaining Funding Capacity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_RevenueFromGrantsRemainingFundingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mrna_DefenseAdvancedResearchProjectsAgencyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mrna_DefenseAdvancedResearchProjectsAgencyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_ContractOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_ContractOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mrna_TheBillAndMelindaGatesFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mrna_TheBillAndMelindaGatesFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_InitialProjectMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_InitialProjectMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mrna_OtherGrantRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mrna_OtherGrantRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865599765832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Revenue - Summary of Total Consolidated Net Revenues from Strategic Collaborators (Details) - Collaboration Revenue by Strategic Collaborator: - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total collaboration revenue</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember', window );">AstraZeneca</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total collaboration revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember', window );">Merck</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total collaboration revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember', window );">Vertex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total collaboration revenue</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total collaboration revenue</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrna_AstraZenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrna_AstraZenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrna_MerckMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrna_MerckMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrna_VertexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrna_VertexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrna_OtherCollaborativePartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrna_OtherCollaborativePartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865676347416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Revenue - Changes in Balances of Receivables and Contract Liabilities (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ChangeInContractwithCustomerLiabilityRollForward', window );"><strong>Contract Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Beginning balance</a></td>
<td class="nump">$ 4,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress', window );">Additions</a></td>
<td class="nump">4,474<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod', window );">Deductions</a></td>
<td class="num">(808)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Ending balance</a></td>
<td class="nump">7,710<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember', window );">Collaboration Revenue by Strategic Collaborator:</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ChangeInContractwithCustomerAssetRollForward', window );"><strong>Contract Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Beginning balance</a></td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress', window );">Additions</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ContractWithCustomerAssetDeductionsDuringPeriod', window );">Deductions</a></td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Ending balance</a></td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ChangeInContractwithCustomerLiabilityRollForward', window );"><strong>Contract Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Beginning balance</a></td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress', window );">Additions</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod', window );">Deductions</a></td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Ending balance</a></td>
<td class="nump">235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligations</a></td>
<td class="nump">$ 314<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ChangeInContractwithCustomerAssetRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Contract with Customer Asset [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ChangeInContractwithCustomerAssetRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ChangeInContractwithCustomerLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Contract with Customer Liability [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ChangeInContractwithCustomerLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ContractWithCustomerAssetDeductionsDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Asset, Deductions During Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ContractWithCustomerAssetDeductionsDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Deductions During Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in measure of progress which increases (decreases) right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in measure of progress which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865592002072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Summary of Cash and Available-for-Sale Securities by Significant Investment Category (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 2,759<span></span>
</td>
<td class="nump">$ 2,619<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">8,201<span></span>
</td>
<td class="nump">5,243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">8,203<span></span>
</td>
<td class="nump">5,247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and cash equivalents | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">5,442<span></span>
</td>
<td class="nump">2,624<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=mrna_CurrentMarketableSecuritiesMember', window );">Current marketable securities | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">2,293<span></span>
</td>
<td class="nump">1,984<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=mrna_NoncurrentMarketableSecuritiesMember', window );">Noncurrent marketable securities | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">468<span></span>
</td>
<td class="nump">639<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and cash equivalents | Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">5,442<span></span>
</td>
<td class="nump">2,624<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">5,442<span></span>
</td>
<td class="nump">2,624<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and cash equivalents | Cash and cash equivalents | Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">5,442<span></span>
</td>
<td class="nump">2,624<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and cash equivalents | Current marketable securities | Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and cash equivalents | Noncurrent marketable securities | Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">413<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">413<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Cash and cash equivalents | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Current marketable securities | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">413<span></span>
</td>
<td class="nump">215<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Noncurrent marketable securities | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">374<span></span>
</td>
<td class="nump">492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">374<span></span>
</td>
<td class="nump">492<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities | Cash and cash equivalents | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities | Current marketable securities | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">374<span></span>
</td>
<td class="nump">492<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities | Noncurrent marketable securities | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember', window );">Debt securities of U.S. government agencies and corporate entities | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">1,972<span></span>
</td>
<td class="nump">1,888<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">1,974<span></span>
</td>
<td class="nump">1,892<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember', window );">Debt securities of U.S. government agencies and corporate entities | Cash and cash equivalents | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember', window );">Debt securities of U.S. government agencies and corporate entities | Current marketable securities | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">1,506<span></span>
</td>
<td class="nump">1,277<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember', window );">Debt securities of U.S. government agencies and corporate entities | Noncurrent marketable securities | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">$ 468<span></span>
</td>
<td class="nump">$ 615<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=mrna_CurrentMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=mrna_CurrentMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=mrna_NoncurrentMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=mrna_NoncurrentMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865598421208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract', window );"><strong>Amortized Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due in one year or less</a></td>
<td class="nump">$ 2,291<span></span>
</td>
<td class="nump">$ 1,981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years</a></td>
<td class="nump">468<span></span>
</td>
<td class="nump">638<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">2,759<span></span>
</td>
<td class="nump">2,619<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in one year or less</a></td>
<td class="nump">2,293<span></span>
</td>
<td class="nump">1,984<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years</a></td>
<td class="nump">468<span></span>
</td>
<td class="nump">639<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate', window );">Total</a></td>
<td class="nump">$ 2,761<span></span>
</td>
<td class="nump">$ 2,623<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865594827096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings', window );">Impairment charges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865675813352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Financial Assets Measured At Fair Value On a Recurring Basis (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">$ 8,203<span></span>
</td>
<td class="nump">$ 5,247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">413<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">374<span></span>
</td>
<td class="nump">492<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember', window );">Debt securities of U.S. government agencies and corporate entities | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">1,974<span></span>
</td>
<td class="nump">1,892<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative Instruments</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value disclosure</a></td>
<td class="nump">3,299<span></span>
</td>
<td class="nump">3,244<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Instruments</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative Instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value disclosure</a></td>
<td class="nump">537<span></span>
</td>
<td class="nump">621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative Instruments</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value disclosure</a></td>
<td class="nump">2,762<span></span>
</td>
<td class="nump">2,623<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Instruments</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">537<span></span>
</td>
<td class="nump">621<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Money market funds | Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">537<span></span>
</td>
<td class="nump">621<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Money market funds | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">413<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Certificates of deposit | Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Certificates of deposit | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">413<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">374<span></span>
</td>
<td class="nump">492<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | U.S. treasury securities | Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | U.S. treasury securities | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">374<span></span>
</td>
<td class="nump">492<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Debt securities of U.S. government agencies and corporate entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">1,974<span></span>
</td>
<td class="nump">1,892<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Debt securities of U.S. government agencies and corporate entities | Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Debt securities of U.S. government agencies and corporate entities | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair&#160;Value</a></td>
<td class="nump">$ 1,974<span></span>
</td>
<td class="nump">$ 1,892<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865598829304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments - Balance Sheet Hedges (Details) - Not Designated as Hedging Instrument - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional Amount</a></td>
<td class="nump">$ 1,367<span></span>
</td>
<td class="nump">$ 368<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue', window );">Fair value, asset</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Fair value, liability</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax', window );">Foreign currency forward contracts</a></td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional Amount</a></td>
<td class="nump">1,367<span></span>
</td>
<td class="nump">368<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue', window );">Fair value, asset</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Fair value, liability</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign currency forward contracts | Other (expense) income, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax', window );">Foreign currency forward contracts</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of derivative instrument not designated as hedging instrument and classified as an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of derivative instrument not designated as hedging instrument and classified as a liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109998896-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865591478200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 430<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in progress</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 494<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865680683896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property and equipment, gross</a></td>
<td class="nump">$ 507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 417<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization', window );">Less: Accumulated depreciation</a></td>
<td class="num">(135)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(120)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property and equipment, gross</a></td>
<td class="nump">125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property and equipment, gross</a></td>
<td class="nump">184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember', window );">Furniture, fixtures and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property and equipment, gross</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property and equipment, gross</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Internally developed software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property and equipment, gross</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrna_FinancingRightOfUseAssetMember', window );">Right-of-use asset, financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property and equipment, gross</a></td>
<td class="nump">108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property and equipment, gross</a></td>
<td class="nump">$ 63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrna_FinancingRightOfUseAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrna_FinancingRightOfUseAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865593341912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_OtherPrepaidExpenseManufacturing', window );">Down payments to manufacturing vendors</a></td>
<td class="nump">$ 224<span></span>
</td>
<td class="nump">$ 217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid expenses</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_TenantIncentivesReceivablesCurrent', window );">Tenant incentives receivables</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest receivable on marketable securities</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 264<span></span>
</td>
<td class="nump">$ 252<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_OtherPrepaidExpenseManufacturing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Prepaid Expense, Manufacturing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_OtherPrepaidExpenseManufacturing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_TenantIncentivesReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tenant Incentives Receivables, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_TenantIncentivesReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865600651544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Balance Sheet Components - Accrued Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_AccruedClinicalTrials', window );">Clinical trials</a></td>
<td class="nump">$ 181<span></span>
</td>
<td class="nump">$ 98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RawMaterialsAccountsPayable', window );">Raw materials</a></td>
<td class="nump">185<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Royalties</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_AccruedDevelopmentOperation', window );">Development operations</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_AccruedManufacturing', window );">Manufacturing</a></td>
<td class="nump">119<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_AccruedOtherExternalGoodsAndServicesCurrent', window );">Other external goods and services</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation-related</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_AccruedPropertyAndEquipmentCurrent', window );">Property and equipment</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_Commercial', window );">Commercial</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">$ 753<span></span>
</td>
<td class="nump">$ 470<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_AccruedClinicalTrials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Trials</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_AccruedClinicalTrials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_AccruedDevelopmentOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Development Operation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_AccruedDevelopmentOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_AccruedManufacturing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Manufacturing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_AccruedManufacturing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_AccruedOtherExternalGoodsAndServicesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Other External Goods And Services Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_AccruedOtherExternalGoodsAndServicesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_AccruedPropertyAndEquipmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Property And Equipment, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_AccruedPropertyAndEquipmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_Commercial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commercial</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_Commercial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_RawMaterialsAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Raw Materials, Accounts Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_RawMaterialsAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865599335416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Balance Sheet Components - Deferred Revenue (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ChangeInContractwithCustomerLiabilityRollForward', window );"><strong>Change In Contract with Customer Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Beginning balance</a></td>
<td class="nump">$ 4,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress', window );">Additions</a></td>
<td class="nump">4,474<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod', window );">Deductions</a></td>
<td class="num">(808)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Ending balance</a></td>
<td class="nump">7,710<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrna_ProductSalesMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ChangeInContractwithCustomerLiabilityRollForward', window );"><strong>Change In Contract with Customer Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Beginning balance</a></td>
<td class="nump">3,799<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress', window );">Additions</a></td>
<td class="nump">4,467<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod', window );">Deductions</a></td>
<td class="num">(796)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Ending balance</a></td>
<td class="nump">7,470<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ChangeInContractwithCustomerLiabilityRollForward', window );"><strong>Change In Contract with Customer Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Beginning balance</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress', window );">Additions</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod', window );">Deductions</a></td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Ending balance</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrna_CollaborationArrangementMember', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ChangeInContractwithCustomerLiabilityRollForward', window );"><strong>Change In Contract with Customer Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Beginning balance</a></td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress', window );">Additions</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod', window );">Deductions</a></td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Ending balance</a></td>
<td class="nump">$ 235<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ChangeInContractwithCustomerLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Contract with Customer Liability [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ChangeInContractwithCustomerLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Deductions During Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in measure of progress which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrna_ProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrna_ProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrna_CollaborationArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrna_CollaborationArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865600656728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> ft&#178; in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>extension_period </div>
<div>campus</div>
</th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2019 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Aug. 31, 2016 </div>
<div>ft&#178; </div>
<div>extension_period</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_OperatingLeaseNumberOfProperties', window );">Number of campuses | campus</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="nump">$ 103,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, operating leases</a></td>
<td class="nump">89,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Amounts representing interest or imputed interest, operating lease</a></td>
<td class="nump">68,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Interest or imputed interest</a></td>
<td class="nump">376,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=mrna_EmbeddedLeasesMember', window );">Embedded Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="nump">73,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, operating leases</a></td>
<td class="nump">$ 44,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrna_CambridgeMassachusettsMember', window );">Cambridge leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of office space (in sqft) | ft&#178;</a></td>
<td class="nump">175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrna_NorwoodMassachusettsMember', window );">Norwood leases | MTC South</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of office space (in sqft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Extension term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods', window );">Number of extension periods | extension_period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Amounts representing interest or imputed interest, operating lease</a></td>
<td class="nump">$ 339,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_LeasesImputedInterestRate', window );">Imputed interest rate</a></td>
<td class="nump">17.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrna_NorwoodMassachusettsMember', window );">Norwood leases | MTC North</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of office space (in sqft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Extension term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods', window );">Number of extension periods | extension_period</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_AllowanceForTenantImprovements', window );">Allowance for tenant improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_LeasesIncrementalBorrowingRate', window );">Incremental borrowing rate</a></td>
<td class="nump">8.20%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_AllowanceForTenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Allowance For Tenant Improvements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_AllowanceForTenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_LeasesImputedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Leases, Imputed Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_LeasesImputedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_LeasesIncrementalBorrowingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Leases, Incremental Borrowing Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_LeasesIncrementalBorrowingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Extension Periods</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_LesseeOperatingLeaseNumberOfExtensionPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_OperatingLeaseNumberOfProperties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Number Of Properties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_OperatingLeaseNumberOfProperties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=mrna_EmbeddedLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=mrna_EmbeddedLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=mrna_CambridgeMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=mrna_CambridgeMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=mrna_NorwoodMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=mrna_NorwoodMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mrna_MTCSouthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mrna_MTCSouthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mrna_MTCNorthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mrna_MTCNorthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865599637112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Balance Sheet Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, operating, net</a></td>
<td class="nump">$ 89<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Right-of-use assets, financing, net</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_OperatingAndFinanceLeaseRightOfUseAsset', window );">Total</a></td>
<td class="nump">188<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Financing lease liabilities, current</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_OperatingAndFinanceLeaseLiabilityCurrent', window );">Total current lease liabilities</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Financing lease liabilities, non-current</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent', window );">Total non-current lease liabilities</a></td>
<td class="nump">234<span></span>
</td>
<td class="nump">207<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_OperatingAndFinanceLeaseLiability', window );">Total</a></td>
<td class="nump">$ 286<span></span>
</td>
<td class="nump">$ 237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other current liabilities<span></span>
</td>
<td class="text">Other current liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other current liabilities<span></span>
</td>
<td class="text">Other current liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</a></td>
<td class="text">us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization<span></span>
</td>
<td class="text">us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_OperatingAndFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating And Finance Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_OperatingAndFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_OperatingAndFinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating And Finance Lease, Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_OperatingAndFinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating And Finance Lease, Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_OperatingAndFinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_OperatingAndFinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating And Finance Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_OperatingAndFinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865600125320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Minimum Lease Payments (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2021</a></td>
<td class="nump">$ 12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less amounts representing interest or imputed interest</a></td>
<td class="num">(68)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Financing Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2021</a></td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_FinanceLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">428<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less amounts representing interest or imputed interest</a></td>
<td class="num">(376)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 183<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_FinanceLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Liability, To Be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_FinanceLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, To Be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865594963448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Strategic Collaborations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember', window );">PCV agreement | PCV products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount', window );">Budgeted amount</a></td>
<td class="nump">$ 243<span></span>
</td>
<td class="nump">$ 243<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Maximum Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_PersonalizedMRNACancerVaccinesProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_PersonalizedMRNACancerVaccinesProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865598452376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Purchase Commitments and Purchase Orders (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=mrna_SupplyAndManufacturingAgreementsMember', window );">Supply and manufacturing agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems', window );"><strong>Purchase Commitment, Excluding Long-term Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Purchase commitments</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=mrna_ClinicalOperationsAndSupportCommitmentMember', window );">Clinical operations and support commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems', window );"><strong>Purchase Commitment, Excluding Long-term Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Purchase commitments</a></td>
<td class="nump">993<span></span>
</td>
<td class="nump">$ 897<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=mrna_ClinicalServicesMember', window );">Clinical Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems', window );"><strong>Purchase Commitment, Excluding Long-term Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Purchase commitments</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=mrna_SupplyAndManufacturingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=mrna_SupplyAndManufacturingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=mrna_ClinicalOperationsAndSupportCommitmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=mrna_ClinicalOperationsAndSupportCommitmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=mrna_ClinicalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=mrna_ClinicalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865600243160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Licenses to Patented Technology (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 26, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount', window );">Commercial milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Consideration paid</a></td>
<td class="nump">$ 84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_TherapeuticAndProphylacticProductsMember', window );">Therapeutic and prophylactic products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentAndRegulatoryMilestonesMaximumAmount', window );">Development and regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_DiagnosticProductsMember', window );">Diagnostic products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentAndRegulatoryMilestonesMaximumAmount', window );">Development and regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Commercial Milestones, Maximum Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentAndRegulatoryMilestonesMaximumAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Development And Regulatory Milestones, Maximum Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentAndRegulatoryMilestonesMaximumAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_TherapeuticAndProphylacticProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_TherapeuticAndProphylacticProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_DiagnosticProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_DiagnosticProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865675810136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Aggregate number of shares authorized for issuance (in shares)</a></td>
<td class="nump">62,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised (in shares)</a></td>
<td class="nump">1,890,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of options exercised</a></td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options to purchase common stock</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockExpense', window );">Restricted stock units</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation cost related to non-vested stock-based compensation</a></td>
<td class="nump">$ 337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period of cost expected to be recognized</a></td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Aggregate number of shares authorized for issuance (in shares)</a></td>
<td class="nump">35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares sold under the ESPP (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Share available for future issuance (in shares)</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted common stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Intrinsic value of restricted stock units</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Performance period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage', window );">Payout percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage', window );">Payout percentage</a></td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mrna_StockOptionAndIncentivePlan2018Member', window );">2018 Equity Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grant (in shares)</a></td>
<td class="nump">27,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Payout Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for award of restricted stock or unit under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mrna_StockOptionAndIncentivePlan2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mrna_StockOptionAndIncentivePlan2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865675710968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Options Activity (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number&#160;of Options (in millions)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period (in shares)</a></td>
<td class="nump">34,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(1,890)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled/forfeited (in shares)</a></td>
<td class="num">(90)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period (in shares)</a></td>
<td class="nump">32,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period (usd per share)</a></td>
<td class="nump">$ 17.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (usd per share)</a></td>
<td class="nump">171.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (usd per share)</a></td>
<td class="nump">14.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled/forfeited (usd per share)</a></td>
<td class="nump">23.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period (usd per share)</a></td>
<td class="nump">21.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Grant Date Fair Value per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue', window );">Outstanding at beginning of period (usd per share)</a></td>
<td class="nump">9.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (usd per share)</a></td>
<td class="nump">75.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue', window );">Exercised (usd per share)</a></td>
<td class="nump">8.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue', window );">Cancelled/forfeited (usd per share)</a></td>
<td class="nump">11.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue', window );">Outstanding at end of period (usd per share)</a></td>
<td class="nump">$ 10.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Outstanding and Exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number&#160;of Options, Exercisable (in shares)</a></td>
<td class="nump">17,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price per Share, Exercisable (usd per share)</a></td>
<td class="nump">$ 11.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue', window );">Weighted- Average Grant Date Fair Value per Share, Exercisable (usd per share)</a></td>
<td class="nump">$ 6.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Contractual Term, Outstanding</a></td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Remaining Contractual Term, Exercisable</a></td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 3,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,976<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 2,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract', window );"><strong>Expected to vest</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number&#160;of Options (in shares)</a></td>
<td class="nump">15,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price per Share (usd per share)</a></td>
<td class="nump">$ 32.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue', window );">Weighted- Average Grant Date Fair Value per Share (usd per share)</a></td>
<td class="nump">$ 16.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Remaining Contractual Term</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 1,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested And Expected To Vest, Outstanding, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Options, Outstanding, Weighted Average Grant Date Fair Value [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865682535176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Restricted Common Stock and Common Stock Units Activity (Details) - Restricted common stock units<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, non-vested at beginning of period (in shares) | shares</a></td>
<td class="nump">2,190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Issued (in shares) | shares</a></td>
<td class="nump">460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(240)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled, forfeited (in shares) | shares</a></td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, non-vested at end of period (in shares) | shares</a></td>
<td class="nump">2,390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Fair Value per Unit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, non-vested at beginning of period (usd per share) | $ / shares</a></td>
<td class="nump">$ 30.85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Issued (usd per share) | $ / shares</a></td>
<td class="nump">165.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (usd per share) | $ / shares</a></td>
<td class="nump">24.77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Canceled, forfeited (usd per share) | $ / shares</a></td>
<td class="nump">32.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, non-vested at end of period (usd per share) | $ / shares</a></td>
<td class="nump">$ 57.28<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865598813624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=mrna_RestrictedStockAndRestrictedStockUnitsRSUMember', window );">RSUs and PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=mrna_RestrictedStockAndRestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=mrna_RestrictedStockAndRestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865594806008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Decrease in valuation allowance</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865681945368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share - Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 1,221<span></span>
</td>
<td class="num">$ (124)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted-average common shares outstanding (in shares)</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Effect of dilutive securities (in shares)</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted-average common shares outstanding (in shares)</a></td>
<td class="nump">430<span></span>
</td>
<td class="nump">353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic EPS (usd per share)</a></td>
<td class="nump">$ 3.05<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted EPS (usd per share)</a></td>
<td class="nump">$ 2.84<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865591223784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share - Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Details)<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted common stock units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139865599391592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 18, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 07, 2021 </div>
<div>USD ($) </div>
<div>dose</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember', window );">BARDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RevenueFromGrantsMaximumAward', window );">Award amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 483<span></span>
</td>
<td class="nump">$ 126<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_NumberOfDosesOfVaccineCandidate', window );">Number of doses of vaccine candidate | dose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Purchase commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | BARDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RevenueFromGrantsPotentialReimbursement', window );">Potential reimbursements</a></td>
<td class="nump">$ 236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RevenueFromGrantsMaximumAward', window );">Award amount</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_NumberOfDosesOfVaccineCandidate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Doses Of Vaccine Candidate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_NumberOfDosesOfVaccineCandidate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_RevenueFromGrantsMaximumAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Grants, Maximum Award</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_RevenueFromGrantsMaximumAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_RevenueFromGrantsPotentialReimbursement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Grants, Potential Reimbursement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_RevenueFromGrantsPotentialReimbursement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>88
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMJ1"OGL3(SB]J+;RZL5'>=1R"ODYI8^'==F2IJ4337L!MB0K*7@;G 5! "\
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M]6+WHOBF^@'@@2O%\^IQ38E6;@ST]RO.U>N+^4VA^0UI]C=02P,$%     @
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M*DT W%\(H=\F9BLOCVZ#?U!+ P04    " #7@Z921(&G0L@$   &$P  &
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M.#TY WR%$\(!C<%BQ38<QP$_!R>J?TO#4-8/'UA"<E4C6G[&:[3CA6IX+9C
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M?UARA8,*[ZD\1B0Z0KB/(P^>Z>'#^P$XI'(LL?I(B[['-9-4\WQ91"K7G*F
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M 7B_$$)_W)@)J@]@%_\#4$L#!!0    ( ->#IE*-P>##B@@  ,X2   9
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M@]\5/"TV2_0][#!U%XH7'MAC#QN*IG4PB]V-"2"%;*Y\<_O7OSQ;KY[^';2
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M6;==5_K?JGO+=0M3*O8CUS_Q4#N=*E'#M\S"_FVA*I$2/E""-N>-=1OV HJ
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M:,20&4BKBR5ERI?0WRY\LHXPZ>FTLG]RCM]NGGP%B=2Z K0!05EOC<YCGGS
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M;N)#]=9$CDMW*(]6TRXG.SM;:CI?;;? 9 [7SPVO*>.V!U_13D)+#IQ:F.W
M%BU8\@%8"O=*VM+ M<PQ?V\?$K&.7;)GMTB. MXS?0YIW(,D2N(C>&D7;>KQ
MTG]$VX.E8-*^#QI^SE?&:KHGOXZXZG>N^MY5__\D]BB8J\RQJ5F&TX!*SZ!^
MP>"8!WBWAV][$FE@!E0!E-NL[)+K%:\PPVJ%>K\:0::H_(SU!K9$*)2@,N9R
M#2=<TGT4@DK+G(X/T/X$B5ND.[92FEFEMV]\X!/$R<"/,=PA%5>I1 Z\JK5Z
M0:=A(![UZ8W@IM&2VT9C#PK^ZB;&<U9$2\. GDM5U8TEX0W?*1A5V W3"/$
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M2]]$J)T G:^5LH>%,]!_92W^!E!+ P04    " #7@Z926@DA'$8(  !#)0
M&0   'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6SM6FUOVS@2_BN$T0\)X-B6
M;"=VD 1(TP978+-;--E=' Z' RW1-J^2J%)4'.^OWV>&E&([B2^[N(\N4$>B
M.#//O(\(7:R,_5XME7+B*<^*ZK*S=*X\[_>K9*ER6?5,J0H\F1N;2X=;N^A7
MI54R9:(\Z\>#P6D_E[KH7%WPVE=[=6%JE^E"?;6BJO-<VO5'E9G592?J- O?
M]&+I:*%_=5'*A;I7[M?RJ\5=O^62ZEP5E3:%L&I^V;F.SC^.:3]O^$VK5;5Q
M+4B3F3'?Z>9+>MD9$""5J<01!XD_C^I&91DQ HP?@6>G%4F$F]<-]UO6';K,
M9*5N3/:[3MWRLC/IB%3-99VY;V;U#Q7T88")R2K^%2N_-\+FI*Z<R0,Q$.2Z
M\'_E4[##!L%D\ 9!' ABQNT%,<I/TLFK"VM6PM)N<*,+5I6I 4X7Y)1[9_%4
M@\Y=_:2@4G71=^!%*_TDT'WT=/$;=$-Q9PJWK,3G(E7I-GT?&%H@<0/D8[R7
MX9VT/3&,NB(>Q-$>?L-6L2'S&^Y53/SK>E8Y"]__>P_/4<MSQ#Q'?]E8[Z$3
MORNQE(]*J,(IJU*A"V?$H[3:U)7(3+$XP7HN"E.<)+)(5"9GF1(9$0MIK2P6
M"NG@*H%<%*:V8BX3G6FGP5L6J5 _:EW2#J&>2FUUL1#2M0(<<@F_2VOJQ1)6
M'L8]<:.L0^(*,\<#M2N&P<ZM4L@^,"T5&*65@'!5)3*3CB3X1W+-<DMK'C7E
M:]4C;:U*S*+0?S1*)*9RHD; 4%5(EMO2*$4%^8KRZ(1,2.FF\> 1^P%/9'JN
M E3/T$MAF&YE1"+SLB9#0Z,[654R6>+6N:K+UKJ1^<SJ=*$:NZW9:O3HS@!3
M(<6#2I:%R<QB#=.0E\31W</-<1?>2:1CEXF?C5T9D_;$+S"(MT'P[RL" ,\D
M25U"E,A1*/3)K-992D0>+7'<D'K_HY96T6++K+NM"^J#6Q(W_42V,/.Y3H+_
M+3PH+>R*P#& 9NQ:5*5,8!WC9,;Q4,)%3QK53&5K$9V-NX/! *60I<Y11*#6
MZZ;R!@\!3.&U%NP\1*,U.67M &+H[[0G;G5! =P8YFWSYK*H(<+5'*VM,+*Z
MN$</61Z++X6XKA>HA. =G7;%:B>!9),A"T0J1R&EQ[:B:%&[BCX;K[MAKRX;
M,J,0W,'&AH0O&F#=C5C8<5%//#01"F]EF;<7>_5>E4[E,VCN$[ -7Q"8DOL4
M5%)/3@$&+7)%((4HP'F=VV&;B\@&58@U_%X))2FG"+C]KMP)-:N4\S,@H@6?
MK\BJJI[]%YV1Q.DBL=Y1;:JQV,U4Z^UQ(JR D&2?\27[[%;-+(Q-MH^F[_6:
M=XCWP6X, \W_=*KW#X-X+6?W^"DQ.5 D?CMI7:%V 0;Q)ATAG11A:$N9XB\V
MHO3*X%W)ODLAT&\=1N]PKA=-BM<E/9I3+9)IJFDO.,\QL)R0;]D?P/N%"MN:
MD^T5DZ* 0H>4K8G[9PFK)7;-UDSQI&RB*3"P/8"2CU+[7A-T-U8O- 'PY."%
M2JX !FX#>$D1E%.M]YZ3&48[SO= +W-3%YQA'^(8E2K+@NXSA5:A4T1B\GU/
ML/D:IUDYY#WWMIV4V-K.=6<X[HG/2*T4\XC8UW&Y#I<9^;S@T6 WTY5]Y"AL
M0C/47+?4-@5^RPUWM=3(-F)!#50U@D.9)((FD!),T(3W^OY&3$9(^FO.VSLN
MU<W$PTI^@I6Y.(15[V0*-Z]GIN6L:?ADW+-A:UPB_Q"/FOLN-8-2\<B;K>DN
MXUP(8;$#]V]!LMRGS?RDIC2ND%$>U&BT!>H/90VJ:B62,&OLF@J7.FG <9_^
MY;<OGTZ0:X\R26@,0*0MK,PA&&F>DD]X+WNV0-QGC@H3J2H(2XG2:!M-/_]Z
M[1L4W=Q^NJ80;74B?3;[..&=<^NB.V_SU]3D^O3"(_+=-O2:2!KD*'4J<014
MP6C5\?D&CUW2R--?,XYS\>TE.,PZC3Y=4:#/'47'XB@^%A_$9(J?Z>!UJE;O
M0#4$U>A83*=B/!8/-#^ .)I,Z'<T%C\]*WXN;FI+;>5\PY0OS7,T)@QG^'\:
MYH.W]T$ 8ME+33SS5W:.8S$<H+9C7'X'@*X?K .WZ:F8GNW#L;T]&DY$% T"
MI,TG+V%]$/%P1+^#L]9P\>24U\_$?_P_=LN#G[E#4%EJSM1/*D=MI$G9QD&^
MX*!79W4*@0BL[KY^B:0FK__L)QUD4HVZQPQ3A=?W1'/'ZK&C]^((RSL5I.VS
M++R=BIJD1FRO\*9-?U_2O[ON]C@$OWB5N3.C%,##87)_?M\)I98Z-@8D;,55
M93*=LL@9WE6H._%;<N7C>[]-QMM2#9C;YT#<\/5?$8RQN(:JBE[C=5[G(73"
MNU,57HRH K[^!OC<CC#C;9>9+GOM[8)RJ^F%3?R31HD7KRT4B<^)L+'(]>;(
M*CK;2?T,1,K20$*I',7X&9W2MEA$IV(TH<LA7>(1+D?/EV.\:R")*-(06W.:
MJ*8C,8HG(4/>,$ET%J'\3 &JJL)409%4TIM.P3JT0P)*/F:2V@]\8>WH=((J
M-CP[]17PJR=#7\EJ[LBOY6XT&'*A&XJ-1 W!4(6)B8>^,(JW,; W(_P %W*X
M58#&*5:?^N9P.&T;9UV<I' 9Z0M]YCYLMFW3VW.>,6[/,\9_\SSC/72'\XS#
M><;A/.-PGG$XSSB<9QS.,P[G&8?SC,-YQN$\XW"><3C/.)QG',XS#N<9_X?S
MC/[&ARVYL@O^? >MEQCY;US:U?8+H6O_8<SS=O]Y$0(,,V %J7.0#GIGXX[O
MA<V-,R5_)C,SSIF<+Y=*(DYH Y[/C7'-#0EHOYNZ^A-02P,$%     @ UX.F
M4A;>3#AC"@  ^!L  !D   !X;"]W;W)K<VAE971S+W-H965T,C$N>&ULK5EM
M<QNW$?XK&-;3:6=H4J+DV$YDS<AR.W5KQQK;23YT^@'$@21BW.$,X$C3OS[/
M+H"[HT0K=M(O$N^ ?=]]=H&[V#G_(6RTCN)3;9OP;+*)L?U^/@]JHVL99J[5
M#596SM<RXM&OYZ'U6E9,5-OYXN3DNWDM33.YO.!W-_[RPG71FD;?>!&ZNI9^
M_UQ;MWLV.9V4%V_->A/IQ?SRHI5K_4['G]H;CZ=YSZ4RM6Z"<8WP>O5L<G7Z
M_?-SVL\;?C9Z%T:_!5FR=.X#/;RLGDU.2"%MM8K$0>+?5E]K:XD1U/B8>4YZ
MD40X_EVX_Y-MARU+&?2UL[^8*FZ>39Y,1*57LK/QK=O]2V=['A$_Y6S@OV*7
M]CY:3(3J0G1U)H8&M6G2?_DI^V%$\.3D"P2+3+!@O9,@UO*%C/+RPKN=\+0;
MW.@'F\K44,XT%)1WT6/5@"Y>7KNZ-A%>CD'(IA+7KHFF6>M&&1TNYA$B:.-<
M97;/$[O%%]B=B==@L GB'TVEJT/Z.53K]5L4_9XO[F7X6OJ9.#N=BL7)XO0>
M?F>]O6?,[^R/V"M>F*"L"YW7XK]7RQ ]DN9_]T@][Z6>L]3S_Y>7_P0[@9TR
MZK51>&^M7#H\H@""^ DQ\<)UJ,E^BQIO$7+MM6:^4['30L(/BF5%78GH1*L]
MX8!0VD<4/*HR:.G59HI"V*+ 6Z*=LDZU;+H5W-=Y:):*ST2H-Q-70;321^%6
MK,O-]<_BJLAE4KR9O[L:O]V9N!&OM5<?_H1>]ZH%$BLS-]*H]:[J%/P;-]YU
MZPV(A6FP55IQLP$,B(50B(M1>!$]O>Y:(I9BV55K3:QD[;J&[7RP.#]#]5I+
M3H:F8NE@$+0VKD(( ^UY30KWJ<[*OM!*UTO$++\]F8D;JTDXH NO(8X\2"N"
M,$J<GCS\C_C112T>E46%R#MK*C9N91J))(&R(>(%1WHF7NDU6>6=TKJ"6X+X
M)?FX<1$8Y#VVV3TLH[#MV<AF#T]&S79;)F\'\IEXB4RK&[."=SBOWBRM6><L
MI/!KGV/7<4J^@.]W)!#_., FT^_9!+<"(^V1DY7Q0'-'/\D_NFZMVVM$CWQ:
M@H^(<P([E7176-]MC-6(I2[,L.Q[=L($?MY)_ _:;SDW(@OW^F.G0X1*:%P(
MD)*M5";N9^(]N,$%-06/.)M;1INDUDCH7__R9''Z^(<PEMV_LV:E(_K=C+R_
MD5M-,6HJZ:L[G*7W$N6>  "*D9Z<%TEB+FCG]^RE)%P$Z$TN@%UD$\2++E P
M!V>3JA8DUD&H7,.9(7*LK9%+8V$U\S?-KYW?3P60D@*AE*FX[,DJ6:.5BY5W
M-1,J*TW-FSCXTW&:,(%R(5+Q!711\CI3EDB""KN6&#8PB^#7UC@K,R/0-JYY
MF"L?6:US,@W.8$]",TTJCPPM;H0N6Q,X*0?2 0(3ZBBJ8>TI]0DFH!4'U,,$
M##&T[ ,%&&4? -/DD;AO"190,LRA+'#Y-)S'*$KN+9S)/8P$$W4"]-3XL766
M01LR(650F*L$@*\]RQE"2-0;9_%'^MJ2U(/41,FE(N8\0?P@,'0K@ E6.+1<
M,Y58[K] "+"2.5X%P<?@_IX5O<?3@])HLUM,9%Q#<"9OS*7$X;![+L,2CU1P
M&'U,W=6B!<@UC,8#RJZZ2)V[E?L</^H2'7RQU"7E&=]K^:$D2_P]=0WEAC6
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M#^+^?#KQX5%.PV V)=DH"*<P'0?1L,M12KX%L_EKB$;!+(19$$W@BELSQW1
M';%"R0 G81"24#P,YC%$43"*CGV\7S88QL%\#'$4#$D^#.81>3=IO!OV)Z-Y
MZX%KF(?Z%-ADS)8FK!F.8!R,&O6X'U$8UW<5G37DFE6P06,?PQ@'PY ]&=/U
M)!C'%%[8@$3]\2B&O_P_5Y]]]617O8VKGC20B#RI<\'VA'&=F\K5BN:'AWB)
M=HM8NL?8]E[E>H^ZEI^Z0<IWG"K5-#&/)/^TXK;S=D@X447! \HTY ;29HK
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M.7SU>L L#- NJK2&Q;RDS9AU34N[!J80^SI$\,-WLSB*?X2/C@^8$%DKI&/
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MUJ21%EZ ]Y7W:;AA ^-GJKO_ 5!+ P04    " #7@Z92] ZH1LX#  #K"
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M.NZU)00)I*VOV.-H.F(+H87E2JUI632DC6]P;*R$WD9!YM%/D\G]<<PPWC2
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M31TO*TP<PM(&K,\-)L!\0PJZSVW7_P%02P,$%     @ UX.F4K[U\&:F P
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M.T-<FK"L^$U#ZQWXO#"&CAM/T+^2\[]02P,$%     @ UX.F4OM!7!S= @
MC@8  !D   !X;"]W;W)K<VAE971S+W-H965T,CDN>&ULG57;;MLP#/T5PAN&
M%ACJ2]*MS9( 2;K;0[$BS3I@PQX4F[:%RE(F*4V[KQ\E7^8630;L1=:%/#R'
ME.CQ3NE;4R):N*^$-).@M'8S"D.3EE@Q<Z(V*.DD5[IBEI:Z",U&(\N\4R7"
M)(K>A!7C,IB._=Z5GH[5U@HN\4J#V585TP]S%&HW">*@W5CRHK1N(YR.-ZS
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M<VAE970S,"YX;6R]5MMNXS80_96!NB@2((ADV8XOM0W82;LMT&"#)-T"+?I
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M23['K9 Z6LS"WIU9S*AW2FJ\,V#[MA7F;8F*UO,HC;8;][)NG-^(%[-.U/B
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M-S2HHV$!.E]I[78+=C",_I?_ E!+ P04    " #7@Z92!FBG#JT#  """
M&0   'AL+W=O<FMS:&5E=',O<VAE970S."YX;6R55E%OVS80_BL'+1@2(+5D
MR6X#SS80)QXV8"V,.-L>ACW0U-DB0I$J2<79O^^1E%4[2[WNQ19%WG??W7W'
MTW2OS9.M$!V\U%+965(YUTS2U/(*:V8'ND%%.UMM:N9H:7:I;0RR,AC5,LVS
M['U:,Z&2^32\6YGY5+=."H4K [:M:V;^6:#4^UDR3 XO'L2N<OY%.I\V;(=K
M=+\W*T.KM$<I18W*"JW X':6W XGB[$_'P[\(7!OCY[!1[+1^LDO?BUG2>8)
MH43N/ *COV>\0RD]$-'XW&$FO4MO>/Q\0/\YQ$ZQ;)C%.RW_%*6K9LE- B5N
M62O=@][_@ET\@2#7TH9?V'=GLP1X:YVN.V-B4 L5_]E+EX?O,<@[@SSPCHX"
MRWOFV'QJ]!Z,/TUH_B&$&JR)G%"^*&MG:%>0G9LOF5%"[2PT:&!=,8-P^<@V
M$NW5-'7DP!]+>0>VB&#Y-\ *^*B5JRPL58GEJ7U*Q'IV^8'=(C\+^)&9 13#
M:\BS?'@&K^BC+0)>\5_1KOIH_[K=6&=(''^?P1_U^*. /_H&_H)9P8&I$NZ%
M;!V6\(GZZC=MC_-[ZYP1F];Y+(/3<*?KFO2Y=IH_55J6:.Q;J?]>SV7G>;E:
M S4MN(J\5 81ZE@<],4!2BVO^MP&2WK(P#/D3/)6,H_"+(%(:ET+ET*1 J6D
M9K+7@"\<&Q?"LB&LDN1W-8''X.I8!Z]=!3>?VAH-<]I,0HJ$XKHFZ4E*U15<
MP/ ZIY,7<#G,1U=PCTJ3]N/Q&.D^M!N6[]@SX>R(<\QBX&*!KA_K*"8J-HRR
M#(IQ <OMEJX"T-N8(KH,P")OC7""+(H,?OSA)A_F/_6U^S\^BN@CDO.IOX!B
MD(U]"-F@&%_UH'$O']R,^KTSPAOWPAN?+?^QAF#YN17/3*)R5($7+EM?A*W1
M-=QUA?7W(>7A7R+MV^(M 9YEX(?'Q#:,XRRAZ6#1/&,R?R3M1?GX)!W2%TCB
M5Y+7$"R4I^)OV!+\=5WKU@=PG&42([$^D5-&52+QX4F87O+\--1#5R@*51[Z
M,0J7O>K'8YI=/_:-1%9"EY;T6@H>&F2#G+76MQ@*XW4LVS"P]KJ5)50D'3J"
M%(]RXETOO.->HJ9Y%5(LHVX\>0NC,3P@W5&">W\G26R5H!3E,/H ;XDH/9H+
MU&Z[,/TL05!FXXCHW_8#]C;.E:_'XW0FACM!9"1NR30;?" UF#CQXL+I)DR9
MC78TL\)C11\):/P!VM]J[0X+[Z#_[)A_ 5!+ P04    " #7@Z92?_NTA3$"
M  "9!   &0   'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q]5$UOVS ,_2N"
M3QO018F3;D/A&,C'BO50+&BP[3#LH-BT+526/(F.N_[Z4;+C9<"2BRU2?(^/
M-.FD,_;950#(7FJEW3*J$)L[SEU602W<Q#2@Z:8PMA9(IBVY:RR(/(!JQ>/I
M]#VOA=11F@3?SJ:):5%)#3O+7%O7POY>@S+=,II%)\>3+"OT#IXFC2AA#_BU
MV5FR^,B2RQJTDT8S"\4R6LWNU@L?'P*^2>C<V9GY2@[&/'OC(5]&4R\(%&3H
M&02]CK !I3P1R?@U<$9C2@\\/Y_8[T/M5,M!.-@8]5WF6"VCCQ'+H1"MPB?3
M?8:AGEO/EQGEPI-U0^PT8EGKT-0#F!344O=O\3+TX0P0SRX X@$0!]U]HJ!R
M*U"DB34=LSZ:V/PAE!K0)$YJ_U'V:.E6$@[3+;C,RB9TR!0,*V#KUE&0<^P=
M6^6Y]%="L0?=3X /?+,%%%*YMPE'TN"9>#;D6_?YX@OYYNS1:*P<^Z1SR/_%
M<](^%A"?"EC'5PD?A9VP^>R&Q=-XUEA36E%?H9V/?9D'VOD%VB^V%%J^AGIO
MV,9H9Y3,^_*%SMG.@@.-XM2X>ZF%SB0U:D].H+%%QWZL#@XM#=[/*XH6HZ)%
M4+2X^*6.M$*-9V;_K;/O5D]R&TC\1A[3>)'PXWEB?C8N-=@R+(5CF6DU]I,S
M>L>]6_7C]C>\7UKJ?BFU8PH*@DXG'RBQ[1>A-] T8?@.!FF4P[&B?P=8'T#W
MA3%X,GR"\6^4_@%02P,$%     @ UX.F4M+7+$$S P  40D  !D   !X;"]W
M;W)K<VAE971S+W-H965T-# N>&ULO59+CQHY$/XKI58.B12F7\ P$2 !DVA'
MRFS0L+,Y1'LPW05MQ6VSMALF^?5;=O=T@ &4PV@OW7Y4??75PRX/=TI_-P6B
MA:=22#,*"FLW'\+09 66S%RI#4K:62E=,DM3O0[-1B/+O5(IPB2*^F')N S&
M0[\VU^.AJJS@$N<:3%663/^8HE"[41 'SPL/?%U8MQ".AQNVQ@7:Q\U<TRQL
M47)>HC1<2="X&@63^,,L]@I>XF^..[,W!N?*4JGO;G*7CX+(,4*!F740C'Y;
MG*$0#HEX_-N !JU-I[@_?D;_Y)TG9Y;,X$R)KSRWQ2@8!)#CBE7"/JC=']@X
MU'-XF1+&?V'7R$8!9)6QJFR4B4')9?UG3TT@]A0(Y[1"TB@DQPK=,PIIHY!Z
M1VMFWJU;9MEXJ-4.M),F-#?PL?':Y V7+HT+JVF7DYX=+^KT@5K!E!ENW&"N
MT:"TK(ZSS.$!,YK#),M4)2V7:UA86F<Z-]"!F2HW2I* 5R:AJJP$LYC#%UN@
M]OL:"Y?Z+<);H8QY!W<R4R7-;M$R+FBA X^+6WC[YAV\ 2[AG@M!YLTPM.2E
MXQIFC4?3VJ/DC$<IW"MI"P,?98[YH7Y(T6E#E#R':)I<!+QG^@K2^#TD41*?
MX#/[??7H IVTS5CJ\=(S>),OLSN86*OYLK)L*1"L@CG3E(#W\"<=?$K"7^P)
MOCTH(8!J?4=Y^N>"X6YKN.L-=\\8GC+!9(; +"QQS:5TA4#&-JBYRD\EJL;K
M>SQWGVS'2:]/(=SN1^^E4!Q?]UJA ZJ]EFKO(M6Z\+*#PG-U=XIDC=3;L]])
MCBB>$!F<)MAO"?9_-Y9(!^QB%/LOK*>#='!$L?\RBOUN?)KD=4OR^B+)1TF-
M0?"?=)(_4_" ;H/)EDZK*[H.=9#.@E'UW>+2P@*S2G/+T5PHM$%K=_#_5OA-
M:_CFE2O\YF5N3L<\CGY=R-&KU6X#=:9X#PGL=83XU6JS@3JHNR/[X5YS*E&O
M?<\VX%M)?0FWJ^V[8.*[X='ZU+T7?-/[!5,_-NB*I6P9$+@BR.CJF@*BZ_Y=
M3ZS:^!:X5)8:JA\6].9![01H?Z64?9XX ^TK:OP?4$L#!!0    ( ->#IE*=
M%<&([P(  'D(   9    >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;)56WV_:
M,!#^5ZQH#ZW4-C_)V@J06F#:'BJALFX/TQY,<A"KCDUM4[K_?F<G30,$QEZ(
M'=_WW7UWQSG]C53/N@ PY*WD0@^\PIC5K>_KK("2ZBNY H$G"ZE*:G"KEKY>
M*:"Y Y7<CX(@]4O*A#?LNW=3->S+M>%,P%01O2Y+JO[< Y>;@1=Z[R\>V;(P
M]H4_[*_H$F9@GE93A3N_8<E9"4(S*8B"Q<"["V\GJ;5W!C\8;'1K3:R2N93/
M=O,M'WB!#0@X9,8R4'R\P@@XMT08QDO-Z34N+;"]?F?_XK2CECG5,)+\)\M-
M,?"N/9+#@JZY>92;KU#KZ5F^3'+M?LFFM@T\DJVUD64-Q@A*)JHG?:OST *$
MR0% 5 .B4P%Q#8A/!20U(#D5T*L!3KI?:7>)&U-#AWTE-T19:V2S"Y=]A\9\
M,6'[9&84GC+$F>&LZ@\B%^2>:J;M8JI @S"TJJ3(R2-DN"=W62;7PC"Q)#.#
M[ZG*-;FTIU)DC+,*@ 0CJHL+]TLF+VOV2CG"=4VEC6*9@;PZ/QN#H8SK<R1Z
MFHW)V:=S\HDP01X8YTBG^[Y!F398/ZLEW5>2H@.2'JBZ(G%X0:(@"CO@H^/P
M,60-/.B CT_WW@6?G.P]O-F&^UC:IKY14]_(\<4'^%HUFTK.,@::_+J;8Q'P
M+_K[B(.X<1 [!\D!!ZZ*MK*97<!'N;L*5U&ECLI.L-=A+TFBOO_:+L^^491&
MR;;1>-\HOOD@VE*2-$J2HTI:K6FU=,5?$?1:7H.=N/8MPNZH>DU4O?^)ZH((
M*2ZSM5*8XZX0>_L!A#L)_K?)^*C)EHZTT9$>U?%=&LIK";NMXOI';0LENI ;
M82>!*8#@A,GQ<K)G.!.PD7-J#34.*2@=!8X=!UO@S=?9>VE'[_7BG=3L&T5I
MG.XD9]\H"7;Z<])!E%SO9-!OC6U[*>/H6#*A"8<%HH*KSYA_55UTU<;(E9OD
M<VGP7G#+ K\-0%D#/%](:=XW]G)HOC:&?P%02P,$%     @ UX.F4O0+V<@<
M P  1PL  !D   !X;"]W;W)K<VAE971S+W-H965T-#(N>&ULM5;?;]HP$/Y7
MK*@/K;0U<0*$5H!4R*956B4$Z_8P[<%-CF#5B9EMH)/VQ\]V0L+/J!/B!6+G
MON^^N[,OUUMS\2KG  J]92R7?6>NU.+>=64\AXS(6[Z 7+^9<9$1I9<B=>5"
M $DL*&.N[WD=-R,T=P8]NS<6@QY?*D9S& LDEUE&Q)\A,+[N.]C9;$QH.E=F
MPQWT%B2%*:CGQ5CHE5NQ)#2#7%*>(P&SOO. [R,<&H"U^$YA+;>>D0GEA?-7
MLWA,^HYG% &#6!D*HO]6, +&#)/6\;LD=2J?!KC]O&'_;(/7P;P0"2/.?M!$
MS?M.UT$)S,B2J0E??X$RH+;ABSF3]A>M"]N6-HZ74O&L!&L%&<V+?_)6)F(+
MH'F. _P2X.\#6B< 00D(W@MHE8"6S4P1BLU#1!09] 1?(V&L-9MYL,FT:!T^
MS4W=ITKHMU3CU& L>+*,%9H2!A)=1Z (9?(&?43/TPA=7]V@*T1S]$09TV62
M/5=IIP;JQJ6#8>' /^$@0$\\5W.)/N4))+MX5XNM%/L;Q4._D?")B%L4X _(
M]WQ\1,_H_7#O"#QJAD<0GX+O1!-4^0\L7W"*CTJ2I@)28J\!GZ$)K"!? OKY
M59NB1P69_-7@J%4Y:EE'K1..OG%%F+ZIEOQ8&0MXQ\)-MU@-\%T0]MS5=FX/
MC;J5Q8ZL=B6KW2@K@AD( 4F3LH*AO>4T; =X5UG4/E 6=#OA<7&=2ERG4=SF
M<DAS.1IJ$%9\X66+W:T<=<\K=O<@I3@,@KUB=P]2ZAW/YUTEZZY1ULCV,Q"Z
M,2^XI*HII]BK.YAWV:SBK6:)SSZM)<7N<?6\O>-:6NV>5^]$?K%?"_0;!3[G
M5&EY4T64;N=_T7M/,*[[%;YPP\)UQ\)GMJP2OW.,@_:)CH3KEH2;>]($I#*!
MZ8F%)?^3Q+JOX,Z%DUBW'!R>F<3P\"2&[;T<NEL3AK[ J9W4)(KY,E?%I[O:
MK:;!!SL#[>T/\?VHF.EJFF+$U!_FE.82,9AI2N\VU$42Q=16+!1?V#GFA2O=
M1>SC7$^Z((R!?C_C7&T6QD$U.P_^ 5!+ P04    " #7@Z92"\/"C!X%  #>
M&   &0   'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6RU65UOVS84_2N$5Q0M
M4$0B*4MRZQAPXCCQL&Q!TFX/PQYHB[:Y2J)+47$*],>/^H@H6Q*C#/5++-F\
MYQ[=C\-+9;SGXFNRI52"IRB,D_/!5LK=1\M*5EL:D>2,[VBL?EES$1&I;L7&
M2G:"DB WBD(+V;9K183%@\DX_^Y.3,8\E2&+Z9T 21I%1'R_H"'?GP_@X/F+
M>[;9RNP+:S+>D0U]H/++[DZH.ZM""5A$XX3Q& BZ/A],X<>%8V<&^8H_&=TG
MM6N0/<J2\Z_9S2(X']@9(QK2E<P@B/IXI)<T##,DQ>-;"3JH?&:&]>MG]'G^
M\.IAEB2AESS\BP5R>S[P!R"@:Y*&\I[O;VCY0,,,;\7#)/\+]L7:H3, JS21
M/"J-%8.(Q<4G>2H#43- L,, E0:HKP$N#7!? Z<T<(X-O Z#86DP[.O!+0W<
MO@9>:>#U-?!+ [^OP:@T&.7E4.0O3_Z,2#(9"[X'(ENMT+*+O()R:Y5S%F?%
M_B"%^I4I.SFY%B26X)X^TCBEX-V,2L+"Y#UX U@,;ED8JHI,QI94KC(#:U7"
M7A2PJ -VNA-G /H? +(1_/(P ^_>O&]!N32C/-#=&<!VCF)WH\QZ<'D9Y:HW
M%^B6*'R7-6P+UMR,=4LR1O"EZ%SW1S$\UXT99497?5 69I1?T_ %%$L59E6=
MJ*I.E,/B+G(L(9N-H!N2*R-?5Y7Z]V]J*5A(&B7_&!SARA'.'3D=CCYS24*P
MR9M!%"[:TEJ N#E(MHT\3N (>V/KL9ZUYB*_6G% SJG(.49RESR60NT*2AKD
MMA0%*CZ D)$E"YG\WD:U@!S66'@>M ^IWC@-JH[M..ULAQ7;H9'M=7<0#_#<
M"L\];0UXE2/O9]2 UP@L'#E')=!<TQ%4O^+F__P2\!LLAD?Y]QOY'[;S'%4\
M1T:>L^G]W=20"VCK?<D^;=IA;0N$1M+3/1$!(!%/8]FZ2<%FF-SV.$&M;!"]
M'"GP U29+3:3Q/1$6LT@/G'PM#9!LSA-\["!%8\B)B4-@!K P3J- Q9O6O>T
MIC#ACEAJQ8%FR9D^JJ&%+$-J=#QLM@/L\*RU";I&SQ?3^YFQWK7X0._$*=-:
M LUB\D*]SV!3%AP?'TK'5<LBB-S#17/8E"!HVW9'U+7(0+/*O++FYB7<0<U!
MKYT%T@J%;#.+(&!9KM2F43!19\"V>,Y+G+I[]RB<BW+-0<P]U$%1*QLR*]OO
M:;2D(BNFU9',*.7IG%ZO2M0>/8IJDYQ9[PQ4Z!,5*Y:H/!I)H;Z;*M(ZB<QC
M7]Z^RNM#NDSHMU3E#V1-)TVCJU9&Y)RVHY$60/2" )H[^J(T/VA6W-6'2*L?
M,JO?'9<J6$PU@* L6J8BH5D/M)X72Z@Z!80[=E&D51.99[;G!/8=.I$62>2?
M.'M:SI!9SGH.GJBI8G"$CB;/ED4=K8NUT&&ST#T'^16C"M82A>&)CWA:@K!9
M@EZ[;>"FXKBCCF#6#IIFR>DSJ\Q+C+KGCC,DUG*$S8/:YRT%%RP,W_X"7?O3
M6Q+M/H%;JE8%!%P321,P5^$)BC3\ (N8Y9V]$_Q?NC(I(M8RA8<GSK66)FR6
MIGYA=IL=U3$28BU)V"Q)_^NHAILG1K]#GK&6,&R>\_Z06[7C'NC**Z02:_W"
MH].FU=%2Y)BEJ*=4.LUIZE@H6Y8<I]ZJO5;-WOS?$K%A:EX)Z5K9V&>>2I<H
M7J87-Y+O\C>M2RY5TO/++24!%=D"]?N:JPVSO,E>WE;_TIC\!U!+ P04
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MVS=:KLHSVK=2:[DL7]Z)>";R(L!\/Y=2_WA3'/O>'?,?_0]02P,$%     @
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M.1^0(5T]5E7'JG5YWR^4I=>C;&;TOJ-V 32?*F7?.NX):?XQ3/X 4$L#!!0
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MQ_\5*SM-=U+;@&U(<DLC]=I5JW35JE:]_3#M!S=Q$JL$9[:37*7]\3.$\F@
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M&FP,;EA@ZP9E W!_+:793VQWZ/X,TK]02P,$%     @ UX.F4I^X4WL6!
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M'7;\Y[\P&#EUC=[V&ZOB'7"-FDNWTPAV\PWW=@+XPG>F]\\-SU) \ZW@#\1
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M\+7@/G?XH -E!7!](Z5Y'=@G0_-$G/T+4$L#!!0    ( ->#IE(S;_%"? ,
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MB6Z9XZP$91WP?"VEV1LV0#=]DS]02P,$%     @ UX.F4N.I(T@L P  20D
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M8;^J_2>L!8T<7JJ$\;^PKWVC -+26%74P<2@X++Z9]_K1+0""*<[(*X#XN.
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M@-9)X&5VO(YL4MK@C]_*28LZ]*CNK:\F@U$6K]Y@,@Q,A@>9M/=+U?CZ&KS
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M):[,Q"ZVQD=0T(UOUXU16"FRCH<7X=;!WDR0F50%57V8.-R8)F-.2Y"C6+6
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M8L_!@_,HVIQ3T?97DLEO4$L#!!0    ( ->#IE*7BKL<P    !,"   +
M7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_
MK]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?2
M0$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-
MTG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z
M6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ UX.F4M_'0U$4!0
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MD;B;1JWMN1./=%8]OWOV%"?;KNWCO%BEY,\8B]6*.AM+YZG/*TL7.IORU_#
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M96>;_BV?C?\17+P 4$L! A0#%     @ UX.F4@=!36*!    L0   !
M         ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #7@Z92
MS&.LU>X    K @  $0              @ &O    9&]C4')O<',O8V]R92YX
M;6Q02P$"% ,4    " #7@Z92F5R<(Q &  "<)P  $P              @ ',
M 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( ->#IE*ER Q:-P4
M &,5   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX
M;6Q02P$"% ,4    " #7@Z92,Y!.=2,&  !/&@  &               @(%Z
M#0  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ UX.F4@-(
M4GOA @  Q@D  !@              ("!TQ,  'AL+W=O<FMS:&5E=',O<VAE
M970S+GAM;%!+ 0(4 Q0    ( ->#IE)$@:="R 0   83   8
M  " @>H6  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " #7
M@Z92>FXH$OL"  !3!P  &               @('H&P  >&PO=V]R:W-H965T
M<R]S:&5E=#4N>&UL4$L! A0#%     @ UX.F4@E;%IR& @  < 4  !@
M         ("!&1\  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0
M   ( ->#IE)4(4 ]_@0  )@5   8              " @=4A  !X;"]W;W)K
M<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " #7@Z92G( _ZT4"  ",!
M&               @($))P  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L!
M A0#%     @ UX.F4H'N:3I_!@  #!L  !@              ("!A"D  'AL
M+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( ->#IE*-P>##B@@
M ,X2   9              " @3DP  !X;"]W;W)K<VAE971S+W-H965T,3 N
M>&UL4$L! A0#%     @ UX.F4N492'0!"   A14  !D              ("!
M^C@  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " #7@Z92
M=FC-O50(  "6%   &0              @($R00  >&PO=V]R:W-H965T<R]S
M:&5E=#$R+GAM;%!+ 0(4 Q0    ( ->#IE+L#Y: 5@@  )L4   9
M      " @;U)  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%
M  @ UX.F4D<S7EA:!   X D  !D              ("!2E(  'AL+W=O<FMS
M:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " #7@Z92M !@)7<(  ",&
M&0              @(';5@  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+
M 0(4 Q0    ( ->#IE+-K$!"E@4   H0   9              " @8E?  !X
M;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ UX.F4G"356!>
M @  +@4  !D              ("!5F4  'AL+W=O<FMS:&5E=',O<VAE970Q
M-RYX;6Q02P$"% ,4    " #7@Z922=$*\^P"  !K!@  &0
M@('K9P  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( ->#
MIE*;*VD5$P0  '$)   9              " @0YK  !X;"]W;W)K<VAE971S
M+W-H965T,3DN>&UL4$L! A0#%     @ UX.F4EH)(1Q&"   0R4  !D
M         ("!6&\  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4
M    " #7@Z92%MY,.&,*  #X&P  &0              @('5=P  >&PO=V]R
M:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( ->#IE+-\3*@* <  &\2
M   9              " @6^"  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL
M4$L! A0#%     @ UX.F4H'4-:\3!P  LA(  !D              ("!SHD
M 'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " #7@Z92] ZH
M1LX#  #K"   &0              @($8D0  >&PO=V]R:W-H965T<R]S:&5E
M=#(T+GAM;%!+ 0(4 Q0    ( ->#IE(@J56:[P,  +8(   9
M  " @1V5  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @
MUX.F4H,Q,BU'!P  >A,  !D              ("!0YD  'AL+W=O<FMS:&5E
M=',O<VAE970R-BYX;6Q02P$"% ,4    " #7@Z92OO7P9J8#   T"P  &0
M            @('!H   >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4
M Q0    ( ->#IE+"R[E!;0(  #$%   9              " @9ZD  !X;"]W
M;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ UX.F4OM!7!S= @
MC@8  !D              ("!0J<  'AL+W=O<FMS:&5E=',O<VAE970R.2YX
M;6Q02P$"% ,4    " #7@Z92X*G\'.\#   <"@  &0              @(%6
MJ@  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( ->#IE+O
MF9K5)@4  $H0   9              " @7RN  !X;"]W;W)K<VAE971S+W-H
M965T,S$N>&UL4$L! A0#%     @ UX.F4MS<+)Z- P  -@D  !D
M     ("!V;,  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ->#IE)-BRAP] 0   8,   9              "
M@5?'  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ UX.F
M4@9HIPZM P  @@@  !D              ("!@LP  'AL+W=O<FMS:&5E=',O
M<VAE970S."YX;6Q02P$"% ,4    " #7@Z92?_NTA3$"  "9!   &0
M        @(%FT   >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0
M   ( ->#IE+2URQ!,P,  %$)   9              " @<[2  !X;"]W;W)K
M<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ UX.F4IT5P8CO @  >0@
M !D              ("!.-8  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q0
M2P$"% ,4    " #7@Z92] O9R!P#  !'"P  &0              @(%>V0
M>&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( ->#IE(+P\*,
M'@4  -X8   9              " @;'<  !X;"]W;W)K<VAE971S+W-H965T
M-#,N>&UL4$L! A0#%     @ UX.F4L3QM^4< P  MPL  !D
M ("!!N(  'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    " #7
M@Z92B(Y-3RX#   \"P  &0              @(%9Y0  >&PO=V]R:W-H965T
M<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( ->#IE(7+?DSQ08  /(O   9
M          " @;[H  !X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#
M%     @ UX.F4HAHI'/* @  /0@  !D              ("!NN\  'AL+W=O
M<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    " #7@Z92SR6ZF30"   /
M!0  &0              @(&[\@  >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM
M;%!+ 0(4 Q0    ( ->#IE*MIEFML@4  ,PE   9              " @2;U
M  !X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ UX.F4D_!
MCWI' P  ?@L  !D              ("!#_L  'AL+W=O<FMS:&5E=',O<VAE
M970U,"YX;6Q02P$"% ,4    " #7@Z92<G9GF%$"   8!@  &0
M    @(&-_@  >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    (
M ->#IE*?N%-[%@0  -$1   9              " @14! 0!X;"]W;W)K<VAE
M971S+W-H965T-3(N>&UL4$L! A0#%     @ UX.F4ODC20+A @  B <  !D
M             ("!8@4! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"
M% ,4    " #7@Z92L*<)ITL#   N"@  &0              @(%Z" $ >&PO
M=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( ->#IE(S;_%"? ,
M .4-   9              " @?P+ 0!X;"]W;W)K<VAE971S+W-H965T-34N
M>&UL4$L! A0#%     @ UX.F4H(977_5!   B10  !D              ("!
MKP\! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    " #7@Z92
M8DT6)+4#  "3#@  &0              @(&[% $ >&PO=V]R:W-H965T<R]S
M:&5E=#4W+GAM;%!+ 0(4 Q0    ( ->#IE)3@+26(@,  !T,   9
M      " @:<8 0!X;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%
M  @ UX.F4OVSB^!/ @  % 4  !D              ("! !P! 'AL+W=O<FMS
M:&5E=',O<VAE970U.2YX;6Q02P$"% ,4    " #7@Z921ZF;Y)X"  #@!P
M&0              @(&&'@$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+
M 0(4 Q0    ( ->#IE(ZFSE8\P(  +D(   9              " @5LA 0!X
M;"]W;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ UX.F4JM!I.:]
M!   &!0  !D              ("!A20! 'AL+W=O<FMS:&5E=',O<VAE970V
M,BYX;6Q02P$"% ,4    " #7@Z92,]*'Z2\%  !F%P  &0
M@(%Y*0$ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( ->#
MIE*-E:0WA@,  "\+   9              " @=\N 0!X;"]W;W)K<VAE971S
M+W-H965T-C0N>&UL4$L! A0#%     @ UX.F4H,DU)%N P  U X  !D
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M=#8Y+GAM;%!+ 0(4 Q0    ( ->#IE*F']7R$ ,  #(1   -
M  "  3-" 0!X;"]S='EL97,N>&UL4$L! A0#%     @ UX.F4I>*NQS
M$P(   L              ( !;D4! %]R96QS+RYR96QS4$L! A0#%     @
MUX.F4M_'0U$4!0  :RT   \              ( !5T8! 'AL+W=O<FMB;V]K
M+GAM;%!+ 0(4 Q0    ( ->#IE*7=W+D+ (  /8H   :              "
M 9A+ 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( ->#
MIE+62",N]P$  "LH   3              "  ?Q- 0!;0V]N=&5N=%]4>7!E
<<UTN>&UL4$L%!@    !- $T $A4  "10 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>214</ContextCount>
  <ElementCount>371</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>69</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1007008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1008009 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Description of the Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/DescriptionoftheBusiness</Role>
      <ShortName>Description of the Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandards</Role>
      <ShortName>Summary of Basis of Presentation and Recent Accounting Standards</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2108103 - Disclosure - Product Sales</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/ProductSales</Role>
      <ShortName>Product Sales</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2111104 - Disclosure - Grant Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/GrantRevenue</Role>
      <ShortName>Grant Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2114105 - Disclosure - Collaboration Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CollaborationRevenue</Role>
      <ShortName>Collaboration Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2118106 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2124107 - Disclosure - Derivative Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/DerivativeFinancialInstruments</Role>
      <ShortName>Derivative Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2127108 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2130109 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2133110 - Disclosure - Other Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/OtherBalanceSheetComponents</Role>
      <ShortName>Other Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2138111 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2143112 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2147113 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2153114 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2155115 - Disclosure - Earnings per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/EarningsperShare</Role>
      <ShortName>Earnings per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2159116 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsPolicies</Role>
      <ShortName>Summary of Basis of Presentation and Recent Accounting Standards (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandards</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsTables</Role>
      <ShortName>Summary of Basis of Presentation and Recent Accounting Standards (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandards</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2309302 - Disclosure - Product Sales (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/ProductSalesTables</Role>
      <ShortName>Product Sales (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/ProductSales</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2312303 - Disclosure - Grant Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/GrantRevenueTables</Role>
      <ShortName>Grant Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/GrantRevenue</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2315304 - Disclosure - Collaboration Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CollaborationRevenueTables</Role>
      <ShortName>Collaboration Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/CollaborationRevenue</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2319305 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/FinancialInstruments</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2325306 - Disclosure - Derivative Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/DerivativeFinancialInstrumentsTables</Role>
      <ShortName>Derivative Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/DerivativeFinancialInstruments</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2328307 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/Inventory</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2331308 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/PropertyandEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/PropertyandEquipmentNet</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2334309 - Disclosure - Other Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/OtherBalanceSheetComponentsTables</Role>
      <ShortName>Other Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/OtherBalanceSheetComponents</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2339310 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/Leases</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2348311 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/StockBasedCompensation</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2356312 - Disclosure - Earnings per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/EarningsperShareTables</Role>
      <ShortName>Earnings per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/EarningsperShare</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Description of the Business - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/DescriptionoftheBusinessAdditionalInformationDetails</Role>
      <ShortName>Description of the Business - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards - Components of Accumulated Other Comprehensive (loss) Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsComponentsofAccumulatedOtherComprehensivelossIncomeDetails</Role>
      <ShortName>Summary of Basis of Presentation and Recent Accounting Standards - Components of Accumulated Other Comprehensive (loss) Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsReconciliationofCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Summary of Basis of Presentation and Recent Accounting Standards - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Product Sales (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/ProductSalesDetails</Role>
      <ShortName>Product Sales (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/ProductSalesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2413405 - Disclosure - Grant Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/GrantRevenueDetails</Role>
      <ShortName>Grant Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/GrantRevenueTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2416406 - Disclosure - Collaboration Revenue - Summary of Total Consolidated Net Revenues from Strategic Collaborators (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CollaborationRevenueSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails</Role>
      <ShortName>Collaboration Revenue - Summary of Total Consolidated Net Revenues from Strategic Collaborators (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2417407 - Disclosure - Collaboration Revenue - Changes in Balances of Receivables and Contract Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CollaborationRevenueChangesinBalancesofReceivablesandContractLiabilitiesDetails</Role>
      <ShortName>Collaboration Revenue - Changes in Balances of Receivables and Contract Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2420408 - Disclosure - Financial Instruments - Summary of Cash and Available-for-Sale Securities by Significant Investment Category (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails</Role>
      <ShortName>Financial Instruments - Summary of Cash and Available-for-Sale Securities by Significant Investment Category (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2421409 - Disclosure - Financial Instruments - Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails</Role>
      <ShortName>Financial Instruments - Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2422410 - Disclosure - Financial Instruments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/FinancialInstrumentsNarrativeDetails</Role>
      <ShortName>Financial Instruments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2423411 - Disclosure - Financial Instruments - Financial Assets Measured At Fair Value On a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails</Role>
      <ShortName>Financial Instruments - Financial Assets Measured At Fair Value On a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2426412 - Disclosure - Derivative Financial Instruments - Balance Sheet Hedges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails</Role>
      <ShortName>Derivative Financial Instruments - Balance Sheet Hedges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2429413 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/InventoryTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2432414 - Disclosure - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/PropertyandEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/PropertyandEquipmentNetTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2435415 - Disclosure - Other Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails</Role>
      <ShortName>Other Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2436416 - Disclosure - Other Balance Sheet Components - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails</Role>
      <ShortName>Other Balance Sheet Components - Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2437417 - Disclosure - Other Balance Sheet Components - Deferred Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails</Role>
      <ShortName>Other Balance Sheet Components - Deferred Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2440418 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2441419 - Disclosure - Leases - Balance Sheet Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails</Role>
      <ShortName>Leases - Balance Sheet Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2442420 - Disclosure - Leases - Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails</Role>
      <ShortName>Leases - Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2444421 - Disclosure - Commitments and Contingencies - Strategic Collaborations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CommitmentsandContingenciesStrategicCollaborationsDetails</Role>
      <ShortName>Commitments and Contingencies - Strategic Collaborations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2445422 - Disclosure - Commitments and Contingencies - Purchase Commitments and Purchase Orders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails</Role>
      <ShortName>Commitments and Contingencies - Purchase Commitments and Purchase Orders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2446423 - Disclosure - Commitments and Contingencies - Licenses to Patented Technology (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails</Role>
      <ShortName>Commitments and Contingencies - Licenses to Patented Technology (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2449424 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2450425 - Disclosure - Stock-Based Compensation - Options Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Options Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2451426 - Disclosure - Stock-Based Compensation - Restricted Common Stock and Common Stock Units Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Restricted Common Stock and Common Stock Units Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2452427 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2454428 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/IncomeTaxes</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2457429 - Disclosure - Earnings per Share - Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/EarningsperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails</Role>
      <ShortName>Earnings per Share - Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2458430 - Disclosure - Earnings per Share - Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/EarningsperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails</Role>
      <ShortName>Earnings per Share - Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="mrna-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2460431 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/SubsequentEvents</ParentRole>
      <Position>69</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="mrna-20210331.htm">mrna-20210331.htm</File>
    <File>a4exhibit31103312021.htm</File>
    <File>a5exhibit31203312021.htm</File>
    <File>a6exhibit32103312021.htm</File>
    <File>exhibit101amendmentno6toba.htm</File>
    <File>exhibit102amendmentno7toba.htm</File>
    <File>exhibit103formofpsuagreeme.htm</File>
    <File>exhibit104directorcompensa.htm</File>
    <File>mrna-20210331.xsd</File>
    <File>mrna-20210331_cal.xml</File>
    <File>mrna-20210331_def.xml</File>
    <File>mrna-20210331_lab.xml</File>
    <File>mrna-20210331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>mrna-20210331_g1.jpg</File>
    <File>mrna-20210331_g2.jpg</File>
    <File>mrna-20210331_g3.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>93
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mrna-20210331.htm": {
   "axisCustom": 0,
   "axisStandard": 23,
   "contextCount": 214,
   "dts": {
    "calculationLink": {
     "local": [
      "mrna-20210331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mrna-20210331_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "mrna-20210331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mrna-20210331_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mrna-20210331_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "mrna-20210331.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 502,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 6,
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 11
   },
   "keyCustom": 43,
   "keyStandard": 328,
   "memberCustom": 32,
   "memberStandard": 34,
   "nsprefix": "mrna",
   "nsuri": "http://www.modernatx.com/20210331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.modernatx.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Description of the Business",
     "role": "http://www.modernatx.com/role/DescriptionoftheBusiness",
     "shortName": "Description of the Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards",
     "role": "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandards",
     "shortName": "Summary of Basis of Presentation and Recent Accounting Standards",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108103 - Disclosure - Product Sales",
     "role": "http://www.modernatx.com/role/ProductSales",
     "shortName": "Product Sales",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111104 - Disclosure - Grant Revenue",
     "role": "http://www.modernatx.com/role/GrantRevenue",
     "shortName": "Grant Revenue",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114105 - Disclosure - Collaboration Revenue",
     "role": "http://www.modernatx.com/role/CollaborationRevenue",
     "shortName": "Collaboration Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118106 - Disclosure - Financial Instruments",
     "role": "http://www.modernatx.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124107 - Disclosure - Derivative Financial Instruments",
     "role": "http://www.modernatx.com/role/DerivativeFinancialInstruments",
     "shortName": "Derivative Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127108 - Disclosure - Inventory",
     "role": "http://www.modernatx.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130109 - Disclosure - Property and Equipment, Net",
     "role": "http://www.modernatx.com/role/PropertyandEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133110 - Disclosure - Other Balance Sheet Components",
     "role": "http://www.modernatx.com/role/OtherBalanceSheetComponents",
     "shortName": "Other Balance Sheet Components",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "i40e5fc820d824be1931d54b51dd263a3_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "i40e5fc820d824be1931d54b51dd263a3_I20210331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2138111 - Disclosure - Leases",
     "role": "http://www.modernatx.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2143112 - Disclosure - Commitments and Contingencies",
     "role": "http://www.modernatx.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147113 - Disclosure - Stock-Based Compensation",
     "role": "http://www.modernatx.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2153114 - Disclosure - Income Taxes",
     "role": "http://www.modernatx.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2155115 - Disclosure - Earnings per Share",
     "role": "http://www.modernatx.com/role/EarningsperShare",
     "shortName": "Earnings per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2159116 - Disclosure - Subsequent Events",
     "role": "http://www.modernatx.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards (Policies)",
     "role": "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsPolicies",
     "shortName": "Summary of Basis of Presentation and Recent Accounting Standards (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards (Tables)",
     "role": "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsTables",
     "shortName": "Summary of Basis of Presentation and Recent Accounting Standards (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309302 - Disclosure - Product Sales (Tables)",
     "role": "http://www.modernatx.com/role/ProductSalesTables",
     "shortName": "Product Sales (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312303 - Disclosure - Grant Revenue (Tables)",
     "role": "http://www.modernatx.com/role/GrantRevenueTables",
     "shortName": "Grant Revenue (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "i40e5fc820d824be1931d54b51dd263a3_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "i40e5fc820d824be1931d54b51dd263a3_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315304 - Disclosure - Collaboration Revenue (Tables)",
     "role": "http://www.modernatx.com/role/CollaborationRevenueTables",
     "shortName": "Collaboration Revenue (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319305 - Disclosure - Financial Instruments (Tables)",
     "role": "http://www.modernatx.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2325306 - Disclosure - Derivative Financial Instruments (Tables)",
     "role": "http://www.modernatx.com/role/DerivativeFinancialInstrumentsTables",
     "shortName": "Derivative Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2328307 - Disclosure - Inventory (Tables)",
     "role": "http://www.modernatx.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331308 - Disclosure - Property and Equipment, Net (Tables)",
     "role": "http://www.modernatx.com/role/PropertyandEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2334309 - Disclosure - Other Balance Sheet Components (Tables)",
     "role": "http://www.modernatx.com/role/OtherBalanceSheetComponentsTables",
     "shortName": "Other Balance Sheet Components (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrna:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2339310 - Disclosure - Leases (Tables)",
     "role": "http://www.modernatx.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrna:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2348311 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.modernatx.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2356312 - Disclosure - Earnings per Share (Tables)",
     "role": "http://www.modernatx.com/role/EarningsperShareTables",
     "shortName": "Earnings per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "mrna:NumberOfDevelopmentProgram",
      "reportCount": 1,
      "unique": true,
      "unitRef": "program",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Description of the Business - Additional Information (Details)",
     "role": "http://www.modernatx.com/role/DescriptionoftheBusinessAdditionalInformationDetails",
     "shortName": "Description of the Business - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "mrna:NumberOfDevelopmentProgram",
      "reportCount": 1,
      "unique": true,
      "unitRef": "program",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ibc252a4be2f74a21a0b81d251afe3cdf_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards - Components of Accumulated Other Comprehensive (loss) Income (Details)",
     "role": "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsComponentsofAccumulatedOtherComprehensivelossIncomeDetails",
     "shortName": "Summary of Basis of Presentation and Recent Accounting Standards - Components of Accumulated Other Comprehensive (loss) Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ib0bb072a6a064b47a2581435e9123a1f_I20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "i40e5fc820d824be1931d54b51dd263a3_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)",
     "role": "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsReconciliationofCashCashEquivalentsandRestrictedCashDetails",
     "shortName": "Summary of Basis of Presentation and Recent Accounting Standards - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "iaa5a33ce37614698a3418806ab20f9b2_I20200331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Product Sales (Details)",
     "role": "http://www.modernatx.com/role/ProductSalesDetails",
     "shortName": "Product Sales (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "i615a67f1a6c2480c89cbe28e804d3b01_I20210331",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413405 - Disclosure - Grant Revenue (Details)",
     "role": "http://www.modernatx.com/role/GrantRevenueDetails",
     "shortName": "Grant Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ibb5c5d2d047b4d979b9497e8b26286bd_D20200901-20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "mrna:RevenueFromGrantsMaximumAward",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "i5d71f6c708c04cfd9aa4a5147b897eae_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416406 - Disclosure - Collaboration Revenue - Summary of Total Consolidated Net Revenues from Strategic Collaborators (Details)",
     "role": "http://www.modernatx.com/role/CollaborationRevenueSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails",
     "shortName": "Collaboration Revenue - Summary of Total Consolidated Net Revenues from Strategic Collaborators (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "i5d71f6c708c04cfd9aa4a5147b897eae_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ibc252a4be2f74a21a0b81d251afe3cdf_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417407 - Disclosure - Collaboration Revenue - Changes in Balances of Receivables and Contract Liabilities (Details)",
     "role": "http://www.modernatx.com/role/CollaborationRevenueChangesinBalancesofReceivablesandContractLiabilitiesDetails",
     "shortName": "Collaboration Revenue - Changes in Balances of Receivables and Contract Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "i0424eee07b4f47f18f3baa3664b5c50f_I20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "i40e5fc820d824be1931d54b51dd263a3_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420408 - Disclosure - Financial Instruments - Summary of Cash and Available-for-Sale Securities by Significant Investment Category (Details)",
     "role": "http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails",
     "shortName": "Financial Instruments - Summary of Cash and Available-for-Sale Securities by Significant Investment Category (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "iacbf0fb43aaa4d53bc16745f38512f25_I20210331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "i40e5fc820d824be1931d54b51dd263a3_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421409 - Disclosure - Financial Instruments - Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity (Details)",
     "role": "http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails",
     "shortName": "Financial Instruments - Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "i40e5fc820d824be1931d54b51dd263a3_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422410 - Disclosure - Financial Instruments - Narrative (Details)",
     "role": "http://www.modernatx.com/role/FinancialInstrumentsNarrativeDetails",
     "shortName": "Financial Instruments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "iacbf0fb43aaa4d53bc16745f38512f25_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423411 - Disclosure - Financial Instruments - Financial Assets Measured At Fair Value On a Recurring Basis (Details)",
     "role": "http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails",
     "shortName": "Financial Instruments - Financial Assets Measured At Fair Value On a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "i2c36846f9be347ffadf3fb034bb04f1c_I20210331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "role": "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "i0ab6f5001f864500b4c8e0d67181a3e1_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426412 - Disclosure - Derivative Financial Instruments - Balance Sheet Hedges (Details)",
     "role": "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails",
     "shortName": "Derivative Financial Instruments - Balance Sheet Hedges (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "i0ab6f5001f864500b4c8e0d67181a3e1_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "i40e5fc820d824be1931d54b51dd263a3_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429413 - Disclosure - Inventory (Details)",
     "role": "http://www.modernatx.com/role/InventoryDetails",
     "shortName": "Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "i40e5fc820d824be1931d54b51dd263a3_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "i40e5fc820d824be1931d54b51dd263a3_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432414 - Disclosure - Property and Equipment, Net (Details)",
     "role": "http://www.modernatx.com/role/PropertyandEquipmentNetDetails",
     "shortName": "Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "i40e5fc820d824be1931d54b51dd263a3_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "i40e5fc820d824be1931d54b51dd263a3_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "mrna:OtherPrepaidExpenseManufacturing",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435415 - Disclosure - Other Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)",
     "role": "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails",
     "shortName": "Other Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "i40e5fc820d824be1931d54b51dd263a3_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "mrna:OtherPrepaidExpenseManufacturing",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "i40e5fc820d824be1931d54b51dd263a3_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "mrna:AccruedClinicalTrials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436416 - Disclosure - Other Balance Sheet Components - Accrued Liabilities (Details)",
     "role": "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails",
     "shortName": "Other Balance Sheet Components - Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "i40e5fc820d824be1931d54b51dd263a3_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "mrna:AccruedClinicalTrials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ibc252a4be2f74a21a0b81d251afe3cdf_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437417 - Disclosure - Other Balance Sheet Components - Deferred Revenue (Details)",
     "role": "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails",
     "shortName": "Other Balance Sheet Components - Deferred Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ib2ee3c9e3ddc46fc8c50d787172d195f_I20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "i40e5fc820d824be1931d54b51dd263a3_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "mrna:OperatingLeaseNumberOfProperties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "campus",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440418 - Disclosure - Leases - Narrative (Details)",
     "role": "http://www.modernatx.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "i40e5fc820d824be1931d54b51dd263a3_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "mrna:OperatingLeaseNumberOfProperties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "campus",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mrna:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "i40e5fc820d824be1931d54b51dd263a3_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441419 - Disclosure - Leases - Balance Sheet Information (Details)",
     "role": "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails",
     "shortName": "Leases - Balance Sheet Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mrna:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "i40e5fc820d824be1931d54b51dd263a3_I20210331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "i40e5fc820d824be1931d54b51dd263a3_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442420 - Disclosure - Leases - Minimum Lease Payments (Details)",
     "role": "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails",
     "shortName": "Leases - Minimum Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "i40e5fc820d824be1931d54b51dd263a3_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "iccb9f67ad61a42038f759003571a1508_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444421 - Disclosure - Commitments and Contingencies - Strategic Collaborations (Details)",
     "role": "http://www.modernatx.com/role/CommitmentsandContingenciesStrategicCollaborationsDetails",
     "shortName": "Commitments and Contingencies - Strategic Collaborations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "iccb9f67ad61a42038f759003571a1508_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical)",
     "role": "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie54f228e1d5b4838858ccaebf45f0e9a_I20210331",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445422 - Disclosure - Commitments and Contingencies - Purchase Commitments and Purchase Orders (Details)",
     "role": "http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails",
     "shortName": "Commitments and Contingencies - Purchase Commitments and Purchase Orders (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie54f228e1d5b4838858ccaebf45f0e9a_I20210331",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "id9b8f829587545b1850dc3d645793a91_I20170626",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446423 - Disclosure - Commitments and Contingencies - Licenses to Patented Technology (Details)",
     "role": "http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails",
     "shortName": "Commitments and Contingencies - Licenses to Patented Technology (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "id9b8f829587545b1850dc3d645793a91_I20170626",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "i40e5fc820d824be1931d54b51dd263a3_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449424 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "role": "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "i40e5fc820d824be1931d54b51dd263a3_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ibc252a4be2f74a21a0b81d251afe3cdf_I20201231",
      "decimals": "-4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450425 - Disclosure - Stock-Based Compensation - Options Activity (Details)",
     "role": "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails",
     "shortName": "Stock-Based Compensation - Options Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ibc252a4be2f74a21a0b81d251afe3cdf_I20201231",
      "decimals": "-4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie43ed5c918a0494eb0f43d56862c3e32_I20201231",
      "decimals": "-4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451426 - Disclosure - Stock-Based Compensation - Restricted Common Stock and Common Stock Units Activity (Details)",
     "role": "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails",
     "shortName": "Stock-Based Compensation - Restricted Common Stock and Common Stock Units Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie43ed5c918a0494eb0f43d56862c3e32_I20201231",
      "decimals": "-4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452427 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)",
     "role": "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454428 - Disclosure - Income Taxes (Details)",
     "role": "http://www.modernatx.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457429 - Disclosure - Earnings per Share - Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)",
     "role": "http://www.modernatx.com/role/EarningsperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails",
     "shortName": "Earnings per Share - Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458430 - Disclosure - Earnings per Share - Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Details)",
     "role": "http://www.modernatx.com/role/EarningsperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails",
     "shortName": "Earnings per Share - Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "i7a973ce00bdc4a798407694abf5f73a8_D20200401-20200430",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "mrna:RevenueFromGrantsMaximumAward",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2460431 - Disclosure - Subsequent Events (Details)",
     "role": "http://www.modernatx.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "i9c022d9b4fbe4b8b8966c5f007b5faf4_D20210401-20210507",
      "decimals": "INF",
      "lang": "en-US",
      "name": "mrna:NumberOfDosesOfVaccineCandidate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "dose",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "i7682e40394cc4e7db96f8cc4de55e962_I20191231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "role": "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "i7682e40394cc4e7db96f8cc4de55e962_I20191231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)",
     "role": "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "i792a9b486fcb49b1b902da2a79b14982_D20200101-20200331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1008009 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20210331.htm",
      "contextRef": "ie20e480bc066475e9f962590283234e4_D20210101-20210331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 69,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/ProductSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "mrna_AccruedClinicalTrials": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical Trials",
        "label": "Accrued Clinical Trials",
        "terseLabel": "Clinical trials"
       }
      }
     },
     "localname": "AccruedClinicalTrials",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_AccruedDevelopmentOperation": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Development Operation",
        "label": "Accrued Development Operation",
        "terseLabel": "Development operations"
       }
      }
     },
     "localname": "AccruedDevelopmentOperation",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_AccruedManufacturing": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Manufacturing",
        "label": "Accrued Manufacturing",
        "terseLabel": "Manufacturing"
       }
      }
     },
     "localname": "AccruedManufacturing",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_AccruedOtherExternalGoodsAndServicesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Other External Goods And Services Current",
        "label": "Accrued Other External Goods And Services Current",
        "terseLabel": "Other external goods and services"
       }
      }
     },
     "localname": "AccruedOtherExternalGoodsAndServicesCurrent",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_AccruedPropertyAndEquipmentCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Property And Equipment, Current",
        "label": "Accrued Property And Equipment, Current",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "AccruedPropertyAndEquipmentCurrent",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_AllowanceForTenantImprovements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance For Tenant Improvements",
        "label": "Allowance For Tenant Improvements",
        "terseLabel": "Allowance for tenant improvements"
       }
      }
     },
     "localname": "AllowanceForTenantImprovements",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets And Liabilities, Lessee [Table Text Block]",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Assets And Liabilities, Lessee"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrna_AstraZenecaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AstraZeneca [Member]",
        "label": "AstraZeneca [Member]",
        "terseLabel": "AstraZeneca"
       }
      }
     },
     "localname": "AstraZenecaMember",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationRevenueSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biomedical Advanced Research And Development Authority [Member]",
        "label": "Biomedical Advanced Research And Development Authority [Member]",
        "terseLabel": "BARDA"
       }
      }
     },
     "localname": "BiomedicalAdvancedResearchAndDevelopmentAuthorityMember",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails",
      "http://www.modernatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_CambridgeMassachusettsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cambridge, Massachusetts [Member]",
        "label": "Cambridge, Massachusetts [Member]",
        "terseLabel": "Cambridge leases"
       }
      }
     },
     "localname": "CambridgeMassachusettsMember",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_ChangeInContractWithCustomerLiabilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in Contract With Customer Liability",
        "label": "Change in Contract With Customer Liability [Line Items]",
        "terseLabel": "Change in Contract With Customer Liability [Line Items]"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerLiabilityLineItems",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrna_ChangeInContractWithCustomerLiabilityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Contract With Customer, Liability",
        "label": "Change In Contract With Customer, Liability [Table]",
        "terseLabel": "Change In Contract With Customer, Liability [Table]"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerLiabilityTable",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrna_ChangeInContractwithCustomerAssetRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Contract with Customer Asset [Roll Forward]",
        "label": "Change In Contract with Customer Asset [Roll Forward]",
        "terseLabel": "Contract Assets:"
       }
      }
     },
     "localname": "ChangeInContractwithCustomerAssetRollForward",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationRevenueChangesinBalancesofReceivablesandContractLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrna_ChangeInContractwithCustomerLiabilityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Contract with Customer Liability [Roll Forward]",
        "label": "Change In Contract with Customer Liability [Roll Forward]",
        "terseLabel": "Contract Liabilities:",
        "verboseLabel": "Change In Contract with Customer Liability [Roll Forward]"
       }
      }
     },
     "localname": "ChangeInContractwithCustomerLiabilityRollForward",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationRevenueChangesinBalancesofReceivablesandContractLiabilitiesDetails",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrna_ChargesToFinancingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Charges To Financing Lease Liabilities",
        "label": "Charges To Financing Lease Liabilities",
        "terseLabel": "Changes in financing lease liabilities"
       }
      }
     },
     "localname": "ChargesToFinancingLeaseLiabilities",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_ClinicalOperationsAndSupportCommitmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Operations And Support Commitment [Member]",
        "label": "Clinical Operations And Support Commitment [Member]",
        "terseLabel": "Clinical operations and support commitment"
       }
      }
     },
     "localname": "ClinicalOperationsAndSupportCommitmentMember",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_ClinicalServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Services",
        "label": "Clinical Services [Member]",
        "terseLabel": "Clinical Services"
       }
      }
     },
     "localname": "ClinicalServicesMember",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Arrangement, Including Arrangements With Affiliate [Member] [Member]",
        "label": "Collaboration Arrangement, Including Arrangements With Affiliate [Member]",
        "terseLabel": "Collaboration Revenue by Strategic Collaborator:"
       }
      }
     },
     "localname": "CollaborationArrangementIncludingArrangementsWithAffiliateMember",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationRevenueChangesinBalancesofReceivablesandContractLiabilitiesDetails",
      "http://www.modernatx.com/role/CollaborationRevenueSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_CollaborationArrangementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Arrangement [Member]",
        "label": "Collaboration Arrangement [Member]",
        "terseLabel": "Collaboration revenue"
       }
      }
     },
     "localname": "CollaborationArrangementMember",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_Commercial": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial",
        "label": "Commercial",
        "terseLabel": "Commercial"
       }
      }
     },
     "localname": "Commercial",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_ContractOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract Options",
        "label": "Contract Options [Member]",
        "terseLabel": "Contract options"
       }
      }
     },
     "localname": "ContractOptionsMember",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_ContractWithCustomerAssetDeductionsDuringPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Asset, Deductions During Period",
        "label": "Contract With Customer, Asset, Deductions During Period",
        "negatedTerseLabel": "Deductions"
       }
      }
     },
     "localname": "ContractWithCustomerAssetDeductionsDuringPeriod",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationRevenueChangesinBalancesofReceivablesandContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Deductions During Period",
        "label": "Contract With Customer, Liability, Deductions During Period",
        "negatedTerseLabel": "Deductions"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityDeductionsDuringPeriod",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationRevenueChangesinBalancesofReceivablesandContractLiabilitiesDetails",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_CurrentMarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current Marketable Securities [Member]",
        "label": "Current Marketable Securities [Member]",
        "verboseLabel": "Current marketable securities"
       }
      }
     },
     "localname": "CurrentMarketableSecuritiesMember",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_CustomerDepositsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer Deposits",
        "label": "Customer Deposits [Member]",
        "terseLabel": "Customer deposits"
       }
      }
     },
     "localname": "CustomerDepositsMember",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/ProductSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_DefenseAdvancedResearchProjectsAgencyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defense Advanced Research Projects Agency [Member]",
        "label": "Defense Advanced Research Projects Agency [Member]",
        "terseLabel": "DARPA"
       }
      }
     },
     "localname": "DefenseAdvancedResearchProjectsAgencyMember",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_DiagnosticProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Diagnostic Products [Member]",
        "label": "Diagnostic Products [Member]",
        "terseLabel": "Diagnostic products"
       }
      }
     },
     "localname": "DiagnosticProductsMember",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_EmbeddedLeasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Embedded Leases",
        "label": "Embedded Leases [Member]",
        "terseLabel": "Embedded Leases"
       }
      }
     },
     "localname": "EmbeddedLeasesMember",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_FinanceLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease, Liability, To Be Paid, After Year Four",
        "label": "Finance Lease, Liability, To Be Paid, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_FinancingRightOfUseAssetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing, Right-Of-Use Asset [Member]",
        "label": "Financing, Right-Of-Use Asset [Member]",
        "terseLabel": "Right-of-use asset, financing"
       }
      }
     },
     "localname": "FinancingRightOfUseAssetMember",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_IncreaseDecreaseInRightOfUseAssetOperatingLeases": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Right Of Use Asset, Operating Leases",
        "label": "Increase (Decrease) In Right Of Use Asset, Operating Leases",
        "negatedTerseLabel": "Right-of-use assets, operating leases"
       }
      }
     },
     "localname": "IncreaseDecreaseInRightOfUseAssetOperatingLeases",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_InitialProjectMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial Project [Member]",
        "label": "Initial Project [Member]",
        "terseLabel": "Initial project"
       }
      }
     },
     "localname": "InitialProjectMember",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_LeasesImputedInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leases, Imputed Interest Rate",
        "label": "Leases, Imputed Interest Rate",
        "terseLabel": "Imputed interest rate"
       }
      }
     },
     "localname": "LeasesImputedInterestRate",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrna_LeasesIncrementalBorrowingRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leases, Incremental Borrowing Rate",
        "label": "Leases, Incremental Borrowing Rate",
        "terseLabel": "Incremental borrowing rate"
       }
      }
     },
     "localname": "LeasesIncrementalBorrowingRate",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "label": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_LesseeOperatingLeaseNumberOfExtensionPeriods": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Number Of Extension Periods",
        "label": "Lessee, Operating Lease, Number Of Extension Periods",
        "terseLabel": "Number of extension periods"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfExtensionPeriods",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrna_MTCNorthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MTC North",
        "label": "MTC North [Member]",
        "terseLabel": "MTC North"
       }
      }
     },
     "localname": "MTCNorthMember",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_MTCSouthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MTC South",
        "label": "MTC South [Member]",
        "terseLabel": "MTC South"
       }
      }
     },
     "localname": "MTCSouthMember",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_MerckMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merck [Member]",
        "label": "Merck [Member]",
        "terseLabel": "Merck"
       }
      }
     },
     "localname": "MerckMember",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationRevenueSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_NoncurrentMarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncurrent Marketable Securities [Member]",
        "label": "Noncurrent Marketable Securities [Member]",
        "verboseLabel": "Noncurrent marketable securities"
       }
      }
     },
     "localname": "NoncurrentMarketableSecuritiesMember",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_NorwoodMassachusettsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Norwood, Massachusetts",
        "label": "Norwood, Massachusetts [Member]",
        "terseLabel": "Norwood leases"
       }
      }
     },
     "localname": "NorwoodMassachusettsMember",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_NumberOfDevelopmentProgram": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Development Program",
        "label": "Number Of Development Program",
        "terseLabel": "Development program"
       }
      }
     },
     "localname": "NumberOfDevelopmentProgram",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/DescriptionoftheBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrna_NumberOfDosesOfVaccineCandidate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Doses Of Vaccine Candidate",
        "label": "Number Of Doses Of Vaccine Candidate",
        "terseLabel": "Number of doses of vaccine candidate"
       }
      }
     },
     "localname": "NumberOfDosesOfVaccineCandidate",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrna_OperatingAndFinanceLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating And Finance Lease, Liability",
        "label": "Operating And Finance Lease, Liability",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseLiability",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_OperatingAndFinanceLeaseLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": {
       "order": 2.0,
       "parentTag": "mrna_OperatingAndFinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating And Finance Lease, Liability, Current",
        "label": "Operating And Finance Lease, Liability, Current",
        "totalLabel": "Total current lease liabilities"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseLiabilityCurrent",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_OperatingAndFinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": {
       "order": 1.0,
       "parentTag": "mrna_OperatingAndFinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating And Finance Lease, Liability, Noncurrent",
        "label": "Operating And Finance Lease, Liability, Noncurrent",
        "totalLabel": "Total non-current lease liabilities"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_OperatingAndFinanceLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating And Finance Lease, Right-Of-Use Asset",
        "label": "Operating And Finance Lease, Right-Of-Use Asset",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseRightOfUseAsset",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_OperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease Liabilities",
        "label": "Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilities",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_OperatingLeaseNumberOfProperties": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Number Of Properties",
        "label": "Operating Lease, Number Of Properties",
        "terseLabel": "Number of campuses"
       }
      }
     },
     "localname": "OperatingLeaseNumberOfProperties",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrna_OtherCollaborativePartiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Collaborative Parties",
        "label": "Other Collaborative Parties [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherCollaborativePartiesMember",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationRevenueSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_OtherGrantRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other grant revenue",
        "label": "Other grant revenue [Member]",
        "terseLabel": "Other grant revenue"
       }
      }
     },
     "localname": "OtherGrantRevenueMember",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_OtherPrepaidExpenseManufacturing": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Prepaid Expense, Manufacturing",
        "label": "Other Prepaid Expense, Manufacturing",
        "terseLabel": "Down payments to manufacturing vendors"
       }
      }
     },
     "localname": "OtherPrepaidExpenseManufacturing",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Personalized MRNA Cancer Vaccines (PCV) Collaboration And License Agreement With Merck Sharp\u00a0And Dohme Corp [Member]",
        "label": "Personalized MRNA Cancer Vaccines (PCV) Collaboration And License Agreement With Merck Sharp\u00a0And Dohme Corp [Member]",
        "terseLabel": "PCV agreement"
       }
      }
     },
     "localname": "PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesStrategicCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_PersonalizedMRNACancerVaccinesProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Personalized MRNA Cancer Vaccines Products [Member]",
        "label": "Personalized MRNA Cancer Vaccines Products [Member]",
        "terseLabel": "PCV products"
       }
      }
     },
     "localname": "PersonalizedMRNACancerVaccinesProductsMember",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesStrategicCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_ProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Sales",
        "label": "Product Sales [Member]",
        "terseLabel": "Product sales"
       }
      }
     },
     "localname": "ProductSalesMember",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails",
      "http://www.modernatx.com/role/ProductSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_RawMaterialsAccountsPayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Raw Materials, Accounts Payable",
        "label": "Raw Materials, Accounts Payable",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "RawMaterialsAccountsPayable",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Commercial Milestones, Maximum Amount",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Commercial Milestones, Maximum Amount",
        "terseLabel": "Commercial milestone payments"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentAndRegulatoryMilestonesMaximumAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Development And Regulatory Milestones, Maximum Amount",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Development And Regulatory Milestones, Maximum Amount",
        "terseLabel": "Development and regulatory milestone payments"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentAndRegulatoryMilestonesMaximumAmount",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Maximum Amount",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Maximum Amount",
        "verboseLabel": "Budgeted amount"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesStrategicCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_RestrictedStockAndRestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock And Restricted Stock Units (RSUs) [Member]",
        "label": "Restricted Stock And Restricted Stock Units (RSU) [Member]",
        "terseLabel": "RSUs and PSUs"
       }
      }
     },
     "localname": "RestrictedStockAndRestrictedStockUnitsRSUMember",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_RevenueFromGrantsCurrentFundingCapacity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Grants, Current Funding Capacity",
        "label": "Revenue From Grants, Current Funding Capacity",
        "terseLabel": "Amount committed for funding"
       }
      }
     },
     "localname": "RevenueFromGrantsCurrentFundingCapacity",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_RevenueFromGrantsMaximumAward": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Grants, Maximum Award",
        "label": "Revenue From Grants, Maximum Award",
        "terseLabel": "Award amount"
       }
      }
     },
     "localname": "RevenueFromGrantsMaximumAward",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails",
      "http://www.modernatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_RevenueFromGrantsNumberOfContractOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Grants, Number Of Contract Options",
        "label": "Revenue From Grants, Number Of Contract Options",
        "verboseLabel": "Number of contract options"
       }
      }
     },
     "localname": "RevenueFromGrantsNumberOfContractOptions",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrna_RevenueFromGrantsNumberOfContractOptionsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Grants, Number Of Contract Options Exercised",
        "label": "Revenue From Grants, Number Of Contract Options Exercised",
        "terseLabel": "Number of contract options exercised"
       }
      }
     },
     "localname": "RevenueFromGrantsNumberOfContractOptionsExercised",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrna_RevenueFromGrantsPotentialReimbursement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Grants, Potential Reimbursement",
        "label": "Revenue From Grants, Potential Reimbursement",
        "terseLabel": "Potential reimbursements"
       }
      }
     },
     "localname": "RevenueFromGrantsPotentialReimbursement",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails",
      "http://www.modernatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_RevenueFromGrantsRemainingFundingCapacity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Grants, Remaining Funding Capacity",
        "label": "Revenue From Grants, Remaining Funding Capacity",
        "terseLabel": "Available funding"
       }
      }
     },
     "localname": "RevenueFromGrantsRemainingFundingCapacity",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted- Average Grant Date Fair Value per Share, Exercisable (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period, Weighted Average Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Exercised (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period, Weighted Average Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Cancelled/forfeited (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding at end of period (usd per share)",
        "periodStartLabel": "Outstanding at beginning of period (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested And Expected To Vest, Outstanding, Weighted Average Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested And Expected To Vest, Outstanding, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted- Average Grant Date Fair Value per Share (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Payout Percentage",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Payout Percentage",
        "terseLabel": "Payout percentage"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Options, Outstanding, Weighted Average Grant Date Fair Value [Roll Forward]",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Options, Outstanding, Weighted Average Grant Date Fair Value [Roll Forward]",
        "terseLabel": "Weighted- Average Grant Date Fair Value per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrna_StockOptionAndIncentivePlan2018Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Option And Incentive Plan 2018 [Member]",
        "label": "Stock Option And Incentive Plan 2018 [Member]",
        "terseLabel": "2018 Equity Plan"
       }
      }
     },
     "localname": "StockOptionAndIncentivePlan2018Member",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_SupplyAndManufacturingAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supply And Manufacturing Agreements",
        "label": "Supply And Manufacturing Agreements [Member]",
        "terseLabel": "Supply and manufacturing agreements"
       }
      }
     },
     "localname": "SupplyAndManufacturingAgreementsMember",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_TenantIncentivesReceivablesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tenant Incentives Receivables, Current",
        "label": "Tenant Incentives Receivables, Current",
        "terseLabel": "Tenant incentives receivables"
       }
      }
     },
     "localname": "TenantIncentivesReceivablesCurrent",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_TheBillAndMelindaGatesFoundationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Bill\u00a0And Melinda Gates Foundation [Member]",
        "label": "The Bill\u00a0And Melinda Gates Foundation [Member]",
        "terseLabel": "The Bill\u00a0&amp; Melinda Gates Foundation"
       }
      }
     },
     "localname": "TheBillAndMelindaGatesFoundationMember",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_TherapeuticAndProphylacticProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Therapeutic And Prophylactic Products [Member]",
        "label": "Therapeutic And Prophylactic Products [Member]",
        "terseLabel": "Therapeutic and prophylactic products"
       }
      }
     },
     "localname": "TherapeuticAndProphylacticProductsMember",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "US Government Agencies And Corporate Debt Securities [Member]",
        "label": "US Government Agencies And Corporate Debt Securities [Member]",
        "terseLabel": "Debt securities of U.S. government agencies and corporate entities"
       }
      }
     },
     "localname": "USGovernmentAgenciesAndCorporateDebtSecuritiesMember",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_VertexMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vertex [Member]",
        "label": "Vertex [Member]",
        "terseLabel": "Vertex"
       }
      }
     },
     "localname": "VertexMember",
     "nsuri": "http://www.modernatx.com/20210331",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationRevenueSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r51",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationRevenueSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r162",
      "r227",
      "r232",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails",
      "http://www.modernatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r247",
      "r248",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r402",
      "r442",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r247",
      "r248",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r402",
      "r442",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r162",
      "r227",
      "r232",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails",
      "http://www.modernatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r158",
      "r227",
      "r230",
      "r403",
      "r441",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/CollaborationRevenueChangesinBalancesofReceivablesandContractLiabilitiesDetails",
      "http://www.modernatx.com/role/CollaborationRevenueSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails",
      "http://www.modernatx.com/role/GrantRevenueDetails",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails",
      "http://www.modernatx.com/role/ProductSalesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r158",
      "r227",
      "r230",
      "r403",
      "r441",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/CollaborationRevenueChangesinBalancesofReceivablesandContractLiabilitiesDetails",
      "http://www.modernatx.com/role/CollaborationRevenueSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails",
      "http://www.modernatx.com/role/GrantRevenueDetails",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails",
      "http://www.modernatx.com/role/ProductSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r238",
      "r247",
      "r248",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r402",
      "r442",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r238",
      "r247",
      "r248",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r402",
      "r442",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
     "auth_ref": [
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Axis]",
        "terseLabel": "Name of Property [Axis]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
     "auth_ref": [
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Domain]",
        "terseLabel": "Name of Property [Domain]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationRevenueSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r159",
      "r160",
      "r227",
      "r231",
      "r444",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails",
      "http://www.modernatx.com/role/ProductSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r159",
      "r160",
      "r227",
      "r231",
      "r444",
      "r460",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails",
      "http://www.modernatx.com/role/ProductSalesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "AOCIAttributableToParentNetOfTaxRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsComponentsofAccumulatedOtherComprehensivelossIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r4",
      "r19",
      "r163",
      "r164"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r417",
      "r436"
     ],
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.",
        "label": "Accrued Royalties",
        "terseLabel": "Royalties"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r54",
      "r55",
      "r56",
      "r61",
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]",
        "terseLabel": "Unrealized Loss on Available-for-Sale Debt Securities"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsComponentsofAccumulatedOtherComprehensivelossIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsComponentsofAccumulatedOtherComprehensivelossIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r22",
      "r58",
      "r60",
      "r61",
      "r432",
      "r454",
      "r458"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsComponentsofAccumulatedOtherComprehensivelossIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r57",
      "r61",
      "r62",
      "r104",
      "r105",
      "r106",
      "r319",
      "r449",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r20",
      "r282"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r279",
      "r280",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r249",
      "r251",
      "r284",
      "r285"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r251",
      "r272",
      "r283"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/EarningsperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/EarningsperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/EarningsperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/EarningsperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "terseLabel": "Area of office space (in sqft)"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r99",
      "r147",
      "r150",
      "r156",
      "r181",
      "r315",
      "r320",
      "r348",
      "r413",
      "r429"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r8",
      "r47",
      "r99",
      "r181",
      "r315",
      "r320",
      "r348"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r341"
     ],
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Assets, fair value disclosure"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r172"
     ],
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r173"
     ],
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r170",
      "r193"
     ],
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r176"
     ],
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Due after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r174",
      "r176",
      "r425"
     ],
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Due after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Amortized Cost, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Fair Value, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate": {
     "auth_ref": [
      "r174",
      "r177",
      "r426"
     ],
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r175"
     ],
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Due in one year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r174",
      "r175",
      "r424"
     ],
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Due in one year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r166",
      "r171",
      "r193",
      "r416"
     ],
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Estimated Fair\u00a0Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r168",
      "r193"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r168",
      "r193"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Investments, non-current"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r252",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails",
      "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r326",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r94",
      "r95",
      "r96"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchases of property and equipment included in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis": {
     "auth_ref": [
      "r407",
      "r408",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by project.",
        "label": "Project [Axis]",
        "terseLabel": "Project [Axis]"
       }
      }
     },
     "localname": "CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails",
      "http://www.modernatx.com/role/CommitmentsandContingenciesStrategicCollaborationsDetails",
      "http://www.modernatx.com/role/GrantRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r34",
      "r92"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Member]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r13",
      "r93",
      "r98",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r87",
      "r92",
      "r97"
     ],
     "calculation": {
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of year",
        "totalLabel": "Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r87",
      "r349"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Non-cash investing and financing activities"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationRevenueChangesinBalancesofReceivablesandContractLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r42",
      "r209",
      "r418",
      "r435"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Share available for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r104",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "verboseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r18",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, par value $0.0001; 1,600 shares authorized as of March 31, 2021 and December 31, 2020; 401 and 399 shares issued and outstanding as of March 31, 2021 and December 31, 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r65",
      "r67",
      "r68",
      "r71",
      "r420",
      "r438"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r98",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Changes in Balances of Receivables and Contract Liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationRevenueTables",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress": {
     "auth_ref": [
      "r216"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in measure of progress which increases (decreases) right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, Cumulative Catch-up Adjustment to Revenue, Change in Measure of Progress",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationRevenueChangesinBalancesofReceivablesandContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r213",
      "r215",
      "r228"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationRevenueChangesinBalancesofReceivablesandContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r213",
      "r214",
      "r228"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Contract with customer, liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationRevenueChangesinBalancesofReceivablesandContractLiabilitiesDetails",
      "http://www.modernatx.com/role/GrantRevenueDetails",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress": {
     "auth_ref": [
      "r216"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in measure of progress which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Measure of Progress",
        "terseLabel": "Additions",
        "verboseLabel": "Additions"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationRevenueChangesinBalancesofReceivablesandContractLiabilitiesDetails",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r213",
      "r214",
      "r228"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.modernatx.com/role/ProductSalesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r213",
      "r214",
      "r228"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, non-current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r75",
      "r403"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r290",
      "r291"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r90",
      "r100",
      "r297",
      "r304",
      "r305",
      "r306"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r90",
      "r145"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.modernatx.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r49",
      "r50",
      "r347"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "terseLabel": "Derivative Instruments"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r327",
      "r328",
      "r333",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "Derivative Financial Instruments"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about derivatives and hedging activities.",
        "label": "Derivative Instruments and Hedging Activities Disclosures [Table]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue": {
     "auth_ref": [
      "r329"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of derivative instrument not designated as hedging instrument and classified as an asset.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value",
        "terseLabel": "Fair value, asset"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue": {
     "auth_ref": [
      "r329"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of derivative instrument not designated as hedging instrument and classified as a liability.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value",
        "terseLabel": "Fair value, liability"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r49",
      "r50",
      "r347"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Derivative Instruments"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Notional Amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails",
      "http://www.modernatx.com/role/ProductSalesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r227",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails",
      "http://www.modernatx.com/role/ProductSalesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationRevenueTables",
      "http://www.modernatx.com/role/GrantRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings (loss) per share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r72",
      "r113",
      "r114",
      "r115",
      "r116",
      "r117",
      "r121",
      "r123",
      "r125",
      "r126",
      "r127",
      "r131",
      "r132",
      "r421",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic EPS (usd per share)",
        "verboseLabel": "Basic (usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/EarningsperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/EarningsperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r72",
      "r113",
      "r114",
      "r115",
      "r116",
      "r117",
      "r123",
      "r125",
      "r126",
      "r127",
      "r131",
      "r132",
      "r421",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted EPS (usd per share)",
        "verboseLabel": "Diluted (usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/EarningsperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r128",
      "r129",
      "r130",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/EarningsperShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Compensation-related"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r273"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized compensation cost related to non-vested stock-based compensation"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-average period of cost expected to be recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "ESPP",
        "verboseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "netLabel": "Options",
        "verboseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/EarningsperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails",
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r109",
      "r118",
      "r120",
      "r134",
      "r185",
      "r211",
      "r212",
      "r279",
      "r280",
      "r281",
      "r300",
      "r301",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r356",
      "r449",
      "r450",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsComponentsofAccumulatedOtherComprehensivelossIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r342",
      "r375",
      "r376",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r341",
      "r342",
      "r343",
      "r344",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r239",
      "r240",
      "r245",
      "r246",
      "r342",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r239",
      "r240",
      "r245",
      "r246",
      "r342",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r375",
      "r376",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r345",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Financing Leases"
       }
      }
     },
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r359",
      "r366"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "terseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r359"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": {
       "order": 2.0,
       "parentTag": "mrna_OperatingAndFinanceLeaseLiabilityCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Financing lease liabilities, current"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current finance lease liability.",
        "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]",
        "terseLabel": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.",
        "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Finance Lease Maturity"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r359"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": {
       "order": 2.0,
       "parentTag": "mrna_OperatingAndFinanceLeaseLiabilityNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Financing lease liabilities, non-current",
        "verboseLabel": "Financing lease liabilities, non-current"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r366"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Payment, Due",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r366"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r366"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r366"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r366"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r366"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.",
        "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r366"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less amounts representing interest or imputed interest",
        "terseLabel": "Interest or imputed interest"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails",
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r358"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": {
       "order": 2.0,
       "parentTag": "mrna_OperatingAndFinanceLeaseRightOfUseAsset",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Right-of-use assets, financing, net"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset.",
        "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]",
        "terseLabel": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r178",
      "r179",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r194",
      "r195",
      "r196",
      "r197",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r239",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign currency forward contracts"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrantMember": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award of money not required to be repaid.",
        "label": "Grant [Member]",
        "terseLabel": "Grant revenue"
       }
      }
     },
     "localname": "GrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/GrantRevenueDetails",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r325",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r102",
      "r147",
      "r149",
      "r152",
      "r155",
      "r157"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income (loss) before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails",
      "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails",
      "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r293",
      "r294",
      "r296",
      "r302",
      "r307",
      "r309",
      "r310",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r100",
      "r119",
      "r120",
      "r146",
      "r292",
      "r303",
      "r308",
      "r440"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestReceivableCurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Interest Receivable, Current",
        "terseLabel": "Interest receivable on marketable securities"
       }
      }
     },
     "localname": "InterestReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r26",
      "r198"
     ],
     "calculation": {
      "http://www.modernatx.com/role/InventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r3",
      "r45"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.modernatx.com/role/InventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.modernatx.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r28",
      "r198"
     ],
     "calculation": {
      "http://www.modernatx.com/role/InventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r27",
      "r198"
     ],
     "calculation": {
      "http://www.modernatx.com/role/InventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in progress"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r77",
      "r144"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.",
        "label": "Investment Income, Net, Amortization of Discount and Premium",
        "negatedTerseLabel": "Amortization/accretion of investments"
       }
      }
     },
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, All Other Investments [Abstract]"
       }
      }
     },
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r180",
      "r411",
      "r427",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.",
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeFinanceLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Operating Lease Maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r366"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r366"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r366"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r366"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r366"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r366"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r366"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less amounts representing interest or imputed interest",
        "verboseLabel": "Amounts representing interest or imputed interest, operating lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails",
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Extension term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r38",
      "r99",
      "r151",
      "r181",
      "r316",
      "r320",
      "r321",
      "r348"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r25",
      "r99",
      "r181",
      "r348",
      "r415",
      "r434"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r40",
      "r99",
      "r181",
      "r316",
      "r320",
      "r321",
      "r348"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r87",
      "r88",
      "r91"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r63",
      "r66",
      "r70",
      "r91",
      "r99",
      "r108",
      "r113",
      "r114",
      "r115",
      "r116",
      "r119",
      "r120",
      "r124",
      "r147",
      "r149",
      "r152",
      "r155",
      "r157",
      "r181",
      "r348",
      "r419",
      "r437"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net income (loss)"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.modernatx.com/role/EarningsperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "verboseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/EarningsperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationRevenueSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r112",
      "r115",
      "r131",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r298",
      "r299",
      "r300",
      "r301",
      "r404",
      "r405",
      "r406",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationRevenueSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Standards and Recently Issued Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Rest of world"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/ProductSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not Designated as Hedging Instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r147",
      "r149",
      "r152",
      "r155",
      "r157"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income (loss) from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r359"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease liabilities",
        "verboseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails",
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r359"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": {
       "order": 1.0,
       "parentTag": "mrna_OperatingAndFinanceLeaseLiabilityCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r359"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": {
       "order": 1.0,
       "parentTag": "mrna_OperatingAndFinanceLeaseLiabilityNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, non-current",
        "verboseLabel": "Operating lease liabilities, non-current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r358"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": {
       "order": 1.0,
       "parentTag": "mrna_OperatingAndFinanceLeaseRightOfUseAsset",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets, operating leases",
        "verboseLabel": "Right-of-use assets, operating, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails",
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r1",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Description of the Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DescriptionoftheBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.",
        "label": "Other Commitment",
        "terseLabel": "Additional commitment"
       }
      }
     },
     "localname": "OtherCommitment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax": {
     "auth_ref": [
      "r53",
      "r58",
      "r331",
      "r335",
      "r339"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.",
        "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax",
        "terseLabel": "Foreign currency forward contracts"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r64",
      "r67",
      "r313",
      "r314",
      "r318"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive loss",
        "verboseLabel": "Other comprehensive loss, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsComponentsofAccumulatedOtherComprehensivelossIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r54",
      "r58"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized loss on available-for-sale debt securities, net of tax of $0 and $0, for the three months ended March 31, 2021 and 2020, respectively"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "auth_ref": [
      "r55",
      "r59"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax",
        "terseLabel": "Unrealized gain (loss) on available-for-sale debt securities, tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r39"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other operating income (expense).",
        "label": "Other Operating Income (Expense) [Member]",
        "terseLabel": "Other (expense) income, net"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r5",
      "r7",
      "r200"
     ],
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Other prepaid expenses"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings": {
     "auth_ref": [
      "r169"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings.",
        "label": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings",
        "terseLabel": "Impairment charges"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "verboseLabel": "Offering expenses"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r80",
      "r82",
      "r167"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedTerseLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r83"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.",
        "label": "Payments to Acquire in Process Research and Development",
        "terseLabel": "Consideration paid"
       }
      }
     },
     "localname": "PaymentsToAcquireInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "PSUs"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r252",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock par value (usd per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "verboseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, par value $0.0001; 162\u00a0shares authorized as of March 31, 2021 and December 31, 2020; no shares issued or outstanding at March 31, 2021 and December 31, 2020"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r6",
      "r32",
      "r33"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from public offerings of common stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r80",
      "r81",
      "r167"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r80",
      "r81",
      "r167"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from sales of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from issuance of common stock through equity plans, net"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProjectMember": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Planned program of work.",
        "label": "Project [Domain]",
        "terseLabel": "Project [Domain]"
       }
      }
     },
     "localname": "ProjectMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails",
      "http://www.modernatx.com/role/CommitmentsandContingenciesStrategicCollaborationsDetails",
      "http://www.modernatx.com/role/GrantRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r202",
      "r361",
      "r364"
     ],
     "calculation": {
      "http://www.modernatx.com/role/PropertyandEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization",
        "negatedTerseLabel": "Less: Accumulated depreciation"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r48",
      "r203",
      "r364"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.modernatx.com/role/PropertyandEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "totalLabel": "Property and equipment, net",
        "verboseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.modernatx.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r14",
      "r201",
      "r358"
     ],
     "calculation": {
      "http://www.modernatx.com/role/PropertyandEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r35",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r205",
      "r462",
      "r463",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/PropertyandEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentOtherTypesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.",
        "label": "Property, Plant and Equipment, Other Types [Member]",
        "terseLabel": "Furniture, fixtures and other"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentOtherTypesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r14",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/PropertyandEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r14",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis": {
     "auth_ref": [
      "r16",
      "r414",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by arrangement, in which the entity has agreed to expend funds to procure goods or services from one or more suppliers.",
        "label": "Purchase Commitment, Excluding Long-term Commitment [Axis]",
        "terseLabel": "Purchase Commitment, Excluding Long-term Commitment [Axis]"
       }
      }
     },
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain": {
     "auth_ref": [
      "r16",
      "r414",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item is intended to be populated, by the entity, with Members identifying each purchase commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate.",
        "label": "Purchase Commitment, Excluding Long-term Commitment [Domain]",
        "terseLabel": "Purchase Commitment, Excluding Long-term Commitment [Domain]"
       }
      }
     },
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Purchase Commitment, Excluding Long-term Commitment [Line Items]",
        "terseLabel": "Purchase Commitment, Excluding Long-term Commitment [Line Items]"
       }
      }
     },
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable": {
     "auth_ref": [
      "r16",
      "r414",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required or determined to be disclosed about arrangements in which the entity has agreed to expend funds to procure goods or services from one or more suppliers. Such disclosure may include identification of the goods or services to be purchased, identity of the seller, pricing, effects on pricing for failing to reach minimum quantities required to be purchased (such as penalties), cancellation rights, and termination provisions.",
        "label": "Purchase Commitment, Excluding Long-term Commitment [Table]",
        "terseLabel": "Purchase Commitment, Excluding Long-term Commitment [Table]"
       }
      }
     },
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": {
     "auth_ref": [
      "r16",
      "r414",
      "r430"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.",
        "label": "Purchase Commitment, Remaining Minimum Amount Committed",
        "terseLabel": "Purchase commitments"
       }
      }
     },
     "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails",
      "http://www.modernatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Abstract]",
        "terseLabel": "Research and Development [Abstract]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r288",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesStrategicCollaborationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails",
      "http://www.modernatx.com/role/CommitmentsandContingenciesStrategicCollaborationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r288",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesStrategicCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r287",
      "r474"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": {
     "auth_ref": [
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.",
        "label": "Research, Development, and Computer Software Disclosure [Text Block]",
        "terseLabel": "Collaboration Revenue"
       }
      }
     },
     "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationRevenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r2",
      "r13",
      "r97"
     ],
     "calculation": {
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "verboseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r9",
      "r15",
      "r97",
      "r461"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash, non-current"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockExpense": {
     "auth_ref": [
      "r90"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for award of restricted stock or unit under share-based payment arrangement.",
        "label": "Restricted Stock or Unit Expense",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted common stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/EarningsperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails",
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r21",
      "r212",
      "r282",
      "r433",
      "r453",
      "r458"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r109",
      "r118",
      "r120",
      "r185",
      "r279",
      "r280",
      "r281",
      "r300",
      "r301",
      "r449",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r142",
      "r143",
      "r148",
      "r153",
      "r154",
      "r158",
      "r159",
      "r162",
      "r226",
      "r227",
      "r403"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "verboseLabel": "Total collaboration revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationRevenueSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r224",
      "r225",
      "r229",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Grant Revenue",
        "verboseLabel": "Product Sales"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenue",
      "http://www.modernatx.com/role/ProductSales"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "terseLabel": "Revenue from External Customers by Geographic Areas"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/ProductSalesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionAndDeferredRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition and Deferred Revenue [Abstract]"
       }
      }
     },
     "localname": "RevenueRecognitionAndDeferredRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r223"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Remaining performance obligations"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationRevenueChangesinBalancesofReceivablesandContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r69",
      "r99",
      "r142",
      "r143",
      "r148",
      "r153",
      "r154",
      "r158",
      "r159",
      "r162",
      "r181",
      "r348",
      "r422"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "netLabel": "Total grant revenue",
        "terseLabel": "Total revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/GrantRevenueDetails",
      "http://www.modernatx.com/role/ProductSalesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r365",
      "r367"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Right-of-use assets obtained through finance lease modifications and reassessments"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r61",
      "r355",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Components of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/EarningsperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/EarningsperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Reconciliation of Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Summary of Cash and Available-for-Sale Securities by Significant Investment Category"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationRevenueChangesinBalancesofReceivablesandContractLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Basic and Diluted Net Loss per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/EarningsperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r251",
      "r271",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r251",
      "r271",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r341",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Financial Assets Measured at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r12",
      "r29",
      "r30",
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory, Current"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Restricted Common Stock Units Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r332",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.",
        "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]",
        "terseLabel": "Schedule Of Foreign Currency Derivatives"
       }
      }
     },
     "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r35",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r288",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails",
      "http://www.modernatx.com/role/CommitmentsandContingenciesStrategicCollaborationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r13",
      "r97",
      "r412",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Reconciliation of Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r252",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period",
        "terseLabel": "Performance period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Canceled, forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Canceled, forfeited (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Issued (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Issued (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding, non-vested at end of period (in shares)",
        "periodStartLabel": "Outstanding, non-vested at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding, non-vested at end of period (usd per share)",
        "periodStartLabel": "Outstanding, non-vested at beginning of period (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Fair Value per Unit"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Aggregate number of shares authorized for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for future grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Outstanding and Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number\u00a0of Options, Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price per Share, Exercisable (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r267"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Total intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Cancelled/forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Granted (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r257",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at end of period (in shares)",
        "periodStartLabel": "Outstanding at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number\u00a0of Options (in millions)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at end of period (usd per share)",
        "periodStartLabel": "Outstanding at beginning of period (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- Average Exercise Price per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]",
        "terseLabel": "Expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r268"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]",
        "terseLabel": "Options Activity"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Number\u00a0of Options (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price per Share (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r250",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails",
      "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Cancelled/forfeited (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Granted (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested",
        "terseLabel": "Intrinsic value of restricted stock units"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Term, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Term, Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance at end of period (in shares)",
        "periodStartLabel": "Balance at beginning of period (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Basis of Presentation and Recent Accounting Standards"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandards"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Internally developed software for sale, licensing or long-term internal use.",
        "label": "Software Development [Member]",
        "terseLabel": "Internally developed software"
       }
      }
     },
     "localname": "SoftwareDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r44",
      "r104",
      "r105",
      "r106",
      "r109",
      "r118",
      "r120",
      "r134",
      "r185",
      "r211",
      "r212",
      "r279",
      "r280",
      "r281",
      "r300",
      "r301",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r356",
      "r449",
      "r450",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsComponentsofAccumulatedOtherComprehensivelossIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r134",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r17",
      "r18",
      "r211",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Shares sold under the ESPP (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r17",
      "r18",
      "r211",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Proceeds from public offering of common stock, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r17",
      "r18",
      "r211",
      "r212",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)",
        "terseLabel": "Exercise of options to purchase common stock, net (in shares)",
        "verboseLabel": "Stock options exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r17",
      "r18",
      "r211",
      "r212"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Proceeds from public offering of common stock, net of issuance costs of $1"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r44",
      "r211",
      "r212"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of options to purchase common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r18",
      "r23",
      "r24",
      "r99",
      "r165",
      "r181",
      "r348"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsComponentsofAccumulatedOtherComprehensivelossIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r357",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails",
      "http://www.modernatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r357",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r357",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails",
      "http://www.modernatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r357",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails",
      "http://www.modernatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r369",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Other Balance Sheet Components"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r178",
      "r179",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r239",
      "r246",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofBasisofPresentationandRecentAccountingStandardsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r295"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "negatedTerseLabel": "Decrease in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.modernatx.com/role/EarningsperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Effect of dilutive securities (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/EarningsperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r122",
      "r127"
     ],
     "calculation": {
      "http://www.modernatx.com/role/EarningsperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Diluted weighted-average common shares outstanding (in shares)",
        "verboseLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/EarningsperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r121",
      "r127"
     ],
     "calculation": {
      "http://www.modernatx.com/role/EarningsperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic weighted-average common shares outstanding (in shares)",
        "verboseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/EarningsperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "verboseLabel": "Weighted average common shares used in calculation of earnings (loss) per share"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=SL6284422-111562"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130533-203044"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998890-113959"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998896-113959"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624181-113959"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "http://asc.fasb.org/topic&trid=2229140"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918631-209977"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(a)(32))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=120398226&loc=d3e511914-122862"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=120398226&loc=d3e511914-122862"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(7)(ii))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=120398226&loc=d3e511914-122862"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6806780-109447"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "730",
   "Topic": "985",
   "URI": "http://asc.fasb.org/subtopic&trid=2197926"
  },
  "r476": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r477": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r478": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r479": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r481": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(dd)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e640-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>94
<FILENAME>0001682852-21-000017-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001682852-21-000017-xbrl.zip
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MKLS+%XTP/$TG-.'D-4TB'I=)Q)41XP4Q$XKQ@^/3)_@TI8R!."LQ'YM6>%B
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MU@ET&7YG2C06-TG+;;+@E2TFA#*6JO6JZOZ=VI%21"<BGK=^'HH)U^2"S\A
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M0^P'ZT*;?[4+=4=VMHC+XBHG+46LQ\8J/2VZ>]2XC3YE:1I%KV*DTLNRXBY
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MY,K,YI2OO-J1?_H73=PK+^?_!U!+ P04    " #7@Z92W*)CD4,%  "8'P
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MS7[QOO?&T!N,+H+A8!WRS4!:=OW%QS$ZAN#=$,:]RZ/>^7!LC/XZ'7Z$7C\
M''%MVWWZ&OOBBOK*RF1IA"BT7=>L9=^_LOB?A>(DA9"G*0W5E@$+)J<@IQ3>
MSXE ?I(E7-*,"PDX>,S%#!S;> \\AC,>49&2*IRDH0G[2N?U7M-U[4Z?SS*2
M+O63TSF F MM,D,'>004@X[@C(AP"IY3+78-DD/,$GQ_Y\"8AG.!^QA&2M((
MAK?AE*37%+>;V8SEN7(6_Y5DA'L33*F@Z-6Z'X7CI1M56- JC/'9];Q.AL8H
M')$TI$D5^E-&8YP"IY3LAL(HCEE(A0I3V5L%5-6.#,@-B^#*A#.JP"R5CUF*
MQAA)MBKC.\EBO,GF(I\39%IR6"L&*P94':@J/$C$,[7IKHN70KC&2OMC(B88
M2VZ,;A.ZA%XHU8C*X2J.$ZVFY"8TUR-\+N!3RA<(]C5]O5=K=F!KVF8DBG#'
M-Q(:J_116;J1N(;3_&EYZYBEVS]^]LX&,(Y=+-\ 45XMEGB>X,H)D?I$)?!=
M4@OZSYP)JIJA7)%Q3_H^.0!<)TYM/SJXH_9^"=RE_XI?I^7Y19;,]'I"(EL=
MG9\[2:;[(LED*9:N&=$,88V4!#4C?*O)*9DF3!7)3-!<D5I5PR1) -70&2P'
M.) ARWE5:\5W90(-1KI-UZRAU#PI<H)CG=1SY@]*B/E4;M=VD^=L2_4M#:,D
MDX26*A,NL.X;2$U"LIRVRYM.Q/(L(<LV2S7 6JESHVI>2)*52<FS57/><DVO
MU5#]N43_9%2:7[7NIF[=+1D]'G,]L^$[6X=M<_O83S#KF7ZS^<VM^KY9][8/
MKYNU-+X%QLA5CHGTMN)5'B1.V\UNP=GD7^720P*+3/GQ14)_R@UP214;UAE9
M0KWH'.YR>P7$%V*T5825)XGN AQ'2PW&,P#8A:B*;XCRZC<ZN;Y^MG';"/V)
MB?Z,)/BVHJO"B26PC;*0\P3;R!+/76)HYYG8);"W?)G\QOL[X;U_(1CV9QDV
M:(] /_@<ZJ6#I15?H_'"F=@0_=TA_*K)_/_J$![\,+-3)?*7:0YVF81=PGG+
MCXZ_\?[^?<$CT'_EOL#2O^,\\XSP>6<D3['XX( WX\4)=UO0A*@6[=&1[WUA
MU3[8]RID@M5U+A^K?.64>'4MSJSUZ?GA?U!+ P04    " #7@Z928A?9SJ(2
M   \Q0  '@   &5X:&EB:70Q,#%A;65N9&UE;G1N;S9T;V)A+FAT;>T]:W?B
MN)+?]U?HIO?V3>8$XP?/I*?/,<8DW@&;L4WW9+_,,5@$WP;,VB;IW%^_)<F$
MIPDD$$R'/C,!;%F6JDI5I7KIRS^JAF+?-574BP9]U&Q5ZIJ"SC+9['=)R6:K
M=A7=VHTZRG&\@.S &89>Y/E#IY_-JOH9.NM%T>@JFWU\?.0>)<X/[K.VF25=
MY;)]WP\QYT;NV=<OY K\Q8[[];^^_".3056_,Q[@880Z 78B[*)QZ WOT7<7
MAS]0)A.W4OS14^#=]R(D\J* OOO!#^_!8?<C+^KCKY-^OF39[R]9^I(O;=]]
M^OK%]1Z0Y_Y^YDD.C['3+A=<T<GE';'D=MR"(^0$B9?XKBO]+< @L]"</1-&
M3WW\^]G &V9ZF+S_JB2,HNM'SXUZ5P+/__-LKEV$?T89I^_=#Z_H:.%NUX>Y
MQ;<[?M\/KC[Q]-\UN9/I.@.O_W3U+]L;X!#I^!&9_L 9_NLR! AG0AQX7=8P
M]/Z#KP017DY_/K+1Y*"?OC?$D]$)(AF2^K/GM;T("3PG?,F2]C-S8D,"P 1?
M$^YM,%P%)MD.O(1AEC8:I:*:MJSI2#'TFE95=5N3ZZAIF+9FZ!8R:LB^U2RD
M_G6K530;W<K?5%1151T9#<VVU2J2]2HRU69=5N#'=\V^19\_E421O_[\J2Q<
M__;;;_ I7=-KPC6'K)9RB]A[:AH\H>DUPVS(Y&W0N<7Z5O]2ZJTJW*V91F-^
M !55D5N6BN K7#W7+I!NV @Z4$TR<#*:<PVN?C=:]2JJ:W^H]3O$'E&,1E.U
M-5N#*=S*)G1L0-_LNJS?(:V&JIJEU U+K6Z.KV4J=8)[(-2V'T7^X*HP(N07
M.>T^GC1H^X&+@PS@M>^,0GPU^7+M>N&H[SQ=>4.*)OK0]7QW><#I PXBK^/T
M8Q*GU,YN3U<$Q[-5$<%P(W?RYO@V1V]E(W?Y7HDK\\EW@9 3[ZWK50!V)95V
MWFV.*TK2SGO-<T4^OWL0"%RA6-QYMR(G[@$$HLA)1?%5W:Z_5Q9>]^1Z?(FE
MU]'6^C<6]D$%!%^;#39+ERY;OL API$S_/U,*)TM<)'('UV!+$2AW_=<-)$2
M(\=U07Y?B:.?B$C*&8G8Q]UE%N*/=BTCBPO"I[A2^,@-5:_"_S81-)8!NHYF
M4UGP^5.N>-TPJB D%"8<H &(*-N4%?N9 <<P? 9/81$Z9+(KP'-DL%LMN(5G
M>( \A>]5-1$NY46XQ-(D$3+O!K=MM)U= J\IWZB$I,BGM23L)X.)I\3 4>;*
MHYVKDANB^O,GH4 TJA5_Q=SJZ_!76M!4$MG*UO3Q"U" R*%G[K/,;72#2Z2*
M>8U,.A11-$GWA14H7LL1/_S*ESBDUFJJ0K<!5=@WI!W/%L:HTO<[/Y!04(X6
MW0< 7(Z#C>F?+<W2GC6*9LM48)>IDAO<W")?A*0@IA:4AUHY>0XU3>-_8.D0
MR*$)Z/8S$MKAE1?!Q#L;C.U<ZR)G-(+&9--\\6K!=]P47^"09EDMM8HJ=TE*
MP5I%\<0_9C<G5M/,5&2S*F_!)=Z3"Z1,4!617&UHNF;9JDE),'TLPH]Z.$!1
MSQDB+<(#5+A(6B;['?IZB^SL"CTV.9\^LIPN8U[<5"X(^8T!?%0B? 5+V]KI
ML---&,\C;>CB$88_PPY&\@/F+I'%?5_>?AUD@*;O Y?(\9F;=(SGNQ/V@-HB
M?XBJ"O'"\<(+K&+99/A*7G%4A-ZR4%5M4K/BK2K7J5=**EVCVU9#UI&EFM\T
M987AYT"+TK)A2 JU1YEJ4P;IJ:N6%0_95*VFH5O+^]3##%;Y$P$(Y1N5&$XN
MGVV0UF4\W!M3UNV40-8@;D>A>*VK6KV.;@WB!31J-4 ]JK2T>E73EY=URJ37
MXH+/"_G7"[%?6LZ78$,O-U3J I:K59.LH!FG@6&F3!W5?9!T811@'%T"TL;#
MZ DD7^1$&#E#%_VOUH2K+KY +S!X:<];D X>1CA(S:[L_.=%\G9L<[7M ^Q?
MR_*,B7O1P;9D_(I9R&2,<4]BCL4O+  Y\!_9C\VM9$>E/C1@"V;JLOW7)=)T
M!0FYLBA*^70(-3F*AI\_Y4'4SD78I&-P\X#CDG;71.^W5>56-^K&S5TZACX_
M)F3]F7;50)$;%5.KWJB@D"%>%*2RE"^6WE-:\&0EGQT7(TX?'LL5CCJBJBE3
M4"R5A-FI#20(:PSJ"P)#*"\)#.E5\N)#*#,_CU&5.12#%GA0:))B@JA[SS!!
M^AR#[[Z8E_,\?%7@+5+N+8MK:TOP<>NTQ#:^I([M.=PI8.__-0%:DQ6MKMEW
M:]V")V:T@AFE7FI+%VEG@WR.LFU>HA_$FKVI;4M:TF-WSO<.IBJL#I45!(YE
M0E#D&GK]#LG-9EU3+9+'\+S/MQ8W^M:J7?Z[ W,W"[AAH1L_ZGF=-U$=;)>+
MN=PA/;S([F'DM/T'C(;C01L'V*6@[, R)^E<R N1,R ^,1<Y(0IQA+I^$/60
M%_NMA1Q'^^CYXX!:"UUB-@Q'N.-U/7@(6J, =[ './*[R.AV<1#NR-7]RR !
M@ P$2J&\=333KP2$H1]- ;&YR+B>BXXN<H5#21%&W6@P#B/D='X,_<<^=N_Q
M[ ( 3,4KBB8YC@(/%DCDP_7D-01KC=R>6Y?PE#-=FI>H_83\(69OP+#J^GW_
MD>1-#G#4\]V0F>G.G0M4>0)V.QCU<41NDS4<HA)]JY"_I)\!CL;!D-S]._X'
M3XP\@%+<^_/PH=<R]-JFO4XG3!Y-GC(,'CN='NGS:=*C3P"'PG%[X$4DYY-U
M#',\[]"^0SQR @(4&#:(0G(']W$G"ORAUR'S&8SA"X/,(ZP%PI\Z_;$+8W9@
M*- Y]>G'<)X#))GQ='","88<JLE:O672R/P[HV4B6?E#-[[7U2IS-Q))5R'!
MFXJJ?2.YAS9-X*/)AZBJ6MJ-3C6RFF'2&[0A\P(;M9IJ6JAI:N0>2_R[I:_0
MJU2/0U9355A.8D.^(U[75MU&F@[?2,ACO-VDHZ)]<4CK$OP_>$$TQBL@_N2/
M$8#""R@$.CUG>$\\.S'4G7Z '?=I!OJ7\)T@B#4<.$^H33Y<3-[R,@8N@:K]
M!X_0)47T!C@;.#\ 52\C:GYBC%R]D!'; [QO;CGY(TRI.&%9<2G2\%*XJR!9
M"8IBM'1;TV^8*[/9- T@6V;Q $J5T;G7!>#_WQA(RUW6\0\6I&YU>M@=]W&*
M,)PV'5Y:I\,GF;:LJ6W+XDCB,VM('J+9RZL,8$@F 3"68FH5FF0=;PESF_C\
M!'Z5"?=7BI-6;E7E#X!_LL5#XE-DM'Z=,^-Z(7NM,.G4([%VT56F?#B534[:
MB]#5H=S*.DG/H\1,5@N+:6^V3*LE4RV *58I,[Q0$0<:V1ATO\"+GBX.NL,D
MK('"T4*6:A.5R+Z=801(-HG?L*J2:[-\!$UYR'-K7EXCMA>Y1_YE[O$FB^J<
MTW&U8-F.6R5Z,0D3."W\G=)E)3$D@-"@7#&^J4AO-2HT@V"%: -N$$N_*A&9
MIEJKDWPD^G"<?&#*-+5O0OSI8A)4Q8<M)-/R0[+)'#E/1%^&;8'7P9<DBRGP
M0:-FZC<HS\XEPE&'.R@W6<5!N%F&S##0LF\-4[/OB/92DTV4DSB!EV"GNKG6
M?\Q+%]%/?KK@TJCZK%F L+BL%NBC=*\MU^4;4V7;;E)_1V=9/9H.R)Y%_"S2
MJ5C>P-[\9FURM5[/4'P8N/ZU5I5,KQ0Y"+"J'#* 8:0M(G>BP45/(VK0&?BN
MUYT82ZC%:DFU2ZMG;8;[.AMGPQ[:Y'(P&*[>K:N@ 3=()33@= <4OI-8SX1T
M7G@^<#J1'YS<.ZL\&^F#2N'04)F8#HG%-H0%R.R[[J0"Y-09L6?VO&:@C&6X
MN.,'E/M>C6'K$I!6!(BK,9I8).>0X(Y=.+%MW O#\537/QI3>,ID&]EZ,-MF
M<V(J75/))UTJAA'<.T/HP25.G9920R'N4/6"E$D%W(27L0^-D,FL(X9.K!,S
M>^(U^C<\B 8.=?(\]G" 41<[H=?N8R[UVHGM_"0URW3J]F/R32QF>%$L2(*4
M]L%76[HU-W2^4"Z*4GXQ>"E](R<1(Z-Q,/+#J;]R3L?U"*=*^RR$"XV8L:BB
M#A-J.U&GAT.Z/OI^%#*?(TPQ)'4>(M1S'J 1QB#F2+GD+@Z(Z.L&_@ U?."5
M0V<^CX;P:J6J$,<I\=[>#S%>:  O2#N,Q LU).5CO;!'F,,0-9M_(F <WH,7
M$7G4!LDZ "(81Z'G/L<OA""MII3QS&P(0!^]?I\&BK2!SXQI] ,P,%I)(/7!
MUO8J.B=S<>A4"*=U*!/FD RS9#5"GF</_'7 B HNN;3:-E&A!HXW1.,AL^-M
M$S9SH&)Q\)3O$MS"MZX?0'\='+.OI2!,L@3X$OTI"9.KJ>?+9"?D#<= F1R7
MDNH1ZL\.!BW,":>Q&412>\-+Y "EK22M>"T^J^//X1GN<_1?&<F$/0F\?$GZ
M)EU&/B 5QV9E]S(FT'!*H2QH8P@4#R^&MAV698R[7= C-M9$]YU2?AB!DI>G
MF>.V9M=I_!$))DJ=A<JFEJF 1-P,HZ30CS<6E=_O%*P(CX B,:H0#M2_1(IJ
M;%W!Y/!NMH,YT(2"S*V@UHFKC$0-L0H7)F7<$X))%1DG4&_*(+TFNWH-@]PZ
M5N0]J%4H'8Q<\Q5NI@0'\^22\$G#3,3_DI]G;T/?BF[7VZ1@7FP/@A8XW&&L
M4ENN2"(QSBV N!.- [H%&.$@)%X/YO'XS]1:N,J;L-:Y]^&]74)>X>(08Z)3
M;'&VR OWWG_!K-]T4OH7"I,=PXN5R5*=59@Z3EH 3MK2-1+?;ME 359L^#0U
M9;F:WU'STJ-DF!-''#$G&-2^'QPOJSP(?2=PR<-L1@]AHPGP@^>/0X29+0 V
M[^.0E+-.SLO>YW$PJ[G(7@Y4VS#'P(8MCVS2])X&DGAT;JK?D#"Q4 F%Y"U%
M.B8 " X[@==FQM,;2R9!<N>Y$E)JY@7*2YR82SRR(TM/ ]NATA"/3"+!:B.?
M'2-X%> ^\.,'G'BT7LRA^.DC3AMH;1PM/_+"B6GL;^\Y?'CDW.-,.\#.CXS3
M!4%UY?0?G:=P01B_< +@,9W25BYSN5SNGZ\ZI$T0=G^46)DKY',[[U7,<:4]
MG'M6YD1I]\=SY;AB83]'O_'E/8"@6-[]T6^"Q GYS4X 7"F4TUB9?."Y;A_O
MFN<O'J^Y.HB,V#XTO<5B$:Q;54T^O>P8]T,DW2"^0EZW!^?/9J>8FFI--55=
M46GB"FR,JH;2HK'+%9781&,TK-A\IWM>\X6BV!DVY(TOG?NTXZW%^Y5 2CU&
MXI/CCHR.Q#V?("?FCI7@#H ,ZKZ9U"0P3 3_34WD1'=]H?SLYHD5:100RWD<
MA\$"36/:JE9@2B=R+K]D:$JC4G:T=$-3I#259>4GGB1Q;+,ZKQROM?((P?TG
M29_3[.72U\<VD7/E1#?O"&[B #I^FJF>:.:=:884OE*V..HVI5,Y5]]9U4GE
MQC<MV) ;I%#5\1-5;?,,V7<Y/4$4MGO-D6Z6!7&SN&Y6$(]&/HLD"HD4SB-Q
MSZS<8HC.G0$Y/0F%/?^1Y;!X&/EM&+9#ZNJQNQ=;UR9(0UFQ#4$D)MJ4RYM,
M)UWXKC@A1DI=TQ&\1T095,4/N.^/6!G++AJ8NHP>G$X'GB3D4*DGG\^[C,WD
MBB'OU#3U\.<YGG_-.DF$0>'X8"!WZ(%LM%;KL.LO\XZ4$]EKF[X5U3/AST>#
M:Y+QQ GELF)\$S@Q+_ 2DD>C@$-W <<RI.@YJTB1=?8S;HL,EH.K])TPKO1+
MGTX7G7S Q5NC^8D,(_^]Q,T.CI&]XGDANF=M,;YT3N28FG[ Q762C!]0,O)"
M;F/)"&U/DC&E"#U)QI-D/ ']EVUZ OH)Z!^CZ0GH)Z!_C*8GH)^ _C&:GH!^
M OK':'H"^@GH'Z/I">@GH'^,IB>@GX#^,9J>@'X"^L=H>@+Z">@?H^E^@?Y2
M)L9^)KK#MYZZ6D,T\WTNY=^D-?M@PU1]2T?%?([/\$)&R(N9$E\H[KH<&STV
M4N*+G)A/,20,>MB.7(^KKTD%=)[+E H7I%Z!-?*'H1\\US4CU\@)=+.US01A
M153Y5E7-%KC3@2N7D:X]]_<S3W)XC)UVN>"*3B[OB"6WXQ8<(2=(O,1W7>GO
MW-G7-U<[*XHKJIU-VNV[NMV&T45-F!.22(I&\ED1"4/=OF(;'=/>$\B$PO9%
MGDB!F USXN@D8FX0YWB5)M.:'-:\CXJS&R)4N$@\*[:'$:N6U\9]_Q$6 CV1
MAQYU]L*9/#.'\-"BKPN'S;SA8)Z]'_JQ(=C>M8#MTIA64^B:8O8;<MVCHEPQ
MD7+CLZ,F)P$!LWKK^4AO@MB!X/-V<IB52X<3PMFV[S[!1R\:]+_^/U!+ P04
M    " #7@Z92 0 ]6BDM   L*0$ '@   &5X:&EB:70Q,#)A;65N9&UE;G1N
M;S=T;V)A+FAT;>U]:7?:R+;H]_<KZJ;O[6OW H(8/,1]>BT9<,([-M" DY/W
MY2R!"M")D#@:['!^_=M[UR")P<:)'43'/<2.AE+5KEU['G[_KV:W,?S<:[%9
M-'=9[_;RNMU@;XIOWWZJ-MZ^;0Z;[,/PYIK52F6##0/+"YW(\3W+??NVU7G#
MWLRB:/'N[=O[^_O2?;7D!].WP_Y;'*KVUO7]D)?LR'[SQ^]X!?[DEOW'__G]
MOXI%UO3'\9Q[$1L'W(JXS>+0\:;LD\W#+ZQ8E$\U_,4R<*:SB%7*%8-]\H,O
MSITE[D=.Y/(_U#B_OQ5___TM?>3WD6\O__C==NZ88__MC3.J34:6?5[GE=II
MS3H_.S/LFFU7^ C^F]CGY7\:,,FW\+AX)XR6+O_;F[GC%6<<O__NS%A$%_>.
M'<W>&>7R_[S)/!?QKU'1<IVI]XYF"W<G/JQ-WA[[KA^\^Z5,_US@G>+$FCON
M\MW_#ITY#UF'W[.^/[>\_RV$ .%BR -G(AX,G?_P=T8%/DY_O1>SJ<$XKN-Q
M-3NC@E-J?9TY(R=B1KE4^?TM/I]:T\Y3:L!"1H&S92IG.\VDT>H/S7:'-;J=
MJW:SU1FVS6O6Z_:'[6YGP+I7;/BA/6"M?WQH7[:'[(/YL<4N6ZT.Z]ZTA\-6
MDYF=)NNW>M=F _[RJ3W\P'[]Y:Q2*5_\^LNY<?';;[_!S^H%73,N2FQPV_C
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MRU*JIH9P'6(P9+>_=?_7' LO-O4GX>W#1A!85TA_LA4*MQ\SR!-/)/*'HP%
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M"VT## LYONOZ(Y1&,Z[H?@_L!="XGL_$/>HZE$AH$G PO4<^B4$?.^*NPX8
MPB!:TMQ!(:=CM6"D$,UTA";O'DW'=T#O@C5A7N%]\.WZ".Q*?PK 5KEP4Y )
MRR^/-67=+A,6FI;P,X:,OI8:,>1V(C0#W[4UG%EL3'N(U)T>>7$;)=O)]D@V
M#ZX&Y@;%<%SN;5BFM7R%!!$IH#5D'Z 0H$CX@$2&?J\F?K030C!7"O-C3!C.
MG0A')-L^&"^AIXV*A$!UW',VE)6$00MLXNW@M< ?@9&4FBXY9SX2"OT((&4
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MD6+^ J7!%=;R-K6]9+ Q'\C);*840?WDDG>I W(J":HGH9>OI 1)J8L'$XC
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MR^!7M)(MJ4P!YK212!< Y:@$=/G/*%OHPB /#]NE@P5"D94I*XNVX(%B6U"
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ML2:DF389W.A:]]+D0TRYYO,,4 ,*!13N@8<(I0E@9[0VVG7Z\J4QAYW1,@1
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MX$+'AKQ&'\7=#&X0G2+(*\)LP)IBSYGEV'LBJ*&?MV\S=>6!O'Z;=9-_]#Z
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MBJ^/@9MUA!,#0"-1,D.P059A3S@V,5#G8P$WA,D2;C,#-ZT$^/B&@O))A@6
MK&ZC\'4:G%=1:R2%63RX[<!;P..Z1\5HWV?&9NUDQY0J;8FX)T3<SMX8<1>?
MI8D.5!"J!Q\4"#=/ZU8S42?2<\Z0!@/67J-M9W <\A%QLM"OR/,R"G )D>E
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M1TX,9T@2IX2W5B/BYF"9<%;H,_U%.4X=N([<>HT\$T0J"\24G@?*(_PU!YT
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M>M?_0AY_0"%P93 &6Y59$8S"*!J,C/>**3(/:;CS0-NI\"V.PAHK/&),,&.
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M+'60L!V8@ZO5Y(W![<"%21-\5#O*>Q>#X]'A-7#.0C$V'V+6+1J,%$ED*>6
MP&O>/\+B*/YC=73:=T_XZOC&)R:/K#KY*V.M3DU5XX7>Q2#=R,C'G'0LUWZT
MD!P]7P:$QFN2RA]9A<9ZC6KQ0\O%WSJ6NF7_6"7WMX]Q^6-C_<X4*/%C37*G
M,MCGH-?S#):H-<X?UB?X4;== VOM*5(19B2T?+L-Z;1"RX6E6PC8I&F.>OG5
M?744R7_)-ZH3YM("KI++3XZ/=S8=/6P=GC;?P;@VM\'J;;</3W;A'NV3P\X!
M;;;6T<[FT9WD\AUXA^87WVYV/J!#&$OC9/O+SOZG#CP7[>PW.X<G#C<V/["=
MMS>K^*7&(@@CZTX0DI++;=U$Q%.6(<926XXM6WGS_GZU^+0%0D_3$/K);'1T
MCXW^[&GDWRR2>LD^9P^3 .NW$?'4AOW#AG'+L%]2Z59ZSGU6]*]!J=E3FGM?
M\PR>0W@^]D6?5GA.KS-J:1<44_W7L \#Z\_G(LY+VP5'8[M L1"\H*(N&0MU
MIJBJ*V-$W1'$O)0HV"B^VT_U,1;O;/6LF/%3YT+2;=T?UI@%.?? [O7S(>9&
M\_RNF.:-<I:7XNY[XNYR4MRY5.>&7*A3KD2=81+JV@M7Y\1&2W0P!/E'B+N7
MS*MY3*#Y 0^D=-;BS/$;\=S56G9_&#J+]ZV,%NNA8 %W>\5RYK!?QH+A5<OM
M#.[I.MW+BV>UK]+#+S)X-#RVUH57ZR4C[CSK%Q9UUW1=LIW SDX=!8M"@H'I
M>I/[?BTU@<C\UXJ*Z&_F]WO#NC.W3'(#.@0] H7?N'+VERWZQZ'='B&N]AO@
MJ%@\*!NZW@W- ^FFN_9\ '=ZGI7-ATWQM!7B7J+7/.O!G\K=HI^1,DY)C>H1
M!5=G7INZ,9+6"39(2N(U(7H6]T*H36UE^/(91-[/-T^?TX7A]6)!=?TLS]HU
MBLH-9U:39,Q#[2+]4<F'MT7Z"FC M$5U(1V*,ACPU&](#(Z8YD8RC85C.%AE
M2!!!>XZ1]Y:C:F-C1M$*R&67@=/?_]?*=O/MS<V$NL..[PVJ$^[)_"RJ=(H,
MZF+G\?[.<% H<)AH\$O U8#3T:\F338;_+.0U"N,?9VQJ.K,<5Y7*I*Z<)PP
M&VET$DQCAO J)W)5JG$3FA%]WY3E3?V1?LSOUOF[A]9(K=9ZUW3Y^KKWK2V2
MSWJE4?<Z#REC[3S<V33Y>O6[6"E'UY<8V^^UAX.[EWQOG^7'[O><]N4NKSG.
MKZ7/4:C;/)C3NHD@0EZ;]H6YZJ?M&^[?%)JF-?X?V!'ZFZ+IN3>%^\J&O_]L
M;6ROOZ\U=UI;M=VM=^N[F]O-=[6W.[O[\+'^?F?G_Z3OQ8;&C:UFZ^ZFQE-]
MJ?ME8RNE1(ZW*JR5B>:I4O8MB*I:VL0R)5(662'C7ZH\D-^3KS-J?I'XJ%\Y
M$,4J::I*J"YLF"[ )J7PC_EK,^N[8;D?3<H[6>^:]E4_*SCR[=AUV>@!5PU&
MY^R&_K ]*$[9.0ME,]_^ZB@G)4EHDW7!H[H\*_LPY;4,O*2TRP%(W0MP>^KM
M7N^T\H,&545!D<@);%RS)KE-J3WP, <#_,Z ;8!;Q6(@IM\?=L[*1)WT'2[*
MNJ5D3V-U9>(C3*8Y-UF[2&4![^KF?==JZ^W!<6]X= P:J+SY>;A.*X67@+DL
M7Q'$4ZR\1+#NX2CXB-]XH_0RP)_]7C<]>;6Z8.*$0N040XK#P1#.#N?%[S!A
M:8S5C[W1% ,=4B+LF"CP>_&N71?*G*&L>]YKP^!/N[V+DE+#;ODYS_JG_57X
MZD*>B),*4,IK>H5K$T$<]_**"!T#[H])#G :!1P9FE3S4M!\]>934T*5.TXS
M5A&Q2!"&Z0_):8")]UF,(1&AW*,I.4G5:SWLAA6&$B"N403NV?<F?RUQS=<(
M4Q /('[-6"7WP//ML 1AB@*TLTXV*#*(5V^0U8*>N=O>XS$67*5*]&T+#JM;
MQEK].3:2??#.F\#/C\Y!?<(AW)H;5C;EJ3"9G9=55$78!2!R5E4LI<,;.Y^V
M-^M8@Z7@'-RT0CH<.6N;2E3<XNLC@$I"207.H] =R;4DY>Z_Z;7(!:<S-3'H
MKY8,=!$*'O* XG;O+,$M#1#N5?#ZN0'>Z [&-L_>^NY>?:/WJ4YJYUD^A)OT
MND>]8O4/9B1%LD=W2OA;3:)KF/BUS)E/[](?GIVUKX"3P$F#WU8+FRGD24A4
MK=574]#+G*5@4_"KZ7U3?GXOOTJ\FD9>W >8 A@&3*S!5?']",[.N^FI*7J5
MYRGZ5/$ '#WK#9)ZN77HCR7VGQG[-FN#4Y*0E#1M,J1+)IBD7H&(;$37:\1<
M4SID-VY5">&:\>$_0Q!U!9Q,6D@!H"1SY#:?%1OQP?NF75_SGA^ZL77@0846
MQ21?89PE0EX((16AQ]_+LIO<EX0=R<Z+8]#+(+'&8"K+/AUHW3A,*GP"/04]
MKX7+B/* J4'I!Z^F3:TN4D@T14+SX5&JO4D^F4OVQA@9Y^$X<^WRI[%D YL#
MC,RTL6]_;,Z$_B [&AD_G>"3? ME]6DJ%!K)QW3V^ L8+DN(/2/$"O_"@56:
M  4(&%2^!F H64XC*QM(!Q^S_G$E@K+"*RA(!Q\!(J$T+.$.('P GD7(*OG[
M )&DV;Z"M=5OX*) _+AS_]=1L*3Y#]"\*(FHK F0_(6A 40Y2O;YZK4Y7_ B
MF$,C\0\'0K'!=*D;KMF]N-9T^F/CK'+7BN^5'3;)Y/T!&%L5D<<_#I*?T9^T
MQ6[X5R.SKM)6!:SBQ)M4HP6_(HRVJ!D])A6X%S<OSBE=-9\&!-*S-)TN>OGI
M:EFT6"X(5F6,96>K,IPU=I3+C6N+^UUD(!]M@,>&:\?TVD;][H3=Q?7CU]F6
MH'\8Z(%\67)GD^]IRCX-Z><15%TO!Q%4F.V@56$F.YDKG-ATTMCPN7$DN<"E
MTWT<3!L4<#C+1D?+F(>MTM)NF?JK=U$_ALH(&JN5+Y!*:[/N#4,_K4>'B]7J
MJ2Z)ZOX5>"V=_FB\1^V>A9L#,+N]SE72X"99!^U[U.D2<,\!N")*,Q8UE9'M
MLSR9W(7:K#[?Q.(=F(U05LG0HFZM7IAG8-Z#<@4W= 2]\\*C+ JC3;]VK=D+
MT3,<;=-5/J<W'!3AYM4)O[!6AO%',K(/P"R+QSO!](<IL)]B-H4X+H-F(T=X
M=1PD2E:AN2J",CXS1]U>/Q3R?"RBBRR+E#8QO!X.C&-0/#^9$SX#+H"KKJ-7
M-KVIKP)']JK@JOLMS6\;FJOEM,/,@KT,UX5NWFNWBUO KW?8\=HCOH=3;S%B
MK:AGO^;5]!;YL(QE3D;FKN]94KT_"G)<2XDB3!EC*&:^6T5<"]\LZU9]\('/
MS^!*<QJZ:3Z&Q5TZ6?'.99[+34Q=2ZR15IKP%4/12C^,1S B3SI<!EC@I&K^
M)U^K#"J.PG?WX_:!F%U*I!=T)X&X:0^%(CD*IJL"4ZRBU#_"5S<XM=_N7<"M
M?8I3^V$8R;WO"+E)DZ^RFN O<#/AEH49F!UUBQWTBOB_3WYG*50OBK2K^P(3
MB8E23Z1;D8\J72P&'W)XB0GAUP_AM ![U6RBXJOR8:,V2]6PEHB=2H@L*W=2
MO)HTE;)>U8&K6$(J1+ I5DCJ(XF8BC13/<Q1*>_2AB%9J(#4+QS42>/\!U7+
M1/CXJAQ&^MR&4793TDJY8)+ZVU?&W4CP5WIATGL:G]KI>3-Z]>MSJU^S)0I?
MTG68#,,EEP].&JGC1)H;X=H2;45"7!O<P5[A8?9',5[0K>'K;N'$8DB9PY#\
MW=X/R^8E1*8BJ'JV"(_=B)5-&(WEVDU: 2[1LR3?;)'O1L1\<ODM3+IB$S',
MZ^6X)<5>3B97*Z25NYIU[! \BT(\?H^OEB2;5MAY%$ 8>_^3WF^R;4*[=%.O
MM6CIA8X\E&M/^1O4?>C2P60RW11S!V<M#W )\1^$>,)CI[#**F2/4L$NST*W
M"(7E*>(Q3)^<.<L&12[6=2?>ZPA--P1?@CX]IT)XE2W6/5J*K!?4,N.8G0W=
M$+-!%8.[:^072U!'>1C1\G:D+=4&I.72WM>N+F)]D_DW]T;LS*!<VK_I713+
M_S=2BZX-SM$ZWJT\H@*6^2"[;XE]B:?GP%,E#JY!,I'L,T[D2,'H7K<[6H@O
M3PCWD&]IY<P@B8MEE])3\*,:UFL14@5 .T7K_FNCYCNFS&WW).1%4G.O/[[3
MDKHOYRC>F[.]),#+L5?2G57@+ G2Q%0E&Q2-R\Z*!+5E:&5&"#81]IJP3JJT
M_9 JD5.$/NV_4,4R@:/@GDD'#KN#?!GFGE80K QOE5FBX]30WC<XJFJ:X,\-
MN/='I2$#YD[7Y$!)7ZQA%S>XF?*>LLN6%'Y!VZ2,;2;YF%+EPJ#*J,O!'0T3
MA5L%H:[N9+8M23459ASY?&6HLUA/. U7M7ZQDIE6QBO&JLK@DF723SY$>TFO
M%PUN5DD.;7,QRJ(:[9VQ5&,O1(D;5L;M-=1*Y!41DY%G!5,Y[ _RJS_2+TLB
MO8QX*U(9RA3)LK1UHI:UR,L8%NE^=XH[K_OMS&CU-^9%[Z%:/ZE-9XJ@[S?*
MBAT,SH919LNH'C;DG:Q<NQBG<U8UWRGW8%R<7?T&>OKV3_WCWK#M;__J[ONQ
MK)WLW_XYE75T_9V?B\68VS^:K'/WMW&BV9U#55GVG=_'T?,[#\V3C7EWC..X
MRMT7+?,LQK]72='=<%0L[51QF%3""5-=UF@7B"QZ/^5EU<LU$59K9E15GDJ)
MTZZ!WR)IKUSP+Q]PT<M]?ZW6NETN7MA8W:+@KGBYI"+6:@>]8:VD7?$DF&VP
MP,%Z+E)&VEGIV7:_]70PV$S5[NSJYVO(5ZOZAZ(C1W83U39<]4;%'O#*>:\L
MW2HO** V63MNBIS641'%6NWM_47J-PO4RP2\5'0^>:LB06J4M'^C]'=<^6TZ
MO91*6'7Z2AE8JU7 K)UV*$_SX*LF8%_KKK +,S0:Y0A&1:UQNQ\NBAXW]PBG
M[5AD;B5CK)=/P*R4=/#S34'7<_ :95YR&:XHAE7FCDVV0RA"N%4]/KQC+T^9
MXZNCR;IN-#":MC2?YP9<[IN)D\7$E=/PC5+\;Q;B-WM?/UPV48.Q=K)^,0>F
M=C0TJ?]+&:09Y4U<1\WND>;WM$?"=(U,38&VOCDA]W0?R$.:V2(+ 0B:LL/[
M27Y7D=^4LS7>,FT"./MA(C6W9(I4;!G^,RQ ?CXNU+YAWA3%1]?='<J'I3RS
MHK?@6NW?O8NT%5S!Q>TP*F4OFB,6;1'/?)4Q_IW>%X.2\<]Z69DL7Z"DH.9J
MNNFQ.4]-%L8\6>B.T1*%+ZK?^RG3/ 7G1AG!12O&P?7.;E7:)$ U"5\PH&\(
MPZ*I5(H,%6(Q3X7*O8<T[>A?DV.46SQ)D93-4TS!Q%R/*C7N)]0<X/6^7AC]
M8E9 ](TK;$O9.+)]JU2U(HCJTU:!H]8'929;J+)2QZ>?#6TBU8URD2*A,=6?
MY.?AJC_*XBCK[T!!I #22,9,+'>!S/SJ32>S*K_S@++'0](.XSZAHZXO67ZC
MC\QX9]R;KW:=<%X8)Z/M$0NM6U;TC4R 0K/Z7H'$:_E6)(DF<6[<56W42S0,
MPKAH(]EQ$^,H6+YBG,0Q/IR%PEUHIXKJO+0%RTK-B1XXI6E1&L;E!HKEL._B
M<@8;/35O-GC:V&G\L]X\@%_>;NUN-3>V[C9VFC7F^MAM)W*6R[%%Z[J2CRZ2
MPJM$657#4QJ6HTY-/5#K77/;3"UJ(:K^MK<.783;OPROS=^)+<6 _!/;A]U1
M1<ER B"/G@^\YM;*C.'24"WVNR]SY$$"9CXS><&3/^8&_^KI5"_(4(BF!HR;
MF]NM[9WF^OO:=O/MSFYC/7V;+5%P/R/M@"*^"("X0;(@+B[6.B5"!Y=KKM S
MD_W/MHL5!Y"INZ&*I8V,]O+:K#K>OWF7/ZJLE_RL5ZP86G#E[C[K5?6MG@[_
M,=GQ(AD+_5ZQT)O6.$QA577!_'^=W()@P=PHGQ^K;Y.W&US^46M=I(UU\_*D
M0?GE]CEIB.^S[FGPV]7;M(MO6;<XL^I%/'G%R+TTD\9]<GB&9>+KI+XHNEO5
MAC?J4R9:6$^8 =?7Q/$:3YK1I*4">!R@UX["]>]%ZZ,,R#?R<DM:EFK[WDE+
M,SKYF"S5Q)0F%VB\TA+UQ>6IY?:M,XN6D/Z[;2"G+7C\@WM 8C3-)I"C6SW[
MMD4/- Q:A<T/V-WH%9Y#_QXI]1Q[5\*DI;:C/[1Y)5E#S[!MH51KX@=WK_S6
M;?F:ENR9MRU\Z%Y9-_H>XQ]L+/\L78^_K[L*K/RSOMNJ;=\21L^^[4O14.>%
MMD-YX#R N/J1#8 >BYUIO-OV(( -O7;C]9Z<([[Z:C$^VZN5X_/!52G'K\N(
M(YP%8S(S,Y;:<9YZ@O_7 S0I77ESW=IV[SKV\]O'K@&+!ZR*W_]\96ZKPI?:
M#K!@VZ^#>$GIQU%:?(643[_WV)*?IT1EL?(F-:A.]3(^&837(8J_3+M8 -L[
M#F$P"N$VBC)JBLOM!PH'8C.XT+'@UE2_HB7_+PHREOR_\%367^7_">5^HUE]
M$;(H8J['*1V\ \,\3ALCF?F=@7*7LGMDVU*<+1+0Y5*<+3B5"7F@.$OK0'DX
MAO-2?M+<"J_TOMO=(F?\M[E^B?>]?G^N7^#WN1[]_3I]J19_"8&IEFIQT:G,
M'Z@6BXWZCGMM>$3_?]6V_E/T)5W*AE\7-7HI&Q:=RNJA)K/I']?>MGL77XD
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M$D$C(15L)DTXT@9V%#,D$!]XB K/NYD>#9G:QZ/A", 5#H&RHQYK1SGF>'+
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MB":3<(FC_K *,'PYB%V;T\+^^-X)HX,SN9WYU.1[\?0CUL%<'H^N_\AUXWM
M^*%Y3/(G?6#F=QYM)>/.666#(2(0RSVW.CHG<" LV0A_QT\D=T$8?^A@,%68
M/D?D!M%^!=H -_C2=K_;D^':[Q=7#I9M,B!.7ZA<G>OG*;MV8E*ZMXD9[Q\
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MTTQ;DFQ:9I-1H E3KER(\#Q$>&^FR@(Q7J=<[4HZ#C18&(J<)PQA&HVG2?K
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MP+6P1FKJE6%6),)BN(%?EE+UCP"B[2G19)1I*SQ!+E?(Y(8(Y(P*2"BJ8I*
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MM.(A!,ND=G"*>2RHTKJJIWZKU(W25' AC#K#IXI&L&B5L%:B2!5!L"P&Z4@
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MTH!OZ.9:KO^XY:W(ZB"N3O_I"5 Q#KB!KCT:QI=G#_XX:ZC2Z57#J#[T,[<
MGC(%O1=X#'R3.+O)]2<OOZA>^HDGC5]3[ 7'Y-J7\8OK7[OILH2\H(;=Z;(W
MOR8(O9_!\EM=]A>QC+^,+S:7WGJ%@CK>Y(^CB5T=UK@/4!L;37C?P;"Q P@<
MIN&-%VCXHO,S8U68@XS7>_) \R37AG_.><//;>+P/+OKMI'$MPX@GH'RR250
M?O]4_>EDW6'T$DUUK*5-D;G5%+6/8N9%H/5DU?@;:!%Q^!.[N8/A;FE;\<XE
M!>YED$M-DKXJ$/WG/?$PD>D_[Y3KLZ8[5?Y%X[></;U0*L CVU5O=\>WMZM>
M=8>/9!F]W:W-81F-%$>NL?-82JY$-,E(*@RFFE'&(Z\2>LA90@]9R$1:SQ2?
M]M;$.OKE/U^SQ;*Y_XZVZ ?<@N_)GVGMMPX^?/G,6]L?Z,?]UI?F]E\'Y];1
M+SNXF<>Q_5>W1?\Z;'YY<]K:?\,__OGN]./^)H7OHO :O/[F]&?K:',?[N5P
M%S</W[$/AQ].6MM-TMH^^ K?T6UN?X3[^@"O[>+6=BN=AX#FDC\T8*-U",BP
M)!%75B#K54!1*ZRI"$99G$VC] JOTLIGRQ886AT8*HF%*X\ZI],RZD)YRXA'
M+ H'J(,=<I$IY*R*4NB$2=#/*:NPSF1NIJ1R[C,[B"!JOM.-55G8"RPOOYR?
M]'9XT#@:]+]ULO+N3AJ_'6>?1Z?WCT;_"AWBY6T4UOMD]_=VC24I 0OKD%0]
M@A)YQT8]5RN2*Y8K7T=F?44&ZK]^+H)>3K0Y3K0+#8FMX,EBJ1'#)B)NF$?6
M>(FHL59Q*[W)_<%8G8J;/_-Z%DN7T>4W^"LRN@09G;+.J#WEU$B$F6/ .BE%
M#G.*"'8R!LX-_#S-!@1/B4%LQR/@H)U*%AJV%QKV,!<E/5V41M2P>FS]:<3L
M8L#C;JRJP_;"YLR:%,":![ Z,Z0"UI<9ZS3BWL,O'AF"HT0B8C%56/DD=2Z0
M)6K4=/29UWNN/ZDH$KM\B9VA&"))914&WJ\YXL$GI*G'R"?&DN'.1"/7-E2-
M!+;8*"Y;O&9$X7?K_:"2D1R5V.E]BQ-;6#%8W#?3N,8$OWN^!F-+?"N.9A>L
MG;8[0P_3/0)0>SV(AYWCPX)G\^#9K'M0R@C*4I(H\B@0UX0A'0)!.!EK"&/<
M*A#JA0E(L6K45I#OSY=6!/G>!7E*3"3UDN=:NU$:B[A@!NF$ Q(J)1F389YD
M5:)&@OP+8G(6M0R#C3?+_D.]\VDTB[RM$2;%P:!RZE4.P)']$>_6)&-EE;AY
M A+NCPV=+<080O?MCYT?V5(<_Q5[,77JTY1G%0"S/77HL.9^\^23"=QR HH<
M(\R!-H<Y<E@3!%BI12+2>\N!_5PV&)>&:'65VH=E/K<I:EDD>*D2?#HCP=\_
M.6L%,=J@9$@N.L0E,D$)9".3E"8=4A3+KG'YM*TR^9G'$=VM ]O[#%?K]!IV
M.(RC8>7]Z7:LZW1_"B2:/QOAMNK@8UZC+LY +NJS*39]I2(.<UQ:['S+N8O/
MT0?XP&3TUE'Z<*@-HAW&[3C^=[=WMF!OS]>KG'#SA-'F_AS3HE T$8:)42AD
M99X[KY%Q@B$G=1()B(J4-(?O:V(*27V2TKQT!V$1V?L0V9FRZS(XSBU04I$L
MXHP*I 4#D8TQ!- S-8MV;8/60USKPD/K1#E>#^*1[81&'.MI8QK:S\V3)[ST
M.;H&'YB _ JR)FMTIEM/5.K-7JB:7&]6RU1 ;"X0N]!S1P&(29XP NZA$">:
M(,-H0@(;I>'X\3CFBFJ+H%CQ"=97@A^ =!0)O@\)GM(093V+G"<4?*2(1V&1
MH0XC+IG'F@CKL%[;>(()>%S^*@&O,GK5R-F6'>6]47]P4AQLCT@ISE:A$PON
MS(<[N^?,H;6]>]K\_ D3V)*4FMQORB >9$*:>)I+[]D0*:/:9>SAE]NF%)M%
M7:6U?HZU(L)+%>&3"R)LG0I:8XNTEP)Q'P4R5FD4H\R!SAA+41QK*V+0>)L?
MHWY"Q\,X,6&LSV3J=[/P/$NCQJ-&^!P.>O8*#*L6JYW>@2Z45^J\*-O?U2H5
M6+LC,P&-*%'A,.4$<:$5XDPD9"2QB COK?9>46.N,LR66.=:"_&CV#6*\#XD
M)\GF#!)"2%8B+K%'7!N%G#0:X6BT,C)@+>W:!GE:]HPGQ4+.(SF.[$D)XWC<
M#*OK/,"OQTM3@&HNH&K.L@RGB5!:$62$!)81G$/6>IH])QI[2Z6E^,J<[F+Z
MJ*O4ULMQ4F1U05F=DHI@E7(!&R1%P(C[1)%A/"'/19#:>:6]7H)&4,P;]TTL
M!L?Q0J1P,68\MC=ELBA_3]>D -5<0/5FEE0(.%,8)@0IK@FH0)HC![^1(Y'D
M[LJ$Y?Y75)=$[143VGI4/2[B>Q_B.^49F#MA=-2($"80YQZT TLY,E)@$95C
M@H3Z1%,5X\4-^="#^"WVCI^E\6)E4E!R>[X\R/>=T<'6\1 F+ [.D*P^C797
M \?>S=(0IJ+T%FMDDPZ(!^.!AF")L&2,.BJ]<FIM@ZU+*6ND,Q4;QPH3D2++
M2Y7E&=M'(%:+P)&E,B*N+6@3H&,@C:E-%# :%O*J@C$E3:4FE*1],8#CN9L_
M'M>U4OF#+[I[B^YT5YSZ,,LY@M!$*NZ0U9HACH-'5GF)&,YK!8NF\8+I=,7F
M45L]8KGQ&D4^ER:?4QXAA>42"XZ"]!QQ0$ODF*7(22:\I-A;S991P[H8..Z7
M353YK<OA$"NK!-7+A5(MR12S"ES=$:[\A8(:FC-"@D/PKP*X8@G9E#C2UFF?
MG<$^I\495NP73U9T'R!&HXCNTD1WRC1HX%*%9)#W.;+*YYH:3.9:U5A'QXQF
M'#2!.ED>E]DDG.H5ZRO9FK]3Y)WR7R=S=JL6[D\2SQZX*_<6K.GKR9+^Z^3=
M,%>V/(>ZS?.U+$@W%])]G24IDKE$B8R(&.L0MU@@:T(VT%+A/8U>X[2V0=>-
M6E9![UM+SPI91IX8(M3#0U, X/X 8,:H@C6W@CMDO#:@I0#+R>[5# !6>YZB
M=CE@!%\F.W.;/>]=\NMB;3$_&UL>H/^0NK;>Q_ ZZC-_:=O2*;O>F^":*G/'
M W^0LP)SWZE#._@:1SF<OS&,_GA0O'B/88)[;4^JUE_[_4W_W^/.(&Y^LYUN
M7I57_<$>G&5[YVNS'5VIW#[7 ??E0GTYDK0/1@A8&480CYXA36U$ I1Y*H*4
MRINU#467<,"M*'M]VK*[=!M<D=U[EMV95&SNJ \A%Y53<5Q,P5#J4/2.,IT2
M+)=;VY!TD=BA)^CMJQ'U&/3A%L.PD0;]0^ >HXE@W <3>0X.A>43D<D"O8+U
M:9XO3U4Q<XQRF[VP9;O=83M=#W,%XN:"N NE8@S&*NI(4("%1+"V AF-.=*$
M84J3<,*FM0W&+A?=+V["IR+5RZ<H1:H?0ZIGTK D\YR)@&RR'G%#$]()=)!L
M;/<, -LGLK9!99VDNAA.;F8O0Q"&8D*I(W')N'43DA4U;&XTNU!H1A*3JE12
M5R5P\&20#L8BDARV7BEO. ,TXZ6@W=,5X'OE*$6 [T. 9YQ\1DKBDT)"FX0X
M,1(YESRB@003B*$J9X772GZ++>5&-\[1($<UC4ZJCD'QO\>=H\SKGZ/UI%Y^
MG->3=7G=M;T1:%D[9TM3X&LN^+I0D\9%9H*+ @7'..*)YYP/31%EAF./K57.
MKFVP4NCN:4KM_7MPBM0N36JGI,,(E5)0#AF22"Y/B9&57B'OK;>$8"KME4'4
MSSKM^W*7[$?C&^=1U9- :OC_W,%$)7;R<>KN7A,[>1X.5F(G[XAP%XK48&<8
M4THA*GD$A.,&66H<LHR)I#P)S(NU#:+Q"L1.EJCI%:,T1?(?7/*GW(9S9P(&
M44\!)\0QD\AB"QC -!8N."DHG/*,E*CI>EM:KHZ:?M7IV9Y?=M3TK1;RL4.J
MYQ_D0S/G1_<#'AV[;L<W^BG!Q7J?*W.<[Q\>]O.P^O[K>J,'S!F>[ R'Q["/
M(KPZ'"V4<;AZA^'C)15>U\-OUM^P.UF9=MJJ%FXOKULY#^<Z#R_4.M"1^) ,
MSAX%CKB)#&EF-'*26^FP5DRKI?7P*U["VLKRO7H)B]0N16JG+-8Z)UC4!(&F
MRA"7WH+J&G*M$LM<KG^&/5O;$.*R_EK\@C7R"UY@)^>DXR=6TA@=P+1\/JB<
MA:.3QE$7OK&B*L_1:5B;R*6\--GK4+3Q^7#L\RS[4(DF.'8<(CC'4 >KD"9:
M(L$X9Y+&9%/5LZ)&P9;%2;A"Q*-(Z=VE]&2FI#L%&74!62<L@J62R#!G4,)1
M29J8%E'53$I_039"9PC'Z$D>;+Q9L!_JG<_ &+-U8'N?X6J=7B.=V^FNKTO]
M+#2T&E2DAF49P++L]\^-IZ7T[2+8>;IY(0(;2SC>A$-*Y"HMA-E<IDFB:#V7
M3@K"4BE-O5(B^[#<YB8#:1'?>Q+?F7J26H@D!4,Q&(>XR#4H/%:(.BN3X(ZG
MF.IH'JV+L:6.45&SM2;3_ [#6RAL3RP^XC%M+M=$19R#78F*N"/,72BU$ZEE
MQ+N(%"$*6(JE2"M*$5%!@9*G8P@\9[TN2<.K34S4$HTTSU?FEV[!*3)_?S(_
MI39",^^%%DA%"YJ)EPP9E@@*G% ;%9<BJ;4-H99EUJE?.-0-?(O@%:RDW9G4
MF,\6ELQTUL=\)_N-OH&4]$;#*NEL$(>C0<>/@ 'EUTM![1K$OMQ84#N#8?[9
MF2[DV_,US"]L]L+%)V;>^1IFHA\NMQ_PW>.\.CL_?&66>VM'<2>EZ$OFS'R8
M>K$FD$]&P89 D@%[XDE+I)D,*!"J;,1,F!1S46Y-5"G*75#E_JE4@8YZ0\=,
MTAUA 184 __2#G&5 ].]44A0GZ@73EJ5<H^TA76P$IW^6!:HK5MSLO6&BY\[
MO5XV3/53XR3:00GVN1$YG:>"6NXB38I;2BQVF@0JB$V1^9 ^[6; )/2Q:%B!
MQKF@\4(5(^PM\<EJ(%2*(XZI1_DX1 P0DR@CI5,Y2FA=LCHU=BJ!0LN5<$*8
M#CH1G)N(BA0<%YIB&9.*2C(?LX03<Y6$%S%^1#&>Z29/O.(L812I!UDF-"(=
M.099AK\55D:1JAC9"L41/</2BO.0F A/YI)'E1YQ-8&Y7UWPJKE^3+C[WWMC
MZ7-L['K#/,=1) _('C0%.D<,(T%P)T@(5#++*B+WB/:T<@+,=0*\N6@>XRIB
MG)!2&'1<DP(R-AB$DY,BQ20H%6L;8IV+A7OKKIAYK,!@@<$+,&BML Q8+5.2
M<&FT99QHC:5U%"?CZ%B?O6<#8,&Z>;%NQKV: B<^:N2IRT'S3B/KL43$^A!5
MXMI;L[;!,5\5I'O.]KRKJTVT^CU4$>&9^EK >.\04S9??0<&*QCZQ[F,>8VK
M4-QVE$7%ND.]V.SK[QZ'<7DWZSW,#RAA1_:D*FZ?WPI/#H[A]:M2*^;2P)X^
MNWB2!&+ID9A;]J@SLMV='T>@UG=&QZ#M[_;\\6 0P[^.1ZW^Z$,<O;:=4$C#
M7*3A0C4.SU0DWE.4G/*(NY"0D4DCDFR.1.=$A9PMLJR.WBND !44JL^M/6Y
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MVJDRHLK!]<?9J,PP=5!TA$['NHQ:_<$5;H$UY-N=#*T>Z!EXB^B,IA1G9&X
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M=D+(K*("]-?]P1^T+^D@-DYB28"8.>$K5^2R8PKQ1F.S9&^<]]J4T,2AS:&
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M-38)/(1V\\^WI'GVB;:./HF=K?>G.UL'8G_W/=ZCG_#^T<'WUM;?;5C'T<7
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MQJWF3-BZV?VZ@Z)?#.UY19W7BJ$<RD-<<8TL 70$^Q).U#H7.& B>:GU+X_
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ML^]-6AE7+_**P9N'_AAH>];.^-EV15_]!CT9) W>41<M<<0E[HG2U!$LO V
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M@KE@P93>)1+A_P)CSJPTBEE.$KB7-'K+'GBT4<3U8>(Z[388X9S0CB*%$T.
MI@(9[!FB 9.HI<WD*T<8;T!H@U'9^P_:>LP!PW5(4:LD(@:W,LY?YU7$\V'B
M.>T#).TTL>#&4YL,XC:8?%01$2$<G(!HL!"L7MKT+?2NF)Y;^?23U=[T0,HW
M,V_R_O[-_(&<"J(O.C*N=0:^6\U0*:A]!]1>GQHLN4^VG76*V.A0C :,*B[
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MOW?0 -VQV^@=]R\7W3N*H\:SXT4 #>#F%2*$JODRW&T=OI OUH!]LSNC7H3
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M/RV^3^25^Y_-L\UM%[1WH,81)XH@#CH<&4\HTC0J2J755KF%>-8UR-\IX%C
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MG!P1CEOM#;$=8B),LX22IQYQ[F0VAP%BHE;1,&V2QB,%!"P8PVI.73"1.^/
M70(_B0N:K ^:8R5HB"Q8+V9'BE_0X(HTSW]L<NVD^UL7\G23[B^>\</H7*YN
MP^B?F=.^G6PK; DQ/B$?.$=<1H6LDPI1ZZ6E2DI&KG#.\PVCOZ!G#@7WTNQI
M8)Y'?Z735G7FV!F,#ADSVH\."[,JN.6X\*E/!!_0T8^*97K/OG._NBQ7]VYG
M]\MC-KQL]/U.[W[]'A/W.VF\=;%RWLM>XY2>,P$@WBVID]=]LIPSWG:,5H'
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ML12DC<KF^A7YX)!["2#55]XI4%TG+P+#EEL37=#44Z6322%&S(IU])+E?2:
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M!,X/C:_Q1SP\CHT;5CKW>!:LM(I16W"6&)>$Z81)\E%:;'TV9*X;D7$CD9\
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M=PSEW6LX.^C &Z#:J\;AW4Z*XZ6.+CBZ2[7,&PU7;P^.C@<+L5V_M#Y-&:_
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MDM(*Q*DG2!OE\P&?XMJ[H!5=6C%U.N$K@EHS"[4(ZJ-;IZO;2N"4C+)($)W
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M",1YG<+2"GEP6[R[2L?+2*DK*%=0;B'-"0JZ+1#=+N>?T-P$"7.)<) "<2\
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M#_%L9P%LLU@-## %H,R"L JDS;B.\^*4][*K2A7\]N;PJ/S=P*F"7XY56KG
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M6__X^D3 Q#\.?)YJ&0L2 U B##WE/%*,*"XBJ9)(<R71/TY;[E8(;(7 ^H7
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M=9A&/I-@!N\X&B1)'Q9Z4 RKG,*/!ZC2O-/)+XU.,#>NRF&WRPMH!%#CL'"
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M<:!++T!=EVIA\^@;0<LMZ/CFV;ZH)7,?F_6?2FY=T^*K; "]R5O<837F&A]
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M,F!>#IO#! T)CT1$PH#Y*@A\[5-,B1;X&\_!&V$^FOE$CV]&7LO;;QN7H*H
MX=+>JLTP ]B3PXHOQXI\8>48'Q$K5I'B<PIG3YT/RP%>0]IJG56TSJ2NZM7A
M\:GWG2<JCOQ$D5"[&I!CK D/:4I<K0+IIX%,5+#&T@,;5#Q@R\SK!8[-4\XK
M7>2*EV?K9G%WR^*W8?$)L+QZR]JGWWD,W.W%D@0!%81%FI(X""(2 Y>+V <9
MGD0[P-&Q1[T_-I[3-\=EN>D L^*LK8?R><S@%AZ.VT41/TL5]E"^RV7J:HM#
M5U%2DWB=*WCG\KN.1,0C+R;29QR+A;LDH3$E:9@&(N9>Y NZ\YK='8BNQ"A/
MR+?Y@CG_H;R>6\Y?#^<WX.D7[_#TNPII$@648<XGCS#.4L(3UR4QTU1'8( F
M0J_3]_D8O+\6T%H_4O,*LQ><M^ZY9SR#Y]3&YEAN1@]=&VR2;&2LR=L/G[<F
MVN;-8!MT_92"KJ^+N:XSU:S7N/1NRL U?7Z^=7.N=))Q^=V-M9>*1!*=NHJP
MF%*2N%P0SF.7BE0)21%!MMQ@XX_/M[+G6<N>:R]\+!$^=[1OO:7W/K92:*V'
M+7O?DSARI8@8D2P%2S;"^Q\\<HGKA4GJ!E&BO7#G-69+VEX V? +(+<Z6'F:
M</S9F]%W/LY_PBIQT10W6R5N(!RO^'NK"E>Y"GF\-SAJ.G8OOPN7\<BCC,0Z
M1,=NI$D<A3%1/ 3XPMW83^C.:Z\5S]^'W+2@@ZT,>M8R:*-A^58:_9HT.K3N
M 9!(A[1]?O(=0YUX)$(2*3\EC')!$N7&)$B#,)1",J'<.Z/SIQ#^]&^3WO9U
M(YM^,_7X1F2.WNL-LCHJ_O,X*/[M3U,X2KTK\NZ;21KO^433+SBI-/U.&;Z6
M@)X-8@%T[B8D$2H@$8MBD%!NHE2X.4FECTW!7<S^;$I#5I%I)K&Y_N\PNP"1
MU\/2*E4Q&<R%7J=HKRL<3F5>GZ_VXCJ7VI03M<1CZU9@QNHZ!?5,)OB>'CB8
M:*N1=[JN!&=R20_RJ6&>Y1VEBTD=5YN_'8MP*&!M,V M^="6?<P*6_W,%$NQ
M=6),21^!=6\X$#T9WP5IIL)>D//Z5N7&GD!"[#ALQ?36289OW:S)77R[E,CK
MRR2[<JK.^_%BW"Y5Y^)4O>M;C%NE*'B:24T?VL?5X.BJ"8+/OTKZ\Z?6CX2@
M/QN)G9MR/>6T//J5&Q>W)IYG&=$6LH0Q)A*?\H!Y(8NYI\(@U&F0^H&F<N6(
MMCO"J<VJB'LW Z3[[>SD^ <8&H> H#ZZWX[1$(&Q0;\G5W_#LR?TV_$9]'W@
MSAH@,(:S(S0TKO; "/G4:8,A<GA\UFE_A?E]_1*TS^%]F.?)^:?T,'.O)AGI
M8--\L ])JH1'8$=3(E3LD10V6*=>#(@YV7G-[GPZN2KS_*IELJ90G.<D_S[I
M$B"B*5<_A6&1T>\B#U]*Z@)71%2ZP X!DRS17ARG4E,=!V[H<U>Z6Y&W\2*O
M_:8A\K1'N03#AVCA2\+\5!,1*D5X%(6Q[X9)E$: K#8H'N.NH.XN%TPKB5W9
M:3[,0.5#---J-GW9>&CM$?Y;X?#@PN%S0S@D;JRBF$8DT2D(!X])PCV6D)@'
M7+NI&WBI"W@H6B\>6@-WW4FV7.]VW=:4OWU-^7!Y3?D5BKW&.Z_O7HC>K/JV
M$/VV$/T="M'/4<Q2G+-^#EM2A#B\]R+$GX>BU/\=PKJ\O<#%V90CFZ,WM3(]
M!46X=_7M^(0=7GVY;!]_ZAQ>G9U].SX=M??/NNW]3QDH.78$_<X>V1RA(MQO
M=T )7[6/]VC[_9>KH_?O.D?[!^[1^Q.W_?X E.II<-+]*VT??[SZ'L62)W$B
MB9\H3AA7 8EIH''Q(JEH& @:S98==F.M72E2/TI2ID0:<\E"*442XXW9.)@]
MXIDLN&-7?-U%AV\<T".>,C4F/\AGZI+N.I?:GL(8I::QI#I6/ >UCY/C':<<
M]ON=D<-/"ZTQ(4GI7&:#,T<.P<;OXMD//-XO\HM,:6?8QT]+\:W*R]E @D2Z
MGJ< WZ9",Q&+. E#&:2N&XD@Y6G-3*QFIL"-FNCVH/WN%C4FND6/OQK?9(5!
ME$?IWUQ*6*DW>'2F^$!O#*!]<!X<%P('\'MU0(_VOL<ND&^2"!+%,4!4*0&=
MNBPB7AC'5( 1*UUU#42M#NX<W.ZRKA?]YNCO@WU"$^?"+OQTL>D,2 2K10-M
MI%G1A1\N (YU]2Z0GSC'3'% 5]U<92D>*Z*;?962ST^4\T1FCW7[0W@/5LLX
MU[)!@PD'9UFA2)\7@Y%A*]R'(;P) Q^F^+<IK)T7I[R77=EU,T>U"S?$:'A'
M_\S*@7W+Z>E+X'S]$XQ$4ZIX+ ):SE=M"QD/BP*^Z(RJL>%CN%.PG]UAUP':
M()+W).!QQ#+CB>0"@'0U'J"/?ZY0"4*"G214&KA:@;*E- G]V!>A2GW (*&.
MOA\LDA,KE:+Y4 WSS7BY/^DNS] */K03LS;PFWK*6]EQ?!C W][1Q^^IGZ;<
M\R41,:;C58J1.)*,!)&*?3\.9"C ]O"6ACW6PL/8<)::0$  S4RH#SCG+ -.
MXB:PH:]E]9P "N-@O [. #Z>GB&7>4]"3.R->;XSVD61N-<OLHY#XX:DF!82
M3CHL8%D*!PBWI[J5@$&V'O/O>+VLJ/AS[]/^WBZR8#GD]G&[BN8'$$2E?<.L
M9 JRP,AEKBZ0?4TSP*C=3^T]0KW(-TH_1V"/4KN3@4E<#@L0UR; PT@M;,/\
M%P2)A#FC?P 6%GZ$A<-JZ--"RG 0&?9;#@;%3*8%#8)%BHK$C,<P'@YETGNA
MLZZ :57H1(Q6DB=4):EBC'J21X#F71$*RA2+/"^)J:9N#4!H3.H_5A8L!G]\
MT@ \AQK]:^\+V('R0SV#3\T);&4)X)##_1\H2X0/XD+&'H$]HH0E0F!BG(0$
M//%U&+@TE1[($C^\099D/=SSGK;$8.%K7@*M\++,96;D3*5/M?/!:"A_0K.#
M O;(ZLT)_2,!]\\X;+P$Z'N:=9!-')W"4RB@!-(TDC6V.,@'T(SE,T33\ CR
M#^\#;/X)=#+0G8>EV?B7:?:0_S3Z[Y(7$ZV7O&Q*98>7WZ67NB'W/2*T9F##
MID"ID>0D84G"N1N$89+NO*:M96E<A*74&6VUNEOT>I_I[7R#>"_AX33B8A_,
MP4!W':_E'.ZU]]Z_/7S;/C89&J,_/CO[!Y_??/G\^>"H[>RU]^%_>_\Y^7SP
MV3EZY[P[:.^UWQSL_0? ;7O_X+A^YM/;SU_^<VP>.?KP]M,>_O!Y0X"!:?%6
MQ9;,PISD0Z<\,[&3H!:MDIY$D*JL!+O<Q%>B@.* *$9E-K;!TJP'8JJRLRSD
M,,\5NAQV!O:QOBXJ8#[(3[7!&$8TXOO#'@?UC=)RTE+6LZ)DTI;%;3W0;F4%
M!PQL06.E=-[!PPYUR4?S,#8*0S%G#GRZW7( 7UB-/M^L>=>,;?% H#=L>J_7
M0VOHDS8B%[ZO>_^_<<#J2'/ 3#T<XKX&H".@S3ITML:9EX"-TJS35!*?W[XQ
M[6E1#'DQ<KS00C7G-_P5:=5S_S#AM^,NS9?TC]];SF<L9PMK;0W?R:B1U<',
M:*S6TOTLG%(/<!(P'MTI]>491OG.+7(3CS5[,O. 7>]7EC4N5A]4F%W9$NS(
M@3X=C4U%,2QA6&59-Z>--D0=0#IY_L/ M\EV#<XXPC8PX,&V+;+RAVUU" JR
MP/GA:6/+V8-O*\(SR)+WH#^0B7E1-D<].,M!&U<_-"8-4_T 9J]S<+#K&&%!
M]QSB?(+>G'?5PPM6 R=3F<@US4O#2RI+4]AYU,6H[4$?CP.EZP=AUK+(A-T=
M6)BLV^]D&. \JIAPZ8+,[.LM&';#K);%,OKH0A<7F;[<K+$N%IN5NX([(@,!
M(L]ZT.^I<5KTD?#ZL %:&SL$.BUU[Q2( ;">\QLBOM]QTPK>U\-!)BTQ5SX3
MX_Q$^V2 ;?=@K*>Z5PE0P^$ FLJ*[8 9NEIEX]> ?HK\P@3&@P%U83UE?7C0
M.EBPX\8+.'J@P.RT9RTTE16&=^%ED:M1I1V!UG2G4[MDU5"B3$"O$'P[[/!B
M%UKL"A@46&I&AL#84:K"PP.=]2K>-4XIWIPT/MPO$ R:>0B89)H-)N)P8HQ9
M#Q;P#+*W*')044;*%,.NO690&F.NY1Q9D3/ U0$!DW54Z50R$.!./BQKV],P
MLC 9H R+]"W;F?4I):R6A,DHC4L(@GBRN;OS1N9NY:C&?1Z6U36(/@?PE0U&
M9M'0.C9RM,\+$ .Z@T(J!_DW !KI:R0LG ;NM(+EZ.1]8Z3*VHM<MBR>J^BM
M>J8R!):0$$I9$,[&.AF6XR4"*=CM#GLYR7NRFE!AVAS_SH>#W#PS^=*T+$$.
M9?D%+_&"1]%L$/1<7YMP0?3H]]1$M5<RWYQU=3I<X+$?"-&6\R2X&V91J?R:
MI(S/I%K^"5%DNB)QW;.W6<[TU#Y6+HX&W^'F*"0M]$ AZ=7N9^?KF>YA)QDN
M9Y:.%O1RB:P"U'JA*S53=5N)BB(?]J==&3.=F]TQ04&JXF=0?R!LA@7NYJ6Y
MQ-.Q7=G&> T]ZHW9#-#:S15'%FM5&,BYY^%=3RQG6;7SL*2G!>_:=0;ZX4X]
M4! ;L)^\   \WOT)&\&[H^IN5)G!"+EU#$P1P"*19+Z>]WS!,"0J'2.VN3PS
M]+)DUZUW[)J!7X(AZ8"5GU>:"*',]%!KKX51@- 2(ML9R&55#?:/1S@&* +)
M:S/SB<<5?L/'"Y :P#SVQVK-!EF)<C0U:L.H%GP-M0+PSJY3\E0/K  :Y!T8
M926!3W,8^6[3MV+D)3 &M-+'&"-<@0_+9Y^GP$E6?\F\&+N0)PH?X>@NJ)M!
M\U[:J);[LUMM?VPT"AAVTBQ B7&;YD#$]FO0 &B][&<]KLQN+>J'7[S*-A7X
MS=Q6,!O[37W\[I%"D@Q7A_<M<ZX+5IE:'WQEYS52S-FH@UX6.=:U?VQ7>'TK
M7(Y*L'!@=<<PTH /@)I..2Q ONDIT+-=^S6NO3E4+;9T?1]K:RRFP; +$+@S
MB\&W"[W&A>[DH-JA!?3NU7;SQ8S00)FR7?-[$-I3?H&I-=\PY]-2AXZ!6]8G
M8A"7,?\6:7WKU%Q-6S6Q&Z95@+8KTPH0H&[\6IDT+>>@5P4JS#RPV[2O1TYF
MG3^]"UVBE[09[[/8H^ ,#<RVKDLY[ XM^LQZ/3#QK:<>W8H-OT>U$&A4P$\E
MKEHY=K<#"A^?;)H5J#\@KB^,.\4Z9^!SQWH!1LW%J.,PJX +#H WJS Z^F/!
MG+5^FWK,XXEC6!">'L(FVZ/\B35=GT\L,X3G*?+EAO]'R\/_MY'\&QH#_\(B
M^3?JE.+/ZNS*^5_XLF-DX8;HMZ5.M,43.<QAVWI\$K=913!OR&RNE5I'O<GI
M:A75YEJ'T9?6YY;S;G\/G=EG>6'0H/$R=74!F%".''325(>ERY8 %2#&REYD
M:HBA.C0VY[KF1 5+_N$Q)N8IFGAIC(<,-*$&-:'&?5MEM#1 UAP)GFG>&9QA
MLZ#C[.'$&][CBN\Z!V7!=<?.Z^T0/5:PTE]ZQN5EYMHS9^?_!ZI1Y=U=Y_-E
M-K@"5@0U#!_@6][/,8;N(Q_@4<TQSRYYS[K#;&!2ULGZ?:1F^^7XB/)K7G24
M\[]V9$>-:-^6,PDMG)YE.1.^:X-_"XT'>N: TYRN2XRV*^J O>JD\YK>8'GQ
M&-DB'(SH'EA=7^2=CCD4'8IN9H\[\3 (YEG%=T[H %>?.W\:WQKBL/^8V$+M
M[#7@PM(=@H$?\I$YB7]2*'8JN'/)A8OQ*KW/+X +#$HTP%9CI:Y.M6.GXQ]M
M:C"\E=&@O<\# RGKZ(>JJR4A^E4HYF0<2#(-M_(D,M]P4M^BORE>PLW$,+<+
M&&#=*3(T#EQEI4TL5A^6PF]3K&9/WSOZ N-5P41$Y(MHM.IB,,+]UER>.>?#
M(BL!+%HJ_&)H>4'4L#V40X@YZ-ACU&$?>H+6E390\)KH>+M4N_5-!9A_@2H5
M T<X!@>DNBB,)6LBYDQ\PVPNMCKD7\V&_D6MP!&36,79QA;%+S9V[[:$,D<@
MX_@6/#,0VDSHM&=$,$RI[OP2S[GJ#]4C-EP%M@"C)1I)W+IZ\#1.#-]5M)AF
M!9AA_QV"Z0)K QLVWJ;J^$;/;E8<UXGI;KC?TA1LI],[,=TB93,M8D#._%[9
M**CQ#OV3MJ(FT=0G127OZ"=R;'M01\-@+/O,)KC7;@*-[K0)*-CL%8$JT-YK
M\&=E8D._T-'2 ?C>S A..[FP\?N3D[29=^9&?7L2"6;>G(QK$;%8\6EO Q#3
M>B4JY!G/K)HNS(T6<_VJX/*'.9^R;5K1HC%"T %;\'9#!FB@4<2D8_U;!3G9
M "G>LV-LMM=T?)BF)VW\->P\(25^5-_7\)(&&?%>+\>0-]6<J'7[5&%R.8:U
MX<%GC9+JJP[J!KT\V=[\TL:-H>NE9\AA^FBYZL <FV)("F@^F?6K_DH]-1ZC
M!>HAF-8M29MK-"9.1J+*K;5X@\/LK4]_+(W,=N(!.,::F%B;?G7-KYO]!$4Q
MN$1=@9_G9L9M2%.%2PV]_+]_T)C^<6J/HCOH(K-3KGU%L$Y(9\6T)+C@H)F0
M,/.\1*G2\*>9M[4"<%HTG(3-2T4-9%/?LVG"CQK0&#YMPAT#F&:6=?:24F//
MN4W%83QE@(:+H0'(F,U5ZMF-Q!W_3]Z[XN-(KX;U0.Q=RJIIC'QRNNB$')SQ
MWE0?&!E3)7W=Q9!6.X<4,$UY9C'9=8. S?F47V23$?0YYE>=[1M(";VJ>*'(
M"=Q_-6AJ;I+08F73C1N=D&P=+6EDC8FVP7"]#OIN=RM^6;[,E8%GPDO1R]J;
M# ,^5@$(-DL9#*O@E^/8S[*Q)HT(C&%9!=Y54G)RW]'>5"WKS8<UUI*7UD<[
MOKMD8VQKQ-:@,1MK9FBMKPL3*X@K \(07YB)%+%L/@W<"LP4# T6O(N!9@2X
M<1S49BRW095[%X5%8W5KL_(L*RKJ  W<R=)L3HK N$J$GYV6LT36X6(W!-[T
M8E?NZ'.[-Q/1ME  H'@QZL.XEZVDB)M: [72M*39%"6Q)G^.\Z;VR'^N+LMM
MR/RNO\+8 REO8_@K)X(Y"3@?UGF@I>$#O&98!<PAG2& <!+87OLKO#)>C8KY
M%]_&FKZ,-68'A#48QHW\7];T]=9<.K2""3JPY#NFW@E8,V.AS;$8RWI"H[N5
MH=>,Y,;HIAS6>->:7MR<6?!>!7Z(C>^;QG(AR.;>X P8$#WS3;2%U-P:DX%.
M\:Z[1"D%;&\"LRYSF*/^438"R&=>MWZ:YLWZ>E?F]\)"0'.B4X(I/KXI"@L$
MJVO?FPH,.S6A3855*PE(]O$0^2FV!,@5Y-'<5EK39?KE8,'+U7+/O6_=$).=
MQ".TO'>:&Y5DC"*\WJ$GUU@J;-LO0%1WLQXO1D_#'CH>T[OW;]\Y!M'7F/34
M[5MS;IB#H2>M\CN%05"/@(%A_9[(9F-E":@:_6_5;=J)2MWKC=,N-"\*^;N>
M'QA58[ BME_ ,N==8W9ZKVC=R,P RS.#]OE8E(\W& \ L>4D_)=1OKK(>_K4
M'O9/]7-YUG3*#@#M@1Z%O48U<J[E&&)-QCN^7T2]BG#&W )FM>*C)IM98W\Q
MF[S9?V-Y.ZO=41/R^W,2*H@=HOR2>CRKB<0J*R ZO3N[59PYQA5..L"'\50"
M76"]4W-_^XSWQNBZ%GM-^67)VU[EF5_DFHN +M'[584PVN6JA)(:%A/_Z41"
MU?=DYH@![ST!*9A57"IQ6@VRQ!<F_D&# FU\)U!A-1)^;CUW]IS81%N::P6E
MK5. HT>G81>5(RZPH1=X#J.'G7:.Q&.BY"L$!\.0H$7+A@^JH5ZJH,NJ:S $
MQNEI<]#1QB%J8E"FAV*F,28XIX3G,*] [[IFQM$%,Y-:*..G>=G,^TQSQ>69
M!E0.6W0ZA#^Z(]XYS;@]I#\#P-/(NF'/X,UNY"9@'Y&D<:<OYDUCJ=@+8I,;
M1V5]#:RR;&"T(A^"$&^<P\^E%VC806 _8%[(%>'7RSVYC[<G]QLPENW)_2UR
M\#T.XOF_3%T#>&QYF=IMT\_[=?4:@WYJ5$THK3 0*+#)\::%0""NC RUC@(4
M:?9[)]R- K<ZVATU>VFBDR9V0H%JCWWMF9U1H(#/32ZF72OE,0-=-40S(Q,B
M9BZM@MUACJT:S=M9>-78H46##@PFH/6W>"FE@D<&%*$-#2;!Q#%6.K\%$X=9
M7C3]9[\#X$,S/;MI#/;B@K%0IH9QW2B &O7T.+R@[GC7:8R)5T[EQJ 0A:+G
MI=L 'M6!%&K,8>W148!EBRYB'FOMF>[J)XUWIIZ:9R%7O\.E%CDQB;%01RK<
M>*!6W!$T&1KGCG:#-L1(N+TC@0; 1'];5R?Y#$2-^=&</RN?YSBWW:9$O-SD
M1I]<IV<S/O3Z.AT>GDX,FYDT9^FLEZ!VZ8U/=2NO,"GKI:IA]-@]O#L1.BT_
M ":I<;6Y];_WZ3-YD_]-O+%_^4?/^.!+Y\\6Q1><WZR5T4"AE=SXI/OHB)4X
MSL^ L\Z<O11D#/^]\L09/QT0?STDG*H!M.59UN^/,V$Y;5X=)AS L++!<&"M
MY2H>X[?VP?_^7@516,E*9U?%!FYVJ@A83-,TN<4.;X\]L?,=&?\),%)Q:B'E
MP>36ZO[X8F\-4HU3L'$!ECM=-%]L3;-YOWQSX3U*:Y\.;+8P,;P37?#;K,NX
M$3HT/D>H'1)X@7A0F'P2!7YE5WMJCXV]YF"0;6=\K+$IHN"&\U-KL!G@/SX3
MJO3IM%5NR&L\R6#F5&5*U38]:V9Y3D'2]ZP[O]XU<[]<___MO6ESVTB6-OI7
M$-6>N=*\)(N;-OOV1,BR7:6WRV6/[:Z>.U\F0#!)H@P";"R2V;_^GB4W@ !%
M:B-(82*FVB+!1"XGSWZ><X,G#\*5]TQF)9LL+!/."D6&9^#_BUTVJ8\EZTZ*
MZ0.ZN##19V9N64O?*CRTSQVX72J2J.X?7GJV 5M.V<U[&[O_\@.4,WKR*TOF
MBTY> ,8#T)3%1-,&/H+-&=4(+56E.79F<!PB7K? ),=!U'I6I\]"UETS2^=K
M1=FD*N+,&>E^+(U--:"V:(E=V'K"VM,G\]08]828$*M6@(S.$8V @,EE<[>U
MJ_VFFGJT^TX1+IVU]'](O#C.2,]3-FIOP$PRCF:B D)^5K2B27.A=9.W1+L+
M]^16YW+TY0ZT8#W WO-GDV=EP#6!WX+JQBGWXZH+6"#+5:&6V&1)C1BQ)D"I
M%YSD0*+*GB<Q(0G?FBAPB_(WZRRE_&H4[UZ +HA* .Z?JG@FT=&6LL,\2*C#
M',8BK FLJ> 0,:R 2K=DEA@O0?( ="UJ+SQ-)C\1+X@2.>KJ])VIN[""X"L;
MUG$^Y%QE^:'I_:WR72'GM[E>=IR\*,9T\ YQ! H\I69$7A[\^IM8.G_G"(-6
MSCX18W]G%<$8!79+_WUI@1AY2O+E8>?/4!Q6O@'/6AQ6-H5"<=B0"^6N/OZA
MK]<1D^[I\.SX]4X1&SYE\8IBYRT1?7SJ!L "XBPA.!N<O#5I9/PF&L&*)"4A
MHX$+3R5YQ0\T*:5TBM #%9-O^6U$ ATD8$+.XM3$#%3=& 8!/O[Q&O2/&R%'
MIA&TMSP;42<TUL((\(8X@X3B:8^PV8&S ))TYYQ9 /;-#\[9#'G$_("3+ C@
MW,(ILJ[\*--@Z44*<^&M<S1]"[K/VTCA]*AW4$3N+6=-(-Y1JJPDW$/*WD;-
MWAFY,?#@V!$+X)(B(%PV7C3G#TR)%WE4:2;-$]1\5$P 3@$/P<8M4K!$F"/
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MD+,%5_4KT] &#6Q!V3>4HUH.L<AF?K*Z'07G17Y#"ON1\^:YF - 328BTR'
M->^D>;G?==\8=I8I7Z%5^R?S7[Y9)?<JZ=4=8Y_5A*&#*#]+BBY=XL13 >T2
MN0@I(XS'SGH1>_D0 +-DX>C!48DWI*FVK=8F\)0"H2\X+RE18Q$(>W>1>0)K
MI^XJZFL94\US,#M3BMP,>F)R.@2 ,I\+.V5Q#1R5 AC)$#M?%RIK9ZC-5JUY
M4&W2.F(@WKH!7U63YC8.,F8D%D .<X:.-\Q>SXE -VTN;T]LY9TPLU8N7P[%
M%Q[\+(,;AG \[@*DYSR2#KG9Q\]_'!=2X-GQ6IDMJJ&B5O=#48!RVC9<^UFX
M]OM%@L[']ELWCI6G]?W;54]K[_RB%IY6F$>YIQ4FK7ICD:_5I$_('BVD*,$*
MN0$$=R@ZFBX&)\"%IV_A_Q=#H/GIKYP@\!NIC#!HQ_FJ [0,H%*>U<**:&%\
M'>?#:4M4"6Q<H1.Y_=@)53NG7.H%)7;@=;%!LB23DKD.;&KJ.CZ\]:&LXBM>
MPX+=3YNH@B-WJEZT"=NK7O"2YA(_4P0%K%R@#ZP8]4@@@.KU^5)I7H.+_JZ3
MKKYI#Y5=(:2#G>/(W(AUHD,OA^VLE""V#8J0":13F+.X)Y1>\?FR+!I2R"O*
M"?.J_C)\FV@ZC+O"S=980.-K/E^VF%5AIZV6$_@3T4;%$08.J7^8'\ZP%AEK
M3T"VCM#!@YX4Q &,M0>% /P\76P_]]/(FT7AF#8%).=R+M1:EP%([DOLV#6*
M?BP#-^'&;)^OKD![267@UT?(F D.F516P54P!7N_:7$:S,%^2LXI%N1QXW)?
M_J%!3-5>N2_(N4P 4!9^..\D$+OR6'V*%YC\\0X!?^SO=-(2@;YN\J"&4KU"
MR!U&#]5!]DNEA3"-?%"MS*D#$K8LAAE_0!?%-X(Y&ULO4&P/R8'6B1T=:?4$
M8Q!&Z,CA'Q2"^KV?5:X5L^1N3LNG@-8BQ6;*K(DK.D"?(VGV2'58O!3*W#:"
M1O\N3"4:E]V-,B"K,*%NH89:6U((T:U70#[ZYBF((-P.GXH@+>2#,N.'TP)4
M]@J/HU![JGL$Z)9+CY9PUV3FKA<8J+K__/GZC\&*)G,RV+&:9T1%KZMPK9*"
M;!A1M#8?DRV("Y.W>")1$52XF*')2.(P. UQ60V\H1IR20>TF0XF[ZI(=7$Z
M_,[5T#1?R%N#_*8&</6$MJ\DJ1/5[Y6:]"O9L=R$!]%3J-_G4ED]OU[_<6P4
M^J'ECSDY&];:/X4$9I6Q<#\[91?!LDSR[9 5$I9&JL()+P \9<")=7>1D$W_
M@G+$KA\JD0%2S_G389AVSXZE'(U^OQS).DD?M3WJ4\RB@U4^TR$T!T=\C5(D
M5$6CE]?OOFHL*ZY4)*/IZ/KRC^MC'8A[JT (/Z*_?NPZOY#+Z -:5#S^T=N/
MOWR@ KZ\ F@G?@W9"X4@/1@5X#>Q#P2=?]+$ A51BKR9*1:3?9=EAC]1D/)1
MR3U7W^5JS?'M4Q'/Z>2YZZ'"HY(MHR:11YU;**3$F;[JG2U#I2VSQTJ%7;?'
MFQ3_TAQ4GVZS&-J4=N"CG@%J):D>O#)2?BRLA()K:%&JW;/3U"I*6[F #_0+
MO;CLFD&WR:ZIP5R:[)KMLFL:%6:]"O.[OW!G2F.1U:"]7>? KM=.C&L_U1 .
M)?Y;$DAF=0@[_*\H"B/JO4;K!34C3"1,+@PE51...X5H("<M]@#/)7[ )(K&
MY %1*4ZRSSW]LIU&;2G4>5SV!7#+<XJTN"8?%(1UR%V5C<]CXE)P#=8(,@UA
M< N!-2V*O:AM-!XC?"UP#*79?!&)H!X/5R0ZV(^@(_>Z"4IE>,44Q_=.E,!L
M:9W$@'5+I4?I()3X$<4YX([[@5P^^I<O5W[W&OE=@[DT\OMY =ZVA+TF( ]_
M0=E9#T$J&+G>=RR^"\=MN9@)_=^;9PV0:*@';X;(8YCMR,U"50>#A5PJM349
MYERPRNYO<1&A:O^4;RW:Z[]A7Q9%3\B?E>LNBNUY.+=A!.\1-X)1LLAACX76
M;&6;[J#4K;Z5:\Z!(T^BZHZ?()4TOO8J^BB#\/M3G4BAY%MFH%_6=?+<2):4
ML7A_/G62V ->&8=N&^5F=S#H_>^TW_ES,?W) 8.XZJN"@.KU%C_>S,&$QV8&
M+'ZPD?"-B*FOJ7PO38&_EMSXK-]=_$"^O=U:\F^Z>'QU^7PSP/;1"',>.?/F
MM?/+UW<]M^7\@M5-F)>3 !60QU:&=S UU>FY;YQ?SWZ_:-%_5S-CWCC7OV$6
M"GF" I%]1X7F-7Z('79\ZU,@:WIVD/^X/Z"/!Z>[5([__2\7P[.G,2,V.QJS
M)V^<3_\][/Z&Z/+!F(X _W: ($%#?.-\?M?^#;1%R4@P\YD2P-O\?;OWQOGC
M_2\?VI<M.*#$HR .**:1JC0&MG,+JBTBZ$7QO_^E=]I]<_D$2N0N(M>H8(TQ
M W;BC#C7"MOP8!X'R7MNJ4RLR6*-/N:730(N294A,,7'<XP[S],5'V=;8HS=
M01(9;=99)7-$ B"[AUXJD_[Q!:4#^RIQ7D8M)OX4,]B Q4>WU<V0M^&2@VHN
M.2CEDOWA8W')2D;XIDJ3WS5'W;*;HS$=&4O5= *W6PS-,;(O>^VQ.$Y>WS.8
M^O),K7YC:M5@+HVIU;A*'SLI;K8,L$;.-&;;/?;8HFQ:.@/&BISIJ%LJ0LN\
M0RD 9,_,?[7?;S&N1LD.-HXCAG+QZ078F'/7(V6EI54#S#I5:(>ZWI^^UF5T
MY;Y'V%E2XPOY).<GO>-6K@[J2)<RP1?K,LM_QFJA0@T!6PX#YPAS5U9RE#%Y
MI>7\C_]]I=3B_ *_J<C<9?SU8N\PY5T_&QR;O#75*4CM@16\Q.VK?K7)LBO9
M"T2Q@+U8EY,CH]JQ]YV@Z!G*G(&0<W/AXI-</\R2%_;.^L?%?KWD!:??L'M=
M)?QRC:B$R:;<P$]E722M[9+9E%[LCUCU'</Y^@$V!+G!C)I;U6144W\Q+0"4
M&&ICATHOPUS+1NGJ&I S8_#FUU[W]_/B%(;#KCS2F?\]"Z=9N%PYE,'Y^;$<
M@RLF&$AN?!>5JZY0+6>$O4VH3C:5TU<I/GE?/_9 L5J;(CHE/85(V13/_Z0<
M)HM8M$WFG4KCL)3[.S@'91]ANG9)1K_)X6^5U5YL5I!4$7NBYS!_I#)WILEO
M>J8*/%U[+KR8,.TIFH408 I=TDZ[W*TL5"R52[.VFWE5Y9VZ*-+RY<NEA]1W
M2DI6>E97 *LX9(YKV+1^,1RB* -#Z >\AS_L]LZ'#)#ON3%P>)._#2R"'"KR
MP=.+\YY$TL_22!9PS 2FX:8^2VGT8*FG^X/5I_7(O*SM)DYYS-@$8(7!H6\#
MF%22[V_%7>^H7Z?:-:K"75U]V3I+ET/>7DN[R0,^FP-MDH"?"YX7@:"-%-YM
M#H%J1J8)Q&KV@)&*,H'HY1=@I9&3HDV-9C$SD9I4VH_JC 0BSR$(J<V3$UD)
MD_F,5&2ELN+:H% 7M#$*O=L=#Q4&('VM^1.F\YD*6%H?H4ZI!4FI?')ZUI,E
M)7_[<OE5MY?@83AK$WBHF33<6)XN53%49@U(I5;G0.)[]EAF[]4EO,:JB!1,
M'ZP;E,F>4<AF63T$-->Z6\(S3YMVBKQ5PUN@7XH\2''0'_9.T?QP\WG%J"1[
M6)ZBG>A$H][,#1"=FL6[.[Z!FRR;4M@O,'DY\"RL1<0V9CY<LG]FU&@38Z)
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M:(]IANVOF6#&Q'D&[G<D NM\1M(\!L4TCI?X)3#43%A'L;)[.IM$EG.,41,
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MMX7K&!@0\R;ID'&5VXZ'DHL%2;X%NG.]-PUW:P.:V6C!+VWCNH]QV0YQ;U8
MYQN*VF#7_FT;9O7H3:JJJIDOBL7,.\%IZK+-0D&%@AY^GTY%CT9\]VZ%U$RR
MUI-\S+Y*_6%Y7Z7BK:I5HZ7/$@]9!O(>TJ;O0)ND[%.;D];9UFU_Z]<1LZ&Y
M?:(YRLSHOVFHKJ&ZAM/=M_?O]AK'KDR<3<\'_OL49L[^*EJ_V( RE7;S@79.
MO6B:V];\B)H#JOD!]2ZZAW-$#_-OU5#>#<].'BKP#LVS<)4K)WV(X-M4 Z_A
MI=WVSM981SW,$]I6[C4'],P'='HX!W1X5MZ#A=[A![.^45^1HO@KCVAMH+E6
MACCV\6[W6A>#L_MIM9OM0UWTW9=VL.?-H1[>H<)M[5^\A(,]..NT/^SU!D]B
MGAZ2I/ZD>W^]EW6L#\E >0*EL!GCB<=X\4&**]F.E-#/7ER08MN 8HT=K(=Y
M1/?+-6B.J;E)C3+XB*'Y0XM4?*E 7'IAP8IAMW<XOM;#/*)>[Z0YHGH?4?^\
MB5C45_CUAQ=-7EIN1S8 PG]AAN#9/4,2==1>#_.$^DVV6LU/Z*2Q &LL!/N]
M)ABP4=@^TB&!\B8\]]%I-RYDWI.K?GIV3[-QFXKN6FC#+_!P>X-M([[-X>[-
MX9X,^B_D< _.CAV</S2>OT;AHCGLE1%[S1T4J+F"[.=0@G;WF D\>WKE>ZW^
MZ;;^J6VWHBYZ^PL\WJ/>H'?<'.SA'6RO-;AX[$S9NA[OP=G;1[WNZ>EQ8W+?
M*<37-"%[(=&CIARIY@>T;69[<T#/S6R'FRM -3Z<@[-8CTZZ#Q6!!V6RKFFU
M^#)"1* 5;6VJU%%=/=33:0ZGOH=S<1"'<W"&WL53IM;NGXC+>V5' AOFJF:W
MJ?OCGA4F!QJ,0<_L/=%":N/A:6)M:^1I?WO#I#G8^A]LKS4XOZ?79N^.]_",
MTEZO]V#/[ ,Q3':Q[L]QQ,U0J2?6@T7R_FK26Z>WU%B=/LP3:FH^]^*8#NDB
M'9Q=^J0EG_MGE_XN5(Q1VJ;W5-QD-\<!;,0XRK!UHYK[PY3<_4>2?\0-JC?;
M ZN]_[#TYT?8HQV;!\UM:6[+TSM!FGO2W).7<D]ZK<'PGH7^!W-;#MGIU#T_
M*7,Z_4RMO/^S)FW9J_K)EP#9[GJJ%1WD;>1=5/ACX6*S^-'2>=7K7#@C;OC>
M(A]8.A/P_]AO>1Y1OV61[[?,[8;!9EBX,7R>1O2+Q 4;0G:3]T/J1-QRQO V
M^%Z],,%O%K+-'@&K48G]U.X'TW$*??B<6S?!69ZI66XQ22I_X!=%$R?*8N?J
MTQ_7[]J]"^?&]3S8IX[S8=/16LZM<,8B\.$&P9?N E;RPY^[J0B6SOFY,Y?3
M&T>X4KDM?^]\[3C3"'X2(HX.0PKD?MD;KOXRHHP8\[.DX_P#W@WL*8Q29^;>
MB,(V9F'J!\X[X8GY"'Z)N]]Q<GUVBJ=^T=6O?>1#G[M^".L:Q[!1(;X,Z%V]
M')]2$Z+#>7OYY=TE?!3 9M"P>$CS+[]?MGO]LX$Z)1N*J./4Z\:5,X=/=Y3+
M[FS6-.)K'_B![VW .<IA$&NQ\>43AGLR$E-XK^<N:)7_PD,HN_I BT"(:10O
M@:Z3E)A3[@:U\!,O"D/A4>..6S]%8"SG_=\OF7CQ"GQX=]FB6SVBNY4MX$%\
M&QZ[EW+'CW3FIO@PT#^_Z3;* OB% ,+W\)*CL,/K%V73&5ZRN8@]'^?.OZ_D
M79_AYL7J,NH%K_U1<=4M)\F\F9H7<#::4XR7'_AN7($'IJD:MPA?KIF E\7
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M2.LV#H@<T;2):/*4T&,],W#CJ2@Y>D.8QDC5)V23,N[@3+AC+P+;?$]U@ T
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MYY4@G!X7#GE,!RV#/IHT6%PR>5B(,/!O5J[]^2B+$RE:1TM)Y:[A'?#4J_Y
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MUD:KW<ZS(D]I=,N+(_=U4)JPR;(X(E&,PL+S%_@6-Q=TO&LVUU6[="O4CU1
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MX9'+=2?\$1:?T$<R[>'.,F\,8H^C1<H-,_4+OLJ.5X-N7P_EQB,W%$G[TX]
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M!F?GCVF[/P,PP.,ZF>K$$XB0/WYZ]_[+[Y<MY_KWJTYUPEA!">X-G]#GNP\
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M^\%HCW+=1$ M9!VBEFV$G*"&?'+H5T'P.('SA;)'>UV:FEH?SIK-\SWKP]'
M;Y;8:#SH_O>7P7VO_S3J_\_7N_&_]J<-&;C5LC]O-B^VD7V<T-^03^HH9)4@
MWFG^YQ%2B_^BV;S<E_B/<UYAI3NC+[?W@^_[7/LCE&H17S:;5UM9=\"/)($:
M";)''(/3I<#&IJ#)-YY#;>(XA<6V$8%"2"VMJ6E^DH(ZAL4<CQ/Q8X4*L2D"
M9"C$=I2(TS%-20);=_:4\85DLT=<3*W=I:5$KI*DWH1_RD@2WJZ(H1@U]&M
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MVHNB[*5U*B3*A(Q^V4YGO3:)I8XIFNRAW3IE4Q"=V@Q>0;A26&9U3^IDC_A
M7KWK= P8ERW.#Y5"JA3F65-OI;;[%,(,:*"0R%&FT>C$+IH#GX#9LI5T0J)?
M7X&%/0M]6ZIJK=#T5FH'4*$5\;OJ)%V_<> 0Q1Y(5H[*DQ9C]M-@.WT_FE*(
MA%HM6GHKM6.H4(N-KP*BM92_?PGI&+^6*J1>P2C=W#-PIU)K<W#MJ02OYT"7
M+Z!.@:HGAJZW,DX*K(:]EIK>Q]R&4-A9$CZ:8U[\7JL4H%KGS[1TQ5*( @$.
M))'4>.!+AG,;P)6!W-EY.YT;3PNACB'<^G"*HZ\&>$8]:GG^G5'WS(G>=ESP
MI":>/#[OLI@7-V?6-MG2]Z&NMH87>BNU<9RA"PUY"MB07F+ CBS*%@S%FL5Y
M$EFTN$,9L'4TKS!0,6G%[I+NOQJ69Q)37/S57;'-IDD%& 9(=E6OO3*AUK)+
MO9W:,\W4LD0$$K]F.V3+OQ4MQIBXQ2*ED<.5$:NAMHV\B4/^]* #_>=21P52
M@.K%_$I+UYZN4" ?1XW'O?SE^MGPRKEUWM3;&5\*69/"?_H\^/WTU;G&RR6U
MITP\\7_;-O-YEX_@";'\K]@):8FOU_\1WG(3Y,H>R&)"^ G"$T<^_GCB<G')
MJXT71.R+93:VJ26O>0H;BP_=TVNP:I29@L./)Z;'@VT3!P3C4M<3OSYSYBT_
MGOC-J4L6)\B5S6UFV][BVF0+3.T[>"&PG)QN[ 18.T=\ 4Q<^?/P]-CIBFHO
M_@T;AOA*V+#[+;'QW;'-8*.K,^-$HOI.W?D#X<8/83.7T*#'Y@M8'_A2/2 _
M@7#E@]L%;1-?I!P1_@S<YZG(AM:5=^/1$XP,ICTBO@LCC]4-.9MQO(AW98HM
M)^J+"F3O_0F>V"Z9$5Z@/Z&#G,R0=3@7%V**IC=OJR9!'5;G!7,SF+P#SY57
M=X$'\IW0V1S<A\XSX7A&Y$77/>R2Z&J>C2/T<YG('W-J"W1N414"_0E]P0(C
M'APBN 7_2W+G/.!74>LF.[1QB'*@RNB1_V[B%[-^/#$X,6G1OOI/P+6$59"_
M%>CMP[@[8IZP3JKIOMZJ\FE^3QR'D %0Q**T098AAO.X_^J*;RPQ>RCY<3;*
MK!R2?:ME64N0TK G(@8+&+_UY-3JXB4VJ/M67$<W8RC1V9^JKGV0C@GA45#>
MJE3:[+:5J^YX#OJV)(#4 $= G 2?OUG /#6";YWD=*LX?.5=?0*O&G-C+AR>
MU>(:6S="3W/,8)J)<OU;QN5Q+_'QMP4X3!1;#]02!5+@:(4F=2$^9*70\O<D
M>J@3XY'9AG^J->M"3K5&%8.M7)LB0PV2]6^@(G)JAZ<[WU;]V*@<I7 <JJS'
MQ);7_8KONM%GXL2N0>_F]+\(Z/;=-LGD_7H='.:5,U6LSO#,^LQ@:091AF%(
M7O=+X3A4\7<]L$Q@IWIDR1R:MUQL:EWY=$YY(Z'KM99^Z+\*DPR!17&_)A]3
MU<Y<R)E(#(02DK<1](A8P@6W/4_<2NJ[GQN[7AK/P08B/8IG-G,*NT&;VU>N
MV;F+3)Z9*H[@4&V43';EQ)3Q)I7++"L6C(9[S&[($%.S,X4EXU_@7=XRCY<*
M*_-0':H<_=CI;K$4^TYW8-XXN,5/V-V<*U) [%_(?F9'.#.[IX\+69UR."K7
MZD?&7\"]><".@XVY!^M"7@=5$)5W)W#?'K#M3<65_6)AR_/UUAH?ZD0KFF*=
M["'%^L0L"V+>]7QF7 TJ8^>=$NZB%MB>%<O.W  +L/ ^$(O:)OX,K#I@I.%/
M02<W-U,(NO*9M*J.EB4(G?@WR5<%VD^CK^K^ED93><=EZ!?_4JBZ@QN;5]Z1
MY);C:F+F;>VJH2KO5F"U8YF[P)$2%-66/AOF4 U^_//8.3Y'1LO*Y11N $<C
M+5,HWG+)N+LZ?UIL$[D8CNJ[G!%K1W[]'N+V7%P[Q.[OFYF3URC*LH?HGCT_
M")*5M6/RZMY8L!ALGL"%$;R7$K@AB2)Z(#]&>6>',GQ9S[T4\*_*X:C:*;JS
MP19B<2+'_^^=_21\NL'TJT,DM\E@=_..:WE$!YNODNZ-[^V"XD89]2$0;S6U
M2[7E*PA<N<G;M? CS+@Z=\$^>G4U*-NP\EX)BZ*E*!W+8B]"F<$2!#LWBR5G
MSR3X+M,F<YH#=J@N44?TYM_$)@963Y^,AI5/E2?\\@#:PRE( AQ2L5OL@!H*
MGC9O7*A@#E5*ZTM7I@MS3VVIX$[1!3 /2]5+8'8ZERK6.@7$H3IRN]K8;Q#\
M@T&UY9W?(@<P9N+10=0@[H6WBDL316QDO8GL4CRI&549Y\211:&K-Z7;5_#$
MVXMDU$P4YS/^]A.+B$JS\%<Q]"]9)GK'6"<;3]7&?@?IO[MZ[4UYWG4E 9GS
M&7'&+/A48(EULPCHH2Z@FS;NUZ+<TAO_*?@#%;NXB5^<>S&?!3$S5/,A9_\+
M:Z[3$7?0O>74=91!4?E2Y7_19)54AQ@>\_R*RURPRCNVIW!;]*'RF+\@$Q4[
M=YF%/N4J3\J@^*MX'9F!X7@]K"X=6HZ+!MFY\\QTK^=OH@K%FT@Q;^USK!4Q
M!C5>6Q_NV 1_J(+_.OK,8'+:<A('EY5VQ*5A?"EL).F1B5NTHGT[7)4;W1L*
M.FJ*+;'UY6_-4?3<.0/><Y;2K=%5/A#1D4SF$&<P#>JKNB).-U7%9[EPE9_G
M_$:X2U[5<DNVJ5P8TEE)?LRM6 56/N"!NK$/X^XCXP4.129:52ZHU!(P9.)R
M9XJM)T(7$X\[$J#X$K()_F WY58'N!0[[ZLFA[H4YM9_;U\Y_A?H=.(<;O"E
MW.*)]BS JD][! 5*8;W+6&[XY)4SK;<^5+D%!=]B9U^\P-8-XYR]@#R*U(EO
M!*NX6+SHF:*=#R55KYU1GFTMRZ1>_?*@*E\-@VD4?FJ[$_MV=\%C@DK00YV.
M7;R8<&K.2(FB?S5,Y9+<.@T$?S//'?J3'L_>(=&4IO!.6:2"9NM.7"J%K2!;
MJI9Z=MO*I=W=]AA[ <#J.[>A_AK60<L3>9K8,T<DKCK3*?AML")N5]=='&_E
M0[-KLO>6\2D!IO@A5)MMQ\Q/JS>3U\8YQIPL\*=?_A]02P,$%     @ UX.F
M4C8P:43F)0  /H\! !4   !M<FYA+3(P,C$P,S,Q7V-A;"YX;6S=?5ES6SFR
MYGO_"D_=UT$;^]+1W3=D6:YRC&UY+%?7O4\,+ F+4Q3I)BF7=7_])$@ME$Q*
M7 #RJ+HC7%JH@R\SOY/(3 ")O__G]XO!BV\PGO1'PW_\Q/Y*?WH!PSA*_>&7
M?_STZ^<WQ/[TG__\RU_^_K\(^:]7G]Z]>#V*EQ<PG+XX'H.?0GKQ1W]Z_N*W
M!)/?7^3QZ.+%;Z/Q[_UOGI!_SO[H>/3U:MS_<CY]P2EG#W\[_AN-(89 *9&,
M 9$>(@D)-/&9RNBYHP;H__[R-RF5!IXCT?@_(HU@)&@J2+*4&9U$8"+/'CKH
M#W__6_DG^ F\0.&&D]FW__CI?#K]^K>7+__XXX^_?@_CP5]'XR\O.:7BY<VG
M?[K^^/<?/O^'F'V:.>=>SGY[^]%)?]D'\;'LY7^]?W<6S^'"D_YP,O7#6 :8
M]/\VF?WPW2CZZ4SG3^)ZL?(3Y3MR\S%2?D08)X+]]?LD_?3/O[QX,5?'>#2
M3Y!?E/_^^NGMO2$O1@G&0S_]_M<XNGA9/O'R>(1\^.B_%+RSOY]>?85__#3I
M7WP=W/[L? SY'S]=X)^28E@JYJ/^Q]T?O[P#$/T@7@YF\K[#[Z\?40;;$@M\
MG\(P05H<9%,I3S^\/OEP=O(:OS@[???V]='GD]>OCMX=?3@^.?OEY.3SV5;B
M/_W4.GK9$/VMPLK@-\,/1O'>AP:%DZ/QS5\.?(#![*>]RPGYXOW7WKN^#_U!
M?]J'20\,M9RE3*+6ADB)[Z6ESA 0WEDCJ(@IW5?7M4@S#F<_"3,B7S\:"<WI
M2QA,)S<_*8JEA+)K/O_'$@QS76XOSO%H.!W[./T-?=CQY60ZNH#QS>.O/HR&
M\7(\1E_78QR<%F")]LD1*:@FP5!%J##&*^:\][*%J&OBNZ^&!5(=C>.+T1C)
M@Y[]IQ=_0/'#UTY^#M:/XP]LN^]BKC_Q<G)Y<3%[)NE/X>+F[XO'K\.0Z:B]
M:>:T0(EVY<WI5QBC,H9?W@$ZWF6P-(,4P0E")4]$9N&)]\H09JT6S&:3'+1@
MS)/(UN$*?V9<J6N.:BQYTQ^667\E*&.9,188B59@_",MBBP@D2"UM19L5)*V
MX,@3N-9AB'AF#*EIBGI>9'I^Y]-0P@4\T1OJF648[C*/H;&7Q(&RA/.DJ-/*
M6\:;N(^5D-9AA7QFK*AD@&J$6(!R?(TCR&R#=)P8S(#0<65)@F)(49S?:&1&
M<NX;!UG'ZQ- /3,"[*CP:H8_FDQ@>@LA4N.YQ!C&:\.(5$$@A.A("B)8&ET,
M5K6P^3T4NXKT<0Q??3^=?/\*PPD<#=/L9;LOJ!0L9"DX2=YA4F\U)\X!)RI'
M"=8DZU1L(>@:V+H44F_/CH=\KVV4>B_ -]_''P_@S6A\Y@=P!NB(9^_E:PC3
MN^]N0/H<F>)>$Z64P*@_9V(M Z)S-B%Q[R V<8L;XNQ2L%V/12V-58U1QWYR
MC@0O_SGY]V7_&^(<3B='TV,_'E]AJO O/[B$7DH*F,F6 )3JH_"H$,XUR2G%
M:'TT5NDFB?TZZ+H4B-=C3WW#5./,V^$WQ#(:7WT E-%F$9E(Z/THQA5)4V*]
M\R1Q+BQ7TGO;I.:S"*)+07<]!FRMYGK338RC2V3=)XB #$17AE!N1'/&2,NY
M*@&E))*[3)P5DABJ>6 J>!5RD[GE$5!="KXK3B2US% Y$.^!S4%:BS,6-1R]
M#QCT/H$2AKE?<%;FX&V["'Q7(3[!9#KNQRG,G.QB4JL5^ B6Q!A1I9 =L1$<
M,3:;K)E@SID68JT"U+T@>R/+/Z1S%;WO/:1>P*D@8BJM.$ZZ@).NQM?8*Z$(
M3KE4&B^RC>Z0474WJ]@5F-/85M4X]7$\^@KCZ=7'@1].,8@K =S7LAL OUXL
ML7XJ:C_-OV*.691SE*>89<9X>5&L!.DU?!U#[,\--DQ'%Z/QM/\_LV][8(0,
M,AM"%?I^R5 XJ]'MT^1$+#."D$V*'^U%ZUXXOQ-G.\:%1K4XFC@D&1)1;!;>
MN$0"6%I>N*P#U<ZX)FLT&Q>C]IL&[.;MMM9PW:67.8X%G\JE LZD(RJ%6>DK
M(=^2(" 8%PD2E:Q)V+<43?="_IV,OKO&JQG_-63 X=/;81Q=P&?__1H69J/<
M<HA9)>(-1"(ILR1P;C"; 0HF"V54:,& U9#6H8%^/C2HI/M&.SD>S%4]*K+0
MP1N""#!PUPXG(!2=..TITTI+VF;?SZ.HUF&$>3Z,J&>!:J0XFX[B[^>C :IR
M4L*:Z56/)99U2H:PB.:2$#FQ2B"8'&@"1J4RK 43?H1286%N_@K.'CVOMEIE
MI#"@\-5S*%UV@EAC+8'$6 K,1^N:;#=8@J5+-8$=>;!D]6TGS==;&QE=7(R&
M"RA,"DJC8$19EQ%%RL1AZ$5\=A84X/N7FY0\'P+I4EI?V?@[Z;Q><I-2O\CN
M!Q]]'R?A8_^U/_6#GC&&@F8"0S!IB Q:$Q>E+%XW)>D5U:9)W+,"3Y=2Y<H\
MJ&&!FNL@-WGX+#Y'DF(V?@[#2?\;S$.T=Z-)B<Y.,\9JO2! 8ZJ&N5JV@""]
M)%YI3QB37H.-P:<V--D,9Y?RY=KT:6BQ:K3Z!%/?'T(Z\>,A!G:3>^6>W(_]
M:<_:A!$^M80'%%^6=1YG3,1_K!4F&&EBDZT_3T/K4MY=F3R5[=)TWZ,/.<G$
M2/1ER<0EC[.C*5\Q;P07 6?-0^Q[W'ZM^:._*A7^&P&%TYP+H"7FPVPW&TLL
MP^E?>9 ^.1<CM%EK60JG2U'WCFQ8M<B\@_YKSK?C2TA+)&1!,)=H(LXRG/Z=
MRL0'[0AF !@:"NI9HSKS*D1="L7K,Z*"%2IF8X^<=+I!IK1, @4C5J-SEEP%
M$ICD1#B1T.4;"VWV@:\#KDO1>F6J5+=-L\,CMWXM1$\]<)(QFR12R[(=OIQY
MXE$H ,=LW,O)D0XN757F1@T+M BACH9I2=SHM0\Q9B @(\YW#I/,8%DN^P64
MXTEY :U/ZRX%5E'P'B8UC#&=""8] 1/IK$B(6I" -N!*:JI5$^ZO/)'<F4!J
M=TX\<G1F([U7+6+VIQ>SS</#5!PUIC0PC 40QPS&64?GVP:ET)@?,<^(3B;;
MJ(/EHDEV^0BFCL93]8E1RRXM5W-DLB $HSA%ZW+(*Y8S+EF0S".&> GS7-$D
M^7K*_74F=JI/BQVM\( -?W_Y4%_O\/N&O4 ^^C*WG\.TCV/>!U6K,<C](?;4
M)>01N5KU6#G[C/^^/_GP^>STS>G'DT]'G]_B;ZOI=,7CV^ES'7DJM5^Y72N_
MJ_3VF.)6IV QR*2:2(_OHTTV$F82MSY#IM!D4_<2++O7C;_!\++,$^AE&+H3
M@@$X(QB?.^(8X\1'B%E3B>%UDXU8-P"Z%,7M:O,?B\!;*+EBU#:9Q0771U G
M/9NEST+@)) 43@(.$(6BDBB1,I.!ATB;;*QX"&3#^(P\*YOOI/6*Q^MNA'F#
M$L\CPTL4\EK:T7#R"O)H#+=[PV#ROC\<C3%6>#N<PA@F96_Q_:?,0XGW,#T?
MI7*N;#*//'LQQ1R4CH2K;(G$E)RX["GA IS)&7/[-D==]BACM:UO"R2+/*B@
MT1V(Q%197=+("Q$(<\Q(*[6CH4F5X,G)Y+ ^N*O,7;F7;DN35CU).Q=HCN1&
M"[T(P0=C@7@I'7HQ%,P+%8@"X$P8]&BBB;M?!:A+:?ES85D5X]8MA'\8#4?W
MN7\]U?6R\?@&8'[)*4HK,7M 3-D1EK3R48ML61/"/0ZK2VG_<Z%=14.W"V<!
M$M,!8S-C-<6@&@RQ3$1"7;""<I\='""<W285FP#JIW1J>(T)PV T.]IUH^NH
MO'),8O@8K2&2&D."+"]Z!,PHE$])-MD']BBJ+@4,._%BR;GB2K:HROO3_/-H
ME&:E0AA_ZT>8G(T&J<>9!BV$(QI8(E(K1W B0$EM@"2-MS(T6JE>!:E+<WQ5
M8E2R0C56_ Q#=,V#<HPS7?2'_<FT..IOMRY:.JD]H+MW(MFR3B2),[Z<B+<@
MD^+"RB;9Q1.XNC095^5'37M4(\D'F"Y6-9C@,DI&/+<!0\94Q$,93>8FT91"
MLDU.'MQ#\9P*&\P8GS%K(SRKLD7)H<),M(0%*DQ@/ ?7Q+T>K+!QV(E\>[;^
MF#5UDR25RWL(_-J]O$+OD_O3'GB<<)R,1 A>CC?XLA\F ,$<T5BFF56T24>'
M%7@Z5>BM3:_=M'^ 1=;%Q;/CT_<?/YW\@I]Y^Z^3MQ_PVY-WIV=M5@97C;6?
M9<*U)*VT9KCDA,CMZ1": P<G%8D2 T1I,&UP!J-$QH$7LE'K6IW[6X6I;G@A
ML_06DB:!ITQD.3EL(9<^<]8P$33^NDDZ_DAX<>C$M X;'KJ?[=5>MQ"X1+Y?
MAV/P@_[_0/H%,R.<<7_V_6&!>3J\ZZQT-.Y/\%>O\=OAEX\P[H_2K5Y4S)HG
MCBK)UI:3FI8X+SVQF%I3(P.S;78+M1*H6_EP&SYV@@S=G$_;;&7:>."#SK0'
MWO9T]OGT^/_\<OKN]<FGLY/_^^O;S__=Q Y+AMF/UI^2[S Z;D_\I\8\E/8/
M3/?CH[-?WKP[_:U1*'_[]#VYE.725 K72P=</SG_.!Y]Z^/37EW].BG=DN8=
M]7 Z.HK3_K?YMOL@%3B:.5%18)3%,R.8Z6,DP2$#3D,X?S;9);<^Q K])B-
MFM4Z9AN(2[/!20]#22-=XF7) S-9Q1P)GEG",V?689[,<I,:V'(X70KO&[%G
M2>_'7>VR<]A?/$7O^-R/O\#D\^A6PGM7/!4YD_*)2F>(]Z7#CA.2!,,-1I&:
M<8<1IG[8:>!''[3F6%T*K!LSH87V:[:IO:7GV\GDLO0B/<T+'7AZSDI+(5BB
MH706%0%3"P&2&).4#52+ *VZS#Z.K$MK40=P)KM;J^H%(@\NJ;C?X/MHF.[_
M8.&3\Z014\YQ>2%>P_R_^/W@LB2=)]_CN1]^@4]^"B<Y0YSVJ TAEIV]T93S
MIXF51F"E^Z%DP649%6=-+HS<KY@5JGOK4M)J%Z3TD3"(F*V7EBF^])3T*22E
M$O/*-#D#N&UT=."Z8'?9OJ34V((#-1>XE^&;K\_=QY<RLUZK0+Q,L52XRIE9
M[8EVD+*(V<DH]LC1)1"[%-(\?X[NRH'6'+W=/[Z +P?*8RK[QTMDCT%]*"V:
M'<[OUH"2."/[)GO]UH?8I9CI^7-T5PX<@J-<4?"1S2X*L(A/,_3S&H@!9]2L
MS9-ITCUI6XYNF.7^R(@';9+O]U!&?3CO0*&]+ M("YD3)N)9D"BIMTZ+E.!!
MW^H5.>^F(V\8TC3?7-&"0/=2X*:FJ;DUYP'*1QL;]8P+/I;+MBR 1Y#ES%#4
ME&@M08D4K(B-[K[;"&>7@I/&9-N')2M>L'!WIPM^/8!EE[MDB^]!8)Z@S(9(
MS2,B"SAU">]5XL[J-E>XK@.N2Q'%GHA5W68-G=>#EHX]2Z/ *!EAS?;-B=).
M'55%(E#F7('<IMW/D\BZU/WL8 YJ%VO5626X/P??NSP>)#-<6*(<%43Z7(Y)
M^$"B9EE 2 KCW;4"I95#=*F=\#X"HCJZWH/SN+MTM!<L93)[1[@IAV4"AF,V
M>D-BLJ B9XG')ML@UP&WX?T_SSJB;F:T=E='/=AM38'F6'H_!I7+?58, R_#
M@#"K,P>PT80F,]$3N+IT9=#>XIEZEFKHC6[NPB[B.F6TH8)C.)5*"])RU"M)
M%-Q0*5,V2L96!R56HUJ'.O9/[W^V-5.])H;G?@RO$$LJFUJ1R/. G!H?F+2)
M)"<!YU03B//E$KW$)3<<O6!J<RW54CCK<,7]N=Q,!;LT.EFI'?.*.D:L=(Y(
M&C',YEP3<,FS!-JR-G?7;7[T@?ZY*+&]&=I&O0]ZWO>L<=R'S)&>I?VF3(8X
MC>&Y@\B$AZ"BW%.1[T=P:_'FP)OJ]A+U[F*TAG2:':^X2_46>T'KQ&BYUBPY
M:LJ9<M0 PSP_8^['C5#22+T?5JW$N!:Y_O1UXSHF;-8Q#/6R6'H\S:_[DUD.
M>#1,'\=PT;^\Z#E\%XS#5T :6VZ,Y1C#6W2P(:%",$CS*C?I][X%UK4X)_YT
M<71;FS9T< CGJ^^GFRSR.GE$G OW6/<B&"E1!<1%0&><*"?>N42$C]H[ZHQU
M3?;L;0=W+0K*/QT%FUOV$!O'/'=4,$=)J9B7561*RA8-0GFPE@IJ!6W2WG3;
MC6-;[.'V5[->%I]'1_'?E_TQ''WS_4&I_+T9C<_\ .Z.:[Z&,.TIAY&VPZE*
M<HI^0WI.G,1)2VBF(J76:]OF3,AF.)_#!HE="??#!N^&IFQR9N"]GU[CF3F+
MJ]O++/Q@,#G-J^'WA TZ6C!$N=(!4[G25SE[XE5$T#KKE)MLEJN"_AELIZA.
MS;U;O0EA"Y['$,Y>*V#9)15QWL3P'L,KCG,:4" Z"6L"$UF&)K7"38$^@\T7
M+6E8W9;U&/?0CR-L#->F5^7T7XGARU;666_*7E!"2*D4,3X*(G7I+Y]%)"P@
M;"6MH[Y)I[_U(6ZX->//.1'7,6#;-A>O81+'_:_E.:.,(?JKRTE_")/)_='7
M.TN^\EE53HZOA[3"@?M5 ]W=+?]VF$?CB^O-7%-T)575]>@X356YOH05U'Q6
MWM[QU2B_\I/^9)0Q+)C@NS$;TY=M_!&_N]Z9@"_IV11_Z,=I*U5O/585==>1
M]( J_S@:]&>W[.U1];=C'M0$RR4_H"D^EZAEKX:X'O&@9E@F]0&-4!:C1\,R
MUX\R_OKRHF@#TH]=L0:CR61>G-UAGC@ RH,:NY9V#T@0_,5H&/N#^8;O45YR
M;LT_/*EV (;L O.@%*FFWUI=0'<YE]B#F*,VR9!,A2>2ZTQ\"$!"= D8! .L
MR5:!G5#7:  Q*__<>^H19FKC\17:^E]^< D]",ZPK!V)FI8K;6/IWJLL,2IG
M+X/++#:IQ*^%[D_386 C!OYP34)U0U8KJ=P7^.8&>; QAJ05L1%HN4?)D9!E
M(B8)'H)S3+,F;0&6HNE25?AP'-K=4(TX\P&GF6LTR64!$LW*N"@;4P4E7H(F
MGJ%@WEG-69/-YZL =:F0VQ7F;&FNMB6VC^-1NHS34F?>*KJ[]_=5PJ[5B"K$
MS(L/WSY;7?*4ZJ(WRBH7A]@AJ%_VF.HJ:)4X_3SVP^GU7<C;"'_O[ZM(O1I1
M97&WY_R2IU07O1'G%X?8@?/+'E-=!:TX?SP:8#PQFE\WLP/WESZG3O/=)Q$V
M4L/V[\0C3VNFDD;OR+*A;@L@GT=3/S@>#2>C03^5<M<'N.'K),_ZP.+?P9=^
MO'O*:+S+]-(033/#M-!6(\,>SWI)3?K#5WY06FY.1OGN=&TI3MTT%EG8&E[9
MFKM :&;":GJI8+?KGH9EM1.3B,OY[6A;*'_I<ZIH\&F$C=2PO<-^Y&G-5-+(
M82\;ZM8%E703Z7J[DR@_W$D4KL[Z7X;]W(^^[-"_V:M_7!S3:'RUP\N^%US-
MC-56@Y4*^@\WB)5M80LWV,R/6913J9/I;.FBIX&II$"0&'DB,C)'7**:>!Z2
MX(J[G)H4JC<%NFMY[(GQ[I;K?AZ/)I.[^X#*14#S&QAG=P]1[G@VCFA6.AXF
MEHE/*9%2FC$J>IY=DXZ"5=!W:I-Y4Z(^++;MW_C5RKK;0B^GC.^@,Z&<YMJ2
M*+DO378,\=9Q$EG.VLTO?^X2;^^A[])2P[.@[?:V;T;;^QN5%S;) X?H& N$
MHT9*GV-'O$%-91.R4^7BM#;WPJ\+L$NK%0<E7Q4+MEVP6!:UW=,*1FTGDVG_
MHKPS;WQ_/%OB'>7W?OP[QF3A?@QWD]!=^L'U&9#:L6\3;,WBW_::/%0,S$#G
MF!(C$A0EDD$D(5"<W:GA,HID6&QRD^>A8^#[K_3=0:?2,[8_/!W"?X,?WX/1
ML]K[<OTFD=S2<H4KD" 8(Z[T.+*@O1!-FE'M#KU+FUZ:,G0S1U[=ZGL*(>YP
M'^4IC!'VY_/QZ/++^9O^MYD$]]78\YF"=883IT 3J2TG5AD@66G0#L,CYIH<
M/:HJQ;..A/?!X?I<V#N=S_K#+P.XG2=Q@NTIAO^/FI-@BN:H!6*MS\0(#8([
M%8UJ<J/C]I /,E/=QB$])Z..P2F2C,.XUPIT54EEH@3W,7-E6-Y+F68SV%V>
MH1JQM<I<M9W=.S-/+<#W2D2:+3)KICEI"(I 2:0T4AT%*K7)!L]J$G1Y?NH8
M@^NR8?]Y]0<_+NNCWW;9-;/6<YOELX]+T&@9[O9G\XY"[\%/+L>0CJ:W=C\=
M^D^%,V/DY2QPJJS@'1 T,T4MK=0J(,Q0W(Y=VI$-1@513T5OE =+5,;P50:A
MYCVG<'Y16B8AA6CCH5<AVEN=-D;(1B0@R"Z4')@DP3I/3-;&RI"9YTUVD=>L
MT^XM>*K"GZT+LIN8JG63AG'_V\S'UMJR\L03*W496!]UE;8-CPVW_8:6M9Z[
M!X4UVN3R^*#7N[3.S@&FOT#ZLM,FM6V'VH-RUY2S@KYO>MU?;:/!NS^NHI,5
M6&I*N?U[]_ 1=25N]#;=/G^'U^2'9]25O&7$=SO(!YCVG/9@J# DJ5*MI.7(
MI]&2N*B,Q.2/L587;MR!J-$W>?:L3_X/3#K1A_C!!)][FC_!!,;?R@W#RGNG
M1"("4KF,0&9B,;4DU.3$E& NAT9M:I^"UJ58;FMF+.MZ7-$B53MLSW#A]-*?
MG$/Z>31*#X )GD-6L?0O9.6V@M)>7DF.82MC1EK.>*L[ 9[$UJ624WVN5+))
M?;+\-AK_7IHFCR),'K(X:2^2=B1HANF'CFI^^734)HL<$39M=&W:D]BZM)FG
M/EDJV:3YH>)9;T&_T%:PS'=;Q!NK'E7KL.G3..L<NETVSDX'D!]Y8$O=M#N6
MO&RTW4XH/_;$ECIJ&<2N;-N)7\]S1YC=OOG@*O+92L3"9M+%*W\?WO0KA.(0
MC"31,4,D=^6:\L!)*@[*V.PC;1((M!>M0M_EK1"NIW?I/>5<.B(<DV5%2A/O
M$FI*&0Z:VZARI_2^A<H/?!ZA8R_/DE;0':%7S4[EVX@TW]B^IF"&<R&HY20F
M7RZ55D LQLNH]\@R8##D3)-5BSW(UJ7$Y\_Y\C1C6ML(>]9O<K$N?->7<IM@
MZ;''58F4UL9;(99\9*SM(^ZG']I:3XTB[T=&O+XNZ?J:I'+^?=[F=-[$:KX
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M@DBT7F=5B[T86KX+F;?UL+I-/ZKUD+YA%>J)I[[3/G[_\-?Q9YR,YIO\,=+
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M8#9%R[2)F?E"WG-RJ)%L:9#"=W)&-GOO3O[5ZJO^N.M5[\>GI[^,)^0=YH%
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M9P_RO]:16(K@:*3DOI7":_P*5&_.,*."<>1#E"";-%#L!?WAV\WO5_/&A]:
M!B=UNTCPJH59ET&T//;M912'.2$^@!;UI\<[JL"CU6<NR4$*7K.D:$70*1GF
M+:\=^M!AQI@A-,DY?L1Z_,!Y]G-1XTV8[[V *D$9C^!T^#^8?WO_YNA%/2R<
M_!U2(H-M^N[%WV^6'QSE7X>IMC,[.I[@?(2UM/1OM(_^Z\,)3#Y508Q/SO#%
M>/)I>7AL08$+Z!D6J<D]"(F!K-M=RJ%8GH+UW2*.FT-]4K[@MOHS?K3DM^A'
M!)^&L\7X7HRGL^G;\OMH7H\D7Y4R>_4EG9YGS+\0.^3;TL_^9S[<G[]>A%:\
MG=!7_\0TFZ\7RO "13A&9IH@_R5$!L@U(U$K,"B=2DTB$!J,Y1LWI@^M'3V&
M]EX,:0EE.?NZ@&EI(M] <QA3]^ <C_LFJ($!>Q.4LUEIVC-8C$8R#32OYEVB
MC=?:I&A!./M$M>4!@_)Q*\LFO.S93%Q6O;X(%Q!&)&4\$P+)HM8T[IB5J,U%
MP-6Z*F+U0'4[B^_&6P_29WU;=C8PPK87[9XB,>ZYT7MW3EO[/$;E^D<N?OJV
M@FIT@;K)FQO?IFXMA)6K52EU EHM.-=*AX !03L=D[*HG=7QOJO533#LN)7<
M>M-BP:Q%F<:CXQE.SJY^=74IH+BTH03%;+"&S#B!+'@ IC229HLDO.W2H&7S
M/6<KN#OOM[?>^A[KDD-O74:-+"[9%K^?81Z0@V>]BL!R$HEV$<.9=[8V$S!<
M>QF4-UV27GJ0SP-(#[ ,M]>X6_MR4_X:^,$;R6CA6"FIK ".+!:5:U5&P8+0
MGAG-979&)VV;E$S>'.J^;C\?A:+URMMCN=?<:)ASJQHL>JX<, .UX%I&LH-J
MVEH-R[,Z"R]%DTB<C9$>ZHBEM>;LHJ@;,]C"Y=T$\/*<M0ODIL<IFV,^S*%+
M8VW81?=VH/*1:&% !ZJXJB 8R 5$RP!KYB4(**ZH8CKU,GRZVO? (<[C5[Y-
M&.S[(.?#^:=/IU^/1ODW&)V7FC=2NUY?7NA<G#-DS4WBVK&@K64Z\-IL&VN)
M;A>*T2!\Z-8SI]O['KG7L UOX[9"[SN)^@7]M%;86990'H_F+>P(]W@RNQ+$
M17*P LDQ>1;4/(0O)>:-"4Q%$8W/HGC1K3'")F]]YCK2C(#>RXLM@5[T-[RX
MZ8TQ6WHS Z@#=T'2F&NV&)F001 P%&DCG;CY_&^$_1V$NJ?FCO><,BZC Z:S
M\3N88:V/_1'3R6A\.C[^VN:8M\L;&Q_O;CSHE6/=+,&IP)5U7&FMBD<%/#E4
M3@ICI+SO6+?+NQ]!VDSB*:L@/4NN'GZ%9&K7.&#:!*Q=Y("7)NG73SEMYOKG
M1_D]'M?Z'^/)U]^&IY7O$:ZD8Z#((7NC&?A:E+#^RWL9642?-'!KG(JM$VLV
MQ/RDPJVVT^:^4F]::D/?EN0.PZQ+'4[2$$[7#4QX;SA@9LG48$W(M4IC3DS:
MX&CIQ$!@6JOY@RB_*_:!&&]Q0K/,W/XX/DK_/A].\/7HW61<NW[</>J!)5!)
M<\64#.3$%8#:"5,SZY0#J\A"7.TVV]/QS(9 OR$EW0N7#8+Y>@R3E%*61-X"
MRS'0+'*UG)=VFM7IXSAP9T%^SW%\%%IZ(-8?RUU@BQ@\<IP-REJ.T-?F/39%
M%JR0M=(1B8CD0B[7]Y#M?85L;Z25>PC9WD0[F@??=@'S/62[+<?W1N%N0U!S
MK0&E0JQX(B1'NPPJ%H4$ACQ%<@2%\DX\46TY0,AV?\JR"2]]G]-_I!47/N'Y
M;)AHJ:XC/?EZ2LOR,*W$%$.1O*2<6?;:$TA?6*V]Q)((9+GDD(HKG7SJKF\\
M=*CV1JR,6XNT[_.7ET,X'M%4N 4J>>MXR'4>>ZRFJ&,1E602 REV!H+9+1%S
MW1N>+*^]B&SM_.WW_N7#;)S^]3-,ZWIW]HE6R?E2MLV]RIHG]7%?T@7DRCU(
M,"5Y&;QQ(#5X%4I,W@6.SF@ILA\\#+<72<YMU*WNJ>Y]7CNIW@5XM6)AL362
MA1?E+:FL!;22YU(@2:Y\P#6RO0V]%PF_@4F]X?Z,.]P)=GQR.ZG?/X@5^:N8
M.4@A0*'2D?[G?>;*&=H<4 FU3OZWWK'C<=()3/#62ZXY;C]_O?K(\JSLZ ^8
MY*MS#>"01!*%U:J79 _9PCQ"8I9V-!&-*D)WZ36T^3'2SM!W/HO;%L&;\[J3
MO"WSWTZ/SF<GXTFU5@<F5S.3K,P,B?86'P4+I-],"IJ<D%.*;?+(>Q_)_K?]
M/6ORK1.Z@^I"BV)Z/0WH,ZU2=<_X93SY*_WM;)"]*HESSP!4[8MNR'Y2VK%B
MLZ+=B N.3<+T6PWHNZH?0C,:')_,-]S7T^DYYI?S8,QW.!F.\P+M_)=OYPTU
MIJ^^U.O):4WA4C9X\@>8ILV<:2B!Q8R.9=K$(4@ALV^S]VT,]=O3TK9LMKC:
MVU9@*P.9OAXMQOIQ/(/3UZ,9C7XZ3'^'TW,<N$Q&OG.I%@+R-%!9,\\PUK+]
M\R.NH%?;'1QX]=U@<-^>CC\VC6G0Y&?-/)YCNWL:%Q>-C&B954Z1X82%@:Q%
ML(+P+@;K,36I5;(QTF]/7YMR>5OY= ]5'&DNI!GF.;Q77ZK,<"!*C$42H!Q(
M$ZKWSF*-!DG&:L%EXMK$%AIV-YQO3HUZ8.6VKIA>MN_XL%#BJE!>_?M\./OZ
M>D2#.I_'(LTOQC^>P&@Y'8Z.CR=X##.\N3+_G<2P*".02D)@2&8+TX)<Q&AE
M9$YFR!XB-Q:;[>C['^\WI^U/0:]N3R=[,&MX_J_W2(.?#F>X3)Y9;#1BH&4$
M@<#)>G%8NU9%%G70C%N(M$I #*I)!8LFH_DVI\)!=>*VHKO=4F^W'1%]/3Z?
MT1 2_02.<8 <32R:,XDU_4^(P+PJM!EZ+YQ/UB7INF7G]@7IFU'/ S)Y6Q]]
MTV.P5V>?3L=?<6&M7V1#OCN%T72@8K(<:F TV>I,ZQHAHQ$9Z5<]5C$AR#;A
MQ-OA_6:T<Y^\WE;'L'/L[_CL;#R:XUK&=2T0UY#3R6?,OXPGOYS/SB=8AU;+
M) X2*!10L^5% 5K/@V*AAERG6EI)")-E:G(HNS'2;TX%VW)YQY7 SK=@E_-B
M83+<+;\WX]'GN<T\%]5T?HAV_?<U"/'->/9_</8>T_AX-+_>(X\4P$5@L1B2
MHRR&!26 Y9BY\SDJI9NX;<U&],UI\^/0C3NT?N>;L&8C6VPY-,V7/ZJ?$X.@
M<DR8)+.0-=, FCQ-55AVVBC%HS>NB>6PWV%^GQ^/1XONF#0]9N8]*/?I.L$O
MDF%(PD58(&,K14.;7D$&J9I=QBAI#"T"O$EAU]Y&L*^\O$-;U =A_+$DY57O
MX V<+1HF6;!19"UKF'6I5^>:02$QDCR)_DP2U6UJ;UX#<?@TN+VJP6J2R;9T
MM$A$6F)95D#J@J9I_MH-. <J?[DU/6MXWD&V[1DG0$;&!+5673TS,+2JUEL$
M(35ZHWD*C7+/]L#T0Z4F&Q&]B4A[+Q!Y=3=_-,JO1_6D<OAY?CXDN?#+Q!B!
MQ4:=%$-?4VV"$2Q(YQB0IPY"&U[TBAF_[@2ZR^L.D%BT R'CIM)L$/Z[V)4N
M^B$6673(QC%TU;;VY(N21F=FZ.<:54;=IK3V#13?]OZ^/2&'"%5<*XBK88SR
MRH3J,J:69D*+01W&V-A!5S:]<=T7T2WBO5N,#9(,7.G,(CF6-6LC,T#T#&Q.
M3EJD7:%))>ZGH[P/V$^/7'<WX;>!SMZXIUO8$$M[05I=HG>:N>0];3"2]I9L
M/"O92)F<25F'%HJW%M$C/.]L3OBZ$]"=V&I@W=T =E%I7+GD8LXLJ%*;U5ED
MT<G$O%,R&,M53DU"H^[ \EUU=F:H34O[ZV&WOQ,GT_<??E^"\\:"CCX2+N]J
MKT-DWE8K-T3K)!8-V*I5_7I4WQ6I1]9:M"9>% .K5_V+2(#+6BFT(J(0+/M:
M9%&!9 %BJ;5J54G%.1UT"V5:@^>[&O7"5(_90=/);/"^RF)I)08?%!26:FL,
M[91@'H-GLG8^2&BTX%V*B=-#KZD*?;>J)C?>^FT>1VPO^!;L+Y6P"XP-3@ZZ
MZ\$A2N+MP, JASN(KT?[XA8<EU/Q*C%.5G*-^0IDX;A<"^Y*+367*-R387&-
MM]N Q VDUC-YR_ZF%R:%5X[6$L,P2T5+2U$LU%1^X[*SO!2%O(L?T8F^&V_>
MWRZ]D^S'?0BN1Y]P#F117OWBZH%[7U G!@ U\R<A"](:ED&$&'F)B%WBL;HQ
M>/W-3Y#!K05WT-)P%PE@:3;\/)SMTHAGH^>W*[W594"K!=!R+IHG$9Q6.D8?
MI$R::_*(,'I(;DT!KH>'U@M#5V[;M:#I>:^?R^_FKEPS"K<%T([C7D2RH@0\
M2:.2(M>'.VVXC[0N*AM%<LKD(M(:)=@6RL&+M84<. =R_$S4P#1Z,OEU+6/)
MI<%H(N38Q+%^PL7:'DRCO0QA?3\^/?UE/*E_-"A"@*;EOO;8@9J]H)G/G*0=
M!$1#VPFM/(]*T%L-\Q$>C/0[!WK+0&VO18^I!ESWT2YJ@@U<3"4J(B'4JO]:
M.5^#:10CHKQ-SMFP6H?XR4R7Q0B?T$S9@ZKN?U9MH6>'"#G8>J#S"GJ7=9QH
MC3,F& /,U\ZC6@MBPSM@3H.E04=3;),*-?L:X/?I=)#IM(.6/::">0^.<U$"
MY7*<,J$@1YXS!3744]103Y4D<TZA"V M.?Y/:S;='.#WV720V;2#EK4HM-=L
MG,1"P>'UH3HEM+-:,(=6,AVL8]Z5PEPRAALP.:<G9N[=&N/W.760.;6;KC4H
M(;@_VS9$;PM'8D!&VHT#V;8!DV?&6$RJ*!WTXRH>OYL/]2BI^ <.CT]J-O-G
MG, QSNVEES##7V XF1=7NSZ#;!%9.%)*##PPG:UBH(LE$0LM)4@NW!,STK>2
MPQ-:*9_,(5(S/7Q23G%W<0R"]+0/F$@;F2<9A%S3K:QF609(*F:3VF0X/8;!
M/Z$)^!AFP".<S1NI[Y.:PC=/'!X6A/ \>J44<\'G6@7$,F]%8 5S @<6Y"/K
MH-.W!+Y/YL<YF5LJ\A,^6WM8$+7*8$Y>LR2\8EHFP<BXDLQX9ZR7,BO[Q&;T
MAA+X/J,?YXQNJ<A/\7SO?(+3AZ6@+?CD3&%Z?FQD8V%!E#H!45FE<^2V2ZS^
M(YK.FPS_^UQ^G'.YF0H_S1/%#@Z'L(8G'IF4M@8K<\MB4IF9#$CNAXHE-$DW
M?@R#?SR5 E- LA)U8>3F(=.U:GVL1[[6"F4Q6)E"FU.+;[!2X$XG?@=A_+%4
M"KQ9TL'%% P/CJ$HM:^I=2QX0]Y-=%I#3(!M<CN?62VAC13AWEI"FQ#R5,JP
M=!G3]UI"F]<2VDA7]E&/91NBGXH26UO *Z.9RB!J!Z;,0K*<.0?>)9V,5(>)
M(7\TRKM1+:%'I[N;\+OW>AZ!YR D).9-30X7H; H([ <2O&"\Y1XDZ+LWT(]
MCXV(WZB>QR:LK4T8V$<&XMT_7;9R[#V9K=/;VF6N;3[8E30UA636!7(SO,A:
M&^5YRDD$;70JT@2_)DVMTWOWT"KBZ'3^(/KJ;5DMXU\+_$^OO*S".2):P5QR
MJ39C2RP$^E9QZ[QS,KO8)#*PYW'L[#(MWH3Y;B 7+4\U+Q"CJ<G*GJ15%-)7
MQC, 62#02@+8Y&ZD&[S]K]:'U,9;3E;_%+9(\;IT2/N1W?_?WI7U-G(CX??]
M+P1X%8^7!3R3;+! !C-(%OLJ\,QH(4M9'8/)O]^B9'MM7>Y6DRW9R8M@6S#[
M8]779%6Q6+5S3F4T(JL(A-)2MC%;(%X$12C@Z@6221';]()K,9NQ8E2W1-[K
MT^(V@U?&)(5N@B0Y,IP!Z+3KS1@8=2$H95V;9LLW%KRZ&BG.!K+Z*.>MQ "Z
MS.FO0%;_0%8OKHP1#+A$T6^%Q#1F9H/P)$6*<TM>E0[+"MU?2FEFSKAXG3/_
MFR%OKT#6S7&WCWY'+8JMG4'[.B(P9AB1%K<58RC:VHF*#* @L;:=!=]I4>Q>
M"N]<%+N/MBJZ0MNF+'MA-9SR^4!;]IE;:1/)DD8BC8C$*(0NA?,Z6QK9?AK3
MB68W/1_\)R90<SVU7IH>:9Y+&>^L")>NM!SDI2!O2(2!M"PF+[QHLAN^WT+K
MU9:C"S34(/?ZG_.PN$= ;KV5R,\/7M1V[_<LX6KH!?$1V*XAAC&:$YV%S(IG
MD+Y);] SF/YR1VLK;CQ./;Q 7<"U]#+/HKN.NUA-E]TX,D 1#;:M\R"U3DYG
MW$Z#E^7&F2A7SD4I6:&B%DF(G)OD)5R!):_X9=<A21_Y-R!'62P_YU_=[*D)
M@&!*4(HK)41>JN=*-+*XD83COFLT==Z()H=V!TC&MV<J:FI14\P-CHK0T$XX
MX%>TOWY(W])L\7N9\<,YUF,%9),X$]*1;'6YXP)HB=&,V[D).D8PUO%676!>
MP_:>N%%;%0U6B9_2/"W=#!'>Q7L4-3IIKK0Y?0D2'+?,HQ#  45+&R5AHS;$
MV< 9! ^.-BF!T0G=>V),?76<-%+KI@_M1/(O]SU=E _T_-]K)/B<A+.7L6/1
MA="H,)V=E!Z4R8EZ(951PGH;\^0$L,NE,R!IZL@HE675)<E)!VX,V"B8=Q*<
MM^"=1<H)9QAHKB?G8?:4W(]N.9_.?UNAP[GU%R^1V\$8-:1V'MB>S&1@C.HH
MLV<9:49M:>;EC&-H&*1@_.0<Q($2V_K+%_'MQ$@MI'<,Y+X,E56)I8 K:);4
M6L>"IEDI#1PXA70@PT.X R7YP:VFP>%>/IUM2K6KA"O_ZNG;N_5Z.?6;=7GJ
M>O&LQ/S7Q0R''O+BMP'20H\-1+3?#P)"\%90'U224@5\AR!3PXS/3!IJ#FA0
M75@#6?3L&>6RXS?T'.;KU8_?PVR#LRS&QD<W"YO9UJ18Y)>POSP,4I%,5?&T
MX%0[@>U1*^(:#91!#)[+A MU5L9YQP0$JT&( VI5138P_VF^GL8R/AJ+OZ:P
M6:+DTQ.4?Q0HB_O?D>>[R.KC3!Y!_/R4CA9%D$Y$1=2VU:24@5A /]:B6+0J
MC2C;U/&H-8'!B63#<-S=+S;S]80KRQQ/E' 5T$(O=9>M!4$$#[C=9YF2;])?
MO KZ\1VJJ[#W($MM=,TW310>.)W=,4NR29I,+8DJ6B)+00BO>"8T@@!K@F2R
M3>W+JM,8*S7X)FA\10;<3#+PL(E_^./X -OS J:-<:4;*TL\H&J4)"YF3Q2:
M#"('=(O;I 4TG-/U3X;'9VK=M;\:8QI$>(\C>Y:6T05?RU/EUP!>*0_Y5AC1
MB:D#U7D-VGDC2[C0H654:C1) <1&8PG-Z-0;ZKV#)F=0UZ';:YG#;Y5M?;0X
M:DZQ83$K)15N!!P_;';$RM)>0.@84LYHIW=I3_V6<XKK*J]S?G ?R;<Y_SZ7
M:"HBM\IDDAV:!I)'30S+@IC,J$B9)IJ;F&\WEBW<E!KU-#!6]^6-7Z7_;LK9
M_+<2P;LDK'HP1I4Z!6>![1^09$$!&%@JHC1*X:+/O3$^<C2%,X7).8@#)3:D
M%,2)H5K(KTL4.)1\\^ 3\]1(ZJC)T>)/(H/0/H$\$&.EKL$O1_U_+" G[:+1
M$IT9A^^+*_UB  11((UCUM*H7(L5ZQ2@0?<W=AUB/N<?%JNT^IS_[4+ <3^Z
M>9Q&MTX3&K6*P:,/1Q/@WN$DL<(!40&8*S%UD[K=UWCE05?(J*^AWQ=W+&K*
MLL$^_&6S#%_=:GM(,EV7L,XOJ4@*[=9/^'F_N=]%3'??XV8QX='EZ*(C'I".
MTD4$K!60F 5$GB-+NDFQTMY(WSA[QM%016O_X4H1SGR3BB^T*]+_98'K]GKJ
M9K^DZ;W?+%?;(.(D!!5Q,> D9U5N!H G* 5.M*& QJBRB<9.2TC'![YQ,C23
M;<7;$<<Q?G+?MQS=UJM& (P7>U5KRXDTOJ3$@28I,& TB$RCOTSKSQ_S+G5]
ML1Q;5+]_.=U=8)?)Y*.GF2BO-9' ++$F.$)!*3"2L<C;M)8X F:T2L@M%OS!
MTKV5 Y[]B3S5CD0!<,42.I.E=P.ZE*24ZBN_ZA1YD&#;5# XCN=J!RN#]?P*
M<2Z1=XLJ&(>P'G.P.P!K6H_E%++K'&94T=_KG!@@_%'9(;/6,@8@&F3"5T&@
M&2O!$0C.&IK0_8]M&H6/RXI7SAS&)44?F;<GPT,L,I9ZKH!3U1H5)G&NZ"(+
M!!59UI)S%AH5P#N&YNK&Y:7:.L^!"T1=,1JQ6JXGG]Q_%LN/F]5Z<9^6NS,Q
M+:5E09<J$V#0D5&1>"T5$=DK33V:5:%+@3@<_9G2\;=]A1]__)NW"RI(M:)[
M6-"4HXO/^06FQ]VH Z@>ID GE9]$,^[V7T--BU8RKKC(GP<'-B5JHB-*ID+P
MY(AG)I(<;!"2*\M3EY/@6U3\B1U^-+WW$6WM>."'*0*)T^!F=_&;FX<4CU^W
MO=NLORZ6T_4?CQN1!I#4*72;2]68K:'CN"(1<LXV01"@.D6*+@0PWC9?47>+
MD07?M^C]PY_+AW>K]/>__0]02P,$%     @ UX.F4@)CP"<0C   M?D  !0
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MNN3]YH[29V4^ Q)^6?(#W..5:?T;;S9XRQ9KKP\OU+&OO3&\6J=<1^GI=\1
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MHH*O=N0&HS)UCLYH5H60T>Y[_BTG_ 9N/!0%[VJE^]=JX,C1_ M64N:[*$8
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MXZ(F(4X?')27H5P"1>/+ >L\YX0CA?!5/CR0$LL:[)!MGY0IAH%6$G?0VLK
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M__9&67B*N6WI<O3R?:?]L<X0P=W%]Q>3+9M/KQ!-?"RW?5\6A4;\T(.EC$0
MQ82)%O3ND8&<D451]LCZ["H)VU\FBG+Q<4V!*0>*?%NN7KXIY#M$>%@,FLA
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M0HIL."TDF$_A&71H+2$91\G!-/J3@=X-\:#RBYC@#=Z;38;_<,26RE[$WT\
M%A_IAV=ZYT3$2L1>5H/(VV3@'9.3GI.[9 #S9N4G@#+S$^!+Q?7JCNCA$6@1
M96E>!N'XZ;0]E.PEC=BLTN0DIN89V7&HCX6B@9!/@>@N4.3P!ZO(B4]8L(S%
M8C"AB5F$2;!-Y4L]I@)1$>A2;$W%9L0+J+<\:;@E$$6Y*81$XEB1[K*P/6%L
M,Q"7K*GG6NI-[E5TLT\AE72#44'^V[=7+0.VP4G)Z:6[]L>XDV48DK.N)7]*
M< ^^1DZKRLXZ76;;MRATK!+3R2P-^@VB\02O,HPOPG1RUSE3;2 '_8?BO#XF
M;@FTFJ11,"P2U2U>EQBO20D9@@ <DE+/:][(S=@E4F##^ZE)P6B4Y.'Z!.:T
MB3D;G#*%;HTZ?W.-_F.P,DN[U^4>[*A V9<'YWWMGV\?)>X'%X\?%8.O@66Z
MK/Z\1\L"E@GU:[OOI,?(HD:N]Y&NZRV5;'?;_L2FRZ?W+WH']?JKF.[]QL<0
M=-C;PZ^<A(U!W1]W"E<Y!8H%^U#.:%"WZ#> F_<<7(5VD:/WPG_^4J,)I(ZD
MH&2OEXC*)]L%3R5=/N(NQ1!72&$A_T<PA!WPUAUT>S2?:S69Q.8?45)/+1%D
MRV$/#<$"QP/TBZ)M&;/,L(#T72:6X0YB;#+JFVC>J)'[A1CLH*!MX(Z]>7$(
MEX=NYF]:FB$_Z;/1V!^J(_1#AC^@DV<;WB%D#<;SFUIMU$0PK:U;W(3/!8OB
M"[\ZM6?-DKZFPS5I6D]^ET%HDO82MNQ&*S9O,NO9AA7.,4>>."0-N90,:/$.
M^ 0D'L=R?P+D GRCCR;>!>#>BI?Q2VX=MCI=Q,^1'$F-9M,#CZ:OZY6?!;Q%
M*>=C=D#7 >6&GX"7_N4&^XO4MT?BF6<WX;Y/ .XG0+A7:XO8E\CC;,/ZY1,P
MW25R?]$RS9G:*3]';M8(PV%%Z!HL>%^BIQIM14$OXA9#_862W\\,Z3C:/J<B
M*I?1+!X<32&&LHHC$-Q*4V:XZ4?=P;R[9]63/1G1\;<3;TU9&P3G3#1%9;/+
MA50!=Y2W>[7&P_/UO2>AK9/MVI0CN3;!OA3 0.2?7A;?!>1\D+>PF4":(E0B
METZLI(R?C<\W5SA)FD_F&6J0DJS#!8IJX]:)5F)+0)E_'7.@UP*PD'V-5@86
M$)L#H%WF-8G;YJ2C*5Z+CCWB$%,<Z-X__NBE\C::WA]MF'Q_XQ.T1C;U\0K5
M.4([LS-*;QRE-"JV&X?Y,:IR6.<OV<U"&JJ,W8='!_/EN6Q"8.\]GB+X0T$$
M[64?^B50NF?0[BYP.7?6S=]H["IPT; /<K(\ZMD6.:/(+4QW@RIR)%4_^]$.
M(DU\>7F/,%B',N!!M$QO:)MLUN[LEM-^B!'O-1OP6LR1(1X;;9*@ZCYK[Y31
M@_525^#>7CD.0G$/&T-(Y?$Q\1#F;\%=R_K%1\BN -0+MT[^307\65*8G&;$
MU#WC"LZ6(*/Z&01OH:3@":ONBMO8<'G>)H<JC?!'-J%%M[F%*GW^^P05,E&'
MP*$96P!FCRHZO&C-G/<XYC;[A<SF)/:'!P/!'IQLMIJ15BA55V2$:LPHNO9(
M3(^.^9]FZ22.<JKBD8(-G0*S>0<QDDMMYG);.V-^<U=XQ>E 9_W*])09[A.(
M!?#XBQX&E4P4#?^ \>(2O7RP)=*TZ#E9T0C/]-EI.H^;F;4]<6[<J/V*?ZII
M_92T;Y,NJF)WJUFRC*O;(H*^+QI<G-4J#C7M)!)5@*'?8)_3ZP:?(<^U+NCN
MC>?MK86,4*^85&C1=_D3P#MP?/P)*'SW#XQ:$&O[&Q5 V/;#Q+?/]<-5?_OE
MW<BO3VO]],&/ZY&WGO:2W99<DZ(1ARXHJJ3':X>!J(AU>@\WP4R3.4UAC@6G
M589&"NXL;EQ=*J;0[1O.,%!:G:AX9$//M]2=-0N15V',8]H0+ZEBR5=%6_:
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MC=*7M9*?U=")\IR>6/MR?-EMW8%$R!.\@*=@N!3=K^Y^O=UKN>#$/0+U""T
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M=56?[_O^7SY5("80"\ =>1DY&0 %!05XB_P!$(MW+J3=+4P!0$$!8 $   M
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M8[XOKD3J@(0)-14=<)%]NI]\5\9Y5G2SJ\"*VG0X<4DK,_P%-M65?UD2#L>
MHOBNHKUD>\6 C6TC!PY!&^HDCE:ZFE/42E&P4+_!.^IB8SP"9-2V+*NV&HNV
M$3=-G9,CTHN3\=EN?>M&,/.U_-G$EL"%;>EUOIF]44-/FF">43P:UPI^-,D
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MBGBN.3F48@ 3]&/'I>-[ZUM3CTR5L+M5R*Z^4#,6LE!Z3EV/3+LO1.RNR2H
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MO,"KL@45=NZ-CZQ6W\.V19G;^2/>]PE]N$W&G.%W"WF(9YV)( #Z-!ED=$8
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M*+*@=($"7EE! %=ZKB//,.\B.VFWSVG'-Q! 5Q<R@-6"%A7/[L+]#,Z%0 B
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MZR!L\"HK K &PSR/-H^I Z%'R+ZW"G0IYE&3>YD,-T@4*PJ&R_#"P1=/!'?
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M<:V0?45R >W^29I0/0?YZQDR-&^+Z6S#P3"]O1@(. 'F-@TA[7,(,VJ0YD\
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M6YNDP%@UB\\UL$EZ%"/=;IFGM%5I[?=UJ0X/9\M*L8^&")BN1O,Z2$_H[CA
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M/%#(?]4KI=U/FUYO!L?7038!:?C_&"-48>?*KG2P:U.*'SH7N V'-IV!;=;
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M4K!WR,'@:0A#/@C(??=_:_Z;-9@[+'1<84$!:)<OKV\B1:1ZFI_RDYKHOD(
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M,EQL?U$X\4+<,>CH-C%F07!'<\Y"*?HR-MN-SZ)ON(/><E?>U]QPC1FM+^R
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M#.G*"5\57^TC^71B6LA5E/ $*I5FRN>17%]=E21*8\<N02/F[EU%\A2=S$6
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MZ&^HT;7I@Y@#J&>MX!!R=CH"_<I^!% *91;96G@:G2TI8WK&EWK^&NE\-",
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MPD2;=(1B=*J + **H%*$Q0OYU(IJ#WQ:EW DHV&J-$LQQZ#C)EE7R_E>D.*
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M;I"_UO,6HE8_"Q(?+E,F>EDRO+4S!X3N5X S] HTYY44[B;2>P$: 0[9XQ=
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M),OXAIP]J#"I4'F>8*OASV84$!:/C+(B+8Y[RP?G.;(\"K47_RX&N+/.$@:
MCV"@UT(% WM25@YOEM!W_*XT6100!M!LT),5YY2G.Y',P/*!OV2:OT&D?O2#
MLW\$(_[CL!&5[^M766S_4-S*BWGP'P2@W%[K2[ 1]GC\ )P) V@,GX$GCTX+
M,*"=H<,ZEJ*0UBCLG3YJ;$W):ANW+5?W-]?3Z&K5TT^8F=)\HH*E?- >MJ '
M&).UUQKI#FZ70A[4?S3!#^#4&)K6?@#*-ET6,"6V'X>X 8X@2.#.TH8#,KB4
M8( #5G!'_Q*T/\W!L?/J<=7;PR;;?K.*3;1>ZKEMM#<<M23D,4@!WAT6F[__
M#^+<RS@DR=H1[(M#Z:+*VB=IS(_*)4)L.UONAP2-)HD#U*!]Q7P?1C#B&J:>
MOE:O.HCLF1BWVC(E&S6\B="L%S']''<1+9Q"T*>!NAZW'+%I>MAV;"'MU3*T
M2%\<,-0MHIG2U@1Z[[T\L5HZ[+64%*ZS33 >%:#*M7#3?DTVQO(J8GNE)**]
M-TV!#JI?16(;JQ*^CYS<<$CK G_*MP.AG(LR/NJ]F7F8-'=HDOGOV^[*@2!N
MRS#  G!$>.WYOC 4C?C*3(AJ!.OJ"QD-#-!D! X4-M4Z%XOP# K2N-Z,K_:^
M!'<0(7\\37H0LQDR9:SMY>EO^YRK+HO[KQT<R-&/<M;+>HU:-?,3'/6'LC4U
MQ9WO!XD2G'\.%_0W.N!,)PM4L(@=#:6/?=3K!)'Z 6SEUJ'QKYH?DUHK?JB!
MPQZ?&. M*PY0@78/WY2*GX)>%=P4T\^X*0M?<7VNMY>CK&PG65BE9EAPH@N7
MHA#7W.D*N!FR52<,];!LV/T" _AH)@=)G6"J?,WYOE_*)8O"3>EXZ\N#A@75
MS)100>]P)WH8P&3]IKP\_)-]K7937OZO=U7)IEV&Z*_H^#5,N(&OSJ; <^&_
ME"$_NJE77PX#-#! <2W\>*F^\O[$2[C#%(Y^EXE5J@/E(_*AW$&%FUO=%N,,
MSVO9B9\DU!I=N@4MX\295+#=^=UA'OQ[#S/==Y;8D<$:QQ9IA-('JO((9\2P
M7-38[_<*JV<3_*I4E![Y\:;0<8 HR;(W0Q22 QM_;Q"9RQ #N_PVO>\'3_X]
MMV7B)"%;)#E%:M_WD_R>V3Q%2: ["OW6[PE<L8NLZ4L-+OC[H>. OQ<<_2@.
M_-W[F14^?C0>;0'58"K,@"(O<?7D!*#[[6!%<5RQ/]$?F8R'TFJQY1[?"N)D
MW'('L,NY4M<MRC&Z%%V)+I 3KG.-<^,U3WYC^#H3[,.K^@(%9;+.,5Q'IA(]
MEU64\)9:U)FW;(SH_E5TL8OLI;UL92'>OKBY58!^,)<671 ,,'M%BY1\9FV>
M,>'"17M4)^<H;JZS6B/JXZJ^4LB/::NC8Y> 40JZQFKB.JE.9;#FEP4F3Y.<
MT_<&OSNE +^WV%C[#VCT?Q]H5%=EZ:/#%.1#@M%^?9*C07)Z/+#H(-4A2-K9
MHS6<I/#HPNUPH^R;+M<()P.$)!UB7[ ^2SJ,-Z!PN^TX5>G.'(\^>BVB(#O6
M. ="PU[SYO/:/8S8ZI1>!BO'MQJ'WZ11C8IBA&:NV70<#5WDECWO/)M]6+&/
M=H< ;<IL*9#M>EI"9E_+X>^6IK+$)+*A)FH7#? 3R2]@,>,*N)9Q:=A](SG!
M!-<FLRR7\\I_UW$Y=UDP4X,MOM@58L9?7E"OQ_6]*%?[$.@9CF<TUOD2^?4>
MO0PMHG")* P@ %>>];?)7WI#73I@ (^[H7X R-8 N)\ !KBY12(,$,\& \PA
MIB9[45URD!^V"U_.*YZ8":\&@$\;LV@34:'_*TFKUE>\$\-[& !.?2*T!J>6
MH_:#AY%Q(@L^/_6_Z1\Z!_5<O.GR"V;O/X?_=(=--;1$K#GOZ0<LSB,<8 H[
MDFI?/FJXNFR[>:]^_J5[?9<UW-SO@^<0(<5:<+->JP=_G<S^<_Q_.(Z^S3R)
M7&*G'P #I,KSPC\R0=W\OSX#M1]G9_[=F/\W/IZU<3+ _-Y#%;4)[^#>$TPA
M)4W.GXUFT;_-=_9_\S GE53D_>3$/IL4G(U?Y]ARVB8?;25@IX_,-4$69?&+
MI41"3>X&8=I5715!E**/-5>.YP@K?,M4Y?0D:W5HL\-'ML=[Q6DR'4DRR6J_
M>3&Y\#W$>M]<\+[C?4?TW)IH>!%T3"T(Y)9EKMD7ES>1-Q;BCK&,<K9H8[LE
M:;1E<;.J3+L@$ 98.FQN."'SAP'$945(57 #%STM+/'EO"::PW1U=21-+8I#
MJ;"E; @[5\T(@9CR;.WVZI/O_7>O.*G3K//;K#TYZR*G+%-+Q!![N#]<E:N:
M3CH77TU0^*Z'=**8B-NKX=?3#!Y=YLQ(F7/OMUD8HR& %)A%)Z(E3>@V6K,(
M+C,$[+N7M/PW<^K(0-T8\@R![(OB-85E$;2C@S9?"*,B%/MGE9I(CA.Q)))K
M+YN=(]G!1N;E;.HMMC  :EYJERMG44@'Q2L>DT<\?>R\O"=9:NUN>8'I-=ES
M@KY)J>;F*^*<935:Q/YQC;@OAGB^WKFK-1)K:MZ)XBIN$Q$OK"4[B)R68S99
M7?=IG/_(Z1O>1V<^]BARBGRG"G*'97OE8]DXNT/E/95O.2?D)3,6E"9^L]QJ
M%=0T]#[^]VF^R$NA?3GBG4<:7/M;D0AQ=[>E4)]6S?I2186/LS1C8)FR6YCZ
M:[K]_,@%]1!FV>FY_K:ZP,H9QHP*TO=5UZ WT2UJ^SZ3>BYMS5-9OV")Z7_%
M$MN\2S_BR)!7(0VQ5CM[4^#B9QA_2Z6XR*?8D;CR\"14V.>>MP\, "H8;A!;
MT/L0<=$VM,ZW13[!-S OLGIJ?]DZ XU[72;-.'J/GE9%T0O0B)AE 24O'F,2
M\#\3\[(+XC'KSXYOKXXG$Z@6E)\P,.@VJU.03Z[-D=U_73*?7%Y/P[XQ2;\7
M'4IGGM=A0 M]"!W7*Y YFB*^U)'_PM KM,@?XZIF)TMLHJX&3%[<ZKLC\=PI
MQ/#[?PUP C]E_H'BWG\@6_Y'V]^U^!)'\;FNKJC!J^&93JI ]WCHR)#E! ;U
M3(@@;A]W$$?CU_LZW)7B,,!BEO "[S!XU6?N>J_A2@6T10\#T#6,@L!T0XK:
M<U<T?-97>S5P)8#_%XQI'#?410?N^*'=@$QOKJ6%YFB=RX?Z?8,!OJ=#OA>[
MWG#8O L]TX/20PS4SL4VRAH^K=/F6_]$ P:XTQ<#=PJ9X8ZESPU ]007_$GH
MGZ+Y7, V'1O!=\W]TX_793+N6AZCJ526!DL3.Y-"DHXX!8V'Y7M6S3->WI1U
M_*V4XP^++BU^0CK\PP\+]R>#4?-#$):(5OJ/TEN)9VT89/8 "X4M,;D=##_3
M4E_V&^*MK32FR?1,8!,\[RASBW.M^#ATV J^MS+ :/WJR-9<OT+!GBG67MI&
MNA$)O/=F?/\*P'7%M+"+(MC*=_J.\N,MBP'7B/PFX-(M]O@[9'6@_'REA?+\
MB_&W\U71J)3A)J%T1).L(5]4BNI$EN*%2<;51&X;GD4^2=""R(/X.[=IAG=#
M]XG4T;^T*8Z;/_\"A@BZJXX:G(6U/C"S3A<'&5:46' ;CG&:UZ8]4?G,QJ\%
MB8Q_'.2Z)O*P80^:D:M.P&GY8KS/5WV',:.DR"SZ3O"*^OOPEJ VETZ:>#N*
MA"8C-<LG>MBS_MW^4XHO\\RQ)L90WTQST9GRGUY-?:3R(5@*CVPC2M&9G3*_
M8.2V,P]AT",O#U=\* =5ENR^7K+LF/W*2\I_9^F.H\:B?_.%G85&4="%:O1J
MI[+TXY5$?BUFIPH4@%&8",:(!U,N*%J\+R'/Q8>,C@(UP:10O<$%U23D]+%5
MD^)!?J/K20NS 'F6!=^R6WI6GA@PRUPPT0_M 8D!4-L8B8JT\<!.B@J ,%(A
MO]\SV>L;[%!'*PC-(AE&<]VY"[POT2;+_\Z0W<D+,5YKBB/L;,-L.W>,E*(K
M4RZ+*XHIJ^IN8<^]<N?M%;;25<#VJR4J2X DC5?^4!?E\'%_\;-H()]P/)/S
MO<P)<Y0^5G5C(P%3BM'6O?!6*+DGTHN:(N@75M04O^:V^5!*5/JF237"6Z;!
M=JY"6];$TI:@S YP.LXHXTYRJ2R_ZU5;O+0(VW9P]CS)<F@*@ R#.FE)-I"H
M7P7Z=6C)[U*A%/\C.KZ$U XEC97*%[I;7**WW;,(^P%XBWLG*4ZK4&PYT^V]
MZ_#M^GX00GF0R!+F ?/)[-?U 18>DOTGPK<WJ)?$\-T.^D%)O?6S#TW+5IZG
MB82<!JLC(L_GS%$L&RY#*4?SMIDF=8A05Z+(G%U9""WSDE30-35J<QGL Q/)
MWJTB5FW.$5L0]0;YV"=)(EJ/OVYQR'%[9L>><R^',FF&V,AI"ZF1@)<'<*3)
M "G<MZ#..U$R CJ=$K7UQ9]BZ]3&F*B@?T87>GY&04M!1V(J( /E<F5Y63)\
M-%>J32I>>BDRO*T1S8GQN.BN$Z4=#[HT*=PFYB07.\B9'],5O-JU%$]/,J"0
M_?!"CXVUQ8Y/"'F%:@01E8K$>/.WM ?B8WHZTX<J$M(T@+N'@>!%P?841^;P
M>4[9C\^W8U2"7Z(*/@%[-BCD.;[F'@*.>V#EF _@8?>^FE57>MO7P Y)HL!J
MKYUJ5A)U7*@AM$R1&DP&9*,#6GRO1?/6AE7(,E2) BRZL@3]J\G?ZP]_"]TQ
M!]:-F/)GU%7RI]H?;PGZ.# /:$S6M4UGH;,%U(9R(4+R7E1QAZP?"$7BV.O0
MWJ8*+\SKIQ*J[!/<I&P?%'#-2XW^Y%=M^3;P0A8;B$_(RQY@EU)AM-V9_[%7
M](!J,(Y7(E( SU]!0>^0!@9X=RH;_M7<S:D@1Z*6\-6KJ.%#G@P:B  OD!L9
M%,7XK2*@\^3T>:F=OAO2*:2PJT"DHD1J0?DC[GT)7&5]A+7;KJNM("TP]H9J
M/4Y1A:^EZ(=H]W3M:]][=EI"><.D,, ]$+E9'Q:(>7%-EWJH5LO:9M(ZZC(4
M3SU=!!/3QBU8M"G[CD&VB_P-<K7X)^2J&N$"#("S'H\ "N32X9*-F2OE<(Y4
M[.$*5WTH@V['*MU!KJ>@&!ZA'O%T11M9*< &9&8W&ICJ,+221Z:QXR#T8'\L
M:C'-Q6C&)$NL]<*SJ?7CCG!M_=)^FX/=+]4C"2N&*<=>TYMQ=1%@F51#794]
MFNY=>0OY[#%,I/ZR(%D[_&$7#8[K<5:VO:W\"CUM<@G[OZPJ\Q]H?V<]8CLR
M0:?[7Q.%&?"![H$-BZ""?.&.N0.XI"V%3S37FF$ 0E(7EJ6.U7,21QQ%W<$C
M W&<%&+?>:E^"B* #,-KN;N3#%/I[#*OC$KQ[U<:5!4+*<8:A<7/9%5'!.)^
MHC<HKH_21'@8R_,U-0@&H!$]S@U7KS#6SVDJ#?$1MQ*"6-]NGI2^?=RS2'%0
M5WA+0MT8HW*UPO:)V6 @V>SFEO/X"ZF=_,)"G1AY7F(B".C>R1[K6N+Q4AIN
M5N5-:G3"Y<[7#H]W5XE)2-,[_0>XX^/D\^3G8!B@''S)Z82[N-@ CX;SW_<9
M@2$LD<MPTVD?^^;7@I+_QC\=NM]W(&E-U80?1Y]$1[9=T\=#*/AX4Y<_CQ3<
M5D\3.M=*CH%]I-F83MM0.H8'$52(K\3$.G57*U&#G T-MPQYJ"9 '_#[^Z,1
M<HR 7%^HJ42+?!4(.$"Q[L],Q)+<2ZR"M R(.2=1OS7H,3<B;>ZYCR)6Y;)Z
MF!>] +W7NG\E6,%$XA>JP-!Z$%:M/'-0U?_LC4X; /?](@;>DNH(!^_V[",=
MOBOM+T @GA[3.)J7:S=F9=Z7;[4&!7IK86;F&9JR-BQE.&_U6+J[='*GD$\(
M7G:@I"/98;(C1&:=D4[IC;)L<\2A*1$%JV%D2T:6!5-H%^S,N<4B3X6O"ARV
MT2V_;YP<1M-1DO(S+^U,J80H]GYZ-8@WQ>A^+\?S&_*C)G(63F>X;1W+RQ<J
M GG:FAKE2%N-%XD3^$T*?LDF_H;^M4]:Q1"A*R]/LJU\C'L\HO"KGAZI$&?H
MB:SRD_(FWX6X'C32!JY[;.T\R\]1'B:[4'_;;*DG';$JW42;JG%W38GO4(%8
M2(5*Z:A[!!G9V+Q>GP]I TVYT!^0;T6J##,%EN=:?WO;AX!NFQ'12267R1T2
M<LAZZW#XC1;3XI0&9[<GBT))S<BC^#[^E=!I":I[_+B8&C/N0=XTM_3);&^]
MYBT,R3.YQ-U8'W?6,_%^80+I#'TB$\2]VV3@U<8V'&LO0E@]_H9F=+>L)M*=
MZU)E-&TFUCXKE,O,:/*%2<>,E23A_&HY?=W<&^9=CC@+!D_A)X/+=<67C'@G
M;!A50#;GST_S[;VX?!K;704Y8SK&:,</N.*R//WEJT%:W;MT IGJ0D.OH=](
M[]!G ):7HLO BY=:#%,U+HS6!6WO0$S+Y1]\+$=_%-%M)O<6;N?)L<A,2?,,
MBY")*0$FD\PJ]=&/+QX]N0\UJ" I$!LK8;HBSF\R)),<SJB#M&+DTF+7VE8:
M4Z0[L6GC\?Q_[7UU6)3;VOZ+B $2$M(@ @("(D@+C(JT= PAH@(B(-TY(M(I
M(2&A- S-T"4@W3ET=PY=P\PW>G9XSMGG^YV]O]KG^IT_WNN:>:[U/N]:SZI[
MK76OYYDI.U=1J4@THF<JES8:]7ZRZ=Y>--9"E4(C^*)0=WM"//>3/7>!1)5M
M0N]PV8(*8?M,VO:6KAOXIR67)W;.Q14T,Y$U*=P'M)#4;EP^^U"#A DN<SZC
M@77F\;$7EFV]FW/7%RRM$O ?L#3,UM#V7.<>7B6OD(.%B[M^S-D<57(=CT_Q
M+-O4&+54,[!I"HZ?HY:QS>$=E<HT*768!7N?"\U>]_UZMY:-*D,0^WU<<#K?
M,\<F-N;2DI+>?9F\Q: %4RXVQ@]DDKARE+1@2D8*_;AY YO[!(@2CYN!\'XY
MXS3-CZ4J);&O<0OJLRX!91+&EUN%KNL+8L,_99VXK9H(NPI8-?*R\WCOY#)R
MM_A4%"8\N.A?\&M/=S1=/KQ&QS6TA^=RG,WH/3^I<_R,ME?VKD="FR/2=!S:
M@6(>10,O'8ON;Y^[(L5MQK]0_7$Q!+,4Z326SS5(:-8@AB9KR5 &?-9K))'A
M\K>X$71!*T8-ARYED![7V"$V+\B[P"SKB8RQZ3O3F/O@"AKD9RF$U<")57]P
ML)R+V</>G+P7Q/5'XX&.@D+T&=EGBK*U_<6:^UNX*2]G;A"-#W,/1RD'OZ'S
M\-%' ZOWU!MR#8;:.Q,?B-A)JX3);JP4]KJ-UJ[UVWP=?7)XDM5U(G70F0GC
M%B>*U^?O-V?I//9=Q0UJX.!'".61PFTG7!I0+.7Y\"WF"%U"8:U2Z5;;3VZ+
MH^)$0MU/;)J=]WU1K,NAU^4-+7BA'@T/;$R.NPN4'M#M=SK"O_(<E<I,S513
M'6@46,"D,@LIJK+M=G;;28*E5KYDCX/%EPQQ*HRB5[F"%#1@/@H6DZPAZ[*=
M]&W)F]#Y4)OP,KL+U<URY965/1Q+ TD[YBE>CS-+*4 *4PJ#"PD (KXK)^MF
MYMWJZNJ(Y>E(H4B/+JR#+ZV'>3+;"IEG,3.G[2F@*LVVYI"M!/+]&Z4-C2F+
M!\+Y!58*%OK@&=WTL6).R%=SGJ)QO'LO($MQ;M(''!#9/>-OO+LA+D_>!S-3
M%U9BG^L6B@,\F+6>Y+?-5[J;)3^!"6MSA?7=!18V(9Y(4F7IT'_],TTP_=S6
ML25F[DT\Y;0G:W'<IVA^,>V:]81DTW[NF.JOD(39STA"Z4+VZ'K8\M65- ZR
M+\:EUFV7&:R"1VA/5?16[2O\I&+[#",9-.MT/$H]ZIJZU[1LU6Y9*2RWJKQU
MD![U>>IGP;EE_CJPU/*3[AK_H.N5<Y+]7:*KJ8L9%KQ'G+'7T]B8K&=J#N82
MXFN%/TO@QJF6W5)26('H?>.I90]\VZ]9=\5& UQHX* ;T\URZ\L)L1@O;<6%
M1$1_$9MS./)?6VMLA%"B 5W"N"9,S>EQM6!>6A+ZF1SS9_<SMQM"N2I\\'XV
MK8Q?VW Q@./6>XFL*7%<IV3H322151W-8C5=56V3!F(8*2Z<Y^<*LLDS)C&>
MQ5/&J4VX'LK-@4N')>K@KBL(;"*%G#+U7FUW9P^+/[]'4L+*0IS6/</@0S.4
M8PVYLC<A+HO@3"V!DM3=/*9C=R+0OC3BIR8V;;\1!]:ZCV-3<R>_JDJ>:DX1
M%K8-.U.XE\G@UZL5RIC9=*#>W2'\7I>,%.N+WI$1^..7&J[^6=B$7:8)2:<I
M?;1GAR0[;$F0LF[-7V[KRI2V:>Q\[TJ%=RI=VJR+$6PP89#1VD/V\5NU8^M/
MFTK-%RFF<?=P6;%#>T2$7%(<DR@?$S4;$WCBA#IJ1G^%,A:H7VE$8%&PE#HO
MI"$2RNT,TSY6X\YN:<%JO$VK%59/A![YT8S< /J(WWA/E%X-O&)]GVR-5.EB
MM%9:'O15#4?/:]Z2]US%IF4:R(ZWK.I3!+IR%BTT;[(>M,S;:"PAXC=CLDSI
M).,S32RGS,(&-XJ-2M0L.!AD(F1C*)4<6/7?2@J>JSSB--MX]';HTF?B%L/P
M]ON5X_OZP2F'?)R Y8'SS<R9:N>VU6Y9\IZ@:Z*BR44QZL_"A/ @[483^5N"
MUXOPJX75%0F/'+3ZPNMV)E:Z^HS7G/!')3B,6G?CR,PU#>]3"K8>W*PF\ =V
MNPD<(3J(T5>CGBO==DS\-B.Z6A*\+Q[A"[VGE;LCWG_>_.)[^'MMY^+4IOP#
M >UFS\7(F=N(5OW,&[IC--/GQI*_&#*%%MYIH77D&U:^3S%)#!M\[<II:)'7
MU3]U(WZ+<<NRTD_])<U=G"\LY1?S5(M^C'7 MWU10OC0@^^>M+<Y,9?8.6$_
MDD6*0\'F.5U.4JQYJFM9?)QT0P@ZP\"[^D4.] FFYNPASO-,_?MZE]>T$V((
M?8H#QI@KG5XO%!89J[9!HF]+T1B1":\YQ^XC0OQJ$=I3<T^SH K*\M6*UGPK
MLI?;M.,=*PY37!*$X:Q\&W(H+T(2R'1!;5/H6@4&T<>(?YTZXK#83NV6*Q?K
M"]FEO0*GV_=DKCU  \$P6G+JSUI!^RT;A6+WQ1K+LK:R38+ZZ[_=VZHSA039
MUN+M!2P-%8<0K5:X#7JV91J;DHU+"IW77]3W'"X!,2IKIXC&)[5\U4A?C_6L
M-$K]*4J/PE]H %5S+6Q_9)C]\T6UO(77SLJUH3VYR<UD-M9S$B*NVBO/']_3
M;SQ!,X(0BU8\6?N\4?T]CLZ%?LA2]=3902U2WC9"HV8R;Y>67CL'V2R !B[Q
M?T0#HIMH8*OX+_%IWE'+HX&$0\@A!MEL\_4I2Y5"D77[65,=-A"$IW'M[N06
MZO1[R)\'L*GC+0<TX(89 4ETF4E=G&L[_E>UTEWLQ\*,_;9NI7^3]NLU#27C
M ZB%R4?&IY/I P-[REK\8Y5"8V837IB)_,&_POKR-SB]+E^%R3Y$Y0912T*N
MK3F_?7#@-^>I-LSPT))'=E\L<KUX*;8K($=Q&S,_J2*:?6W;\2**@JFC;P:X
MO#NMB[8]H:]_PX^B[4P?=Q2^#/L8</S9B=YQ@'F*UYR DN+TJJZ$$[R!4P!<
M4(IWH3K=1)O7NJV0VI&"-YPD;*S[J:)R<ZHSYQ\["OG1!\PG7+4_H.*/^)?^
M@P^;)AIH7DS%Z&=$ X^:P2:1(4AW$[W]'=#>8[L_@!C^_'3$UX4I1%6%^=)S
M*AW-G[##3#M%Y&;B0<TH9F^]C;%[FFF%H&>G5!<25B!^<8G5%")F)WM;R[&1
M19/& O:]9(2\A%0?EB^K7( ([W2R?ZDEXG69N+DX"L&_NZ*19PR\W[QDH!^F
M@\OCM.$/;%81VC"A**4-A5VH9:B&Q>*_WB8/]$"R#-@+Y?J7AP".#DJ(;N_)
M=G#8J%SF[=3X("BW8MP2MN6%"N=_WCB,9MC<G.<-PL-D";Y[=OJ%,9"\_@$-
M[&Z1GR%N_5/RM.K4V@]390&?45@_>#O\A6DE]A-QBBPQ=Z+5PH+&BEN50>@Y
M' -6X4]FF.+"P[>>:K!S!^$F=$JN[[$^BW]E4ZI?]'<4K-S;_HNH8=32'!H
MIDX%3M& #Y($]EO)0"6@\B,T\(5P?6H+18]0Z/\MFE=9!>O/VD!%D-HC2-T]
MQ=^BB<TN)Y_JGR:&( %4)PH-S*"!\QMB?\L$8P]("MD(V70'(;#_DYS=(2:0
MNE ABKLI%^#$&!E T5(G:@DY4^_WZM!_FEYD5>#E2I),8+OYZF>MK#^K4(L
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MLIY12 MN/ZKF!69M.UN^NFP&FL<QQ@SOW)#E[:<UJDB'E9/DK@[(NVJ(I.V
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M"'-:R'%0E5DJ4&ITYG3EY(L%_D%BPO\H2N.4<D3<<\P0=$\Q<67-^^VD#F^
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M?(6RQ/A[.%\=TV(!)A@G:AT+<*C>%$TUK)</)?O& YEW:\0B(&31,^E5=X9
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MJN%[M,F=U/HSO]58X^"!I*BK E3L9I=H VU7%"1P7;K^U,#Q%+\A^1TA_)/
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MI%?IWOZ1=*_V*.8!ZF&WL/5$=;_5E?N,K[UHJ7?DJ.4&MRCQE+A_4&XY62+
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M()V04%[%F!7OE993P'QLEJ3'59\KS:M;K'T:8@I%KPC_OSN@]Q4"8S!/+*A
MZXJ8YW%K;*:HZV2=WYK[>AE)_\'G^J89#LYC@0\R(;Q+;]J6 <Q#:%M(NKNF
M?39'I#Q_Q]'8(>B('7@43W\$FG_PN<\97&KX<WK68GDL9$:^'OU\; P82PN/
M@UI!GH)B2,FMZP/)V.7D?;(G#%)Q6%$KL^5V/YO8D'_L:3]@.WZ?%U8B-$!M
M2XMO9*/GQH0%0LJ>"'0<V75C@]-J;E]9G*$%)&^S7M?#P2<MU*[*TUP5]G9U
M6/HMF>1HVBI=O"T+3>18=.ALSJ.XP@5S^Y>BWV83YI<7ED:LN!-=J0A*:@F,
M!0< =V5!N'C";U*"=@:D7A$,25%[,4KR&QP(-7] :J'D&^R5^!1Q5=-NNV-$
MTGTKGT!E2Y!??.Z+?OC$&IB6UAS;KDZD9OQ.D+>9%6V^ I=5)GF#-M1'1VVY
M:<E8OA8_-*7Y0PCP4:3XC D#1U'RP3-IS6'AA;"]AD? O%[,Y:F,/72S=,4R
MY4M(VK #+?C5 A"=C/^0E%O5B/(1\#)M WA/VG%74]J!;!YKAW/W^7'M<1X_
M JPC[/,L%M%^O*I601=/[D#]U>^S.OD*H@%"RDMRO"\0^<,IF5E _)02__BF
M2PEHTH;ZQG;\68AW3<Y [JC @;V*\5&5LI+<<MY>-[D8&:7^-'7LVY2"[$R=
M"UXJZH[*]^ .A&=71VQS?.@%EJ]4+&>A03,*=3'2'];;M,CSD$CI$$_MR2VN
MY>CZT8_OY2,@^<%G&D3HE3'0U4XY)3"B],=#D(<\EXUW@)H(]U !@*?&_A7Y
M?FV%%&G6+3ACQ(]@D&29(3TQ[+%]@\%SA3EV(K7"EGM%O$-;YU#A6B$4*DEC
M$_]=VJ!-P4)3O-1V05UR81!Z:VJ#?2Q)#'$)7C=(D!.,%HRX8J?7NTZ*Q,[T
MIC^.(2APHJ<+F!/7]EU7\N;'(G8F&'/F(UL+:7PW8&.J2-M<7/QG)#A E##0
MR'4#[^7 &K5O#VFS.0>GG5U?J^K P(@=5K:?'J%3.Y*X8%VLL-5DW;IT-0%H
MOEMODIR@.FW99.PG_@L;>CD7!;A^!%PRSDK50-#-BF4\C"8> ;VD>LHY=@R<
M%"VAOC8?=EYZ^A\FQG9KCGI$W3P"U*<X:^T%3U1:OTA;V6"-\<>.FZGH1EX"
M*)".ETI_"^+7..](#DW3>H5F!]&^=I?G6!\(5(V9:GNNX?@);0!)]) +3VM:
M&Q :W&MAU1P;AZU5&<@Y5'7T6T?9AYP%=:,"[^ '!_)^ T1V)]/1_ 0[0EP_
MR&08"N0Y)<):UE['L.,DR;VR21]@_ +UC:]H1T,VG_2VXS553AUGG&F..V3T
M@R,I>8$T?^%# RU$QIC'JK$F#T,=V#GPE4Y%7WOEE7OFW@>/O$+Z. _EMQ'^
M"8<T P(]$)1IYB<;NJW L76L!C=FR6=Z^K9\&"'T,P_--3DX_8L^?L7&8X2.
M8!;%ZY-WW+B&]$Y>H.Y]=8 420DOOKPZR(!SQZ-!NU6M47J@IL"QF6VZCC*
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MAAW;\N,!F]2EO#_-  &RPB52Y-,.+\),&T<.#$["R R\%]I=:,GH6!AY@8^
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M-]$GM['JWQ8\[R8!Y60E VCA*4/E"J#\W>R>)H1V3\4\M$^T/JL$+.1!4K6
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M_E[J)9+O'CTJ(ED[N=E66M96<?U$4-ZO_4]L!>LJE(A[^;^>^]2.\9_PYT6
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ME5WJ5K* !\TG97%"O11]%<$"(WJ4V4E[HH&\2A25E@W? AM3#NJZL#$VWM1
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M3WHY*?J+Q<FTCW6/@+#K=(NF%U*\)63]F3$TIS8EW-T/6M=7HK0!RU@M\.-
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M TFAJUSQCX#?Q&<=\2NW>&K31^ZH#/X<+7';XY)S<>MK1J"EH044%4HW2&#
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M,"Z<NTKE)+\(&B]*S%5[Z5A8H_9B>&B W=;OQV<H6?RW"DU#Q;-S4VO%L$>
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M??='H5[=U#]1YSAQZA04ANL/5_='C@ CK^_46JQ\6B,:'?GE/E?\[BU;>YM
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M&4AN1:D2P%B\!10=N6H!KU.,/%W)$X()JO8^'5,S/ZT&]T*0S:BH "_!'X^
M#4[A_*_BB9EO O)/CE;JI:".*PD""9Q_+O.C\UBF>#TYH[<B]6)\W>D[8-2D
M_X5$:&$E">1 F-;-PG)._W7&^UH3QF,J2L8%N&M7ADN&>PB^XZQ<,TT@K(2J
M2[2GYBY3ER-;)>7FR)?<)Y*WDHKM2_H*XU7Y) B($\ -02W*4"TOV9/XQ'//
M_07J']RD?^NM;E?09=?YY+153BUU85+MQD"(BK=!E(?G)&43*#J=X8EZ)@%$
M'+_.Q%V*2B$5A>#P;-WO>Z,I!?525=*OTSFR*A6,)VWR4(F(-0SSZNNVJ4=
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M<_V2)%^;J/9B]KA2]^:_2C;)@&0Y,"2SI3&Z\J'^OBSR6@']%]IF=V9I#H^
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MB/IL,>6)4S]Y?-U@OD5)-KSF-9[M;U$&,3L3[L")\*!=4=NDY=[D(L]Q=MX
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M868K<4:K?YV>6RSY%=#+XI[ HX$DCW,[L*@M'WST:[XOL>?NLR^G?>G\UB-
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M_M.;&C^"P_QJEP5\?N\I+X_Y0W"6F?Y2U8AS:2D!,>:L^B/]1KCXUF9]W%[
M64L+ 59:PJK:ZCIRUEQ&B*5*35TK.G4G T$71%5JG<U=K$V/FU0\$$B<B6XJ
M4,B=B:90#[25_Y*5*-]RS\+JT6FTO,0]MM23,@#'@X-MZE-KG4$V4\A +QUD
M87LH,C)\AO9'DLBP%ZE&.,V X0\R %42%</F_R81#87?P+%W^FLNTS/&B4$V
MZKTWFY<46KI/%0:=GHID'#0LB@9>C]N'CN_?;EKFUU@;$PL+T7:>?P$)$OX
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MK)YZ\K2T].RYNL5S%86V\8[Q+G$)&-PT'=!^TVSDW,,VZPRC_A%H=J?[BL_
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MBB782^H7*,%&^. -6%^FF<DO3]P9%>?[D;-[SS^YQX&5++"?)YA0D76H(]&
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M85^TPN[4A&RZCL-JYHCLMU,PD8HR#G8]]?*!))41WO9G;J)JL[$_3KQ</Y9
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MQ/6G:4DBSNPQ;QR<')CGSE\K$8[_>A6JM;$GS3+\!RK?WS E3B-!#LY/5,K
MXOVH8:8$E-Z>$ 866.P7,,7?OBZCK3)\KZ5=[.O72>F)/6MGD=*AUDF=P;\;
MF=^O]Q=)&4#4.NF/]686MYQ:#5?./U4MM>B^&S/W9_X)R. ,J;1/7+SYR#J<
M^!CW#;THWS2:H:):8K$JZY,LFH1C\R6%OT6]6HM,C8$? +5'5-D.Z6Q-#H+7
MHWG^S&5M"C5T_1EPAY^)MXSO',WA<I'*?S,7SC-QQ4K=&;[.P.?9-3G2GO:H
MP,T"@V?IO__A_D7)V#-HXX=:*8T]Y:?YH("V=R4[WN8QPA#0HL<[89G$FC=K
M+Y"G(^5VNKT*)4>*5W)\QYF?%-ZEV;X'W"\BK7YD8^3EG@1E#(]/!(?].LH_
MZ1G1N/DY.#'?CIR767I7KY7 4CZ<#N.]G4&168OC$TT.'I64G8)C7DA5;ZQG
M&Y)G8TMRS&<09Y%#Z0I\Y9W)$.T;F1IC>ZS#>=S(-+E"Z;^A=%]0Q-)#ICXC
M85:FSY),RN%P-['>9#/HF+H WB1T-G/+M#H]B/$(#&JY]9;XXR9I-C<9*K6B
M>4H%U#1EX3T,RB1ZQL.5HEKPXS$,OSB."LY1,DB(/B,%HT"&%U;FYSWZ:95^
MZ2NQ3!ET@!ID8L$FB?TE+%BZ@PITO8<E]\HJ*2=Z6'A%<NGH/(RX:A3B=-R4
MFW<!+J0WJ#$'G&5^!FUQNZBW$?WZPV4EPA8[%#M27^!<D3,PR@.:32$)85ZA
M\E\P5>B\QFCN #&[TOKU41R;5=V4TN>U,2.%*7\HYL63*Q35V?0'78IBY0/0
M3>-"L57+T!,.Q(*RLLT>,O09?:1!'IH<@JJ1!-7L[H(F]4($&K[P E.O+-<.
MH5PN0_;T^!Y1_,LO:D-0K318M@/'&;WQGEC+\C@5=>;6Q*:OI*]^&"CJ.\;6
MH3T@;CNL6HCR1Z-C%#!24Z(AHQ>M9^Z-)?[8HP+J::Q//M4]UP;KFTPC5Z^Z
M[;=/7?9< ]E8B \"XB]^H0(:!TE;'9;GJ0!]N 9B'Y J,5< :7$0HB&6LRD[
MLG&GKAW$VMQ,33?<,U!Y!#D7W[Z3*T \/$<JFBL&F38DD/]JDIWFZBYNIJ$I
M!P)XPYL0:/36)4H,18KL3@4P'0(7):8AP#WDCQ.-G_F47C4JP,+#0Z)&LUOM
M%Q6P5EB61_Y;JG^_E@:^,[\.;]]#';,QI900D:0;8E><<J=[AV?&B54"^/'W
M9>6!''>H@':3ZCY:Z8_*L=NU'(^>]:0"2G\DV^3?0V3?D^M=UK<!X<[XC';/
M2)=R$.:_4P%^L#5]*,1"EE"7"2%L,.=K#S8>>O>;;KUW0KHB("UPU$(A6^BH
M7B5%JY-&K#3T=IQ@9)/LMU#,M\N:)]D&>BUOKH*PHU;(WZGY$TR/Q5X!=VJ
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MISCXSYCZ@--Q,HDW29(SGH(M/E\Y&IZR"U]66C.E15_2( %<U$D =N-!]\
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MSIJ8# <+95BO#<JU#I<<=AJ)<$?=W#K1/.(TO=/,L+N<XL/5EA=QV*#]L=?
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M+Z G:K(0/L7!]Y?A6)HSY1IJ+W)<)O[TZ$":R)CI/_&B2!XTHT^ 4A.9:V*
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MOU5&B O,GZYN0=W6?Y8K6<_G*P&S"350Z*<59V96-]=AF4J%KO&Z&]XTFGP
M1O34<P0;?XK.;DES.?-/[X95,1N%NQK1C\10UA4)RM_+ZCJ,"QY0FY3<"E 3
M+4M0T;NLRU3.N#8\5H7H^3A>UAX%8U#G3IH]S==MNL%_L#7PWCO_^PE9%5\.
M?E]8]T-!X897(B%OGCK@$9HH->Q82Y$SE5-I67X<HV]&GT6Q8^030_UHM[?
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MW-'XHN%^:6OTJI7'_LCC$&"?:J*EEN+HT;G.V_47@K2AZ^RKTT78* #>%IA
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MN(+UP<OE!:"9CU7!;_"U^&"G)X9TR*'9B(#++-".JB_H![&C_<%R03,QW'R
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M;J"4D,8=+_U!'J?_X.F\0;O-2\#2V]$%"+\M'.#?-,,<*/N3+ FG(2T@?11
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M^(S#':J*5'U%;3G<C_UU34Y)90])W3@&=Y<7)O. 7LP@S.O@0N*A-G4.3"(
MZH3"NE![S;X34VMH8$5! >/]SZ<=JG%E@Q*4':7(P76KJIK@W@1A*VC=%:%H
MBJ]Z>8EOA4.$H=;]F,D,G,\@\I'N)1UZ,_3&:*O%#UR/I2CC^['R7RO:3IWH
M$*A%Z%@<D#D$W*AT(C7QQ)"3)T6P';(632$#7GQR\I -GYV)[#^6%=NW3;'L
M^<Y_B3HRR=C_(87Q43GR?ZLG6.H7J)OY4[TV'T*W4("3@_]KS".I($A2FOS7
M]/ G0+EK]93GOV&45!9V$3/AUOEZ"%SR]AN^O/C]++/FP]"MA3^F!_J?9/C_
M.1C^#ZE[R$,DI_1G]1^@FQECTPQ<JH=KUCNR\#M7.?_Q2_[G:/_%Q9G7/BCR
M7Q8TC.I_PW[(-,*IX9G^UPC]V]C!7OW>'2Y]>EKP;ZKFM^)_4_&_ T^<0'_3
M^+1T?6_UU=^2(Q'TO!#7^W][2Y[_+_]?_B\%'37]?P!02P,$%     @ UX.F
M4BELO_=0[   4RL* !4   !M<FYA+3(P,C$P,S,Q7VQA8BYX;6SLO6N3W+B5
M-OA]?@76,S';'5%P\P*2H#TS;Y1N'L6J)86DME^O8B,#UZJTLY)EDJG+_/H%
M>,EDWI@ $V11WIWPJ*4JDGC. _+!P0%PSG_\KV\/*_!%Y,4R6__G[_S?>[\#
M8LTROES?_>?O?OOT"N+?_:__^I=_^8__ \+__>S#&_ B8YL'L2[!\UR04G#P
M=5G>@[]P4?P=R#Q[ '_)\K\OOQ (_ZNZZ7GV^#U?WMV7(/ "__"W^1\\1AFE
MG@>1[PN(B&"0<A%#(CW$2)!ZB?!N[OZ 4!2+0#(8J_^#* E]2&,OA!Q[?A+S
MD/JAK!ZZ6J[__@?]!R6% ,JX=5']\S]_=U^6CW_XY9>O7[_^_AO-5[_/\KM?
M L\+?VFO_EUS^;>CZ[^&U=5^FJ:_5+_=7EHL3UVH'NO_\K]_??.1W8L' I?K
MHB1KIALHEG\HJA^^R1@I*\XOX@)GK]#_@NUE4/\(^@$,_=]_*_CO_NM? *CI
MR+.5^" DT/_][</KLTVFO^@K?EF+.]VS[T6^S/C'DN3E&T+%2J&OGE9^?Q3_
M^;MB^?"X$NW/[G,A3S]VE>=[3]4H4XW2CS7*?SW7V"]7P'>$MSS&Z@!<9>Y;
M5QC[.'WK#.XGI0]B?,"=9JZ&7+]0+]=\JG=WV]35T,='[.JUR$JRFN"UV#73
M@;S2/WBC_M8THQ_4(Z95.XUT=Z"*;Z58<U&KY=ZCP9+_Y^_4WQ:; MX1\KBX
M50/>._E!D-5+)>>E>)]GCR(OOR^B% 5AFF 8)F$"D5"C5TI3I<-)D'*?^SZE
MP:+<OML+L8:_?6QA5&V9-?0["TO+,U]L+HILD[/=6/>P.C6 J;%+CW;XES5Y
M$,4C:6Y0:+5;4!OP7QHGR*3ZGUPR :K+P$_+-2C^(<N?_^.7G7U7D+N:C++5
M-&QID*!&"5J89[G*V!Z>E78:LOR0B(P9$['W,58D2%+0RHKF$8J1P/M%K,JB
M_0G4/X&>WS@6_WJQK5^.^OLV;PTA.;O0&<T5O[!,N4R/)=SK%^UBVEE<9G:O
M2LVT O$[D.5<Y,HI/F'0T0O\\9[DXIERP_CS[.%1K(O*N[O-<_4.".TP/_N^
MN^0]^:Y_=/N5Y/SE/S;+\OMKY2+FE6-=O"OO1?[IGJS?/>I'%']2CRB+U^MZ
MF%G0D,<Q0AZ428H@4AXS) %BD'@!PEX@0T+3A7+H:6:J-U-!M_D8NP:,]TV^
M+HJ-FL)4FJ4M+"Q5:[).-U/!.7;DR*I:V0/U](>#KM&@8S6@WT'WNL9R4)E^
M VKC0<=Z4)D/2F4_: BX 34%0+TJ-0GN-'OJ;G,Y!DR&?=(Q9>H>.1RC)F_?
M;LQ[R-=D\5S]8LG(ZJ/(ORCWK_A5/%"1+R**TR1).0RCF$+$TQ1B&JO1BO.
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M]HRYU#>+UB=5-WM6#K5MP!.&UOMZ+O2I^M7K-1??_B_Q?1$SRD,4ZV!F1)2
M*=II0A!$)) AB4)$L&7%KX,6YN9XU2!!@Q)4,('":5OVZY#(?LUQ0L_(TF+-
MS(#J7V>LO[K^U^%S)ZX =L:LXQI@YRZ\,D7>L^^=U%6O<O&/C5BS[[??EL4B
M\J,(\Q1#$M(4(LI]F :$PXB&6/U&H-AL_[I%FW/[Y#LXP18H^*RA#LV"UT.X
MF?/AF,:1I6$0@\,3W5WF9)3T=CW-/DU2N\L\G$UE9W#K,,WI!LX_DI78U:_?
MKV:_/9<@N8=U\CGL8:X<#*%G2(Q"GR91$LN(4]\JZ&/9_MRTZ/5:G[$<$-NV
MY=U,AD9D<V1)TOC #N#-;ET1RBR'!='IU)P="KF2+Y=R90MA4ND:R,^AC U]
MC+LZ%Q^6Q=^KX=QGJ?*@6 *]4._[X$$*,=)'2X@78.9+S.WV??0U-C>Q.ED:
M89#CU$NQF52Y(FYT71K F9-*$8=DC%T,8MO>D]=[.+3<I*3#T3W#M.-33M:%
M5-_B[9I_%/F7)5NN[][)>L_R4L_TMC4D=-7VXO2OFK39@4]Y&"0)Y 0%$$7*
M:THC+X0B3%B:I"R4H=6Y-9?@YJ9-6Z1[55N&)3=WVHEF:O9473.R^@WL%6O]
M&X,^EWKI%-^D^CH&LX=Z/$H;P_3[.7E<EF2E4TNL^5+O2BU>KYEV*_FS3?DV
M*_\JRO=DR1<BE3)DF,(@T(%R?;J81B2$G,8A#1''"%ME&3)M>&ZZV^XPJ?+!
M/I[,#@&6:[;:\&I)"A#&](:3 CR2[]6N3WTI:0[SKW;EZ^P4V[C;S-1XC,X8
M66D;R*"+&;2@ =V40,$&WT4)-'!WRFM+E4M5-6Y[4L6T9>10#:WOMU.Z(B\7
M'TM25I' /XGL+B>/]TM&5M7<*R&!1S#%,(G]!*)0370QCP(H?5\I&T52_=I$
MUGI;F9N&=?%936?[N>S7&F<,C2PL-N08JX>1\3U2H>[OR(3ZUZ%$]#<PB1X8
MV=A^_&87#]V428LJX%^^_%+Y4-O-?RR2B,6Q!Y'ZZ-4$TPL@$1)#GX0BIH()
M0>TJP9QK:6Y?_ XHJ)':[K \QZB9?^&$IY&_^R.*1MLF>8$+MWLBSS4V\0;(
M"S8?[W:\=,,P:?@@"J&+6>E4K^*+6&65P]XY/=-6W?B4O1>YS/*'5UE>[54N
MWBS7XK72JV*!J._%DD@H) \ABID/*2$$"NS)R/-$@H25BK@ -3?!:6VJ4ROO
MK.J>G+O9UO31:3<;TZI3<;5QX+,V#U3V64:TG/2SF;9-W7LCR^!T'6>MG"Z9
M=BFR3G!-JL<NF3R4;J?/=K-'8W_1]/8ARTN=;^EY5I0Z\7>Q(!)%$4<22H1U
M"FVD9H%!0J#OQTBYC 0E>I.&^39V6P!6ZCW!9O8M0J A7K=1XR+Y9C([)J6C
M+XD:;-4PI/SJ'1NFO(VY9>,BAB?=LV'*T*5-&\;/N2;=VW:/?)4>ZH-8BZ]U
MO;B%C'$8TSB +$)(9WRCD,H@@C$2@2^0'XA4VF=\.]O>W!S0E]]*L2YTKH:R
MKUCD(&K-%,LA82,+5)L";G=ZI@*KSTE7<!W7VS0DQGT>N/--/D$JN(OVG\X&
M=_FV47PFQC8/FQ4I!?]3GA7%;^M<D)66LS^1Y?J94..8^$2^+1+I12Q$^@ @
M$FIJ7%6)(@QRR2A.PX!+RJ_9[3H(U=RD:0<3:)Q7;H0=UE%.G"[W],_"$]N9
M!2J[P$&'W0!:V0:4<9,Y:G9<3^B]&0*;DTMGQZ6EGV?Y\(%+'.W2R3NI3TZ^
M6F5?BVW-("D\S_=3'PH6AQ!%20S36/TS3#P681%SG""K58Z>QN:FK5NL53U9
M?5"X@FM2S\>>:,/%#T?TC;W^,9PY^S40 TJ<+H/TM3?M2HB!Y4>+(2;W#-.1
M@^+C=8ZPI@A>G2CLW:8L2K+F^A@V_]NF/KNS(#SQN(QT*AO"(1(I5A+CAY!2
M/\),A,SGPD9B!N*8F_J\E%*PZ@/B&KO>!%]L1X;AB1Z']I*9/DW _<C2U5H
M&A/:I(MM2<\F\V+'#+"SPYVJ74FD2\$;"F52+;R2KT.9O/9Q Q,?-EM WZLW
MLNP6!WKV7>_=K39&8>ZSD$@/)C**($)I %,9QS (D$^)S^,PM#J#;M#FW)2Q
MA7P#*M!UT<5=]2H->]#!*A/ZS630,:ECA^RR]1U\HP88KF:AZ[NEWEE\6Q3"
M_5$K"UZ<9BPT:';:'(7F/!QE);2X=9@*O7QX7&7?A:@*B3=)[A&5) D8A331
M"59CK-RS. Z@B), 4^$1%!MM;>UI8VXJ\_+C^_=V^G&*N#1)24I("*5,/8AX
MG$"<QAY4A.%4L@!A%BW4($.SB:CKMC5W\LS$]DI"1A;7%AVHX#DLCV!@ODL-
M/=7,I)K98^>A1O9=.DP37Z]9]B"VD^<WNE=TJFSM$D@6"YIR#$,L$X@PEQ!'
M00Q#P4,<JK="V'ED/6W-32-KJ& 7[FG!#O*_^D@VDP)'U(TL"8-9L]8& SY<
M:D1?<Y-JA8'=AYIA<LO@1('9PT.VKM3H:/*X2/S 3Y(@JOT"E%(?TH#&,(H2
M['E,8FF65,RLN;DIR,LF45X%N1XC;T[$6*PS"O8QWJ\E[GD<V\.XDL(AJ0<-
MF+D^#V%?(U,G)30P^$2&0I.[G#HD3=X$%N$@#6@$TY"IZ5H:I)!XF$ >I3R-
M&8E$8G6JH+>UN4E*S_ Z**-%/]57.2:SRSEQ!7>NG)/Q$DGT-S@'!Z4_U8/9
M3>YV@+YI,@I\;TK_%"\VXJ^"Y)^^9@N/I3Z/90H%CK&:]) 88L(9Y"C&7N(%
M(6-6 2'+]N>F.>J-"Z_?%]I'N)G.C$CCV$'H<_M&M_!O] $A*JH<##= 6P"4
M">-N)37@;NRMI7T0GGRKJ0$_)EM/31[CM/Y$DP.GFPY^NQ.'B3CT*4T@QI&
M*/ Y3&,10"Z(1ZE,"(NL,H?90YB;NFVANBXXT=<-9H(W+KDC:]Z% A0[VG=6
MC+*%:CB)$]2DZ$,QA]H4!BP9UJ@P>=+0K*Q2Z!PX^KQ0T>3(T=M(W^?B48VF
MMVM>'9JL%GV+716@76H&'G./(8^H"67,(&),0)K*  8X%4GJ"T*#P"YSZW6
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M\\W#9E55V7Q.2G;_V^-N5O@I^R"^B/5&M <8?Q5$U^5])]_GV9UZO8N%3-.
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M*Y+5]Q+>K^&CTCBV+-=B^KJ3F'Y/H&MFP6>-'C3PKZD)T$OS%14!7-$];3T
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M193&+$VB$))(KYPD/H%8Q@CZ3&M"( (:8:OJ3[,Q;6ZJM T%@08YV$(''>Q
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M4H@2'L$T])#R0BE*DC 6 :?&:Z3GVYG;F- @K4O9&/J?EZ@T6")U0]#(*MJ
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MGI&="K<C=^IY"##F,(K>UB7^Q=;+W18:L&[3Y[4]$LZ4H*G,#/$JD3( (:.
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MA'1?'<TPJBOJO';';J4+GQJ8LU-?%+QJ;EIW_6*Y8@KG&I0"2O-:F_,-,?J
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MC*J,1=:89M:6WIX4/ZWV&HM\7BVDK7S/JKG8>EP4R@F4O "IIAA )@M >(&
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M.8"%.51RC<RADF2B%$@II,L!E1S<)7!Z?UZ@>D.[4%7= [U+O+()K*J3W/.
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M"3/ TE* LN2%D$ABJKSHZ#9QIL945P)1O;LS!%HT-X(;;RDB<U^ 51C2R"X
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ML P.3OE8J(YTANA*O?Y]O]3K@<=XIT/2*-$&VD:&WJ?X;MPE&*O^;H2E\*S
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ME(JV2L&JH-\NR8!3S+T0ZV>U[VEM]W-C'Y9%GJ%,YZ!,4P%@40I %$X!%[+
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M8VLXX,C#6/NL2^IW8UY7=2ES)5]_LU$'9DKSMQD6*48\U2"G:0H@$QE@&8$
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M-A/X,GC6Q!EA@?J+ZL048,2J/"/@>%C69XP);\VKOT'()ILZDXRI3!)0,B8
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M?U2."7' ",/X[$-3]N>#LE'H9N#VT&_-R'=\,7]L+GM*E-*LS!% C"-;Z+0
M1 H",I26:4$X5(CZ^&.=9IW:$7XKK0T1Z<1-5EMY/=G+#7DWX@J.9_3;TUK>
MNV2'Z9[(R4[FNV#77H.@"DE6;A./RE->6!Q3E-_# PNZ-\UEV^#D$P.QK1T_
M8YG0%*842,@Y@)#G@' , 11(*<CRM,"97R"@V\33BPS\N%F)?[1'0+%_5%2-
MQ)X5W]W@=^.H\)".>.SNZZX=L"R\%T1!:\2[S3QNP7@O-$ZJQ_L]/9"?A'A^
M>E[8:8S%]OMRK9K^ZDVY2_LM^=F0XR^KJFH[LRBJH=), B4I 3#3&: IIB!E
M19ZJ7-I4"1]#RE> J=E4.XD3*V1BG5I?V7QAKYJ V4[ 1[90R8/BF[U*XIXD
MYKM&CG06$?G(Q';_[M7;NMM6IT!B14U^L,+^>'>,]MW1BE1F1>X,(=HZB1$:
M[@S%-2@;^LHP+B\.1.B$(8>.,XPK?V(+:QM^_*S4YA?[-; >OF_S:L8+6)H#
M)#:K83OR%(H!FD$.,DF%RHN2(BU]./'21%/COE;.I!8TZ21-_K"R>L;?7,36
MC<M"(!:9LX:!Y<T^UY (R3(7YQJ53:YI?,P:5S\?,,/+!JDTR:FU6W]7);S:
MUN'/B"(4YM8I!8U!598%() 5@!6XH!E%0G"O#@H#Y9@:MSRHY>IIOK3?]G\/
MD,;DL!!N3#,"O+'#5RZE0C61>HT>=^WMZIXJ4?H?W AG]+0J!U%>/O'*'2^G
MU"R/X?RHLEIO9J^L,U2MO[#UYOMOYEO:&% PSU"94U"F.39$2! @#'' REQ@
M)O*T<"MI>&F"J9';OHR)%=++9KH(8S^#A0 G,C5YX^+,-]>4[R$2\^@>B9B_
M'1/(Q;%'889KFG6O_-7/#>U38HO;U%[;NLGA3&>TY!PK@!6W00,T ^8-)B"G
MJ.0Y1"S5S*\GR>$$TWN7F^H^5L"[Q$#;-BG]?])_2],T^UN2W:$T[:K_L.?-
MY]6Z=A>QRH;)_UK'R!?976)3C-I@>5$?5[M_3?^6P+3Y54%I-]*\JI[; I7[
M)85<1\WH76*&L?4 YU_5XKMOVY2C57<SGFY9R^C44R_CQV89:^GNDK<UQB'[
MGYS7/VRODZ,Y1NYK<E[#TQXF%S[G'Y7_T*9(OC%V"EO\EV+K-^9?JIE $F-)
M4T H%@"FAI)8SB30J2P*C8B4I5/_]IXYIL9%G9A)(V=B!4UJ2=UC]2_!V?^&
M!P(I\DL^ !^O"/XK"-P0R']IY-'B^:^HMA_6?^VC0^-\S-EC;JO7VKBBKC57
M*A$2Q&!5*FFLC8Q!P)!.00:I*$OSA<#:LSW(V7FF=T^^$[,.3/2-W#F'I=L>
M?C,^D=_Q/6"L@!&ZF/4B$#;@YMQ$(P?8].AZ&E#3]^$!A5[>?5%K9ILN_J*8
M>:/:'F<V')9D:8:TX$ 4>0FL^P!0SG/ N194"*0Q<?(8]$\SM?U]*VBRL)(F
MBYVH'C4V+J/:SP#AL(I, 3N8:B&37P+#Y%%') A<(Q4!&0*;7]&.JVCT5MRX
M_/1XY3*N:G!0Z^+ZIV_(=.37LTWXA88 ;=\;&Q'Q=FDH>UG-17T,RV9"L@(5
MVC I82F I6%7GMG"VIB7DHH,4^U50"^>J%,CY_O'QW6=)YEL!>W\"'M*#$A@
MC+/0;M;>-)8O\GX1LF_,GL)WQU^$P)F(49<E>.)A'&G'SS.,BOK9M,*X,PXM
M@]&:]Q_4E]7:;G$?C7GR;&RCK"QY"LW70!)H^[QP<R!/)<"%H(3C@N?0LR3&
M^8FFQOYM48A6V&0K;=*(ZULKXP*ZUYUPH3"+3+E#X1I04*,?BYN+:UP8?N1"
M&_U*GA;=N/+Y869ID]RG#HS=[RTK50_/JG$%/J]G#&.HE5  XU3;IKX*$"XP
MP'D&$<M*#HE7-I[KQ%,C#?.E*OT,0F>(W<R[&,!%9HY6Y.:,>K<]I'Z_LR7$
MN#*&V=S88ZUG_SE@7SY?K$):4,YSCVH/^2)R;-UX/S_PM'S8!;VITE?DN8),
MY$!+7!H*RC#@M,A!EI(,EUH45*1>Y]PSDTR-;G8R)K60 TLEGH/3\31Y(TBQ
MSX&^^/B?VWH "'KB.C?/N&>E'DU/3CE]GQWVSG<L\FEU+_[Y/%^K;0K0F]7:
MIF3MTH-LMM!,"XH1*K!Y_VTG#@(E(!I#(%-6YJS(\BS-!M3S\A3#Z5T8OR;7
M>S/09\/1=6C1$UO_0VVL"DDU,*'-=W'<R"4&UN/P3B>YM6!:V5URV,+1TD#H
M0C*6KPBCDME ?(YY;N@P0]J7/5>;U9-:/Y@#7C7?=)FA/-5(F?,52(WQ R#-
M)6#*EG4JRLS&196*.7EG>N:8FM'329G(5DR?+E_G472X)KT=F\B<LX6ED_!Z
M)JPS/CX=T6[&::SN:,=XA6J2U@M ?\.T\X^.V#RM5_;#1FK]'YU:P=>?S1";
MJJNX=]1VLO[E@S&^WK#YN@E_%CDO<ITSP%-#KC"U51&($J!@ BN="]LIUR\,
M;3*Z^;R+XX2^-5'9M_4ZFPR\+UXW-N+78?K7MHY591N,=B5E[Y*3AL/U1Q(+
M56*QBG+A.Z7U_VL4IO55[O^2LK4#UW2\HK9#!1QF)]AZ($OS?GW?I;)Z9GWW
MC# A0MQ*N9>V'25KVP&.D/S0-]VH;ZR#WL?OD,LC \[WV];GNQ8H[]>KQS5[
MFC',.,PR"7*26UNT-%9I1@G0G-OS@^T^E3F?\2_/,[5S_GZ+H2^-B!XGV1X\
M'4[[85"*S Z-D,D[?="-Z7U(J#P._F$@&^GP/PPZ/T? =4!ZG0$]CX_G$+BN
MPX%3P.'C06O<-W7!#HI/;^V O* %Y%( D6$,8,$PH!0QZQDE$E+-<R5\[H/]
M19@:H6Y%#5W>OF\9W,RQN.#&YN'^<O<[V'=:1#'BAH,X0@7\/BFF4 G? 27'
MBO@N(]U<FJ,^IE6-XVS&*2LPHCF@6 L F>: F;^#4N*TT(1+L[D,K-"Q/\_4
M^.RP4$=31>.N*Z,QN,74)9#=B"P =+'OB0[J8GQL48M8&.,<#I'J8QQ,]5)E
M,L[IVU,MX^S'!_*#8:/[99VK:QTV7]G"NFKN#4NMU]\-(37^:4RUI PAP 1.
M;:<[;IL %4 (IHNRU#3E7L5-G6:=''?8_=I6T:F; *F=W)YDX82X(W6$QC$V
MD700UC_LB7R7,&L0-5*']IM[H1249IPF'I=T?+ XH2"OAX<1TH-:FX%M/:H]
MU_%OJ\V#JN:/2QOM=E_]AY*/9KJ]#]Q7E=K<;W8W:J24&4TS"C@F$D -"> $
MY@ 7O*0B36F>>Y6H#R/6U"BMOJ7ZVN2G,BNK'Y4%6BLWKAM_!2*3X4ZA@[M'
MHU*RT\G6<FNUVO_475(K5M-FC*O&L&"'Y-1 DHU*NF'1/&;EP*,/H^WS50Z^
MSW+$46G+KN52* "I(H 52@--\Y1S4@B-A%]0S(69IA>B\LNP\BS7$,50%AS#
M DB4V^8K&0.DA AHK@N2(4JSK/39V0+@.<96]=X,9AWN36'-E1Y:_>8:O&Z;
M40#0(N\N1X5<]I+DPNT25U (2?N7IAJ5QZ_H>TS,USX^,*NE3<2P_H!YW>#D
M]3>Q>+:%7W]9+1_-N_BT^U5=$EJ56BK.(> ET0#:Q'R>(P:,$5Q26)0YPUZ^
M/F\))L<EK0+)3DQ;M*/5(;%* *O%WN\'-33Q7RHW]HFZ )%Y*0+V_JDN0_$+
MFNSB+<2XZ2Y#,3I)>!D\T$!^7*_^6XE-FX:0(JESQ2E01-GV*B(%!&<<8%06
MI< BT]JI /#9T2?':XUPR1\/*]O.U)>M#H!S9**A<,1F&5<D_+GCG,9!>>%@
M@G'?^7.ZG;S/9S\T-"A3K*UM]*":/]\N[X6P_0FJ#THH<ZJU:>7*'&E(J@3
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M"NE%[^AP%HF0I'PXP:@4>U:W8\(\_Z%;4@<:R[7+\/[^FQ&V+4$@6)JA,H=
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M/: 5F'(["4W9Q:9:XUW42NFQR6@_#%Y;C%X8:MP&H_WZGK07O?)QCTFMG<U
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M'BS GA5?7EY''RXGX_6-3:8:F&0&#5D*1&J'>%602#)*1AW \=2%T_EPW=T
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MHU..*7C779K6W95WPT3#]Y5'"K,)*"#A5R5-9!+_]ND2Y38[OYZ7VI(2@P]
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MKNTZ2N8-P.9.H\TE_0*DR<&B6B5'>83,B/?2$6VE"T9Q[NI4XCPDI.\,ERJ
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M1.F-LS+HD-2/W)(MG]V[ZH_5UJ0[T340#?TR]>/YBG3.K$(J,9 3Z&++@#O
M0F)$12:2B\%Z6R6<OD-#/Z]CW:/C6/'V;1->3D;XK<ET)7KDXF)QJJY8<3FY
M)!,0Y<H($\LY<27Q1B@16.D:\\C1WF(?GEZGG_>L2K:B0Y$V8#=N_"P,'>$M
M?CD;H).M("I/M#&E0#T$XE$F1%/#*$> JUPI$_(A*8V\L1_N@G8DY09P\A&^
MPO@:;ML49Q<H!,G1UPIH!65TQ#MO$?8\,LVM9[>#W;O-P;Y/2"-ARH&*?91I
M?824&T+)0%C)*:#M4R+E<D9J$F(41$OIT3QJ2+9*C>.:@'Y1<9P:MV!B+YDV
M@(6;ECNK(7NWTDC1Z&2U("P!'KW1:G2@))"@DV;6:J;JI-IOI:B1<Z8;&]*-
MW!L T,O);'Z>?YE,TEWW[=-DE 8^9T&C=\0XCB<PQ3^\D*6A(3#%O<Z>5JG*
MWTY2OP:G(YT_>M'I1 $-0.DCJ@,)*&/47Z$Y'4T6H\96PAH$'46(+!*E2^6!
M88FXR"@17E(M.3#GJ_3*>I*J?FU2'4!UIX8&,/4+C%%&HS)U+ET-Q\,BG_GP
M*ZS9<11T4&B^K2A!@W&&.$L#2@NWAV).6EDE]^\'=/6;6UH'5UVJH@%D%;M;
M+.Y:1@-JRE3/C%L!?4 ,/7&/.%4*[T04QG*5C*CB,#TDI-^\T7J'W,'";J L
M\48JMY7?@RB<\EDE(B(OO;TT)8%;_$I0QL&+[+2KZF#?TM)(*GO'KO6!LFX
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M3P>[8[34)/)>3L8+4?UU.+]\>3V;3ZY@NF;P^X!E71JB(4AL*N4/1A G/27
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MJKQH;R:GR5#[%! [4"-]OU._O/33"T"_]D9&CYY4F<K1H@="'(=R'!A+' M
M#,LQ&Y4,=P]R8;<\6/]XK2:CW:[14T/N#9BGW:4WP+T19=:>&)%+CWT7T,'@
M@C!?6NPKE2!6:;6V.XE-!K>US%@ES340012VRO]*=/[5CV!1;X,2&T8,GLL/
M,'*__XT[O[GL(_[XM3^.KDOWT]??XJ4?7\!']*1?YPRH!.>,8TQR8KTL(Z-I
M(J'T94Y1IA!$-ME4N20_+9O][HUJD4O#6'GN.VG@0H9 %1#*H4RG58IXT)*
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M8[[>*":$9&BE@%@99;T@'BDBAJP3SXF0S'>;A_CX\\>-78Z"G",8?&ZVV&U
M3#)A?/$2C#=D,VB>P3M$D"H+CCQR9\8WQ_:+J/>AST[L/APFT2YQ>]58BZC<
M5'A=!4ZO?K_*::)8,$X&A!1Y).6M&;@ZO=UZS9037CK=)%2U]TK/R+H[$#[/
M(G9(69YCV<PF46NYFK_#59ZM2X7CI]G\8O[Q6YL8^"YO;![[WIOL<6+>*'E"
M;8&;ZB_7&R%DI*:+C98.=VV\;9,1=J95-$*($LGL@10\(XO(.D!E%62/P3)D
MUF"3KM!_SRJ:?=#9L(IF'Z%W8$ZTR  CVU]G4>?R.E%J>]L WG !*JO:R<Y:
MB4W*"L;*'#V'"IN]8'F"S-%],-+!-KF?OH92^E#7'3!:LOFRA, %0F8Q^.1X
MG=O[_S-'VV+BR<S1?00T=KSJ VU2_)(O5]-(N[MRYM.W"]K)T_@@G1&+8"6F
M!,F11ZRT*^!EC!"Y5SXF'XLM.T6P=GUC3QFC>TETWIJ]8V/FQRE^G-&V^XZ(
MZ(QE/E7EX3(1X6WMC"A 9$^;*"&1M5L!T[8WC!Q1&@83@["O@U-ID!2_R&*2
M7CB(MH84?-3@7<1*?2:K.2 KI<5A=K*,X7,H[#G&/#LY"L;6?D<0?/?O9^E]
M_GAY4=_T[<WTHD9?9OE!]FGFB32)5H .:S$+?7&NMFO,+BID1EL96N<4[[GF
M%Y!UO!<8!\HZ;HF,,]XP-0:3%W&*%]L8P9W3#'."J&L-.]+IZ62*((RWQ>6J
MP79K7=QRE>,>%&>[*8:5?@<6TW7CPP_S5_%_+J>+_,N,3,#:!?5Q+DT,$1$5
MDR"%-Z *(FWXJ,!8:=%(GZUL$O/>=Z'CYA^,!O"3R+7;B[3?5_/XGQ]P66,P
MG[_DV7+]R$,NR+8\:9B+KUV6.="%UNV]P-MR]V7O\T7M.[P.5=6>#SG4Y5RC
MYN8.@157I"@2?"@$0<43!)8<2.;H)Z($JYKX0L<M^UBEN//;?[C[]MM>CCPG
M%0QYWTEYVJZ\[B4LAC:45,R[PE-LDF!PY+K'-91/B-2'RO*4\CXSW;GVQ@]*
M,7CR>2WUZ&-+[D.;\N)JI7,"JYD )90&]%Y!*3ZKB.B2?(':]';GW'WW'5OH
MAV_?;:Y7?^(BO?VR3L/])]G9.9&Y\M-?7W*LJ2#S^J.WEZOE"F<U'6G]NVJ6
M+ZOHU_*_TU@W%E:44R#)J %EM0.748-1R8B85"RJ3>O.4<D^:UV^SS[Y+G/A
M?-#6@?MW&['];3[[NB:=_(/58EHI7ZO7/V93DDQ<3;_664$/B&7<H_"<I)-)
M3KX./RODK]BB?=)T&F.;:]^C5CUNY&/,G7$R67<%[)_(6)E_RWF3G;]%/URL
M'TG?U;N+./\XJQ?YY)I/YU<RN65$(L];>U,@:$F.,BH#SIL(R1G-=60YAR8-
M<IM1-&ZDI(L-,29&SLPA^ T7M3SJ:SXB^WC')[=T$IXFHP]W@4F34(8, J4G
M;!/ D04+G!D1"GIK'EXDO AWX697/FO*+;?9<E=WR&1X%6[0@HI!@PHE \::
M0Z7IO-(Z),::A&$&H^"LC?A]T+M=,Y\2 QV8+>\ND%33YZMFV 9-X*G.<L58
MZ!0I"K!@A&Q*RO1_C*I-4XX[B^@EW_>D.'AXEW*H4#H"U*;&E1:N18A8:^*)
M%TH7<"HQX$)EIQ6+OE&B[KUEC)Q'>; XM^#B -Z.G0"Q-HJN(AZO9NF7622^
MD3%4*1*,NTWV'\_%!!4E9%?S";WFX(6U@,@Y<J594>(Y6V_WU_6!BD.$.6_*
MV0ZTR)4BO1[24$0A_U];R#8I4(YCW3T)-/U<99FR:M,LZMXJ>LET'/-@.EPL
M'6#J<,;=DCU+#[8M1N&95/7N#VLY<$B .3M DZ(5)M.V;=*-H 4QX^K#(["U
M;T2^M: [ /M-@.GV=-B<!,*H$IQ58*-SI 0$[?^D'92DA8A6QZ2:A!.WKFAD
MBW]TL,Q;2.Z(^>"KX0%XW2I+VFAKUTPO2VTZ;S($*R(X*X77ALD4F[0F?60M
M(Y_F78/N &EUH/$>NUIZ__L?&V*<-JB""T2'LW7>009GJOWC@[$B%X6YU:"U
M[:L:N=U^;R <3H(=P'&395NG8ZR9>%OD2'H[<P[)U;17B0(\AE*K%F2)Q5KE
MFV2';%G/3A!4?QL(#B&U$<&W7*PF[ROO-C:T=UYB@5C[42HK.;CL'8C:,C!F
MK3C;)?N+'GH'9O3I(<3NO;67$2)CN,F'L[\'S&R@7FR*Q<D(C.Q-(MQ[.O%M
MJFGZ0@G%1.9V4-2,Z04<(;&',C^ ?2-+?=/A[/I\==(2S#7D)"2AOF8V*W+
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MY<O:#_@15_EGG"[6Q>%W@^5",.^85: MJQWILP ?2*J2O'*NO$4KGTV3'9.
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MH)M?U"^!%.3_^5__#U!+ 0(4 Q0    ( ->#IE(5?-D7*P@  &DD   8
M          "  0    !A-&5X:&EB:70S,3$P,S,Q,C R,2YH=&U02P$"% ,4
M    " #7@Z92/[S&Z2\(  !-(P  &               @ %A"   835E>&AI
M8FET,S$R,#,S,3(P,C$N:'1M4$L! A0#%     @ UX.F4MRB8Y%#!0  F!\
M !@              ( !QA   &$V97AH:6)I=#,R,3 S,S$R,#(Q+FAT;5!+
M 0(4 Q0    ( ->#IE)B%]G.HA(  #S%   >              "  3\6  !E
M>&AI8FET,3 Q86UE;F1M96YT;F\V=&]B82YH=&U02P$"% ,4    " #7@Z92
M 0 ]6BDM   L*0$ '@              @ $=*0  97AH:6)I=#$P,F%M96YD
M;65N=&YO-W1O8F$N:'1M4$L! A0#%     @ UX.F4O)SU2VV%0  ?9\  !X
M             ( !@E8  &5X:&EB:70Q,#-F;W)M;V9P<W5A9W)E96UE+FAT
M;5!+ 0(4 Q0    ( ->#IE+SY,$?@0T  &U9   >              "  71L
M  !E>&AI8FET,3 T9&ER96-T;W)C;VUP96YS82YH=&U02P$"% ,4    " #7
M@Z92]:B>SS_P 0 K(Q4 $0              @ $Q>@  ;7)N82TR,#(Q,#,S
M,2YH=&U02P$"% ,4    " #7@Z9277V,"QP4  !#V   $0
M@ &?:@( ;7)N82TR,#(Q,#,S,2YX<V102P$"% ,4    " #7@Z92-C!I1.8E
M   ^CP$ %0              @ 'J?@( ;7)N82TR,#(Q,#,S,5]C86PN>&UL
M4$L! A0#%     @ UX.F4K1]:8_L50  'IP# !4              ( ! Z4"
M &UR;F$M,C R,3 S,S%?9&5F+GAM;%!+ 0(4 Q0    ( ->#IE("8\ G$(P
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M+3(P,C$P,S,Q7VQA8BYX;6Q02P$"% ,4    " #7@Z92NXEE;XV.  #*G08
M%0              @ &?)@< ;7)N82TR,#(Q,#,S,5]P<F4N>&UL4$L%!@
0   0 !  4@0  %^U!P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
